PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Teasdale, TW; Emslie, H; Quirk, K; Evans, J; Fish, J; Wilson, BA				Teasdale, Thomas W.; Emslie, Hazel; Quirk, Kirsten; Evans, Jonathan; Fish, Jessica; Wilson, Barbara A.			Alleviation of carer strain during the use of the NeuroPage device by people with acquired brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							PAGING SYSTEM; CAREGIVER BURDEN; RELATIVES; MEMORY	Background: Previous studies have demonstrated the efficacy of a paging system, NeuroPage (Cambridgeshire Primary Care Trust Corporation, Fulbourn, Cambridgeshire, UK), in compensating for memory and planning dysfunctions in people with acquired brain injury (ABI; mainly stroke or traumatic brain injury). In this study, the degree to which this efficacy is accompanied by a reduced experience of strain among carers of patients with ABI was investigated. Methods: Carers of 99 people with ABI completed a questionnaire concerning strain resulting from caring for the injured individual. The questionnaire was completed at the following three time points: before the use of NeuroPage, at the end of a 7-week period of use, and, for one subgroup, a further 7 weeks after withdrawal of NeuroPage. Results: There were significant reductions in strain reported by carers following the 7-week period of NeuroPage use (Cohen's d = 0.3-0.4). This finding persisted when the carer was a spouse or a parent. The reduced strain among carers continued even after withdrawal of NeuroPage. Conclusion: The efficacy of the NeuroPage paging system for people with ABI appears to result in reduced strain for their carers.	[Emslie, Hazel; Fish, Jessica; Wilson, Barbara A.] MRC, Cognit & Brain Sci Unit, Cambridge CB2 7EF, England; [Teasdale, Thomas W.] Univ Copenhagen, Dept Psychol, Copenhagen, Denmark; [Quirk, Kirsten; Evans, Jonathan; Wilson, Barbara A.] Princess Wales Hosp, Oliver Zangwill Ctr, Ely, Wales; [Evans, Jonathan] Univ Glasgow, Fac Med, Sect Psychol Med, Glasgow G12 8QQ, Lanark, Scotland	Wilson, BA (corresponding author), MRC, Cognit & Brain Sci Unit, Cambridge CB2 7EF, England.	barbara.wilson@mrc-cbu.cam.ac.uk		Fish, Jessica/0000-0002-9337-1489	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_U105559837] Funding Source: Medline		Baronet AM, 1999, CLIN PSYCHOL REV, V19, P819, DOI 10.1016/S0272-7358(98)00076-2; Chipchase SY, 2001, DISABIL REHABIL, V23, P768; Ferrario SR, 2003, INT J GERIATR PSYCH, V18, P1110, DOI 10.1002/gps.1021; Fish J, 2008, J NEUROL NEUROSUR PS, V79, P930, DOI 10.1136/jnnp.2007.125203; Howell D. C., 2002, STAT METHODS PSYCHOL; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LoPresti EF, 2004, NEUROPSYCHOL REHABIL, V14, P5, DOI 10.1080/09602010343000101; Oddy M, 2003, NEUROPSYCHOL REHABIL, V13, P259, DOI 10.1080/09602010244000345; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Wilson BA, 2005, BRAIN INJURY, V19, P891, DOI 10.1080/02699050400002363; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477	13	15	15	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUL	2009	80	7					781	783		10.1136/jnnp.2008.162966			3	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	458TQ	WOS:000267046800015	19246477	Bronze			2021-06-18	
J	Walz, NC; Yeates, KO; Taylor, HG; Stancin, T; Wade, SL				Walz, Nicolay Chertkoff; Yeates, Keith Owen; Taylor, H. Gerry; Stancin, Terry; Wade, Shari L.			First-Order Theory of Mind Skills Shortly After Traumatic Brain Injury in 3-to 5-Year-Old Children	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							APPEARANCE-REALITY DISTINCTION; CHILDHOOD HEAD-INJURY; FALSE BELIEF; SOCIAL COMPETENCE; OUTCOMES; COGNITION; RECOVERY; TERM	Post-acute effects of early childhood traumatic brain injury (TBI) on first-order theory of mind (ToM) skills were examined in 86 children with orthopedic injury (OI). 42 children with moderate TBI, and 17 children with severe TBI aged 3 to 5 years at the time of injury. Three-year-olds with TBI performed more poorly than 3-year-olds with OI on an apperance-reality task. The severe TBI group was impaired on false-contents tasks compared to the moderate TBI and OI groups. Age and IQ were strong predictors of ToM performance; however, the relationship between ToM and IQ was not as strong for children with TBI.	[Walz, Nicolay Chertkoff] Cincinnati Childrens Hosp, Med Ctr, Div Behav Med & Clin Psychol, Dept Pediat, Cincinnati, OH 45229 USA; [Walz, Nicolay Chertkoff; Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Ctr Biobehav Hlth, Res Inst, Columbus, OH USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Pediat Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Cleveland, Case Med Ctr, Cleveland, OH 44106 USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Wade, Shari L.] Cincinnati Childrens Hosp, Med Ctr, Div Pediat Rehabil, Cincinnati, OH 45229 USA	Walz, NC (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Behav Med & Clin Psychol, Dept Pediat, MLC 10006,2800 Winslow Ave, Cincinnati, OH 45229 USA.	nicolay.walz@cchmc.org	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD046690] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD42729, R01 HD042729-05, K23 HD046690, R01 HD042729] Funding Source: Medline		Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; Blair C, 2002, AM PSYCHOL, V57, P111, DOI 10.1037//0003-066X.57.2.111; Bloom P, 2000, COGNITION, V77, pB25, DOI 10.1016/S0010-0277(00)00096-2; Carlson SM, 2001, CHILD DEV, V72, P1032, DOI 10.1111/1467-8624.00333; *CDCP, 2000, TRAUM BRAIN INJ US A; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2009, J CLIN EXP NEUROPSYC, V31, P835, DOI 10.1080/13803390802572419; EILIOTT C, 1990, DIFFERENTIAL ABILITY; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FLAVELL JH, 1983, COGNITIVE PSYCHOL, V15, P95, DOI 10.1016/0010-0285(83)90005-1; FLAVELL JH, 1986, MONOGR SOC RES CHILD, V51, pR1, DOI 10.2307/1165866; GOPNIK A, 1988, CHILD DEV, V59, P26, DOI 10.2307/1130386; Grady CL, 2002, CAN J PSYCHIAT, V47, P327, DOI 10.1177/070674370204700403; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Ladd GW, 1999, ANNU REV PSYCHOL, V50, P333, DOI 10.1146/annurev.psych.50.1.333; Langlois JA, 2006, TRAUMATIC BRAIN INJU; PARKER JG, 1987, PSYCHOL BULL, V102, P357, DOI 10.1037/0033-2909.102.3.357; Perner J, 2002, CHILD DEV, V73, P752, DOI 10.1111/1467-8624.00436; PERNER J, 1987, BRIT J DEV PSYCHOL, V5, P125, DOI 10.1111/j.2044-835X.1987.tb01048.x; Rice C, 1997, DEV PSYCHOL, V33, P54, DOI 10.1037/0012-1649.33.1.54; Snodgrass C, 2006, BRAIN INJURY, V20, P825, DOI 10.1080/02699050600832585; Stancin T, 2008, J DEV BEHAV PEDIATR, V29, P253, DOI 10.1097/DBP.0b013e31816b6b0f; Stuss DT, 2004, BRAIN COGNITION, V55, P69, DOI 10.1016/s0278-2626(03)00271-9; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 1997, J INT NEUROPSYCH SOC, V3, P1; TAYLOR HG, 2008, J INT NEUROPSYCH SOC, V14, P1; TEASDALE G, 1974, LANCET, V2, P81; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Wade SL, 2008, REHABIL PSYCHOL, V53, P180, DOI 10.1037/0090-5550.53.2.180; WIIG EH, 1995, TEST LANGUAGE COMPET; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	38	15	15	0	8	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	JUL-AUG	2009	34	4					507	519		10.1080/87565640902964490			13	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	478GN	WOS:000268575900009	20183714	Green Accepted			2021-06-18	
J	Dixon, MR; Tibbetts, PA				Dixon, Mark R.; Tibbetts, Pamela A.			THE EFFECTS OF CHOICE ON SELF-CONTROL	JOURNAL OF APPLIED BEHAVIOR ANALYSIS			English	Article						brain injury; choice; delayed reinforcement; impulsivity; self-control	DEFICIT HYPERACTIVITY DISORDER; DELAYED REINFORCEMENT; BRAIN-INJURY; CHILDREN; IMPULSIVITY; PREFERENCE; PARADIGM; BEHAVIOR; AUTISM	Three adolescents with traumatic brain injury performed a physical therapy task in the absence of programmed consequences or duration requirements. Next, the experimenter gave the participants the options of a smaller immediate reinforcer with no response requirement or a larger delayed reinforcer with a response requirement. Self-control training exposed participants to a procedure during which they chose between a smaller immediate reinforcer and a progressively increasing delayed reinforcer whose values varied and were determined by a die roll. The participants chose whether they or the experimenter rolled the die. All participants initially demonstrated low baseline durations of the physical therapy task, chose the smaller immediate reinforcer during the choice baseline, and changed their preference to the larger delayed reinforcer during self-control training.	[Dixon, Mark R.] So Illinois Univ, Inst Rehabil, Behav Anal & Therapy Program, Carbondale, IL 62901 USA	Dixon, MR (corresponding author), So Illinois Univ, Inst Rehabil, Behav Anal & Therapy Program, Carbondale, IL 62901 USA.	mdixon@siu.edu					Binder LM, 2000, J APPL BEHAV ANAL, V33, P233, DOI 10.1901/jaba.2000.33-233; DeLeon IG, 1996, J APPL BEHAV ANAL, V29, P519, DOI 10.1901/jaba.1996.29-519; Dixon MR, 2004, J APPL BEHAV ANAL, V37, P101, DOI 10.1901/jaba.2004.37-101; Dixon MR, 2003, J APPL BEHAV ANAL, V36, P371, DOI 10.1901/jaba.2003.36-371; Dixon MR, 2001, J APPL BEHAV ANAL, V34, P491, DOI 10.1901/jaba.2001.34-491; Dixon MR, 2000, J APPL BEHAV ANAL, V33, P611, DOI 10.1901/jaba.2000.33-611; FALCOMATA TF, 2004, EUROPEAN J BEHAV ANA, V5, P5; FERSTER CB, 1953, J EXP PSYCHOL, V45, P218, DOI 10.1037/h0062158; Fisher WW, 1997, J APPL BEHAV ANAL, V30, P423, DOI 10.1901/jaba.1997.30-423; GROSCH J, 1981, J EXP ANAL BEHAV, V35, P3, DOI 10.1901/jeab.1981.35-3; MAZUR JE, 1978, J EXP ANAL BEHAV, V30, P11, DOI 10.1901/jeab.1978.30-11; Neef NA, 2005, J APPL BEHAV ANAL, V38, P23, DOI 10.1901/jaba.2005.146-02; Neef NA, 2001, J APPL BEHAV ANAL, V34, P397, DOI 10.1901/jaba.2001.34-397; Neef NA, 2001, J APPL BEHAV ANAL, V34, P57, DOI 10.1901/jaba.2001.34-57; RAGOTZY SP, 1988, J EXP ANAL BEHAV, V49, P191, DOI 10.1901/jeab.1988.49-191; Reeve SA, 2007, J APPL BEHAV ANAL, V40, P123, DOI 10.1901/jaba.2007.11-05; SCHWEITZER JB, 1988, J EXP ANAL BEHAV, V50, P173, DOI 10.1901/jeab.1988.50-173; Stromer R, 2000, J APPL BEHAV ANAL, V33, P359, DOI 10.1901/jaba.2000.33-359; Vollmer TR, 1999, J APPL BEHAV ANAL, V32, P451, DOI 10.1901/jaba.1999.32-451	19	15	18	0	16	JOURNAL APPL BEHAV ANAL	LAWRENCE	DEPT HUMAN DEVELOPMENT, UNIV KANSAS, LAWRENCE, KS 66045 USA	0021-8855			J APPL BEHAV ANAL	J. Appl. Behav. Anal.	SUM	2009	42	2					243	252		10.1901/jaba.2009.42-243			10	Psychology, Clinical	Psychology	460YJ	WOS:000267229000004	19949512	Green Published, Bronze			2021-06-18	
J	Foley, C; Bracker, K; Drellich, S				Foley, Catherine; Bracker, Kiko; Drellich, Sharon			Hypothalamic-pituitary axis deficiency following traumatic brain injury in a dog	JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE			English	Article						central diabetes insipidus; growth hormone deficiency; hypothyroidism; hypoadrenocorticism	CENTRAL DIABETES-INSIPIDUS; HEAD TRAUMA; HYPOPITUITARISM; SECONDARY; DYSFUNCTION; CAT	Objective To describe endocrine dysfunction associated with traumatic brain injury in a dog. Summary A 12-week-old dog presented with traumatic brain injury and did not respond to traditional supportive care. Continued hypothermia, electrolyte derangements, hypotension, and hyposthenuria prompted screening for and detection of several hypothalamic-pituitary disorders including: hypoadrenocorticism, central diabetes insipidus, hypothyroidism, and growth hormone deficiency. Electrolyte abnormalities, urine osmolarity, and blood pressure improved with treatment for the associated disorders. New or Unique Information Provided This is the first report of generalized hypothalamic-pituitary dysfunction or panhypopituitarism following traumatic brain injury in a dog.	[Foley, Catherine; Bracker, Kiko; Drellich, Sharon] Angell Anim Med Ctr, Boston, MA 02130 USA	Foley, C (corresponding author), Angell Anim Med Ctr, 350 S Huntington Ave, Boston, MA 02130 USA.	ce.foley@yahoo.com					Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; AUTHEMENT JM, 1989, J AM VET MED ASSOC, V194, P683; Barrett AW, 2007, AM POLIT RES, V35, P3, DOI 10.1177/1532673X06292816; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Campbell FE, 2005, AUST VET J, V83, P732, DOI 10.1111/j.1751-0813.2005.tb11578.x; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; De Tanti A, 2005, BRAIN INJURY, V19, P1277, DOI 10.1080/02699050500309270; DiBartola S. P., 2006, FLUID ELECTROLYTE AC, P47; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; GREENWOOD FC, 1964, BRIT MED J, V1, P25, DOI 10.1136/bmj.1.5374.25; GUYTON AC, 2006, TXB MED PHYSL, P923; HOERLEIN B, 1978, CANINE NEUROLOGY DIA, P7; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Mellanby RJ, 2005, J FELINE MED SURG, V7, P135, DOI 10.1016/j.jfms.2004.08.002; MILLER ME, 1979, ANATOMY DOG, P107; Platt SR, 1999, J AM ANIM HOSP ASSOC, V35, P117, DOI 10.5326/15473317-35-2-117; Platt SR, 2001, J VET INTERN MED, V15, P581, DOI 10.1892/0891-6640(2001)015&lt;0581:TPVOTM&gt;2.3.CO;2; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; SIEGEL ET, 1977, ENDOCRINE DIS DOG, P8; Smith JR, 2004, J SMALL ANIM PRACT, V45, P405, DOI 10.1111/j.1748-5827.2004.tb00256.x; Urban RJ, 2005, BRAIN INJURY, V19, P349, DOI 10.1080/02699050400004807	22	15	15	1	8	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1479-3261			J VET EMERG CRIT CAR	J. Vet. Emerg. Crit. Care	JUN	2009	19	3					269	274		10.1111/j.1476-4431.2009.00409.x			6	Veterinary Sciences	Veterinary Sciences	456KM	WOS:000266844700006	19691512				2021-06-18	
J	Ross, LF; Harvey, LA; Lannin, NA				Ross, Leo F.; Harvey, Lisa A.; Lannin, Natasha A.			Do people with acquired brain impairment benefit from additional therapy specifically directed at the hand? A randomized controlled trial	CLINICAL REHABILITATION			English	Article							RESEARCH ARM TEST; UPPER EXTREMITY FUNCTION; INDUCED MOVEMENT THERAPY; CHRONIC STROKE PATIENTS; MOTOR FUNCTION-TEST; CLINICAL-TRIAL; SINGLE-BLIND; EXERCISE THERAPY; INTENSITY; REHABILITATION	Objective: To determine the benefits of additional therapy specifically directed at the hand in people with acquired brain impairment. Design: An assessor-blinded randomized controlled trial. Setting: Rehabilitation hospital. Participants: A sample of 39 adults with hand impairment following stroke (90%) or traumatic brain injury (10%). The median (interquartile) time since injury was 1.6 months (0.5-3.5 months). Intervention: The experimental group (n = 20) received an additional one-hour session of task-specific motor training for the hand five times a week over a six-week period. The training was administered on a one-to-one basis. The control group (n 19) received standard care which consisted of 10 minutes of hand therapy three times a week. Both groups continued to receive therapy directed at the shoulder and elbow. Outcome measures: Primary outcomes were the Action Research Arm and Summed Manual Muscle Tests measured at the beginning and end of the six-week period. Results: The mean (SD) Action Research Arm Test values for experimental participants improved from the beginning to the end of study from 10 points (15) to 21 points (23) and the equivalent values for the Summed Manual Muscle Test improved from 35% (33) to 49% (35). There were similar improvements in control participants. The mean between-group differences for the Action Research Arm and Summed Manual Muscle Tests were -6 points (95% confidence interval (CI), -20 to 8) and 3% (95% CI, -10 to 16), respectively. Conclusion: Hand and overall arm function of all participants improved over the six-week period, however there was not a clear benefit from providing additional hand therapy.	[Harvey, Lisa A.; Lannin, Natasha A.] Univ Sydney, Rehabil Studies Unit, No Clin Sch, Fac Med, Ryde 1680, Australia; [Ross, Leo F.] Ipswich Hosp, Brisbane, Qld, Australia	Harvey, LA (corresponding author), Univ Sydney, Rehabil Studies Unit, No Clin Sch, Fac Med, POB 6, Ryde 1680, Australia.	l.harvey@usyd.edu.au	Lannin, Natasha A/A-4195-2013	Lannin, Natasha A/0000-0002-2066-8345; Harvey, Lisa A/0000-0002-4365-0236	Queensland Health Allied Health Research Scheme	This research was conducted with financial support from a Queensland Health Allied Health Research Scheme award.	Ballinger C, 1999, CLIN REHABIL, V13, P301, DOI 10.1191/026921599673198490; Beaton D E, 2001, J Hand Ther, V14, P128; Bernhardt J, 2004, STROKE, V35, P1005, DOI 10.1161/01.STR.0000120727.40792.40; Brandsma J W, 2001, J Hand Ther, V14, P273; Desrosiers J, 2005, CLIN REHABIL, V19, P581, DOI 10.1191/0269215505cr896oa; Duncan P, 2003, STROKE, V34, P2173, DOI 10.1161/01.STR.0000083699.95351.F2; Fergusson D, 2002, BMJ-BRIT MED J, V325, P652, DOI 10.1136/bmj.325.7365.652; Harvey L, 1994, J Hand Ther, V7, P251; Hsueh IP, 2002, CLIN REHABIL, V16, P382, DOI 10.1191/0269215502cr509oa; Hyde SA, 2000, NEUROMUSCULAR DISORD, V10, P257, DOI 10.1016/S0960-8966(99)00135-2; Kwakkel G, 2002, J NEUROL NEUROSUR PS, V72, P473; Kwakkel G, 1997, STROKE, V28, P1550, DOI 10.1161/01.STR.28.8.1550; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; Kwakkel G, 2006, DISABIL REHABIL, V28, P823, DOI 10.1080/09638280500534861; Lannin NA, 2003, ARCH PHYS MED REHAB, V84, P297, DOI 10.1053/apmr.2003.50031; Lannin NA, 2007, STROKE, V38, P111, DOI 10.1161/01.STR.0000251722.77088.12; Law M, 1990, Can J Occup Ther, V57, P82; Law M, 2005, COPM CANADIAN OCCUPA; MacDonald A, 2004, PHYS WORLD, V17, P18; Morris DM, 2001, ARCH PHYS MED REHAB, V82, P750, DOI 10.1053/apmr.2001.23183; Pang MY, 2006, ARCH PHYS MED REHAB, V87, P1, DOI 10.1016/j.apmr.2005.08.113; Parry RH, 1999, CLIN REHABIL, V13, P187, DOI 10.1191/026921599676198929; Partridge C, 2000, Physiother Res Int, V5, P230, DOI 10.1002/pri.203; Platz T, 2005, CLIN REHABIL, V19, P714, DOI 10.1191/0269215505cr904oa; Platz T, 2001, ARCH PHYS MED REHAB, V82, P961, DOI 10.1053/apmr.2001.23982; POLLACK M, 2005, CLIN GUIDELINES STRO; Rodgers H, 2003, CLIN REHABIL, V17, P579, DOI 10.1191/0269215503cr652oa; Taub E, 2006, STROKE, V37, P1045, DOI 10.1161/01.STR.0000206463.66461.97; van der Lee JH, 2002, CLIN REHABIL, V16, P646, DOI 10.1191/0269215502cr534oa; van der Lee JH, 2001, J REHABIL MED, V33, P110; van der Lee JH, 2001, CLIN REHABIL, V15, P20, DOI 10.1191/026921501677557755; Van der Lee JH, 2001, ARCH PHYS MED REHAB, V82, P14, DOI 10.1053/apmr.2001.18668; van der Lee JH, 1999, STROKE, V30, P2369, DOI 10.1161/01.STR.30.11.2369; Van Peppen RPS, 2004, CLIN REHABIL, V18, P833, DOI 10.1191/0269215504cr843oa; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; Winstein CJ, 2004, ARCH PHYS MED REHAB, V85, P620, DOI 10.1016/j.apmr.2003.06.027; Woldag H, 2003, CLIN REHABIL, V17, P723, DOI 10.1191/0269215503cr669oa; Wolf SL, 2001, STROKE, V32, P1635, DOI 10.1161/01.STR.32.7.1635; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095	39	15	15	0	13	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	JUN	2009	23	6					492	503		10.1177/0269215508101733			12	Rehabilitation	Rehabilitation	457LI	WOS:000266929300002	19321521				2021-06-18	
J	Pedersen, MO; Larsen, A; Pedersen, DS; Stoltenberg, M; Penkowa, M				Pedersen, Mie Ostergaard; Larsen, Agnete; Pedersen, Dan Sonne; Stoltenberg, Meredin; Penkowa, Milena			Metallic gold treatment reduces proliferation of inflammatory cells, increases expression of VEGF and FGF, and stimulates cell proliferation in the subventricular zone following experimental traumatic brain injury	HISTOLOGY AND HISTOPATHOLOGY			English	Article						Dissolucytosis; Growth factor; Metallic gold; Regeneration; Traumatic brain injury	ENDOTHELIAL GROWTH-FACTOR; NEURAL STEM-CELLS; INTERLEUKIN-1 RECEPTOR ANTAGONIST; CENTRAL-NERVOUS-SYSTEM; II-DEFICIENT MICE; REACTIVE ASTROCYTES; IN-VITRO; ANTIRHEUMATIC DRUGS; RHEUMATOID-ARTHRITIS; EXTRACELLULAR-MATRIX	Traumatic brain injury represents a leading cause of morbidity in young individuals and there is an imperative need for neuroprotective treatments limiting the neurologic impairment following such injury. It has recently been demonstrated that bio-liberated gold ions liberated from small metallic gold implants reduce inflammation and neuronal apoptosis, while generating an increased neuronal stem cell response following focal brain damage. In this study mice were subjected to a unilateral traumatic cryo-lesion with concomitant injection of 25-45 mu m gold particles near the lesion. Placebo-treated mice subjected to cryo-lesion served as controls. The effects of gold-treatment were investigated by examining gold-induced growth factor expression (VEGF and FGF) in the first two weeks after the insult, and the extent of the neurostimulatory effect of gold was explored by comparing cell proliferation in the subventricular zone as judged by immunohistochemical staining for CDC47. Vimentin staining revealed a decrease in activated microglia and a transient astrogliosis in response to the gold liberation. Moreover, gold ions significantly increase the expression of VEGF and FGF following trauma and a significant increase in cell proliferation in both the ipsilateral and the contralateral subventricular zone was found in response to gold-treatment. In conclusion: we confirmed the previously demonstrated anti-inflammatory effect of bioliberated gold ions, and further show that metallic gold increases growth factor expression and adult neurogenesis.	[Pedersen, Mie Ostergaard; Pedersen, Dan Sonne; Penkowa, Milena] Univ Copenhagen, Panum Inst, Sect Neuroprotect, Dept Neurosci & Pharmacol, DK-2200 Copenhagen N, Denmark; [Larsen, Agnete; Stoltenberg, Meredin] Univ Aarhus, Inst Anat, Aarhus, Denmark	Pedersen, MO (corresponding author), Univ Copenhagen, Panum Inst, Sect Neuroprotect, Dept Neurosci & Pharmacol, Blegdamsvej 3,Bldg 18-1-45, DK-2200 Copenhagen N, Denmark.	mieped@stud.ku.dk		Larsen, Agnete/0000-0001-8765-8443	IMK Almene Fond; Aase and Ejnar Danielsens Fond; Hede Nielsen Fonden; Direktor Jacob Madsen og Hustru Olga Madsens Fond; Horslev Fonden; Vera og Carl Michaelsens Legat; Fonden til Laegevidenskabens Fremme; Eva & Henry Fraenkels Mindefond; Dir. Leo Nielsens Legat; Kathrine og Vigo Skovgaards Fond; Kong Christian d. X's fond; Th. Maigaard's Eftf. Fru Lily Benthine Lunds Fond [1/6 1978]; Toyota Fonden; Hotelejer Edvard Johnsen og hustrus fond; Health Science at Aarhus University; Aarhus University Research Foundation	The authors are grateful for the skillful technical assistance and help of Magdalena Maria Kus, Dorete Jensen, Albert Meier, and Majken Sand. We thank our colleges Linda Locht, MD and Sara Marklund for their help in the operating theatre. We gratefully acknowledge the financial support from the following foundations: IMK Almene Fond, Aase and Ejnar Danielsens Fond, Hede Nielsen Fonden, Direktor Jacob Madsen og Hustru Olga Madsens Fond, the Horslev Fonden, Vera og Carl Michaelsens Legat, Fonden til Laegevidenskabens Fremme, Eva & Henry Fraenkels Mindefond, Dir. Leo Nielsens Legat, Kathrine og Vigo Skovgaards Fond, Kong Christian d. X's fond, Th. Maigaard's Eftf. Fru Lily Benthine Lunds Fond af 1/6 1978, Toyota Fonden, Hotelejer Edvard Johnsen og hustrus fond as well as the Faculty of Health Science at Aarhus University and the Aarhus University Research Foundation.	Agasse F, 2007, EUR J NEUROSCI, V26, P3036, DOI 10.1111/j.1460-9568.2007.05915.x; Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; AZUMI N, 1987, AM J CLIN PATHOL, V88, P286, DOI 10.1093/ajcp/88.3.286; Bot PT, 2008, CURR MED CHEM, V15, P786, DOI 10.2174/092986708783955554; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Danscher G, 2002, HISTOCHEM CELL BIOL, V117, P447, DOI 10.1007/s00418-002-0400-8; Danscher G, 2006, PROG HISTOCHEM CYTO, V41, P57, DOI 10.1016/j.proghi.2006.06.001; Das S, 2008, J NEUROSCI RES, V86, P1199, DOI 10.1002/jnr.21585; Eisler R, 2003, INFLAMM RES, V52, P487, DOI 10.1007/s00011-003-1208-2; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; Griem P, 1996, Z RHEUMATOL, V55, P348; Heyworth BE, 2008, J HAND SURG-AM, V33A, P40, DOI 10.1016/j.jhsa.2007.10.009; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ihrie RA, 2008, CELL TISSUE RES, V331, P179, DOI 10.1007/s00441-007-0461-z; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kabir N, 2005, ENDOCRINOLOGY, V146, P4054, DOI 10.1210/en.2005-0122; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Larsen A, 2008, HISTOCHEM CELL BIOL, V130, P681, DOI 10.1007/s00418-008-0448-1; Larsen A, 2007, HISTOCHEM CELL BIOL, V128, P1, DOI 10.1007/s00418-007-0295-5; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Meng H, 2006, NEUROSCI LETT, V393, P97, DOI 10.1016/j.neulet.2005.09.044; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Monfils MH, 2006, EUR J NEUROSCI, V24, P739, DOI 10.1111/j.1460-9568.2006.04939.x; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Nagashima M, 2000, RHEUMATOLOGY, V39, P1255, DOI 10.1093/rheumatology/39.11.1255; Nagashima M, 1999, CLIN EXP IMMUNOL, V116, P360; Nakagawa T, 2005, NEUROBIOL DIS, V20, P275, DOI 10.1016/j.nbd.2005.03.009; Paxinos G., 1997, MOUSE BRAIN STEREOTA; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Penkowa M, 2003, EXP NEUROL, V181, P130, DOI 10.1016/S0014-4886(02)00051-1; Penkowa M, 1999, GLIA, V25, P343; Penkowa M, 1999, EXP NEUROL, V156, P149, DOI 10.1006/exnr.1998.7009; Penkowa M, 1999, J NEUROSCI, V19, P2535; Penkowa M, 2006, DAN MED BULL, V53, P105; Quintana A, 2005, J NEUROSCI RES, V82, P701, DOI 10.1002/jnr.20680; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; Schanzer A, 2004, BRAIN PATHOL, V14, P237; Schiff MH, 2000, SEMIN ARTHRITIS RHEU, V30, P196, DOI 10.1053/sarh.2000.16641; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Simard AR, 2004, NEUROREPORT, V15, P2305, DOI 10.1097/00001756-200410250-00001; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Sun Yong, 2002, Sheng Li Ke Xue Jin Zhan, V33, P313; Suzuki S, 1998, GENE, V216, P85, DOI 10.1016/S0378-1119(98)00323-0; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Thibeault SL, 2008, ANN OTO RHINOL LARYN, V117, P221, DOI 10.1177/000348940811700310; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Traber KE, 1999, INT IMMUNOL, V11, P143, DOI 10.1093/intimm/11.2.143; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiao ZF, 2007, CELL RES, V17, P73, DOI 10.1038/sj.cr.7310126; YANNI G, 1994, ANN RHEUM DIS, V53, P315, DOI 10.1136/ard.53.5.315; Yoshida S, 1999, INT IMMUNOL, V11, P151, DOI 10.1093/intimm/11.2.151; Zachary I, 2005, NEUROSIGNALS, V14, P207, DOI 10.1159/000088637; Zhang CX, 2003, CURR OPIN CHEM BIOL, V7, P481, DOI 10.1016/S1367-5931(03)00081-4; Zhang HX, 2003, J CELL BIOL, V163, P1375, DOI 10.1083/jcb.200308040	62	15	15	0	5	F HERNANDEZ	MURCIA	PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN	0213-3911	1699-5848		HISTOL HISTOPATHOL	Histol. Histopath.	MAY	2009	24	5					573	586					14	Cell Biology; Pathology	Cell Biology; Pathology	417ZG	WOS:000264116400006	19283666				2021-06-18	
J	Kim, HK; Park, S; Srinivasan, MA				Kim, Hyun K.; Park, Shinsuk; Srinivasan, Mandayam A.			Developments in brain-machine interfaces from the perspective of robotics	HUMAN MOVEMENT SCIENCE			English	Article						Brain-machine interface; Neuroprosthesis; Neuro-robot	MOTOR CORTICAL REPRESENTATION; ARM MOVEMENTS; COMPUTER INTERFACE; MUSCLE ACTIVATION; IMPEDANCE CONTROL; CONTROL SIGNALS; NEURAL-CONTROL; FORCE; CORTEX; PERFORMANCE	Many patients suffer from the loss of motor skills, resulting from traumatic brain and spinal cord injuries, stroke, and many other disabling conditions. Thanks to technological advances in measuring and decoding the electrical activity of cortical neurons, brain-machine interfaces (BMI) have become a promising technology that can aid paralyzed individuals. In recent studies on BMI, robotic manipulators have demonstrated their potential as neuroprostheses. Restoring motor skills through robot manipulators controlled by brain signals may improve the quality of life of people with disability. This article reviews current robotic technologies that are relevant to BMI and suggests strategies that could improve the effectiveness of a brain-operated neuroprosthesis through robotics. (C) 2009 Elsevier B.V. All rights reserved.	[Park, Shinsuk] Korea Univ, Dept Mech Engn, Seoul 136713, South Korea; [Kim, Hyun K.] Samsung Elect Co Ltd, Mechatron & Mfg Technol Ctr, Suwon, South Korea; [Srinivasan, Mandayam A.] MIT, Touch Lab, Cambridge, MA 02139 USA	Park, S (corresponding author), Korea Univ, Dept Mech Engn, Anam Dong, Seoul 136713, South Korea.	sspark@alum.mit.edu					Ambrose RO, 2000, IEEE INTELL SYST APP, V15, P57, DOI 10.1109/5254.867913; Bicchi A, 2001, IROS 2001: PROCEEDINGS OF THE 2001 IEEE/RJS INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND SYSTEMS, VOLS 1-4, P1864, DOI 10.1109/IROS.2001.976345; Birbaumer N, 1999, NATURE, V398, P297, DOI 10.1038/18581; BROOKS RA, 1986, IEEE T ROBOTIC AUTOM, V2, P14, DOI 10.1109/JRA.1986.1087032; Buneo CA, 2003, EXP BRAIN RES, V153, P134, DOI 10.1007/s00221-003-1586-2; Burdet E, 2001, NATURE, V414, P446, DOI 10.1038/35106566; Burstedt MKO, 1997, EXP BRAIN RES, V117, P67, DOI 10.1007/s002210050200; CALANCIE B, 1994, BRAIN, V117, P1143, DOI 10.1093/brain/117.5.1143; CAMINITI R, 1991, J NEUROSCI, V11, P1182; Carmena JM, 2003, PLOS BIOL, V1, P193, DOI 10.1371/journal.pbio.0000042; CRAMMOND DJ, 1994, J NEUROPHYSIOL, V71, P1281; Dietz V, 2004, J APPL PHYSIOL, V96, P1954, DOI 10.1152/japplphysiol.00942.2003; Dimitrijevic MR, 1998, ANN NY ACAD SCI, V860, P360, DOI 10.1111/j.1749-6632.1998.tb09062.x; Endo G, 2005, IEEE INT CONF ROBOT, P596; EVARTS EV, 1968, J NEUROPHYSIOL, V31, P14; FLANAGAN JR, 1993, EXP BRAIN RES, V95, P131; Franklin DW, 2003, EXP BRAIN RES, V151, P145, DOI 10.1007/s00221-003-1443-3; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; GEORGOPOULOS AP, 1983, EXP BRAIN RES, V49, P327; GISZTER SF, 1993, J NEUROSCI, V13, P467; Gomi H, 1996, SCIENCE, V272, P117, DOI 10.1126/science.272.5258.117; Grasso R, 2004, BRAIN, V127, P1019, DOI 10.1093/brain/awh115; HANNAFORD B, 1991, IEEE T SYST MAN CYB, V21, P1764; Hashimoto K, 2006, IEEE INT CONF ROBOT, P1213, DOI 10.1109/ROBOT.2006.1641874; HAYATI S, 1989, PROCEEDINGS - 1989 IEEE INTERNATIONAL CONFERENCE ON ROBOTICS AND AUTOMATION, VOL 1-3, P1310, DOI 10.1109/ROBOT.1989.100161; Hirai K, 1998, IEEE INT CONF ROBOT, P1321, DOI 10.1109/ROBOT.1998.677288; Hochberg LR, 2006, NATURE, V442, P164, DOI 10.1038/nature04970; HOGAN N, 1985, J DYN SYST-T ASME, V107, P1, DOI 10.1115/1.3140702; Hogan N, 2002, J MECH MED BIOL, V2, P359, DOI 10.1142/S0219519402000460; Humphrey D R, 1983, Adv Neurol, V39, P347; Jones L, 1997, PRESENCE-TELEOP VIRT, V6, P29, DOI 10.1162/pres.1997.6.1.29; Kakei S, 1999, SCIENCE, V285, P2136, DOI 10.1126/science.285.5436.2136; KALASKA JF, 1989, J NEUROSCI, V9, P2080; Kamitani Y, 2005, NAT NEUROSCI, V8, P679, DOI 10.1038/nn1444; KHATIB O, 1986, INT J ROBOT RES, V5, P90, DOI 10.1177/027836498600500106; KIM H, 2006, THESIS MIT CAMBRIDGE; Kim HK, 2007, IEEE T BIO-MED ENG, V54, P1520, DOI 10.1109/TBME.2007.900818; Kim HK, 2006, IEEE T BIO-MED ENG, V53, P1164, DOI 10.1109/TBME.2006.870235; Kim J, 2004, PRESENCE-TELEOP VIRT, V13, P328, DOI 10.1162/1054746041422370; KIMURA H, 2003, 8 INT C SIM AD BEH, P201; Kubler A, 2001, PSYCHOL BULL, V127, P358, DOI 10.1037//0033-2909.127.3.358; Lebedev MA, 2001, EUR J NEUROSCI, V13, P1002, DOI 10.1046/j.0953-816x.2001.01457.x; Leuthardt EC, 2004, J NEURAL ENG, V1, P63, DOI 10.1088/1741-2560/1/2/001; Li CSR, 2001, NEURON, V30, P593, DOI 10.1016/S0896-6273(01)00301-4; MASSIMINO MJ, 1994, HUM FACTORS, V36, P145; MATARIC M, 1998, P 5 INT C SOC AD BEH, P165; McMahon T.A., 1984, MUSCLES REFLEXES LOC; MEEK S G, 1989, Journal of Rehabilitation Research and Development, V26, P53; Mellinger J, 2007, NEUROIMAGE, V36, P581, DOI 10.1016/j.neuroimage.2007.03.019; MICHELMAN P, 1994, P IEEE RSJ GI INT C, V1, P253; Moran DW, 1999, J NEUROPHYSIOL, V82, P2676; MORITA T, 1995, IEEE INT CONF ROBOT, P2469, DOI 10.1109/ROBOT.1995.525630; MORRELL JB, 1995, P IEEE RSJ INT C INT, V1, P391; Musallam S, 2004, SCIENCE, V305, P258, DOI 10.1126/science.1097938; MUSSAIVALDI FA, 1985, J NEUROSCI, V5, P2732; NIEMEYER G, 1991, IEEE J OCEANIC ENG, V16, P152, DOI 10.1109/48.64895; Obermaier B, 2003, IEEE T NEUR SYS REH, V11, P422, DOI 10.1109/TNSRE.2003.816866; Park JH, 2001, IEEE T ROBOTIC AUTOM, V17, P870, DOI 10.1109/70.976014; PESERAN B, 2002, NAT NEUROSCI, V5, P805; Pratt GA, 1995, P 1995 IEEE RSJ INT, V1, P399, DOI [10.1109/ IROS.1995.525827., DOI 10.1109/IROS.1995.525827]; Rancourt D, 2001, J MOTOR BEHAV, V33, P193, DOI 10.1080/00222890109603150; Romo R, 2000, NEURON, V26, P273, DOI 10.1016/S0896-6273(00)81156-3; SALISBURY K, 1988, IEEE T AERO ELEC SYS, V24, P591, DOI 10.1109/7.9687; Santhanam G, 2006, NATURE, V442, P195, DOI 10.1038/nature04968; SCHMIDT EM, 1980, ANN BIOMED ENG, V8, P339, DOI 10.1007/BF02363437; SCHMIDT EM, 1999, CRC METH NEUROSCI S, P1; Schwartz AB, 2004, ANNU REV NEUROSCI, V27, P487, DOI 10.1146/annurev.neuro.27.070203.144233; Schwartz AB, 2001, CURR OPIN NEUROBIOL, V11, P701, DOI 10.1016/S0959-4388(01)00272-0; SCHWARTZ AB, 1994, SCIENCE, V265, P540, DOI 10.1126/science.8036499; Scott SH, 1997, J NEUROPHYSIOL, V77, P1016; SCOTT SH, 1995, J NEUROPHYSIOL, V73, P2563; Scott SH, 2001, NATURE, V413, P161, DOI 10.1038/35093102; Sergio LE, 1998, J NEUROPHYSIOL, V80, P1577; Serruya MD, 2002, NATURE, V416, P141, DOI 10.1038/416141a; Shen LM, 1997, J NEUROPHYSIOL, V77, P1195; Shenoy KV, 2003, NEUROREPORT, V14, P591, DOI 10.1097/00001756-200303240-00013; Sheridan T.B., 1992, TELEROBOTICS AUTOMAT; TAGA G, 1995, BIOL CYBERN, V73, P97, DOI 10.1007/s004220050166; Talwar SK, 2002, NATURE, V417, P37, DOI 10.1038/417037a; Taylor DM, 2002, SCIENCE, V296, P1829, DOI 10.1126/science.1070291; Taylor DM, 2003, IEEE T NEUR SYS REH, V11, P195, DOI 10.1109/TNSRE.2003.814451; Todorov E, 2000, NAT NEUROSCI, V3, P391, DOI 10.1038/73964; Todorov E., 2003, IN PRESS, V3, P125; Tonietti G, 2005, IEEE INT CONF ROBOT, P526; Tresch MC, 1999, NAT NEUROSCI, V2, P162; TURKI L, 1995, P 4 IEEE INT WORKSH, V5, P141; Wessberg J, 2000, NATURE, V408, P361, DOI 10.1038/35042582; Williamson MM, 1998, NEURAL NETWORKS, V11, P1379, DOI 10.1016/S0893-6080(98)00048-3; WILLIAMSON MM, 1996, P 4 INT C SIM AD BEH, P124; Wolpaw JR, 2002, CLIN NEUROPHYSIOL, V113, P767, DOI 10.1016/S1388-2457(02)00057-3; WOLPAW JR, 1991, ELECTROENCEPHALOGRAP, V78, P252, DOI DOI 10.1016/0013-4694(91)90040-B; Zinn M, 2004, IEEE INT CONF ROBOT, P249, DOI 10.1109/ROBOT.2004.1307159	92	15	16	0	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0167-9457	1872-7646		HUM MOVEMENT SCI	Hum. Mov. Sci.	APR	2009	28	2					191	203		10.1016/j.humov.2008.12.001			13	Neurosciences; Psychology; Psychology, Experimental; Sport Sciences	Neurosciences & Neurology; Psychology; Sport Sciences	433AV	WOS:000265176700003	19230997				2021-06-18	
J	Pyne-Geithman, GJ; Caudell, DN; Cooper, M; Clark, JF; Shutter, LA				Pyne-Geithman, Gail J.; Caudell, Danielle N.; Cooper, Matthew; Clark, Joseph F.; Shutter, Lori A.			Dopamine D-2-Receptor-Mediated Increase in Vascular and Endothelial NOS Activity Ameliorates Cerebral Vasospasm After Subarachnoid Hemorrhage In Vitro	NEUROCRITICAL CARE			English	Article						Vasospasm; Intracranial; Subarachnoid hemorrhage (SAH); Dopamine; Nitric oxide; Nitric oxide synthase	NITRIC-OXIDE SYNTHASE; TRAUMATIC BRAIN-INJURY; SMOOTH-MUSCLE; INTRAVENOUS-INFUSION; DOUBLE-BLIND; BLOOD-FLOW; NIMODIPINE; THERAPY; PHOSPHORYLATION; BROMOCRIPTINE	Cerebral vasospasm after subarachnoid hemorrhage (SAH) is a serious complication resulting in delayed neurological deficit, increased morbidity, mortality, longer hospital stays, and rehabilitation time. It afflicts approximately 35 per 100,000 Americans per year, and there is currently no effective therapy. We present in vitro data suggesting that increasing intrinsic nitric oxide relaxation pathways in vascular smooth muscle via dopaminergic agonism ameliorates cerebral vasospasm after SAH. Cerebrospinal fluid (CSF) from patients with cerebral vasospasm after SAH (CSFV) was used to induce vasospasm in porcine carotid artery in vitro. Dopamine was added to test its ability to reverse spasm, and specific dopamine receptor antagonists were used to determine which receptor mediated the protection. Immunohistochemical techniques confirmed the presence of dopamine receptor subtypes and the involvement of NOS in the mechanism of dopamine protection. Dopamine receptor 1, 2, and 3 subtypes are all present in porcine carotid artery. Dopamine significantly reversed spasm in vitro (67% relaxation), and this relaxation was prevented by Haloperidol, a D2R antagonist (10% relaxation, P < 0.05), but not by D-1 or D-3-receptor antagonism. Both eNOS and iNOS expression were increased significantly in response to CSFV alone, and this was significantly enhanced by addition of dopamine, and blocked by Haloperidol. Cerebral vasospasm is significantly reversed in a functional measure of vasospasm in vitro by dopamine, via a D2R-mediated pathway. The increase in NOS protein seen in both the endothelium and vascular smooth muscle in response to CSFV is enhanced by dopamine, also in a D2R-dependent mechanism.	[Pyne-Geithman, Gail J.; Caudell, Danielle N.; Cooper, Matthew; Clark, Joseph F.; Shutter, Lori A.] Univ Cincinnati, Dept Neurol, Cincinnati, OH 45267 USA; [Shutter, Lori A.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH 45267 USA; [Shutter, Lori A.] Vet Adm Med Ctr, Cincinnati, OH 45220 USA	Pyne-Geithman, GJ (corresponding author), Univ Cincinnati, Dept Neurol, 3125 Eden Ave,2324 Vontz Ctr, Cincinnati, OH 45267 USA.	pynegj@ucmail.uc.edu	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R0 1NS049428]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [T35DK060444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049428] Funding Source: NIH RePORTER	The authors thank Dr. Kenneth Wagner for excellent discussions and Mrs. Shauna Beiler for porcine tissue supply. They also thank Amanda Harm and Ashlie Saffire for immunohistochemical technical assistance. This project was funded by NIH 5R0 1NS049428 (Pyne-Geithman PI).	AFSHAR JKB, 1995, J NEUROSURG, V83, P118, DOI 10.3171/jns.1995.83.1.0118; Borel CO, 2003, STROKE, V34, P427, DOI 10.1161/01.STR.0000053848.06436.AB; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Cadoux-Hudson TAD, 2001, ACTA NEUROCHIR, V143, P65, DOI 10.1007/s007010170140; CALNE DB, 1974, BMJ-BRIT MED J, V4, P442, DOI 10.1136/bmj.4.5942.442; Choi JK, 2006, NEUROIMAGE, V30, P700, DOI 10.1016/j.neuroimage.2005.10.029; Clark JF, 2001, ACTA NEUROCHIR, V143, P721, DOI 10.1007/s007010170052; Costa MA, 2006, LIFE SCI, V78, P1543, DOI 10.1016/j.lfs.2005.07.024; Czerniczyniec A, 2007, BBA-BIOENERGETICS, V1767, P1118, DOI 10.1016/j.bbabio.2007.07.005; Ghafourifar P, 2005, TRENDS PHARMACOL SCI, V26, P190, DOI 10.1016/j.tips.2005.02.005; GILSBACH JM, 1990, NEUROSURGERY, V26, P458, DOI 10.1227/00006123-199003000-00013; Haynes V, 2004, J BIOENERG BIOMEMBR, V36, P341, DOI 10.1023/B:JOBB.0000041765.27145.08; Koide M, 2002, NEUROSURGERY, V51, P1468, DOI 10.1227/01.NEU.0000036389.57399.DS; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; Lee KH, 2006, NEUROCRIT CARE, V4, P68, DOI 10.1385/NCC:4:1:068; Melis MR, 1996, EUR J NEUROSCI, V8, P2056, DOI 10.1111/j.1460-9568.1996.tb00725.x; MILLER JA, 1995, STROKE, V26, P2260, DOI 10.1161/01.STR.26.12.2260; MONCADA S, 1991, PHARMACOL REV, V43, P109; OHMAN J, 1991, J NEUROSURG, V74, P8, DOI 10.3171/jns.1991.74.1.0008; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; Pluta RM, 2005, JAMA-J AM MED ASSOC, V293, P1477, DOI 10.1001/jama.293.12.1477; Pluta RM, 1996, J NEUROSURG, V84, P648, DOI 10.3171/jns.1996.84.4.0648; Pluta RM, 2005, PHARMACOL THERAPEUT, V105, P23, DOI 10.1016/j.pharmthera.2004.10.002; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; Pyne GJ, 2000, BBA-GEN SUBJECTS, V1474, P283, DOI 10.1016/S0304-4165(00)00030-1; Pyne GJ, 1998, BIOPHYS J, V74, pA256; Salum C, 2006, PSYCHOPHARMACOLOGY, V185, P133, DOI 10.1007/s00213-005-0277-z; Sammut S, 2006, NEUROPSYCHOPHARMACOL, V31, P493, DOI 10.1038/sj.npp.1300826; Sato M, 2000, CIRC RES, V87, P195, DOI 10.1161/01.RES.87.3.195; Schneider WN, 1999, BRAIN INJURY, V13, P863; SEEMAN P, 1994, TRENDS PHARMACOL SCI, V15, P264, DOI 10.1016/0165-6147(94)90323-9; Teitelman E, 2001, AM J PSYCHIAT, V158, P970, DOI 10.1176/appi.ajp.158.987.970-a; VONESSEN C, 1981, STROKE, V12, P331, DOI 10.1161/01.STR.12.3.331; VONESSEN C, 1980, SURG NEUROL, V13, P181; WEIR B, 1978, J NEUROSURG, V48, P173, DOI 10.3171/jns.1978.48.2.0173; WHITFIELD PC, 1994, BRIT J HOSP MED, V52, P539; Wolf EW, 1998, J NEUROSURG, V89, P279, DOI 10.3171/jns.1998.89.2.0279; Zafonte RD, 2000, J HEAD TRAUMA REHAB, V15, P1179, DOI 10.1097/00001199-200010000-00014; Zafonte RD, 2001, J HEAD TRAUMA REHAB, V16, P112, DOI 10.1097/00001199-200102000-00014	39	15	18	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2009	10	2					225	231		10.1007/s12028-008-9143-2			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	414XP	WOS:000263898800013	18807216	Green Accepted			2021-06-18	
J	Richardson, RM; Varenika, V; Forsayeth, JR; Bankiewicz, KS				Richardson, R. M.; Varenika, V.; Forsayeth, J. R.; Bankiewicz, K. S.			Future Applications: Gene Therapy	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article						Gene therapy; Convection enhanced delivery; Restorative neurosurgery	CONVECTION-ENHANCED DELIVERY; PHASE-I TRIAL; PARKINSON-DISEASE; NEUROTROPHIC FACTOR; MONKEY BRAIN; OPEN-LABEL; SAFETY; TOLERABILITY; IMPROVEMENT; LIPOSOMES	Gene therapy for brain disorders is one of the most promising frontiers in the practice of restorative neurosurgery. There are significant experimental gene therapy initiatives underway that have led to currently active clinical trials using direct intracerebral delivery of viral vectors, and these treatments have been reported as safe and well tolerated. In the future, other clinical trials will likely use viral vectors to transfer genes that bestow on recipient tissue a desired enzymatic or neurotrophic activity relevant to the treatment of other neurodegenerative diseases, stroke, and traumatic brain injury.	[Richardson, R. M.; Varenika, V.; Forsayeth, J. R.; Bankiewicz, K. S.] Univ Calif San Francisco, Dept Neurol Surg, Lab Mol Therapeut, San Francisco, CA 94103 USA	Richardson, RM (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Lab Mol Therapeut, 1855 Folsom St,Room 226, San Francisco, CA 94103 USA.	richardsonma@neurosurg.ucsf.edu	Richardson, R Mark/C-6819-2016	Richardson, R Mark/0000-0003-2620-7387	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS064692] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32 NS064692-01] Funding Source: Medline		Bankiewicz KS, 2006, MOL THER, V14, P564, DOI 10.1016/j.ymthe.2006.05.005; Eberling JL, 2008, NEUROLOGY, V70, P1980, DOI 10.1212/01.wnl.0000312381.29287.ff; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Hadaczek P, 2006, MOL THER, V14, P69, DOI 10.1016/j.ymthe.2006.02.018; Hadaczek P, 2006, HUM GENE THER, V17, P291, DOI 10.1089/hum.2006.17.291; Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140-6736(07)60982-9; Krauze MT, 2005, BRAIN RES PROTOC, V16, P20, DOI 10.1016/j.brainresprot.2005.08.003; Krauze MT, 2005, EXP NEUROL, V196, P104, DOI 10.1016/j.expneurol.2005.07.009; Lonser RR, 2007, NEUROLOGY, V68, P254, DOI 10.1212/01.wnl.0000247744.10990.e6; Marks WJ, 2008, LANCET NEUROL, V7, P400, DOI 10.1016/S1474-4422(08)70065-6; Richardson RM, 2008, NEUROSURGERY, V63, P629, DOI 10.1227/01.NEU.0000325491.89984.CE; Saito R, 2005, EXP NEUROL, V196, P381, DOI 10.1016/j.expneurol.2005.08.016; Slevin JT, 2005, J NEUROSURG, V102, P216, DOI 10.3171/jns.2005.102.2.0216; Szerlip NJ, 2007, J NEUROSURG, V107, P560, DOI 10.3171/JNS-07/09/0560; VALLES F, NEUROIMAGE IN PRESS; Varenika V, 2008, J NEUROSURG, V109, P874, DOI 10.3171/JNS/2008/109/11/0874	16	15	15	1	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680			NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	APR	2009	20	2					219	+		10.1016/j.nec.2009.04.004			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	480HM	WOS:000268724500011	19555883	Green Accepted			2021-06-18	
J	Greenwald, BND; Rigg, JL				Greenwald, Bria N. D.; Rigg, John L.			Neurorehabilitation in Traumatic Brain Injury: Does It Make a Difference?	MOUNT SINAI JOURNAL OF MEDICINE			English	Article						brain injury; evidence; rehabilitation	REHABILITATION; ATTENTION; SEIZURES; CRITERIA	Each year, 1.4 million people in the United States are seen in a hospital for a traumatic brain injury. Those with moderate-to-serve traumatic brain injury frequently go through a course of inpatient neurorehabilitation prior to discharge back into the community. A broad overview of neurorehabilitation is presented, including the standards for admission to inpatient rehabilitation and the members and roles of the neurorehabilitation team. Common medical complications that are managed after moderate-to-severe traumatic brain injury are reviewed. The spectrum of arousal issues is summarized. The evidence regarding neurorehabilitation is then reviewed. Future studies that are underway to better understand the utility of neurohabilitation are then discussed. Mt Sinai J Med 76:182-189, 2009(C) 2009 Mount Sinai School of Medicine	[Greenwald, Bria N. D.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Rigg, John L.] SE Reg Med Command, Dwight D Eisenhower Army Med Ctr, Traumat Brain Injury Program, Ft Gordon, GA USA	Greenwald, BND (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA.	brian.greenwald@mountsinai.org					ALADAWI S, 2005, J APPL RES, V5, P2005; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P1182, DOI 10.1016/S0003-9993(96)90145-8; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Giacino JT, 2006, ARCH PHYS MED REHAB, V87, pS67, DOI 10.1016/j.apmr.2006.07.272; Giacino JT, 2004, NEUROREHABILITATION, V19, P293; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Horn SD, 2007, MED CARE, V45, pS50, DOI 10.1097/MLR.0b013e318070c07b; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Marshall S, 2007, BRAIN INJURY, V21, P133, DOI 10.1080/02699050701201383; Napolitano E, 2005, MED SCI MONITOR, V11, pRA212; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Teasell R, 2007, BRAIN INJURY, V21, P107, DOI 10.1080/02699050701201524; TURNERSTOKES L, 2005, COCHRANE DB SYST REV, V3, DOI DOI 10.1016/S0079-6123(09)17707-5; WATANABE TK, 2001, PHYS MED REHABILITAT, V15, P283; WHYTE J, 1992, ARCH PHYS MED REHAB, V73, P940; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3	22	15	15	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0027-2507	1931-7581		MT SINAI J MED	Mt. Sinai J. Med.	MAR-APR	2009	76	2					182	189		10.1002/msj.20103			8	Medicine, General & Internal	General & Internal Medicine	427OE	WOS:000264787800011	19306378				2021-06-18	
J	Karasu, A; Sabanci, PA; Cansever, T; Hepgul, KT; Imer, M; Dolas, I; Taviloglu, K				Karasu, Aykut; Sabanci, Pulat Akin; Cansever, Tufan; Hepgul, Kemal Tanju; Imer, Murat; Dolas, Ilyas; Taviloglu, Korhan			Epidemiological study in head injury patients	ULUSAL TRAVMA VE ACIL CERRAHI DERGISI-TURKISH JOURNAL OF TRAUMA & EMERGENCY SURGERY			Turkish	Article						Epidemiology; craniocerebral trauma; traumatic brain injury	TRAUMATIC BRAIN-INJURY	BACKGROUND The aim of this study was to determine the hospital-based epidemiological data of the head injury patients who admitted to our Emergency Surgery Department. METHODS The records of the patients (284 males [66%], 146 females [34%]; mean age 30 19) with head injury who admitted to our Emergency Surgery Department between 01.01.2006 - 31.12.2006 were analyzed retrospectively. RESULTS Among the age groups, most head injuries occurred in children (22%) and young adults (30%). The most common trauma types were due to falls (40%) and motor vehicle accidents (37%). The mortality rate in head injury patients was 11%, serious morbidity was 2%, and the rate of deaths from head injury among all deaths in 2006 was 30%. CONCLUSION According to these data, the most common causes of death in head-injured patients are falls (0-16 years of age) and outside vehicle traffic accidents and cranial gunshot wounds (16-35 years of age), especially for males. Admission Glasgow Coma Score is an important prognostic factor in head-injured patients. Primary precautions for head injury must be taken according to each age group. Further development of the diagnosis and treatment options will help to lower the mortality and morbidity of patients with traumatic brain injury.	[Karasu, Aykut; Sabanci, Pulat Akin; Cansever, Tufan; Hepgul, Kemal Tanju; Imer, Murat; Dolas, Ilyas] Istanbul Univ, Istanbul Fac Med, Dept Neurosurg, TR-34093 Istanbul, Turkey; [Taviloglu, Korhan] Istanbul Univ, Istanbul Fac Med, Dept Trauma, TR-34093 Istanbul, Turkey; [Taviloglu, Korhan] Istanbul Univ, Istanbul Fac Med, Emergency Surg Serv, TR-34093 Istanbul, Turkey	Sabanci, PA (corresponding author), Istanbul Univ, Istanbul Fac Med, Dept Neurosurg, TR-34093 Istanbul, Turkey.	sabanci.akin@gmail.com	SABANCI, PULAT AKIN/AAT-1325-2020; Hepgul, Kemal Tanju/AAV-1510-2020; Dolas, Ilyas/AAD-6885-2020				Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P201; Kahende J., 2007, Morbidity and Mortality Weekly Report, V56, P993; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Kiris T, 1998, ULUSAL TRAVMA DERGIS, V4; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McNett Molly, 2007, J Neurosci Nurs, V39, P68; Peden M, 2002, INJURY CHART BOOK GR; Ragnarsson KT, 2006, J HEAD TRAUMA REHAB, V21, P379, DOI 10.1097/00001199-200609000-00002; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009	9	15	17	0	2	TURKISH ASSOC TRAUMA EMERGENCY SURGERY	ISTANBUL	KOPRULU MEHMET PASA SOC, DENIZ ABDAL MAH, DADASOGLU AP, 25-1 SEHREMINI, ISTANBUL, 00000, TURKEY	1306-696X			ULUS TRAVMA ACIL CER	Ulus. Travma Acil Cerrahi Derg.	MAR	2009	15	2					159	163					5	Emergency Medicine	Emergency Medicine	415QF	WOS:000263948700011	19353319				2021-06-18	
J	Wakeland, W; Agbeko, R; Vinecore, K; Peters, M; Goldstein, B				Wakeland, Wayne; Agbeko, Rachel; Vinecore, Kevin; Peters, Mark; Goldstein, Brahm			Assessing the prediction potential of an in silico computer model of intracranial pressure dynamics	CRITICAL CARE MEDICINE			English	Article						computer modeling; in silico; prediction; traumatic brain injury; intracranial pressure	MATHEMATICAL-MODEL; CEREBRAL HEMODYNAMICS; AUTOREGULATION; INJURY; SYSTEM; TESTS	Objective: Traumatic brain injury (TBI) frequently results in poor outcome, suggesting that new approaches are needed. We hypothesized that a patent-specific in silico computer model of intracranial pressure (ICP) dynamics may predict the ICP response to therapy. Design: In silico model analysis of prospectively collected data. Setting: Twenty-three and 16-bed pediatric intensive care units in two tertiary care academic hospitals. Patients: Nine subjects with severe TBI undergoing ICP monitoring (7 M/2 F, age range 3-17 years). Interventions: Random changes in head-of-bed (HOB) (0 degrees, 10 degrees, 20 degrees, 30 degrees, 40 degrees) elevation and respiratory rate (to achieve a Delta ETco(2) = +/- 3-4 mm Hg) were performed daily according to a study protocol as long as an intracerebral monitoring device was in place. Methods and Main Outcome Measures: A six-compartment dynamic ICP model was developed based on published equations and parametric data (baseline model parameter values). For each of 24 physiologic challenge sessions, patient-specific model parameter values were estimated that minimized the model fitness error, the difference between model-calculated ICP and observed ICP, both for baseline parameters and patient-specific parameter. Next, model prediction error was measured using two analyses. First, a "within" session analysis estimated parameter values using data from an initial Segment A, and then used those parameter values to predict the ICP during a later Segment B. The predicted ICP for B was compared with the observed ICP for B. Second, a "between" session analysis was performed. This analysis used parameter values estimated from earlier sessions to predict the ICP in later sessions. Fitness and prediction errors were measured in terms of mean absolute error (MAE). To normalize the errors, MAE was divided by the mean absolute deviation (MAD) for the associated segment or session, yielding a measure for both model fitness error and model prediction error that is favorable when <1. Results: For baseline parameter values, MAE/MAD was <1 in 2 of 24 (8%) sessions. For session-specific parameter values, MAE/MAD was <1 in 21 of 24 (88%) sessions and <0.5 in 9 of 24 (38%) sessions. Sessions with low (<12 mm Hg) (n = 8; 33%) or high (>18 mm Hg) (n = 6; 25%) ICP had lower error than moderate ICP (12-18 mm Hg) (n = 10; 42%). MAE/MAD was <1 for 6 of 22 (27%) for within-session predictions and 3 of 31 (10%) for between-session predictions. Conclusions: The protocol for collecting physiologic data in subjects with severe TBI was feasible. The in silico ICP model with session-specific parameters accurately reproduced observed ICP response to changes in head-of-bed and respiration rate. We demonstrated modest success at predicting future ICP within a session and to a lesser extent between sessions. (Crit Care Med 2009; 37: 1079-1089)	[Wakeland, Wayne] Portland State Univ, Syst Sci Grad Program, Portland, OR 97207 USA; [Agbeko, Rachel; Peters, Mark] Inst Child Hlth, Partex Unit, Crit Care Grp, London, England; [Vinecore, Kevin] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Peters, Mark] Great Ormond St Hosp Sick Children, Paediat Intens Care Unit, London WC1N 3JH, England; [Goldstein, Brahm] Novo Nordisk Inc, Princeton, NJ USA	Wakeland, W (corresponding author), Portland State Univ, Syst Sci Grad Program, Portland, OR 97207 USA.	wakeland@pdx.edu	Peters, Mark/AAD-7518-2019	Peters, Mark/0000-0003-3653-4808	Thrasher Research Fund; GOSH/UCL Institute of Child Health; Department of Health's NIHR Biomedical Research CentresNational Institute for Health Research (NIHR)	Supported, in part, by a grant from the Thrasher Research Fund. This work was undertaken at GOSH/UCL Institute of Child Health, which received a proportion of funding from the Department of Health's NIHR Biomedical Research Centres funding scheme.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Almog Y, 1998, J AUTONOM NERV SYST, V69, P39, DOI 10.1016/S0165-1838(98)00006-X; Czosnyka M, 1997, J NEUROL NEUROSUR PS, V63, P721, DOI 10.1136/jnnp.63.6.721; Goldstein B, 1994, Pediatr Rev, V15, P213, DOI 10.1542/pir.15-6-213; HOFFMANN B, 1987, ACTA NEUROCHIR SUPP, V40, P117; Hu X, 2007, IEEE T BIO-MED ENG, V54, P597, DOI 10.1109/TBME.2006.890130; Lodi CA, 1998, AM J PHYSIOL-HEART C, V274, pH1729; Rosner Michael J., 1993, P57; TEASDALE G, 1974, LANCET, V2, P81; Ursino M, 2000, AM J PHYSIOL-HEART C, V279, pH2439; URSINO M, 1995, IEEE T BIO-MED ENG, V42, P529, DOI 10.1109/10.387192; Ursino M, 1997, J APPL PHYSIOL, V82, P1256; Ursino M, 2001, ANN BIOMED ENG, V29, P563, DOI 10.1114/1.1380423; Ursino M, 2000, J VASC RES, V37, P123, DOI 10.1159/000025723; Vinecore K, 2007, PEDIATR CRIT CARE ME, V8, P563, DOI 10.1097/01.PCC.0000288715.66726.64; Wakeland W, 2005, WIT TR BIOMED HEALTH, V8, P57; Wakeland W, 2005, ACT NEUR S, V95, P321; WAKELAND W, 2004, ANN INT C IEEE ENG M, P746; Wakeland W, 2008, COMPUT BIOL MED, V38, P1024, DOI 10.1016/j.compbiomed.2008.07.004; White JRM, 2002, CRIT CARE MED, V30, pS478, DOI 10.1097/00003246-200211001-00013; SYSTEMS THINKING ED	22	15	15	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	MAR	2009	37	3					1079	1089		10.1097/CCM.0b013e31819b629d			11	Critical Care Medicine	General & Internal Medicine	413FW	WOS:000263779300040	19237921				2021-06-18	
J	Doll, H; Truebel, H; Kipfmueller, F; Schaefer, U; Neugebauer, EAM; Wirth, S; Maegele, M				Doll, Hinnerk; Truebel, Hubert; Kipfmueller, Florian; Schaefer, Ute; Neugebauer, Edmund A. M.; Wirth, Stefan; Maegele, Marc			Pharyngeal Selective Brain Cooling Improves Neurofunctional and Neurocognitive Outcome after Fluid Percussion Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						cognition; neurofunction; selective brain cooling; therapeutic hypothermia; traumatic brain injury	CONTROLLED CORTICAL IMPACT; MODERATE HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; CARDIAC-ARREST; THERAPEUTIC HYPOTHERMIA; BEHAVIORAL DEFICITS; PROTECTION; CARE; DYSFUNCTION; TEMPERATURE	Therapeutic hypothermia (TH) after cardiac arrest reduces mortality and improves neurological outcome. Experimental TH after traumatic brain injury (TBI) indicated similar effects, but benefits were not reproducible in large clinical trials. Therefore, a novel approach of pharyngeal selective brain cooling (pSBC) was tested in respect to neurological outcome in a model of experimental TBI. Male Sprague-Dawley rats were subjected to lateral fluid percussion (LFP) brain injury and received pSBC for 3 h post-injury. All animals were examined for neuromotor and sensorimotor dysfunction and coordination: before and after injury, and during recovery on day post-injury (DPI) 7 and 14 using (i) the standardized Composite Neuroscore (NS) test and (ii) the Rotarod test. Recovery of cognitive function was assessed on days 10-14 using (iii) the Barnes Circular Maze (BCM). In pSBC-animals, brain temperature was selectively lowered to 33 +/- 0.5 degrees C at 15 min post-injury, keeping rectal temperature at a physiologic level. All animals subjected to TBI via LFP showed an identical pattern of severe neurofunctional impairment at 24 h after injury. In the time course of the experiment, pSBC-animals showed superior neurofunctional recovery on DPI 7 (p = 0.03) and 14 (p = 0.002). Similarly, distance, time, and maximum speed on the Rota-Rod were significantly increased in pSBC-animals on DPI 7 (p < 0.01) and 14 (p < 0.01), as well as latency, distance, and mean number of errors in the BCM on DPI 14 (p < 0.01). The novel approach of pSBC was associated with improved neuromotor, sensormotor, and neurocognitive outcome after experimental TBI.	[Doll, Hinnerk; Truebel, Hubert; Kipfmueller, Florian; Wirth, Stefan] Univ Witten Herdecke, Dept Pediat, HELIOS, Klinikum Wuppertal, D-42283 Wuppertal, Germany; [Truebel, Hubert] Bayer HealthCare, Wuppertal, Germany; [Doll, Hinnerk; Schaefer, Ute; Neugebauer, Edmund A. M.; Maegele, Marc] Univ Witten Herdecke, IFOM, Cologne, Germany; [Maegele, Marc] Univ Witten Herdecke, CMMC, Dept Traumat & Orthopaed Surg, Cologne, Germany	Truebel, H (corresponding author), Univ Witten Herdecke, Dept Pediat, HELIOS, Klinikum Wuppertal, Heusnerstr 40, D-42283 Wuppertal, Germany.	hubert.trubel@yale.edu			Witten/Herdecke University (Germany)	The skillful illustrations and art work by Lukas Kretschmer and the technical assistance by Rainer Kobrich, Ph.D. (Maquet (R), Germany) and the research group of Prof. Zarnker at Witten/Herdecke University are greatly appreciated. This study was supported by a staff position (Rotationsstelle 2006) at the Witten/Herdecke University (Germany).	Alderson P, 2004, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001048.PUB2, 10.1002/14651858.CD001048.pub2]; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Bastian P, 2006, MOL CANCER RES, V4, P411, DOI 10.1158/1541-7786.MCR-06-0030; Bernard SA, 2003, CRIT CARE MED, V31, P2041, DOI 10.1097/01.CCM.0000069731.18472.61; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Davies A R, 2005, Crit Care Resusc, V7, P238; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gunn TR, 1999, PEDIATRICS, V103, P1079, DOI 10.1542/peds.103.5.1079; Harris BA, 2007, BRIT J ANAESTH, V98, P93, DOI 10.1093/bja/ael308; Holzer M, 2002, NEW ENGL J MED, V346, P549; Horn AR, 2006, SAMJ S AFR MED J, V96, P976; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Maegele M, 2007, EUR SURG RES, V39, P372, DOI 10.1159/000107097; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; Markgraf CG, 2001, J NEUROTRAUM, V18, P175, DOI 10.1089/08977150150502604; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mock C, 2004, LANCET, V363, P2172, DOI 10.1016/S0140-6736(04)16510-0; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Nantulya VM, 2002, BRIT MED J, V324, P1139, DOI 10.1136/bmj.324.7346.1139; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; Polderman KH, 2002, CRIT CARE MED, V30, P1932, DOI 10.1097/00003246-200208000-00058; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Reynolds JC, 2007, RESUSCITATION, V74, P13, DOI 10.1016/j.resuscitation.2006.10.032; Robertson CL, 2000, CRIT CARE MED, V28, P3218, DOI 10.1097/00003246-200009000-00017; Schafer S, 2008, DRUG DISCOV TODAY, V13, P913, DOI 10.1016/j.drudis.2008.03.026; Scott Eileen M, 2006, AORN J, V83, P1090, DOI 10.1016/S0001-2092(06)60120-8; Scott EM, 2006, AORN J, V83, P1107; SINSON G, 1995, J NEUROCHEM, V65, P2209; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Thoresen M, 2001, PEDIATR RES, V49, P594, DOI 10.1203/00006450-200104000-00024; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tooley JR, 2005, ARCH DIS CHILD-FETAL, V90, P262, DOI 10.1136/adc.2003.044305; Trubel H, 2004, INTENS CARE MED, V30, P1829, DOI 10.1007/s00134-004-2350-1; Trubel H, 2003, BIOMED TECH, V48, P298, DOI 10.1515/bmte.2003.48.11.298; Wen YS, 2005, J TRAUMA, V58, P577, DOI 10.1097/01.TA.0000152635.99243.30; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X	53	15	16	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2009	26	2					235	242		10.1089/neu.2008.0741			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	410NS	WOS:000263585100006	19196073				2021-06-18	
J	Palchak, MJ; Holmes, JF; Kuppermann, N				Palchak, Michael J.; Holmes, James F.; Kuppermann, Nathan			Clinician Judgment Versus a Decision Rule for Identifying Children at Risk of Traumatic Brain Injury on Computed Tomography After Blunt Head Trauma	PEDIATRIC EMERGENCY CARE			English	Article; Proceedings Paper	Annual Meeting of the Pediatric-Academic-Societies	MAY 01-04, 2004	San Francisco, CA	Pediat Acad Soc		head trauma; decision making	EMERGENCY PHYSICIANS; CANCER-RISKS; MANAGEMENT; RADIATION	Objective: To compare a decision rule with clinician judgment for identifying children at risk of traumatic brain injury (TBI) after blunt head trauma. Methods: We performed an observational study of children with blunt head trauma. Emergency department physicians documented suspicion for TBI before cranial computed tomography (CT), rating suspicion as very low, low, intermediate, or high. Our outcome variable was TBI on CT We compared clinician judgment (very low vs. higher suspicion) for TBI on CT with a decision rule derived from the same database. Results: Of 1865 children enrolled for whom physician suspicion was recorded, 1168 (62.6%) underwent CT and comprised the study Population. Eighty-nine (7.6%; 95% confidence interval [CI], 6.2% to 9.3%) of the 1168 had TBIs on CT. The decision rule had a sensitivity of 88 (98.9%) of 89 versus 84 (94.4%) of 89 for clinician judgment (difference, 4.5%; 95% CI, -0.9% to 9.9%). The specificity of the decision rule was 288 (26.7%) of 1079 versus 329 (30.5%) 1079 for clinician judgment (difference, 3.8%; 95% Cl, 0.5% to 7.1%). Application of the decision rule to the study population would have resulted in 289 (24.7%) fewer CT scans, although missing I child with a TBI (who was discharged home from the emergency department). Conclusions: A decision rule trended toward greater sensitivity than clinician judgment for identifying children with TBI on CT after blunt head trauma but was less specific. Because decisions to order cranial CT did not strictly follow clinician judgment, however, use of the decision rule would have resulted in less frequent use of CT.	[Kuppermann, Nathan] Univ Calif Davis, Med Ctr, Dept Emergency Med, Sacramento, CA 95817 USA; [Kuppermann, Nathan] Univ Calif Davis, Med Ctr, Dept Pediat, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med, Dept Emergency Med, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Dept Pediat, Davis, CA 95616 USA	Kuppermann, N (corresponding author), Univ Calif Davis, Med Ctr, Dept Emergency Med, PSSB 2110,2315 Stockton Blvd, Sacramento, CA 95817 USA.	nkuppermann@ucdavis.edu					Aitken ME, 1998, ARCH PEDIAT ADOL MED, V152, P1176; Bandiera G, 2003, ANN EMERG MED, V42, P395, DOI 10.1016/S0196-0644(03)00422-0; Bergman DA, 1999, PEDIATRICS, V104, P1407; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Brenner DJ, 2003, P NATL ACAD SCI USA, V100, P13761, DOI 10.1073/pnas.2235592100; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Graham ID, 1998, ACAD EMERG MED, V5, P134, DOI 10.1111/j.1553-2712.1998.tb02598.x; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; LANDIS JR, 1977, BIOMETRICS, V33, P174; *NAT CTR HLTH STAT, 2006, TRAUM BRAIN INJ US E; National Center for Injury Prevention and Control, 2002, TRAUM BRAIN INJ US A; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983	16	15	15	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	FEB	2009	25	2					61	65		10.1097/PEC.0b013e318196e9c0			5	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	408PA	WOS:000263445800001	19194349				2021-06-18	
J	Persaud-Sawin, DA; Banach, L; Harry, GJ				Persaud-Sawin, Dixie-Ann; Banach, Lynna; Harry, Gaylla Jean			Raft Aggregation with Specific Receptor Recruitment Is Required for Microglial Phagocytosis of A beta(42)	GLIA			English	Article						microglia; phagocytosis; rafts; CD36	TRAUMATIC BRAIN-INJURY; GPI-ANCHORED PROTEINS; AMYLOID BETA-PEPTIDE; ALZHEIMERS-DISEASE; LIPID RAFTS; MACROPHAGE PHAGOCYTOSIS; ANTIINFLAMMATORY DRUGS; SCAVENGER RECEPTOR; APOPTOTIC CELL; CD36	Microglial phagocytosis contributes to the maintenance of brain homeostasis. Mechanisms involved, however, remain unclear. Using A beta 42 solely as a stimulant, we provide novel insight into regulation of microglial phagocytosis by rafts. We demonstrate the existence of an A beta 42 threshold level of 250 pg/mL, above which microglial phagocytic function is impaired. Low levels of A beta 42 facilitate fluorescent bead uptake, whereas phagocytosis is inhibited when A beta 42 accumulates. We also show that region-specific raft clustering occurs before microglial phagocytosis. Low A beta 42 levels stimulated this type of raft aggregation, but high A beta 42 levels inhibited it. Additionally, treatment with high A beta 42 concentrations caused a redistribution of the raft structural. protein flotillin1 from low to higher density fractions along a sucrose gradient. This suggests a loss of raft structural integrity. Certain non-steroidal anti-inflammatory drugs, e.g., the cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs, celecoxib, raise A beta 42 levels. We demonstrated that prolonged celecoxib exposure can disrupt rafts in a manner similar to that seen in an elevated A beta 42 environment: abnormal raft aggregation and Flot1 distribution. This resulted in aberrant receptor recruitment to rafts and impaired receptor-mediated phagocytosis by microglial cells. Specifically, recruitment of the scavenger receptor CD36 to rafts during active phagocytosis was affected. Thus, we propose that maintaining raft integrity is crucial for determining microglial phagocytic outcomes and disease progression. (C) 2008 Wiley-Liss, Inc.	[Persaud-Sawin, Dixie-Ann] NIEHS, Neurobiol Lab, Neurotoxicol Grp, NIH, Res Triangle Pk, NC 27709 USA	Persaud-Sawin, DA (corresponding author), NIEHS, Neurobiol Lab, Neurotoxicol Grp, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	sawind@niehs.nih.gov			Division of Intramural Research of NIEHS (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1Z01ES101623-05]; NTEHS Chemistry Contract [10015-42-05]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [Z01ES101623] Funding Source: NIH RePORTER	Grant sponsor: Division of Intramural Research of NIEHS (NIH); Grant number: #1Z01ES101623-05; Grant sponsor: NTEHS Chemistry Contract; Grant number: #10015-42-05.	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Aronoff DM, 2004, J IMMUNOL, V173, P559, DOI 10.4049/jimmunol.173.1.559; Arvanitis DN, 2005, J NEUROCHEM, V94, P1696, DOI 10.1111/j.1471-4159.2005.03331.x; Babuke T, 2007, EUR J CELL BIOL, V86, P525, DOI 10.1016/j.ejcb.2007.03.003; Bamberger ME, 2003, J NEUROSCI, V23, P2665; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bottcher A, 2006, ARTHRITIS RHEUM-US, V54, P927, DOI 10.1002/art.21660; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Butovsky O, 2005, MOL CELL NEUROSCI, V29, P381, DOI 10.1016/j.mcn.2005.03.005; Chan WY, 2007, BRAIN RES REV, V53, P344, DOI 10.1016/j.brainresrev.2006.11.002; Cheng JL, 2006, BIOCHEM BIOPH RES CO, V351, P246, DOI 10.1016/j.bbrc.2006.10.042; Chung HY, 1999, J BIOL CHEM, V274, P32301, DOI 10.1074/jbc.274.45.32301; Ciesielski-Treska J, 2004, GLIA, V46, P101, DOI 10.1002/glia.10363; Coraci IS, 2002, AM J PATHOL, V160, P101, DOI 10.1016/S0002-9440(10)64354-4; Coras R, 2007, MOL CANCER THER, V6, P1745, DOI 10.1158/1535-7163.MCT-06-0763; Cuzzocrea S, 2002, BIOCHEM PHARMACOL, V63, P785, DOI 10.1016/S0006-2952(01)00908-X; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; El Khoury JB, 2003, J EXP MED, V197, P1657, DOI 10.1084/jem.20021546; Eto M, 2003, EUR J NEUROSCI, V17, P2659, DOI 10.1046/j.1460-9568.2003.02711.x; Fantini Jacques, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S1462399402005392; Fiala M, 2005, J ALZHEIMERS DIS, V7, P221, DOI 10.3233/jad-2005-7304; Fullekrug J, 2004, ANN NY ACAD SCI, V1014, P164, DOI 10.1196/annals.1294.017; Gamerdinger M, 2007, MOL PHARMACOL, V72, P141, DOI 10.1124/mol.107.034009; Gasparini L, 2004, J NEUROCHEM, V91, P521, DOI 10.1111/j.1471-4159.2004.02743.x; Gregory CD, 2004, IMMUNOLOGY, V113, P1, DOI 10.1111/j.1365-2567.2004.01959.x; Griffin WST, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-5; Hancock JF, 2006, NAT REV MOL CELL BIO, V7, P456, DOI 10.1038/nrm1925; Hashimoto M, 2003, J NEUROCHEM, V85, P1468, DOI 10.1046/j.1471-4159.2003.01791.x; Hull M, 2006, NEUROCHEM INT, V48, P663, DOI 10.1016/j.neuint.2005.08.013; Janich P, 2007, FEBS LETT, V581, P1783, DOI 10.1016/j.febslet.2007.03.065; Johnson AJ, 2002, BIOCHEM J, V366, P831, DOI 10.1042/BJ20020279; Kaisho T, 2006, J ALLERGY CLIN IMMUN, V117, P979, DOI 10.1016/j.jaci.2006.02.023; Kay JG, 2006, J BIOL CHEM, V281, P11949, DOI 10.1074/jbc.M600857200; KEYSTONE EC, 1977, ARTHRITIS RHEUM, V20, P1396, DOI 10.1002/art.1780200714; Kim HY, 2006, J BIOL CHEM, V281, P11872, DOI 10.1074/jbc.M511706200; Koenigsknecht J, 2004, J NEUROSCI, V24, P9838, DOI 10.1523/JNEUROSCI.2557-04.2004; Koenigsknecht-Talboo J, 2005, J NEUROSCI, V25, P8240, DOI 10.1523/JNEUROSCI.1808-05.2005; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; KOROTZER AR, 1993, BRAIN RES, V624, P121, DOI 10.1016/0006-8993(93)90068-X; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Krysko DV, 2006, APOPTOSIS, V11, P1709, DOI 10.1007/s10495-006-9527-8; Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235; Kunjathoor VV, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-23; Kusumi A, 2004, TRAFFIC, V5, P213, DOI 10.1111/j.1600-0854.2004.0178.x; Langhorst MF, 2005, CELL MOL LIFE SCI, V62, P2228, DOI 10.1007/s00018-005-5166-4; Leuchtenberger S, 2006, CURR PHARM DESIGN, V12, P4337, DOI 10.2174/138161206778793029; Lingwood D, 2007, NAT PROTOC, V2, P2159, DOI 10.1038/nprot.2007.294; Liu H, 2007, CELL BIOL INT, V31, P508, DOI 10.1016/j.cellbi.2006.11.018; Liu Y, 2005, BRAIN, V128, P1778, DOI 10.1093/brain/awh531; Lucas M, 2006, J IMMUNOL, V177, P4047, DOI 10.4049/jimmunol.177.6.4047; Macdonald JL, 2005, J LIPID RES, V46, P1061, DOI 10.1194/jlr.D400041-JLR200; Makranz C, 2006, GLIA, V53, P441, DOI 10.1002/glia.20303; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Mitrasinovic OM, 2002, J BIOL CHEM, V277, P29889, DOI 10.1074/jbc.M200868200; Monaco S, 2006, CURR MED CHEM, V13, P1903, DOI 10.2174/092986706777585022; Moore KJ, 2002, J BIOL CHEM, V277, P47373, DOI 10.1074/jbc.M208788200; Nair P, 2006, NUTR HOSP, V21, P638; Nixon RA, 2007, J CELL SCI, V120, P4081, DOI 10.1242/jcs.019265; O'Banion MK, 1997, ADV EXP MED BIOL, V433, P177; O'Brien BA, 2002, DIABETES, V51, P2481, DOI 10.2337/diabetes.51.8.2481; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; PARK JY, 2008, IMPLICATIONS PARKINS, V56, P1215; Persaud-Sawin DA, 2004, PEDIATR RES, V56, P449, DOI 10.1203/01.PDR.0000136152.54638.95; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; Puglielli L, 2008, NEUROBIOL AGING, V29, P795, DOI 10.1016/j.neurobiolaging.2007.01.010; Quintana A, 2008, DEV NEUROBIOL, V68, P195, DOI 10.1002/dneu.20584; Reddy SM, 2002, J IMMUNOL, V169, P702, DOI 10.4049/jimmunol.169.2.702; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; Ricciarelli R, 2004, FREE RADICAL BIO MED, V36, P1018, DOI 10.1016/j.freeradbiomed.2004.01.007; Rogers J, 2002, GLIA, V40, P260, DOI 10.1002/glia.10153; Sadowski MJ, 2006, P NATL ACAD SCI USA, V103, P18787, DOI 10.1073/pnas.0604011103; Salman H, 1999, CANCER LETT, V147, P175, DOI 10.1016/S0304-3835(99)00290-6; Seitz HM, 2007, J IMMUNOL, V178, P5635, DOI 10.4049/jimmunol.178.9.5635; Selkoe DJ, 2001, J ALZHEIMERS DIS, V3, P75, DOI 10.3233/JAD-2001-3111; Seveau S, 2001, MOL BIOL CELL, V12, P3550, DOI 10.1091/mbc.12.11.3550; Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9; Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468; Simons K, 2000, TRENDS CELL BIOL, V10, P459, DOI 10.1016/S0962-8924(00)01847-X; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Stipursky J, 2007, GLIA, V55, P1023, DOI 10.1002/glia.20522; Streit WJ, 2005, NEUROL RES, V27, P685, DOI 10.1179/016164105X49463; Streit WJ, 2006, TRENDS NEUROSCI, V29, P506, DOI 10.1016/j.tins.2006.07.001; Stuart LM, 2007, J BIOL CHEM, V282, P27392, DOI 10.1074/jbc.M702887200; Sue W, 2006, AM J CLIN NUTR, V83, p470S; Swanson JA, 1999, J CELL SCI, V112, P307; Tahara K, 2006, BRAIN, V129, P3006, DOI 10.1093/brain/awl249; Thorne RF, 2000, J BIOL CHEM, V275, P35264, DOI 10.1074/jbc.M003969200; Thorne RF, 2006, BIOCHEM BIOPH RES CO, V351, P51, DOI 10.1016/j.bbrc.2006.09.156; Tian TH, 2007, NAT CELL BIOL, V9, P905, DOI 10.1038/ncb1615; Tohyama Y, 2006, IUBMB LIFE, V58, P304, DOI 10.1080/15216540600746377; Triantafilou M, 2006, J BIOL CHEM, V281, P31002, DOI 10.1074/jbc.M602794200; Urano Y, 2005, J LIPID RES, V46, P904, DOI 10.1194/jlr.M400333-JLR200; Wang RB, 2006, J SURG RES, V136, P58, DOI 10.1016/j.jss.2006.06.003; Wang YJ, 2006, DRUG DISCOV TODAY, V11, P931, DOI 10.1016/j.drudis.2006.08.004; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com	100	15	16	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	FEB	2009	57	3					320	335		10.1002/glia.20759			16	Neurosciences	Neurosciences & Neurology	392BF	WOS:000262277200008	18756527	Green Accepted			2021-06-18	
J	Gregory, NG; Spence, JY; Mason, CW; Tinarwo, A; Heasman, L				Gregory, N. G.; Spence, J. Y.; Mason, C. W.; Tinarwo, A.; Heasman, L.			Effectiveness of poll stunning water buffalo with captive bolt guns	MEAT SCIENCE			English	Article						Captive bolt; Gun; Stunning; Water buffalo; Slaughter; Concussion; Abattoir		Practical experience has indicated that shooting water buffalo with a captive bolt gun in the front of the head does not always produce an effective stun. Slaughtermen have been claiming that the poll position is more reliable, but under present EU regulations this shooting position is not allowed for domesticated bovines. This study examined the effectiveness of shooting water buffalo with captive bolt guns in the poll region. The depth of concussion was assessed in 30 water buffalo from physical collapse, presence or absence of corneal and palpebral reflexes, normal rhythmic breathing, eyeball rotation, nystagmus and whether the animal was re-shot. All except one animal collapsed immediately. The one animal that failed to collapse was not breathing. The prevalence of a shallow depth of concussion in the poll shot animals was 53%. Two had been shot through the spinal cord, and with the exception of those plus one other in which the bolt did not penetrate the brain, the other animals were considered to be adequately stunned. Post mortem examination of the brain showed that 79% of the under thirty month old animals were shot in the midbrain or brain stem, but these regions had to be avoided in over thirty month old animals because of the risk of damaging the brain stem sample needed for BSE testing, In addition, three water buffalo were shot in the crown position and one in the front of the head. The frontal position was ineffective as the animal did not collapse, and all animals shot in the crown position resumed breathing shortly after shooting, indicating a shallow depth of concussion. It is concluded that poll shooting can be effective in water buffalo, but it produces a shallow depth of concussion compared with frontal shooting in cattle. It requires accurate placement of the gun to ensure that buffalo are not shot through the spinal cord instead of the brain. Vigilance is needed in ensuring that the animals are stuck Promptly so that none recover consciousness. (C) 2008 Elsevier Ltd. All rights reserved.	[Gregory, N. G.] BBSRC, Hatfield AL9 7TA, Herts, England; [Spence, J. Y.; Mason, C. W.; Tinarwo, A.] Humane Slaughter Assoc, Old Sch, Wheathampstead AL4 8AN, England; [Heasman, L.] Westpoint Vet Grp, Warnham RH12 3SH, England; [Gregory, N. G.] Univ London Royal Vet Coll, Hatfield AL9 7TA, Herts, England	Gregory, NG (corresponding author), BBSRC, Hawkshead Lane, Hatfield AL9 7TA, Herts, England.	ngregory@rvc.ac.uk		Tinarwo, Ambrose/0000-0002-3699-3599	Scottish Executive Environment and Rural Affairs Department	This work was supported by the Scottish Executive Environment and Rural Affairs Department. We wish to thank the abattoirs and their staff for their assistance with this work, and Frances Moreno and Mar Alonso of the Meat Hygiene Service for help in establishing the trials.	ARNE L, 1975, HDB CLIN NEUROLOGY, V23, P459; CURRIER RD, 1969, HDB CLIN NEUROLOGY, V2, P217; DALY CC, 1986, HUMANE SLAUGHTER ANI, P15; FORSTER S, 2007, BETABUNG WASSERBUFFE; Gregory NG, 2008, MEAT SCI, V80, P2, DOI 10.1016/j.meatsci.2008.05.019; Gregory NG, 2007, MEAT SCI, V77, P499, DOI 10.1016/j.meatsci.2007.04.026; MEYER F, 2005, RUNDSCHAU FLEISCHHYG, P248; OMAE T, 1989, HDB CLIN NEUROLOGY, V54, P287; SAPER CB, 1985, HDB CLIN NEUROLOGY, V45, P107	9	15	16	0	51	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0309-1740			MEAT SCI	Meat Sci.	JAN	2009	81	1					178	182		10.1016/j.meatsci.2008.07.016			5	Food Science & Technology	Food Science & Technology	372UU	WOS:000260928300024	22063979				2021-06-18	
J	Johnstone, B; Yoon, DP; Rupright, J; Reid-Arndt, S				Johnstone, Brick; Yoon, Dong Pil; Rupright, Jon; Reid-Arndt, Stephanie			Relationships among spiritual beliefs, religious practises, congregational support and health for individuals with traumatic brain injury	BRAIN INJURY			English	Article						Religion; spirituality; rehabilitation; traumatic brain injury; Brief Multidimensional Measure of Religiousness; Spirituality	QUALITY-OF-LIFE; MEDICAL REHABILITATION; OUTCOMES; FORGIVENESS; PREDICTORS; PAIN	Objective: To determine relationships among spiritual beliefs, religious practises, congregational support and health for individuals with traumatic brain injury (TBI). Design: A cross-sectional analysis of 61 individuals with TBI evaluated in an outpatient clinic using the Brief Multidimensional Measure of Religiousness/Spirituality (BMMRS) and the Medical Outcomes Scale-Short Form 36 (SF-36). Results: For persons with TBI the BMMRS Meaning and Values/Beliefs sub-scales were significantly correlated with the SF-36 General Health Perception sub-scale and the BMMRS Religious Support sub-scale was significantly correlated with the SF-36 General Mental Health sub-scale. Hierarchical regressions indicated that the BMMRS Values/Beliefs and Forgiveness sub-scales accounted for 16% additional variance in SF-36 General Health Perception scores beyond that accounted for by demographic variables (i.e. age, income); no BMMRS sub-scales accounted for additional variance in predicting the SF-36 General Mental Health sub-scale beyond that accounted for by demographic variables (i.e. age, income). Conclusions: The physical health of individuals with TBI is associated with spiritual beliefs but not religious practises or congregational support. Better mental health is associated with increasing congregationally based social support for persons with TBI. Religious practises (i.e. praying, etc.) are not related to either physical or mental health, as some persons with TBI may increase prayer with declining health status.	[Johnstone, Brick; Reid-Arndt, Stephanie] Univ Missouri, Dept Hlth Psychol, Columbia, MO 65212 USA; [Yoon, Dong Pil] Univ Missouri, Sch Social Work, Columbia, MO 65212 USA; [Rupright, Jon] Univ Missouri, Dept Phys Med & Rehabil, Columbia, MO 65212 USA	Johnstone, B (corresponding author), Univ Missouri, Dept Hlth Psychol, DC116-88, Columbia, MO 65212 USA.	johnstoneg@health.missouri.edu		Johnstone, Brick/0000-0001-8845-9649	Centre on Religion; Professions at the University of Missouri; Pew Charitable Trusts	This article was supported with funding from the Centre on Religion and the Professions at the University of Missouri, funded by the Pew Charitable Trusts.	Baskin TW, 2004, J COUNS DEV, V82, P79, DOI 10.1002/j.1556-6678.2004.tb00288.x; Carson JW, 2005, J PAIN, V6, P84, DOI 10.1016/j.jpain.2004.10.012; Cigrang JA, 2003, J CLIN PSYCHOL MED S, V10, P133, DOI 10.1023/A:1025494309495; COHEN S, 2002, LINK RELIG HLTH PSYC, P101; Fetzer Institute & National Institute on Aging Working Group, 1999, MULT MEAS REL SPIR U; Fitchett G, 1999, REHABIL PSYCHOL, V44, P333, DOI 10.1037//0090-5550.44.4.333; Forchheimer M, 2004, AM J PHYS MED REHAB, V83, P390, DOI 10.1097/01.PHM.0000124441.78275.C9; Haley KC, 2001, J RELIG HEALTH, V40, P305, DOI 10.1023/A:1012561909054; Hart T, 2007, REHABIL PSYCHOL, V52, P152, DOI 10.1037/0090-5550.52.2.152; Herrmann M, 2000, DISABIL REHABIL, V22, P539, DOI 10.1080/096382800416788; Idler EL, 2003, RES AGING, V25, P327, DOI 10.1177/0164027503025004001; Idler EL, 1997, J GERONTOL B-PSYCHOL, V52, pS306, DOI 10.1093/geronb/52B.6.S306; JOHNSTONE B, J RELIG HLT IN PRESS; Johnstone B, 2007, DISABIL REHABIL, V29, P1153, DOI 10.1080/09638280600955693; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; Kilpatrick SD, 1999, REHABIL PSYCHOL, V44, P388, DOI 10.1037/0090-5550.44.4.388; Kim J, 2000, REHABIL PSYCHOL, V45, P365, DOI 10.1037/0090-5550.45.4.365; Knight JR, 2007, SOUTH MED J, V100, P349, DOI 10.1097/SMJ.0b013e3180316a32; Koenig H.G., 2001, HDB RELIG HLTH; Koeske, 2006, INT J PSYCHOL RELIG, V16, DOI [https://doi.org/10.1207/s15327582ijpr1603_3, DOI 10.1207/S15327582IJPR1603_3, 10.1207/s15327582ijpr1603_3]; Mahalik J, 2007, J RELIG DISABIL HLTH, V11, P65; McColl MA, 2000, DISABIL REHABIL, V22, P555, DOI 10.1080/096382800416805; McCullough ME, 2001, CURR DIR PSYCHOL SCI, V10, P194, DOI 10.1111/1467-8721.00147; McNamara Patrick, 2006, Neuropsychiatr Dis Treat, V2, P341, DOI 10.2147/nedt.2006.2.3.341; Miller WR, 2003, AM PSYCHOL, V58, P24, DOI 10.1037/0003-066X.58.1.24; Neff JA, 2006, J SCI STUD RELIG, V45, P449, DOI 10.1111/j.1468-5906.2006.00318.x; Pargament K.I., 1998, HDB RELIG MENTAL HLT, P111, DOI [10.1016/B978-012417645-4/50075-4, DOI 10.1016/B978-012417645-4/50075-4]; PARGAMENT KI, 1994, J SCI STUD RELIG, V33, P347, DOI 10.2307/1386494; Pargament KI, 1995, J SOC ISSUES, V51, P13, DOI 10.1111/j.1540-4560.1995.tb01321.x; PARGAMENT KI, 1990, AM J COMMUN PSYCHOL, V18, P793, DOI 10.1007/BF00938065; Piedmont R. L., 2007, RES SOCIAL SCI STUDY, V17, P177; Powell LH, 2003, AM PSYCHOL, V58, P36, DOI 10.1037/0003-066X.58.1.36; Powell T, 2007, BRAIN INJURY, V21, P31, DOI 10.1080/02699050601106245; Pruchno RA, 2006, MED DECIS MAKING, V26, P112, DOI 10.1177/0272989X06286482; Ray O, 2004, AM PSYCHOL, V59, P29, DOI 10.1037/0003-066X.59.1.29; Rippentrop AE, 2005, PAIN, V116, P311, DOI 10.1016/j.pain.2005.05.008; Seybold KS, 2001, CURR DIR PSYCHOL SCI, V10, P21, DOI 10.1111/1467-8721.00106; Sloan RP, 1999, LANCET, V353, P664, DOI 10.1016/S0140-6736(98)07376-0; Tartaro J, 2005, J HEALTH PSYCHOL, V10, P753, DOI 10.1177/1359105305057311; TASKER SL, 2003, ILLNESS CRISIS LOSS, V11, P337, DOI DOI 10.1177/1054137303256585; Tate DG, 2002, AM J PHYS MED REHAB, V81, P400, DOI 10.1097/00002060-200206000-00002; UnderwoodGordon L, 1997, AM J PHYS MED REHAB, V76, P255, DOI 10.1097/00002060-199705000-00021; Ware JE., 1993, SF 36 HLTH SURVEY MA	43	15	17	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	5					411	419	PII 909745375	10.1080/02699050902788501			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	439NL	WOS:000265633700005	19306162				2021-06-18	
J	Katz-Leurer, M; Rotem, H; Keren, O; Meyer, S				Katz-Leurer, Michal; Rotem, Hemda; Keren, Ofer; Meyer, Shirley			The relationship between step variability, muscle strength and functional walking performance in children with post-traumatic brain injury	GAIT & POSTURE			English	Article						Children; Traumatic brain injury; Gait; Variability; Muscle strength	CEREBRAL-PALSY; GAIT VARIABILITY; SCALE; YOUNG; COST	The objective of this study was to investigate the association between step variability, muscle strength and functional walking performance in children post-traumatic brain injury (TBI) and typically developed (TD) children. A convenience sample of 16 children post-TBI and 16 TD age and sex matched controls participated in this cross sectional study. The main outcome measures included step length and step time variability, measured with an electronic walkway, strength of four lower-extremity muscle groups, tested bilaterally with a hand held dynamometer, walking performance as assessed by the 2-min walk test, energy expenditure index (EEI) and rating of perceived exertion (OMNI scale). Significant differences were found in walking parameters between the groups (e.g., 2-min walk test: TBI 109 +/- 31 compared to TD 168 +/- 19 m). Children post-TBI had significantly greater variability in step time and step length in comparison to TD controls (e.g., step length variability: TBI 16.3 +/- 13.6 compared to TD 4.9 +/- 2.0). TD children had significantly higher mean strength values than children post-TBI in the knee extensor and hip abductor muscle groups (p < 0.05). The 2-min walk test correlated inversely with the step time and length variability only among children post-TBI while muscle strength values correlated positively with the 2-min walk test only in TD children. This study found that step time and length variability and lower-extremity muscle strength correlated differently to distance covered during the 2-min walk test among children post-TBI and among TD children. (C) 2008 Elsevier B.V. All rights reserved.	[Katz-Leurer, Michal] Tel Aviv Univ, Sch Hlth Profess, Sackler Fac Med, Phys Therapy Dept, IL-69978 Tel Aviv, Israel; [Katz-Leurer, Michal; Rotem, Hemda; Keren, Ofer; Meyer, Shirley] Alyn Childrens Orthoped Hosp & Rehabil Ctr, Jerusalem, Israel	Katz-Leurer, M (corresponding author), Tel Aviv Univ, Sch Hlth Profess, Sackler Fac Med, Phys Therapy Dept, IL-69978 Tel Aviv, Israel.	michalkz@post.tau.ac.il					Crompton J, 2007, DEV MED CHILD NEUROL, V49, P106, DOI 10.1111/j.1469-8749.2007.00106.x; Damiano DL, 1998, ARCH PHYS MED REHAB, V79, P119, DOI 10.1016/S0003-9993(98)90287-8; Hausdorff JM, 1999, J APPL PHYSIOL, V86, P1040; Hausdorff JM, 1998, MOVEMENT DISORD, V13, P428, DOI 10.1002/mds.870130310; Katz-Leurer M, 2008, BRAIN INJURY, V22, P153, DOI 10.1080/02699050801895399; Kosak M, 2005, J REHABIL RES DEV, V42, P103, DOI 10.1682/JRRD.2003.11.0171; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Leitner Y, 2007, J NEUROL, V254, P1330, DOI 10.1007/s00415-006-0522-3; Littlewood RA, 2004, CLIN NUTR, V23, P99, DOI 10.1016/S0261-5614(03)00100-6; Livingstone MBE, 2000, MED SCI SPORT EXER, V32, P1513, DOI 10.1097/00005768-200008000-00022; Provost Beth, 2007, Pediatr Phys Ther, V19, P2, DOI 10.1097/01.pep.0000249418.25913.a3; Robertson RJ, 2006, MED SCI SPORT EXER, V38, P158, DOI 10.1249/01.mss.0000190595.03402.66; Rosano C, 2007, NEUROEPIDEMIOLOGY, V29, P193, DOI 10.1159/000111582; Taylor NF, 2004, ARCH PHYS MED REHAB, V85, P77, DOI 10.1016/S0003-9993(03)00379-4; TEASDALE G, 1974, LANCET, V2, P81; Thies SB, 2005, GAIT POSTURE, V22, P26, DOI 10.1016/j.gaitpost.2004.06.004; Thorpe DE, 2005, ARCH PHYS MED REHAB, V86, P2342, DOI 10.1016/j.apmr.2005.07.301; ZARRUGH MY, 1978, EUR J APPL PHYSIOL O, V38, P215, DOI 10.1007/BF00430080	18	15	15	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362			GAIT POSTURE	Gait Posture	JAN	2009	29	1					154	157		10.1016/j.gaitpost.2008.06.013			4	Neurosciences; Orthopedics; Sport Sciences	Neurosciences & Neurology; Orthopedics; Sport Sciences	396LC	WOS:000262592200029	18701292				2021-06-18	
J	Moochhala, S; Wu, J; Lu, J				Moochhala, Shabbir; Wu, Jian; Lu, Jia			Hemorrhagic shock: an overview of animal models	FRONTIERS IN BIOSCIENCE-LANDMARK			English	Article						Hemorrhagic Shock; Animal Models; Review	TRAUMATIC BRAIN-INJURY; 3-PERCENT HYPERTONIC SALINE; UNCONTROLLED HEMORRHAGE; FLUID RESUSCITATION; SURVIVAL-TIME; PORCINE MODEL; RODENT MODEL; RAT MODEL; HEPATOCELLULAR FUNCTION; REGIONAL HEMODYNAMICS	Extensive efforts have been made to try to elucidate the pathophysiological mechanisms and the immunologic alterations associated with severe hemorrhage. A broad variety of experimental conditions have been established that enable investigators to study the effects of hypovolemic shock and to assess the potential benefits of a wide spectrum of treatment options. However, translating these experimental findings into clinically applicable therapy has been challenging, suggesting the need for a better understanding of the animal models being used. As certain advantages and disadvantages are associated with the different models of hemorrhage (such as controlled and uncontrolled hemorrhagic shock and combined trauma with hemorrhagic shock models, for this review, we have selected representative studies that reflect the current status of experimental shock research that looks at acute blood loss, and that may serve as a guide when considering which model or models to apply	[Moochhala, Shabbir; Wu, Jian; Lu, Jia] Def Med & Environm Res Inst, DSO Natl Labs Kent Ridge, Combat Casualty Care Programme, Combat Care Lab, Singapore 117510, Singapore	Moochhala, S (corresponding author), Def Med & Environm Res Inst, DSO Natl Labs Kent Ridge, Combat Casualty Care Programme, Combat Care Lab, 27 Med Dr, Singapore 117510, Singapore.	mshabbir@dso.org.sg		MOOCHHALA, SHABBIR/0000-0003-4521-3192			Alam HB, 2002, J TRAUMA, V52, P18, DOI 10.1097/00005373-200201000-00006; Alkan A, 2006, EUR J EMERG MED, V13, P281, DOI 10.1097/00063110-200610000-00007; Atan MS, 2004, J NEUROSURG, V101, P138, DOI 10.3171/jns.2004.101.1.0138; Awasthi V, 2007, J APPL PHYSIOL, V103, P28, DOI 10.1152/japplphysiol.00136.2006; Batchinsky AI, 2007, CRIT CARE MED, V35, P519, DOI 10.1097/01.CCM.0000254065.44990.77; BELLAMY RF, 1984, MIL MED, V149, P55; Bruscagin V, 2002, J TRAUMA, V52, P1147, DOI 10.1097/00005373-200206000-00021; Bruttig SP, 2005, SHOCK, V24, P92, DOI 10.1097/01.shk.0000168872.37660.d2; Burris D, 1999, J TRAUMA, V46, P216, DOI 10.1097/00005373-199902000-00003; Cabrales P, 2007, SHOCK, V27, P380, DOI 10.1097/01.shk.0000239782.71516.ba; Cheung ATW, 2007, ARTIF CELL BLOOD SUB, V35, P173, DOI 10.1080/10731190601188257; Cheung AT, 2006, CLIN HEMORHEOL MICRO, V34, P325; Chiara O, 2003, CRIT CARE MED, V31, P1915, DOI 10.1097/01.CCM.0000074725.62991.42; Coimbra R, 1997, J TRAUMA, V42, P602, DOI 10.1097/00005373-199704000-00004; Cooper ES, 2007, CRIT CARE MED, V35, P1724, DOI 10.1097/01.CCM.0000266590.25109.F2; Drobin D, 2005, J TRAUMA, V59, P976, DOI 10.1097/01.ta.0000178902.24330.f5; FJITZPATRICK CM, 2005, J TRAUMA, V59, P273; Fujiyoshi N, 2006, SURGERY, V140, P810, DOI 10.1016/j.surg.2006.03.003; Garcia-Martinez D, 2006, SHOCK, V26, P379, DOI 10.1097/01.shk.0000226339.48033.8b; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Hall C, 2007, ARTIF CELL BLOOD SUB, V35, P259, DOI 10.1080/10731190701378568; HAUSER GJ, 1995, RES COMMUN MOL PATH, V90, P289; Hermann J, 2007, ANESTHESIOLOGY, V107, P273, DOI 10.1097/01.anes.0000270756.11669.64; Josephsen GD, 2005, MICROSC MICROANAL, V11, P500, DOI 10.1017/S1431927605050567; Kaplan LJ, 2006, J TRAUMA, V61, P90, DOI 10.1097/01.ta.0000222578.85413.4e; Kauvar DS, 2006, J AM COLL SURGEONS, V202, P888, DOI 10.1016/j.jamcollsurg.2006.03.003; Kentner R, 2007, RESUSCITATION, V72, P295, DOI 10.1016/j.resuscitation.2006.05.025; Kerby JD, 2007, SHOCK, V27, P652, DOI 10.1097/01.shk.0000248584.10400.dc; Krausz MM, 2000, SHOCK, V13, P230, DOI 10.1097/00024382-200003000-00010; Krismer AC, 2006, CRIT CARE MED, V34, P2175, DOI 10.1097/01.CCM.0000229886.98002.2B; Kudo Y, 2006, CRIT CARE MED, V34, P2820, DOI 10.1097/01.CCM.0000242522.48734.64; Kuebler JF, 2001, J SURG RES, V97, P196, DOI 10.1006/jsre.2001.6155; Lee J, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2715189; Lin T, 2007, SURGERY, V141, P784, DOI 10.1016/j.surg.2007.01.014; LONGNECKER DE, 1976, ANESTHESIOLOGY, V45, P516; LONGNECKER DE, 1982, ANESTHESIOLOGY, V57, P177, DOI 10.1097/00000542-198209000-00006; Macias CA, 2007, ANN SURG, V245, P305, DOI 10.1097/01.sla.0000236626.57752.8e; Norio H, 2002, J TRAUMA, V52, P1056, DOI 10.1097/00005373-200206000-00006; PAGEL PS, 1991, ANESTHESIOLOGY, V74, P539, DOI 10.1097/00000542-199103000-00024; PAGEL PS, 1991, ANESTHESIOLOGY, V74, P900, DOI 10.1097/00000542-199105000-00016; Paran H, 2005, AM J SURG, V190, P463, DOI 10.1016/j.amjsurg.2005.03.032; Pinto FCG, 2006, J TRAUMA, V60, P758, DOI 10.1097/01.ta.0000214581.89316.73; Poloujadoff MP, 2007, ANESTHESIOLOGY, V107, P591, DOI 10.1097/01.anes.0000281926.54940.6a; Puig NR, 2002, INT IMMUNOPHARMACOL, V2, P95, DOI 10.1016/S1567-5769(01)00151-5; Raddatz A, 2006, AM J RESP CRIT CARE, V174, P198, DOI 10.1164/rccm.200508-1221OC; Raman KG, 2006, AM J PHYSIOL-GASTR L, V291, pG556, DOI 10.1152/ajpgi.00055.2006; Reynolds PS, 2007, SHOCK, V28, P45, DOI 10.1097/shk.0b013e31802eb779; Riddez L, 2002, SHOCK, V17, P377, DOI 10.1097/00024382-200205000-00006; Rupani B, 2007, SURGERY, V141, P481, DOI 10.1016/j.surg.2006.10.008; Rushing GD, 2006, ANN SURG, V243, P652, DOI 10.1097/01.sla.0000216759.36819.1b; Sanui M, 2006, CRIT CARE MED, V34, P433, DOI 10.1097/01.CCM.0000196206.83534.39; SAWYER DC, 1971, J APPL PHYSIOL, V30, P36; Schulman AM, 2003, J TRAUMA, V55, P298, DOI 10.1097/01.TA.0000028970.50515.A0; SEYDE WC, 1984, ANESTHESIOLOGY, V61, P686, DOI 10.1097/00000542-198412000-00010; SEYDE WC, 1985, AM J PHYSIOL, V249, pH164; Shah KJ, 2002, SHOCK, V18, P242, DOI 10.1097/00024382-200209000-00007; Shirhan M, 2004, LIFE SCI, V76, P661, DOI 10.1016/j.lfs.2004.07.015; Sinert R, 2005, ACAD EMERG MED, V12, P1141, DOI [10.1111/j.1553-2712.2005.tb01488.x, 10.1197/j.aem.2005.07.016]; Solomonov E, 2000, CRIT CARE MED, V28, P749, DOI 10.1097/00003246-200003000-00024; Sondeen JL, 2004, SHOCK, V22, P163, DOI 10.1097/01.shk.0000129202.76706.bd; Stapley SA, 2002, SHOCK, V17, P146, DOI 10.1097/00024382-200202000-00011; Stepaniak PC, 2007, AVIAT SPACE ENVIR MD, V78, pA14; Stern SA, 2000, SHOCK, V14, P616, DOI 10.1097/00024382-200014060-00008; Stern SA, 2000, ACAD EMERG MED, V7, P847, DOI 10.1111/j.1553-2712.2000.tb02060.x; Suzuki T, 2006, CYTOKINE, V34, P76, DOI 10.1016/j.cyto.2006.04.007; Szalay L, 2006, AM J PHYSIOL-REG I, V290, pR812, DOI 10.1152/ajpregu.00658.2005; Takasu A, 2002, RESUSCITATION, V54, P303, DOI 10.1016/S0300-9572(02)00148-X; Takasu A, 2006, J TRAUMA, V61, P1330, DOI 10.1097/01.ta.0000245980.12711.6a; Toda Y, 2007, INT J MOL MED, V19, P237; Todd SR, 2007, J TRAUMA, V62, P636, DOI 10.1097/TA.0b013e31802ee521; Varela JE, 2003, SHOCK, V20, P476, DOI 10.1097/01.SHK.0000094036.09886.9b; Voelckel WG, 2003, CRIT CARE MED, V31, P1160, DOI 10.1097/01.CCM.0000060014.75282.69; Watters JM, 2006, J TRAUMA, V61, P75, DOI 10.1097/01.ta.0000222723.54559.47; WEISKOPF RB, 1981, ANESTH ANALG, V60, P481; Westphal G, 2007, ARTIF ORGANS, V31, P284, DOI 10.1111/j.1525-1594.2007.00377.x; Wettstein R, 2003, CRIT CARE MED, V31, P1824, DOI 10.1097/01.CCM.0000069340.16319.F2; Wichmann MW, 1996, J SURG RES, V63, P256, DOI 10.1006/jsre.1996.0257; WIGGERS CJ, 1950, PHYSL SHOCK; Yang RJ, 2006, J TRAUMA, V61, P1343, DOI 10.1097/01.ta.0000222955.14191.08; Yang RK, 2006, MOL MED, V12, P105, DOI 10.2119/2006-00010.Yang; Yang SB, 2003, IEE P-VIS IMAGE SIGN, V150, P6, DOI 10.1049/ip-vis:20030165; Yannopoulos D, 2007, ANESTH ANALG, V104, P157, DOI 10.1213/01.ane.0000249047.80184.5a; Young MA, 2005, CRIT CARE MED, V33, P1794, DOI 10.1097/01.CCM.0000172648.55309.13	83	15	18	0	14	FRONTIERS IN BIOSCIENCE INC	IRVINE	16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA	1093-9946	1093-4715		FRONT BIOSCI-LANDMRK	Front. Biosci.	JAN	2009	14						4631	4639		10.2741/3555			9	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	497LM	WOS:000270060800071	19273377				2021-06-18	
J	Muccio, CF; De Simone, M; Esposito, G; De Blasio, E; Vittori, C; Cerase, A				Muccio, Carmine Franco; De Simone, Marta; Esposito, Gennaro; De Blasio, Elvio; Vittori, Cesare; Cerase, Alfonso			Reversible post-traumatic bilateral extensive restricted diffusion of the brain. A case study and review of the literature	BRAIN INJURY			English	Article; Proceedings Paper	22nd Congress of the Associazione-Italiana-di-Neuroradiologia	OCT 04-06, 2006	Milan, ITALY	Assoc Italiana Neuroradiol		Apparent diffusion coefficient; diffusion weighted imaging; excitotoxic injury; magnetic resonance imaging; reversible restricted diffusion; traumatic brain injury	AXONAL INJURY; MAGNETIC-RESONANCE; WEIGHTED MR; IMAGING ABNORMALITIES; CORPUS-CALLOSUM; CELLULAR EDEMA; HEAD-INJURY; TIME-COURSE; STROKE; COEFFICIENT	Primary objective: To increase the knowledge about diffuse traumatic brain injury (TBI) by reporting the magnetic resonance imaging (MRI) findings observed in a patient with reversible extensive restricted diffusion of the brain at diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) maps. Case study: An 18-year-old patient was admitted after high-energy closed TBI. Glasgow Coma Scale score was 4. Head computed tomography showed small left frontal and temporal haemorrhagic contusions and a small haemorrhage in the left thalamus. Ten days later, brain MRI showed diffuse high-signal intensity on T2-weighted images and DWI and restricted diffusion in the subcortical white matter of both centri semiovali, genu and splenium of corpus callosum and parietal cortex bilaterally (mean ADC value = 0.434-0.811 10-3 mm2 s-1). Eleven days later, follow-up brain MRI showed gliotic changes in the left splenium of corpus callosum, a clearcut decrease of T2-weighted high-signal intensity and resolution of abnormalities at DWI and ADC maps in all other involved sites. This was confirmed 36 days later. Three months later, the patient did not show neurological, cognitive or neuropsychiatric deficits. Conclusions: In the patient reported herein, closed TBI most likely induced diffuse excitotoxic injury of the brain which resulted in mainly reversible cytotoxic or intramyelinic oedema.	[Muccio, Carmine Franco; De Simone, Marta; Esposito, Gennaro] Azienda Osped Gaetano Rummo, Unit Neuroradiol, Dept Neurosci, I-82100 Benevento, Italy; [De Blasio, Elvio] Azienda Osped Gaetano Rummo, Dept Resuscitat & Intens Care, I-82100 Benevento, Italy; [Vittori, Cesare] Policlin Univ Santa Maria Scotte, Azienda Osped Univ Senese, Unit Neuroanesthesia & NeuroCrit Care, Dept Anesthesia & Crit Care, Siena, Italy; [Cerase, Alfonso] Policlin Univ Santa Maria Scotte, Azienda Osped Univ Senese, Unit Diagnost & Therapeut Neuroradiol, Siena, Italy; [Cerase, Alfonso] Policlin Univ Santa Maria Scotte, Azienda Osped Univ Senese, InterDepartmental Ctr Nucl Magnet Resonance, Siena, Italy	Muccio, CF (corresponding author), Azienda Osped Gaetano Rummo, Unit Neuroradiol, Dept Neurosci, Via Angelo 1, I-82100 Benevento, Italy.	cfmuccio@yahoo.it		Muccio, Carmine Franco/0000-0003-4582-4348; Cerase, Alfonso/0000-0003-4753-6649			Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BATTISTI C, 2009, NEUROLOGICAL SC 0321; Chu K, 2002, ARCH NEUROL-CHICAGO, V59, P123, DOI 10.1001/archneur.59.1.123; Colagrande S, 2005, RADIOL MED, V109, P1; DARDZINSKI BJ, 1993, MAGNET RESON MED, V30, P318, DOI 10.1002/mrm.1910300307; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Ebisu T, 1997, RADIOLOGY, V203, P823, DOI 10.1148/radiology.203.3.9169711; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fiehler J, 2004, STROKE, V35, P514, DOI 10.1161/01.STR.0000114873.28023.C2; Fiehler J, 2003, STROKE, V34, pE87, DOI 10.1161/01.STR.0000078660.31648.3C; Gallucci M, 2007, NEURORADIOLOGY, V49, P541, DOI 10.1007/s00234-007-0235-z; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KLATZO I, 1994, ACTA NEUROCHIR, P3; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Mark LP, 2001, AM J NEURORADIOL, V22, P1813; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Marmarou A, 2001, J NEUROSURG, V94, P349; Mascalchi M, 2005, RADIOL MED, V109, P155; Mateo Magdalena A, 2003, Lippincotts Case Manag, V8, P203, DOI 10.1097/00129234-200309000-00005; Maxwell WL, 1997, J NEUROTRAUM, V14, P755; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Moritani T, 2005, AM J NEURORADIOL, V26, P216; Muttikkal TJE, 2008, NEURORADIOL J, V21, P817, DOI 10.1177/197140090802100611; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Nicoli F, 2003, STROKE, V34, pE82, DOI 10.1161/01.STR.0000078659.43423.0A; Pizzini F, 2003, RIV NEURORADIOL, V16, P207, DOI 10.1177/197140090301600202; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Schlaug G, 1997, NEUROLOGY, V49, P113, DOI 10.1212/WNL.49.1.113; SHARP FR, 1998, STROKE PATHOPHYSIOLO, P54; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Takanashi J, 2005, ARCH NEUROL-CHICAGO, V62, P1481, DOI 10.1001/archneur.62.9.1481; Takayama H, 2000, CLIN NEUROL NEUROSUR, V102, P135, DOI 10.1016/S0303-8467(00)00079-2; Turkin AM, 2003, RIV NEURORADIOL, V16, P1055, DOI 10.1177/197140090301600602; Unterberg AW, 1997, ACT NEUR S, V70, P106; Warach S, 1996, STROKE, V27, P1254; Zheng WB, 2007, NEURORADIOLOGY, V49, P271, DOI 10.1007/s00234-006-0187-8	50	15	15	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	5					466	472	PII 910862176	10.1080/02699050902841912			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	439NL	WOS:000265633700011	19408169				2021-06-18	
J	Ryan, KA; Rapport, LJ; Harper, KT; Fuerst, D; Bieliauskas, L; Khan, O; Lisak, R				Ryan, Kelly A.; Rapport, Lisa J.; Harper, Kaja Telmet; Fuerst, Darren; Bieliauskas, Linas; Khan, Omar; Lisak, Robert			Fitness to drive in multiple sclerosis: Awareness of deficit moderates risk	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Multiple sclerosis; Driving; Awareness of deficit; Fitness to drive	TRAUMATIC BRAIN-INJURY; OLDER DRIVERS; NEUROPSYCHOLOGICAL ASPECTS; AUTOBIOGRAPHICAL MEMORY; EXECUTIVE FUNCTIONS; STROKE PATIENTS; PERFORMANCE; IMPAIRMENT; PREDICTORS; INDIVIDUALS	Fitness to drive was examined among 78 individuals with multiple sclerosis (MS) who participated with a knowledgeable informant. Illness severity, neuropsychological functioning, and external social influences each made unique contributions to the prediction of driving status. Among drivers, perceptions of social influences against driving accounted for the most variance in miles driven, whereas social influences, informants' perceptions of the patients' fitness to drive, and illness severity accounted for the most variance in adverse driving incidents. Importantly, awareness of deficit moderated fitness to drive: Drivers who were unaware of their deficits perceived less need to engage in compensatory behaviors; moreover, as perceived need to compensate decreased, miles driven and driving incidents increased. The findings have implications for interventions with persons with MS who drive.	[Rapport, Lisa J.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Bieliauskas, Linas] Univ Michigan Hlth Syst, Ann Arbor, MI USA; [Khan, Omar; Lisak, Robert] Wayne State Univ, Sch Med, Dept Neurol, Multiple Sclerosis Ctr, Detroit, MI 48201 USA	Rapport, LJ (corresponding author), Wayne State Univ, Dept Psychol, 5057 Woodward Ave, Detroit, MI 48202 USA.	rapport@wayne.edu					Anstey KJ, 2005, CLIN PSYCHOL REV, V25, P45, DOI 10.1016/j.cpr.2004.07.008; Arthur W, 2001, HUM FACTORS, V43, P1, DOI 10.1518/001872001775992507; Ball K, 1998, ACCIDENT ANAL PREV, V30, P313, DOI 10.1016/S0001-4575(97)00102-4; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; BEATTY PA, 1977, J NERV MENT DIS, V164, P42, DOI 10.1097/00005053-197701000-00008; BEATTY WW, 1995, NEUROPSYCHOLOGY, V9, P198, DOI 10.1037/0894-4105.9.2.198; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Benedict RHB, 2002, CLIN NEUROPSYCHOL, V16, P381, DOI 10.1076/clin.16.3.381.13859; Benton A., 1994, MULTILINGUAL APHASIA; BENTON AL, 1978, ARCH NEUROL-CHICAGO, V35, P364, DOI 10.1001/archneur.1978.00500300038006; BOYLE EA, 1991, ARCH NEUROL-CHICAGO, V48, P1150, DOI 10.1001/archneur.1991.00530230058022; Brassington JC, 1998, NEUROPSYCHOL REV, V8, P43, DOI 10.1023/A:1025621700003; Brouwer W H, 1994, Disabil Rehabil, V16, P149; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; CAMPBELL MK, 1993, J GERONTOL, V48, pS230, DOI 10.1093/geronj/48.4.S230; Carone DA, 2005, J INT NEUROPSYCH SOC, V11, P574, DOI 10.1017/S135561770505068X; Chipchase SY, 2003, DISABIL REHABIL, V25, P712, DOI 10.1080/0963828031000062651; Coleman BR., 2005, DRIVER REHABILITATIO, P165; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; Daigneault G, 2002, J CLIN EXP NEUROPSYC, V24, P221, DOI 10.1076/jcen.24.2.221.993; Fisk GD, 1997, ARCH PHYS MED REHAB, V78, P1338, DOI 10.1016/S0003-9993(97)90307-5; Fisk GD, 2002, ARCH PHYS MED REHAB, V83, P469, DOI 10.1053/apmr.2002.31179; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Goodyear K, 2003, CLIN MED, V3, P86, DOI 10.7861/clinmedicine.3-1-86; GRANT I, 1989, CURR PROB N, V10, P17; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Heikkila VM, 1999, ACTA NEUROL SCAND, V99, P349, DOI 10.1111/j.1600-0404.1999.tb07363.x; Hohol MJ, 1997, ARCH NEUROL-CHICAGO, V54, P1018, DOI 10.1001/archneur.1997.00550200074013; Hopewell CA, 2002, J HEAD TRAUMA REHAB, V17, P48, DOI 10.1097/00001199-200202000-00007; HUNT L, 1993, J AM GERIATR SOC, V41, P747, DOI 10.1111/j.1532-5415.1993.tb07465.x; Kenealy PM, 2000, J CLIN EXP NEUROPSYC, V22, P125, DOI 10.1076/1380-3395(200002)22:1;1-8;FT125; Kenealy PM, 2002, J INT NEUROPSYCH SOC, V8, P855, DOI 10.1017/S1355617702860143; KNECHT J, 1977, SCHWEIZ MED WSCHR, V107, P373; Knight RG, 1997, J CLIN EXP NEUROPSYC, V19, P7, DOI 10.1080/01688639708403832; Kotterba S, 2003, EUR NEUROL, V50, P160, DOI 10.1159/000073057; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lings S, 2002, ACTA NEUROL SCAND, V105, P169, DOI 10.1034/j.1600-0404.2002.1o165.x; LINGS S, 1991, APPL ERGON, V22, P75, DOI 10.1016/0003-6870(91)90305-2; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; Lundqvist A, 2000, APPL COGNITIVE PSYCH, V14, P135, DOI 10.1002/(SICI)1099-0720(200003/04)14:2<135::AID-ACP628>3.0.CO;2-S; Lyman JM, 2001, ACCIDENT ANAL PREV, V33, P413, DOI 10.1016/S0001-4575(00)00055-5; Mackenzie C, 2003, APHASIOLOGY, V17, P107, DOI 10.1080/729255215; Marcotte TD, 2000, J INT NEUROPSYCH SOC, V6, P233; Marie RM, 2001, REV NEUROL-FRANCE, V157, P402; MAROTTOLI RA, 1993, J GERONTOL, V48, pS255, DOI 10.1093/geronj/48.5.S255; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Nouri F.M., 1992, CLIN REHABIL, V6, DOI [https://doi.org/10.1177/026921559200600402, DOI 10.1177/026921559200600402]; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Owsley C, 1999, J GERONTOL A-BIOL, V54, pM203, DOI 10.1093/gerona/54.4.M203; Owsley C, 2004, J AM GERIATR SOC, V52, P1901, DOI 10.1111/j.1532-5415.2004.52516.x; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P96; Provinciali L, 1999, ACTA NEUROL SCAND, V100, P156; Rao S., 1990, MANUAL BRIEF REPEATA; RAO SM, 1984, ARCH NEUROL-CHICAGO, V41, P625, DOI 10.1001/archneur.1984.04210080033010; RAO SM, 1991, NEUROLOGY, V41, P692, DOI 10.1212/WNL.41.5.692; Rapport L, 2006, J HEAD TRAUMA REHAB, V21, P34, DOI 10.1097/00001199-200601000-00004; RAPPORT LJ, 1993, ARCH PHYS MED REHAB, V74, P621, DOI 10.1016/0003-9993(93)90160-C; Regard M, 1981, THESIS U VICTORIA BR; Reitan R., 1988, HALSTEAD REITAN NEUR; RON MA, 1991, PSYCHOL MED, V21, P59, DOI 10.1017/S0033291700014653; Ryan KA, 2007, CLIN NEUROPSYCHOL, V21, P239, DOI 10.1080/13854040600582460; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; Schanke Anne-Kristine, 1995, Tidsskrift for den Norske Laegeforening, V115, P1349; Schultheis MT, 2002, ARCH PHYS MED REHAB, V83, P1175, DOI 10.1053/apmr.2002.34279; Schultheis MT, 2001, NEUROLOGY, V56, P1089, DOI 10.1212/WNL.56.8.1089; Schulz M, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2000PA000571; SCOTT CA, 2007, J INT NEUROPSYCHO S1, V13, P58; Shawaryn MA, 2002, ARCH PHYS MED REHAB, V83, P1123, DOI 10.1053/apmr.2002.33730; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sherman TE, 2007, J CLIN EXPT NEUROPSY, V12, P1; Smith A., 1991, SYMBOL DIGIT MODALIT; Sperling RA, 2001, ARCH NEUROL-CHICAGO, V58, P115, DOI 10.1001/archneur.58.1.115; Spreen O., 1991, COMPENDIUM NEUROPSYC; Tabachnick BG, 2007, USING MULTIVARIATE S; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697	79	15	15	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2009	31	1					126	139	PII 793716857	10.1080/13803390802119922			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	384IT	WOS:000261739200013	18608652				2021-06-18	
J	Thomas, MD; Skilbeck, CE; Slatyer, M				Thomas, M. D.; Skilbeck, C. E.; Slatyer, M.			Pre-injury estimates of subjective quality of life following traumatic brain injury	BRAIN INJURY			English	Article						Subjective Quality of life; traumatic brain injury; confirmatory factor analysis; Quality of Life Inventory	SATISFACTION; RECOMMENDATIONS; DOMAINS; MODEL	Primary objective: To compare the pre-injury subjective quality of life (SQOL) estimates of a representative sample of adults with TBI, using the Quality of Life Inventory (QOLI) with the measure's generic US-based norms and identify a factor structure for the instrument within the local TBI population. Research design: A population-based, cross-sectional design conducted with data collected by the Neurotrauma Register of Tasmania (2003-2005). Methods and procedures: As soon as possible following their emergence from post-traumatic amnesia, 470 participants provided pre-injury estimates of their SQOL using the QOLI. The distribution of this sample was compared with the measure's normative distribution. The sample was separated evenly into two groups (n = 235) for separate exploratory and confirmatory factor analyses. Main outcomes and results: Small differences were found between the pre-injury estimates and the QOLI's US-based normative distribution. Corrections were provided to clinical classification ranges for this population. Three factors were identified and confirmed for the QOLI in separate TBI samples. Conclusion: The results of this study support the use of the QOLI in measuring SQOL in TBI rehabilitation and outcomes research.	[Thomas, M. D.; Skilbeck, C. E.] Charles Sturt Univ, Sch Social Sci & Liberal Studies, Bathurst, NSW 2795, Australia; [Slatyer, M.] Univ Tasmania, Sch Med, Hobart, Tas 7001, Australia; [Slatyer, M.] Royal Hobart Hosp, Hobart, Tas, Australia	Thomas, MD (corresponding author), Charles Sturt Univ, Sch Social Sci & Liberal Studies, Panorama Ave, Bathurst, NSW 2795, Australia.	psychflyer@hotmail.com			Motor Accident Insurance Board (Tasmania, Australia)	We would like to express our gratitude to the participants and staff involved in this study. This research was made possible by project funding for the Neurotrauma Register of Tasmania, by the Motor Accident Insurance Board (Tasmania, Australia).	ABBEY A, 1985, SOC INDIC RES, V16, P1, DOI 10.1007/BF00317657; BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; Brown P, 1998, MOVEMENT DISORD, V13, P56, DOI 10.1002/mds.870130114; Browne M. W., 1993, ALTERNATIVE WAYS ASS; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Claiborne N, 1999, SOC WORK HEALTH CARE, V28, P77, DOI 10.1300/J010v28n03_05; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Eng W, 2005, J ANXIETY DISORD, V19, P143, DOI 10.1016/j.janxdis.2004.01.007; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fortune N, 1999, DEFINITION INCIDENCE; Frisch M. B, 1994, QUALITY LIFE INVENTO; Frisch M.B., 1992, PSYCHOL ASSESSMENT, V4, P92, DOI [DOI 10.1037/1040-3590.4.1.92, 10.1037/1040-3590.4.1.92]; Frisch MB, 1998, CLIN PSYCHOL-SCI PR, V5, P19, DOI 10.1111/j.1468-2850.1998.tb00132.x; Frisch MB., 1999, USE PSYCHOL TESTING, P1277; Hillier SL, 1997, BRAIN INJURY, V11, P649; Johnston MV, 2002, ARCH PHYS MED REHAB, V83, pS26, DOI 10.1053/apmr.2002.37100; Joreskog KG., 1993, LISREL 8 USERS REFER; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Kendall E, 1998, J REHABIL, V64, P16; McAlinden NM, 2006, COMPR PSYCHIAT, V47, P309, DOI 10.1016/j.comppsych.2005.09.003; MOFFAT S, 2006, CRIME JUSTICE B; *MWBIRP, 1999, DEV IMPL NEW S WAL N; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; O'Cleirigh C, 2006, AIDS BEHAV, V10, P53, DOI 10.1007/s10461-005-9027-9; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RUSSELL WR, 1977, TRAUMATIC AMNESIAS; Silver JM, 2005, TXB TRAUMATIC BRAIN; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Tabachnick B., 2001, USING MULTIVARIATE S; *TASM POL, 2006, CRIM INV; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Ullman J.B., 2001, USING MULTIVARIATE S; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9	41	15	15	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	6					516	527	PII 911809026	10.1080/02699050902926333			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	451SF	WOS:000266489800005	19484625				2021-06-18	
J	Thomas, S; Mayer, L; Sperber, K				Thomas, Sunil; Mayer, Lloyd; Sperber, Kirk			Mitochondria Influence Fas Expression in GP120-Induced Apoptosis of Neuronal Cells	INTERNATIONAL JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; caspase; dementia; fas; HIV; mitochondria	TRAUMATIC BRAIN INJURY; DEATH; DEMENTIA; ASSOCIATION; MECHANISMS; INFECTION; MEMBRANE; SYSTEM; AIDS	The human immunodeficiency virus-1 (HIV-1) destroys the immune system and also induces neurological disease culminating into dementia (HIV-associated dementia). Though the HIV viral protein gp120 induces apoptosis in neuronal cells, the mechanism of action is still poorly defined. Recent studies show that cells die during apoptosis by Fas aggregation aided by the mitochondrial proapoptotic proteins. Our studies show an increase in expression of Fas and its associated downstream proteins after treatment of the neuroblastoma cells, SH-SY5Y, with gp120. Fas and its associated death proteins, FADD and caspase-8 (DISC), are downregulated when treated with the caspase inhibitors. The results indicate that mitochondrial-death proteins like caspases may influence the upregulation of the death receptor Fas, and the inhibition of caspases prevents gp120-induced apoptosis.	[Thomas, Sunil; Mayer, Lloyd; Sperber, Kirk] Mt Sinai Sch Med, Immunobiol Ctr, New York, NY USA; [Thomas, Sunil] Univ Texas Med Branch Galveston, Dept Pathol, Galveston, TX 77550 USA	Thomas, S (corresponding author), Univ Texas Med Branch Galveston, Dept Pathol, Keiller Bldg,Room 1-138,301 Univ Blvd, Galveston, TX 77550 USA.	sunthoma@utmb.edu					AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; Badley AD, 2000, BLOOD, V96, P2951, DOI 10.1182/blood.V96.9.2951.h8002951_2951_2964; Casha S, 2005, EXP NEUROL, V196, P390, DOI 10.1016/j.expneurol.2005.08.020; Castedo M, 2003, ANN NY ACAD SCI, V1010, P19, DOI 10.1196/annals.1299.004; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; Damdimopoulos AE, 2002, J BIOL CHEM, V277, P33249, DOI 10.1074/jbc.M203036200; Desbarats J, 1996, P NATL ACAD SCI USA, V93, P11014, DOI 10.1073/pnas.93.20.11014; Dianzani U, 2003, CURR HIV RES, V1, P405, DOI 10.2174/1570162033485131; Garden GA, 2002, J NEUROSCI, V22, P4015, DOI 10.1523/JNEUROSCI.22-10-04015.2002; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Huang HL, 2003, ONCOGENE, V22, P8168, DOI 10.1038/sj.onc.1206979; KATSIKIS PD, 1995, J EXP MED, V181, P2029, DOI 10.1084/jem.181.6.2029; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212; LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407; LIPTON SA, 1992, NEUROLOGY, V42, P1403, DOI 10.1212/WNL.42.7.1403; MCARTHUR JC, 1993, NEUROLOGY, V43, P2245, DOI 10.1212/WNL.43.11.2245; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; Qiu JH, 2002, J NEUROSCI, V22, P3504; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Sas K, 2007, J NEUROL SCI, V257, P221, DOI 10.1016/j.jns.2007.01.033; Shi B, 1996, J CLIN INVEST, V98, P1979, DOI 10.1172/JCI119002; Xu Y, 2004, P NATL ACAD SCI USA, V101, P7070, DOI 10.1073/pnas.0304859101; Zhang LL, 2004, J BIOL CHEM, V279, P33865, DOI 10.1074/jbc.M403499200	25	15	15	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0020-7454	1563-5279		INT J NEUROSCI	Int. J. Neurosci.		2009	119	2					157	165	PII 907383722	10.1080/00207450802335537			9	Neurosciences	Neurosciences & Neurology	390SD	WOS:000262183100001	19125371				2021-06-18	
J	Zoghi-Moghadam, M; Sadegh, AM				Zoghi-Moghadam, Mohamad; Sadegh, Ali M.			Global/local head models to analyse cerebral blood vessel rupture leading to ASDH and SAH	COMPUTER METHODS IN BIOMECHANICS AND BIOMEDICAL ENGINEERING			English	Article						head impact; ASDH; bridging veins; global; local; finite element model	DIFFUSE AXONAL INJURY; FINITE-ELEMENT-ANALYSIS; ACUTE SUBDURAL-HEMATOMA; BRAIN-INJURY; IMPACT; BIOMECHANICS; SIMULATIONS; CONCUSSION; PRIMATE	Blunt and rotational head impacts due to vehicular collisions, falls and contact sports cause relative motion between the brain and skull. This increases the normal and shear stresses in the (skull/brain) interface region consisting of cerebrospinal fluid (CSF) and subarachnoid space (SAS) trabeculae. The relative motion between the brain and skull can explain many types of traumatic brain injuries (TBI) including acute subdural hematomas (ASDH) and subarachnoid hemorrhage (SAH) which is caused by the rupture of bridging veins that transverse from the deep brain tissue to the superficial meningeal coverings. The complicated geometry of the SAS trabeculae makes it impossible to model all the details of the region. Investigators have compromised this layer with solid elements, which may lead to inaccurate results. In this paper, the failure of the cerebral blood vessels due to the head impacts have been investigated. This is accomplished through a global/local modelling approach. Two global models, namely a global solid model (GSM) of the skull/brain and a global fluid model (GFM) of the SAS/CSF, were constructed and were validated. The global models were subjected to two sets of impact loads (head injury criterion, HIC=740 and 1044). The relative displacements between the brain and skull were determined from GSM. The CSF equivalent fluid pressure due to the impact loads were determined by the GFM. To locally study the mechanism of the injury, the relative displacement between the brain and skull along with the equivalent fluid pressure were implemented into a new local solid model (LSM). The strains of the cerebral blood vessels were determined from LSM. These values were compared with their relevant experimental ultimate strain values. The results showed an agreement with the experimental values indicating that the second impact (HIC=1044) was strong enough to lead to severe injury. The global/local approach provides a reliable tool to study the cerebral blood vessel ruptures leading to ASDH and/or SAH.	[Zoghi-Moghadam, Mohamad; Sadegh, Ali M.] CUNY City Coll, Dept Mech Engn, New York, NY 10031 USA	Sadegh, AM (corresponding author), CUNY City Coll, Dept Mech Engn, New York, NY 10031 USA.	sadegh@ccny.cuny.edu					Abel JM, 1978, P 22 STAPP CAR CRASH; Al-Bsharat AS, 1999, P 43 STAPP CAR CRASH; *ANSYS INC, 2001, US MAN VERS 6 1; Anzelius A, 1943, ACTA PATHOL MICROB S, V48, P153; Bandak F.A, 1994, STAPP CAR CRASH C SO, P145; Blumenfeld H, 2002, NEUROANATOMY CLIN CA; Bradshaw DRS, 2001, J BIOMECH, V34, P85, DOI 10.1016/S0021-9290(00)00135-4; Emily Sun R.S, 1998, DEV IMPROVED INJURY; ENGIN AE, 1969, J BIOMECH, V2, P325, DOI 10.1016/0021-9290(69)90089-X; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1972, P 16 STAPP CAR CRASH; Gurdjian ES, 1944, J NEUROSURG, V1, P393, DOI 10.3171/jns.1944.1.6.0393; GURDJIAN ES, 1961, J NEUROSURG, V18, P58, DOI 10.3171/jns.1961.18.1.0058; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; Guyton A.C., 2006, TXB MED PHYSL; Hardy WN, 2001, P 45 STAPP CAR CRASH; Hodgson V.R., 1979, P 23 STAPP CAR CRASH; HODGSON VR, 1983, P 27 STAPP CAR CRASH; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Huang HM, 1999, J TRAUMA, V47, P538, DOI 10.1097/00005373-199909000-00019; Ivarsson J, 2000, J BIOMECH, V33, P181, DOI 10.1016/S0021-9290(99)00144-X; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; KLEIVEN S, 2002, P 46 STAPP CAR CRASH; Kleiven S, 2002, TRAFFIC INJ PREV, V3, P303, DOI DOI 10.1080/15389580214633; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; LEE MC, 1987, P 31 STAPP CAR CRASH; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Monson KL, 2003, J BIOMECH ENG-T ASME, V125, P288, DOI 10.1115/1.1554412; MONSON KL, 2000, CRASHWORTHINESS OCCU, V49, P255; Nahum A. M., 1977, P 21 STAPP CAR CRASH; Newman J, 2000, P 44 STAPP CAR CRASH; NEWMAN JA, 1980, P 24 STAPP CAR CRASH; Nishimoto T, 1998, J BIOMECH ENG-T ASME, V120, P140, DOI 10.1115/1.2834294; Nishimoto T, 2000, JSAE REV, V21, P117, DOI 10.1016/S0389-4304(99)00079-X; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Ono K., 1980, P 24 STAPP CAR CRASH; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; RUAN JS, 1993, P 37 STAPP CAR CRASH; Sarkar S, 2004, TRENDS BIOMATER ARTI, V17, P130; Trosseille X., 1992, P 36 STAPP CAR CRASH; TURQUIER F, 1996, P 40 STAPP CAR CRASH; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; VIANO DC, 1997, INT J CRASHWORTHINES, V2, P191; Ward C, 1980, P 24 STAPP CAR CRASH; WILLINGER R, 1995, J NEUROTRAUM, V12, P743, DOI 10.1089/neu.1995.12.743; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Young PG, 2003, J SOUND VIB, V267, P1107, DOI 10.1016/S0022-460X(03)00200-1; ZHANG L, 2001, P 45 STAPP CAR CRASH; ZHANG L, 2002, P 46 STAPP CAR CRASH; Zhou C, 1995, P 39 STAPP CAR CRASH; ZOGHIMOGHADAM M, 2006, THESIS CITY U NEW YO; 1995, GRAYS ANATOMY	57	15	19	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1025-5842	1476-8259		COMPUT METHOD BIOMEC	Comput. Methods Biomech. Biomed. Eng.		2009	12	1					1	12	PII 903082957	10.1080/10255840802020420			12	Computer Science, Interdisciplinary Applications; Engineering, Biomedical	Computer Science; Engineering	390SB	WOS:000262182900001	18821190				2021-06-18	
J	Lemoyne, R; Coroian, C; Mastroianni, T; Grundfest, W				Lemoyne, Robert; Coroian, Cristian; Mastroianni, Timothy; Grundfest, Warren			QUANTIFIED DEEP TENDON REFLEX DEVICE FOR RESPONSE AND LATENCY, THIRD GENERATION	JOURNAL OF MECHANICS IN MEDICINE AND BIOLOGY			English	Article						Reflex quantification; wireless accelerometers; neurorehabilitation; traumatic brain injury	STRETCH REFLEX; DEMYELINATING POLYNEUROPATHY; QUANTITATIVE-EVALUATION; SPINAL SHOCK; SPASTICITY; PATELLAR; INJURY	Deep tendon reflex is fundamental for a neurological examination. A hyperactive reflex response is correlated with spasticity, which can also be associated with the degree of damage to the supraspinal input, essentially assessing the severity of traumatic brain injury. Clinical evaluation of the myotatic stretch reflex is provided by the National Institute of Neurological Disorders and Stroke (NINDS) Myotatic Reflex Scale (0 to 4); however, the results of the NINDS Myotatic Reflex Scale vary in terms of interpretation and lack temporal data. Deep tendon reflex can assess the severity and degree of peripheral neuropathy. Subsequent to the neurological examination, suspect patients are often referred to a specialist for definitive electrodiagnostic testing. A study by Cocito found that 28% of the prescriptions for testing were considered to be inappropriate. Therefore, the solution is a fully quantified tendon reflex evaluation system. The input force of the reflex hammer is derived from a predetermined potential energy setting. Tandem wireless three-dimensional (3D) microelectromechanical systems (MEMS) accelerometers quantify the output and latency time of the reflex. The wireless 3D MEMS accelerometers are positioned to a standard anchor point near the ankle and reflex hammer swing arm. Reflex response is quantified by the maximum and minimum components of the acceleration profile. The temporal disparity between hammer strike and response defines the latency of the reflex loop. The quantified data collected from wireless 3D MEMS accelerometers are conveyed to a portable computer. Enclosed are the initial test and evaluation and the description of such a device, which quantitatively evaluates the reflex response and latency using wireless 3D MEMS accelerometers, while demonstrating precision for reproducibility.	[Lemoyne, Robert; Coroian, Cristian] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Mastroianni, Timothy] Cognit Engn, Pittsburgh, PA USA; [Grundfest, Warren] Univ Calif Los Angeles, Biomed Engn IDP, Los Angeles, CA 90095 USA	Lemoyne, R (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.	rlemoyne@ucla.edu	LeMoyne, Robert/AAI-9686-2020	LeMoyne, Robert/0000-0003-3587-3250	UCLA IGERT NSFNational Science Foundation (NSF)	Support from the UCLA IGERT NSF fellowship has been instrumental.	Cocito D, 2006, NEUROL SCI, V26, P419, DOI 10.1007/s10072-006-0525-y; Cozens JA, 2000, J NEUROL NEUROSUR PS, V68, P581, DOI 10.1136/jnnp.68.5.581; Faist M, 1999, BRAIN, V122, P567, DOI 10.1093/brain/122.3.567; Frijns CJM, 1997, CLIN NEUROL NEUROSUR, V99, P31, DOI 10.1016/S0303-8467(96)00593-8; Hiersemenzel LP, 2000, NEUROLOGY, V54, P1574, DOI 10.1212/WNL.54.8.1574; Jafari R, 2005, PROCEEDINGS OF MOBIQUITOUS 2005, P479; Kandel E.R., 2000, PRINCIPLES NEURAL SC; Karandreas N, 2000, Electromyogr Clin Neurophysiol, V40, P83; Ko HY, 1999, SPINAL CORD, V37, P402, DOI 10.1038/sj.sc.3100840; KURUOGLU HR, 1994, MUSCLE NERVE, V17, P145, DOI 10.1002/mus.880170203; Lebiedowska MK, 2003, ARCH PHYS MED REHAB, V84, P828, DOI 10.1016/S0003-9993(02)04946-8; LEMOYNE R, 2005, UCLA COMMUNICATION; LeMoyne R, 2005, 35 SOC NEUR ANN M; LEMOYNE R, 2006, 15 INT C MECH MED BI; LEMOYNE R, 2006, 36 SOC NEUR ANN M; LeMoyne R, 2007, 37 SOC NEUR ANN M; Lemoyne R, 2008, J MECH MED BIOL, V8, P75, DOI 10.1142/S0219519408002462; Litvan I, 1996, NEUROLOGY, V47, P969, DOI 10.1212/WNL.47.4.969; Mamizuka N, 2007, J BIOMECH, V40, P2107, DOI 10.1016/j.jbiomech.2006.10.003; Manschot S, 1998, J NEUROL NEUROSUR PS, V64, P253, DOI 10.1136/jnnp.64.2.253; Moore DS, 1999, INTRO PRACTICE STAT; Pagliaro P, 1999, J ELECTROMYOGR KINES, V9, P141, DOI 10.1016/S1050-6411(98)00045-5; TOFT E, 1989, ACTA NEUROL SCAND, V79, P384, DOI 10.1111/j.1600-0404.1989.tb03805.x; van Dijk GW, 1999, NEUROLOGY, V53, P1573, DOI 10.1212/WNL.53.7.1573; VandeCrommert HWAA, 1996, BRAIN RES, V734, P341, DOI 10.1016/0006-8993(96)00885-2; Voerman GE, 2005, DISABIL REHABIL, V27, P33, DOI 10.1080/09638280400014600	26	15	15	0	4	WORLD SCIENTIFIC PUBL CO PTE LTD	SINGAPORE	5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE	0219-5194			J MECH MED BIOL	J. Mech. Med. Biol.	DEC	2008	8	4					491	506		10.1142/S0219519408002772			16	Biophysics; Engineering, Biomedical	Biophysics; Engineering	389LN	WOS:000262094200003					2021-06-18	
J	Mitchell, CS; Lee, RH				Mitchell, Cassie S.; Lee, Robert H.			Pathology Dynamics Predict Spinal Cord Injury Therapeutic Success	JOURNAL OF NEUROTRAUMA			English	Article						combination therapy; neuroprotection; secondary insult; spinal cord injury; therapeutic treatment window; traumatic brain injury	NMDA RECEPTOR ACTIVATION; MEDIATED NEURONAL APOPTOSIS; SODIUM-CHANNEL BLOCKERS; SECONDARY INJURY; INFLAMMATORY RESPONSE; NITRIC-OXIDE; MITOCHONDRIAL-FUNCTION; CEREBELLAR GLOMERULUS; GLUTAMATE SPILLOVER; WHITE-MATTER	Secondary injury, the complex cascade of cellular events following spinal cord injury (SCI), is a major source of post-insult neuron death. Experimental work has focused on the details of individual factors or mechanisms that contribute to secondary injury, but little is known about the interactions among factors leading to the overall pathology dynamics that underlie its propagation. Prior hypotheses suggest that the pathology is dominated by interactions, with therapeutic success lying in combinations of neuroprotective treatments. In this study, we provide the first comprehensive, system-level characterization of the entire secondary injury process using a novel relational model methodology that aggregates the findings of similar to 250 experimental studies. Our quantitative examination of the overall pathology dynamics suggests that, while the pathology is initially dominated by "fire-like," rate-dependent interactions, it quickly switches to a "flood-like," accumulation-dependent process with contributing factors being largely independent. Our evaluation of similar to 20,000 potential single and combinatorial treatments indicates this flood-like pathology results in few highly influential factors at clinically realistic treatment time frames, with multi-factor treatments being merely additive rather than synergistic in reducing neuron death. Our findings give new fundamental insight into the understanding of the secondary injury pathology as a whole, provide direction for alternative therapeutic strategies, and suggest that ultimate success in treating SCI lies in die pursuit of pathology dynamics in addition to individually involved factors.	[Lee, Robert H.] Emory Univ, Atlanta, GA 30322 USA; Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA	Lee, RH (corresponding author), Emory Univ, 107 Woodruff Circle,Suite 2001, Atlanta, GA 30322 USA.	rlee2@emory.edu		Mitchell, Cassie/0000-0002-5472-6355	National Science Foundation (NSF)National Science Foundation (NSF); Integrative Graduate Education and Research Traineeship FellowshipNational Science Foundation (NSF) [DGE-0333411]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH); NIBIBUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [NS046891]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046851] Funding Source: NIH RePORTER	This work is supported by the National Science Foundation (NSF) Via a Graduate Research Fellowsl-dp and an Integrative Graduate Education and Research Traineeship Fellowship (DGE-0333411) to C.S.M. Additional support was provided by the Human Brain Project (NINDS, NIMH, NIBIB NS046891) to R.H.L.	Agrawal SK, 1996, J NEUROSCI, V16, P545; Agrawal SK, 1997, J NEUROSCI, V17, P1055; Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Alano CC, 2002, J NEUROCHEM, V80, P531, DOI 10.1046/j.0022-3042.2001.00738.x; ANDERSON DK, 1980, J NEUROSURG, V53, P375, DOI 10.3171/jns.1980.53.3.0375; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Ates O, 2007, J CLIN NEUROSCI, V14, P658, DOI 10.1016/j.jocn.2006.03.023; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Barut S, 2005, SURG NEUROL, V64, P213, DOI 10.1016/j.surneu.2005.03.042; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; Blight AR, 2006, J NEUROTRAUM, V23, P586, DOI 10.1089/neu.2006.23.586; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Carriedo SG, 1998, J NEUROSCI, V18, P7727; Choo AM, 2007, J NEUROSURG-SPINE, V6, P255, DOI 10.3171/spi.2007.6.3.255; Churchwell KB, 1996, J NEUROSCI, V16, P7447; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Cullen DK, 2006, J NEUROTRAUM, V23, P986; Cullen DK, 2006, J NEUROTRAUM, V23, P1304, DOI 10.1089/neu.2006.23.1304; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; FADEN AI, 1987, J NEUROCHEM, V48, P1809, DOI 10.1111/j.1471-4159.1987.tb05740.x; Faden AI, 2007, ARCH NEUROL-CHICAGO, V64, P794, DOI 10.1001/archneur.64.6.794; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; FEHLINGS MG, 1995, SPINE, V20, P2187, DOI 10.1097/00007632-199510001-00002; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Fujiki M, 2005, BRAIN RES, V1053, P175, DOI 10.1016/j.brainres.2005.06.055; Gaviria M, 2006, NEUROBIOL DIS, V22, P694, DOI 10.1016/j.nbd.2006.01.011; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Gomes-Leal W, 2004, EXP NEUROL, V190, P456, DOI 10.1016/j.expneurol.2004.06.028; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; HALL ED, 1993, RES P ARNMD, V71, P81; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Hu S, 1997, NEUROCHEM INT, V30, P427, DOI 10.1016/S0197-0186(96)00078-2; Iwai T, 2002, CARDIOVASC RES, V55, P141, DOI 10.1016/S0008-6363(02)00282-1; JURKOWITZALEXANDER MS, 1992, J NEUROCHEM, V59, P344, DOI 10.1111/j.1471-4159.1992.tb08910.x; Kandel E.R., 2000, PRINCIPLES NEURAL SC; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; LEMKE M, 1987, BIOCHEM BIOPH RES CO, V147, P1170, DOI 10.1016/S0006-291X(87)80192-4; Li S, 2001, NEUROSCIENCE, V107, P675, DOI 10.1016/S0306-4522(01)00385-2; Liu D, 1999, NEUROSCIENCE, V93, P1383, DOI 10.1016/S0306-4522(99)00278-X; Liu-Snyder P, 2007, J EXP BIOL, V210, P1455, DOI 10.1242/jeb.02756; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; Lovas G, 2000, BRAIN, V123, P308, DOI 10.1093/brain/123.2.308; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; Mattiasson G, 2004, CYTOM PART A, V62A, P89, DOI 10.1002/cyto.a.20089; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Mitchell CS, 2007, J NEURAL ENG, V4, P380, DOI 10.1088/1741-2560/4/4/004; Mitchell CS, 2007, J NEURAL ENG, V4, P276, DOI 10.1088/1741-2560/4/3/013; Nicholls DG, 2000, PHYSIOL REV, V80, P315; OBRIEN MF, 1994, SPINE, V19, P2321, DOI 10.1097/00007632-199410150-00012; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Popovich PG, 2002, J NEUROPATH EXP NEUR, V61, P623, DOI 10.1093/jnen/61.7.623; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; Saftenku EE, 2005, J THEOR BIOL, V234, P363, DOI 10.1016/j.jtbi.2004.11.036; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schwab ME, 1996, PHYSIOL REV, V76, P319; Schwartz G, 2001, J NEUROSURG, V94, P245, DOI 10.3171/spi.2001.94.2.0245; Shi R, 2006, J NEUROPHYSIOL, V95, P3384, DOI 10.1152/jn.00350.2005; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Tator C H, 1999, Neurosurg Focus, V6, pe8; Tian DS, 2007, BRAIN RES, V1135, P177, DOI 10.1016/j.brainres.2006.11.085; Tian DS, 2006, J NEUROSCI RES, V84, P1053, DOI 10.1002/jnr.20999; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Totoiu MO, 2005, J COMP NEUROL, V486, P373, DOI 10.1002/cne.20517; Vela JM, 2002, J NEUROTRAUM, V19, P1503, DOI 10.1089/089771502320914723; VOLTERRA A, 1994, J NEUROSCI, V14, P2924; White RJ, 1996, J NEUROSCI, V16, P5688; Wingrave JM, 2003, J NEUROSCI RES, V73, P95, DOI 10.1002/jnr.10607; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Xu GY, 2004, EXP NEUROL, V187, P329, DOI 10.1016/j.expneurol.2004.01.029; YANASE M, 1995, J NEUROSURG, V83, P884, DOI 10.3171/jns.1995.83.5.0884; Yoshioka A, 1996, J NEUROSCI RES, V46, P427; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhao WH, 2004, J NEUROPATH EXP NEUR, V63, P964, DOI 10.1093/jnen/63.9.964	84	15	16	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2008	25	12					1483	1497		10.1089/neu.2008.0658			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	400IY	WOS:000262862500010	19125684	Green Published			2021-06-18	
J	McGrath, N; Dowds, MM; Goldstein, R				McGrath, Neal; Dowds, Murdo M., Jr.; Goldstein, Richard			Clinical Supervision of a Client With Traumatic Brain Injury in a Host Home Placement Using Video Teleconferencing: A Case Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						clinical supervision; community reintegration; traumatic brain injury; video teleconferencing	TELEREHABILITATION; TELEHEALTH	To examine the use of video teleconferencing (VTC) technology in the supervision of a 41-year-old man with expressive aphasia during community reintegration in a host home setting 3 years after severe traumatic brain injury (TBI). Design: U sing a 3-month A-B-A design, weekly VTC meetings were substituted for in-person visits by the client's case coordinator. Main outcome measures: Weekly ratings of satisfaction with the medium of communication used (VTC vs in-person meetings) by each participant. Results: The client and the case coordinator found VTC meetings to be as effective as face-to-face supervision visits for communication of clinical concerns and problems. The client reported feeling self-conscious about having the equipment in his living space because of privacy concerns. The mentor reported that VTC helped focus on questions and answers in goal-oriented conversations, was easier to schedule, and had the advantage of not requiring preparation of the house for in-person meetings. Reported disadvantages included feelings of camera shyness as well as impatience due to slow video transmission speed at times. The case coordinator also found VTC meetings easier to schedule and reported savings in travel time and expense. Reported disadvantages included reduced transmission quality and speed on some occasions. The cost break-even point for VTC was reached at I year with substitution of VTC sessions for half of weekly case coordinator home visits and 2 home visits per year by the coordinator's supervisor. Conclusion: VTC might be liberally substituted for in-person supervision visits in the context of an ongoing clinical relationship during Community reintegration following TBI.	[McGrath, Neal] Ctr Comprehens Serv New England, Braintree, MA 02184 USA; [Dowds, Murdo M., Jr.] Harvard Univ, Sch Med, Boston, MA USA; [Goldstein, Richard] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA	McGrath, N (corresponding author), Ctr Comprehens Serv New England, 639 Granite St Suite 215, Braintree, MA 02184 USA.	nealmc-grath@rcn.com					Ball C J, 1995, J Telemed Telecare, V1, P22; BASHSHUR RL, 1995, J MED SYST, V19, P81, DOI 10.1007/BF02257059; DONIGER M, 1986, CANADIAN J PSYCHIAT, V31, P32; EDGINGTON ES, 1967, J PSYCHOL, V65, P195, DOI 10.1080/00223980.1967.10544864; Glueckauf RL, 2002, REHABIL PSYCHOL, V47, P49, DOI 10.1037/0090-5550.47.1.49; GUYATT GH, 1990, ANN INTERN MED, V112, P293, DOI 10.7326/0003-4819-112-4-293; Hauber RP, 2002, J HEAD TRAUMA REHAB, V17, P535, DOI 10.1097/00001199-200212000-00005; Liss HJ, 2002, REHABIL PSYCHOL, V47, P8, DOI 10.1037/0090-5550.47.1.8; Rosen MJ, 1999, NEUROREHABILITATION, V12, P11; Schopp L, 2000, PROF PSYCHOL-RES PR, V31, P179, DOI 10.1037/0735-7028.31.2.179; Todman J. B., 2001, SINGLE CASE SMALL N; VANDAMME G, 1993, SCRT SINGLE CASE RAN; WANG S, 2003, STROKE          0918; 2003, FED REG         0220, V68; 2000, FED REG         1228, V65	15	15	15	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2008	23	6					388	393		10.1097/01.HTR.0000341434.74875.c8			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	379WZ	WOS:000261428300004	19033831				2021-06-18	
J	Thompson, JM; Scott, KC; Dubinsky, L				Thompson, James M.; Scott, Kenneth C.; Dubinsky, Leslie			Battlefield brain Unexplained symptoms and blast-related mild traumatic brain injury	CANADIAN FAMILY PHYSICIAN			English	Article									[Thompson, James M.] Vet Affairs Canada Head Off, Charlottetown, PE, Canada; [Dubinsky, Leslie] Vet Affairs Canada Reg Off, Halifax, NS, Canada	Thompson, JM (corresponding author), Vet Affairs Canada Head Off, Charlottetown, PE, Canada.						Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; *DEF VET BRAIN IN, 2006, CLIN PRACT GUID REC; Engel CC, 2006, PHILOS T R SOC B, V361, P707, DOI 10.1098/rstb.2006.1829; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; KATES N, 1996, SHARED MENTAL HLTH C; McCrea M, 2008, MILD TRAUMATIC BRAIN; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; *UK MIN DEF, 2008, MILD TRAUM BRAIN INJ; *US DEP DEF, 2006, MED RES PREV MIT TRE; *VET AFF CAN, 2008, OP STRESS INJ CIN	14	15	18	0	5	COLL FAMILY PHYSICIANS CANADA	MISSISSAUGA	2630 SKYMARK AVE, MISSISSAUGA, ONTARIO L4W 5A4, CANADA	0008-350X			CAN FAM PHYSICIAN	Can. Fam. Phys.	NOV	2008	54	11					1549	1551					3	Primary Health Care; Medicine, General & Internal	General & Internal Medicine	394FU	WOS:000262432200018	19005124				2021-06-18	
J	Pillay, NS; Kellaway, LA; Kotwal, GJ				Pillay, Nirvana S.; Kellaway, Laurie A.; Kotwal, Girish J.			Early detection of memory deficits and memory improvement with vaccinia virus complement control protein in an Alzheimer's disease model	BEHAVIOURAL BRAIN RESEARCH			English	Article						Alzheimer's disease; inflammation; cheeseboard maze; complement; memory	BETA-PEPTIDE; BRAIN-INJURY; A-BETA; ACTIVATION; SYSTEM; RAT; INFLAMMATION; RECOVERY; CASCADE; BINDING	Vaccinia virus complement control protein (VCP) inhibits both the classical and alternate complement pathways. In diseases such as traumatic brain injury (TBI) and Alzheimer's disease (AD), pathological inflammation is caused by amongst several factors, prolonged or inappropriate activation of the complement system and is a significant cause of neurodegeneration. This study investigates for the first time the use of a cheeseboard maze to evaluate cognitive deficits and the effect of VCP on memory processes in 2- and 3-month-old mice that express mutant amyloid precursor protein (APPswe) and mutant presenilin 1 (Ps1dE9) that correspond to a form of early onset AD. A four-phase training schedule was carried out on the cheeseboard maze before intracranial injections of 5 mu l of VCP (1.7 mu g/mu l) or 5 mu l saline. Two weeks later the effect of VCP on memory was evaluated. A statistically significant decrease in goal latency in VCP-treated mice than saline-treated transgenic mice in both the first probe and reverse tasks was observed. Similarly, after a second intracranial VCP or saline injection performed 2 months later, the 6.5- and 7.5-month aged VCP-injected mice performed significantly better in goal latency in both second probe and reverse tasks than saline-treated mice. These data also demonstrated that the use of a dry maze is a sensitive technique for distinguishing cognitive measures between non-transgenic and APPswe/PS1De9 transgenic mice at a much earlier stage. (C) 2008 Elsevier B.V. All rights reserved.	[Kotwal, Girish J.] InflaMed Inc, Louisville, KY 40241 USA; [Kotwal, Girish J.] Inst Infect Dis & Mol Med, Cape Town, South Africa	Kotwal, GJ (corresponding author), InflaMed Inc, 4664 Shenandoah Dr, Louisville, KY 40241 USA.	GJKOTW01@gmail.com					Barnum SR, 2002, IMMUNOL RES, V26, P7, DOI 10.1385/IR:26:1-3:007; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bergamaschini L, 1999, CLIN EXP IMMUNOL, V115, P526; Bradt BM, 1998, J EXP MED, V188, P431, DOI 10.1084/jem.188.3.431; Daly J, 1998, NEUROBIOL AGING, V19, P619, DOI 10.1016/S0197-4580(98)00100-6; DALY J, 1997, IMMUNOLOGIST, V5, P157; DOUGLAS RJ, 1966, J COMP PHYSIOL PSYCH, V62, P171, DOI 10.1037/h0023668; Gerlai R, 1999, TRENDS NEUROSCI, V22, P47, DOI 10.1016/S0166-2236(98)01346-0; Hall CS, 1934, J COMP PSYCHOL, V18, P385, DOI 10.1037/h0071444; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; Jarvenpaa T, 2003, NEUROBIOL AGING, V24, P941, DOI 10.1016/S0197-4580(03)00008-3; JIANG HX, 1994, J IMMUNOL, V152, P5050; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kirschfink M, 1997, IMMUNOPHARMACOLOGY, V38, P51, DOI 10.1016/S0162-3109(97)00057-X; Kirwan CB, 2005, NEUROBIOL LEARN MEM, V83, P65, DOI 10.1016/j.nlm.2004.08.001; Kotwal G, 1998, 10TH INTERNATIONAL CONGRESS ON IMMUNOLOGY, VOLS 1 AND 2, P315; KOTWAL GJ, 1988, NATURE, V335, P176, DOI 10.1038/335176a0; KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434; Kotwal GJ, 1997, J LEUKOCYTE BIOL, V62, P415; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Murthy KHM, 2001, CELL, V104, P301, DOI 10.1016/S0092-8674(01)00214-8; OKUSAWA S, 1987, J IMMUNOL, V139, P2635; OKUSAWA S, 1988, J EXP MED, V168, P443, DOI 10.1084/jem.168.1.443; Pillay NS, 2007, BRAIN RES, V1153, P158, DOI 10.1016/j.brainres.2007.03.056; Pillay Nirvana S., 2004, Current Alzheimer Research, V1, P295, DOI 10.2174/1567205043331965; Pillay NS, 2005, ANN NY ACAD SCI, V1056, P450, DOI 10.1196/annals.1352.021; Savonenko A, 2005, NEUROBIOL DIS, V18, P602, DOI 10.1016/j.nbd.2004.10.022; Tacnet-Delorme P, 2001, J IMMUNOL, V167, P6374, DOI 10.4049/jimmunol.167.11.6374; Takabayashi T, 1996, J IMMUNOL, V156, P3455; Tenner AJ, 2001, NEUROBIOL AGING, V22, P849, DOI 10.1016/S0197-4580(01)00301-3; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X	31	15	15	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	OCT 10	2008	192	2					173	177		10.1016/j.bbr.2008.03.038			5	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	333RO	WOS:000258170200003	18490064				2021-06-18	
J	MacDonald, CL; Schwarze, N; Vaishnavi, SN; Epstein, AA; Snyder, AZ; Raichle, ME; Shimony, JS; Brody, DL				MacDonald, C. L.; Schwarze, N.; Vaishnavi, S. N.; Epstein, A. A.; Snyder, A. Z.; Raichle, M. E.; Shimony, J. S.; Brody, D. L.			Verbal memory deficit following traumatic brain injury: Assessment using advanced MRI methods	NEUROLOGY			English	Article							DIFFUSE AXONAL INJURY		[Brody, D. L.] Washington Univ, Dept Neurol, St Louis, MO 63110 USA; [Vaishnavi, S. N.; Epstein, A. A.; Snyder, A. Z.; Raichle, M. E.; Shimony, J. S.] Washington Univ, Dept Radiol & Radiol Sci, St Louis, MO 63110 USA	Brody, DL (corresponding author), Washington Univ, Dept Neurol, 660 S Euclid Ave,Box 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS049237-02, K08 NS049237-01, K08 NS049237-05, K08 NS049237, K08 NS049237-03, K08 NS049237-04] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS049237] Funding Source: NIH RePORTER		Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; STRICH SJ, 1961, LANCET, V2, P443; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046	7	15	15	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	OCT 7	2008	71	15					1199	1201		10.1212/01.wnl.0000327521.69520.7f			6	Clinical Neurology	Neurosciences & Neurology	356XE	WOS:000259810100013	18838668	Green Published, Green Accepted			2021-06-18	
J	Hsiao, KY; Hsiao, CT; Weng, HH; Chen, KH; Lin, LJ; Huang, YM				Hsiao, K-Y; Hsiao, C-T; Weng, H-H; Chen, K-H; Lin, L-J; Huang, Y-M			Factors predicting mortality in victims of blunt trauma brain injury in emergency department settings	EMERGENCY MEDICINE JOURNAL			English	Article							GLASGOW COMA SCALE; HEAD-INJURY; HYPOTENSION; TOMOGRAPHY; MODERATE; HYPOXIA; SCORE; RISK	Objective: The aim of the s-tudy was to identify risk factors for mortality in patients brought to the emergency department (ED) after blunt traumatic brain injury (TBI). Methods: The medical records of such patients who visited the ED from June 2004 to May 2005 were retrospectively reviewed. Data (age, gender, initial Glasgow coma scale (GCS) scores, initial vital signs, brain computed tomography scan findings and cause of trauma) were collected from the records of 204 TBI patients, who were treated at the ED and needed intensive care. Among these patients, 48 died in the intensive care unit (ICU) of the hospital. Logistic regression was used to assess factors affecting mortality after trauma. Results: Age (odds ratio (OR) 1.04; 95% CI 1.01 to similar to 1.07), GCS score less than 9 (OR 19.29; 95% CI 5.04 to similar to 73.82) and skull bone fracture (OR 10.44; 95% CI 3.59 to similar to 30.38) were identified as possible risk factors of mortality in TBI patients. Conclusion: These predictors appear to be clinically relevant and may help improve ED triage of TBI patients in need of ICU care.	[Hsiao, K-Y; Hsiao, C-T; Lin, L-J] Chang Gung Mem Hosp, Dept Emergency Med, Chiayi, Taiwan; [Weng, H-H] Chang Gung Mem Hosp, Dept Diagnost Radiol, Chiayi, Taiwan; [Chen, K-H] Chang Gung Mem Hosp, Dept Phys Med & Rehabil, Chiayi, Taiwan; [Hsiao, K-Y; Hsiao, C-T; Weng, H-H; Chen, K-H; Lin, L-J; Huang, Y-M] Chang Gung Univ, Coll Med, Tao Yuan, Taiwan; [Huang, Y-M] Chang Gung Mem Hosp, Dept Nursing, Chiayi, Taiwan; [Weng, H-H] Kaohsiung Med Univ, Grad Inst Occupat Safety & Hlth, Coll Hlth Sci, Kaohsiung, Taiwan	Huang, YM (corresponding author), Chiayi Chang Gung Mem Hosp, Dept Emergency Med, 6 W Sect,Chia Pu Rd, Puzih City 613, Chiayi County, Taiwan.	richard.smith@msa.hinet.net	Weng, Hsu-Huei/N-8329-2014	Weng, Hsu-Huei/0000-0002-2020-8912			Celli P, 1997, Minerva Chir, V52, P1467; Cho DY, 1997, INTENS CARE MED, V23, P77, DOI 10.1007/s001340050294; Davis DP, 2006, J TRAUMA, V60, P985, DOI 10.1097/01.ta.0000205860.96209.1c; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Miller KJ, 2005, J NEUROSURG, V103, P239, DOI 10.3171/jns.2005.103.2.0239; Newgard CD, 2005, EMERG MED J, V22, P855, DOI 10.1136/emj.2004.020206; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Perel P, 2007, J EVAL CLIN PRACT, V13, P464, DOI 10.1111/j.1365-2753.2006.00713.x; SERVADEI F, 1988, SURG NEUROL, V30, P364, DOI 10.1016/0090-3019(88)90199-1; Shafi S, 2005, J TRAUMA, V59, P830, DOI 10.1097/01.ta.0000188147.36232.c0; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TINTINALLI JE, 2003, EMERGENCY MED COMPRE, P1557	14	15	15	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	OCT	2008	25	10					670	673		10.1136/emj.2007.053405			4	Emergency Medicine	Emergency Medicine	358EF	WOS:000259899000013	18843067				2021-06-18	
J	Jagannathan, P; Jagannathan, J				Jagannathan, Pavan; Jagannathan, Jay			RETRACTED: Molecular mechanisms of traumatic brain injury in children (Retracted article. See vol. 26, pg Nil_0078, 2009)	NEUROSURGICAL FOCUS			English	Article; Retracted Publication						management; outcome; pediatric trauma	SEVERE HEAD-INJURY; FLUID-PERCUSSION INJURY; D-ASPARTATE ANTAGONISTS; LONG-TERM POTENTIATION; DEVELOPING RAT-BRAIN; CEREBRAL-BLOOD-FLOW; CEREBROSPINAL-FLUID; APOPTOTIC NEURODEGENERATION; IN-VITRO; INTRACRANIAL HYPERTENSION	Despite advances in molecular biology and genetics, the precise pathophysiology of traumatic brain injury (TBI) in children is unknown. In this paper the authors review what is currently known about intra- and extracellular responses to pediatric TBI and relate these factors to future investigations. Although hyperemia and vascular congestion have long been thought to be the hallmarks of pediatric TBI, on a cellular level, calcium influx as well as modulation of local neurotransmitters appears to play a major role in its onset. Recent genetic and proteomic research has identified specific neurotrophic factors as well as apoptotic and antiapoptotic genes that appear to control the progression of inflammation and neuronal damage. The search for a therapeutic target will ultimately require a thorough understanding of these factors and their interplay on a proteomic, genomic, and neuromic level.	[Jagannathan, Jay] Univ Virginia Hlth Syst, Dept Neurosurg, Charlottesville, VA 22908 USA; [Jagannathan, Pavan] Landon Sch, Bethesda, MD USA	Jagannathan, J (corresponding author), Univ Virginia Hlth Syst, Dept Neurosurg, Box 800212, Charlottesville, VA 22908 USA.	jj5a@hscmail.mcc.virginia.edu					Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; Adelson P D, 2000, Clin Neurosurg, V47, P319; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Blitzer R, 2003, J AM ACAD CHILD PSY, V42, P998, DOI 10.1097/01.CHI.0000046894.27264.9D; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Di X, 2000, ACT NEUR S, V76, P379; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CCM.0000080493.04978.73; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Franz G, 2002, J CEREBR BLOOD F MET, V22, P951, DOI 10.1097/00004647-200208000-00006; Gao WM, 2007, J NEUROTRAUM, V24, P43, DOI 10.1089/neu.2006.0061; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Golarai G, 2001, J NEUROSCI, V21, P8523; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183; Hellmich HL, 2007, BRAIN RES, V1127, P119, DOI 10.1016/j.brainres.2006.09.094; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; Ikonomidou C, 1995, CURR OPIN NEUROL, V8, P487, DOI 10.1097/00019052-199512000-00017; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ikonomidou C, 1996, CRIT REV NEUROBIOL, V10, P239; Ikonomidou C, 2000, SCIENCE, V287, P1056, DOI 10.1126/science.287.5455.1056; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; Ishimaru MJ, 1999, J COMP NEUROL, V408, P461; Isoniemi H, 2006, J NEUROTRAUM, V23, P1600, DOI 10.1089/neu.2006.23.1600; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jiang Y, 2006, NEUROSCI LETT, V408, P155, DOI 10.1016/j.neulet.2006.08.082; Jones PA, 2005, ACT NEUR S, V95, P29; JOURDAN C, 1993, NEUROCHIRURGIE, V39, P304; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kingham PJ, 2001, J NEUROCHEM, V76, P1475, DOI 10.1046/j.1471-4159.2001.00146.x; Konrad K, 2003, COGNITIVE BRAIN RES, V16, P425, DOI 10.1016/S0926-6410(03)00057-0; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Kwak S, 2006, CURR OPIN NEUROBIOL, V16, P281, DOI 10.1016/j.conb.2006.05.004; Lau A, 2006, J NEUROSCI, V26, P11540, DOI 10.1523/JNEUROSCI.3507-06.2006; Liu LD, 2004, SCIENCE, V304, P1021, DOI 10.1126/science.1096615; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Ohsumi Y, 2004, SEMIN CELL DEV BIOL, V15, P231, DOI 10.1016/j.semcdb.2003.12.004; Ottens AK, 2007, PROG BRAIN RES, V161, P401, DOI 10.1016/S0079-6123(06)61029-7; Pickard JD, 2005, ACT NEUR S, V95, P459; Pierre P, 1998, CELL, V93, P1135, DOI 10.1016/S0092-8674(00)81458-0; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Crespo ART, 2007, BRAIN INJURY, V21, P441, DOI 10.1080/02699050701311125; Robertson CL, 2004, DEV BRAIN RES, V151, P141, DOI 10.1016/j.devbrainres.2004.04.007; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Sitcheran R, 2005, EMBO J, V24, P510, DOI 10.1038/sj.emboj.7600555; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; Tang YP, 1999, NATURE, V401, P63; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; TAYLOR CP, 1995, TRENDS PHARMACOL SCI, V16, P309, DOI 10.1016/S0165-6147(00)89060-4; Walter B, 2004, J NEUROTRAUM, V21, P1076, DOI 10.1089/0897715041651024; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027	85	15	16	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	OCT	2008	25	4							E6	10.3171/FOC.2008.25.10.E6			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	355HX	WOS:000259701100006	17608357	Bronze			2021-06-18	
J	Kendall, E; Terry, DJ				Kendall, Elizabeth; Terry, Deborah J.			Understanding adjustment following traumatic brain injury: Is the Goodness-of-Fit coping hypothesis useful?	SOCIAL SCIENCE & MEDICINE			English	Article						Traumatic brain injury; Goodness-of-Fit hypothesis; Coping; Psychosocial adjustment; Australia	PSYCHOSOCIAL ADJUSTMENT; COMMUNITY SAMPLE; MENTAL-HEALTH; STRATEGIES; CONTROLLABILITY; FUTURE; MODEL	Coping efforts have been recognised as an important aspect of resilience following traumatic brain injury, but little is known about what constitutes effective coping in this population. This longitudinal research examined the usefulness of the Goodness-of-Fit hypothesis, drawn from the Lazarus and Folkman [(1984). Stress, appraisal and coping. NY: Springer.] theory of stress and coping, as a way of understanding coping effectiveness. The hypothesis suggests that the nature and success of specific coping strategies will be associated with the controllability of the event. If an event is relatively uncontrollable, then emotion-focused or perception-focused coping may be more effective than problem-focused coping. In contrast, a controllable event may be best managed through problem-focused coping. Ninety people with traumatic brain injury, drawn from the inpatient rehabilitation unit of a major metropolitan hospital in Australia, and their relatives participated in this longitudinal study. No support was found for the Goodness-of-Fit model, either in the short term or the long term. Although the use of problem-focused coping strategies was positively associated with short-term and long-term role functioning, it was not associated with long-term emotional well-being if the situation was perceived to be controllable. The findings suggest that the persistent use of problem-focused coping in response to the difficulties created by traumatic brain injury can be associated with emotional distress in the long term. Reasons for this finding are explored and its implications are discussed. (C) 2008 Elsevier Ltd. All rights reserved.	[Kendall, Elizabeth] Griffith Univ, Griffith Inst Hlth & Med Res, Ctr Natl Res Disabil & Rehabil Med, Meadowbrook, Qld 4131, Australia; [Terry, Deborah J.] Univ Queensland, Sch Psychol, Brisbane, Qld, Australia	Kendall, E (corresponding author), Griffith Univ, Griffith Inst Hlth & Med Res, Ctr Natl Res Disabil & Rehabil Med, Logan Campus,Univ Dr, Meadowbrook, Qld 4131, Australia.	e.kendall@griffith.edu.au	kendall, elizabeth/F-5065-2013	Kendall, Elizabeth/0000-0003-2399-1460			Aiken L.S., 1991, MULTIPLE REGRESSION; ALDWIN CM, 1987, J PERS SOC PSYCHOL, V53, P337, DOI 10.1037/0022-3514.53.2.337; Bedford A, 1997, PERS INDIV DIFFER, V22, P493, DOI 10.1016/S0191-8869(96)00242-5; BEDFORD A, 1976, BRIT J SOC CLIN PSYC, V15, P387, DOI 10.1111/j.2044-8260.1976.tb00050.x; Billings A G, 1981, J Behav Med, V4, P139, DOI 10.1007/BF00844267; Brown JE, 2000, QUAL LIFE RES, V9, P75, DOI 10.1023/A:1008995814965; Cohen J., 1983, APPL MULTIPLE REGRES; CONWAY VJ, 1992, AUST J PSYCHOL, V44, P1, DOI 10.1080/00049539208260155; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; DAVIS PJ, 1987, J PERS SOC PSYCHOL, V52, P155, DOI 10.1037/0022-3514.52.1.155; DEROGATIS LR, 1986, J PSYCHOSOM RES, V30, P77, DOI 10.1016/0022-3999(86)90069-3; Endler NS, 2000, PERS INDIV DIFFER, V29, P951, DOI 10.1016/S0191-8869(99)00246-9; Folkman S, 2004, ANNU REV PSYCHOL, V55, P745, DOI 10.1146/annurev.psych.55.090902.141456; FOLKMAN S, 1980, J HEALTH SOC BEHAV, V21, P219, DOI 10.2307/2136617; Heppner P. P., 1991, HDB SOCIAL CLIN PSYC, P681; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; Jennett B, 1981, MANAGEMENT HEAD INJU; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KENDALL E, 1997, J HEAD TRAUMA REHAB, V12, P69; KENDALL E, 2001, BRAIN IMPAIR, V2, P81; Lazarus R. S., 1990, PSYCHOL INQUIRY, V1, P3, DOI DOI 10.1207/S15327965PLI0101_1; Lazarus R.S., 1984, STRESS APPRAISAL COP; LAZARUS RS, 1993, PSYCHOSOM MED, V55, P234, DOI 10.1097/00006842-199305000-00002; Luthar SS, 2000, CHILD DEV, V71, P543, DOI 10.1111/1467-8624.00164; MCCOLL MA, 1995, SOC SCI MED, V41, P395, DOI 10.1016/0277-9536(94)00338-T; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Park CL, 2001, J CONSULT CLIN PSYCH, V69, P481, DOI 10.1037//0022-006X.69.3.481; Stanton AL, 2002, PSYCHO-ONCOLOGY, V11, P93, DOI 10.1002/pon.574; TAYLOR SE, 1988, PSYCHOL BULL, V103, P193, DOI 10.1037/0033-2909.103.2.193; Terry DJ, 1998, J PERS SOC PSYCHOL, V74, P1078, DOI 10.1037/0022-3514.74.4.1078; THOITS PA, 1984, REV PERSONALITY SOCI; VITALIANO PP, 1990, J PERS SOC PSYCHOL, V59, P582, DOI 10.1037/0022-3514.59.3.582; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Zakowski SG, 2001, ANN BEHAV MED, V23, P158, DOI 10.1207/S15324796ABM2303_3	36	15	16	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0277-9536			SOC SCI MED	Soc. Sci. Med.	OCT	2008	67	8					1217	1224		10.1016/j.socscimed.2008.05.033			8	Public, Environmental & Occupational Health; Social Sciences, Biomedical	Public, Environmental & Occupational Health; Biomedical Social Sciences	362MC	WOS:000260200800003	18625542				2021-06-18	
J	Ciavarro, C; Dobson, M; Goodman, D				Ciavarro, Chad; Dobson, Mike; Goodman, David			Implicit learning as a design strategy for learning games: Alert Hockey	COMPUTERS IN HUMAN BEHAVIOR			English	Article						Implicit learning; Computer games; Brain concussion	ROLE MODELS	Concussion education and prevention for youth hockey players has been an issue of recent concern amongst sport medicine practitioners and hockey's administrative bodies. This article details the assessment of a sports-action hockey video game that aims to reduce the aggressive and negligent behaviours that can lead to concussions. The game, termed Alert Hockey, was designed to modify game playing behaviour by embedding an implicit teaching mechanism within the gameplay. In Alert Hockey, participants were expected to learn by simply playing to win, in contrast to playing to learn. We studied learning in an experimental simulated environment where the possibility to win the game was exaggerated as a consequence of desirable safety behaviours (positive learning group) and effectively reduced as a consequence of undesirable (negative learning group) behaviour. The positive learning group significantly improved their mean score on a composite behavioural indicator compared with no significant change amongst control group participants. The results demonstrate that implicit learning embedded in a sports-action game can lead to changes in game-play behaviour. (C) 2008 Elsevier Ltd. All rights reserved.	[Goodman, David] Simon Fraser Univ, Sch Kinesiol, Burnaby, BC V5A 1S6, Canada; [Ciavarro, Chad; Dobson, Mike] Simon Fraser Univ, Surrey, BC, Canada	Goodman, D (corresponding author), Simon Fraser Univ, Sch Kinesiol, 8888 Univ Blvd, Burnaby, BC V5A 1S6, Canada.	cdc@sfu.ca; mdobson@sfu.ca; goodman@sfu.ca					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Berry D. C., 1993, IMPLICIT LEARNING TH; Bryant AL, 2003, J ADOLESCENT RES, V18, P36, DOI 10.1177/0743558402238276; Burton J. K., 2004, HDB RES ED COMMUNICA, P3; CIAVARRO C, 2005, ED MEDIA 2005 MONTR; Cleeremans A, 1998, TRENDS COGN SCI, V2, P406, DOI 10.1016/S1364-6613(98)01232-7; De Castell S, 2003, J CURRICULUM STUD, V35, P649, DOI 10.1080/0022027032000145552; DeKeyser R. M., 1995, STUD SECOND LANG ACQ, V17, P379, DOI DOI 10.1017/S027226310001425X; DESTREBECQZ A, 2003, ATTENTION IMPLICIT L; DOBSON M, 2005, DIGRA 2005 JUN 16 20; DRYDEN K, 2004, GLOBE MAIL      0327, pA21; Egenfeldt-Nielsen S., 2005, THESIS IT U COPENHAG; *ESA, 2005, ESS FACTS COMP VID G; FRENSCH PA, 1998, HDB IMPLICIT LEARNIN; HADDON L, 1988, SCREEN, V29, P52, DOI 10.1093/screen/29.2.52; HAZELTINE E, 2003, ATTENTION IMPLICIT L; Jimenez L., 2003, ATTENTION IMPLICIT L; Jonassen DH, 1997, ETR&D-EDUC TECH RES, V45, P65, DOI 10.1007/BF02299613; Lieberman D A, 2001, J Ambul Care Manage, V24, P26; *LUD, 2005, RES CTR; MAUSHAK NJ, 2001, NAT CONV ASS ED COMM; McCrory P, 2005, BRIT J SPORT MED, V39, P116, DOI 10.1136/bjsm.2004.015958; PLEISS MK, 1995, EDUC PSYCHOL, V30, P159, DOI 10.1207/s15326985ep3003_6; Rapp DN, 2006, COMPUT HUM BEHAV, V22, P603, DOI 10.1016/j.chb.2005.12.004; REBER AS, 1967, J VERB LEARN VERB BE, V6, P855, DOI 10.1016/S0022-5371(67)80149-X; REBER AS, 1989, J EXP PSYCHOL GEN, V118, P219, DOI 10.1037/0096-3445.118.3.219; Rose M, 2005, J COGNITIVE NEUROSCI, V17, P918, DOI 10.1162/0898929054021193; Salen K., 2004, RULES PLAY GAME DESI; Shanks DR, 2005, PSYCHOL RES-PSYCH FO, V69, P369, DOI 10.1007/s00426-004-0211-8; Sheldon JP, 2001, RES Q EXERCISE SPORT, V72, P304, DOI 10.1080/02701367.2001.10608965; Silverman Barry G, 2002, J Healthc Inf Manag, V16, P80; Smith M., 1988, CHILDREN SPORT, P301; Squire K., 2003, Educational Technology, V43, P17; STEINKUEHLER C, 2004, 6 INT C LEARN SCI LO; Tomlin R., 1994, STUD SECOND LANG ACQ, V16, P183, DOI [DOI 10.1017/S0272263100012870, 10.1017/S0272263100012870]; Vyse Stuart A., 1997, BELIEVING MAGIC PSYC; Weinstein MD, 1995, SEX ROLES, V33, P831, DOI 10.1007/BF01544782; Williams JN, 2005, STUD SECOND LANG ACQ, V27, P269, DOI 10.1017/S0272263105050138	38	15	15	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0747-5632	1873-7692		COMPUT HUM BEHAV	Comput. Hum. Behav.	SEP	2008	24	6			SI		2862	2872		10.1016/j.chb.2008.04.011			11	Psychology, Multidisciplinary; Psychology, Experimental	Psychology	364TQ	WOS:000260358600028					2021-06-18	
J	Davis, RL; Buck, DJ; Saffarian, N; Mohan, S; DeSilva, U; Fernando, SC; Stevens, CW				Davis, Randall L.; Buck, Daniel J.; Saffarian, Neda; Mohan, Shekher; DeSilva, Udaya; Fernando, Samodha C.; Stevens, Craig W.			beta-funaltrexamine inhibits inducible nitric-oxide synthase expression in human astroglial cells	JOURNAL OF NEUROIMMUNE PHARMACOLOGY			English	Article						neuroinflammation; opioids; astrocytes; nitric oxide; fentanyl; morphine	TRAUMATIC BRAIN-INJURY; MESSENGER-RNA; ANTAGONIST; MODULATION; MICROGLIA; NEURONS; RATS	The inducible isoform of nitric-oxide synthase (iNOS) is involved in neuropathogenesis associated with infection and disease in the brain. Hence, there is considerable interest in the identification of therapeutic interventions to prevent iNOS-mediated pathology. Astroglia are a major site of iNOS expression during neuropathogenesis. To mimic a key component of neuroinflammation, human A172 astroglial cells were exposed in vitro to a cytokine mixture containing interferon gamma, tumor necrosis factor alpha, and interleukin-1 beta, resulting in significant iNOS expression. Next, we assessed the effects of the mu opioid receptor antagonist, beta-funaltrexamine (beta-FNA), on cytokine induced iNOS expression in human astroglia. beta-FNA dose-dependently inhibited iNOS expression. beta-FNA transcriptionally (or pre-transcriptionally) inhibited cytokine-induced iNOS activation as indicated by a significant decrease in NOS2 messenger RNA expression. Further characterization of the novel, anti-inflammatory actions of beta-FNA may provide insights for pharmacologic strategies to treat or prevent brain pathologies associated with neuroinflammation.	[Davis, Randall L.; Buck, Daniel J.; Saffarian, Neda; Mohan, Shekher; Stevens, Craig W.] Oklahoma State Univ, Ctr Hlth Sci, Dept Pharmacol Physiol, Tulsa, OK 74107 USA; [DeSilva, Udaya; Fernando, Samodha C.] Oklahoma State Univ, Div Agr Sci & Nat Resources, Stillwater, OK 74078 USA	Davis, RL (corresponding author), Oklahoma State Univ, Ctr Hlth Sci, Dept Pharmacol Physiol, 1111 W 17th St, Tulsa, OK 74107 USA.	randall.davis@okstate.edu		DeSilva, Udaya/0000-0003-2517-6566	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R21AA014955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R15DA012448] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA 014955] Funding Source: Medline; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R15 DA012448-04A1, DA 012448] Funding Source: Medline		Davis RL, 2007, J NEUROIMMUNOL, V186, P141, DOI 10.1016/j.jneuroim.2007.03.021; Davis RL, 2004, ALCOHOL, V32, P195, DOI 10.1016/j.alcohol.2004.01.006; Davis RL, 2002, ALCOHOL CLIN EXP RES, V26, P1404, DOI 10.1097/01.ALC.0000030841.92766.80; Hettinger AM, 2001, BIOL REPROD, V65, P507, DOI 10.1095/biolreprod65.2.507; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Lee J, 2004, IMMUNOPHARM IMMUNOT, V26, P17, DOI 10.1081/IPH-120029941; Liu B, 2000, J PHARMACOL EXP THER, V293, P607; Liu YX, 2002, J PHARMACOL EXP THER, V302, P1212, DOI 10.1124/jpet.102.035956; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Marchetti B, 2005, BRAIN RES REV, V48, P302, DOI 10.1016/j.brainresrev.2004.12.030; Poluektova L, 2005, GLIA, V52, P344, DOI 10.1002/glia.20253; QI JA, 1990, J PHARMACOL EXP THER, V252, P1006; Ruzicka BB, 1995, MOL BRAIN RES, V34, P209, DOI 10.1016/0169-328X(95)00165-O; Zhao H, 2002, NEUROSCIENCE, V114, P1019, DOI 10.1016/S0306-4522(02)00233-6; Zhao P, 2006, J NEUROPATH EXP NEUR, V65, P945, DOI 10.1097/01.jnen.0000235123.05677.4b	15	15	15	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1557-1890			J NEUROIMMUNE PHARM	J. Neuroimmune Pharm.	SEP	2008	3	3					150	153		10.1007/s11481-008-9102-x			4	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	337AI	WOS:000258407500002	18278557	Green Accepted			2021-06-18	
J	Feliciano, CE; De Jesus, O				Feliciano, Caleb E.; De Jesus, Orlando			Conservative management outcomes of traumatic acute subdural hematomas	PUERTO RICO HEALTH SCIENCES JOURNAL			English	Article						acute subdural hematoma; conservative treatment; traumatic brain injury	CRITERIA; SCALE	Background: Traumatic brain injury represents a significant cause of mortality and permanent disability in the adult population. Acute subdural hematoma is one of the conditions most strongly associated with severe brain injury. Knowledge on the natural history of the illness and the outcomes of patients conservatively managed may help the neurosurgeon in the decision-making process. Methods: We present the clinical course and outcomes of a group of 38 patients with traumatic acute subdural hematomas conservatively treated. Outcomes analysis taking into consideration age, Glasgow Coma Scale scores on admission, and radiological findings is provided. Results: Patients less than 65 years old had a favorable or functionally independent outcome in 85% of the cases. Patients with Glasgow Coma Scale scores greater than 8 had a functionally independent outcome in 78%, of the cases. Patients with acute subdural hematomas with thicknesses :510 mm and midline shifts <= 5 rum showed functionally independent outcomes in 82% of the cases. Conclusion: The conservative management of patients with acute subdural hematomas can be a viable alternative in certain cases. Those patients younger than 65 years old, with small acute subdural hematomas and Glasgow Coma Scale scores greater than 8, will have the best functional outcomes.	[Feliciano, Caleb E.; De Jesus, Orlando] Univ Puerto Rico, Dept Surg, Sect Neurol Surg, San Juan, PR 00936 USA	Feliciano, CE (corresponding author), Univ Puerto Rico, Dept Surg, Sect Neurol Surg, Med Sci Campus,POB 365067, San Juan, PR 00936 USA.	cfeliciano@rcm.upr.edu; odejesus@pol.net					Bullock MR, 2006, NEUROSURGERY, V58, P16, DOI [10.1227/01.NEU.0000210364.29290.C9, DOI 10.1227/01.NEU.0000210364.29290.C9]; CROCE MA, 1994, J TRAUMA, V36, P820, DOI 10.1097/00005373-199406000-00012; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1974, LANCET, V2, P1; Kawamata T, 1995, SURG NEUROL, V44, P438, DOI 10.1016/0090-3019(95)00249-9; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; MATHEW P, 1993, ACTA NEUROCHIR, V121, P100, DOI 10.1007/BF01809258; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; WONG CW, 1995, ACTA NEUROCHIR, V135, P38, DOI 10.1007/BF02307412; Zumkeller M, 1996, NEUROSURGERY, V39, P708, DOI 10.1097/00006123-199610000-00011	16	15	15	0	2	UNIV PUERTO RICO MEDICAL SCIENCES CAMPUS	SAN JUAN	OFFICE DEAN ACADEMIC AFFAIRS BOX 365067, SAN JUAN, PR 00936-5067 USA	0738-0658			P R HEALTH SCI J	P. R. Health Sci. J.	SEP	2008	27	3					220	223					4	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	349BX	WOS:000259254900006	18782966				2021-06-18	
J	Bledsoe, KA; Kramer, AH				Bledsoe, Kathleen A.; Kramer, Andreas H.			Propylene glycol toxicity complicating use of barbiturate coma	NEUROCRITICAL CARE			English	Article						propylene glycol; barbiturate coma; pentobarbital; phenobarbital; refractory status epilepticus	REFRACTORY STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; LORAZEPAM INFUSION; ETOMIDATE INFUSION; THERAPY; ANESTHESIA; PROPOFOL; PATIENT; EDEMA	Introduction Barbiturate coma is a necessary medical therapy in certain instances, such as the treatment of refractory status epilepticus or severe intracranial hypertension, but its use is often wrought with serious complications. Potential complications include hemodynamic instability, respiratory depression, and immunosuppression with frequent nosocomial infections. High doses of barbiturates may also lead to the accumulation of propylene glycol, the vehicle used in the intravenous formulations of both pentobarbital and phenobarbital, thereby yielding another less-recognized complication of therapy. Results We present a case of propylene glycol toxicity associated with the use of high-dose intravenous pentobarbital and phenobarbital during the treatment of refractory status epilepticus.	[Bledsoe, Kathleen A.] Univ Virginia Hlth Syst, Dept Pharm, Charlottesville, VA 22908 USA; [Kramer, Andreas H.] Univ Calgary, Foothills Med Ctr, Dept Crit Care Med, Calgary, AB T2N 2T9, Canada; [Kramer, Andreas H.] Univ Calgary, Foothills Med Ctr, Dept Clin Neurosci, Calgary, AB T2N 2T9, Canada	Bledsoe, KA (corresponding author), Univ Virginia Hlth Syst, Dept Pharm, POB 800674, Charlottesville, VA 22908 USA.	kv9k@virginia.edu					Arroliga AC, 2004, CRIT CARE MED, V32, P1709, DOI 10.1097/01.CCM.0000134831.40466.39; ARULANANTHAM K, 1978, J PEDIATR-US, V93, P515, DOI 10.1016/S0022-3476(78)81183-4; BEDICHEK E, 1991, ARCH INTERN MED, V151, P2297, DOI 10.1001/archinte.151.11.2297; Brain Trauma Foundation; American Association of Neurological Surgeons, 2007, J NEUROTRAUM, V24, pS71, DOI [10.1089/neu.2007.9985, DOI 10.1089/NEU.2007.9985]; Cairns CJS, 2002, INTENS CARE MED, V28, P1357, DOI 10.1007/s00134-002-1399-y; CHOI SD, 1985, ANESTHESIOLOGY, V62, P442, DOI 10.1097/00000542-198504000-00012; Claassen J, 2002, EPILEPSIA, V43, P146, DOI 10.1046/j.1528-1157.2002.28501.x; DEMEY HE, 1987, CRIT CARE MED, V15, P540, DOI 10.1097/00003246-198705000-00021; EBERHARDT KEW, 1992, INFECTION, V20, P12, DOI 10.1007/BF01704886; ECKSTEIN JW, 1961, ANESTHESIOLOGY, V22, P525, DOI 10.1097/00000542-196107000-00002; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; LEVY ML, 1995, NEUROSURGERY, V37, P363, DOI 10.1227/00006123-199508000-00035; Llompart-Pou JA, 2007, J ENDOCRINOL INVEST, V30, P393, DOI 10.1007/BF03346316; LOUIS S, 1967, AM HEART J, V74, P523, DOI 10.1016/0002-8703(67)90011-7; Parker MG, 2002, INTENS CARE MED, V28, P81, DOI 10.1007/s00134-001-1125-1; PARTINEN M, 1981, BRIT MED J, V282, P520, DOI 10.1136/bmj.282.6263.520; Parviainen I, 2002, NEUROLOGY, V59, P1249, DOI 10.1212/01.WNL.0000032253.88378.D7; Ploppa A, 2006, CRIT CARE MED, V34, P478, DOI 10.1097/01.CCM.0000199067.71968.6E; Reves JG, 2005, MILLERS ANESTHESIA, P326; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; Stover JF, 1998, EUR J CLIN PHARMACOL, V54, P529, DOI 10.1007/s002280050508; Tayar J, 2002, NEW ENGL J MED, V346, P1253, DOI 10.1056/NEJM200204183461618; TODD MM, 1985, ANESTH ANALG, V64, P681; VERRESEN L, 1986, CRIT CARE MED, V14, P753, DOI 10.1097/00003246-198608000-00021; Wilson KC, 2000, NEW ENGL J MED, V343, P815, DOI 10.1056/NEJM200009143431115; Wilson KC, 2005, CHEST, V128, P1674, DOI 10.1378/chest.128.3.1674; Yaucher NE, 2003, PHARMACOTHERAPY, V23, P1094, DOI 10.1592/phco.23.10.1094.32762; Yorgin PD, 1997, AM J KIDNEY DIS, V30, P134, DOI 10.1016/S0272-6386(97)90577-1; Zar T, 2007, SEMIN DIALYSIS, V20, P217, DOI 10.1111/j.1525-139X.2007.00280.x	30	15	15	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2008	9	1					122	124		10.1007/s12028-008-9065-z			3	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	340PM	WOS:000258657500019	18270846				2021-06-18	
J	Hellmich, HL; Eidson, K; Cowart, J; Crookshanks, J; Boone, DK; Shah, S; Uchida, T; DeWitt, DS; Prough, DS				Hellmich, Helen L.; Eidson, Kristine; Cowart, Jeremy; Crookshanks, Jeanna; Boone, Deborah K.; Shah, Syed; Uchida, Tatsuo; DeWitt, Douglas S.; Prough, Donald S.			Chelation of neurotoxic zinc levels does not improve neurobehavioral outcorne after traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						traumatic brain injury; zinc chelation.; behavioral outcome	INTRACELLULAR ZINC; NEURONAL INJURY; HIPPOCAMPUS; RESPONSES; ISCHEMIA; DISEASE; STRESS	Increases of synaptically released zinc and intracellular accumulation of zinc in hippocampal neurons after traumatic or ischemic brain injury is neurotoxic and chelation of zinc has been shown to reduce neurodegeneration. Although our previous studies showed that zinc chelation in traumatically brain-injured rats correlated with an increase in whole-brain expression of several neuroprotective genes and reduced numbers of apoptotic neurons, the effect on functional outcome has not been determined, and the question of whether this treatment may actually be clinically relevant has not been answered. In the present study, we show that treatment of TBI rats with the zinc chelator calcium EDTA reduces the numbers of injured, Fluoro-jade-positive neurons in the rat hippocampus 24 h after injury but does not improve neurobehavioral outcome (spatial memory deficits) 2 weeks post-injury. Our data suggest that,zinc chelation, despite providing short-term histological neuroprotection, fails to improve long-term functional outcome, perhaps because long-term disruptions in homeostatic levels of zinc adversely influence hippocampus-dependent spatial memory. (c) 2008 Elsevier Ireland Ltd. All rights reserved.	[Hellmich, Helen L.; Eidson, Kristine; Cowart, Jeremy; Crookshanks, Jeanna; Boone, Deborah K.; Shah, Syed; DeWitt, Douglas S.; Prough, Donald S.] Univ Texas Galveston, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; [Uchida, Tatsuo] Univ Texas Galveston, Med Branch, Dept Prevent Med & Community Hlth, Off Biostat, Galveston, TX 77555 USA	Hellmich, HL (corresponding author), Univ Texas Galveston, Med Branch, Dept Anesthesiol, 301 Univ Blvd,Route 0830, Galveston, TX 77555 USA.	hhellmic@utmb.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042849] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01 NS042849-01A1, R01 NS042849-05, R01 NS042849-04, R01 NS042849] Funding Source: Medline		Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Bodnar LM, 2005, BIOL PSYCHIAT, V58, P679, DOI 10.1016/j.biopsych.2005.05.009; Calderone A, 2004, J NEUROSCI, V24, P9903, DOI 10.1523/JNEUROSCI.1713-04.2004; Canzoniero LMT, 1999, J NEUROSCI, V19; Canzoniero LMT, 2003, NEUROPHARMACOLOGY, V45, P420, DOI 10.1016/S0028-3908(03)00171-0; Cernak I, 2006, EXPERT OPIN INV DRUG, V15, P1371, DOI 10.1517/13543784.15.11.1371; Chen WQ, 2006, EXP BIOL MED, V231, P1564, DOI 10.1177/153537020623100917; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Cuajungco MP, 2000, ANN NY ACAD SCI, V920, P292; Daumas S, 2004, EUR J NEUROSCI, V20, P597, DOI 10.1111/j.1460-9568.2004.03484.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Frassinetti S, 2006, J ENVIRON PATHOL TOX, V25, P597, DOI 10.1615/JEnvironPatholToxicolOncol.v25.i3.40; Frazzini V, 2006, BIOGERONTOLOGY, V7, P307, DOI 10.1007/s10522-006-9045-7; Frederickson CJ, 2002, J HISTOCHEM CYTOCHEM, V50, P1659, DOI 10.1177/002215540205001210; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; Hao Q, 2005, J ALZHEIMERS DIS, V8, P161; Hellmich HL, 2007, BRAIN RES, V1127, P119, DOI 10.1016/j.brainres.2006.09.094; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Hellmich HL, 2004, NEUROSCI LETT, V355, P221, DOI 10.1016/j.neulet.2003.10.074; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Hirzel K, 2006, NEURON, V52, P679, DOI 10.1016/j.neuron.2006.09.035; Koh JY, 2001, MOL NEUROBIOL, V24, P99, DOI 10.1385/MN:24:1-3:099; Lavoie N, 2007, J PHYSIOL-LONDON, V578, P275, DOI 10.1113/jphysiol.2006.121848; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Lin DD, 2001, J NEUROPHYSIOL, V85, P1185; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; Mocchegiani E, 2005, PROG NEUROBIOL, V75, P367, DOI 10.1016/j.pneurobio.2005.04.005; Molnar P, 2001, BRAIN RES, V910, P205, DOI 10.1016/S0006-8993(01)02720-2; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Ruiz A, 2004, J NEUROPHYSIOL, V91, P1091, DOI 10.1152/jn.00755.2003; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SAS Institute, 2004, SAS STAT 9 1 US GUID; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; Stork CJ, 2006, J NEUROSCI, V26, P10430, DOI 10.1523/JNEUROSCI.1588-06.2006; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; White AR, 2006, EXPERT REV NEUROTHER, V6, P711, DOI 10.1586/14737175.6.5.711	37	15	15	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 1	2008	440	2					155	159		10.1016/j.neulet.2008.05.068			5	Neurosciences	Neurosciences & Neurology	325XX	WOS:000257623400014	18556117	Green Accepted			2021-06-18	
J	Degeneffe, CE; Burcham, CM				Degeneffe, Charles Edmund; Burcham, Christyn M.			Adult Sibling Caregiving for Persons with Traumatic Brain Injury: Predictors of Affective and Instrumental Support	JOURNAL OF REHABILITATION			English	Article							MENTAL-RETARDATION; DISABILITIES; CHILDREN; PARENTS; FUTURE; ROLES	This study investigated the amount and predictors of affective and instrumental caregiving supports provided by a national sample of 233 adult siblings of persons with traumatic brain injury (TBI). Affective support encompasses emotionally-based care such as companionship, encouragement, praise, and intimacy. Instrumental support consists of assistance in performing functional tasks such as completing chores, running errands, handling finances and preparing food. Participants provided significantly more affective than instrumental supports. Hierarchical multiple regression analyses identified predictors of the type of supports the siblings provided. Participants of a different gender than their injured siblings were more likely to provide both instrumental and affective supports. Also, as the age differences increased between the non-injured and injured siblings, participants were more likely to provide affective care. Instrumental support was positively related to age of the non-injured siblings and level of the injured siblings' cognitive-behavioral impairments. Instrumental support was negatively related to geographic distance. Clinical and research implications of these findings are discussed.	[Degeneffe, Charles Edmund] San Diego State Univ, ARPE Interwork Inst, San Diego, CA 92182 USA	Degeneffe, CE (corresponding author), San Diego State Univ, ARPE Interwork Inst, Mail Code 1127,5500 Campanile Dr, San Diego, CA 92182 USA.	cdegenef@mail.sdsu.edu					AKIYAMA H, 1996, J GERONTOL B-PSYCHOL, V51, P374; ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; Cunningham J. M., 2005, HLTH CARE DISABILITY, P475; Degeneffe CE, 2006, REHABIL COUNS BULL, V49, P130, DOI 10.1177/00343552060490030101; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; DEGENEFFE CE, REHABILITAT IN PRESS; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Eckstein D., 2000, INDIVIDUAL PSYCHOL, V56, P481; Erdfelder E, 1996, BEHAV RES METH INS C, V28, P1, DOI 10.3758/BF03203630; Gill D. J., 2000, REHABILITATION NURSI, V25, P48, DOI [DOI 10.1002/J.2048-7940.2000.TB01862.X, 10.1002/j.2048-7940.2000.tb01862.x]; GREENBERG JS, 1993, GERONTOLOGIST, V33, P542, DOI 10.1093/geront/33.4.542; GRIFFITHS DL, 1994, FAM RELAT, V43, P221, DOI 10.2307/585326; Harland P., 2000, INT J DISABIL DEV ED, V47, P293, DOI [DOI 10.1080/713671116, 10.1080/713671116]; HORWITZ AV, 1993, J MARRIAGE FAM, V55, P623, DOI 10.2307/353343; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Krauss MW, 1996, MENT RETARD, V34, P83; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; LOBATO D, 1983, J AUTISM DEV DISORD, V13, P347, DOI 10.1007/BF01531585; MARASCUILO LA, 1983, MULTIVARIATE STAT SO; MAURER J, 1991, HEAD INJURY FAMILY M, P29; *NIH, 1999, REP NIH CONS DEV C R; Orsillo SM, 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199303000-00010, 10.1097/00001199-199303000-00010]; Orsmond GI, 2000, AM J MENT RETARD, V105, P486, DOI 10.1352/0895-8017(2000)105<0486:BASOAW>2.0.CO;2; Pruchno RA, 1996, FAM RELAT, V45, P318, DOI 10.2307/585504; SACHS PR, 1991, TREATING FAMILIES BR; SELTZER GB, 1991, FAM RELAT, V40, P310, DOI 10.2307/585017; Seltzer M. M., 1996, AGING FAMILIES ADULT; SELTZER MM, 1989, AM BEHAV SCI, V33, P107, DOI 10.1177/0002764289033001010; Seltzer MM, 1997, FAM RELAT, V46, P395, DOI 10.2307/585099; Smith MJ, 2007, AM J ORTHOPSYCHIAT, V77, P29, DOI 10.1037/0002-9432.77.1.29; SPRIGGS VT, 1998, PROMOTING CULTURAL C, P149; Willer B, 1999, ARCH PHYS MED REHAB, V80, P399, DOI 10.1016/S0003-9993(99)90276-9; ZETLIN AG, 1986, AM J MENT DEF, V91, P217	34	15	15	0	6	NATL REHABILITATION ASSOC-NRA	ALEXANDRIA	633 S WASHINGTON ST, ALEXANDRIA, VA 22314-4109 USA	0022-4154			J REHABIL	J. Rehabil.	JUL-SEP	2008	74	3					10	20					11	Rehabilitation	Rehabilitation	361NQ	WOS:000260134800002					2021-06-18	
J	McIntosh, SE; Swanson, ER; Barton, ED				McIntosh, Scott E.; Swanson, Eric R.; Barton, Erik D.			Cricothyrotomy in air medical transport	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						air medical transport; airway; cricothyrotomy	PREHOSPITAL SURGICAL CRICOTHYROTOMY; TRAUMATIC BRAIN-INJURY; EMERGENCY; INTUBATION; EXPERIENCE; EFFICACY; PATIENT; SUCCESS; RATES; FIELD	Background: Airway management is an essential skill for air medical transport (AMT) providers. The endpoint of airway maneuvers is a cricothyrotomy which may be live-saving if other measures fail. We reviewed cricothyrotomy cases in our AMT program to evaluate the success rate and the circumstances surrounding the procedure. Methods: This was a retrospective review of cases in which a cricothyrotomy was performed at the University of Utah AirMed night program during the years of 1995 to 2004. Data included incidence, indications, complications, neurologic outcome, and success rates of the procedure. Results: Of the 14,994 transports during the study period, 17 cricothyrotomies were performed. Airway obstruction by blood and/or vomit was the most frequent indication (47%) followed by airway edema/distorted anatomy (24%). The total number of cricothyrotomies decreased during the study period. Seven (41%) patients survived with a reasonable neurologic outcome. The remaining 10 patients died during initial treatment or subsequent hospitalization. Success rate of the procedure in our series was 100%. These results were compared with those of other cricothyrotomy studies. Conclusion: Cricothyrotomy has become less common as an emergency rescue technique. However, AMT personnel have a high success rate when performing the cricothyrotomy procedure. This rate is as high as or higher than other emergency personnel.	[McIntosh, Scott E.; Swanson, Eric R.; Barton, Erik D.] Univ Utah, Hlth Sci Ctr, Div Emergency Med, Salt Lake City, UT 84132 USA	McIntosh, SE (corresponding author), Univ Utah, Hlth Sci Ctr, Div Emergency Med, 30 N Med Dr, Salt Lake City, UT 84132 USA.	scott.mcintosh@hsc.utah.edu					Bair AE, 2003, J EMERG MED, V24, P151, DOI 10.1016/S0736-4679(02)00715-1; Boyle Michael F., 1993, Journal of Emergency Medicine, V11, P41, DOI 10.1016/0736-4679(93)90008-U; Chang RS, 1998, ACAD EMERG MED, V5, P247, DOI 10.1111/j.1553-2712.1998.tb02621.x; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; ERLANDSON M J, 1989, Journal of Emergency Medicine, V7, P115; Eyer SD, 1997, J TRAUMA, V42, P837; Foley LJ, 2000, CRIT CARE CLIN, V16, P429, DOI 10.1016/S0749-0704(05)70121-4; Fortune JB, 1997, J TRAUMA, V42, P832, DOI 10.1097/00005373-199705000-00013; Jacobson LE, 1996, J TRAUMA, V41, P15, DOI 10.1097/00005373-199607000-00004; JENNETT B, 1975, LANCET, V1, P480; Ma OJ, 1998, AM J EMERG MED, V16, P125, DOI 10.1016/S0735-6757(98)90027-4; MCGILL J, 1982, ANN EMERG MED, V11, P361, DOI 10.1016/S0196-0644(82)80362-4; MIKLUS RM, 1989, J TRAUMA, V29, P506, DOI 10.1097/00005373-198904000-00016; NUGENT WL, 1991, ANN EMERG MED, V20, P367, DOI 10.1016/S0196-0644(05)81656-7; Oliver R., 1992, Journal of Trauma, V33, P159, DOI 10.1097/00005373-199207000-00072; Robinson K J, 2001, Air Med J, V20, P27, DOI 10.1016/S1067-991X(01)70006-5; Rose W D, 1994, Air Med J, V13, P475, DOI 10.1016/S1067-991X(05)80289-5; Sing RF, 1996, ACAD EMERG MED, V3, P41, DOI 10.1111/j.1553-2712.1996.tb03301.x; SPAITE DW, 1990, ANN EMERG MED, V19, P279, DOI 10.1016/S0196-0644(05)82045-1; Swanson Eric R, 2002, Air Med J, V21, P28, DOI 10.1067/mmj.2002.125936; Vilke Gary M., 1994, Journal of Emergency Medicine, V12, P217, DOI 10.1016/0736-4679(94)90702-1; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; XEROPOTAMOS NS, 1993, INJURY, V24, P222, DOI 10.1016/0020-1383(93)90172-3	23	15	16	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2008	64	6					1543	1547		10.1097/TA.0b013e3181271b60			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	313MG	WOS:000256744100023	18545121				2021-06-18	
J	Chang, CH; Liao, JJ; Chuang, CH; Lee, CT				Chang, Chih-Hung; Liao, Jui-Jung; Chuang, Chung-Hua; Lee, Chien-Te			Recurrent hyponatremia after traumatic brain injury	AMERICAN JOURNAL OF THE MEDICAL SCIENCES			English	Article						hyponatremia; head injury; syndrome of inappropriate antidiuretic hormone secretion	ANTIDIURETIC-HORMONE SECRETION; CENTRAL-NERVOUS-SYSTEM; PITUITARY DYSFUNCTION; PREVALENCE; DISEASE; WATER	Dysregulation of the neuroendocrine system is a frequent complication after traumatic brain injury (TBI). Symptoms of these hormonal abnormalities might be subtle and thus easily ignored. Hyponatremia usually indicates underlying disorders that disrupt fluid homeostasis. In most patients with TBI, hyponatremia is a feature of the syndrome of inappropriate antidiuretic hormone (SIADH) secretion due to pituitary dysfunction after head injury. Usually TBI-associated hyponatremia is transient and reversible. We report the case of a 48-year-old man with TBI-associated hyponatremia with delayed recovery and recurrent hyponatremia precipitated by subsequent surgery. In this report, we emphasize the importance of identifying patients with slow recovery of the injured brain, which could complicate with SIADH and acute hyponatremia. Differentiating TBI-associated SIADH from other important causes of hyponatremia such as cerebral salt wasting, and hypocortisonism are also reviewed. Prevention of its recurrence by avoiding further risk is mandatory in managing patients with TBI.	[Chang, Chih-Hung; Chuang, Chung-Hua; Lee, Chien-Te] Chang Gung Univ, Coll Med, Kaohsiung Med Ctr, Chang Gung Mem Hosp,Div Nephrol,Dept Internal Med, Kaohsiung Hsien 833, Taiwan; [Liao, Jui-Jung] Chang Gung Univ, Coll Med, Kaohsiung Med Ctr, Chang Gung Mem Hosp,Div Neurosurg,Dept Surg, Kaohsiung Hsien 833, Taiwan	Lee, CT (corresponding author), Chang Gung Univ, Coll Med, Kaohsiung Med Ctr, Chang Gung Mem Hosp,Div Nephrol,Dept Internal Med, 123,Ta Pei Rd, Kaohsiung Hsien 833, Taiwan.	ctlee33@adm.cgmh.org.tw					Agha A, 2005, QJM-INT J MED, V98, P463, DOI 10.1093/qjmed/hci075; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Cole Chad D, 2004, Neurosurg Focus, V16, pE9; CORT JH, 1954, LANCET, V1, P752; KAUFMAN HH, 1993, MED CLIN N AM, V77, P43, DOI 10.1016/S0025-7125(16)30271-1; Kumar PD, 2001, ANN INTERN MED, V135, P932, DOI 10.7326/0003-4819-135-10-200111200-00027; Lee CT, 2000, AM J EMERG MED, V18, P264, DOI 10.1016/S0735-6757(00)90118-9; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Nathan BR, 2007, NEUROCRIT CARE, V6, P72, DOI 10.1385/NCC:6:1:72; Palmer BF, 2000, NEPHROL DIAL TRANSPL, V15, P262, DOI 10.1093/ndt/15.2.262; Palmer BF, 2003, TRENDS ENDOCRIN MET, V14, P182, DOI 10.1016/S1043-2760(03)00048-1; PETERS JP, 1950, T ASSOC AM PHYSICIAN, V63, P57; Powner DJ, 2006, NEUROCRIT CARE, V5, P61, DOI 10.1385/NCC:5:1:61; Rabinstein AA, 2006, CLIN NEUROPHARMACOL, V29, P87, DOI 10.1097/00002826-200603000-00006; Singh S, 2002, CRIT CARE MED, V30, P2575, DOI 10.1097/00003246-200211000-00028; Upadhyay A, 2006, AM J MED, V119, pS30, DOI 10.1016/j.amjmed.2006.05.005; WELT LG, 1952, ARCH INTERN MED, V90, P355, DOI 10.1001/archinte.1952.00240090076007; Wong LL, 2002, ENDOCRIN METAB CLIN, V31, P121, DOI 10.1016/S0889-8529(01)00007-X	21	15	15	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0002-9629			AM J MED SCI	Am. J. Med. Sci.	MAY	2008	335	5					390	393		10.1097/MAJ.0b013e318149e6f1			4	Medicine, General & Internal	General & Internal Medicine	306VO	WOS:000256276100012	18480658				2021-06-18	
J	Kim, E				Kim, Edward			Does traumatic brain injury predispose individuals to develop schizophrenia	CURRENT OPINION IN PSYCHIATRY			English	Article						epidemiology; psychosis; schizophrenia; traumatic brain injury	HEAD-INJURY; MAJOR DEPRESSION; PSYCHOSIS; RISK; DISORDERS	Purpose of review Psychosis following traumatic brain injury has been studied in both prospective and retrospective studies that have been frequently limited by unclear criteria for classifying psychiatric syndromes or case ascertainment bias regarding traumatic brain injury. Schizophrenia is a psychotic disorder commonly attributed to the interaction of genetic vulnerability and environmental events, yet its relationship with traumatic brain injury has not been systematically reviewed. Recent findings The literature is not conclusive and highlights the challenges to observational research in conditions in which case ascertainment is difficult. The evidence supports a risk-modifying effect of traumatic brain injury in individuals who are genetically at risk for schizophrenia, but is less supportive of traumatic brain injury as an independent risk factor for schizophrenia in individuals without such risk. Summary Research in psychotic disorders following traumatic brain injury must distinguish schizophrenia from other psychotic syndromes, and take familial risk factors into consideration.	[Kim, Edward] Bristol Myers Squibb Co, Outcomes Res USA, Plainsboro, NJ 08536 USA; [Kim, Edward] Robert Wood Johnson Med Sch, Dept Psychiat, Plainsboro, NJ USA	Kim, E (corresponding author), Bristol Myers Squibb Co, Outcomes Res USA, 777 Scudders Mill Rd, Plainsboro, NJ 08536 USA.	edward.kim@bms.com					AbdelMalik P, 2003, ARCH GEN PSYCHIAT, V60, P231, DOI 10.1001/archpsyc.60.3.231; Arciniegas DB, 2003, INT REV PSYCHIATR, V15, P328, DOI 10.1080/09540260310001606719; Cochrane J, 2000, CAN J PSYCHIAT, V45, P185, DOI 10.1177/070674370004500210; Compton MT, 2007, SCHIZOPHR RES, V94, P64, DOI 10.1016/j.schres.2007.04.002; Corcoran C, 2003, SCHIZOPHRENIA BULL, V29, P671, DOI 10.1093/oxfordjournals.schbul.a007038; David AS, 2005, J NEUROL NEUROSUR PS, V76, pI53, DOI 10.1136/jnnp.2004.060475; Davison K, 1969, BRIT J PSYCHIATRY SP, V4, P113; Folsom DP, 2006, PSYCHIAT RES, V144, P167, DOI 10.1016/j.psychres.2005.12.002; Fujii DE, 2001, J NEUROPSYCH CLIN N, V13, P61, DOI 10.1176/appi.neuropsych.13.1.61; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Harrison G, 2006, SCHIZOPHR RES, V88, P119, DOI 10.1016/j.schres.2006.07.001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kraus P, 1999, J HIGH ENERGY PHYS; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; McAllister TW, 1997, COMMUNITY MENT HLT J, V33, P341, DOI 10.1023/A:1025055426260; Nielsen AS, 2002, SCHIZOPHR RES, V55, P93, DOI 10.1016/S0920-9964(01)00205-5; Ravdin LD, 2003, CLIN J SPORT MED, V13, P21, DOI 10.1097/00042752-200301000-00005; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Tsuang M, 2000, BIOL PSYCHIAT, V47, P210, DOI 10.1016/S0006-3223(99)00289-9	21	15	18	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0951-7367			CURR OPIN PSYCHIATR	Curr. Opin. Psychiatr.	MAY	2008	21	3					286	289		10.1097/YCO.0b013e3282fbcd21			4	Psychiatry	Psychiatry	291YK	WOS:000255233200011	18382229				2021-06-18	
J	Wietek, BM; Baron, CH; Erb, M; Hinninghofen, H; Badtke, A; Kaps, HP; Grodd, W; Enck, P				Wietek, B. M.; Baron, C. H.; Erb, M.; Hinninghofen, H.; Badtke, A.; Kaps, H. -P.; Grodd, W.; Enck, P.			Cortical processing of residual ano-rectal sensation in patients with spinal cord injury: an fMRI study	NEUROGASTROENTEROLOGY AND MOTILITY			English	Article						anorectum; functional magnetic resonance imaging; spinal cord injury; visceral sensation	DORSAL COLUMN PATHWAY; FUNCTIONAL CLASSIFICATION; INTERNATIONAL STANDARDS; BRAIN ACTIVATION; SELF-STIMULATION; CEREBRAL ACTIVATION; MICTURITION; WOMEN; RESPONSES; CONTRACTION	Eleven paraplegic patients with complete traumatic spinal cord injuries (SCI) [according to American Spinal Injury Association (ASIA) criteria] at different levels (Th3-L3) were investigated during non-painful stimulation of the distal rectum and anal canal, using event related functional magnetic resonance imaging. Although a complete lesion was clinically diagnosed in all, four of them experienced reproducible sensations during anal and/or rectal stimulation. In six patients, individual data analysis revealed significant activation in the right secondary somatosensory cortex SII, the posterior cingular gyrus, the prefrontal cortex, and the left posterior cerebellar lobe during either anal or rectal stimulation or both. A Region of interest analysis using a data mask from healthy controls confirmed that SCI patients demonstrate cortical activation in areas similar to those activated in healthy volunteers, but to a less extensive degree. This supports the notion that the diagnosis of complete spinal cord transsection by ASIA criteria alone may be insufficient for assessment of 'completeness' of cord lesions, and that visceral sensitivity testing may be required in addition.	[Wietek, B. M.] Univ Tubingen, Dept Diagnost Radiol, Expt Sect Radiol, D-72076 Tubingen, Germany; [Baron, C. H.; Badtke, A.; Kaps, H. -P.] Univ Tubingen, BG Trauma Ctr, Dept Paraplegia Orthoped Surg Rehabil, Tubingen, Germany; [Erb, M.; Grodd, W.] Univ Tubingen Hosp, Dept Neuroradiol, Sect Exp MR CNS, Tubingen, Germany; [Hinninghofen, H.; Enck, P.] Univ Tubingen Hosp, Dept Psychosomat Med, Tubingen, Germany	Wietek, BM (corresponding author), Univ Tubingen, Dept Diagnost Radiol, Expt Sect Radiol, D-72076 Tubingen, Germany.	bmwietek@med.uni-tuebingen.de		Erb, Michael/0000-0002-9311-4693			AlChaer ED, 1996, J NEUROPHYSIOL, V76, P2675; AlChaer ED, 1996, J NEUROPHYSIOL, V76, P2661; *AM SPIN INJ ASS, 1996, INT STAND NEUR CLASS; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Athwal BS, 2001, BRAIN, V124, P369, DOI 10.1093/brain/124.2.369; Aziz Q, 1998, GASTROENTEROLOGY, V114, P559, DOI 10.1016/S0016-5085(98)70540-2; Aziz Q, 2000, J CLIN NEUROPHYSIOL, V17, P604, DOI 10.1097/00004691-200011000-00006; Blok BFM, 1998, BRAIN, V121, P2033, DOI 10.1093/brain/121.11.2033; Blok BFM, 1997, BRAIN, V120, P111, DOI 10.1093/brain/120.1.111; Cohen ME, 1998, SPINAL CORD, V36, P554, DOI 10.1038/sj.sc.3100602; Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894; Damasio A., 1994, DESCARTESERROR EMOTI; Derbyshire SWG, 2003, AM J GASTROENTEROL, V98, P12, DOI 10.1111/j.1572-0241.2003.07168.x; DITUNNO JF, 1994, PARAPLEGIA, V32, P70, DOI 10.1038/sc.1994.13; Ersoz M, 2004, SPINAL CORD, V42, P110, DOI 10.1038/sj.sc.3101525; Finnerup NB, 2004, ACTA NEUROL SCAND, V109, P194, DOI 10.1034/j.1600-0404.2003.00219.x; Fukuyama H, 1996, NEUROREPORT, V7, P3009, DOI 10.1097/00001756-199611250-00042; GILDENBERG PL, 1984, J NEUROL NEUROSUR PS, V47, P94, DOI 10.1136/jnnp.47.1.94; Greving I, 1998, NEUROGASTROENT MOTIL, V10, P509; Hobday DI, 2001, BRAIN, V124, P361, DOI 10.1093/brain/124.2.361; Karama S, 2002, HUM BRAIN MAPP, V16, P1, DOI 10.1002/hbm.10014; Kern MK, 2004, AM J PHYSIOL-GASTR L, V286, pG304, DOI 10.1152/ajpgi.00201.2003; Klose U, 1999, MAGN RESON IMAGING, V17, P471, DOI 10.1016/S0730-725X(98)00173-8; Komisaruk BR, 2004, BRAIN RES, V1024, P77, DOI 10.1016/j.brainres.2004.07.029; Komisaruk BR, 1997, ARCH NEUROL-CHICAGO, V54, P1513, DOI 10.1001/archneur.1997.00550240063014; Lotze M, 2001, NEUROIMAGE, V14, P1027, DOI 10.1006/nimg.2001.0901; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; Naliboff BD, 2001, PSYCHOSOM MED, V63, P365, DOI 10.1097/00006842-200105000-00006; Nicotra A, 2006, BRAIN, V129, P718, DOI 10.1093/brain/awh699; Ramer LM, 2005, SPINAL CORD, V43, P134, DOI 10.1038/sj.sc.3101715; Rapp AM, 2007, BRAIN LANG, V100, P142, DOI 10.1016/j.bandl.2006.04.004; SAKAKIBARA R, 1995, J AUTONOM NERV SYST, V55, P165, DOI 10.1016/0165-1838(95)00039-Z; SHERWOOD AM, 1992, J NEUROL SCI, V110, P90, DOI 10.1016/0022-510X(92)90014-C; Sipski ML, 2001, CLIN AUTON RES, V11, P279, DOI 10.1007/BF02332972; SUN WM, 1995, GASTROENTEROLOGY, V108, P990, DOI 10.1016/0016-5085(95)90194-9; Talairach J., 1988, COPLANAR STEREOTAXIC; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Whipple B, 2002, J SEX MARITAL THER, V28, P79, DOI 10.1080/009262302317251043; WIETEK B, 2002, NEUROGASTROENT MOTIL, V14, P567; Wood JN, 2003, NAT REV NEUROSCI, V4, P139, DOI 10.1038/nrn1033; WYNDAELE JJ, 1991, PARAPLEGIA, V29, P490, DOI 10.1038/sc.1991.67; Zhang H, 2005, NEUROIMAGE, V24, P174, DOI 10.1016/j.neuroimage.2004.08.027	42	15	15	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1350-1925	1365-2982		NEUROGASTROENT MOTIL	Neurogastroenterol. Motil.	MAY	2008	20	5					488	497		10.1111/j.1365-2982.2007.01063.x			10	Gastroenterology & Hepatology; Clinical Neurology; Neurosciences	Gastroenterology & Hepatology; Neurosciences & Neurology	288NC	WOS:000254992100009	18298436				2021-06-18	
J	Pauldine, R; Beck, G; Salinas, J; Kaczka, DW				Pauldine, Ronald; Beck, George; Salinas, Jose; Kaczka, David W.			Closed-loop strategies for patient care systems	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						closed-loop; critical care medicine; mass casualty	CRITICALLY ILL PATIENTS; BISPECTRAL INDEX; MECHANICAL VENTILATION; INTRAHOSPITAL TRANSPORT; FUZZY-LOGIC; INTRAVENOUS ANESTHESIA; SODIUM-NITROPRUSSIDE; PROPOFOL ANESTHESIA; SECONDARY INSULTS; DECISION TABLES	Military operations, mass casualty events, and remote work sites present unique challenges to providers of immediate medical care, who may lack the necessary skills for optimal clinical management Moreover, the number of patients in these scenarios may overwhelm available health care resources. Recent applications of closed-loop control (CLC) techniques to critical care medicine may offer possible solutions for such environments. Here, feedback of a monitored variable or group of variables is used to control the state or output of a dynamic system. Some potential advantages of CLC in patient management include limiting task saturation when there is simultaneous demand for cognitive and active clinical intervention, improving quality of care through optimization of the titration of medications, conserving limited consumable supplies, preventing secondary insults in traumatic brain injury, shortening the duration of mechanical ventilation, and achieving appropriate goal-directed resuscitation. The uses of CLC systems in critical care medicine have been increasingly explored across a wide range of therapeutic modalities. This review will provide an overview of control system theory as applied to critical care medicine that must be considered in the design of autonomous CLC systems, and introduce a number of clinical applications under development in the context of deployment of such applications to austere environments.	[Pauldine, Ronald] Johns Hopkins Bayview Med Ctr, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21218 USA; [Beck, George] Impact Instrumentat Inc, W Caldwell, NJ USA; [Salinas, Jose] USA, Inst Surg Res, Trauma Informat Syst Dev, Ft Sam Houston, TX 78234 USA; [Kaczka, David W.] Johns Hopkins Univ, Dept Biomed Engn, Dept Anesthesiol & Crit Care Med, Baltimore, MD USA	Pauldine, R (corresponding author), Johns Hopkins Bayview Med Ctr, Dept Anesthesiol & Crit Care Med, A3W-387, Baltimore, MD 21218 USA.	rpauldi1@jhmi.edu	Kaczka, David W./U-2580-2018	Kaczka, David W./0000-0003-4378-5242			Absalom AR, 2003, BRIT J ANAESTH, V90, P737, DOI 10.1093/bja/aeg137; Alkins SA, 2002, AVIAT SPACE ENVIR MD, V73, P677; Anderson JP, 2002, BIOMED SCI INSTRUM, V38, P289; ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; ASSEF SJ, 1993, MAYO CLIN PROC, V68, P1074, DOI 10.1016/S0025-6196(12)60901-X; Bacal K, 2004, MIL MED, V169, P631, DOI 10.7205/MILMED.169.8.631; Barker SJ, 2002, ANESTH ANALG, V95, P967, DOI 10.1213/01.ANE.0000029029.03601.08; Barr J, 2001, ANESTHESIOLOGY, V95, P324, DOI 10.1097/00000542-200108000-00011; Bekar A, 1998, NEUROSURG REV, V21, P98, DOI 10.1007/BF02389312; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; Branson R, 2002, RESP CARE, V47, P451; Branson Richard D, 2002, Respir Care, V47, P427; Chase J Geoffrey, 2005, Diabetes Technol Ther, V7, P274, DOI 10.1089/dia.2005.7.274; Chee F, 2002, ANAESTH INTENS CARE, V30, P295, DOI 10.1177/0310057X0203000306; Claure N, 1997, J PEDIATR-US, V131, P910, DOI 10.1016/S0022-3476(97)70042-8; Cook RI, 1996, J CLIN ANESTH, V8, pS29, DOI 10.1016/S0952-8180(96)90009-4; Davey A L, 2001, Air Med J, V20, P27, DOI 10.1016/S1067-991X(01)70043-0; De Haes A, 2002, ANAESTHESIA, V57, P1237; DEASLA RA, 1985, J THORAC CARDIOV SUR, V89, P115; Dojat M, 2001, Respir Care Clin N Am, V7, P379, DOI 10.1016/S1078-5337(05)70048-4; DUMONT GA, 2002, CONCEPTS METHODS TEC; Egan TD, 2003, ANESTHESIOLOGY, V99, P1039, DOI 10.1097/00000542-200311000-00003; Eleveld DJ, 2005, ANESTH ANALG, V101, P758, DOI 10.1213/01.ane.0000167069.54613.50; FRUMIN MJ, 1957, J LAB CLIN MED, V49, P617; Gehring Hartmut, 2002, Respir Care, V47, P48; Glass PSA, 2001, ANESTHESIOLOGY, V95, P1, DOI 10.1097/00000542-200107000-00005; HOLLAND RR, 1975, JAMA-J AM MED ASSOC, V233, P455, DOI 10.1001/jama.233.5.455; Hoskins SL, 2006, J BURN CARE RES, V27, P377, DOI 10.1097/01.BCR.0000216512.30415.78; Jaber S, 2004, ANESTHESIOLOGY, V100, P782, DOI 10.1097/00000542-200404000-00006; Johannigman JA, 2008, J TRAUMA, V64, pS295, DOI 10.1097/TA.0b013e31816bce54; Johansen JW, 2006, BEST PRACT RES-CLIN, V20, P81, DOI 10.1016/j.bpa.2005.08.004; Kaczka David W, 2004, Respir Care Clin N Am, V10, P369, DOI 10.1016/j.rcc.2004.04.001; Kaczka DW, 2004, ANN BIOMED ENG, V32, P596, DOI 10.1023/B:ABME.0000019179.87974.7d; Kaczka DW, 2004, RESP CARE CLIN N AM, V10, p[369, vii]; Kenny GNC, 1999, BRIT J ANAESTH, V83, P223, DOI 10.1093/bja/83.2.223; Kern SE, 1997, ARTIF INTELL MED, V11, P9, DOI 10.1016/S0933-3657(97)00022-5; Konrad F, 1996, ANAESTHESIST, V45, P802, DOI 10.1007/s001010050313; Latorre F, 1998, ANESTH ANALG, V86, P867, DOI 10.1097/00000539-199804000-00035; Liu N, 2006, EUR J ANAESTH, V23, P465, DOI 10.1017/S0265021506000196; MACKENZIE AF, 1993, ANAESTHESIA, V48, P202, DOI 10.1111/j.1365-2044.1993.tb06901.x; MCKINLEY S, 1991, CRIT CARE MED, V19, P166, DOI 10.1097/00003246-199102000-00009; Milne SE, 1998, ANAESTHESIA, V53, P56, DOI 10.1111/j.1365-2044.1998.53s110.x; MITAMURA Y, 1971, IEEE T BIO-MED ENG, VBM18, P330, DOI 10.1109/TBME.1971.4502864; Nasraway SA, 2002, CRIT CARE MED, V30, P1483, DOI 10.1097/00003246-200207000-00014; Nemoto T, 1999, AM J RESP CRIT CARE, V160, P550, DOI 10.1164/ajrccm.160.2.9809013; OLKKOLA KT, 1994, EUR J ANAESTH, P99; PHILLIPS CL, 1988, FEEDBACK CONTROL SYS; Riess ML, 2002, EUR J ANAESTH, V19, P18, DOI 10.1017/S0265021502000030; Robinson Kathy, 2004, J Emerg Nurs, V30, P160, DOI 10.1016/j.jen.2004.01.004; SASTRY A, 1989, ADAPTIVE CONTROL STA; Schaublin J, 1996, BRIT J ANAESTH, V77, P636; Shiffman RN, 1997, J AM MED INFORM ASSN, V4, P382, DOI 10.1136/jamia.1997.0040382; Sneyd JR, 2004, BRIT J ANAESTH, V93, P725, DOI 10.1093/bja/aeh253; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Struys MMRF, 2006, BEST PRACT RES-CLIN, V20, P211, DOI 10.1016/j.bpa.2005.08.012; Struys Michel M R F, 2002, Curr Opin Anaesthesiol, V15, P421, DOI 10.1097/00001503-200208000-00003; Struys MMRF, 2004, ANESTHESIOLOGY, V100, P640, DOI 10.1097/00000542-200403000-00026; Tonner PH, 2006, BEST PRACT RES-CLIN, V20, P191, DOI 10.1016/j.bpa.2005.08.011; van den Nieuwenhuyzen MCO, 2000, CLIN PHARMACOKINET, V38, P181, DOI 10.2165/00003088-200038020-00003; Vivien B, 2003, ANESTHESIOLOGY, V99, P9, DOI 10.1097/00000542-200307000-00006	60	15	17	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2008	64	4		S			S289	S294		10.1097/TA.0b013e31816bce43			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	288WT	WOS:000255017400002	18385581				2021-06-18	
J	Pascual, JL; Maloney-Wilensky, E; Reilly, PM; Sicoutris, C; Keutmann, MK; Stein, SC; Leroux, PD; Gracias, VH				Pascual, Jose L.; Maloney-Wilensky, Eileen; Reilly, Patrick M.; Sicoutris, Corinna; Keutmann, Michael K.; Stein, Sherman C.; Leroux, Peter D.; Gracias, Vicente H.			Resuscitation of hypotensive head-injured patients: Is hypertonic saline the answer?	AMERICAN SURGEON			English	Article							TRAUMATIC BRAIN-INJURY; INTRACRANIAL-PRESSURE; HEMORRHAGIC-SHOCK; TISSUE OXYGEN; HYPERTENSION; SEVERITY; MANNITOL; MODEL	Hypertonic saline (HTS) may decrease intracranial pressure (ICP) in severe traumatic brain injury (STBI) and effectively resuscitates hypotensive patients. No data exist on institutional standardization of HTS for hypotensive patients with STBI. It remains unclear how HTS affects brain tissue oxygenation (PbtO(2)) in STBI. We hypothesized HTS could be safely standardized in patients with STBI and would lower ICP while improving cerebral perfusion pressure (CPP) and PbtO(2). Under institutional guidelines in a Level I trauma center, 12 hypotensive STBI intensive care unit subjects received HTS. Inclusion criteria included mean arterial pressure (MAP) <= 90 mmHg, Glasgow Coma Scale (GCS) <= 8, ICP <= 20 mmHg, and serum [Na+] < 155 mEq/L. All patients under-went ICP monitoring. Hemodynamics, CPP, ICP, and PbtO(2) data were collected before and hourly for 6 hours after FITS infusion. Guideline criteria compliance was greater than 95 per cent. No major complications occurred. Mean ICP levels dropped by 45 per cent (P < 0.01) and this drop persisted for 6 hours. CPP levels increased by 20 per cent (P < 0.05). PbtO(2) remained persistently elevated for all time points after HTS infusion. Institutional use of HTS in STBI can be safely implemented in a center caring for neurotrauma patients. HTS infusion in hypotensive STBI reduces ICP and raises CPP. Brain tissue oxygenation tends to improve after HTS infusion.	[Pascual, Jose L.; Reilly, Patrick M.; Sicoutris, Corinna; Gracias, Vicente H.] Univ Penn, Sch Med, Div Traumatol & Surg Crit Cate, Dept Surg, Philadelphia, PA 19104 USA; [Maloney-Wilensky, Eileen; Keutmann, Michael K.; Stein, Sherman C.; Leroux, Peter D.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	Gracias, VH (corresponding author), Univ Penn, Sch Med, Div Traumatol & Surg Crit Cate, Dept Surg, 3440 Market St, Philadelphia, PA 19104 USA.	graciasv@uphs.upenn.edu	Pascual, Jose/ABI-2291-2020	Pascual, Jose/0000-0002-1613-7912			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; *BRAIN TRAUM FDN, 2003, AM ASS NEUR SURG JOI; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Favre JB, 1996, SCHWEIZ MED WSCHR, V126, P1635; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; Hartl R, 1997, ACT NEUR S, V70, P126; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MAAS AIR, 1993, ACTA NEUROCHIR, P50; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; Pascual JL, 2002, ANN SURG, V236, P634, DOI 10.1097/00000658-200211000-00014; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Qureshi AI, 2002, J NEUROSURG ANESTH, V14, P22, DOI 10.1097/00008506-200201000-00005; Rizoli SB, 1998, J IMMUNOL, V161, P6288; Saltarini M, 2002, Eur J Emerg Med, V9, P262, DOI 10.1097/00063110-200209000-00011; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; Taylor G, 1996, J PEDIATR SURG, V31, P65, DOI 10.1016/S0022-3468(96)90321-8; TEASDALE G, 1974, LANCET, V2, P81; van den Brink WA, 1998, J NEUROTRAUM, V15, P813, DOI 10.1089/neu.1998.15.813; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Wade CE, 1997, SURGERY, V122, P609, DOI 10.1016/S0039-6060(97)90135-5; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011	26	15	18	0	3	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	MAR	2008	74	3					253	259					7	Surgery	Surgery	267OR	WOS:000253519000016	18376694				2021-06-18	
J	Gall, C; Mueller, I; Kaufmann, C; Franke, GH; Sabel, BA				Gall, C.; Mueller, I.; Kaufmann, C.; Franke, G. H.; Sabel, B. A.			Visual field defects after cerebral lesions from the patient's perspective. Health- and vision-related quality of life assessed by SF-36 and NEI-VFQ	NERVENARZT			German	Article						quality of life; perimetry; visual field defect; National Eye Institute - Visual Function Questionnaire; SF-36 Health Survey	FUNCTION QUESTIONNAIRE; DEPRESSION; REHABILITATION; THERAPY; PEOPLE	Background. In patients with visual field defects, measurement of health-related quality of life (hQoL) and vision-related quality of life (vQoL) is an important adjunct to clinical measures such as perimetry. The purpose of this study was to describe hQoL and vQoL of patients with visual field defects after cerebral lesions such as infarction, traumatic brain injury, and tumor. Methods. The National Eye Institute - Visual Function Questionnaire (NEI-VFQ) for vQoL and the SF-36 Health Survey for hQoL were administered to 24 patients about 2 years after occurrence of the visual field defect. Visual fields were measured by standard perimetry and a near-threshold campimetric method. Visual acuity was measured by the Landolt-Ring-Test. Results. The NEI-VFQ scores - but not SF-36 scores - were not only lower than those of a disease-free group but also lower than those of patients with visual impairments not caused by cerebral damage. Rank correlations between the size of the visual field defect and NEI-VFQ subscales were significantly high or modest. With SF-36 scores these correlations were generally low and moderate at best. Conclusion. The NEI-VFQ is a valuable measure of self-reported visual impairment in patients with visual field defects after cerebral lesions. The measurement of unspecific hQoL is not sufficient to reflect the problems of patients with visual field defects.	[Gall, C.; Mueller, I.; Sabel, B. A.] Otto Von Guericke Univ, Fac Med, Inst Med Psychol, D-39120 Magdeburg, Germany; [Kaufmann, C.] Humboldt Univ, Inst Psychol, D-1086 Berlin, Germany; [Franke, G. H.] Studeingang Rehabilitationspsychol, Magdeburg, Germany	Gall, C (corresponding author), Otto Von Guericke Univ, Fac Med, Inst Med Psychol, Leipzig Str 44, D-39120 Magdeburg, Germany.	carolin.gall@med.ovgu.de	Sabel, Bernhard A./E-6579-2013	Sabel, Bernhard/0000-0002-4472-5543; Franke, Gabriele Helga/0000-0002-2459-0362			Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0; Brody BL, 2001, OPHTHALMOLOGY, V108, P1901; Bullinger M, 1997, PSYCHOTHER PSYCH MED, V47, P76; Bullinger M, 2003, Rehabilitation (Stuttg), V42, P218; BULLINGER M, 1998, SF36 FRAGEBOGEN GESU; Carta A, 1998, CURR EYE RES, V17, P506, DOI 10.1076/ceyr.17.5.506.5191; Cole SR, 2000, INVEST OPHTH VIS SCI, V41, P1017; Deramo VA, 2003, ARCH OPHTHALMOL-CHIC, V121, P1297, DOI 10.1001/archopht.121.9.1297; FRANKE GH, 2002, SCL90R SYMPTOM CHECK; Franke GH, 1998, Z MED PSYCHOL, V7, P178; Gutierrez P, 1997, ARCH OPHTHALMOL-CHIC, V115, P777, DOI 10.1001/archopht.1997.01100150779014; Jampel HD, 2002, J GLAUCOMA, V11, P154, DOI 10.1097/00061198-200204000-00012; Kasten E, 1997, SPATIAL VISION, V10, P499, DOI 10.1163/156856897X00456; Kasten E, 2006, BEHAV BRAIN RES, V175, P18, DOI 10.1016/j.bbr.2006.07.024; KERKHOFF G, 1990, NERVENARZT, V61, P711; Kerkhoff G, 2000, J NEUROL NEUROSUR PS, V68, P691, DOI 10.1136/jnnp.68.6.691; Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P733, DOI 10.1001/archopht.119.5.733; Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227; Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050; Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496; Miskala PH, 2004, ARCH OPHTHALMOL-CHIC, V122, P758, DOI 10.1001/archopht.122.5.758; Muller I, 2006, NERVENARZT, V77, P694, DOI 10.1007/s00115-006-2054-6; Parrish RK, 1997, ARCH OPHTHALMOL-CHIC, V115, P1447, DOI 10.1001/archopht.1997.01100160617016; Paz SH, 2003, ARCH OPHTHALMOL-CHIC, V121, P1021, DOI 10.1001/archopht.121.7.1021; Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041; SPILKER B, 1998, QUALITY LIFE PHARMAC; Stelmack JA, 2002, INVEST OPHTH VIS SCI, V43, P2859; WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59; Wolffsohn JS, 2000, BRIT J OPHTHALMOL, V84, P1035, DOI 10.1136/bjo.84.9.1035	29	15	15	0	6	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0028-2804	1433-0407		NERVENARZT	Nervenarzt	FEB	2008	79	2					185	+		10.1007/s00115-007-2342-9			9	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	259LY	WOS:000252942000005	17934709				2021-06-18	
J	Lima, RR; Guimaraes-Silva, J; Oliveira, JL; Costa, AMR; Souza-Rodrigues, RD; Dos Santos, CD; Picanco-Diniz, CW; Gomes-Leal, W				Lima, Rafael R.; Guimaraes-Silva, Joanilson; Oliveira, Jorge L.; Costa, Ana Maria R.; Souza-Rodrigues, Renata D.; Dos Santos, Claudia D.; Picanco-Diniz, Cristovam W.; Gomes-Leal, Walace			Diffuse axonal damage, myelin impairment, astrocytosis and inflammatory response following microinjections of NMDA into the rat striatum	INFLAMMATION			English	Article						white matter damage; basal ganglia; excitotoxicity; neutrophils; macrophages	SPINAL-CORD-INJURY; CENTRAL-NERVOUS-SYSTEM; WHITE-MATTER INJURY; VASCULAR MECHANISMS; THERAPEUTIC TARGET; CEREBRAL-ISCHEMIA; HEAD-INJURY; BETA-APP; CNS; MACROPHAGES	White matter damage and inflammatory response are important secondary outcomes after acute neural disorders. Nevertheless, a few studies addressed the temporal outcomes of these pathological events using non-traumatic models of acute brain injury. In the present study, we describe acute inflammatory response and white matter neuropathology between 1 and 7 days after acute excitotoxic striatal damage. Twenty micrometer sections were stained by hematoxylin and eosin technique for gross histopathological analysis and immunolabed for neutrophils (anti-mbs-1), activated macrophages/microglia (anti-ed1), astrocytes (anti-gfap), damaged axons (anti-beta app) and myelin basic protein (MBP). Recruitment peak of neutrophils and macrophages occurred at 1 and 7 days post-nmda injection, respectively. Diffuse damaged axons (beta-app + end-bulbs) were apparent at 7 days, concomitant with progressive myelin impairment and astrocytosis. Further studies using electron microscopy and blockers of inflammatory response and glutamatergic receptors should be performed to confirm and address the mechanisms of white matter damage following an excitotoxic lesion.	[Gomes-Leal, Walace] Univ Lund Hosp, Lund Strateg Res Ctr Stem Cell Biol & Cell Therap, SE-22184 Lund, Sweden; [Gomes-Leal, Walace] Univ Lund Hosp, Wallenberg Neurosci Ctr, Sect Restorat Neurol, Lab Neurogenet Cell Therapy, SE-22184 Lund, Sweden; [Lima, Rafael R.; Guimaraes-Silva, Joanilson; Oliveira, Jorge L.; Costa, Ana Maria R.; Souza-Rodrigues, Renata D.; Dos Santos, Claudia D.; Picanco-Diniz, Cristovam W.; Gomes-Leal, Walace] Fed Univ Para, Dept Morphol, Ctr Biol Sci, Lab Expt Neuroprotect & Neuroregenerat, BR-66075900 Belem, Para, Brazil	Gomes-Leal, W (corresponding author), Univ Lund Hosp, Lund Strateg Res Ctr Stem Cell Biol & Cell Therap, SE-22184 Lund, Sweden.	leal@ufpa.br	Souza-Rodrigues, Renata Duarte/AAL-7367-2021; Diniz, Cristovam W.P./G-1474-2010; Lima, Rafael/B-2248-2013; LEAL, WALACE/AAO-9171-2021; Lima, Rafael Rodrigues/M-7726-2019	Diniz, Cristovam W.P./0000-0001-6611-6880; Lima, Rafael/0000-0003-1486-4013; Lima, Rafael Rodrigues/0000-0003-1486-4013			Anderson CM, 2000, GLIA, V32, P1; Aschner M, 1998, NEUROTOXICOLOGY, V19, P269; Aschner M, 1998, NEUROTOXICOLOGY, V19, P7; AYRES M, 2005, BIOSTAT 4 0; BLIGHT AR, 1994, NEUROSCIENCE, V60, P263, DOI 10.1016/0306-4522(94)90220-8; Bolton SJ, 1998, EXP NEUROL, V154, P231, DOI 10.1006/exnr.1998.6927; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; Dommergues MA, 2003, NEUROSCIENCE, V121, P619, DOI 10.1016/S0306-4522(03)00558-X; Dos Santos CD, 2007, BRAIN RES, V1172, P130, DOI 10.1016/j.brainres.2007.07.037; Esiri MM, 2007, J NEUROIMMUNOL, V184, P4, DOI 10.1016/j.jneuroim.2006.11.013; Frost SB, 2006, BEHAV BRAIN RES, V169, P206, DOI 10.1016/j.bbr.2006.01.014; Galtrey CM, 2007, BRAIN RES REV, V54, P1, DOI 10.1016/j.brainresrev.2006.09.006; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Goda M, 2002, J NEUROTRAUM, V19, P1445, DOI 10.1089/089771502320914679; Gomes-Leal W, 2005, BRAIN RES, V1066, P57, DOI 10.1016/j.brainres.2005.10.069; Gomes-Leal W, 2004, EXP NEUROL, V190, P456, DOI 10.1016/j.expneurol.2004.06.028; Hamby AM, 2007, STROKE, V38, P632, DOI 10.1161/01.STR.0000250742.61241.79; Hughes PM, 2003, J NEUROPATH EXP NEUR, V62, P1276, DOI 10.1093/jnen/62.12.1276; Irving EA, 2001, ACTA NEUROPATHOL, V102, P627, DOI 10.1007/s004010100416; Jones TB, 2005, CURR PHARM DESIGN, V11, P1223, DOI 10.2174/1381612053507468; Kanellopoulos GK, 2000, STROKE, V31, P1945, DOI 10.1161/01.STR.31.8.1945; Karadottir R, 2005, NATURE, V438, P1162, DOI 10.1038/nature04302; Knoller N, 2005, J NEUROSURG-SPINE, V3, P173, DOI 10.3171/spi.2005.3.3.0173; Lazarov-Spiegler O, 1998, MOL MED TODAY, V4, P337, DOI 10.1016/S1357-4310(98)01298-2; Li S, 2001, NEUROSCIENCE, V107, P675, DOI 10.1016/S0306-4522(01)00385-2; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Mahapatra RK, 2004, LANCET NEUROL, V3, P736, DOI 10.1016/S1474-4422(04)00936-6; Matute C, 2007, J ANAT, V210, P693, DOI 10.1111/j.1469-7580.2007.00733.x; Matute C, 2006, TRENDS MOL MED, V12, P289, DOI 10.1016/j.molmed.2006.05.004; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mitsios N, 2006, PATHOBIOLOGY, V73, P159, DOI 10.1159/000096017; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Popovich PG, 2001, J NEUROPATH EXP NEUR, V60, P676, DOI 10.1093/jnen/60.7.676; Popovich PG, 2002, J NEUROPATH EXP NEUR, V61, P623, DOI 10.1093/jnen/61.7.623; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; ROBINSON AP, 1986, IMMUNOLOGY, V57, P239; Rogove AD, 1998, CURR BIOL, V8, P19, DOI 10.1016/S0960-9822(98)70016-8; Schabitz WR, 2000, STROKE, V31, P1709, DOI 10.1161/01.STR.31.7.1709; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schwartz M, 2006, TRENDS NEUROSCI, V29, P68, DOI 10.1016/j.tins.2005.12.005; Stys PK, 2005, J NEUROL SCI, V233, P3, DOI 10.1016/j.jns.2005.03.031; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Taylor TN, 1996, STROKE, V27, P1459, DOI 10.1161/01.STR.27.9.1459; Verkhratsky A, 2007, NEUROSCIENTIST, V13, P28, DOI 10.1177/1073858406294270; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126; Yoles E, 1998, EXP NEUROL, V153, P1, DOI 10.1006/exnr.1998.6811	49	15	17	0	2	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0360-3997	1573-2576		INFLAMMATION	Inflammation	FEB	2008	31	1					24	35		10.1007/s10753-007-9046-y			12	Cell Biology; Immunology	Cell Biology; Immunology	260JR	WOS:000253007100003	17899345				2021-06-18	
J	Amantini, A; Amadori, A; Fossi, S				Amantini, A.; Amadori, A.; Fossi, S.			Evoked potentials in the ICU	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article; Proceedings Paper	Brain Annual Meeting	MAY 09-12, 2007	Brescia, ITALY			critical care; brain injury acute; trauma; hypoxia-ischaemia; brain; evoked potentials; somatosensory	ANOXIC-ISCHEMIC COMA; SEVERE HEAD-INJURY; SEVERE BRAIN-INJURY; PREDICTION; EEG; PROGNOSIS	The most informative neurophysiological techniques available in the neurosurgical intensive care unit are electroencephalograph and somatosensory evoked potentials. Such tools, which give an evaluation of cerebral function in comatose patients, support clinical evaluation and are complementary to neurolmaging. They serve both diagnostic/prognostic and monitoring purposes. While for the former, discontinuous monitoring is sufficient, for the latter, to obtain increased clinical impact, continuous monitoring is necessary. To perform and interpret these examinations in the neurosurgical intensive care unit, both the technician and the neurophysiologist need specific training in the intensive care field. There is sufficient evidence to show that somatosensory evoked potentials are the best single indicator of early prognosis in traumatic and hypoxic-ischaemic coma compared to the Glasgow Coma Score, computed tomography scan and electroencephalograph. Indeed, somatosensory evoked potentials should always be combined with clinical examination to determine the prognosis of coma. Despite widespread use of somatosensory evoked potentials and their prognostic utility in acute brain injury, few studies exist on continuous somatosensory evoked potential monitoring in the intensive care unit. We carried out a pilot study of continuous electroencephalograph-somatosensory evoked potential monitoring in the neurosurgical intensive care unit (traumatic brain injury and intracranial haemorrhage, Glasgow Coma Score <9, intracranial pressure monitoring). All patients stable from a clinical and computed tomography scan point of view showed no significant somatosensory evoked potential modifications, while in the case of clinical deterioration (2396), somatosensory evoked potentials always showed significant modifications. While somatosensory evoked potentials correlated with short-term outcome, intracranial pressure showed a poor correlation. We believe neurophysiological monitoring is an ideal complement to the other parameters monitored in the neurosurgical intensive care unit. Whereas intracranial pressure is simply a pressure index, electroencephalograph-somatosensory evoked potential monitoring reflects to what extent cerebral parenchyma still remains metabolically active during acute brain injury.	[Amantini, A.; Fossi, S.] Univ Florence, Univ Careggi, Azienda Osped, Dept Neurol & Psychiat Sci,UO Neurophysiopatol, I-50134 Florence, Italy; [Amadori, A.] Univ Florence, Univ Careggi, Azienda Osped, Dept Neurol & Psychiat Sci,Neurointens Care Unit, I-50134 Florence, Italy	Amantini, A (corresponding author), Univ Florence, Dept Neurol & Psychiat Sci, Az Osped Careggi, Vle Morgagni 85, I-50134 Florence, Italy.	amantini@unifi.it					Amantini A, 2005, CLIN NEUROPHYSIOL, V116, P229, DOI 10.1016/j.clinph.2004.07.008; Attia J, 1998, CRIT CARE CLIN, V14, P497, DOI 10.1016/S0749-0704(05)70013-0; Bassetti C, 1996, J NEUROL NEUROSUR PS, V61, P610, DOI 10.1136/jnnp.61.6.610; Carter BG, 2005, INTENS CARE MED, V31, P765, DOI 10.1007/s00134-005-2633-1; Carter BG, 2001, CRIT CARE MED, V29, P178, DOI 10.1097/00003246-200101000-00036; Claassen J, 2005, J CLIN NEUROPHYSIOL, V22, P92, DOI 10.1097/01.WNP.0000145006.02048.3A; Facco E, 2000, INTENS CARE MED, V26, P998, DOI 10.1007/s001340051294; Facco E, 2002, CLIN NEUROPHYSIOL, V113, P1855, DOI 10.1016/S1388-2457(02)00259-6; Fischer C., 2002, Annales de Readaptation et de Medecine Physique, V45, P448, DOI 10.1016/S0168-6054(02)00295-7; Forsyth RJ, 2001, COCHRANE DB SYST REV, V3; Fossi S, 2006, NEUROPHYSIOL CLIN, V36, P195, DOI 10.1016/j.neucli.2006.09.001; Guerit JM, 1999, NEUROPHYSIOL CLIN, V29, P301, DOI 10.1016/S0987-7053(99)90044-8; GUERIT JM, 1999, ELECTROENCEPHALOGR S, V52, P117; GUERIT JM, 2005, 27 INT C CLIN NEUR S; KONASIEWICZ SJ, 1994, CAN J NEUROL SCI, V21, P219, DOI 10.1017/S0317167100041196; KRAFT GH, 1999, MUSCLE NERVE       S, V8, pS123; Logi F, 2003, CLIN NEUROPHYSIOL, V114, P1615, DOI 10.1016/S1388-2457(03)00086-5; Moulton RJ, 1998, CAN J NEUROL SCI, V25, pS7, DOI 10.1017/S031716710003465X; REGAN D, 1989, SCI MED; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; Rothstein TL, 2000, J CLIN NEUROPHYSIOL, V17, P486, DOI 10.1097/00004691-200009000-00007; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; Zandbergen EGJ, 2000, J CLIN NEUROPHYSIOL, V17, P498, DOI 10.1097/00004691-200009000-00008; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8	24	15	17	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.		2008	25			42			196	202		10.1017/S0265021507003183			7	Anesthesiology	Anesthesiology	283AY	WOS:000254610100034	18289442				2021-06-18	
J	Careau, E; Vincent, C; Noreau, L				Careau, Emmanuelle; Vincent, Claude; Noreau, Luc			Assessing interprofessional teamwork in a videoconference-based telerehabilitation setting	JOURNAL OF TELEMEDICINE AND TELECARE			English	Article							TRAUMATIC BRAIN-INJURY; WORK; DISABILITIES; PREVALENCE; PEOPLE; TEAMS	We studied the workings of a rehabilitation team in a videoconference setting to note the pros and cons of videoconferencing in the development of interprofessional care plans (ICPs). We recorded every videoconference held by the teams of the specialized centre and the regional centre for clients with traumatic brain injuries over an 18-month period. Thirteen recorded videoconferences, lasting for 30-98 min, were analysed through an observation grid. On the whole, efficient teamwork was observed: the mean productivity level was 96%, while the percentage of time dedicated to the resolution of technical issues was 2%. During the videoconferences, the clinical coordinator and the client addressed the group most often. One of the most commonly mentioned advantages was the good visual contact provided by videoconferencing. The most often quoted disadvantage was the poor sound quality. The findings from the study support the adoption of videoconferencing and suggest a few guidelines for the development of ICPs.	[Careau, Emmanuelle] Ctr Interdisciplinary Res Rehabil & Social Integr, Inst Readaptat Deficience Phys Quebec, Quebec City, PQ G1M 2S8, Canada; [Careau, Emmanuelle] Univ Laval, Fac Med, Quebec City, PQ G1K 7P4, Canada; [Vincent, Claude; Noreau, Luc] Univ Laval, Dept Rehabil, Quebec City, PQ G1K 7P4, Canada	Careau, E (corresponding author), Ctr Interdisciplinary Res Rehabil & Social Integr, Inst Readaptat Deficience Phys Quebec, 525 Wilfrid Hamel Blvd E, Quebec City, PQ G1M 2S8, Canada.	enmanuelle.careau@rea.ulaval.ca			Centre de readaptation InterAction; Institut de readaptation en deficience physique de Quebec; Agence de developpement de reseaux locaux de services de sante et de services sociaux de la Capitale Nationale et du Bas-St-Laurent; University Laval's Centre for Interdisciplinary Research in Rehabilitation and Social Integration; Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR) [2008-2011]	We thank everyone who took part in the study. Financial support was provided by the Centre de readaptation InterAction, the Institut de readaptation en deficience physique de Quebec, the Agence de developpement de reseaux locaux de services de sante et de services sociaux de la Capitale Nationale et du Bas-St-Laurent and University Laval's Centre for Interdisciplinary Research in Rehabilitation and Social Integration. The first author holds a doctoral scholarship from the Canadian Institute of Health Research (2008-2011).	Aas I. H. M., 2003, Behaviour and Information Technology, V22, P91, DOI 10.1080/0044929021000088407; Aas IHM, 2001, J TELEMED TELECARE, V7, P212, DOI 10.1258/1357633011936426; Bender A D, 1990, Med Group Manage J, V37, P30; BENDER AD, 1990, MED GROUP MANAGE J, V37, P35; Bernard M. M., 2005, VIE VIEILLISSEMENT, V4, P25; BLOUIN M, 1997, PLAN INTERVENTION DI, V2, P57; BROUSSEAU T, 2003, GUIDE ELABORATION PL; Casto M., 1994, INTERPROFESSIONAL CA; Creswell J.W., 2013, QUAL INQ; Drahota A, 2008, NURS RES, V57, P293, DOI 10.1097/01.NNR.0000313489.49165.97; Elovic E, 1999, TOP SPINAL CORD INJ, V5, P1, DOI DOI 10.1310/V75J-RE76-20GH-X7BY; Finlayson M, 2005, NEUROREHABILITATION, V20, P267; GADOURY M, 1999, CADRE REFERENCE CLIN; Gervais M, 1999, ETUDE EXPLORATOIRE B; GRISE MC, 2007, PHYSIOQUEBEC, V31, P15; Guilfoyle C, 2003, J TELEMED TELECARE, V9, P230, DOI 10.1258/135763303322225571; Hegeman K M, 1988, Rehabil Nurs, V13, P254; JAMET C, 2005, RECHERCHE SOINS INFI, V82, P62; JESSIMAN SM, 2003, REV ORTHOPHONIE AUDI, V27, P45; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; KAIRY D, DISABIL REH IN PRESS; MARIANO C, 1989, NURS OUTLOOK, V37, P285; MOSCATO BS, 1994, J NEUROPSYCH CLIN N, V6, P134; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; Roberts S, 2008, NURS EDUC TODAY, V28, P85, DOI 10.1016/j.nedt.2006.06.004; RUBIN IM, 1972, MILBANK MEML FUND Q, V50, P317, DOI 10.2307/3349352; Savard L, 2003, NEUROREHABILITATION, V18, P93; Schopp LH, 2000, J TELEMED TELECARE, V6, P146, DOI 10.1258/1357633001934474; St-Arnaud Y, 1989, PETITS GROUPES PARTI; SUNDSTROM E, 1990, AM PSYCHOL, V45, P120, DOI 10.1037/0003-066X.45.2.120; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TREMBLAY J, 2000, J READAPTATION MED, V20, P95; VINCENT C, SUIVI CLIENTELES TRA; Watts L., 1997, P C HUM FACT COMP SY, P534; WEBER MD, 1991, AM J PHYSL 3, V261, P12	35	15	16	0	5	ROYAL SOC MEDICINE PRESS LTD	LONDON	1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND	1357-633X			J TELEMED TELECARE	J. Telemed. Telecare		2008	14	8					427	434		10.1258/jtt.2008.080415			8	Health Care Sciences & Services	Health Care Sciences & Services	393FH	WOS:000262355900006	19047453				2021-06-18	
J	Donders, J				Donders, Jacobus			Subtypes of learning and memory on the California Verbal Learning Test-Second Edition (CVLT-II) in the standardization sample	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						cluster analysis; California Verbal Learning Test-Second Edition; learning; memory; subtypes	TRAUMATIC BRAIN-INJURY; TEST-2ND EDITION; CLUSTER-ANALYSIS; PERFORMANCE; PATTERNS	The purpose of this study was to determine representative, core profile subtypes of learning and memory, based on four variables representing different latent constructs, in the standardization sample of the California Verbal Learning Test-Second Edition (CVLT-II; Delis, Kramer, Kaplan, Ober, 2000). Two-stage cluster analysis identified six reliable subtypes. Variability in both level and pattern of performance contributed to the differentiation of these subtypes. Level of education was meaningfully related to variability in overall performance of the subtypes. Implications for the interpretation of CVLT-II findings obtained in clinical practice are discussed.	Mary Free Bed Rehabil Hosp, Psychol Serv, Grand Rapids, MI 49503 USA	Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com					Baldo JV, 2002, J INT NEUROPSYCH SOC, V8, P539, DOI 10.1017/S135561770281428X; BLASHFIELD RK, 1976, PSYCHOL BULL, V83, P377, DOI 10.1037/0033-2909.83.3.377; CARTER RL, 1989, PSYCHOMETRIKA, V54, P9, DOI 10.1007/BF02294446; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; DELIS D, 1994, CALIFORNIA VERBAL LE; DELIS D, 1987, CALIFORNIA VERBAL LE; Delis DC, 2005, J INT NEUROPSYCH SOC, V11, P708, DOI 10.1017/S1355617705050812; DELIS DC, 2000, CALIFORNIA VERBAL LE; DESPHANDE SA, 1996, J CLIN EXPT NEUROPSY, V18, P836; Donders J, 2001, ASSESSMENT, V8, P193, DOI 10.1177/107319110100800207; Donders J, 1999, DEV NEUROPSYCHOL, V16, P163, DOI 10.1207/S15326942DN1602_2; DONDERS J, ASSESSMENT IN PRESS; Donders J, 2006, PSYCHOL ASSESSMENT, V18, P458, DOI 10.1037/1040-3590.18.4.458; Fuerst DR, 1995, CHILD NEUROPSYCHOL, V1, P38, DOI 10.1080/09297049508401341; Hair JF., 2002, READING UNDERSTANDIN, P147; Jacobs ML, 2007, ARCH CLIN NEUROPSYCH, V22, P143, DOI 10.1016/j.acn.2006.12.002; MILLIGAN GW, 1980, PSYCHOMETRIKA, V45, P325, DOI 10.1007/BF02293907; MILLIGAN GW, 1985, PSYCHOMETRIKA, V50, P159, DOI 10.1007/BF02294245; MILLIGAN GW, 2003, HDB PSYCHOL RES METH, V2, P165; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; SAS Institute Inc., 1990, SAS STAT US GUID VER, V1; Schinka JA, 1998, PSYCHOL ASSESSMENT, V10, P171, DOI 10.1037/1040-3590.10.2.171; Stricker JL, 2002, J INT NEUROPSYCH SOC, V8, P425, DOI 10.1017/S1355617702813224; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925	24	15	15	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2008	30	7					741	748		10.1080/13803390701689595			8	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	345EH	WOS:000258978400001	18608653				2021-06-18	
J	Hermens, H; Huijgen, B; Giacomozzi, C; Ilsbroukx, S; Macellari, V; Prats, E; Rogante, M; Schifini, MF; Spitali, MC; Tasies, S; Zampolini, M; Vollenbroek-Hutten, M				Hermens, Hermie; Huijgen, Barbara; Giacomozzi, Claudia; Ilsbroukx, Stephan; Macellari, Velio; Prats, Elisabet; Rogante, Marco; Schifini, Maria Francesca; Spitali, Maria Cristina; Tasies, Sonia; Zampolini, Mauro; Vollenbroek-Hutten, Miriam			Clinical assessment of the HELLODOC tele-rehabilitation service	ANNALI DELL ISTITUTO SUPERIORE DI SANITA			English	Article						tele-rehabilitation; home rehabilitation; arm/hand function; neurologic patients	CHRONIC STROKE PATIENTS; BLIND	Within the EU project HELLODOC, the clinical effectiveness was investigated of the home care activity desk (H-CAD). Eighty-one patients with chronic stroke, traumatic brain injury (TBI) and multiple sclerosis (MS) were recruited; 50 out of 81 received 1 month of H-CAD intervention, with one training session a day lasting 30 minutes for 5 days a week. The overall satisfaction of both patients and therapists was high. The Action Research Arm (ARA) and the Nine Hole Peg Test (NHPT) were used as main outcome measures. They proved the H-CAD system to be at least as effective as usual care. Maybe due to limited length and intensity of treatment, during the training month subjects improved on the individual H-CAD exercises but, as in the usual care group, the arm/hand function remained at the same level.	[Giacomozzi, Claudia; Macellari, Velio; Rogante, Marco] Ist Super Sanita, Dipartimento Tecnol & Salute, I-00161 Rome, Italy; [Ilsbroukx, Stephan] Natl Multiple Sclerosis Ctr, Melsbroek, Belgium; [Prats, Elisabet; Tasies, Sonia] Fundacio Inst Guttmann, Barcelona, Spain; [Schifini, Maria Francesca; Spitali, Maria Cristina; Zampolini, Mauro] Unita Organ Riabilitaz Intens Neuromotoria, Trevi, Italy; [Hermens, Hermie; Huijgen, Barbara; Vollenbroek-Hutten, Miriam] Roessingh Res & Dev BV, Enschede, Netherlands	Hermens, H (corresponding author), Roessingh Res & Dev, Roessinghsbleekweg 33B, NL-7522 AH Enschede, Netherlands.	h.hermens@rrd.nl	Giacomozzi, Claudia/AAH-1640-2021; Giacomozzi, Claudia/G-5018-2016; Zampolini, Mauro/B-7749-2009	Giacomozzi, Claudia/0000-0001-6950-4934; Giacomozzi, Claudia/0000-0001-6950-4934; Vollenbroek-Hutten, Miriam/0000-0001-8730-1487			Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; LYLE RC, 1981, INT J REHABIL RES, V4, P483, DOI 10.1097/00004356-198112000-00001; MAHONEY F I, 1965, Md State Med J, V14, P61; Penta M, 2001, STROKE, V32, P1627, DOI 10.1161/01.STR.32.7.1627; Senn S., 1997, STAT ISSUES DRUG DEV; van der Lee JH, 1999, STROKE, V30, P2369, DOI 10.1161/01.STR.30.11.2369; Vaney C, 2004, MULT SCLER, V10, P417, DOI 10.1191/1352458504ms1048oa; VOLLENBROEKHUTT.MM, 2006, POWER ANAL CLIN TRIA; WAGENAAR RC, 1990, SCAND J REHABIL MED, V22, P1; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wolf SL, 2001, STROKE, V32, P1635, DOI 10.1161/01.STR.32.7.1635	11	15	15	0	5	PENSIERO SCIENTIFICO	ROME	VIA SAN GIOVANNI VALDARNO 8, ROME, 00198, ITALY	0021-2571			ANN I SUPER SANITA	Ann. Ist. Super. Sanita		2008	44	2					154	163					10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	V15PB	WOS:000207812800005	18660565	DOAJ Gold			2021-06-18	
J	Jellish, WS; Zhang, X; Langen, KE; Spector, MS; Scalfani, MT; White, FA				Jellish, Walter S.; Zhang, Xin; Langen, Kenneth E.; Spector, Matthew S.; Scalfani, Michael T.; White, Fletcher A.			Intrathecal magnesium sulfate administration at the time of experimental ischemia improves neurological functioning by reducing acute and delayed loss of motor neurons in the spinal cord	ANESTHESIOLOGY			English	Article							GLUTAMATE TRANSPORTER GLT-1; TRAUMATIC BRAIN-INJURY; NECROSIS-FACTOR-ALPHA; RECEPTOR CHANNELS; HIPPOCAMPAL CA1; AMPA RECEPTOR; BLOOD-FLOW; CEREBRAL-ISCHEMIA; CA2+ PERMEABILITY; TNF-ALPHA	Background: In this study, the authors determined the effect of magnesium sulfate on intrathecal glutamate concentrations, hindlimb motor function, and histopathology after a transient episode of spinal cord ischemia. Methods: Fifty-two New Zealand White rabbits underwent spinal cord ischemia for 30 min. Fifteen minutes before ischemia, animals received intrathecal magnesium sulfate (MgSO4) (3 mg/kg) or placebo (artificial cerebrospinal fluid). Intrathecal microdialysis samples were measured for glutamate using high-performance liquid chromatography. Neurologic function and spinal cord histopathology were assessed throughout the recovery period. Results: Intrathecal glutamate levels in placebo-treated animals were higher after spinal cord ischemia compared with sham- and MgSO4-treated animals. MgSO4-treated animals had increased lower extremity motor function compared with the placebo group (64.7% vs 14.3%, P < 0.01). Histologic examination of placebo-treated animals revealed significant motor neuron cell loss at thoracolumbar levels by Day 7 (P < 0.05), whereas lower lumbar regions displayed significant neuron loss on Day 1. Spinal cords from MgSO4-treated animals exhibited less neuronal loss in lumbar regions. Similar effects were present in the thoracolumbar segments on Day 7. A significant correlation existed between diminished neuronal loss and hind leg movement (Tarlov score) and demonstrates that the neurologic outcome after MgSO4 treatment was related to lower lumbar ventral horn cell survival (r(2) = 0.812, P < 0.001). Conclusions: These results demonstrate that MgSO4 affords significant spinal cord motor neuron protection by diminishing acute neuronal loss at the foci of the ischemic injury (L3-L6) with delayed neuronal degeneration in adjacent spinal cord regions (T7-L2).	[Jellish, Walter S.; Zhang, Xin; Langen, Kenneth E.; Spector, Matthew S.; Scalfani, Michael T.; White, Fletcher A.] Loyola Univ, Med Ctr, Dept Anesthesiol, Maywood, IL 60153 USA; [Jellish, Walter S.; Zhang, Xin; Langen, Kenneth E.; Spector, Matthew S.; Scalfani, Michael T.; White, Fletcher A.] Loyola Univ Chicago, Stritch Sch Med, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA	Jellish, WS (corresponding author), Loyola Univ, Med Ctr, Dept Anesthesiol, 2160 S 1st Ave,Bldg 103,Room 3114, Maywood, IL 60153 USA.	wjellis@lumc.edu	White, Fletcher/F-3203-2015; White, Fletcher A/F-2895-2012	White, Fletcher/0000-0002-8408-9262; 	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS049136-02, R01 NS049136] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049136] Funding Source: NIH RePORTER		Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Bartlett MS, 1937, PROC R SOC LON SER-A, V160, P0268, DOI 10.1098/rspa.1937.0109; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; BENVENISTE H, 1989, J CEREBR BLOOD F MET, V9, P629, DOI 10.1038/jcbfm.1989.90; BENVENISTE H, 1988, ACTA NEUROL SCAND, V78, P529, DOI 10.1111/j.1600-0404.1988.tb03697.x; Brock MV, 1997, ANN THORAC SURG, V64, P999, DOI 10.1016/S0003-4975(97)00621-8; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CHI OZ, 1990, ARCH INT PHARMACOD T, V304, P196; DAGOSTINO RB, 1990, AM STAT, V44, P316, DOI 10.2307/2684359; DEGIROLAMI U, 1982, J NEUROPATH EXP NEUR, V41, P129, DOI 10.1097/00005072-198203000-00004; Dingledine R, 1999, PHARMACOL REV, V51, P7; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; Gorter JA, 1997, J NEUROSCI, V17, P6179; Hamann M, 2002, EUR J NEUROSCI, V15, P308, DOI 10.1046/j.0953-816x.2001.01861.x; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Ishikawa T, 1999, CELL MOL NEUROBIOL, V19, P199, DOI 10.1023/A:1006973026514; Jellish WS, 2005, EXP BRAIN RES, V167, P526, DOI 10.1007/s00221-005-0064-4; JOHNSON SH, 1993, STROKE, V24, P1547, DOI 10.1161/01.STR.24.10.1547; Juvonen T, 2002, SCAND CARDIOVASC J, V36, P136, DOI 10.1080/cdv.36.3.136.160; Kaplan S, 2004, EUR SURG RES, V36, P20, DOI 10.1159/000075070; Kawahara Y, 2004, NATURE, V427, P801, DOI 10.1038/427801a; Kemp PA, 1999, BRIT J PHARMACOL, V126, P621, DOI 10.1038/sj.bjp.0702342; Lalo U, 2006, J NEUROSCI, V26, P2673, DOI 10.1523/JNEUROSCI.4689-05.2006; Lang-Lazdunski L, 2000, J VASC SURG, V32, P179, DOI 10.1067/mva.2000.105960; Lang-Lazdunski L, 2001, ANN THORAC SURG, V72, P2180, DOI 10.1016/S0003-4975(01)02919-8; LEHRE KP, 1995, J NEUROSCI, V15, P1835; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; MARSALA J, 1991, NEUROSCIENCE, V45, P479, DOI 10.1016/0306-4522(91)90243-H; MARSALA M, 1994, J CEREBR BLOOD F MET, V14, P604, DOI 10.1038/jcbfm.1994.75; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; McKee JA, 2005, NEUROCRIT CARE, V2, P342, DOI 10.1385/NCC:2:3:342; McKee JA, 2005, CRIT CARE MED, V33, P661, DOI 10.1097/01.ccm.0000156293.35868.b2; Mitani A, 2003, J NEUROSCI, V23, P7176, DOI 10.1523/JNEUROSCI.23-18-07176.2003; MOORE WM, 1991, ANN SURG, V213, P427, DOI 10.1097/00000658-199105000-00007; Ogoshi F, 2005, EXP NEUROL, V193, P384, DOI 10.1016/j.expneurol.2004.12.026; Petralia RS, 1997, J COMP NEUROL, V385, P456, DOI 10.1002/(SICI)1096-9861(19970901)385:3<456::AID-CNE9>3.0.CO;2-2; RAM Z, 1991, STROKE, V22, P922, DOI 10.1161/01.STR.22.7.922; REINHART RA, 1991, J AM COLL CARDIOL, V17, P651, DOI 10.1016/S0735-1097(10)80179-2; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Saeki H, 2004, ANESTH ANALG, V99, P1805, DOI 10.1213/01.ANE.0000138039.04548.3D; Sakurai M, 1997, J THORAC CARDIOV SUR, V113, P159, DOI 10.1016/S0022-5223(97)70411-2; SIMPSON JI, 1994, ANESTHESIOLOGY, V81, P1493, DOI 10.1097/00000542-199412000-00025; SIMPSON RK, 1990, NEUROCHEM RES, V15, P635, DOI 10.1007/BF00973755; Stellwagen D, 2005, J NEUROSCI, V25, P3219, DOI 10.1523/JNEUROSCI.4486-04.2005; Tanaka H, 2000, BRAIN RES, V886, P190, DOI 10.1016/S0006-8993(00)02951-6; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; TORREGROSA G, 1994, J CARDIOVASC PHARM, V23, P1004, DOI 10.1097/00005344-199406000-00020; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; Van der Schyf CJ, 2006, EXPERT OPIN INV DRUG, V15, P873, DOI 10.1517/13543784.15.8.873; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; Vink R, 2002, EXPERT OPIN INV DRUG, V11, P1375, DOI 10.1517/13543784.11.10.1375; Wakamatsu H, 1999, ANESTH ANALG, V88, P56, DOI 10.1097/00000539-199901000-00011; Weng YC, 2007, EXP NEUROL, V204, P433, DOI 10.1016/j.expneurol.2006.12.003; Xiao AY, 2002, J NEUROSCI, V22, P1350, DOI 10.1523/JNEUROSCI.22-04-01350.2002	59	15	20	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	JAN	2008	108	1					78	86		10.1097/01.anes.0000296109.04010.82			9	Anesthesiology	Anesthesiology	245AA	WOS:000251905400013	18156885	Bronze			2021-06-18	
J	Liu, WG; Ma, L; Wen, L; Shen, F; Sheng, HS; Zhou, B; Hu, WW; Zheng, XJ; Yang, XF				Liu, Weiguo; Ma, Li; Wen, Liang; Shen, Fang; Sheng, Hansong; Zhou, Bo; Hu, Weiwei; Zheng, Xiujue; Yang, Xiaofeng			Drilling skull plus injection of urokinase in the treatment of epidural haematoma: A preliminary study	BRAIN INJURY			English	Article						traumatic brain injury; epidural haematoma; drilling skull; urokinase; drainage	EXTRADURAL HEMATOMAS; MANAGEMENT; THROMBOLYSIS; ASPIRATION; HEMORRHAGE; DRAINAGE; THERAPY; MODEL; CT	Primary objective: This study was performed to evaluate the effectiveness of a minimally invasive approach to manage patients with epidural haematoma (EDH). The surgical indication and key points were investigated. Research design: Descriptive, retrospective study. Methods and procedures: Twenty-one patients with traumatic EDH were treated through the following method: After anaesthesia, twist drill trepanations were performed followed by a placement of drainage tubes. Twenty ku urokinase in 3 ml saline was injected into the haematoma cyst through the tube, which was closed for 3 hours before connection to a vacuum ball with negative pressure. The injection was repeated three times a day after operation. The fibrinolytic agents were not used in the 'acute group' because of the risk of rebleeding. CT scans were performed according to the changes of clinical manifestations. Main outcomes and results: The drainage tubes were left for 3-5 days before most clots were resolved. The patients discharged after 7 days' hospitalization on average. No infections or recurrence of EDHs were observed in this series. Conclusion: Drilling skull plus injection of urokinase through drainage tube is a safe and effective method with less injury in the treatment of a selected part of patients with EDHs.	[Yang, Xiaofeng] Zhejiang Univ, Dept Neurosurg, First Affiliated Hosp, Coll Med, Hangzhou 310027, Peoples R China; [Hu, Weiwei; Zheng, Xiujue] Zhejiang Univ, Coll Med, Second Affiliated Hosp, Dept Neurosurg, Hangzhou 310027, Peoples R China; [Liu, Weiguo; Ma, Li; Wen, Liang; Shen, Fang; Sheng, Hansong; Zhou, Bo] Zhejiang Univ, Coll Med, Inst Brain Med, Hangzhou 310027, Peoples R China	Yang, XF (corresponding author), Zhejiang Univ, Dept Neurosurg, First Affiliated Hosp, Coll Med, Qing Chun Rd 79, Hangzhou 310027, Peoples R China.	martin735w@163.com	shen, fang/G-8439-2011				Bezircioglu H, 1996, J TRAUMA, V41, P696, DOI 10.1097/00005373-199610000-00016; Bonilha L, 2003, CLIN NEUROL NEUROSUR, V106, P69, DOI 10.1016/j.clineuro.2003.08.001; Bullock AR, 2006, NEUROSURGERY, V58, pVI; BULLOCK R, 1985, NEUROSURGERY, V16, P602, DOI 10.1227/00006123-198505000-00003; COOPER PR, 1986, NEUROSURGERY, V18, P700; DOI E, 1982, Neurologia Medico-Chirurgica, V22, P461, DOI 10.2176/nmc.22.461; FINDLAY JM, 1988, J NEUROSURG, V69, P723, DOI 10.3171/jns.1988.69.5.0723; GUPTA SK, 1992, CLIN NEUROL NEUROSUR, V94, P127, DOI 10.1016/0303-8467(92)90069-F; Kalita J, 2003, NEUROL INDIA, V51, P104; KUDAY C, 1994, ACTA NEUROCHIR, V131, P203, DOI 10.1007/BF01808613; Lee EJ, 1998, J TRAUMA, V45, P946, DOI 10.1097/00005373-199811000-00017; Liu JT, 2006, ACTA NEUROCHIR, V148, P313, DOI 10.1007/s00701-005-0723-z; Maggi G, 1998, J Neurosurg Sci, V42, P95; MOHADJER M, 1990, J NEUROSURG, V73, P217, DOI 10.3171/jns.1990.73.2.0217; Montes JM, 2000, STROKE, V31, P834, DOI 10.1161/01.STR.31.4.834; NARAYAN RK, 1985, J NEUROSURG, V62, P580, DOI 10.3171/jns.1985.62.4.0580; Naval NS, 2007, J NEUROL SCI, V261, P80, DOI 10.1016/j.jns.2007.04.037; PANG D, 1983, J NEUROSURG, V59, P958, DOI 10.3171/jns.1983.59.6.0958; Rohde V, 2000, MINIM INVAS NEUROSUR, V43, P9, DOI 10.1055/s-2000-8411; Shah MV, 1999, AM J NEURORADIOL, V20, P115; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; van Eck ATCJ, 2002, J CLIN NEUROSCI, V9, P573, DOI 10.1054/jocn.2001.1061; Yilmazlar S, 2005, ACTA NEUROCHIR, V147, P1241, DOI 10.1007/s00701-005-0623-2	23	15	19	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	2					199	204		10.1080/02699050801895407			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	258DW	WOS:000252849600011	18240049				2021-06-18	
J	McIntosh, SE; Swanson, ER; McKeone, A; Barton, ED				McIntosh, Scott E.; Swanson, Eric R.; McKeone, Anna; Barton, Erik D.			LOCATION OF AIRWAY MANAGEMENT IN AIR MEDICAL TRANSPORT	PREHOSPITAL EMERGENCY CARE			English	Article						airway management; flight crews; air medical transport; helicopter; intubation; prehospital transport	TRAUMATIC BRAIN-INJURY; ENDOTRACHEAL INTUBATION; SUCCESS	Background. Prehospital providers are constantly challenged with the task of managing airways in unpredictable and often inhospitable environments. Air medical transport (AMT) crews must be prepared to work in restrictive spaces with limited resources while in the aircraft. This study examines flight crew success rate and circumstances surrounding airway management in different locations. Methods. This was a retrospective analysis of intubations performed by a university-based air medical transport team from January 1, 1995, to May 31, 2007. Patient records and prospectively gathered airway management quality assurance data were reviewed for location of intubation, patient characteristics, and success rates. Success was defined as placing a cuffed tube in the trachea nonsurgically. Results. Nine hundred thirty-eight patients required 939 advanced airway management procedures, and 936 cases had information sufficient for analysis. Six hundred twenty-seven (67%) of these intubations took place on scene, 235 (25.1%) at the referring hospital, 67 en-route (7.2%), and seven (0.7%) at the receiving hospital. The overall intubation success rate was 96% and the highest rate was for hospital intubations (98.8%), followed by scene (94.9%) and en-route (89.6%) airway encounters. Intubation success was more likely in the hospital setting (odds ratio [OR] = 8.7, 95% confidence interval [CI] 2.2-35.0, p = 0.002] and on the scene [OR = 2.3, 95% CI 0.95-5.7, p = 0.065] compared with those en-route. Unanticipated patient deterioration was noted as the most common reason for in-flight airway management. Type of aircraft was not significantly associated with intubation success (p = 0.132). Conclusions. Airway management was performed with a high success rate in a variety of locations and patient characteristics by our air medical crew. When in the hospital environment, flight crew success rates were comparable to those of other emergency personnel. Caution should be used, however, when considering intubating in-flight because of slightly lower success rates.	[McIntosh, Scott E.; Swanson, Eric R.; Barton, Erik D.] Univ Utah, Div Emergency Med, Salt Lake City, UT 84132 USA; [McKeone, Anna] Univ Utah, Affiliated Residency Emergency Med, Salt Lake City, UT 84132 USA	McIntosh, SE (corresponding author), Univ Utah, Div Emergency Med, 30 N Med Dr, Salt Lake City, UT 84132 USA.	scott.mcintosh@hsc.utah.edu					*BELL HEL, 2006, BELL HEL PROD SPEC M; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Duchynski R, 1998, Air Med J, V17, P46, DOI 10.1016/S1067-991X(98)90019-0; Foley LJ, 2000, CRIT CARE CLIN, V16, P429, DOI 10.1016/S0749-0704(05)70121-4; Harrison T, 1997, AM J EMERG MED, V15, P558, DOI 10.1016/S0735-6757(97)90156-X; Hunt R, 2007, HYBRIDOMA, V26, P231, DOI 10.1089/hyb.2007.0507; Ma OJ, 1998, AM J EMERG MED, V16, P125, DOI 10.1016/S0735-6757(98)90027-4; Rose W D, 1994, Air Med J, V13, P475, DOI 10.1016/S1067-991X(05)80289-5; Sakles JC, 1998, ANN EMERG MED, V31, P325, DOI 10.1016/S0196-0644(98)70342-7; Sing RF, 1996, ACAD EMERG MED, V3, P41, DOI 10.1111/j.1553-2712.1996.tb03301.x; Slater EA, 1998, J TRAUMA, V45, P588, DOI 10.1097/00005373-199809000-00031; Stone C K, 1994, Air Med J, V13, P319, DOI 10.1016/S1067-991X(05)80337-2; Thomas S H, 1999, Prehosp Emerg Care, V3, P310, DOI 10.1080/10903129908958960; Vilke Gary M., 1994, Journal of Emergency Medicine, V12, P217, DOI 10.1016/0736-4679(94)90702-1; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wang Henry E, 2004, Prehosp Emerg Care, V8, P58; PC 12 SPECIFICATIONS	17	15	15	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1090-3127			PREHOSP EMERG CARE	Prehosp. Emerg. Care		2008	12	4					438	442		10.1080/10903120802301518			5	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	360RB	WOS:000260074100005	18924006				2021-06-18	
J	Mcwilliams, J; Schmitter-Edgecombe, M				Mcwilliams, Jennifer; Schmitter-Edgecombe, Maureen			Semantic memory organization during the early stage of recovery from traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; semantic memory; semantic knowledge; object definition test; semantic organisation; closed-head injury	CLOSED-HEAD-INJURY; ALZHEIMERS TYPE; POSTTRAUMATIC AMNESIA; PRACTICAL SCALE; TEMPORAL-LOBE; KNOWLEDGE; DEMENTIA; DEFICITS; PERFORMANCE; IMPAIRMENT	Primary objective: This study used an object definitions test to examine semantic memory and the organization of semantic knowledge during the early stage of recovery from traumatic brain injury (TBI). Research design: Twenty-four participants with moderate-to-severe TBI and 24 controls described three living and three non-living objects as if they were describing them to someone who had never heard of or seen such things before. Methods and procedures: The verbal definitions were examined at a feature level and for whether they communicated the core concept (i.e. could a blind rater identify the object). Main outcomes and results: Compared to the control group, the TBI group less often provided object definitions that communicated the core concept and included superordinate category information. The TBI group also produced a smaller proportion of physical specific features and the production of fewer physical specific features was associated with lower production of the core concept. Despite these group differences, both groups produced more specific feature information about the objects than general feature information; and more physical specific features for living objects and associative specific features for non-living objects. Conclusions: The findings were interpreted as suggesting a decreased efficiency in ability to access semantic information following moderate-to-severe TBI, which influenced core concept production, despite intact organization of semantic knowledge.	[Mcwilliams, Jennifer; Schmitter-Edgecombe, Maureen] Washington State Univ, Dept Psychol, Pullman, WA 99164 USA	Schmitter-Edgecombe, M (corresponding author), Washington State Univ, Dept Psychol, POB 4820, Pullman, WA 99164 USA.	schmitter-e@wsu.edu					Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Bell BD, 2001, NEUROPSYCHOLOGY, V15, P434, DOI 10.1037//0894-4105.15.4.434; Benton A., 1994, MULTILINGUAL APHASIA; Caramazza A, 1998, J COGNITIVE NEUROSCI, V10, P1, DOI 10.1162/089892998563752; Carlesimo GA, 1998, CORTEX, V34, P1, DOI 10.1016/S0010-9452(08)70734-2; COEHLO CA, 1995, BRAIN INJURY, V9, P471; COLLINS AM, 1975, PSYCHOL REV, V82, P407, DOI 10.1037/0033-295X.82.6.407; Constantinidou F, 2004, BRAIN LANG, V89, P216, DOI 10.1016/S0093-934X(03)00399-7; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Devlin JT, 1998, J COGNITIVE NEUROSCI, V10, P77, DOI 10.1162/089892998563798; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; FARAH MJ, 1991, J EXP PSYCHOL GEN, V120, P339, DOI 10.1037/0096-3445.120.4.339; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Garrard P, 2005, BRAIN LANG, V93, P79, DOI 10.1016/j.bandl.2004.08.003; GERMAN DJ, 1990, NATL COLL ED TEST AD; HAUT M W, 1990, Brain Injury, V4, P281, DOI 10.3109/02699059009026178; Haut MW, 1991, NEUROPSYCHOLOGY, V5, P81, DOI 10.1037/0894-4105.5.2.81; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P109, DOI 10.1080/026990598122746; Hodges JR, 1996, BRAIN LANG, V54, P302, DOI 10.1006/brln.1996.0077; HUX K, 1993, J MED SPEECH-LANG PA, V1, P121; HUX K, 1997, J MED SPEECH-LANG PA, V5, P181; KERR C, 1995, BRAIN INJURY, V9, P777, DOI 10.3109/02699059509008234; King KA, 2006, APHASIOLOGY, V20, P233, DOI 10.1080/02687030500473155; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Lee GP, 1997, CLIN NEUROPSYCHOL, V11, P59, DOI 10.1080/13854049708407030; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Majdan A, 1996, J CLIN EXP NEUROPSYC, V18, P416, DOI 10.1080/01688639608408998; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Perri R, 2000, CORTEX, V36, P213, DOI 10.1016/S0010-9452(08)70525-2; Ralph MAL, 1997, NEUROPSYCHOLOGIA, V35, P1251, DOI 10.1016/S0028-3932(97)00052-3; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Schmitter-Edgecombe M, 2005, BRAIN LANG, V94, P331, DOI 10.1016/j.bandl.2005.01.007; Schmitter-Edgecombe M., 1993, NEUROPSYCHOLOGY, V7, P136, DOI DOI 10.1037/0894-4105.7.2.136; Schmitter-Edgecombe M, 2008, J CLIN EXP NEUROPSYC, V30, P212, DOI 10.1080/13803390701363803; Smith A., 1991, SYMBOL DIGIT MODALIT; Solso R.L., 2001, COGNITIVE PSYCHOL; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; WARRINGTON EK, 1987, BRAIN, V110, P1273, DOI 10.1093/brain/110.5.1273; WARRINGTON EK, 1983, BRAIN, V106, P859, DOI 10.1093/brain/106.4.859; Zachary R.A., 1991, SHIPLEY I LIVING SCA	47	15	17	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2008	22	3					243	253		10.1080/02699050801935252			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	267LW	WOS:000253511500005	18297596				2021-06-18	
J	Robertson, RH; Knight, RG				Robertson, R. Heidi; Knight, Robert G.			Evaluation of social problem solving after traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						assertiveness; social skill; role-play; behavioural skills; self-awareness	NEUROPSYCHOLOGICAL ASSESSMENT; SELF-AWARENESS; DYSFUNCTION; DEPRESSION; DEFICITS; OUTPATIENTS; INTEGRATION; VALIDITY; SKILLS	A trial of a procedure for the assessment of social problem-solving skills (the Social Problem-Solving Test; SPST), designed to assess 18 component skills distributed across five domains of functioning, is reported. A group of 48 persons with traumatic brain injury (TBI) observed seven videotaped scenarios involving a complex social interaction between two people. They were first questioned about their interpretation of the event, and how the actors should respond, and then asked to complete a role-play in which they were required to implement a strategy to reach a specified goal. Their performance on each of the components was compared with the results from 20 aged-matched family controls. The TBI participants were most impaired in their ability to perform in a socially skilled manner in the role-play and evaluate this performance, and their orientation towards resolving the problem was characterised by greater anxiety and evaluation of difficulty. The results support the usefulness of procedures designed to identify the specific deficits in social problem solving of persons in post-acute rehabilitation.	[Knight, Robert G.] Univ Otago, Dept Psychol, Dunedin, New Zealand; [Robertson, R. Heidi] Casuarina Lodge, Acquired Brain Injury Unit, Brisbane, Qld, Australia	Knight, RG (corresponding author), Univ Otago, Dept Psychol, POB 56, Dunedin, New Zealand.	rknight@psy.otago.ac.nz					Bach LJ, 2006, NEUROPSYCHOL REHABIL, V16, P397, DOI 10.1080/09602010500412830; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Chaytor N, 2007, J INT NEUROPSYCH SOC, V13, P377, DOI 10.1017/S1355617707070592; CORNELIUS SW, 1987, PSYCHOL AGING, V2, P144, DOI 10.1037/0882-7974.2.2.144; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Frye AA, 2000, COGNITIVE THER RES, V24, P637, DOI 10.1023/A:1005583210589; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Guilford JP, 1978, ALTERNATIVE USES MAN; GUTH M, 1999, HDI PROFESSIONAL SER, V15; Hanes KR, 1996, ARCH CLIN NEUROPSYCH, V11, P185, DOI 10.1016/0887-6177(95)00034-8; Holtzer R, 2000, BRAIN INJURY, V14, P959, DOI 10.1080/02699050050191904; Kant GL, 1997, COGNITIVE THER RES, V21, P73, DOI 10.1023/A:1021820326754; Kendall E, 1997, J HEAD TRAUMA REHAB, V12, P68, DOI 10.1097/00001199-199706000-00007; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; LEZAK MD, 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; Marsh NV, 2006, NEUROPSYCHOL REHABIL, V16, P684, DOI 10.1080/09602010500220290; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; MUESER KT, 1992, SCHIZOPHRENIA OVERVI, P182; Nelson HE, 1982, NATL ADULT READING T; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Ponsford J., 1995, TRAUMATIC BRAIN INJU, P1; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Rath JF, 2004, ARCH CLIN NEUROPSYCH, V19, P613, DOI 10.1016/j.acn.2003.08.006; Rath JF, 2003, REHABIL PSYCHOL, V48, P137, DOI 10.1037/0090-5550.48.3.137; Rath JF, 2000, J HEAD TRAUMA REHAB, V15, P724, DOI 10.1097/00001199-200002000-00010; SARASON BR, 1985, J PERS SOC PSYCHOL, V49, P469; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; Stuss DT, 2004, BRAIN COGNITION, V55, P69, DOI 10.1016/s0278-2626(03)00271-9; TALLMAN I, 1993, SOC PSYCHOL QUART, V56, P157, DOI 10.2307/2786776; Trower P., 1978, SOCIAL SKILLS MENTAL; WANG PL, 1986, COGNITIVE COMPETENCY; Wilson BA, 1996, BEHAV ASSESSMENT DYS	37	15	15	0	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2008	18	2					236	250		10.1080/09602010701734438			15	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	276HD	WOS:000254131000005	18350415				2021-06-18	
J	Salerian, AJ; Saleri, NG; Salerian, JA				Salerian, Alen J.; Saleri, Nansen G.; Salerian, Justin A.			Brain temperature may influence mood: A hypothesis	MEDICAL HYPOTHESES			English	Article							CORE TEMPERATURE; ANTIDEPRESSANTS	Lowering core body and brain temperature has been shown to be beneficial for multiple sclerosis, cardiovascular accidents, traumatic brain injuries and myocardial infarction. Svante Arrhenius' rate taw governs human thermoregulation and all biochemical reactions including complex chemical processes involved in mood disorders. We reviewed the studies on core body and brain temperature's influence on mood, mood disorders and their treatment. Our review suggests the majority of therapeutic strategies against mania are hypothermic white thermogenic strategies are used to combat depressive disorders. We hypothesize that therapeutic manipulation of brain temperature may represent a key mechanism in the treatment of mood disorders possibly because of brain temperature's profound influence on human biology governed by Svante Arrhenius' rate law. We postulate that brain temperature may rise with mania and fall with depression. (c) 2007 Published by Elsevier Ltd.	[Salerian, Alen J.; Saleri, Nansen G.; Salerian, Justin A.] Washington Ctr Psychiat, Washington, DC 20015 USA	Salerian, AJ (corresponding author), Washington Ctr Psychiat, 5225 Wisconsin Ave,Suite 104, Washington, DC 20015 USA.	gsalerian@psychiatrydc.com					BLATTEIS C, 2001, PHYSL PATHOPHYSIOLOG; CHAL V, 1976, BRIT J PHARMACOL, V57, P1487; Chong TW, 2004, SCHIZOPHR RES, V69, P149, DOI 10.1016/S0920-9964(03)00222-6; DULLOO AG, 1987, ANN NUTR METAB, V31, P69, DOI 10.1159/000177253; Duncan N. B., 1995, Journal of Management Information Systems, V12, P37; DUNCAN WC, 1995, NEUROPSYCHOPHARMACOL, V12, P17, DOI 10.1016/0893-133X(94)00055-5; ELKASSEM M, 1983, PHARMACOL BIOCHEM BE, V19, P257, DOI 10.1016/0091-3057(83)90049-7; GLEITER CH, 1989, CONVULSIVE THER, V5, P152; Hasegawa H, 2005, J APPL PHYSIOL, V99, P1397, DOI 10.1152/japplphysiol.00435.2005; HEH CW, 1988, NEUROPSYCHOPHARMACOL, V1, P149, DOI 10.1016/0893-133X(88)90006-1; Kudoh A, 2003, ANESTH ANALG, V97, P275, DOI 10.1213/01.ANE.0000068821.29712.AC; LERER B, 1985, BIOL PSYCHIAT, V20, P20, DOI 10.1016/0006-3223(85)90132-5; Liu YL, 2004, EUR J PHARMACOL, V498, P219, DOI 10.1016/j.ejphar.2004.07.004; MARKS MJ, 1984, PHARMACOL BIOCHEM BE, V21, P953, DOI 10.1016/S0091-3057(84)80079-9; Mendelson JH, 2005, NEUROPSYCHOPHARMACOL, V30, P1751, DOI 10.1038/sj.npp.1300753; Oerther S, 2000, J PHARMACOL EXP THER, V292, P731; OKUMARA A, 2005, BRAIN DEV, V27, P1554; Ren M, 2003, P NATL ACAD SCI USA, V100, P6210, DOI 10.1073/pnas.0937423100; Salerian AJ, 2006, MED HYPOTHESES, V66, P636, DOI 10.1016/j.mehy.2005.07.021; SOUBRIE P, 1989, PSYCHIAT RES, V27, P149, DOI 10.1016/0165-1781(89)90130-3	20	15	16	0	5	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses		2008	70	3					497	500		10.1016/j.mehy.2007.06.032			4	Medicine, Research & Experimental	Research & Experimental Medicine	268WI	WOS:000253610300007	17951014				2021-06-18	
J	White, H; Cook, D; Venkatesh, B				White, H.; Cook, D.; Venkatesh, B.			The role of hypertonic saline in neurotrauma	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article; Proceedings Paper	Brain Annual Meeting	MAY 09-12, 2007	Brescia, ITALY			saline solution hypertonic; intracranial pressure; intracranial; hypertension; mannitol	TRAUMATIC BRAIN-INJURY; ELEVATED INTRACRANIAL-PRESSURE; 7.5-PERCENT SODIUM-CHLORIDE; SEVERE HEAD-INJURY; CEREBRAL EDEMA; 10-PERCENT SALINE; RESUSCITATION; HYPERTENSION; FLUID; INFUSION	Animal and human studies suggest that hypertonic saline is a potential therapeutic agent to assist with the medical treatment of patients with traumatic brain injury. It may have a place as osmotherapy to decrease brain size, predominately of uninjured brain and has several potential advantages over mannitol. Hypertonic saline has clinically desirable physiological effects on cerebral blood flow, intracranial pressure and inflammatory responses in models of neurotrauma. Animal studies support its use, but definitive human trials using mortality end-points in brain trauma are lacking. Hypertonic saline may be considered a therapeutic adjunct to the medical management of traumatic brain injury, awaiting definitive evidence to support routine use.	[Cook, D.; Venkatesh, B.] Univ Queensland, Princess Alexandra Hosp, Dept Intens Care, Brisbane, Qld 4102, Australia; [White, H.] Univ Queensland, Dept Anesthesiol, QE 2 Hosp, Brisbane, Qld 4102, Australia	Venkatesh, B (corresponding author), Univ Queensland, Princess Alexandra Hosp, Dept Intens Care, Brisbane, Qld 4102, Australia.	bala_venkatesh@health.qld.gov.au	Cook, David/D-7318-2013	Venkatesh, Bala/0000-0002-3234-5244			ADAMS RD, 1959, ARCH NEURO PSYCHIATR, V81, P154, DOI 10.1001/archneurpsyc.1959.02340140020004; Bentsen G, 2004, ACTA ANAESTH SCAND, V48, P1089, DOI 10.1111/j.1399-6576.2004.00497.x; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; CROSS JS, 1989, ANN SURG, V209, P684, DOI 10.1097/00000658-198906000-00005; DUBICK MA, 1994, J TRAUMA, V36, P323, DOI 10.1097/00005373-199403000-00007; Eilig I, 2001, ANESTH ANALG, V92, P669, DOI 10.1213/00000539-200103000-00023; Einhaus S L, 1996, J Tenn Med Assoc, V89, P81; FENSTERMACHER JD, 1966, AM J PHYSIOL, V211, P341; Finfer S, 2004, NEW ENGL J MED, V350, P2247; GUNNAR W, 1988, SURGERY, V103, P398; Hartl R, 1997, ZBL CHIR, V122, P181; Hartl R, 1997, J TRAUMA, V42, pS41, DOI 10.1097/00005373-199705001-00008; Hartl R, 1996, J CEREBR BLOOD F MET, V16, P1108; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; HUANG PP, 1995, ANN SURG, V221, P543, DOI 10.1097/00000658-199505000-00012; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kramer GC, 2003, J TRAUMA, V54, pS89, DOI 10.1097/01.TA.0000065609.82142.F1; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; Murphy N, 2004, HEPATOLOGY, V39, P464, DOI 10.1002/hep.20056; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Qureshi AI, 1999, J TRAUMA, V47, P659, DOI 10.1097/00005373-199910000-00009; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Qureshi AI, 1998, J NEUROSURG ANESTH, V10, P188, DOI 10.1097/00008506-199807000-00010; RAMMING S, 1994, J TRAUMA, V37, P705, DOI 10.1097/00005373-199411000-00003; Schatzmann C, 1998, ACT NEUR S, V71, P31; SCHMOKER JD, 1992, J TRAUMA, V33, P476, DOI 10.1097/00005373-199209000-00024; Schwarz S, 2002, STROKE, V33, P136, DOI 10.1161/hs0102.100877; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; SHACKFORD SR, 1997, J TRAUMA S, V42, P48; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P463; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Weed LH, 1919, AM J PHYSIOL, V48, P531; White H, 2006, ANESTH ANALG, V102, P1836, DOI 10.1213/01.ane.0000217208.51017.56; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021	44	15	16	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.		2008	25			42			104	109		10.1017/S0265021507003420			6	Anesthesiology	Anesthesiology	283AY	WOS:000254610100018	18289426				2021-06-18	
J	Shein, NA; Doron, H; Horowitz, M; Trembovler, V; Alexandrovich, AG; Shohami, E				Shein, Na'ama A.; Doron, Hanny; Horowitz, Michal; Trembovler, Victoria; Alexandrovich, Alexander G.; Shohami, Esther			Altered cytokine expression and sustained hypothermia following traumatic brain injury in heat acclimated mice	BRAIN RESEARCH			English	Article						closed head injury; inflammation; neuroprotection	CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; SPINAL-CORD-INJURY; POSTTRAUMATIC HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; INFLAMMATORY RESPONSE; TNF-ALPHA; ACTIVATED MICROGLIA; GENE-EXPRESSION; CROSS-TOLERANCE	Long-term exposure to moderate ambient heat (heat acclimation, HA, 30 days at 34 +/- 1 degrees C) provides protection toward a variety of stressors including traumatic brain injury. As previous studies suggested an anti-inflammatory effect of HA and given the ability of augmented pre-injury anti-inflammatory cytokine expression to harbor neuroprotection and to attenuate early post-injury expression of pro-inflammatory mediators, we hypothesized that HA-induced neuroprotection may involve enhanced pre-injury expression of anti-inflammatory mediators or a reduction in post-injury TNF alpha (TNF alpha) expression. Since the attenuation of inflammatory-associated entities has also been linked to mild hypothermia, an established neuroprotective paradigm, the effect of HA on post-injury body temperature was also studied. HA mice and normothermic (NT) counterparts were examined using a closed head injury model. Cytokines were measured within the ipsilateral cortex. Pre-injury protein levels of anti-inflammatory interleukins 10 and 4 (IL-10, IL-4) were quantified by enzyme-linked immunosorbent assays (ELISA). mRNA and protein levels of TNF alpha were quantified during the initial 2 h post-injury using semi-quantitative and real-time polymerase chain reaction (sqRT-PCR and qRT-PCR) or ELISA, respectively. Rectal temperatures were measured. HA induced augmented pre-injury IL-10 expression and a post-injury reduction in TNF alpha mRNA levels, as well as altered expression dynamics of TNF alpha protein. TNF alpha protein levels decreased relative to the sham state in HA mice only; HA mice displayed sustained post-injury hypothermia, namely significantly lower body temperature at 4 h post-injury. Given the evidence on the neuroprotective nature of hypothermia and anti-inflammatory cytokines, we suggest that these changes may contribute to PIA-induced neuroprotection. (C) 2007 Elsevier B.V. All rights reserved.	[Shein, Na'ama A.; Doron, Hanny; Horowitz, Michal] Hebrew Univ Jerusalem, Fac Med Dent, Environm Physiol Lab, Dept Physiol, IL-91120 Jerusalem, Israel; [Shein, Na'ama A.; Doron, Hanny; Trembovler, Victoria; Alexandrovich, Alexander G.; Shohami, Esther] Hebrew Univ Jerusalem, Dept Pharmacol, IL-91120 Jerusalem, Israel	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Fac Med Dent, Environm Physiol Lab, Dept Physiol, IL-91120 Jerusalem, Israel.	horowitz@cc.huji.ac.il; esty@cc.huji.ac.il					Arieli Y, 2003, BRAIN RES, V962, P15, DOI 10.1016/S0006-8993(02)03681-8; Asadullah K, 2003, PHARMACOL REV, V55, P241, DOI 10.1124/pr.55.2.4; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Bettelli E, 1998, J IMMUNOL, V161, P3299; CHAO CC, 1993, J IMMUNOL, V151, P1473; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dietrich WD, 2007, PROG BRAIN RES, V162, P201, DOI 10.1016/S0079-6123(06)62011-6; Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Frenkel D, 2003, J IMMUNOL, V171, P6549, DOI 10.4049/jimmunol.171.12.6549; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; Giulian D, 1996, NEUROCHEM INT, V29, P65, DOI 10.1016/0197-0186(95)00140-9; GIULIAN D, 1993, STROKE, V24, pI84; Hensler T, 2000, INFLAMM RES, V49, P524, DOI 10.1007/s000110050626; Horowitz M, 2003, NEWS PHYSIOL SCI, V18, P215, DOI 10.1152/nips.01453.2003; Horowitz M, 2004, J APPL PHYSIOL, V97, P1496, DOI 10.1152/japplphysiol.00306.2004; Horowitz M, 2002, COMP BIOCHEM PHYS A, V131, P475, DOI 10.1016/S1095-6433(01)00500-1; Horowitz M, 1998, NEWS PHYSIOL SCI, V13, P218; Ishikawa M, 1999, STROKE, V30, P1679, DOI 10.1161/01.STR.30.8.1679; Ishikawa T, 1999, CELL MOL NEUROBIOL, V19, P199, DOI 10.1023/A:1006973026514; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; Maloyan A, 2005, PHYSIOL GENOMICS, V23, P79, DOI 10.1152/physiolgenomics.00279.2004; Maloyan A, 1999, AM J PHYSIOL-REG I, V276, pR1506; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; SAIA RS, IN PRESS SHOCK  0705; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schwab M, 1998, ACTA NEUROBIOL EXP, V58, P29; Schwimmer H, 2004, MOL BRAIN RES, V130, P95, DOI 10.1016/j.molbrainres.2004.07.011; Schwimmer H, 2006, J APPL PHYSIOL, V100, P1992, DOI 10.1152/japplphysiol.00850.2005; Shein NA, 2005, J CEREBR BLOOD F MET, V25, P1456, DOI 10.1038/sj.jcbfm.9600142; SHEIN NA, IN PRESS J NEUR 0822; Shein NA, 2007, PROG BRAIN RES, V161, P353, DOI 10.1016/S0079-6123(06)61025-X; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SHOHAMI E, 1994, ACTA NEUROCHIR, P443; Sredni-Kenigsbuch D, 2002, INT J NEUROSCI, V112, P665, DOI 10.1080/00207450290025725; Trembovler V, 1999, J INTERF CYTOK RES, V19, P791, DOI 10.1089/107999099313640; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Vila N, 2003, STROKE, V34, P671, DOI 10.1161/01.STR.0000057976.53301.69; YOUSEF MK, 1975, AM J PHYSIOL, V229, P427	54	15	16	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 14	2007	1185						313	320		10.1016/j.brainres.2007.09.024			8	Neurosciences	Neurosciences & Neurology	247FY	WOS:000252064400033	17963735				2021-06-18	
J	Sharma, V; Babu, PP; Singh, A; Singh, S; Singh, R				Sharma, Varsha; Babu, P. Prakash; Singh, Arun; Singh, Sangeeta; Singh, Rameshwar			Iron-induced experimental cortical seizures: Electroencephalographic mapping of seizure spread in the subcortical brain	SEIZURE-EUROPEAN JOURNAL OF EPILEPSY			English	Article						epilepsy; iron epilepsy; etectroencephalography; multi-unit activity; ethosuximide; mapping of intracerebral epileptic activity	FLUID PERCUSSION INJURY; POSTTRAUMATIC EPILEPSY; RAT HIPPOCAMPUS; ELECTRICAL-STIMULATION; EPILEPTIFORM ACTIVITY; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; ABSENCE EPILEPSY; MODEL; ETHOSUXIMIDE	The iron-induced model of post-traumatic chronic focal epilepsy in rats was studied by depth-electrode mapping to investigate the spread of epileptiform activity into subcortical brain structures after its onset in the cortical epileptic focus. Electrical seizure activity was recorded in the hippocampal CA1 and CA3 areas, amygdata and caudate-putamen, in rats with iron-induced chronic cortical focal epilepsy. These experiments showed that the epileptiform activity with its onset in the cortical focus synchronously propagated into the studied subcortical brain areas. Seizure behaviours seemed to increase in correspondence with the spread of the epileptic electrographic activity in subcortical areas. Comparison of the cortical focus etectroencephalographic and associated muttipte-unit action potential recordings with those from the subcortical structures showed that the occurrence and evolution of the epileptiform activity in the subcortical structures were in parallel with that in the cortical focus. The intracerebral anatomic progression and delineation of seizure spread (mapped by field potential (EEG) and multipte-unit action potentials (MUA) recordings) indicated participation of these regions in the generalization of seizure activity in this model of epilepsy. The seizure-induced activation of the hippocampus appeared to evolve into an epileptic focus independent of the cortical focus. The present study demonstrates the propagation of epileptic activity from the cortical focus into the limbic and basal ganglia regions. Treatment of iron-induced epileptic rats with ethosuximide, an anti-absence drug, resulted in suppression of the epileptiform activity in the cortical focus as well as in the subcortical brain areas. (c) 2007 British Epilepsy Association. Published by Elsevier Ltd. AR rights reserved.	Jawaharlal Nehru Univ, Sch Life Sci, Neurobiol Lab, New Delhi 110067, India; Univ Hyderabad, Dept Biotechnol, Hyderabad 500046, Andhra Pradesh, India; Bareilly Coll, Dept Zool, Bareilly 243001, Uttar Pradesh, India	Sharma, V (corresponding author), Jawaharlal Nehru Univ, Sch Life Sci, Neurobiol Lab, 118 & 303, New Delhi 110067, India.	varsha.sharma@gmail.com	Singh, Arun/ABC-5154-2020	Singh, Arun/0000-0003-4273-542X			Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; BABB TL, 1987, ELECTROEN CLIN NEURO, V66, P467, DOI 10.1016/0013-4694(87)90093-9; Baram TZ, 1997, DEV BRAIN RES, V98, P265, DOI 10.1016/S0165-3806(96)00190-3; BARAM TZ, 1992, DENDRON, P39; Benardo LS, 2003, EPILEPSIA, V44, P27, DOI 10.1046/j.1528-1157.44.s10.2.x; Bouilleret V, 2000, BRAIN RES, V852, P255, DOI 10.1016/S0006-8993(99)02092-2; BRAILOWSKY S, 1990, EPILEPSIA, V31, P369, DOI 10.1111/j.1528-1157.1990.tb05490.x; Brunson KL, 1998, DEV BRAIN RES, V111, P119, DOI 10.1016/S0165-3806(98)00130-8; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; de Vasconcelos AP, 1999, BRAIN RES, V838, P110, DOI 10.1016/S0006-8993(99)01729-1; Deransart C, 2003, EPILEPSIA, V44, P1513, DOI 10.1111/j.0013-9580.2003.26603.x; Gruslin E, 1999, BRAIN RES, V835, P290, DOI 10.1016/S0006-8993(99)01605-4; HANDFORTH A, 1995, BRAIN RES REV, V20, P1, DOI 10.1016/0165-0173(94)00003-8; Imao K, 1998, BIOCHEM MOL BIOL INT, V45, P11; JANERO DR, 1989, BIOCHEM PHARMACOL, V38, P4344, DOI 10.1016/0006-2952(89)90537-6; Kandel A, 1996, EPILEPSY RES, V23, P123, DOI 10.1016/0920-1211(95)00097-6; LOSCHER W, 1991, EPILEPSY RES, V8, P79, DOI 10.1016/0920-1211(91)90075-Q; LOTHMAN EW, 1991, CURR OPIN NEUROL NEU, V4, P253; Manning JPA, 2004, NEUROSCIENCE, V123, P5, DOI 10.1016/j.neuroscience.2003.09.026; MEDVEDEV A, 1996, ELECTROENCEPHALGR CL, V92, P157; MORI A, 1990, PAVLOVIAN J BIOL SCI, V25, P54; MORIWAKI A, 1992, ELECTROEN CLIN NEURO, V83, P281, DOI 10.1016/0013-4694(92)90087-X; MORIWAKI A, 1990, NEUROSCI LETT, V110, P72, DOI 10.1016/0304-3940(90)90789-C; PELLEGRINI A, 1989, BRAIN RES, V497, P344, DOI 10.1016/0006-8993(89)90280-1; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Samuelsson C, 2003, EPILEPSY RES, V56, P165, DOI 10.1016/j.eplepsyres.2003.09.004; Samuelsson C, 2000, NEUROSCI LETT, V289, P185, DOI 10.1016/S0304-3940(00)01284-2; SHARMA D, 1993, NEUROBIOL AGING, V14, P319, DOI 10.1016/0197-4580(93)90117-T; Sharma Varsha, 1999, Indian Journal of Experimental Biology, V37, P461; Sharma Varsha, 1999, Indian Journal of Experimental Biology, V37, P468; SILVABARRAT C, 1986, ELECTROEN CLIN NEURO, V64, P455, DOI 10.1016/0013-4694(86)90079-9; SINGH R, 1990, EPILEPSIA, V31, P15, DOI 10.1111/j.1528-1157.1990.tb05354.x; STRINGER JL, 1994, EPILEPSY RES, V19, P229; STRINGER JL, 1994, BRAIN RES, V636, P221, DOI 10.1016/0006-8993(94)91020-0; Talley EM, 2000, MOL BRAIN RES, V75, P159, DOI 10.1016/S0169-328X(99)00307-1; Tian GF, 2005, NAT MED, V11, P973, DOI 10.1038/nm1277; Timofeev I, 2004, NEUROSCIENCE, V123, P299, DOI 10.1016/j.neuroscience.2003.08.051; VERGNES M, 1990, BRAIN RES, V523, P87, DOI 10.1016/0006-8993(90)91638-W; Wiest MC, 2003, NAT NEUROSCI, V6, P913, DOI 10.1038/nn1107; WILLMORE LJ, 1981, NEUROLOGY, V31, P63, DOI 10.1212/WNL.31.1.63; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; WILLMORE LJ, 1986, BRAIN RES, V382, P422; YOKOI I, 1995, FREE RADICAL BIO MED, V19, P473, DOI 10.1016/0891-5849(95)00050-8	44	15	16	0	3	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	1059-1311	1532-2688		SEIZURE-EUR J EPILEP	Seizure	DEC	2007	16	8					680	690		10.1016/j.seizure.2007.05.012			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	235DF	WOS:000251213000004	17629512				2021-06-18	
J	Vibert, D; Redfield, RC; Hausler, R				Vibert, Dominique; Redfield, Robin C.; Hausler, Rudolf			Benign paroxysmal positional vertigo in mountain bikers	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						benign paroxysmal positional vertigo; inner ear; mountain bike; otoconia; sport; vertigo	BIKING INJURIES; TRAUMA	We evaluated 4 men who had benign paroxysmal positional vertigo (BPPV) that occured several hours after intensive mountain biking but without head trauma. The positional maneuvers in the planes of the posterior and horizontal canals elicited BPPV, as well as transitory nystagmus. This was attributed to both the posterior and horizontal semicircular canals (SCCs) on the left side in 1 patient, in these 2 SCCs on the right side in another patient, and to the right posterior SCC in the other 2 patients. The symptoms disappeared after physiotherapeutic maneuvers in 2 patients and spontaneously in the other 2 patients. Cross-country or downhill mountain biking generates frequent vibratory impacts, which are only partially filtered through the suspension fork and the upper parts of the body. Biomechanically, during a moderate jump, before landing, the head is subjected to an acceleration close to negative 1g, and during impact it is subjected to an upward acceleration of more than 2g. Repeated acceleration-deceleration events during intensive off-road biking might generate displacement and/or dislocation of otoconia from the otolithic organs, inducing the typical symptoms of BPPV. This new cause of posttraumatic BPPV should be considered as an injury of minor severity attributed to the practice of mountain biking.	[Vibert, Dominique; Hausler, Rudolf] Univ Bern, Inselspital, Dept Otolaryngol Head & Neck Surg, CH-3010 Bern, Switzerland; [Redfield, Robin C.] USAF Acad, Dept Engn Mech, Colorado Springs, CO USA	Vibert, D (corresponding author), Univ Bern, Inselspital, Dept ENT Head & Neck Surg, CH-3010 Bern, Switzerland.						BALOH RW, 1987, NEUROLOGY, V37, P371, DOI 10.1212/WNL.37.3.371; BARBER H O, 1964, Laryngoscope, V74, P891; Bertholon P, 2005, ANN OTO RHINOL LARYN, V114, P105, DOI 10.1177/000348940511400204; BRANDT T, 1990, VERTIGO ITS MULTISEN, P261; DIX MR, 1952, P ROY SOC MED, V45, P341, DOI 10.1177/003591575204500604; Gaulrapp H, 2001, KNEE SURG SPORT TR A, V9, P48, DOI 10.1007/s001670000145; Katsarkas A, 1999, ACTA OTO-LARYNGOL, V119, P745, DOI 10.1080/00016489950180360; Kim PTW, 2006, J TRAUMA, V60, P312, DOI 10.1097/01.ta.0000202714.31780.5f; Kronisch RL, 2002, CLIN J SPORT MED, V12, P158, DOI 10.1097/00042752-200205000-00003; Kronisch RL, 2002, SPORTS MED, V32, P523, DOI 10.2165/00007256-200232080-00004; LONGRIDGE NS, 1978, J OTOLARYNGOL, V7, P395; MCCLURE JA, 1985, J OTOLARYNGOL, V14, P30; PARNES LS, 1992, LARYNGOSCOPE, V102, P988; Redfield RC, 2004, TECH PAPERS ISA, V449, P43; SCHUKNECHT HF, 1969, ARCH OTOLARYNGOL, V90, P765; Shang E., 1996, Deutsche Zeitschrift fuer Sportmedizin, V47, P283; Vibert D, 2003, ANN OTO RHINOL LARYN, V112, P246, DOI 10.1177/000348940311200310	17	15	15	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	DEC	2007	116	12					887	890		10.1177/000348940711601203			4	Otorhinolaryngology	Otorhinolaryngology	243VI	WOS:000251825000005	18217506				2021-06-18	
J	Doering, P; Danscher, G; Larsen, A; Bruhn, M; Sondergaard, C; Stoltenberg, M				Doering, P.; Danscher, G.; Larsen, A.; Bruhn, M.; Sondergaard, C.; Stoltenberg, M.			Changes in the vesicular zinc pattern following traumatic brain injury	NEUROSCIENCE			English	Article						AMG; nanocrystals; zinc ions; ZnSeAMG; ZnT3; brain lesion	ACID-INDUCED SEIZURES; NEURONAL CELL-DEATH; I PLUS II; HIPPOCAMPAL-NEURONS; SYNAPTIC ZINC; NITRIC-OXIDE; MOUSE; METALLOTHIONEIN; TRANSLOCATION; ACCUMULATION	The present study aims at evaluating the significance of zinc ions on the development of brain damage in a model of traumatic brain injury (TBI). The zinc ion specific autometallographic technique, the ZnSeAMG method, using silver enhancement of in vivo-captured zinc ions bound in zinc-selenium nanocrystals was applied to follow changes in the vesicular zinc pattern. Balb/c mice, ZnT3 knockout (ZnT3-Ko) mice, a mouse genetically knocked out for the protein ZnT3 responsible for sequestering zinc into synaptic vesicles, and littermates from the genetically un-manipulated mother type mice, wild type (Wt), were used. The Wt and the Balb/c mice exhibited instantaneously a boost in the zinc staining adjacent to the lesion involving all six neocortical layers. Ultra-structural analyses revealed that the in vivo created ZnSe nanocrystals were still confined to the vesicles of the zinc-enriched (ZEN) neurons in the neuropil. No differences between the Balb/c and Wt mice were seen at any time points. In the ZnT3-Ko mice the ZEN terminals stayed void of AMG grains, but a number of neuronal somata around the lesion became loaded with ZnSe nanocrystals. These silver-enhanced ZnSe nanocrystals were confined to the cytoplasm of the somata and their proximal dendrites. No such soma staining was seen in the Wt or Balb/c mice. We speculate that vesicular zinc may not contribute to neuronal damage following TBI. (c) 2007 IBRO. Published by Elsevier Ltd. All rights reserved.	[Doering, P.; Danscher, G.; Larsen, A.; Bruhn, M.; Sondergaard, C.; Stoltenberg, M.] Univ Aarhus, Dept Neurobiol, DK-8000 Aarhus C, Denmark	Doering, P (corresponding author), Univ Aarhus, Dept Neurobiol, DK-8000 Aarhus C, Denmark.	pdj@neuro.au.dk		Larsen, Agnete/0000-0001-8765-8443			Andreasen A, 1997, J NEUROSCI METH, V72, P15, DOI 10.1016/S0165-0270(96)00149-5; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Bancila V, 2004, J NEUROCHEM, V90, P1243, DOI 10.1111/j.1471-4159.2004.02587.x; Blasco-Ibanez JM, 2004, NEUROSCI LETT, V355, P101, DOI 10.1016/j.neulet.2003.10.053; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Brown CE, 2004, J COMP NEUROL, V479, P156, DOI 10.1002/cne.20308; Brown CE, 2003, NEUROSCIENCE, V119, P795, DOI 10.1016/S0306-4522(03)00292-6; Carrasco J, 2000, EUR J NEUROSCI, V12, P2311, DOI 10.1046/j.1460-9568.2000.00128.x; Cho IH, 2003, J NEUROSCI RES, V74, P736, DOI 10.1002/jnr.10794; CHOI DW, 1993, P NATL ACAD SCI USA, V90, P9741, DOI 10.1073/pnas.90.21.9741; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; Cole TB, 2000, EPILEPSY RES, V39, P153, DOI 10.1016/S0920-1211(99)00121-7; Colvin RA, 2003, EUR J PHARMACOL, V479, P171, DOI 10.1016/j.ejphar.2003.08.067; Cote A, 2005, J PHYSIOL-LONDON, V566, P821, DOI 10.1113/jphysiol.2005.089458; Danscher G, 2004, J HISTOCHEM CYTOCHEM, V52, P1619, DOI 10.1369/jhc.4A6371.2004; DANSCHER G, 1982, HISTOCHEMISTRY, V76, P281, DOI 10.1007/BF00543951; Danscher G, 2005, J HISTOCHEM CYTOCHEM, V53, P141, DOI 10.1369/jhc.4R6460.2005; Danscher G, 2001, NEUROSCIENCE, V105, P941, DOI 10.1016/S0306-4522(01)00243-3; Danscher G, 2006, PROG HISTOCHEM CYTO, V41, P57, DOI 10.1016/j.proghi.2006.06.001; Dineley KE, 2003, J NEUROCHEM, V85, P563, DOI 10.1046/j.1471-4159.2003.01678.x; Dominguez MI, 2003, NEUROSCIENCE, V116, P791, DOI 10.1016/S0306-4522(02)00731-5; Frederickson CJ, 2005, J ALZHEIMERS DIS, V8, P155; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; Frederickson CJ, 2004, NEUROSCIENTIST, V10, P18, DOI 10.1177/1073858403255840; Frederickson CJ, 2004, J NEUROSCI METH, V139, P79, DOI 10.1016/j.jneumeth.2004.04.033; FREDERICKSON CJ, 1988, BRAIN RES, V446, P383, DOI 10.1016/0006-8993(88)90899-2; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; HOLM IE, 1988, HISTOCHEMISTRY, V89, P289, DOI 10.1007/BF00493154; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Kim EY, 1999, EUR J NEUROSCI, V11, P327, DOI 10.1046/j.1460-9568.1999.00437.x; Kim YH, 1999, NEUROSCIENCE, V89, P175, DOI 10.1016/S0306-4522(98)00313-3; Kitamura Y, 2006, J PHARMACOL SCI, V100, P142, DOI 10.1254/jphs.FP0050805; Knipp M, 2005, BIOCHEMISTRY-US, V44, P3159, DOI 10.1021/bi047636d; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Land PW, 2005, EUR J NEUROSCI, V21, P647, DOI 10.1111/j.1460-9568.2005.03903.x; Lee JM, 2002, NEUROSCIENCE, V115, P871, DOI 10.1016/S0306-4522(02)00513-4; Lee JY, 2006, EUR J NEUROSCI, V23, P435, DOI 10.1111/j.1460-9568.2005.04553.x; Lee JY, 2003, EXP NEUROL, V184, P337, DOI 10.1016/S0014-4886(03)00382-0; Lee JY, 2000, J NEUROSCI, V20; Maret W, 2003, J NUTR, V133, p1460S, DOI 10.1093/jn/133.5.1460S; Maret W, 2000, J NUTR, V130, p1455S, DOI 10.1093/jn/130.5.1455S; Mocchegiani E, 2005, PROG NEUROBIOL, V75, P367, DOI 10.1016/j.pneurobio.2005.04.005; Palmiter RD, 2004, P NATL ACAD SCI USA, V101, P4918, DOI 10.1073/pnas.0401022101; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; Penkowa M, 1999, J COMP NEUROL, V412, P303, DOI 10.1002/(SICI)1096-9861(19990920)412:2<303::AID-CNE9>3.0.CO;2-G; PEREZCLAUSELL J, 1985, BRAIN RES, V337, P91, DOI 10.1016/0006-8993(85)91612-9; PEREZCLAUSELL J, 1986, BRAIN RES, V362, P358, DOI 10.1016/0006-8993(86)90463-4; PerezClausell J, 1996, J CHEM NEUROANAT, V11, P99, DOI 10.1016/0891-0618(96)00131-7; Riba-Bosch A, 2004, NEUROSCIENCE, V125, P803, DOI 10.1016/j.neuroscience.2004.02.017; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Sondergaard LG, 2005, HORM METAB RES, V37, P133, DOI 10.1055/s-2005-861290; Sorensen JC, 1998, BRAIN RES, V812, P265, DOI 10.1016/S0006-8993(98)00943-3; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suh SW, 2005, NEUROSCI LETT, V377, P164, DOI 10.1016/j.neulet.2004.11.096; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Takeda A, 2000, BRAIN RES REV, V34, P137, DOI 10.1016/S0165-0173(00)00044-8; Takeda A, 2001, BIOMETALS, V14, P343, DOI 10.1023/A:1012982123386; THEORET Y, 1988, BRAIN RES, V449, P341, DOI 10.1016/0006-8993(88)91050-5; Tsuchiya D, 2002, J CEREBR BLOOD F MET, V22, P1231; Wall MJ, 2005, CEREBELLUM, V4, P224, DOI 10.1080/14734220500242084; Wang SZ, 2002, CONSERV GENET, V3, P321, DOI 10.1023/A:1019925910992; Wang ZY, 2001, BRAIN RES, V921, P165, DOI 10.1016/S0006-8993(01)03114-6; Wei G, 2004, NEUROSCIENCE, V125, P867, DOI 10.1016/j.neuroscience.2004.03.011; Weiss JH, 2000, TRENDS NEUROSCI, V23, P365, DOI 10.1016/S0166-2236(00)01610-6; Wenzel HJ, 1997, P NATL ACAD SCI USA, V94, P12676, DOI 10.1073/pnas.94.23.12676; Yeiser EC, 1999, NEUROSCI LETT, V277, P75, DOI 10.1016/S0304-3940(99)00825-3	66	15	16	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	NOV 30	2007	150	1					93	103		10.1016/j.neuroscience.2007.09.066			11	Neurosciences	Neurosciences & Neurology	242AI	WOS:000251696500012	17996379				2021-06-18	
J	Braga, LW; Souza, LN; Najjar, YJ; Dellatolas, G				Braga, Lucia W.; Souza, Ligia N.; Najjar, Yana J.; Dellatolas, Georges			Magnetic resonance imaging (MRI) findings and neuropsychological sequelae in children after severe traumatic brain injury: The role of cerebellar lesion	JOURNAL OF CHILD NEUROLOGY			English	Article						traumatic brain injury; MRI; cerebellum; neuropsychology	COGNITIVE-AFFECTIVE SYNDROME; POSTERIOR-FOSSA TUMORS; CLOSED-HEAD INJURY; LONG-TERM SEQUELAE; MEMORY IMPAIRMENT; EARLY-CHILDHOOD; CONSEQUENCES; ADOLESCENTS; DAMAGE; ATTENTION	We studied the relationships between magnetic resonance imaging (MRI) findings and neuropsychological sequelae in children after severe traumatic brain injury. Twenty-three children ages 7-13 years underwent MRI assessment of brain lesion topography and volume and neuropsychological evaluations, more than I year after sustaining severe traumatic brain injury. Most children had lesions to the corpus callosum and frontal lobes. Total lesion volume and extent of cerebral atrophy did not impact on the neuropsychological evaluation. Additional relationships were observed: left frontal lesions with lower semantic verbal fluency, right occipital lesions with lower visual recognition task scores, dyscalculia with cerebellar lesions, and cerebellar damage with lower cognitive performances and lower visual recognition memory. This study demonstrates the significance of the cerebellum's role in neuropsychological outcomes after traumatic brain injury and the importance of the lesion depth classification in predicting functional results.	Sarah Network Rehabil Hosp, BR-70335901 Brasilia, DF, Brazil; INSERM, U780, Villejuif, France	Braga, LW (corresponding author), Sarah Network Rehabil Hosp, Q501 Conj A Terro, BR-70335901 Brasilia, DF, Brazil.	luciabraga@sarah.br	Braga, Lucia/AAQ-1030-2020				Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Beldarrain MG, 2002, NEUROLOGY, V59, P791; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Blackman JA, 2003, J HEAD TRAUMA REHAB, V18, P493, DOI 10.1097/00001199-200311000-00003; Braga WL, 2000, INT HDB NEUROPSYCHOL, P283; Callu D, 2005, BRAIN COGNITION, V58, P217, DOI 10.1016/j.bandc.2004.11.008; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Dellatolas G, 2000, EUR CHILD ADOLES PSY, V9, P102; Dellatolas G, 2003, J INT NEUROPSYCH SOC, V9, P771, DOI 10.1017/S1355617703950107; Emanuelson I, 1998, Pediatr Rehabil, V2, P65; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Fenwick T, 1999, CHILD NEUROPSYCHOL, V5, P213, DOI 10.1076/0929-7049(199912)05:04;1-R;FT213; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Gadian D G, 1999, Adv Neurol, V81, P307; Gebhart AL, 2002, ANN NY ACAD SCI, V978, P318, DOI 10.1111/j.1749-6632.2002.tb07577.x; Gottwald B, 2004, J NEUROL NEUROSUR PS, V75, P1524, DOI 10.1136/jnnp.2003.018093; Gottwald B, 2003, NEUROPSYCHOLOGIA, V41, P1452, DOI 10.1016/S0028-3932(03)00090-3; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Grill J, 2004, J NEUROSURG, V101, P152, DOI 10.3171/ped.2004.101.2.0152; Grodd W, 2005, NEUROSURG CLIN N AM, V16, P77, DOI 10.1016/j.nec.2004.07.008; Harrington DL, 2004, BRAIN, V127, P561, DOI 10.1093/brain/awh065; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hoofien D, 2001, BRAIN INJURY, V15, P189; JAMBAQUE I, 1993, NEUROPSYCHOLOGIA, V31, P1321, DOI 10.1016/0028-3932(93)90101-5; JENKINS A, 1986, LANCET, V2, P445; Jurado MA, 2000, BRAIN INJURY, V14, P789; Kesler SR, 2000, BRAIN INJURY, V14, P851; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Levisohn L, 2000, BRAIN, V123, P1041, DOI 10.1093/brain/123.5.1041; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Nelson J E, 2002, Pediatr Rehabil, V5, P37, DOI 10.1080/1363849021000007088; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Ronning C, 2005, PEDIATR NEUROSURG, V41, P15, DOI 10.1159/000084860; *SAR NETW REH HOSP, 1989, SAR SCAL MOT DEV; Schmahmann JD, 2004, J NEUROPSYCH CLIN N, V16, P367, DOI 10.1176/appi.neuropsych.16.3.367; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; Stewart-Scott AM, 1998, BRAIN INJURY, V12, P317, DOI 10.1080/026990598122629; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Van Mier HI, 2002, ANN NY ACAD SCI, V978, P334; Verger K, 2001, BRAIN INJURY, V15, P211; Verger K, 2001, REV NEUROLOGIA, V33, P30, DOI 10.33588/rn.3301.2001103; WESCHSLER D, 2002, ESCALA INTELIGENCIA; Wood AG, 2004, NEUROLOGY, V63, P1035, DOI 10.1212/01.WNL.0000140707.61952.CA	50	15	16	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738			J CHILD NEUROL	J. Child Neurol.	SEP	2007	22	9					1084	1089		10.1177/0883073807306246			6	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	213MU	WOS:000249672600003	17890405				2021-06-18	
J	Seel, RT; Wright, G; Wallace, T; Newman, S; Dennis, L				Seel, Ronald T.; Wright, Greg; Wallace, Tracey; Newman, Sary; Dennis, Leanne			The utility of the FIM plus FAM for assessing traumatic brain injury day program outcomes	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						day program; FIM plus FAM; functional outcomes; prognosis; psychometrics; recovery; rehabilitation; traumatic brain injury	FUNCTIONAL ASSESSMENT MEASURE; COGNITIVE REHABILITATION; FIM+FAM; IMPACT	Objective: To evaluate the effectiveness of the FIM+FAM as a primary outcome measure for traumatic brain injury (TBI) comprehensive day programs. Design: Retrospective data analysis. Setting: Single center, TBI comprehensive day program facility. Participants: A demographically and regionally diverse sample of 105 persons with moderate or severe TBI admitted to the Shepherd Pathways comprehensive TBI day rehabilitation program. Main outcome measures: Functional Independence Measure + Functional Assessment Measure (FIM+FAM). Results: Twenty-eight percent or fewer of participants reached ceiling effects on 25 of the 30 FIM+FAM items at day program admission with only 2% of clients rated above ceiling score levels on the FIM+FAM total score. The criteria of Guyatt et al showed that 20 of the 30 FIM+FAM items showed clinically meaningful improvements in 60% or more of clients. On average, clients with TBI improved over 27 points on the FIM+FAM total score. Fifteen of 30 items showed ceiling effects of 33% or less at discharge where only 25% of clients exceeded the FIM+FAM total score ceiling threshold. Discharge FIM+FAM motor scale was a very good predictor of the need for additional single service physical therapy. However, reaching ceiling rating on the FIM+FAM cognitive scale demonstrated poor specificity (0.28) and negative predictive power (0.42) for the need for additional speech/cognitive therapy services. Conclusions: The FIM+FAM demonstrated utility as an outcome measure for TBI comprehensive day program treatment in the current milieu. Future research is required to replicate and extend the current findings.	Shepherd Ctr, Crawford Res Inst, ATT, Atlanta, GA 30309 USA	Seel, RT (corresponding author), Shepherd Ctr, Crawford Res Inst, ATT, 2020 Peachtree Rd, Atlanta, GA 30309 USA.	ron_seel@shepherd.org		Wallace, Tracey/0000-0002-6820-4363			Barnes MP, 1999, BRIT MED BULL, V55, P927, DOI 10.1258/0007142991902727; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Donaghy S, 1998, ARCH PHYS MED REHAB, V79, P1231, DOI 10.1016/S0003-9993(98)90267-2; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Hall K. M., 1992, NEUROREHABILITATION, V2, DOI [10.3233/NRE-1992-2410, DOI 10.3233/NRE-1992-2410]; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hawley CA, 1999, J NEUROL NEUROSUR PS, V67, P749, DOI 10.1136/jnnp.67.6.749; Hobart JC, 2001, NEUROLOGY, V57, P639, DOI 10.1212/WNL.57.4.639; Hoffman JM, 2003, ARCH PHYS MED REHAB, V84, P1165, DOI 10.1016/S0003-9993(03)00232-6; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Malec JF, 2002, ARCH PHYS MED REHAB, V83, P1759, DOI 10.1053/apmr.2002.36072; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Malec JF, 1999, NEUROPSYCHOL REHABIL, V9, P253, DOI 10.1080/096020199389365; MAYER D, 2004, ESSENTIAL EVIDENCE B, pCH21; Pentland B, 1999, CLIN REHABIL, V13, P498, DOI 10.1191/026921599676188597; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Turner-Stokes L, 2002, DISABIL REHABIL, V24, P383, DOI 10.1080/096382801101550	23	15	15	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2007	22	5					267	277		10.1097/01.HTR.0000290971.56130.c8			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	216RA	WOS:000249895500002	17878768				2021-06-18	
J	Golan, JD; Marcoux, J; Golan, E; Schapiro, R; Johnston, KM; Maleki, M; Khetarpal, S; Jacques, L				Golan, Jeff Dror; Marcoux, Judith; Golan, Eyal; Schapiro, Robert; Johnston, Karen M.; Maleki, Mahanuned; Khetarpal, Suneel; Jacques, Line			Traumatic brain injury in intoxicated patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	73rd Annual Meeting of the American-Association-of-Neurological-Surgeons/Congress of Neurological Surgeons Cerebrovascular Section/American-Society-of-Interventional-and-Therapeutic-Neuroradiology	APR 16-21, 2005	New Orleans, LA	Amer Assoc Neurol Surg		traumatic brain injury; alcohol intoxication; intracranial pressure	BLOOD-ALCOHOL LEVEL; GLASGOW COMA SCALE; HEAD-INJURY; SEVERITY; PRESSURE; EXPERIENCE; MANAGEMENT; ABUSE; SCORE	Background. we sought to evaluate the effect alcohol intoxication may have had in nonsurgically treated patients with severe traumatic brain injury. Methods: The Montreal General Hospital Traumatic Brain Injury Registry was used to identify all adult patients with a Glasgow Coma Scale score <= 8 at admission, within a 15-month period. All charts were retrospectively reviewed. Results: Twenty-three patients had toxic blood alcohol levels (BAL >= 21.7 mmol/L), 24 were alcohol negative (BAL < 3 mmol/L), and 10 were alcohol-influenced or had unknown BAL. Patients were more likely to have intracranial pressure monitoring if they had multiple intracranial hemorrhages, sustained multiple injuries, or had a postresuscitative Glasgow Coma Scale score <= 8. Intoxicated patients had a mean delay of 151 minutes more in the insertion time of an intracranial pressure monitoring device, compared with alcohol-negative patients. Conclusions: Alcohol was a confounding factor in the treatment of some of our patients.	McGill Univ, Montreal Neurol Hosp, Dept Neurosurg, Montreal, PQ H3A 2B4, Canada; McGill Univ, Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada; Univ Toronto, Dept Intens Care Med, Toronto, ON, Canada; Univ Toronto, Div Neurosurg, Univ Ctr, Toronto, ON, Canada; Univ S Florida, Coll Med, Dept Surg, Tampa, FL 33620 USA	Golan, JD (corresponding author), McGill Univ, Montreal Neurol Hosp, Dept Neurosurg, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	jeffgolan@hotmail.com	Golan, Eyal/D-3086-2014	Golan, Eyal/0000-0002-2904-9321			Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anderson RCE, 2004, J NEUROSURG, V101, P53, DOI 10.3171/ped.2004.101.2.0053; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; Bullock RM, 2000, J NEUROTRAUM, V17, P449; ChathamShowalter PE, 1996, PSYCHOSOMATICS, V37, P285, DOI 10.1016/S0033-3182(96)71567-0; Cunningham RM, 2002, ALCOHOL ALCOHOLISM, V37, P236, DOI 10.1093/alcalc/37.3.236; Fabbri A, 2001, J TRAUMA, V50, P521, DOI 10.1097/00005373-200103000-00018; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1977, LANCET, V1, P878; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; Macewen William, 1879, Glasgow Med J, V11, P1; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NATH FP, 1986, INJURY, V17, P150, DOI 10.1016/0020-1383(86)90320-7; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; Smith GS, 1999, ANN EMERG MED, V33, P659, DOI 10.1016/S0196-0644(99)70195-2; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Tate PS, 1999, BRAIN INJURY, V13, P767; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 2000, INTENS CARE MED, V26, P153, DOI 10.1007/s001340050037; Wiesmann M, 2001, J CLIN NEUROSCI, V8, P126, DOI 10.1054/jocn.2000.0749; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604	37	15	16	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2007	63	2					365	369		10.1097/TA.0b013e31811ec178			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	200AC	WOS:000248735300022	17693837				2021-06-18	
J	Stippler, M; Fischer, MR; Puccio, AM; Wisniewski, SR; Carson-Walter, EB; Dixon, CE; Walter, KA				Stippler, Martina; Fischer, Michael R.; Puccio, Ava M.; Wisniewski, Stephen R.; Carson-Walter, Eleanor B.; Dixon, C. Edward; Walter, Kevin A.			Serum and cerebrospinal fluid magnesium in severe traumatic brain injury outcome	JOURNAL OF NEUROTRAUMA			English	Article						magnesium replacement; outcome; serum magnesium; traumatic brain injury	MAGNETIC-RESONANCE-SPECTROSCOPY; HEAD-INJURY; SULFATE; EDEMA; NEUROPROTECTION; ANTIOXIDANT; METABOLISM; CHILDREN; EFFICACY; HUMANS	Serum magnesium concentration has a neuroprotective effect in experimental models of traumatic brain injury (TBI). This study was designed to assess the relationship between initial serum magnesium, cerebrospinal fluid (CSF) magnesium, neurological outcome and the efficacy of magnesium replacement therapy (MgSO4). A retrospective analysis was performed on a prospectively collected dataset from 216 patients admitted during 1996-2006 to the University of Pittsburgh Medical Center with severe TBI. Admission serum and CSF magnesium were dichotomized into low and normal magnesium concentration groups for serum and normal and high concentration groups for CSF. A logistic-regression analysis was performed with 6-month Glasgow Outcome Scale (GOS) scores as outcome variable. The outcome of a subset of 31 patients who presented with low serum magnesium and who were rapidly corrected within 24 h of admission was also analyzed. Low initial serum magnesium was measured in 56.67% of all patients. Patients with an initial serum magnesium of < 1.3 mEq/ L were 2.37 times more likely to have a poor outcome (CI: 1.18-4.78, p = 0.016). The prognostic significance of depressed serum magnesium remained, even in patients whose serum magnesium levels were corrected within 24 h ( OR = 11.03, CI: 1.87-68.14, p = 0.008). Patients with an initial high CSF magnesium were 7.63 more likely to have a poor outcome ( p = 0.05). Elevated CSF magnesium correlated with depressed serum magnesium only in patients with poor outcome ( p = 0.013). Patients with low serum magnesium and high CSF magnesium are most likely to have poor outcome after severe TBI. Rapid correction of serum magnesium levels does not reverse the prognostic value of these markers.	Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA; Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA	Walter, KA (corresponding author), Univ Rochester, Dept Neurosurg, Box 670,601 Elmwood Ave, Rochester, NY 14642 USA.	Kevin_Walter@URMC.Rochester.edu		Wisniewski, Stephen/0000-0002-3877-9860	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS030318-14A2] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER		Altura BM, 1995, CELL MOL BIOL RES, V41, P347; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; BULLOCK MR, 2000, MANAGEMENT PROGNOSIS, P7; Canavero S, 2003, SURG NEUROL, V60, P165, DOI 10.1016/S0090-3019(03)00159-9; CHUTKOW JG, 1974, NEUROLOGY, V24, P780, DOI 10.1212/WNL.24.8.780; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; Esen F, 2003, J NEUROSURG ANESTH, V15, P119, DOI 10.1097/00008506-200304000-00009; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; Fujimura M, 2005, NEUROCRIT CARE, V2, P59, DOI 10.1385/NCC:2:1:059; Ghabriel MN, 2006, ACTA NEUROCHIR SUPPL, V96, P402; GRUBBS RD, 1987, MAGNESIUM, V6, P113; Heath DL, 1998, SCAND J CLIN LAB INV, V58, P161, DOI 10.1080/00365519850186751; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1999, MAGNESIUM RES, V12, P269; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; KEMP PA, 1993, CLIN SCI, V85, P175, DOI 10.1042/cs0850175; Lee JS, 2004, J NEUROTRAUM, V21, P549, DOI 10.1089/089771504774129883; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; McKee JA, 2005, NEUROCRIT CARE, V2, P342, DOI 10.1385/NCC:2:3:342; McKee JA, 2005, CRIT CARE MED, V33, P661, DOI 10.1097/01.ccm.0000156293.35868.b2; Mendez DR, 2005, PEDIATR RES, V57, P347, DOI 10.1203/01.PDR.0000150803.36315.FF; Muir JK, 1999, EXP NEUROL, V159, P584, DOI 10.1006/exnr.1999.7187; Natale JE, 2007, PEDIATR CRIT CARE ME, V8, P1, DOI 10.1097/01.pcc.0000256620.55512.5f; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Rigg JL, 2005, J HEAD TRAUMA REHAB, V20, P389, DOI 10.1097/00001199-200507000-00010; Sakamoto T, 2005, J TRAUMA, V58, P1103, DOI 10.1097/01.TA.0000169950.51735.C4; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1988, J BIOL CHEM, V263, P757	37	15	19	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2007	24	8					1347	1354		10.1089/neu.2007.0277			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	202QQ	WOS:000248918500006	17711396				2021-06-18	
J	Zazzali, JL; Marshall, GN; Shetty, V; Yamashita, DDR; Sinha, UK; Rayburn, NR				Zazzali, James L.; Marshall, Grant N.; Shetty, Vivek; Yamashita, Dennis-Duke R.; Sinha, Uttam K.; Rayburn, Nadine R.			Provider perceptions of patient psychosocial needs after orofacial injury	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							TRAUMATIC BRAIN-INJURY; MENTAL-ILLNESS; REHABILITATION; FRACTURES	Purpose: Vulnerable populations are at particular risk for developing psychosocial sequelae after they experience orofacial injury. To enhance understanding of awareness, perspectives, and beliefs regarding attendant psychosocial issues, surgeons who provide orofacial injury care to indigent patients were surveyed. Materials and Methods: We surveyed 26 oral and maxillofacial surgeons and 15 otolaryngology surgeons at a large, urban, Level I trauma center. The survey, which measured providers' perceptions of pertinent contextual elements and patients' psychosocial needs after assaultive orofacial injury, was based on semistructured interviews with 15 oral and maxillofacial surgeons. The overall survey response rate was 85.4% (35 of 41). Results: Respondents ranked interpersonal violence as the dominant cause of orofacial injury among patients. Anxiety (eg, post-traumatic stress), depression, and legal issues were the most significant psychosocial sequelae identified by respondents. Alcohol abuse, drug abuse, and homelessness were identified as the most important contributors to orofacial reinjury and patient noncompliance with postsurgical instructions. Less than half of respondents (44.7%) believed that patients' problems with depression, anxiety, or substance abuse were currently addressed in an adequate way in the hospital. The vast majority (94.7%) believed that a psychosocial aftercare program was needed, and most agreed that such a program would decrease the risk of reinjury and would promote patient compliance with aftercare instructions and return for scheduled follow-up care. Respondents identified the specialty mental health service in their hospital or a community-based setting as the preferred locations for such a program, and they indicated that lack of financial resources and trained personnel were the most significant barriers to implementation of such a program within the setting of trauma services. Conclusions: Surgeons who provide care to indigent patients with orofacial injury perceive a great need for psychosocial aftercare programs for patients, and they believe that such programs could reduce the risk of reinjury and promote patient compliance. (c) 2007 American Association of Oral and Maxillofacial Surgeons.	RAND Corp, Santa Monica, CA 90407 USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ So Calif, Los Angeles, CA USA	Zazzali, JL (corresponding author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90407 USA.	zazzali@rand.org			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01DA016850] Funding Source: Medline; NIDCR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R21DE014973] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R21DE014973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA016850] Funding Source: NIH RePORTER		Barnes MP, 1999, BRIT MED BULL, V55, P927, DOI 10.1258/0007142991902727; BAYLEY E W, 1992, Journal of Burn Care and Rehabilitation, V13, P471; Foster M, 2003, SOC SCI MED, V56, P2201, DOI 10.1016/S0277-9536(02)00236-8; Glynn SM, 2003, J ORAL MAXIL SURG, V61, P785, DOI 10.1016/S0278-2391(03)00239-8; HALL SC, 1991, J NATL MED ASSOC, V83, P421; Lee Shannon, 2004, WMJ, V103, P78; Lento J, 2004, J ORAL MAXIL SURG, V62, P925, DOI 10.1016/j.joms.2004.02.009; Link BG, 1999, AM J PUBLIC HEALTH, V89, P1328, DOI 10.2105/AJPH.89.9.1328; Link BG, 1997, J HEALTH SOC BEHAV, V38, P177, DOI 10.2307/2955424; Sheffield C G 3rd, 1988, J Burn Care Rehabil, V9, P172, DOI 10.1097/00004630-198803000-00010; Shetty V, 2003, J ORAL MAXIL SURG, V61, P808, DOI 10.1016/S0278-2391(03)00156-3; Shetty Vivek, 2003, Dent Clin North Am, V47, P141, DOI 10.1016/S0011-8532(02)00059-9; Stewart MG, 1997, OTOLARYNG HEAD NECK, V117, P72, DOI 10.1016/S0194-5998(97)70210-9; Van Loey NEE, 2001, BURNS, V27, P103, DOI 10.1016/S0305-4179(00)00099-1; Zatzick DF, 2001, MED CARE, V39, P327, DOI 10.1097/00005650-200104000-00004; Zatzick DF, 2001, GEN HOSP PSYCHIAT, V23, P114, DOI 10.1016/S0163-8343(01)00140-2	16	15	16	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	AUG	2007	65	8					1584	1589		10.1016/j.joms.2006.09.028			6	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	199OV	WOS:000248706000023	17656287				2021-06-18	
J	Buxbaum, LJ; Ferraro, M; Whyte, J; Gershkoff, A; Coslett, HB				Buxbaum, Laurel J.; Ferraro, Mary; Whyte, John; Gershkoff, Arthur; Coslett, H. Branch			Amantadine treatment of hemispatial neglect - A double-blind, placebo-controlled study	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						amantadine; neglect treatment; pharmacology of hemispatial neglect; hemispatial neglect treatment; NMDA; glutamate antagonists; Parkinsonian syndromes	TRAUMATIC BRAIN-INJURY; UNILATERAL SPATIAL NEGLECT; DOPAMINE AGONIST THERAPY; PARKINSONS-DISEASE; PRISM ADAPTATION; DAMAGED PATIENTS; VISUAL NEGLECT; METHYLPHENIDATE; APOMORPHINE; DEFICITS	Objective: The resemblance of some aspects of the hemispatial neglect syndrome (hypokinesia, decreased arousal) to aspects of Parkinsonian syndromes, and the success of amantadine in treating disorders of attention, prompted a placebo-controlled, double-blind trial of amantadine, an inhibitor of the N-methyl d-aspartate (NMDA) glutamate receptor that modulates dopamine transmission, in four patients with chronic hemispatial neglect. Design: Patients received placebo or 100 mg of amantadine twice a day in an ABA design. Dependent measures of drug effect included an extensive battery of tests assessing arousal, hemiinattention, hemihypokinesia, personal neglect, disability, anosognosia, family burden, and naturalistic action. Results: There was no evidence of increased adverse effects with the treatment drug compared with placebo. Of the 17 measures used to assess treatment response in the four patients (68 measures total), linear regressions revealed significant positive treatment effects on very few (four) measures (uncorrected for multiple comparisons), and scattered negative responses to treatment were evident on three measures. The vast majority of measures showed no change in response to treatment. Conclusions: Possible reasons for failure of treatment effects in the present study are discussed. Additional study will be required to determine whether there are neglect patients who may benefit from amantadine.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; MossRehab, Philadelphia, PA USA; Univ Penn, Philadelphia, PA 19104 USA	Buxbaum, LJ (corresponding author), Moss Rehabil Res Inst, Korman 213,1200 W Tabor Rd, Philadelphia, PA 19141 USA.			Whyte, John/0000-0002-4381-1474			Adair JC, 1998, BRAIN COGNITION, V37, P351, DOI 10.1006/brcg.1998.1002; ADAIR JC, 1995, J NEUROL NEUROSUR PS, V58, P724, DOI 10.1136/jnnp.58.6.724; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Barrett AM, 1999, ARCH PHYS MED REHAB, V80, P600, DOI 10.1016/S0003-9993(99)90205-8; BISIACH E, 1986, NEUROPSYCHOLOGIA, V24, P759, DOI 10.1016/0028-3932(86)90075-8; BISIACH E, 1990, NEUROLOGY, V40, P1278, DOI 10.1212/WNL.40.8.1278; Buxbaum LJ, 2004, NEUROLOGY, V62, P749, DOI 10.1212/01.WNL.0000113730.73031.F4; Buxbaum LJ, 2001, NEUROPSYCHOLOGIA, V39, P653, DOI 10.1016/S0028-3932(01)00011-2; Cocchini G, 2001, NEUROPSYCHOL REHABIL, V11, P17, DOI 10.1080/09602010042000132; CORWIN JV, 1986, EXP NEUROL, V94, P683, DOI 10.1016/0014-4886(86)90247-5; COSLETT HB, 1990, BRAIN, V113, P475, DOI 10.1093/brain/113.2.475; COSLETT HB, 1978, NEUROLOGY, V28, P229; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; Farne A, 2004, J NEUROL NEUROSUR PS, V75, P1401, DOI 10.1136/jnnp.2002.003095; Farne A, 2002, NEUROPSYCHOLOGIA, V40, P718, DOI 10.1016/S0028-3932(01)00186-5; FLEET WS, 1987, NEUROLOGY, V37, P1765, DOI 10.1212/WNL.37.11.1765; FRIEDRICH WN, 1983, AM J MENT DEF, V88, P41; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; Geminiani G, 1998, J NEUROL NEUROSUR PS, V65, P344, DOI 10.1136/jnnp.65.3.344; Giacino JT, 2003, J HEAD TRAUMA REHAB, V18, P4, DOI 10.1097/00001199-200301000-00003; Grujic Z, 1998, NEUROLOGY, V51, P1395, DOI 10.1212/WNL.51.5.1395; GUARIGLIA C, 1992, NEUROPSYCHOLOGIA, V30, P1001, DOI 10.1016/0028-3932(92)90051-M; HEILMAN KM, 1979, NEUROPSYCHOLOGIA, V17, P315, DOI 10.1016/0028-3932(79)90077-0; HEILMAN KM, 1978, NEUROLOGY, V28, P229, DOI 10.1212/WNL.28.3.229; HOROWSKI R, 1978, EUR J PHARMACOL, V51, P157, DOI 10.1016/0014-2999(78)90340-0; Hurford P, 1998, ARCH PHYS MED REHAB, V79, P346, DOI 10.1016/S0003-9993(98)90019-3; Katz N, 1999, ARCH PHYS MED REHAB, V80, P379, DOI 10.1016/S0003-9993(99)90273-3; Lange KW, 1997, NEUROSCI BIOBEHAV R, V21, P393, DOI 10.1016/S0149-7634(96)00043-7; Larisch R, 1998, NUCL MED COMMUN, V19, P781, DOI 10.1097/00006231-199808000-00009; LEVY D, 1995, EUR NEUROL, V35, P341, DOI 10.1159/000117157; MARSHALL JF, 1979, EXP NEUROL, V65, P398, DOI 10.1016/0014-4886(79)90107-9; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Mehta MA, 2000, J PSYCHOPHARMACOL, V14, P299, DOI 10.1177/026988110001400314; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; MIYASHITA N, 1995, NEUROREPORT, V6, P1257, DOI 10.1097/00001756-199506090-00007; Mukand JA, 2001, ARCH PHYS MED REHAB, V82, P1279, DOI 10.1053/apmr.2001.25149; Nadeau SE, 1997, BRAIN LANG, V58, P355, DOI 10.1006/brln.1997.1707; Pierce SR, 2002, ARCH PHYS MED REHAB, V83, P256, DOI 10.1053/apmr.2002.27333; Robertson I.H., 1993, UNILATERAL NEGLECT C, P257; Robertson IH, 2001, NEUROIMAGE, V14, pS85, DOI 10.1006/nimg.2001.0838; Robertson IH, 1998, NATURE, V395, P169, DOI 10.1038/25993; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rossetti Y, 1998, NATURE, V395, P166, DOI 10.1038/25988; Schneider WN, 1999, BRAIN INJURY, V13, P863; Schwartz MF, 2002, NEUROPSYCHOL REHABIL, V12, P311, DOI 10.1080/09602010244000084; SMALL M, 1994, EUR NEUROL, V34, P147, DOI 10.1159/000117028; Suen H.K., 1989, ANAL QUANTITATIVE BE; Thomas A, 2004, J NEUROL NEUROSUR PS, V75, P141; Tomassini V, 2004, J NEUROL SCI, V218, P103, DOI 10.1016/j.jns.2003.11.005; VALLAR G, 1986, NEUROPSYCHOLOGIA, V24, P609, DOI 10.1016/0028-3932(86)90001-1; Vallar G, 1997, PHILOS T ROY SOC B, V352, P1401, DOI 10.1098/rstb.1997.0126; Vallar G, 2001, NEUROIMAGE, V14, pS52, DOI 10.1006/nimg.2001.0822; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; WICHMANN T, 1997, MOVEMENT DISORDERS N; WILSON BA, 1989, BEHAV INATTENTION TE; Young LC, 1941, ANN MATH STAT, V12, P293, DOI 10.1214/aoms/1177731711; 1996, GUIDE UNIFORM DATA S; 2003, NATURALISTIC ACTION	58	15	15	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL	2007	86	7					527	537		10.1097/PHM.0b013e31806e3392			11	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	181OE	WOS:000247445200003	17581287				2021-06-18	
J	Avdibegovic, E; Becirovic, E; Selimbasic, Z; Hasanovic, M; Sinanovic, O				Avdibegovic, Esmina; Becirovic, Elvir; Selimbasic, Zihnet; Hasanovic, Mevludin; Sinanovic, Osman			Cerebral cortical atrophy and silent brain infarcts in psychiatric patients	PSYCHIATRIA DANUBINA			English	Article						silent brain infarct; cerebral cortical atrophy; cognitive dysfunction; mental disorders	STROKE; DEPRESSION; RISK; MORTALITY; PATHOGENESIS; INDIVIDUALS; DEMENTIA; DISORDER; SCAN	Aim To assess the frequency of silent brain infarcts and cerebral cortical atrophy in psychiatric patients with cognitive dysfunction. Methods One hundred and ninety four patients with cognitive dysfunction determined by the use of the Benton Visual Retention Test and Wechsler Memory Scale were analyzed according to age, gender, education, duration of psychiatric treatment, presence of mental disorders, neurological findings, and CT scan of neurocranium. The results were analyzed using descriptive statistics. Results Average age of the group of patients studied was 48 +/- 9.7 years, and average duration of psychiatric treatment was 6 +/- 7.3 years. Regarding mental disorders, patients suffered from posttraumatic stress disorder (PTSD) in comorbidity with depression (21.1%), depressive disorder (14.4%), Complex PTSD (13.9%), PTSD (11.3%), and post-concussion syndrome (7.7%). Cerebral cortical atrophy was determined in 47.4%, silent brain infarct in 3.6%, whereas the combination of cerebral cortical atrophy and silent brain infarct was found in 26.3% of patients. In 22.6% of patients with cognitive dysfunction on the Benton Visual Retention Test and Wechsler Memory Scale CT scan findings were completely normal. Cerebral cortical atrophy was more frequent in patients with PTSD in comorbidity with depression (43%), PTSD (39.0%), Complex PTSD (26%), depression (25%), whereas the silent brain infarct was more frequent in patients with post-concussion syndrome (53.3%) and depression (42.8%). Conclusion Cerebral cortical atrophy and silent brain infarct are frequent findings in computerized tomography of the brain in psychiatric patients with cognitive dysfunction. Cerebral atrophy is frequent in patients with PTSD, whereas in patients with depression, besides cerebral atrophy, silent brain infarct is also frequently present.	[Avdibegovic, Esmina; Becirovic, Elvir; Selimbasic, Zihnet; Hasanovic, Mevludin] Univ Tuzla, Univ Clin Ctr Tuzla, Psychiat Clin, Sch Med, Tuzla 75000, Bosnia & Herceg; [Sinanovic, Osman] Univ Tuzla, Univ Clin Ctr Tuzla, Neurol Clin, Sch Med, Tuzla 75000, Bosnia & Herceg	Avdibegovic, E (corresponding author), Univ Tuzla, Univ Clin Ctr Tuzla, Psychiat Clin, Sch Med, 18th Hrvatske Brigade 49, Tuzla 75000, Bosnia & Herceg.	esmina@bih.net.ba	Avdibegovic, Esmina/P-3415-2019; Hasanovic, Mevludin/AAU-3608-2020	Avdibegovic, Esmina/0000-0002-3486-8903; Hasanovic, Mevludin/0000-0002-5884-0884			Baldwin R, 2005, BRIT J PSYCHIAT, V186, P308, DOI 10.1192/bjp.186.4.308; BENAVENTE W, 2005, CURR CARDIAL REP, V7, P23; Benton AL., 1974, REVISED VISUAL RETEN; Bergeson AG, 2004, CLIN NEUROPSYCHOL, V18, P509, DOI 10.1080/1385404049052414; Caeiro L, 2006, J PSYCHIATR NEUROSCI, V31, P377; Coutts SB, 2005, NEUROLOGY, V65, P513, DOI 10.1212/01.WNL.0000169031.39264.ff; FUJIKAWA T, 1995, STROKE, V26, P946, DOI 10.1161/01.STR.26.6.946; Hedges Dawson W, 2003, Cogn Behav Neurol, V16, P219, DOI 10.1097/00146965-200312000-00003; Ho BC, 2003, ARCH GEN PSYCHIAT, V60, P585, DOI 10.1001/archpsyc.60.6.585; Leary MC, 2003, CEREBROVASC DIS, V16, P280, DOI 10.1159/000071128; Liebetrau M, 2004, STROKE, V35, P1816, DOI 10.1161/01.STR.0000131928.47478.44; Maes M, 2000, ALCOHOL, V20, P117, DOI 10.1016/S0741-8329(99)00066-X; Masuda J, 2001, CURR OPIN NEUROL, V14, P77, DOI 10.1097/00019052-200102000-00012; Medalia Alice, 2004, J Psychiatr Pract, V10, P17, DOI 10.1097/00131746-200401000-00003; Mochizuki H, 2005, CLIN NEUROPHYSIOL, V116, P223, DOI 10.1016/j.clinph.2004.07.007; Pitman RK, 2001, J CLIN PSYCHIAT, V62, P47; Ramasubbu R, 2003, CAN J PSYCHIAT, V48, P250; Sairenchi T, 2005, HYPERTENS RES, V28, P901, DOI 10.1291/hypres.28.901; Soderlund H, 2004, ACTA NEUROL SCAND, V109, P398, DOI 10.1111/j.1600-0404.2004.00239.x; Terai Satoshi, 2004, Nihon Ronen Igakkai Zasshi, V41, P521; Thomas AJ, 2004, J AFFECT DISORDERS, V79, P81, DOI 10.1016/S0165-0327(02)00349-x; VANDERKOLK BA, 2001, TRAUMATIC STRESS; Vermeer SE, 2002, STROKE, V33, P21, DOI 10.1161/hs0102.101629; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066; Wechsler D, 1975, WECHSLER MEMORY SCAL; Werring DJ, 2004, BRAIN, V127, P2265, DOI 10.1093/brain/awh253; Yatsu Frank M, 2004, Curr Atheroscler Rep, V6, P307, DOI 10.1007/s11883-004-0063-0	27	15	15	0	3	MEDICINSKA NAKLADA	ZAGREB	VLASKA 69, HR-10000 ZAGREB, CROATIA	0353-5053			PSYCHIAT DANUB	Psychiatr. Danub.	JUN	2007	19	1-2					49	55					7	Psychiatry	Psychiatry	270GV	WOS:000253710100008	17603416				2021-06-18	
J	Meffre, D; Delespierre, B; Gouezou, M; Schumacher, M; Stein, DG; Guennoun, R				Meffre, Delphine; Delespierre, Brigitte; Gouezou, Monique; Schumacher, Michael; Stein, Donald G.; Guennoun, Rachida			3 beta-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase mRNA expression in rat brain: Effect of pseudopregnancy and traumatic brain injury	JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY			English	Article; Proceedings Paper	17th International Symposium of the Journal-of-Steroid-Biochemistry-and-Molecular-Biology	MAY 31-JUN 03, 2006	Seefeld, AUSTRIA	Journal Steroid Biochem & Mol Biol		neurosteroids; 3 beta-hydroxysteroid dehydrogenase; brain; in sitiu hybridization; traumatic brain injury; progesterone	TISSUE-SPECIFIC EXPRESSION; CENTRAL-NERVOUS-SYSTEM; BINDING-PROTEIN 25-DX; IN-SITU HYBRIDIZATION; SPINAL-CORD; SCHWANN-CELLS; FEMALE RATS; PROGESTERONE NEUROPROTECTION; CORTICAL CONTUSION; MYELIN FORMATION	Evidence that endogenous progesterone (PROG) is neuroprotective after traumatic brain injury (TBI) is supported by the findings that pseudopregnant female rats present less edema and achieve better functional recovery than do male rats. PROG in the nervous system may originate from steroidogenic glands or can be locally synthesized. 3 beta-Hydroxysteroid dehydrogenase/5-ene-4-ene isomerase (3 beta-HSD) is the key enzyme in the biosynthesis of PROG. In the present study, we investigated the effects of pseudopregnancy and TBI on brain 3 beta-HSD mRNA expression and on PROG levels. Twenty-four hours after bilateral contusion of the medial prefrontal cortex of rats, 3 beta-HSD mRNA expression was analyzed by in situ hybridization while PROG levels were measured by gas chromatography/mass spectrometry. Similar levels of 3 beta-HSD mRNA expression were observed in males and pseudopregnant females in the non-injured groups. At this time point, there was a significant decrease in the 3 beta-HSD mRNA expression in the contusion site within the frontal cortex in both males and pseudopregnant females. In all other regions analyzed, 3 beta-HSD mRNA expression was not affected by TBI and there was no difference between males and pseudopregnant females. The high decrease in the expression of the 3 beta-HSD mRNA in the lesion site 24h after TBI suggests a possible decrease in locally synthesized PROG in lesion site without change in the other brain regions. This decrease has less impact in pseudopregnant females since they have high plasmatic and brain levels of PROG compared to males. (c) 2007 Elsevier Ltd. All rights reserved.	INSERM, UMT788, F-94276 Le Kremlin Bicetre, France; Univ Paris 11, Le Kremlin Bicetre, France; Emory Univ, Dept Emergency Med, Brain Res Lab, Atlanta, GA 30322 USA	Guennoun, R (corresponding author), INSERM, UMT788, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	guennoun@kb.inserm.fr	Schumacher, Michael/G-3581-2013; Guennoun, Rachida/F-2420-2011; Stein, Donald/AAJ-5139-2020	Schumacher, Michael/0000-0001-6117-5371; Guennoun, Rachida/0000-0002-9219-7300; MEFFRE, Delphine/0000-0002-9204-2245	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [1R01N540825, 1R01N538664] Funding Source: Medline		ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; BAULIEU EE, 1991, BIOL CELL, V71, P3, DOI 10.1016/0248-4900(91)90045-O; Baulieu EE, 1997, RECENT PROG HORM RES, V52, P1; Beaudoin C, 1997, J ENDOCRINOL, V154, P379, DOI 10.1677/joe.0.1540379; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chan JR, 1998, P NATL ACAD SCI USA, V95, P10459, DOI 10.1073/pnas.95.18.10459; Coirini H, 2003, J NEUROCHEM, V84, P119, DOI 10.1046/j.1471-4159.2003.01512.x; Coirini H, 2002, NEUROSCIENCE, V113, P883, DOI 10.1016/S0306-4522(02)00224-5; CORPECHOT C, 1993, ENDOCRINOLOGY, V133, P1003, DOI 10.1210/en.133.3.1003; De Nicola AF, 2003, ANN NY ACAD SCI, V1007, P317, DOI 10.1196/annals.1286.030; Deniselle MCG, 2002, NEUROBIOL DIS, V11, P457, DOI 10.1006/nbdi.2002.0564; Donath J, 1997, J STEROID BIOCHEM, V62, P107, DOI 10.1016/S0960-0760(97)00012-5; DUPONT E, 1994, MOL CELL NEUROSCI, V5, P119, DOI 10.1006/mcne.1994.1014; Furukawa A, 1998, J NEUROCHEM, V71, P2231; GUENNOUN R, 1995, MOL BRAIN RES, V30, P287, DOI 10.1016/0169-328X(95)00016-L; Guennoun R, 1997, EUR J NEUROSCI, V9, P2236, DOI 10.1111/j.1460-9568.1997.tb01642.x; Hashimoto N, 2003, NEUROSCI LETT, V340, P45, DOI 10.1016/S0304-3940(03)00079-X; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; KAYNARD AH, 1992, ENDOCRINOLOGY, V130, P2192, DOI 10.1210/en.130.4.2192; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2000, J STEROID BIOCHEM, V73, P159, DOI 10.1016/S0960-0760(00)00064-9; LABRIE F, 1992, J STEROID BIOCHEM, V41, P421, DOI 10.1016/0960-0760(92)90368-S; LORENCE MC, 1991, MOL CELL ENDOCRINOL, V80, P21, DOI 10.1016/0303-7207(91)90139-J; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; Paxinos G., 1982, RAT BRAIN STEREOTAXI; RAIMONDI SG, 1989, J STEROID BIOCHEM, V32, P413, DOI 10.1016/0022-4731(89)90215-X; Robert F, 2001, EUR J NEUROSCI, V13, P916, DOI 10.1046/j.0953-816x.2001.01463.x; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; SANNE JL, 1995, J NEUROCHEM, V65, P528; Saredi S, 2005, NEUROSCIENCE, V135, P869, DOI 10.1016/j.neuroscience.2005.06.033; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Simard J, 2005, ENDOCR REV, V26, P525, DOI 10.1210/er.2002-0050; SIMARD J, 1993, J BIOL CHEM, V268, P19659; Soma KK, 2005, ENDOCRINOLOGY, V146, P4386, DOI 10.1210/en.2005-0569; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Tonetta S A, 1987, Adv Exp Med Biol, V219, P665; Vongher JM, 1999, PHARMACOL BIOCHEM BE, V64, P777, DOI 10.1016/S0091-3057(99)00140-9; Young J, 1996, STEROIDS, V61, P144, DOI 10.1016/0039-128X(95)00220-K; ZHAO HF, 1991, J BIOL CHEM, V266, P583; ZHAO HF, 1990, ENDOCRINOLOGY, V127, P3237, DOI 10.1210/endo-127-6-3237	50	15	15	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-0760			J STEROID BIOCHEM	J. Steroid Biochem. Mol. Biol.	MAY	2007	104	3-5					293	300		10.1016/j.jsbmb.2007.03.003			8	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	191DL	WOS:000248110100028	17428656				2021-06-18	
J	Sheftell, FD; Tepper, SJ; Lay, CL; Bigal, ME				Sheftell, F. D.; Tepper, S. J.; Lay, C. L.; Bigal, M. E.			Post-traumatic headache: emphasis on chronic types following mild closed head injury	NEUROLOGICAL SCIENCES			English	Article; Proceedings Paper	Seminar Focus on Primary Headaches - Recent Advances in Mechanisms and Management	MAY 24-26, 2007	Stresa, ITALY			post-traumatic headache; whiplash; posttraumatic syndrome	SPREADING DEPRESSION; MINOR HEAD; MIGRAINE; NECK; SYMPTOMS; WHIPLASH	The syndrome known as chronic post-traumatic headache (CPTH) is controversial, particularly when it occurs following mild closed head injury or "whiplash". Problems with the diagnosis include issues related to classification, epidemiology, pathophysiology (psychogenic vs. organic) and treatment. In addition, there are cultural differences that may influence prevalence and diagnosis, as in some countries with little medico-legal recourse the disorder is virtually unknown. In this paper we review some of these controversies clinicians are left to formulate their own understanding based on available evidence and clinical experience. This is perhaps as it should be given that the best practice combines knowledge of the evidence with individual clinical experience.	New England Ctr Headache, Stamford, CT 06902 USA; Yale Univ, Sch Med, New Haven, CT USA; Roosevelt Hosp, Headache Inst, New York, NY USA; Albert Einstein Coll Med, Bronx, NY 10467 USA	Sheftell, FD (corresponding author), New England Ctr Headache, 778 Long Ridge Rd, Stamford, CT 06902 USA.	Ninotores1@aol.com					Alberti A, 2001, HEADACHE, V41, P579, DOI 10.1046/j.1526-4610.2001.041006579.x; BARNAT MR, 1986, HEADACHE, V26, P271, DOI 10.1111/j.1526-4610.1986.hed2606271.x; Bartsch T, 2005, HEADACHE CURRENTS, V2, P42, DOI DOI 10.1111/j.1743-5013.2005.20201.x; Berry H, 2000, ARCH NEUROL-CHICAGO, V57, P592, DOI 10.1001/archneur.57.4.592; Bogduk N, 2000, ARCH NEUROL-CHICAGO, V57, P590, DOI 10.1001/archneur.57.4.590; Burstein R, 2000, ANN NEUROL, V47, P614, DOI 10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N; COUCH JR, 2000, AM HEAD SOC 42 ANN S; EDMEADS J, 1985, HEADACHE, V25, P117, DOI 10.1111/j.1526-4610.1985.hed2502117.x; Gardner K, 1997, NEUROLOGY, V49, P1231, DOI 10.1212/WNL.49.5.1231; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; Gilkey SJ, 1997, HEADACHE, V37, P583, DOI 10.1046/j.1526-4610.1997.3709583.x; GUALTIERI CT, 1995, NEUROPSY NEUROPSY BE, V8, P127; Gursoy-Ozdemir Y, 2004, J CLIN INVEST, V113, P1447, DOI 10.1172/JCI200421227; Hayes JS, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P249; Hines ME, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P375; KELLY R, 1988, HEADACHE PROBLEMS DI, P217; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Malec JF, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P15; MATHEW NT, 2005, HEADACHE, V31, P315; McDonald GJ, 1999, NEUROSURGERY, V45, P61, DOI 10.1097/00006123-199907000-00015; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PACKARD RC, 1993, HEADACHE, V33, P365, DOI 10.1111/j.1526-4610.1993.hed3307365.x; PACKARD RC, 2005, CURRENT HEADACHE REP, V4, P19; RASKIN NH, 1988, POSTTRAUMATIC HEADAC; RUFF M, 1994, DIAGNOSTIC STAT MANU; Ruff RM, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P99; Russell MB, 1996, EUR J NEUROL, V3, P424, DOI 10.1111/j.1468-1331.1996.tb00243.x; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Solomon S, 2005, HEADACHE, V45, P53, DOI 10.1111/j.1526-4610.2005.05011.x; SPEED WG, 1987, PSYCHIAT ASPECTS POS, P211; STRICH S, 1985, LANCET, V2, P443; TAYLOR AR, 1966, LANCET, V2, P178; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; YOUNG WB, 2005, CHRONIC DAILY HEADAC, P185	35	15	17	0	1	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	MAY	2007	28			2			S203	S207		10.1007/s10072-007-0777-1			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	175IA	WOS:000247006100026	17508171				2021-06-18	
J	Hobbs, CJ; Osman, J				Hobbs, C. J.; Osman, J.			Genital injuries in boys and abuse	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							SEXUAL-ABUSE; PREVALENCE	Aims: To describe a cohort of boys with genital injuries in whom child abuse was suspected. Methods: Boys with genital injury (penile and/or scrotal) and referred to paediatricians in Leeds, population 750 000, with concerns regarding possible abuse from 1983 to 2003 were identified from medical reports. Results: 86 boys (average age 62.7 months, median age 48 months) were referred between 1983 and 2003. The injury was judged inflicted in 63, unexplained, suspicious or inconsistent with the history given in 17 and accidental in six. The number of discrete injuries ranged from one in 57, two in 15, three in 12, to more than three in two cases. Genital injuries included burns in seven boys, bruises in 27, incised wounds, lacerations or scars in 39, and other traumatic lesions in 27. Non-genital findings included anal findings in 28,.10 bruises in 17, fractures in three, burns in 12, mouth injuries in four, brain and retinal haemorrhages in one, and poor nourishment or underweight in 14. The categories of abuse were physical (eight), sexual (19), both physical and sexual (eight), physical and neglect (four), and physical, sexual and neglect (one). The category of abuse was unspecified in 39 children. Conclusions: Genital injury in boys may be the result of abuse which may be physical or sexual in nature.	St James Univ Hosp, Dept Community Paediat, Leeds LS9 7TF, W Yorkshire, England; Hull Royal Infirm, Dept Accident & Emergency Med, Kingston Upon Hull HU3 2JZ, N Humberside, England	Hobbs, CJ (corresponding author), St James Univ Hosp, Dept Community Paediat, Leeds LS9 7TF, W Yorkshire, England.	chris.hobbs@leedsth.nhs.uk					FINKELHOR D, 1990, CHILD ABUSE NEGLECT, V14, P19, DOI 10.1016/0145-2134(90)90077-7; FINKELHOR D, 1995, JAMA-J AM MED ASSOC, V274, P1692, DOI 10.1001/jama.274.21.1692; Finkelhor D., 1984, CHILD SEXUAL ABUSE N, P150; Heger A, 2002, CHILD ABUSE NEGLECT, V26, P645, DOI 10.1016/S0145-2134(02)00339-3; Hobbs C, 2005, ARCH DIS CHILD, V90, P952, DOI 10.1136/adc.2003.037739; HOBBS CJ, 1987, LANCET, V2, P837; HOBBS CJ, 1989, CHILD ABUSE NEGLECT, V13, P195, DOI 10.1016/0145-2134(89)90006-9; HOBBS CJ, 1986, LANCET, V2, P792; Holmes WC, 1998, JAMA-J AM MED ASSOC, V280, P1855, DOI 10.1001/jama.280.21.1855; REINHART MA, 1987, CHILD ABUSE NEGLECT, V11, P229, DOI 10.1016/0145-2134(87)90062-7; Royal College of Physicians, 1997, PHYS SIGNS SEX AB CH; SPENCER MJ, 1986, PEDIATRICS, V78, P133	12	15	15	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888			ARCH DIS CHILD	Arch. Dis. Child.	APR	2007	92	4					328	331		10.1136/adc.2006.111195			4	Pediatrics	Pediatrics	148VD	WOS:000245103800012	17376938	Green Published			2021-06-18	
J	Gilad, GM; Gilad, VH				Gilad, Gad M.; Gilad, Varda H.			Astroglia growth retardation and increased microglia proliferation by lithium and ornithine decarboxylase inhibitor in rat cerebellar cultures: Cytotoxicity by combined lithium and polyamine inhibition	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						alpha-difluoromethylornithine; astrocytes; neuroprotection	BIPOLAR AFFECTIVE-DISORDER; DIBUTYRYL-CYCLIC AMP; PROTEIN-KINASE-C; STRESS-RESPONSE; SIGNAL-TRANSDUCTION; INDUCED DETACHMENT; COMMON MECHANISM; GRANULE NEURONS; BRAIN; ASTROCYTES	Lithium, the most prevalent treatment for manic-depressive illness, might have a neuroprotective effect after brain injury. In culture, lithium can exert neurotoxic effects associated with reduction in polyamine synthe_ sis but neuroprotective effects as cultured neurons mature. Cumulative evidence suggests that lithium may exert some of its effects on neurons indirectly, by initially acting on glial cells. We used rat cerebellar cultures to ascertain the effects of lithium on ornithine decarboxylase (ODC) activity, the enzyme catalyzing the first step in polyamine synthesis, and to compare effects of lithium with those of the ODC inhibitor alpha-difluoromethylornithine (DFMO) on neuron survival and glial growth. Switching cultures from high (25 mM) to low (5 mM) KCl concentrations served as the traumatic neuronal insult. The results indicate the following. 1) Whereas high depolarizing KCl concentration enhances neuron survival, it inhibits astroglial growth. 2) Lithium (LiCl; 15 mM) enhances neuronal survival but inhibits astroglial growth. 3) Lithium treatment leads to reduced ODC activity. 4) DFMO enhances neuron survival but inhibits astroglial growth. 5) Lithium and DFMO lead to transformation of astroglia from epithelioid (flat) to process-bearing morphology and to increased numbers of microglia. 6) Combined lithium plus DFMO treatment is cytolethal to both neurons and glia in culture. In conclusion, lithium treatment results in growth retardation and altered cell morphology of cultured astroglia and increased microglia proliferation, and these effects may be associated with inhibition of polyamine synthesis. This implies that direct effects on astrocytes and microglia may contribute to the effects of lithium on neurons. (c) 2006 Wiley-Liss, Inc.	G&V Gilad Ltd, IL-67639 Tel Aviv, Israel	Gilad, GM (corresponding author), G&V Gilad Ltd, 7 Plugot St, IL-67639 Tel Aviv, Israel.	gm-gilad@zahav.net.il	Gilad, Gad M/E-7193-2010				Aldskogius H, 1998, PROG NEUROBIOL, V55, P1, DOI 10.1016/S0301-0082(97)00093-2; AVISSAR S, 1988, NATURE, V331, P440, DOI 10.1038/331440a0; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BUEB JL, 1992, BIOCHEM J, V282, P545, DOI 10.1042/bj2820545; Chen Y, 1996, BRAIN RES, V711, P245, DOI 10.1016/0006-8993(95)01199-4; Coyle JT, 2003, NEURON, V38, P157, DOI 10.1016/S0896-6273(03)00195-8; CRIGNON S, 1996, EUR J PHARMACOL, V315, P111; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; D'MELLO SR, 1994, EXP CELL RES, V211, P332, DOI 10.1006/excr.1994.1095; EBSTEIN RP, 1980, J PHARMACOL EXP THER, V213, P161; FLAMIGNI F, 1986, J MOL CELL CARDIOL, V18, P3, DOI 10.1016/S0022-2828(86)80977-4; GILAD GM, 1989, INT J DEV NEUROSCI, V7, P133, DOI 10.1016/0736-5748(89)90064-6; GILAD GM, 1987, INT J DEV NEUROSCI, V5, P79, DOI 10.1016/0736-5748(87)90053-0; Gilad GM, 2003, CELL MOL NEUROBIOL, V23, P637, DOI 10.1023/A:1025036532672; GILAD GM, 1981, J HISTOCHEM CYTOCHEM, V29, P687, DOI 10.1177/29.6.6788836; GILAD GM, 1988, BRAIN RES, V458, P249, DOI 10.1016/0006-8993(88)90467-2; GILAD GM, 1992, BIOCHEM PHARMACOL, V44, P401, DOI 10.1016/0006-2952(92)90428-L; GILAD GM, 1990, BRAIN RES, V508, P215, DOI 10.1016/0006-8993(90)90399-V; GILAD GM, 1986, INT J DEV NEUROSCI, V4, P195, DOI 10.1016/0736-5748(86)90059-6; Gilad GM, 1999, NEUROSCI LETT, V268, P33, DOI 10.1016/S0304-3940(99)00375-4; GILAD GM, 1992, LIFE SCI, V50, pPL149, DOI 10.1016/0024-3205(92)90289-2; Gilad GM, 1998, INT J DEV NEUROSCI, V16, P271, DOI 10.1016/S0736-5748(98)00033-1; Gilad GM, 1996, J NEUROCHEM, V67, P1992; GILAD GM, 1995, J NEUROSCI RES, V41, P594, DOI 10.1002/jnr.490410505; JOPE RS, 1994, BIOCHEM PHARMACOL, V47, P429, DOI 10.1016/0006-2952(94)90172-4; KANBA S, 1991, NEUROPHARMACOLOGY, V30, P497, DOI 10.1016/0028-3908(91)90012-Z; LACHMAN HM, 1989, LIFE SCI, V45, P1413, DOI 10.1016/0024-3205(89)90031-3; Levine S, 2000, CELL PROLIFERAT, V33, P203, DOI 10.1046/j.1365-2184.2000.00170.x; LI PP, 1993, J NEUROCHEM, V61, P1722, DOI 10.1111/j.1471-4159.1993.tb09809.x; Lubrich B, 2000, NEUROPHARMACOLOGY, V39, P680, DOI 10.1016/S0028-3908(99)00162-8; Lubrich B, 1999, NEUROPSYCHOPHARMACOL, V21, P519, DOI 10.1016/S0893-133X(99)00037-8; Manji HK, 2000, MOL PSYCHIATR, V5, P578, DOI 10.1038/sj.mp.4000811; MANJI HK, 1993, J NEUROCHEM, V61, P2303, DOI 10.1111/j.1471-4159.1993.tb07474.x; MASANA MI, 1992, J NEUROCHEM, V59, P200, DOI 10.1111/j.1471-4159.1992.tb08891.x; MATSUI I, 1980, BIOCHIM BIOPHYS ACTA, V633, P87, DOI 10.1016/0304-4165(80)90040-9; MOONEN G, 1975, CELL TISSUE RES, V163, P365; MORUZZI MS, 1993, MOL CELL BIOCHEM, V124, P1, DOI 10.1007/BF01096375; Nichols CG, 1996, CIRC RES, V78, P1, DOI 10.1161/01.RES.78.1.1; Nonaka S, 1998, P NATL ACAD SCI USA, V95, P2642, DOI 10.1073/pnas.95.5.2642; Pardo R, 2003, J NEUROCHEM, V87, P417, DOI 10.1046/j.1471-4159.2003.02015.x; PERIYASAMY S, 1994, J NEUROCHEM, V63, P1319; Queiroz G, 1999, NEUROSCIENCE, V91, P1171, DOI 10.1016/S0306-4522(98)00644-7; RICHARDS JF, 1990, LIFE SCI, V47, P233, DOI 10.1016/0024-3205(90)90325-L; Rowe Michael K., 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404008385; SCHUBER F, 1989, BIOCHEM J, V260, P1; SCHUBERT T, 1991, PSYCHOPHARMACOLOGY, V104, P45, DOI 10.1007/BF02244552; SEILER N, 1985, NEUROCHEM RES, V10, P529, DOI 10.1007/BF00964656; Seiler N, 1991, Prog Drug Res, V37, P107; SEILER N, 1984, NEUROCHEM RES, V9, P871, DOI 10.1007/BF00964520; Shao L, 2006, LIFE SCI, V78, P1317, DOI 10.1016/j.lfs.2005.07.007; SINGH SS, 1995, LIFE SCI, V57, P685, DOI 10.1016/0024-3205(95)00320-6; Song L, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-20; Sparapani M, 1998, J NEUROCHEM, V71, P1898; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; WALZ W, 1983, PROG NEURO-PSYCHOPH, V7, P697, DOI 10.1016/0278-5846(83)90048-9; Wolfson M, 1998, BRAIN RES, V787, P34, DOI 10.1016/S0006-8993(97)00775-0; Xu JH, 2003, STROKE, V34, P1287, DOI 10.1161/01.STR.0000066308.25088.64; YOUNG LT, 1991, BRAIN RES, V553, P323, DOI 10.1016/0006-8993(91)90843-K; Zamfirescu G, 2000, Rom J Physiol, V37, P81; Zhou R, 2005, J NEUROSCI, V25, P4493, DOI 10.1523/JNEUROSCI.4530-04.2005	61	15	16	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	FEB 15	2007	85	3					594	601		10.1002/jnr.21152			8	Neurosciences	Neurosciences & Neurology	139ZP	WOS:000244472000014	17171700				2021-06-18	
J	Chieregato, A; Tanfani, A; Compagnone, C; Pascarella, R; Targa, L; Fainardi, E				Chieregato, Arturo; Tanfani, Alessandra; Compagnone, Christian; Pascarella, Rosario; Targa, Luigi; Fainardi, Enrico			Cerebral blood flow in traumatic contusions is predominantly reduced after an induced acute elevation of cerebral perfusion pressure	NEUROSURGERY			English	Article						brain ischemia; catecholamines; computed tomography; contusion; intracranial pressure; regional blood flow; xenon; X-ray	FOCAL ISCHEMIA; HEAD-INJURY; BRAIN; DOPAMINE; CT; NOREPINEPHRINE; NORADRENALINE; THRESHOLDS; ACTIVATION; DAMAGE	Objective: To evaluate the response to an acute elevation of cerebral perfusion pressure (CPP) of the regional cerebral blood flow (rCBF) measured in the edematous area of traumatic contusions. Methods: rCBF was measures in the intracontusional low-density area, in the pericontusional healthy-appearing brain tissue surrounding the contusion, in a healthy-appearing area in he contralateral hemisphere, in 16 head-injured patients with 16 traumatic contusions larger than 2 cm at the baseline, and after 20 minutes of nonrepinephrine-induced 20-mmHg elevation of CPP levels. Results: After an induced acute elevation of CPP from baseline values of 65.8 ml/100 g/min (standard deviation, 608) to final values of 88.7 ml/100 g/min (standard deviation, 8.6) to final values of 88.7 ml/100 g/min (standard deviation, 8.9; P <= 0.0001), we found that rCBF mean levels decreased in the intracontusional low-density area (P = 0.0278), and change in rCBF was inversely associated to the baseline values. After grouping contusions according to the rCBF response to induced acute CPP elevation, rCBF mean values recorded at baseline were significantly lower contusional low-density area (P = 0.0435). Conclusion: Our findings suggest that CPP elevation induced by norepinephrine is effective in improving contusional rCBF only in selected cases, which are represented by a subset of contusions with critical perfusion, which can be identified by rCBF measurements. Conversely, in contusions with rCBF higher than critical low values, the CPP elevation could probably induce a temporary breakdown of the blood brain barrier, and the norepinephrine leads to a vasoconstriction with a worsening of regional perfusion.	Maurizio Bufalini Hosp, Intens Care Unit, Cesena, Italy	Chieregato, A (corresponding author), Osped Bufalini, Viale Ghirotti 286, I-47023 Cesena, Italy.	achiere@ausl-cesena.emr.it	Pascarella, Rosario/AAL-2639-2021	Pascarella, Rosario/0000-0002-0512-9298; Compagnone, Christian/0000-0001-9951-5503			BULLOCK R, 1990, ACT NEUR S, V51, P286; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Chieregato A, 2005, ACTA NEUROCHIR SUPPL, V95, P159; Chieregato A, 2004, J NEUROTRAUM, V21, P655, DOI 10.1089/0897715041269669; CHIUEH CC, 1978, BRAIN RES, V145, P291, DOI 10.1016/0006-8993(78)90863-6; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; DARBY JM, 1994, J NEUROSURG, V80, P857, DOI 10.3171/jns.1994.80.5.0857; EDVINSSON L, 2000, CEREBRAL BLOOD FLOW, P191; Furuya Y, 2003, NEUROSURGERY, V52, P340, DOI 10.1227/01.NEU.0000043931.83041.AA; GUR D, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P68; HARDEBO JE, 1977, ACTA PHYSIOL SCAND, V101, P342, DOI 10.1111/j.1748-1716.1977.tb06016.x; Hoelper BM, 2000, ACTA NEUROCHIR SUPPL, V76, P21; Horn P, 2001, AM J NEURORADIOL, V22, P1543; JENNETT B, 1975, LANCET, V1, P480; JING ZA, 1992, J TRAUMA, V33, P83, DOI 10.1097/00005373-199207000-00016; JOHANSSON BB, 1997, PRIMER CEREBROVASCUL, P142; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; Kawamata T, 2002, ACTA NEUROCHIR SUPPL, V81, P281; Kim DH, 2003, NEUROSURGERY, V53, P1044, DOI 10.1227/01.NEU.0000088567.59324.78; Kroppenstedt SN, 2002, ACT NEUR S, V81, P225; Latchaw RE, 2003, STROKE, V34, P1084, DOI 10.1161/01.STR.0000064840.99271.9E; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Nellgard BMG, 1999, BRAIN RES, V847, P262, DOI 10.1016/S0006-8993(99)02059-4; Obrist WD, 1998, J CEREBR BLOOD F MET, V18, P1192, DOI 10.1097/00004647-199811000-00005; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Pindzola RR, 1998, NEUROSURGERY, V43, P1488; RAPOPORT SI, 1997, PRIMER CEREBROVASCUL, P25; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Servadei F, 2000, NEUROSURGERY, V46, P70; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; Stocchetti N, 1998, ACT NEUR S, V71, P162; TEASDALE G, 1974, LANCET, V2, P81; TODA N, 1976, BRIT J PHARMACOL, V58, P121, DOI 10.1111/j.1476-5381.1976.tb07700.x; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Wintermark M, 2005, STROKE, V36, pE83, DOI 10.1161/01.STR.0000177884.72657.8b; WOLFSON SK, 1990, STROKE, V21, P751, DOI 10.1161/01.STR.21.5.751; YONAS H, 1993, J NEUROSURG, V79, P483, DOI 10.3171/jns.1993.79.4.0483; YONAS H, 1990, J NEUROSURG, V73, P266, DOI 10.3171/jns.1990.73.2.0266	41	15	18	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2007	60	1					115	122		10.1227/01.NEU.0000249194.76527.28			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	125DG	WOS:000243421400022	17228259				2021-06-18	
J	Giles, GM; Mohr, JD				Giles, Gordon Muir; Mohr, James D.			Overview and inter-rater reliability of an incident-based rating scale for aggressive behaviour following traumatic brain injury: The Overt Aggression Scale-Modified for Neurorehabiltation Extended (OAS-MNR-E)	BRAIN INJURY			English	Article						traumatic brain injury; Overt Aggression Scale; incident rating; direct-care staff	HEAD-INJURY; LONG-TERM; AGITATION; DISTURBANCES	Primary objective: The presentation and evaluation of the Overt Aggression Scale-Modified for Neurorehabilitation-Extended ( OAS-MNR-E). Research design: Inter-rater reliability study using data collection procedures mirroring clinical practice. Methods and procedures: Fifteen clinical staff representing five different disciplines received a 30-minute orientation to the study and a 30-minute overview of the OAS-MNR-E. There were 34 patients who engaged in a rateable behaviour and were observed by two raters. There were 199 observed aggressive behaviours during the 6-week study period. Main outcomes and results: All sub-scales of the OAS-MNR-E had high percentage agreement (> 92%) and the kappa statistic was uniformly excellent (> 0.77). Multiple ratings within a sub-scale resulted in lower reliabilities. Incidents with multiple interventions were of longer duration. Interventions were on average more intrusive when used in combination than when used singly. Conclusions: The OAS-MNR-E can be easily incorporated into facility routines and is reliable. The rating tool reported here can provide data that assists in programme design, evaluation and treatment planning.	Samuel Merritt Coll, Oakland, CA 94609 USA; Idylwood Care Ctr, Oakland, CA USA; Crestwood Treatment Ctr, Oakland, CA USA; Mohr Consulting Grp, San Francisco, CA USA	Giles, GM (corresponding author), Samuel Merritt Coll, 450 30th St, Oakland, CA 94609 USA.	ggiles@samuelmerritt.edu					Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Angelino E, 2002, BRAIN INJURY, V16, P269, DOI 10.1080/02699050110103968; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; BOWERS L, 1999, J MENTAL HLTH, V8, P339; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; Giles GM, 2005, BRAIN INJURY, V19, P753, DOI 10.1080/02699050500110108; GILES GM, 2000, THESIS CALIFORNIA SC; Harmsen M, 2004, BRAIN INJURY, V18, P787, DOI 10.1080/02699050410001671757; Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; Kadyan V, 2004, AM J PHYS MED REHAB, V83, P747, DOI 10.1097/01.PHM.0000140790.30468.F4; KAY SR, 1988, J NERV MENT DIS, V176, P539, DOI 10.1097/00005053-198809000-00007; Levy M, 2005, NEUROREHABILITATION, V20, P279; LION JR, 1981, HOSP COMMUNITY PSYCH, V32, P497; McMillan TM, 2001, BRAIN DAM B, P257; Paxton R, 1997, J MENTAL HLTH, V6, P149, DOI [10.1080/09638239718914, DOI 10.1080/09638239718914]; Robson C., 1993, REAL WORLD RES RESOU; SILVER JM, 1991, J NEUROPSYCHIAT, V3, P22; SORGI P, 1991, J NEUROPSYCHIAT, V3, P52; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; Tooth LR, 2004, ARCH PHYS MED REHAB, V85, P1371, DOI 10.1016/j.apmr.2003.12.002; van der Naalt J, 2000, BRAIN INJURY, V14, P781; WILSON J, 1999, REHABILITATION SEVER, P54; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	28	15	15	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	5					505	511		10.1080/02699050701311729			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	175FI	WOS:000246998000007	17522990				2021-06-18	
J	Spinella, M				Spinella, Marcello			Measuring the executive regulation of emotion with self-rating scales in a nonclinical population	JOURNAL OF GENERAL PSYCHOLOGY			English	Article						emotion; executive; FrSBe; prefrontal; regulation	SYSTEMS BEHAVIOR SCALE; TRAUMATIC BRAIN-INJURY; ANXIETY STRESS SCALES; FRONTAL-LOBE; PSYCHOMETRIC PROPERTIES; POSTSTROKE DEPRESSION; CIRCUITS; DISORDER; NEUROPSYCHIATRY; DYSFUNCTION	Prefrontal systems play an important role in the regulation of emotion as evidenced by clinical neuroimaging studies. Both subjective and objective neuropsychological tests provide functional evidence of executive dysfunction in emotional deregulation. The present authors evaluated these relationships here in a nonclinical community sample using the Frontal Systems Behavior Scale, Profile of Mood States (POMS), and Depression Anxiety Stress Scales (DASS). Positive correlations uniformly emerged between prefrontal system dysfunction and negative emotional states (anger, depression, anxiety, stress, confusion, and fatigue), whereas positive emotion (vigor) showed a modest inverse correlation with prefrontal system dysfunction, even after control for demographic influences. These relationships may result from cognitive strategies for managing emotion mediated by reciprocal connections between prefrontal systems and the limbic system. The findings corroborated those of other methodologies, supporting the Frontal Systems Behavior Scale (FrSBe) as a valid tool to measure prefrontal function in nonclinical populations.	Richard Stockton Coll New Jersey, Div Social & Behav Sci, Pomona, NJ 08240 USA	Spinella, M (corresponding author), Richard Stockton Coll New Jersey, Div Social & Behav Sci, POB 195, Pomona, NJ 08240 USA.						Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; Bartzokis G, 2001, ARCH GEN PSYCHIAT, V58, P461, DOI 10.1001/archpsyc.58.5.461; Bassarath L, 2001, CAN J PSYCHIAT, V46, P728; Beblo T, 1999, NEUROPSY NEUROPSY BE, V12, P236; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; Brown TA, 1997, BEHAV RES THER, V35, P79, DOI 10.1016/S0005-7967(96)00068-X; Cahn-Weiner DA, 2002, NEUROPSY NEUROPSY BE, V15, P79, DOI 10.1097/01.WNN.0000012908.05122.F4; Cecil KM, 2002, BIPOLAR DISORD, V4, P357, DOI 10.1034/j.1399-5618.2002.02235.x; Chiaravalloti ND, 2003, COGN BEHAV NEUROL, V16, P54, DOI 10.1097/00146965-200303000-00007; Fossati P, 2003, AM J PSYCHIAT, V160, P1938, DOI 10.1176/appi.ajp.160.11.1938; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; GROVE JR, 1992, INT J SPORT PSYCHOL, V23, P93; Hariri AR, 2000, NEUROREPORT, V11, P43, DOI 10.1097/00001756-200001170-00009; Helmstaedter C, 2001, EPILEPSY BEHAV, V2, P384, DOI 10.1006/ebeh.2001.0259; Kim JS, 2000, NEUROLOGY, V54, P1805, DOI 10.1212/WNL.54.9.1805; Kim JS, 2002, NEUROLOGY, V58, P1106, DOI 10.1212/WNL.58.7.1106; Levesque J, 2003, BIOL PSYCHIAT, V53, P502, DOI 10.1016/S0006-3223(02)01817-6; Lovibond S.H., 1995, MANUAL DEPRESSION AN; Luna B, 2001, NEUROIMAGE, V13, P786, DOI 10.1006/nimg.2000.0743; Malizia AL, 1999, J PSYCHOPHARMACOL, V13, P372, DOI 10.1177/026988119901300418; MALLOY P, 1993, ARCH CLIN NEUROPSYCH, V8, P185, DOI 10.1016/0887-6177(93)90035-Y; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Masterman DL, 1997, J PSYCHOPHARMACOL, V11, P107, DOI 10.1177/026988119701100203; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Menza M, 2000, Curr Psychiatry Rep, V2, P421, DOI 10.1007/s11920-000-0027-1; Moritz S, 2002, ARCH CLIN NEUROPSYCH, V17, P477, DOI 10.1016/S0887-6177(01)00130-5; Ochsner KN, 2002, J COGNITIVE NEUROSCI, V14, P1215, DOI 10.1162/089892902760807212; Paquette V, 2003, NEUROIMAGE, V18, P401, DOI 10.1016/S1053-8119(02)00030-7; Paradiso S, 1999, J NEUROL NEUROSUR PS, V67, P664, DOI 10.1136/jnnp.67.5.664; Paulsen JS, 2000, J INT NEUROPSYCH SOC, V6, P815, DOI 10.1017/S1355617700677081; Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087; Pluck GC, 2002, J NEUROL NEUROSUR PS, V73, P636, DOI 10.1136/jnnp.73.6.636; PORRINO LJ, 1981, J COMP NEUROL, V198, P121, DOI 10.1002/cne.901980111; Rankin KP, 2003, NEUROLOGY, V60, P266, DOI 10.1212/01.WNL.0000041497.07694.D2; REDDON JR, 1985, J PSYCHOPATHOL BEHAV, V7, P243, DOI 10.1007/BF00960756; REEP R, 1984, BRAIN BEHAV EVOLUT, V25, P5, DOI 10.1159/000118849; Sheline YI, 2003, BIOL PSYCHIAT, V54, P338, DOI 10.1016/S0006-3223(03)00347-0; Shimoda K, 1999, BIOL PSYCHIAT, V45, P187, DOI 10.1016/S0006-3223(98)00178-4; SHIWACH R, 1994, ACTA PSYCHIAT SCAND, V90, P241, DOI 10.1111/j.1600-0447.1994.tb01587.x; Soloff PH, 2000, BIOL PSYCHIAT, V47, P540, DOI 10.1016/S0006-3223(99)00202-4; Spinella M, 2004, INT J NEUROSCI, V114, P83, DOI 10.1080/00207450490249356; Spinella M, 2003, ADDICT BIOL, V8, P67, DOI 10.1080/1355621031000069909; Stout JC, 2003, ASSESSMENT, V10, P79, DOI 10.1177/1073191102250339; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Tekin S, 2002, J PSYCHOSOM RES, V53, P647, DOI 10.1016/S0022-3999(02)00428-2; Toren P, 2000, J ANXIETY DISORD, V14, P239, DOI 10.1016/S0887-6185(99)00036-5; Velligan DI, 2002, PSYCHIAT RES, V113, P227, DOI 10.1016/S0165-1781(02)00264-0	47	15	15	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0022-1309	1940-0888		J GEN PSYCHOL	J. Gen. Psychol.	JAN	2007	134	1					101	111		10.3200/GENP.134.1.101-111			11	Psychology, Multidisciplinary	Psychology	129XN	WOS:000243763500007	17283857				2021-06-18	
J	Thomale, UW; Bender, M; Casalis, P; Rupprecht, S; Griebenow, M; Neumann, K; Woiciechowsky, C; Unterberg, AW; Stover, JF				Thomale, Ulrich W.; Bender, Marcel; Casalis, Pablo; Rupprecht, Stefan; Griebenow, Martin; Neumann, Konrad; Woiciechowsky, Christian; Unterberg, Andreas W.; Stover, John F.			Tacrolimus depresses local immune cell infiltration but fails to reduce cortical contusion volume in brain-injured rats	IMMUNOBIOLOGY			English	Article						traumatic brain injury; ICAM-1; microglia; macrophages; granulocytes	NECROSIS-FACTOR-ALPHA; CLOSED-HEAD INJURY; FLUID PERCUSSION INJURY; NITRIC-OXIDE SYNTHASE; SPINAL-CORD-INJURY; CEREBRAL-ISCHEMIA; NEUTROPHIL INFILTRATION; NEUROPROTECTIVE ACTION; INFLAMMATORY RESPONSE; MOLECULAR-MECHANISMS	The immunosuppressant drug tacrolimus (FK-506) failed to show an anti-edematous effect despite suppressing pro-inflammatory cytokines in cerebrospinal fluid following focal traumatic brain injury. By questioning the role of the inflammatory response as a pharmacological target, we investigated the effects of FK-506 on immune cell infiltration in brain-injured rats. Following induction of a cortical contusion, male Sprague-Dawley rats received FK-506 or physiological saline intraperitoneally. Brains were removed at 24 h, 72 h or 7 days, respectively. Frozen brain sections (7 mu m) were stained immunohistologically for markers of endothelial activation (intercellular adhesion molecule-1-ICAM-1), neutrophil infiltration (His-48), and microglial and macrophage activation (Ox-6; ED-1), respectively. Immunopositive cells were counted microscopically. Contusion volume (CV) was quantified morphometrically 7 days after trauma. Inflammatory response was confined to the ipsilateral cortex and hippocampal formation, predominating in the contusion and pericontusional cortex. Strongest ICAM-1 expression coincided with sustained granulocyte accumulation at 72 h which was suppressed by FK-506. Ox-6 + cells prevailing at 72 h were also significantly reduced by FK-506. ED-1 + cells reaching highest intensity at 7 days were significantly attenuated at 72 h. Cortical CV was not influenced. FK-506 significantly decreased post-traumatic local inflammation which, however, was not associated with a reduction in cortical CV. These results question the importance of post-traumatic local immune cell infiltration in the secondary growth of a cortical contusion. (c) 2007 Elsevier GmbH. All rights reserved.	Med Univ Berlin, Dept Neurosurg, Campus Virchow Med Ctr, D-13353 Berlin, Germany; Charite, Dept Biometry & Clin Epidemiol, D-10117 Berlin, Germany; Heidelberg Univ, Dept Neurosurg, D-69120 Heidelberg, Germany; Univ Zurich Hosp, Div Surg Intens Care Med, CH-8091 Zurich, Switzerland	Thomale, UW (corresponding author), Med Univ Berlin, Dept Neurosurg, Campus Virchow Med Ctr, D-13353 Berlin, Germany.	uthomale@charite.de		Misch, Martin/0000-0001-5283-5753			AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Benetoli A, 2004, PHARMACOL BIOCHEM BE, V77, P607, DOI 10.1016/j.pbb.2003.12.022; Bochelen D, 1999, J PHARMACOL EXP THER, V288, P653; Butcher SP, 1997, J NEUROSCI, V17, P6939; CLARK RK, 1993, BRAIN RES BULL, V31, P565, DOI 10.1016/0361-9230(93)90124-T; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Cross AK, 2001, MICROSC RES TECHNIQ, V54, P10, DOI 10.1002/jemt.1115; Darakchiev BJ, 1997, ACT NEUR S, V70, P98; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Furuichi Y, 2004, BRAIN RES, V1014, P120, DOI 10.1016/j.brainres.2004.04.031; GarciaCriado FJ, 1997, TRANSPLANTATION, V64, P594, DOI 10.1097/00007890-199708270-00008; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Gold BG, 1999, DRUG METAB REV, V31, P649, DOI 10.1081/DMR-100101940; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; Kaminska B, 2004, J CELL MOL MED, V8, P45, DOI 10.1111/j.1582-4934.2004.tb00259.x; Klettner A, 2003, CNS NEUROL DISORD-DR, V2, P153, DOI 10.2174/1568007033482878; Kubes P, 2000, BRAIN PATHOL, V10, P127; Kurz JE, 2005, BRAIN RES, V1048, P153, DOI 10.1016/j.brainres.2005.04.062; Kurz JE, 2005, J NEUROTRAUM, V22, P476, DOI 10.1089/neu.2005.22.476; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Madsen JR, 1998, EXP NEUROL, V154, P673, DOI 10.1006/exnr.1998.6974; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Masri MA, 2003, MOL IMMUNOL, V39, P1073, DOI 10.1016/S0161-5890(03)00075-0; Mechoulam R, 2002, TRENDS MOL MED, V8, P58, DOI 10.1016/S1471-4914(02)02276-1; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nottingham S, 2002, EXP NEUROL, V177, P242, DOI 10.1006/exnr.2002.7975; PAXINOS G, 1996, RAT BRAIN STEREOTAXI; Price CJS, 2003, J NEUROL NEUROSUR PS, V74, P1476, DOI 10.1136/jnnp.74.11.1476; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schoning B, 2002, NEUROL SCI, V23, P211, DOI 10.1007/s100720200043; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Squadrito F, 1999, BRIT J PHARMACOL, V127, P498, DOI 10.1038/sj.bjp.0702528; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stover JF, 2001, J NEUROSURG, V94, P782, DOI 10.3171/jns.2001.94.5.0782; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; Tamura F, 1998, J GASTROEN HEPATOL, V13, P703, DOI 10.1111/j.1440-1746.1998.tb00717.x; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Thomale UW, 2006, INTENS CARE MED, V32, P149, DOI 10.1007/s00134-005-2845-4; Tsujikawa A, 1998, STROKE, V29, P1431, DOI 10.1161/01.STR.29.7.1431; Vela JM, 2002, J NEUROTRAUM, V19, P1503, DOI 10.1089/089771502320914723; Whalen MJ, 2000, CRIT CARE MED, V28, P3710, DOI 10.1097/00003246-200011000-00029; Yoshimoto T, 2002, BRAIN RES, V947, P191, DOI 10.1016/S0006-8993(02)02922-0; ZHANG J, 1995, NEUROL RES, V17, P285, DOI 10.1080/01616412.1995.11740328	52	15	16	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0171-2985			IMMUNOBIOLOGY	Immunobiology		2007	212	7					567	576		10.1016/j.imbio.2007.01.007			10	Immunology	Immunology	209FV	WOS:000249375300004	17678714				2021-06-18	
J	Yilmaz, S; Pekdemir, M				Yilmaz, Serkan; Pekdemir, Murat			An unusual primary blast injury - Traumatic brain injury due to primary blast injury	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article									Kocaeli Univ, Dept Emergency Med, Sch Med, TR-41380 Kocaeli, Turkey	Yilmaz, S (corresponding author), Kocaeli Univ, Dept Emergency Med, Sch Med, TR-41380 Kocaeli, Turkey.	cmdsercy@yahoo.com; mpekdemir@yahoo.com	Pekdemir, Murat/F-9741-2018; Yilmaz, Serkan/G-2731-2018	Pekdemir, Murat/0000-0002-3917-0192; Yilmaz, Serkan/0000-0003-1496-6976			Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; SINGER P, 2005, CRIT CARE MED, V33, P61; SIRI KK, 2003, NEUROSCI RES, V46, P377	5	15	15	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	JAN	2007	25	1					97	98		10.1016/j.ajem.2006.04.014			2	Emergency Medicine	Emergency Medicine	121ES	WOS:000243141500023	17157696				2021-06-18	
J	Kirkness, CJ; Burr, RL; Cain, KC; Newell, DW; Mitchell, PH				Kirkness, Catherine J.; Burr, Robert L.; Cain, Kevin C.; Newell, David W.; Mitchell, Pamela H.			Effect of continuous display of cerebral perfusion pressure on outcomes in patients with traumatic brain injury	AMERICAN JOURNAL OF CRITICAL CARE			English	Article							BLOOD-FLOW; SEVERITY SCORE; HEAD-INJURY; DAMAGE; METABOLISM; DISABILITY; ISCHEMIA; INSULTS	BACKGROUND Clinical bedside monitoring systems do not provide prominent displays of data on cerebral perfusion pressure (CPP). Immediate visual feedback would allow more rapid intervention to prevent or minimize suboptimal pressures. OBJECTIVE To evaluate the effect of a highly visible CPP display on immediate and long-term functional outcome inpatients with traumatic brain injury. METHODS A total of 157 patients with traumatic brain injury at a level I trauma center who had invasive arterial blood pressure and intracranial pressure monitoring were randomized to beds with or without an additional, prominent continuous CPP display. Primary end points were scores on the Extended Glasgow Outcome Scale (GOSE) and Functional Status Examination (FSE) 6 months after injury. Secondary end points were GOSE scores at discharge and 3 months after injury and FSE score 3 months after injury. RESULTS Although GOSE and FSE scores at 6 months were better in the group with the highly visible CPP display, the differences were not significant. Slope of recovery for GOSE and FSE over all follow-up time points did not differ significantly between groups. However, the intervention positive effect on odds of survival at hospital discharge was strong and significant. Within a subgroup of more severely injured patients, the intervention group was much less likely than the control group to have CPP deviations. CONCLUSION The Presence of a highly visible display of CPP was associated with significantly better odds of survival and overall condition at discharge.	[Kirkness, Catherine J.; Burr, Robert L.; Cain, Kevin C.; Mitchell, Pamela H.] Univ Washington, Biostat & Off Nursing Res, Seattle, WA 98195 USA; [Newell, David W.] Swedish Med Ctr, Seattle Neurosci Inst, Seattle, WA USA	Kirkness, CJ (corresponding author), Univ Washington, Biostat & Off Nursing Res, 1959 Pacific NE St,Box 357266, Seattle, WA 98195 USA.	kirkness@u.washington.edu			NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01 NR04901] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR004901] Funding Source: NIH RePORTER		BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; Brown JIM, 1998, NEUROSURGERY, V42, P1057, DOI 10.1097/00006123-199805000-00060; BULLOCK MR, GUIDELINES MANAGEMEN; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; KENNER GIA, 2002, NURSING CARE ACTIVIT; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kirkness CJ, 2005, ACTA NEUROCHIR SUPPL, V95, P13; LITTLE RJA, 1988, J BUS ECON STAT, V6, P287, DOI 10.2307/1391878; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Raudenbush SW., 2002, HIERARCHICAL LINEAR, V2nd ed; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; Rubin DB., 1987, MULTIPLE IMPUTATION; Schafer J.L., 1997, MONOGRAPHS STAT APPL, V72; Schroder ML, 1998, NEUROSURGERY, V42, P1276, DOI 10.1097/00006123-199806000-00042; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Singer J.D., 2003, APPL LONGITUDINAL DA; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	37	15	15	0	0	AMER ASSOC CRITICAL CARE NURSES	ALISO VIEJO	101 COLUMBIA, ALISO VIEJO, CA 92656 USA	1062-3264	1937-710X		AM J CRIT CARE	Am. J. Crit. Care	NOV	2006	15	6					600	610					11	Critical Care Medicine; Nursing	General & Internal Medicine; Nursing	V44BU	WOS:000202979000010	17053267				2021-06-18	
J	Yuan, HB; Huang, Y; Zheng, S; Zuo, Z				Yuan, H. -B.; Huang, Y.; Zheng, S.; Zuo, Z.			Hypothermic preconditioning reduces Purkinje cell death possibly by preventing the over-expression of inducibl nitric oxide synthase in rat cerebellar slices after an in vitro simulated ischemia	NEUROSCIENCE			English	Article						neuroprotection; oxygen-glucose deprivation; heat shock protein; hypothermia; inducible nitric oxide synthase; preconditioning	GLOBAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; HEAT-SHOCK PROTEINS; MILD HYPOTHERMIA; POSTISCHEMIC HYPOTHERMIA; AMINOGUANIDINE TREATMENT; INFLAMMATORY RESPONSE; GLUCOSE DEPRIVATION; FOCAL ISCHEMIA; NEUROPROTECTION	We showed that hypothermic preconditioning (HPC) increased survival of Purkinje neurons in rat cerebellar slices after oxygen-glucose deprivation (OGD). HPC also reduced the OGD-increased expression of high mobility group I (Y) proteins, a transcription factor that can enhance inducible nitric oxide synthase (iNOS) expression. iNOS is a putatively damaging protein that contributes to ischemic brain injury. Heat shock proteins (HSPs) can be induced by various stimuli to protect cells. We hypothesize that HPC induces neuroprotection by reducing the expression of putatively damaging proteins such as iNOS and/or by increasing the expression of putatively protective proteins such as HSPs. Cerebellar slices were prepared from adult male Sprague-Dawley rats and incubated in circulating artificial cerebrospinal fluid. OGD was for 20 min at 37 degrees C and was followed by a 5-h recovery at 37 degrees C before slices were used for morphological, immunohistochemical and Western analyses. HPC was performed by incubating slices at 33 degrees C for 20 min at 1 h before the OGD. HPC and aminoguanidine, an MOS inhibitor, prevented OGD-induced Purkinje cell death/injury. OGD increased the expression of MOS and nitrosylated proteins. These increases were abolished by aminoguanidine and HPC. Interestingly, the expression of HSP70 was increased by OGD but not by HPC. Our results suggest that an increased MOS expression contributes to the pathophysiology of OGD-induced Purkinje neuronal death in our model. Our results also suggest the involvement of inhibiting the expression of the putatively damaging iNOS proteins in the HPC-induced neuroprotection. HSP70 may not contribute to the HPC-induced neuroprotection. (c) 2006 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Virginia Hlth Syst, Dept Anesthesiol, Charlottesville, VA 22908 USA; Natl Yang Ming Univ, Dept Anesthesiol, Vet Gen Hosp, Taipei 112, Taiwan	Zuo, Z (corresponding author), Univ Virginia Hlth Syst, Dept Anesthesiol, 1 Hosp Dr,POB 800710, Charlottesville, VA 22908 USA.	zz3c@virginia.edu	Zuo, Zhiyi/F-3950-2010	Zuo, Zhiyi/0000-0002-3542-5047	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM065211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045983] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM065211] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS045983] Funding Source: Medline		ALTMAN J, 1972, J COMP NEUROL, V145, P399, DOI 10.1002/cne.901450402; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; BAK IJ, 1980, BRAIN RES, V197, P341, DOI 10.1016/0006-8993(80)91120-8; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BERNTMAN L, 1981, ANESTHESIOLOGY, V55, P495, DOI 10.1097/00000542-198111000-00003; Bickler PE, 2005, ANESTHESIOLOGY, V103, P532, DOI 10.1097/00000542-200509000-00016; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Chang CP, 2004, J PHARMACOL SCI, V95, P56, DOI 10.1254/jphs.95.56; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2002, J NEUROTRAUM, V19, P639, DOI 10.1089/089771502753754109; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; Danielisova V, 2004, PHYSIOL RES, V53, P533; deVera ME, 1995, BIOCHEM SOC T, V23, P1008, DOI 10.1042/bst0231008; Du C, 1996, J CEREBR BLOOD F MET, V16, P195, DOI 10.1097/00004647-199603000-00003; Dybdahl B, 2002, CIRCULATION, V105, P685, DOI 10.1161/hc0602.103617; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Gidday JM, 1999, J CEREBR BLOOD F MET, V19, P331, DOI 10.1097/00004647-199903000-00011; Giffard RG, 2004, J NEUROSURG ANESTH, V16, P53, DOI 10.1097/00008506-200401000-00010; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; Holtz ML, 2001, BRAIN RES, V898, P49, DOI 10.1016/S0006-8993(01)02140-0; Irazuzta JE, 1999, BRAIN RES, V847, P143, DOI 10.1016/S0006-8993(99)02120-4; Jiang XH, 2005, SURF REV LETT, V12, P59, DOI 10.1142/S0218625X05006792; KARIBE H, 1994, BRAIN RES, V649, P12, DOI 10.1016/0006-8993(94)91043-X; Kawakami S, 2000, BRAIN RES, V858, P198, DOI 10.1016/S0006-8993(00)01980-6; KELLY S, 2002, CURR MED RES OPIN, V18, P55; Ko HK, 2001, BRAIN RES, V894, P297, DOI 10.1016/S0006-8993(00)03188-7; Li J, 2002, BRAIN RES, V958, P399, DOI 10.1016/S0006-8993(02)03700-9; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; Lipton P, 1999, PHYSIOL REV, V79, P1431; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; Mancuso A, 2000, BRAIN RES, V887, P34, DOI 10.1016/S0006-8993(00)02963-2; Marion DW, 1996, CRIT CARE MED, V24, pS81; Masada T, 2002, ACT NEUR S, V81, P265; MONCADA S, 1991, PHARMACOL REV, V43, P109; Moro MA, 1998, EUR J NEUROSCI, V10, P445, DOI 10.1046/j.1460-9568.1998.00028.x; Moseley PL, 1998, ANN NY ACAD SCI, V856, P206, DOI 10.1111/j.1749-6632.1998.tb08327.x; Nishio S, 2000, J NEUROSURG, V93, P845, DOI 10.3171/jns.2000.93.5.0845; Niwa K, 1999, NEUROSCI LETT, V271, P109, DOI 10.1016/S0304-3940(99)00534-0; NOBACK CR, 1991, HUMAN NERVOUS SYSTEM, P281; Olsson T, 2004, EXP BRAIN RES, V154, P442, DOI 10.1007/s00221-003-1683-2; PerezPinzon MA, 1997, J CEREBR BLOOD F MET, V17, P175, DOI 10.1097/00004647-199702000-00007; Perrella MA, 1999, J BIOL CHEM, V274, P9045, DOI 10.1074/jbc.274.13.9045; Popovic R, 2000, ANESTHESIOLOGY, V92, P1343, DOI 10.1097/00000542-200005000-00024; Rodrigo J, 2001, BRAIN RES, V909, P20, DOI 10.1016/S0006-8993(01)02613-0; Ruetten H, 1996, BIOCHEM BIOPH RES CO, V225, P525, DOI 10.1006/bbrc.1996.1206; Shirhan M, 2004, LIFE SCI, V76, P661, DOI 10.1016/j.lfs.2004.07.015; Sreedhar AS, 2004, FEBS LETT, V562, P11; Sugimoto K, 2002, NEUROSCI LETT, V331, P25, DOI 10.1016/S0304-3940(02)00834-0; THARION J, 1982, J THORAC CARDIOV SUR, V84, P66; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; WOLFF DJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P290, DOI 10.1006/abbi.1995.1040; Yenari MA, 2002, ADV EXP MED BIOL, V513, P281; Yuan HB, 2004, ANESTHESIOLOGY, V100, P331, DOI 10.1097/00000542-200402000-00023; Zheng S, 2003, NEUROSCIENCE, V118, P99, DOI 10.1016/S0306-4522(02)00767-4; Zuo ZY, 1997, MOL PHARMACOL, V52, P606	59	15	22	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	OCT 13	2006	142	2					381	389		10.1016/j.neuroscience.2006.06.053			9	Neurosciences	Neurosciences & Neurology	098NT	WOS:000241530300007	16890370				2021-06-18	
J	Coles, JP				Coles, Jonathan P.			Imaging of cerebral blood flow and metabolism	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						cerebral blood flow; cerebral metabolism; imaging; ischaemia; perfusion	TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; DIFFUSE AXONAL INJURY; ACUTE ISCHEMIC-STROKE; PERFUSION COMPUTED-TOMOGRAPHY; POSITRON-EMISSION-TOMOGRAPHY; PROTON MR SPECTROSCOPY; CT PERFUSION; HEAD-INJURY; XENON CT	Purpose of review To review the techniques for imaging cerebral blood flow and metabolism following injury to the brain. Recent findings Xenon enhanced computerized tomography (Xenon CT), CT perfusion and single photon emission CT provide measurements of cerebral perfusion, while positron emission tomography (PET), and magnetic resonance imaging and spectroscopy (MRI and MRS) are able to assess both perfusion and cerebral metabolism. Xenon CT and CT perfusion are readily available and have proved useful in a variety of causes of brain injury. PET is an extremely useful research tool for defining cerebral physiology, but is limited in its availability. Despite the continuing development of MRI and MRS imaging, the scanning environment remains hostile for critically ill patients, and further research is required before the techniques become generally available. Summary Imaging of cerebral blood flow and metabolism has been shown to be useful following a variety of causes of brain injury, as it can help to define the cause and extent of injury, identify appropriate treatments and predict outcome. Imaging based on CT techniques (Xenon CT and CT perfusion) can be implemented easily in most hospital centres, and are able to provide quantitative perfusion data in addition to structural images.	[Coles, Jonathan P.] Addenbrookes Hosp, Univ Dept Anaesthesia, Box 93,Hills Rd, Cambridge CB2 2QQ, England	Coles, JP (corresponding author), Addenbrookes Hosp, Univ Dept Anaesthesia, Box 93,Hills Rd, Cambridge CB2 2QQ, England.	jpc44@wbic.cam.ac.uk			Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission; Technology Foresight Award from the UK Government; Royal College of Anaesthetists/British Journal of Anaesthesia project grant; Academy of Medical Sciences/Health Foundation; Addenbrooke's Charities; Wellcome Foundation; Beverley and Raymond Sackler studentship award	The studies published by this author were supported by the Medical Research Council, a Technology Foresight Award from the UK Government and by a Royal College of Anaesthetists/British Journal of Anaesthesia project grant. Dr Coles is currently a Clinician Scientist funded by the Academy of Medical Sciences/Health Foundation and has previously been funded by Research Training Fellowships from the Addenbrooke's Charities, the Wellcome Foundation and by a Beverley and Raymond Sackler studentship award.	Al-Rawi PG, 2005, ACTA NEUROCHIR SUPPL, V95, P123; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/neu.2004.21.1539; Association of Anaesthetists of Great Britain and Ireland, 2002, PROV AN SERV MAGN RE; Bandera E, 2006, STROKE, V37, P1334, DOI 10.1161/01.STR.0000217418.29609.22; Barber PA, 2005, J NEUROL NEUROSUR PS, V76, P1528, DOI 10.1136/jnnp.2004.059261; Barker PB, 2004, CLINICAL MR NEUROIMAGING: DIFFUSION, PERFUSION AND SPECTROSCOPY, P7, DOI 10.1017/CBO9780511544958.003; Baron JC, 2005, CEREBROVASC DIS, V20, P154, DOI 10.1159/000087199; BARON JC, 1989, J CEREBR BLOOD F MET, V9, P723, DOI 10.1038/jcbfm.1989.105; Baumgartner C, 2005, J DIGIT IMAGING, V18, P219, DOI 10.1007/s10278-004-1048-9; Belli A, 2006, J NEUROCHEM, V96, P861, DOI 10.1111/j.1471-4159.2005.03602.x; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; BUSZA AL, 1992, STROKE, V23, P1602, DOI 10.1161/01.STR.23.11.1602; Butcher KS, 2005, STROKE, V36, P1153, DOI 10.1161/01.STR.0000166181.86928.8b; Calamante F, 1999, J CEREBR BLOOD F MET, V19, P701, DOI 10.1097/00004647-199907000-00001; Chalela JA, 2005, NEUROLOGY, V64, P1979, DOI 10.1212/01.WNL.0000156360.70336.18; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; Davis SM, 2005, CURR OPIN NEUROL, V18, P47, DOI 10.1097/00019052-200502000-00010; Derdeyn CP, 2005, NEUROIMAG CLIN N AM, V15, P341, DOI 10.1016/j.nic.2005.05.001; DRAYER BP, 1978, STROKE, V9, P123, DOI 10.1161/01.STR.9.2.123; Eskey CJ, 2005, NEUROIMAG CLIN N AM, V15, P367, DOI 10.1016/j.nic.2005.05.002; ESKEY CJ, 2005, NEUROIMAG CLIN N AM, V15, pR11; Ewing JR, 2005, J MAGN RESON IMAGING, V22, P737, DOI 10.1002/jmri.20451; FISHER M, 1995, JAMA-J AM MED ASSOC, V274, P908; Garnett MR, 2001, CURR OPIN NEUROL, V14, P753, DOI 10.1097/00019052-200112000-00012; Gillard JH, 2000, NEUROL RES, V22, P457; Gomori JM, 2005, NEUROL RES, V27, pS50, DOI 10.1179/016164105X35558; Guadagno JV, 2005, CEREBROVASC DIS, V19, P239, DOI 10.1159/000084087; Gupta R, 2005, NEUROIMAG CLIN N AM, V15, P531, DOI 10.1016/j.nic.2005.08.007; Harrigan MR, 2005, NEUROCRIT CARE, V2, P352, DOI 10.1385/NCC:2:3:352; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Hendrikse J, 2005, NEUROSURGERY, V57, P486, DOI 10.1227/01.NEU.0000170563.70822.10; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Hunter JV, 2005, AM J NEURORADIOL, V26, P482; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Inoue Y, 2005, J NEUROTRAUM, V22, P1411, DOI 10.1089/neu.2005.22.1411; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Jost SC, 2005, J NEUROSURG, V103, P25, DOI 10.3171/jns.2005.103.1.0025; Karapanayiotides T, 2005, STROKE, V36, P21, DOI 10.1161/01.STR.0000149946.86087.e5; KETY SS, 1945, AM J PHYSIOL, V143, P53; Kimura H, 2005, J MAGN RESON IMAGING, V22, P189, DOI 10.1002/jmri.20382; Kinoshita T, 2005, EUR J RADIOL, V56, P5, DOI 10.1016/j.ejrad.2005.04.001; Koenig M, 1998, RADIOLOGY, V209, P85, DOI 10.1148/radiology.209.1.9769817; Kucinski T, 2005, AM J NEURORADIOL, V26, P815; Latchaw RE, 2003, STROKE, V34, P1084, DOI 10.1161/01.STR.0000064840.99271.9E; Liu YJ, 2003, RADIOLOGY, V229, P366, DOI 10.1148/radiol.2292020639; MARION DW, 1991, J CEREBR BLOOD F MET, V11, P347, DOI 10.1038/jcbfm.1991.69; Marmarou A, 2005, ACT NEUR S, V95, P149; MEIER P, 1954, J APPL PHYSIOL, V6, P731; Miles KA, 2004, NEURORADIOLOGY, V46, pS194, DOI 10.1007/s00234-004-1333-9; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; Munari M, 2005, CRIT CARE MED, V33, P2068, DOI 10.1097/01.CCM.0000179143.19233.6A; Nabavi DG, 1999, RADIOLOGY, V213, P141, DOI 10.1148/radiology.213.1.r99oc03141; O'Connell MT, 2005, ACTA NEUROCHIR SUPPL, V95, P165; Ohashi M, 2005, J NEURORADIOLOGY, V32, P337, DOI 10.1016/S0150-9861(05)83165-7; Owen AM, 2005, NEUROPSYCHOL REHABIL, V15, P290, DOI 10.1080/09602010443000579; Parsons MW, 2000, NEUROLOGY, V55, P498, DOI 10.1212/WNL.55.4.498; Parsons MW, 2005, ANN NEUROL, V58, P672, DOI 10.1002/ana.20638; Pereira AC, 1999, STROKE, V30, P1577, DOI 10.1161/01.STR.30.8.1577; Perkio J, 2005, STROKE, V36, P44, DOI 10.1161/01.STR.0000150495.96471.95; Pickard JD, 2005, ACT NEUR S, V95, P459; Rivers CS, 2006, STROKE, V37, P98, DOI 10.1161/01.STR.0000195197.66606.bb; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Saunders DE, 2000, BRIT MED BULL, V56, P334, DOI 10.1258/0007142001903256; Schaefer PW, 2006, AM J NEURORADIOL, V27, P20; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Scharf J, 2006, J COMPUT ASSIST TOMO, V30, P105, DOI 10.1097/01.rct.0000187417.15321.ca; Schellinger PD, 2006, NEURORADIOLOGY, V48, P69, DOI 10.1007/s00234-005-0012-9; Seitz RJ, 2005, RADIOLOGY, V237, P1020, DOI 10.1148/radiol.2373041435; Seitz RJ, 2005, J MAGN RESON IMAGING, V22, P199, DOI 10.1002/jmri.20366; Shimosegawa E, 2005, ANN NEUROL, V57, P495, DOI 10.1002/ana.20427; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Silverman DHS, 2005, RADIOL CLIN N AM, V43, P67, DOI 10.1016/j.rcl.2004.09.012; Sobesky J, 2005, STROKE, V36, P980, DOI 10.1161/01.STR.0000160751.79241.a3; Stengel A, 2004, MAGN RESON MED, V52, P228, DOI 10.1002/mrm.20171; Ueda T, 2005, NEUROIMAG CLIN N AM, V15, P543, DOI 10.1016/j.nic.2005.07.003; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; von Oettingen G, 2000, NEURORADIOLOGY, V42, P168, DOI 10.1007/s002340050039; WELCH KMA, 1992, NEUROL CLIN, V10, P1; Wintermark M, 2006, AM J NEURORADIOL, V27, P26; Wintermark M, 2005, AM J NEURORADIOL, V26, P104; Wintermark M, 2001, AM J NEURORADIOL, V22, P905; Yamauchi H, 2005, J NUCL MED, V46, P1973; ZIERLER KL, 1962, CIRC RES, V10, P393, DOI 10.1161/01.RES.10.3.393	83	15	17	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	OCT	2006	19	5					473	480		10.1097/01.aco.0000245270.90377.00			8	Anesthesiology	Anesthesiology	V42RZ	WOS:000209632200001	16960477				2021-06-18	
J	Schopp, LH; Good, GE; Barker, KB; Mazurek, MO; Hathaway, SL				Schopp, Laura H.; Good, Glenn E.; Barker, Katharine B.; Mazurek, Micah O.; Hathaway, Stefani L.			Masculine role adherence and outcomes among men with traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; men; masculinity; rehabilitation outcome	REHABILITATION; PERSPECTIVE; RETURN; WORK	Primary objective: Traumatic brain injury ( TBI) is a significant health problem disproportionately affecting men and is often associated with changes in masculine role functioning in life domains such as vocational functioning, sexual and interpersonal functioning and personal independence. These changes could have serious implications for men's adjustment following injury. The aim of this study was to examine the relations among traditional masculine role adherence, psychosocial adjustment and rehabilitation outcomes in men with TBI. Research design: A correlational design was chosen to examine the relations among variables. Spearman correlations and Wilcoxon Rank Sum tests were used to examine relationships between masculine role variables and outcome variables. Methods and procedures: The study included 33 men with TBI who had been discharged from inpatient rehabilitation within 5 years. Participants completed surveys on traditional masculine gender role adherence and gender role conflict and additional data, including measures of functional outcome, life satisfaction, psychosocial outcomes and earnings, were obtained through the TBI Model System longitudinal data collection system. Main outcomes and results: The results revealed significant associations between masculine role adherence and satisfaction with life, follow- up earnings and FIM change from admission to discharge. Conclusions: In the current study, particular masculine role variables corresponded to different functional and psychological outcomes. Understanding these differences provides new directions for treatment and offers important information about aspects of traditional masculine roles that may enhance or hinder adjustment to injury.	Univ Missouri, Dept Hlth Psychol, Columbia, MO 65212 USA; Univ Missouri, Dept Educ Sch & Conseling Psychol, Columbia, MO 65212 USA	Schopp, LH (corresponding author), Univ Missouri, Dept Hlth Psychol, 1 Hosp Dr,DC046-46, Columbia, MO 65212 USA.	schoppl@health.missouri.edu	Mazurek, Micah/AAR-6192-2020; Mazurek, Micah/ABE-8748-2020	Mazurek, Micah/0000-0001-7715-6538; 			Aloni R, 1999, BRAIN INJURY, V13, P269, DOI 10.1080/026990599121647; Bounds TA, 2003, NEUROREHABILITATION, V18, P189; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Crowe SF, 1999, BRAIN INJURY, V13, P347; Curtiss G, 2000, J HEAD TRAUMA REHAB, V15, P1113, DOI 10.1097/00001199-200010000-00005; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Dumont C, 2004, J HEAD TRAUMA REHAB, V19, P431, DOI 10.1097/00001199-200411000-00002; Eisler RM., 1995, NEW PSYCHOL MEN, P207; ELOVIC E, 1996, MED REHABILITATION T, P1; Garden F. H., 1990, J HEAD TRAUMA REHAB, V5, P52, DOI DOI 10.1097/00001199-199005020-00009; Gaudet L, 2001, SEX DISABIL, V19, P111, DOI 10.1023/A:1010673722429; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; GOOD GE, 1995, J COUNS PSYCHOL, V42, P3, DOI 10.1037/0022-0167.42.1.3; GOOD GE, 2001, NEW HDB PSYCHOTHERAP, V2, P22; Gosling J, 1999, BRAIN INJURY, V13, P785; Hibbard MR, 2000, NEUROREHABILITATION, V15, P109; Howes H, 2005, BRAIN INJURY, V19, P135, DOI 10.1080/02699050410001720077; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kraus Jess F., 1994, P3; KRAVETZ S, 2001, REHABIL PSYCHOL, V10, P437; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lueptow LB, 2001, SOC FORCES, V80, P1, DOI 10.1353/sof.2001.0077; Mahalik JR, 1999, PROF PSYCHOL-RES PR, V30, P333; MAHALIK JR, 2003, PSYCHOL MEN MASCULIN, V4, P3, DOI DOI 10.1037/1524-9220.4.1.3; Marongiu S, 2000, SCAND J PSYCHOL, V41, P175, DOI 10.1111/1467-9450.00185; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; ONEIL JM, 1990, MEN CONFLICT PROBLEM, P23; ONEIL JM, 1995, J COUNS PSYCHOL, V42, P3; PLECK CG, 1974, MEN MASCULINITY; Pleck J. H., 1981, MYTH MASCULINITY; PRIDAL CG, 2001, NEW HDB PSYCHOTHERAP, V2, P309; Sandel ME, 1996, BRAIN INJURY, V10, P719, DOI 10.1080/026990596123981; SCHEIN VE, 1989, SEX ROLES, V20, P103, DOI 10.1007/BF00288030; *U NY BUFF CTR FUN, 1990, GUID US UN DAT SET M; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011; ZASLER ND, 1995, PHYS MED REHABIL STA, V9, P361	41	15	15	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2006	20	11					1155	1162		10.1080/02699050600983735			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	110DD	WOS:000242357600006	17123932				2021-06-18	
J	Mussack, T; Kirchhoff, C; Buhmann, S; Biberthaler, P; Ladurner, R; Gippner-Steppert, C; Mutschler, W; Jochum, M				Mussack, Thomas; Kirchhoff, Chlodwig; Buhmann, Sonja; Biberthaler, Peter; Ladurner, Roland; Gippner-Steppert, Cornelia; Mutschler, Wolf; Jochum, Marianne			Significance of Elecsys (R) S100 immunoassay for real-time assessment of traumatic brain damage in multiple trauma patients	CLINICAL CHEMISTRY AND LABORATORY MEDICINE			English	Article						multiple trauma; primary brain damage; receiver-operating characteristics; S100; traumatic brain injury	SEVERE HEAD-INJURY; CALCIUM-BINDING PROTEINS; SERUM S-100B PROTEIN; CARDIOPULMONARY-RESUSCITATION; CARDIAC-SURGERY; CEREBRAL INJURY; MARKER; MULTICENTER; TOMOGRAPHY; S100-BETA	Background: The neuroprotein S100 released into the circulation has been suggested as a reliable marker for primary brain damage. However, safe identification of relevant traumatic brain injury (TBI) may possibly be hampered by S100 release from peripheral tissue. The objective of this study was to measure early S100 levels using the Elecsys((R)) S100 immunoassay for real-time assessment of severe TBI in multiple trauma. Methods: Consecutively admitted multiple trauma patients (injury severity score >= 16 points) were stratified according to the results of the initial cerebral computed tomography (CCT) examination. S100 serum levels were determined at admission and at 6, 12, 24, 48 and 72 h after trauma. Data were correlated to creatine phosphokinase (CK) and lactate dehydrogenase (LDH) serum levels. Using receiver operating characteristic (ROC) analysis, the discriminating power of S100 measurement was calculated for the detection of CCT+ findings. Results: Median S100 levels of CCT+ patients (n=9; 37 years) decreased from 3.30 mu g/L at admission to 0.41 mu g/L 72 h after trauma. They revealed no significant differences to CCT- patients (n=18; 44 years), but remained elevated compared to controls. Median CK and LDH levels correlated with the corresponding S100 levels during the first 24 h after trauma. ROC analysis displayed a maximum area under the curve of only 0.653 at 12 h after trauma. No significant difference was calculated for the differentiation between CCT+ and CCT- patients. Conclusions: Measurements of S100 serum levels using the Elecsys((R)) S100 immunoassay are not reliable for the real-time detection of severe TBI in multiple trauma patients. Due to soft tissue trauma or bone fractures, S100 is mainly released from peripheral sources such as adipocytes or skeletal muscle cells.	Klinikum Univ Munchen, Dept Surg Innestadt, D-80336 Munich, Germany; Klinikum Univ Munchen, Inst Clin Radiol, D-80336 Munich, Germany; Klinikum Univ Munchen, Dept Clin Chem & Clin Biochem Innenstadt, D-80336 Munich, Germany	Mussack, T (corresponding author), Klinikum Univ Munchen, Dept Surg Innestadt, Nussbaumstr 20, D-80336 Munich, Germany.	thomas.mussack@med.uni-muenchen.de					Alber B, 2005, CLIN CHEM LAB MED, V43, P557, DOI 10.1515/CCLM.2005.097; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2004, UNFALLCHIRURG, V107, P197, DOI 10.1007/s00113-004-0730-1; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; HAIMOTO H, 1987, LAB INVEST, V57, P489; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; KAHN HJ, 1991, MODERN PATHOL, V4, P698; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mussack T, 2006, CLIN BIOCHEM, V39, P349, DOI 10.1016/j.clinbiochem.2005.12.007; Mussack T, 2003, EUR J MED RES, V8, P457; Mussack T, 2001, WORLD J SURG, V25, P539, DOI 10.1007/s002680020082; Mussack T, 2001, RESUSCITATION, V49, P193, DOI 10.1016/S0300-9572(00)00346-4; Nast-Kolb D, 2001, J TRAUMA, V51, P835, DOI 10.1097/00005373-200111000-00003; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Pelinka LE, 2003, SHOCK, V19, P422, DOI 10.1097/01.shk.0000055345.58165.52; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Snyder-Ramos SA, 2004, ANAESTHESIA, V59, P344, DOI 10.1111/j.1365-2044.2004.03663.x; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; USUI A, 1989, CLIN CHEM, V35, P1942; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	39	15	16	0	2	WALTER DE GRUYTER & CO	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1434-6621			CLIN CHEM LAB MED	Clin. Chem. Lab. Med.	SEP	2006	44	9					1140	1145		10.1515/CCLM.2006.190			6	Medical Laboratory Technology	Medical Laboratory Technology	093TT	WOS:000241193800019	16958611				2021-06-18	
J	Piatt, JH				Piatt, Joseph H., Jr.			Detected and overlooked cervical spine injury in comatose victims of trauma: report from the Pennsylvania Trauma Outcomes Study	JOURNAL OF NEUROSURGERY-SPINE			English	Article						spinal cord injury; traumatic brain injury; coma	GUNSHOT WOUNDS; HEAD-INJURIES; PATIENT; CLEARANCE; RISK	Object. This study was undertaken to determine whether a clinically useful rule could be formulated for identifying the presence of traumatic brain injury (TBI) in patients who are at exceptionally low risk of cervical spine injury. Methods. The Pennsylvania Trauma Outcomes Study database was searched for cases of TBI in which the admission Glasgow Coma Scale (GCS) score was less than or equal to 8. Cases of cervical injury were identified based on diagnostic codes. Associations between cervical injury and various clinical variables were tested using chi-square analysis. The probability of cervical injury was modeled using logistic regression. Decision tree models were constructed. Statistical determinants of overlooked cervical injury were examined. The prevalence of cervical injury among 41,142 cases of TBI was 8%. Mechanism of injury, thoracolumbosacral (TLS) fracture, age, limb fracture, admission GCS score, hypotension, and facial fracture were associated with cervical injury and were incorporated into the following logistic regression model: probability = 1/(1 + exp[4.248 - 0.417 X mechanism -0.264 X age - 0.678 X TLS - 0.299 X limb - 0.218 X GCS - 0.231 X hypotension - 0.157 X facial]). The results of applying this model provided a rule for cervical spine clearance applicable to 28% of the cases with a negative predictive value (NPV) of 97.0%. Decision tree analysis yielded a rule applicable to 24% of the cases with an NPV of 98.2%. The prevalence of overlooked cervical injury in all individuals with severe TBI was 0.3%; the prevalence of overlooked cervical injury in patients with cervical injury was 3.9%. Overlooked cervical injury was less common in patients with associated TLS fractures (odds ratio 0.453, 95% confidence interval 0.245-0.837). Conclusions. This analysis identified no acceptable rule to justify relaxing vigilance in the search for cervical injury in patients with severe TBI. Provider vigilance and consequent rates of overlooked cervical injury can be affected by environmental cues and presumably by other behavioral and organizational factors.	St Christophers Hosp Children, Neurosurg Sect, Philadelphia, PA 19134 USA; Drexel Univ, Coll Med, Dept Pediat, Philadelphia, PA 19104 USA	Piatt, JH (corresponding author), St Christophers Hosp Children, Neurosurg Sect, Erie Ave Front St, Philadelphia, PA 19134 USA.	joseph.piatt@tenethealth.com		Piatt, Joseph/0000-0002-9332-8376			Avellino AM, 2005, CHILD NERV SYST, V21, P122, DOI 10.1007/s00381-004-1058-4; BAYLESS P, 1989, AM J EMERG MED, V7, P139, DOI 10.1016/0735-6757(89)90125-3; Blackmore CC, 1999, RADIOLOGY, V212, P117, DOI 10.1148/radiology.212.1.r99jl08117; Brohi K, 2005, J TRAUMA, V58, P897, DOI 10.1097/01.ta.0000171984.25699.35; Brooks RA, 2001, J TRAUMA, V50, P862; Chiu WC, 2001, J TRAUMA, V50, P457, DOI 10.1097/00005373-200103000-00009; D'Alise MD, 1999, J NEUROSURG, V91, P54, DOI 10.3171/spi.1999.91.1.0054; HILLS MW, 1993, J TRAUMA, V34, P549, DOI 10.1097/00005373-199304000-00011; Holly LT, 2002, J NEUROSURG, V96, P285, DOI 10.3171/spi.2002.96.3.0285; Kaups KL, 1998, J TRAUMA, V44, P865, DOI 10.1097/00005373-199805000-00020; KENNEDY FR, 1994, SOUTHERN MED J, V87, P621, DOI 10.1097/00007611-199406000-00008; LAHAM JL, 1994, PEDIATR NEUROSURG, V21, P221, DOI 10.1159/000120839; Lanoix R, 2000, J TRAUMA, V49, P860, DOI 10.1097/00005373-200011000-00011; MICHAEL D B, 1989, Journal of Neurotrauma, V6, P177; OMALLEY KF, 1988, J TRAUMA, V28, P1476, DOI 10.1097/00005373-198810000-00013; ROSS SE, 1992, INJURY, V23, P317, DOI 10.1016/0020-1383(92)90178-U; Schenarts PJ, 2001, J TRAUMA, V51, P663, DOI 10.1097/00005373-200110000-00007; SOICHER E, 1991, BRIT J SURG, V78, P1013, DOI 10.1002/bjs.1800780837; Widder S, 2004, J TRAUMA, V56, P1179, DOI 10.1097/01.TA.0000130758.71098.78	19	15	16	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	SEP	2006	5	3					210	216		10.3171/spi.2006.5.3.210			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	076CH	WOS:000239934100004	16961081				2021-06-18	
J	Prough, DS; Kramer, GC; Uchida, T; Stephenson, RT; Hellmich, HL; DeWitt, DS				Prough, Donald S.; Kramer, George C.; Uchida, Tatsuo; Stephenson, Rachael T.; Hellmich, Helen L.; DeWitt, Douglas S.			Effects of hypertonic arginine on cerebral blood flow and intracranial pressure after traumatic brain injury combined with hemorrhagic hypotension	SHOCK			English	Article						cerebral blood flow; hemorrhagic hypotension; hypertonic arginine; intracranial pressure; rats; traumatic brain injury	NITRIC-OXIDE SYNTHASE; LACTATED RINGERS SOLUTION; FLUID-PERCUSSION INJURY; CORTICAL IMPACT INJURY; SEVERE HEAD-INJURY; CEREBROVASCULAR REACTIVITY; SALINE RESUSCITATION; SUPEROXIDE-DISMUTASE; CONTROLLED-TRIAL; OXYGEN DELIVERY	Hypertonic saline solutions improve cerebral blood flow (CBF) when used for acute resuscitation from hemorrhagic hypotension accompanying some models of traumatic brain injury (TBI); however, the duration of increased CBF is brief. Because the nitric oxide synthase substrate L-arginine provides prolonged improvement in CBF after TBI, we investigated whether a hypertonic resuscitation fluid containing L-arginine would improve CBF in comparison to hypertonic saline without L-arginine in a model of moderate, paramedian, fluid-percussion TBI followed immediately by hemorrhagic hypotension (mean arterial pressure [MAP] = 60 mm Hg for 45 min). Sprague-Dawley rats were anesthetized with 4.0% isoflurane, intubated and ventilated with 1.5%-2.0% isoflurane in oxygen/air (50:50). After preparation for TBI and measurement of CBF using laser Doppler flowmetry and measurement of intracranial pressure (ICP) using an implanted transducer, rats were subjected to moderate (2.0 atm) TBI, hemorrhaged for 45 min, and randomly assigned to receive an infusion of hypertonic saline (7.5%, 2,400 mOsm total; 6 mL/kg; n = 6) or hypertonic saline with 50, 100, or 300 mg/kg L-arginine (2,400 mOsm; 6 mL/kg; n = 6 in each of the three dose groups) and then monitored for 120 min after the end of infusion. CBF was measured continuously and calculated as a percent of the pre-TBI baseline during the hemorrhage period, after reinfusion of one of the hypertonic arginine solutions, and 30, 60, and 120 min after reinfusion. All four hypertonic solutions initially improved MAP, which, by 120 min after infusion, had decreased nearly to the levels observed during hemorrhage. ICP remained below baseline levels during resuscitation in all groups, although ICP was slightly greater (P = NS) than baseline in the hypertonic saline group. CBF increased similarly in all groups during infusion and then decreased similarly in all groups. At 120 min after infusion, CBF was highest in the group infused with hypertonic saline, but the difference was not significant. We conclude that the improvement of MAP, ICP, and CBF produced by hypertonic saline alone after TBI and hemorrhagic hypotension is not significantly enhanced by the addition Of L-arginine at these doses.	Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX 77555 USA	Prough, DS (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, 301 Univ Blvd, Galveston, TX 77555 USA.	dsprough@utmb.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X			Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Beckman JS, 1996, ADV NEUROL, V71, P339; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BECKMAN JS, 1991, J CEREB BLOOD FLO S2, V11, pS629; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2003, J NEUROTRAUM, V20, P77, DOI 10.1089/08977150360517209; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; DEWITT D S, 1992, Anesthesiology (Hagerstown), V77, pA689, DOI 10.1097/00000542-199209001-00689; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; DeWitt DS, 2001, J CEREBR BLOOD F MET, V21, P253, DOI 10.1097/00004647-200103000-00009; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DeWitt DS, 1996, CRIT CARE MED, V24, P109, DOI 10.1097/00003246-199601000-00019; DEWITT DS, 1991, ANESTHESIOLOGY, V3, P211; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; *DOHSP COMM FLUID, 1999, STAT SCI TREAT COMB, V1; Elliott SJ, 1998, AM J PHYSIOL-HEART C, V275, pH1585; FABIAN RH, 1995, J CEREBR BLOOD F MET, V15, P242, DOI 10.1038/jcbfm.1995.30; FARACI FM, 1991, AM J PHYSIOL, V261, pH1038; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; HABERL RL, 1989, AM J PHYSIOL, V256, pH1247; HE Z, 1995, BRAIN RES, V699, P208, DOI 10.1016/0006-8993(95)00907-8; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; KONTOS HA, 1985, CIRC RES, V57, P142, DOI 10.1161/01.RES.57.1.142; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; Liu PK, 2002, ANN NY ACAD SCI, V962, P226, DOI 10.1111/j.1749-6632.2002.tb04071.x; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MORIKAWA E, 1992, BRIT J PHARMACOL, V107, P905, DOI 10.1111/j.1476-5381.1992.tb13382.x; MORIKAWA E, 1994, STROKE, V25, P429, DOI 10.1161/01.STR.25.2.429; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; PELLIGRINO DA, 1993, J NEUROSURG ANESTH, V5, P221; Prat R, 1997, NEUROL RES, V19, P393, DOI 10.1080/01616412.1997.11740832; Prough DS, 1999, J NEUROSURG ANESTH, V11, P102, DOI 10.1097/00008506-199904000-00006; PROUGH DS, 1991, ANESTH ANALG, V73, P736; PROUGH DS, 1985, CRIT CARE MED, V13, P1040, DOI 10.1097/00003246-198512000-00011; PROUGH DS, 1986, J NEUROSURG, V64, P627, DOI 10.3171/jns.1986.64.4.0627; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; Shackford SR, 1997, J TRAUMA, V42, pS48, DOI 10.1097/00005373-199705001-00009; SHACKFORD SR, 1994, J TRAUMA, V37, P899, DOI 10.1097/00005373-199412000-00005; SZABO C, 1994, CIRC SHOCK, V44, P104; SZABO C, 1992, CIRC SHOCK, V37, P307; TANAKA K, 1991, NEUROSCI LETT, V127, P129, DOI 10.1016/0304-3940(91)90911-C; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; VASSAR MJ, 1993, J TRAUMA, V34, P622, DOI 10.1097/00005373-199305000-00003; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WHITLEY JM, 1991, J NEUROSURG ANESTH, V3, P47, DOI 10.1097/00008506-199103000-00008; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	60	15	19	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	SEP	2006	26	3					290	295		10.1097/01.shk.0000225405.66693.49			6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	076HO	WOS:000239947800010	16912655				2021-06-18	
J	Rutner, D; Kapoor, N; Ciuffreda, KJ; Craig, S; Han, ME; Suchoff, IB				Rutner, Daniella; Kapoor, Neera; Ciuffreda, Kenneth J.; Craig, Shoshana; Han, M. E.; Suchoff, Irwin B.			Occurrence of ocular disease in traumatic brain injury in a selected sample: A retrospective analysis	BRAIN INJURY			English	Article						ocular disease; traumatic brain injury; cerebrovascular accident; relative risk		Primary objective: To determine retrospectively the relative risk of ocular disease in a selected, visually-symptomatic sample of clinic patients having traumatic brain injury (TBI; n = 160) vs. cerebrovascular accident (CVA; n = 60), with all initially presenting at the clinic with symptoms and/or signs of vision dysfunction. Methods and procedures: To review retrospectively 220 medical records of individuals with TBI (n = 160) vs. CVA (n = 60), as determined by a computer-based query spanning the years 2000-2003, to ascertain the frequency of occurrence of ocular disease in the two major sub-groups of acquired brain injury. Main outcomes and results: Conditions with high relative risk unique to TBI included corneal abrasion, blepharitis, chalazion/dhordeolum, dry eye, traumatic cataract, vitreal prolapse and optic atrophy. This is distinct from those ophthalmic conditions unique to CVA, which included sub-conjunctival haemorrhage and ptosis. Conclusion: These new findings should alert clinicians to the potential increased frequency of occurrence of specific ocular diseases in a selected, visually-symptomatic population with TBI and their associated rehabilitative and quality-of-life implications.	SUNY Coll Optometry, Dept Vis Sci, Raymond J Greenwald Rehabil Ctr, Dept Clin Sci, New York, NY 10036 USA	Ciuffreda, KJ (corresponding author), SUNY Coll Optometry, Dept Vis Sci, Raymond J Greenwald Rehabil Ctr, Dept Clin Sci, 33 W 42nd St, New York, NY 10036 USA.	kciuffreda@sunyopt.edu					Benjamin W. J., 1998, BORISHS CLIN REFRACT; Birnbaum MH., 1993, OPTOMETRIC MANAGEMEN; Brewitt H, 2001, SURV OPHTHALMOL, V45, pS199, DOI 10.1016/S0039-6257(00)00202-2; GANLEY JP, 1983, VITAL HLTH STAT, V228, P1; GIANUTSOS R, 1988, ARCH PHYS MED REHAB, V69, P573; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; HAN ME, 2003, J OPTOMETRIC VISUAL, V34, P119; HATCH SW, 1998, OPHTHALMIC RES EPIDE; Hellerstein L F, 1995, J Am Optom Assoc, V66, P634; HELLERSTEIN LF, 2002, UNDERSTANDING MANAGI, P178; JACKOWSKI MM, 2004, ANN M AM AC OPT PART; KAPOOR N, 2005, TXB TRAUMATIC BRAIN, P405; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; KRAUS JF, 2005, TXB TRAUMATIC BRAIN, P3; Miller NR., 1998, WALSH HOYTS CLIN NEU, V5; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; REDING MJ, 1988, STROKE, V19, P1354, DOI 10.1161/01.STR.19.11.1354; Richter E. F., 2001, VISUAL VESTIBULAR CO, P10; Scheiman M, 2002, CLIN MANAGEMENT BINO; Seiller BL, 2000, PHYS MED REHABILITAT, P342; SUCHOFF I, 2000, PHYS MED REHABILITAT, P608; Suchoff I., 2001, Visual Vestibular Conseq Acq Brain Inj, P1; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; SUCHOFF IB, 2000, LIGHTHOUSE HDB VISIO, V1, P517; Suter P. S., 2004, TRAUMATIC BRAIN INJU, P209; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TORNER JC, 1995, HEAD INJURY POSTCONC, P19; Vogel M S, 1992, J Am Optom Assoc, V63, P542; Zost MG, 2001, DIAGNOSIS MANAGEMENT, P75	29	15	15	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2006	20	10					1079	1086		10.1080/02699050600909904			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	093FA	WOS:000241152100010	17060141				2021-06-18	
J	Sundstrom, T; Guez, M; Hildingsson, C; Toolanen, G; Nyberg, L; Riklund, K				Sundstrom, Torbjorn; Guez, Michel; Hildingsson, Christer; Toolanen, Goran; Nyberg, Lars; Riklund, Katrine			Altered cerebral blood flow in chronic neck pain patients but not in whiplash patients: a Tc-99m-HMPAO rCBF study	EUROPEAN SPINE JOURNAL			English	Article						whiplash; chronic neck pain; Tc-99m-HMPAO rCBF-SPECT; brain imaging; regional cerebral blood flow	POSITRON-EMISSION-TOMOGRAPHY; COMPUTED-TOMOGRAPHY; THALAMIC-STIMULATION; GENDER-DIFFERENCES; NEURAL ACTIVITY; RISK-FACTORS; BRAIN; INJURY; ACTIVATION; RESPONSES	A cross-sectional study to investigate regional cerebral blood flow (rCBF) in patients with chronic whiplash syndrome and chronic neck pain patients without previous history of trauma along with a healthy control group. Chronic neck pain is a common disorder and a history of cervical spine injury including whiplash trauma constitute a risk factor for persistent neck pain. The aetiology of the late whiplash syndrome is unknown with no specific diagnostic criteria based on imaging, physiological, or psychological examination. Earlier studies indicate a parieto-occipital hypoperfusion but it is unclear if the hypoperfusion represents a response to chronic pain. The rCBF was monitored in 45 patients with chronic neck pain: 27 cases with chronic whiplash syndrome and 18 age and gender matched cases with non-traumatic chronic neck pain. The rCBF was estimated with single-photon emission computed tomography (SPECT) using technetium-99m hexamethylpropylene amine oxime (HMPAO). The non-traumatic patients displayed rCBF changes in comparison with the whiplash group and the healthy control group. These changes included rCBF decreases in a right temporal region close to hippocampus, and increased rCBF in left insula. The whiplash group displayed no significant differences in rCBF in comparison with the healthy controls. The present study suggests different pain mechanisms in patients with chronic neck pain of non-traumatic origin compared to those with chronic neck pain due to a whiplash trauma.	Umea Univ, Norrlands Univ Hosp, Dept Radiat Sci, S-90185 Umea, Sweden; Umea Univ, Norrlands Univ Hosp, Dept Surg & Perioperat Sci, S-90185 Umea, Sweden; Umea Univ, Dept Psychol, S-90185 Umea, Sweden	Sundstrom, T (corresponding author), Umea Univ, Norrlands Univ Hosp, Dept Radiat Sci, S-90185 Umea, Sweden.	torbjorn.sundstrom@diagrad.umu.se	Nyberg, Lars/M-5986-2019; Nyberg, Lars/C-2514-2009; Sundstrom, Torbjorn/X-5745-2019	Nyberg, Lars/0000-0002-3367-1746; Nyberg, Lars/0000-0002-3367-1746; Sundstrom, Torbjorn/0000-0002-9071-8993; Riklund, Katrine/0000-0001-5227-8117			ANDERSSON HI, 1993, CLIN J PAIN, V9, P174, DOI 10.1097/00002508-199309000-00004; Banic B, 2004, PAIN, V107, P7, DOI 10.1016/j.pain.2003.05.001; BARNSLEY L, 1994, PAIN, V58, P283, DOI 10.1016/0304-3959(94)90123-6; CHANG LT, 1978, IEEE T NUCL SCI, V25, P638, DOI 10.1109/TNS.1978.4329385; CLONINGER CR, 1986, PSYCHIAT DEV, V4, P167; Cote P, 1998, SPINE, V23, P1689, DOI 10.1097/00007632-199808010-00015; Cote P, 2000, SPINE, V25, P1109; Croft PR, 2001, PAIN, V93, P317, DOI 10.1016/S0304-3959(01)00334-7; Curatolo M, 2001, CLIN J PAIN, V17, P306, DOI 10.1097/00002508-200112000-00004; Davis KD, 2000, J NEUROSURG, V92, P64, DOI 10.3171/jns.2000.92.1.0064; Derbyshire SWG, 2002, J PAIN, V3, P401, DOI 10.1054/jpai.2002.126788; Derbyshire SWG, 2002, NEUROIMAGE, V16, P158, DOI 10.1006/nimg.2002.1066; Di Piero V, 2001, PSYCHOPHARMACOLOGY, V158, P252; Freitag P, 2001, NEUROREHAB NEURAL RE, V15, P31, DOI 10.1177/154596830101500105; Guez M, 2002, ACTA ORTHOP SCAND, V73, P455, DOI 10.1080/00016470216329; Hsieh JC, 1999, EUR J PAIN, V3, P51, DOI 10.1016/S1090-3801(99)90188-X; IADAROLA MJ, 1995, PAIN, V63, P55, DOI 10.1016/0304-3959(95)00015-K; Jones AKP, 1997, ANN RHEUM DIS, V56, P601, DOI 10.1136/ard.56.10.601; Kastrup A, 1999, J CEREBR BLOOD F MET, V19, P1066, DOI 10.1097/00004647-199910000-00002; Kupers RC, 2000, PAIN, V87, P295, DOI 10.1016/S0304-3959(00)00295-5; Kwiatek R, 2000, ARTHRITIS RHEUM-US, V43, P2823, DOI 10.1002/1529-0131(200012)43:12<2823::AID-ANR24>3.0.CO;2-E; Larsson A, 2003, NUCL MED COMMUN, V24, P411, DOI 10.1097/00006231-200304000-00011; Liotti M, 2000, BIOL PSYCHIAT, V48, P30, DOI 10.1016/S0006-3223(00)00874-X; MARSHALL PD, 1995, INJURY, V26, P17, DOI 10.1016/0020-1383(95)90546-A; Nakabeppu Y, 2001, ANN NUCL MED, V15, P459, DOI 10.1007/BF02988354; Newberg AB, 2005, J NEUROIMAGING, V15, P43, DOI 10.1177/1051228404271005; Nilsson LG, 1997, AGING NEUROPSYCHOL C, V4, P1, DOI 10.1080/13825589708256633; Otte A, 1998, EUR J NUCL MED, V25, P306; Otte A, 1996, EUR J NUCL MED, V23, P72, DOI 10.1007/BF01736993; OTTE A, 1995, LANCET, V345, P1513, DOI 10.1016/S0140-6736(95)91075-1; Otte A, 1997, J NEUROL NEUROSUR PS, V63, P368, DOI 10.1136/jnnp.63.3.368; Petrovic P, 1999, PAIN, V83, P459, DOI 10.1016/S0304-3959(99)00150-5; Peyron R, 2000, NEUROPHYSIOL CLIN, V30, P263, DOI 10.1016/S0987-7053(00)00227-6; REIMAN EM, 1984, NATURE, V310, P683, DOI 10.1038/310683a0; Richter M, 2004, J NEUROL NEUROSUR PS, V75, P758, DOI 10.1136/jnnp.2003.026963; Rodriquez AA, 2004, MUSCLE NERVE, V29, P768, DOI 10.1002/mus.20060; SPITZER WO, 1995, SPINE, V20, pS1; Sterling M, 2003, PAIN, V104, P509, DOI 10.1016/S0304-3959(03)00078-2; Sugiura M, 2000, NEUROIMAGE, V11, P541, DOI 10.1006/nimg.2000.0564; Viikari-Juntura E, 2001, OCCUP ENVIRON MED, V58, P345, DOI 10.1136/oem.58.5.345; Wik G, 2003, NEUROREPORT, V14, P619, DOI 10.1097/00001756-200303240-00019	41	15	16	0	3	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0940-6719			EUR SPINE J	Eur. Spine J.	AUG	2006	15	8					1189	1195		10.1007/s00586-005-0040-5			7	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	085QM	WOS:000240618600005	16614854	Green Published			2021-06-18	
J	Gontkovsky, ST; Sherer, M; Nick, TG; Nakase-Thompson, R; Yablon, SA				Gontkovsky, Samuel T.; Sherer, Mark; Nick, Todd G.; Nakase-Thompson, Risa; Yablon, Stuart A.			Effect of urbanicity of residence on TBI outcome at one year post-injury	BRAIN INJURY			English	Article						disability rating scale; medical complications; outcome; traumatic brain injury; urbanicity	DISABILITY RATING-SCALE; TRAUMATIC BRAIN-INJURY; HEAD; RECOVERY	Objective: To determine the impact of urbanicity of residence and occurrence of medical complications on outcome after traumatic brain injury (TBI). Study design: A consecutive series of persons admitted for inpatient TBI rehabilitation followed for 1 year post-injury. Setting: Inpatient brain injury rehabilitation programme in the southeastern US. Participants: One hundred and eleven persons with severe (67%), moderate (18%) or mild (15%) TBI. Outcome measure: Functional status at 2 year post-injury as measured by the Disability Rating Scale (DRS). Results: Functional status at follow-up was predicted by age, DRS at admission for rehabilitation, injury severity, alcohol use, continued need for medications and medical complications (validated R-2 = 0.57; p < 0.0001). Urbanicity of residence was not predictive of functional status. Conclusions: As expected, participants who experienced more medical complications and required continued use of medications had poorer functional outcomes. Contrary to expectation, more rural residents did not have poorer outcomes than persons residing in more urban areas.	Methodist Rehabil Ctr, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; Cincinnati Childrens Hosp, Med Ctr, Ctr Biostat & Epidemiol, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA	Sherer, M (corresponding author), Methodist Rehabil Ctr, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.	marks@mmrcrehab.org					Anderson S, 2004, J COGNITIVE REHABILI, V22, P6; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; DIKMEN S, 1996, NEUROPSYCHOLOGICAL A, P552; Dunn L, 2003, J NEUROL NEUROSUR PS, V74, P1060, DOI 10.1136/jnnp.74.8.1060; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Farmer JE, 2003, J HEAD TRAUMA REHAB, V18, P116, DOI 10.1097/00001199-200303000-00003; Gabella B, 1997, ANN EPIDEMIOL, V7, P207, DOI 10.1016/S1047-2797(96)00150-0; Goodall CR, 1998, AM STAT, V52, P101, DOI 10.2307/2685467; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hanlon RE, 1999, BRAIN INJURY, V13, P873; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Johnstone B, 2003, NEUROREHABILITATION, V18, P197; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; McCauley SR, 2001, J INT NEUROPSYCH SOC, V7, P457, DOI 10.1017/S1355617701744025; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; Schootman M, 1999, BRAIN INJURY, V13, P995; Schootman M, 1998, BIOM HLTH R, V21, P73; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SIMPSON D, 1981, MED J AUSTRALIA, V2, P660, DOI 10.5694/j.1326-5377.1981.tb113043.x; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Williamson D. J. G., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [10.1037/10198-001, DOI 10.1037/10198-001]; WOODWARD A, 1984, MED J AUSTRALIA, V141, P13, DOI 10.5694/j.1326-5377.1984.tb132660.x	25	15	15	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2006	20	7					701	709		10.1080/02699050600744103			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	062LV	WOS:000238947200004	16809202				2021-06-18	
J	Kennedy, RE; Livingston, L; Marwitz, JH; Gueck, S; Kreutzer, JS; Sander, AM				Kennedy, RE; Livingston, L; Marwitz, JH; Gueck, S; Kreutzer, JS; Sander, AM			Complicated mild traumatic brain injury on the inpatient rehabilitation unit - A multicenter analysis	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						functional outcome; inpatient rehabilitation; medical complications; mild brain injury; traumatic brain injury	DISABILITY RATING-SCALE; MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; DOUBLE-BLIND; MODERATE; CLASSIFICATION; RECOVERY; LENGTH; STAY; RISK	Objective: To determine characteristics of patients with complicated mild traumatic brain injury (CMTBI) on the inpatient rehabilitation unit and to accentuate limits of current classification systems for patients with mild TBI. Design: Multicenter analysis of individuals with a Glasgow Coma Scale (GCS) score of 13 to 15 (lowest score in 24 h) and positive computed tomography findings admitted to inpatient rehabilitation for TBI. Setting: 16 TBI Model System centers funded by the National Institute on Disability and Rehabilitation Research. Participants: 373 adults with CMTBI. Main Outcome Measures: Functional Independence Measure (FIM) and Disability Rating Scale (DRS) scores, length of stay, and medical complications. Results: 16% of the sample experienced serious cranial complications (eg, cerebrospinal fluid leak, intracranial hypertension), with seizures being the most common during the course of inpatient rehabilitation. Most patients demonstrated substantial improvements on functional outcome measures during rehabilitation (mean admission FIM 68.2, discharge FIM 100.6; admission DRS 9.1, discharge DRS 4.8). Age, acute length of stay, and FIM score on rehabilitation admission were significant predictors of rehabilitation length of stay. Factors not predictive of rehabilitation duration were GCS score, ethilicity, gender, incidence of fractures, and incidence of cranial/noncranial complications. Conclusion: Despite favorable GCS scores, some patients with CMTBI suffer a variety of serious cranial and noncranial complications. Such patients appear to benefit from additional brain injury services offered in inpatient rehabilitation. Further study of the unique treatment needs of these patients is warranted.	Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Inst Rehabil & Res, Houston, TX 77030 USA	Kennedy, RE (corresponding author), Virginia Commonwealth Univ, Dept Biostat, Med Coll Virginia Campus,Box 980032, Richmond, VA 23298 USA.	rkennedy@hsc.vcu.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A011403, H133A020516] Funding Source: Medline		ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bontke C. F., 1993, J HEAD TRAUMA REHAB, V8, P34; Centers for Disease Control and Prevention, 2003, MILD TRAUM BRAIN INJ; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN S, 2003, J INT NEUROPSYCH SOC, V9, P172; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HALLAHAN DP, 1997, ADV LEARN BEHAV DISA, V11, P27; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; High WM, 1996, J HEAD TRAUMA REHAB, V11, P85, DOI 10.1097/00001199-199610000-00008; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; JOHNSON PC, 1994, DERMATOL CLIN, V12, P9, DOI 10.1016/S0733-8635(18)30197-9; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; *KESSL MED REH RES, 2002, TRAUM BRAIN INJ MOD; Kraus J, 2000, HEAD INJURY, P1; Kraus J. F., 1999, REHABILITATION ADULT, P3; Kraus Jess F., 1994, P3; Lee ST, 1995, ACTA NEUROCHIR, V137, P151, DOI 10.1007/BF02187187; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; LEVIS HS, 1997, J NERV MENT DIS, V167, P675; Merchant RE, 1999, ANN NY ACAD SCI, V890, P42, DOI 10.1111/j.1749-6632.1999.tb07979.x; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; *STAT U NEW YORK, 1997, GUID UN DAT SET MED; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	45	15	15	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2006	21	3					260	271		10.1097/00001199-200605000-00006			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	044YL	WOS:000237709600006	16717503				2021-06-18	
J	Revelly, JP; Imperatori, L; Maravic, P; Schaller, MD; Chiolero, R				Revelly, JP; Imperatori, L; Maravic, P; Schaller, MD; Chiolero, R			Are terminally ill patients dying in the ICU suitable for non-heart beating organ donation?	INTENSIVE CARE MEDICINE			English	Article						coma; terminal care; treatment withdrawal; organ donation; non-heart beating organ donor	TRANSPLANTATION	Objective: To evaluate the feasibility of implementing a program of controlled non-heart beating organ donation, in patients undergoing the withdrawal of intensive care treatment. Design and setting: Prospective observational study. Medical and Surgical ICUs in a tertiary university hospital. Patients: Consecutive patients younger than 70 years dying in the ICU after treatment withdrawal for dire neurological prognosis. Measurements and results: We analyzed prospectively collected data from the ICU clinical information system. Seventy-three of 516 ICU deaths (13%) were identified, equally distributed among traumatic, stroke, and anoxic brain injury. The management and the course in these three diagnostic categories were similar. All patients underwent withdrawal of mechanical ventilation and half were extubated. Median time to death was of 4.8 h (IQR 1.4-11.5). In 70% of cases the patient received analgesia and 30% sedation. Such treatment was not related to earlier death. Hypotension was observed in 50% of patients during the 30 min preceding cardiac death. Conclusions: With our current management of terminal patients controlled non-heart beating organ procedure may be difficult due to the duration and variability of the dying process. This observation suggests that we can perform better by evaluating this process more closely.	CHU Vaudois, Surg Intens Care Unit, CH-1011 Lausanne, Switzerland; CHU Vaudois, Transplantat Ctr, CH-1011 Lausanne, Switzerland	Revelly, JP (corresponding author), CHU Vaudois, Surg Intens Care Unit, CH-1011 Lausanne, Switzerland.	jrevelly@chuv.hospvd.ch					Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987, DOI 10.1164/rccm.200409-1295OC; Bell MDD, 2005, BRIT J ANAESTH, V94, P474, DOI 10.1093/bja/aei048; Bell MDD, 2003, J MED ETHICS, V29, P176, DOI 10.1136/jme.29.3.176; Brook NR, 2004, CLIN TRANSPLANT, V18, P627, DOI 10.1111/j.1399-0012.2004.00287.x; Daar AS, 2004, TRANSPL P, V36, P1885, DOI 10.1016/j.transproceed.2004.08.130; KOOTSTRA G, 1995, TRANSPLANT P, V27, P2965; Mayor SA, 1999, NEUROLOGY, V52, P1602, DOI 10.1212/WNL.52.8.1602; REVELLY JP, 2005, INTENS CARE MED, V31, pS156; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; Sudhindran S, 2003, CLIN TRANSPLANT, V17, P93, DOI 10.1034/j.1399-0012.2003.00014.x; Truog RD, 2003, CRIT CARE MED, V31, P2391, DOI 10.1097/01.CCM.0000090869.19410.3C; VALLOTTON M, 2004, CARE PATIENTS END LI	12	15	15	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAY	2006	32	5					708	712		10.1007/s00134-006-0116-7			5	Critical Care Medicine	General & Internal Medicine	036QQ	WOS:000237090300011	16534569				2021-06-18	
J	Schmitter-Edgecombe, M				Schmitter-Edgecombe, M			Implications of basic science research for brain injury rehabilitation - A focus on intact learning mechanisms	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	Galveston Brain Injury Conference (GBIC)	APR, 2005	Galveston, TX	Moody Fdn		attention; automaticity; automatic processes; cognitive rehabilitation; controlled processes; implicit learning; implicit memory; skill learning; traumatic brain injury	CLOSED-HEAD INJURY; IMPLICIT MEMORY TESTS; DIVIDED ATTENTION; EXPLICIT MEMORY; SEARCH PERFORMANCE; ACQUISITION; ASSOCIATIONS; RETENTION; DEFICITS; 1-YEAR	Within a theoretical framework for rehabilitation that distinguishes between automatic and controlled processes, this article reviews basic science research and addresses the following issues: What cognitive abilities remain relatively intact after severe traumatic brain injury, and how can we incorporate intact skills into rehabilitative techniques? The reviewed research indicates that individuals with severe traumatic brain injury (a) generally perform similar to controls on cognitive tasks (or task components) that require automatic and implicit processes as opposed to consciously controlled processes; (b) can learn through implicit learning mechanisms; and (c) can acquire and use automatic processes in complex, cognitive task performance.	Washington State Univ, Dept Psychol, Pullman, WA 99164 USA	Schmitter-Edgecombe, M (corresponding author), Washington State Univ, Dept Psychol, POB 644820, Pullman, WA 99164 USA.	schmitter-e@wsu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS047690-01, R01 NS047690, R01 NS047690-02, R01 NS47690-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047690] Funding Source: NIH RePORTER		ANDERSON JR, 1982, PSYCHOL REV, V89, P369, DOI 10.1037/0033-295X.89.4.369; Anderson SI, 1996, BRAIN INJURY, V10, P115, DOI 10.1080/026990596124601; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; BADDELEY A, 1987, NEUROBEHAVIORAL RECO, P295; Berry D. C., 1993, IMPLICIT LEARNING TH; BRAUN CMJ, 1989, INT J CLIN NEUROPSYC, V11, P167; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS DN, 1984, CLOSED HEAD INJURY P; *CDCP, INJ FACT BOOK 2001 2; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DUKE IW, 1992, HDB HEAD TRAUMA ACUT, P165; FAHY JF, 1995, J INT NEUROPSYCH SOC, V1, P183; FINUF P, 1995, REPORTED TRAUMATIC B; FISK AD, 1987, HUMAN FACTORS PSYCHO, P159; GLISKY EL, 1988, J LEARN DISABIL-US, V21, P333, DOI 10.1177/002221948802100604; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P292, DOI 10.1080/01688638608401320; GLISKY EL, 1995, NEUROPSYCHOL REHABIL, V5, P299, DOI 10.1080/09602019508401474; Glisky EL, 1996, J HEAD TRAUMA REHAB, V11, P31, DOI 10.1097/00001199-199604000-00004; GLISKY EL, 1986, J HEAD TRAUMA REHAB, V1, P54, DOI DOI 10.1097/00001199-198609000-00009; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; GREENE RL, 1986, Q J EXP PSYCHOL-A, V38, P663, DOI 10.1080/14640748608401619; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; Haut M W, 1990, Arch Clin Neuropsychol, V5, P299, DOI 10.1016/0887-6177(90)90028-N; JACOBY LL, 1991, J MEM LANG, V30, P513, DOI 10.1016/0749-596X(91)90025-F; JACOBY LL, 1993, J EXP PSYCHOL GEN, V122, P139, DOI 10.1037/0096-3445.122.2.139; Kapur N, 2004, NEUROPSYCHOL REHABIL, V14, P41, DOI 10.1080/09602010343000138; Kraus Jess F., 1994, P3; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LONG C, 1988, NEUROPSYCHOLOGICAL A; McCauley SR, 2001, J INT NEUROPSYCH SOC, V7, P457, DOI 10.1017/S1355617701744025; McDowall J, 1996, NEW ZEAL J PSYCHOL, V25, P2; Miller E, 1970, Cortex, V6, P121; Mulligan NW, 1996, MEM COGNITION, V24, P453, DOI 10.3758/BF03200934; Mulligan NW, 1997, MEM COGNITION, V25, P11, DOI 10.3758/BF03197281; MUTTER SA, 1994, J CLIN EXP NEUROPSYC, V16, P271, DOI 10.1080/01688639408402638; Nissley HM, 2002, NEUROPSYCHOLOGY, V16, P111, DOI 10.1037//0894-4105.16.1.111; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PAGE M, 2001, J INT NEUROPSYCH SOC, V7, P413; PAVAWALLA S, 2005, 33 ANN M INT NEUR SO; PERMA RB, 2000, J COGN REHABIL, P16; Riley GA, 2004, NEUROPSYCHOL REHABIL, V14, P257, DOI 10.1080/09602010343000057; Riley GA, 2000, NEUROPSYCHOL REHABIL, V10, P133, DOI 10.1080/096020100389219; ROEDIGER HL, 1990, AM PSYCHOL, V45, P1043, DOI 10.1037/0003-066X.45.9.1043; Schmitter-Edgecombe M, 1999, MEM COGNITION, V27, P512, DOI 10.3758/BF03211545; Schmitter-Edgecombe M, 2001, J INT NEUROPSYCH SOC, V7, P615, DOI 10.1017/S1355617701755099; Schmitter-Edgecombe M, 2000, NEUROPSYCHOLOGY, V14, P559; Schmitter-Edgecombe M., 1993, NEUROPSYCHOLOGY, V7, P136, DOI DOI 10.1037/0894-4105.7.2.136; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; SchmitterEdgecombe M, 1996, NEUROPSYCHOLOGY, V10, P155; SchmitterEdgecombe M, 1996, J HEAD TRAUMA REHAB, V11, P17, DOI 10.1097/00001199-199604000-00003; SchmitterEdgecombe M, 1997, NEUROPSYCHOLOGY, V11, P296, DOI 10.1037/0894-4105.11.2.296; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; SCHNEIDER W, 1982, PERCEPT PSYCHOPHYS, V31, P160, DOI 10.3758/BF03206216; SEGER CA, 1998, HDB IMPLICIT LEARNIN, P295; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; Shum D, 1996, J HEAD TRAUMA REHAB, V11, P43, DOI 10.1097/00001199-199604000-00005; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; Squires EJ, 1997, NEUROPSYCHOLOGIA, V35, P1103, DOI 10.1016/S0028-3932(97)00039-0; SRINIVAS K, 1990, J MEM LANG, V29, P389, DOI 10.1016/0749-596X(90)90063-6; TERRACE HS, 1963, J EXP ANAL BEHAV, V6, P1, DOI 10.1901/jeab.1963.6-1; VAKIL E, 1994, J CLIN EXP NEUROPSYC, V16, P539, DOI 10.1080/01688639408402665; VAKIL E, 1991, J CLIN EXP NEUROPSYC, V13, P291, DOI 10.1080/01688639108401044; Vakil E, 1997, J Int Neuropsychol Soc, V3, P327; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020; Wilson BA, 1996, J HEAD TRAUMA REHAB, V11, P54, DOI 10.1097/00001199-199604000-00006; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson BA, 2000, NEUROPSYCHOL REV, V10, P233, DOI 10.1023/A:1026464827874	73	15	16	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2006	21	2					131	141		10.1097/00001199-200603000-00006			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	031PK	WOS:000236716300005	16569987				2021-06-18	
J	Ernst, C; Christie, BR				Ernst, C; Christie, BR			Temporally specific proliferation events are induced in the hippocampus following acute focal injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						dentate gyrus; latent period; neurogenesis; hippocampus; electrolytic lesion; Fluorojade-B; neuron; stem cell; glia	GRANULE CELL NEUROGENESIS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; DENTATE GYRUS; NEURONAL DEGENERATION; MICROGLIAL REACTION; GENE-EXPRESSION; ADULT-RAT; ENHANCED NEUROGENESIS; RODENT HIPPOCAMPUS	In models of global brain injury, such as stroke or epilepsy, a large increase in neurogenesis occurs in the dentate gyrus (DG) days after the damage is induced. In contrast, more focal damage in the DG produces an increase in neurogenesis within 24 hr. To determine how cell proliferation and differentiation differs in the DG after acute injury in the DG, focal electrolytic lesions were made and mitotic activity was assessed at early (1 day) and late (5 day) time points. At the early time point, bromodeoxyuridine (BrdU)-positive cells were diffusely spread throughout the extent of the hippocampus that was ipsilateral to the lesion. No significant increase in the subgranular zone (SGZ) of the DG was observed. When BrdU was administered at the later time point, the number of BrdU(+) cells in the SGZ of the DG was significantly increased. This fourfold increase in BrdU(+) cells also resulted in a significant increase in neurogenesis, as measured 6 weeks following BrdU administration. This increase in neurogenesis was not observed when BrdU was administered at the early time point. These results indicate that focal injury in the DG activates two temporally specific proliferation events and that enhanced neurogenesis is observed only following a latent period after the lesion is made. (c) 2005 Wiley-Liss, Inc.	Univ British Columbia, Dept Psychol, Brain Res Ctr, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Program Neurosci, Vancouver, BC, Canada	Christie, BR (corresponding author), Univ British Columbia, Dept Psychol, Brain Res Ctr, 2136 W Mall, Vancouver, BC V6T 1Z4, Canada.	bchristie@psych.ubc.ca	Christie, Brian/AAF-3766-2019	Christie, Brian/0000-0002-6830-0160			ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; BETHEA JR, 1992, J NEUROIMMUNOL, V36, P179, DOI 10.1016/0165-5728(92)90049-Q; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COFFEY PJ, 1990, NEUROSCIENCE, V35, P121, DOI 10.1016/0306-4522(90)90126-O; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Eadie BD, 2005, J COMP NEUROL, V486, P39, DOI 10.1002/cne.20493; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Farmer J, 2004, NEUROSCIENCE, V124, P71, DOI 10.1016/j.neuroscience.2003.09.029; Ferland RJ, 2002, NEUROSCIENCE, V115, P669, DOI 10.1016/S0306-4522(02)00514-6; FONTANA A, 1982, J IMMUNOL, V129, P2413; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; GEHRMANN J, 1991, ACTA NEUROPATHOL, V82, P442, DOI 10.1007/BF00293378; GEHRMANN J, 1995, NEUROPATH APPL NEURO, V21, P277, DOI 10.1111/j.1365-2990.1995.tb01062.x; GEHRMANN J, 1992, ACTA NEUROPATHOL, V84, P588; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Gray WP, 1998, BRAIN RES, V790, P52, DOI 10.1016/S0006-8993(98)00030-4; Harry GJ, 2004, NEUROTOX RES, V5, P623; Horner PJ, 2003, TRENDS NEUROSCI, V26, P597, DOI 10.1016/j.tins.2003.09.010; Ivacko JA, 1996, PEDIATR RES, V39, P39, DOI 10.1203/00006450-199601000-00006; Jiang W, 2003, BRAIN RES, V977, P141, DOI 10.1016/S0006-8993(03)02438-7; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Joannides A, 2004, LANCET, V364, P172, DOI 10.1016/S0140-6736(04)16630-0; KAPLAN MS, 1984, J NEUROSCI, V4, P1429; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; Kee NJ, 2001, EXP BRAIN RES, V136, P313, DOI 10.1007/s002210000591; MILLER MW, 1988, BRAIN RES, V457, P44, DOI 10.1016/0006-8993(88)90055-8; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Obernier JA, 2002, ALCOHOL CLIN EXP RES, V26, P547, DOI 10.1111/j.1530-0277.2002.tb02573.x; Overstreet LS, 2004, J NEUROSCI, V24, P3251, DOI 10.1523/JNEUROSCI.5173-03.2004; Parent JM, 1997, J NEUROSCI, V17, P3727; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; RIVADEPATY I, 1994, EXP NEUROL, V128, P77, DOI 10.1006/exnr.1994.1114; Rosenblum WI, 1997, J NEUROTRAUM, V14, P313, DOI 10.1089/neu.1997.14.313; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; SCHREIBER SS, 1995, TRENDS NEUROSCI, V18, P446, DOI 10.1016/0166-2236(95)94495-Q; Scott BW, 2000, EXP NEUROL, V165, P231, DOI 10.1006/exnr.2000.7458; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Zupanc GKH, 2001, BRAIN BEHAV EVOLUT, V58, P250, DOI 10.1159/000057569	47	15	15	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	FEB 15	2006	83	3					349	361		10.1002/jnr.20724			13	Neurosciences	Neurosciences & Neurology	015BX	WOS:000235528000001	16342206				2021-06-18	
J	Borlongan, CV; Fournier, C; Stahl, CE; Yu, GL; Xu, L; Matsukawa, N; Newman, M; Yasuhara, T; Hara, K; Hess, DC; Sanberg, PR				Borlongan, CV; Fournier, C; Stahl, CE; Yu, GL; Xu, L; Matsukawa, N; Newman, M; Yasuhara, T; Hara, K; Hess, DC; Sanberg, PR			Gene therapy, cell transplantation and stroke	FRONTIERS IN BIOSCIENCE-LANDMARK			English	Article						nervous system; neuron; cancer; tumor; neuroteratocarcinoma cells; NT2N; intracerebral transplantation; treatment; therapeutic; gene therapy; neuroprotection; stroke; review	CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; EMBRYONAL CARCINOMA-CELLS; IN-VITRO CHARACTERIZATION; MARROW STROMAL CELLS; HUMAN NEURONAL CELLS; RAT PARKINSON MODEL; HUMAN NT2N NEURONS; HNT NEURONS; TYROSINE-HYDROXYLASE	The use of neuroteratocarcinoma cells for transplantation therapy in stroke has emerged as a strategy for cell replacement therapy that has begun its transition from basic science laboratories to a clinical setting. Procurement logistics and novel neuroprotective functions associated with these cells allow neuroteratocarcinoma cells to serve as efficacious alternatives to using fetal cells as donor cell grafts for stroke therapy, although the optimal transplantation regimen must still be determined. In particular, the limitations of current stroke treatments and management reveal an urgent need to examine the efficacy of experimental treatments, such as neural transplantation, in order to develop better treatment therapies. This chapter will discuss the characteristics of NT2N cells, the role of the host brain microenvironment, the need for more rigorous laboratory research and clinical trials for the intracerebral transplantation of NT2N cells in stroke, the mechanisms underlying the grafts' beneficial effects, and the need for immunosuppression. This chapter will highlight some of the most recent findings regarding NT2N cells.	Med Coll Georgia, Dept Neurol, Augusta, GA 30904 USA; Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30904 USA; Med Coll Georgia, Sch Grad Studies, Augusta, GA 30904 USA; Vet Adm Med Ctr, Res & Affiliat Serv Line, Augusta, GA 30912 USA; Dwight D Eisenhower Army Med Ctr, Dept Med, Ft Gordon, GA 30905 USA; Univ S Florida, Coll Med, Ctr Excellence Aging & Brain Repair, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Neurosurg, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Surg, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pharmacol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Psychol, Tampa, FL 33612 USA	Borlongan, CV (corresponding author), Med Coll Georgia, Dept Neurol, BI 3080,1120 15th St, Augusta, GA 30904 USA.	cborlongan@mail.mcg.edu	Borlongan, Cesar/I-5696-2012	Borlongan, Cesar/0000-0002-2966-9782			Alexi T, 2000, PROG NEUROBIOL, V60, P409, DOI 10.1016/S0301-0082(99)00032-5; Bjorklund A, 1992, Curr Opin Neurobiol, V2, P683, DOI 10.1016/0959-4388(92)90039-N; Borlongan CV, 2000, EXPERT OPIN INV DRUG, V9, P2319, DOI 10.1517/13543784.9.10.2319; Borlongan CV, 1998, NEUROREPORT, V9, P2837, DOI 10.1097/00001756-199808240-00028; Borlongan CV, 1998, EXP NEUROL, V149, P310, DOI 10.1006/exnr.1997.6730; Borlongan CV, 1998, NEUROREPORT, V9, P3703, DOI 10.1097/00001756-199811160-00025; Borlongan CV, 1999, LANCET, V353, pSL29; Brundin P, 2001, NAT MED, V7, P512, DOI 10.1038/87796; Cao YJ, 2001, GENE THER, V8, P1357, DOI 10.1038/sj.gt.3301536; Carrol JE, 2000, NEUROREPORT, V11, pR1; Chang CF, 2002, NEUROPHARMACOLOGY, V43, P418, DOI 10.1016/S0028-3908(02)00092-8; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chiang YH, 1999, J CEREBR BLOOD F MET, V19, P1329, DOI 10.1097/00004647-199912000-00006; Christie SD, 2004, CAN J NEUROL SCI, V31, P87, DOI 10.1017/S0317167100002882; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Cordelier P, 2003, MOL THER, V7, P801, DOI 10.1016/S1525-0016(03)00093-5; EMERICH DF, 1992, NEUROSCI BIOBEHAV R, V16, P437, DOI 10.1016/S0149-7634(05)80185-X; Faiella A, 2000, HUM MOL GENET, V9, P227, DOI 10.1093/hmg/9.2.227; FAIELLA A, 1994, P NATL ACAD SCI USA, V91, P5335, DOI 10.1073/pnas.91.12.5335; FAULL RLM, 1995, ADV BEHAV BIOL, V43, P173; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; FREED WJ, 1989, BRAIN RES, V485, P349, DOI 10.1016/0006-8993(89)90579-9; Freeman TB, 2000, P NATL ACAD SCI USA, V97, P13877, DOI 10.1073/pnas.97.25.13877; FREUND TF, 1985, J NEUROSCI, V5, P603; Gortz P, 2004, BRAIN RES, V1018, P18, DOI 10.1016/j.brainres.2004.05.076; HENDERSON BTH, 1991, ARCH NEUROL-CHICAGO, V48, P822, DOI 10.1001/archneur.1991.00530200062020; Hill WD, 2001, BRAIN RES BULL, V55, P375, DOI 10.1016/S0361-9230(01)00503-2; Hoffer B, 1997, J NEURAL TRANSM-SUPP, P1; Huang DQ, 2004, J MOL NEUROSCI, V24, P323, DOI 10.1385/JMN:24:2:323; Hughes PE, 1999, PROG NEUROBIOL, V57, P421, DOI 10.1016/S0301-0082(98)00057-4; Hurlbert MS, 1999, CELL TRANSPLANT, V8, P143, DOI 10.1177/096368979900800106; Iacovitti L, 1997, NEUROREPORT, V8, P1471, DOI 10.1097/00001756-199704140-00029; Isacson O, 2001, PARKINSONISM RELAT D, V7, P205, DOI 10.1016/S1353-8020(00)00059-6; Johnston RE, 2001, BRAIN RES, V900, P268, DOI 10.1016/S0006-8993(01)02327-7; KAWAJA MD, 1991, J COMP NEUROL, V307, P695, DOI 10.1002/cne.903070414; KLEPPNER SR, 1995, J COMP NEUROL, V357, P618, DOI 10.1002/cne.903570410; Kofler P, 1998, CELL TRANSPLANT, V7, P175, DOI 10.1016/S0963-6897(97)00162-0; Kondziolka D, 2000, NEUROLOGY, V55, P565, DOI 10.1212/WNL.55.4.565; Kordower J H, 2000, Prog Brain Res, V127, P333; LEE VMY, 1986, J NEUROSCI, V6, P514; Lee VMY, 2000, PROG BRAIN RES, V128, P299; Li Y, 2002, J NEUROL SCI, V193, P137, DOI 10.1016/S0022-510X(01)00657-8; Lin S.Z., 1999, SOC NEUR ABSTR, V25, P1344; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/0897715042664876; MAHALIK TJ, 1994, EXP NEUROL, V129, P27, DOI 10.1006/exnr.1994.1144; MAHALIK TJ, 1985, J COMP NEUROL, V240, P60, DOI 10.1002/cne.902400105; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Matsuoka T, 1997, BIOCHEM BIOPH RES CO, V237, P719, DOI 10.1006/bbrc.1997.7087; Meltzer CC, 2001, NEUROSURGERY, V49, P586, DOI 10.1097/00006123-200109000-00011; Misiuta IE, 2003, DEV BRAIN RES, V145, P107, DOI 10.1016/S0165-3806(03)00221-9; MIYAZONO M, 1995, LAB INVEST, V73, P273; Miyazono M, 1996, J COMP NEUROL, V376, P603, DOI 10.1002/(SICI)1096-9861(19961223)376:4<603::AID-CNE8>3.0.CO;2-5; Mukhtar M, 2000, HUM GENE THER, V11, P347, DOI 10.1089/10430340050016076; Nelson PT, 2002, AM J PATHOL, V160, P1201, DOI 10.1016/S0002-9440(10)62546-1; NIKKHAH G, 1994, J NEUROSCI, V14, P3449; NIKKHAH G, 1994, BRAIN RES, V633, P133, DOI 10.1016/0006-8993(94)91532-6; NISHINO H, 1990, NEUROSCI RES, pS54, DOI 10.1016/0921-8696(90)90031-W; Nishino H, 2000, Prog Brain Res, V127, P461; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Saporta S, 1999, NEUROSCIENCE, V91, P519, DOI 10.1016/S0306-4522(98)00610-1; SAPORTA S, 2002, J NEUROSURG, P9763; Sarnacki PG, 1998, EXP NEUROL, V153, P386; Schinstine M., 1996, Society for Neuroscience Abstracts, V22, P1959; Schmeisser F, 2002, HUM GENE THER, V13, P2113, DOI 10.1089/104303402320987815; SCHUELER SB, 1993, J NEUROSCI, V13, P4496; Studer L, 1998, NAT NEUROSCI, V1, P290; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; Tomac AC, 2000, NEUROSCIENCE, V95, P1011; Tornatore C, 1996, CELL TRANSPLANT, V5, P145, DOI 10.1016/0963-6897(95)02041-1; TROJANOWSKI JQ, 1993, EXP NEUROL, V122, P283, DOI 10.1006/exnr.1993.1128; Trojanowski JQ, 1997, EXP NEUROL, V144, P92, DOI 10.1006/exnr.1996.6393; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Willing AE, 2002, EUR J NEUROSCI, V16, P2271, DOI 10.1046/j.1460-9568.2002.02300.x; ZETTERSTROM RH, 1994, NEUROSCIENCE, V62, P899, DOI 10.1016/0306-4522(94)90482-0; Zigova T, 1999, EXP NEUROL, V157, P251, DOI 10.1006/exnr.1999.7054; Zigova T, 2000, DEV BRAIN RES, V122, P87, DOI 10.1016/S0165-3806(00)00055-9; Zivin JA, 2000, NEUROLOGY, V55, P467, DOI 10.1212/WNL.55.4.467	79	15	16	0	1	FRONTIERS IN BIOSCIENCE INC	IRVINE	16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA	1093-9946	1093-4715		FRONT BIOSCI-LANDMRK	Front. Biosci.	JAN 1	2006	11						1090	U46		10.2741/1865			12	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	973MX	WOS:000232528000091	16146799				2021-06-18	
J	Johnstone, B; Reid-Arndt, S; Franklin, KL; Harper, J				Johnstone, Brick; Reid-Arndt, Stephanie; Franklin, Kelly Lora; Harper, John			Vocational outcomes of state vocational rehabilitation clients with traumatic brain injury: A review of the Missouri Model Brain Injury System Studies	NEUROREHABILITATION			English	Article; Proceedings Paper	1st International Conference on Vocational Outcomes in Traumatic Brain Injury	APR 14-16, 2005	Vancouver, CANADA			traumatic brain injury; state vocational rehabilitation; rehabilitation	COMMUNITY INTEGRATION; GENDER-DIFFERENCES; HEAD-INJURY; EMPLOYMENT; WORK; PREDICTORS; SAMPLE; IMPACT; RETURN	Although there is considerable research on the vocational outcomes of individuals with traumatic brain injuries (TBI), there has been minimal research on the characteristics of persons with TBI who seek services from state vocational rehabilitation services. Such research is deemed critical given the significant number of individuals who request such services, as well as the significant federal and state costs associated with these programs. The current article reviews a series of studies completed collaboratively between the University of Missouri-Columbia and Missouri Division of Vocational Rehabilitation (DVR). Information is reported regarding the typical demographic, injury severity, and neuropsychological characteristics of DVR clients with TBI, as well as the most common DVR services provided to them and their vocational outcomes (i. e., successful, unsuccessful). Studies are reviewed which indicate that the provision of specific DVR services predict successful vocational outcomes, although traditional medical and neuropsychological variables do not. Additional studies are reviewed which examine the impact of gender, race, age, geographic location (i. e., rural vs. urban), and concomitant disabilities on vocational outcomes. Results indicate the importance of considering environmental and social factors when providing vocational rehabilitation services to clients with TBI, and that specific DVR services can lead to successful vocational outcomes regardless of TBI severity. Implications for future clinical services and research are presented.	Univ Missouri, Dept Hlth Psychol, Sch Hlth Profess, Columbia, MO 65212 USA	Johnstone, B (corresponding author), Univ Missouri, Dept Hlth Psychol, Sch Hlth Profess, DC116-88,1 Hosp Dr, Columbia, MO 65212 USA.	johnstoneg@health.missouri.edu		Johnstone, Brick/0000-0001-8845-9649	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A980008] Funding Source: Medline		Bogan AM, 1997, BRAIN INJURY, V11, P431; Bounds TA, 2003, NEUROREHABILITATION, V18, P189; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; *BUR CENS, 1995, CURR POP SURV; Burnett DM, 2000, BRAIN INJURY, V14, P713; Cook J. A., 2003, J VOCATIONAL REHABIL, V18, P25; COOPER KD, 1983, NEUROEPIDEMIOLOGY, V2, P70; CUMMINGS RW, 1987, EXCEPT CHILDREN, V54, P167; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fleming J, 1999, BRAIN INJURY, V13, P417; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; HARING KA, 1990, J LEARN DISABIL, V23, P108, DOI 10.1177/002221949002300206; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Johnstone B, 2003, NEUROREHABILITATION, V18, P197; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P161, DOI 10.1053/apmr.2003.50098; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Johnstone B, 2003, BRAIN INJURY, V17, P95, DOI 10.1080/0269905021000010212; Johnstone B, 2002, J RURAL HEALTH, V18, P109, DOI 10.1111/j.1748-0361.2002.tb00882.x; JOHNSTONE B, IN PRESS J VOCATIONA; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kaye H. S., 1998, VOCATIONAL REHABILIT; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Lewis DR, 2003, J INTELLECT DEV DIS, V28, P24, DOI 10.1080/1366825031000086876; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Mitrushina M., 1999, HDB NORMATIVE DATA N; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Partridge T M, 1996, Work, V7, P63, DOI 10.3233/WOR-1996-7108; PRIGATANO GP, 1989, B MENNINGER CLIN, V53, P414; ROESSLER RT, 1992, J REHABIL, P17; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; *RUR POL RES I, 1999, METR NONM COUNTR DEF; SCHOOTMAN M, 1999, BRAIN INJURY; SCUCCIMARRA DJ, 1990, J LEARN DISABIL, V23, P213, DOI 10.1177/002221949002300403; Skeel RL, 2003, REHABIL PSYCHOL, V48, P145, DOI 10.1037/0090-5550.48.3.145; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; *USDA, RSA PROGR DAT STAT; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; Zasler ND, 1997, J HEAD TRAUMA REHAB, V12, P42, DOI 10.1097/00001199-199710000-00005	45	15	15	0	9	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2006	21	4					335	347					13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	145VU	WOS:000244894700008	17361050				2021-06-18	
J	Winkens, I; Van Heugten, CM; Fasotti, L; Duits, AA; Wade, DT				Winkens, Ieke; Van Heugten, Caroline M.; Fasotti, Luciano; Duits, Annelien A.; Wade, Derick T.			Manifestations of mental slowness in the daily life of patients with stroke: a qualitative study	CLINICAL REHABILITATION			English	Article							CLOSED-HEAD INJURY; COGNITIVE IMPAIRMENT; PROCESSING-SPEED; FLEXIBILITY; ATTENTION	Objective: To explore the consequences of mental slowness in the daily life of patients with stroke. Design: In a cross-sectional survey semi-structured interviews were completed. Interviews were transcribed and coded by two independent reviewers. Qualitative analysis was done by means of the 'constant comparison method'. Setting: Three rehabilitation centres in the Netherlands. Participants: A convenience sample of 13 patients with stroke, suffering from mental slowness, was derived from December 2003 to May 2004. Main outcome measures: Interview descriptions of the everyday consequences of mental slowness. Results: Patients experienced many problems in daily life due to mental slowness. These could be divided into two main groups: (1) problems in cognitive functioning; (2) psychological and somatic complaints. In response to these problems, some patients mentioned the use of compensation strategies in order to reduce the demands on their information processing capacity. Conclusions: Mental slowness in cognitive functioning affects a wide range of activities, causing emotional symptoms in many patients and stimulating the spontaneous use of compensation strategies in some patients.	Inst Rehabil Res, IRv, NL-6430 AD Hoensbroek, Netherlands; St Maartensklin Res, Nijmegen, Netherlands; Acad Hosp Maastricht, Dept Med Psychol, Maastricht, Netherlands	Winkens, I (corresponding author), Inst Rehabil Res, IRv, POB 192, NL-6430 AD Hoensbroek, Netherlands.	i.winkens@irv.nl		Wade, Derick/0000-0002-1188-8442			Anderson John R., 1976, LANGUAGE MEMORY THOU; Anderson John Robert, 1993, RULES MIND; Ballard C, 2003, DEMENT GERIATR COGN, V16, P52, DOI 10.1159/000069994; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; Gerritsen MJJ, 2003, J CLIN EXP NEUROPSYC, V25, P1, DOI 10.1076/jcen.25.1.1.13622; Glaser B. G., 1967, DISCOVERY GROUNDED T; Hochstenbach J, 1998, J CLIN EXP NEUROPSYC, V20, P503, DOI 10.1076/jcen.20.4.503.1471; HOCHSTENBACH J, 1999, THESIS CATHOLIC U NI; KAIL R, 1994, ACTA PSYCHOL, V86, P199, DOI 10.1016/0001-6918(94)90003-5; MUHR T, 1998, ATLAS TI KNOWLEDGE W; Rasquin SMC, 2004, DEMENT GERIATR COGN, V18, P138, DOI 10.1159/000079193; Rasquin SMC, 2002, J NEUROL SCI, V203, P115, DOI 10.1016/S0022-510X(02)00264-2; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; SPIKMAN JM, 1996, J CLIN EXP NEUROPSYC, V37, P467; TATEMICHI TK, 1994, J NEUROL NEUROSUR PS, V57, P202, DOI 10.1136/jnnp.57.2.202; Timmerman ME, 1999, NEUROPSYCHOLOGIA, V37, P467, DOI 10.1016/S0028-3932(98)00085-2; *TRANSM ZORGM CVA, 1996, MOD VERB KWAL ZORG C; VANZOMEREN AH, 1987, NEUROBEHAVIORAL RECO; VANZOMEREN AH, 2003, NIET AANGEBOREN HERS; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Visser-Keizer AC, 2002, J CLIN EXP NEUROPSYC, V24, P1032, DOI 10.1076/jcen.24.8.1032.8383; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002	23	15	15	0	7	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.		2006	20	9					827	834		10.1177/0269215506070813			8	Rehabilitation	Rehabilitation	101IL	WOS:000241734400008	17005506				2021-06-18	
S	Wong, SBC; Chapman, SB; Cook, LG; Anand, R; Gamino, JF; Devous, MD		Moller, AR		Wong, Stephanie B. Chiu; Chapman, Sandra B.; Cook, Lori G.; Anand, Raksha; Gamino, Jacquelyn F.; Devous, Michael D., Sr.			A SPECT study of language and brain reorganization three years after pediatric brain injury	REPROGRAMMING THE BRAIN	PROGRESS IN BRAIN RESEARCH		English	Article; Proceedings Paper	Symposium on Reprogramming the Human Brain	APR 07-08, 2005	Univ Texas Dallas, Richardson, TX		Univ Texas Dallas	children; plasticity; recovery; language; SPECT; functional brain imaging; cognition; brain injury	CLOSED-HEAD INJURY; DEFICIT HYPERACTIVITY DISORDER; TECHNETIUM-99M-HMPAO SPECT; CHILDREN; DISCOURSE; MILD; MRI; ADOLESCENTS; ATTENTION; TOMOGRAPHY	Using single photon emission computed tomography (SPECT), we investigated brain plasticity in children 3 years after sustaining a severe traumatic brain injury (TBI). First, we assessed brain perfusion patterns (i.e., the extent of brain blood flow to regions of the brain) at rest in eight children who suffered severe TBI as compared to perfusion patterns in eight normally developing children. Second, we examined differences in perfusion between children with severe TBI who showed good versus poor recovery in complex discourse skills. Specifically, the children were asked to produce and abstract core meaning for two stories in the form of a lesson. Inconsistent with our predictions, children with severe TBI showed areas of increased perfusion as compared to normally developing controls. Adult studies have shown the reverse pattern with TBI associated with reduced perfusion. With regard to the second aim and consistent with previously identified brain-discourse relations, we found a strong positive association between perfusion in right frontal regions and discourse abstraction abilities, with higher perfusion linked to better discourse outcomes and lower perfusion linked to poorer discourse outcomes. Furthermore, brain-discourse patterns of increased perfusion in left frontal regions were associated with lower discourse abstraction ability. The results are discussed in terms of how brain changes may represent adaptive and maladaptive plasticity. The findings offer direction for future studies of brain plasticity in response to neurocognitive treatments.	Univ Texas, Ctr Brain Hlth, Dallas, TX 75235 USA; Univ Texas, Inst Biomed Sci & Technol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Nucl Med Ctr, Dallas, TX USA	Chapman, SB (corresponding author), Univ Texas, Ctr Brain Hlth, Dallas, TX 75235 USA.	schapman@utdallas.edu					ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Bigler ED, 1996, J LEARN DISABIL-US, V29, P515, DOI 10.1177/002221949602900507; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; Casey BJ, 2005, TRENDS COGN SCI, V9, P104, DOI 10.1016/j.tics.2005.01.011; CHANG LT, 1978, IEEE T NUCL SCI, V25, P638, DOI 10.1109/TNS.1978.4329385; Chapman S. B., 1997, AM J SPEECH-LANG PAT, V6, P66; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Chapman SB, 2005, ALZ DIS ASSOC DIS, V19, P202, DOI 10.1097/01.wad.0000189050.41064.03; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Chapman SB, 2003, PEDIATR NEUROL, V29, P34, DOI 10.1016/S0887-8994(03)00012-2; Chapman SB, 2001, J HEAD TRAUMA REHAB, V16, P441, DOI 10.1097/00001199-200110000-00004; CHAPMAN SB, 1999, BRAIN DAM B, P235; CHAPMAN SB, 2001, ANN AM ASS ADV SCI M; Christensen J.R., 2001, CHILDREN TRAUMATIC B; Chugani HT, 1996, BRAIN DEV-JPN, V18, P347, DOI 10.1016/0387-7604(96)00032-0; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; CHUGANI HT, 1991, J CEREBR BLOOD F MET, V11, P35, DOI 10.1038/jcbfm.1991.4; COOK LG, 2006, IN PRESS COGNITIVE B; Dapretto M, 2005, NEUROREPORT, V16, P1661, DOI 10.1097/01.wnr.0000183332.28865.11; DELIS DC, 1990, ADV PSYCHOL ASSESS, P101; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Fletcher JM, 1987, NEUROBEHAVIORAL RECO, P279; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Goldstone BP, 2001, READ TEACH, V55, P362; Graham DI, 1996, NEUROTRAUMA, P43; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Gullion CM, 1996, BIOL PSYCHIAT, V40, P1106, DOI 10.1016/S0006-3223(95)00636-2; ICHISE M, 1994, J NUCL MED, V35, P217; JACOBS A, 1994, J NUCL MED, V35, P942; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JOHNSON NS, 1983, CHILDRENS LANGUAGE, P314; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Kennard MA, 1938, J NEUROPHYSIOL, V1, P477; Kilgard MP, 2002, BIOL CYBERN, V87, P333, DOI 10.1007/s00422-002-0352-z; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; Langlois JA, 2001, TRAUMATIC BRAIN INJU; LEVIN HS, 1993, J CLIN EXP NEUROPSYC, V15, P21; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Montes LGA, 2005, SALUD MENT, V28, P1; Moses P, 2002, NEUROIMAGE, V16, P415, DOI 10.1006/nimg.2002.1064; Nichelli P, 1995, NEUROREPORT, V6, P2309, DOI 10.1097/00001756-199511270-00010; POSTMAN WA, 2006, CUNY SENT PROC C NEW; Reilly JS, 1998, BRAIN LANG, V61, P335, DOI 10.1006/brln.1997.1882; Robertson DA, 2000, PSYCHOL SCI, V11, P255, DOI 10.1111/1467-9280.00251; Schulz KP, 2004, AM J PSYCHIAT, V161, P1650, DOI 10.1176/appi.ajp.161.9.1650; STEIN BL, 1992, J READING BEHAV, V24, P217, DOI 10.1080/10862969209547773; Talairach J, 1988, CO PLANAR STEREOTAXI; TURKINGTON TG, 1993, J NUCL MED, V34, P1587; Umile EM, 1998, BRAIN INJURY, V12, P577; Yorkston KM, 1997, ARCH PHYS MED REHAB, V78, P1096, DOI 10.1016/S0003-9993(97)90134-9	60	15	15	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0079-6123		978-0-444-51602-2	PROG BRAIN RES			2006	157						173	+		10.1016/S0079-6123(06)57011-6			15	Neurosciences	Neurosciences & Neurology	BGH62	WOS:000247002900011	17167907				2021-06-18	
J	Gahm, C; Holmin, S; Rudehill, S; Mathiesen, T				Gahm, C; Holmin, S; Rudehill, S; Mathiesen, T			Neuronal degeneration and iNOS expression in experimental brain contusion following treatment with colchicine, dexamethasone, tirilazad mesylate and nimodipine	ACTA NEUROCHIRURGICA			English	Article						brain injury; colchicine; dexamethasone; iNOS; neuronal degeneration; nimodipine; tirilazad mesylate	NITRIC-OXIDE SYNTHASE; EXPERIMENTAL HEAD-INJURY; SMOOTH-MUSCLE-CELLS; SUBARACHNOID HEMORRHAGE; CORTICAL INJURY; RAT; APOPTOSIS; TRAUMA; NEUROPROTECTION; CYTOKINE	Background. The pathophysiological mechanisms of secondary neurological injury after traumatic brain injury are complex. Posttraumatic biochemical reactions include parenchymal inflammation, free radical production, increased intracellular calcium and lipid peroxidation and nitric oxide production. The relative importance of each mechanism is unknown in brain contusions. This study was undertaken to investigate protection by the neuroprotective and/or anti-inflammatory drugs that have different putative mechanisms of action: colchicine, dexamethasone, tirilazad mesylate and nimodipine. Method. A brain contusion was produced using a weight-drop model in rats. The animals were treated with either one of the drugs at previously defined relevant dosage or control. Fluoro-Jade labelling, TUNEL-staining and immunohisto-chemistry were used to study neuronal degeneration, cellular apoptosis and iNOS expression. In addition, the number of surviving neurons after 14 days was determined. Findings. The number of degenerating neurons was significantly reduced in all treatment groups at 24 hours while the total number of apoptotic cells including inflammatory cells and glia was unchanged. iNOS-expression was reduced in all treatment groups at 24 hours but not later. Only colchicine and tirilazad mesylate significantly enhanced neuronal survival at 14 days after injury. Conclusions. The findings underscored that an early neuroprotective effect does not necessarily lead to increased long-term neuronal survival. The absence of a significant long-term effect with nimodipine and dexamethasone agrees with clinical studies. Colchicine with an anti-macrophage/anti-inflammatory activity and the free radical scavenger tirilazad mesylate were effective for amelioration of experimental contusion with moderate energy transfer. Early neuroprotection may to some extent target iNOS via different pathways since all tested drugs affected both iNOS expression and neuronal degeneration.	Karolinska Univ Hosp, Neurosurg Sect, Dept Clin Neurosci, Karolinska Inst, S-17176 Stockholm, Sweden	Gahm, C (corresponding author), Karolinska Univ Hosp, Neurosurg Sect, Dept Clin Neurosci, Karolinska Inst, S-17176 Stockholm, Sweden.	caroline.gahm@karolinska.se		Mathiesen, Tiit/0000-0001-9463-1919; Holmin, Staffan/0000-0002-1628-1615			ALDERSON P, 2000, COCHRANE DATABASE SY, V25; Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; Cattaruzza M, 2000, BRIT J PHARMACOL, V129, P1155, DOI 10.1038/sj.bjp.0703192; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Conti AC, 1998, J NEUROSCI, V18, P5663; Dimlich R V, 1990, Adv Neurol, V52, P365; Ercan M, 2001, NEUROSURG REV, V24, P127, DOI 10.1007/PL00012396; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gahm C, 2000, NEUROSURGERY, V46, P169; GANSTER RW, 2000, NITRIC OXIDE BIOL PA, P129; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1988, EXP NEUROL, V99, P594, DOI 10.1016/0014-4886(88)90176-8; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Hatton J, 2001, CNS DRUGS, V15, P553, DOI 10.2165/00023210-200115070-00005; Haynes LE, 2001, NEUROSCIENCE, V104, P57, DOI 10.1016/S0306-4522(01)00070-7; Holmin, 1996, ACTA NEUROCHIR, V138, P418, DOI 10.1007/BF01420304; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hortobagyi T, 2000, PFLUG ARCH EUR J PHY, V441, P409, DOI 10.1007/s004240000441; HUBSCHMANN OR, 1985, J NEUROSURG, V62, P698, DOI 10.3171/jns.1985.62.5.0698; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Kavanagh RJ, 2001, BRIT J ANAESTH, V86, P110, DOI 10.1093/bja/86.1.110; Langham J., 2000, COCHRANE DATABASE SY; LIPTON SA, 2003, NATURE, V12, P626; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MALAWISTA SE, 1968, ARTHRITIS RHEUM-US, V11, P191, DOI 10.1002/art.1780110210; Marczin N, 1996, BRIT J PHARMACOL, V118, P1085, DOI 10.1111/j.1476-5381.1996.tb15510.x; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1995, J NEUROTRAUM, V12, P929, DOI 10.1089/neu.1995.12.929; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; Mathiesen T, 1995, ACTA NEUROCHIR, V137, P155, DOI 10.1007/BF02187188; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; MINCGOLOMB D, 1994, BRIT J PHARMACOL, V112, P720, DOI 10.1111/j.1476-5381.1994.tb13136.x; Mitchell IJ, 1998, NEUROSCIENCE, V84, P489, DOI 10.1016/S0306-4522(97)00534-4; MOLAD Y, 2002, CURR RHEUMATOL REP, V42, P52; Murray GD, 1996, ACTA NEUROCHIR, V138, P1163, DOI 10.1007/BF01809745; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RINK A, 1995, AM J PATHOL, V147, P1575; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Salahudeen A, 1996, TRANSPLANTATION, V62, P1628, DOI 10.1097/00007890-199612150-00017; SANADA T, 1993, J NEUROTRAUM, V10, P65, DOI 10.1089/neu.1993.10.65; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; TEASDALE G, 1990, ACT NEUR S, V51, P315; Ustun ME, 2001, J NEUROSURG ANESTH, V13, P227; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; YUI Y, 1991, J BIOL CHEM, V266, P12544; Zhu DY, 1999, LIFE SCI, V65, pPL221	66	15	16	0	2	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	OCT	2005	147	10					1071	1084		10.1007/s00701-005-0590-7			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	966XH	WOS:000232055600018	16044358				2021-06-18	
J	Layman, DE; Dijkers, MPJM; Ashman, TA				Layman, DE; Dijkers, MPJM; Ashman, TA			Exploring the impact of traumatic brain injury on the older couple: 'Yes, but how much of it is age, I can't tell you ...'	BRAIN INJURY			English	Article						head injuries; closed; aging; adaptation; psychological; family health; quality of life; qualitative research; couples; sexuality; support; interpersonal; role changes	QUALITY-OF-LIFE; HEAD-INJURY; FOLLOW-UP; MARITAL RELATIONSHIPS; SOCIAL-ADJUSTMENT; INDIVIDUALS; PSYCHOPATHOLOGY; REHABILITATION; DYSFUNCTION; SYMPTOMS	Primary objective: To qualitatively explore the partner relationships of older couples faced with traumatic brain injury (TBI). Research design: Qualitative analysis comparing individuals with TBI and a comparison group. Methods and procedures: Twenty-one individuals were interviewed using a semi-structured format focusing on various aspects of their partner relationship. A qualitative analysis of transcripts identified general themes. Main outcomes and results: Variability of relationship experiences (relationship relatedness and persistence of the partnership) was shown across groups. Aspects of relationship commitment to the partnership were revealed. Many individuals with TBI and their partners attributed various relationship changes to ageing and age-related issues and not to the TBI. Conclusions: These findings suggest that the effects of TBI are not clearly distinguished from age-related causes for change in the partners and their relationship. Older couples' experiences may be different from those of younger couples impacted by TBI, in the areas of sexuality, inter-personal support and role functions.	Jamaica Hosp Med Ctr, Dept Phys Med & Rehabil, Queens, NY USA; Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA	Layman, DE (corresponding author), Jamaica Hosp Med Ctr, 8900 Van Wyck Expressway, Jamaica, NY 11418 USA.	dave@layman.com	Ashman, Teresa/B-1621-2013	Dijkers, Marcel/0000-0002-8362-5596			Barrett AE, 1999, GERONTOLOGIST, V39, P695, DOI 10.1093/geront/39.6.695; Bell K R, 2001, Phys Med Rehabil Clin N Am, V12, P169; Brooks N, 1988, Acta Neurochir Suppl (Wien), V44, P59; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; CDC, 1999, TRAUM BRAIN INJ US R; Downe-Wamboldt B, 1992, Health Care Women Int, V13, P313; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; Golden Z, 2003, INT J NEUROSCI, V113, P733, DOI 10.1080/00207450390200044; Gosling J, 1999, BRAIN INJURY, V13, P785; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hibbard MR, 2000, NEUROREHABILITATION, V15, P109; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; JACOBS HE, 1987, J HEAD TRAUMA REHAB, V2, P37; Katz S, 1999, INT J REHABIL RES, V22, P45, DOI 10.1097/00004356-199903000-00006; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; Kumashiro M, 2002, J PERS, V70, P1009, DOI 10.1111/1467-6494.05030; Lazarus R.S., 1984, STRESS APPRAISAL COP; Lazarus RS, 1998, CLINICAL GEROPSYCHOLOGY, P109, DOI 10.1037/10295-007; LEVENSON RW, 1993, PSYCHOL AGING, V8, P301, DOI 10.1037/0882-7974.8.2.301; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PARLESZ A, 1998, INT J REHABILITATION, V21, P339; Patton MQ., 1990, QUALITATIVE EVALUATI; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; RICHARDS L, 1997, QSR NUD IST 4 USER G; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Sandelowski M, 1991, Image J Nurs Sch, V23, P161, DOI 10.1111/j.1547-5069.1991.tb00662.x; Schulz R, 1996, AM PSYCHOL, V51, P702, DOI 10.1037/0003-066X.51.7.702; Sinnakaruppan I, 2001, BRAIN INJURY, V15, P653; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; White GW, 2004, ARCH PHYS MED REHAB, V85, pS3, DOI 10.1016/j.apmr.2003.08.109; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	44	15	15	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2005	19	11					909	923		10.1080/02699050500109928			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	983YY	WOS:000233269500006	16243747				2021-06-18	
J	Fargo, JD; Schefft, BK; Dulay, MF; Privitera, MD; Yeh, HS				Fargo, JD; Schefft, BK; Dulay, MF; Privitera, MD; Yeh, HS			Confrontation naming in individuals with temporal lobe epilepsy: A quantitative analysis of paraphasic error subtypes	NEUROPSYCHOLOGY			English	Article						epilepsy; seizures; paraphasias; confrontation naming; lateralization	CLOSED-HEAD-INJURY; POSTICTAL LANGUAGE DYSFUNCTION; SPREADING-ACTIVATION THEORY; ALZHEIMERS-DISEASE; VERBAL MEMORY; SENTENCE PRODUCTION; SEMANTIC KNOWLEDGE; CASE-SERIES; IMPAIRMENT; RETRIEVAL	Although confrontation naming deficits have been observed in dominant temporal lobe epilepsy (DTLE), the relative contribution of impoverished phonologic word retrieval and/or semantic knowledge remains unclear. Analysis of verbal-semantic, phonemic-literal, and combination paraphasias produced during confrontation naming by participants with seizure disorders (52 DTLE; 47 nondominant temporal lobe epilepsy [NDTLE]; 54 psychogenic nonepileptic seizures [PNES]) indicated that the frequency of: (a) verbal-semantic paraphasias was similar across groups, (b) phonemic-literal paraphasias was highest in DTLE, and (c) combination paraphasias was lowest in PNES. Confrontation naming ability was most strongly related to phonemic-literal paraphasia frequency in DTLE and to verbal IQ in both NDTLE and PNES. Greater confrontation naming deficits in DTLE may be attributed to impairments in phonological processing.	Univ Cincinnati, Dept Psychol, Cincinnati, OH 45221 USA; Utah State Univ, Dept Psychol, Res & Evaluat Methodol Program, Logan, UT 84322 USA; Univ Cincinnati, Med Ctr, Dept Neurol, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Dept Neurosurg, Cincinnati, OH 45267 USA	Schefft, BK (corresponding author), Univ Cincinnati, Dept Psychol, POB 210376, Cincinnati, OH 45221 USA.	scheffbk@email.uc.edu	Fargo, Jamison/E-8361-2010				ARDILA A, 1993, BRAIN LANG, V44, P165, DOI 10.1006/brln.1993.1011; Barbarotto R, 1998, NEUROPSYCHOLOGIA, V36, P397, DOI 10.1016/S0028-3932(97)00124-3; Basso A, 1996, J CLIN EXP NEUROPSYC, V18, P77, DOI 10.1080/01688639608408264; BAYLES KA, 1983, BRAIN LANG, V19, P98, DOI 10.1016/0093-934X(83)90057-3; Beausoleil N, 2003, APHASIOLOGY, V17, P143, DOI 10.1080/729255219; Bell BD, 2001, NEUROPSYCHOLOGY, V15, P434, DOI 10.1037//0894-4105.15.4.434; BLAXTON TA, 1993, BRAIN LANG, V44, P221, DOI 10.1006/brln.1993.1015; Bookheimer SY, 1998, NEUROREPORT, V9, P2409, DOI 10.1097/00001756-199807130-00047; Bowman ES, 1998, PSYCHIAT CLIN N AM, V21, P649, DOI 10.1016/S0193-953X(05)70029-0; CAPPA SF, 1990, NEUROPSYCHOLOGIA, V28, P503, DOI 10.1016/0028-3932(90)90076-Z; CARAMAZZA A, 1978, PSYCHOL BULL, V85, P898, DOI 10.1037/0033-2909.85.4.898; CHARBOLLA DR, 1996, MAYO CLIN P, V71, P493; Cragar DE, 2002, NEUROPSYCHOL REV, V12, DOI 10.1023/A:1015491123070; CUMMINGS JL, 1985, NEUROLOGY, V35, P394, DOI 10.1212/WNL.35.3.394; Damasio H, 2004, COGNITION, V92, P179, DOI 10.1016/j.cognition.2002.07.001; Daum I, 1996, J CLIN EXP NEUROPSYC, V18, P648, DOI 10.1080/01688639608408289; DELL GS, 1992, COGNITION, V42, P287, DOI 10.1016/0010-0277(92)90046-K; DELL GS, 1986, PSYCHOL REV, V93, P283, DOI 10.1037/0033-295X.93.3.283; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Fedio P, 1997, BRAIN COGNITION, V33, P98, DOI 10.1006/brcg.1997.0886; Ficker DM, 2001, NEUROLOGY, V56, P1590, DOI 10.1212/WNL.56.11.1590; FLICKER C, 1987, BRAIN LANG, V31, P187, DOI 10.1016/0093-934X(87)90069-1; GAINOTTI G, 1986, BRAIN LANG, V29, P18, DOI 10.1016/0093-934X(86)90031-3; Gates JR, 2000, EPILEPSY BEHAV, V1, P2, DOI 10.1006/ebeh.2000.0029; Gates JR, 1991, EPILEPSY BEHAV, P251; Geschwind N., 1967, CORTEX, V3, P97, DOI 10.1016/S0010-9452(67)80007-8; GLASER WR, 1992, COGNITION, V42, P61, DOI 10.1016/0010-0277(92)90040-O; Goodglass H, 1997, J Int Neuropsychol Soc, V3, P128; Goodglass H, 1998, BRAIN LANG, V64, P1, DOI 10.1006/brln.1998.1950; GOODGLASS H, 1980, AM SCI, V68, P647; Goodglass H., 1993, UNDERSTANDING APHASI; Goodglass H., 1983, ASSESSMENT APHASIA R; Gurd JM, 1997, BEHAV NEUROL, V10, P31, DOI 10.3233/BEN-1997-10106; HENRY TR, 1993, ARCH NEUROL-CHICAGO, V50, P582, DOI 10.1001/archneur.1993.00540060022011; Hermann B.P., 1992, HDB HEAD TRAUMA ACUT; HERMANN BP, 1992, CORTEX, V28, P423, DOI 10.1016/S0010-9452(13)80152-9; Hillis AE, 2002, COGN NEUROPSYCHOL, V19, P523, DOI 10.1080/02643290244000077; HOWELL RA, 1994, CORTEX, V30, P469, DOI 10.1016/S0010-9452(13)80342-5; HUFF FJ, 1988, BRAIN LANG, V34, P262, DOI 10.1016/0093-934X(88)90138-1; Humphreys GW, 2003, COGN NEUROPSYCHOL, V20, P263, DOI 10.1080/02643290342000023; Johnson CJ, 1996, PSYCHOL BULL, V120, P113, DOI 10.1037/0033-2909.120.1.113; Jones-Gotman M, 2000, CAN J NEUROL SCI, V27, pS39, DOI 10.1017/S0317167100000639; JONESGOTMAN M, 2000, CAN J NEUROL SCI S1, V27, pS50; Jordan FM, 1996, APHASIOLOGY, V10, P755, DOI 10.1080/02687039608248448; Kaplan E., 1983, BOSTON NAMING TEST; KEMPEN G, 1983, COGNITION, V14, P185, DOI 10.1016/0010-0277(83)90029-X; Krumholz A, 1999, NEUROLOGY, V53, pS76; LaBarge E., 1992, NEUROPSYCHOLOGY, V6, P77, DOI [10.1037/0894-4105.6.1.77, DOI 10.1037/0894-4105.6.1.77]; Lambon Ralph Matthew A., 2000, Neuropsychologia, V38, P186; LETHLEAN JB, 1994, J NEUROLINGUIST, V8, P207, DOI 10.1016/0911-6044(94)90027-2; Levelt W. J. M., 1989, SPEAKING INTENTION A; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; Lewis FM, 1998, APHASIOLOGY, V12, P193, DOI 10.1080/02687039808249446; Loring D. W., 1999, INS DICT NEUROPSYCHO; Maess B, 2002, J COGNITIVE NEUROSCI, V14, P455, DOI 10.1162/089892902317361967; Martin N, 1996, LANG COGNITIVE PROC, V11, P257, DOI 10.1080/016909696387187; MAYEUX R, 1980, NEUROLOGY, V30, P120, DOI 10.1212/WNL.30.2.120; Nagarajan L, 1996, ACTA NEUROL SCAND, V93, P81; NEBES RD, 1989, PSYCHOL BULL, V106, P377, DOI 10.1037/0033-2909.106.3.377; Ogden-Epker M, 2001, CLIN NEUROPSYCHOL, V15, P183, DOI 10.1076/clin.15.2.183.1900; PAIVIO A, 1991, CAN J PSYCHOL, V45, P255, DOI 10.1037/h0084295; Perri R, 2000, CORTEX, V36, P213, DOI 10.1016/S0010-9452(08)70525-2; Privitera M, 1996, EPILEPSIA, V37, P936, DOI 10.1111/j.1528-1157.1996.tb00530.x; Ralph MAL, 2002, APHASIOLOGY, V16, P56, DOI 10.1080/02687040143000448; Ralph MAL, 1998, NEUROPSYCHOLOGIA, V36, P775, DOI 10.1016/S0028-3932(97)00169-3; Ralph MAL, 2001, J COGNITIVE NEUROSCI, V13, P341, DOI 10.1162/08989290151137395; Ramani V, 2000, NONEPILEPTIC SEIZURE, P311; ROELOFS A, 1992, COGNITION, V42, P107, DOI 10.1016/0010-0277(92)90041-F; Salmon DP, 1996, BRAIN COGNITION, V31, P148, DOI 10.1006/brcg.1996.0039; SASS KJ, 1992, J CLIN EXP NEUROPSYC, V14, P662, DOI 10.1080/01688639208402854; Sawrie SM, 2000, BRAIN, V123, P770, DOI 10.1093/brain/123.4.770; Schefft BK, 2003, EPILEPSY BEHAV, V4, P161, DOI 10.1016/S1525-5050(03)00026-X; SCHWARTZ MF, 1979, BRAIN LANG, V7, P277, DOI 10.1016/0093-934X(79)90024-5; Shiel A, 1992, CLIN REHABIL, V6, P283; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wheeler DW, 1997, BRAIN LANG, V59, P147, DOI 10.1006/brln.1997.1816; White R F, 1990, J Neuropsychiatry Clin Neurosci, V2, P422	77	15	15	0	3	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	SEP	2005	19	5					603	611		10.1037/0894-4105.19.5.603			9	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	970HU	WOS:000232296700005	16187878				2021-06-18	
J	Lung, HL; Shan, SW; Tsang, D; Leung, KN				Lung, HL; Shan, SW; Tsang, D; Leung, KN			Tumor necrosis factor-alpha mediates the proliferation of rat C6 glioma cells via beta-adrenergic receptors	JOURNAL OF NEUROIMMUNOLOGY			English	Article						tumor necrosis factor-alpha; b-adrenergic receptor; cell proliferation; rat C6 glioma cells	CLOSED-HEAD INJURY; TNF-ALPHA; GLIAL-CELL; GENE-EXPRESSION; NERVOUS-SYSTEM; BRAIN-INJURY; BETA-1-ADRENERGIC RECEPTOR; INFLAMMATORY CYTOKINES; MESSENGER-RNA; ASTROCYTES	In the present study, we observed that isoproterenol, a beta-adrenergic receptor (beta-AR) agonist, stimulated rat C6 glioma cell proliferation, while propranolol, a beta-AR blocker, greatly reduced the proliferative effect of TNF-alpha on C6 cells. The gene and protein expressions of both beta 1- and beta 2-ARs were enhanced in C6 cells after TNF-alpha treatment, and the increase in beta-AR was due to an increased number of binding sites and not due to increase in receptor affinity. We further showed that protein kinase C (PKC) was involved in the TNF-alpha-induced beta-AR expression. Collectively, our results indicate that TNF-alpha-induced proliferation in C6 glioma cells might be via the induction and activation of beta-ARs, (C) 2005 Elsevier B.V. All rights reserved.	Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China	Leung, KN (corresponding author), Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China.	knleung@cuhk.edu.hk	Lung, Hong Lok/C-4494-2009	SHAN, SW/0000-0001-6876-9914			BARNA BP, 1990, J NEUROIMMUNOL, V30, P239, DOI 10.1016/0165-5728(90)90108-Y; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BENVENISTE EN, 1989, J NEUROIMMUNOL, V25, P209, DOI 10.1016/0165-5728(89)90139-2; BUCKLAND PR, 1990, NUCLEIC ACIDS RES, V18, P682, DOI 10.1093/nar/18.3.682; CHUNG IY, 1990, J IMMUNOL, V144, P2999; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; DEBLASI A, 1990, DRUG EXP CLIN RES, V16, P107; Desai D, 2004, BIOCHEM BIOPH RES CO, V318, P642, DOI 10.1016/j.bbrc.2004.04.073; DIBNER MD, 1981, J BIOL CHEM, V256, P7343; ELALOUF JM, 1993, J CLIN INVEST, V91, P264, DOI 10.1172/JCI116180; Feuerstein G, 1998, CELL MOL NEUROBIOL, V18, P695, DOI 10.1023/A:1020226020062; Friedlander DR, 1998, J NEUROBIOL, V37, P291, DOI 10.1002/(SICI)1097-4695(19981105)37:2<291::AID-NEU8>3.0.CO;2-F; Gabryel B, 2001, NEUROTOX RES, V3, P205, DOI 10.1007/BF03033192; GOCAYNE J, 1987, P NATL ACAD SCI USA, V84, P8296, DOI 10.1073/pnas.84.23.8296; GUBITS RM, 1992, J NEUROSCI RES, V33, P297, DOI 10.1002/jnr.490330213; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; HodgesSavola C, 1996, GLIA, V17, P52, DOI 10.1002/(SICI)1098-1136(199605)17:1<52::AID-GLIA5>3.0.CO;2-9; HOUGH C, 1990, BIOCHEM BIOPH RES CO, V170, P46, DOI 10.1016/0006-291X(90)91238-N; Huang H, 1998, LIFE SCI, V62, P889, DOI 10.1016/S0024-3205(98)00006-X; John GR, 2003, NEUROSCIENTIST, V9, P10, DOI 10.1177/1073858402239587; KEMPSKI O, 1992, PROG BRAIN RES, V94, P69; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Lau CBS, 2004, LIFE SCI, V75, P797, DOI 10.1016/j.lfs.2004.04.001; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; Leker RR, 1999, J NEUROL SCI, V162, P114, DOI 10.1016/S0022-510X(98)00301-3; LIBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lung HL, 2004, INT J MOL MED, V13, P465; Lung HL, 2001, LIFE SCI, V68, P2081, DOI 10.1016/S0024-3205(01)00997-3; MACHIDA CA, 1990, J BIOL CHEM, V265, P12960; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MORGANTIKOSSMAN.MC, 1992, TRENDS PHARMACOL SCI, V13, P291; Morin D, 1996, LIFE SCI, V60, P315, DOI 10.1016/S0024-3205(96)00632-7; MUNOZFERNANDEZ MA, 1993, BIOCHEM BIOPH RES CO, V194, P319, DOI 10.1006/bbrc.1993.1822; MUNOZFERNANDEZ MA, 1991, EXP CELL RES, V194, P161, DOI 10.1016/0014-4827(91)90147-M; MURPHY S, 1987, NEUROSCIENCE, V22, P381, DOI 10.1016/0306-4522(87)90342-3; Nakamura A, 1998, J NEUROIMMUNOL, V88, P144, DOI 10.1016/S0165-5728(98)00109-X; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PARKER KK, 1980, SCIENCE, V208, P179, DOI 10.1126/science.6102413; Roymans D, 2001, J NEUROCHEM, V76, P610, DOI 10.1046/j.1471-4159.2001.00077.x; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; SUTIN J, 1993, EXP NEUROL, V120, P214, DOI 10.1006/exnr.1993.1056; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Van Kolen K, 2004, J NEUROCHEM, V89, P442, DOI 10.1111/j.1471-4159.2004.02339.x; VERNADAKIS A, 1992, PROG BRAIN RES, V94, P391; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Wang L, 2001, ENDOCRINOLOGY, V142, P3041, DOI 10.1210/en.142.7.3041; Yang GY, 1998, NEUROREPORT, V9, P2131, DOI 10.1097/00001756-199806220-00041; YU NC, 1995, MOL PHARMACOL, V48, P550; ZHONG HY, 1993, MOL PHARMACOL, V44, P1085	57	15	15	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728	1872-8421		J NEUROIMMUNOL	J. Neuroimmunol.	SEP	2005	166	1-2					102	112		10.1016/j.jneuroim.2005.05.011			11	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	958ZQ	WOS:000231487100011	16005083				2021-06-18	
J	Pantovic, R; Draganic, P; Erakovic, V; Blagovic, B; Milin, C; Simonic, A				Pantovic, R; Draganic, P; Erakovic, V; Blagovic, B; Milin, C; Simonic, A			Effect of indomethacin on motor activity and spinal cord free fatty acid content after experimental spinal cord injury in rabbits	SPINAL CORD			English	Article						chromatography; free fatty acids; indomethacin; rabbit; spinal cord injury	ARACHIDONIC-ACID; PROSTAGLANDIN SYNTHESIS; LIPID-METABOLISM; BLOOD-FLOW; RAT; INHIBITOR; TRAUMA; EDEMA; DEXAMETHASONE; ACCUMULATION	Study design: Determination of functional and biochemical parameters as well as the effect of specific therapies on these parameters, in the experimental model of neurotrauma in rabbits. Objective: To assess the effect of indomethacin (0.1 - 3.0 mg/kg for 9 days), a potent inhibitor of endogenous prostaglandin synthesis, on the motor activity and on the spinal cord tissue concentration of free palmitic, stearic, oleic, arachidonic and docosahexaenoic acids in an experimental model of a spinal cord injury in rabbits. Setting: Faculty of Medicine, University of Rijeka, Croatia. Methods: The animals were randomly divided into nine experimental groups, four sham and/ or vehicle-treated and five indomethacin-treated ( including one sham-operated and four injured groups). Laminectomy was followed by contusion of the spinal cord, using a modi. cation of the technique of Albin. Motor activity was controlled daily during the course of the next nine postoperation days and scored using Tarlov's system. Spinal cord samples from the impact injury site were taken and frozen in liquid nitrogen. Total lipids were isolated and purified by a modi. cation of the method of Folch. Free fatty acids (FFAs) were separated from the total lipid extract by preparative thin-layer chromatography, converted to the corresponding methyl esters and identified using gas chromatography, using nonadecanoic acid as the internal standard. Results: The concentrations of all analysed free fatty acids were increased in the spinal cord after neurotrauma, in comparison to control tissues. Treatment of injured rabbits with indomethacin resulted in a significant decrease in spinal cord FFAs and exerted a positive effect on neurotrauma-induced motor impairment. Conclusion: These results indicate a mechanism whereby indomethacin protects rabbits from the sequellae of neuronal damage caused by trauma, and suggests that it may be beneficial in the therapy of neurotrauma.	Univ Rijeka, Fac Med, Dept Chem & Biochem, HR-51000 Rijeka, Croatia; PLIVA Res Inst Ltd, Zagreb, Croatia	Pantovic, R (corresponding author), Univ Rijeka, Fac Med, Dept Chem & Biochem, B Branchetta 20, HR-51000 Rijeka, Croatia.		Blagovic, Branka/S-4391-2018	Blagovic, Branka/0000-0001-5075-8256; Erakovic Haber, Vesna/0000-0003-0016-768X			ALBIN MS, 1968, J NEUROSURG, V29, P113, DOI 10.3171/jns.1968.29.2.0113; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Banik NL, 2000, NEUROCHEM RES, V25, P1509, DOI 10.1023/A:1007684311023; Banovac K, 2001, SPINAL CORD, V39, P370, DOI 10.1038/sj.sc.3101166; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; BINGHAM WG, 1975, J NEUROSURG, V43, P162, DOI 10.3171/jns.1975.43.2.0162; DEMEDIUK P, 1985, P NATL ACAD SCI USA, V82, P7071, DOI 10.1073/pnas.82.20.7071; DEMEDIUK P, 1989, J NEUROSCI RES, V23, P95, DOI 10.1002/jnr.490230113; DEMEDIUK P, 1985, PROG BRAIN RES, V63, P211; DUCKER TB, 1971, J NEUROSURG, V35, P700, DOI 10.3171/jns.1971.35.6.0700; FADEN AI, 1987, J NEUROCHEM, V48, P1809, DOI 10.1111/j.1471-4159.1987.tb05740.x; Farooqui AA, 1997, J NEUROCHEM, V69, P889; FAROOQUI AA, 1991, BRAIN RES REV, V16, P171, DOI 10.1016/0165-0173(91)90004-R; FOLCH J, 1957, J BIOL CHEM, V226, P497; GUTH L, 1994, EXP NEUROL, V126, P76, DOI 10.1006/exnr.1994.1043; Guven MB, 1999, PEDIATR NEUROSURG, V31, P189, DOI 10.1159/000028860; HALT PS, 1992, ARCH NEUROL-CHICAGO, V49, P1178, DOI 10.1001/archneur.1992.00530350096025; Horrocks L A, 1985, Cent Nerv Syst Trauma, V2, P115; HSU CY, 1986, J NEUROL SCI, V74, P289, DOI 10.1016/0022-510X(86)90114-0; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; JONSSON HT, 1976, PROSTAGLANDINS, V11, P51, DOI 10.1016/0090-6980(76)90172-6; MORELAND DB, 1989, SURG NEUROL, V31, P277, DOI 10.1016/0090-3019(89)90052-9; MURPHY EJ, 1994, MOL CHEM NEUROPATHOL, V23, P13, DOI 10.1007/BF02858504; Olby N, 1999, J VET INTERN MED, V13, P399, DOI 10.1892/0891-6640(1999)013&lt;0399:CCITMO&gt;2.3.CO;2; OLSSON Y, 1992, PROG BRAIN RES, V91, P197; Pantovic R, 2002, PERIOD BIOL, V104, P95; Schwab JM, 2000, J NEUROIMMUNOL, V111, P122, DOI 10.1016/S0165-5728(00)00372-6; SHARMA HS, 1995, RESTOR NEUROL NEUROS, V7, P207, DOI 10.3233/RNN-1994-7403; SHARMA HS, 1993, ACTA NEUROPATHOL, V85, P145; SHARMA HS, 2002, MUSCLE NERVE, V11, P583; Shehab D, 2002, J NUCL MED, V43, P346; SIEGAL T, 1988, SPINE, V13, P1171; SIEGAL T, 1990, NEUROSURGERY, V26, P967, DOI 10.1227/00006123-199006000-00008; SIEGAL T, 1988, NEUROSURGERY, V22, P334, DOI 10.1227/00006123-198802000-00010; SIMPSON RK, 1991, J SPINAL DISORD, V4, P420, DOI 10.1097/00002517-199112000-00003; Slavik RS, 1999, NEUROL RES, V21, P491; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Toborek M, 1999, J NEUROCHEM, V73, P684, DOI 10.1046/j.1471-4159.1999.0730684.x; Toborek M, 2000, EXP NEUROL, V161, P609, DOI 10.1006/exnr.1999.7308; VANHEDEMAN LS, 1974, J NEUROSURG, V40, P37; VISER WM, 1974, J NEUROSURG, V40, P77; WINKLER T, 1993, NEUROSCIENCE, V52, P1057, DOI 10.1016/0306-4522(93)90552-Q; Yin K S, 2001, J Spinal Cord Med, V24, P119; YOSHIHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P484, DOI 10.1016/0006-291X(90)92117-I; Zhang ZY, 1997, EXP NEUROL, V143, P141, DOI 10.1006/exnr.1996.6355; Zheng ZH, 1996, NEUROCHEM INT, V28, P551, DOI 10.1016/0197-0186(95)00131-X; ZUPAN G, 1995, CROAT CHEM ACTA, V68, P485	47	15	16	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	SEP	2005	43	9					519	526		10.1038/sj.sc.3101763			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	962GA	WOS:000231717800002	15852057	Bronze			2021-06-18	
J	Casselbrant, ML; Mandel, EM				Casselbrant, ML; Mandel, EM			Balance disorders in children	NEUROLOGIC CLINICS			English	Article							BENIGN PAROXYSMAL VERTIGO; BASILAR ARTERY MIGRAINE; CONGENITAL PERILYMPHATIC FISTULA; FLUCTUATING HEARING-LOSS; TRAUMATIC BRAIN-INJURY; MIDDLE-EAR EFFUSION; OTITIS-MEDIA; VESTIBULAR SYSTEM; MENIERES-DISEASE; CHILDHOOD	Balance disorders in children may be difficult to recognize. Children often are unable to describe their symptoms and may seem just clumsy. The episodes may be of short duration, autonomic symptoms may be prominent, or symptoms may be thought of as a behavioral disorder. Dizziness may indicate a problem in the vestibular system, a problem in other sensory systems, or an abnormality of other organ systems. Management of these disorders depends on an accurate diagnosis. Disorders associated with dizziness in children are divided into three categories: (1) acute nonrecurring spontaneous vertigo; (2) recurrent vertigo; and (3) nonvertiginous dizziness, disequilibrium, and ataxia.	Childrens Hosp Pittsburgh, Dept Pediat Otolaryngol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA USA	Casselbrant, ML (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat Otolaryngol, 3705 5th Ave, Pittsburgh, PA 15213 USA.	margaretha.casselbrant@chp.edu					Anoh-Tanon MJ, 2000, PEDIATR NEUROL, V23, P49, DOI 10.1016/S0887-8994(00)00140-5; BALKANY TJ, 1986, EAR HEARING, V7, P138, DOI 10.1097/00003446-198606000-00004; BARABAS G, 1983, PEDIATRICS, V72, P188; BASSER LS, 1964, BRAIN, V87, P141, DOI 10.1093/brain/87.1.141; BICKERSTAFF ER, 1961, LANCET, V1, P15; Bille BS, 1962, ACTA PAED STOCK S136, V136, P1; BLAYNEY AW, 1984, CLIN OTOLARYNGOL, V9, P77, DOI 10.1111/j.1365-2273.1984.tb01477.x; BRANDT T, 1980, ANN NEUROL, V7, P195, DOI 10.1002/ana.410070302; BRUININKS RH, 1978, BRUININKSOSERETSKY T; Busis S N, 1976, Pediatr Ann, V5, P478; CASSELBRANT ML, 1995, ANN OTO RHINOL LARYN, V104, P620, DOI 10.1177/000348949510400806; Casselbrant ML, 1998, ANN OTO RHINOL LARYN, V107, P401, DOI 10.1177/000348949810700507; CASSELBRANT ML, 1983, ANN OTO RHINOL LARYN, V107, P46; Casselbrant ML, 2003, PEDIAT OTOLARYNGOLOG, P351; Cohen H, 1997, INT J PEDIATR OTORHI, V42, P107, DOI 10.1016/S0165-5876(97)00113-4; CROWE T K, 1990, Physical and Occupational Therapy in Pediatrics, V10, P1; CYR DG, 1992, INSIGHTS, V7, P1; Dandy W, 1941, SURG GYNECOL OBSTET, V72, P421; DUNN DW, 1976, AM J DIS CHILD, V130, P1099, DOI 10.1001/archpedi.1976.02120110061008; EVIATAR L, 1977, PEDIATRICS, V59, P833; EVIATAR L, 1981, ANN NEUROL, V9, P126, DOI 10.1002/ana.410090205; FARMER TW, 1963, ARCH NEUROL-CHICAGO, V8, P471, DOI 10.1001/archneur.1963.00460050021002; FILIPO R, 1985, J LARYNGOL OTOL, V99, P193, DOI 10.1017/S0022215100096523; Folio M. R., 1983, PEABODY DEV MOTOR SC; FRIED MP, 1980, LARYNGOSCOPE, V90, P1548; Furman JM, 1999, NEW ENGL J MED, V341, P1590, DOI 10.1056/NEJM199911183412107; FURMAN JM, 2003, PEDIAT OTOLARYNGOLOG, P273; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; GATES GA, 1980, EAR NOSE THROAT J, V59, P358; Gawron W, 2002, DIABETOLOGIA, V45, P728, DOI 10.1007/s00125-002-0813-x; GOLDEN GS, 1975, PEDIATRICS, V56, P722; Golz A, 1998, OTOLARYNG HEAD NECK, V119, P695, DOI 10.1016/S0194-5998(98)70039-7; GOLZ A, 1991, J LARYNGOL OTOL, V105, P987, DOI 10.1017/S002221510011802X; GOODHILL V, 1973, ANN OTO RHINOL LARYN, V82, P2, DOI 10.1177/000348947308200103; GRUNDFAST KM, 1978, ANN OTO RHINOL LARYN, V87, P761, DOI 10.1177/000348947808700603; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HARKER LA, 1987, OTOLARYNG HEAD NECK, V96, P239; Hart MC, 1998, LARYNGOSCOPE, V108, P665, DOI 10.1097/00005537-199805000-00008; HASLAM RHA, 2000, NELSON TXB PEDIAT, P1810; HAUSLER R, 1987, AM J OTOLARYNG, V8, P187, DOI 10.1016/S0196-0709(87)80001-7; HORAK FB, 1988, DEV MED CHILD NEUROL, V30, P64, DOI 10.1111/j.1469-8749.1988.tb04727.x; JONES NS, 1990, ANN OTO RHINOL LARYN, V99, P477, DOI 10.1177/000348949009900612; Kaga K, 1999, INT J PEDIATR OTORHI, V49, P215, DOI 10.1016/S0165-5876(99)00206-2; KOEHLER B, 1980, EUR J PEDIATR, V134, P149, DOI 10.1007/BF01846035; LANZI G, 1994, CEPHALALGIA, V14, P458, DOI 10.1046/j.1468-2982.1994.1406458.x; LOVE JT, 1978, OTOLARYNG HEAD NECK, V86, P450, DOI 10.1177/019459987808600314; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MERCIA FW, 1942, JAMA-J AM MED ASSOC, V118, P1282; MEYERHOFF WL, 1978, LARYNGOSCOPE, V88, P1504; Orlin MN, 1997, PEDIATRICS, V99, P334, DOI 10.1542/peds.99.3.334; PARKER HL, 1946, MAYO CLIN P, V38, P642; PARKER W, 1989, AM J OTOL, V10, P364; SEKITANI T, 1993, ACTA OTO-LARYNGOL, P9; Weber PC, 2003, AM J OTOLARYNG, V24, P138, DOI 10.1016/S0196-0709(02)32418-9; WEBER PC, 1994, OTOLARYNG HEAD NECK, V110, P381, DOI 10.1177/019459989411000405; WEISSMAN JL, 1994, OTOLARYNG HEAD NECK, V111, P243, DOI 10.1016/S0194-5998(94)70598-4	56	15	15	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	AUG	2005	23	3					807	+		10.1016/j.ncl.2005.03.003			24	Clinical Neurology; Neurosciences	Neurosciences & Neurology	955TB	WOS:000231249400009	16026677				2021-06-18	
J	Kumar, S; Rao, SL; Nair, RG; Pillai, S; Chandramouli, BA; Subbakrishna, DK				Kumar, S; Rao, SL; Nair, RG; Pillai, S; Chandramouli, BA; Subbakrishna, DK			Sensory gating impairment in development of post-concussive symptoms in mild head injury	PSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article; Proceedings Paper	56th National Conference of the Indian-Psychiatric-Society	JAN, 2004	Mysore, INDIA	Indian Psychiat Soc		information processing; mild head injury; sensory gating	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; COMBAT VETERANS; STARTLE REFLEX; P50; SCHIZOPHRENIA; HABITUATION; ATTENTION; SEQUELAE; LESIONS	Post-concussive symptoms reported by mild head injury (MHI) patients have been inadequately understood. Post-concussive symptoms reported by patients with MHI have so far been explained in terms of impairment in neurocognitive functions or deficits in modulation of flow of information. There are no studies that have looked into sensory gating impairment in MHI and its relation to post-concussive symptoms. The purpose of the present paper was to investigate the role of sensory gating impairment in post-concussive symptoms in mild head injury patients. Thirty MHI patients were evaluated for their neuropsychological functions, sensory gating deficits, and post-concussive symptoms. Neuropsychological functions were in the domain of attention, executive functions, and learning and memory. Sensory gating was assessed by Structured Interview for Assessing Perceptual Anomalies and post-concussive symptoms were assessed using the Neurobehavioral Rating Scale. Multiple regression method was used to identify predictors for post-concussive symptoms. Post-concussive symptoms were predicted by sensory gating deficits when sensory gating deficit was one of the predictors along with neuropsychological functions. Post-concussive symptoms were predicted by scores of Digit Vigilance and Digit Symbol Substitution Test, when predictors were restricted to neuropsychological functions. Sensory gating deficits were correlated with performance on Digit Symbol Substitution test. Post-concussive symptoms reported by MHI patients are the result of poor modulation of incoming sensory information.	Natl Inst Mental Hlth & Neurosci, Dept Clin Psychol, Div Neuropsychol, Bangalore 560029, Karnataka, India; Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India; Natl Inst Mental Hlth & Neurosci, Dept Biostat, Bangalore, Karnataka, India	Rao, SL (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Clin Psychol, Div Neuropsychol, Bangalore 560029, Karnataka, India.	raos@vsnl.com		Kumar, Sanjay/0000-0001-5018-4184			ADLER LE, 1992, BIOL PSYCHIAT, V32, P607, DOI 10.1016/0006-3223(92)90073-9; ADLER LE, 1990, PSYCHIAT RES, V31, P297, DOI 10.1016/0165-1781(90)90099-Q; Ambrosini A, 2001, NEUROSCI LETT, V306, P132, DOI 10.1016/S0304-3940(01)01871-7; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas D, 2000, J NEUROPSYCH CLIN N, V12, P77, DOI 10.1176/jnp.12.1.77; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; BOUTROS NN, 1991, CLIN ELECTROENCEPHAL, V22, P40, DOI 10.1177/155005949102200109; Boutros NN, 1999, BIOL PSYCHIAT, V45, P917, DOI 10.1016/S0006-3223(98)00253-4; BOUTROS NN, 1995, PSYCHIAT RES, V57, P83, DOI 10.1016/0165-1781(95)02637-C; BRAFF DL, 1990, ARCH GEN PSYCHIAT, V47, P181; BRAFF DL, 1992, ARCH GEN PSYCHIAT, V49, P206; Bunney WE, 1999, SCHIZOPHRENIA BULL, V25, P577, DOI 10.1093/oxfordjournals.schbul.a033402; DAWSON ME, 1993, J ABNORM PSYCHOL, V102, P633, DOI 10.1037/0021-843X.102.4.633; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; FRANKS RD, 1983, BIOL PSYCHIAT, V18, P989; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Ghisolfi ES, 2004, INT J PSYCHOPHYSIOL, V51, P209, DOI 10.1016/j.ijpsycho.2003.09.002; Gillette GM, 1997, LIFE SCI, V61, P1421, DOI 10.1016/S0024-3205(97)00688-7; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; Gronwall D, 1989, MILD HEAD INJURY, P153; Grunwald T, 2003, BIOL PSYCHIAT, V53, P511, DOI 10.1016/S0006-3223(02)01673-6; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Kisley MA, 2004, PSYCHOPHYSIOLOGY, V41, P604, DOI 10.1111/j.1469-8986.2004.00191.x; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MAJ M, 1994, ARCH GEN PSYCHIAT, V51, P51; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; Meyers J, 1995, REY COMPLEX FIGURE R; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Nelson EB, 1998, AM J PSYCHIAT, V155, P137, DOI 10.1176/ajp.155.1.137; Neylan TC, 1999, BIOL PSYCHIAT, V46, P1656, DOI 10.1016/S0006-3223(99)00047-5; RAO SL, 2004, IN PRESS NIMHANS NEU; RAO SL, 2004, NIMHANS NEUROPSYCHO; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Schall U, 1996, NEUROREPORT, V7, P652, DOI 10.1097/00001756-199601310-00065; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; SWERDLOW NR, 1993, BIOL PSYCHIAT, V33, P298, DOI 10.1016/0006-3223(93)90300-3; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; TEASDALE G, 1974, LANCET, V2, P81; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wechsler, 1981, WAIS R MANUAL	44	15	15	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-1316	1440-1819		PSYCHIAT CLIN NEUROS	Psychiatry Clin. Neurosci.	AUG	2005	59	4					466	472		10.1111/j.1440-1819.2005.01400.x			7	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	946LS	WOS:000230574300014	16048453	Bronze			2021-06-18	
J	Caspi, Y; Gil, S; Ben-Ari, IZ; Koren, D; Aaron-Peretz, J; Klein, E				Caspi, Y; Gil, S; Ben-Ari, IZ; Koren, D; Aaron-Peretz, J; Klein, E			Memory of the traumatic event is associated with increased risk for PTSD: A retrospective study of patients with traumatic brain injury	JOURNAL OF LOSS & TRAUMA			English	Article; Proceedings Paper	18th Annual Meeting of the International-Society-for-Traumatic-Stress-Studies	NOV 07-10, 2002	Baltimore, MD	Int Soc Traumat Stress Studies			POSTTRAUMATIC-STRESS-DISORDER; AMNESIA	Studies of the relationship between explicit episodic memory of a traumatic event ( MTE) and posttraumatic stress disorder ( PTSD) are inconclusive. The authors examined whether memory for the details of the traumatic event as reported by patients with mild traumatic brain injury was associated with the development of PTSD. In a retrospective study of 120 participants, MTE was found to be associated with an increased risk of PTSD, particularly for the reexperiencing symptom cluster. Although less frequently, PTSD was nonetheless present even in the absence of explicit memory. Possible explanations for mechanisms that enable this phenomenon are considered.	Rambam Med Ctr, Dept Psychiat, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel; Rambam Med Ctr, Neurocognit Clin, IL-31096 Haifa, Israel	Klein, E (corresponding author), Rambam Med Ctr, Dept Psychiat, POB 9602, IL-31096 Haifa, Israel.	e_klein@rambam.health.gov.il		Koren, Danny/0000-0003-0238-766X			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Basso MR, 2000, J PERS INTERPERS LOS, V5, P125, DOI 10.1080/10811440008409748; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1984, J CLIN PSYCHOL, V40, P1365, DOI 10.1002/1097-4679(198411)40:6<1365::AID-JCLP2270400615>3.0.CO;2-D; BERNSTEIN EM, 1986, J NERV MENT DIS, V174, P727, DOI 10.1097/00005053-198612000-00004; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; BLANCHARD EB, 1997, CRASH ASSESSMENT TRE; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Brewin CR, 2001, BEHAV RES THER, V39, P373, DOI 10.1016/S0005-7967(00)00087-5; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Elhai JD, 2001, ASSESSMENT, V8, P75, DOI 10.1177/107319110100800107; First M., 1994, STRUCTURED CLIN INTE; FOA EB, 1999, J CLIN PSYCHIAT, V60, P5; Freedman SA, 1999, BRIT J PSYCHIAT, V174, P353, DOI 10.1192/bjp.174.4.353; GIL S, IN PRESS AM J PSYCHI; Hyman IE, 1998, CLIN PSYCHOL REV, V18, P933, DOI 10.1016/S0272-7358(98)00041-5; Kaplan CP, 2000, BRAIN INJURY, V14, P251; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; KULKA R, 1990, TRAUMA VIETNAM WAR E; LEDOUX JE, 1990, J NEUROSCI, V10, P1062; Leskin GA, 1998, CLIN PSYCHOL REV, V18, P983, DOI 10.1016/S0272-7358(98)00039-7; MACCIOCCHI SN, 1993, CURR OPIN NEUROL, V6, P773, DOI 10.1097/00019052-199310000-00016; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; MCFARLANE AC, 1989, BRIT J PSYCHIAT, V154, P221, DOI 10.1192/bjp.154.2.221; McFarlane AC, 2000, AUST NZ J PSYCHIAT, V34, P896, DOI 10.1080/000486700264; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; Pitman RK, 2002, BIOL PSYCHIAT, V51, P189, DOI 10.1016/S0006-3223(01)01279-3; PRIGATANO GP, 1987, J CLIN PSYCHOL, V44, P816; Resnick PJ, 1997, PSYCHIAT CLIN N AM, V20, P473, DOI 10.1016/S0193-953X(05)70323-3; Roediger H., 1997, RECOVERED MEMORIES F, P118; ROSENBERG SJ, 1984, J CLIN PSYCHOL, V40, P785, DOI 10.1002/1097-4679(198405)40:3<785::AID-JCLP2270400325>3.0.CO;2-4; ROTHBAUM BO, 2000, POSTTRAUMATIC STRESS, P101; SAPOLSKY RM, 1990, J NEUROSCI, V10, P2897, DOI 10.1523/jneurosci.10-09-02897.1990; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Seedat S, 2001, Curr Psychiatry Rep, V3, P288, DOI 10.1007/s11920-001-0021-2; SHALEV A, 1992, AM J PSYCHIAT, V153, P219; van der Kolk B. A., 2001, TRAUMA COGNITIVE SCI; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; YOUNG A, 2000, PL S STRESS, P51	44	15	15	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1532-5024	1532-5032		J LOSS TRAUMA	J. Loss Trauma	JUL-SEP	2005	10	4					319	335		10.1080/15325020590956756			17	Psychology, Social	Psychology	940PX	WOS:000230157500001					2021-06-18	
J	Mori, K; Iwata, J; Miyazaki, M; Nakao, Y; Maeda, M				Mori, K; Iwata, J; Miyazaki, M; Nakao, Y; Maeda, M			Functional recovery of neuronal activity in rat whisker-barrel cortex sensory pathway from freezing injury after transplantation of adult bone marrow stromal cells	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						bone marrow stromal cell; cortical freezing lesion; local cerebral glucose utilization; transplantation	CEREBRAL GLUCOSE-UTILIZATION; TRAUMATIC BRAIN-INJURY; GROWTH-FACTOR; 2-DEOXYGLUCOSE UPTAKE; C-14 2-DEOXYGLUCOSE; AXONAL INJURY; ALBINO-RAT; THALAMUS; ACTIVATION; FOREBRAIN	The effect of transplantation of adult bone marrow stromal cells (MSCs) into the freeze-lesioned left barrel field cortex in the rat was investigated by measurement of local cerebral glucose utilization (ICMRglc) in the anatomic structures of the whisker-to-barrel cortex sensory pathway. Bone marrow stromal cells or phosphate-buffered saline (PBS) were injected intracerebrally into the boundary zone 1 h after induction of the freezing cortical lesion. Three weeks after surgery, the 21 [C-14]deoxyglucose method was used to measure ICMRgfc during right whisker stimulation. The volume of the primary necrotic freezing lesion was significantly reduced (P < 0.05), and secondary retrograde degeneration in the left ventral posteromedial (VPM) thalamic nucleus was diminished in the MSC-treated group. Local cerebral glucose utilization measurements showed that the freezing cortical lesion did not alter the metabolic responses to stimulation in the brain stem trigeminal nuclei, but eliminated the responses in the left VPM nucleus and periphery of the barrel cortex in the PBS-treated group. The left/right (stimulated/unstimulated) ICMRglc ratios were significantly improved in both the VPM nucleus and periphery of the barrel cortex in the MSC-treated group compared with the PBS-treated group (P < 0.05). These results indicate that MSC transplantation in adults may stimulate metabolic and functional recovery in injured neuronal pathways.	Juntendo Univ, Izunagaoka Hosp, Dept Neurosurg, Izunagaoka, Shizuoka 4102295, Japan; Juntendo Casualty Ctr, Shizuoka, Japan	Mori, K (corresponding author), Juntendo Univ, Izunagaoka Hosp, Dept Neurosurg, 1129 Nagaoka, Izunagaoka, Shizuoka 4102295, Japan.	KMORI1919@hkg.odn.ne.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [16591459] Funding Source: KAKEN		Alzheimer C, 2002, ADV EXP MED BIOL, V513, P335; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; BARRON KD, 1973, J NEUROPATH EXP NEUR, V32, P218, DOI 10.1097/00005072-197304000-00004; Buki A, 2000, J NEUROSCI, V20, P2825; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; CIRICILLO SP, 1994, NEUROSCIENCE, V59, P975, DOI 10.1016/0306-4522(94)90300-X; COOPER RM, 1984, EXP NEUROL, V86, P261, DOI 10.1016/0014-4886(84)90185-7; Dormady SP, 2001, J HEMATOTH STEM CELL, V10, P125, DOI 10.1089/152581601750098372; EAGLESON KL, 1992, EXP NEUROL, V116, P156, DOI 10.1016/0014-4886(92)90163-K; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; GINSBERG MD, 1989, J CEREBR BLOOD F MET, V9, P329, DOI 10.1038/jcbfm.1989.51; GONZALEZ MF, 1985, J COMP NEUROL, V231, P457, DOI 10.1002/cne.902310405; HALL RD, 1974, BRAIN RES, V66, P23, DOI 10.1016/0006-8993(74)90076-6; HEFTI F, 1986, J NEUROSCI, V6, P2155; HOSOKAWA S, 1985, BRAIN RES, V343, P8, DOI 10.1016/0006-8993(85)91152-7; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; KATAOKA K, 1989, STROKE, V20, P1226, DOI 10.1161/01.STR.20.9.1226; Klatzo I, 1965, Prog Brain Res, V15, P73; Kolb Bryan, 2003, Phys Med Rehabil Clin N Am, V14, pS7, DOI 10.1016/S1047-9651(02)00056-6; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X; Lee JB, 2003, NEUROPATHOLOGY, V23, P169, DOI 10.1046/j.1440-1789.2003.00496.x; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; MATA M, 1980, J NEUROCHEM, V34, P213, DOI 10.1111/j.1471-4159.1980.tb04643.x; MEYER JS, 1993, NEUROL RES, V15, P362; Munoz-Elias G, 2003, STEM CELLS, V21, P437, DOI 10.1634/stemcells.21-4-437; Nakao Y, 2001, P NATL ACAD SCI USA, V98, P7593, DOI 10.1073/pnas.121179898; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; PAXINOS G, 1997, RAT BRAIN STEROTAXIC; PEREIRA RF, 1999, SCIENCE, V284, P143; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Reilly JF, 1996, EXP NEUROL, V140, P139, DOI 10.1006/exnr.1996.0124; SHARP FR, 1986, NEUROSCI LETT, V71, P247, DOI 10.1016/0304-3940(86)90567-7; SHARP FR, 1985, J COMP NEUROL, V234, P489, DOI 10.1002/cne.902340407; SHIRAISHI K, 1989, J CEREBR BLOOD F MET, V9, P765, DOI 10.1038/jcbfm.1989.110; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SOKOLOFF L, 1982, ADV NEUROCHEM, V4, P1; SORENSEN JC, 1989, NEUROSCI LETT, V98, P33, DOI 10.1016/0304-3940(89)90369-8; Takai K, 1997, BLOOD, V89, P1560, DOI 10.1182/blood.V89.5.1560.1560_1560_1565; TAKAMI K, 1992, EXP BRAIN RES, V90, P1; TITMUS MJ, 1990, PROG NEUROBIOL, V35, P1, DOI 10.1016/0301-0082(90)90039-J; TOKUNO T, 1992, J CEREBR BLOOD F MET, V12, P954, DOI 10.1038/jcbfm.1992.132; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; YAMADA K, 1991, J CEREBR BLOOD F MET, V11, P472, DOI 10.1038/jcbfm.1991.90; YUAN B, 1986, J NEUROSCI, V6, P3611	55	15	17	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2005	25	7					887	898		10.1038/sj.jcbfm.9600083			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	940CW	WOS:000230122300011	15843791	Bronze			2021-06-18	
J	Bakir, A; Temiz, U; Umur, S; Aydin, V; Torun, F				Bakir, A; Temiz, U; Umur, S; Aydin, V; Torun, F			High-velocity gunshot wounds to the head: Analysis of 135 patients	NEUROLOGIA MEDICO-CHIRURGICA			English	Article						high-velocity missile; shrapnel; head injury	PENETRATING CRANIOCEREBRAL INJURIES; GLASGOW-COMA-SCALE; CIVILIAN PRACTICE; SURGICAL-MANAGEMENT; TRAUMATIC ANEURYSMS; LEBANESE CONFLICT; BONE FRAGMENTS; BRAIN; PROGNOSIS; CHILDREN	Head injuries due to high-velocity missiles and shrapnel as a result of military conflicts have become a very important cause of death or severe neurological deficits. Military-type missiles have high velocities and transfer higher amounts of energy to neural tissue, compared to civil-type missiles. This physical phenomenon also causes greater neural tissue destruction. Shrapnel particles derive from blasts and cause less severe injury because of the irregular particle shape and low energy transmission. This study analyzed 135 patients with head trauma, 80 patients (59%) injured by missiles and 55 patients (41%) by shrapnel. Glasgow Coma Scale (GCS) scores at admission were 3 to 7 in 69 patients, 8 to 10 in 29 patients, and 11 to 15 in 37 patients. The most common anatomical localizations were the right frontoparietal region in 42 patients and the left frontoparietal region in 40 patients. one hundred patients (74%) were operated on immediately and 35 patients (26%) were treated conservatively in the intensive care unit. Ten of the 135 patients died (7.4%), seven from missile injury and three from shrapnel injury. In this study, we found that high mortality was associated with low GCS score at admission, presence of multilobar or skull base injuries, and involvement of ventricles. Early and aggressive surgical intervention decreased the mortality.	Mevki Mil Hosp, Dept Neurosurg, Ankara, Turkey; Celal Bayar Univ, Dept Neurosurg, Fac Med, Manisa, Turkey; Adnan Menderes Univ, Fac Med, Dept Neurosurg, Aydin, Turkey; Ankara Univ, Fac Med, Dept Neurosurg, TR-06100 Ankara, Turkey	Bakir, A (corresponding author), Mevki Mil Hosp, Dept Neurosurg, Ankara, Turkey.	abdbak@hotmail.com					Aarabi B, 1998, NEUROSURGERY, V42, P500, DOI 10.1097/00006123-199803000-00014; AARABI B, 1987, NEUROSURGERY, V20, P610, DOI 10.1227/00006123-198704000-00018; AARABI B, 1989, NEUROSURGERY, V25, P923, DOI 10.1227/00006123-198912000-00011; AARABI B, 1995, NEUROSURG CLIN N AM, V6, P775; AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; Amirjamshidi A, 2003, SURG NEUROL, V60, P105, DOI 10.1016/S0090-3019(03)00358-6; BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; BRANDT F, 1983, NEUROCHIRURGIA, V26, P164; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; BRUNNER FX, 1995, OPERATIVE NEUROSURGI, P27; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; Dosoglu M, 1999, NEUROCHIRURGIE, V45, P201; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; GEORGE ED, 1999, MISSILE WOUNDS HEAD, V1, P130; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; HAMMON WM, 1971, J NEUROSURG, V34, P142, DOI 10.3171/jns.1971.34.2part1.0142; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; HUBSCHMANN O, 1979, J TRAUMA, V19, P6, DOI 10.1097/00005373-197901000-00002; JACOBS DG, 1995, AM SURGEON, V61, P647; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KAUFMAN HH, 1983, ACTA NEUROCHIR, V67, P115, DOI 10.1007/BF01401671; KENNEDY F, 1993, J TRAUMA, V35, P75, DOI 10.1097/00005373-199307000-00013; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; LEVY ML, 1993, NEUROSURGERY, V33, P1018; Martins RS, 2003, SURG NEUROL, V60, P98, DOI 10.1016/S0090-3019(03)00302-1; MEIROWSKY AM, 1982, J NEUROSURG, V57, P617, DOI 10.3171/jns.1982.57.5.0617; MINER ME, 1990, NEUROSURGERY, V26, P20, DOI 10.1227/00006123-199001000-00002; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; Nathoo N, 2002, SURG NEUROL, V58, P225, DOI 10.1016/S0090-3019(02)00828-5; ORDOG GJ, 1987, J TRAUMA, V27, P1272; Paret G, 1996, J TRAUMA, V41, P859, DOI 10.1097/00005373-199611000-00017; RISH BL, 1980, J NEUROSURG, V53, P772, DOI 10.3171/jns.1980.53.6.0772; Rosenfeld JV, 2002, J CLIN NEUROSCI, V9, P9, DOI 10.1054/jocn.2001.0949; SABA MI, 1988, OPERATIVE NEUROSURGI, P37; SABA MI, 1995, OPERATIVE NEUROSURGI, P89; Semple PL, 2001, S AFR MED J, V91, P141; SHERMAN WD, 1980, WESTERN J MED, V132, P99; SHOUNG HM, 1985, ACTA NEUROCHIR, V74, P27, DOI 10.1007/BF01413272; Splavski B, 1998, SURG NEUROL, V50, P194, DOI 10.1016/S0090-3019(98)00047-0; STONE JL, 1995, NEUROSURGERY, V37, P1104, DOI 10.1227/00006123-199512000-00010; SUDDABY L, 1987, CAN J NEUROL SCI, V14, P268, DOI 10.1017/S0317167100026597; TAHA JM, 1991, NEUROSURGERY, V29, P380, DOI 10.1227/00006123-199109000-00007	43	15	16	0	3	JAPAN NEUROSURGICAL SOC	TOKYO	5-25-16 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0470-8105	1349-8029		NEUROL MED-CHIR	Neurol. Med.-Chir.	JUN	2005	45	6					281	287		10.2176/nmc.45.281			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	936GQ	WOS:000229843900001	15973060	Bronze			2021-06-18	
J	Martz, E				Martz, E			Associations and predictors of posttraumatic stress levels according to person-related, disability-related, and trauma-related variables among individuals with spinal cord injuries	REHABILITATION PSYCHOLOGY			English	Article							VEHICLE ACCIDENT VICTIMS; PSYCHOLOGICAL IMPACT; BRAIN-INJURY; RISK-FACTORS; DISORDER; SURVIVORS; PREVALENCE; SYMPTOMS; PTSD; ADAPTATION	Objective: To examine the associations and predictors of posttraumatic stress among individuals with spinal cord injuries (SCI) in the framework of a Person X Disability X Traumatic Event model. Design: An exploratory study involving analyses of variance, correlations, and a hierarchical multiple regression of a cross-sectional sample. Participants: Three hundred twelve individuals with SCI using a veteran or a civilian SCI clinic. Main Outcome Measures: Purdue Posttraumatic Stress Disorder-Revised scale (PPTSD-R). Results: Four out of all the examined variables had significant regression coefficients: spiritual-religious coping, pain level, severity of SCI, and number of traumatic events. Severity of SCI was a significant predictor, but data suggested that severity of SCI had a curvilinear association with both total posttraumatic stress levels and hyperarousal scores. Conclusion: Treatment of an individual's pain may reduce posttraumatic stress symptoms. Clinicians also can evaluate for previous trauma unrelated to the onset of the SCI and can intervene with the goal of reducing the impact of previous trauma on the individual's present emotional state and reactions to SCI.	Univ Missouri, Rehabil Counceling Program, Educ Sch & Counseling Psychol Dept, Columbia, MO 65202 USA	Martz, E (corresponding author), Univ Missouri, Rehabil Counceling Program, Educ Sch & Counseling Psychol Dept, 4B Hill Hall, Columbia, MO 65202 USA.	martze@missouri.edu					ABENHAIM L, 1992, J CLIN EPIDEMIOL, V45, P103, DOI 10.1016/0895-4356(92)90002-5; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Amir M, 1999, J TRAUMA STRESS, V12, P139, DOI 10.1023/A:1024754618063; Asmundson GJG, 1998, J ANXIETY DISORD, V12, P57, DOI 10.1016/S0887-6185(97)00049-2; Bernat JA, 1998, J TRAUMA STRESS, V11, P645, DOI 10.1023/A:1024485130934; Blanchard EB, 1997, J TRAUMA STRESS, V10, P215, DOI 10.1023/A:1024826028483; Boyer B, 1998, SCI PSYCHOSOCIAL PRO, V11, P75; Boyer BA, 2000, REHABIL PSYCHOL, V45, P339, DOI 10.1037/0090-5550.45.4.339; BRACKEN MB, 1980, PARAPLEGIA, V18, P74, DOI 10.1038/sc.1980.13; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Breslau N, 1999, AM J PSYCHIAT, V156, P902, DOI 10.1176/ajp.156.6.902; Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P1044; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; Butler RW, 1996, J PEDIATR PSYCHOL, V21, P499, DOI 10.1093/jpepsy/21.4.499; Chibnall J.T., 1990, PSYCHOL, V4, P283, DOI [10.1080/08870449008400397, DOI 10.1080/08870449008400397]; CORDOVA MJ, 1995, J CONSULT CLIN PSYCH, V63, P981, DOI 10.1037/0022-006X.63.6.981; DELIMAR D, 1995, MIL MED, V160, P635; Desivilya HS, 1996, J TRAUMA STRESS, V9, P881; Difede J, 1999, J TRAUMA STRESS, V12, P363, DOI 10.1023/A:1024788812393; Fullerton CS, 2001, AM J PSYCHIAT, V158, P1486, DOI 10.1176/appi.ajp.158.9.1486; GREEN BL, 1993, INT HDB TRAUMATIC ST, P135, DOI DOI 10.1007/978-1-4615-2820-3_11; HAGSTROM R, 1995, J TRAUMA STRESS, V8, P391, DOI 10.1007/BF02102965; Harvey MR, 1996, J TRAUMA STRESS, V9, P3, DOI 10.1007/BF02116830; Joseph S, 1999, J TRAUMA STRESS, V12, P437, DOI 10.1023/A:1024762919372; Kennedy P, 2001, SPINAL CORD, V39, P1, DOI 10.1038/sj.sc.3101100; Kennedy P, 2001, SPINAL CORD, V39, P381, DOI 10.1038/sj.sc.3101172; KUTZ I, 1994, ISRAEL J PSYCHIAT, V31, P48; Ladwig KH, 1999, AM J PSYCHIAT, V156, P912, DOI 10.1176/ajp.156.6.912; LAUTERBACH D, 1996, ASSESSMENT, V3, P17, DOI DOI 10.1177/107319119600300102; MARINO RJ, 2000, INT STANDARDS NEUROL; Martz E, 2004, J LOSS TRAUMA, V9, P139, DOI 10.1080/15325020490423343; Martz E, 2001, REHABIL COUNS BULL, V44, P217, DOI 10.1177/003435520104400404; Nielsen MS, 2003, REHABIL PSYCHOL, V48, P289, DOI 10.1037/0090-5550.48.4.289; NIELSEN MS, 2003, SCI PSYCHOSOCIAL PRO, V16, P137; Norman E M, 1991, Appl Nurs Res, V4, P171; PEDHAZUR PJ, 1997, MULTIPLE REGRESSION; PENT W, 2000, EFFECTIVE TREATMENT, P224; Perry S W, 1987, J Pain Symptom Manage, V2, P29, DOI 10.1016/S0885-3924(87)80043-X; Post Robert M., 1995, P203; Powers Pauline S., 1994, Journal of Burn Care and Rehabilitation, V15, P147, DOI 10.1097/00004630-199403000-00008; Radnitz CL, 1998, J ABNORM PSYCHOL, V107, P676, DOI 10.1037/0021-843X.107.4.676; Radnitz CL, 2000, J ANXIETY DISORD, V14, P313, DOI 10.1016/S0887-6185(00)00025-6; Radnitz CL, 1998, J TRAUMA STRESS, V11, P505, DOI 10.1023/A:1024404729251; Radnitz CL, 1995, SCI PSYCHOSOCIAL PRO, V8, P145; ROCA RP, 1992, AM J PSYCHIAT, V149, P1234; SCHNURR PP, 1993, J ABNORM PSYCHOL, V102, P288, DOI 10.1037/0021-843X.102.2.288; Schnurr PP, 2002, J CLIN PSYCHOL, V58, P877, DOI 10.1002/jclp.10064; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; SHONTZ FC, 1977, SOCIAL PSYCHOL ASPEC, P333; SHONTZ FC, 1975, PSYCHOLOGICAL ASPECT; Smith MY, 1999, J TRAUMA STRESS, V12, P485, DOI 10.1023/A:1024719104351; TERR LC, 1991, AM J PSYCHIAT, V148, P10; THOMPSON RN, 1999, THESIS W VIRGINIA U; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589	55	15	16	0	6	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2005	50	2					149	157		10.1037/0090-5550.50.2.149			9	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	931ND	WOS:000229491100008					2021-06-18	
J	Beresford, TP; Arciniegas, D; Clapp, L; Martin, B; Alfers, J				Beresford, TP; Arciniegas, D; Clapp, L; Martin, B; Alfers, J			Reduction of affective lability and alcohol use following traumatic brain injury: A clinical pilot study of anti-convulsant medications	BRAIN INJURY			English	Article							RELAPSE PREVENTION; AFFECTIVE-DISORDER; GABA(A) RECEPTOR; AXIS-I; CARBAMAZEPINE; ASSOCIATION; DIVALPROEX; VALPROATE; RELEASE; GENE	Objective: A large and under-recognized sub-set of patients suffer both traumatic brain injury (TBI) and alcohol dependence (ADep). This group appears to use alcohol to self-treat affective and anxiety lability following TBI, resulting in new ADep or worsened prior ADep. This study hypothesized that treatment of such patients with mood-stabilizing medications would relieve post-TBI emotional dysregulation and facilitate reduction in alcohol use. Design: This study reported retrospective medical record data from outpatients in the Substance Abuse Treatment Programme who were treated for labile mood. Medications followed clinical indication and were given in non-blind fashion. Method: Subjects included 18 patients who (1) complained of debilitating affective lability following TBI, ( 2) described drinking alcohol to ease lability symptoms, (3) met DSM-IV criteria for current ADep and (4) were treated with a mood stabilizing medication. Results: During 6 weeks of treatment, 16 (89%) achieved abstinence from alcohol. All but two (14/16 or 88%) also showed improvement in their affective and anxiety symptoms. Conclusions: These preliminary data are limited by the retrospective collection, clinical impression and non-blinded trial. Nonetheless, the results suggest further investigation of anti-convulsants as potentially useful agents in co-morbid emotional lability and ADep following TBI.	Denver Vet Affairs Med Ctr, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA; Spalding Rehabil Hosp, Brain Injury Rehabil Unit, Aurora, CO USA	Beresford, TP (corresponding author), Denver Vet Affairs Med Ctr, 151,1055 Clermont St, Denver, CO 80220 USA.	thomas.beresford@uchsc.edu	Arciniegas, David/A-3792-2009		NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA12095] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R03AA012095] Funding Source: NIH RePORTER		Arciniegas D B, 2000, Semin Clin Neuropsychiatry, V5, P290, DOI 10.1053/scnp.2000.9554; BOURDON KH, 1992, PUBLIC HEALTH REP, V107, P663; Brady KT, 2002, DRUG ALCOHOL DEPEN, V67, P323, DOI 10.1016/S0376-8716(02)00105-9; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; ERB DE, 1991, EXP BRAIN RES, V83, P253; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Ichikawa J, 1999, EUR J PHARMACOL, V380, pR1, DOI 10.1016/S0014-2999(99)00517-8; Johnson BA, 2003, LANCET, V361, P1677, DOI 10.1016/S0140-6736(03)13370-3; Kawata Y, 2001, BRIT J PHARMACOL, V133, P557, DOI 10.1038/sj.bjp.0704104; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Longo LP, 2002, J ADDICT DIS, V21, P55, DOI 10.1300/J069v21n02_05; Miller Norman S., 1994, P471; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; Oruc L, 1997, NEUROPSYCHOBIOLOGY, V36, P62; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Papadimitriou GN, 1998, AM J MED GENET, V81, P73, DOI 10.1002/(SICI)1096-8628(19980207)81:1<73::AID-AJMG14>3.3.CO;2-#; Perucca E, 2002, CNS DRUGS, V16, P695, DOI 10.2165/00023210-200216100-00004; PETTY F, 1995, J AFFECT DISORDERS, V34, P275, DOI 10.1016/0165-0327(95)00025-I; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Schneider U, 2001, ALCOHOL ALCOHOLISM, V36, P219, DOI 10.1093/alcalc/36.3.219; White HS, 1999, EPILEPSIA, V40, pS2, DOI 10.1111/j.1528-1157.1999.tb00913.x	21	15	15	0	2	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	2005	19	4					309	313		10.1080/02699050410001720121			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	917MN	WOS:000228466400007	15832875				2021-06-18	
J	Wilson, MS; Chen, XB; Ma, XC; Ren, DX; Wagner, AK; Reynolds, IJ; Dixon, CE				Wilson, MS; Chen, XB; Ma, XC; Ren, DX; Wagner, AK; Reynolds, IJ; Dixon, CE			Synaptosomal dopamine uptake in rat striatum following controlled cortical impact.	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						traumatic brain injury; dopamine; transporter; striatum; rat; Western blotting; radioligand binding	TRAUMATIC BRAIN-INJURY; WATER MAZE PERFORMANCE; METHYLPHENIDATE TREATMENT; OXIDATIVE STRESS; FRONTAL-CORTEX; TRANSPORTER; AMANTADINE; DEFICITS; TRIAL; MOTOR	Functional deficits following traumatic brain injury (TBI) are associated with alterations in markers of dopaminergic neurotransmission. To assess the effects of TBI on the expression and functional integrity of dopamine transporters, we measured transporter protein levels and investigated synaptosomal dopamine uptake in the rat striatum. Two or four weeks after lateral controlled cortical impact or sham injury, Western blotting revealed a decrease in transporter protein in the ipsilateral striatum of injured rats relative to shams (P < 0.05). However, no significant difference in synaptosomal uptake (K-m, V-max) was found between injured and sham-injured animals. Our data suggest that striatal dopamine transporters are capable of normal function at 2 weeks and 4 weeks after injury. However, it is unclear whether neurons in the injured striatum can properly regulate the activity of dopamine transporters in vivo. (c) 2005 Wiley-Liss, Inc.	Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA	Dixon, CE (corresponding author), 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.	dixonec@upmc.edu	Reynolds, Ian Jeffery/ABH-3197-2020; Reynolds, Ian/C-4358-2008	Reynolds, Ian/0000-0003-3028-5070	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-33150] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150] Funding Source: NIH RePORTER		Berman SB, 1996, J NEUROCHEM, V67, P593; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; KMIECIAKKOLADA K, 1987, POL J PHARMACOL PHAR, V39, P47; LANGSTON JW, 1986, CLIN NEUROPHARMACOL, V9, P485, DOI 10.1097/00002826-198612000-00001; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; McIntosh TK, 1996, LAB INVEST, V74, P315; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Miller GW, 1999, TRENDS PHARMACOL SCI, V20, P424, DOI 10.1016/S0165-6147(99)01379-6; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Reith MEA, 1997, EUR J PHARMACOL, V324, P1, DOI 10.1016/S0014-2999(97)00065-4; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Tillerson JL, 2001, J NEUROSCI, V21, P4427, DOI 10.1523/JNEUROSCI.21-12-04427.2001; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	33	15	15	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	APR 1	2005	80	1					85	91		10.1002/jnr.20419			7	Neurosciences	Neurosciences & Neurology	914CW	WOS:000228203400009	15704194				2021-06-18	
J	Maurer, E; Martin, J; Milewski, P; Dinkel, M				Maurer, E; Martin, J; Milewski, P; Dinkel, M			Remarks on relevant CNS examination and monitoring techniques on the ICU, and the effectiveness of a basic course in imparting the necessary knowledge and skills	ANASTHESIOLOGIE & INTENSIVMEDIZIN			German	Article						neurological diagnosis; intensive care; neurological examination; electroencephalography; evoked potentials	SOMATOSENSORY-EVOKED-POTENTIALS; TRAUMATIC BRAIN-INJURY; OUTCOME PREDICTION; HEAD-INJURY; COMA; PROGNOSIS	Intensive care physicians in operative ICUs are often called upon to deal with neurological and neurotraumatological disorders. For this purpose, they need a basic knowledge of neurological diagnosis and monitoring. Since relevant guidelines are lacking, a curriculum for a two-day course of further training in this area was defined. The current article presents the proposed basic knowledge and invites discussion. After the completion of three such courses, we investigated how effectively the necessary basic knowledge and skills needed for the clinical neurological examination, the EEG, and evoked potentials in the ICU patient can be imparted in such a course. Former course participants were sent a structured questionnaire aimed at determining the state of their knowledge before and after the course, and whether there had been any increase in the use of the three measures. The results showed that it is possible to impart an adequate knowledge of the clinical neurological examination and evoked potentials in a two-day workshop.	Klin Eichert, Abt Anasthesie & Operat Intens Med, Goppingen, Germany; Herz & Gefassklin GmbH, Abt Anasthesie & Operat Intens Med, Bad Neustadt an der Saale, Germany	Maurer, E (corresponding author), Klinikum Eichert, Klin Anasthesiol Operat Intens Med & Schmerzthera, Eicherstr 3, D-73006 Goppingen, Germany.	ekhard.maurer@web.de					Attia J, 1998, CRIT CARE CLIN, V14, P497, DOI 10.1016/S0749-0704(05)70013-0; Banoub M, 2003, ANESTHESIOLOGY, V99, P716, DOI 10.1097/00000542-200309000-00029; BARELLI A, 1991, CRIT CARE MED, V19, P1374, DOI 10.1097/00003246-199111000-00013; Carter BG, 2001, CRIT CARE MED, V29, P178, DOI 10.1097/00003246-200101000-00036; Carter BG, 1999, INTENS CARE MED, V25, P722, DOI 10.1007/s001340050936; Chen R, 1996, CRIT CARE MED, V24, P672, DOI 10.1097/00003246-199604000-00020; Claassen J, 2001, CRIT CARE MED, V29, P494, DOI 10.1097/00003246-200103000-00005; Engelhardt W, 1997, ANASTH INTENSIVMED, V38, P366; GOODWIN SR, 1991, CRIT CARE MED, V19, P518, DOI 10.1097/00003246-199104000-00011; HUTCHINSON DO, 1991, ELECTROEN CLIN NEURO, V78, P228, DOI 10.1016/0013-4694(91)90037-5; KEREN O, 1993, STROKE, V24, P1789, DOI 10.1161/01.STR.24.12.1789; LAWRENCE R, 2003, CRIT CARE MED, V31; Madl C, 1996, ARCH NEUROL-CHICAGO, V53, P512, DOI 10.1001/archneur.1996.00550060054017; Maurer E, 1998, ANASTH INTENSIV NOTF, V33, P430, DOI 10.1055/s-2007-994280; MAURER E, 2002, ZUCKSCHWERDT VERLAG; Meixensberger J., 1998, Intensivmedizin und Notfallmedizin, V35, P72; Moulton RJ, 1998, CAN J NEUROL SCI, V25, pS7, DOI 10.1017/S031716710003465X; MUMENTHALER M, 1988, KLINISCHE UNTERSUCHU; Mumenthaler M, 1990, NEUROLOGIE; Raggueneau JL, 2001, ANN FR ANESTH, V20, P108; RIFFEL B, 1989, ANAESTHESIST, V38, P51; Rothstein TL, 2000, J CLIN NEUROPHYSIOL, V17, P486, DOI 10.1097/00004691-200009000-00007; RUMPL E, 1996, NOTFALLBEHANDLUNG, V21, P121; RUMPL E, 1998, EEG ANDERUNGEN BEI A; SCHWARZ G, 1994, ANASTH INTENSIVMED, V35, P376; SCHWERDTFEGER K, 1997, ANASTHESIOL INTENSIM, V32, P199; SIMPSON TP, 1999, BRIT J INTESNSI 0701; Sleigh JW, 1999, J NEUROSURG, V91, P577, DOI 10.3171/jns.1999.91.4.0577; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; XU S, 1995, CHUNG HUA WAI KO TSA, V33, P238; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8; ZEITLHOFER J, 1989, ANAESTHESIST, V38, P10	32	15	15	0	0	AKTIV DRUCK & VERLAG GMBH	EBELSBACH	AN DER LOHWIESE 36, EBELSBACH, 97500, GERMANY	0170-5334	1439-0256		ANASTH INTENSIVMED	Anasthesiol. Intensivmed.	MAR	2005	46						84	+					6	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	922KS	WOS:000228837400006					2021-06-18	
J	Fountas, KN; Sitkauskas, A; Feltes, CH; Kapsalaki, EZ; Dimopoulos, VG; Kassam, M; Grigorian, AA; Robinson, JS; Ragauskas, A				Fountas, KN; Sitkauskas, A; Feltes, CH; Kapsalaki, EZ; Dimopoulos, VG; Kassam, M; Grigorian, AA; Robinson, JS; Ragauskas, A			Is non-invasive monitoring of intracranial pressure waveform analysis possible? Preliminary results of a comparative study of non-invasive vs. invasive intracranial slow-wave waveform analysis monitoring in patients with traumatic brain injury	MEDICAL SCIENCE MONITOR			English	Article						arterial blood pressure; B waves; cerebral auto-regulation; cerebral perfusion pressure ultrasound	INTRA-CRANICAL PRESSURE; SEVERE HEAD-INJURY; AUTOREGULATION; EXPERIENCE; MANAGEMENT	Background: An increasing body of evidence supports the concept that intracranial pressure (ICP) slow B waves represent the auto-regulatory response of spontaneous fluctuations of cerebral perfusion pressure. A relationship between cerebral auto-regulation and clinical outcome in patients with traumatic brain injury has also been established. The objective of our prospective clinical study was to compare the B slow ICP waves obtained invasively by standard ICP monitoring to those obtained noninvasively using a new ultrasound technology. Material/Methods: In the participating institutions, over a period of six months, thirteen consecutive patients (8 males and 5 females) with severe closed bead injuries (GCS <8) were included in our IRB-approved study. Intracranial pressure and B slow waves, as well as arterial blood pressure and waveforms, were evaluated by standard invasive techniques. Additionally, a new non-invasive ultrasound device, Vittamed (Telematics Scientific Laboratory, Kaunas, Lithuania), was employed for monitoring intracranial blood volume slow waves. Using these modalities, it was possible to compare the changes that occurred with invasive monitoring (Correlation factor RI) and the changes that occurred using noninvasive technology (Correlation factor RN). Results: Bland Altman plot analysis showed positive correlation between the invasively and non-invasively obtained slow intracranial B waves (2sigma=8.9%, p<0.0001) and cerebral auto-regulation indexes (RI and RN) (SD=5%, p<0.0001). Positive RI and RN values were correlated with poor clinical outcome. Conclusions: Ultrasonographic technology (Vittamed) may have significant application in non-invasive continuous cerebrovascular auto-regulation monitoring in patients with severe head injuries.	Mercer Univ, Sch Med, Dept Neurosurg, Med Ctr Cent Georgia, Macon, GA 31207 USA; Kaunas Univ, Dept Neurosurg, Sch Med, Kaunas, Lithuania; Mercer Univ, Sch Med, Dept Neuroradiol, Med Ctr Cent Georgia, Macon, GA 31207 USA; Kaunas Univ Technol, Telemat Sci Lab, Kaunas, Lithuania	Fountas, KN (corresponding author), 840 Pine St,Suite 800, Macon, GA 31201 USA.	knfountasmd@excite.com	Ragauskas, Art/J-7486-2016	Ragauskas, Art/0000-0002-3536-554X			ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; CHAMBERS IR, 1990, NEUROSURGERY, V26, P421, DOI 10.1227/00006123-199003000-00007; COTTER DJ, 1982, MED INSTRUM, V16, P9; Czosnyka M, 2002, ACT NEUR S, V81, P117; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; CZOSNYKA M, 1993, INTRACRANIAL PRESSUR, V8, P699; FELDMAN Z, 1993, HEAD INJURY, P247; Fountas KN, 2002, CHILD NERV SYST, V18, P211, DOI 10.1007/s00381-002-0573-4; FOUNTAS KN, 2000, NEUROSURGERY, V47, P537; KAISER AM, 1987, DEV MED CHILD NEUROL, V29, P320; Kanter M J, 1991, Neurosurg Clin N Am, V2, P257; KANTER RK, 1985, CRIT CARE MED, V13, P837, DOI 10.1097/00003246-198510000-00012; KURAMOTO S, 1986, Neurological Research, V8, P93; Lang EW, 2003, J NEUROTRAUM, V20, P69, DOI 10.1089/08977150360517191; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; LYONS MK, 1990, MAYO CLIN PROC, V65, P684, DOI 10.1016/S0025-6196(12)65131-3; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; Merwa R, 2004, PHYSIOL MEAS, V25, P347, DOI 10.1088/0967-3334/25/1/038; MILLER JD, 1978, BRIT J HOSP MED, V19, P497; NADVI SS, 1994, BRIT J NEUROSURG, V8, P573, DOI 10.3109/02688699409002950; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; OSTRUP RC, 1987, J NEUROSURG, V67, P206, DOI 10.3171/jns.1987.67.2.0206; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Penson RP, 1998, J ROY SOC HEALTH, V118, P289, DOI 10.1177/146642409811800515; Ragauskas A, 2003, MED ENG PHYS, V25, P667, DOI 10.1016/S1350-4533(03)00082-1; Rosner M J, 1976, Clin Neurosurg, V23, P494; RYDER HW, 1953, AMA ARCH NEUROL PSY, V70, P563, DOI 10.1001/archneurpsyc.1953.02320350015003; Sahuquillo J, 2000, ACTA NEUROCHIR SUPPL, V76, P485; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Schmidt Bernhard, 2002, Eur J Ultrasound, V16, P37, DOI 10.1016/S0929-8266(02)00044-7; Schmidt EA, 2001, J NEUROL NEUROSUR PS, V70, P198, DOI 10.1136/jnnp.70.2.198; Sidi A, 1999, J CLIN MONITOR COMP, V15, P185, DOI 10.1023/A:1009993232534; Steinmeier R, 1996, STROKE, V27, P2236, DOI 10.1161/01.STR.27.12.2236	36	15	15	0	2	INT SCIENTIFIC INFORMATION, INC	MELVILLE	150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	FEB	2005	11	2					CR58	CR63					6	Medicine, Research & Experimental	Research & Experimental Medicine	897UA	WOS:000227029700010	15668632				2021-06-18	
J	Travers, C; King, R				Travers, C; King, R			An investigation of organic factors in the neuropsychological functioning of patients with borderline personality disorder	JOURNAL OF PERSONALITY DISORDERS			English	Article							TRAUMATIC BRAIN-INJURY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; CHILDHOOD ABUSE; HIPPOCAMPAL; NEUROBIOLOGY; DYSFUNCTION; AMYGDALA; ADULTS; WOMEN	The hypothesis to be tested in this study was that the cognitive deficits that have been documented in patients with Borderline Personality Disorder (BPD) are largely the consequence of organic insult, either developmental or acquired. Using a cross-sectional design, 80 subjects (males and females) who met the criteria for BPD participated in the study. They completed a battery of neuropsychological tests and a comprehensive interview assessing organic status as well as measures of the potentially confounding factors of current levels of depression and anxiety. It was expected that BPD-patients with a probable history of organic insult would perform significantly worse than would BPD patients without such a history. Analyses of the results provided partial support for the hypothesis. Subjects with both BPD and a history of organic insult were significantly more impaired on several measures including measures of attention than were BPD only subjects. The results suggested that the impaired cognitive performance of persons diagnosed with BPD may, in part, be attributed to organic factors.	Univ Queensland, Betty Byrne Henderson Womens Hlth Res Ctr, St Lucia, Qld 4067, Australia; Univ Queensland, Dept Psychiat, St Lucia, Qld 4067, Australia	Travers, C (corresponding author), Royal Brisbane & Womens Hosp, Betty Byrne Henderson Womens Hlth Res Ctr, Level 6,Ned Hanlon Bldg, Herston, Qld 4029, Australia.	traversc@psychiatry.uq.edu.au	King, Robert/F-5922-2010; Travers, Catherine/AAD-4938-2019; Travers, Catherine/F-5495-2010	Travers, Catherine/0000-0002-7762-2305; 			Abrahams S, 1999, BRAIN COGNITION, V41, P39, DOI 10.1006/brcg.1999.1095; ANDRULONIS PA, 1981, PSYCHIAT CLIN N AM, V4, P47; ANDRULONIS PA, 1982, J NERV MENT DIS, V170, P670, DOI 10.1097/00005053-198211000-00006; ANDRULONIS PA, 1984, BRIT J PSYCHIAT, V144, P358, DOI 10.1192/bjp.144.4.358; Army U. S, 1944, ARM IND TEST BATT MA; Barkley R. A., 1997, ASSESSMENT CHILDHOOD, P71; Bazanis E, 2002, PSYCHOL MED, V32, P1395, DOI 10.1017/S0033291702006657; Beck AT., 1970, DEPRESSION CAUSES TR; Benton A., 1976, MULTILINGUAL APHASIA; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Biederman J, 1999, BIOL PSYCHIAT, V46, P1234, DOI 10.1016/S0006-3223(99)00192-4; Bowden S., 1992, CLIN NEUROPSYCHOL, V6, P43; Burgess J. W., 1990, JEFFERSON J PSYCHIAT, V8, P34; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; Corsi P. M., 1972, THESIS MCGILL U MONT; CUMMINGS LB, 1998, THESIS SCH PROFESSIO; Driessen M, 2000, ARCH GEN PSYCHIAT, V57, P1115, DOI 10.1001/archpsyc.57.12.1115; Dunn L. M., 1997, PPVT 3 PEABODY PICTU; Fastenau PS, 1999, CLIN NEUROPSYCHOL, V13, P30, DOI 10.1076/clin.13.1.30.1976; First M.B., 1994, STRUCTURAL CLIN INTE; First M.B., 1996, STRUCTURED CLIN INTE; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; HERMAN JL, 1989, AM J PSYCHIAT, V146, P490; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; JUDD PH, 1993, J PERS DISORD, V7, P275, DOI 10.1521/pedi.1993.7.4.275; KAPUR N, 1988, MEMORY DISORDERS CLI; KORFINE L, 1998, THESIS HAVARD U; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; O'Leary KM, 2000, PSYCHIAT CLIN N AM, V23, P41, DOI 10.1016/S0193-953X(05)70142-8; OGATA SN, 1990, AM J PSYCHIAT, V147, P1008; OLEARY KM, 1991, AM J PSYCHIAT, V148, P106; Osterrieth P. A, 1944, ARCH PSYCHOL, V30, P286; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; SAPOLSKY RM, 1990, J NEUROSCI, V10, P2897, DOI 10.1523/jneurosci.10-09-02897.1990; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schmahl CG, 2003, PSYCHIAT RES-NEUROIM, V122, P193, DOI 10.1016/S0925-4927(03)00023-4; SILVER AA, 1994, LIT REDEFINITION, P187; Spencer TJ, 2002, J CLIN PSYCHIAT, V63, P3; Spielberger CD, 1983, STATE TRAIT ANXIETY; Spreen O., 1991, COMPENDIUM NEUROPSYC; Sprock J, 2000, J CLIN PSYCHOL, V56, P1587, DOI 10.1002/1097-4679(200012)56:12<1587::AID-9>3.0.CO;2-G; *SPSS INC, 2001, SPSS ADV MOD; *SPSS INC, 2001, SPSS SAMPL POW 2 0; STREETER CC, 1995, J NERV MENT DIS, V183, P577, DOI 10.1097/00005053-199509000-00003; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; SWIRSKYSACCHETT.T, 1993, J CLIN PSYCHOL, V493, P385; Taylor E. M., 1959, APPRAISAL CHILDREN C; TEICHER MH, 1993, J NEUROPSYCH CLIN N, V5, P301; THOMPSON RF, 1976, AM PSYCHOL, V31, P209, DOI 10.1037/0003-066X.31.3.209; Torgersen S, 2000, COMPR PSYCHIAT, V41, P416, DOI 10.1053/comp.2000.16560; VANREEKUM R, 1993, J PSYCHIATR NEUROSCI, V18, P121; vanReekum R, 1996, J PSYCHIATR NEUROSCI, V21, P13; WALSH K, 1978, BRAIN IMPAIRMENT; Wechsler D., 1987, MANUAL WECHSLER MEMO; Wechsler D., 1981, WAIS R MANUAL WECHSL; YEUDALL LT, 1986, J CLIN PSYCHOL, V42, P918, DOI 10.1002/1097-4679(198611)42:6<918::AID-JCLP2270420617>3.0.CO;2-Y	59	15	15	0	4	GUILFORD PUBLICATIONS INC	NEW YORK	72 SPRING STREET, NEW YORK, NY 10012 USA	0885-579X			J PERS DISORD	J. Pers. Disord.	FEB	2005	19	1					1	18		10.1521/pedi.19.1.1.62181			18	Psychiatry	Psychiatry	910WQ	WOS:000227963300001	15899717				2021-06-18	
J	Marmor, M; Parnes, N; Aladgem, D; Birshan, V; Sorkine, P; Halpern, P				Marmor, M; Parnes, N; Aladgem, D; Birshan, V; Sorkine, P; Halpern, P			Characteristics of road traffic accidents treated in an urban trauma center	ISRAEL MEDICAL ASSOCIATION JOURNAL			English	Article						road traffic accidents; urban trauma center	MOTOR-VEHICLE ACCIDENTS; EPIDEMIOLOGY; INJURY	Background: Road traffic accidents are the leading cause of accidental injury and death for persons under the age of 35. The medical literature presents surprisingly little information on the general characteristics of such accidents in the urban setting. Objectives: To characterize RTA patients arriving at an urban trauma center. Methods: We prospectively examined the charts of all patients admitted to the Tel Aviv Sourasky Medical Center due to RTA injuries during two periods in 1995. Results: Of the 1,560 patients examined, the male:female ratio was 1:1 and median age was 27 years (47% aged 20-30 years); 51% of the accidents took place between 8 a.m. and 4 p.m. and on working week days; automobiles comprised 47.1% of the vehicles involved, motorized two-wheel vehicles 37.1%, bicycles 3.8%, and pedestrians 12%. The Glasgow Coma Scale was 15 on arrival in 98.7% of the patients. The trunk was the most commonly injured body part (84.7%); whiplash injury to the neck was diagnosed in 343 patients (22%), and brain concussion in 183 (11.7%). Computed tomography studies were performed in 34 patients (2.2%). The vast majority of patients (1,438, 92.2%) was discharged home; 14 (0.9%) were admitted to the intensive care unit, and 2 (0.13%) died during hospitalization. The average time spent in the emergency department in the morning shift was 2.1 hours. Conclusions: We could identify distinguishing factors of this population: equal gender distribution, peak RTA incidence in the young adult working population during working hours, automobile drivers being the most injured subgroup, a disproportionate number of motorcycle and motor scooter involvement, and a relatively extensive amount of time and resources spent treating these injuries despite their generally minor nature.	Tel Aviv Sourasky Med Ctr, Dept Emergency Med, IL-64239 Tel Aviv, Israel; Tel Aviv Sourasky Med Ctr, Dept Orthoped B, IL-64239 Tel Aviv, Israel; Tel Aviv Sourasky Med Ctr, Intens Care Unit, IL-64239 Tel Aviv, Israel	Halpern, P (corresponding author), Tel Aviv Sourasky Med Ctr, Dept Emergency Med, 6 Weizman St, IL-64239 Tel Aviv, Israel.	dr_halperin@tasmc.health.gov.il	Marmor, Meir/AAC-8596-2020; Marmor, Michael/L-9014-2015				Aharonson-Daniel L, 2001, Harefuah, V140, P919; Andrade S M, 2001, Rev Saude Publica, V35, P318, DOI 10.1590/S0034-89102001000300017; Charbotel B, 2001, EUR J EPIDEMIOL, V17, P773, DOI 10.1023/A:1015667114529; Goldberg J, 2002, ANN EMERG MED, V40, P429, DOI 10.1067/mem.2002.128187; HYOT DB, 1997, ESSENTIALS SURG SCI, P271; Jirojwong Sansnee, 2002, Southeast Asian Journal of Tropical Medicine and Public Health, V33, P193; Levine N, 1995, ACCIDENT ANAL PREV, V27, P785, DOI 10.1016/0001-4575(95)00038-0; LIDDELL FDK, 1982, J EPIDEMIOL COMMUN H, V36, P140, DOI 10.1136/jech.36.2.140; LINDQVIST KS, 1991, ACCIDENT ANAL PREV, V23, P509, DOI 10.1016/0001-4575(91)90016-X; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; Nofal RH, 1996, J ROY SOC HEALTH, V116, P304, DOI 10.1177/146642409611600508; Norwood SH, 2002, J TRAUMA, V53, P503, DOI 10.1097/00005373-200209000-00018; Petridou E, 1997, ACCIDENT ANAL PREV, V29, P687, DOI 10.1016/S0001-4575(97)00038-9; RICHTER ED, 1981, INT J EPIDEMIOL, V10, P145, DOI 10.1093/ije/10.2.145; Simoncic M, 2001, ACCIDENT ANAL PREV, V33, P147, DOI 10.1016/S0001-4575(00)00025-7	15	15	15	0	10	ISRAEL MEDICAL ASSOC JOURNAL	RAMAT GAN	2 TWIN TOWERS, 11TH FL, 35 JABOTINSKY ST, PO BOX 3604, RAMAT GAN 52136, ISRAEL	1565-1088			ISR MED ASSOC J	Isr. Med. Assoc. J.	JAN	2005	7	1					9	12					4	Medicine, General & Internal	General & Internal Medicine	886SM	WOS:000226248800003	15658138				2021-06-18	
J	Backhaus, SL; Fichtenberg, NL; Hanks, RA				Backhaus, SL; Fichtenberg, NL; Hanks, RA			Detection of sub-optimal performance using a floor effect strategy in patients with traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							MINOR HEAD-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; RECOGNITION MEMORY TEST; TESTS; EXAGGERATION; IMPAIRMENT; SEQUELAE; BATTERY	This archival study examined the effectiveness of using a normative floor effect method to detect suboptimal performance in a clinical sample of 120 cases consecutively referred for a neuropsychological evaluation. These cases were divided into moderate-severe TBI, mild TBI, and poor effort litigants (demonstrating suboptimal effort). Percentiles, sensitivity, specificity, positive and negative predictive power, and overall correct classification rates were calculated using the moderate-severe TBI sample as the clinical reference group. Several levels of stringency for the floor effect using different base rates were also examined. Setting the floor at the 50th percentile consistently appeared to provide for the best overall hit rate when comparing cases with mild brain injury versus poor effort. At this level, a strong trend (greater than one third of total scores) toward the generation of positive scores offers compelling evidence that, in general, the neuropsychological data have been invalidated by poor motivation. Clinical implications are discussed.	Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI 48202 USA	Hanks, RA (corresponding author), Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, 261 Mack Blvd, Detroit, MI 48201 USA.	Rhanks@dmc.org					BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BENTON A, 1975, NEUROLOGY, V25, P907, DOI 10.1212/WNL.25.10.907; Benton A, 1989, MULTILINGUAL APHASIA; BENTON AL, 1959, RIGHT LEFT DISCRIINA; BINDER L, 1992, J CONSULT CLIN PSYCH, V3, P175; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Frederick RI, 2000, J CLIN EXP NEUROPSYC, V22, P720, DOI 10.1076/jcen.22.6.720.951; Frederick RI, 1994, NEUROPSYCHOLOGY, V8, P118, DOI 10.1037/0894-4105.8.1.118; GOEBEL RA, 1983, J CLIN PSYCHOL, V39, P731, DOI 10.1002/1097-4679(198309)39:5<731::AID-JCLP2270390515>3.0.CO;2-T; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MARTIN RC, 1993, J CLIN EXP NEUROPSYC, V15, P867, DOI 10.1080/01688639308402604; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; Millis Scott R., 1996, P481; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; MILLIS SR, 1994, PERCEPT MOTOR SKILL, V79, P384, DOI 10.2466/pms.1994.79.1.384; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P271, DOI 10.1016/0887-6177(95)00040-2; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; REITAN RM, 1955, J COMP PHYSIOL PSYCH, V48, P474, DOI 10.1037/h0048581; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Smith A., 1973, SYMBOL DIGIT MODALIT; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; SWEET JJ, 1999, FORENSIC NEUROPSYCHO; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; van Gorp WG, 1999, J CLIN EXP NEUROPSYC, V21, P245; Warrington EK., 1984, RECOGNITION MEMORY T	34	15	15	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	DEC	2004	18	4					591	603		10.1080/13854040490888558			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	895BH	WOS:000226835400008	15841959				2021-06-18	
J	Braham, R; Finch, CF; McCrory, P				Braham, R; Finch, CF; McCrory, P			The incidence of head/neck/orofacial injuries in non-elite Australian Football	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article							LEVEL	injuries to the head/neck/orofacial region are common in contact and collision sports such as Australian Football. A total of 294 players who did not wear headgear from 23 teams from a large metropolitan community football league in Victoria. Austratia. were monitored for head/neck/orofacial injuries over one playing season. This short report describes the incidence of head/neck/orofacial injuries in this cohort. Overall. there were 37 head/neck/orofacial injuries reported at a rate of 2.6 injuries/1000 participation hours. Over 70% of these were the result of being struck by another player through inadvertent contact during competitive play. Facial lacerations were most common (0.97/1000 player hours). followed by concussion (0.49/1000 player hours). Nine of the cases were referred to hospital for further treatment.	Monash Univ, Sport Injury Prevent Res Unit, Clayton, Vic 3168, Australia; Univ New S Wales, NSW Injury Risk Management Res Ctr, Kensington, NSW 2033, Australia; Univ Melbourne, Inst & Ctr Hlth Excerise & Sports Med, Parkville, Vic 3052, Australia	Braham, R (corresponding author), Monash Univ, Sport Injury Prevent Res Unit, Clayton, Vic 3168, Australia.		McCrory, Paul/Q-8688-2019				Braham RA, 2004, BRIT J SPORT MED, V38, DOI 10.1136/bjsm.2002.004002; Finch C, 2002, AUST NZ J PUBL HEAL, V26, P462, DOI 10.1111/j.1467-842X.2002.tb00348.x; Gabbe B, 2002, J SCI MED SPORT, V5, P149, DOI 10.1016/S1440-2440(02)80036-6; McCrory PR, 2000, MED J AUSTRALIA, V172, P217, DOI 10.5694/j.1326-5377.2000.tb123912.x; Orchard J, 1998, J SCI MED SPORT, V1, P82; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x	6	15	15	0	1	SPORTS MEDICINE AUSTRALIA	DICKSON	PO BOX 237, DICKSON, ACT 2602, AUSTRALIA	1440-2440			J SCI MED SPORT	J. Sci. Med. Sport	DEC	2004	7	4					451	453		10.1016/S1440-2440(04)80263-9			3	Sport Sciences	Sport Sciences	890TE	WOS:000226532900008	15712501				2021-06-18	
J	Gastone, P; Fabrizia, C; Homere, M; Francesco, C; Alberto, M; Nicola, D				Gastone, P; Fabrizia, C; Homere, M; Francesco, C; Alberto, M; Nicola, D			Chronic subdural hematoma: Results of a homogeneous series of 159 patients operated on by residents	NEUROLOGY INDIA			English	Article						chronic subdural hematoma; surgical training; head injury	CLOSED-SYSTEM DRAINAGE; SURGICAL-TREATMENT; CRANIOTOMY; RECURRENCE	Aims: A series of cases with chronic subdural hematoma operated upon by residents in neurosurgery is analysed. Materials and Methods: 159 patients treated between 1998 and 2001 were included in the study. Mean age was 76.4 years and male/female ratio was 1.7/1. The patients were classified both on admission and at discharge according to the Markwalder scale. The standard operative procedure consisted of an enlarged single burr-hole, rinsing the subdural space with iso-osmotic saline solution and insertion of a subdural drain. Conclusion: In CSDH, operation by the residents is safe and the results are comparable to those of the major series of the literature as the surgical procedure is standardized.	Univ Florence, Neurosurg Clin, I-50121 Florence, Italy	Gastone, P (corresponding author), Osped CTO, Neurosurg Clin, Largo P Palagi 1, I-50139 Florence, Italy.	dilorenzo@unifi.it		Cacciola, Francesco/0000-0001-6290-9189			Drapkin A J, 1991, Br J Neurosurg, V5, P467, DOI 10.3109/02688699108998475; Ernestus RI, 1997, SURG NEUROL, V48, P220, DOI 10.1016/S0090-3019(97)80031-6; HAMILTON MG, 1993, NEUROSURGERY, V33, P67; KOTWICA Z, 1991, British Journal of Neurosurgery, V5, P461, DOI 10.3109/02688699108998474; Lind CRP, 2003, J NEUROSURG, V99, P44, DOI 10.3171/jns.2003.99.1.0044; MARKWALDER TM, 1981, J NEUROSURG, V55, P390, DOI 10.3171/jns.1981.55.3.0390; Mellergard P, 1996, ACTA NEUROCHIR, V138, P708, DOI 10.1007/BF01411476; Mori K, 2001, NEUROL MED-CHIR, V41, P371, DOI 10.2176/nmc.41.371; Nakajima H, 2002, SURG NEUROL, V58, P385, DOI 10.1016/S0090-3019(02)00921-7; Penchet G, 1998, NEUROCHIRURGIE, V44, P247; RICHTER HP, 1984, ACTA NEUROCHIR, V71, P179, DOI 10.1007/BF01401313; Sambasivan M, 1997, SURG NEUROL, V47, P418, DOI 10.1016/S0090-3019(97)00188-2; Suzuki K, 1998, SURG NEUROL, V50, P231, DOI 10.1016/S0090-3019(97)00339-X; Weigel R, 2003, J NEUROL NEUROSUR PS, V74, P937, DOI 10.1136/jnnp.74.7.937	14	15	20	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0028-3886	1998-4022		NEUROL INDIA	Neurol. India	DEC	2004	52	4					475	477					3	Neurosciences	Neurosciences & Neurology	887RV	WOS:000226324100013	15626837				2021-06-18	
J	Glass, TF; Reeves, B; Sharp, FR				Glass, TF; Reeves, B; Sharp, FR			The impact of excitotoxic blockade on the evolution of injury following combined mechanical and hypoxic insults in primary rat neuronal culture	NEUROBIOLOGY OF DISEASE			English	Article						excitotoxicity; NMDA; AMPA; glutamate; traumatic brain injury; hypoxia; lschemia; culture; neuronal	TRAUMATIC BRAIN-INJURY; METABOTROPIC GLUTAMATE RECEPTORS; BINDING PROTEIN-PHOSPHORYLATION; SEVERE HEAD-INJURY; STRIATAL NEURONS; NMDA RECEPTORS; CREB SHUTOFF; ISCHEMIA; CHILDREN; DEATH	Traumatic brain injury (TBI) involves alterations in neuronal physiology, often complicated by secondary hypoxic or hypotensive events. Excitotoxicity is an important process induced in both TBI and hypoxic or ischemic insults to the brain. We investigated two hypotheses: (1) excitotoxicity is more prominent following combined mechanical and hypoxic injury than either alone; (2) both AMPA and NNMA receptor activation mediate combined mechanical and hypoxic injury. Media in primary mixed neuronal cultures were replaced with conditioned media containing MK801 (NMDA antagonist) and/or NBQX (AMPA/kainate antagonist). Cultures were then subjected to mechanical injury. Afterward, media were exchanged for hypoxic media containing the antagonist, and plates were placed in hypoxia chambers for 7 h. At 24 h following hypoxia, LDH release, trypan blue uptake, and morphologic changes were assessed. Blockade had no effect after mechanical injury. After hypoxia, MK801 and combined MK801/NBQX decreased LDH and trypan blue to control levels. NBQX alone after hypoxia had less impact. After combined mechanical injury and hypoxia, both MK801 and NBQX partially reduced LDH and trypan blue. Combining the antagonists led to reduction to control values for both endpoints. We conclude that excitotoxic processes are more prominent after combined than isolated injuries in neurons and that increased cell death is mediated by both NMDA and AMPA receptor activation following combined injuries. (C) 2004 Elsevier Inc. All rights reserved.	Childrens Hosp, Med Ctr, Dept Pediat Emergency Med, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Neurol, Cincinnati, OH 45267 USA; Univ Cincinnati, Neurosci Program, Cincinnati, OH 45267 USA	Glass, TF (corresponding author), Childrens Hosp, Med Ctr, Dept Pediat Emergency Med, Locat C 2008,3333 Burnet Ave, Cincinnati, OH 45229 USA.	todd.glass@cchme.org					Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Boswell WC, 1996, SOUTHERN MED J, V89, P218, DOI 10.1097/00007611-199602000-00012; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; Chen DL, 2003, J BIOL CHEM, V278, P13595, DOI 10.1074/jbc.C200694200; Chen HM, 2003, J WORLD BUS, V38, P1, DOI 10.1016/S1090-9516(02)00105-0; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Glass TF, 2002, NEUROSCI LETT, V328, P133, DOI 10.1016/S0304-3940(02)00510-4; Glass TF, 1999, J NEUROTRAUM, V16, P771, DOI 10.1089/neu.1999.16.771; Halterman MW, 1999, EXP NEUROL, V159, P65, DOI 10.1006/exnr.1999.7160; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; Hardingham GE, 2002, BBA-PROTEINS PROTEOM, V1600, P148, DOI 10.1016/S1570-9639(02)00455-7; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; HOVDA DA, 1990, ACT NEUR S, V51, P331; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Koura SS, 1998, ACT NEUR S, V71, P244; Lea PM, 2001, MENT RETARD DEV D R, V7, P235, DOI 10.1002/mrdd.1033; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Mao L, 2002, NEUROSCIENCE, V115, P395, DOI 10.1016/S0306-4522(02)00400-1; Mao LM, 2002, MOL PHARMACOL, V62, P473, DOI 10.1124/mol.62.3.473; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Nishizawa Y, 2001, LIFE SCI, V69, P369, DOI 10.1016/S0024-3205(01)01142-0; Nucci C, 2000, BIOCHEM BIOPH RES CO, V278, P360, DOI 10.1006/bbrc.2000.3811; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Schroder ML, 1996, J NEUROTRAUM, V13, P17, DOI 10.1089/neu.1996.13.17; Schurov IL, 1999, J NEUROENDOCRINOL, V11, P43	31	15	17	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	DEC	2004	17	3					378	384		10.1016/j.nbd.2004.07.017			7	Neurosciences	Neurosciences & Neurology	878UD	WOS:000225671600003	15571974				2021-06-18	
J	Yildirim, E; Solaroglu, I; Okutan, O; Ozisik, K; Kaptanoglu, E; Sargon, MF; Sakinci, U				Yildirim, E; Solaroglu, I; Okutan, O; Ozisik, K; Kaptanoglu, E; Sargon, MF; Sakinci, U			Ultrastructural changes in tracheobronchial epithelia following experimental traumatic brain injury in rats: Protective effect of erythropoietin	JOURNAL OF HEART AND LUNG TRANSPLANTATION			English	Article							NEUROGENIC PULMONARY-EDEMA; ACUTE LUNG INJURY; CENTRAL-NERVOUS-SYSTEM; MUCOCILIARY TRANSPORT; NITRIC-OXIDE; RESPIRATORY EPITHELIUM; HEME OXYGENASE-1; IN-VITRO; ANTIOXIDANT; TRANSPLANTATION	Background: We aimed to demonstrate the time dependent ultrastructural changes in tracheobronchial epithelia after traumatic brain injury. And also, protective effect of erythropoietin was demonstrated. Methods: We used 56 Wistar-Albino female rats weighing 170 to 200 g. The rats were allocated into 7 groups. First group was the control. The second underwent craniotomy without trauma. The third, fourth, and fifth groups were respectively 2-, 8-, and 24-hour trauma groups. The sixth and seventh groups were respectively treatment (erythropoietin, 1,000 IU/kg) and vehicle (0,4 ml/rat) groups. Weight-drop method was used for achieving head trauma. Samples were obtained from both trachea and main bronchi. Modified electron microscopic scoring model was used to reveal the ultrastructural changes in both trauma and treatment groups. Results: There was no statistical difference between control and sham groups (p > 0.05). Scores of all trauma groups were significantly different from the controls (p < 0.05). Trauma produced obvious gradual damage on ultrastructure of the tracheobronchial epithelia. Erythropoietin decreased tracheobronchial scores after traumatic brain injury in significant levels. Erythropoietin attenuated ultrastructural scores for each organelle in significant levels (p < 0.05 for each organelle). Conclusions: The data suggested that ultrastructural damage is obvious at 2 hours deteriorating with time. Erythropoietin protects epithelia against damage after traumatic brain injury. Pharmaceutical lung preservation may help gaining efficacious donor lungs in brain death. But, further time dependent experiments are needed to determine the liability of the donor lung after traumatic brain injury. This fact is to be known for achieving higher graft survival rates. Copyright (C) 2004 by the International Society for Heart and Lung Transplantation.	Univ Hacettepe, Ankara Numune Educ & Res Hosp, Dept Thorac Surg, TR-06100 Ankara, Turkey; Univ Hacettepe, Ankara Numune Educ & Res Hosp, Dept Neurosurg, TR-06100 Ankara, Turkey; Univ Hacettepe, Fac Med, Dept Anat, TR-06100 Ankara, Turkey	Yildirim, E (corresponding author), Asagiovecler Mh 79 sk 8-3, TR-06460 Ankara, Turkey.	erseyda@yahoo.com	Solaroglu, Ihsan/ABF-7606-2020; YILDIRIM, Erkan/AAO-6961-2020; Solaroglu, Ihsan/ABE-8816-2020	Solaroglu, Ihsan/0000-0002-9472-1735; Sargon, Mustafa Fevzi/0000-0001-6360-6008			ALBERTS B, 1994, MOL BIOL CELL, P569; Atkinson JLD, 1997, NEUROSURGERY, V41, P1214, DOI 10.1097/00006123-199711000-00052; BanyMohammed FM, 1996, PEDIATR RES, V40, P381, DOI 10.1203/00006450-199609000-00003; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Berger SP, 2000, KIDNEY INT, V58, P2314, DOI 10.1046/j.1523-1755.2000.00415.x; BODENHAM A, 1989, BRIT MED J, V299, P1009, DOI 10.1136/bmj.299.6706.1009; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buemi M, 2002, CLIN SCI, V103, P275, DOI 10.1042/cs1030275; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; CECKA JM, 1988, DONOR PRESERVATION F, P399; Cerami A, 2001, SEMIN HEMATOL, V38, P33, DOI 10.1053/shem.2001.27484; CORMAN J, 1991, ANN CHIR, V45, P791; DETTBARN CL, 1989, HEART LUNG, V18, P583; Eid Tore, 2002, Clin Breast Cancer, V3 Suppl 3, pS109, DOI 10.3816/CBC.2002.s.021; FRIZZELL RA, 1988, AM REV RESPIR DIS, V138, pS3, DOI 10.1164/ajrccm/138.6_Pt_2.S3; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Hall SRR, 2002, ANESTH ANALG, V94, P948; HASANI A, 1994, EUR RESPIR J, V7, P1497, DOI 10.1183/09031936.94.07081497; Hoffman SW, 1997, STROKE, V28, P844, DOI 10.1161/01.STR.28.4.844; Holt AW, 1999, MED J AUSTRALIA, V170, P479, DOI 10.5694/j.1326-5377.1999.tb127848.x; Juul SE, 1998, EARLY HUM DEV, V52, P235, DOI 10.1016/S0378-3782(98)00030-9; Kaptanoglu E, 2002, J NEUROSURG ANESTH, V14, P114, DOI 10.1097/00008506-200204000-00005; Kondo CS, 2002, CRIT CARE, V6, P81, DOI 10.1186/cc1458; KONRAD F, 1995, INTENS CARE MED, V21, P482, DOI 10.1007/BF01706201; Marti HH, 1997, KIDNEY INT, V51, P416, DOI 10.1038/ki.1997.55; PEARSON FG, 2002, THORACIC SURG, P215; PEARSON FG, 2002, THORACIC SURG, P9; Pieper GM, 2001, ANTIOXID REDOX SIGN, V3, P81, DOI 10.1089/152308601750100542; Pyeron A M, 2001, J Neurosci Nurs, V33, P203; SAID SI, 1995, NEUROSCIENCE, V65, P943, DOI 10.1016/0306-4522(95)00021-A; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schutz A, 2002, CELLS TISSUES ORGANS, V170, P246, DOI 10.1159/000047928; Schwarz S, 1997, NERVENARZT, V68, P956, DOI 10.1007/s001150050222; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; SLEIGH MA, 1988, AM REV RESPIR DIS, V137, P726, DOI 10.1164/ajrccm/137.3.726; Taira M, 2002, AM J PHYSIOL-LUNG C, V282, pL556, DOI 10.1152/ajplung.00360.2001; Trout L, 1998, AM J PHYSIOL-LUNG C, V274, pL258; Tsuchihashi S, 2003, SURGERY, V133, P556, DOI 10.1067/msy.2003.124; WAUCHOB TD, 1984, ANAESTHESIA, V39, P529, DOI 10.1111/j.1365-2044.1984.tb07355.x	40	15	16	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1053-2498	1557-3117		J HEART LUNG TRANSPL	J. Heart Lung Transplant.	DEC	2004	23	12					1423	1429		10.1016/j.healun.2003.10.006			7	Cardiac & Cardiovascular Systems; Respiratory System; Surgery; Transplantation	Cardiovascular System & Cardiology; Respiratory System; Surgery; Transplantation	884LS	WOS:000226087100015	15607673				2021-06-18	
J	Rush, BK; Malec, JF; Moessner, AM; Brown, AW				Rush, BK; Malec, JF; Moessner, AM; Brown, AW			Preinjury personality traits and the prediction of early neurobehavioral symptoms following mild traumatic brain injury	REHABILITATION PSYCHOLOGY			English	Article							HEAD-INJURY; INDIVIDUALS; CONCORDANCE; POPULATION; SEVERITY; RATINGS; ADULTS	Objective: To determine if preinjury personality predicts early outcome in mild traumatic brain injury (MTBI) compared with orthopedic injury (01). Study Design:, Participants and significant others (SO) completed preinjury personality and early postinjury symptom questionnaires. Setting: Inpatient hospital and outpatient follow-up. Subjects: Eighty-seven people with MTBI and 82 with OI. Outcome Measures- NEO Personality Inventory-Revised (NEO-PI-R); Neurobehavioral Functioning Inventory (NFI). Results: Personality ratings and symptom endorsement were within normal limits. Concordance between self- and SO ratings was moderate (r greater than or equal to 50). In both groups, there were very modest associations between preinjury personality and early symptoms. Significant effects were primarily due to overlapping item-content between the personality and symptom questionnaires. Conclusions- Preinjury personality holds limited predictive value for MTBI outcome.	Mayo Clin, Coll Med, Dept Psychiat & Psychol, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Nursing, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Phys Med & Rehabil, Rochester, MN 55905 USA	Rush, BK (corresponding author), Mayo Clin, Coll Med, Dept Psychiat & Psychol, 200 1st St SW,Generose ME-248, Rochester, MN 55905 USA.	rush.beth@mayo.edu		Brown, Allen W./0000-0001-7228-3351			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Cherpitel CJ, 1999, ALCOHOL CLIN EXP RES, V23, P121, DOI 10.1097/00000374-199901000-00017; CICERONE KD, 2000, TRAUMATIC BRAIN INJU, P95; Costa P. T., 1991, REVISED NEO PERSONAL; DIGMAN JM, 1990, ANNU REV PSYCHOL, V41, P417, DOI 10.1146/annurev.ps.41.020190.002221; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; HOVLAND D, 2000, NEUROPSYCHOLOGICAL M, P187; John Oliver P., 1990, HDB PERSONALITY THEO, P66; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; KAY T, 1991, REHABILITATION POSTC, P109; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; Kurtz JE, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199806000-00002; Lehr E, 1990, PSYCHOL MANAGEMENT T; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Malec JF, 2004, REHABIL PSYCHOL, V49, P55, DOI 10.1037/0090-5550.49.1.55; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Nemeth AJ, 1996, ARCH CLIN NEUROPSYCH, V11, P677, DOI 10.1016/S0887-6177(96)80004-7; NORMAN WT, 1963, J ABNORM PSYCHOL, V66, P574, DOI 10.1037/h0040291; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; Peterson T, 1999, ANN EMERG MED, V33, P192, DOI 10.1016/S0196-0644(99)70393-8; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schretlen DJ, 2000, REHABIL PSYCHOL, V45, P260, DOI 10.1037/0090-5550.45.3.260; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Stella Julian, 2002, Emerg Med (Fremantle), V14, P58, DOI 10.1046/j.1442-2026.2002.00287.x; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	33	15	15	0	4	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2004	49	4					275	281		10.1037/0090-5550.49.4.275			7	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	874OR	WOS:000225360200001					2021-06-18	
J	Greenwood, RJ; Strens, LHA; Watkin, J; Losseff, N; Brown, MM				Greenwood, RJ; Strens, LHA; Watkin, J; Losseff, N; Brown, MM			A study of acute rehabilitation after head injury	BRITISH JOURNAL OF NEUROSURGERY			English	Article						acute rehabilitation; head injury; resource use	TRAUMATIC BRAIN-INJURY	In 1999 a report from the Royal College of Surgeons of England drew attention to the fact that, in the UK, there is little structured acute inpatient rehabilitation for patients admitted after traumatic brain injury (TBI). This paper reports the results of a retrospective study of acute inpatient rehabilitation (AR) after TBI, comparing aspects of resource use in 92 patients who received structured unit-based multidisciplinary AR with 97 patients who received usual practice. About 10% of patients admitted via casualty after TBI required AR after neurosurgical consultation or care. These patients remained in AR for a mean of 20.5 days; length of stay in an acute bed was not prolonged compared with patients in usual practice. Sixty per cent of patients discharged home from unit-based care were referred to community-based rehabilitation on discharge compared with no patients discharged home from neurosurgical care. There is an urgent need to discuss and plan at national level the structured secondary provision of acute rehabilitation after acquired brain injury.	Natl Hosp Neurol & Neurosurg, Acute Brain Injury Serv, London WC1N 3BG, England; UCL, Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, London, England; UCL, Inst Neurol, Dept Headache Brain Injury & Neurorehabil, London, England	Greenwood, RJ (corresponding author), Natl Hosp Neurol & Neurosurg, Acute Brain Injury Serv, Queen Sq, London WC1N 3BG, England.	richard.greenwood@uclh.org	Brown, Martin M/B-3288-2009				COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Edwards MJ, 2003, DISABIL REHABIL, V25, P405, DOI 10.1080/0963828031000062642; *HOUS COMM, 2001, HEAD INJ REH; LIVINGSTON MG, 1986, BRIT MED J, V293, P742, DOI 10.1136/bmj.293.6549.742; MCKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; *ROYAL COLL PHYS, 2002, NAT CLIN GUID STROK; *ROYAL COLL SURG E, 1999, REP WORK PART MAN PA; Royal College of Physicians, 2000, MED REH PEOPL PHYS C; Seeley HM, 2001, EMERG MED J, V18, P358, DOI 10.1136/emj.18.5.358; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; Shiel A, 2001, CLIN REHABIL, V15, P501, DOI 10.1191/026921501680425225; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; Swann IJ, 2001, EMERG MED J, V18, P352, DOI 10.1136/emj.18.5.352; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Turner-Stokes L, 2004, CLIN MED, V4, P61, DOI 10.7861/clinmedicine.4-1-61; TURNERSTOKES L, 2003, REHABILITATION FOLLO	17	15	15	0	1	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	OCT	2004	18	5					462	466		10.1080/02688690400012327			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	881JL	WOS:000225863000002	15799146				2021-06-18	
J	Spikman, JM; Van Der Naalt, J; Van Weerden, TW; Van Zomeren, AH				Spikman, JM; Van Der Naalt, J; Van Weerden, TW; Van Zomeren, AH			Indices of slowness of information processing in head injury patients: Tests for selective attention related to ERP latencies	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						selective attention; event-related potentials; head injury	EVENT-RELATED POTENTIALS; AUDITORY ODDBALL TASK; REACTION-TIME; GO/NOGO TASK; INHIBITION; COMPONENTS; DEFICITS; RECOVERY; PERFORMANCE; AMPLITUDE	We explored the relation between neuropsychological (attention tests involving time constraints) and neurophysiological (N2 and P3 event-related potential (ERP) latencies) indices of slowness of information processing after closed head injury (CHI). A group of 44 CHI patients performed worse than healthy controls on most neuropsychological indices, and had significantly longer ERP latencies. Significant correlations between neuropsychological measures and ERP latencies were found only for the 3 subtasks of the Stroop test. In additional multiple regression analyses P3 latency appeared the best predictor in Stroop Color only. A possible explanation is that stimulus evaluation processes comprise a relatively large part of performance on this subtask. In Stroop Color-Word, response related processes are supposed to play a greater role, reducing the role of the preceding input related processes. The absence of significant correlations between P3 latency and scores on the other attention tests suggests a relatively small role of stimulus evaluation processes in these tasks, implying that these tasks are not sensitive to slowness of these processes. The Stroop test appears to be the only attention test administered in which slowness ill Stimulus evaluation processes requiring selective attention contributes significantly to the delay in final performance on the task.	Rehabil Ctr Friesland, Beetsterzwaag, Netherlands	Spikman, JM (corresponding author), Acad Hosp, Dept Neurol, AZG, Hanzeplein 1, NL-9713 AB Groningen, Netherlands.	J.m.spikman@neuro.azg.nl		Spikman, Jacoba/0000-0002-6477-0763			Bokura H, 2001, CLIN NEUROPHYSIOL, V112, P2224, DOI 10.1016/S1388-2457(01)00691-5; BROUWER WH, 1985, THESIS STATE U GRONI; Bruin KJ, 2001, CLIN NEUROPHYSIOL, V112, P1660, DOI 10.1016/S1388-2457(01)00601-0; Campbell K. B., 1995, HDB NEUROPSYCHOLOGY, V10, P269; CAMPBELL KB, 1990, NEW TRENDS ADV TECHN, P202; Clark C. R., 1992, Brain Injury, V6, P509, DOI 10.3109/02699059209008148; Curry S H, 1996, Electroencephalogr Clin Neurophysiol Suppl, V46, P283; DONCHIN E, 1981, PSYCHOPHYSIOLOGY, V18, P493, DOI 10.1111/j.1469-8986.1981.tb01815.x; Donchin E., 1988, BEHAVIORAL BRAIN SCI, V11, P355, DOI DOI 10.1017/S0140525X00058027; Donchin E, 1986, PSYCHOPHYSIOLOGY SYS, P244; Donchin E., 1986, PSYCHOPHYSIOLOGY SYS, P702; Falkenstein M, 2002, J PSYCHOPHYSIOL, V16, P167, DOI 10.1027//0269-8803.16.3.167; Falkenstein M, 1999, ACTA PSYCHOL, V101, P267, DOI 10.1016/S0001-6918(99)00008-6; Ferraro FR, 1996, BRAIN COGNITION, V32, P429, DOI 10.1006/brcg.1996.0075; GOODIN D, 1994, ELECTROEN CLIN NEURO, V91, P18, DOI 10.1016/0013-4694(94)90014-0; Gron G, 1996, J CLIN EXP NEUROPSYC, V18, P406, DOI 10.1080/01688639608408997; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; Hillyard A.S., 1987, HDB PHYSL NERVOUS SY, P519; HILLYARD SA, 1983, ANNU REV PSYCHOL, V34, P33, DOI 10.1146/annurev.ps.34.020183.000341; Hillyard Steven A., 1995, P665; Keren O, 1998, J HEAD TRAUMA REHAB, V13, P15; KOK A, 1990, ACTA PSYCHOL, V74, P203; Kok A, 1997, BIOL PSYCHOL, V45, P19, DOI 10.1016/S0301-0511(96)05221-0; Kok A, 2000, BIOL PSYCHOL, V54, P107, DOI 10.1016/S0301-0511(00)00054-5; Mazzini L, 2001, ARCH PHYS MED REHAB, V82, P57, DOI 10.1053/apmr.2001.18076; MCCARTHY G, 1981, SCIENCE, V21, P171; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Potter DD, 2002, J INT NEUROPSYCH SOC, V8, P828, DOI 10.1017/S1355617702860118; Reinvang I, 2000, NEUROPSYCHOLOGIA, V38, P995, DOI 10.1016/S0028-3932(99)00153-0; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; Spikman JM, 2001, BRAIN COGNITION, V47, P446, DOI 10.1006/brcg.2001.1320; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; STOCKX LC, 1986, J CLIN EXPT NEUROPSY, V8, P421; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Timmerman ME, 1999, NEUROPSYCHOLOGIA, V37, P467, DOI 10.1016/S0028-3932(98)00085-2; UNSAL A, 1995, PSYCHOPHYSIOLOGY, V32, P249, DOI 10.1111/j.1469-8986.1995.tb02953.x; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; VANZOMEREN AH, 1981, THESIS STATE U GRONI; WARREN LR, 1979, INT J NEUROSCI, V9, P217, DOI 10.3109/00207457909147677	53	15	18	0	2	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	OCT	2004	10	6					851	861		10.1017/S1355617704106061			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	862PB	WOS:000224502000006	15637776	Green Published			2021-06-18	
J	Adekoya, N; Majumder, R				Adekoya, N; Majumder, R			Fatal traumatic brain injury, West Virginia, 1989-1998	PUBLIC HEALTH REPORTS			English	Article							MOTOR-VEHICLE CRASHES; ELDERLY PERSONS; UNITED-STATES; RURAL TRAUMA; RISK; MORTALITY; FALLS; COMMUNITY; FIREARMS; SYSTEM	Objective. The objective of this study was to describe fatal cases of traumatic brain injury (TBI) among West Virginia residents. Methods. The authors analyzed data from the National Center for Health Statistics Multiple Cause of Death tapes for the period 1989-1998. They compared West Virginia's annualized average TBI death rate with the rates of other states and with the rate among U.S. residents for the same period. U.S. Bureau of Census population estimates were used as denominators. Results. A total of 4,416 TBI deaths occurred in West Virginia in 1989-1998, for an annual average death rate of 23.6 per 100,000 population. From 1989 to 1998, TBI death rates declined 5% (p=0.4042). Seventy-five percent (n=3,31 5) of fatalities occurred among men. Adults greater than or equal to65 years of age accounted for the highest percentage of fatal injuries (n= 1,135). The leading external causes of fatal TBI were: firearm-related (39% of reported fatalities), motor vehicles-related (34%), and fall-related (10%). Firearm-related TBI became the leading cause of TBI fatalities in 1991, surpassing motor vehicle-related TBI. Seventy-five percent of firearm-related TBI deaths were suicides (n=1,302). West Virginia's TBI death rate (23.6 per 100,000) was higher than the national rate (20.6 per 100,000). In 23 states, the average TBI death rates over the 10-year period were higher than West Virginia's. Whereas modest declines in TBI death rates occurred for motor vehicle-related and firearm-related causes in West Virginia, a concomitant 38% increase occurred in the fall-related TBI death rate during the decade. Conclusion. Data presented in this report can be used to develop targeted prevention programs in West Virginia.	Ctr Dis Control & Prevent, Epidemiol Program Off, Surveillance Sust Branch, CDC, Atlanta, GA 30341 USA; W Virginia Univ, Rehabil Res & Training Ctr, Morgantown, WV 26506 USA	Adekoya, N (corresponding author), Ctr Dis Control & Prevent, Epidemiol Program Off, Surveillance Sust Branch, CDC, MS-K74,4770 Buford Hwy, Atlanta, GA 30341 USA.	nba7@cdc.gov					BAKER SP, 1987, NEW ENGL J MED, V316, P1384, DOI 10.1056/NEJM198705283162206; BAKER SP, 1992, OVERVIEW INJURY MORT; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; BRODSKY H, 1983, SOC SCI MED, V17, P731, DOI 10.1016/0277-9536(83)90261-7; *CDCP NAT CTR INJ, WELC WISQARS TM FAT; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P303; Clark DE, 1999, ACAD EMERG MED, V6, P125, DOI 10.1111/j.1553-2712.1999.tb01050.x; Cummings P, 1997, JAMA-J AM MED ASSOC, V278, P1084, DOI 10.1001/jama.278.13.1084; Cummings P, 2001, INJURY CONTROL, P64; Derrig RA, 2002, ACCIDENT ANAL PREV, V34, P101, DOI 10.1016/S0001-4575(01)00004-5; Ensrud KE, 2002, J AM GERIATR SOC, V50, P1629, DOI 10.1046/j.1532-5415.2002.50453.x; ESCOBEDO LG, 1992, ACCIDENT ANAL PREV, V24, P643, DOI 10.1016/0001-4575(92)90016-C; ESPOSITO TJ, 1995, J TRAUMA, V39, P955, DOI 10.1097/00005373-199511000-00022; Gabella B, 1997, ANN EPIDEMIOL, V7, P207, DOI 10.1016/S1047-2797(96)00150-0; Gotsch K. E., 2001, Morbidity and Mortality Weekly Report, V50, P1; Helmkamp, 2000, Ann Epidemiol, V10, P478, DOI 10.1016/S1047-2797(00)00116-2; Hopkins DP, 2001, AM J PREV MED, V20, P16, DOI 10.1016/S0749-3797(00)00297-X; Hoyert DL, 2001, PEDIATRICS, V108, P1241, DOI 10.1542/peds.108.6.1241; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; Lerner E B, 2000, Air Med J, V19, P134, DOI 10.1016/S1067-991X(00)90003-8; Murphy S L, 2000, Natl Vital Stat Rep, V48, P1; *NAT CTR HLTH STAT, 1995, VIT STAT US MORT; Ota FS, 2001, AM J EMERG MED, V19, P204, DOI 10.1053/ajem.2001.22662; *PUBL HLTH SERV US, 2001, NAT STRAT SUIC PREV; RAY WA, 1989, LANCET, V1, P687; Rivara FP, 1999, AM J PREV MED, V16, P1, DOI 10.1016/S0749-3797(98)00111-1; Rogers FB, 1999, J TRAUMA, V47, P802, DOI 10.1097/00005373-199910000-00038; Rogers FB, 1997, ARCH SURG-CHICAGO, V132, P376; ROZENFELD S, 2003, PAN AM J PUBLIC HLTH, V13, P369; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; SPEECHLEY M, 1991, J AM GERIATR SOC, V39, P46, DOI 10.1111/j.1532-5415.1991.tb05905.x; THAPA PB, 1995, AM J EPIDEMIOL, V142, P202, DOI 10.1093/oxfordjournals.aje.a117619; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tinetti ME, 2003, NEW ENGL J MED, V348, P42, DOI 10.1056/NEJMcp020719; TINETTI ME, 1995, J AM GERIATR SOC, V43, P1214, DOI 10.1111/j.1532-5415.1995.tb07396.x; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Wiebe DJ, 2003, ACCIDENT ANAL PREV, V35, P711, DOI 10.1016/S0001-4575(02)00049-0; Wintemute GJ, 1999, NEW ENGL J MED, V341, P1583, DOI 10.1056/NEJM199911183412106; World Health Organization, 1977, INT CLASS DIS MAN IN; 1999, MMWR MORB MORTAL WKL, V48, P369	41	15	15	1	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0033-3549	1468-2877		PUBLIC HEALTH REP	Public Health Rep.	SEP-OCT	2004	119	5					486	492		10.1016/j.phr.2004.07.006			7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	860BC	WOS:000224311200006	15313112	Green Published			2021-06-18	
J	Bazarian, JJ; Fisher, SG; Flesher, W; Lillis, R; Knox, KL; Pearson, TA				Bazarian, JJ; Fisher, SG; Flesher, W; Lillis, R; Knox, KL; Pearson, TA			Lateral automobile impacts and the risk of traumatic brain injury	ANNALS OF EMERGENCY MEDICINE			English	Article							MOTOR-VEHICLE COLLISIONS; CAR SIDE IMPACTS; PATTERNS; SEVERITY; CRASHES; HEAD	Study objectives: We determine the relative risk and severity of traumatic brain injury among occupants of lateral impacts compared with occupants of nonlateral impacts. Methods: This was a secondary analysis of the National Highway Traffic Safety Administration's National Automotive Sampling System, Crashworthiness Data Systems for 2000. Analysis was restricted to occupants of vehicles in which at least 1 person experienced an injury with Abbreviated Injury Scale score greater than 2. Traumatic brain injury was defined as an injury to the head or skull with an Abbreviated Injury Scale score greater than 2. Outcomes were analyzed using the chi(2) test and multivariate logistic regression, with adjustment of variance to account for weighted probability sampling. Results: Of the 1,115 occupants available for analysis, impact direction was lateral for 230 (18.42%) occupants and nonlateral for 885 (81.58%) occupants. One hundred eighty-seven (16.07%) occupants experienced a traumatic brain injury, 14.63% after lateral and 16.39% after nonlateral impact. The unadjusted relative risk of traumatic brain injury after lateral impact was 0.89 (95% confidence interval [CI] 0.51 to 1.56). After adjusting for several important crash-related variables, the relative risk of traumatic brain injury was 2.60 (95% CI 1.1 to 6.0). Traumatic brain injuries were more severe after lateral impact according to Abbreviated Injury Scale and Glasgow Coma Scale scores. The proportion of fatal or critical crash-related traumatic brain injuries attributable to lateral impact was 23.5%. Conclusion: Lateral impact is an important independent risk factor for the development of traumatic brain injury after a serious motor vehicle crash. Traumatic brain injuries incurred after lateral impact are more severe than those resulting from nonlateral impact. Vehicle modifications that increase head protection could reduce crash-related severe traumatic brain injuries by up to 61% and prevent up to 2,230 fatal or critical traumatic brain injuries each year in the United States.	Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Community & Prevent Med, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Res Accid Invest Team, Rochester, NY 14642 USA	Bazarian, JJ (corresponding author), Univ Rochester, Med Ctr, Dept Emergency Med, Box 655,601 Elmwood Ave, Rochester, NY 14642 USA.	jeff_bazarian@urmc.rochester.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 K23 NS 41952-03] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS041952] Funding Source: NIH RePORTER		ARAJARVI E, 1988, ACCIDENT ANAL PREV, V20, P251, DOI 10.1016/0001-4575(88)90053-X; *ARCNETWORK, HEAD INJ AR NOT CRAS; ARGAN P, 1989, AM J DIS CHILD, V143, P1317; ARGOGAST KB, 2001, J TRAUMA, V51, P469; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; *AUTOLIV, SID IMP AIRB; Bring G, 1996, ACCIDENT ANAL PREV, V28, P359, DOI 10.1016/0001-4575(96)00002-4; DISCHINGER PC, 1993, J TRAUMA, V35, P454, DOI 10.1097/00005373-199309000-00020; Dischinger PC, 1998, ACCIDENT ANAL PREV, V30, P831, DOI 10.1016/S0001-4575(98)00036-0; FRAME P, 1998, NHTSAS NEW HEAD PROT; GABLER HC, AGGRESSIVITY LIGHT T; HALAND Y, 1993, ACCIDENT ANAL PREV, V25, P199, DOI 10.1016/0001-4575(93)90060-A; *INS I HIGHW SAF, SPEC ISS HEAD PROT I; *INS I HIGHW SAF, 2001 2002 MOD SID AI; JENNINGS B, DRIVE MAGAZINE; KAHANE CJ, 809004 NHTSA DOT HS; KANG AI, 2001, STAPP CAR CRASH J, V45, P369; McLellan BA, 1996, J TRAUMA, V41, P708, DOI 10.1097/00005373-199610000-00019; MILTNER E, 1995, ACCIDENT ANAL PREV, V27, P105, DOI 10.1016/0001-4575(94)E0019-H; Morris A, 1995, ACCIDENT ANAL PREV, V27, P749, DOI 10.1016/0001-4575(95)00020-8; *NAT HIGHW TRAFF S, 1999, MOT VEH CRASH DAT FA, P72; *NAT HIGHW TRAFF S, 1992, NAT AUT SAMPL SYST C; *NAT HIGHW TRAFF S, 2000, NAT AUT SAMPL SYST C; *NAT HIGHW TRAFF S, 1993, NAT AUT SAMPL SYST C; *NAT HIGHW TRAFF S, 1994, NAT AUT SAMPL SYST C; *NAT HIGHW TRAFF S, 1991, NAT AUT SAMPL SYST C; *NAT HIGHW TRAFF S, 1988, NAT AUT SAMPL SYST C; ORSAY EM, 1990, ANN EMERG MED, V19, P258; Reiff DA, 2001, J TRAUMA, V51, P340, DOI 10.1097/00005373-200108000-00020; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ., 1995, GUIDELINES SURVEILLA	31	15	16	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	AUG	2004	44	2					142	152		10.1016/j.annemergmed.2004.03.029			11	Emergency Medicine	Emergency Medicine	842AY	WOS:000222975900009	15278087				2021-06-18	
J	Tombaugh, TN; Rees, L; Baird, B; Kost, J				Tombaugh, TN; Rees, L; Baird, B; Kost, J			The effects of list difficulty and modality of presentation on a computerized version of the Paced Serial Addition Test (PSAT)	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							PROCESSING SPEED DEFICITS; MINOR HEAD-INJURY; MULTIPLE-SCLEROSIS; PASAT; RECOVERY; VALIDITY; TASK	The Paced Serial Addition Test (PSAT) presents a series of digits at different speeds with the requirement that the two most recent numbers be added together. Although the PSAT is a relatively difficult test, its level of difficulty may be decreased by changing the number list to make the answers simpler and by presenting the digits visually rather than aurally. In view of this, the present experiment varied both task difficulty (easy vs. hard) and mode of presentation (visual vs. auditory). Task difficulty was manipulated by using two different lists composed of single digits whose answers ranged between 2 and 10 (easy) or 2 and 18 (hard). All stimuli were presented by computer which permitted measurement of response latencies, as well as correctness of responding. The results showed that mode of presentation, but not task difficulty, produced highly significant effects. Additional evidence showed that the ability to compute answers to simple addition problems must be considered as a modulator variable. However, an individual's basic arithmetic ability is not as critical as the modality in which a stimulus is presented. The lower performance associated with the auditory version (i.e., PASAT) was interpreted as an interference effect caused by both the stimulus and the response occurring in a single auditory information processing channel. This interpretation suggests that the PASAT's well documented sensitivity to traumatic brain injury (TBI) may be due, at least in part, to an increased susceptibility to interference effects rather than attributable solely to a decreased rate of information processing.	Carleton Univ, Dept Psychol, Ottawa, ON K1S 5B6, Canada; Ottawa Concuss Clin, Ottawa, ON, Canada; Rehabil Ctr, Ottawa, ON, Canada	Tombaugh, TN (corresponding author), Carleton Univ, Dept Psychol, 1125 Colonel By Dr, Ottawa, ON K1S 5B6, Canada.	tom_tombaugh@carleton.ca					BATEMAN GD, 1997, DISS ABSTR INT, V57, P5315; Chronicle EP, 1998, NEUROPSYCHOL REHABIL, V8, P273; Crawford JR, 1998, NEUROPSYCHOL REHABIL, V8, P255, DOI 10.1080/713755575; DEARY IJ, 1991, PERS INDIV DIFFER, V12, P983, DOI 10.1016/0191-8869(91)90027-9; Diamond BJ, 1997, J CLIN EXP NEUROPSYC, V19, P34, DOI 10.1080/01688639708403834; Diehr MC, 1998, ASSESSMENT, V5, P375, DOI 10.1177/107319119800500407; EGAN V, 1988, PERS INDIV DIFFER, V9, P179, DOI 10.1016/0191-8869(88)90046-3; FEINSTEIN A, 1994, J CLIN EXP NEUROPSYC, V16, P436, DOI 10.1080/01688639408402654; Fos L A, 2000, Appl Neuropsychol, V7, P140, DOI 10.1207/S15324826AN0703_4; French J. W., 1963, KIT REFERENCE TESTS; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL D, 1998, COMMUNICATION; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hiscock M, 1998, J CLIN EXP NEUROPSYC, V20, P463, DOI 10.1076/jcen.20.4.463.1466; JOHNSON DA, 1988, J CHILD PSYCHOL PSYC, V29, P199, DOI 10.1111/j.1469-7610.1988.tb00704.x; Kewman D G, 1988, Brain Inj, V2, P131, DOI 10.3109/02699058809150937; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; SAMPSON H, 1960, AUST J PSYCHOL, V12, P70, DOI 10.1080/00049536008255188; SAMPSON H, 1958, CAN J PSYCHOLOGY, V12, P179, DOI 10.1037/h0083750; Sherman EMS, 1997, CLIN NEUROPSYCHOL, V11, P34, DOI 10.1080/13854049708407027; SNYDER PJ, 1993, J CLIN EXP NEUROPSYC, V15, P18; Snyder PJ, 2001, BRAIN COGNITION, V46, P279, DOI 10.1016/S0278-2626(01)80084-1; Snyder PJ, 2001, NEUROPSYCHOLOGY, V15, P617, DOI 10.1037//0894-4105.15.4.617; Spreen O., 1998, COMPENDIUM NEUROPSYC; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; VANZOMERAN AH, 1994, CLIN NEUROPSYCHOLOGY; VANZOMERAN AH, 1987, NEUROBEHAVIORAL RECO; WEBER MA, 1986, THESIS U VICTORIA BR	30	15	15	0	4	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR	2004	26	2					257	265		10.1076/jcen.26.2.257.28080			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	810QW	WOS:000220719800011	15202545				2021-06-18	
J	Bhatoe, HS				Bhatoe, HS			Missile injuries of the anterior skull base	SKULL BASE-AN INTERDISCIPLINARY APPROACH			English	Article						brain abscess; gunshot wound; head injury; meningitis; missile injury; orbitocranial injury	GUNSHOT WOUNDS; HEAD WOUNDS; PROGNOSIS	Missile injuries of the anterior skull base usually occur during war or warlike situations. These injuries may be isolated or associated with multiple traumatic injuries. We report 23 such cases managed during military conflicts and peacekeeping operations. All were adult males. Four of these patients sustained bullet injuries; the rest were injured from shrapnel. Eighteen patients had injury to the visual apparatus with permanent blindness. Proptosis was seen In 16, cerebrospinal fluid (CSF) leak from the wound in seven, and CSF orbitorrhea in three patients. Sixteen had irreparable injury to the eye necessitating evisceration/ enucleation, and two had retrobulbar optic nerve injury. Three patients were comatose [Glasgow Coma Scale (GCS) 3/15], and 14 had altered sensorium. Six patients were fully conscious. All were investigated by computed tomography (CT), which revealed injury to the eyeball and skull base, orbital fracture, frontal hematoma, contusion, and pneumocephalus. Seventeen patients underwent emergency surgery, and six patients were initially managed conservatively. Neurosurgical management consisted of making bifrontal flaps, craniotomy/craniectomy, debridement, and repair of the base with fascia lata. Reconstruction of the orbital rim was required in three cases. All were managed postoperatively with cerebral decongestants and antibiotics in antimeningitic dosages. There was one death in the postoperative period; outcome was good in 16 and moderate in four patients. Twelve patients had retained intracranial splinters; three of these developed recurrent suppurative meningitis. Of the six patients initially managed conservatively, three were subsequently operated for CSF rhinorrhea. Gross communition, dural loss, and injury to the frontal scalp often preclude the use of pericranial repair of the skull base. Fascia lata is extremely useful for reconstruction and repair. Anterior cranial fossa injury probably carries a better prognosis; however, there is increased risk of suppurative complications due to breach of air-fined sinuses by the missile and contamination of the intradural compartment, as compared with supratentorial vault injuries not involving the orbit or paranasal sinuses. Three patients who underwent no operative procedure and remain asymptomatic are under follow-up.	Army Hosp R&R, Dept Neurosurg, Delhi 110010, India	Bhatoe, HS (corresponding author), Army Hosp R&R, Dept Neurosurg, Delhi 110010, India.	hsbhatoe@indiatimes.com					Aarabi B, 1998, NEUROSURGERY, V42, P500, DOI 10.1097/00006123-199803000-00014; AARABI B, 1987, NEUROSURGERY, V20, P610, DOI 10.1227/00006123-198704000-00018; Betz P, 1997, FORENSIC SCI INT, V86, P155, DOI 10.1016/S0379-0738(97)02121-X; Bhatoe HS, 2001, NEUROL INDIA, V49, P29; BHATOE HS, 1997, ASIAN ARCH CRITICAL, V46, P63; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; Cooper PR, 1993, HEAD INJURY, P355; Dillon J D Jr, 1975, Surg Neurol, V4, P515; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; Jankovic S, 1998, MIL MED, V163, P490; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KENNEDY F, 1993, J TRAUMA, V35, P75, DOI 10.1097/00005373-199307000-00013; LEVY M, 2000, OUTCOME PREDICTION F; SHOUNG HM, 1985, ACTA NEUROCHIR, V74, P27, DOI 10.1007/BF01413272; Splavski B, 1998, SURG NEUROL, V50, P194, DOI 10.1016/S0090-3019(98)00047-0; SWAN KG, 1991, SURG CLIN N AM, V71, P221	16	15	16	0	0	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	1531-5010			SKULL BASE-INTERD AP	Skull Base-Interdiscip. Appr.	FEB	2004	14	1					1	8		10.1055/s-2004-821351			8	Clinical Neurology; Otorhinolaryngology; Surgery	Neurosciences & Neurology; Otorhinolaryngology; Surgery	800PM	WOS:000220040200001	16145579	Green Published			2021-06-18	
J	O'Neil-Pirozzi, TM; Kendrick, H; Goldstein, R; Glenn, M				O'Neil-Pirozzi, TM; Kendrick, H; Goldstein, R; Glenn, M			Clinician influences on use of portable electronic memory devices in traumatic brain injury rehabilitation	BRAIN INJURY			English	Article							AIDS; REMEMBER; PEOPLE	Primary objective: To explore the relationship between a group of clinicians' own experience, training and confidence with portable electronic memory devices and their use of the same in traumatic brain injury (TBI) rehabilitation. Research design: Survey study. Methods and procedures: Eighty-one TBI clinicians from various disciplines and work settings completed a survey distributed in person or by mail. Main outcomes and results: Twenty-nine respondents (36%) reported using portable electronic memory devices with patients with TBI. Using regression analysis, respondent device training and confidence teaching patients device use were statistically associated with respondents' use of such devices in TBI rehabilitation. Conclusions: Portable electronic memory device use with persons following TBI may be under-utilized. The importance of ongoing clinician training and of maximizing clinician confidence utilizing these devices in TBI rehabilitation is emphasized. The representativeness of the respondent sample is discussed. Specific training strategies and continued research needs are presented.	Northeastern Univ, CCC SLP, Speech Language Pathol & Audiol Dept, Boston, MA 02115 USA; Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Profess Dev Dept, Boston, MA USA; Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA	O'Neil-Pirozzi, TM (corresponding author), Northeastern Univ, CCC SLP, Speech Language Pathol & Audiol Dept, 103 Forsyth Bldg, Boston, MA 02115 USA.	toneilpi@lynx.dac.neu.edu					*AM SPEECH LANG HE, 1997, HLTH CAR ISS BRIEF L; Fuhrer MJ, 2001, AM J PHYS MED REHAB, V80, P528, DOI 10.1097/00002060-200107000-00013; GALVIN JC, 2002, ASSIST TECHNOL, P153; Glisky E. L, 1995, HDB MEMORY DISORDERS, P557; GOLPER LAC, 2002, CURR TRENDS HLTH CAR; Hart T, 2003, BRAIN INJURY, V17, P401, DOI 10.1080/0269905021000038438; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; KIRSCH NL, 1987, J HEAD TRAUMA REHAB, V2, P77; LYNCH WJ, 1995, J HEAD TRAUMA REHAB, V10, P94, DOI 10.1097/00001199-199502000-00011; PETRO SJ, 1991, INT J AGING HUM DEV, V33, P295, DOI 10.2190/0J3N-F3QB-TEDH-CUYX; Scherer Marcia J., 2000, LIVING STATE STUCK A; Scherer MJ, 2002, DISABIL REHABIL, V24, P1, DOI 10.1080/09638280110066262; Sohlberg M. M., 2001, COGNITIVE REHABILITA; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; *STAT CORP, 2001, STAT 7 0; Tate RL, 1997, BRAIN INJURY, V11, P907, DOI 10.1080/026990597122972; TEMKIN T, 1999, NEEDS ASSESSMENT RES; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161; ZENCIUS A, 1990, Brain Injury, V4, P33, DOI 10.3109/02699059009026146	23	15	15	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2004	18	2					179	189		10.1080/0269905031000149560			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	751DR	WOS:000187038000006	14660229				2021-06-18	
J	Lenzlinger, PM; Saatman, KE; Hoover, RC; Cheney, JA; Bareyre, FM; Raghupathi, R; Arnold, LD; McIntosh, TK				Lenzlinger, PM; Saatman, KE; Hoover, RC; Cheney, JA; Bareyre, FM; Raghupathi, R; Arnold, LD; McIntosh, TK			Inhibition of vascular endothelial growth factor receptor (VEGFR) signaling by BSF476921 attenuates regional cerebral edema following traumatic brain injury in rats	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						blood brain-barrier; cerebral edema; head injury; neuromotor function	LATERAL FLUID-PERCUSSION; SPINAL-CORD; BARRIER BREAKDOWN; UP-REGULATION; IN-VITRO; ANGIOGENESIS; EXPRESSION; PERMEABILITY; ISCHEMIA; DAMAGE	Purpose: In the present study we assessed the ability of BSF476921, an inhibitor of vascular endothelial growth factor receptor (VEGFR) kinase signal transduction, to reduce edema formation and neurologic motor dysfunction following lateral fluid percussion (FP) brain injury in rats. Methods: Anesthetized adult male rats were subjected to either lateral FP brain injury of moderate severity (n = 37) or sham injury (n = 22, surgery without brain injury). Animals were randomized to receive i.p. injections of either BSF476921 (30 mg/kg bw; injured n = 15, sham n = 11) or sterile water (injured n = 14, sham n = 11) at 1, 11 and 22 hours post-injury. After assessment of motor function using a standard 28-point neuroscore, animals were sacrificed 24 hours following trauma and their brains evaluated for regional water content using the wet-weight/dry-weight technique. Results: Although brain-injured animals showed a significant motor deficit compared to uninjured animals, no differences were detected between BSF476921- and vehicle-treated animals at the acute 24 hour post-injury time point. However, BSF476921 significantly attenuated regional edema formation in brain-injured animals in the ipsilateral hippocampus (p < 0.05) and in the cortex adjacent to the injury (p < 0.05) when compared to vehicle treatment. Conclusions: To our knowledge, this is the first report of a small molecule VEGFR kinase inhibitor reducing cerebral edema in a widely accepted model of brain injury.	Univ Penn, Dept Neurosurg, Head Injury Ctr, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; BASF AG, Biores Corp, Worcester, MA USA	McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, Head Injury Ctr, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	mcintosh@seas.upenn.edu	Lenzlinger, Philipp/A-3822-2008		NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM R01-34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS R01-40978, NS P50-08803, T32 NS07413-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007413, P50NS008803, R01NS040978] Funding Source: NIH RePORTER		Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Bao WL, 1999, ACTA PHARMACOL SIN, V20, P313; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Bartholdi D, 1997, EUR J NEUROSCI, V9, P2549, DOI 10.1111/j.1460-9568.1997.tb01684.x; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; BOUMA GJ, 1992, J NEUROTRAUMA S1, V9, P333; Carmeliet P, 1997, AM J PHYSIOL-HEART C, V273, pH2091; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eriksson U, 2002, NAT MED, V8, P775, DOI 10.1038/nm0802-775; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Hayashi T, 1997, STROKE, V28, P2039, DOI 10.1161/01.STR.28.10.2039; Hayashi T, 1998, J CEREBR BLOOD F MET, V18, P887, DOI 10.1097/00004647-199808000-00009; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; ISCHER S, 1999, AM J PHYSIOL, V276, pC812; Issa R, 1999, LAB INVEST, V79, P417; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kovacs Z, 1996, STROKE, V27, P1865, DOI 10.1161/01.STR.27.10.1865; Lee MY, 1999, NEUROSCI LETT, V265, P107, DOI 10.1016/S0304-3940(99)00219-0; Lennmyr F, 1998, J NEUROPATH EXP NEUR, V57, P874, DOI 10.1097/00005072-199809000-00009; MARMAROU A, 1991, J NEUROSURG S, V75, P59; Matsuzaki H, 2001, FASEB J, V15, P1218; Mayhan WG, 1999, AM J PHYSIOL-CELL PH, V276, pC1148; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; National Research Council, 1996, GUIDE CARE USE LAB A, P1; Neufeld G, 1999, FASEB J, V13, P9; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Papavassiliou E, 1997, J NEUROSCI RES, V49, P451, DOI 10.1002/(SICI)1097-4547(19970815)49:4<451::AID-JNR6>3.0.CO;2-7; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P654, DOI 10.1097/00005072-199906000-00010; Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P313, DOI 10.1097/00005072-199904000-00001; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Proescholdt MA, 1999, J NEUROPATH EXP NEUR, V58, P613, DOI 10.1097/00005072-199906000-00006; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Salhia B, 2000, BRAIN RES, V883, P87, DOI 10.1016/S0006-8993(00)02825-0; Skold M, 2000, EUR J NEUROSCI, V12, P3675, DOI 10.1046/j.1460-9568.2000.00263.x; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; Tsao MN, 1999, J NEUROPATH EXP NEUR, V58, P1051, DOI 10.1097/00005072-199910000-00003; Unterberg AW, 1997, ACT NEUR S, V70, P106; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Wick A, 2002, J NEUROSCI, V22, P6401; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369	51	15	15	1	6	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2004	22	2					73	79					7	Neurosciences	Neurosciences & Neurology	837VV	WOS:000222670200003	15272142				2021-06-18	
J	Haga, KK; Gregory, LJ; Hicks, CA; Ward, MA; Beech, JS; Bath, PW; Williams, SCR; O'Neill, MJ				Haga, KK; Gregory, LJ; Hicks, CA; Ward, MA; Beech, JS; Bath, PW; Williams, SCR; O'Neill, MJ			The neuronal nitric oxide synthase inhibitor, TRIM, as a neuroprotective agent: effects in models of cerebral ischaemia using histological and magnetic resonance imaging techniques	BRAIN RESEARCH			English	Article						cerebral ischaemia; TRIM; nitric oxide (NO); histology; magnetic resonance spectroscopy; Mongolian gerbil; rat; neuroprotection	TRAUMATIC BRAIN-INJURY; 1-(2-TRIFLUOROMETHYLPHENYL) IMIDAZOLE TRIM; ARTERY OCCLUSION; ANTIOXIDANT LY231617; RECEPTOR ANTAGONIST; 7-NITRO INDAZOLE; FOCAL ISCHEMIA; INFARCT VOLUME; NOS INHIBITOR; ARL 17477	Most neuroprotective compounds that appear promising in the pre-clinical phase of testing are subsequently dismissed as relatively ineffective when entered into large-scale clinical trials. Many pre-clinical studies of potential neuroprotective candidates evaluate efficacy in only one or possibly two different models of ischaemia. In this study we examined the effects of 1,2-trifluoromethylphenyl imidazole (TRIM), a novel neuronal nitric oxide synthase (nNOS) inhibitor, in three models of cerebral ischaemia (global gerbil, global rat and focal rat). In addition, to follow the progression of the pathology, we also compared traditional histology methods with more advanced magnetic resonance imaging (MRI) as endpoint measures for neurological damage and neuroprotection. TRIM (50 mg/kg i.p.) prevented ischaemia-induced hippocampal damage following global ischaemia in gerbils when administered before or immediately post-occlusion, but failed to protect when administration was delayed until 30 min post-occlusion. Further studies indicated that the compound (administered at 50 mg/kg, i.p., immediately after occlusion) also protected in a rat four-vessel occlusion (4-VO) model using both histological and diffusion-weighted (DW) imaging techniques. In a final study, TRIM (50 mg/kg i.p. 30 min after occlusion) provided a significant reduction in infarct volume at 4 and 24 h as measured using diffusion-weighted (DW) and proton density (PD)weighted magnetic resonance imaging (MRI). This was confirmed using histological techniques. These studies confirm that nNOS inhibitors may have utility in stroke and provide evidence that combined magnetic resonance and histological methods can provide a powerful method of assessing neuronal damage in rodent models of cerebral ischaemia. (C) 2003 Elsevier B.V. All rights reserved.	Eli Lilly & Co, Lilly Res Ctr Ltd, Dept Histopathol, Windlesham GU20 6PH, Surrey, England; Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland; Kings Coll London, Inst Psychiat, Dept Neurol, Neuroimaging Res Grp, London SE5 8AF, England; Univ Manchester, Hope Hosp, Salford M6 8HD, Lancs, England; Cambridge Ctr Brain Repair, Cambridge, England; Univ Nottingham, Div Stroke Med, Nottingham NG5 1PB, England	O'Neill, MJ (corresponding author), Eli Lilly & Co, Lilly Res Ctr Ltd, Dept Histopathol, Erl Wood Manor, Windlesham GU20 6PH, Surrey, England.	ONEILL_MICHAEL-J@Lilly.Com	Williams, Steve C/D-6979-2011; Bath, Philip/F-9020-2011	Williams, Steve C/0000-0003-4299-1941; Bath, Philip/0000-0003-2734-5132; opoku, anita/0000-0001-7243-8157			BABBEDGE RC, 1993, BRIT J PHARMACOL, V110, P225, DOI 10.1111/j.1476-5381.1993.tb13796.x; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; BLOCK F, 1995, BRAIN RES, V694, P308, DOI 10.1016/0006-8993(95)00821-7; BUISSON A, 1993, J NEUROCHEM, V61, P690; CALDWELL M, 1995, EUR J PHARMACOL, V285, P203, DOI 10.1016/0014-2999(95)00502-C; Cash D, 2001, BRAIN RES, V905, P91, DOI 10.1016/S0006-8993(01)02508-2; Chabrier PE, 1999, CELL MOL LIFE SCI, V55, P1029, DOI 10.1007/s000180050353; CHOI DW, 1993, P NATL ACAD SCI USA, V90, P9741, DOI 10.1073/pnas.90.21.9741; CLEMENS JA, 1993, STROKE, V24, P716, DOI 10.1161/01.STR.24.5.716; Coert BA, 1999, J NEUROSURG, V90, P332, DOI 10.3171/jns.1999.90.2.0332; DAWSON DA, 1994, BRIT J PHARMACOL, V113, P247, DOI 10.1111/j.1476-5381.1994.tb16201.x; DAWSON DA, 1994, CEREBROVAS BRAIN MET, V6, P299; Dawson VL, 1996, J NEUROSCI, V16, P2479; Escott KJ, 1998, J CEREBR BLOOD F MET, V18, P281, DOI 10.1097/00004647-199803000-00006; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; Green IC, 1999, DRUG DISCOV TODAY, V4, P47, DOI 10.1016/S1359-6446(98)01296-3; Gregory LJ, 2001, J MAGN RESON IMAGING, V14, P207, DOI 10.1002/jmri.1175; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HANDY RLC, 1995, BRIT J PHARMACOL, V116, P2349, DOI 10.1111/j.1476-5381.1995.tb15078.x; Handy RLC, 1996, BRIT J PHARMACOL, V119, P423, DOI 10.1111/j.1476-5381.1996.tb16003.x; Harukuni I, 1999, CRIT CARE MED, V27, P2508, DOI 10.1097/00003246-199911000-00030; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Lei BP, 1999, STROKE, V30, P669, DOI 10.1161/01.STR.30.3.669; LISZCZAK TM, 1984, ACTA NEUROPATHOL, V65, P150, DOI 10.1007/BF00690469; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; MONCADA S, 1991, PHARMACOL REV, V43, P109; Moore PK, 1997, TRENDS PHARMACOL SCI, V18, P204, DOI 10.1016/S0165-6147(97)90624-6; NAGAFUJI T, 1995, MOL CHEM NEUROPATHOL, V26, P107, DOI 10.1007/BF02815009; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; O'Neill MJ, 2000, NEUROPHARMACOLOGY, V39, P1575, DOI 10.1016/S0028-3908(99)00250-6; O'Neill MJ, 2000, BRAIN RES, V871, P234, DOI 10.1016/S0006-8993(00)02471-9; Olesen SP, 1997, ACTA NEUROL SCAND, V95, P219, DOI 10.1111/j.1600-0404.1997.tb00102.x; ONeill MJ, 1996, EUR J PHARMACOL, V310, P115, DOI 10.1016/0014-2999(96)00387-1; ONeill MJ, 1997, BRAIN RES, V760, P170, DOI 10.1016/S0006-8993(97)00293-X; Panahian N, 1996, NEUROSCIENCE, V72, P343, DOI 10.1016/0306-4522(95)00563-3; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; Schulz JB, 1996, J NEUROCHEM, V67, P430; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Togashi H, 1998, NEUROSCI LETT, V240, P53, DOI 10.1016/S0304-3940(97)00918-X; TRAYSTMAN RJ, 1991, J APPL PHYSIOL, V71, P1185; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wei G, 1999, BBA-MOL BASIS DIS, V1455, P23, DOI 10.1016/S0925-4439(99)00051-4; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; YOSHIDA T, 1995, NEUROSCI LETT, V194, P214, DOI 10.1016/0304-3940(95)11752-I; Zhang FY, 1996, STROKE, V27, P317, DOI 10.1161/01.STR.27.2.317; Zhang ZG, 1996, J CEREBR BLOOD F MET, V16, P599, DOI 10.1097/00004647-199607000-00009	52	15	17	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 12	2003	993	1-2					42	53		10.1016/j.brainres.2003.08.063			12	Neurosciences	Neurosciences & Neurology	753UR	WOS:000187249400005	14642829				2021-06-18	
J	Padosch, SA; Bottiger, BW				Padosch, Stephan A.; Boettiger, Bernd W.			Neuronal apoptosis following cerebral ischaemia: pathophysiology and possible therapeutic implications	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						cerebral ischaemia; neuroprotection; apoptosis; death receptors; erythropoietin; Bcl proteins	TRANSIENT BRAIN ISCHEMIA; INDUCIBLE FACTOR-I; ERYTHROPOIETIN PROTECTS; CARDIAC-ARREST; BCL-XL; NEUROPROTECTION; INJURY; VIVO; INHIBITION; TOLERANCE	Purpose of review Neuronal apoptosis following cerebral ischaemia has become an issue of extraordinary scientific interest in the past decade. Besides necrosis, this highly relevant pathomechanism has been shown to be markedly involved in the pathogenesis of delayed postischaemic neuronal damage. As a result, a variety of possible neuroprotective strategies and therapeutic options subsequent to cerebral ischaemia have emerged. This article provides an overview of the pathophysiologic mechanisms underlying delayed neuronal apoptotic degeneration after cerebral ischaemia. Based on these facts, selected therapeutic implications are discussed in detail. Recent findings Recent findings from experimental studies have demonstrated a new therapeutic neuroprotective potential of pharmaceutical blockade of death-inducing ligands (e.g. Fas/CD95 ligand), enhancement of survival signal transduction with endogenous ligands (e.g. erythropoietin) and therapeutically modulating the balance between intracellular anti-and proapoptotic Bcl proteins with intriguing molecular techniques after cerebral ischaemia. Summary Neuronal apoptosis is highly relevant in the pathophysiology of neurodegenerative disorders, neurotrauma and cerebral ischaemia/reperfusion. Within the past few years, a variety of therapeutic strategies have emerged based on our increasing knowledge of the pathophysiology of apoptosis. Whereas inhibition of single factors in apoptotic cascades (e.g. proteases) has produced rather unsatisfying results, new opportunities have emerged at the molecular level due to advances in molecular medicine. These approaches offer promising opportunities for neuroprotective therapeutic strategies subsequent to cerebral ischaemia. It is tempting to speculate that a combination ('cocktail') of these antiapoptotic interventions might even increase their neuroprotective potential.	[Boettiger, Bernd W.] Heidelberg Univ, Dept Anaesthesiol, D-69120 Heidelberg, Germany; [Padosch, Stephan A.] Univ Bonn, Dept Legal Med, Bonn, Germany	Bottiger, BW (corresponding author), Heidelberg Univ, Dept Anaesthesiol, Neuenheimer Feld 110, D-69120 Heidelberg, Germany.	bernd_boettiger@med.uni-heidelberg.de			'Deutsche Forschungsgemeinschaft' (DFG)German Research Foundation (DFG) [Bo 1686/1-1]	The authors are indebted to Jutta von Bergmann for excellent assistance in graphic design and to Sherryl Sundell for proofreading of the manuscript. This work was supported in part by a grant from 'Deutsche Forschungsgemeinschaft' (DFG) to Bernd W. Bottiger (Bo 1686/1-1).	Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Asoh S, 2000, J BIOL CHEM, V275, P37240, DOI 10.1074/jbc.M005841200; Asoh S, 2002, P NATL ACAD SCI USA, V99, P17107, DOI 10.1073/pnas.262460299; Battin MR, 2003, PEDIATRICS, V111, P244, DOI 10.1542/peds.111.2.244; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; Bilsland James, 2002, Curr Opin Investig Drugs, V3, P1745; Calapai G, 2000, EUR J PHARMACOL, V401, P349, DOI 10.1016/S0014-2999(00)00466-0; Cao GD, 2002, J NEUROSCI, V22, P5423; Cao YJ, 2002, GENE THER, V9, P415, DOI 10.1038/sj.gt.3301676; Catania MA, 2002, EUR J PHARMACOL, V437, P147, DOI 10.1016/S0014-2999(02)01292-X; Cerami A, 2002, NEPHROL DIAL TRANSPL, V17, P8, DOI 10.1093/ndt/17.suppl_1.8; Chavez JC, 2002, J NEUROSCI, V22, P8922; Chong ZZ, 2002, J CEREBR BLOOD F MET, V22, P503, DOI 10.1097/00004647-200205000-00001; Dietz GPH, 2002, MOL CELL NEUROSCI, V21, P29, DOI 10.1006/mcne.2002.1165; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Fiscus RR, 2002, NEUROSIGNALS, V11, P175, DOI 10.1159/000065431; Fisher JW, 2003, EXP BIOL MED, V228, P1; Ginsberg MD, 2003, STROKE, V34, P214, DOI 10.1161/01.STR.0000048846.09677.62; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hou ST, 2002, INT REV CYTOL, V221, P93; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Jin KL, 2002, J NEUROCHEM, V80, P119, DOI 10.1046/j.0022-3042.2001.00678.x; Jin KL, 2001, J CEREBR BLOOD F MET, V21, P1411, DOI 10.1097/00004647-200112000-00005; Juul S, 2002, ACTA PAEDIATR, V91, P36, DOI 10.1080/080352502320764184; Kilic E, 2002, ANN NEUROL, V52, P617, DOI 10.1002/ana.10356; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Love S, 2000, NEUROREPORT, V11, P2495, DOI 10.1097/00001756-200008030-00030; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Padosch SA, 2003, NEUROSCI LETT, V338, P247, DOI 10.1016/S0304-3940(02)01408-8; Padosch SA, 2001, ANAESTHESIST, V50, P905, DOI 10.1007/s00101-001-0247-8; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; Prass K, 2002, J CEREBR BLOOD F MET, V22, P520, DOI 10.1097/00004647-200205000-00003; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Sims NR, 2002, NEUROCHEM INT, V40, P511, DOI 10.1016/S0197-0186(01)00122-X; Siren AL, 2001, EUR ARCH PSY CLIN N, V251, P179, DOI 10.1007/s004060170038; Siren AL, 2001, ACTA NEUROPATHOL, V101, P271, DOI 10.1007/s004010000297; Tsai TH, 2002, METHODS, V28, P253, DOI 10.1016/S1046-2023(02)00230-X; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Vogel P, 2003, ANESTHESIOLOGY, V99, P112, DOI 10.1097/00000542-200307000-00020; Wang XK, 2003, J PHARMACOL EXP THER, V304, P172, DOI 10.1124/jpet.102.040246; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; Yoshida M, 2002, ACTA NEUROPATHOL, V104, P267, DOI 10.1007/s00401-002-0554-4; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526; Zhang ZJ, 2001, MOL BRAIN RES, V95, P75, DOI 10.1016/S0169-328X(01)00247-9	46	15	19	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	OCT	2003	16	5					439	445		10.1097/00001503-200310000-00001			7	Anesthesiology	Anesthesiology	V24WJ	WOS:000208440200001	17021494				2021-06-18	
J	Goozee, JV; Murdoch, BE; Theodoros, DG				Goozee, JV; Murdoch, BE; Theodoros, DG			Electropalatographic assessment of tongue-to-palate contacts exhibited in dysarthria following traumatic brain injury: Spatial characteristics	JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY			English	Article							EPG DATA REDUCTION; LINGUAL ACTIVITY; SPEAKERS	Consonant imprecision has been reported to be a common feature of the dysarthric speech disturbances exhibited by individuals who have sustained a traumatic brain injury (TBI). Inaccurate tongue placements against the hard palate during consonant articulation may be one factor underlying the imprecision. To investigate this hypothesis, electropalatography (EPG) was used to assess the spatial characteristics of the tongue-to-palate contacts exhibited by three males (aged 23-29 years) with dysarthria following severe TBI. Five nonneurologically impaired adults served as control subjects. Twelve single-syllable words of CV or CVC construction (where initial C = /t, d, S, z, k, g/, V=/i, a/) were read aloud three times by each subject while wearing an EPG palate. Spatial characteristics were analyzed in terms of the location, pattern, and amount of tongue-to-palate contact at the frame of maximum contact during production of each consonant. The results revealed that for the majority of consonants, the patterns and locations of contacts exhibited by the TBI subjects were consistent with the contacts generated by the group of control subjects. One notable exception was one subject's production of the alveolar fricatives in which complete closure across the palate was demonstrated, rather than the characteristic groove configuration. Major discrepancies were also noted in relation to the amount of tongue-to-palate contact exhibited, with two TBI subjects consistently demonstrating increased contacts compared to the control subjects. The implications of these findings for the development of treatment programs for dysarthric speech disorders subsequent to TBI are highlighted.	Univ Queensland, Dept Speech Pathol & Audiol, Motor Speech Res Unit, Brisbane, Qld, Australia	Goozee, JV (corresponding author), Univ Queensland, Dept Speech Pathol & Audiol, St Lucia, Qld 4072, Australia.		Theodoros, Deborah/F-1362-2010; Murdoch, Bruce E/C-1397-2012				ADAMS SG, 1993, J SPEECH HEAR RES, V36, P41, DOI 10.1044/jshr.3601.41; BYRD D, 1995, J SPEECH HEAR RES, V38, P821, DOI 10.1044/jshr.3804.821; DAGENAIS PA, 1994, J PHONETICS, V22, P225, DOI 10.1016/S0095-4470(19)30202-5; Darley F., 1975, MOTOR SPEECH DISORDE; GIBBON F, 1990, BRIT J DISORD COMMUN, V25, P329; Gibbon Fiona, 1999, COARTICULATION SPEEC, P229; Goozee JV, 1999, J MED SPEECH-LANG PA, V7, P209; HARDCASTLE W, 1989, CLIN LINGUIST PHONET, V3, P1, DOI 10.3109/02699208908985268; HARDCASTLE W, 1976, PHYSL SPEECH PRODUCT; HARDCASTLE WJ, 1991, J PHONETICS, V19, P251, DOI 10.1016/S0095-4470(19)30343-2; HARDCASTLE WJ, 1991, BRIT J DISORD COMMUN, V26, P41; HARDCASTLE WJ, 1987, J SPEECH HEAR RES, V30, P171, DOI 10.1044/jshr.3002.171; HARDCASTLE WJ, 1985, BRIT J DISORD COMMUN, V20, P249; HARDCASTLE WJ, 1984, PHONETICS LABORATORY, V4, P1; HARDCASTLE WJ, 1997, INSTRUMENTAL CLIN PH, P149; JONES W, 1995, EUR J DISORDER COMM, V30, P183; MORGAN BR, 1995, CASE STUDIES CLIN LI, P181; Murdoch B. E., 1987, AUSTR J HUMAN COMMUN, V15, P15; NGUYEN N, 1996, QMC WORKING PAPERS S, V1, P5; THEODOROS DG, 1994, BRAIN INJURY, V8, P101, DOI 10.3109/02699059409150963; Yorkston K.M., 1981, ASSESSMENT INTELLIGI	21	15	15	0	6	DELMAR LEARNING	CLIFTON PARK	EXECUTIVE WOODS, 5 MAXWELL DR, CLIFTON PARK, NY 12065 USA	1065-1438			J MED SPEECH-LANG PA	J. Med. Speech-Lang. Pathol.	SEP	2003	11	3					115	129					15	Audiology & Speech-Language Pathology; Clinical Neurology	Audiology & Speech-Language Pathology; Neurosciences & Neurology	722PH	WOS:000185384900004					2021-06-18	
J	Simpson, G; Winstanley, J; Bertapelle, T				Simpson, G; Winstanley, J; Bertapelle, T			Suicide prevention training after traumatic brain injury - Evaluation of a staff training workshop	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						evaluation; suicide prevention; training; traumatic brain injury	ATTITUDES	Objectives: To evaluate a suicide prevention training workshop for staff working in the field of traumatic brain injury (TBI) and to develop new measures for evaluation of similar training in the future. Design: A prospective controlled pre- and posttest evaluation with a 6-month follow-up. Subjects: Multidisciplinary TBI rehabilitation and disability staff from the state of Victoria attending the workshop (n = 50) and an equivalent control group (n = 28) recruited from New South Wales. Setting: A statewide training workshop was held at a major rehabilitation center in Melbourne. Outcome measures: Three designed measures including an objective knowledge test, a self-assessment inventory of knowledge/skills and an attitudinal inventory. Results: Participants recorded statistically significant increases in their scores comparing the pre- to postworkshop evaluations. Many of these gains were maintained at the 6-month follow-up evaluation. In contrast, the control group had scores equivalent to those of workshop participants on the pretest evaluations but recorded no similar increase at follow-up. Factor analysis found that the knowledge and skills self-assessment inventory had 2 factors, each having good internal reliability. Conclusion: The current workshop has proved effective in increasing staff knowledge and skills in the assessment and management of people with TBI exhibiting suicidal behaviors. Finally, the initial development of a knowledge and skills self-assessment measure shows promise, providing a resource for the ongoing evaluation of suicide prevention training in the TBI field.	Liverpool Hosp, Brain Injury Rehabil Unit, Sydney, NSW 1871, Australia; Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia; Royal Rehabil Ctr, Sydney, NSW, Australia	Simpson, G (corresponding author), Liverpool Hosp, Brain Injury Rehabil Unit, Locked Bag 7103, Sydney, NSW 1871, Australia.	grahame.simpson@swsahs.nsw.gov.au	Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060; Winstanley, Julie/0000-0002-9353-6757			ACHTE KA, 1971, ACTA PSYCHIAT SCAND, P1; *AM SOC TRAIN DEV, 1998, NEW BAS TRAIN TRAIN, V2; *AUSTR BUR STAT, 1999, SUIC 1921 1998; *AUSTR BUR STAT, 1997, CAUS DEATH 1996; *AUSTR BUR STAT, 1999, CAUS DEATH 1998; Broad M. L., 1992, TRANSFER TRAINING AC; Cox J F, 1997, Crisis, V18, P178, DOI 10.1027/0227-5910.18.4.178; Crawford MJ, 1998, J ACCID EMERG MED, V15, P18; DAVIS M, 1991, CANADIAN J COUNSELLI, V25, P73; DOMINO G, 1982, J CLIN PSYCHOL, V38, P257, DOI 10.1002/1097-4679(198204)38:2<257::AID-JCLP2270380205>3.0.CO;2-I; INMAN DJ, 1984, DEATH EDUC, V8, P179, DOI 10.1080/07481188408252456; Juhnke G. A., 1994, COUNS EDUC SUPERV, V34, P52; Kuipers P, 2000, J HEAD TRAUMA REHAB, V15, P1275, DOI 10.1097/00001199-200012000-00007; Mackenzie TB, 1990, SUICIDE LIFE CYCLE R, P205; MCINTOSH JL, 1985, DEATH STUD, V9, P267, DOI 10.1080/07481188508252523; MICHEL K, 1992, BRIT J PSYCHIAT, V160, P757, DOI 10.1192/bjp.160.6.757; Morgan HG, 1996, J ROY SOC MED, V89, P87; Morriss R, 1999, J AFFECT DISORDERS, V52, P77, DOI 10.1016/S0165-0327(98)00080-9; Mrazek P., 1994, REDUCING RISKS MENTA; NEIMEYER RA, 1981, J COUNS PSYCHOL, V28, P176, DOI 10.1037/h0077970; NEIMEYER RA, 1994, DEATH STUD, V18, P131, DOI 10.1080/07481189408252648; POTTER LB, 1995, SUICIDE LIFE-THREAT, V25, P82; ROY A, 1986, SUICIDE; RUTZ W, 1989, ACTA PSYCHIAT SCAND, V80, P151, DOI 10.1111/j.1600-0447.1989.tb01318.x; SCHNEIDER SG, 1991, J PERS SOC PSYCHOL, V61, P776, DOI 10.1037/0022-3514.61.5.776; Siegal S., 1956, NONPARAMETRIC STAT B; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; SIMPSON GK, 2002, MIND BRAIN TBI FUNCT; SIMPSON GK, 2001, SUICIDE PREVENTION T; STENAGER EN, 1992, ARCH NEUROL-CHICAGO, V49, P1296, DOI 10.1001/archneur.1992.00530360098025; STREINER DL, 1993, CAN J PSYCHIAT, V38, P140, DOI 10.1177/070674379303800214; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Tierney R J, 1994, Crisis, V15, P69	34	15	15	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2003	18	5					445	456		10.1097/00001199-200309000-00006			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	725BF	WOS:000185522200006	12973274				2021-06-18	
J	Macniven, JA; Poz, R; Bainbridge, K; Gracey, F; Wilson, BA				Macniven, JA; Poz, R; Bainbridge, K; Gracey, F; Wilson, BA			Emotional adjustment following cognitive recovery from 'persistent vegetative state': psychological and personal perspectives	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY	Previously, the cognitive recovery of a 26 year old woman, Kate, who developed a severe encephalomyelopathy and was in a 'minimally conscious/persistent vegetative state' for 6 months was reported. After 6 months, Kate began to respond to her environment and, at 2 years post-illness, neuropsychological assessment indicated that Kate was functioning within the normal range on tests of general intellectual functioning, executive functioning and most memory functions (with the exception of visual recognition memory). Although Kate has a severe dysarthria necessitating the use of a communication board and severe physical disabilities that require her to use a wheelchair, she has demonstrated an almost complete cognitive recovery and is among a tiny percentage of minimally conscious patients to do so. This single case report describes the emotional factors central to Kate's rehabilitation. Using a newly developed model of cognitive rehabilitation as a framework, the pivotal role that emotional and psychological factors played in Kate's adjustment to the consequences of her illness and the role of psychotherapeutic intervention in facilitating this adjustment are discussed.	Addenbrookes Hosp, MRC, Cognit & Brain Sci Unit, Cambridge CB2 2QQ, England; Univ Nottingham Hosp, Queens Med Ctr, Nottingham NG7 2UH, England; W Suffolk Hosp, Bury St Edmunds, Suffolk, England; Sect Cambridge, Cambridge, England; Oliver Zangwill Ctr, Ely, England	Wilson, BA (corresponding author), Addenbrookes Hosp, MRC, Cognit & Brain Sci Unit, Box 58, Cambridge CB2 2QQ, England.			Gracey, Fergus/0000-0002-1416-7894			BLOWERS GH, 1995, BRIT J CLIN PSYCHOL, V34, P1; Demark J, 2002, BRAIN INJURY, V16, P91, DOI 10.1080/02699050110102059; Ekman P., 1976, PICTURES FACIAL AFFE; GAINOTTI G, 1993, NEUROPSYCHOL REHABIL, V3, P259, DOI 10.1080/09602019308401440; Judd D. P., 1999, COUNS PSYCHOL, V14, P4; Kelly G.A., 1955, PSYCHOL PERSONAL CON; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; Meissner W. W., 1996, THERAPEUTIC ALLIANCE; NICHOLSON S, 1995, AUSTR NZ J FAMILY TH, V16, P23; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Segal Z.V., 2002, MINDFULNESS BASED CO; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Tyerman A, 2001, NEUROREHABILITATION, V16, P59; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020; Wilson BA, 2001, BRAIN INJURY, V15, P1083, DOI 10.1080/02699050110082197	15	15	16	0	4	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2003	17	6					525	533		10.1080/0269905031000086254			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	672GG	WOS:000182512400006	12745707				2021-06-18	
J	Yousaf, I; Flynn, P; Mcconnell, R				Yousaf, I; Flynn, P; Mcconnell, R			Symptomatic intraspinal pneumocoele resulting from closed head injury	BRITISH JOURNAL OF NEUROSURGERY			English	Article						head injury; intraspinal pneumocele; pneumocephalus; radicular symptoms		Intraspinal pneumocoele is rarely associated with closed head injury. We describe a case of intra-spinal pneumocoele following a closed head injury. We believe this to be the first case presenting with radicular symptoms.	Royal Victoria Hosp, Dept Neurosurg, Belfast BT6 12BA, Antrim, North Ireland; Royal Victoria Hosp, Dept Neuroradiol, Belfast BT6 12BA, Antrim, North Ireland	Yousaf, I (corresponding author), Royal Victoria Hosp, Dept Neurosurg, Grosvenor Rd, Belfast BT6 12BA, Antrim, North Ireland.			Yousaf, Irfan/0000-0003-4992-5154			Aribas OK, 2001, EUR J CARDIO-THORAC, V20, P645, DOI 10.1016/S1010-7940(01)00851-X; CHENG TM, 1994, J NEUROSURG, V81, P453, DOI 10.3171/jns.1994.81.3.0453; Dexter F, 1996, ANESTHESIOLOGY, V84, P442, DOI 10.1097/00000542-199602000-00024; GRAF CJ, 1981, J NEUROSURG, V54, P392, DOI 10.3171/jns.1981.54.3.0392; KAKITSUBATA Y, 1994, ACTA RADIOL, V35, P305; MANGIARDI JR, 1987, SURG NEUROL, V27, P587, DOI 10.1016/0090-3019(87)90161-3; Romano L, 1996, Radiol Med, V92, P642; Uemura K, 2000, BRIT J NEUROSURG, V14, P154	8	15	15	0	0	CARFAX PUBLISHING	BASINGSTOKE	RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	JUN	2003	17	3					248	249		10.1080/0268869031000153143			2	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	715PK	WOS:000184981000008	14565522				2021-06-18	
J	Doninger, NA; Heinemann, AW; Bode, RK; Sokol, K; Corrigan, JD; Moore, D				Doninger, NA; Heinemann, AW; Bode, RK; Sokol, K; Corrigan, JD; Moore, D			Predicting community integration following traumatic brain injury with health and cognitive status measures	REHABILITATION PSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; IMPAIRED AWARENESS; NEUROPSYCHOLOGICAL DEFICITS; INPATIENT REHABILITATION; BEHAVIORAL LIMITATIONS; SURVEY SF-36; QUESTIONNAIRE; TESTS; REPLICATION; DYSFUNCTION	Objective: To examine measurement properties of the Community Integration Questionnaire (CIQ) and the Short-Form Health Survey (SF-36) and assess the contributions of cognitive functioning and health to community integration. Design: Rating scale analyses and regression analysis data on basic cognitive functioning and health collected from 289 individuals with traumatic brain injury. Results: Person reliabilities indicated substantial measurement error. Ceiling effects weakened the model (adjusted R-2 = .143) specifying the contributions of age, gender, cognitive functioning, and health to community integration. Conclusions: Poor measurement properties and definitional problems associated with community integration weakened the results. The extent to which potential familial and environmental characteristics contributing to role fulfillment change across time requires further research.	Northwestern Univ, Inst Rehabil, Sch Med, Evanston, IL 60208 USA; Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Wright State Univ, Dept Community Hlth, Dayton, OH 45435 USA	Doninger, NA (corresponding author), Univ Chicago, Dept Psychiat, 5841 S Maryland Ave,Mail Code 3077, Chicago, IL 60637 USA.	ndoninge@yoda.bsd.uchicago.edu	Heinemann, Allen W./AAI-2790-2021; Heinemann, Allen W/K-6283-2012; Corrigan, John D./E-2921-2011	Heinemann, Allen W./0000-0003-2782-7326; Heinemann, Allen W/0000-0003-2782-7326; 			ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; Bode R K, 2001, J Appl Meas, V2, P78; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; ENGLEHART C, 1994, CLIN NEUROPSYCHOL, V8, P405; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fayers PM, 1997, QUAL LIFE RES, V6, P393, DOI 10.1023/A:1018491512095; Fisher W P Jr, 1997, J Outcome Meas, V1, P329; Fisher WP., 1992, RASCH MEASUREMENT T, V6, P238; Fleming J, 1999, BRAIN INJURY, V13, P417; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; GOLDSTEIN FC, 1987, NEUROBEHAVIORAL RECO, P217; Goldstein K., 1939, ORGANISM; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; HALL K, 1996, ARCH PHYSICAL MED RE, V75, pSC10; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; Heiles C., 1993, PROTOSTARS PLANETS, P279; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; HENRICHS WR, 1990, PROFESSIONAL PSYCHOL, V21, P171; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Johnson David, 1994, CURRENT WRITING, V6, P73; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LINACRE JM, 1999, WINSTEPS PC COMPATIB; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Millis S R, 1994, Int J Neurosci, V79, P165; *N CAL NEUR GROUP, 1988, MAN NEUR COGN STAT E; Nabors NA, 2000, ANN M INT NEUR SOC D; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; Rasch G., 1980, PROBABILISTIC MODELS; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SmithKnapp K, 1996, BRAIN INJURY, V10, P651, DOI 10.1080/026990596124070; STARRATT C, 1992, 100 ANN CONV AM PSYC; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1990, J CLIN EXP NEUROPSYC, V12, P34; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; STUSS DT, 1987, FRONTAL LOBES REVIS; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; WARE J, 1993, SF 3L HLTH SURVEY MA; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weinstein EA, 1955, DENIAL ILLNESS; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1980, INT CLASS IMP DIS HA; World Health Organization, 1993, INT CLASS IMP DIS HA; Wright B. D., 1982, RATING SCALE ANAL RA	66	15	15	0	3	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2003	48	2					67	76		10.1037/0090-5550.48.2.67			10	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	674FV	WOS:000182627500001					2021-06-18	
J	Golden, Z; Golden, CJ				Golden, Z; Golden, CJ			Impact of brain injury severity on personality dysfunction	INTERNATIONAL JOURNAL OF NEUROSCIENCE			English	Article						head trauma; Halstead-Reitan; loss of consciousness; MMPI-2; personality		Although the cognitive effects of traumatic brain injury (TBI) have been well investigated, emotional problems are less well understood. The purpose of this study was to explore the relationship of the length of loss of consciousness (LOC) and the severity of cognitive impairment (HRNB) to personality changes after head trauma. The subjects included 320 chronic TBI patients. A multivariate analysis was conducted using HRNB (three levels), as measured by a modified Halstead-Reitan Impairment Index and LOC (four levels), as the independent variables, and 30 scales from the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) as the dependent variables. Multivariate Fs were significant for both HRNB and LOC. Follow-up ANOVAs and t-tests revealed a consistent pattern of findings across both variables. The data indicated that the reported emotional problems increased with the severity, of both LOC and HRNB, except in the most severe groups. The severe subjects when defined by either variable displayed high levels of denial and a lack of awareness of their problems. LOC and HRNB contributed independently to the degree of personality problems, however, LOC was found to be a stronger predictor of personality change than was HRNB at milder levels of severity. The implications of these findings for both treatment and understanding of the mechanisms of head injury are discussed.	Ely High Sch, Pompano Beach, FL USA; Nova SE Univ, Ft Lauderdale, FL 33314 USA	Golden, CJ (corresponding author), Nova SE Univ, Ctr Psychol Studies, 3301 Coll Ave, Ft Lauderdale, FL 33314 USA.						Alyman C. A., 1999, DISS ABSTR INT B, V59, P6482; BLACK FW, 1975, PERCEPT MOTOR SKILL, V40, P87, DOI 10.2466/pms.1975.40.1.87; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Golden CJ., 2000, NEUROPSYCHOLOGICAL I; Hoffman R. G., 1999, J FORENSIC NEUROPSYC, V1, P3, DOI DOI 10.1300/J151V01N02_02; LANDRY TH, 1997, DISS ABSTR INT B, V57, P5381; Marcelli D, 1977, Ann Med Psychol (Paris), V2, P839; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; YOUNGJOHN JR, 1997, PSYCHOL ASSESSMENT, V9, P77	10	15	15	0	3	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0020-7454			INT J NEUROSCI	Int. J. Neurosci.	MAY	2003	113	5					733	745		10.1080/00207450390200044			13	Neurosciences	Neurosciences & Neurology	681XT	WOS:000183061400009	12745630				2021-06-18	
J	Turner, AP; Bombardier, CH; Rimmele, CT				Turner, AP; Bombardier, CH; Rimmele, CT			A typology of alcohol use patterns among persons with recent traumatic brain injury or spinal cord injury: Implications for treatment matching	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						alcoholism; brain injuries; rehabilitation; spinal cord injuries	SUBSTANCE-ABUSE; CHANGE QUESTIONNAIRE; READINESS; VALIDITY	Objective: To describe empirically valid and clinically meaningful types of alcohol use among persons with recent traumatic brain or spinal cord injury. Design: Cross-sectional cohort survey. Setting: Acute inpatient rehabilitation program in a level I trauma center. Participants: A total of 218 (87%) of 250 consecutive initial admissions who met inclusion criteria and completed interviews. Interventions: Not applicable. Main Outcome Measures: Alcohol and drug use questionnaires, alcohol problem questions, admission toxicology results, readiness to change, and treatment preference questions. Results: Participants were on average 37 years old, 84% were men, and 82% were white. Four types were identified by using k-means cluster analysis based on preinjury alcohol consumption, alcohol problems, and alcohol dependence. Cluster groups differed on extrinsic variables such as drug use, readiness to change, and interest in treatment or in attending Alcoholics Anonymous. The 4 types corresponded to those with a history of (1) alcohol abuse; (2) alcohol dependence; (3) alcohol dependence in remission, partial remission, or relapsed; and (4) normal or nondrinkers. Conclusion: More effective care may be possible if clinicians match common patient types to specific interventions such as education, motivational interventions, formal substance abuse treatment, and relapse prevention.	Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Sch Med, Seattle, WA 98104 USA; Univ Washington, Vet Adm Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Sch Med, Seattle, WA 98104 USA; Seattle VA Puget Sound Hlth Care Syst, Dept Psychiat & Behav Sci, Seattle, WA USA	Bombardier, CH (corresponding author), Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Sch Med, Box 359740,325 9th Ave, Seattle, WA 98104 USA.	chb@u.washington.edu	Turner, Aaron/A-7902-2009	Turner, Aaron/0000-0001-6897-8003	ODCDC CDC HHS [R49/CCR11714-01] Funding Source: Medline		Allen J, 1997, ADDICTION, V92, P1671; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BABOR TF, 1990, BEHAV ASSESS, V12, P5; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Bombardier CH, 1997, ARCH PHYS MED REHAB, V78, P592, DOI 10.1016/S0003-9993(97)90424-X; Bombardier CH, 1998, ARCH PHYS MED REHAB, V79, P1110, DOI 10.1016/S0003-9993(98)90180-0; Bombardier CH, 1997, REHABIL PSYCHOL, V42, P259; Bombardier CH, 2000, J HEAD TRAUMA REHAB, V15, P696, DOI 10.1097/00001199-200002000-00008; CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604; CONNORS GJ, 1996, ADDICTION S, V91, P5; CORRIGAN JD, 1995, BRAIN INJURY, V9, P221, DOI 10.3109/02699059509008195; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DONOVAN DM, 1982, J CONSULT CLIN PSYCH, V50, P241, DOI 10.1037/0022-006X.50.2.241; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FILLMORE KM, 1994, ADDICTION, V89, P1143, DOI 10.1111/j.1360-0443.1994.tb02791.x; HEATHER N, 1993, ADDICTION, V88, P1667, DOI 10.1111/j.1360-0443.1993.tb02042.x; HEINEMANN AW, 1988, ARCH PHYS MED REHAB, V69, P619; JELLINEK EM, 1952, Q J STUD ALCOHOL, V13, P673, DOI 10.15288/QJSA.1952.13.673; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LANGLEY M J, 1990, Brain Injury, V4, P77, DOI 10.3109/02699059009026151; MAISTO SA, 1990, BEHAV ASSESS, V12, P117; Marlatt G. A., 1985, RELAPSE PREVENTION M; Meyers R. J., 1995, CLIN GUIDE ALCOHOL T; MEYERS RJ, 1997, SOURCEBOOK PSYCHOL T, P257; Miller W.R., 1984, MANUAL COMPREHENSIVE; Miller WR, 1997, J CLIN PSYCHOL, V53, P263, DOI 10.1002/(SICI)1097-4679(199704)53:3<263::AID-JCLP10>3.0.CO;2-G; Miller WR, 1991, MOTIVATIONAL INTERVI; Minugh PA, 1997, ACAD EMERG MED, V4, P1059, DOI 10.1111/j.1553-2712.1997.tb03680.x; MOREY LC, 1984, J ABNORM PSYCHOL, V93, P408, DOI 10.1037/0021-843X.93.4.408; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; ROLLNICK S, 1992, BRIT J ADDICT, V87, P743; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117	34	15	16	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2003	84	3					358	364		10.1053/apmr.2003.50107			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	653KL	WOS:000181434300007	12638103				2021-06-18	
J	Zasler, ND; Martelli, MF				Zasler, ND; Martelli, MF			Mild traumatic brain injury: Impairment and disability assessment caveats	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							HEAD-INJURY; CLASSIFICATION	Mild traumatic brain injury (MTBI) accounts for approximately 80% of all brain injuries, and persistent sequelae can impede physical, emotional, social, marital, vocational, and avocational functioning. Evaluation of impairment and disability following MTBI typically can involve such contexts as social security disability application, personal injury litigation, worker's compensation claims, disability insurance policy application, other health care insurance policy coverage issues, and the determination of vocational and occupational competencies and limitations. MTBI is still poorly understood and impairment and disability assessment in MTBI can present a significant diagnostic challenge. There are currently no ideal systems for rating impairment and disability for MTBI residua. As a result, medicolegal examiners and clinicians must necessarily familiarise themselves with the variety of disability and impairment evaluation protocols and understand their limitations. The current paper reviews recommended procedures and potential obstacles and confounding issues.	Concuss Care Ctr, Glen Allen, VA 23060 USA; Virginia Commonwealth Univ Hlth Syst, Glen Allen, VA USA	Zasler, ND (corresponding author), Concuss Care Ctr, 10120 W Broad St,Suites G, Glen Allen, VA 23060 USA.						American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Medical Association, 1993, GUID EV PERM IMP; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; [Anonymous], 1996, Neurology, V47, P592; BINDER LM, 1996, AM J PSYCHIAT, V153, P1; BLAU TH, 1984, PSYCHOL EXPERT WITNE; Brodsky S. L, 1991, TESTIFYING COURT GUI; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Dodrill CB, 1997, CLIN NEUROPSYCHOL, V11, P1, DOI 10.1080/13854049708407025; Green DR, 2000, NAT IMMUNOL, V1, P15, DOI 10.1038/76868; JOHNSON MT, 2000, EXPERT TESTIMONY FED; KRAUS JF, 1995, EPIDEMIOLOGY BRAIN I; Larrabee GJ, 2000, J CLIN EXP NEUROPSYC, V22, P702, DOI 10.1076/1380-3395(200010)22:5;1-9;FT702; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LeesHaley PR, 1997, BRAIN INJURY, V11, P791; LORING DW, 1995, ANN M AM AC NEUR SEA; Martelli M F, 2001, Phys Med Rehabil Clin N Am, V12, P571; Martelli MF, 1999, NEUROREHABILITATION, V13, P45; Martelli MF, 1998, NEUROREHABILITATION, V11, P51, DOI 10.1016/S1053-8135(98)00009-2; MARTELLI MF, 2000, ATTORNEYS GUIDE ETHI; MARTELLI MF, 1999, GUIDE FUNCTIONAL CAP; MARTELLI MF, IN PRESS PRACTICES B; ROHLING ML, 1995, HEALTH PSYCHOL, V14, P537, DOI 10.1037/0278-6133.14.6.537; Rohling ML, 2000, ARCH CLIN NEUROPSYCH, V15, P843, DOI 10.1016/S0887-6177(00)80349-2; Sbordone RJ, 2000, ARCH CLIN NEUROPSYCH, V15, P465; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P12; ZASLER ND, 1996, HEAD INJURY POSTCONS; ZASLER ND, 1996, MED REHABILITATION T; ZASLER ND, 1998, AMA GUIDES NEWSL NOV, P1; ZASLER ND, UNPUB PRINCIPLES PRA; ZASLER ND, 2002, STATE ART REV PHYSIC, V16; ZASLER ND, 1997, ARCH PHYS MED REHAB, V78, P12	33	15	15	0	0	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR-MAY	2003	13	1-2			SI		31	41		10.1080/09602010			11	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	665EK	WOS:000182106500003	21854326				2021-06-18	
J	Meythaler, JM; Fisher, WS; Rue, LW; Johnson, A; Davis, L; Brunner, RC				Meythaler, JM; Fisher, WS; Rue, LW; Johnson, A; Davis, L; Brunner, RC			Screening for venous thromboembolism in traumatic brain injury: Limitations of D-dieter assay	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; fibrin fibrinogen degradation products; rehabilitation; thromboembolism; ultrasonography; Doppler	DEEP-VEIN THROMBOSIS; COST-EFFECTIVENESS ANALYSIS; D-DIMER; COMPRESSION ULTRASONOGRAPHY; IMPEDANCE PLETHYSMOGRAPHY; DIAGNOSIS; PROPHYLAXIS; ADMISSION; STROKE; FIBRIN	Objectives: To assess whether 2 different D-dieter fibrin degradation assays-a second-generation latex immunosorbent agglutination (LIA) and an enzyme-linked immunosorbent assay (ELISA)-are predictive for the development of deep venous thrombosis (DVT) at the currently accepted level of 500 mug/L of D-dieter assay during the first weeks after traumatic brain injury (TBI) and to correlate over 8 weeks the second-generation LIA assay with the ELISA assay after acute TBI. Design: A case series of persons with TBI were screened for DVT at 2 weeks (+/-3d) using real-time, spectral Doppler ultrasound, as well as D-dieter fibrin split products. All persons were rescreened at 4, 6, and 8 weeks ( 3d) after injury using D-dieter LIA and ELISA assays. Setting: A university hospital with a directly connected comprehensive in- and outpatient rehabilitation center that are part of the Traumatic Brain Injury Model Systems. Participants: Over 3 years, 35 TBI subjects with a mean Glasgow Coma Scale score of 6.5 were consecutively enrolled into the trial while on acute care. Persons were at least 16 years of age with no history of treatment for DVT. Interventions: Not applicable. Main Outcome Measures: Data were analyzed for the levels of D-dieter and risk as established by a predictive value of 500 mug/L. Changes in D-dieter values over time and within subjects were assessed by analysis of variance (ANOVA) with repeated measures, and the methods were correlated. Results: The mean LIA level at 2 weeks was 4.3mg/L and averaged 1.6 mg/L at 8 weeks from injury (P=.012, ANOVA), and the ELISA dropped from 4748 mug/L to 1695 mug/L (P=.0022, ANOVA). Except for 1 ELISA value in 1 patient, D-dieter levels were elevated beyond 500 mug/L at 2 weeks. There was a very good correlation between the LIA and the ELISA at 2, 4, 6, and 8 weeks after TBI (P<.0001). In individual cases, there were only occasional discrepancies between the LIA and ELISA methods. There were no positive DVTs at 2 weeks using ultrasound, so prediction of the sensitivity and the specificity of D-dieter with DVT was not possible. Conclusion: Using the currently recommended levels of D-dieter to predict DVT is not clinically useful in the acute TBI population.	Univ Alabama Birmingham, Sch Med, Dept Phys Med & Rehabil, Birmingham, AL 35249 USA; Univ Alabama Birmingham, Sch Med, Div Neurol Surg, Birmingham, AL 35249 USA; Univ Alabama Birmingham, Sch Med, Dept Trauma Surg, Birmingham, AL 35249 USA	Meythaler, JM (corresponding author), Univ Alabama Birmingham, Spain Rehabil Ctr R157, 619 19th St S, Birmingham, AL 35249 USA.	JMeythal@uab.edu					Becker DM, 1996, ARCH INTERN MED, V156, P939, DOI 10.1001/archinte.156.9.939; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; BRANDSTATER ME, 1992, ARCH PHYS MED REHAB, V73, pS379; BREDBACKA S, 1994, J NEUROSURG ANESTH, V6, P75; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P1182, DOI 10.1016/S0003-9993(96)90145-8; COON WW, 1984, CLIN CHEST MED, V5, P391; Crippa L, 1997, HAEMATOLOGICA, V82, P446; FOGELHOLM R, 1992, J NEUROL NEUROSUR PS, V55, P1121, DOI 10.1136/jnnp.55.12.1121; Freyburger G, 1998, THROMB HAEMOSTASIS, V79, P32; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; GITEL SN, 1979, J BONE JOINT SURG AM, V61, P653, DOI 10.2106/00004623-197961050-00002; GREEN D, 1988, JAMA-J AM MED ASSOC, V260, P1255, DOI 10.1001/jama.260.9.1255; HAGER K, 1995, GERONTOLOGY, V41, P159; Harvey RL, 1996, STROKE, V27, P1516, DOI 10.1161/01.STR.27.9.1516; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; KARIO K, 1991, THROMB RES, V62, P501, DOI 10.1016/0049-3848(91)90023-P; Kelly J, 2002, ARCH INTERN MED, V162, P747, DOI 10.1001/archinte.162.7.747; Lamb G C, 1993, J Am Paraplegia Soc, V16, P153; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P1, DOI 10.1016/S0003-9993(96)90210-5; Meythaler JM, 1998, ARCH PHYS MED REHAB, V79, P115, DOI 10.1016/S0003-9993(98)90220-9; OSTER G, 1987, JAMA-J AM MED ASSOC, V257, P203, DOI 10.1001/jama.257.2.203; OUDKERK M, 1993, ARCH INTERN MED, V153, P947, DOI 10.1001/archinte.153.8.947; PEDERSEN OM, 1991, ARCH INTERN MED, V151, P2217, DOI 10.1001/archinte.151.11.2217; Perrier A, 1997, ARCH INTERN MED, V157, P2309, DOI 10.1001/archinte.157.20.2309; Perrier A, 1996, ARCH INTERN MED, V156, P531, DOI 10.1001/archinte.156.5.531; ROSBERG B, 1981, ANN CLIN RES, V13, P84; SASAHARA AA, 1979, AM J CARDIOL, V43, P1214, DOI 10.1016/0002-9149(79)90156-5; SEVITT S, 1961, BRIT J SURG, V48, P475, DOI 10.1002/bjs.18004821103; SEVITT S, 1969, THROMBOSIS, P29; STAMATAKIS JD, 1977, BRIT MED J, V2, P223, DOI 10.1136/bmj.2.6081.223; STEINBERG DP, 1993, ARCH PHYS MED REHAB, V64, P1243; Takahashi H, 1997, J NEUROSURG, V86, P768, DOI 10.3171/jns.1997.86.5.0768; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; van der Graaf F, 2000, THROMB HAEMOSTASIS, V83, P191; VERSTRAETE M, 1993, NEW ENGL J MED, V329, P1418, DOI 10.1056/NEJM199311043291911; WEINMANN EE, 1994, NEW ENGL J MED, V331, P1630, DOI 10.1056/NEJM199412153312407; YABLON SA, 1997, ARCH PHYS MED REHAB, V78, P1027	39	15	16	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					285	290		10.1053/apmr.2003.50116			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	643QV	WOS:000180872700020	12601662				2021-06-18	
J	Black, KL; Hanks, RA; Wood, DL; Zafonte, RD; Cullen, N; Cifu, DX; Englander, J; Francisco, GE				Black, KL; Hanks, RA; Wood, DL; Zafonte, RD; Cullen, N; Cifu, DX; Englander, J; Francisco, GE			Blunt versus penetrating violent traumatic brain injury: Frequency and factors associated with secondary conditions and complications	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						blunt injury; complications; conditions; penetrating injury; traumatic brain injury; violence	HEAD-INJURY; GUNSHOT WOUNDS; COMA; SCALE	To compare types and frequency of medical complications and comorbidities associated with violence-related penetrating traumatic brain injury (TBI) as compared to violence-related blunt TBI. Method: Data were collected prospectively at four medical centers participating in the TBI Model Systems (TBIMS) of Care project. A total of 317 individuals met the inclusion criteria for the TBIMS (i.e., showed evidence of a TBI, were age 16 or older, presented to the TBIMS emergency department within 24 hours of injury, and received acute and rehabilitation services within the model system). Main Outcome Measures : Frequency of medical complications and comorbid diseases. Results: Patients with penetrating injuries suffered significantly higher rates of respiratory failure (P = .004), pneumonitis/pneumonia, (P = .002), skull fracture (P = .001), cerebrospinal fluid leak (P = .0005), and hypotonia (P = .001) than did patients with blunt injuries. Prediction of complications and comorbidities via multiple regression revealed that a penetrating violent injury and the severity of injury were independent predictors of a higher rate of medical complications, whereas age and gender did not account for unique variance in the equation. Conclusions: Penetrating injuries are associated with higher rates of certain medical complications, especially to the pulmonary and central nervous systems. Acute care physicians and physiatrists must be prepared to treat these complications more often in patients with penetrating injuries.	Inst Rehabil, Dept Phys Med & Rehabil, Detroit, MI 48201 USA; Univ Pittsburgh, Med Ctr Hlth Syst, Pittsburgh, PA USA; Toronto Rehabil Inst, Toronto, ON, Canada; Virginia Commonwealth Univ Med Coll Virginia, Richmond, VA USA; Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; Inst Rehabil & Res, Brain Injury Program, Houston, TX USA	Black, KL (corresponding author), Inst Rehabil, Dept Phys Med & Rehabil, 261 Mack Blvd, Detroit, MI 48201 USA.			Cullen, Nora/0000-0001-6359-9418; Cifu, David/0000-0003-1600-9387			AARABI B, 1990, NEUROSURGERY, V27, P692, DOI 10.1227/00006123-199011000-00004; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; Andrews BT, 1992, PHYS MED REHAB CLIN, V3, P249; ANDREWS BT, 1990, PHYS MED REHAB STATE, V4, P495; Ansari SA, 1998, BRIT J NEUROSURG, V12, P340; BLACK K, 1999, TOP SPINAL CORD INJ, V5, P47; JENNETT B, LANCET, V1, P480; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Zafonte RD, 1997, BRAIN INJURY, V11, P403; Zafonte RD, 1998, ARCH PHYS MED REHAB, V79, P1469, DOI 10.1016/S0003-9993(98)90246-5	13	15	15	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	2002	17	6					489	496		10.1097/00001199-200212000-00001			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	617NN	WOS:000179367900001	12802240				2021-06-18	
J	Burger, R; Bendszus, M; Vince, GA; Roosen, K; Marmarou, A				Burger, R; Bendszus, M; Vince, GA; Roosen, K; Marmarou, A			A new reproducible model of an epidural mass lesion in rodents. Part 1: Characterization by neurophysiological monitoring, magnetic resonance imaging, and histopathological analysis	JOURNAL OF NEUROSURGERY			English	Article						trauma; mass lesion; ischemia-reperfusion; laser Doppler flowmetry; partial pressure of oxygen; magnetic resonance imaging; rat	CEREBRAL BLOOD-FLOW; ACUTE SUBDURAL-HEMATOMA; INCREASED INTRACRANIAL-PRESSURE; TRAUMATIC BRAIN INJURY; SYSTEMIC VASCULAR-RESPONSES; LASER-DOPPLER SPECTROSCOPY; SEVERE HEAD-INJURY; TISSUE OXYGEN; COMPUTERIZED-TOMOGRAPHY; HYDROGEN CLEARANCE	Object. The goal of this study was to characterize a new model of an epidural mass lesion in rodents by means of neurophysiological monitoring, magnetic resonance imaging, and histopathological analysis. Methods. Changes in intracranial pressure (ICP), cerebral perfusion pressure (CPP), and laser Doppler flowmetry (LDF) values, intraparenchymal tissue partial oxygen pressure (PtiO(2)), and electroencephalography (EEG) activity were evaluated in the rat during controlled, epidural expansion of a latex balloon up to a maximum ICP of 60 nun Hg. The initial balloon inflation was followed by periods of sustained inflation (30 +/- 1 minute) and reperfusion (180 +/- 5 minutes). Histopathological analysis and magnetic resonance (MR) imaging were performed to characterize the lesion. The time to maximum balloon expansion and the average balloon volume were highly reproducible. Alterations in EEG activity during inflation first appeared when the CPP decreased to 57 mm Hg, the LDF value to 66% of baseline values, and the NO, to 12 mm Hg. During maximum compression, the CPP was reduced to 34 mm Hg, the LDF value to 40% of baseline, and the NO, to 4 to 5 mm Hg. The EEG tracing was isoelectric during prolonged inflation and the values of LDF and NO, decreased due to accompanying hypotonia. After reperfusion, the CPP was significantly decreased (p < 0.05) due to the elevation of lCP. Both the LDF value and EEG activity displayed incomplete restoration, whereas the value of NO, returned to normal. Histological analysis and MR imaging revealed brain swelling with a midline shift and a combined cortical-subcortical ischemic lesion beyond the site of balloon compression. Conclusions. This novel model of an epidural mass lesion in rodents closely resembles the process observed in humans. Evaluation of pathophysiological and morphological changes was feasible by using neurophysiological monitoring and MR imaging.	Univ Regensburg, Dept Neurosurg, D-93053 Regensburg, Germany; Univ Wurzburg, Dept Neurosurg, Wurzburg, Germany; Univ Wurzburg, Dept Neuroradiol, Wurzburg, Germany; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA	Burger, R (corresponding author), Univ Regensburg, Dept Neurosurg, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.	RBurger@t-online.de		Vince, Giles/0000-0002-0222-8733			Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Bardt TF, 1998, ACT NEUR S, V71, P153; Bendszus M, 2002, J NEUROSURG, V97, P1419, DOI 10.3171/jns.2002.97.6.1419; BONNER R, 1981, APPL OPTICS, V20, P2097, DOI 10.1364/AO.20.002097; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; Burger R, 1999, J NEUROTRAUM, V16, P1149, DOI 10.1089/neu.1999.16.1149; CHEN MH, 1991, J NEUROSURG, V74, P944, DOI 10.3171/jns.1991.74.6.0944; CROCKARD HA, 1976, J NEUROL SCI, V27, P29, DOI 10.1016/0022-510X(76)90232-X; DELAPAZ RL, 1991, AM J NEURORADIOL, V12, P89; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DIMAGL U, 1989, J CEREB BLOOD FLOW M, V9, P589; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; DUHAIME AC, 1994, J NEUROTRAUM, V11, P669, DOI 10.1089/neu.1994.11.669; EYRE JA, 1988, CLIN PHYS PHYSIOL M, V9, P65, DOI 10.1088/0143-0815/9/1/006; FITCH W, 1977, J NEUROL NEUROSUR PS, V40, P843, DOI 10.1136/jnnp.40.9.843; FITCH W, 1977, J NEUROL NEUROSUR PS, V40, P833, DOI 10.1136/jnnp.40.9.833; FLECKENSTEIN W, 1989, FUNKTIONSANALYSE BIO, V19, P211; FUJISAWA H, 1994, ACT NEUR S, V60, P193; GINSBERG MD, 1989, STROKE, V20, P1627, DOI 10.1161/01.STR.20.12.1627; GOODMAN SJ, 1972, J NEUROSURG, V37, P514, DOI 10.3171/jns.1972.37.5.0514; HABERL RL, 1989, AM J PHYSIOL, V256, pH1247; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HEINRICH U, 1985, ADV EXP MED BIOL, V191, P77; HEKMATPANAH J, 1970, J NEUROSURG, V32, P21, DOI 10.3171/jns.1970.32.1.0021; HEKMATPANAH J, 1970, J NEUROSURG, V32, P16, DOI 10.3171/jns.1970.32.1.0016; Herguido MJ, 1999, NEUROSCIENCE, V93, P71, DOI 10.1016/S0306-4522(99)00163-3; HOSSMANN KA, 1973, ARCH NEUROL-CHICAGO, V29, P375, DOI 10.1001/archneur.1973.00490300037004; JAKOBSSON K E, 1990, Neurological Research, V12, P153; JAKOBSSON KE, 1989, INTRACRANIAL PRESSUR, V7, P853; JAMJOOM A, 1992, Acta Neurochirurgica, V115, P86, DOI 10.1007/BF01406363; JENKINS A, 1990, British Journal of Neurosurgery, V4, P45, DOI 10.3109/02688699009000681; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; KLINTWOR.GK, 1965, AM J PATHOL, V47, P525; KURODA Y, 1992, NEUROSURGERY, V31, P1062, DOI 10.1227/00006123-199212000-00012; KURODA Y, 1992, NEUROSURGERY, V30, P687; LANGFITT TW, 1964, J NEUROSURG, V21, P989, DOI 10.3171/jns.1964.21.11.0989; LANGFITT TW, 1965, NEUROLOGY, V15, P761, DOI 10.1212/WNL.15.8.761; Lee EJ, 1998, J TRAUMA, V45, P946, DOI 10.1097/00005373-199811000-00017; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; LOBATO RD, 1988, J NEUROSURG, V68, P48, DOI 10.3171/jns.1988.68.1.0048; LOFGREN J, 1973, ACTA NEUROL SCAND, V49, P599; LUBBERS DW, 1994, OXYGEN TRANSPORT TIS, V15, P567; MAAS AIR, 1993, ACTA NEUROCHIR, P50; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MENDELOW AD, 1986, INTRACRANIAL PRESSUR, V6, P515; Metzger H, 1977, Adv Exp Med Biol, V94, P49; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; NAKATANI S, 1972, INTRACRANIAL PRESSUR, P144; NUMOTO M, 1970, J NEUROSURG, V33, P381, DOI 10.3171/jns.1970.33.4.0381; Oliff HS, 1997, J CEREBR BLOOD F MET, V17, P571, DOI 10.1097/00004647-199705000-00012; PARZHUBER A, 1994, UNFALLCHIRURG, V97, P615; Patel TR, 1999, BRAIN RES, V829, P125, DOI 10.1016/S0006-8993(99)01378-5; SCHETTINI A, 1989, J NEUROSURG, V71, P578, DOI 10.3171/jns.1989.71.4.0578; SEYDE WC, 1986, ANESTHESIOLOGY, V64, P480, DOI 10.1097/00000542-198604000-00011; SHALIT MN, 1974, J NEUROSURG, V40, P594, DOI 10.3171/jns.1974.40.5.0594; SKARPHEDINSSON JO, 1988, ACTA PHYSIOL SCAND, V134, P133, DOI 10.1111/j.1748-1716.1988.tb08469.x; SMITH DR, 1977, SURG NEUROL, V7, P233; STERN MD, 1977, AM J PHYSIOL, V232, pH441; Tsuchida E, 1999, J NEUROTRAUM, V16, P595, DOI 10.1089/neu.1999.16.595; Uranishi R, 1999, J VASC RES, V36, P100, DOI 10.1159/000025631; van den Brink WA, 1998, J NEUROTRAUM, V15, P813, DOI 10.1089/neu.1998.15.813; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; WEINSTEI.JD, 1968, J NEUROSURG, V28, P513, DOI 10.3171/jns.1968.28.6.0513; XU BN, 1993, NEUROSURGERY, V32, P289, DOI 10.1227/00006123-199302000-00019; Yilmazlar S, 1997, J Neurosurg Sci, V41, P379; ZIDAN AH, 1978, J NEUROSURG, V49, P61, DOI 10.3171/jns.1978.49.1.0061; ZWETNOW NN, 1986, ACTA NEUROCHIR, V80, P47, DOI 10.1007/BF01809557; Zwienenberg M, 1999, J NEUROTRAUM, V16, P1095, DOI 10.1089/neu.1999.16.1095	72	15	17	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2002	97	6					1410	1418		10.3171/jns.2002.97.6.1410			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	626YG	WOS:000179901000023	12507141				2021-06-18	
J	Nassiri, JD; Daniel, JC; Wilckens, J; Land, BC				Nassiri, JD; Daniel, JC; Wilckens, J; Land, BC			The implementation and use of the standardized assessment of concussion at the US Naval Academy	MILITARY MEDICINE			English	Article							SPORTS	The Standardized Assessment of Concussion (SAC), a sideline mental status assessment tool, was used for the U.S. Naval Academy football team. Baseline SAC data were obtained for 298 subjects; the SAC was also used in immediate assessment and subsequent monitoring of 21 concussed players. Analysis of baseline data revealed no significant difference in SAC score based on position on team, position category (offense, defense, or special team), test form used, graduating class year, or history of prior concussion, nor was there any correlation on the basis of age. Among injured players, there was a significant drop in mean SAC total score from baseline to immediately following concussion. Surveys by athletic trainers and physicians who used the SAC indicated that, despite identifying potential limitations, they considered it to be easy and quick to administer and a useful tool in the assessment, monitoring, and management of concussed athletes at U.S. Naval Academy.	USN, Med Clin, Dept Mil Med, Annapolis, MD 21402 USA; USN, Med Clin, Dept Orthoped, Annapolis, MD 21402 USA; Womack Army Med Ctr, Dept Family Practice, Ft Bragg, NC 28310 USA	Daniel, JC (corresponding author), Amer Embassy Jakarta, Unit 8132, NAMRU 2, FPO, AP 96520 USA.						Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; GUSKIEWICZ KM, 2001, NEUROLOGICAL SPORTS, P123; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; MCCREA, 2001, NEUROLOGICAL SPORTS, P109; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M., 2000, STANDARDIZED ASSESSM; OLESNIEWICZ MH, 2001, NEUROLOGICAL SPORTS, P281; Schnirring L, 2001, PHYSICIAN SPORTSMED, V29, P11; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	9	15	15	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	OCT	2002	167	10					873	876					4	Medicine, General & Internal	General & Internal Medicine	653EB	WOS:000181421300020	12392259				2021-06-18	
J	Shkrum, MJ; McClafferty, KJ; Nowak, ES; German, A				Shkrum, MJ; McClafferty, KJ; Nowak, ES; German, A			Driver and front seat passenger fatalities associated with air bag deployment. Part 1: A Canadian study	JOURNAL OF FORENSIC SCIENCES			English	Article; Proceedings Paper	51st Annual Meeting of the American-Academy-of-Forensic-Sciences	FEB 15-21, 1999	ORLANDO, FL	Amer Acad Forens Sci		forensic science; motor vehicles; air bags; wounds and injuries	RESTRAINT EFFECTIVENESS; INJURY; RUPTURE; TRAUMA; CHILD; REDUCTIONS; COLLISIONS; CRASHES; AIRBAGS; DEATH	Real world motor vehicle collision research of injuries due to deployment of "first-generation" air bags has been conducted by Transport Canada since 1993. Fifty-three fatal crashes (36 frontal impacts; 17 side collisions) involving 48 drivers and 10 right front passengers were reviewed. In the Canadian data, air bag deployment in five of nine low severity frontal crashes (delta-V (Delta/V) < 25 km/h or 15 mph) was linked to five deaths, four of whom were autopsied (four adults with craniocervical (basal skull and C-2 fracture with brainstem avulsion, "closed head injury"-no autopsy) or chest trauma (aortic or pulmonary artery tears), one child with atlanto-occipital dislocation). An occupant who is close ("out-of-position") to the air bag at the time of deployment is at risk for injury In 27 high severity frontal impacts, unusual (e.g., Pulmonary "blast" hemorrhage in one autopsied case) or isolated potentially survivable injuries (e.g. clinically documented ruptured right atrium: probable flail chest observed during the autopsy on a decomposed body) localized to the head, neck or chest in three possibly out-of-position drivers pointed to the deployed air bag as a source of injury In one of 17 side collisions an out-of-position driver sustained a radiographically confirmed C-1-C-2 dislocation in a minimally intruded vehicle.	London Hlth Sci Ctr, Dept Pathol, London, ON N6A 4G5, Canada; Transport Canada, Collis Invest Rd Safety & Motor Vehicle Regulat D, Ottawa, ON, Canada; Univ Western Ontario, Fac Engn Sci, Multidisciplinary Accid Res Team, London, ON N6A 5B9, Canada; Univ Western Ontario, Fac Med, London, ON, Canada	Shkrum, MJ (corresponding author), London Hlth Sci Ctr, Dept Pathol, 375 South St, London, ON N6A 4G5, Canada.						ANTOSIA RE, 1995, ANN EMERG MED, V25, P794, DOI 10.1016/S0196-0644(95)70210-5; AUGENSTEIN JS, 1995, J TRAUMA, V38, P502, DOI 10.1097/00005373-199504000-00007; AUGENSTEIN JS, 1996, P 15 INT TECHN C ENH; AUGENSTEIN JS, 1998, P 1L INT TECHN C ENH; BLACKSIN MF, 1993, J TRAUMA, V35, P840, DOI 10.1097/00005373-199312000-00006; BLOCH B, 1998, P 16 INT TECHN C ENH; Braver ER, 1997, JAMA-J AM MED ASSOC, V278, P1437, DOI 10.1001/jama.278.17.1437; BREED D, 1993, 930650 SAE; Brown DK, 1995, J TRAUMA, V39, P1204, DOI 10.1097/00005373-199512000-00039; Campbell K., 1974, 740565 SAE; Chandler P, 1996, APPL COGNITIVE PSYCH, V10, P151, DOI 10.1002/(SICI)1099-0720(199604)10:2<151::AID-ACP380>3.0.CO;2-U; CHIDESTER AB, 1998, P 16 INT TECHN C ENH; COBEN LE, 1997, 970492 SAE; COLLINS MP, 1989, ANN THORAC SURG, V47, P612, DOI 10.1016/0003-4975(89)90446-3; Cooper G J, 1989, J R Army Med Corps, V135, P58; Cooper JT, 1998, J FORENSIC SCI, V43, P1077; DALMOTAS DJ, 1995, J TRAUMA, V38, P476, DOI 10.1097/00005373-199504000-00002; DALMOTAS DJ, P 16 INT TECHN C ENH; DALMOTAS DJ, 1996, P 40 AAAM C 1996 OCT; DALMOTAS DJ, 1996, P 15 INT TECHN C ENH; deGuzman BJ, 1997, NEW ENGL J MED, V337, P573, DOI 10.1056/NEJM199708213370815; Dunn JA, 1996, ANN THORAC SURG, V62, P577, DOI 10.1016/0003-4975(96)00367-0; EVANS L, 1990, ACCIDENT ANAL PREV, V22, P167, DOI 10.1016/0001-4575(90)90067-U; FRAME P, 1998, 980905 SAE; GERMAN A, 1998, P 16 INT TECHN C ENH; GERMAN A, P CAN SOC MECH ENG C; Giguere JF, 1998, J PEDIATR SURG, V33, P811, DOI 10.1016/S0022-3468(98)90648-0; GRAHAM JD, 1998, PEDIATRICS, P102; Hanna K M, 1997, Tenn Med, V90, P195; HIGHT PV, 1985, 850437 SAE; Hollands CM, 1996, J TRAUMA, V41, P920, DOI 10.1097/00005373-199611000-00033; HORSCH J, 1990, 902324 SAE; HUELKE DF, 1995, J TRAUMA, V38, P482, DOI 10.1097/00005373-199504000-00003; HUELKE DF, 1993, ACCIDENT ANAL PREV, V25, P717, DOI 10.1016/0001-4575(93)90036-V; HUELKE DF, 1995, 950866 SAE; HUELKE DF, 1996, P 15 INT TECHN C ENH; Jolly BT, 1998, ANN EMERG MED, V31, P783, DOI 10.1016/S0196-0644(98)70245-8; Jolly BT, 1998, ANN EMERG MED, V31, P782, DOI 10.1016/S0196-0644(98)70244-6; JUMBELIC MI, 1995, J FORENSIC SCI, V40, P492; KAHANE CJ, 1996, NATL HIGHWAY TRAFFIC; KING AI, 1995, J TRAUMA, V38, P570, DOI 10.1097/00005373-199504000-00017; LANCASTER GI, 1993, NEW ENGL J MED, V328, P358, DOI 10.1056/NEJM199302043280519; Lau I., 1986, 861882 SAE; LAU IV, 1993, ACCIDENT ANAL PREV, V25, P29, DOI 10.1016/0001-4575(93)90094-D; LAU VK, 1981, J TRAUMA, V21, P1022, DOI 10.1097/00005373-198112000-00003; Link MS, 1998, NEW ENGL J MED, V338, P1805, DOI 10.1056/NEJM199806183382504; LUND AK, 1995, J TRAUMA, V38, P469, DOI 10.1097/00005373-199504000-00001; MALLIARIS AC, 1996, 960659 SAE; MARQUARDT JF, 1977, P 21 AAAM C 1977 SEP; MARSH JC, 1993, 930646 SAE; Martinez R, 1996, ANN EMERG MED, V28, P709; Maxeiner H, 1997, J TRAUMA, V42, P1148, DOI 10.1097/00005373-199706000-00029; McCaffrey M, 1999, J PEDIATR ORTHOPED, V19, P60, DOI 10.1097/00004694-199901000-00014; MCCLAFFERTY KJ, 1997, P CAN MULT ROAD SAF; MELVIN JW, 1993, 933119 SAE; MERTZ HJ, 1985, 851199 SAE; Morgenstern K, 1998, CHEST, V114, P624, DOI 10.1378/chest.114.2.624; MORRIS AP, 1996, P 15 INT TECHN C ENH; Morrison AL, 1998, AM J FOREN MED PATH, V19, P218, DOI 10.1097/00000433-199809000-00003; *NAT HIGHW TRAFF S, 1992, NAT TECHN INF SERV P; *NAT HIGHW TRAFF S, 1996, ANN EMERG MED, V28, P241; *NAT HIGHW TRAFF S, 1982, NAT HIGHW TRAFF SAF; Perez J, 1996, ANN EMERG MED, V28, P722, DOI 10.1016/S0196-0644(96)70099-9; Pillgram-Larsen Johan, 1997, Tidsskrift for den Norske Laegeforening, V117, P2437; Prasad P., 1984, 841656 SAE; Shkrum MJ, 1999, J FORENSIC SCI, V44, P44; Smith DP, 1997, J TRAUMA, V42, P341, DOI 10.1097/00005373-199702000-00032; SMOCK WS, 1995, J TRAUMA, V38, P489, DOI 10.1097/00005373-199504000-00004; STRUBLE DE, 1998, 980648 SAE; Tumbas N.S., 1988, 880072 SAE; VIANO DC, 1995, J TRAUMA, V38, P538, DOI 10.1097/00005373-199504000-00013; VIANO DC, 1988, B NEW YORK ACAD MED, V64, P376; WERNER JV, 1994, 940802 SAE; Wilson JV, 1943, LANCET, V1, P257; ZADOR PL, 1993, AM J PUBLIC HEALTH, V83, P661, DOI 10.2105/AJPH.83.5.661; 1995, AIR BAG INJURIES MOS, P30; 1995, INSURANCE I HIGHWAY, V30, P1; 1998, AIR BAG DEACTIVATION; 1996, INSURANCE I HIGHWAY, V31, P6	79	15	15	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-1198	1556-4029		J FORENSIC SCI	J. Forensic Sci.	SEP	2002	47	5					1028	1034					7	Medicine, Legal	Legal Medicine	596UY	WOS:000178185800018	12353540				2021-06-18	
J	Harker, WF; Dawson, DR; Boschen, KA; Stuss, DT				Harker, WF; Dawson, DR; Boschen, KA; Stuss, DT			A comparison of independent living outcomes following traumatic brain injury and spinal cord injury	INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH			English	Article						community integration; independent living; productivity; spinal cord injure; traumatic brain injure	EMPLOYMENT; QUALITY; LIFE; REHABILITATION; DISABILITIES; COMMUNITY; PROFILE; PEOPLE; STATE	This study compares independent living outcomes in persons with traumatic brain injury (TBI) and spinal cord injury (SCI). Both injuries represent life-altering events that are known to have a negative impact on independent living and are predominantly experienced by members of the same demographic group. However, the types of resultant impairments and disabilities experienced by the two populations differ substantially. The TBI participants were recruited consecutively from Canada's largest tertiary care trauma centre and followed prospectively for four years. The SCI participants were recruited via a mailed survey to members of a provincial branch of the Canadian Paraplegic Association. Independent living outcomes were measured using DeJong and Hughes' (1982) classification system of productivity status, the Reintegration to Normal Living Index, and questions on assistance from environmental supports in the form of wheelchair use and paid/unpaid personal assistance. The TBI group was found to be significantly more productive. have higher levels of satisfaction with their current experience of community integration, and use fewer environmental supports than their SCI counterparts (P less than or equal to 0.0001). Methodological and demographic differences between the samples are discussed in relation to the results. The results suggest that various aspects of independent living in these two defined groups (TBI and SCI) although highly related require specific attention and that clinicians and researchers working with TBI and SCI might benefit from further collaborative efforts.	Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; Univ Hlth Network, Toronto Gen Hosp, Toronto, ON, Canada; Univ Toronto, Dept Occupat Therapy, Toronto, ON, Canada; Toronto Rehabil Inst, Lyndhurst Ctr, Toronto, ON, Canada; Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Neurol, Toronto, ON, Canada; Univ Toronto, Dept Rehabil Sci, Toronto, ON, Canada; Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada	Dawson, DR (corresponding author), Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.		Dawson, Deirdre R/I-8882-2014	Dawson, Deirdre R/0000-0001-7517-6121			Boschen K.A, 1997, J DEV DISABIL, V5, P91; Boschen KA, 1998, INT J REHABIL RES, V21, P285, DOI 10.1097/00004356-199809000-00004; BOSCHEN KA, 1999, J REHABILITATION OUT, V3, P1; BOSCHEN KA, 2000, AM J PHYSICAL MED RE, V81, P1618; BOSCHEN KA, IN PRESS CANADIAN J; BOSCHEN KA, 1993, CANADIAN J REHABILIT, V7, P50; BOSCHEN KA, 1995, UNPUB VARIABLES AFFE; BROWN D, 1992, ARCH PHYSICAL MED RE, V73, P788; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Caplan B, 1984, Int Rehabil Med, V6, P58; CASTLE R, 1994, PARAPLEGIA, V32, P182, DOI 10.1038/sc.1994.33; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; DAWSON DR, 2001, STABILITY PSYCHOL FA; DAWSON DR, UNPUB RELATIONSHIP A; DEJONG G, 1979, ARCH PHYS MED REHAB, V60, P435; DEJONG G, 1982, ARCH PHYS MED REHAB, V63, P68; DEJONG G, 1984, ARCH PHYS MED REHAB, V65, P66; DeVivo MJ, 1997, SPINAL CORD, V35, P809, DOI 10.1038/sj.sc.3100501; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Drewes A M, 1989, Int Disabil Stud, V11, P178; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; FRIEDEN L, 1985, AM J OCCUP THER, V39, P734, DOI 10.5014/ajot.39.11.734; FRIEDEN L, 1979, ILRU SOURCE BOOK TEC; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; KENNEDY DW, 1990, PARAPLEGIA, V28, P130, DOI 10.1038/sc.1990.15; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUSE JS, 1991, REHABIL PSYCHOL, V36, P89, DOI 10.1037/0090-5550.36.2.89; Krause JS, 1996, ARCH PHYS MED REHAB, V77, P737; McColl MA, 1999, BRAIN INJURY, V13, P311, DOI 10.1080/026990599121511; MOORE AD, 1995, BRAIN INJURY, V9, P103; NOSEK MA, 1992, REHABIL COUNS BULL, V36, P6; NOSEK MA, 1992, REHABIL COUNS BULL, V36, P21; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; SKINNER HA, 1991, UNPUB MEASURING SOCI; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER BS, 1993, BRAIN INJURY REHABIL; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583	42	15	15	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0342-5282			INT J REHABIL RES	Int. J. Rehabil. Res.	JUN	2002	25	2					93	102		10.1097/00004356-200206000-00003			10	Rehabilitation	Rehabilitation	557WE	WOS:000175931000003	12021596				2021-06-18	
J	Al-Haddad, SA; Kirollos, R				Al-Haddad, SA; Kirollos, R			A 5-year study of the outcome of surgically treated depressed skull fractures	ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND			English	Article						head injury; depressed skull fractures; post-traumatic epilepsy; neurosurgical infection; outcome	ANTIBIOTIC-PROPHYLAXIS; NONMISSILE INJURIES; INFECTION; MANAGEMENT	Background: Many changes and improvement have taken place in the management of head injured patients in the last 20 years. There have been few recent studies analysing the overall outcomes including early complications of depressed skull fractures. The aim of our study was, therefore, to examine the factors influencing the surgical outcome of patients with depressed skull fractures. Methods: We reviewed case notes of 73 consecutive surgically treated depressed skull fractures during the period from 1 January 1994 to 31 December 1998 admitted to the Walton Centre for Neurology and Neurosurgery Liverpool. Results: There was a male preponderance of 9:1. Alleged assault was the most common cause of depressed skull fractures followed by road traffic accidents. Postoperative infection rate was 8.2%. More than 80% of patients received prophylactic antibiotics. We failed to show any statistically significant association between the use of antibiotics and reduction of the rate of infection. However, prevalence of infection was significantly associated with brain contusion, low GCS score and dural tear (P < 0.05). Prevalence of early post-traumatic epilepsy was 12.3%. No patients received prophylactic anticonvulsants. There was no significant association between dural tear and prevalence of post-traumatic epilepsy. Mortality rate was 1.4%. Conclusions: Paediatric populations have better outcome; 7 out of 10 patients in this series progressed to full recovery. Use of prophylactic antibiotics did not reduce the infection rate. Presence of dural tear was not associated with an increase risk of post-traumatic epilepsy.	Walton Ctr Neurol & Neurosurg, Liverpool L9 7LJ, Merseyside, England			Al-Haddad, S. A. R./AAM-6449-2020				*AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP D; Bartlett J, 1998, BRIT J NEUROSURG, V12, P349, DOI 10.1080/02688699844871; BRAAKMAN R, 1971, J NEUROL NEUROSUR PS, V34, P106, DOI 10.1136/jnnp.34.1.106; BRAAKMAN R, 1972, J NEUROL NEUROSUR PS, V32, P395; BROOKES M, 1990, J EPIDEMIOL COMMUN H, V44, P147, DOI 10.1136/jech.44.2.147; BROWN EM, 1994, LANCET, V344, P1547; COLLICOTT PE, 1980, JAMA-J AM MED ASSOC, V243, P1156; DUNN LT, 1994, ANN ROY COLL SURG, V76, P147; GERAGHTY J, 1984, J NEUROSURG, V60, P724, DOI 10.3171/jns.1984.60.4.0724; HAINES SJ, 1982, J NEUROSURG, V56, P103, DOI 10.3171/jns.1982.56.1.0103; JAMIESON KG, 1972, J NEUROSURG, V36, P333; JENNETT B, 1972, J NEUROSURG, V36, P333, DOI 10.3171/jns.1972.36.3.0333; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1974, J NEUROSURG, V41, P208, DOI 10.3171/jns.1974.41.2.0208; Jennett B, 1975, EPILEPSY NONMISSILE; MALIS LI, 1979, NEUROSURGERY, V5, P339, DOI 10.1227/00006123-197909000-00006; Mendelow A D, 1983, J R Coll Surg Edinb, V28, P80; MENDELOW AD, 1989, J R COLL SURG EDINB, V71, P186; MILLER JD, 1968, LANCET, V2, P991; PAGNI CA, 1990, ACT NEUR S, V50, P38; Plese J P, 1981, Arq Neuropsiquiatr, V39, P286; SANDE GM, 1980, SCOT MED J, V25, P227, DOI 10.1177/003693308002500308; VANDENHEEVER CM, 1989, J NEUROSURG, V71, P186, DOI 10.3171/jns.1989.71.2.0186; *WORK PART NEUR SO, 1996, REC TRANSF PAT AC HE; Wylen EL, 1999, SURG NEUROL, V51, P452, DOI 10.1016/S0090-3019(98)00040-8	25	15	16	0	1	ROYAL COLL SURGEONS ENGLAND	LONDON	35-43 LINCOLN'S INN FIELDS, LONDON WC2A 3PN, ENGLAND	0035-8843			ANN ROY COLL SURG	Ann. R. Coll. Surg. Engl.	MAY	2002	84	3					196	200					5	Surgery	Surgery	560TW	WOS:000176098300014	12092875				2021-06-18	
J	Johnstone, B; Hogg, JR; Schopp, LH; Kapila, C; Edwards, S				Johnstone, B; Hogg, JR; Schopp, LH; Kapila, C; Edwards, S			Neuropsychological deficit profiles in senile dementia of the Alzheimer's type	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Alzheimer's disease; cognitive decline; premorbid intelligence	PREMORBID INTELLIGENCE; DISEASE; PATTERN; IMPAIRMENT; SUBGROUPS; DECLINE	Recent studies using Wide Range Achievement Test - Revised (WRAT-R) Reading scores as estimates of premorbid abilities have demonstrated that distinct neuropsychological deficit profiles may be associated with specific cognitive disorders such as traumatic brain injury [Brain Inj. 9 (1995) 377] and lupus [Appl. Neuropsychol. 7 (2000) 96], and that these deficit scores predict both functional and financial outcomes [J. Head Trauma Rehab. 14 (1999) 220]. Although the main cognitive deficits associated with senile dementia of the Alzheimer's type (SDAT) are well known, the relative degree of impairment in each has yet to be adequately determined. The present study calculated indices of relative decline (Z(Diff)) for 32 patients with probable SDAT by comparing estimates of premorbid functioning to concurrent neuropsychological test scores. The results suggest that intelligence is least declined in SDAT [Wechsler Adult Intelligence Scale - Revised (WAIS-R) FIQ, Z(Diff)= -0.72], followed by attention [Wechsler Memory Scale - Revised (WMS-R) Attention Index, Z(Diff)= -1.14], memory (WMS-R General Memory, Z(Diff)= -2.12; WMS-R Delay Memory, Z(Diff)= -2.33), speed of processing (Trails A, Z(Diff)= -2.85), and cognitive flexibility (Trails B, z(Diff) = -5.33). Clinical and research implications are discussed. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Univ Missouri, Sch Med, Dept Phys Med & Rehabil, Columbia, MO 65212 USA	Johnstone, B (corresponding author), Univ Missouri, Sch Med, Dept Phys Med & Rehabil, DC046-00,1 Hosp Dr, Columbia, MO 65212 USA.			Johnstone, Brick/0000-0001-8845-9649			BECKER JT, 1988, ARCH NEUROL-CHICAGO, V45, P263, DOI 10.1001/archneur.1988.00520270037018; BERG L, 1990, ANN NEUROL, V28, P648, DOI 10.1002/ana.410280508; BOTWINICK J, 1986, ARCH NEUROL-CHICAGO, V43, P1124, DOI 10.1001/archneur.1986.00520110024008; Christensen H., 1991, PSYCHOL ASSESS J CON, V3, P147; CHUI HC, 1985, NEUROLOGY, V35, P1544, DOI 10.1212/WNL.35.11.1544; Crowe SF, 2000, ARCH CLIN NEUROPSYCH, V15, P9, DOI 10.1016/S0887-6177(98)00040-7; Fisher NJ, 1996, J CLIN EXP NEUROPSYC, V18, P349, DOI 10.1080/01688639608408993; Ivnik RJ, 2000, NEUROPSYCHOLOGY, V14, P163, DOI 10.1037/0894-4105.14.2.163; JACOBS D, 1994, NEUROLOGY, V44, P1215, DOI 10.1212/WNL.44.7.1215; Jastak J., 1984, WIDE RANGE ACHIEVEME; Johnstone B, 1996, J Int Neuropsychol Soc, V2, P282; Johnstone B, 1996, ARCH CLIN NEUROPSYCH, V11, P513, DOI 10.1016/0887-6177(96)82330-4; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; Johnstone B, 1999, J HEAD TRAUMA REHAB, V14, P220, DOI 10.1097/00001199-199906000-00003; JOHNSTONE B, 1992, PHYSICAL MED REHABIL, P495; KASNIAK AW, 1986, CANADIAN J NEUROLOGI, V13, P420; LORING DW, 1985, NEUROPSYCHOLOGIA, V23, P351, DOI 10.1016/0028-3932(85)90021-1; MASUR DM, 1994, NEUROLOGY, V44, P1427, DOI 10.1212/WNL.44.8.1427; MAYEUX R, 1985, NEUROLOGY, V35, P453, DOI 10.1212/WNL.35.4.453; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MITRUSHINA M, 1993, DEV BRAIN DYSFUNCT, V6, P324; Reitan R, 1986, TRAIL MAKING TEST MA; Schopp LH, 1998, ARCH CLIN NEUROPSYCH, V13, P637, DOI 10.1016/S0887-6177(97)00096-6; Skeel R L, 2000, Appl Neuropsychol, V7, P96, DOI 10.1207/S15324826AN0702_5; Wechsler D., 1987, MANUAL WECHSLER MEMO; Wechsler D., 1981, WAIS R MANUAL WECHSL; WEINTRAUB S, 1993, HDB NEUROPSYCHOLOGY, V8, P253	27	15	15	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	APR	2002	17	3					273	281	PII S0887-6177(01)00112-3	10.1016/S0887-6177(01)00112-3			9	Psychology, Clinical; Psychology	Psychology	536ZN	WOS:000174731900004	14589727				2021-06-18	
J	Hanke, J				Hanke, J			Anatomical correlations of intrinsic axon repair after partial optic nerve crush in rats	ANNALS OF ANATOMY-ANATOMISCHER ANZEIGER			English	Article						diffuse axonal injury; impaired axoplasmic transport; cytoskeletal change; retinal ganglion cells	RETINAL GANGLION-CELLS; TRAUMATIC BRAIN-INJURY; NEUROFILAMENT PROTEINS; TAIL DOMAIN; TRANSPORT; PHOSPHORYLATION; MODEL; HEAD; RECOVERY; ACCELERATION	About 15% of retinal ganglion cells survive diffuse axonal injury of the optic nerve in adult rats. Following initial blindness, discrimination of visual stimuli in behavioral tests recovers within three weeks. To investigate the mechanisms promoting this functional recovery the axonal transport and the neurofilaments were studied. Intraocularly applied MiniRuby is transported until the place of crush and accumulated in enlarged axon terminals. Three weeks after lesion the anterograde transport of MiniRuby recovers distal to the place of crush. At the same point in time the retrograde transport of surviving retinal ganglion cells is restored which was visualized by horseradish peroxidase injected into the superior colliculus. The heavy neurofilament was stained immunohistochemically and analyzed statistically up to three weeks after optic nerve crush. The stained filaments in the axon fibers of retinal ganglion cells appear wavelike and/or fragmented up to day 8, but first signs of heavy neurofilament restitution in the fibers of the optic nerve are seen at day 12 after axonal injury. Because these results cannot be explained by longlasting axon regeneration, the present results provide convincing evidence for intrinsic axon repair soon after diffuse axonal injury that correlates in time with recovery of vision.	Otto Von Guericke Univ, Fac Med, Inst Med Psychol, D-39120 Magdeburg, Germany	Hanke, J (corresponding author), Inst Anat, Leipziger Str 44, D-39120 Magdeburg, Germany.	Joachim.Hanke@medizin.uni-magdeburg.de	Sabel, Bernhard A./E-6579-2013				Bien A, 1999, J NEUROTRAUM, V16, P153, DOI 10.1089/neu.1999.16.153; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; Gennarelli T.A., 1986, MECHANISMS SECONDARY, P15; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRILL RJ, 1999, CNS REGENERATION BAS, P27; HESS DT, 1987, BRAIN RES BULL, V18, P581, DOI 10.1016/0361-9230(87)90124-9; HISANAGA S, 1991, J BIOL CHEM, V266, P21798; Julien JP, 1998, PROG NUCLEIC ACID RE, V61, P1, DOI 10.1016/S0079-6603(08)60823-5; LASEK RJ, 1993, BRAIN RES, V616, P58, DOI 10.1016/0006-8993(93)90192-P; LORENZ T, 1978, P NATL ACAD SCI USA, V75, P505, DOI 10.1073/pnas.75.1.505; LUDWIN SK, 1992, J NEUROL SCI, V109, P140, DOI 10.1016/0022-510X(92)90160-M; Marszalek JR, 1996, J CELL BIOL, V135, P711, DOI 10.1083/jcb.135.3.711; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MAYOR HD, 1961, J BIOPHYS BIOCHEM CY, V9, P909, DOI 10.1083/jcb.9.4.909; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MCKERRACHER L, 1992, J NEUROBIOL, V23, P568, DOI 10.1002/neu.480230510; MIYASAKA H, 1993, J BIOL CHEM, V268, P22695; Nixon RA, 1998, BIOESSAYS, V20, P798, DOI 10.1002/(SICI)1521-1878(199810)20:10<798::AID-BIES5>3.0.CO;2-7; NIXON RA, 1993, BRAIN PATHOL, V3, P29, DOI 10.1111/j.1750-3639.1993.tb00723.x; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raghupathi R, 1998, P W PHARMACOL SOC, V41, P241; Rousseau V, 1999, NEUROREPORT, V10, P3387, DOI 10.1097/00001756-199911080-00024; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Sabel BA, 1999, RESTOR NEUROL NEUROS, V15, P177; Sabel BA, 1997, ADV NEUROL, V73, P251; SAUTTER J, 1993, EUR J NEUROSCI, V5, P680, DOI 10.1111/j.1460-9568.1993.tb00533.x; Schmitt U, 1996, EXP NEUROL, V139, P17, DOI 10.1006/exnr.1996.0076; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; SMITH RS, 1993, EUR J NEUROSCI, V5, P1127, DOI 10.1111/j.1460-9568.1993.tb00967.x; Terada S, 1996, SCIENCE, V273, P784, DOI 10.1126/science.273.5276.784; TOYOSHIMA I, 1995, NEUROSCI LETT, V189, P69, DOI 10.1016/0304-3940(95)11451-2; Vorwerk CK, 1999, CURR EYE RES, V19, P59, DOI 10.1076/ceyr.19.1.59.5336; WATSON DF, 1991, BRAIN RES, V539, P103, DOI 10.1016/0006-8993(91)90691-N; XIE XY, 1991, J NEUROSCI, V11, P3257	45	15	19	0	1	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0940-9602	1618-0402		ANN ANAT	Ann. Anat.-Anat. Anz.	MAR	2002	184	2					113	123		10.1016/S0940-9602(02)80002-4			11	Anatomy & Morphology	Anatomy & Morphology	535LH	WOS:000174645600002	11936190				2021-06-18	
J	Reed, AR; Welsh, DG				Reed, AR; Welsh, DG			Secondary injury in traumatic brain injury patients - A prospective study	SAMJ SOUTH AFRICAN MEDICAL JOURNAL			English	Article							COMATOSE PATIENTS; HEAD-INJURY; HEMATOMA	Objective. Secondary insults of hypotension and hypoxia significantly impact on outcome in patients with traumatic brain injury (TBI). More than 4 hours' delay in evacuation of intracranial haematomas has been demonstrated to have an additional impact on outcome. The objective of this study was to document the incidence of these preventable secondary insults in patients admitted with moderate or severe brain injury. Methodology. All moderate and severe head injury patients admitted to Groote Schuur Hospital over a 3-month period were studied prospectively. Data were obtained from ambulance dockets, referral letters, patient charts and attending medical staff. Preventable secondary insults (hypotension, hypoxia) and time delay to assessment and surgery were documented. Outcome was assessed using the Glasgow outcome scale (GOS) at discharge or outpatient follow-up. Results. Ninety-six patients were studied. Forty-nine patients experienced at least one recorded preventable event of hypoxia or hypotension. Seventeen had an intracranial haematoma requiring evacuation. The mean time interval between injury and surgery was 455 minutes. No haematoma was evacuated within 4 hours of injury. Patients referred via a primary or secondary care facility experienced a mean additional delay of 70 minutes. These results demonstrated a significant incidence of secondary injury and delay to assessment and surgery. We believe that education and a raised awareness of the impact of secondary insults may have a positive impact on TBI outcome in our referral area.	Groote Schuur Hosp, Dept Anaesthesia, ZA-7925 Cape Town, South Africa; Groote Schuur Hosp, Dept Neurosurg, ZA-7925 Cape Town, South Africa	Reed, AR (corresponding author), Groote Schuur Hosp, Dept Anaesthesia, ZA-7925 Cape Town, South Africa.						CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; JENNETT B, 1975, LANCET, V1, P480; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SEELIG JM, 1984, NEUROSURGERY, V15, P617, DOI 10.1227/00006123-198411000-00001; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363	8	15	21	0	2	MED ASSOC S AFRICA	JOHANNESBURG	MED HOUSE CENTRAL SQ 7430 PINELANDS  PRIV BAG X1, JOHANNESBURG, SOUTH AFRICA	0256-9574			SAMJ S AFR MED J	SAMJ S. Afr. Med. J.	MAR	2002	92	3					221	224					4	Medicine, General & Internal	General & Internal Medicine	553YE	WOS:000175704200028	12040951				2021-06-18	
J	Hilsabeck, RC; LeCompte, DC; Marks, AR; Grafman, J				Hilsabeck, RC; LeCompte, DC; Marks, AR; Grafman, J			The Word Completion Memory Test (WCMT): a new test to detect malingered memory deficits	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						malingering; neuropsychological; analogue; coaching; WCMT	MMPI-2 VALIDITY SCALES; HEAD-INJURY; IMPAIRMENT; FRAMEWORK	In recent years, much research has focused on developing tests to detect malingering. A drawback of existing tests is their poor ability to detect malingerers possessing more "sophisticated" knowledge of neuropsychological deficits. The current study presents preliminary validation data on a new measure, the Word Completion Memory Test (WCMT), which is the first malingering test to utilize a sophisticated coaching methodology in its development. The WCMT was administered to control participants, memory-impaired patients, and coached simulators. The coached simulators were provided with specific information about and examples of memory deficits commonly experienced following closed head injury (CHI; e.g., anterograde vs. retrograde amnesia). They also read a detailed scenario describing the lifestyle and motivations likely experienced by CHI litigants, and then practiced their roles by taking a quiz about their deficits. Results showed that 93% of coached simulators and 100% of control and memory-impaired participants were correctly classified by the WCMT. (C) 2001 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Univ Calif San Diego, Med Ctr, San Diego, CA 92103 USA; BMC Software, Houston, TX USA; NINDS, NIH, Bethesda, MD USA	Hilsabeck, RC (corresponding author), Univ Calif San Diego, Med Ctr, 200 W Arbor Dr, San Diego, CA 92103 USA.		Hilsabeck, Robin/ABC-5093-2020	Grafman, Jordan H./0000-0001-8645-4457			BEETAR JT, 1995, ARCH CLIN NEUROPSYCH, V10, P57, DOI 10.1016/0887-6177(94)E0005-A; Chouinard M J, 1997, J Int Neuropsychol Soc, V3, P545; CRAIK FIM, 1972, J VERB LEARN VERB BE, V11, P671, DOI 10.1016/S0022-5371(72)80001-X; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; FRANZEN M D, 1990, Neuropsychology Review, V1, P247, DOI 10.1007/BF01112573; Frederick R.I., 1997, VALIDITY INDICATOR P; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; GUILMETTE TJ, 1994, PERCEPT MOTOR SKILL, V78, P1179, DOI 10.2466/pms.1994.78.3c.1179; Haines ME, 1995, NEUROPSYCHOL REV, V5, P125, DOI 10.1007/BF02208438; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HILSABECK RC, 1997, WORLD COMPLETION MEM; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Inman TH, 1998, PSYCHOL ASSESSMENT, V10, P128, DOI 10.1037/1040-3590.10.2.128; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; JACOBY LL, 1991, J MEM LANG, V30, P513, DOI 10.1016/0749-596X(91)90025-F; Lamb DG, 1994, PSYCHOL ASSESSMENT, V6, P8; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MARTIN RC, 1992, FORENSIC REPORTS, V5, P393; Rey A, 1964, EXAMEN CLIN PSYCHOL; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; ROGERS R, 1988, CLIN ASSESSMENT MALI; ROSE FE, 1995, CLIN NEUROPSYCHOL, V10, P163; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; WETTER MW, 1995, PROF PSYCHOL-RES PR, V26, P474, DOI 10.1037/0735-7028.26.5.474; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; Youngjohn J.R., 1995, ASSESSMENT, V2, DOI [https://doi.org/10.1177/1073191195002003007, DOI 10.1177/1073191195002003007]	31	15	15	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	OCT	2001	16	7					669	677		10.1016/S0887-6177(00)00077-9			9	Psychology, Clinical; Psychology	Psychology	473RK	WOS:000171061700004	14589785	Bronze			2021-06-18	
J	Pusch, F; Wildling, E; Freitag, H; Weinstabl, C				Pusch, F; Wildling, E; Freitag, H; Weinstabl, C			Procalcitonin as a diagnostic marker in patients with aspiration after closed head injury	WIENER KLINISCHE WOCHENSCHRIFT			English	Article						closed head injury; procalcitonin; aspiration; prognostic; C-reactive protein	GENE-RELATED PEPTIDE; C-REACTIVE PROTEIN; GLASGOW COMA SCALE; SERUM PROCALCITONIN; CALCITONIN; PNEUMONIA; MORTALITY; SEPSIS; LUNG	Background: Aspiration of gastric content frequently induces early onset of pneumonia in patients with impaired consciousness after closed head injury and thus worsens the prognosis. Early detection of aspiration and appropriate therapy are essential. The purpose of the study was to assess the diagnostic value of procalcitonin (ProCT) in aspiration of gastric content and to evaluate its prognostic impact in patients with closed head injury. Methods: Twenty-three patients with isolated closed head injury (Glasgow Coma Scale [GCS] score less than or equal to 8) were studied. Bronchoscopy was done on admission; chest radiographs and routine laboratory examination including C-reactive protein were performed daily. ProCT was analyzed 12, 24, 36 and 72 hours after trauma using an immunoluminometric assay. Results: ProCT was higher throughout the study period in 9 patients with persistent radiological signs suspect for aspiration of gastric content and there was evidence of aspiration of gastric content during bronchoscopy on admission. Median ProCT values of 1.397 ng/ml (range, 0.372 to 8.358 ng/ml) on admission increased to 2.144 ng/ml (range, 0.716 to 6.910 ng/ml) 24 hours after trauma, and then decreased to baseline values of 1.711 ng/ml (range, 0.611 to 6.639 ng/ml) as early as 36 hours after trauma. In patients without signs of aspiration of gastric content, ProCT values did not exceed 0.418 ng/ml. Non-survivors had higher serum levels of ProCT throughout the study period. Conclusion: Our findings suggest that ProCT is a useful diagnostic marker for detecting aspiration of gastric content while the prognostic value of ProCT for predicting survival after isolated closed head injury was moderate.	Univ Vienna, Dept Anesthesiol & Gen Intens Care, A-1090 Vienna, Austria; Gen Hosp, Dept Anesthesiol & Gen Intens Care, Korneuburg, Austria	Pusch, F (corresponding author), Univ Vienna, Dept Anesthesiol & Gen Intens Care, Waehringer Guertel 18-20, A-1090 Vienna, Austria.						Adnet F, 1996, LANCET, V348, P123, DOI 10.1016/S0140-6736(05)64630-2; Adnet F, 1997, CHEST, V112, P466, DOI 10.1378/chest.112.2.466; ASSICOT M, 1993, LANCET, V341, P515, DOI 10.1016/0140-6736(93)90277-N; BECKER KL, 1980, ARCH PATHOL LAB MED, V104, P196; Carsin H, 1997, BURNS, V23, P218, DOI 10.1016/S0305-4179(96)00124-6; Cho DY, 1997, INTENS CARE MED, V23, P77, DOI 10.1007/s001340050294; DANDONA P, 1994, J CLIN ENDOCR METAB, V79, P1605, DOI 10.1210/jc.79.6.1605; DOYLE RL, 1995, AM J RESP CRIT CARE, V152, P1818, DOI 10.1164/ajrccm.152.6.8520742; GOLDMAN G, 1993, SURGERY, V114, P13; HOLLAND JP, 1994, STROKE, V25, P2055, DOI 10.1161/01.STR.25.10.2055; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; LIND L, 1995, INTENS CARE MED, V21, P63, DOI 10.1007/BF02425156; Mimoz O, 1998, INTENS CARE MED, V24, P185, DOI 10.1007/s001340050543; NYLEN ES, 1992, HORM METAB RES, V24, P439, DOI 10.1055/s-2007-1003354; Nylen ES, 1996, AM J MED SCI, V312, P12, DOI 10.1016/S0002-9629(15)41740-9; Nylen ES, 1998, CRIT CARE MED, V26, P1001, DOI 10.1097/00003246-199806000-00015; REDDINGTON M, 1995, CAN J PHYSIOL PHARM, V73, P1047, DOI 10.1139/y95-148; SKOLNICK A, 1990, JAMA-J AM MED ASSOC, V264, P565; Woratyla S P, 1995, Conn Med, V59, P643	19	15	16	0	0	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0043-5325			WIEN KLIN WOCHENSCHR	Wien. Klin. Wochen.	SEP 17	2001	113	17-18					676	680					5	Medicine, General & Internal	General & Internal Medicine	475UZ	WOS:000171188800007	11603102				2021-06-18	
J	Gauggel, S; Leinberger, R; Richardt, M				Gauggel, S; Leinberger, R; Richardt, M			Goal setting and reaction time performance in brain-damaged patients	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	21st Annual Mid-Year Conference of the International-Neuropsychological-Society	JUL   10, 1998	BUDAPEST, HUNGARY	Int Neuropsychol Soc			FEEDBACK; INVENTORY; FLUENCY; LESIONS; TASK; ERA	A god-setting approach was used to examine the way in which 62 patients with closed head injuries or cerebral vascular accidents and 47 orthopedic control patients alter their performance on a four-choice reaction time (RT) task. Both patient groups were randomly assigned to two conditions: one in which a specific and high goal was assigned and one in which a "do your best" god was given. Statistical analysis indicated that patients with a specific and high goal responded faster than patients with a "do your best" goal. No clinical or neuropsychological variables (e.g., attention, memory) had a moderating influence on the goal setting effect. These results demonstrate that goal setting as a motivational technique is a reliable and robust technique and can enhance performance (intensity of behavior) not only in healthy participants but also in brain-damaged patients.	Chemnitz Univ Technol, Dept Psychol, D-09120 Chemnitz, Germany	Gauggel, S (corresponding author), Chemnitz Univ Technol, Dept Psychol, Willelm Raabe Str 43, D-09120 Chemnitz, Germany.			Gauggel, Siegfried/0000-0002-2742-4917			Baldo JV, 1998, NEUROPSYCHOLOGY, V12, P259, DOI 10.1037/0894-4105.12.2.259; BANDURA A, 1983, J PERS SOC PSYCHOL, V45, P1017, DOI 10.1037/0022-3514.45.5.1017; BANDURA A, 1986, SOCIAL FDN THOUGHT A; Beck R, 1996, AGRO FOOD IND HI TEC, V7, P3; BLACKBURN HL, 1958, J ABNORM SOC PSYCH, V56, P359, DOI 10.1037/h0044132; BORTZ J, 1993, STATISTIK; BROWN RA, 1974, J CLIN PSYCHOL, V30, P50, DOI 10.1002/1097-4679(197401)30:1<50::AID-JCLP2270300112>3.0.CO;2-0; Carver C.S., 1981, ATTENTION SELF REGUL; EREZ M, 1977, J APPL PSYCHOL, V62, P624, DOI 10.1037/0021-9010.62.5.624; Gauggel S, 2000, NEUROPSYCHOLOGY, V14, P125; Goldstein K, 1942, EFFECTS BRAIN INJURI; Gordon S, 1955, AM J MENT DEF, V60, P371; HOLLENBECK JR, 1987, ORGAN BEHAV HUM DEC, V40, P392, DOI 10.1016/0749-5978(87)90023-9; HOLLENBECK JR, 1989, J APPL PSYCHOL, V74, P951, DOI 10.1037/0021-9010.74.6.951; Horn W, 1983, LEISTUNGSPRUFSYSTEM; HYLAND ME, 1988, J PERS SOC PSYCHOL, V55, P642, DOI 10.1037/0022-3514.55.4.642; KERNAN MC, 1988, MOTIV EMOTION, V12, P75, DOI 10.1007/BF00992473; KLIEBHAN JM, 1967, AM J MENT DEF, V72, P220; Kluge B, 1996, ARCHAOL NACHR, V1, P254; LATHAM GP, 1983, ACAD MANAGE J, V26, P406, DOI 10.2307/256253; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Lindenberger U, 1998, PSYCHOL METHODS, V3, P218, DOI 10.1037/1082-989X.3.2.218; Locke E, 1990, THEORY GOALSETTING T; LOCKE EA, 1991, ORGAN BEHAV HUM DEC, V50, P288, DOI 10.1016/0749-5978(91)90023-M; LOCKE EA, 1981, PSYCHOL BULL, V90, P125, DOI 10.1037/0033-2909.90.1.125; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Prigatano GP, 1997, ARCH PHYS MED REHAB, V78, P621, DOI 10.1016/S0003-9993(97)90428-7; PRINCIPATO FR, 1983, ED TRAINING MENT APR, P141; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rousseau DM, 1997, ANNU REV PSYCHOL, V48, P515, DOI 10.1146/annurev.psych.48.1.515; SHANKWEILER DP, 1959, J COMP PHYSIOL PSYCH, V52, P546, DOI 10.1037/h0040338; STONE EF, 1984, ORGAN BEHAV HUM PERF, V34, P195, DOI 10.1016/0030-5073(84)90003-5; STURM W, 1982, NERVENARZT, V53, P395; Sturm W, 1983, DIAGNOSTICA, V29, P346; VILKKI J, 1994, NEUROPSYCHOLOGIA, V32, P1257, DOI 10.1016/0028-3932(94)90107-4; WARNER DA, 1971, AM J MENT DEF, V75, P681; WARNER DA, 1980, ED TRAINING MENTALLY, P143; WEINBERG RS, 1994, MED SCI SPORT EXER, V26, P469	38	15	17	0	4	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	2001	23	3					351	361		10.1076/jcen.23.3.351.1178			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	439JG	WOS:000169112900009	11404812				2021-06-18	
J	King, BH; Wright, DM; Snape, M; Dourish, CT				King, BH; Wright, DM; Snape, M; Dourish, CT			Case series: Amantadine open-label treatment of impulsive and aggressive behavior in hospitalized children with developmental disabilities	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						aggression; impulsivity; hyperactivity; N-methyl-D-aspartate (NMDA)	TRAUMATIC BRAIN INJURY; MK-801	Objective: A growing body of literature implicates interactions between glutamatergic and neostriatal dopaminergic neurotransmitter systems in the development and expression of impulsivity. hyperactivity, and stereotypy. Amantadine hydrochloride, a drug used in young children for influenza prophylaxis, acts both as an indirect dopamine agonist as well as an N-methyl-D-aspartate (NMDA) receptor antagonist. Thus an open clinical trial of this medication for the treatment of symptoms of impulse control disorders in children was performed. Method: A total of eight children (seven with neurodevelopmental disorders and all inpatients) with target behaviors refractory to other treatments were selected after parental informed consent. All patients were male and ranged in age from 4 to 12 years. Outcome was based on subjective consensus clinical ratings by the multidisciplinary treatment team. Results: For four of the children, amantadine was associated with marked clinical improvement. In the remainder. improvement was also observed. Amantadine was well tolerated. Conclusions: On the basis of this experience, it appears that amantadine hydrochloride or related NMDA antagonists may warrant additional study in this and related populations.	Dartmouth Med Sch, Dept Psychiat, Hanover, NH USA; Vernalis Grp PLC, Winnersh, England	King, BH (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Dept Psychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.		Dourish, Colin T/B-7873-2014	Dourish, Colin T/0000-0002-3403-6330			*AM AC PED, 1991, REP COMM INF DIS, P274; FARNEBO LO, 1971, EUR J PHARMACOL, V16, P27, DOI 10.1016/0014-2999(71)90053-7; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P924, DOI 10.1016/S0003-9993(97)90051-4; GLEZEN WP, 1993, PEDIATR INFECT DIS J, V12, P106; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; KING BH, 1995, DEV NEUROSCI-BASEL, V17, P47, DOI 10.1159/000111272; KORNHUBER J, 1994, J NEURAL TRANSM-SUPP, P91; Masters KJ, 1997, J AM ACAD CHILD PSY, V36, P301, DOI 10.1097/00004583-199703000-00001; Mattes J, 1980, Psychopharmacol Bull, V16, P67; *MED EC CO, 1999, PHYS DESK REF, P986; SHIELDS WD, 1985, NEUROLOGY, V35, P579, DOI 10.1212/WNL.35.4.579; STOOF JC, 1992, CLIN NEUROL NEUROSUR, V94, pS4; WENK GL, 1995, EUR J PHARM-ENVIRON, V293, P267, DOI 10.1016/S0922-4106(05)80053-7; WRIGHT PF, 1976, J INFECT DIS, V134, P144, DOI 10.1093/infdis/134.2.144	14	15	15	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	JUN	2001	40	6					654	657		10.1097/00004583-200106000-00009			4	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	433XR	WOS:000168786400009	11392342				2021-06-18	
J	Harry, GJ; Sills, R; Schlosser, MJ; Maier, WE				Harry, G. Jean; Sills, Robert; Schlosser, Michael J.; Maier, William E.			Neurodegeneration and glia response in rat hippocampus following nitro-L-arginine methyl ester (L-NAME)	NEUROTOXICITY RESEARCH			English	Article						Interleukin-1 alpha; Interleukin-6; microglia; tumor necrosis factor alpha; trimethyltin	OXIDE SYNTHASE ACTIVITY; TRAUMATIC BRAIN-INJURY; MESSENGER-RNA; ENDOTHELIAL-CELLS; INHIBITION; EXPRESSION; INDUCTION; ISCHEMIA; NEURONS; ASTROCYTES	Hippocampal neurodegeneration and glia response was examined following administration of the nitric oxide synthase inhibitor, N-w-nitro-L-arginine methyl ester (L-NAME). Male Long-Evans rats received L-NAME (50 mg/kg, ip) either once or twice a day for 4 days. Both dosing schedules decreased NOS activity by approximately 90%. At 10 and 30 days following cessation of L-NAME (2x/day), moderate neuronal death was evident in CA 1-2 pyramidal cells and dentate granule cells. Neurodegeneration was accompanied by increased astrocyte glial fibrillary acidic protein (GFAP) immunoreactivity yet, minimal astrocyte hypertrophy. Microglia response was limited to an increase in ramified microglia at 10 days, returning to normal by 30 days. As early as 4 days post-dosing (2x/day), GFAP mRNA levels were significantly elevated as were mRNA levels for tumor necrosis factor-alpha(TNF alpha), interleukin-1 alpha (IL-1 alpha), and interleukin 6 (IL-6). No alterations were seen with L-NAME dosing limited to once a day. The co-administration of a hippocampal neurotoxicant, trimethyltin (TMT), with the last dose of L-NAME (2x/day), produced an additive response pattern of neuronal degeneration including both CA1-2 and CA3-4 pyramidal neurons accompanied by TMT-induced astrocyte hypertrophy and prominent microglia reactivity. This was preceded by elevations in mRNA levels for GFAP, TNF alpha, IL-1 alpha, and IL-6 similar to those seen with each substance alone. These data suggest that high levels of L-NAME can produce a pro-inflammatory environment in the brain and that neurodegeneration and neuroglia responses in the hippocampus can be induced by an alteration in the balance and regulation of local nitric oxide levels.	[Harry, G. Jean; Sills, Robert; Maier, William E.] Natl Inst Environm Hlth Sci, Res Triangle Pk, NC 27709 USA; [Schlosser, Michael J.] Searle Metab & Safety Evaluat, 4901 Searle Pkwy, Skokie, IL 60077 USA; [Maier, William E.] Univ N Carolina, Curriculum Toxicol, Chapel Hill, NC 27515 USA; [Maier, William E.] Parke Davis Pharmaceut Res, 2800 Plymouth Rd, Ann Arbor, MI USA	Harry, GJ (corresponding author), Natl Inst Environm Hlth Sci, Res Triangle Pk, NC 27709 USA.	harry@niehs.nih.gov			USEPAUnited States Environmental Protection Agency [CT901915]; NIEHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [T32 ES07126]	This research was supported in part by USEPA grant CT901915 and NIEHS grant T32 ES07126.	Ayers NA, 1997, NEUROCHEM RES, V22, P81, DOI 10.1023/A:1027385522859; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Black SM, 1995, NEUROBIOL DIS, V2, P145, DOI 10.1006/nbdi.1995.0016; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CARREAU A, 1994, EUR J PHARMACOL, V256, P241, DOI 10.1016/0014-2999(94)90549-5; CHAO CC, 1992, J IMMUNOL, V149, P2736; CHAO CC, 1993, CLIN IMMUNOL IMMUNOP, V67, P178, DOI 10.1006/clin.1993.1062; Chen T Y, 1998, Acta Anaesthesiol Sin, V36, P127; CORRADIN SB, 1993, EUR J IMMUNOL, V23, P2045, DOI 10.1002/eji.1830230851; CROSS AH, 1994, J CLIN INVEST, V93, P2684, DOI 10.1172/JCI117282; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; Dawson V.L., 1994, NEUROSCIENTIST, V1, P9; Dawson VL, 1998, PROG BRAIN RES, V118, P215; DAWSON VL, 1995, CLIN EXP PHARMACOL P, V22, P305, DOI 10.1111/j.1440-1681.1995.tb02005.x; de Oliveira CF, 2000, EUR J PHARMACOL, V391, P121, DOI 10.1016/S0014-2999(99)00929-2; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; DWYER MA, 1991, BIOCHEM BIOPH RES CO, V176, P1136, DOI 10.1016/0006-291X(91)90403-T; ENDOH M, 1994, BRAIN RES, V651, P92, DOI 10.1016/0006-8993(94)90683-1; ENDOH M, 1994, NEUROSCIENCE, V63, P679, DOI 10.1016/0306-4522(94)90514-2; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; HIBBS JB, 1990, INT CONGR SER, V897, P189; IADECOLA C, 1994, NEUROCHEM RES, V19, P501, DOI 10.1007/BF00967330; Iwase K, 1998, MOL BRAIN RES, V53, P1, DOI 10.1016/S0169-328X(97)00139-3; Kaufman PL, 1999, P NATL ACAD SCI USA, V96, P9455, DOI 10.1073/pnas.96.17.9455; Koyanagi M, 2000, HYPERTENSION, V35, P86, DOI 10.1161/01.HYP.35.1.86; LAMAS S, 1992, J CLIN INVEST, V90, P879, DOI 10.1172/JCI115963; LASZLO F, 1995, EUR J PHARMACOL, V283, P47, DOI 10.1016/0014-2999(95)00281-O; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; Luvara G, 1998, ARTERIOSCL THROM VAS, V18, P1408, DOI 10.1161/01.ATV.18.9.1408; MACNAUL KL, 1993, BIOCHEM BIOPH RES CO, V196, P1330, DOI 10.1006/bbrc.1993.2398; MAIER WE, 1995, J NEUROIMMUNOL, V59, P65, DOI 10.1016/0165-5728(95)00026-X; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Mesenge C, 1996, J NEUROTRAUM, V13, P11, DOI 10.1089/neu.1996.13.11; MINCGOLOMB D, 1994, BRIT J PHARMACOL, V112, P720, DOI 10.1111/j.1476-5381.1994.tb13136.x; Mollace V, 1995, ADV NEUROIMMUNOL, V5, P421, DOI 10.1016/0960-5428(95)00026-7; MONCADA C, 1992, NEUROREPORT, V3, P530; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURPHY S, 1990, J NEUROCHEM, V55, P349, DOI 10.1111/j.1471-4159.1990.tb08860.x; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; Murphy S, 1995, NITRIC OXIDE NERVOUS, P164; NAKASHIMA MN, 1995, CELL MOL NEUROBIOL, V15, P341, DOI 10.1007/BF02089944; NATHAN C, 1992, FASEB J, V6, P3051; NOMURA Y, 1993, NEUROSCI RES, V18, P103, DOI 10.1016/0168-0102(93)90013-G; PARK SK, 1994, J NEUROSCI RES, V39, P405, DOI 10.1002/jnr.490390407; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; SAKAI N, 1995, J NEUROCHEM, V65, P895; SALVEMINI D, 1992, BRIT J PHARMACOL, V106, P931, DOI 10.1111/j.1476-5381.1992.tb14437.x; SANCESARIO G, 1994, STROKE, V25, P436, DOI 10.1161/01.STR.25.2.436; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; SPARROW JR, 1994, J MOL NEUROSCI, V5, P219, DOI 10.1007/BF02736723; STREIT WJ, 1987, J NEUROCYTOL, V16, P249, DOI 10.1007/BF01795308; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; Takeuchi A, 1998, EUR J NEUROSCI, V10, P1613, DOI 10.1046/j.1460-9568.1998.00168.x; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; WALLACE MN, 1994, NEUROSCIENCE, V59, P905, DOI 10.1016/0306-4522(94)90294-1; Wu J, 2000, BRIT J ANAESTH, V84, P183; XIE QW, 1994, J BIOL CHEM, V269, P4705; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205; ZIELASEK J, 1992, CELL IMMUNOL, V141, P111, DOI 10.1016/0008-8749(92)90131-8; ZIELASEK J, 1995, J NEUROIMMUNOL, V58, P81, DOI 10.1016/0165-5728(94)00192-Q; Zou LB, 1998, NEUROPHARMACOLOGY, V37, P323, DOI 10.1016/S0028-3908(98)00042-2	67	15	17	0	0	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1029-8428	1476-3524		NEUROTOX RES	Neurotox. Res.	MAY	2001	3	3					307	319		10.1007/BF03033270			13	Neurosciences	Neurosciences & Neurology	VJ3BB	WOS:000574918300010	15111256				2021-06-18	
J	Martin, G				Martin, G			The death of Henry II of France: A sporting death and post-mortem	AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY			English	Article						athletic injuries; brain concussion; head injury; Henry II King of France; history of medicine; orbital injury; Pare; sixteenth century; tournaments; Vesalius		In 1559 Henry II King of France was wounded in a tournament and died. A broken lance entered his right orbit, destroying his eye and leaving behind many splinters. The skull was not penetrated but infection spread intracranially. Both Ambroise Pare and Vesalius saw him and predicted death. Nine days after wounding, both attended the King's post-mortem. The story shows how difficult life was without antisepsis, anaesthesia, antibiotics or investigations. The King's stubbornness highlights the dangers of continuing to play after concussion.	Wakefield Hosp, Wellington 6039, New Zealand	Martin, G (corresponding author), Wakefield Hosp, POB 16-116, Wellington 6039, New Zealand.						BARBER R, 1989, TOURNAMENTS JOUSTS C; Barrett N R, 1973, Ann R Coll Surg Engl, V52, P216; Baumgartner Frederic J., 1988, HENRY 2 KING FRANCE; OMALLEY CD, 1964, A VESALIUS BRUSELS 1; Pare A, 1649, WORKS FAMOUS CHIRURG; SMITH DM, 1961, RENAISSANCE, P321	6	15	15	0	0	BLACKWELL SCIENCE ASIA	CARLTON	54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA	0004-8682			AUST NZ J SURG	Aust. N. Z. J. Surg.	MAY	2001	71	5					318	320		10.1046/j.1440-1622.2001.02102.x			3	Surgery	Surgery	445YU	WOS:000169486800013	11374484				2021-06-18	
J	Wang, JN; Lu, MQ; Yang, FZ; Zhang, XR; Baeyens, WRG; Campana, AMG				Wang, JN; Lu, MQ; Yang, FZ; Zhang, XR; Baeyens, WRG; Campana, AMG			Microdialysis with on-line chemiluminescence detection for the study of nitric oxide release in rat brain following traumatic injury	ANALYTICA CHIMICA ACTA			English	Article						microdialysis; chemiluminescence; nitric oxide; rat brain; traumatic injury	PERFORMANCE LIQUID-CHROMATOGRAPHY; REAL-TIME MEASUREMENT; LUMINOL-H2O2 CHEMILUMINESCENCE; FLUORESCENCE DETECTION; CEREBRAL-ISCHEMIA; VIVO; NITRATE; ASSAY	An on-line method was developed for the real-time detection of nitric oxide (NO) release in rat brain in vivo following traumatic injury by coupling microdialysis sampling to flow-injection chemiluminescence (CL) detection. The NO released from rat cerebellum was detected based on the CL reaction of luminol and H2O2 with a detection limit of 1 nmol l(-1). The perfusate how was set at 5 mul min(-1) in order to minimize NO loss before reaching CL detector. With this flow rate, about 5 s was equired for the solution to pass through the membrane of microdialysis probe to the detector due to the dead volume of the probe and CL cell. It was observed that the efficiency of NO penetrated from rat cerebellum into perfusate stream increased along with decrease of perfusate flow rate. The maximum efficiency of 20% could be achieved at the flow rate of 5 mul min(-1) with carefully home-made microdialysis probe. The developed method was applied to the study of the production of NO in rat cerebellum following the traumatic brain injury. The results indicated that the NO increased dramatically following traumatic brain injury and was inhibited after the injection of inhibitors such as L-arginine. (C) 2001 Elsevier Science B.V. All rights reserved.	Tsing Hua Univ, Dept Chem, Beijing 100084, Peoples R China; Xian Med Univ, Dept Orthopaed, Xian 710061, Peoples R China; State Univ Ghent, Fac Pharmaceut Sci, B-9000 Ghent, Belgium; Univ Granada, Dept Analyt Chem, E-18071 Granada, Spain	Zhang, XR (corresponding author), Tsing Hua Univ, Dept Chem, Beijing 100084, Peoples R China.		Garcia-Campana, Ana M./H-7752-2015	Garcia-Campana, Ana M./0000-0002-3191-3350; Zhang, Xinrong/0000-0002-3174-303X			Aoki T, 1997, ANAL CHIM ACTA, V349, P11, DOI 10.1016/S0003-2670(97)00273-0; Byrnes CA, 1997, PEDIATR PULM, V24, P312; deCastro MDL, 1997, ANAL CHIM ACTA, V351, P23, DOI 10.1016/S0003-2670(97)00341-3; Ishida J, 1998, ANAL CHIM ACTA, V365, P227, DOI 10.1016/S0003-2670(97)00616-8; Jones PA, 1998, NEUROSCI LETT, V249, P75, DOI 10.1016/S0304-3940(98)00372-3; KEML M, 1990, CIRC RES, V66, P1561; KIKUCHI K, 1993, ANAL CHEM, V65, P1794, DOI 10.1021/ac00061a025; KIKUCHI K, 1993, J BIOL CHEM, V268, P23106; Kojima H, 1997, NEUROSCI LETT, V233, P157, DOI 10.1016/S0304-3940(97)00648-4; Lada MW, 1996, ANAL CHEM, V68, P2790, DOI 10.1021/ac960178x; Lagerwerf FM, 1998, ANAL BIOCHEM, V257, P45, DOI 10.1006/abio.1997.2515; Mao LQ, 1998, TALANTA, V46, P1547, DOI 10.1016/S0039-9140(98)00027-7; Maskus M, 1996, ANAL CHEM, V68, P3128, DOI 10.1021/ac951063g; Obata T, 1998, COMP BIOCHEM PHYS A, V119, P309, DOI 10.1016/S1095-6433(97)00431-5; Ohta K, 1997, NEUROREPORT, V8, P2229, DOI 10.1097/00001756-199707070-00028; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; Rizzo V, 1998, J CHROMATOGR A, V798, P103, DOI 10.1016/S0021-9673(97)01186-2; Samouilov A, 1998, ANAL BIOCHEM, V258, P322, DOI 10.1006/abio.1998.2609; Yoon KW, 1996, STROKE, V27, P122, DOI 10.1161/01.STR.27.1.122	19	15	15	1	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0003-2670			ANAL CHIM ACTA	Anal. Chim. Acta	FEB 9	2001	428	2					173	181		10.1016/S0003-2670(00)01247-2			9	Chemistry, Analytical	Chemistry	393GN	WOS:000166461000003					2021-06-18	
J	Rauch, RJ; Ferry, SM				Rauch, RJ; Ferry, SM			Social networks as support interventions following traumatic brain injury	NEUROREHABILITATION			English	Article						TBI; social networks; social support; rehabilitation	SEVERE HEAD-INJURY; MODERATE; STRESS; REHABILITATION; INTEGRATION; INDIVIDUALS; DIMENSIONS; ADJUSTMENT	The social network and social support needs of people following traumatic brain injury (TBI) are considerable and related to both health outcomes and community integration. We review what is known of the structure of social networks following TBI and explore the relationship of these networks to social support and health. Social network interventions in TBI are described and discussed. Empirically based suggestions are given for the development of interventions based on culturally sensitive programmes which develop social networks and support in a naturalistic manner.	Thompson House Hosp, Down Lisburn Hlth & Social Serv Trust, Brain Injury Rehabil Serv, Lisburn BT28 3BP, North Ireland; Queens Univ, Sch Psychol, Belfast BT1 7NN, Antrim, North Ireland	Rauch, RJ (corresponding author), Thompson House Hosp, Down Lisburn Hlth & Social Serv Trust, Brain Injury Rehabil Serv, 19-21 Magheralave Rd, Lisburn BT28 3BP, North Ireland.						ANTONUCCI TC, 1986, J CONSULT CLIN PSYCH, V54, P432, DOI 10.1037/0022-006X.54.4.432; BENNET D, 1983, THEORY PRACTISE PSYC; BIEGEL DE, 1994, HEALTH SOC WORK, V19, P206; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; BRUGHA T, 1995, SOCIAL SUPPORT PSYCH; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310; DEAN A, 1977, J NERV MENT DIS, V165, P403, DOI 10.1097/00005053-197712000-00006; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; Glang A, 1997, J HEAD TRAUMA REHAB, V12, P32, DOI 10.1097/00001199-199704000-00005; HARING TG, 1992, J APPL BEHAV ANAL, V25, P319, DOI 10.1901/jaba.1992.25-319; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; HENDERSON S, 1978, BRIT J PSYCHIAT, V132, P74, DOI 10.1192/S0007125000283001; HORWITZ A, 1999, HDB STUDY MENTAL HLT; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Johnson K, 1998, BEHAV MODIF, V22, P502, DOI 10.1177/01454455980224004; KAPLAN S, 1991, CLIN NEUROPSYCHOL, V5, P360, DOI DOI 10.1080/13854049108404103; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; Kessler R. C., 1985, SOCIAL SUPPORT HLTH; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KUIPERS P, 1999, J COGNITIVE REHABILI, V17, P6; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; MCCORMICK IA, 1987, AM J COMMUN PSYCHOL, V15, P73, DOI 10.1007/BF00919758; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; NORBECK JS, 1983, J HEALTH SOC BEHAV, V24, P30, DOI 10.2307/2136301; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; SANDLER IN, 1984, AM J COMMUN PSYCHOL, V12, P37, DOI 10.1007/BF00896927; Smith J, 1998, CANADIAN J REHABILIT, V11, P131; THOITS PA, 1992, MEANING MEASUREMENT; THORNICROFT G, 1991, BRIT J PSYCHIAT, V159, P245, DOI 10.1192/bjp.159.2.245; VEIEL HOF, 1985, SOC PSYCHIATR, V20, P156, DOI 10.1007/BF00583293; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Wellman B., 1985, SOCIAL SUPPORT THEOR; WETHINGTON E, 1986, J HEALTH SOC BEHAV, V27, P78, DOI 10.2307/2136504; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLER BS, 1993, CIRCLES SUPPORT INDI; Wood-Dauphinee S, 1992, CANADIAN J REHABILIT, V6, P3; Zencius AH, 1999, BRAIN INJURY, V13, P723	39	15	16	3	7	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2001	16	1					11	16					6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	439YA	WOS:000169144100003	11455099				2021-06-18	
J	Visocchi, M; Tartaglione, T; Romani, R; Meglio, M				Visocchi, M; Tartaglione, T; Romani, R; Meglio, M			Spinal cord stimulation prevents the effects of combined experimental ischemic and traumatic brain injury - An MR study	STEREOTACTIC AND FUNCTIONAL NEUROSURGERY			English	Article						brain injury; cerebral ischemia; spinal cord stimulation	CEREBRAL BLOOD-FLOW; HEMODYNAMICS	Spinal cord stimulation (SCS) interferes with cerebral blood flow (CBF). In this paper we try to evaluate the possible preventing effect of SCS in an animal model of combined ischemic and traumatic injury. We studied 20 New Zealand rabbits undergoing ligature of both carotid arteries and a right hemispheric craniectomy and about 3 h mechanical injury (200 mg) over the dura. In 10 animals (control group) SCS was not delivered; in 10 (SCS group) cervical SCS was started 20 min after arterial ligation and before the craniectomy and the mechanical injury. MR examination was performed in all the animals at the end of the experiments. Compared to the control group none but one of the SCS showed lesional pattern far from the craniectomy suggesting a 'preventing' effect of SCS on the secondary damage associated with our model combined ischemic and traumatic brain injury. Copyright (C) 2002 S. Karger AG, Basel.	Catholic Univ Rome, Inst Neurosurg, I-00168 Rome, Italy; Catholic Univ Rome, Inst Radiol, I-00168 Rome, Italy			TARTAGLIONE, TOMMASO/K-5390-2017; visocchi, massimiliano/AAA-4267-2019	TARTAGLIONE, TOMMASO/0000-0003-3896-4078; visocchi, massimiliano/0000-0002-5277-4468			ALEXANDER DJ, 1980, LAB ANIM SCI, V30, P871; Garcia-March G, 1989, Acta Neurochir Suppl (Wien), V46, P102; GONZALEZ-DARDER J, 1991, Neurological Research, V13, P229; HOSOBUCHI Y, 1991, PACE, V14, P122, DOI 10.1111/j.1540-8159.1991.tb04056.x; HOSOBUCHI Y, 1986, APPL NEUROPHYSIOL, V234, P11371; Isono M, 1995, STEREOT FUNCT NEUROS, V64, P40, DOI 10.1159/000098732; KANNO T, 1989, PACE, V12, P733, DOI 10.1111/j.1540-8159.1989.tb02724.x; MATSUI T, 1989, PACE, V12, P726, DOI 10.1111/j.1540-8159.1989.tb02723.x; MEGLIO M, 1991, PACE, V14, P127, DOI 10.1111/j.1540-8159.1991.tb04057.x; MEGLIO M, 1991, ACTA NEUROCHIR, V111, P43, DOI 10.1007/BF01402512; MEGLIO M, 1986, APPL NEUROPHYSIOL, V49, P139; VISOCCHI M, 1994, STEREOT FUNCT NEUROS, V62, P186, DOI 10.1159/000098616; VISOCCHI M, 1994, STEREOT FUNCT NEUROS, V62, P103, DOI 10.1159/000098604; Visocchi M, 1999, J Neurosurg Sci, V43, P93; Visocchi M, 1996, RIV NEURORADIOL, V9, P21, DOI 10.1177/197140099600900102; Visocchi M, 2001, ACTA NEUROCHIR, V143, P177; VISOCCHI M, 1996, INS P 3 INT C, P142; VISOCCHI M, 1992, INS 1 INT C MOND ED, P59	18	15	17	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1011-6125			STEREOT FUNCT NEUROS	Stereotact. Funct. Neurosurg.		2001	76	3-4					276	281		10.1159/000066731			6	Neurosciences; Neuroimaging; Surgery	Neurosciences & Neurology; Surgery	605ZK	WOS:000178706800026	12378109				2021-06-18	
J	Bergsneider, M				Bergsneider, M			Management of hydrocephalus with programmable valves after traumatic brain injury and subarachnoid hemorrhage	CURRENT OPINION IN NEUROLOGY			English	Article							NORMAL-PRESSURE HYDROCEPHALUS; CLINICAL-EXPERIENCE; HAKIM VALVE; SHUNT VALVE	Programmable shunt valves are a recent technological advance that enhance the management of most patients with hydrocephalus secondary to subarachnoid hemorrhage or traumatic brain injury. An improved understanding of the intracranial pressure dynamics occurring both before and after a cerebrospinal fluid diversionary shunt has provided a more scientific basis for the application of these valves. Curr Opin Neurol 13:661-664. (C) 2000 Lippincott Williams & Wilkins.	Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90095 USA	Bergsneider, M (corresponding author), Univ Calif Los Angeles, Div Neurosurg, Box 957039, Los Angeles, CA 90095 USA.						Bergsneider M, 1999, ARCH NEUROL-CHICAGO, V56, P1224, DOI 10.1001/archneur.56.10.1224; BLACK PM, 1994, NEUROSURGERY, V34, P1110, DOI 10.1227/00006123-199406000-00040; Boon AJW, 1998, J NEUROSURG, V88, P490, DOI 10.3171/jns.1998.88.3.0490; CHAPMAN PH, 1990, NEUROSURGERY, V26, P181, DOI 10.1227/00006123-199002000-00001; Guyot LL, 2000, NEUROL RES, V22, P25; KAMANO S, 1991, SURG NEUROL, V35, P381, DOI 10.1016/0090-3019(91)90050-J; LARSSON A, 1992, ACTA NEUROCHIR, V117, P15, DOI 10.1007/BF01400629; LUMENTA CB, 1990, CHILD NERV SYST, V6, P270, DOI 10.1007/BF00307663; MATSUMAE M, 1989, CHILD NERV SYST, V5, P356, DOI 10.1007/BF00271892; MCQUARRIE IG, 1984, NEUROSURGERY, V15, P484, DOI 10.1227/00006123-198410000-00002; Miyake H, 2000, J NEUROSURG, V92, P181, DOI 10.3171/jns.2000.92.1.0181; Miyake H, 1999, CHILD NERV SYST, V15, P363, DOI 10.1007/s003810050415; PANG DL, 1994, NEUROSURGERY, V35, P643, DOI 10.1227/00006123-199410000-00010; Pollack IF, 1999, NEUROSURGERY, V45, P1399, DOI 10.1097/00006123-199912000-00026; PUDENZ RH, 1991, SURG NEUROL, V35, P200, DOI 10.1016/0090-3019(91)90072-H; Reinprecht A, 1997, CHILD NERV SYST, V13, P588, DOI 10.1007/s003810050145; REINPRECHT A, 1995, ACTA NEUROCHIR, V134, P119, DOI 10.1007/BF01417677; Rohde V, 1998, ACTA NEUROCHIR, V140, P1127, DOI 10.1007/s007010050226; Sheehan JP, 1999, NEUROSURGERY, V45, P1120, DOI 10.1097/00006123-199911000-00021; WEINER HL, 1995, NEUROSURGERY, V37, P877, DOI 10.1227/00006123-199511000-00005; Yamashita N, 1999, J NEUROSURG, V91, P26, DOI 10.3171/jns.1999.91.1.0026; Yoshioka H, 2000, SURG NEUROL, V53, P119, DOI 10.1016/S0090-3019(99)00185-8; Zemack G, 2000, J NEUROSURG, V92, P941, DOI 10.3171/jns.2000.92.6.0941	23	15	20	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1350-7540			CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2000	13	6					661	664		10.1097/00019052-200012000-00008			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	425HG	WOS:000168284700008	11148666				2021-06-18	
J	Guerit, JM				Guerit, JM			The usefulness of EEG, exogenous evoked potentials, and cognitive evoked potentials in the acute stage of post-anoxic and post-traumatic coma	ACTA NEUROLOGICA BELGICA			English	Article						EEG; evoked potentials; coma; brain death; prognosis; anoxia; head trauma	INTENSIVE-CARE UNIT; MISMATCH NEGATIVITY; PROGNOSTIC VALUE; HEAD-INJURY; PREDICTION; DIAGNOSIS; STATES; DEATH	Three-modality evoked potentials (TMEPs) have been used for several years in association with the EEG as a diagnostic and prognostic tool in acute anoxic or traumatic coma. Cognitive EPs have been recently introduced. EEG and cognitive EPs provide functional assessment of the cerebral cortex. TMEP parameters can be described by two indices: the index of global cortical function (IGCF) and the index of brainstem conduction (IBSC). Although it remains a unique tool for epilepsy assessment, the value of EEG is largely limited by its high sensitivity to the electrical environmental noise, its dependence on sedative drugs. and its inability to test the brainstem. Major TMEP alterations (absence of cortical activities more than 24 hours after the onset of post-anoxic coma, major pontine involvement in head trauma) are associated in all cases with an ominous prognosis (death or vegetative state). However even if mild TMEP changes are associated with a good prognosis in 65% (post-anoxic coma) to 90% (head trauma) of cases, some patients never recover despite exogenous TMEPs that are only mildly altered in the acute stage. Thus, cognitive EPs can usefully complement exogenous EPs as a prognostic tool in coma. Indeed, even if the absence of cognitive EPs in comatose patients does not have any prognostic value, their presence implies a very high (more than 90%) probability of consciousness recovery. The major technical challenge for the future will be the development of reliable tools for continuous EEG and TMEP monitoring.	Clin Univ St Luc, Unite Explorat Electrophysiol Syst Nerveux, B-1200 Brussels, Belgium	Guerit, JM (corresponding author), Clin Univ St Luc, Unite Explorat Electrophysiol Syst Nerveux, Ave Hippocrate 10, B-1200 Brussels, Belgium.						Berkhoff M, 2000, CLIN NEUROPHYSIOL, V111, P297, DOI 10.1016/S1388-2457(99)00246-1; Chatrian GE, 1996, ELECTROEN CLIN NEURO, V99, P103, DOI 10.1016/0013-4694(96)96059-9; de Tourtchaninoff M, 1999, QJM-MON J ASSOC PHYS, V92, P407, DOI 10.1093/qjmed/92.7.407; Ducrocq X, 1998, J NEUROL SCI, V159, P145, DOI 10.1016/S0022-510X(98)00158-0; Facco E., 1993, Neurophysiologie Clinique, V23, P237, DOI 10.1016/S0987-7053(05)80233-3; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; FISCHER C, 1994, NEUROSURGERY, V35, P45, DOI 10.1227/00006123-199407000-00007; Guerit J. M., 1993, Neurophysiologie Clinique, V23, P209, DOI 10.1016/S0987-7053(05)80231-X; Guerit J M, 1992, Eur J Med, V1, P233; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; Guerit JM, 1999, NEUROPHYSIOL CLIN, V29, P301, DOI 10.1016/S0987-7053(99)90044-8; Guerit JM, 1998, ELECTROEN CLIN NEURO, V106, P1, DOI 10.1016/S0013-4694(97)00077-1; GUERIT JM, 1999, ELECTROENCEPHALOGR S, V52, P117; GUERIT JM, 1999, CURR OPIN ORGAN TRAN, V4, P143; GUTLING E, 1995, NEUROLOGY, V45, P915, DOI 10.1212/WNL.45.5.915; HANTSON P, 2000, REANIM URGENCES, V9, P197; JORDAN KG, 1995, NEUROL CLIN, V13, P579, DOI 10.1016/S0733-8619(18)30035-5; Kane NM, 2000, AUDIOL NEURO-OTOL, V5, P186, DOI 10.1159/000013879; Niedermeyer E., 1982, ELECTROENCEPHALOGRAP; RAEGRANT AD, 1991, ELECTROEN CLIN NEURO, V79, P349, DOI 10.1016/0013-4694(91)90199-E; SOHMER H, 1986, ELECTROEN CLIN NEURO, V64, P334, DOI 10.1016/0013-4694(86)90157-4; Task Force on Death and Dying of the Institute of Society Ethics and the Life Sciences, 1972, JAMA-J AM MED ASSOC, V221, P48; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8	24	15	18	0	6	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0300-9009	2240-2993		ACTA NEUROL BELG	Acta Neurol. Belg.	DEC	2000	100	4					229	236					8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	404BD	WOS:000167076800005	11233678				2021-06-18	
J	Duerstock, BS; Bajaj, CL; Pascucci, V; Schikore, D; Lin, KN; Borgens, RB				Duerstock, BS; Bajaj, CL; Pascucci, V; Schikore, D; Lin, KN; Borgens, RB			Advances in three-dimensional reconstruction of the experimental spinal cord injury	COMPUTERIZED MEDICAL IMAGING AND GRAPHICS			English	Article						three-dimensional reconstruction; 3D computer visualization; 3D morphometry; spinal cord injury; neurotrauma; serial light microscopy; registration	3-DIMENSIONAL RECONSTRUCTION; ELECTRON-MICROSCOPY; RAT; SECTIONS; MICROGRAPHS; CONTUSION; ALIGNMENT; NUCLEUS; CELLS	Three-dimensional (3D) computer reconstruction is an ideal tool for evaluating the centralized pathology of mammalian spinal cord injury (SCI) where multiple anatomical features are embedded within each other. Here, we evaluate three different reconstruction algorithms to three-dimensionally visualize SCIs, We also show for the first time, that determination of the volume and surface area of pathological features is possible using the reconstructed 3D images themselves. We compare these measurements to those calculated by older morphometric approaches. Finally, we demonstrate dynamic navigation into a 3D spinal cord reconstruction (C) 2000 Elsevier Science Ltd. All rights reserved.	Purdue Univ, Sch Vet Med, Ctr Paralysis Res, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Borgens, RB (corresponding author), Purdue Univ, Sch Vet Med, Ctr Paralysis Res, Dept Basic Med Sci, 1244 VCPR, W Lafayette, IN 47907 USA.	cpr@vet.purdue.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR509137] Funding Source: Medline		ALLEN BA, 1990, COMPUT MED IMAG GRAP, V14, P319, DOI 10.1016/0895-6111(90)90106-L; Arndt S, 1994, Neuroimage, V1, P191, DOI 10.1006/nimg.1994.1004; BAJAJ C, 1996, P 5 INT IM ROUNDT SA, V405, P169; Bajaj CL, 1996, GRAPH MODEL IM PROC, V58, P524, DOI 10.1006/gmip.1996.0044; Bajaj CL, 1997, VISUALIZATION '97 - PROCEEDINGS, P167, DOI 10.1109/VISUAL.1997.663875; BAJAJ CL, 1998, IN PRESS COMP METH A; BALENTINE JD, 1978, LAB INVEST, V39, P236; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; BERGOGNONI M, 1999, P 13 INT C IEEE ENG, P1119; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; Borgens RB, 2000, FASEB J, V14, P27; BORGENS RB, 1992, SPINAL CORD DYSFUNCT, V3, P110; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bresnahan JC, 1991, J NEUROTRAUM, V8, P91, DOI 10.1089/neu.1991.8.91; BRON C, 1990, J MICROSC-OXFORD, V157, P115, DOI 10.1111/j.1365-2818.1990.tb02952.x; Cabral B, 1994, P 1994 S VOL VIS, V1994, P91, DOI DOI 10.1145/197938.197972; CHAWLA SD, 1981, CANCER BIOCHEM BIOPH, V5, P153; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; DEVERELL MH, 1993, ANAL CELL PATHOL, V5, P253; DEVIVO MJ, 1994, SPINAL CORD INJURY C, P234; Drebin R. A., 1988, Computer Graphics, V22, P65; Durikovic R, 1998, MED BIOL ENG COMPUT, V36, P276, DOI 10.1007/BF02522471; Gaunt W. A., 1978, 3 DIMENSIONAL RECONS; HALL PM, 1991, VISUALIZATION PHYSIC, P235; HALLIDAY GM, 1993, SYNAPSE, V15, P1, DOI 10.1002/syn.890150102; HARRIS KM, 1988, J NEUROSCI, V8, P4455; HASHIMOTO S, 1988, ACTA OTO-LARYNGOL, V105, P64, DOI 10.3109/00016488809119447; HIBBARD LS, 1993, J MICROSC-OXFORD, V171, P39, DOI 10.1111/j.1365-2818.1993.tb03357.x; HONGHUI G, 1996, SPIE, V2644, P2; LISS AG, 1995, J MICROSC-OXFORD, V178, P160, DOI 10.1111/j.1365-2818.1995.tb03592.x; MARTONE ME, 1993, J NEUROSCI, V13, P4636; MONTGOMERY K, 1993, SPIE, V1905, P114; Moriarty LJ, 1998, J NEUROL SCI, V155, P121, DOI 10.1016/S0022-510X(97)00203-7; NAVARRO A, 1994, ANAT RECORD, V240, P572, DOI 10.1002/ar.1092400414; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; PROTHERO JS, 1986, COMPUT BIOMED RES, V19, P361, DOI 10.1016/0010-4809(86)90048-0; Roesch S, 1996, J NEUROSCI METH, V69, P197, DOI 10.1016/S0165-0270(96)00062-3; ROSS MD, 1994, HIGH PERFORMANCE COMPUTING SYMPOSIUM 1994: GRAND CHALLENGES IN COMPUTER SIMULATION, P120; SALISBURY JR, 1994, HISTOL HISTOPATHOL, V9, P773; TOGA AW, 1990, 3 DIMENSIONAL NEUROI, P189; VUILLEMIN M, 1992, EUR J MORPHOL, V30, P181; Williams BS, 1996, COMPUT MED IMAG GRAP, V20, P433, DOI 10.1016/S0895-6111(96)00041-9; YOUNG SJ, 1987, J ELECTRON MICR TECH, V6, P207, DOI 10.1002/jemt.1060060211	43	15	18	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0895-6111	1879-0771		COMPUT MED IMAG GRAP	Comput. Med. Imaging Graph.	NOV-DEC	2000	24	6					389	406		10.1016/S0895-6111(00)00034-3			18	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging	Engineering; Radiology, Nuclear Medicine & Medical Imaging	362XT	WOS:000089804100005	11008186				2021-06-18	
J	Watt, N; Penn, C				Watt, N; Penn, C			Predictors and indicators of return to work following traumatic brain injury in South Africa: Findings from a preliminary experimental database	SOUTH AFRICAN JOURNAL OF PSYCHOLOGY			English	Article							SEVERE HEAD-INJURY; REHABILITATION; EMPLOYMENT; PEOPLE	Traumatic brain injury (TBI) affects a substantial portion of the South African population every year. However. there is little empirical evidence available regarding eventual outcome after injury in South Africa. in particular, there is little information regarding the ability of head injured individuals to return to their places of employment following injury, or what factors are most closely related to a successful return to work. This study explored the return to work of a specific group of individuals with TBI, in relation to a number of domains, including: rate and nature of return to work, pre-morbid and accident variables that appeared to be related to return to work, and the relationship between return to work and other aspects of outcome, specifically communicative, cognitive, physical and emotional outcome. The study took the form of a detailed record review of a group of subjects seeking medico-legal compensation, using a specially designed data recording form and computerised database. Results indicated a poor rate of return to work in this sample (32%), with significant changes in work status post-injury. The strongest pre-morbid predictors of outcome were found to be first language and pre-injury educational level, with African language speakers and those with an educational level of matriculation or less being at a significant disadvantage Numerous communicative and cognitive difficulties were significantly related to a failure to RTW, including difficulties in: motor speech, comprehension, expression, attention, speed of processing, incidental visual memory, cognitive flexibility and insight. These results indicate the multi-factorial nature of outcome following head injury in the sample.	Univ Witwatersrand, Dept Speech Pathol & Audiol, ZA-2050 Johannesburg, South Africa	Watt, N (corresponding author), Univ Witwatersrand, Dept Speech Pathol & Audiol, Private Bag 3, ZA-2050 Johannesburg, South Africa.						AINSLEY J, 1989, COGNITIVE REHABI NOV, P28; BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BLAIR JR, 1989, J REHABIL, V55, P46; Bowman ML, 1996, CLIN NEUROPSYCHOL, V10, P382, DOI 10.1080/13854049608406699; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BROWN DSO, 1990, 4 UNISA HLTH PSYCH U; CHRISTENSEN AL, 1992, SCAND J REHABIL MED, P34; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DRESSER AC, 1973, ARCH NEUROL-CHICAGO, V29, P111, DOI 10.1001/archneur.1973.00490260055011; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; GILCHRIST E, 1979, ARCH NEUROL-CHICAGO, V36, P355, DOI 10.1001/archneur.1979.00500420065008; GILES GM, 1993, BRAIN INJURY REHABIL; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hartley L. L., 1995, COGNITIVE COMMUNICAT; HOWELL DC, 1992, STAT METHODS PSYCHOL; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JANSEN P, 1988, THESIS UNISA; Johnson R, 1987, Int Disabil Stud, V9, P49; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; KAPLAN S, 1991, CLIN NEUROPSYCHOL, V5, P360, DOI DOI 10.1080/13854049108404103; Kinsella GJ, 1998, NEUROPSYCHOL REHABIL, V8, P351, DOI 10.1080/713755576; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LYONS JL, 1988, AM J OCCUP THER, V42, P364, DOI 10.5014/ajot.42.6.364; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; NELL V, 1990, 1 UNISA HSRC HLTH PS; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; PUTNAM SH, 1992, CLIN NEUROPSYCHOL, V6, P383; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; ROLLAND J, 1993, LIVING APHASIA PSYCH, pCH13; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; SARNO MT, 1988, SCAND J REHABIL MED, P55; Siegel S., 1956, NONPARAMETRIC STAT B; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Teasdale TW, 1997, NEUROPSYCHOL REHABIL, V7, P23, DOI 10.1080/713755521; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VARNEY NR, 1988, J CLIN EXP NEUROPSYC, V10, P250, DOI 10.1080/01688638808408239; VOGENTHALER DR, 1986, THESIS SO ILLINOIS U; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	50	15	16	0	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0081-2463	2078-208X		S AFR J PSYCHOL	South Afr. J. Psychol.	SEP	2000	30	3					27	37		10.1177/008124630003000305			11	Psychology, Multidisciplinary	Psychology	381ZF	WOS:000165793400005					2021-06-18	
J	Squier, M; Chamberlain, P; Zaiwalla, Z; Anslow, P; Oxbury, J; Gould, S; McShane, MA				Squier, M; Chamberlain, P; Zaiwalla, Z; Anslow, P; Oxbury, J; Gould, S; McShane, MA			Five cases of brain injury following amniocentesis in mid-term pregnancy	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							MIDTRIMESTER AMNIOCENTESIS; TRIMESTER AMNIOCENTESIS; NEURONAL MIGRATION; CYST	This paper describes the neuroimaging and neuropathological findings in five cases of severe brain damage after traumatic mid-trimester amniocentesis, all performed between 1986 and 1994. Although fetal injury after amniocentesis has been reported, reports of brain injury are infrequent. Continuous ultrasound monitoring may reduce the risk of fetal injury but follow-up ultrasound scans can be falsely reassuring. Withdrawal of blood-stained fluid, particularly if it contains tissue fragments, should alert the operator to the possibility of fetal damage. Histological examination of such tissue fragments may confirm the nature of the fetal damage. The consequences of fetal brain injury are severe, all five of our cases showed evidence of disruption of brain development compatible with mid-term injury. Obstetricians and their patients should be aware of the small but significant risk of brain damage after mid-term amniocentesis.	Radcliffe Infirm, Dept Neuropathol, Oxford OX2 6HE, England; John Radcliffe Hosp, Womens Ctr, Dept Obstet, Oxford, England; John Radcliffe Hosp, Dept Neuroradiol, Oxford OX3 9DU, England; John Radcliffe Hosp, Dept Neurol, Oxford OX3 9DU, England; John Radcliffe Hosp, Dept Pathol, Oxford OX3 9DU, England; John Radcliffe Hosp, Dept Pediat, Oxford OX3 9DU, England	Squier, M (corresponding author), Radcliffe Infirm, Dept Neuropathol, Oxford OX2 6HE, England.	waney.squier@clneuro.ox.ac.uk					ACHIRON R, 1986, ACTA OBSTET GYN SCAN, V65, P869, DOI 10.3109/00016348609157041; ANANDAKUMAR C, 1992, AUST NZ J OBSTET GYN, V32, P97, DOI 10.1111/j.1479-828X.1992.tb01916.x; BARKOVICH AJ, 1995, AM J NEURORADIOL, V16, P822; BARTH PG, 1987, CAN J NEUROL SCI, V14, P1; BENZIE RJ, 1994, PRENATAL DIAG, V14, P235, DOI 10.1002/pd.1970140402; Bruce S, 1984, Pediatr Dermatol, V2, P140, DOI 10.1111/j.1525-1470.1984.tb00459.x; CHONG SKF, 1989, PRENATAL DIAG, V9, P677, DOI 10.1002/pd.1970090912; COOK LN, 1974, PEDIATRICS, V53, P421; CREASMAN WT, 1968, J AMER MED ASSOC, V204, P949; ELLER KM, 1995, OBSTET GYNECOL, V85, P865, DOI 10.1016/0029-7844(94)00315-5; EVRARD P, 1992, HDB NEUROPSYCHOLOGY, V6; EZRA DB, 1989, OPHTHALMOLOGICA, V198, P140; FINEGAN JAK, 1985, BRIT J OBSTET GYNAEC, V92, P1015, DOI 10.1111/j.1471-0528.1985.tb02996.x; FRIEDE RL, 1989, DEV NEUROPATHOLOGY, P372; GOTTDIENER JS, 1975, NEW ENGL J MED, V293, P1302, DOI 10.1056/NEJM197512182932508; HERSHEY DW, 1993, OPHTHALMOLOGY, V100, P1601; HYMAN CJ, 1973, OBSTET GYNECOL, V41, P43; KARP LE, 1977, OBSTET GYNECOL, V49, P115; KUBAN KCK, 1985, ANN NEUROL, V17, P539, DOI 10.1002/ana.410170603; LEAKE RD, 1974, OBSTET GYNECOL, V43, P884; MUROFUSHI K, 1974, ACTA NEUROPATHOL, V27, P317, DOI 10.1007/BF00690696; NAYLOR G, 1990, Eye (London), V4, P845; PATEL CK, 1993, BRIT J OPHTHALMOL, V77, P530, DOI 10.1136/bjo.77.8.530; PORTMAN MA, 1982, AM J OBSTET GYNECOL, V144, P731, DOI 10.1016/0002-9378(82)90447-1; RAIMER SS, 1984, ARCH DERMATOL, V120, P1360, DOI 10.1001/archderm.120.10.1360; ROESSMANN U, 1986, ACTA NEUROPATHOL, V70, P302, DOI 10.1007/BF00686088; RON M, 1982, ACTA OBSTET GYN SCAN, V61, P43, DOI 10.3109/00016348209156950; RUMMELT V, 1993, OPHTHALMOLOGY, V100, P776; SCHINZEL A, 1981, ARCH DIS CHILD, V56, P405, DOI 10.1136/adc.56.5.405-a; Shafrir Y, 1996, ANN NEUROL, V40, P42; SHERWOOD A, 1978, NEUROPATH APPL NEURO, V4, P245, DOI 10.1111/j.1365-2990.1978.tb00543.x; SIDMAN RL, 1973, BRAIN RES, V62, P1, DOI 10.1016/0006-8993(73)90617-3; VERJAAL M, 1981, PRENATAL DIAG, V1, P173, DOI 10.1002/pd.1970010303; Whittle MJ, 1998, LANCET, V351, P226, DOI 10.1016/S0140-6736(98)22004-6; WILLIAMSON RA, 1985, OBSTET GYNECOL, V65, P751; Wilson RD, 1998, LANCET, V351, P242; YOUROUKOS S, 1980, ARCH DIS CHILD, V55, P814, DOI 10.1136/adc.55.10.814	37	15	16	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0012-1622	1469-8749		DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	AUG	2000	42	8					554	560		10.1017/S0012162200001043			7	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	346CF	WOS:000088852400009	10981934				2021-06-18	
J	Proctor, A; Wilson, B; Sanchez, C; Wesley, E				Proctor, A; Wilson, B; Sanchez, C; Wesley, E			Executive function and verbal working memory in adolescents with closed head injury (CHI)	BRAIN INJURY			English	Article							INDIVIDUAL-DIFFERENCES; DYSEXECUTIVE SYNDROME	The relationship between executive function (EF) and working memory (WM) was studied in eight adolescents with closed head injury (CHI) and eight controls, matched for age, gender and socioeconomic status (SES). A cognitive-linguistic test (Scales of Cognitive Ability for Traumatic Brain Injury, SCATBI) was used to group CHI participants by severity. EF was tested with a measure of daily functioning (Pro-Ex) and WM was tested with a recognition memory task (RMT). When all subject test data were grouped, a positive linear correlation was found for the Pro-Ex and the RMT. A strong-to-moderate positive correlation was found for components of the EF measure and the RMT. Severity of injury influenced test performance for both the EF and WM measures, with a significance between group effects found on the RMT task. Results indicate a relationship between executive function and working memory, severity of injury and test performance and the need to assess EF of CHI adolescents with a measure of daily functioning.	Univ Illinois, Dept Speech & Hearing Sci, Champaign, IL 61820 USA; Eastern Illinois Univ, Charleston, IL 61920 USA	Proctor, A (corresponding author), Univ Illinois, Dept Speech & Hearing Sci, 901 S 6th St, Champaign, IL 61820 USA.	aproctor@UIUC.edu					ADAMOVITCH B, 1992, SCALES COGNITIVE ABI; ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; Baddeley, 1998, HUMAN MEMORY THEORY; Baddeley A, 1996, Q J EXP PSYCHOL-A, V49, P5; BADDELEY A, 1988, BRAIN COGNITION, V7, P212, DOI 10.1016/0278-2626(88)90031-0; Baddeley A., 1986, OXFORD PSYCHOL SERIE, V11; Baddeley A.D., 1999, MODELS WORKING MEMOR, P28, DOI DOI 10.1017/CBO9781139174909.005; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; BRASWELL D, 1992, PROFILE EXECUTIVE CO; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; DANEMAN M, 1983, J EXP PSYCHOL LEARN, V9, P561, DOI 10.1037/0278-7393.9.4.561; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; ENCKLA MB, 1996, ATTENTION MEMORY EXE, P263; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; ESTWISLE DR, 1994, CHILD DEV, V63, P1521; Gathercole S. E., 1993, WORKING MEMORY LANGU; GOLDMAN R, 1991, GOLDMAN FRISTOE WOOD; Lehto JH, 1996, Q J EXP PSYCHOL-A, V49, P29, DOI 10.1080/027249896392793; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; LEZAK MD, 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; NORMAN DA, 1980, 99 CHIP U CAL SAN DI; SHAH P, 1999, MODELS WORKING MEMOR, P1, DOI DOI 10.1017/CBO9781139174909.004; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; VANDERLINDEN M, 1992, COGNITIVE NEUROPSYCH, V9, P301, DOI 10.1080/02643299208252063; WARD JD, 1987, BRAIN INJURY, V12, P21; Wickelgren I, 1997, SCIENCE, V275, P1580, DOI 10.1126/science.275.5306.1580; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; WILSON BM, 1998, THESIS U ILLINOIS UR; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P159	31	15	20	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2000	14	7					633	647					15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	335AV	WOS:000088220600004	10914645				2021-06-18	
J	Pettersen, JA; Skelton, RW				Pettersen, JA; Skelton, RW			Glucose enhances long-term declarative memory in mildly head-injured varsity rugby players	PSYCHOBIOLOGY			English	Article							ELDERLY HUMANS; SENILE DEMENTIA; COMPLEX MEMORY; YOUNG-ADULTS; BRAIN-DAMAGE; RECOVERY; MECHANISM; DEFICITS; TESTS; AGE	In the present investigation, we sought to determine whether glucose could enhance declarative memory in head-injured individuals, as has been shown previously with elderly and Alzheimer's patients who had preexisting memory impairments. Varsity rugby players, both with and without a history of concussions, were given glucose- or saccharin-sweetened beverages and then tested on a series of neuropsychological tests of attention and memory; their blood-glucose levels were monitored. Beverages and tests were administered in a counterbalanced, crossover design, enabling within-subjects comparisons. Previously concussed participants were found to perform slightly worse than participants with no history of concussions (controls) on the preliminary screening interview tests and tests of memory and divided attention given in the saccharin (placebo) condition. Glucose was shown to enhance performance of the previously concussed participants and impair the performance of controls on tests of long-term declarative memory. The effects of glucose on memory appeared to be related to the participants' ability to clear glucose from the blood.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada	Skelton, RW (corresponding author), Univ Victoria, Dept Psychol, POB 3050, Victoria, BC V8W 3P5, Canada.	skelton@uvic.ca	Skelton, Ronald/E-5605-2012				ALVES WM, 1987, CLIN SPORT MED, V6, P211; ALVES WM, 1991, ATHLETIC INJURIES HE, P283; AZARI NP, 1991, PSYCHOPHARMACOLOGY, V105, P521, DOI 10.1007/BF02244373; BADDELEY A, 1987, NEUROBEHAVIORAL RECO, P295; BARTH JT, 1989, MILD HEAD INJURY, P255; Brown W. L. jr., 1958, Acta Hymenopterologica, V1, P1; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; Caveness W F, 1979, Adv Neurol, V22, P1; COPE DN, 1986, J HEAD TRAUMA REHAB, V1, P34; CRAFT S, 1994, PSYCHOBIOLOGY, V22, P95; CRAFT S, 1992, J CLIN EXP NEUROPSYC, V14, P253, DOI 10.1080/01688639208402827; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GOLD PE, 1988, NEUROBIOL AGING, V9, P709, DOI 10.1016/S0197-4580(88)80136-2; GOLD PE, 1991, NEUR CONT B, V6, P391; GONDERFREDERICK L, 1987, PHYSIOL BEHAV, V41, P503, DOI 10.1016/0031-9384(87)90087-4; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL D, 1992, NZ J SPORTS MED, V20, P19; Gronwall D, 1989, MILD HEAD INJURY, P153; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; HALL JL, 1989, NEUROPSYCHOLOGIA, V27, P1129, DOI 10.1016/0028-3932(89)90096-1; HOCK FJ, 1987, NEUROPSYCHOBIOLOGY, V17, P145, DOI 10.1159/000118355; INGERSOLL CD, 1993, SPORTS MED, V16, P342, DOI 10.2165/00007256-199316050-00005; Jennett B, 1975, EPILEPSY NONMISSILE; JONES MK, 1974, NEUROPSYCHOLOGIA, V12, P21, DOI 10.1016/0028-3932(74)90023-2; KANE RL, 1992, NEUROPSYCHOL REV, V3, P45; KASTE M, 1982, LANCET, V2, P1186; KOPF SR, 1994, BEHAV NEURAL BIOL, V62, P237, DOI 10.1016/S0163-1047(05)80022-6; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEVIN HS, 1989, COMPREHENSIVE NEUROL, V2, P53; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MANNING CA, 1993, NEUROBIOL AGING, V14, P523, DOI 10.1016/0197-4580(93)90034-9; MANNING CA, 1992, BEHAV NEURAL BIOL, V58, P125, DOI 10.1016/0163-1047(92)90351-4; Manning CA, 1997, PSYCHOBIOLOGY, V25, P103; MANNING CA, 1990, PSYCHOL SCI, V1, P307, DOI 10.1111/j.1467-9280.1990.tb00223.x; MARIADAS AC, 1989, NIMHANS J, V7, P37; MATEER CA, 1992, PHYSICAL MED REHABIL, V6, P143; MCLEAN A JR, 1991, Brain Injury, V5, P375, DOI 10.3109/02699059109008110; MESSIER C, 1990, BEHAV BRAIN RES, V39, P135, DOI 10.1016/0166-4328(90)90100-S; MESSIER C, 1991, NEUR CONT B, V6, P473; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; NICHOLSON CD, 1990, PSYCHOPHARMACOLOGY, V101, P147, DOI 10.1007/BF02244119; PARSONS MW, 1992, NEUROBIOL AGING, V13, P401, DOI 10.1016/0197-4580(92)90114-D; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; PETTERSEN JA, 2000, UNPUB PREVENTION CON; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; REEVES D, 1989, 891 US NAV AER MED R; REID SE, 1971, SURG GYNECOL OBSTETR, V133, P929; ROSENTHAL M, 1983, DIABETES, V32, P408, DOI 10.2337/diabetes.32.5.408; RUSSELL EW, 1975, J CONSULT CLIN PSYCH, V43, P800, DOI 10.1037/0022-006X.43.6.800; SALTHOUSE TA, 1991, DEV PSYCHOL, V27, P763, DOI 10.1037/0012-1649.27.5.763; Smith A., 1968, LEARNING DISORDERS, P83; Smith A., 1973, SYMBOL DIGIT MODALIT; Sparks J P, 1985, Br J Sports Med, V19, P71; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; WENK GL, 1989, PSYCHOPHARMACOLOGY, V99, P431, DOI 10.1007/BF00589888; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005; WRIGHTSON P, 1992, NZ J SPORTS MED, V20, P18	63	15	15	0	2	PSYCHONOMIC SOC INC	AUSTIN	1710 FORTVIEW RD, AUSTIN, TX 78704 USA	0889-6313			PSYCHOBIOLOGY	Psychobiology	MAR	2000	28	1					81	89					9	Psychology; Psychology, Multidisciplinary	Psychology	308CU	WOS:000086693600008					2021-06-18	
J	Sieg, F; Wahle, P; Pape, HC				Sieg, F; Wahle, P; Pape, HC			Cellular reactivity to mechanical axonal injury in an organotypic in vitro model of neurotrauma	JOURNAL OF NEUROTRAUMA			English	Article						axonal/dendritic injury; calretinin; dorsal thalamus; in vitro trauma model; MAP-2; NF-M; organotypic culture; visual cortex	MICROTUBULE-ASSOCIATED PROTEIN-2; TRAUMATIC BRAIN INJURY; RAT VISUAL-CORTEX; LATERAL GENICULATE-NUCLEUS; CALCIUM-BINDING PROTEINS; STRETCH-INDUCED INJURY; CAJAL-RETZIUS CELLS; DIFFERENTIAL EXPRESSION; IN-VITRO; CALRETININ-IMMUNOREACTIVITY	An in vitro model of traumatic brain injury is described that is based on organotypic cocultures (OTCs) of rat neocortex and thalamus connected by reciprocal axonal projections. Localized mechanical compression of this projection was: inflicted with a mechanical device, and the effects on cell. viability, axonal morphology, and protein expression levels were analyzed. Within 24 h after insult, major cell damage occured in infragranular cortical layers containing the corticothalamic projection neurons and in thalamic regions adjacent to the mechanical impact as was assessed through the use of the vital stain Syto 21, and propidium iodide labeling, A small, but significant number of calretinin-positive interneurons in cortical and thalamic areas displayed symptoms of injury, Axonal elements, as revealed by neurofilament (NF-HIM) immunohistochemistry, in the corticothalamic transition zone displayed pathomorphological changes, such as axonal bulbs and swellings, already 4 h after insult. Densitometric analysis revealed that MAP-2a,b expression was not significantly changed within 4 h after injury. A significant reduction in MAP-2a,b amount was evident at 20 h after injury in thalamus (by 31.6%) and cortex (by 30%) maintained for 12 days in vitro (DIV), but not in OTCs aged 20 DIV, The axonally localized form MAP-2c significantly increased in cortex of 12-DIV OTCs at 4 and 20 h after insult (65.6% and 33.4%, respectively). MAP-2c levels in cortex of 20 DIV initially increased by 47.7% and declined below control values 20 h after injury. Thalamic areas revealed a delay in MAP-2c reactivity, in that expression was significantly elevated only at 20 h after injury (by 84.4% in 12-DIV and by 39.6% in 20-DIV OTCs, respectively). These data may reflect the regenerative ability of juvenile, but not of older neurons in response to mechanical axonal injury.	Otto Von Guericke Univ, Inst Physiol, Fak Med, D-39120 Magdeburg, Germany; Ruhr Univ Bochum, Fak Biol, D-4630 Bochum, Germany	Pape, HC (corresponding author), Otto Von Guericke Univ, Inst Physiol, Fak Med, Leipziger Str 44, D-39120 Magdeburg, Germany.	hanschristian.pape@medizin.uni-magdeburg.de		Sieg, Frank/0000-0001-9637-3239			ANDRESSEN C, 1993, CELL TISSUE RES, V271, P181, DOI 10.1007/BF00318606; ARAI M, 1992, BRAIN RES, V596, P215, DOI 10.1016/0006-8993(92)91550-X; Audesirk G, 1997, DEV BRAIN RES, V102, P247, DOI 10.1016/S0165-3806(97)00100-4; BINDER LI, 1984, P NATL ACAD SCI-BIOL, V81, P5613, DOI 10.1073/pnas.81.17.5613; BISBY MA, 1992, MOL NEUROBIOL, V6, P107, DOI 10.1007/BF02780547; BOLZ J, 1990, NATURE, V346, P359, DOI 10.1038/346359a0; BOLZ J, 1992, J NEUROSCI, V12, P3054; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BROERS JLV, 1985, P NATL ACAD SCI USA, V82, P4409, DOI 10.1073/pnas.82.13.4409; CELIO MR, 1990, NEUROSCIENCE, V35, P375, DOI 10.1016/0306-4522(90)90091-H; Conti AC, 1998, J NEUROSCI, V18, P5663; DelRio JA, 1996, J NEUROSCI, V16, P6896; DOLL T, 1993, J CELL SCI, V106, P633; Dusart I, 1997, J NEUROSCI, V17, P3710; Elder GA, 1998, J CELL BIOL, V141, P727, DOI 10.1083/jcb.141.3.727; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Faddis BT, 1997, J NEUROSCI, V17, P951; GARNER CC, 1988, J CELL BIOL, V106, P779, DOI 10.1083/jcb.106.3.779; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Gulyas AI, 1996, J NEUROSCI, V16, P3397; Hartel R, 1997, NEUROSCIENCE, V78, P1; HAYES RL, 1995, J NEUROTRAUM, V12, P933, DOI 10.1089/neu.1995.12.933; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HUBER G, 1984, J NEUROSCI, V4, P151; Jacobs AJ, 1997, J NEUROSCI, V17, P5206; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; Jones EG, 1998, NEUROSCIENCE, V85, P331, DOI 10.1016/S0306-4522(97)00581-2; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kanayama G, 1997, PSYCHIAT CLIN NEUROS, V51, P157, DOI 10.1111/j.1440-1819.1997.tb02379.x; KIROKAWA N, 1996, J CELL BIOL, V132, P667; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCAS JH, 1992, J NEUROTRAUM, V9, P117, DOI 10.1089/neu.1992.9.117; Massey, 1969, INTRO STAT ANAL; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; OBLINGER MM, 1988, J NEUROSCI, V8, P1747; Obst K, 1997, EUR J NEUROSCI, V9, P2571, DOI 10.1111/j.1460-9568.1997.tb01686.x; OBST K, 1995, EUR J NEUROSCI, V7, P2139, DOI 10.1111/j.1460-9568.1995.tb00636.x; PAXINOS G, 1991, ATLAS DEV BRAIN; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; RIEDERER B, 1985, P NATL ACAD SCI USA, V82, P6006, DOI 10.1073/pnas.82.17.6006; RIEDERER BM, 1995, J HISTOCHEM CYTOCHEM, V43, P1269, DOI 10.1177/43.12.8537643; Riederer BM, 1996, J COMP NEUROL, V364, P704, DOI 10.1002/(SICI)1096-9861(19960122)364:4<704::AID-CNE8>3.0.CO;2-7; RIEDERER BM, 1992, EUR J NEUROSCI, V4, P1376, DOI 10.1111/j.1460-9568.1992.tb00163.x; Ross D. T., 1992, Society for Neuroscience Abstracts, V18, P1088; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Schierle GS, 1997, CEREB CORTEX, V7, P130, DOI 10.1093/cercor/7.2.130; SHAW G, 1988, BRAIN RES, V460, P227, DOI 10.1016/0006-8993(88)90367-8; Sieg F, 1998, DEV BRAIN RES, V110, P83, DOI 10.1016/S0165-3806(98)00097-2; Smith DH, 1999, J NEUROSCI, V19, P4263; STOPPINI L, 1993, NEUROSCIENCE, V57, P985, DOI 10.1016/0306-4522(93)90043-F; Super H, 1997, DEV BRAIN RES, V98, P9, DOI 10.1016/S0165-3806(96)00154-X; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TETZLAFF W, 1991, J NEUROSCI, V11, P2528; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIERECK C, 1989, J NEUROSCI, V9, P3547; Weisenhorn DMV, 1996, EXP BRAIN RES, V108, P101; WEISSHAAR B, 1992, DEVELOPMENT, V116, P1151; Wilkemeyer MF, 1996, J NEUROSCI RES, V43, P707, DOI 10.1002/(SICI)1097-4547(19960315)43:6<707::AID-JNR7>3.0.CO;2-I; ZHANG Y, 1995, J COMP NEUROL, V361, P210, DOI 10.1002/cne.903610203	74	15	16	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	1999	16	12					1197	1213		10.1089/neu.1999.16.1197			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	266WC	WOS:000084322400007	10619198				2021-06-18	
J	Van Balen, HGG; De Mey, HRA; Van Limbeek, J				Van Balen, HGG; De Mey, HRA; Van Limbeek, J			A neurocorrective approach for MMPI-2 use with brain-damaged patients	INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH			English	Article						brain damage; MMPI-2; personality assessment; psychosocial adjustment; rehabilitation	PROFILES; INJURY	Conventional administration of the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) to aetiologically distinct brain-damaged out-patients (n = 137) revealed significant indications of psychological maladjustment. An adjustment for the endorsement of aetiology-specific items pertaining to traumatic brain injury (TBI), stroke, and whiplash was considered necessary, however, because these items may represent potentially valid symptoms or manifestations of neurological damage or dysfunction. These so-called neurologically relevant items (NRIs) were identified in a previous study. With this corrective approach, based on the complete MMPI-2 item pool, it was shown that T-score elevations could at least in part be attributed to symptoms associated with I,rain injury, regardless of the type of brain damage. Similarly, after prorated correction for the endorsement of NRIs, codetyping appeared to be substantially changed with respect to both occurrence and content of the MMPI-2 defined code:types. The validity of the NRI concept was supported by comparing NRI/non-NRI endorsement ratios of traumatically brain-injured patients with those of non-neurological patients, and with those having anxiety and somatoform disorders. To prevent unjustified interpretations when administering the MMPI-2 to brain-damaged patients, an adjustment procedure for NRI-endorsement is proposed, and difficulties in interpretation are discussed.	St Maartensklin, Nijmegen Ctr Motor Behav & Cognit, NL-6500 GM Nijmegen, Netherlands; St Maartensklin Res, Nijmegen, Netherlands; St Maartensklin, Div Rehabil Med, Nijmegen, Netherlands; Univ Nijmegen, Dept Clin & Personal Psychol, Nijmegen, Netherlands	Van Balen, HGG (corresponding author), St Maartensklin, Nijmegen Ctr Motor Behav & Cognit, POB 9011, NL-6500 GM Nijmegen, Netherlands.						ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P111; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Butcher, 1989, MINNESOTA MULTIPHASI; CRIPE LI, 1997, CLIN NEUROPSYCHOLOGY, P119; DEMEY HR, 1995, GEDRAG GEZONDHEID, V23, P179; Derksen J.J.L., 1997, MMPI 2 HANDLEIDING B; GASS CS, 1992, ARCH CLIN NEUROPSYCH, V7, P17, DOI 10.1016/0887-6177(92)90015-F; Gass CS, 1996, PSYCHOL ASSESSMENT, V8, P135, DOI 10.1037/1040-3590.8.2.135; GASS CS, 1991, J CLIN PSYCHOL, V47, P253, DOI 10.1002/1097-4679(199103)47:2<253::AID-JCLP2270470210>3.0.CO;2-A; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; Graham JR, 1993, MMPI 2 ASSESSING PER; Greene RL, 1997, J PERS ASSESS, V68, P20, DOI 10.1207/s15327752jpa6801_3; GREENE RL, 1991, MMPI 2 MMPI INTERPRE; KENDALL PC, 1978, J CONSULT CLIN PSYCH, V46, P370, DOI 10.1037/0022-006X.46.2.370; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MACK JL, 1979, MMPI CLIN RES TRENDS, P53; MILLER HB, 1995, J CLIN EXP NEUROPSYC, V17, P58, DOI 10.1080/13803399508406581; SLOORE H, 1993, MMPI 2 VRAGENBOEKJE; VanBalen HGG, 1997, INT J REHABIL RES, V20, P355, DOI 10.1097/00004356-199712000-00002; WOOTEN AJ, 1983, J CLIN PSYCHOL, V39, P392, DOI 10.1002/1097-4679(198305)39:3<392::AID-JCLP2270390313>3.0.CO;2-H	20	15	15	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0342-5282			INT J REHABIL RES	Int. J. Rehabil. Res.	DEC	1999	22	4					249	259		10.1097/00004356-199912000-00001			11	Rehabilitation	Rehabilitation	270FQ	WOS:000084525100001	10669974				2021-06-18	
J	Reynolds, HN; Cottingham, C; McCunn, M; Habashi, NM; Scalea, TM				Reynolds, HN; Cottingham, C; McCunn, M; Habashi, NM; Scalea, TM			Extracorporeal lung support in a patient with traumatic brain injury: the benefit of heparin-bonded circuitry	PERFUSION-UK			English	Article							ACUTE RESPIRATORY-FAILURE; CLINICAL-TRIAL; CO2 REMOVAL; VENTILATION		Univ Maryland Med, R Adams Cowley Shock Trauma Ctr, Div Crit Care Med, Baltimore, MD 21201 USA; Univ Maryland Med, R Adams Cowley Shock Trauma Ctr, Div Trauma Surg, Baltimore, MD 21201 USA	Reynolds, HN (corresponding author), Univ Maryland Med, R Adams Cowley Shock Trauma Ctr, Div Crit Care Med, 22 S Greene St, Baltimore, MD 21201 USA.						BINDSLEV L, 1987, ANESTHESIOLOGY, V67, P117, DOI 10.1097/00000542-198707000-00024; BINDSLEV L, 1991, ACTA ANAESTH SCAND, V35, P125, DOI 10.1111/j.1399-6576.1991.tb03409.x; GATTINONI L, 1986, JAMA-J AM MED ASSOC, V256, P881, DOI 10.1001/jama.256.7.881; KNOCH M, 1992, INT J ARTIF ORGANS, V15, P103; LARM O, 1983, BIOMATER ARTIF CELL, V11, P161, DOI 10.3109/10731198309118804; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; Mottaghy K, 1989, ASAIO Trans, V35, P146, DOI 10.1097/00002480-198904000-00006; OREILLY RA, 1985, PHARMACOL BASIS THER, V58, P1338; SELL LL, 1986, J PEDIATR SURG, V21, P1087, DOI 10.1016/0022-3468(86)90015-1; Toomasian J M, 1988, ASAIO Trans, V34, P410; WILLMS D, 1992, CHEST, V102, P968, DOI 10.1378/chest.102.3.968	11	15	15	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0267-6591	1477-111X		PERFUSION-UK	Perfusion-UK	NOV	1999	14	6					489	493		10.1177/026765919901400612			5	Cardiac & Cardiovascular Systems; Peripheral Vascular Disease	Cardiovascular System & Cardiology	299ED	WOS:000086182000011	10585157				2021-06-18	
J	Kosmidis, MH; Breier, A; Fantie, BD				Kosmidis, MH; Breier, A; Fantie, BD			Avoidance learning in schizophrenia: a dissociation between the effects of aversive and non-aversive stimuli	SCHIZOPHRENIA RESEARCH			English	Article						learning; operant conditioning; schizophrenia	CLOSED-HEAD-INJURY; ANTICIPATORY BEHAVIOR DEFICITS; ONSET SCHIZOPHRENIA; PREFRONTAL CORTEX; PERFORMANCE; DYSFUNCTION; DEMENTIA; TESTS; AGE	Patients with schizophrenia did not take significantly more trials than normal controls to learn to use a visual warning signal to avoid a non-aversive stimulus on a simple computer-administered avoidance learning task. When the stimulus to be avoided was aversive (i.e. a loud buzzer), however, the schizophrenic group could be divided into two subgroups based upon their performance; almost one half of the schizophrenic group failed to learn how to avoid this task successfully. The other half, like the normal controls and the closed head injury group in our previous studies, benefited from the aversiveness of the stimulus to be avoided, and learned to avoid more quickly than in the non-aversive condition. A post-hoc analysis of the differences between these two subgroups of the patients suggested that the discrepancy in learning was related to the age of onset of illness. (C) 1999 Elsevier Science B.V. All rights reserved.	American Univ, Dept Psychol, Human Neuropsychol Lab, Washington, DC 20016 USA; NIMH, Expt Therapeut Branch, Bethesda, MD 20892 USA	Fantie, BD (corresponding author), American Univ, Dept Psychol, Human Neuropsychol Lab, 4400 Massachusetts Ave NW, Washington, DC 20016 USA.		Kosmidis, Mary H/AAN-2104-2021	Fantie, Bryan D./0000-0002-1901-378X; Kosmidis, Mary/0000-0001-8790-1220			BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; BLEIBERG J, 1985, INT J CLIN NEUROPSYC, V7, P153; Bleuler E., 1950, DEMENTIA PRAECOX GRO; Charbonneau D, 1996, CAN J NEUROL SCI, V23, P271, DOI 10.1017/S031716710003821X; CROW TJ, 1991, PROGR PSYCHIAT, V28, P163; Damasio A., 1994, DESCARTESERROR EMOTI; Damasio A. R., 1993, CLIN NEUROPSYCHOLOGY, V3, P409; DENNYBROWN D, 1951, MOD TRENDS NEUROL, P13; DUNCAN CC, 1987, CURRENT TRENDS EVE S, V40, P670; FANTIE BD, 1994, CLIN NEUROPSYCHOL, V8, P379, DOI 10.1080/13854049408402040; FERSTL R, 1994, SCHIZOPHRENIA B, V20, P117; First M., 1995, STRUCTURED CLIN INTE; FREEDMAN PE, 1987, J NEUROL NEUROSUR PS, V50, P398, DOI 10.1136/jnnp.50.4.398; FRITH CD, 1988, BRIT J PSYCHIAT, V153, P437, DOI 10.1192/bjp.153.4.437; Frith CD., 1992, COGN NEUROPSYCHOL; Goldberg E, 1986, NEUROPSYCHOLOGICAL A, P48; GOLDBERG G, 1987, FRONTAL LOBE REVISIT; GOLDBERG TE, 1988, INT J NEUROSCI, V42, P51, DOI 10.3109/00207458808985758; GOLDBERG TE, 1987, ARCH GEN PSYCHIAT, V44, P1008; Goldberg Terry E., 1995, P1245; Hanewinkel R, 1996, J ABNORM PSYCHOL, V105, P459; Hoff AL, 1996, SCHIZOPHR RES, V20, P21, DOI 10.1016/0920-9964(95)00065-8; Jeste DV, 1997, AM J GERIAT PSYCHIAT, V5, P302, DOI 10.1097/00019442-199700540-00005; JOHNSTONE EC, 1989, PSYCHOL MED, V19, P91, DOI 10.1017/S0033291700011053; Kohler C, 1998, BIOL PSYCHIAT, V43, P165, DOI 10.1016/S0006-3223(97)00033-4; KOLB B, 1983, J NERV MENT DIS, V171, P435, DOI 10.1097/00005053-198307000-00008; KOSMIDIS MH, 1995, J CLIN EXP NEUROPSYC, V17, P622, DOI 10.1080/01688639508405150; LINDSTROM E, 1994, ACTA PSYCHIAT SCAND, V89, P274, DOI 10.1111/j.1600-0447.1994.tb01513.x; MAZZIOTTA JC, 1985, NEUROLOGY, V34, P825; McKay A. P., 1995, BROKEN MEMORIES CASE, P124; Paivio A., 1971, IMAGERY VERBAL PROCE; PERLICK D, 1992, SCHIZOPHR RES, V6, P257, DOI 10.1016/0920-9964(92)90009-T; Rapaport D., 1945, DIAGNOSTIC PSYCHOL T; ROTHKE S, 1987, INT J CLIN NEUROPSYC, V9, P81; SEIDMAN LJ, 1983, PSYCHOL BULL, V94, P195, DOI 10.1037/0033-2909.94.2.195; SHAKOW D, 1979, ADAPTATION SCHIZOPHR; SHALLICE T, 1991, ARCH GEN PSYCHIAT, V48, P618; Stuss D.T., 1986, FRONTAL LOBES; SUTTON S, 1961, AM J PSYCHOL, V74, P224, DOI 10.2307/1419407; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; Wilder KE, 1998, SCHIZOPHR RES, V30, P169, DOI 10.1016/S0920-9964(97)00135-7	41	15	16	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-9964			SCHIZOPHR RES	Schizophr. Res.	JUL 27	1999	38	1					51	59		10.1016/S0920-9964(98)00181-9			9	Psychiatry	Psychiatry	216BC	WOS:000081419800006	10427610				2021-06-18	
J	Odland, RM; Sutton, RL				Odland, RM; Sutton, RL			Hyperosmosis of cerebral injury	NEUROLOGICAL RESEARCH			English	Article						osmosis; osmotic pressure; cerebral edema; stroke; traumatic brain injury; colloid osmotic pressure	BRAIN EDEMA; MICRODIALYSIS; GLUCOSE; OSMOLALITY; GLUTAMATE; ISCHEMIA; PRESSURE; LACTATE; FLUID	Changes in tissue osmolarity or cerebrospinal fluid osmolarity after cerebral injury have received little attention in the literature, but osmosis may be an important cause of early cerebral edema; This paper reviews concepts and terms relating to osmosis, and reviews the few papers in the literature which have studied osmolarity after cerebral injury. In studies of both traumatic brain injury and ischemia, tissue osmolarity is elevated. Osmolarity of cerebrospinal fluid has also been shown to increase with injury. There have been no human studies examining osmolarity of tissue or cerebrospinal fluid after cerebral injury. Theoretical implications of the osmotic gradient are discussed.	Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA; Univ Minnesota, Minneapolis, MN USA	Odland, RM (corresponding author), Hennepin Cty Med Ctr, 701 Pk Ave, Minneapolis, MN 55415 USA.						ARIEFF AI, 1973, J CLIN INVEST, V52, P571, DOI 10.1172/JCI107218; AUKLAND K, 1974, ACTA PHYSIOL SCAND, V90, P485, DOI 10.1111/j.1748-1716.1974.tb05611.x; BANDARANAYAKE NM, 1978, STROKE, V9, P249, DOI 10.1161/01.STR.9.3.249; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bullock R., 1995, NEUROCHEMICAL MONITO, P64; DURING MJ, 1993, LANCET, V341, P1607; Fisher M, 1997, STROKE, V28, P866, DOI 10.1161/01.STR.28.4.866; FISHMAN RA, 1986, STROKE, P119; GAZENDAM J, 1979, J NEUROSURG, V51, P70, DOI 10.3171/jns.1979.51.1.0070; GO KG, 1981, ARCH NEUROL-CHICAGO, V38, P581, DOI 10.1001/archneur.1981.00510090075009; GO KG, 1979, J NEUROSURG, V51, P78, DOI 10.3171/jns.1979.51.1.0078; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; HAMMEL HT, 1984, PHYS CHEM LIQ, V13, P255, DOI 10.1080/00319108408080784; HAMMEL HT, 1983, PHYS CHEM LIQ, V13, P25, DOI 10.1080/00319108308080760; HAMMEL HT, 1976, OSMOSIS TENSILE SOLV, P1; HAMMEL HT, 1976, OSMOSIS TENSILE SOLV, P15; HAMMEL HT, 1976, OSMOSIS TENSILE SOLV, P70; HATASHITA S, 1986, J CEREBR BLOOD F MET, V6, P546, DOI 10.1038/jcbfm.1986.100; Hatashita S, 1990, Adv Neurol, V52, P85; HATASHITA S, 1976, P 7 INT S INTR PRESS, P969; Hillegred L., 1991, MICRODIALYSIS NEUROS, P389; HILLERED L, 1995, NEUROCHEMICAL MONITO, P59; HOFF JT, 1988, OUTFLOW CEREBROSPINA, P295; Hossman K, 1976, DYNAMICS BRAIN EDEMA, P219; KAWAMATA T, 1995, NEUROCHEMICAL MONITO, P72; KELLY MJ, 1973, PHYSICAL PRINCIPLES, P77; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KLATZO I, 1984, BRAIN EDEMA, P1; KUTCHAI HC, 1988, PHYSIOLOGY, P5; LANDOLT H, 1994, ACTA NEUROCHIR, P475; LANGEMANN H, 1995, CLIN NEUROL NEUROSUR, V97, P149, DOI 10.1016/0303-8467(94)00067-G; MATSUOKA Y, 1982, EXP NEUROL, V77, P599, DOI 10.1016/0014-4886(82)90231-X; MCDOWELL ME, 1955, AM J PHYSIOL, V180, P545; Mori T., 1998, Journal of Neurotrauma, V15, P30; Onal C, 1997, ACTA NEUROCHIR, V139, P661, DOI 10.1007/BF01412002; PATBERG WR, 1977, EXP NEUROL, V54, P141, DOI 10.1016/0014-4886(77)90241-2; SCHIELKE GP, 1991, J CEREBR BLOOD F MET, V11, P466, DOI 10.1038/jcbfm.1991.89; Starling E H, 1896, J Physiol, V19, P312; STROCK PE, 1969, SURG GYNECOL OBSTETR, V129, P1213; SU CT, 1982, PLAST RECONSTR SURG, V70, P202, DOI 10.1097/00006534-198208000-00014; TOMITA M, 1979, EXP NEUROL, V65, P66, DOI 10.1016/0014-4886(79)90248-6; TORNHEIM PA, 1980, J NEUROSCI METH, V3, P21, DOI 10.1016/0165-0270(80)90031-X; TRANUMJENSEN J, 1981, CIRC RES, V49, P364, DOI 10.1161/01.RES.49.2.364; WILLMSKR.K, 1969, AM J PATHOL, V54, P327; Zauner A, 1996, ACT NEUR S, V67, P40	45	15	16	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUL	1999	21	5					500	508		10.1080/01616412.1999.11740965			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	218JU	WOS:000081550100011	10439432				2021-06-18	
J	Asikainen, I; Nybo, T; Muller, K; Sarna, S; Kaste, M				Asikainen, I; Nybo, T; Muller, K; Sarna, S; Kaste, M			Speed performance and long-term functional and vocational outcome in a group of young patients with moderate or severe traumatic brain injury	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						speed performance; traumatic brain injury; outcome	CLOSED HEAD-INJURY; CHILDREN; RECOVERY; SCALE; REHABILITATION	We studied specific aspects of speed performance in neuropsychological tests and functional and vocational long-term outcome among moderate or severe traumatic brain injury (TBI) patients admitted to a rehabilitation programme. A group of 140 patients with mild, moderate or severe TBI,vas followed up for a minimum of 5 years in a rehabilitation programme. Severity of TBI was estimated using the Glasgow Coma Scale (GCS) scores on emergency hospital admission. The patients, grouped by age at injury into the categories: 7 or younger, 8-16 and 17 years of age or older, were tested five or more gears post-injury with comprehensive neuropsychological tests, including a speed performance test with the Stroop material, the Purdue Pegboard (PB) test and simple visual and auditive reaction times. The outcome variables were functional outcome, as measured by the Glasgow Outcome Scale (GOS) score, and capacity for employment at the end of follow-up, i.e, on average 12 years post-injury The patients,vith mild TBI mere excluded from further analysis of outcome. The study was carried out at the Kauniala outpatient neurological clinic. In the Stroop test, patients with a GOS score of 3 and patients who were incapable of employment were slower (P = 0.0046 and P = 0.0015, respectively) than those with a GOS score of 1 or 2 and those capable of independent or subsidized employment, respectively. The PB test also differentiated significantly between the patients with a GOS score of 3 and those with a GOS score of 1 or 2 at the end of follow-up (P = 0.0413), and predicted incapacity for employment (P = 0.032), those with worse outcome being slower. Simple reaction times did not differ significantly between the GOS scores at the end of follow-up, and neither did they predict capacity or incapacity for employment. Our data suggest that the Stroop and PB tests can help estimate functional outcome, as measured by the GOS, among patients with initially moderate or severe TBI and who were referred to a rehabilitation programme. The same tests could also be useful in predicting long-term vocational outcome. Eur J Neurol 6:179-185 (C) 1999 Lippincott Williams & Wilkins.	Kauniala Hosp, Dept Neurol, Kauniainen 02700, Finland; Finnish Inst Occupat Hlth, Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Clin Neurosci, FIN-00014 Helsinki, Finland	Asikainen, I (corresponding author), Kauniala Hosp, Dept Neurol, Kylpylantie 19, Kauniainen 02700, Finland.			Kaste, Markku/0000-0001-6557-6412; Sarna, Seppo/0000-0003-3458-1627			Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; BOWER A J, 1990, British Journal of Neurosurgery, V4, P253, DOI 10.3109/02688699008992734; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; Chugani HT, 1996, BRAIN DEV-JPN, V18, P347, DOI 10.1016/0387-7604(96)00032-0; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; COHEN RA, 1993, NEUROPSYCHOLOGY ATTE, P260; COSTEFF H, 1988, BRAIN DEV-JPN, V10, P371, DOI 10.1016/S0387-7604(88)80095-0; DERENZI E, 1965, CORTEX, V1, P410; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENSEN AR, 1966, ACTA PSYCHOL, V25, P36, DOI 10.1016/0001-6918(66)90004-7; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRIEL RL, 1988, PEDIATR NEUROL, V4, P337, DOI 10.1016/0887-8994(88)90079-3; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LEVIN HS, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P89; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P171; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; SILVER SM, 1992, AM PSYCHIAT TXB NEUR, P363; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; Tiffin J., 1968, PURDUE PEGBOARD EXAM; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452	29	15	15	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1351-5101			EUR J NEUROL	Eur. J. Neurol.	MAR	1999	6	2					179	185		10.1111/j.1468-1331.1999.tb00011.x			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	178LM	WOS:000079267200011	10053230				2021-06-18	
J	Duhaime, AC; Raghupathi, R				Duhaime, AC; Raghupathi, R			Age-specific therapy for traumatic injury of the immature brain: experimental approaches	EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	IIIrd International Congress of Pathophysiology	JUN 28-JUL 03, 1998	LAHTI, FINLAND			brain, traumatic injury; immature brain, trauma; traumatic injury, brain, age-specific therapy	ACUTE SUBDURAL-HEMATOMA; EXCITATORY AMINO-ACIDS; CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; PROGRAMMED CELL-DEATH; DIFFUSE AXONAL INJURY; COMA DATA-BANK; NERVOUS-SYSTEM; IN-VIVO; NEURONAL APOPTOSIS		Univ Penn, Div Neurosurg, Sch Med, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	Duhaime, AC (corresponding author), Univ Penn, Div Neurosurg, Sch Med, 34th & Civ Ctr Bldg, Philadelphia, PA 19104 USA.	DUHAIME@EMAIL.CHOP.EDU					Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; BARKS JDE, 1992, BRAIN PATHOL, V2, P235, DOI 10.1111/j.1750-3639.1992.tb00697.x; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BUCKLEY NM, 1986, COMP BIOCHEM PHYS A, V83, P1, DOI 10.1016/0300-9629(86)90080-0; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; BULLOCK R, 1990, ACT NEUR S, V51, P274; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAO Y, 1994, P NATL ACAD SCI USA, V91, P9612, DOI 10.1073/pnas.91.20.9612; CHEN MH, 1991, J NEUROSURG, V74, P944, DOI 10.3171/jns.1991.74.6.0944; DAVIES AM, 1995, TRENDS NEUROSCI, V18, P355, DOI 10.1016/0166-2236(95)93928-Q; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; DICKERSON JW, 1967, PROC R SOC SER B-BIO, V166, P384, DOI 10.1098/rspb.1967.0002; DIGIACOMO JE, 1992, BIOL NEONATE, V61, P25, DOI 10.1159/000243527; DUHAIME A, 1992, COMPLICATIONS SEQUEL, P169; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, J NEUROTRAUM, V13, P79, DOI 10.1089/neu.1996.13.79; DUHAIME AC, 1996, NEUROLOGICAL SURG, P1777; DUHAIME AC, 1996, 25 ANN M CHARL S CAR; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FERNANDEZ SC, 1996, J NEUROTRAUM, V13, P612; FINIELS F, 1995, J NEUROCHEM, V65, P1027; FLYNN TJ, 1984, NEUROCHEM RES, V9, P935, DOI 10.1007/BF00964525; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; Ikonomidou C, 1996, PEDIATR RES, V39, P1020, DOI 10.1203/00006450-199606000-00015; INGLIS F, 1992, J NEUROTRAUM, V9, P75, DOI 10.1089/neu.1992.9.75; Kanthan R, 1996, J NEUROL NEUROSUR PS, V60, P703; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; Lawrence MS, 1996, J NEUROSCI, V16, P486; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1995, PEDIATR NEUROSURG, V23, P34, DOI 10.1159/000120933; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MADSEN FF, 1990, ACTA NEUROCHIR, V106, P164, DOI 10.1007/BF01809461; MADSEN FF, 1990, ACTA NEUROCHIR, V106, P24, DOI 10.1007/BF01809329; MADSEN FF, 1987, ACTA NEUROCHIR, V88, P65, DOI 10.1007/BF01400517; MADSEN FF, 1990, ACTA NEUROCHIR, V105, P150, DOI 10.1007/BF01670000; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MCINTOSH T, 1988, FRONTIERS EXCITATORY; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MERRY DE, 1994, DEVELOPMENT, V120, P301; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; OLNEY JW, 1993, APMIS, V101, P103; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PAMPIGLIONE G, 1971, P ROY SOC MED, V64, P429, DOI 10.1177/003591577106400441; Preston GA, 1996, MOL CELL BIOL, V16, P211; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RAGHUPATHI R, 1995, J NEUROTRAUM, V12, P966; RINK A, 1995, AM J PATHOL, V147, P1575; RORKE LB, 1992, BRAIN PATHOL, V2, P211, DOI 10.1111/j.1750-3639.1992.tb00694.x; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; SCHWARTZ LM, 1991, BIOESSAYS, V13, P389, DOI 10.1002/bies.950130805; SHAPIRA Y, 1994, STROKE, V25, P1637, DOI 10.1161/01.STR.25.8.1637; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Shaver EG, 1996, PEDIATR NEUROSURG, V25, P123, DOI 10.1159/000121109; STRAUSS KI, 1996, J NEUROTRAUM, V13, P620; THOMAS JM, 1971, GROWTH, V35, P259; TZIKA AA, 1993, JMRI-J MAGN RESON IM, V3, P719, DOI 10.1002/jmri.1880030506; VANNUCCI RC, 1992, BRAIN PATHOL, V2, P229, DOI 10.1111/j.1750-3639.1992.tb00696.x; WAGERLE LC, 1986, PEDIATR RES, V20, P131, DOI 10.1203/00006450-198602000-00007	80	15	15	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0940-2993	1618-1433		EXP TOXICOL PATHOL	Exp. Toxicol. Pathol.	FEB	1999	51	2					172	177		10.1016/S0940-2993(99)80091-8			6	Pathology; Toxicology	Pathology; Toxicology	177NZ	WOS:000079218000009	10192586				2021-06-18	
J	Gill, DRJ; Torchia, ME				Gill, DRJ; Torchia, ME			The spiral compression plate for proximal humeral shaft nonunion: A case report and description of a new technique	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						proximal humeral shaft nonunion; narrowed dynamic compression plate	EXPERIENCE; NAILS	We present a case of humeral nonunion managed with a dynamic compression plate (DCP) contoured in a spiral fashion to preserve the deltoid muscle insertion. A forty-one-year-old woman sustained a closed proximal third humeral shaft fracture with an associated supraclavicular brachial plexus injury. She presented five months later with an atrophic nonunion of the proximal humeral shaft, inferior subluxation of the humeral head, and a resolving brachial plexopathy. Autogenous cancellous bone grafting and open reduction and internal fixation with a narrow DCP was performed. The deltoid muscle insertion was preserved by contouring the plate to fix the proximal humerus laterally over the greater tuberosity and anteriorly over the mid-humeral shaft. During the postoperative period, the humeral head reduced spontaneously. Five months after surgery, the fracture healed, and an excellent clinical result was achieved. We recommend the use of the spiral DCP for proximal shaft fractures and nonunions when preservation of the deltoid insertion is desirable.	Mayo Clin & Mayo Fdn, Dept Orthopaed Surg, Rochester, MN 55905 USA	Torchia, ME (corresponding author), Mayo Clin & Mayo Fdn, Dept Orthopaed Surg, 200 1st St SW, Rochester, MN 55905 USA.						BARQUET A, 1989, J TRAUMA, V29, P95, DOI 10.1097/00005373-198901000-00020; BELL MJ, 1985, J BONE JOINT SURG BR, V67, P293; BRIEN WW, 1990, J BONE JOINT SURG AM, V72A, P1208, DOI 10.2106/00004623-199072080-00012; COFIELD RH, 1984, J BONE JOINT SURG AM, V66A, P899, DOI 10.2106/00004623-198466060-00010; FOSTER RJ, 1985, J BONE JOINT SURG AM, V67A, P857, DOI 10.2106/00004623-198567060-00005; Gregory, 1997, J Am Acad Orthop Surg, V5, P215; HEALY WL, 1987, CLIN ORTHOP RELAT R, P206; HEIM D, 1993, J TRAUMA, V35, P226, DOI 10.1097/00005373-199308000-00009; Henley M. Bradford, 1993, P91; JUPITER JB, 1990, J BONE JOINT SURG AM, V72A, P701, DOI 10.2106/00004623-199072050-00009; McKee MD, 1996, J ORTHOP TRAUMA, V10, P492, DOI 10.1097/00005131-199610000-00008; NEER CS, 1982, J BONE JOINT SURG AM, V64, P319, DOI 10.2106/00004623-198264030-00001; ROSEN H, 1990, ORTHOP CLIN N AM, V21, P725; Schatzker J, 1996, RATIONALE OPERATIVE; VANDERGRIEND R, 1986, J BONE JOINT SURG AM, V68A, P430, DOI 10.2106/00004623-198668030-00018; WU CC, 1992, CAN J SURG, V35, P661	16	15	17	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0890-5339			J ORTHOP TRAUMA	J. Orthop. Trauma	FEB	1999	13	2					141	144		10.1097/00005131-199902000-00013			4	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	165LB	WOS:000078521300013	10052791				2021-06-18	
J	Slaughter, J; Johnstone, G; Petroski, G; Flax, J				Slaughter, J; Johnstone, G; Petroski, G; Flax, J			The usefulness of the Brief Symptom Inventory in the neuropsychological evaluation of traumatic brain injury	BRAIN INJURY			English	Article								Changes in the health care delivery system are forcing clinicians to use less timely and more cost efficient measures. In rehabilitation, more efficient measures of emotional-behavioural functioning are bring administered to patients with traumatic brain injury (TBI), including thr Brief Symptom Inventory (BSI), a 53 item short version of the Symptom Checklist-90 chat assesses nine different dimensions of emotional-behavioural functioning. Because the BSI was developed for use with psychiatric populations, research of the: measure with TBI populations is needed, The current study evaluated the utility of the BSI in a sample of 62 patients (34 male, 28 female, average age 35, average education 12 years) with TBI evaluated as outpatients at a midwestern rehabilitation hospital. Results indicated that: (1) subjects endorsed clinically elevated distress on seven of the nine subscales when compared to the nonnative sample; (2) the Obsessive-Compulsive (OC) subscale achieved the highest t-score (70.31); 3) the most frequent two-point profiles included the OC-Somatic (21%) and OC-Psychoticism (13%) subscales; and (3) the Global Symptom Index was significantly correlated with all nine subscales. II was concluded that caution must be used when administering the BSI to individuals with TBI due in a lack of a TBI standardization sample, the limited number of test items per subscale, and questionable labels for the different subscales (e.g. OC subscale items appear to br more reflective of TBI-related cognitive impairment than obsessive-compulsive traits).	Univ Missouri, Sch Med, Dept Psychiat Med & Rehabil, Columbia, MO USA	Slaughter, J (corresponding author), Dept Psychiat & Neurol, 1 Hosp Dr, Columbia, MO 65212 USA.						BURKE J M, 1990, Brain Injury, V4, P223, DOI 10.3109/02699059009026171; Burke J M, 1989, Brain Inj, V3, P35, DOI 10.3109/02699058909008071; BUTCHER JN, 1990, MMPI 2 MINNESOTA MUL, V2; DAHLSTROM WG, 1972, MMPI HDB GUIDE USE C, V2; DAHLSTROM WG, 1972, MMPI HDB GUIDE USE C, V1; DEROGATIS LR, 1982, BRIEF S INVENTORY BS; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; KAITARO T, 1995, BRAIN INJURY, V9, P713, DOI 10.3109/02699059509008227; Kaplan CP, 1998, BRAIN INJURY, V12, P199, DOI 10.1080/026990598122674; TATE DG, 1994, PARAPLEGIA, V32, P473, DOI 10.1038/sc.1994.75	10	15	15	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	1999	13	2					125	130		10.1080/026990599121782			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	167HQ	WOS:000078626800005	10079957				2021-06-18	
J	Jenkins, LW; Lu, YC; Johnston, WE; Lyeth, BG; Prough, DS				Jenkins, LW; Lu, YC; Johnston, WE; Lyeth, BG; Prough, DS			Combined therapy affects outcomes differentially after mild traumatic brain injury and secondary forebrain ischemia in rats	BRAIN RESEARCH			English	Article						hypothermia; traumatic brain injury; cerebral ischemia; hippocampus; spatial memory; excitotoxicity; rat	POSTISCHEMIC HYPOTHERMIA; NEUROBEHAVIORAL DEFICITS; BEHAVIORAL DEFICITS; CEREBRAL-ISCHEMIA; GLOBAL-ISCHEMIA; HIPPOCAMPUS; SCOPOLAMINE; MK-801; VULNERABILITY; MECHANISMS	Muscarinic and NMDA receptors contribute to post-traumatic hypersensitivity to secondary ischemia. However, the effect of these receptor antagonists an behavior and CA1 neuronal death after traumatic brain injury (TBI) with acute (1 h after TBI) forebrain ischemia has not been systematically assessed. We examined cognitive and motor dysfunction and the relationship of behavior deficits to neuronal death in this model using muscarinic and NMDA antagonists. Three behavioral groups (n = 10/group) of Wister rats were subjected to mild TBI and 6 min of forebrain ischemia imposed 1 h after TBI with 45 days survival. Motor and spatial memory performance were assessed using the rotarod task and Morris water maze. Seven additional groups (n = 6/group) were evaluated only for CA1 death after 7 days survival following sham, individual or combined injury with and without drug treatments. Rats were given 0.3 mg/kg MK-801 (M) and 1.0 mg/kg scopolamine (S) alone or combined (M-S) before or 45 min after TBI. Rotarod performance was tested at days 1-5 and maze performance on days 11-15 and 40-44 after M-S treatment. The 7-day studies showed M-S treatment(p < 0.01) reduced CA1 neuronal death better than either S or M alone. Behavioral groups had inadvertent post-ischemic hypothermia that decreased CA1 death and likely influenced behavioral morbidity. M-S given before TBI (p < 0.01) decreased memory deficits on day 15, while M-S treatment given after TBI was ineffective. Unexpectedly, M-S treatment before or after TBI produced transient motor deficits (p < 0.01). Memory improvement occurred independent of CA1 death. (C) 1999 Elsevier Science B.V. All rights reserved.	Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77550 USA; Second Mil Med Univ, Chang Zheng Hosp, Dept Neurosurg, Shanghai, Peoples R China; Univ Calif Davis, Dept Neurosurg, Sacramento, CA 95817 USA	Jenkins, LW (corresponding author), Univ Pittsburgh, Dept Neurosurg, 200 Lothrop St,Suite B-400, Pittsburgh, PA 15260 USA.		Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X; Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035365] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35365] Funding Source: Medline		ALBERS GW, 1990, CLIN NEUROPHARMACOL, V13, P177, DOI 10.1097/00002826-199006000-00001; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; BOTHE HW, 1986, STROKE, V17, P1160, DOI 10.1161/01.STR.17.6.1160; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; DIETRICH WD, 1995, J CEREBR BLOOD F MET, V15, P960, DOI 10.1038/jcbfm.1995.122; Dietrich WD, 1996, ADV NEUROL, V71, P177; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; GREEN EJ, 1995, BRAIN RES, V702, P145, DOI 10.1016/0006-8993(95)01034-1; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hamm RJ, 1994, NEUROBIOLOGY CENTRAL, V1, P86; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1991, J NEUROTRAUM, V8, pS173; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; JASPERS RMA, 1990, NEUROSCI LETT, V117, P149, DOI 10.1016/0304-3940(90)90135-V; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1989, CONT ISSUES NEUROLOG, V1, P47; Levin H.S., 1996, TRAUMATIC BRAIN INJU, P105; LYDEN PD, 1992, EXP NEUROL, V116, P122, DOI 10.1016/0014-4886(92)90160-R; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marion DW, 1996, CRIT CARE MED, V24, pS81; MILLER JD, 1982, CLIN NEUR, V29, P162; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MORRIS RGM, 1981, BEHAV BRAIN RES, V2, P266, DOI 10.1016/0166-4328(81)90088-7; Seifert W, 1983, NEUROBIOLOGY HIPPOCA, P405; SHUAIB A, 1993, NEUROSCIENCE, V56, P915, DOI 10.1016/0306-4522(93)90137-5	40	15	16	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 30	1999	817	1-2					132	144		10.1016/S0006-8993(98)01237-2			13	Neurosciences	Neurosciences & Neurology	159XZ	WOS:000078201800016	9889350				2021-06-18	
J	Newcombe, R; Merry, G				Newcombe, R; Merry, G			The management of acute neurotrauma in rural and remote locations - A set of guidelines for the care of head and spinal injuries	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						head injury; spinal injury; neurotrauma; trauma management		The Neurosurgical Society of Australasia through its Trauma Committee has a long involvement in the problem of neurotrauma. The management of acute neurotrauma in rural and remote locations is of particular interest and is part of a general policy which includes education, prevention, organization of an integrated neurotrauma system and support for the Early Management of Severe Trauma (EMST) programme instituted by the Royal Australasian College of Surgeons. The management of acute neurotrauma requires a consultative approach especially in the multiple injured patient and where transfer or retrieval is necessary. As acute neurotrauma may present to general practitioners, rural surgeons or emergency departments in country hospitals, a set of guidelines has been developed to assist in the early management of acute neurotrauma. These guidelines have been previously published by the Neurosurgical Society of Australasia and the Royal Australasian College of Surgeons. They have been extensively used since 1992 by rural health and distance education groups, Royal Flying Doctor Service Emergency Management of Severe Trauma Course of the Royal Australasian College of Surgeons and by overseas education programs for neurotrauma care. This revision updates the guidelines and makes them accessible through the Journal. Reprints are available for practitioners in rural and remote settings, trauma course participants and others.	Neurosurg Soc Australasia, Trauma Comm, Deakin, ACT 2600, Australia; Royal Australasian Coll Surg, Trauma Comm, Deakin, ACT 2600, Australia	Newcombe, R (corresponding author), Neurosurg Soc Australasia, Trauma Comm, Suite A1,161 Strickland Crescent, Deakin, ACT 2600, Australia.			Fuller, John/0000-0002-9825-9103				0	15	15	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	JAN	1999	6	1					85	93		10.1016/S0967-5868(99)90619-7			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	169QZ	WOS:000078761200026					2021-06-18	
J	Satish, U; Streufert, S; Eslinger, PJ				Satish, U; Streufert, S; Eslinger, PJ			Complex decision making after orbitofrontal damage: Neuropsychological and strategic management simulation assessment	NEUROCASE			English	Article						orbitofrontal damage; executive function; computer simulation assessment	MINOR HEAD-INJURY; TRAUMATIC BRAIN INJURY; FRONTAL-LOBE; BEHAVIORAL COMPLEXITY; PREFRONTAL CORTEX; MILD CONCUSSION; SEQUELAE; SYMPTOMS; RECOVERY; CONSEQUENCES	Neuropsychological tests have considerable value in identifying deficits following brain injury, but may not adequately measure certain residual problems which limit adaptive functioning after recovery. This paper reports the case of a 48-year-old woman who suffered right orbitofrontal damage after traumatic brain injury and experienced marked difficulties handling real-world (e.g, work-related) challenges despite very good recovery. Neuropsychological measurement indicated mild difficulties in select measures of executive functions, but no severe deficiencies were encountered. Therefore, further study was undertaken with a validated, computer-scored Strategic Management Simulation technique to assess how multiple, interactive aspects of executive competency might have been affected. Results revealed significantly impaired scores on several decision-making parameters, including initiative, information utilization, breadth of strategy, opportunistic actions and aspects of emergency handling which we attributed to the effects of orbitofrontal damage. Contextual or single-task problems were handled considerably better. The data suggest that the Strategic Management Simulation may provide a particularly valuable paradigm for assessing executive function deficits as a complement to neuropsychological measurement, although further studies are needed to establish its reliability and validity in relationship to neuropsychological impairments. Refined analysis of altered decision-making competencies after orbitofrontal damage may suggest new avenues for rehabilitative intervention.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Behav Sci, Hershey, PA 17033 USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Med,Sect Neurol, Hershey, PA 17033 USA		usxs4@psu.edu					ALEXANDER G, 1990, PROGR BRAIN RES, V85; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BARBAS H, 1995, NEUROSCI BIOBEHAV R, V19, P499, DOI 10.1016/0149-7634(94)00053-4; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; BIJUR PE, 1990, PEDIATRICS, V86, P337; BLEIBERG J, 1991, P MILD HEAD INJ C CO; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; BREUER K, 1996, CORPORATE TRAINING E; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; CLARK E, 1992, CURR PSYCHOL RES REV, V11, P21, DOI 10.1007/BF02686825; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; DAMASIO AR, 1990, FRONTAL LOBE FUNCTIO, P217; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; Denker P., 1944, NY STATE J MED, V44, P379; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1989, MILD HEAD INJURY, P229; Eslinger Paul J., 1996, P415; ESLINGER PJ, 1993, NEUROPSYCHOLOGIA, V31, P17, DOI 10.1016/0028-3932(93)90077-D; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; ESLINGER PJ, 1991, NEUROLOGY, V41, P450, DOI 10.1212/WNL.41.3.450; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; GENTILINI M, 1989, MILD HEAD INJURY, P163; Goldstein F. C., 1995, CLIN NEUROPSYCHOL, P49, DOI [10.1007/978-1-4757-9709-1_3, DOI 10.1007/978-1-4757-9709-1_3]; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; GRAFMAN J, 1986, BRAIN, V109, P1127, DOI 10.1093/brain/109.6.1127; GRONWALL D, 1974, LANCET, V2, P605; HARLOW JM, 1868, RECOVERY SEVERE INJU; Harlow JM, 1848, BOSTON MED SURG J, V39, P389, DOI DOI 10.1056/NEJM184812130392001; HARRINGTON DE, 1993, ARCH PHYS MED REHAB, V74, P579, DOI 10.1016/0003-9993(93)90155-4; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Jones R. D., 1996, P375; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; LEININGER B, 1992, REHABILITATION POST, P169; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1993, CURR OPIN NEUROL, V6, P841, DOI 10.1097/00019052-199312000-00003; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; NEAFSEY EJ, 1990, PROG BRAIN RES, V85, P147; PACKARD RC, 1993, HEADACHE, V33, P365, DOI 10.1111/j.1526-4610.1993.hed3307365.x; Price JL, 1996, PROG BRAIN RES, V107, P523; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Satish U, 1997, J APPL SOC PSYCHOL, V27, P2047, DOI 10.1111/j.1559-1816.1997.tb01640.x; Satish U, 1997, J APPL SOC PSYCHOL, V27, P2117, DOI 10.1111/j.1559-1816.1997.tb01643.x; Streufert S, 1997, J APPL SOC PSYCHOL, V27, P2068, DOI 10.1111/j.1559-1816.1997.tb01641.x; Streufert S, 1997, J APPL SOC PSYCHOL, V27, P2122, DOI 10.1111/j.1559-1816.1997.tb01644.x; Streufert S., 1988, Computers in Human Behaviour, V4, P77, DOI 10.1016/0747-5632(88)90034-9; STREUFERT S, 1985, ADV ENVIRON PSYCHOL, V5, P99; Streufert S., 1978, BEHAV COMPLEX ENV; STUSS DT, 1995, NEUROLOGY, V45, P1251, DOI 10.1212/WNL.45.7.1251; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; Tiller SG, 1998, PERCEPT MOTOR SKILL, V86, P1240, DOI 10.2466/pms.1998.86.3c.1240; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437	60	15	15	0	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1355-4794	1465-3656		NEUROCASE	Neurocase		1999	5	4					355	364		10.1093/neucas/5.4.355			10	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	232XQ	WOS:000082395600009					2021-06-18	
J	Newman, LM; Diekema, DS; Shubkin, CD; Klein, EJ; Quan, L				Newman, LM; Diekema, DS; Shubkin, CD; Klein, EJ; Quan, L			Pediatric wilderness recreational deaths in western Washington State	ANNALS OF EMERGENCY MEDICINE			English	Article							INJURIES; EPIDEMIOLOGY; TREKKERS; SPORTS	Study objective: To determine the causes and characteristics of pediatric recreational wilderness deaths. Methods: All deaths of children between 12 months and 20 years of age involving a wilderness recreational activity in 5 western Washington counties between 1987 and 1996 were identified by medical examiners' logs. Univariate analysis was used to examine variables such as age, gender, activity, mechanism of injury, adult presence, blood alcohol level, safety equipment, and mode of evacuation. Results: Of 40 cases meeting inclusion criteria, 90% involved male subjects and 83% of victims were 13 to 19 years old. Hiking (33%), swimming (20%), and river rafting (10%) were the most common activities. Death was most often by drowning (55%) or closed head injury (26%). No victim was alone. All children younger than 10 years of age were accompanied by an adult, in contrast to only 26% of individuals 10 years or older. Only 4 victims had drugs or alcohol in their system. Na victim wore a personal flotation device or helmet, and only 5% had foul weather gear. Although nearly one third of victims were transported by airlift, more than half of the victims were dead at the scene. Conclusion: Males and teenagers were the 2 major risk groups for recreational wilderness deaths. Traditional activities such as hiking and swimming were the most common causes of death. Children younger than 10 years died despite the presence of an adult, whereas teenagers were usually with groups of peers. The majority of victims were not prepared for adverse events with basic safety equipment.	Univ Washington, Dept Family Med, Seattle, WA 98195 USA	Diekema, DS (corresponding author), Childrens Hosp & Reg Med Ctr, Dept Emergency Serv, Mailstop CH-04,4800 Sand Point Way NE,POB 5371, Seattle, WA 98105 USA.						BIJUR PE, 1995, ARCH PEDIAT ADOL MED, V149, P1009, DOI 10.1001/archpedi.1995.02170220075010; DIETZ PE, 1974, AM J PUBLIC HEALTH, V64, P303, DOI 10.2105/AJPH.64.4.303; GENTILE DA, 1992, ANN EMERG MED, V21, P853, DOI 10.1016/S0196-0644(05)81034-0; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P32; KRAUS JF, 1984, ANNU REV PUBL HEALTH, V5, P163; *NAT SAF COUNC, 1995, ACC FACTS, P118; *NAT SPORT GOOD AS, 1988, SPORTS PART 1988; *NAT SPORT GOOD AS, 1987, SPORT PART 1987; ORLOWSKI JP, 1987, PEDIATR ANN, V17, P128; Plueckhahn V D, 1967, Med J Aust, V2, P118; RENNIE D, 1989, JAMA-J AM MED ASSOC, V261, P1045, DOI 10.1001/jama.261.7.1045; SCHUSSMAN LC, 1990, J WILDERNESS MED, V1, P235, DOI 10.1580/0953-9859-1.4.235; SHLIM DR, 1989, JAMA-J AM MED ASSOC, V261, P1017, DOI 10.1001/jama.261.7.1017; SPRING I, 1988, 100 HIKES WASHINGTON, P20; *US CENS BUR, 1990 US CENS DAT; WINTEMUTE GJ, 1987, AM J PUBLIC HEALTH, V77, P830, DOI 10.2105/AJPH.77.7.830	16	15	15	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	DEC	1998	32	6					687	692		10.1016/S0196-0644(98)70068-X			6	Emergency Medicine	Emergency Medicine	149DW	WOS:000077590700008	9832665				2021-06-18	
J	Shen, PJ; Gundlach, AL				Shen, PJ; Gundlach, AL			Differential spatiotemporal alterations in adrenoceptor mRNAs and binding sites in cerebral cortex following spreading depression: Selective and prolonged up-regulation of alpha(1B)-adrenoceptors	EXPERIMENTAL NEUROLOGY			English	Article						adrenergic receptors; receptor gene regulation; cerebral cortex; spreading depression; in situ hybridization histochemistry; autoradiography	ALPHA-ADRENERGIC RECEPTOR; MESSENGER-RNA EXPRESSION; LOCUS-COERULEUS NEURONS; TRAUMATIC BRAIN INJURY; IMMEDIATE-EARLY GENE; ADULT-RAT BRAIN; BETA-2-ADRENERGIC RECEPTORS; NORADRENALINE INNERVATION; MOLECULAR-CLONING; CORTICAL-NEURONS	Noradrenaline, an important transmitter in the CNS, is involved in cerebral plasticity and functional recovery after injury. Experimental brain injury, including KCl application onto the brain surface, induces a slow-moving cortical depolarization/depression wave called cortical spreading depression (CSD). Interestingly, CSD does not produce neuronal damage but can protect cortical. neurons against subsequent neurotoxic insults, although the mechanisms involved are unknown. This study examined the status of alpha- and beta-adrenoceptors (ARs) in cerebral cortex following CSD. Anesthetized rats had unilateral CSD induced by a 10-min topical application of KCl to the frontoparietal cortex and were killed at various times thereafter. Levels of alpha(1)-, alpha(2)-, beta(1)-, and beta(2)-AR mRNA and binding were examined using in situ hybridization histochemistry and radioligand autoradiography. Levels of alpha(1b)-AR mRNA in the affected neocortex were significantly increased by 20-40% at 1, 2, and 7 days (P less than or equal to 0.01) compared with contralateral levels, but were ndt sig nificantly above control values at 2 and 4 weeks after CSD induction. Cortical alpha(1B)-AR binding sites were also increased by 45-65% 1 and 2 weeks (P less than or equal to 0.01) after CSD in a similar, but delayed, profile to alpha(1b)-AR mRNA. CSD rapidly increased beta(1)-AR mRNA by 45% at 1 h (P less than or equal to 0.01) and produced a delayed decrease of 25% in alpha(2a)-AR mRNA at 2 days and 1 week (P less than or equal to 0.05), but had no effect on corresponding levels of binding sites. In contrast, CSD had no effect on the remaining AR-subtype mRNAs or binding levels in neocortex under identical conditions. These results reveal a long-term up-regulation of alpha(1B)-ARs induced by an acute cortical stimulation/depression. Subtype-selective responses of ARs to CSD reflect an important differential regulation of expression of each receptor in vivo and suggest that alpha(1B)-ARs are particularly likely to be involved in cortical adaptive responses to physical injury at both local and distant locations. (C) 1998 Academic Press.	Univ Melbourne, Austin & Repatriat Med Ctr, Dept Med, Clin Pharmacol & Therapeut Unit, Heidelberg, Vic 3084, Australia	Gundlach, AL (corresponding author), Univ Melbourne, Austin & Repatriat Med Ctr, Dept Med, Clin Pharmacol & Therapeut Unit, Heidelberg, Vic 3084, Australia.	agund@austin.unimelb.edu.au	Gundlach, Andrew/X-6421-2018	Gundlach, Andrew/0000-0002-6066-9692			Arabia AM, 1998, MOL BRAIN RES, V61, P195, DOI 10.1016/S0169-328X(98)00189-2; ARABIA AM, 1996, P AUST SOC CLIN EXP, V3, P84; Arakawa S, 1997, NEUROSCIENCE, V78, P1147, DOI 10.1016/S0306-4522(96)00679-3; ASTONJONES G, 1991, PROG BRAIN RES, V88, P501; AUDET MA, 1988, J COMP NEUROL, V274, P307, DOI 10.1002/cne.902740302; Bickler PE, 1996, NEUROPHARMACOLOGY, V35, P679, DOI 10.1016/S0028-3908(96)00030-5; BING GY, 1991, MOL BRAIN RES, V11, P43, DOI 10.1016/0169-328X(91)90019-T; BLENDY JA, 1991, J NEUROCHEM, V57, P1548, DOI 10.1111/j.1471-4159.1991.tb06350.x; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BUCKLAND PR, 1990, NUCLEIC ACIDS RES, V18, P682, DOI 10.1093/nar/18.3.682; Caggiano AO, 1996, J COMP NEUROL, V376, P447, DOI 10.1002/(SICI)1096-9861(19961216)376:3<447::AID-CNE7>3.0.CO;2-2; CARTER DA, 1993, ENDOCRINOLOGY, V133, P2263, DOI 10.1210/en.133.5.2263; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; Day HEW, 1997, J CHEM NEUROANAT, V13, P115, DOI 10.1016/S0891-0618(97)00042-2; DIETRICH WD, 1994, J CEREBR BLOOD F MET, V14, P20, DOI 10.1038/jcbfm.1994.4; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; DYVE S, 1995, SYNAPSE, V19, P88, DOI 10.1002/syn.890190204; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; Ferry B, 1997, EUR J NEUROSCI, V9, P1356, DOI 10.1111/j.1460-9568.1997.tb01490.x; FLORDELLIS CS, 1991, P NATL ACAD SCI USA, V88, P1019, DOI 10.1073/pnas.88.3.1019; FOLLESA P, 1993, MOL PHARMACOL, V43, P132; GAO B, 1995, J BIOL CHEM, V270, P5614, DOI 10.1074/jbc.270.10.5614; GROSS RA, 1982, NEUROPHARMACOLOGY, V21, P655, DOI 10.1016/0028-3908(82)90008-9; GUNDLACH AL, 1995, BRAIN RES, V672, P214, DOI 10.1016/0006-8993(94)01338-I; GUSTAFSON I, 1990, J CEREBR BLOOD F MET, V10, P885, DOI 10.1038/jcbfm.1990.145; HADCOCK JR, 1993, J NEUROCHEM, V60, P1, DOI 10.1111/j.1471-4159.1993.tb05816.x; HANSEN AJ, 1980, ACTA PHYSIOL SCAND, V109, P1, DOI 10.1111/j.1748-1716.1980.tb06557.x; HARLEY C, 1991, PROG BRAIN RES, V88, P307; Hildebrand B, 1996, N-S ARCH PHARMACOL, V354, P404, DOI 10.1007/BF00168429; HUDSON A L, 1992, Molecular Neuropharmacology, V1, P219; INOUE M, 1991, J CEREBR BLOOD F MET, V11, P242, DOI 10.1038/jcbfm.1991.56; JACOBS O, 1994, NEUROSCIENCE, V59, P827, DOI 10.1016/0306-4522(94)90287-9; KAMISAKI Y, 1992, EUR J PHARMACOL, V217, P57, DOI 10.1016/0014-2999(92)90511-2; Karkanias GB, 1996, J NEUROENDOCRINOL, V8, P449, DOI 10.1046/j.1365-2826.1996.04716.x; KASAMATSU T, 1991, PROG BRAIN RES, V88, P599; KOBAYASHI S, 1995, J CEREBR BLOOD F MET, V15, P721, DOI 10.1038/jcbfm.1995.92; KOKAIA Z, 1993, MOL BRAIN RES, V19, P277, DOI 10.1016/0169-328X(93)90126-A; KRAIG RP, 1991, J NEUROSCI, V11, P2187; KUHAR MJ, 1990, METHODS NEUROTRANSMI, P177; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LAURITZEN M, 1988, BRAIN RES, V475, P317, DOI 10.1016/0006-8993(88)90620-8; LAZ TM, 1994, MOL PHARMACOL, V46, P414; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; LEVIN BE, 1994, RESTOR NEUROL NEUROS, V7, P5, DOI 10.3233/RNN-1994-7102; LEW R, 1985, BRIT J PHARMACOL, V85, P341, DOI 10.1111/j.1476-5381.1985.tb08867.x; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; MACHIDA CA, 1990, J BIOL CHEM, V265, P12960; MANTYH PW, 1995, J NEUROSCI, V15, P152; MARRANNES R, 1988, BRAIN RES, V457, P226, DOI 10.1016/0006-8993(88)90690-7; MASON ST, 1979, J PHARM PHARMACOL, V31, P209, DOI 10.1111/j.2042-7158.1979.tb13480.x; MATSUSHIMA K, 1995, STROKE, V26, P1047, DOI 10.1161/01.STR.26.6.1047; Matsushima K, 1996, J CEREBR BLOOD F MET, V16, P221, DOI 10.1097/00004647-199603000-00006; MCCUNE SK, 1993, NEUROSCIENCE, V57, P143, DOI 10.1016/0306-4522(93)90116-W; MORRIS ER, 1986, GUMS STABILIZERS FOO, V3, P3; NEDERGAARD M, 1988, BRAIN RES, V449, P395, DOI 10.1016/0006-8993(88)91062-1; NICHOLAS AP, 1993, NEUROSCIENCE, V56, P1023, DOI 10.1016/0306-4522(93)90148-9; Nicholas AP, 1996, TRENDS PHARMACOL SCI, V17, P245, DOI 10.1016/0165-6147(96)10022-5; Obrenovitch TP, 1996, BRIT J PHARMACOL, V117, P931, DOI 10.1111/j.1476-5381.1996.tb15283.x; OLENIK C, 1991, MOL BRAIN RES, V10, P259, DOI 10.1016/0169-328X(91)90069-A; OLESKEVICH S, 1989, J NEUROSCI, V9, P3803; OSHEA BD, 1993, J NEUROENDOCRINOL, V5, P697, DOI 10.1111/j.1365-2826.1993.tb00542.x; OSHEA RD, 1994, IN SITU HYBRIDIZATIO, P57; PAVLASEK J, 1993, BRAIN RES, V628, P145, DOI 10.1016/0006-8993(93)90949-N; PETITTI N, 1992, J NEUROSCI, V12, P3869; PIERIBONE VA, 1994, J NEUROSCI, V14, P4252; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; RAINBOW TC, 1984, P NATL ACAD SCI-BIOL, V81, P1585, DOI 10.1073/pnas.81.5.1585; Reutter MA, 1997, J NEUROCHEM, V68, P47; Riekkinen M, 1996, EUR J PHARMACOL, V300, P9, DOI 10.1016/0014-2999(95)00842-X; ROBINSON JP, 1989, J NEUROCHEM, V52, P690, DOI 10.1111/j.1471-4159.1989.tb02510.x; SEGUELA P, 1990, NEUROSCIENCE, V35, P249, DOI 10.1016/0306-4522(90)90079-J; Shen P.-J., 1996, Society for Neuroscience Abstracts, V22, P1768; Shen PJ, 1998, EUR J NEUROSCI, V10, P2217, DOI 10.1046/j.1460-9568.1998.00231.x; SHEN PJ, 1995, MOL BRAIN RES, V28, P222, DOI 10.1016/0169-328X(94)00208-V; SHEN PJ, 1997, P AUST NEUROSCI SOC, V8, P96; SHINOHARA M, 1979, SCIENCE, V203, P188, DOI 10.1126/science.758688; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; STEINDLER DA, 1981, BRAIN RES, V223, P367, DOI 10.1016/0006-8993(81)91149-5; STOROZHUK VM, 1995, NEUROSCIENCE, V68, P315, DOI 10.1016/0306-4522(95)00131-2; SUTIN J, 1992, BRAIN RES BULL, V29, P277, DOI 10.1016/0361-9230(92)90057-5; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; UNGERSTEDT U, 1971, ACTA PHYSIOL SCAND, P1; UNNERSTALL JR, 1985, PHARMACOL BIOCHEM BE, V22, P859, DOI 10.1016/0091-3057(85)90538-6; VOIGT MM, 1990, NUCLEIC ACIDS RES, V18, P1053, DOI 10.1093/nar/18.4.1053; Williams AM, 1997, NEUROSCIENCE, V76, P901; WinzerSerhan UH, 1997, NEUROSCIENCE, V76, P241; WinzerSerhan UH, 1997, NEUROSCIENCE, V76, P261; WISDEN W, 1994, IN SITU HYBRIDIZATIO, P9	91	15	15	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	DEC	1998	154	2					612	627		10.1006/exnr.1998.6915			16	Neurosciences	Neurosciences & Neurology	157TW	WOS:000078078600031	9878196				2021-06-18	
J	Green, ML; Foster, MA; Morris, MK; Muir, JJ; Morris, RD				Green, ML; Foster, MA; Morris, MK; Muir, JJ; Morris, RD			Parent assessment of psychological and behavioral functioning following pediatric acquired brain injury	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						assessment; validity; pediatric; psychopathology; acquired brain injury; parent-report; CBCL; PIC-R; DICA-R; VABS	ATTENTION-DEFICIT DISORDER; CLOSED-HEAD-INJURY; PSYCHIATRIC DIAGNOSES; STRUCTURED INTERVIEWS; CHILDREN; DEPRESSION; CHECKLIST; HYPERACTIVITY; ADOLESCENTS; RELIABILITY	Objective: Compare the measured prevalence rate of psychopathology and behavior disorders in 29 children with acquired brain injuries using four parent-report instruments. Method: Two questionnaires, the Child Behavior Checklist (CBCL) and the Personality Inventory for Children (PIC-R) and two interview measures, the Diagnostic Interview for Children and Adolescents (DICA-R) and the Vineland Adaptive Behavior Scales (VABS), were completed following injury or diagnosis. Results: The DICA-R identified the highest prevalence of anxiety disorders and acting-out behaviors, whereas the CBCL identified the lowest prevalence. Opposite results were found within the domain of attentional problems. Interview measures were more concordant for global psychological impairment than were questionnaires. Discussion: Discordant findings across measures are discussed in terms of type of disorder, classification model, response format, item characteristics, and scaling.	Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA	Green, ML (corresponding author), Georgia State Univ, Dept Psychol, Univ Plaza, Atlanta, GA 30303 USA.	mlgreen@mindspring.com			NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R18MH047958] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH47958] Funding Source: Medline		Achenbach TM, 1983, MANUAL CHILD BEHAV C; BIEDERMAN J, 1993, J CHILD PSYCHOL PSYC, V34, P1241, DOI 10.1111/j.1469-7610.1993.tb01785.x; BOYLE MH, 1993, J ABNORM CHILD PSYCH, V21, P663, DOI 10.1007/BF00916449; BRESLAU N, 1985, J AM ACAD CHILD PSY, V24, P87, DOI 10.1016/S0002-7138(09)60415-5; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Butler K, 1997, CHILD NEUROPSYCHOL, V3, P98, DOI 10.1080/09297049708401371; CARLSON GA, 1987, J AM ACAD CHILD PSY, V26, P645, DOI 10.1097/00004583-198709000-00006; CLARK E, 1987, J PSYCHOEDUCATIONAL, V5, P99; COHEN MJ, 1994, J EMOT BEHAV DISORD, V2, P31, DOI 10.1177/106342669400200104; Cole DA, 1997, J CONSULT CLIN PSYCH, V65, P110, DOI 10.1037/0022-006X.65.1.110; CRAIGHEAD WE, 1995, PSYCHOL ASSESSMENT, V7, P171, DOI 10.1037/1040-3590.7.2.171; Derogatis L, 1992, SCL 90 R ADM SCORING; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; DYKENS EM, 1992, J AM ACAD CHILD PSY, V31, P1131, DOI 10.1097/00004583-199211000-00023; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; HARTMANN DP, 1977, J APPL BEHAV ANAL, V10, P103, DOI 10.1901/jaba.1977.10-103; HEPPERLIN CM, 1990, J AFFECT DISORDERS, V18, P105, DOI 10.1016/0165-0327(90)90066-H; HERJANIC B, 1982, J ABNORM CHILD PSYCH, V10, P307, DOI 10.1007/BF00912324; HODGES K, 1993, J CHILD PSYCHOL PSYC, V34, P49, DOI 10.1111/j.1469-7610.1993.tb00967.x; HODGES K, 1990, PSYCHOL ASSESSMENT J, V2, P489, DOI DOI 10.1037/1040-3590.2.4.489; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; HOOPER SR, 1995, ANXIETY DISORDERS CH; JENSEN PS, 1993, AM J PSYCHIAT, V150, P1203; Jensen PS, 1996, J ABNORM CHILD PSYCH, V24, P151, DOI 10.1007/BF01441482; Kamphaus R.W., 1996, CLIN ASSESSMENT CHIL; KASHANI JH, 1985, J AM ACAD CHILD PSY, V24, P437, DOI 10.1016/S0002-7138(09)60561-6; Kazdin AE, 1995, CONDUCT DISORDERS CH; KLINE RB, 1988, CAN J BEHAV SCI, V20, P251, DOI 10.1037/h0079929; KRONENBERG Y, 1988, ACTA PSYCHIAT SCAND, V77, P194, DOI 10.1111/j.1600-0447.1988.tb05100.x; LACHAR D, 1986, ASSESSMENT CHILD ADO; LACHAR D, 1979, ACTUARIAL ASSESSMENT; LEVIN HS, 1995, TRAUMATIC HEAD INJUR; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; MCCUBBIN HI, 1983, FAMILY ASSESSMENT IN; PEARSON DA, 1994, J SCHOOL PSYCHOL, V32, P33, DOI 10.1016/0022-4405(94)90027-2; PERRIN EC, 1991, J PEDIATR PSYCHOL, V16, P411, DOI 10.1093/jpepsy/16.4.411; PRENDERGAST M, 1988, J CHILD PSYCHOL PSYC, V29, P289, DOI 10.1111/j.1469-7610.1988.tb00717.x; RABINOWITZ J, 1993, J MIND BEHAV, V14, P297; REICH W, 1987, J ABNORM CHILD PSYCH, V15, P601, DOI 10.1007/BF00917244; Reich W., 1988, REVISED VERSION DIAG; Reynolds W. M., 1994, HDB DEPRESSION CHILD; RIS MD, 1994, J CLIN EXP NEUROPSYC, V16, P21, DOI 10.1080/01688639408402615; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Sparrow S., 1984, VINELAND ADAPTIVE BE; STEINGARD R, 1992, J AM ACAD CHILD PSY, V31, P449, DOI 10.1097/00004583-199205000-00010; SYLVESTER CE, 1987, J AM ACAD CHILD PSY, V26, P668, DOI 10.1097/00004583-198709000-00010; WILSON FE, 1983, BEHAV ASSESS, V5, P15; WIRT RD, 1977, MULTIDIMENSIONAL DES	49	15	15	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693			J PEDIATR PSYCHOL	J. Pediatr. Psychol.	OCT	1998	23	5					289	299		10.1093/jpepsy/23.5.289			11	Psychology, Developmental	Psychology	164XX	WOS:000078489800002	9782677	Bronze, Green Published			2021-06-18	
J	Ruchholtz, S; Waydhas, C; Muller, A; Lewan, UM; Nast-Kolb, D; Euler, E; Pfeiffer, KJ; Schweiberer, L				Ruchholtz, S; Waydhas, C; Muller, A; Lewan, UM; Nast-Kolb, D; Euler, E; Pfeiffer, KJ; Schweiberer, L			Percutaneous computed tomographic-controlled ventriculostomy in severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	11th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 14-17, 1998	SANIBEL, FLORIDA	E Assoc Surg Trauma		percutaneous computed tomographic-controlled; ventriculostomy; intracranial pressure monitoring; severe traumatic brain injury	SEVERE HEAD-INJURIES; INTRACRANIAL-PRESSURE; NEEDLE TREPHINATION; FIBEROPTIC DEVICE; TISSUE PRESSURE; EXPERIENCE	Objective: Percutaneous computed tomographic (CT)-controlled ventriculostomy (PCV) was introduced for the monitoring of intracranial pressure in patients with severe traumatic brain injury who did not require simultaneous decompressive trepanation, Methods: PCV (n = 14) was compared with conventional burr hole ventriculostomy (n = 13) based on prospectively collected data. Results: PCV proved to be a successful technique in all cases and also when a burr hole ventriculostomy was impossible previously. There were no complications. In burr hole ventriculostomy, there were one unsuccessful insertion and one catheter contamination, The main advantage of PCV over burr hole ventriculostomy was a significant (p < 0.05) reduction in the time required to perform the procedure, In ventriculostomy directly after the initial evaluation in the emergency department, the operation time was reduced from 45 +/- 11 to 22 +/- 14 minutes. The interval between cranial computed tomography and start of operation was reduced from 78 +/- 38 to 33 +/- 12 minutes, and between initial cranial computed tomography and intensive care unit admittance, from 138 +/- 37 to 73 +/- 28 minutes. For patients requiring ventriculostomy while being treated in the intensive care unit, the duration of the procedure (i.e., absence from the intensive care unit) was able to be reduced from 111 +/- 24 to 81 +/- 21 minutes. Conclusion: Distinct time savings are the major advantages of PCV, allowing exact catheter positioning even with very narrow ventricles.	Univ Munich, Klinikum Innenstadt, Dept Surg, D-8000 Munich, Germany; Univ Munich, Klinikum Innenstadt, Dept Radiol, D-8000 Munich, Germany; Univ Munich, Klinikum Grosshadern, Dept Neurosurg, D-8000 Munich, Germany	Ruchholtz, S (corresponding author), Klinikum Univ Essen, Dept Traumatol, Hufelandstr 55, D-45147 Essen, Germany.						BARDENHEUE M, 1994, UNFALLCHIRURG, V97, P230; BECKER DP, 1977, J NEUROSURG, V47, P492; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; Burton C, 1965, J Trauma, V5, P643, DOI 10.1097/00005373-196509000-00008; CHAMBERS IR, 1993, NEUROSURGERY, V33, P866; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GAHJAR JB, 1993, ADV NEUROSURG, V21, P173; GAMBARDELLA G, 1992, NEUROSURGERY, V31, P918, DOI 10.1227/00006123-199211000-00014; GILSBACH J, 1988, NEUROCHIRURGIA, V31, P114; GLISBACH J, 1979, NEUROCHIRURGIA, V21, P128; GOPINATH SP, 1995, NEUROSURGERY, V36, P1137, DOI 10.1227/00006123-199506000-00011; HALLOWAY KL, 1996, J NEUROSURG, V85, P419; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KANTER RK, 1985, CRIT CARE MED, V13, P837, DOI 10.1097/00003246-198510000-00012; MAHONEY BD, 1981, NEUROSURGERY, V8, P551, DOI 10.1227/00006123-198105000-00006; MARMAROU A, 1991, J NEUROSURG, V75, P159; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; MAYALL CG, 1984, NEW ENGL J MED, V310, P553; MEYER B, 1994, ACTA NEUROCHIR, V127, P232, DOI 10.1007/BF01808772; MORLINGANE JR, 1980, ACTA NEUROCHIR WIEN, V54, P181; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NEGRON RA, 1975, J NEUROSURG, V42, P609, DOI 10.3171/jns.1975.42.5.0609; NORTH B, 1986, NEUROSURGERY, V18, P730, DOI 10.1227/00006123-198606000-00009; OSTRUP RC, 1987, J NEUROSURG, V67, P206, DOI 10.3171/jns.1987.67.2.0206; PARAMORE CG, 1994, ACTA NEUROCHIR, V127, P79, DOI 10.1007/BF01808552; PIEK J, 1990, INTENS CARE MED, V16, P184, DOI 10.1007/BF01724800; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SAUL TG, 1982, J NEUROSURG, V56, P798; SMITH RW, 1976, J NEUROSURG, V44, P567, DOI 10.3171/jns.1976.44.5.0567; Sundbarg G, 1988, Br J Neurosurg, V2, P485, DOI 10.3109/02688698809029603; ZENTNER J, 1995, NEUROSURG REV, V18, P31, DOI 10.1007/BF00416475	32	15	15	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	1998	45	3					505	511		10.1097/00005373-199809000-00013			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	120ZG	WOS:000075987300019	9751541				2021-06-18	
J	Scheibel, RS; Levin, HS; Clifton, GL				Scheibel, RS; Levin, HS; Clifton, GL			Completion rates and feasibility of outcome measures: Experience in a multicenter clinical trial of systemic hypothermia for severe head injury	JOURNAL OF NEUROTRAUMA			English	Article						completion rates; outcome; head injury; clinical trial; hypothermia	PRACTICAL SCALE; COMA; DISABILITY	The National Acute Brain Injury Study: Hypothermia (NABIS:H) is an ongoing multicenter trial of systemic hypothermia for the treatment of severe head injury. Follow-up rates for the study's 3- and 6-month outcome assessments have been maintained at high levels by establishing close contact with family members, by reimbursing cost of travel, and by sending examiners to the subject's location whenever necessary. Two years into the study, global disability data (e.g., Glasgow Outcome Scale) have been obtained on 86% of patients due for 3-month assessment (n = 131) and for all subjects due at 6 months (n = 100), Over half of the patients have completed neuropsychological testing with high reliability ratings, These preliminary findings suggest that the procedures used to document data quality and increase follow-up and completion rates are being successful.	Baylor Coll Med, PM&R Res Off, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Univ Texas, Houston Med Sch, Dept Neurosurg, Houston, TX USA	Levin, HS (corresponding author), Baylor Coll Med, PM&R Res Off, Dept Phys Med & Rehabil, 333 Moursund Ave,Rm A205, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS032786] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-32786] Funding Source: Medline		Benton AL, 1978, MULTILINGUAL APHASIA; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; FOULKES MA, 1991, J NEUROSURG, V75, pS1, DOI 10.3171/sup.1991.75.1s.00s1; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LEVIN H S, 1990, Annales de Readaptation et de Medecine Physique, V33, P35; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MARHSALL LF, 1991, J NEUROSURG, V75, pS28; Matthews C, 1964, INSTRUCTIONAL MANUAL; PETRUCELLI E, 1982, INT BIBLIO ABBREVIAT; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Smith A., 1968, LEARNING DISORDERS, P83; TEASDALE G, 1974, LANCET, V2, P81	20	15	15	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1998	15	9					685	692		10.1089/neu.1998.15.685			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	118ZT	WOS:000075871400004	9753216				2021-06-18	
J	Yang, SY; Cui, JZ				Yang, SY; Cui, JZ			Expression of the basic fibroblast growth factor gene in mild and more severe head injury in the rat	JOURNAL OF NEUROSURGERY			English	Article						brain injury; basic fibroblast growth factor gene expression; exogenous basic fibroblast growth factor; treatment; rat	CENTRAL-NERVOUS-SYSTEM; DIFFUSE BRAIN INJURY; MESSENGER-RNA; NEURONS; IMMUNOREACTIVITY; DIFFERENTIATION; INCREASE; ISCHEMIA; MODEL	Object. The goal of this study was to investigate the relationship between basic fibroblast growth factor (bFGF) gene expression and neuropathological changes in the hippocampus after varying degrees of brain injury. Methods. Mild and severe brain injury in rats was produced by using Marmarou's method. There were 25 animals in each brain injury group and 25 additional animals served as controls. Basic fibroblast growth factor gene expression was investigated by means of RNA hybridization, in situ hybridization, immunohistochemical analysis, and histological analysis using hematoxylin and eosin staining. A 3.7-kb bFGF messenger (m)RNA was detected in the rat hippocampus in both control and injured rats. In the mild injury group its expression was increased at 12 hours after injury and peaked on the 3rd day. Neuronal degeneration in the hippocampal CA2 and CA3 sectors was maximum on that day. In the severe injury group, the expression of the bFGF gene was the same as that in the mild injury group at corresponding times, but the number of surviving neurons in the CA2 and CA3 sectors was much lower than in the mild injury group. In situ hybridization showed that the main cells that expressed bFGF mRNA were pyramidal and granulocytic neurons in all three experimental groups. The number of neurons expressing bFGF mRNA in the severe injury group was less than that in the mild injury group, but the intensity of expression was greater. Immunohistochemical staining showed that the number of neurons expressing the bFGF protein was less in the severe injury group than in the mild injury group. Conclusions. It is concluded that after mild injury then is a close relationship between the expression of the bFGF gene and the degree of histological change in the hippocampus; this indicates that as one of the growth factors, bFGF may participate in the protection and repair processes of neurons following brain injury. In severe injury there is a reduced expression of bFGF. The reason for this appears to be that more of the cells that have the potential to express bFGF have died, reducing the ability of express the bFGF gene. Conversely, it is possible that there may be an intrinsic insufficiency of expression of the gene, compatible with the known vulnerability of the hippocampus to many pathological conditions. Consideration should be given to supplying exogenous bFGF to protect the brain, particularly the hippocampus, after injury.	Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 30052, Peoples R China	Yang, SY (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, 154 An Shan Rd, Tianjin 30052, Peoples R China.						CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUEVAS P, 1994, NEUROL RES, V16, P365; CUEVAS P, 1986, 8TH INT S MICR AN CE, P731; DAI ZS, 1995, J NEUROSCI, V15, P5466; ERNFORS P, 1990, J NEUROSCI RES, V27, P10, DOI 10.1002/jnr.490270103; FINKLESTEIN SP, 1990, STROKE, V21, P122; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Ghosh MM, 1995, BIOREMED SER, V3, P15; GIORDANO S, 1992, DEV BIOL, V152, P293, DOI 10.1016/0012-1606(92)90136-5; HAMERMAN D, 1987, P SOC EXP BIOL MED, V186, P384; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IWATA H, 1991, BRAIN RES, V550, P329, DOI 10.1016/0006-8993(91)91336-Y; KIYOTA Y, 1991, BRAIN RES, V545, P322, DOI 10.1016/0006-8993(91)91307-M; KUMON Y, 1993, BRAIN RES, V605, P169, DOI 10.1016/0006-8993(93)91369-4; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MENON VK, 1994, EXP NEUROL, V129, P142, DOI 10.1006/exnr.1994.1155; MORRISON RS, 1987, J NEUROSCI RES, V17, P99, DOI 10.1002/jnr.490170202; Sambrook J., 1989, MOL CLONING LAB; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; SCHMITZ GG, 1991, ANAL BIOCHEM, V192, P222, DOI 10.1016/0003-2697(91)90212-C; SHIMASAKI S, 1988, BIOCHEM BIOPH RES CO, V157, P256, DOI 10.1016/S0006-291X(88)80041-X; VICARIOABEJON C, 1995, NEURON, V15, P105, DOI 10.1016/0896-6273(95)90068-3; WALICKE PA, 1988, J NEUROSCI, V8, P2618; YUGUCHI T, 1994, MOL BRAIN RES, V25, P50, DOI 10.1016/0169-328X(94)90277-1	26	15	20	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	AUG	1998	89	2					297	302		10.3171/jns.1998.89.2.0297			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	104CM	WOS:000074994900017	9688126				2021-06-18	
J	Al-Turki, A; Armstead, WM				Al-Turki, A; Armstead, WM			Altered release of prostaglandins by opioids contributes to impaired cerebral hemodynamics following brain injury	CRITICAL CARE MEDICINE			English	Article						pigs, newborn; cerebral circulation; opioids; prostaglandins; brain injury; trauma; radioimmunoassay; cerebrospinal fluid; thromboxane; prostacyclin	PIAL ARTERY VASODILATION; NEWBORN PIG BRAIN; HEAD-INJURY; VASCULAR-RESPONSES; UNITED-STATES; RAT-BRAIN; ISCHEMIA; ABNORMALITIES; ACETYLCHOLINE; PHOSPHOLIPIDS	Objectives: After fluid percussion brain injury (FPI) in the newborn pig, pial arteries constrict and responses to dilator stimuli, including opioids, are blunted. This study was designed to determine if altered release of prostaglandins contributes to blunted opioid dilation of cerebral arteries in newborn piglets following brain injury. Design: Prospective, in vivo, cerebral hemodynamic animal study. Setting: University research laboratory. Subjects: Newborn (1- to 5-days old) piglets of either gender. Interventions: In anesthetized, newborn, 1- to 5-day-old pigs, a closed cranial window was used to measure pial artery diameter and to collect cortial periarachnoid cerebrospinal fluid (CSF) for determination of 6-keto-PGF(1 alpha), the stable metabolite of prostaglandin I-2 (PGI(2)) and thromboxane B-2 (TXB2), the stable metabolite of TXA(2), via radioimmunoassay. FPI of moderate severity (1.9 to 2.3 atmospheres) was produced by using a pendulum to strike a piston on a saline-filled cylinder that was fluid coupled to the brain via a hollow screw inserted through the cranium. Measurements and Main Results: Methionine enkephalin (Met) vasodilation was blunted after FPI but was partially restored with indomethacin pretreatment (5 mg/kg iv) (8 +/- 1 [SEM] %, 13 +/- 1%, and 20 +/- 1% vs. 1 +/- 1%, 3 +/- 1%, and 5 +/- 1% vs. 7 +/- 1%, 10 +/- 1%, and 15 +/- 1%, respectively, for 10(-10), 10(-8),and 10(-6) M Met during control conditions, after FPI, and after FPI pretreated with indomethacin, n = 6). Similarly, restoration of Met dilation after FPI was observed with SQ 29,548, a TXA(2) antagonist. Met-induced 6-keto-PGF(1 alpha) release was blunted following FPI (889 +/- 20, 1130 +/- 33, and 1886 +/- 59 vs. 2630 +/- 36, 2775 +/- 30, and 2825 +/- 36 pg/mL for control, 10(-10), and 10(-6) M Met before and after FPI, respectively, n = 6). In contrast, Met-induced TXB2 release was enhanced after FPI (340 +/- 20, 423 +/- 25, and 473 +/- 30 pg/mL vs. 518 +/- 30, 726 +/- 90, and 901 +/- 35 pg/mL for control, 10(-10), and 10(-6) M Met before and after FPI, respectively, n = 6). Leucine enkephalin-and dynorphin-induced dilation and associated prostaglandin release were similarly altered following FPI. beta endorphin-induced constriction was enhanced following FPI, and these potentiated responses were blunted after indomethacin or SQ 29,548 pretreatment. Conclusions: These data show that FPI increases CSF 6-keto-PGF(1 alpha) and TXB2 concentrations. These data suggest that altered release of prostaglandins by opioids contribute to impaired cerebral hemodynamics following FPI in piglets.	Childrens Hosp Philadelphia, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Penn, Dept Crit Care Med, Philadelphia, PA 19104 USA	Armstead, WM (corresponding author), Childrens Hosp Philadelphia, Dept Anesthesia, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.						ARMSTEAD WM, 1990, J PHARMACOL EXP THER, V255, P1083; Armstead WM, 1996, J NEUROTRAUM, V13, P115, DOI 10.1089/neu.1996.13.115; ARMSTEAD WM, 1994, BRAIN RES, V660, P19, DOI 10.1016/0006-8993(94)90834-6; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; ARMSTEAD WM, 1992, P SOC EXP BIOL MED, V199, P149; ARMSTEAD WM, 1988, AM J PHYSIOL, V255, pH401; ARMSTEAD WM, 1989, J PHARMACOL EXP THER, V251, P1012; AVELDANO MI, 1975, J NEUROCHEM, V25, P919, DOI 10.1111/j.1471-4159.1975.tb04432.x; BAZAN NG, 1971, J NEUROCHEM, V18, P1387, DOI 10.1111/j.1471-4159.1971.tb00003.x; DEVINE JO, 1995, BRAIN RES, V675, P257, DOI 10.1016/0006-8993(95)00081-Z; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; ELLIS EF, 1989, J NEUROTRAUM, V6, P331; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Hall E D, 1985, Cent Nerv Syst Trauma, V2, P75; HALL ED, 1987, BRAIN RES, V435, P174, DOI 10.1016/0006-8993(87)91599-X; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; LEFFLER CW, 1989, STROKE, V20, P541, DOI 10.1161/01.STR.20.4.541; LEFFLER CW, 1989, PEDIATR RES, V25, P180; LEFFLER CW, 1990, PROSTAGLANDINS, V40, P241, DOI 10.1016/0090-6980(90)90012-K; LEFFLER CW, 1985, PROSTAGLANDINS, V30, P811, DOI 10.1016/0090-6980(85)90009-7; LEFFLER CW, 1992, AM J PHYSIOL, V263, pH746; LESCOHIER I, 1993, PEDIATRICS, V91, P721; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P373, DOI 10.1089/neu.1993.10.373; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SPINEDI A, 1990, J NEUROCHEM, V54, P778, DOI 10.1111/j.1471-4159.1990.tb02318.x; Tepas J J 3rd, 1995, Semin Pediatr Surg, V4, P120; Thorogood MC, 1996, ANESTHESIOLOGY, V84, P614, DOI 10.1097/00000542-199603000-00017; THOROGOOD MC, 1995, AM J PHYSIOL-HEART C, V269, pH1776; VINK R, 1990, J NEUROSCI, V10, P3524; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WESTCOTT JY, 1987, PROSTAGLANDINS, V34, P877, DOI 10.1016/0090-6980(87)90068-2; ZALESKA MM, 1989, J NEUROCHEM, V52, P255, DOI 10.1111/j.1471-4159.1989.tb10925.x	39	15	15	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	MAY	1998	26	5					917	925		10.1097/00003246-199805000-00029			9	Critical Care Medicine	General & Internal Medicine	ZL791	WOS:000073471900023	9590323				2021-06-18	
J	Lannoo, E; Colardyn, F; De Deyne, C; Vandekerckhove, T; Jannes, C; De Soete, G				Lannoo, E; Colardyn, F; De Deyne, C; Vandekerckhove, T; Jannes, C; De Soete, G			Cerebral perfusion pressure and intracranial pressure in relation to neuropsychological outcome	INTENSIVE CARE MEDICINE			English	Article						cerebral perfusion pressure; closed head injury; intracranial pressure; mean arterial pressure; neuropsychological outcome	SEVERE HEAD-INJURY	Objective: The study attempted to examine the relationship between neuropsychological functioning and reduced cerebral perfusion pressure (CPP), raised intracranial pressure (ICP), and reduced mean arterial pressure (MAP), monitored during intensive care treatment. Design: This prospective follow-up study included consecutive patients and evaluated outcome at 6 months postinjury by the administration of a neuropsychological test battery. Setting: The study was conducted at the University Hospital of Gent, Belgium. Patients and participants: Over a 30-month period, 43 patients were included. Inclusion criteria were the following: hospital admission following closed head injury, ICP monitoring, no medical history of central nervous system disease or mental retardation, survival for at least 6 months, and informed consent for participation. Interventions: All patients received the hospital's standard treatment for head injury, which remained unchanged during the study period. Measurements and results: Reduced CPP was analyzed using the number of observed values below 70 mmHg, raised ICP using the number of values above 20 mmHg, and MAP using the number of values below 80 mmHg. The neuropsychological test battery included 11 measures of attention, information processing, motor reaction time, memory, learning, visuoconstruction, verbal fluency, and mental flexibility. No linear relationships were found between overall neuropsychological impairment and episodes of reduced CPP, raised ICP, or reduced MAP. Conclusions: Although reduced CPP and raised ICP are frequent, often fatal, complications of head injury, in survivors they do not seem to be related to later neuropsychological functioning.	State Univ Ghent Hosp 4K3, Dept Neuropsychol, B-9000 Ghent, Belgium; State Univ Ghent Hosp, Dept Intens Care, B-9000 Ghent, Belgium; State Univ Ghent Hosp, Dept Neurosurg, B-9000 Ghent, Belgium; State Univ Ghent Hosp 4K3, Dept Psychiat, B-9000 Ghent, Belgium; State Univ Gent, Dept Data Anal, Gent, Belgium	Lannoo, E (corresponding author), State Univ Ghent Hosp 4K3, Dept Neuropsychol, De Pintelaan 185, B-9000 Ghent, Belgium.	Engelien.Lannoo@rug.ac.be					ANGGARD E, 1994, LANCET, V343, P1199, DOI 10.1016/S0140-6736(94)92405-8; CHAN KH, 1992, J NEUROSURG ANESTH, V4, P188, DOI 10.1097/00008506-199207000-00007; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CORTBUS F, 1994, ACTA NEUROCHIR, V130, P117, DOI 10.1007/BF01405511; DIKMEN S, 1995, J HEAD TRAUMA REHAB, V10, P74, DOI 10.1097/00001199-199502000-00008; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P67; FEPSY, 1995, NORMATIVE DATA, V3; FEPSY, 1995, NORMATIVE DATA, V2; Heaton R., 1993, WISCONSIN CARD SORTI; JENNETT B, 1975, LANCET, V1, P480; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; KAWAHARA N, 1989, ACTA NEUROCHIR, V100, P142, DOI 10.1007/BF01403602; Lannoo E, 1997, PSYCHOL BELG, V37, P141; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Mannarou A, 1991, J NEUROSURG S, V75, P21; MARMAROU A, 1992, J NEUROTRAUM, V9, pS327; Marmarou A, 1991, J NEUROSURG, V75, pS159; MILLER JD, 1977, J NEUROSURG, V47, P508; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Spreen O., 1991, COMPENDIUM NEUROPSYC; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630	25	15	15	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	MAR	1998	24	3					236	241		10.1007/s001340050556			6	Critical Care Medicine	General & Internal Medicine	ZG445	WOS:000073003000007	9565805				2021-06-18	
J	von Bierbrauer, A; Weissenborn, K				von Bierbrauer, A; Weissenborn, K			P300 after minor head injury (a follow-up examination)	ACTA NEUROLOGICA BELGICA			English	Article						minor head injury; cognitive auditory evoked potential; P300; follow-up	EVENT-RELATED POTENTIALS; EVOKED-POTENTIALS; AUDITORY-STIMULI; MENTAL STATE; LATENCY; ENCEPHALOPATHY; CONCUSSION; RECOVERY	Background and methods : The aim of the study was to examine whether - like in severe head injuries - the endogenous evoked potential P300 is influenced by minor head injury (MHI) and how the eventual abnormalities develop within a follow-up period of 8 weeks. after trauma. Therefore we examined the cognitive auditory evoked potential P300 (latency: amplitude), the neurologic state and the performance in psychometric testing (Mini-Mental-State, Number Connection test part A and B) in 15 patients within the first 24 hours as well as 1, 3 and 8 weeks after MHI. The P300 results were compared to the age-related normal ranges under consideration of the intra-individual variability. For both parameters normative values were established before in our own laboratory. Results : For the patient group as a whole the mean values for P300 latency and amplitude were always within the age-related normal range and normal intraindividual long-term variability of healthy controls, respectively. Significant posttraumatic prolongations of P300 latency were exclusively observed in the only 20% of our patients with clinically suspected posttraumatic organic brain syndrome. These prolongations of latency decreased during follow-up and on the last examination the latencies were normalised Compared to psychometric tests, P300 latency seems to be more sensitive in early detection of cerebral dysfunction. Conclusions : We conclude that, in contrast to severe head injury, in general the P300 is not affected by minor head injury. If there are clinical signs of organic brain syndrome following MHI posttraumatic prolongation of P300 latency is a marker of cerebral dysfunction and may serve as a valuable parameter for follow-up examination and documentation.	Hannover Med Sch, Dept Neurol & Clin Neurophysiol, D-3000 Hannover, Germany	von Bierbrauer, A (corresponding author), Univ Marburg Klinikum, Zentrum Innere Med, Med Abt, Poliklin, Baldinger Str, D-35033 Marburg, Germany.						BROOKS N, 1979, INT REHABIL MED, V1, P166; Brown W S, 1982, Bull Los Angeles Neurol Soc, V47, P91; COHEN SN, 1983, NEUROLOGY, V33, P1219, DOI 10.1212/WNL.33.9.1219; CONN HO, 1977, AM J DIG DIS, V22, P541, DOI 10.1007/BF01072510; Donchin E., 1979, EVOKED BRAIN POTENTI, P13, DOI DOI 10.1007/978-1-4684-3462-0_2; DRAKE ME, 1987, CLIN EVOKED POTENTIA, V5, P19; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOODIN DS, 1978, ELECTROEN CLIN NEURO, V44, P447, DOI 10.1016/0013-4694(78)90029-9; GOODIN DS, 1978, BRAIN, V101, P635, DOI 10.1093/brain/101.4.635; GRONWALL D, 1974, LANCET, V2, P605; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; KWENTUS JA, 1985, PSYCHOSOMATICS, V1, P8; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; MANDELBERG IA, 1976, J NEUROL NEUROSUR PS, V36, P1001; NOSEWORTHY JH, 1981, ARCH NEUROL-CHICAGO, V38, P275, DOI 10.1001/archneur.1981.00510050041004; NOTERMANS SLH, 1986, EUR ARCH PSY CLIN N, V235, P292, DOI 10.1007/BF00515916; OLBRICH HM, 1986, SURG NEUROL, V26, P112, DOI 10.1016/0090-3019(86)90362-9; POLICH J, 1986, ELECTROEN CLIN NEURO, V65, P236, DOI 10.1016/0168-5597(86)90059-6; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; RAPPAPORT M, 1981, CLIN ELECTROENCEPHAL, V12, P167, DOI 10.1177/155005948101200403; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUIJS MBM, 1993, NEUROPEDIATRICS, V24, P307, DOI 10.1055/s-2008-1071562; RUSSEL WR, 1971, TRAUMATIC AMNESIAS; SKLARE DA, 1984, ELECTROEN CLIN NEURO, V59, P420, DOI 10.1016/0168-5597(84)90043-1; WEISSENBORN K, 1990, ELECTROEN CLIN NEURO, V75, P289, DOI 10.1016/0013-4694(90)90107-U; WEISSENBORN K, 1990, THESIS HANNOVER; WEISSENBORN K, 1988, Z EEG EMG, V19, P276; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31; ZAMRINI EY, 1991, INT J NEUROSCI, V61, P113, DOI 10.3109/00207459108986279	29	15	15	0	1	ACTA MEDICA BELGICA	BRUSSELS	AVENUE CIRCULAIRE 138-A, B-1180 BRUSSELS, BELGIUM	0300-9009			ACTA NEUROL BELG	Acta Neurol. Belg.	MAR	1998	98	1					21	26					6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	ZT707	WOS:000074116600004	9606435				2021-06-18	
J	Martin, RC; Franzen, MD; Orey, S				Martin, RC; Franzen, MD; Orey, S			Magnitude of error as a strategy to detect feigned memory impairment	CLINICAL NEUROPSYCHOLOGIST			English	Article; Proceedings Paper	24th Annual Meeting of the International-Neuropsychological-Society	FEB 14-17, 1996	CHICAGO, ILLINOIS	Int Neuropsychol Soc, US PHS, Natl Inst Aging, Alzheimers Dis Cooperat Study			MILD HEAD-INJURY; SIMULATION; VALIDATION; DEFICITS	The present study introduced a magnitude of error method as a new malingering detection strategy. Thirty university students were requested to either simulate a memory impairment or to try their best. Magnitude of response error was also investigated in a group of 30 nonlitigating moderate to severe closed-head-injured patients, and 7 suspected clinical malingerers. Probability of selection values were calculated across multiple choice items from tests of recognition memory adapted for the WMS-R Logical and Visual Reproduction Memory subtests. These value scores were employed to identify analog and clinical malingerers. Analog and suspected clinical malingerers were much more likely to select low probability multiple-choice items, and often endorsed choices that neither controls nor moderate to severe CHI patients endorsed. Probability of selection value scores were able to classify 86% of the analog and 100% of the suspected clinical malingerers with 100% specificity for controls.	Univ Alabama, Dept Neurol, Epilepsy Ctr, Civitan Int Res Ctr 312, Birmingham, AL 35294 USA; Allegheny Gen Hosp, Allegheny Neuropsychiat Inst, Pittsburgh, PA 15212 USA; Univ Kentucky, Lexington, KY USA	Martin, RC (corresponding author), Univ Alabama, Dept Neurol, Epilepsy Ctr, Civitan Int Res Ctr 312, 1719 6th Ave S, Birmingham, AL 35294 USA.						Benton A. L., 1994, CONTRIBUTIONS NEUROP; BENTON AL, 1961, ARCH GEN PSYCHIAT, V4, P79; BERG EA, 1948, J GEN PSYCHOL, V6, P143; BERNARD LC, 1990, J CLIN PSYCHOL, V46, P432, DOI 10.1002/1097-4679(199007)46:4<432::AID-JCLP2270460410>3.0.CO;2-0; Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; BOLTER JF, 1985, ANN M NAT AC NEUR PH; BRUHN AR, 1975, J PERS ASSESS, V39, P244, DOI 10.1207/s15327752jpa3903_5; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; CICCHETTI DV, 1994, J CLIN EXP NEUROPSYC, V16, P155, DOI 10.1080/01688639408402625; DEFILIPPIS NA, 1975, BOOKLET CATEGORY TES; Fleiss J., 1986, DESIGN ANAL CLIN EXP; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Halstead WC., 1947, BRAIN INTELLIGENCE Q; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; IVERSON GL, 1994, ARCH CLIN NEUROPSYCH, V9, P437, DOI 10.1016/0887-6177(94)90006-X; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Martin RC, 1996, J CLIN EXP NEUROPSYC, V18, P265, DOI 10.1080/01688639608408281; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.4.390; Milanovich JR, 1996, ARCH CLIN NEUROPSYCH, V11, P53, DOI 10.1016/0887-6177(95)00016-X; MILLER H, 1972, LANCET, V1, P580; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; Paul D. S., 1992, INT J CLIN NEUROPSYC, V14, P1; Rawling P, 1990, NEUROPSYCHOLOGY, V4, P223, DOI 10.1037/0894-4105.4.4.223; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; Rosenfeld JP, 1996, CLIN NEUROPSYCHOL, V10, P163, DOI 10.1080/13854049608406678; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Wechsler D., 1987, WECHSLER MEMORY SCAL	32	15	15	0	14	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB	1998	12	1					84	91		10.1076/clin.12.1.84.1722			8	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	ZE592	WOS:000072810000009					2021-06-18	
J	Chobor, KL; Schweiger, A				Chobor, KL; Schweiger, A			Processing of lexical ambiguity in patients with traumatic brain injury	JOURNAL OF NEUROLINGUISTICS			English	Article							SENTENCE COMPREHENSION	The goal of this study was to determine the type of cognitive functions required for the interpretation of lexical ambiguity. Brain-injured and normal subjects performed lexical decision (reaction time) and matching tasks, using three categories of ambiguous words: homonymy, polysemy and metaphor. Patients showed much slower reaction times on metaphor than normals, while accuracy rates for matching were comparable, suggesting relative intactness of the semantic interpretations of these words despite a retrieval deficit.	NYU Med Ctr, Dept Neurol, New York, NY 10016 USA; CUNY, Grad Ctr, Dept Speech & Hearing Sci, New York, NY 10021 USA	Chobor, KL (corresponding author), NYU Med Ctr, Dept Neurol, New York, NY 10016 USA.						BEARDSLEY MC, 1962, PHILOS PHENOMEN RES, V22, P293, DOI 10.2307/2104415; Brown JW, 1997, SYNTH LIBR, V258, P35; BROWNELL HH, 1990, NEUROPSYCHOLOGIA, V28, P375, DOI 10.1016/0028-3932(90)90063-T; BROWNELL HH, 1984, BRAIN LANG, V100, P717; CHIARELLO C, 1988, RIGHT HEMISPHERE CON, P59; DURKIN K, 1989, J PSYCHOLINGUIST RES, V18, P577, DOI 10.1007/BF01067161; GAGNON L, 1994, SEMANTIC PROCESSING; GARDNER H, 1983, COGNITIVE PROCESSING, P169; GARDNER H, 1994, 41 NEBR S MOT 1992 1; GAZZANIGA MS, 1983, AM PSYCHOL, V38, P525, DOI 10.1037/0003-066X.38.5.525; GILHOOLY KJ, 1980, BEHAV RES METH INSTR, V12, P428, DOI 10.3758/BF03201694; GOLDSTEIN K, 1948, LANGUAGE LANGUAGE DI; HARRIS AJ, 1958, MANUAL DIRECTIONS AD; Heaton R. K, 1981, WISCONSIN CARD SORTI; Kertesz A., 1982, W APHASIA BATTERY; KRASHEN SD, 1976, STUDIES NEUROLINGUIS, V2, P157; Lakoff G., 1993, METAPHOR THOUGHT; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Luria A. R., 1966, HIGHER CORTICAL FUNC; MILBERG W, 1987, BRAIN LANG, V31, P138, DOI 10.1016/0093-934X(87)90065-4; ONIFER W, 1981, MEM COGNITION, V9, P225, DOI 10.3758/BF03196957; Ortony A., 1993, METAPHOR THOUGHT; Raven J., 1960, GUIDE STANDARD PROGR; SEARLEMAN A, 1977, PSYCHOL BULL, V84, P503, DOI 10.1037/0033-2909.84.3.503; SIMPSON GB, 1984, PSYCHOL BULL, V96, P316, DOI 10.1037/0033-2909.96.2.316; SIMPSON GB, 1987, COGNITIVE SYSTEMS, V2, P213; SWINNEY D, 1982, PERSPECTIVES MENTAL; SWINNEY DA, 1979, J VERB LEARN VERB BE, V18, P645, DOI 10.1016/S0022-5371(79)90355-4; Winner E., 1977, BRAIN, V100, P719; Zachary R.A., 1991, SHIPLEY I LIVING SCA; ZIFF P, 1967, FDN LANGUAGE, V3, P403	31	15	15	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0911-6044			J NEUROLINGUIST	J. Neurolinguist.	JAN-APR	1998	11	1-2					119	136		10.1016/S0911-6044(98)00009-8			18	Linguistics; Neurosciences; Psychology, Experimental	Linguistics; Neurosciences & Neurology; Psychology	ZN372	WOS:000073639300010					2021-06-18	
S	Reichlin, S		McCann, SM; Lipton, JM; Sternberg, EM; Chrousos, GP; Gold, PW; Smith, CC		Reichlin, S			Alternative pathways of neural control of the immune process	NEUROIMMUNOMODULATION: MOLECULAR ASPECTS, INTEGRATIVE SYSTEMS, AND CLINICAL ADVANCES	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	3rd Congress of the International-Society-of-Neuroimmunomodulation on Neuroimmunomodulation - Molecular Aspects, Integrative Systems, and Clinical Advances	NOV 13-15, 1996	BETHESDA, MARYLAND	Int Soc Neuroimmunomodulat, NIH, NCI, Natl Inst Aging, NIAID, Natl Inst Arthritis & Muskuloskeletal & Skin Dis, NICHHD, NIDR, NIMH, Natl Inst Nursing Res, NIH, Off Alternat Med, NIH, Off Behav & Social Sci Res, NIH, Off Rare Dis Res, NIH, Off Res Womens Hlth, Glaxowellcome Inc, TIG Instrumenten Gesell Ag, Vector Lab			TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; CORTICOTROPIN-RELEASING HORMONE; BLOOD-BRAIN-BARRIER; MESSENGER-RNA; FACTOR-ALPHA; PROINFLAMMATORY CYTOKINES; INTERLEUKIN-6 PRODUCTION; IMMOBILIZATION STRESS; PLASMA INTERLEUKIN-6	Less well established alternative neuromodulatory pathways are neuropeptide-mediated axon reflexes of sensory neurons, gut immunotrafficing, gut transmucosal transport of endogenous bacterial toxin, and the direct secretion of immunoregulatory cytokines by the brain. TNF-alpha and IL-1ra enter peripheral blood after their intracerebroventricular (i.c.v.) injection. Closed head injury or stroke increases blood IL-6 and the acute phase response; neuroblastomas immunosuppress by secreting TGF-beta. The IL-6 that appears in the blood after i.c.v. IL-1 in the rat is partly derived by secretion from the brain into the superior sagital sinus (Romero et al.; 1996. Am. J. Physiol. 270: R518) and is not dependent on peripheral sympathetic activation. Central endothelium and choroid plexus are potential sources of sagital sinus IL-6. TNF-alpha, which appears in blood after i.c.v. LPS, but not IL-1 beta, is due largely to toxin leaving the brain compartment and activating peripheral immunoreactive tissues. Antigens and cytokine immunoregulators drain into cervical lymph. Changes in glial milieu induced by intrinsic neuronal activity could by secretion from brain to blood modulate peripheral immunoreactivity.	Univ Arizona, Hlth Sci Ctr, Dept Internal Med, Neuroendocrine Lab, Tucson, AZ 85724 USA	Reichlin, S (corresponding author), Univ Arizona, Hlth Sci Ctr, Dept Internal Med, Neuroendocrine Lab, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	reichlin@u.arizona.edu					Ader R., 1991, PSYCHONEUROIMMUNOLOG; ADER R, 1991, PSYCHONEUROIMMUNOLOG, V2, P611; ANDERSSON PB, 1992, J EXP MED, V176, P255, DOI 10.1084/jem.176.1.255; Banks WA, 1995, NEUROIMMUNOMODULAT, V2, P241, DOI 10.1159/000097202; BENVENISTE EN, 1994, RES P ARNMD, V72, P71; BODMER S, 1991, J NEUROIMMUNOL, V34, P33, DOI 10.1016/0165-5728(91)90096-P; BODNAR RJ, 1989, CANCER RES, V49, P6280; BREDER CD, 1993, J COMP NEUROL, V337, P543, DOI 10.1002/cne.903370403; CHAO CC, 1995, DEV NEUROSCI-BASEL, V17, P97, DOI 10.1159/000111278; CHEN GJ, 1991, J LEUKOCYTE BIOL, V50, P349; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P135; Cole SW, 1996, PSYCHOSOM MED, V58, P219, DOI 10.1097/00006842-199605000-00005; Cousins N, 1979, ANATOMY ILLNESS PERC; CSERR HF, 1992, IMMUNOL TODAY, V13, P507, DOI 10.1016/0167-5699(92)90027-5; DERIJK RH, 1994, PSYCHONEUROENDOCRINO, V19, P155, DOI 10.1016/0306-4530(94)90005-1; DESIMONI MG, 1995, ENDOCRINOLOGY, V136, P897, DOI 10.1210/en.136.3.897; DESIMONI MG, 1993, AM J PHYSIOL, V265, pR739; DESIMONI MG, 1990, J EXP MED, V171, P1773, DOI 10.1084/jem.171.5.1773; DUNN AJ, 1991, J NEUROCHEM, V57, P1615, DOI 10.1111/j.1471-4159.1991.tb06359.x; ERICSSON A, 1995, J COMP NEUROL, V361, P681, DOI 10.1002/cne.903610410; FAGGIONI R, 1995, NEUROIMMUNOMODULAT, V2, P2, DOI 10.1159/000096828; Fiebich BL, 1996, J NEUROCHEM, V66, P1426; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; GOTTSCHALL PE, 1992, NEUROENDOCRINOLOGY, V56, P935, DOI 10.1159/000126328; GOTTSCHALL PE, 1994, BRAIN RES, V637, P197, DOI 10.1016/0006-8993(94)91233-5; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; HUANG OH, 1995, AM J PHYSL 2, V273, pR731; IRWIN M, 1988, AM J PHYSIOL, V255, pR744; IRWIN M, 1994, ADV NEUROIMMUNOL, V4, P29, DOI 10.1016/S0960-5428(06)80188-9; IRWIN M, 1994, ANN NY ACAD SCI, V741, P203; KAKUCSKA I, 1993, ENDOCRINOLOGY, V133, P815, DOI 10.1210/en.133.2.815; KIECOLTGLASER JK, 1991, PSYCHONEUROIMMUNOLOG, V2, P849; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; KRUGER MJ, 1995, NEUROIMMUNOMODULAT, V2, P216; LECHAN RM, 1990, BRAIN RES, V514, P135, DOI 10.1016/0006-8993(90)90445-H; LEE SC, 1993, J IMMUNOL, V150, P2659; Lewis CE, 1994, PSYCHOIMMUNOLOGY CAN; LOCKE SE, 1983, MIND IMMUNITY; MACLEAN D, 1981, PSYCHONEUROIMMUNOLOG, P475; MADDEN KS, 1995, ANNU REV PHARMACOL, V35, P417, DOI 10.1146/annurev.pa.35.040195.002221; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MINAMI M, 1991, NEUROSCI LETT, V123, P254, DOI 10.1016/0304-3940(91)90944-O; NATHANSON JA, 1989, P NATL ACAD SCI USA, V86, P1684, DOI 10.1073/pnas.86.5.1684; NILSSON C, 1992, BRAIN RES REV, V17, P109, DOI 10.1016/0165-0173(92)90011-A; REICHLIN S, 1995, ENDOCRINOLOGY, P2964; Ringheim GE, 1995, J NEUROIMMUNOL, V63, P113, DOI 10.1016/0165-5728(95)00134-4; ROMERO LI, 1996, AM J PHYSIOL, V270, pRK18; ROSZMAN TL, 1985, J NEUROIMMUNOL, V10, P59, DOI 10.1016/0165-5728(85)90034-7; SCHETTINI G, 1994, PHARMACOL RES, V30, P13, DOI 10.1016/1043-6618(94)80083-9; SUNDAR SK, 1990, J NEUROSCI, V10, P3701; Takaki Atsushi, 1994, Neuroimmunomodulation, V1, P335, DOI 10.1159/000097185; TARKOWSKI E, 1995, STROKE, V26, P1393, DOI 10.1161/01.STR.26.8.1393; TARLOW MJ, 1993, NEUROPATH APPL NEURO, V19, P324, DOI 10.1111/j.1365-2990.1993.tb00447.x; Urbaschek B, 1985, MICROBIOLOGY 1985, P39; VanDam AM, 1996, FASEB J, V10, P351; VREDEVOE DL, 1995, NEUROIMMUNOMODULAT, V2, P16, DOI 10.1159/000096830; WEISS JM, 1994, ANN NY ACAD SCI, V741, P338, DOI 10.1111/j.1749-6632.1994.tb23117.x; WEISS JM, 1989, NEUROIMMUNE NETWORKS, P193	58	15	15	0	3	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-072-7	ANN NY ACAD SCI	Ann.NY Acad.Sci.		1998	840						301	316		10.1111/j.1749-6632.1998.tb09570.x			16	Endocrinology & Metabolism; Immunology; Multidisciplinary Sciences; Neurosciences	Endocrinology & Metabolism; Immunology; Science & Technology - Other Topics; Neurosciences & Neurology	BL14S	WOS:000074444500028	9629258				2021-06-18	
J	Tate, RL				Tate, RL			"It is not only the kind of injury that matters, but the kind of head": The contribution of premorbid psychosocial factors to rehabilitation outcomes after severe traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							SEQUELAE	Two studies are reported examining the influence of premorbid psychosocial variables in determining rehabilitation outcomes after traumatic brain injury (TBI). The focus of Study 1 was indices of premorbid social maladjustment (PSM). A consecutive series of 85 subjects with TBI admitted to a rehabilitation unit was assessed 6 years post-trauma. Eleven subjects (13%) had evidence of PSM. These subjects were matched on age, gender, and severity of injury with 11 subjects in the series without evidence of PSM. There were no differences between the groups regarding overall outcome on the Glasgow Outcome Scale, level of psychosocial reintegration, or severity of neuropsychological impairments. The aim of Study 2 was to examine premorbid personality characteristics in subjects with TBI. An independent sample of 30 subjects was followed prospectively. As soon after the injury as feasible, a detailed psychosocial history was obtained from a close relative, who also rated the premorbid personality of the TBI person using the Eysenck Personality Questionnaire-Revised (EPQ-R). Nine subjects had evidence of poor premorbid histories and 17 subjects had unremarkable histories. Significant group differences were demonstrated for three of the six EPQ-R scales (Psychoticism, Addiction, and Criminality). Comparison of the two groups regarding the severity of neuropsychological impairments and level of psychosocial reintegration achieved by 6 months post-trauma, however, revealed no significant differences, replicating the results of the first study. Correlational analyses indicated that only severity of injury, and not premorbid personality variables, was related to psychosocial functioning.	Univ Sydney, Dept Psychol A16, Sydney, NSW 2006, Australia		robynt@psychvax.psych.su.oz.au					Brooks N, 1988, Acta Neurochir Suppl (Wien), V44, P59; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; COOPER KD, 1983, NEUROEPIDEMIOLOGY, V2, P70; DeFilippis NA, 1979, BOOKLET CATEGORY TES; Delis DC, 1987, CALIFORNIA VERBAL LE; DODWELL D, 1988, PSYCHOL MED, V18, P495, DOI 10.1017/S0033291700008035; Eysenck H. J., 1991, MANUAL EYSENCK PERSO; FAHY TJ, 1967, LANCET, V2, P475; Field, 1976, EPIDEMIOLOGY HEAD IN; Heaton R. K, 1981, WISCONSIN CARD SORTI; JAMIESON KG, 1971, HEAD INJURIES, P12; JAMIESON KG, 1966, 13 NAT HLTH MED RES; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1984, CLOSED HEAD INJURY P, P37; JONESGOTMAN M, 1977, NEUROPSYCHOLOGIA, V15, P653, DOI 10.1016/0028-3932(77)90070-7; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KOZOL HL, 1946, ARCH NEURO PSYCHIATR, V56, P245, DOI 10.1001/archneurpsyc.1946.02300200002001; KOZOL HL, 1945, ARCH NEURO PSYCHIATR, V53, P358, DOI 10.1001/archneurpsyc.1945.02300050032004; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; Lazarus R.S., 1984, STRESS APPRAISAL COP; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Lewis A. J., 1942, P ROY SOC MED, V35, P607; Lishman W. A., 1987, ORGANIC PSYCHIAT PSY; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; LONDON PS, 1967, ANN ROY COLL SURG, V41, P4; ODDY M, 1984, CLOSED HEAD INJURY P, P108; Prigatano G. P., 1987, COMMUNITY REENTRY HE, P1; Prigatano G. P., 1987, NEUROPSYCHOL REHABIL, P355; Selecki B R, 1967, Med J Aust, V2, P113; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Smith A., 1982, SYMBOL DIGIT MODALIT; Symonds C P, 1937, Proc R Soc Med, V30, P1081; Symonds CP, 1943, LANCET, V1, P7; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; TATE RL, 1996, P 5 C INT ASS STUD T; TSUANG MT, 1985, AM J PSYCHIAT, V142, P538; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Walsh K. W, 1991, UNDERSTANDING BRAIN; WEINSTEIN GS, 1981, J CLIN PSYCHIAT, V42, P120; Wilson, 1991, NATL ADULT READING T	43	15	16	0	4	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JAN	1998	8	1					1	18		10.1080/713755554			18	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	YW987	WOS:000071994900001					2021-06-18	
J	Vaz, R; Sarmento, A; Borges, N; Cruz, C; Azevedo, I				Vaz, R; Sarmento, A; Borges, N; Cruz, C; Azevedo, I			Effect of mechanogated membrane ion channel blockers on experimental traumatic brain oedema	ACTA NEUROCHIRURGICA			English	Article						brain oedema; mechanogated; ion channels; trauma	SMOOTH-MUSCLE CELLS; HEAD-INJURY; VASCULAR-PERMEABILITY; ENDOTHELIAL-CELLS; ARACHIDONIC-ACID; XENOPUS OOCYTES; K+ CHANNELS; FATTY-ACIDS; EDEMA; STRETCH	Traumatic head injury leads to marked swelling of endothelial cells, both in human patients and in Marmarou's rat model. We used this model to test the hypothesis of mechanogated ion channels being involved in the formation of traumatic brain oedema. All mechanogated channel blockers tested (gadolinium, amiloride, gentamicin) significantly reduced traumatic brain oedema evaluated by Evans blue extraction ratio, either when given 15 minutes before or 30 minutes after induction of trauma (evaluation 2 hours after trauma). These results clearly support our hypothesis, opening a new way for the investigation of the treatment of a clinical situation endowed with high morbidity and mortality.	Hosp Sao Joao, Fac Med, Dept Neurosurg, P-4200 Oporto, Portugal; Hosp Sao Joao, Fac Med, Inst Pharmacol & Therapeut, P-4200 Oporto, Portugal	Vaz, R (corresponding author), Hosp Sao Joao, Fac Med, Dept Neurosurg, Alameda Prof Hernani Monteiro, P-4200 Oporto, Portugal.		Borges, Nuno/K-7051-2013; Sarmento, Antonio/M-5235-2013	Sarmento, Antonio/0000-0001-5269-7231; Borges, Nuno/0000-0001-6357-0615; Vaz, Rui/0000-0001-7527-8187			BENDER AS, 1994, ACTA NEUROCHIR, P28; BULLOCK R, 1985, J NEUROSURG, V63, P64, DOI 10.3171/jns.1985.63.1.0064; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; DENK W, 1992, J NEUROPHYSIOL, V68, P927; Friedman A, 1996, NAT MED, V2, P1382, DOI 10.1038/nm1296-1382; GRABOWSKI EF, 1985, J LAB CLIN MED, V105, P36; HADJUCKZOK G, 1994, J CLIN INVEST, V94, P2392; HAMILL OP, 1992, TRENDS PHARMACOL SCI, V13, P373, DOI 10.1016/0165-6147(92)90115-M; Hamill OP, 1996, PHARMACOL REV, V48, P231; Hariri R J, 1994, Neurosurg Clin N Am, V5, P687; HIGGINS CF, 1995, J PHYSIOL-LONDON, V482P, pS31; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; JORGENSEN F, 1985, ACTA PHYSIOL SCAND, V124, P249; JUKKA Y, 1995, BIOPHYS J, V68, P1888; KIM DH, 1995, J PHYSIOL-LONDON, V484, P643, DOI 10.1113/jphysiol.1995.sp020693; KIMELBERG HK, 1979, BRAIN RES, V173, P111; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KIRBER MT, 1992, FEBS LETT, V297, P24, DOI 10.1016/0014-5793(92)80319-C; KITA H, 1994, ACTA NEUROCHIR, P452; LANE JW, 1993, BRIT J PHARMACOL, V108, P116, DOI 10.1111/j.1476-5381.1993.tb13449.x; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; MARMAROU A, 1994, ACTA NEUROCHIR, P421; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; MEVES H, 1994, PROG NEUROBIOL, V43, P175, DOI 10.1016/0301-0082(94)90012-4; MILLER VM, 1988, AM J PHYSIOL, V255, pH446; MILLET B, 1988, BIOPHYS J, V53, pA155; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NARUSE K, 1993, AM J PHYSIOL, V264, pC1037; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NOMURA K, 1990, J MEMBRANE BIOL, V115, P241, DOI 10.1007/BF01868639; PENN RD, 1982, HEAD INJURY, P233; PETROU S, 1994, J GEN PHYSIOL, V103, P471, DOI 10.1085/jgp.103.3.471; STRIRINSKY VP, 1989, J CELL BIOL, V109, P331; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; VANDENBRINK WA, 1994, ACTA NEUROCHIR WIE S, V60, P455; Vaz R, 1997, ACTA NEUROCHIR, V139, P215, DOI 10.1007/BF01844754; VIGNE P, 1989, J BIOL CHEM, V264, P7663; Wahl M, 1993, Acta Neurochir Suppl (Wien), V57, P64; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; YOUNG W, 1994, NEUROBIOLOGY CENTRAL, P123	42	15	15	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		1998	140	4					371	375		10.1007/s007010050111			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	ZT038	WOS:000074041400011	9689329				2021-06-18	
J	Feldman, Z; Gurevitch, B; Artru, AA; Shapira, Y; Reichenthal, E				Feldman, Z; Gurevitch, B; Artru, AA; Shapira, Y; Reichenthal, E			Neurologic outcome with hemorrhagic hypotension after closed head trauma in rats: Effect of early versus delayed conservative fluid therapy	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						blood pressure; head trauma; hemorrhage; intravenous fluid; neurologic outcome; rats	BRAIN INJURY; INTRACRANIAL-PRESSURE; HYPERTONIC SALINE; SMALL-VOLUME; SHOCK; RESUSCITATION; MANAGEMENT; INFUSION	Objective: This study examined (1) whether two previously reported, well-established models in rats, one a model of hemorrhagic hypotension and the other a model of closed head trauma, could be combined to evaluate neurologic outcome when hemorrhage occurs subsequent to head injury, and (2) the ability of the traditional, conservative approach to fluid therapy (3 mL of intravenous fluid for 1 mL of blood loss) to reverse the detrimental effects of hemorrhagic hypotension after closed head trauma, In addition, two strategies of fluid therapy (early and delayed) were examined. Methods: Fifty-six Sprague-Dawley male rats were divided into five groups with head injury at time 0 in groups 3 to 5, hemorrhage at 1 hour in groups 1, 2, 4, and 5, and intravenous fluid at 15 minutes (groups 2 and 5) or 60 minutes (groups 1 and 4) after hemorrhage. Head injury was delivered using a weight-drop impact of 0.5 J onto the closed cranium, Neurologic Severity Score (NSS) was determined at 1 hour (just before hemorrhage) and at 4 hours. Results: NSS at 1 hour did not differ between groups 3 to 5 (15.5 (9-24) to 16 (2-21), median (range)), The amount of bleeding did not differ between groups during the first 15 minutes of hemorrhage (2.8 +/- 0.8 to 3.7 +/- 2.0 mL, mean +/- SD), After 60 minutes, cumulative blood loss in the delayed fluid therapy groups was less (3.1 +/- 1.13 mL in group 1 and 4.25 +/- 2.39 mL in group 4) than in the early fluid therapy groups (7.73 +/- 4.41 mL in group 2 and 6.85 +/- 2.36 mL in group 5) (analysis of variance, p < 0.01), The NSS of group 3 (head injury only) improved at 4 hours after injury (12 (5-20)), whereas the NSS of groups 4 and 5 (head injury followed by hemorrhage) deteriorated (24 (17-25) and 19.5 (9-25), respectively) (Kruskal-Wallis test, p < 0.05). In all the hemorrhage groups, fluid therapy failed to restore blood pressure to prehemorrhage levels. Conclusion: It is concluded that the two individual models of hemorrhagic hypotension and closed head trauma in rats can be combined to evaluate outcome when hemorrhage occurs subsequent to head injury, Furthermore, traditional, conservative fluid therapy, whether early or delayed, failed to restore blood pressure or to improve NSS when hemorrhage occurred after head injury, Blood loss was greater with early fluid therapy whether or not head injury was present.	SOROKA MED CTR,DEPT NEUROSURG,IL-84101 BEER SHEVA,ISRAEL; SOROKA MED CTR,DEPT ANESTHESIOL,IL-84101 BEER SHEVA,ISRAEL; BEN GURION UNIV NEGEV,FAC HLTH SCI,BEER SHEVA,ISRAEL; UNIV WASHINGTON,SCH MED,DEPT ANESTHESIOL,SEATTLE,WA 98195							BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; CHESNUT R., 1993, HEAD INJURY, V3rd, P459; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR SUPP, V59, P121; GRADY MS, 1995, ANESTHETIC MANAGEMEN, P87; GUNNAR W, 1988, SURGERY, V103, P398; HARIRI RJ, 1993, J NEUROSURG, V79, P421, DOI 10.3171/jns.1993.79.3.0421; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KRAUSZ MM, 1992, J TRAUMA, V33, P6, DOI 10.1097/00005373-199207000-00002; LAM AM, 1995, ANESTHETIC MANAGEMEN, P181; MARSHALL LF, 1982, CLIN NEUR, V29, P312; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; RABINOVICI R, 1989, SURG GYNECOL OBSTET, V169, P137; SHAPIRA Y, 1995, J NEUROSURG ANESTH, V7, P17, DOI 10.1097/00008506-199501000-00004; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; TOMPKINS P, 1997, 10 INT S INTR PRESS, P5; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011	22	15	15	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	1997	43	4					667	672		10.1097/00005373-199710000-00017			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	YD167	WOS:A1997YD16700023	9356065				2021-06-18	
J	Jacobs, HE				Jacobs, HE			The Clubhouse: Addressing work-related behavioral challenges through a supportive social community	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						behavior; Clubhouse; community; service delivery systems; vocational	TRAUMATIC BRAIN INJURY; EMPLOYMENT; RETURN	Behavioral challenges in the workplace are not always the sole dominion of the person with disability after brain injury. These challenges may also emanate from the work site or the vocational services that are used to help people return to work. Although present-day vocational services have helped numerous persons with disabilities after brain injury return to work, most remain unemployed. Other approaches may bene some of these people and address some of the longstanding limitations of existing vocational programming. One such approach is the Clubhouse, a member-directed, community-based program of supports that is gaining increasing attention in supportive programming. This article discusses salient factors that affect can work tenure after brain injury, the origins and design of the Clubhouse model, and examples of its application in helping people with presumed behavioral challenges sustain employment.								ANDERSON S, 1994, MENTAL ILLNESS NORMA; Beard J, 1982, PSYCHOSOC REHABIL, V5, P47; BEARD JH, 1978, SCHIZOPHRENIA BULL, V4, P622, DOI 10.1093/schbul/4.4.622; BILBY R, 1993, CLUBH PAP SEL PAP 7; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CATALANO R, 1981, J HEALTH SOC BEHAV, V22, P284, DOI 10.2307/2136522; CORTHELL DW, 1993, EMPLOYMENT OUTCOMES; DEMELLO C, 1994, TBI CHALLENGE, V2, P54; DOOLEY D, 1980, PSYCHOL BULL, V87, P450, DOI 10.1037/0033-2909.87.3.450; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JACOBS HE, 1995, TBI CHALLENGE, V3, P26; Jacobs HE, 1996, J VOCATIONAL REHABIL, V7, P169, DOI DOI 10.1016/1052-2263(96)00219-X; JACOBS HE, 1995, TBI CHALLENGE, V3, P46; JACOBS HE, 1994, TBI CHALLENGE, V2, P46; JELLINEK HM, 1982, ARCH PHYS MED REHAB, V63, P87; KAPLAN SP, 1993, REHABIL COUNS BULL, V36, P151; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; KAY T, 1993, COMMUNITY BASED EMPL; Millis S R, 1994, Int J Neurosci, V79, P165; NAGELE DA, 1993, KEEPING PERSONS HEAD; Thomas DF, 1996, J VOCATIONAL REHABIL, V7, P243; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; ULICNY GR, 1993, COMMUNITY BASED EMPL; WEHMAN P, 1989, ARCH PHYS MED REHAB, V70, P109; Wehman P., 1988, J HEAD TRAUMA REHAB, V3, P82, DOI DOI 10.1097/00001199-198812000-00012; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047	27	15	15	0	1	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1997	12	5					14	27		10.1097/00001199-199710000-00003			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	YA515	WOS:A1997YA51500003					2021-06-18	
J	Motohashi, O; Suzuki, M; Shida, N; Umezawa, K; Sugai, K; Yoshimoto, T				Motohashi, O; Suzuki, M; Shida, N; Umezawa, K; Sugai, K; Yoshimoto, T			Hirudin suppresses the invasion of inflammatory cells and the appearance of vimentin-positive astrocytes in the rat cerebral ablation model	JOURNAL OF NEUROTRAUMA			English	Article						hirudin; reactive astrocyte reactive gliosis; thrombin; trauma	GROWTH-FACTOR; ENDOTHELIAL-CELLS; LEUKOCYTE ADHESION; NEURITE OUTGROWTH; THROMBIN-RECEPTOR; PROTEASE NEXIN-1; PROLIFERATION; MACROPHAGES; CULTURE; ASTROBLASTS	Hirudin is a specific and direct-acting thrombin inhibitor superior to heparin as an anticoagulant. Thrombin is a multifunctional molecule that acts as a serine protease locally generated from prothrombin during blood coagulation related to injury and/or inflammation. We previously reported that thrombin might be involved in the inflammatory response, glial reaction, and scar formation that occurred in central nervous system (CNS). Here we studied the suppressive effects of hirudin on the inflammation, vimentin-positive astrocytes, and glial fibrillary acidic protein (GFAP)-positive astrocytes using rat cerebral ablation models. Hirudin and vehicle solution soaked in Gelform (R) were administered to the cavity of the traumatic brain defect. Brains were examined by conventional histologic and immunohistologic technique. Antibodies for monocytes/macrophages, GFAP, and vimentin were used to assess the infiltration of inflammatory cells and reaction of astrocytes. The number of the inflammatory cells, vimentin-positive astrocytes, and GFAP-positive astrocytes were quantitatively analyzed. Hirudin suppressed the infiltration of inflammatory cells and the increase in vimentin-positive astrocytes, but had no effects on the increase in GFAP-positive astrocytes. These data suggest that thrombin may play an important role in inflammatory and glial responses to CNS injury, and that hirudin can be a candidate for the therapeutic agent that minimizes the secondary brain damage following the inflammation, and the glial reaction mediated by vimentin-positive astrocytes near the lesion site.	IWATE MED UNIV, DEPT NEUROSURG, MORIOKA, IWATE 020, JAPAN	Motohashi, O (corresponding author), TOHOKU UNIV, SCH MED, DEPT NEUROSURG, AOBA KU, 1-1 SEIRYO MACHI, SENDAI, MIYAGI 98077, JAPAN.						ALBRIGHTSON CR, 1992, J PHARMACOL EXP THER, V263, P404; BIGNAMI A, 1989, INT J DEV NEUROSCI, V7, P343, DOI 10.1016/0736-5748(89)90056-7; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; DIJKSTRA CD, 1985, ADV EXP MED BIOL, V186, P409; FENTON JW, 1991, HAEMOSTASIS, V21, P27; FITZGERALD D, 1994, ANN NY ACAD SCI, V714, P41, DOI 10.1111/j.1749-6632.1994.tb12029.x; FURUKAWA S, 1986, BIOCHEM BIOPH RES CO, V136, P57, DOI 10.1016/0006-291X(86)90876-4; GABALDON M, 1992, ATHEROSCLEROSIS, V93, P217, DOI 10.1016/0021-9150(92)90258-I; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; GURWITZ D, 1990, J CELL PHYSIOL, V142, P155, DOI 10.1002/jcp.1041420119; HARLAN JM, 1986, J CELL BIOL, V103, P1129, DOI 10.1083/jcb.103.3.1129; HERBERT JM, 1994, BIOCHEM J, V303, P227, DOI 10.1042/bj3030227; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; JANECZKO K, 1991, FOLIA HISTOCHEM CYTO, V29, P55; JOHNSON PH, 1994, ANNU REV MED, V45, P165, DOI 10.1146/annurev.med.45.1.165; JONES A, 1990, IMMUNOLOGY, V71, P236; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; LORET C, 1989, J BIOL CHEM, V264, P8319; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; OHTANI H, 1992, VIRCHOWS ARCH A, V420, P403, DOI 10.1007/BF01600511; PERRAUD F, 1987, INT J DEV NEUROSCI, V5, P181, DOI 10.1016/0736-5748(87)90028-1; PURO DG, 1990, GRAEF ARCH CLIN EXP, V228, P169, DOI 10.1007/BF02764313; REANTRAGOON S, 1994, ARCH BIOCHEM BIOPHYS, V314, P315, DOI 10.1006/abbi.1994.1448; SCHIFFER D, 1986, BRAIN RES, V374, P110, DOI 10.1016/0006-8993(86)90399-9; SHANKAR R, 1992, J BIOL CHEM, V267, P9376; SMINIA T, 1986, THYMUS, V8, P141; SMINIA T, 1986, IMMUNOBIOLOGY, V172, P72, DOI 10.1016/S0171-2985(86)80053-5; SMINIA T, 1986, CALCIFIED TISSUE INT, V39, P263, DOI 10.1007/BF02555216; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; TAS PWL, 1990, EXP CELL RES, V189, P22, DOI 10.1016/0014-4827(90)90251-5; TESFAMARIAM B, 1994, CIRC RES, V74, P930, DOI 10.1161/01.RES.74.5.930; VANDERBRUGGEGAMELKOORN GJ, 1985, IMMUNOBIOLOGY, V169, P553, DOI 10.1016/S0171-2985(85)80009-7; WORTWEIN G, 1994, BEHAV BRAIN RES, V63, P127, DOI 10.1016/0166-4328(94)90083-3	34	15	16	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	1997	14	10					747	754		10.1089/neu.1997.14.747			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	YE057	WOS:A1997YE05700006	9383093				2021-06-18	
J	Butler, PB; Farmer, SE; Major, RE				Butler, PB; Farmer, SE; Major, RE			Improvement in gait parameters following late intervention in traumatic brain injury: a long-term follow-up report of a single case	CLINICAL REHABILITATION			English	Article								Objective: To evaluate the effect of using an optimally adjusted fixed ankle foot orthosis to control knee pain and promote improvement in gait parameters in a subject with hemiplegia following a traumatic brain injury 11 years previously. Design: This is the report of a single case, using gait laboratory facilities to monitor force alignment relative to the knee and single leg balance time with the subject barefoot. Subject: A 35-year-old woman with a right hemiplegia seen 11 years after onset. Intervention: A polypropylene fixed ankle foot orthosis was supplied to the hemiplegic limb and shoe modifications were made to optimize the position of the ground reaction force relative to the knee during stance phase of gait. This orthosis was used on a daily basis for one year. Results: Knee pain was controlled after three months use of the orthosis. Graphical results of force alignment during stance phase of gait are presented for initial assessment and at one and four years postorthotic supply. A large knee-extending effect was noted on the hemiplegic limb at initial assessment and this was reduced by 67% of its initial value at one year. A compensatory early heel lift was initially noted on the opposite limb and this was reduced by 42% of the initial height at one year. These results were maintained at four years. Right leg standing balance was not initially possible but was recorded as 5 s duration at three months and this was maintained at one and at four years. Conclusions: The use of an optimally adjusted ankle foot orthosis was effective in controlling knee pain and improving barefoot gait parameters with maintenance of the improvement alter use of the orthosis was discontinued. Further research is required to fully establish the potential of this approach in subjects with traumatic brain injury.	ROBERT JONES & AGNES HUNT ORTHOPAED HOSP NHS TRUS,ORTHOT RES & LOCOMOTOR ASSESSMENT UNIT,OSWESTRY SY10 7AG,SHROPS,ENGLAND; NEWCASTLE GEN HOSP,DEPT REG MED PHYS,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Butler, PB (corresponding author), ROBERT JONES & AGNES HUNT ORTHOPAED HOSP NHS TRUS,MOVEMENT CTR,OSWESTRY SY10 7AG,SHROPS,ENGLAND.						BUTLER PB, 1992, DEV MED CHILD NEUROL, V34, P567; Butler PB, 1991, PHYSIOTHERAPY, V77, P81, DOI DOI 10.1016/S0031-9406(10)63580-8; KADABA MP, 1989, ORTHOP T, V13, P329; MAJOR RE, 1992, CLIN REHABIL S, V6, P52; Meadows CB, 1995, CONS C LOW LIMB ORTH, P57; ROSENTHAL RK, 1975, J BONE JOINT SURG AM, VA 57, P545, DOI 10.2106/00004623-197557040-00019; STALLARD J, 1987, PHYSIOTHERAPY, V73, P398; TAIT JH, 1979, J MED ENG TECHNOL, V3, P252, DOI 10.3109/03091907909160665; TEGROEN JA, 1964, S AFR MED J, V38, P502; Wells R P, 1981, Bull Prosthet Res, V10-35, P15; Winter D. A., 1987, BIOMECHANICS MOTOR C; ZIV I, 1984, DEV MED CHILD NEUROL, V26, P94	12	15	15	0	2	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON, ENGLAND NW1 3BH	0269-2155			CLIN REHABIL	Clin. Rehabil.	AUG	1997	11	3					220	226		10.1177/026921559701100305			7	Rehabilitation	Rehabilitation	YA659	WOS:A1997YA65900005	9360034				2021-06-18	
J	Henley, CM; Wey, K; Takashima, A; Mills, C; Granmayeh, E; Krishnappa, I; Robertson, CS				Henley, CM; Wey, K; Takashima, A; Mills, C; Granmayeh, E; Krishnappa, I; Robertson, CS			S-adenosylmethionine decarboxylase activity is decreased in the rat cortex after traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						S-adenosylmethionine decarboxylase; polyamines; brain injury; edema; trauma	CORTICAL IMPACT INJURY; MURINE LEUKEMIA-CELLS; ORNITHINE DECARBOXYLASE; CEREBRAL-ISCHEMIA; ALPHA-DIFLUOROMETHYLORNITHINE; POLYAMINE METABOLISM; CA-2+ FLUXES; STIMULATION; METHIONINE; RECOVERY	S-Adenosyl-L-methionine decarboxylase (SAMdc) and L-ornithine decarboxylase (ODC) are major enzymes regulating polyamine synthesis. Following ischemia, putrescine content increases as a result of post-traumatic activation of ODC and inhibition of SAMdc. These alterations are thought to mediate edema and cell death. The purpose of this study was to quantify SAMdc activity and edema in the brain following controlled cortical impact injury. Anesthetized adult male rats underwent a right parietal craniectomy and were subjected to cortical impact injury. Tissues were obtained from three bilateral regions: parietal cortex, motor area (CPm); parietal cortex, somatosensory area (CPs); and the pyriform cortex (CPF). SAMdc activity was determined in the postmitochondrial fraction from homogenates of fresh, unfrozen tissues by measuring the decarboxylation of S-adenosyl-L-[carboxyl-C-14] methionine. Basal SAMdc activity was determined in unoperated rats, and regional differences were noted: Activity was lower in the CPF than in the CPm and CPs. SAMdc activity decreased to the greatest extent in the ipsilateral CPm (impact site) from 1 to 72 h following traumatic brain injury. Significant edema was found in the ipsilateral CPm 1, 8, 16, 24, and 48 h after injury. Decreased SAMdc activity impairs the conversion of putrescine to polyamines and may contribute to delayed pathological changes in the brain after traumatic injury.	BAYLOR COLL MED, DEPT NEUROSURG, HOUSTON, TX 77030 USA	Henley, CM (corresponding author), BAYLOR COLL MED, BOBBY R ALFORT DEPT OTORHINOLARYNGOL & COMMUNICAT, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS027616, P01NS027616] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27616] Funding Source: Medline		BACKOUS DD, 1994, OTOLARYNG HEAD NECK, V111, P377, DOI 10.1177/019459989411100401; Baskaya MFK, 1996, NEUROSURGERY, V38, P140; Baskaya MK, 1996, J NEUROTRAUM, V13, P85, DOI 10.1089/neu.1996.13.85; BONDY SC, 1986, BRAIN RES, V371, P96, DOI 10.1016/0006-8993(86)90814-0; BYERS TL, 1993, BIOCHEM J, V290, P115, DOI 10.1042/bj2900115; BYERS TL, 1992, BIOCHEM J, V287, P717, DOI 10.1042/bj2870717; CESTARO B, 1994, ACTA NEUROL SCAND, V89, P32, DOI 10.1111/j.1600-0404.1994.tb05407.x; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CROZAT A, 1992, ENDOCRINOLOGY, V130, P1131, DOI 10.1210/en.130.3.1131; DEMPSEY R J, 1988, Neurological Research, V10, P141; DIENEL GA, 1984, J NEUROCHEM, V42, P1053, DOI 10.1111/j.1471-4159.1984.tb12710.x; DIENEL GA, 1985, J NEUROCHEM, V44, P600, DOI 10.1111/j.1471-4159.1985.tb05454.x; GILAD GM, 1992, BIOCHEM PHARMACOL, V44, P401, DOI 10.1016/0006-2952(92)90428-L; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Henley C., 1996, Society for Neuroscience Abstracts, V22, P1184; Henley CM, 1996, J NEUROTRAUM, V13, P487, DOI 10.1089/neu.1996.13.487; HENLEY CM, 1995, HEARING RES, V84, P99, DOI 10.1016/0378-5955(95)00017-X; IQBAL Z, 1985, BIOCHEM BIOPH RES CO, V133, P563, DOI 10.1016/0006-291X(85)90943-X; KLEIHUES P, 1975, BRAIN RES, V95, P61, DOI 10.1016/0006-8993(75)90207-3; KOENIG H, 1983, P NATL ACAD SCI-BIOL, V80, P7210, DOI 10.1073/pnas.80.23.7210; KOENIG H, 1983, NATURE, V305, P530, DOI 10.1038/305530a0; KOMULAINEN H, 1987, BRAIN RES, V401, P50, DOI 10.1016/0006-8993(87)91162-0; KOZUKA M, 1988, JPN J PHARMACOL, V46, P225, DOI 10.1254/jjp.46.225; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MATSUI Y, 1987, EUR J PHARMACOL, V144, P211, DOI 10.1016/0014-2999(87)90521-8; MORRISON LD, 1993, DEV BRAIN RES, V73, P237, DOI 10.1016/0165-3806(93)90143-X; MUSZYNSKI CA, 1993, J CEREBR BLOOD F MET, V13, P1033, DOI 10.1038/jcbfm.1993.131; PAJUNEN AEI, 1978, J NEUROCHEM, V30, P281, DOI 10.1111/j.1471-4159.1978.tb07066.x; PASCHEN W, 1988, BRAIN RES, V453, P9, DOI 10.1016/0006-8993(88)90138-2; PASCHEN W, 1994, NEUROPHARMACOLOGY PO, P223; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1982, AM J PHYSIOL, V243, pC212; PEGG AE, 1983, METHOD ENZYMOL, V94, P234; Rao AM, 1997, MOL BRAIN RES, V44, P134, DOI 10.1016/S0169-328X(96)00245-8; ROHN G, 1992, EXP NEUROL, V117, P210, DOI 10.1016/0014-4886(92)90129-E; RUSSELL DH, 1985, DRUG METAB REV, V16, P1, DOI 10.3109/03602538508991430; SATO H, 1988, BIOCHEM BIOPH RES CO, V150, P491, DOI 10.1016/0006-291X(88)90547-5; SCOTT RH, 1994, NEUROPHARMACOLOGY PO, P205; SEYOUM G, 1994, EXP TOXICOL PATHOL, V46, P177, DOI 10.1016/S0940-2993(11)80077-1; SHOHAMI E, 1992, EXP NEUROL, V117, P189, DOI 10.1016/0014-4886(92)90126-B; STURMAN JA, 1975, J NEUROCHEM, V25, P267, DOI 10.1111/j.1471-4159.1975.tb06964.x; TROUT JJ, 1986, LAB INVEST, V55, P622	42	15	15	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUL	1997	69	1					259	265					7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	XF431	WOS:A1997XF43100031	9202318				2021-06-18	
J	Ruhmann, O; Wirth, CJ; Gosse, F				Ruhmann, O; Wirth, CJ; Gosse, F			Trapezius transfer in deltoid paralysis	ORTHOPADE			German	Article						trapezius transfer; brachial plexus palsy	BRACHIAL-PLEXUS INJURIES; SHOULDER; SURGERY	In most cases the genesis of brachial plexus palsy is traumatic, often because of bike accidents. If physiotherapy and neurosurgical procedures such as nerve repair do not have the desired outcome, muscle transfer operations are possible. The results of our favored transfer of the trapezius muscle to compensate paralysis of the deltoid muscle will be presented. Preoperatively radiological, clinical and electromyographic examinations are necessary. Our results are based upon the clinical and radiological check ups and the subjective assessment of the patients. Thirty-one patients (7 female, 24 male) underwent a trapezius transfer between March 1994 and December 1996. The average age was 29 years (range 18-46 years). We performed the operations using a modification of Saha's technique. With the patient in lateral decubitus position and protection of the opposite plexus, a sagital skin incision is the first step, followed by the preparation of trapezius and deltoid muscle as well as the bony parts of the shoulder (acromion, clavicle, scapular spine). The deltoid origin is cut from the lateral third of the clavicle, the acromion and the lateral half of the scapular spine. The next step is transection of the root of the acromion and the lateral clavicle. After elevation of the remaining trapezius insertions from the clavicle and scapular spine, the proximal humerus is exposured by splitting the partly detached deltoid muscle longitudinally. Then the acromion fragment and humerus are prepared for the bone-to-bone contact. In 90 degrees of abduction the acromion fragment with its trapezius insertion is transferred and fixed to the humerus with two 4.5-mm screws. Finally the deltoid is sutured on the top of the trapezius and the skin is closed over two suction drains. Postoperatively we immobilize the operated arm in an abduction support for 6 weeks. The physiotherapy program starts on the first postoperative day with active training of elbow, hand and fingers and electrostimulation of the transferred trapezius muscle. Six weeks after the procedure we take an X-ray and start with progressive adduction of the arm. The preoperative subluxation of the humeral head was abolished in all cases. We achieved an average increase of active abduction from 7.3 degrees (range 0-45 degrees) preoperatively to 39.2 degrees (range 25 degrees-80 degrees) 1 year after the operation; the increase of forward flexion was from 20 degrees (range 0 degrees-85 degrees) to 43 degrees(range 20 degrees-90 degrees). All patients were satisfied with the improvement of stability and function of the operated shoulder. Finally we can conclude that the trapezius transfer for flail shoulder gives a satisfactory outcome regarding shoulder function and stability as well as the subjective situation of the patients.		Ruhmann, O (corresponding author), HANNOVER MED SCH,ORTHOPAD KLIN,HEIMCHENSTR 1-7,D-30625 HANNOVER,GERMANY.						AZIZ W, 1990, J BONE JOINT SURG BR, V72, P701; BATEMAN J, 1954, SHOULDER ENV; BERGER A, 1991, ANN PLAS SURG, V26, P70, DOI 10.1097/00000637-199101000-00011; BERGER A, 1995, MICROSURG, V16, P43, DOI 10.1002/micr.1920160112; BERGER A, 1994, MICROSURG, V15, P760, DOI 10.1002/micr.1920151104; CHARNLEY J, 1964, J BONE JOINT SURG BR, V46, P614; CHUANG DC, 1995, CLIN ORTHOP RELAT R, V314, P104; Chuinard R C, 1980, Orthopedics, V3, P901, DOI 10.3928/0147-7447-19800901-14; CHUNLIN H, 1991, CHINESE MED J, V104, P753; COFIELD RH, 1979, J BONE JOINT SURG AM, V61, P668, DOI 10.2106/00004623-197961050-00005; Davidson WD, 1936, J AMER MED ASSOC, V106, P2237; GOLDNER JL, 1988, HAND CLIN, V4, P223; Haas SL, 1935, J AMER MED ASSOC, V104, P99, DOI 10.1001/jama.1935.02760020015005; HARMON PH, 1950, J BONE JOINT SURG AM, V32-A, P583, DOI 10.2106/00004623-195032030-00013; HILDEBRANDT A, 1905, DEUT MED WOCHENSCHR, V39, P1578; Jager M, 1977, Aktuelle Probl Chir Orthop, V1, P80; JURGENSBECKER A, 1996, DT ARZTEBL, V93, P3262; KARVE A, 1986, J HAND SURG-BRIT, V11, P81; Knofler E W, 1978, Beitr Orthop Traumatol, V25, P137; LEFFERT RD, 1988, HAND CLIN, V4, P273; LEFFERT RD, 1980, MANAGEMENT PERIPHERA, P805; NAGANO A, 1989, CLIN ORTHOP RELAT R, V247, P97; NARAKAS AO, 1993, CLIN NEUROL NEUROSUR, V95, P89; Ober F R, 1932, JAMA-J AM MED ASSOC, V99, P2182; PFEIL J, 1985, Z ORTHOP GRENZGEB, V123, P872, DOI 10.1055/s-2008-1044770; PRONK GM, 1989, J REHABIL SCI, V2, P30; RICHARDS RR, 1988, J BONE JOINT SURG AM, V70A, P416, DOI 10.2106/00004623-198870030-00014; RICHARDS RR, 1985, CLIN ORTHOPAEDICS, V189, P250; RIEDEL G, 1928, ERG CHIR ORTHOP, V21, P489; RORABECK CH, 1980, J TRAUMA, V20, P491, DOI 10.1097/00005373-198006000-00010; ROUHOLAMIN E, 1991, INJURY, V22, P271, DOI 10.1016/0020-1383(91)90004-X; Rudigier J, 1991, BIBLIOTHEK HANDCHIRU; RUSSE O, 1978, UNFALLHEILKUNDE, V81, P299; RUSSE O, 1975, HEFTE UNFALLHEILKD, V126, P179; Saha AK., 1967, ACTA ORTHOP SCAND S, V97, P5	35	15	17	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0085-4530			ORTHOPADE	Orthopade	JUL	1997	26	7					634	642					9	Orthopedics	Orthopedics	XQ765	WOS:A1997XQ76500010					2021-06-18	
J	Fleming, JM; Strong, J; Ashton, R; Hassell, M				Fleming, JM; Strong, J; Ashton, R; Hassell, M			A 1-year longitudinal study of severe traumatic brain injury in Australia using the Sickness Impact Profile	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							SEVERE HEAD-INJURY; DISABILITY RATING-SCALE; FOLLOW-UP; SOCIAL-ADJUSTMENT; REHABILITATION; RECOVERY; RELIABILITY	Objective: To document outcome and to investigate patterns of physical and psychosocial recovery in the first year following severe traumatic brain injury (TBI) in an Australian patient sample. Design: A longitudinal prospective study of a cohort of patients, with data collection at 3, 6, 9, and 12 months post injury. Setting: A head injury rehabilitation unit in a large metropolitan public hospital. Patients: A sample of 55 patients selected from 120 consecutive admissions with severe TBI. Patients who were more than 3 months post injury on admission, who remained confused, or who had severe communication deficits or a previous neurologic disorder were excluded. Interventions: All subjects participated in a multidisciplinary inpatient rehabilitation program, followed by varied participation in outpatient rehabilitation and community-based sen ices. Main Outcome Measures: The Sickness impact Profile (SIP) provided physical, psychosocial, and total dysfunction scores at each follow-up. Outcome at 1 year was measured by the Disability Rating Scale. Results: Multivariate analysis of variance indicated that the linear trend of recovery over time was less for psychosocial dysfunction than for physical dysfunction (F(1,51) = 5.87, P < .02). One rear post injury, 22% of subjects had returned to their previous level of employability, and 42% were able to live independently. Conclusions: Recovery from TBI in this Australian sample followed a pattern similar to that observed in other countries, with psychosocial dysfunction being more persistent. Self-report measures such as the SIP in TBI research are limited by problems of diminished self-awareness.	UNIV QUEENSLAND,DEPT PSYCHOL,ST LUCIA,QLD 4067,AUSTRALIA; PRINCESS ALEXANDRA HOSP,HEAD INJURY UNIT,WOOLLOONGABBA,QLD 4102,AUSTRALIA	Fleming, JM (corresponding author), PRINCESS ALEXANDRA HOSP,OCCUPAT THERAPY DEPT,IPSWICH RD,WOOLLOONGABBA,QLD 4102,AUSTRALIA.		Strong, Jenny/F-1211-2010; Fleming, Jennifer M/B-4436-2011	Strong, Jenny/0000-0002-9367-8755; 			BADCOCK KA, 1988, COMMUNITY HEALTH ST, V12, P428; BARTKO JJ, 1976, J NERV MENT DIS, V163, P307, DOI 10.1097/00005053-197611000-00003; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOND MR, 1976, SCAND J REHABIL MED, V8, P127; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Brzuzy S, 1996, J HEAD TRAUMA REHAB, V11, P74, DOI 10.1097/00001199-199606000-00011; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; Fleming JM, 1996, BRAIN INJURY, V10, P1; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Keppel G., 1982, DESIGN ANAL RES HDB, V2nd; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; LYLE DM, 1986, J NEUROSURG, V65, P15, DOI 10.3171/jns.1986.65.1.0015; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; NORUSSI MJ, 1990, SPSS PC PLUS STAT 4; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; POSNFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Wehman P., 1988, J HEAD TRAUMA REHAB, V3, P82, DOI DOI 10.1097/00001199-198812000-00012	40	15	15	0	5	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1997	12	3					27	40		10.1097/00001199-199706000-00004			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	XC699	WOS:A1997XC69900004					2021-06-18	
J	Stoffel, M; Berger, S; Staub, F; Eriskat, J; Jacob, K; Baethmann, A				Stoffel, M; Berger, S; Staub, F; Eriskat, J; Jacob, K; Baethmann, A			The effect of dietary alpha-tocopherol on the experimental vasogenic brain edema	JOURNAL OF NEUROTRAUMA			English	Article						alpha-tocopherol; experimental head injury; free radical damage; rats; vasogenic brain edema	HUMAN-ENDOTHELIAL-CELLS; UNSATURATED FATTY-ACIDS; BASIC COMPUTER-PROGRAM; FETAL-RAT BRAIN; VITAMIN-E; LIPID-PEROXIDATION; MULTIPLE COMPARISONS; MEMBRANE INTEGRITY; ARACHIDONIC-ACID; SUPEROXIDE ANION	It has become increasingly obvious that free radicals and lipid peroxidation contribute to brain damage from trauma by mediating edema formation and ischemia. It should, therefore, be expected that the actual level of endogenous antioxidants, as for example, vitamin C and E in plasma, has an influence on the extent of free radical-induced injury. In this communication we investigate the effect of dietary changes in the free radical scavenger alpha-tocopherol on posttraumatic cerebral swelling in Sprague-Dawley rats. Low, normal, and high plasma levels of alpha-tocopherol were established by respective diets supplied over 2 weeks. Animals of all groups received the same food without alpha-tocopherol. One group was fed a vitamin E-free diet. The pellet-food for the other animals was supplemented either with 5-mg alpha-tocopherol/100 g or 250-mg alpha-tocopherol/100 g dry mass, respectively. The vitamin E-free diet lowered the alpha-tocopherol level in plasma to 30% of control, whereas supplementation with 250 mg/100 g led to a plasma concentration of 200% of control. The animals were then subjected to a focal cold injury of the left cerebral hemisphere. Twenty-four hours after trauma the brain was removed and the water content of each hemisphere was determined by the wet-dry weight method. Swelling of the traumatized hemisphere was calculated as the difference in weight between the traumatized and contralateral control hemisphere. The 2-week alpha-tocopherol supplementation or -deletion diet, respectively, did not either afford significant reduction or lead to an enhancement of traumatic brain swelling. Likewise, the increase in brain water content of the traumatized hemisphere was not affected. It is concluded that supplementation or depletion of alpha-tocopherol for 2 weeks, resulting in a marked increase or decrease of the vitamin E plasma level, does not influence formation of posttraumatic vasogenic brain edema.	UNIV MUNICH, KLINIKUM GROSSHADERN, INST SURG RES, D-81366 MUNICH, GERMANY; UNIV MUNICH, KLINIKUM GROSSHADERN, INST CLIN CHEM, D-81366 MUNICH, GERMANY							BAETHMAN A, 1978, NEUROSURG REV, V1, P85; BAETHMANN A, 1992, NEUROCHEMICAL CORREL, P295; BURTON GW, 1983, ARCH BIOCHEM BIOPHYS, V221, P281, DOI 10.1016/0003-9861(83)90145-5; BUSTO R, 1984, ANN NEUROL, V15, P441, DOI 10.1002/ana.410150507; CHAN AC, 1990, LIPIDS, V25, P17, DOI 10.1007/BF02562422; CHAN PH, 1978, SCIENCE, V201, P358, DOI 10.1126/science.663662; CHAN PH, 1984, J NEUROSCI RES, V12, P595; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; CHAN PH, 1982, BRAIN RES, V248, P151, DOI 10.1016/0006-8993(82)91156-8; CLIFTON G L, 1989, Journal of Neurotrauma, V6, P71, DOI 10.1089/neu.1989.6.71; DEKEYSER J, 1992, LANCET, V339, P1562, DOI 10.1016/0140-6736(92)91830-2; DEMOPOULOS HB, 1982, CAN J PHYSIOL PHARM, V60, P1415, DOI 10.1139/y82-210; DEMOPOULOS HB, 1982, PATHOLOGY OXYGEN, P127; DRAKE JR, 1980, AM J CLIN NUTR, V33, P2386; Elmadfa I., 1985, VITAMIN E EIGENSCHAF; FOLBERGROVA J, 1993, J CEREBR BLOOD F MET, V13, P145, DOI 10.1038/jcbfm.1993.17; FRIEDRICH W, 1987, HDB VITAMINE; FUKUZAWA K, 1981, ARCH BIOCHEM BIOPHYS, V206, P173, DOI 10.1016/0003-9861(81)90078-3; GURDJIAN ES, 1978, SURG GYNECOL OBSTET, V146, P805; HALKSMILLER M, 1986, J NEUROPATH EXP NEUR, V45, P471, DOI 10.1097/00005072-198607000-00008; HALL ED, 1986, J NEUROSURG, V64, P951, DOI 10.3171/jns.1986.64.6.0951; HALL ED, 1988, OXYGEN RADICALS TISS, P127; KAGAN VE, 1990, BIOCHEM PHARMACOL, V40, P2403, DOI 10.1016/0006-2952(90)90080-5; Klatzo I, 1980, Adv Neurol, V28, P359; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LEBEL CP, 1989, BIOCHEM BIOPH RES CO, V163, P860, DOI 10.1016/0006-291X(89)92301-2; LO WD, 1986, J NEUROCHEM, V46, P394, DOI 10.1111/j.1471-4159.1986.tb12981.x; MACHLIN LJ, 1982, ANN NY ACAD SCI, V393, P48, DOI 10.1111/j.1749-6632.1982.tb31231.x; MATSUBARA T, 1986, J CELL PHYSIOL, V127, P207, DOI 10.1002/jcp.1041270203; MAZA SR, 1987, AM HEART J, V114, P1206, DOI 10.1016/0002-8703(87)90198-0; MEYDANI M, 1988, LIPIDS, V23, P405, DOI 10.1007/BF02535510; MULLER DPR, 1989, ANN NY ACAD SCI, V570, P146; MURAKAMI K, 1997, BRAIN EDEMA, V10; NAKAJIMA M, 1991, NEUROSCI LETT, V133, P49, DOI 10.1016/0304-3940(91)90054-W; OLESEN SP, 1987, ACTA PHYSIOL SCAND, V129, P181, DOI 10.1111/j.1748-1716.1987.tb08057.x; ORTEGA BD, 1972, STEROIDS BRAIN EDEMA, P167; PHELPS DL, 1979, PEDIATRICS, V63, P933; REDDANNA P, 1989, ANN NY ACAD SCI, V570, P136; SHUKLA A, 1995, FREE RADICAL RES, V22, P303, DOI 10.3109/10715769509145642; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Stein DG, 1991, J NEUROTRAUM, V8, P281, DOI 10.1089/neu.1991.8.281; THEODORSSONNORHEIM E, 1986, COMPUT METH PROG BIO, V23, P57, DOI 10.1016/0169-2607(86)90081-7; THEODORSSONNORHEIM E, 1987, COMPUT BIOL MED, V17, P85, DOI 10.1016/0010-4825(87)90003-5; TOIVANEN JL, 1987, PROSTAG LEUKOTR ESS, V26, P265, DOI 10.1016/0262-1746(87)90036-9; TORACK RM, 1959, AM J PATHOL, V35, P1135; TRAN K, 1992, LIPIDS, V27, P38, DOI 10.1007/BF02537056; ULLRICH V, 1989, FREE RADICAL RES COM, V7, P265, DOI 10.3109/10715768909087951; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; VATASSERY GT, 1988, J NEUROCHEM, V51, P621, DOI 10.1111/j.1471-4159.1988.tb01083.x; VONANDRIAN U, 1992, THESIS LUDWIG MAXIMI; WEI EP, 1985, AM J PHYSIOL, V248, pH157; YOSHIDA S, 1983, NEUROLOGY, V33, P166, DOI 10.1212/WNL.33.2.166; ZAMORA R, 1991, J NUTR, V121, P50	55	15	15	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	1997	14	5					339	348		10.1089/neu.1997.14.339			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	XE298	WOS:A1997XE29800005	9199399				2021-06-18	
J	Hoffman, SW; Stein, DG				Hoffman, SW; Stein, DG			Extract of Ginkgo biloba (EGb 761) improves behavioral performance and reduces histopathology after cortical contusion in the rat	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						traumatic brain injury; free radical scavenger; platelet activating factor antagonist; cognitive performance; spontaneous motor behavior; gliosis; neuronal sparing	FOREBRAIN CHOLINERGIC NEURONS; FACTOR PAF RECEPTOR; BASAL FOREBRAIN; FRONTAL-CORTEX; HIPPOCAMPAL-NEURONS; EXCITOTOXIC LESIONS; FREE-RADICALS; BRAIN EDEMA; ACID; GLUTAMATE	Male rats received bilateral frontal cortex contusions and were injected with 100 mg/kg of EGb 761 or an equal volume of vehicle beginning 5 min after injury and then with 1 injection/day for 7 days. The rats were tested for spontaneous motor behavior on days 1, 5, 10, and 15 postinjury and then for 10 days of spatial navigation performance in the Morris Water Maze (MWM), beginning on the day 8 after the contusion. Brain tissue was removed for examination on the 18th day after injury. Contused rats given EGb 761 performed more like intact rats on measures of spontaneous motor activity while vehicle-treated counterparts remained more active than either shams or ECb 761-treated animals by the conclusion of testing. Contusion-only rats were worse than shams on spatial performance, while those given EGb 761 were less impaired. Histological analyses indicated that EGb 761 failed to prevent loss of tissue at the primary site of impact. However, the extract reduced retrograde degeneration of neurons, gliosis in the thalamus, and ex vacuo hydrocephalus. EGb 761 treatment also decreased the loss of ChAT-positive neurons in the dorsomedial caudate-putamen and in the nucleus basalis magnocellularis (NBM). The results of this study indicate that EGb 761 could be a possible treatment for traumatic brain injury. (C) 1997 Elsevier Science Ireland Ltd.	EMORY UNIV, GRAD SCH ARTS & SCI, ATLANTA, GA 30322 USA	Hoffman, SW (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHARMACOL & TOXICOL, BOX 980613, RICHMOND, VA 23298 USA.		Stein, Donald/AAJ-5139-2020				ASANO T, 1989, MOL CHEM NEUROPATHOL, V10, P101, DOI 10.1007/BF03159717; ATTELLA MJ, 1989, EXP NEUROL, V105, P62, DOI 10.1016/0014-4886(89)90172-6; BARTH TM, 1990, STROKE, V21, P153; BAZAN NG, 1992, EFFECTS GINKGO BILOB, P172; BITO H, 1993, J LIPID MEDIATOR, V6, P169; BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BRAILOWSKY S, 1991, RESTOR NEUROL NEUROS, V3, P267, DOI 10.3233/RNN-1991-3505; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; CHAPMAN AG, 1989, NEUROSCI LETT, V107, P256, DOI 10.1016/0304-3940(89)90827-6; CHOPIN P, 1992, PSYCHOPHARMACOLOGY, V106, P26, DOI 10.1007/BF02253584; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DEFEUDIS FV, 1991, GINKGO BILOBA EXTRAC, P187; DELBARRE B, 1992, DRUG DEVELOP RES, V26, P419; Dimlich R V, 1990, Adv Neurol, V52, P365; DORMAN DC, 1992, AM J VET RES, V53, P138; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619; GAETANI P, 1994, NEUROCHEM RES, V19, P839, DOI 10.1007/BF00967453; GALLYAS F, 1970, ACTA NEUROPATHOL, V16, P35, DOI 10.1007/BF00686961; GAYKEMA RPA, 1991, J COMP NEUROL, V303, P563, DOI 10.1002/cne.903030405; GODUKHIN OV, 1980, NEUROSCIENCE, V5, P2151, DOI 10.1016/0306-4522(80)90131-1; Grassel E, 1992, Fortschr Med, V110, P73; HAGAN JJ, 1983, BEHAV BRAIN RES, V9, P83, DOI 10.1016/0166-4328(83)90015-3; HALLIWELL B, 1992, ANN NEUROL, V32, pS10, DOI 10.1002/ana.410320704; HITZENBERGER G, 1992, WIEN MED WOCHENSCHR, V142, P371; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; JUURLINK BHJ, 1992, NEUROREPORT, V3, P1135, DOI 10.1097/00001756-199212000-00026; KARCHER L, 1984, N-S ARCH PHARMACOL, V327, P31, DOI 10.1007/BF00504988; KIRKBY RJ, 1978, PHYSIOL BEHAV, V20, P669, DOI 10.1016/0031-9384(78)90263-9; KLEIJNEN J, 1992, BRIT J CLIN PHARMACO, V34, P352, DOI 10.1111/j.1365-2125.1992.tb05642.x; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; KOLB B, 1984, BRAIN RES REV, V8, P65, DOI 10.1016/0165-0173(84)90018-3; KORDOWER JH, 1992, EXP NEUROL, V117, P1, DOI 10.1016/0014-4886(92)90105-Y; KORNECKI E, 1991, LIPIDS, V26, P1243, DOI 10.1007/BF02536540; KRISTOFIKOVA Z, 1992, DEMENTIA, V3, P304; KUNIEVSKY B, 1992, J PHARMACOL EXP THER, V263, P562; LESCAUDRON L, 1992, EXP NEUROL, V116, P85, DOI 10.1016/0014-4886(92)90179-T; MASTERS JN, 1989, ENDOCRINOLOGY, V124, P3083, DOI 10.1210/endo-124-6-3083; MITCHELL JA, 1988, Q J EXP PSYCHOL-B, V40, P243; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; MUIR JL, 1993, BEHAV BRAIN RES, V57, P123, DOI 10.1016/0166-4328(93)90128-D; OBERPICHLER H, 1990, J CEREBR BLOOD F MET, V10, P133, DOI 10.1038/jcbfm.1990.17; PALMER AM, 1989, EXP BRAIN RES, V75, P659; PFISTER HW, 1992, STROKE, V23, P1798, DOI 10.1161/01.STR.23.12.1798; PORSOLT RD, 1990, PHARMACOL BIOCHEM BE, V36, P963, DOI 10.1016/0091-3057(90)90107-S; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; STOKES KA, 1990, BEHAV NEURAL BIOL, V53, P334, DOI 10.1016/0163-1047(90)90198-F; SUTTON RL, 1994, ACTA NEUROCHIR, P446; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; WEISS JH, 1994, NEUROSCIENCE, V60, P659, DOI 10.1016/0306-4522(94)90494-4; WRATHALL JR, 1992, EUR J PHARMACOL, V218, P273, DOI 10.1016/0014-2999(92)90179-8; YABE T, 1992, PHARMACOL BIOCHEM BE, V42, P595, DOI 10.1016/0091-3057(92)90004-Y	52	15	16	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.	APR	1997	11	1-2					1	12					12	Neurosciences	Neurosciences & Neurology	XB752	WOS:A1997XB75200001	21551523				2021-06-18	
J	Yamaki, T; Murakami, N; Iwamoto, Y; Sakakibara, T; Kobori, N; Ueda, S; Kikuchi, T; Uwahodo, Y				Yamaki, T; Murakami, N; Iwamoto, Y; Sakakibara, T; Kobori, N; Ueda, S; Kikuchi, T; Uwahodo, Y			Evaluation of learning and memory dysfunction and histological findings in rats with chronic stage contusion and diffuse axonal injury	BRAIN RESEARCH			English	Article						cortical contusion; diffuse axonal injury; learning acquisition; memory retention; water maze; hippocampus; entorhinal cortex	TRAUMATIC BRAIN INJURY; CONTROLLED CORTICAL IMPACT; ENTORHINAL CORTEX; COGNITIVE DEFICITS; HIPPOCAMPAL; LESIONS; DAMAGE; CORTICOSTERONE; ACQUISITION	We previously reported a modified fluid percussion device capable of consistently producing experimental cortical contusion (CC) and diffuse axonal injury (DAI) in separate groups of rats by lateral and midline fluid percussion, respectively. The purpose of the present study was to compare the differences in learning acquisition and memory retention impairments between these two types of injured rats in the chronic stage using the Morris water maze technique. We also compared the histological differences between these two different types of traumatic brain injury. The results showed a statistically significant difference in learning acquisition impairment between the sham and CC rats and also between the sham and DAI rats. However, a significant difference in memory retention impairment was observed only between the sham and DAI rats. Histologically, the neuronal cell loss of CA3 pyramidal cells in the hippocampus was observed on the ipsilateral side in the CC and bilaterally in DAI. The neuronal cell loss was seen in bilateral entorhinal cortex layer II in DAI, but it was not seen in CC. From these results, we speculate that the marked cell loss in the hippocampus CA3 region in both CC and DAI rats was related to the impairment of spatial learning acquisition. The marked cell loss in entorhinal cortex layer LI in DAI rats may be one of the important factors in the impairment of spatial memory retention. (C) 1997 Elsevier Science B.V.	OTSUKA PHARMACEUT CO LTD,TOKUSHIMA INST NEW DRUG RES 3,TOKUSHIMA 77101,JAPAN	Yamaki, T (corresponding author), KYOTO PREFECTURAL UNIV MED,DEPT NEUROSURG,KAMIGYO KU,KAWARAMACHI HIROKOJI,KYOTO 602,JAPAN.						Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; AUER RN, 1984, ACTA NEUROPATHOL, V64, P177, DOI 10.1007/BF00688108; BARTESAGHI R, 1994, NEUROSCIENCE, V61, P457, DOI 10.1016/0306-4522(94)90426-X; BRIERLEY JB, 1976, GREENFIELDS NEUROPAT, P43; CATALANI A, 1993, BRAIN RES, V624, P209, DOI 10.1016/0006-8993(93)90079-3; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P414; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; JARRARD LE, 1986, HIPPOCAMPUS, V4, P93; JONES RSG, 1993, TRENDS NEUROSCI, V16, P58, DOI 10.1016/0166-2236(93)90018-H; LEVISOHN LF, 1991, BRAIN RES, V564, P230, DOI 10.1016/0006-8993(91)91458-D; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MOSS M, 1981, J NEUROSCI, V1, P227; MURAKAMI N, 1993, ADV NEUROTRAUMA RES, V5, P42; PARKIN AJ, 1984, CORTEX, V20, P479, DOI 10.1016/S0010-9452(84)80053-2; PERTERSON DA, 1994, J NEUROSCI, V14, P6872; PLUSINELLI WA, 1982, ANN NEUROL, V11, P491; PRASAD MR, 1994, J NEUROCHEM, V63, P773; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; SCHENK F, 1985, EXP BRAIN RES, V58, P11; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; SUTHERLAND RJ, 1989, BEHAV NEURAL BIOL, V52, P331, DOI 10.1016/S0163-1047(89)90457-3; UEKI A, 1994, J NEUROL SCI, V125, P14, DOI 10.1016/0022-510X(94)90236-4; WHITEGBADEBO D, 1993, J NEUROTRAUM, V10, P297, DOI 10.1089/neu.1993.10.297; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613	40	15	20	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 28	1997	752	1-2					151	160		10.1016/S0006-8993(96)01469-2			10	Neurosciences	Neurosciences & Neurology	WT623	WOS:A1997WT62300017	9106451				2021-06-18	
S	Giulian, D		Reis, DJ; Posner, JB		Giulian, D			Immune responses and dementia	FRONTIERS OF NEUROLOGY: A SYMPOSIUM IN HONOR OF FRED PLUM	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	Meeting on Frontiers of Neurology - A Symposium in Honor of Fred Plum	OCT   05, 1996	CORNELL UNIV MED COLL, NEW YORK, NEW YORK	CHARLES A DANA FDN	CORNELL UNIV MED COLL		CENTRAL-NERVOUS-SYSTEM; AMYLOID BETA-PROTEIN; MONONUCLEAR PHAGOCYTES; MAMMALIAN BRAIN; DEFICIENCY SYNDROME; ALZHEIMERS-DISEASE; AMEBOID MICROGLIA; TRAUMATIC INJURY; NEUROTOXINS; RELEASE		Baylor Coll Med, Dept Neurol, Houston, TX 77031 USA	Giulian, D (corresponding author), Baylor Coll Med, Dept Neurol, Houston, TX 77031 USA.						BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BOLSI DINO, 1927, RIV PAT NERV E MENT, V32, P65; Davies Peter, 1994, P327; EIKELENBOOM P, 1994, TRENDS PHARMACOL SCI, V15, P447, DOI 10.1016/0165-6147(94)90057-4; FAGAN AM, 1990, EXP NEUROL, V110, P105, DOI 10.1016/0014-4886(90)90055-W; FIULIAN D, 1994, DEV NEUROSCI, V16, P128; FLARIS NA, 1993, GLIA, V7, P34, DOI 10.1002/glia.440070108; GAMES D, 1992, NEUROBIOL AGING, V13, P569, DOI 10.1016/0197-4580(92)90057-5; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1995, J NEUROSCI, V15, P7712; Giulian D, 1996, J NEUROSCI, V16, P3139; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Giulian D, 1996, J NEUROSCI, V16, P6021; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GIULIAN D, 1993, P NATL ACAD SCI USA, V90, P2769, DOI 10.1073/pnas.90.7.2769; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; GIULIAN D, 1995, NEUROCHEM INT, V27, P119, DOI 10.1016/0197-0186(95)00067-I; Giulian D., 1992, CURRENT TOPICS NEURO, V12, P23; HEYES MP, 1989, ANN NEUROL, V26, P275; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; KETTENMANN H, 1990, J NEUROSCI RES, V26, P278, DOI 10.1002/jnr.490260303; KOO EH, 1993, P NATL ACAD SCI USA, V90, P4748, DOI 10.1073/pnas.90.10.4748; MASLIAH E, 1992, J NEUROPATH EXP NEUR, V51, P585; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MCGEER PL, 1990, LANCET, V335, P1037, DOI 10.1016/0140-6736(90)91101-F; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; PETITO CK, 1992, ANN NEUROL, V32, P658, DOI 10.1002/ana.410320509; PIKE CJ, 1991, EUR J PHARM-MOLEC PH, V207, P367, DOI 10.1016/0922-4106(91)90014-9; RIOHORTEGA P, 1932, CYTOLOGY CELLULAR PA, P481; ROBERTS PJ, 1987, BIOCHEM SOC T, V15, P218, DOI 10.1042/bst0150218; SAITO K, 1993, BIOCHEM J, V291, P11, DOI 10.1042/bj2910011; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; Terry R. D., 1994, ALZHEIMERS DIS; Wujek JR, 1996, NEUROBIOL AGING, V17, P107, DOI 10.1016/0197-4580(95)02020-9; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	40	15	15	0	2	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-096-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		1997	835						91	110		10.1111/j.1749-6632.1997.tb48621.x			20	Multidisciplinary Sciences; Clinical Neurology; Neurosciences	Science & Technology - Other Topics; Neurosciences & Neurology	BK36C	WOS:000071899600009	9616765				2021-06-18	
J	Sataloff, RT; Mandel, S; Muscal, E; Park, CH; Rosen, DC; Kim, SM; Spiegel, JR				Sataloff, RT; Mandel, S; Muscal, E; Park, CH; Rosen, DC; Kim, SM; Spiegel, JR			Single-photon-emission computed tomography (SPECT) in neurotologic assessment: A preliminary report	AMERICAN JOURNAL OF OTOLOGY			English	Article						[Tc-99m]; HMPAO SPECT; postconcussion syndrome; headache; hearing loss; vertigo; dizziness; tinnitus	TRAUMATIC BRAIN INJURY; CLOSED-HEAD-INJURY; HM-PAO-SPECT; TECHNETIUM-99M-HMPAO SPECT; CT; MRI	The single-photon-emission computed tomography (SPECT) scan enables clinicians to probe dynamic and metabolic changes in brain tissue through measurement of regional cerebral blood flow (rCBF). Diagnostic benefits of the SPECT scan in clinical neurology have been demonstrated. SPECT scanning has been shown to be more sensitive than morphologic imaging techniques [magnetic resonance imaging (MRI) and computed tomography (CT)] in many conditions. However, the use of the scan in assessing neurotologic complaints remains inadequately investigated. Few studies have explored the value of SPECT in establishing the causes of dizziness, hearing loss, and tinnitus. We studied SPECT along with MRI, CT scan, electroencephalogram (EEG), and other evaluations in patients with these neurotologic complaints. SPECT abnormalities were more frequent and prominent than those visualized by other imaging modalities. Overall, 78% of SPECT scans revealed abnormalities. Abnormalities were found in 46% of MRIs, 40% of CTs, and 29% of EEGs. The disparity between SPECT scanning and other procedures was also seen once patients were divided by their chief complaints. This study illustrates the sensitivity of SPECT scanning in evaluating neurotologic complaints and highlights the need for additional research into the importance of SPECT scanning in comprehensive neurotologic evaluation.	THOMAS JEFFERSON UNIV,DEPT OTOLARYNGOL,PHILADELPHIA,PA 19103; THOMAS JEFFERSON UNIV,DEPT NEUROL,PHILADELPHIA,PA 19103; AMER INST VOICE & EAR RES,PHILADELPHIA,PA; THOMAS JEFFERSON UNIV,DEPT RADIAT ONCOL & NUCL MED,DIV NUCL MED,PHILADELPHIA,PA 19107			Muscal, Eyal/ABD-2159-2020	Muscal, Eyal/0000-0003-1866-6129			ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; BONI F, 1990, ACTA OTORHINOLAYRNGO, V10, P539; BULLOCK R, 1990, ACT NEUR S, V51, P286; Casani A, 1990, Acta Otorhinolaryngol Ital, V10, P539; DUCOURS JL, 1990, NUCL MED COMMUN, V11, P361, DOI 10.1097/00006231-199005000-00003; GRAD A, 1989, ARCH NEUROL-CHICAGO, V46, P281, DOI 10.1001/archneur.1989.00520390047014; GRAY BG, 1992, J NUCL MED, V33, P52; HOLMAN BL, 1992, J NUCL MED, V33, P1888; ICHISE M, 1994, J NUCL MED, V35, P217; JAMIESON D, 1988, RADIOL CLIN N AM, V26, P1075; KURODA S, 1990, Neurological Surgery, V18, P167; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LAUBERT A, 1987, HNO, V35, P372; MASDEU JC, 1994, NEUROLOGY, V44, P1970, DOI 10.1212/WNL.44.10.1970; Morinaga K, 1991, No To Shinkei, V43, P891; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; ODER W, 1991, INTENS CARE MED, V17, P149, DOI 10.1007/BF01704718; PRICHARD JW, 1992, ANN NEUROL, V32, P395, DOI 10.1002/ana.410320316; ROPER SN, 1991, J NUCL MED, V32, P1684; ROPER SN, 1991, J NUCL MED, V32, P2070; SPENCER SS, 1994, EPILEPSIA, V35, pS72, DOI 10.1111/j.1528-1157.1994.tb05990.x; TUOHIMAA P, 1987, ORL J OTORHINOLARYNG, V45, P315	22	15	15	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0192-9763			AM J OTOL	Am. J. Otol.	NOV	1996	17	6					909	916					8	Otorhinolaryngology	Otorhinolaryngology	VQ203	WOS:A1996VQ20300020	8915421				2021-06-18	
J	Zafonte, RD; Mann, NR; Fichtenberg, NL				Zafonte, RD; Mann, NR; Fichtenberg, NL			Sleep disturbance in traumatic brain injury: Pharmacologic options	NEUROREHABILITATION			English	Article						traumatic brain injury; sleep; pharmacology; behavior	MINOR HEAD-INJURIES; DISORDERS; CONCUSSION; PATTERNS; SEQUELAE; ILLNESS; QUALITY	The role of sleep disturbance in the behavioral and functional sequelae following Traumatic Brain Injury is becoming increasingly well understood. Sleep disturbances occurs commonly in Traumatic Brain injury patients. Survivors of Traumatic Brain Injury may experience sleep dysfunction during all stages of recovery. An effective understanding of the pathophysiology of sleep disturbance and the role medications play in both causation and treatment is essential for facilitation of rehabilitation management and functional recovery.		Zafonte, RD (corresponding author), WAYNE STATE UNIV,REHABIL INST MICHIGAN,261 MACK BLVD,DETROIT,MI 48201, USA.		Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604			Alexandre A, 1979, Acta Neurochir Suppl (Wien), V28, P188; ASERINSKY E, 1953, SCIENCE, V118, P273, DOI 10.1126/science.118.3062.273; BELYAVIN A, 1987, NEUROPHARMACOLOGY, V26, P485, DOI 10.1016/0028-3908(87)90032-3; BERGAMASCO B, 1968, ELECTROEN CLIN NEURO, V24, P374, DOI 10.1016/0013-4694(68)90198-3; BOYESON M, 1994, AM J PMR, V72, P286; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; CHATRIAN GE, 1963, ELECTROEN CLIN NEURO, V15, P272, DOI 10.1016/0013-4694(63)90096-8; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P3013; DONIO E, 1968, PROG BRAIN RES, V28, P113; DOUGLASS AB, 1994, SLEEP, V17, P160, DOI 10.1093/sleep/17.2.160; Edwards G B, 1993, Am J Crit Care, V2, P125; ERWIN CW, 1970, ARCH GEN PSYCHIAT, V23, P375; ESPIE CA, 1991, JAMA-J AM MED ASSOC, V262, P1479; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; FREEMON FR, 1974, ELECTROEN CLIN NEURO, V36, P657, DOI 10.1016/0013-4694(74)90232-6; GALLIARD J, 1982, ENCEPHALE, V8, P413; GATES J, 1996, GOODMAN GILMANS PHAR; GILLIN JC, 1983, PSYCHIAT ANN, V13, P367, DOI 10.3928/0048-5713-19830501-02; GRANT SM, 1991, DRUGS, V41, P889, DOI 10.2165/00003495-199141060-00007; GREENBLATT D, 1990, AM J MED S, V88, P185; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; HARRINGTON RA, 1983, DRUGS, V25, P451, DOI 10.2165/00003495-198325050-00002; HAYTHORNTHWAITE JA, 1991, J PAIN SYMPTOM MANAG, V6, P65, DOI 10.1016/0885-3924(91)90520-E; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; KUPFER D, SLEEP DISTURBANCE AC; KUPFER DJ, 1981, AM J PSYCHIAT, V138, P429; LESSARD CS, 1974, AEROSPACE MED, V45, P664; MARKAND ON, 1976, NEUROLOGY, V26, P769, DOI 10.1212/WNL.26.8.769; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MULLANEY DJ, 1980, SLEEP, V3, P83, DOI 10.1093/sleep/3.1.83; NAUTA WJH, 1946, J NEUROPHYSIOL, V9, P285; NIRENBERG A, AM J PSYCHIAT, p151Y; PACESCHOTT EF, 1994, SLEEP, V17, P688, DOI 10.1093/sleep/17.8.688; PASSOUANT P, 1965, ELECTROEN CLIN NEURO, V18, P7266; PERTOUKA S, 1980, AM J PSYCHIAT, V137, P1518; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; RADULOVACKI M, 1985, BRAIN MECH SLEEP; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SHAPIRO CM, 1993, BRIT MED J, V306, P1532, DOI 10.1136/bmj.306.6891.1532; TRIMBLE MR, 1983, EPILEPSIA, V24, pS55, DOI 10.1111/j.1528-1157.1983.tb04644.x; VILLABLACA JR, 1976, EXP NEUROL, V53, P31, DOI 10.1016/0014-4886(76)90279-X	44	15	15	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	1053-8135			NEUROREHABILITATION	Neurorehabilitation	NOV	1996	7	3					189	195		10.1016/1053-8135(96)00191-6			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	VQ826	WOS:A1996VQ82600004	24525888				2021-06-18	
J	Petersen, SR; Jeevanandam, M; Holaday, NJ; Lubhan, CL				Petersen, SR; Jeevanandam, M; Holaday, NJ; Lubhan, CL			Arterial-jugular vein free amino acid levels in patients with head injuries: Important role of glutamine in cerebral nitrogen metabolism	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							BLOOD-BRAIN-BARRIER; PLASMA; MUSCLE	Traumatic brain injury is the single largest contributor of trauma center deaths, Injury to the brain cannot be considered as an isolated event, affecting only this organ, Profound hypoglutaminemia, commonly seen in patients with head injuries may be caused by the diminished release of glutamine from the brain to the systemic circulation, To assess this hypothesis, we have simultaneously measured the free amino acid (AA) levels in systemic arterial(A, radial artery), cerebral venous (JV, jugular bulb), and systemic venous (PA, pulmonary artery) plasma in 11 adult patients with severe head injuries once within 48 hours of the initial injury before starting nutritional support and again after 3 to 4 days of enteral feeding, Cerebral organ (A-JV) changes of AA levels were compared with whole body systemic (A-PA) changes, Arterial total AA levels when compared with reported normal values are diminished by 46% in patients with isolated severe injuries, Cerebral outflow of glutamine is 6% of the total AA output compared with 73% in normals, The systemic outflow of glutamine in patients with brain injuries is 28% of total AA flow, Despite this high systemic output, significant hypoglutaminemia persists, Feeding for 3 days did not appreciable change the arterial plasma AA levels except that of glutamate and citrulline. A significant (p = 0.01) linear relationship between glutamine (product) and glutamate (precursor) was seen in JV samples but not in A or PA samples, The ratio of plasma glutamine to glutamate was decreased significantly only in JV during nutritional support, and this was caused mainly by an increase in glutamate levels, This may be owing to defective amidation to glutamine, inasmuch as gamma aminobutyric acid (GABA) levels were only minimally affected, Nutritional support improves the net release of glutamine from the brain, This suggests that supplementing the diet with glutamine may be beneficial to support systemic requirements in patients with severe head injuries.		Petersen, SR (corresponding author), ST JOSEPHS HOSP,MED CTR,CTR TRAUMA,350 W THOMAS RD,PHOENIX,AZ 85013, USA.						ASKANAZI J, 1980, ANN SURG, V192, P78, DOI 10.1097/00000658-198007000-00014; COLOMBO JP, 1992, ANN NUTR METAB, V36, P23, DOI 10.1159/000177695; ERIKSSON LS, 1983, J NEUROCHEM, V41, P1324, DOI 10.1111/j.1471-4159.1983.tb00828.x; FELIG P, 1973, P SOC EXP BIOL MED, V142, P230; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; GRILL V, 1992, METABOLISM, V41, P28, DOI 10.1016/0026-0495(92)90186-E; JEEVANANDAM M, 1989, AM J CLIN NUTR, V49, P814; JEEVANANDAM M, 1995, CLIN NUTR, V14, P365, DOI 10.1016/S0261-5614(95)80054-9; MANS AM, 1982, J NEUROCHEM, V38, P705, DOI 10.1111/j.1471-4159.1982.tb08689.x; MCHENRY LC, 1966, NEW ENGL J MED, V274, P82, DOI 10.1056/NEJM196601132740206; NEWSHOLME EA, 1995, CLIN NUTR, V14, P129, DOI 10.1016/S0261-5614(95)80033-6; OLENDORF WH, 1971, AM J PHYSIOL, V221, P1629; PARDRIDGE WM, 1983, PHYSIOL REV, V63, P1481; PETERSEN SR, 1993, J TRAUMA, V34, P653, DOI 10.1097/00005373-199305000-00007; RECORD CO, 1976, EUR J CLIN INVEST, V6, P387, DOI 10.1111/j.1365-2362.1976.tb00533.x; SCHURR A, 1987, BRAIN RES, V421, P125	16	15	16	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	1996	41	4					687	695		10.1097/00005373-199610000-00015			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	VL848	WOS:A1996VL84800015	8858029				2021-06-18	
J	Roos, R				Roos, R			Guidelines for managing concussion in sports - A persistent headache	PHYSICIAN AND SPORTSMEDICINE			English	Article							CONTACT-SPORTS	In their approach to managing athletes who sustain concussions, sports physicians differ at least as widely as do the many published guidelines on the subject. The scarcity of scientific evidence makes practical decisions about when an athlete can safely return to the field difficult. Efforts to forge a consensus are underway, but controversy persists around such questions as whether a brief loss of consciousness should be classified as a severe concussion.								BRUKNER P, 1993, CLIN SPORTS MED, P157; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; *CO MED SOC SPORTS, 1991, GUID MAN CONC SPORTS; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SCHNEIDER RC, 1985, SPORTS INJURIES; STRICH SJ, 1961, LANCET, V2, P443; SWENSON EJ, 1996, ANN M AM MED SOC SPO; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1	8	15	15	0	2	MCGRAW HILL HEALTHCARE PUBLICATIONS	MINNEAPOLIS	4530 WEST 77TH ST, MINNEAPOLIS, MN 55435-5000	0091-3847			PHYSICIAN SPORTSMED	Physician Sportsmed.	OCT	1996	24	10					67	&		10.3810/psm.1996.10.1327			6	Primary Health Care; Orthopedics; Sport Sciences	General & Internal Medicine; Orthopedics; Sport Sciences	VK628	WOS:A1996VK62800020	20086946				2021-06-18	
J	Gauggel, S; Niemann, T				Gauggel, S; Niemann, T			Evaluation of a short-term computer-assisted training programme for the remediation of attentional deficits after brain injury: A preliminary study	INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH			English	Article						attention; remediation; brain injury; computer; evaluation	HEAD-INJURY	In this study the efficiency of a computer-assisted training programme designed to remedy attention deficits caused by cerebrovascular accident and closed head injury was evaluated. Four patients, aged between 40 and 53 years of age at a neurological rehabilitation hospital, received 2 to 4 weeks of training in alertness, vigilance, divided attention and selective attention after they had undergone a 2-week waiting period. Their performance in several tests of attention, verbal and visual memory, and intelligence was measured at three points in time; before and after the waiting period and after the training was completed. Furthermore, their general life satisfaction and mood were measured across time. The patients demonstrated improvements in training tasks, tests of attention and a visual memory test, despite there having been no improvements in two verbal memory tests and a general intelligence test. However, it is not possible to relate these gains in performance solely to the training itself. Spontaneous recovery and positive transfer between the assessments have added to the increase in performance.		Gauggel, S (corresponding author), UNIV MARBURG,DEPT PSYCHOL,GUTENBERGSTR 18,D-35032 MARBURG,GERMANY.			Gauggel, Siegfried/0000-0002-2742-4917			Anastasi A., 1988, PSYCHOL TESTING; Baumler G., 1985, FARBE WORT INTERFERE; BEMYISHAY Y, 1987, NEUROPSYCHOLOGICAL R, P155; BRACY OL, 1983, COGNITIVE REHABILITA, V1, P7; Brickenkamp R., 1975, TEST D2 AUFMERKSAMKE, V5; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Gray J M, 1989, Brain Inj, V3, P163, DOI 10.3109/02699058909004548; Horn W, 1983, LEISTUNGSPRUFSYSTEM; KEWMAN DG, 1985, REHABIL PSYCHOL, V9, P297; Klauer K. J., 1993, KOGNITIVES TRAINING, P15; Lienert G.A., 1969, TESTAUFBAU TESTANALY; MALEC J, 1984, COGNITIVE REHABILITA, V2, P18; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Osterrieth P. A, 1944, ARCH PSYCHOL, V30, P286; OSWALD WD, 1978, ZAHLEN VERBINDUNGS T; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; Poser U., 1992, Z NEUROPSYCHOLOGIE, V1, P3; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROBERTSON I, 1990, APHASIOLOGY, V4, P381, DOI 10.1080/02687039008249090; Ruff R. M., 1989, J HEAD TRAUMA REHAB, V4, P20, DOI [10.1097/00001199-198909000-00006, DOI 10.1097/00001199-198909000-00006]; SCHUHFRIED G, 1977, HDB WIENER DETERMINA; SIVAK M, 1984, ARCH PHYS MED REHAB, V65, P163; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; STRACHE W, 1987, International Journal of Rehabilitation Research, V10, P141, DOI 10.1097/00004356-198700105-00028; STURM W, 1983, ARCH PSYCHIAT NERVEN, V233, P9, DOI 10.1007/BF00540034; Sturm W., 1994, Z NEUROPSYCHOLOGIE, V5, P15; Sturm W, 1983, DIAGNOSTICA, V29, P346; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VANZOMEREN AH, 1994, CLIN NEUROPSYCHOL AT; Weber A. M., 1990, J HEAD TRAUMA REHABI, V5, P73, DOI [10.1097/00001199-199003000-00012, DOI 10.1097/00001199-199003000-00012]; WEBSTER JS, 1983, CLIN NEUROPSYCHOL, V5, P69; WECHSLER D, 1945, J PSYCHOL, V19, P21; Wood R L, 1987, Int Disabil Stud, V9, P149; WOOD RL, 1986, J HEAD TRAUMA REHAB, V1, P43, DOI DOI 10.1097/00001199-198609000-00008	35	15	15	0	1	CHAPMAN HALL LTD	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN	0342-5282			INT J REHABIL RES	Int. J. Rehabil. Res.	SEP	1996	19	3					229	239		10.1097/00004356-199609000-00004			11	Rehabilitation	Rehabilitation	VP115	WOS:A1996VP11500004	8910125				2021-06-18	
J	Nichols, JS; Beel, JA; Munro, LG				Nichols, JS; Beel, JA; Munro, LG			Detection of impaired cerebral autoregulation using spectral analysis of intracranial pressure waves	JOURNAL OF NEUROTRAUMA			English	Article						autoregulation; cerebrovascular reactivity; intracranial pressure; ischemia; spectral analysis; traumatic brain injury; FFT	HEAD-INJURED PATIENTS; FLUID PULSE-WAVE; BLOOD-FLOW; AUTO-REGULATION; PERFUSION-PRESSURE; SYSTEMS-ANALYSIS; CEREBROVASCULAR BED; HYDRAULIC MODEL; VOLUME INDEX; DYNAMICS	Successful resuscitation following severe traumatic brain injury (TBI) requires rapid evaluation of intracranial pressure (ICP), cerebrovascular reactivity (autoregulation), and cerebral metabolism. During impaired autoregulation, inadequate cerebral blood flow (CBF) can lead to ischemia while excessive CBF can result in elevated ICP. Without information regarding the state of autoregulation, treatment of either situation may ameliorate one problem but exacerbate the other. It has been hypothesized that fast Fourier transform (FFT) analysis of arterial blood pressure (BP) and ICP waves can differentiate states of intact and impaired autoregulation. BP and ICP waves were recorded in canines before and after ischemic injury during arterial normotension, hypertension, and hypotension induced with dopamine or nitroprusside infusion. Transfer functions (TFn) were calculated from FFT spectra as ratios of ICP and BP harmonic peak amplitudes to distinguish states of vasoreactivity. During normotension and hypertension, autoregulation was intact and TF1 averaged 0.05. During hypotension, TF1 averaged 0.22 (8x baseline, p < 0.010). During impaired autoregulation following ischemic injury, TF1 averaged 0.50 (18x baseline, p < 0.010; 2x nitroprusside levels, p < 0.01). This large difference in TF relative to baseline extended over a large range of BP (60 < BP < 180 mm Hg). Based on these data and previous results, it was estimated that TF can differentiate impaired autoregulation from effects solely related to elevated ICP or active vasodilation for ICP < 30-40 mm Hg. This suggests that for specific, but widely applicable physiologic conditions, spectral analysis can identify states of impaired autoregulation and, as an adjunct to traditional monitoring techniques, aid in acute resuscitation and prevention of secondary injury in TBI.	PROVENANT ST ANTHONY CENT HOSP,DIV NEUROL SURG,DENVER,CO; UNIV COLORADO,HLTH SCI CTR,DIV NEUROSURG,DENVER,CO 80204							AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AVEZAAT CJJ, 1986, ACTA NEUROCHIR, V79, P13, DOI 10.1007/BF01403461; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; CARDOSO ER, 1983, J NEUROSURG, V59, P817, DOI 10.3171/jns.1983.59.5.0817; CARDOSO ER, 1989, INTRACRANIAL PRESSUR, V7; CHOPP M, 1983, NEUROSURGERY, V13, P5, DOI 10.1227/00006123-198307000-00002; CHOPP M, 1980, J NEUROSURG, V53, P516, DOI 10.3171/jns.1980.53.4.0516; CONTANT CF, 1995, J NEUROSCI METH, V57, P15, DOI 10.1016/0165-0270(94)00106-Q; CONTANT CF, 1993, INTRACRANIAL PRESSUR, V8; CZOSNYKA M, 1988, ACTA NEUROCHIR, V93, P140, DOI 10.1007/BF01402897; CZOSNYKA M, 1994, ACTA NEUROCHIR, V126, P113, DOI 10.1007/BF01476419; CZOSNYKA M, 1993, ACTA NEUROCHIR, V121, P159, DOI 10.1007/BF01809269; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FOLTZ EL, 1981, SURG NEUROL, V15, P283, DOI 10.1016/S0090-3019(81)80009-2; GRAY WJ, 1987, J NEUROSURG, V67, P369, DOI 10.3171/jns.1987.67.3.0369; GRAY WJ, 1987, J NEUROSURG, V67, P377, DOI 10.3171/jns.1987.67.3.0377; HAMER J, 1977, J NEUROSURG, V46, P36, DOI 10.3171/jns.1977.46.1.0036; HIRAI O, 1984, SURG NEUROL, V21, P67, DOI 10.1016/0090-3019(84)90404-X; KASUGA Y, 1987, J NEUROSURG, V66, P907, DOI 10.3171/jns.1987.66.6.0907; KASUGA Y, 1989, INTRACRANIAL PRESSUR, V7; KLASSEN P A, 1991, Neurological Research, V13, P194; LAKIN W D, 1992, Neurological Research, V14, P219; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LIN ES, 1991, BRIT J ANAESTH, V66, P476, DOI 10.1093/bja/66.4.476; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL WJ, 1969, ARCH NEUROL-CHICAGO, V21, P547; MATSUMOTO T, 1986, ACTA NEUROCHIR, V82, P50, DOI 10.1007/BF01456319; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MICHENFELDER JD, 1977, ANESTHESIOLOGY, V46, P188, DOI 10.1097/00000542-197703000-00006; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1983, J NEUROSURG, V59, P439, DOI 10.3171/jns.1983.59.3.0439; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; PIPER IR, 1993, NEUROSURGERY, V32, P805, DOI 10.1227/00006123-199305000-00014; PIPER IR, 1990, J NEUROSURG, V73, P871, DOI 10.3171/jns.1990.73.6.0871; PIPER IR, 1989, INTRACRANIAL PRESSUR, V7; PORTNOY HD, 1983, NEUROSURGERY, V13, P482, DOI 10.1227/00006123-198311000-00002; PORTNOY HD, 1982, J NEUROSURG, V56, P666, DOI 10.3171/jns.1982.56.5.0666; PORTNOY HD, 1981, NEUROSURGERY, V9, P14, DOI 10.1227/00006123-198107000-00004; PROCTOR HJ, 1988, J TRAUMA, V28, P347, DOI 10.1097/00005373-198803000-00010; REED G, 1985, AM J MED SCI, V289, P37, DOI 10.1097/00000441-198501000-00007; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS349; ROBERTSON CS, 1989, J NEUROSURG, V71, P673, DOI 10.3171/jns.1989.71.5.0673; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; SCHALEN W, 1991, ACTA ANAESTH SCAND, V35, P113, DOI 10.1111/j.1399-6576.1991.tb03258.x; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; STRANDGAARD S, 1984, STROKE, V15, P413, DOI 10.1161/01.STR.15.3.413; STRANDGAARD S, 1973, BMJ-BRIT MED J, V1, P507, DOI 10.1136/bmj.1.5852.507; TAKIZAWA H, 1987, NEUROSURGERY, V20, P355, DOI 10.1227/00006123-198703000-00001; TAKIZAWA H, 1986, J NEUROL NEUROSUR PS, V49, P1135, DOI 10.1136/jnnp.49.10.1135; TAKIZAWA H, 1986, J NEUROL NEUROSUR PS, V49, P1367, DOI 10.1136/jnnp.49.12.1367; WYLIE CR, 1975, ADV ENG MATH, P214	56	15	15	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1996	13	8					439	456		10.1089/neu.1996.13.439			18	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	VH009	WOS:A1996VH00900002	8880608				2021-06-18	
J	Dreinhofer, KE; Schwarzkopf, SR; Haas, NP; Tscherne, H				Dreinhofer, KE; Schwarzkopf, SR; Haas, NP; Tscherne, H			Fractures of the femoral head - Long-term results of conservative and operative treatment	UNFALLCHIRURG			German	Article						fractures; femoral head; multiple injuries	HIP; DISLOCATION; THERAPY	From 1974 to 1989, we treated 32 patients with a femoral head fracture: 28 were associated with a traumatic posterosuperior dislocation of the hip (6 Pipkin type I, 7 type II, 4 type III and 11 type IV), 1 with a posteroinferior and 3 with an anterior displacement of the femoral head. Twenty-four patients had been involved in a traffic accident, 23 had associated injuries, and the average polytrauma score (PTS) was 21. All dislocations primarily treated at our hospital were reduced by closed methods within 4 h (mean 105 min). Eleven patients received no further operative treatment, 21 were treated by open reduction and screw fixation of the fragment of the head (n=7), fixation of the acetabular fracture (n=3) or removal of the fragments of the head (n=10). Four Pipkin type III fractures received primary total hip replacement. Twenty-six of the surviving 29 patients were reviewed after an average follow-up of 5 years (2-11). Radiological signs of mild arthrosis were seen in 4, moderate degeneration in 2. Partial avascular necrosis was found in 4, subchondral collapse in 1 and heterotopic ossification in 8 patients. According to the Thompson and Epstein criteria 15 of 26 patients presented fair to poor results.		Dreinhofer, KE (corresponding author), UNIV ULM,ORTHOPAD KLIN,REHABIL KRANKENHAUSES,ORTHOPAD ABT,OBERER ESELSBERG 45,D-89081 ULM,GERMANY.		Dreinhoefer, Karsten/AAO-9680-2021	Dreinhoefer, Karsten/0000-0001-6021-2804			BARNBECK F, 1987, ZBL CHIR, V112, P783; Birkett J, 1869, Med Chir Trans, V52, P133; BRAV EA, 1962, J BONE JOINT SURG AM, V44, P1115, DOI 10.2106/00004623-196244060-00007; BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629; BRUMBACK RJ, 1986, HIP, P181; BUTLER JE, 1981, J BONE JOINT SURG AM, V63, P1292, DOI 10.2106/00004623-198163080-00011; CANALE ST, 1979, J BONE JOINT SURG AM, V61, P7, DOI 10.2106/00004623-197961010-00003; CAUCHOIX J, 1951, Rev Chir Orthop Reparatrice Appar Mot, V37, P266; CHARNLEY J, 1972, Journal of Bone and Joint Surgery British Volume, V54, P61; DELEE JC, 1980, J BONE JOINT SURG AM, V62, P960, DOI 10.2106/00004623-198062060-00012; DELEE JC, 1991, FRACTURES DISLOCATIO; DUQUENNOY A, 1975, REV CHIR ORTHOP, V61, P209; DUSSAULT RG, 1980, RADIOLOGY, V135, P627, DOI 10.1148/radiology.135.3.7384446; EPSTEIN HC, 1985, CLIN ORTHOP RELAT R, V201, P9; EPSTEIN HC, 1972, ORTHOP REV, V1, P33; FRIEDL W, 1994, CHIRURG, V65, P981; Funsten RV, 1938, J BONE JOINT SURG, V20, P124; Gruen G S, 1988, J Orthop Trauma, V2, P5, DOI 10.1097/00005131-198802000-00002; HAAG C, 1993, HEFTE UNFALLHEILKD, V228, P76; HOUGAARD K, 1986, ARCH ORTHOP TRAUM SU, V106, P32, DOI 10.1007/BF00435649; HOUGAARD K, 1988, J BONE JOINT SURG AM, V70A, P233, DOI 10.2106/00004623-198870020-00011; HOUGAARD K, 1994, CORTHOP INTER ED, V2, P507; JACOB JR, 1987, CLIN ORTHOPAEDICS, V214, P249; KELLY RP, 1971, J TRAUM, V11, P97, DOI 10.1097/00005373-197102000-00001; KLASEN HJ, 1984, J BONE JOINT SURG BR, V66, P45; LEVIN PE, 1991, HIP ITS DISORDERS, P222; MAROSKE D, 1983, CHIRURG, V54, P400; MERLEDAUBIGNE R, 1954, J BONE JOINT SURG AM, V36, P451; MULLER ME, 1991, MANUAL INTERNAL FIXA, P519; OBERHAMMER J, 1975, HEFTE UNFALLHEILKD, V24, P272; OESTERN HJ, 1985, UNFALLCHIRURG, V88, P465; POHLEMANN T, 1991, HUFTKOPF NEKROSE, P187; ROEDER LF, 1980, CLIN ORTHOP RELAT R, V147, P121; ROSENTHAL RE, 1979, J TRAUMA, V19, P572, DOI 10.1097/00005373-197908000-00005; SCHWEIKERT CH, 1979, HEFTE UNFALLHEILKD, V140, P113; STEWART MJ, 1975, ACTA ORTHOP SCAND, V46, P507; STOCKENHUBER N, 1994, CHIRURG, V65, P976; STULBERG BN, 1989, CLIN ORTHOP RELAT R, V240, P181; SUDKAMP NP, 1990, ORTHOPADE, V19, P369; Swiontkowski M F, 1992, J Orthop Trauma, V6, P437, DOI 10.1097/00005131-199212000-00008; SWIONTKOWSKI MF, 1991, CURR ORTHOPAED, V5, P99; THOMPSON VP, 1951, J BONE JOINT SURG AM, V33-A, P746, DOI 10.2106/00004623-195133030-00023; TSCHERNE H, 1987, CHIRURG, V58, P631; Webb L X, 1990, J Orthop Trauma, V4, P376, DOI 10.1097/00005131-199012000-00002; WECKBACH A, 1989, UNFALLHEILKUNDE, V207, P121; WENDA K, 1991, KURZFASSUNG REFERATE, P163	46	15	16	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0177-5537			UNFALLCHIRURG	Unfallchirurg	JUN	1996	99	6					400	409					12	Emergency Medicine; Surgery	Emergency Medicine; Surgery	UV689	WOS:A1996UV68900003	8767135				2021-06-18	
J	Meintjes, E; Hosgood, G; Daniloff, J				Meintjes, E; Hosgood, G; Daniloff, J			Pharmaceutic treatment of acute spinal cord trauma	COMPENDIUM ON CONTINUING EDUCATION FOR THE PRACTICING VETERINARIAN			English	Article							21-AMINOSTEROID U74006F; INJURY; METHYLPREDNISOLONE; NALOXONE; RECOVERY; ISCHEMIA; RATS; CATS; DEXAMETHASONE; PATHOGENESIS	Spinal cord concussion or laceration is one of the most frequent neurologic disorders seen in small animal practice. However, the complex set of events that follow spinal cord injury are not yet completely understood, and much controversy exists. Ischemic and biochemical changes that occur after mechanical trauma are believed to contribute to continued cellular destruction known as second injury. Early treatment is critical to limit the spread of secondary injury. Numerous pharmacologic agents for the treatment of acute spinal cord injury have been described, but there are many opposing views regarding the efficacy of these agents. The use and side effects of glucocorticoids, nonsteroidal antiinflammatory drugs, calcium-channel antagonists, narcotic antagonists, and numerous other potentially beneficial drugs are discussed in this article. The experimental compound tirilazad mesylate is apparently safer and more effective than drugs currently available and may be available commercially in the near future.	LOUISIANA STATE UNIV,DEPT VET ANAT,BATON ROUGE,LA 70803; LOUISIANA STATE UNIV,DEPT VET CLIN SCI,SCH VET MED,BATON ROUGE,LA 70803				Hosgood, Giselle/0000-0002-8851-8597			AKDEMIR H, 1993, RES EXP MED, V194, P297; ANDERSON DK, 1988, J NEUROSURG, V69, P562, DOI 10.3171/jns.1988.69.4.0562; BASKIN DS, 1993, J SPINAL DISORD, V6, P38; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; BELLAH JR, 1983, J AM VET MED ASSOC, V183, P1002; BERG RJ, 1985, COMP CONT EDUC PRACT, V7, P646; BLIGHT AR, 1993, ADV NEUROL, V59, P91; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; BRAUGHLER JM, 1982, J NEUROSURG, V56, P838, DOI 10.3171/jns.1982.56.6.0838; BRAUGHLER JM, 1987, J NEUROSURG, V67, P102, DOI 10.3171/jns.1987.67.1.0102; BRAUND KG, 1990, VET MED-US, V85, P740; BRAUND KG, 1990, VET MED-US, V85, P684; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CAUBIT X, 1993, INT J DEV BIOL, V37, P327; COLLINS GH, 1989, BRAIN RES BULL, V22, P89, DOI 10.1016/0361-9230(89)90132-9; DELABAUME S, 1981, NEUROSCIENCE, V6, P315, DOI 10.1016/0306-4522(81)90125-1; DELAY G, 1993, J NEUROTRAUMA, V10, P25; DONG YO, 1992, CHUNG HUA WAI KO TSA, V149, P437; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; FRANCEL PC, 1993, J NEUROSURG, V79, P742, DOI 10.3171/jns.1993.79.5.0742; GALANDIUK S, 1993, ANN SURG, V218, P419, DOI 10.1097/00000658-199310000-00003; GOLDBERGER ME, 1990, EXP NEUROL, V107, P113, DOI 10.1016/0014-4886(90)90149-M; GORSKA T, 1993, BRAIN RES BULL, V32, P241, DOI 10.1016/0361-9230(93)90183-C; GRIFFITHS IR, 1975, J NEUROSURG, V42, P155, DOI 10.3171/jns.1975.42.2.0155; GRISSOM TE, 1994, ANESTH ANALG, V79, P66; GUHA A, 1987, J NEUROSURG, V66, P423, DOI 10.3171/jns.1987.66.3.0423; HALL ED, 1988, J NEUROSURG, V68, P462, DOI 10.3171/jns.1988.68.3.0462; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HALL ED, 1993, ADV NEUROL, V59, P241; HALL ED, 1986, J NEUROSURG, V64, P951, DOI 10.3171/jns.1986.64.6.0951; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; HELGREN ME, 1993, EXP NEUROL, V123, P17, DOI 10.1006/exnr.1993.1137; HOERLEIN BF, 1985, J AM ANIM HOSP ASSOC, V21, P67; HOERLEIN BF, 1983, J AM ANIM HOSP ASSOC, V19, P216; HOERLEIN BF, 1982, ARCH AM COLL VET SUR, V4, P11; JANSSEN L, 1989, SPINE, V14, P23, DOI 10.1097/00007632-198901000-00005; JANSSENS LAA, 1991, J SMALL ANIM PRACT, V32, P572, DOI 10.1111/j.1748-5827.1991.tb00889.x; Kajihara K, 1973, Surg Neurol, V1, P16; KIWERSKI JE, 1993, INJURY, V24, P457, DOI 10.1016/0020-1383(93)90149-Z; Kliot M, 1990, Neurosurg Clin N Am, V1, P751; KOYANAGI I, 1993, NEUROSURGERY, V33, P285, DOI 10.1227/00006123-199308000-00016; KUHLENGEL KR, 1990, J COMP NEUROL, V293, P74, DOI 10.1002/cne.902930107; NACIMIENTO AC, 1979, SOC NEUROSCI, V5, P727; OSTERHOLM JL, 1974, J NEUROSURG, V40, P5, DOI 10.3171/jns.1974.40.1.0003; PARKER AJ, 1990, PHYSIOL BEHAV, V48, P41, DOI 10.1016/0031-9384(90)90258-6; POINTILLART V, 1993, J NEUROTRAUM, V10, P201, DOI 10.1089/neu.1993.10.201; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; QUAYUMI AK, 1994, J THORAC CARDIOVASC, V107, P1203; ROCHAT MC, 1991, COMP CONT EDUC PRACT, V13, P923; ROSS IB, 1993, SURG NEUROL, V40, P461, DOI 10.1016/0090-3019(93)90048-6; RYMER WZ, 1993, ADV NEUROL, V59, P157; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SHORES A, 1990, VET MED-US, V85, P724; Siemering G. B., 1992, Veterinary Surgery, V21, P406; SORJONEN DC, 1989, COMP CONT EDUC PRACT, V11, P248; WIETHOLTER H, 1990, J NEUROSCI METH, V32, P199, DOI 10.1016/0165-0270(90)90141-2; XU J, 1992, J NEUROTRAUM, V9, P245, DOI 10.1089/neu.1992.9.245; YOUNG W, 1993, ADV NEUROL, V59, P249; Young W, 1988, Clin Neurosurg, V34, P675; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	62	15	15	0	2	VETERINARY LEARNING SYSTEMS	TRENTON	425 PHILLIPS BLVD #100, TRENTON, NJ 08618	0193-1903			COMP CONT EDUC PRACT	Compend. Contin. Educ. Pract. Vet.	JUN	1996	18	6					625	&					10	Veterinary Sciences	Veterinary Sciences	UR745	WOS:A1996UR74500002					2021-06-18	
J	Schmitt, U; Cross, R; Pazdernik, TL; Sabel, BA				Schmitt, U; Cross, R; Pazdernik, TL; Sabel, BA			Loss and subsequent recovery of local cerebral glucose use in visual targets after controlled optic nerve crush in adult rats	EXPERIMENTAL NEUROLOGY			English	Article							RETINAL GANGLION-CELLS; SUPERIOR COLLICULUS; METABOLIC-ACTIVITY; 2-DEOXYGLUCOSE UPTAKE; AXONAL INJURY; GRADED CRUSH; BRAIN INJURY; ALBINO-RAT; HOODED RAT; SYSTEM	A mild crush of the adult rat optic nerve serves as a model to study the restoration of function after traumatic brain injury. It causes a progressive degeneration of retinal ganglion cells, but visually guided behavior is partially restored within 2-3 weeks. The purpose of this study was to determine to what extent local cerebral glucose use (LCGU) decreases and if it recovers in retinofugal targets following unilateral optic nerve crush. At intervals of 2, 9, and 22 days after crush, LCGU was monitored in rats in which the visual system was stimulated by a strobe-light and pattern. In the ipsilateral retinofugal targets there was only a minimal loss of LCGU use, but in the contralateral retinofugal targets, LCGU was reduced at Postlesion Day 2: to 50% in the superior colliculus (SC), to 60% in the lateral geniculate nucleus of the thalamus (LGN), and to 87% in the visual cortex. On Postoperative Days 9 and 22 we observed a partial restoration of LCGU in the contralateral SC and LGN to 68 and 79%, respectively. As recovery of visual performance is known to follow a similar time course, we conclude that restoration of metabolic activity in target structures may contribute to the restoration of vision after optic nerve crush. (C) 1996 Academic Press, Inc.	UNIV KANSAS,MED CTR,RL SMITH RES CTR,KANSAS CITY,KS 66160	Schmitt, U (corresponding author), OTTO VONGUERICKE UNIV,INST MED PSYCHOL,SCH MED,LEIPZIGERSTR 44,D-39120 MAGDEBURG,GERMANY.		Sabel, Bernhard A./E-6579-2013	Sabel, Bernhard/0000-0002-4472-5543			ALLCUTT D, 1984, DEV BRAIN RES, V16, P219, DOI 10.1016/0165-3806(84)90027-0; ALLCUTT D, 1984, DEV BRAIN RES, V16, P231, DOI 10.1016/0165-3806(84)90028-2; COOPER RM, 1984, EXP NEUROL, V86, P261, DOI 10.1016/0014-4886(84)90185-7; COOPER RM, 1985, EXP NEUROL, V89, P322, DOI 10.1016/0014-4886(85)90093-7; COOPER RM, 1991, EXP NEUROL, V113, P79, DOI 10.1016/0014-4886(91)90149-7; DREHER B, 1985, BRAIN BEHAV EVOLUT, V26, P10, DOI 10.1159/000118764; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; ERB DE, 1991, EXP BRAIN RES, V83, P253; FERRARI R, 1991, INT J NEUROSCI, V58, P199, DOI 10.3109/00207459108985435; FINGER S, 1978, RECOVERY BRAIN DAMAG; FINGER S, 1982, BRAIN DAMAGE RECOVER; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; HERTA MF, 1984, COMP NEUROLOGY OPTIC, P687; HEYWOD CA, 1988, EXP BRAIN RES, V70, P513; Laurence S., 1978, RECOVERY BRAIN DAMAG, P369; LINDEN R, 1983, BRAIN RES, V272, P145, DOI 10.1016/0006-8993(83)90371-2; MCINTOSH AR, 1989, BEHAV BRAIN RES, V32, P1, DOI 10.1016/S0166-4328(89)80066-X; PAZDERNIK TL, 1982, BRAIN RES, V243, P197, DOI 10.1016/0006-8993(82)91139-8; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; ROONEY BJ, 1988, BRAIN RES, V439, P311, DOI 10.1016/0006-8993(88)91488-6; SAUTTER J, 1993, EUR J NEUROSCI, V5, P680, DOI 10.1111/j.1460-9568.1993.tb00533.x; SAUTTER J, 1991, BRAIN RES, V565, P23, DOI 10.1016/0006-8993(91)91732-G; SCHMITT UW, 1994, INVEST OPHTAL VIS SC, V35, P1125; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; STEIN DG, 1992, ADV EXP MED BIOL, V325, P1; THURLOW GA, 1988, EXP NEUROL, V100, P563, DOI 10.1016/0014-4886(88)90040-4; THURLOW GA, 1989, EXP NEUROL, V104, P272, DOI 10.1016/0014-4886(89)90040-X; THURLOW GA, 1991, J COMP NEUROL, V306, P697, DOI 10.1002/cne.903060411; THURLOW GA, 1988, J COMP NEUROL, V274, P595, DOI 10.1002/cne.902740408; TOGA AW, 1981, J COMP NEUROL, V199, P443, DOI 10.1002/cne.901990402; TOGA AW, 1987, DEV BRAIN RES, V37, P209, DOI 10.1016/0165-3806(87)90242-2; YAMADORI T, 1981, J HIRNFORSCH, V22, P313	32	15	18	0	0	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0014-4886			EXP NEUROL	Exp. Neurol.	MAY	1996	139	1					17	24		10.1006/exnr.1996.0076			8	Neurosciences	Neurosciences & Neurology	UK439	WOS:A1996UK43900003	8635564				2021-06-18	
J	Janjua, KJ; Goswami, V; Sagar, G				Janjua, KJ; Goswami, V; Sagar, G			Whiplash injury associated with acute bilateral internal carotid arterial dissection	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						whiplash injury; blunt carotid trauma	TRAUMA; BELT	Internal carotid arterial occlusion, being a rare occurrence following whiplash injury, is frequently missed, We report an unusual case of a 41-year-old woman driver who was involved in a head-on collision with a truck. On admission she was noted to have sustained closed head and neck trauma with a severe whiplash injury and lower limb paraparesis, Subsequent investigations showed a right parietal lobe infarct and bilateral internal carotid arterial dissection, We conclude that acute whiplash injury can result in bilateral internal carotid arterial dissection and that clinicians treating these patients should be aware of this complication.	UNIV BIRMINGHAM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; CITY HOSP NHS TRUST,BIRMINGHAM,W MIDLANDS,ENGLAND							ATKINSON TJ, 1991, ORAL SURG ORAL MED O, V72, P408, DOI 10.1016/0030-4220(91)90548-Q; BENITO MC, 1990, J TRAUMA, V30, P116, DOI 10.1097/00005373-199001000-00021; DAVIS JW, 1990, J TRAUMA, V30, P1514, DOI 10.1097/00005373-199012000-00013; LI MS, 1994, J TRAUMA, V36, P265, DOI 10.1097/00005373-199402000-00025; LITTLE JM, 1969, LANCET, V2, P926; MARTIN RF, 1991, J VASC SURG, V14, P789, DOI 10.1067/mva.1991.32076; MOKRI B, 1988, J NEUROSURG, V68, P189, DOI 10.3171/jns.1988.68.2.0189; NORRIS SH, 1983, J BONE JOINT SURG BR, V65, P608; RAMADAN F, 1995, J VASC SURG, V21, P46, DOI 10.1016/S0741-5214(95)70243-1; REDDY K, 1990, J TRAUMA, V30, P630, DOI 10.1097/00005373-199005000-00020; WALL SD, 1982, AM J ROENTGENOL, V138, P307, DOI 10.2214/ajr.138.2.307; WOZASEK GE, 1990, J TRAUMA, V30, P332, DOI 10.1097/00005373-199003000-00013	12	15	15	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	1996	40	3					456	458		10.1097/00005373-199603000-00024			3	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	UA973	WOS:A1996UA97300025	8601868				2021-06-18	
J	Yamaguchi, T; Ozawa, Y; Suzuki, M; Yamamoto, M; Nakamura, T; Yamaura, A				Yamaguchi, T; Ozawa, Y; Suzuki, M; Yamamoto, M; Nakamura, T; Yamaura, A			Indeloxazine hydrochloride improves impairment of passive avoidance performance after fluid percussion brain injury in rats	NEUROPHARMACOLOGY			English	Article						fluid percussion brain injury; passive avoidance performance; cerebral activator; monoamine; acetylcholine	HEAD-INJURY; AMINO-ACIDS; MEMORY; METABOLITES; MODEL; DEGENERATION; HIPPOCAMPUS; RECEPTORS; RECOVERY	We studied behavioral and histological changes after fluid percussion brain injury and the effects of indeloxazine hydrochloride, a cerebral activator, on these post-traumatic changes in rats. An acquisition trial in passive avoidance task was conducted on the 3rd day after injury. The latency of step-through in injured rats was significantly (p<0.05) shorter than that in sham-operated rats on the 4th, 10th and 14th days after the operation. There were injury-induced neurological deficits on days 1-4 post-injury. Histological changes were observed in the peripheral area of the cortical lesion at the impact site and in the thalamus but not in the hippocampus on the 14th day. Indeloxazine (10 and 20 mg/kg, p.o.) administered once a day from the 3rd (30 min prior to the acquisition trial) to the 9th day after injury significantly (p < 0.05) improved the impairment of the passive avoidance performance without affecting locomotor activity. Indeloxazine showed no significant effects on either neurological deficits or the cortical lesion area. These results suggest that impairment of passive avoidance performance occurs without apparent histological damage in the hippocampus after fluid percussion brain injury and is attenuated by post-traumatic treatment with indeloxazine. Copyright (C) 1996 Elsevier Science Ltd.	CHIBA UNIV,SCH MED,DEPT NEUROL SURG,CHIBA 280,JAPAN	Yamaguchi, T (corresponding author), YAMANOUCHI PHARMACEUT CO LTD,CLIN PHARMACOL RES LABS,DEPT PHARMACOL,TOKYO 174,JAPAN.						ALTMAN HJ, 1984, PSYCHOPHARMACOLOGY, V84, P496, DOI 10.1007/BF00431456; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON ED, 1993, 2 GLASG INT NEUR S, P167; DOUGLAS RJ, 1967, PSYCHOL BULL, V67, P416, DOI 10.1037/h0024599; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1990, CAN J PSYCHOL, V44, P223; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; GRONWALL D, 1974, LANCET, V2, P605; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HARADA M, 1979, BIOCHEM PHARMACOL, V28, P2645, DOI 10.1016/0006-2952(79)90041-8; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KMIECIAKKOLADA K, 1987, POL J PHARMACOL PHAR, V39, P47; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; LINDGREN S, 1969, ACTA PHYSIOL SCAND, V76, P340, DOI 10.1111/j.1748-1716.1969.tb04477.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OGREN SO, 1985, ACTA PHYSL SCAND S, V544, P1; OLTON DS, 1978, BRAIN RES, V139, P295, DOI 10.1016/0006-8993(78)90930-7; PICCIOTTO MR, 1995, NATURE, V374, P65, DOI 10.1038/374065a0; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SARTER M, 1991, TRENDS PHARMACOL SCI, V12, P456, DOI 10.1016/0165-6147(91)90636-7; SHIMIZUSASAMATA M, 1993, PHARMACOL BIOCHEM BE, V45, P335, DOI 10.1016/0091-3057(93)90248-R; SHIMIZUSASAMATA M, 1991, ARCH INT PHARMACOD T, V314, P74; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Sunami K, 1989, Neurol Med Chir (Tokyo), V29, P975, DOI 10.2176/nmc.29.975; YAMADA K, 1991, J CEREBR BLOOD F MET, V11, P472, DOI 10.1038/jcbfm.1991.90; YAMAGUCHI T, 1985, BIOGENIC AMINES, V3, P21; YAMAGUCHI T, 1995, BRAIN RES, V669, P107, DOI 10.1016/0006-8993(94)01268-M; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAMOTO M, 1990, Brain Dysfunction, V3, P130; YAMAMOTO M, 1993, NEUROPHARMACOLOGY, V32, P695, DOI 10.1016/0028-3908(93)90083-F	48	15	16	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0028-3908			NEUROPHARMACOLOGY	Neuropharmacology	MAR	1996	35	3					329	336		10.1016/0028-3908(95)00171-9			8	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	UQ415	WOS:A1996UQ41500012	8783208				2021-06-18	
J	Mozzoni, MP; Bailey, JS				Mozzoni, MP; Bailey, JS			Improving training methods in brain injury rehabilitation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						decision matrix; feedback; outcome measurement	CHILDREN; BEHAVIOR	The effects of therapist training techniques upon treatment outcomes in traumatic brain injury (TBI) has not been widely studied. This study demonstrates that outcome scores are likely to increase when therapists work on outcome-related activities and use identified training methods. Six therapists working with five persons with TBI were subjects for this study. Therapists were targeted because their clients were not making progress on the functional independent measurement (FIM). Baseline teaching data were collected from videotapes, targeting 14 training elements within the areas of task, prompting, reinforcement, and client's behavior. Therapists were given feedback based upon the teaching diagnostic of the decision matrix. The results show that diagnostic-based intervention with therapists can result in direct, immediate, and obvious improvements in outcome measures across patients.	VANDERBILT STALLWORTH REHABIL HOSP,NASHVILLE,TN; FLORIDA STATE UNIV,TALLAHASSEE,FL 32306							BALCAZAR F, 1986, J ORGAN BEHAV MANAGE, V7, P65; BARLOW DH, 1984, SINGLE CASE EXPT DES; Bloomer J., 1979, BAY AREA FUNCTIONAL; BORNSTEIN MR, 1977, J APPL BEHAV ANAL, V10, P183, DOI 10.1901/jaba.1977.10-183; CARR EG, 1985, BEHAV MODIF, V9, P403, DOI 10.1177/01454455850094001; CARR EG, 1980, J APPL BEHAV ANAL, V13, P139; CORREA VI, 1984, J APPL BEHAV ANAL, V17, P57, DOI 10.1901/jaba.1984.17-57; CUVO AJ, 1978, VOCATIONAL EVALUATIO, V11, P13; CUVO AJ, 1983, PROGR BEHAVIOR MODIF; Daniels A.C., 1989, PERFORMANCE MANAGEME; DUKER PC, 1980, BEHAV ANAL MODIF, V4, P71; GILES GM, 1988, AM J OCCUP THER, V42, P658, DOI 10.5014/ajot.42.10.658; GRANGER CV, 1990, GUIDE UNIFORM DATA S; Hagen C., 1972, LEVELS COGNITIVE FUN; HARCHIK AE, 1992, J APPL BEHAV ANAL, V25, P599, DOI 10.1901/jaba.1992.25-599; HOLLANDSWORTH JG, 1978, J APPL BEHAV ANAL, V11, P259, DOI 10.1901/jaba.1978.11-259; HORNER RD, 1975, J APPL BEHAV ANAL, V8, P301, DOI 10.1901/jaba.1975.8-301; HOSEK S, 1986, UCLA R3424 HLTH CAR; JACOBS HE, 1993, BEHAVIOR ANAL GUIDEL; JENNETT B, 1975, LANCET, V1, P489; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; Kazdin A. E., 1982, SINGLE CASE RES DESI; KAZDIN AE, 1984, BEHAVIOR MODIFICATIO; KOEGEL RL, 1977, J APPL BEHAV ANAL, V10, P197, DOI 10.1901/jaba.1977.10-197; KOOP S, 1980, AM J MENT DEF, V84, P616; LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91; LEHMANN JF, 1984, ARCH PHYS MED REHAB, V65, P260; MARTIN G, 1988, BEHAVIOR MODIFICATIO; MERBITZ C, 1989, ARCH PHYS MED REHAB, V70, P308; PIE HE, 1993, CONTINUING CARE, V5, P25; SKINNER BF, 1938, BEHAVIOR ORGANISMS; STRAIN PS, 1976, J APPL BEHAV ANAL, V9, P31, DOI 10.1901/jaba.1976.9-31; SULZERAZAROFF B, 1991, BEHAVIOR ANAL LASTIN; Wood R. L., 1987, BRAIN INJURY REHABIL; ZAHARA DJ, 1984, CLIN PSYCHOL REV, V4, P477, DOI 10.1016/0272-7358(84)90022-9	35	15	15	0	0	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	1996	11	1					1	17		10.1097/00001199-199602000-00003			17	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	TU021	WOS:A1996TU02100003					2021-06-18	
J	Wilson, SL; Brock, D; Powell, GE; Thwaites, H; Elliott, K				Wilson, SL; Brock, D; Powell, GE; Thwaites, H; Elliott, K			Constructing arousal profiles for vegetative state patients - A preliminary report	BRAIN INJURY			English	Article							SENSORY STIMULATION; COMA; CONSCIOUSNESS	Arousal profiles are a method that we have developed for using data derived from time sampling to examine how behaviours such as the frequency with which the eyes are observed open, and the frequency of spontaneous movements, vary in the periods immediately before and immediately after sensory stimulation treatment. We believe changes in such behaviours reflect changes in arousal. The use of this new technique is illustrated with examples from a pilot study using data from 15-day treatment blocks, gathered for 10-minute periods immediately before and after sensory stimulation treatment from three patients using single-case research methods. The patients were diagnosed as being in vegetative state following traumatic brain injury. The possible significance of the differing characteristics of the profiles is discussed.	ROYAL HOSP NEURODISABIL,OCCUPAT THERAPY DEPT,LONDON,ENGLAND; COLCHESTER INST,ESSEX SCH OCCUPAT THERAPY,COLCHESTER,ESSEX,ENGLAND	Wilson, SL (corresponding author), UNIV SURREY,DEPT PSYCHOL,GUILDFORD GU2 5XH,SURREY,ENGLAND.			Wilson, Sarah L./0000-0001-8347-5156			MALKMUR D, 1980, REHABILITATION HEADI; POWELL GE, 1994, CLIN REHABIL, V8, P54; TEASDALE G, 1974, LANCET, V2, P81; WATSON M, 1991, Brain Injury, V5, P421, DOI 10.3109/02699059109008115; WILSON S L, 1991, Brain Injury, V5, P393, DOI 10.3109/02699059109008112; Wilson S. L., 1992, CLIN REHABIL, V6, P181, DOI [10.1177/026921559200600301, DOI 10.1177/026921559200600301]; Wilson SL, 1993, NEUROPSYCHOL REHABIL, V3, P191, DOI 10.1080/09602019308401435; WILSON SL, 1993, NEUROPSYCHOL REHABIL, V3, P149; WILSON SL, 1993, 3RD ANN C INT ASS ST; WOOD RL, 1993, NEUROPSYCHOL REHABIL, V3, P177	10	15	16	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB	1996	10	2					105	113		10.1080/026990596124593			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UB726	WOS:A1996UB72600004	8696310				2021-06-18	
J	Himmelseher, S; Pfenninger, E; Georgieff, M				Himmelseher, S; Pfenninger, E; Georgieff, M			The effect of basic fibroblast growth factor on glutamate-injured neuroarchitecture and arachidonic acid release in adult hippocampal neurons	BRAIN RESEARCH			English	Article						excitotoxicity; basic fibroblast growth factor; arachidonic acid; mature hippocampal neuron; neuroprotection	TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; MICROTUBULE-ASSOCIATED PROTEIN-2; PYRAMIDAL NEURONS; CEREBRAL-ISCHEMIA; ASTROGLIAL CELLS; PRIMARY CULTURES; TRANSPORT SITES; RAT; DAMAGE	During development in culture, basic fibroblast growth factor (bFGF) protected immature primary hippocampal neurons against glutamate-induced neurotoxicity. We investigated the effects of bFGF on mature, differentiated rat hippocampal neurons cultured for 10-12 days after an 8-min exposure to 500 mu M glutamate. Seven days post-injury, hippocampal cells demonstrated severe reductions in cellular viability and axonal and dendritic outgrowth, which were accompanied by a marked increase in [H-3]arachidonic acid (ARA) release from prelabelled neurons. bFGF applied post-injury attenuated cell death and cytoarchitectural destruction at all concentrations used (500 pg/ml, 1, 10, 20 ng/ml). However, neurite elongation and branching processes were only significantly protected by 10 ng/ml bFGF. [H-3]ARA release decreased in a dose-related fashion within a concentration range of 1-10 ng/ml bFGF.20 ng/ml bFGF was not superior to 10 ng/ml bFGF. Therefore, bFGF's neurotropic actions appear to be concentration-dependent. Our data suggest that bFGF applied post-injury may have a neuroprotective potential for mature, differentiated, completely polarized hippocampal neurons.		Himmelseher, S (corresponding author), UNIV ULM KLINIKUM, ANASTHESIOL KLIN, SEKT EXPTL ANASTHESIOL, PK STR 11, D-89070 ULM, GERMANY.						ABE K, 1987, J NEUROCHEM, V48, P503, DOI 10.1111/j.1471-4159.1987.tb04121.x; ANDERSON KJ, 1991, BRAIN RES, V562, P285, DOI 10.1016/0006-8993(91)90633-7; ANDERSON KJ, 1990, NEUROSCIENCE, V38, P311, DOI 10.1016/0306-4522(90)90030-8; ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; ASAI T, 1993, MOL BRAIN RES, V17, P174, DOI 10.1016/0169-328X(93)90088-7; BALCAR VJ, 1992, LIFE SCI, V51, P1467, DOI 10.1016/0024-3205(92)90556-5; BANKER GA, 1980, SCIENCE, V209, P809, DOI 10.1126/science.7403847; BARTLETT WP, 1984, J NEUROSCI, V4, P1954; BARTLETT WP, 1984, J NEUROSCI, V4, P1944; BAZAN NG, 1989, ANN NY ACAD SCI, V559, P1; BENKE TA, 1993, P NATL ACAD SCI USA, V90, P7819, DOI 10.1073/pnas.90.16.7819; BLAUSTEIN MP, 1988, TRENDS NEUROSCI, V11, P438, DOI 10.1016/0166-2236(88)90195-6; CACERES A, 1986, J NEUROSCI, V6, P714; COOK JA, 1989, ANAL BIOCHEM, V179, P1, DOI 10.1016/0003-2697(89)90191-7; DAVIS L, 1987, NATURE, V330, P477, DOI 10.1038/330477a0; DEMEDIUK P, 1989, ANN NY ACAD SCI, V559, P431; DESHAIES RJ, 1988, TRENDS BIOCHEM SCI, V13, P384, DOI 10.1016/0968-0004(88)90180-6; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DUMUIS A, 1990, NATURE, V347, P182, DOI 10.1038/347182a0; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FLETCHER TL, 1989, DEV BIOL, V136, P446, DOI 10.1016/0012-1606(89)90269-8; GLAUM SR, 1990, J PHARMACOL EXP THER, V253, P1293; GOUREAU O, 1993, P NATL ACAD SCI USA, V90, P4276, DOI 10.1073/pnas.90.9.4276; HARA H, 1991, EUR J PHARMACOL, V209, P195; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; JAHR CE, 1993, P NATL ACAD SCI USA, V90, P11573, DOI 10.1073/pnas.90.24.11573; KELLER M, 1985, NEUROCHEM INT, V7, P655, DOI 10.1016/0197-0186(85)90063-4; KEYSER DO, 1990, NEURON, V5, P545, DOI 10.1016/0896-6273(90)90092-T; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LAZAREWICZ JW, 1992, ADV EXP MED BIOL, V318, P73; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LOGAN A, 1992, J NEUROSCI, V12, P3828; MACMILLAN V, 1993, STROKE, V24, P1735, DOI 10.1161/01.STR.24.11.1735; MATTSON MP, 1993, EXP NEUROL, V121, P1, DOI 10.1006/exnr.1993.1066; MATTSON MP, 1989, BRAIN RES, V478, P337, DOI 10.1016/0006-8993(89)91514-X; MATTSON MP, 1989, J NEUROSCI, V9, P3728; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; MCKAY R, 1990, COLD SPRING HARB SYM, V55, P291; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; MURPHY T, 1989, ANN NY ACAD SCI, V559, P474; NAKATA N, 1993, BRAIN RES, V605, P354, DOI 10.1016/0006-8993(93)91766-L; PETITO CK, 1984, J CEREBR BLOOD F MET, V4, P194, DOI 10.1038/jcbfm.1984.28; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; REGEHR WG, 1990, NATURE, V345, P807, DOI 10.1038/345807a0; SANFELIU C, 1990, BRAIN RES, V526, P241, DOI 10.1016/0006-8993(90)91228-9; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SIMAN R, 1989, J NEUROSCI, V9, P1579; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TAKAMI K, 1993, EXP BRAIN RES, V97, P185; VOLTERRA A, 1992, J NEUROCHEM, V59, P600, DOI 10.1111/j.1471-4159.1992.tb09411.x; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; WALICKE PA, 1988, DEV BRAIN RES, V40, P71, DOI 10.1016/0165-3806(88)90009-0; WATSON JD, 1987, MOL BIOL GENE, P962; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; YING Z, 1993, J CEREBR BLOOD F MET, V13, P378, DOI 10.1038/jcbfm.1993.51	59	15	15	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 22	1996	707	1					54	63		10.1016/0006-8993(95)01220-6			10	Neurosciences	Neurosciences & Neurology	TU737	WOS:A1996TU73700006	8866713				2021-06-18	
J	Persinger, MA				Persinger, MA			Clinical neurological indicators are only moderately correlated with quantitative neuropsychological test scores in patients who display mild-moderate brain impairment following closed-head injuries	PERCEPTUAL AND MOTOR SKILLS			English	Article								Quantitative comparisons were completed between mean scores for standardized neuropsychological tests (requiring 6 hr.), numbers of neurological signs (tests requiring 15 min.), anomalies within the electroencephalogram, subjective symptoms during a structured interview (requiring 20 min.), and an indicator of an organic brain syndrome for 81 patients who had sustained significant mechanical impacts to their skulls. The composite of neuropsychological scores was correlated 0.70 with a composite of neurological indicators and EEG anomalies. There were no significant correlations between neuropsychological or neurological scores and the numbers of subjective complaints, abnormal personality indicators, duration of coma or the interval of posttraumatic dysmnesia. However, the scores for the severity of the organic brain syndrome, partial complex epileptic symptoms, and subjective complaints were inversely correlated (rho=-0.35) with the duration of coma, the period of posttraumatic amnesia, and the numbers of qualitative electroencephalographic anomalies.		Persinger, MA (corresponding author), LAURENTIAN UNIV,DEPT PSYCHOL,CLIN NEUROPSYCHOL LAB,RAMSEY LAKE RD,SUDBURY,ON P3E 2C6,CANADA.						CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; LACHAR D, 1985, MMPI CLIN ASSESSMENT; Levin H. S., 1987, NEUROBEHAVIORAL RECO, P318; LEVIN HS, 1993, HEAD INJURY, P525; Lopes da Silva F, 1987, ELECTROENCEPHALOGRAP; MAKAREC K, 1990, J RES PERS, V24, P323, DOI 10.1016/0092-6566(90)90024-Z; Miller L., 1993, PSYCHOTHERAPY BRAIN; PARKER R, 1990, TRAUMATIC BRAIN INJU; PERSINGER MA, 1995, PSYCHOL REP, V77, P707, DOI 10.2466/pr0.1995.77.3.707; PERSINGER MA, 1995, PERCEPT MOTOR SKILL, V80, P1011, DOI 10.2466/pms.1995.80.3.1011; PERSINGER MA, 1994, PSYCHOL REP, V75, P1059, DOI 10.2466/pr0.1994.75.3.1059; PERSINGER MA, 1993, PSYCHOL REP, V72, P1059, DOI 10.2466/pr0.1993.72.3c.1059; Reitan RM., 1985, HALSTEAD REITAN NEUR; RICHARDS P, 1992, PERCEPT MOTOR SKILL, V74, P1027, DOI 10.2466/PMS.74.4.1027-1030; Roberts RJ, 1990, NEUROPSYCHOLOGY, V4, P65; SCHOENHUBER R, 1989, MILD HEAD INJURY, P142; TILLER SG, UNPUB TEST RETEST SC; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; 1983, NEUROPSYCHOLOGICAL S	19	15	15	0	0	PERCEPTUAL MOTOR SKILLS	MISSOULA	PO BOX 9229, MISSOULA, MT 59807	0031-5125			PERCEPT MOTOR SKILL	Percept. Mot. Skills	DEC	1995	81	3	2				1283	1292		10.2466/pms.1995.81.3f.1283			10	Psychology, Experimental	Psychology	TQ120	WOS:A1995TQ12000040	8684927				2021-06-18	
J	YLVISAKER, M; FEENEY, T; MAHERMAXWELL, N; MESERVE, N; GEARY, PJ; DELORENZO, JP				YLVISAKER, M; FEENEY, T; MAHERMAXWELL, N; MESERVE, N; GEARY, PJ; DELORENZO, JP			SCHOOL REENTRY FOLLOWING SEVERE TRAUMATIC BRAIN INJURY - GUIDELINES FOR EDUCATIONAL-PLANNING	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						EDUCATIONAL PLANNING; SCHOOL REENTRY; TRAUMATIC BRAIN INJURY	FRONTAL-LOBE DAMAGE; HEAD-INJURY; CHILDREN; CHILDHOOD; CONSEQUENCES; DISABILITIES; BEHAVIOR; SEQUELAE; LESION	The primary purpose of this article is to present a conceptual framework designed to guide educational planning for students returning to school after severe traumatic brain injury (TBI). Eleven basic principles are offered that derive educational implications from important characteristics of many students with TBI. The article concludes with specific program considerations for students representing four different profiles of cognitive, behavioral, and academic functioning. While embracing the ideal of fully individualized educational planning, the authors argue that specific sets of services and supports are important to consider for students with identifiable profiles of ability and disability after TBI.	BOARD COOPERAT EDUC SERV,ALBANY,NY; NASSAU CTY BOARD COOPERAT EDUC SERV,MASSAPEQUA,NY; MONROE 2 ORLEANS CTY BOARD COOPERAT EDUC SERV,ROCHESTER,NY; NEW YORK STATE DEPT EDUC,OFF SPECIAL EDUC SERV,ALBANY,NY	YLVISAKER, M (corresponding author), COLL ST ROSE,DEPT COMMUN DISORDERS,432 WESTERN AVE,ALBANY,NY 12205, USA.						BEGALI V, 1992, HEAD INJURY CHILDREN; BENTON A, 1991, DEV NEUROPSYCHOL, V7, P275, DOI 10.1080/87565649109540495; Bigler E D, 1988, Arch Clin Neuropsychol, V3, P279, DOI 10.1016/0887-6177(88)90020-0; BLOSSER JL, 1989, TOP LANG DISORD, V9, P67, DOI 10.1097/00011363-198903000-00007; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Carr E.G., 1994, COMMUNICATION BASED; *CEC, 1986, FIN REP CEC AD HOC C; COHEN SB, 1991, J HEAD TRAUMA REHAB, V6, P56; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; DEPOMPEI R, 1994, TOP LANG DISORD, V15, P68, DOI 10.1097/00011363-199411000-00007; DEPOMPEI R, 1986, LANGUAGE SPEECH HEAR, V18, P292; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GLANG A, 1992, J HEAD TRAUMA REHAB, V7, P93; GOETZ L, 1987, INNOVATIVE PROGRAM D; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; GRATTAN LM, 1992, BRAIN COGNITION, V20, P185, DOI 10.1016/0278-2626(92)90068-W; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; Hart T, 1993, J HEAD TRAUMA REHAB, V8, P1; Horner R. H, 1988, GENERALIZATION MAINT; JACOBS HE, 1993, BEHAVIOR ANAL GUIDEL; Johnson D.W., 1987, LEARNING TOGETHER AL; Johnson DW., 1991, JOINING TOGETHER GRO; LASH M, 1992, YOUR CHILD GOES SCH; Levin H. S., 1991, FRONTAL LOBE FUNCTIO; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; MATEER CA, 1992, BRAIN COGNITION, V20, P196; MIRA M, 1988, TRAUMATIC HEAD INJUR; Mira M. P., 1992, TRAUMATIC BRAIN INJU; MIRA MP, 1991, FOCUS EXCEPT CHILD, V23, P1; Orelove FP, 1991, ED CHILDREN MULTIPLE; PEARSON S, 1990, TRAUMATIC BRAIN INJU; PEARSON S, 1994, FAMILIES LIVING BRAI; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/pms.1991.73.3f.1139; PRESSLEY M, 1992, COGNITIVE STRATEGY R; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; RAINES SR, 1992, UNDERSTANDING TRAUMA; RAINFORTH B, 1993, COLLABORATIVE TEAMS; ROSEN CD, 1992, HEAD TRAUMA ED REINT; SAVAGE RC, 1991, J HEAD TRAUMA REHAB, V6, P1; Savage RC, 1987, J HEAD TRAUMA REHAB, V2, P1; SAVAGE RC, 1991, HEAD INJURY FAMILY M; SAVAGE RC, 1994, ED DIMENSIONS ACQUIR; STELLING MW, 1986, AM J DIS CHILD, V140, P710, DOI 10.1001/archpedi.1986.02140210108037; STOKES TF, 1977, J APPL BEHAV ANAL, V10, P349, DOI 10.1901/jaba.1977.10-349; Stuss D.T., 1986, FRONTAL LOBES; SZEKERES SF, 1994, TOP LANG DISORD, V15, P21, DOI 10.1097/00011363-199411000-00004; Szekeres Shirley F., 1992, Seminars in Speech and Language, V13, P293, DOI 10.1055/s-2008-1064204; TAYLOR HG, IN PRESS TRAUMATIC H; TELZROW C, 1990, TRAUMATIC BRAIN INJU; TELZROW CF, 1991, J HEAD TRAUMA REHAB, V6, P23; THOUSAND JS, 1990, FOCUS EXCEPT CHILD, V23, P1; Tyler J. S., 1993, TEACH EXCEPT CHILDRE, V25, P24; TYLER JS, 1991, LD FORUM TRANSLATING; TYLER JS, 1993, PERSPECTIVES TRAUMAT; VANDIJK J, 1986, SENSORY IMPAIRMENTS; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; WILLIAMS J, 1991, HEAD INJURY FAMILY M; Wolcott G. F, 1995, ED MANUAL WHAT ED NE; YLVISAKER M, 1993, NEUROPSYCHOL REHABIL, V3, P367, DOI 10.1080/09602019308401447; YLVISAKER M, 1994, TOP LANG DISORD, V15, P37, DOI 10.1097/00011363-199411000-00005; Ylvisaker M, 1991, J HEAD TRAUMA REHAB, V6, P10, DOI DOI 10.1097/00001199-199103000-00006; YLVISAKER M, 1994, ED DIMENSIONS ACQUIR; YLVISAKER M, IN PRESS HEAD INJURY; YLVISAKER M, 1991, ADV CHILD NEUROPSYCH; Ylvisaker Mark, 1995, Seminars in Speech and Language, V16, P32, DOI 10.1055/s-2008-1064109	72	15	15	0	3	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1995	10	6					25	41		10.1097/00001199-199512000-00006			17	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	TJ661	WOS:A1995TJ66100006					2021-06-18	
J	YLVISAKER, M; FEENEY, T; MULLINS, K				YLVISAKER, M; FEENEY, T; MULLINS, K			SCHOOL REENTRY FOLLOWING MILD TRAUMATIC BRAIN INJURY - A PROPOSED HOSPITAL-TO-SCHOOL PROTOCOL	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						HOSPITAL-TO-SCHOOL PROTOCOL; SCHOOL REENTRY; MILD TRAUMATIC BRAIN INJURY	MINOR HEAD TRAUMA; CHILDREN; CHILDHOOD; MORBIDITY; LESION	Mild traumatic brain injury (TBI) in children is generally associated with excellent long-term outcome. In rare cases sequelae persist indefinitely. More commonly, cognitive and behavioral symptoms persist for a few days to a few weeks, possibly resulting in academic and social failure that could generate consequences that outlive the neurological sequelae. This article presents a mild TBI hospital-to-school protocol that uses real academic and social tasks and contexts as the screening procedure and creates a system of temporary accommodations in the event of persisting cognitive or behavioral consequences of the injury.	THE SAGE COLL,DEPT EDUC,TROY,NY; ALBANY SCHENECTADY SCHOHARIE & SARATOGA BOARDS CO,ALBANY,NY; BROOME TIOGA CTY BOARD COOPERAT EDUC SERV,BINGHAMTON,NY	YLVISAKER, M (corresponding author), COLL ST ROSE,DEPT COMMUN DISORDERS,432 WESTERN AVE,ALBANY,NY 12205, USA.						BENTON A, 1991, DEV NEUROPSYCHOL, V7, P275, DOI 10.1080/87565649109540495; BIJUR PE, 1990, PEDIATRICS, V86, P269; BOLL TJ, 1983, J CLIN CHILD PSYCHOL, V12, P74, DOI 10.1080/15374418309533114; CASEY R, 1986, PEDIATRICS, V78, P497; CASEY R, 1987, PEDIATRICS, V80, P159; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1985, INJURED CHILD; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; GRATTAN LM, 1992, BRAIN COGNITION, V20, P185, DOI 10.1016/0278-2626(92)90068-W; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; JENNETT B, 1972, DEV MED CHILD NEUROL, V14, P137; Levin H. S., 1991, FRONTAL LOBE FUNCTIO; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; Stuss D.T., 1986, FRONTAL LOBES; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; YLVISAKER M, 1995, SEMIN SPEECH LANG, V15, P32	23	15	15	0	4	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1995	10	6					42	49		10.1097/00001199-199512000-00007			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	TJ661	WOS:A1995TJ66100007					2021-06-18	
J	KELLER, T				KELLER, T			RAILWAY SPINE REVISITED - TRAUMATIC NEUROSIS OR NEUROTRAUMA	JOURNAL OF THE HISTORY OF MEDICINE AND ALLIED SCIENCES			English	Article										KELLER, T (corresponding author), UNIV CALIF DAVIS E BAY,DIV NEUROSURG,1411 E 31ST ST,OAKLAND,CA 94602, USA.						[Anonymous], 1895, SITZUNGSBERICHTE PHY, V137, P132; BAILEY P, 1907, TXB LEGAL MED TAXICO, V1, P360; BAKER RH, 1920, SURG GYNECOL OBSTET, V31, P359; BAKER RP, 1983, J NEUROSURG, V58, P760, DOI 10.3171/jns.1983.58.5.0760; Beard, 1881, AM NERVOUSNESS ITS C; Beard GM, 1869, BOSTON MED SURG J, V80, P217; Bevan AD, 1895, RAILW SURG, V2, P121; BUZZARD T, 1867, LANCET, V1, P389; BUZZARD T, 1867, LANCET, V1, P390; CHARCOT J, 1995, LECONS MALADIES SYST, V3, P355; CLEVENGER SV, 1889, JAMA-J AM MED ASSOC, V12, P50; CLEVENGER SV, 1889, SPINAL CONCUSSION SU, P208; Cushing H, 1903, BOSTON MED SURG J, V148, P0250, DOI 10.1056/NEJM190303051481002; Dana C. L., 1884, MED REC, V26, P617; DANA CL, 1888, POSTGRADUATE, V3, P104; DENIS F, 1984, CLIN ORTHOP RELAT R, V189, P142; DERCUM FX, 1989, THERAPEUTIC GAZETTE, V13, P649; DUNBAR S, 1968, HIST TRAVEL AM, V3, P1052; EDES R, 1882, BOSTON MED SURG J, V107, P265; ERICHHSEN J, 1875, CONCUSSION SPINE NER, P275; Erichsen John Eric, 1866, RAILWAY OTHER INJURI; FARR W, 1975, VITAL STATISTICS MEM, P349; FRENCH R, 1969, R WHYTT SOUL MED, P90; FREUD S, 1924, COLLECT PAPERS, V1, P42; GOEPP RM, 1929, STATE BOARD QUESTION, P306; GRAY M, 1978, NEUROSES COMPREHENSI, P204; HAMMOND W, 1876, SPINAL IRRITATION; Hodges R. M., 1881, BOSTON MED SURG J, V104, P386; Hodges R. M., 1881, BOSTON MED SURG J, V104, P361, DOI [10.1056/NEJM188104211041601, DOI 10.1056/NEJM188104211041601]; HUDDLESON J, 1932, ACCIDENTS NEUROSES C, P108; Judd H., 1889, JAMA-J AM MED ASSOC, V13, P188, DOI [10.1001/jama.1889.04440040008002, DOI 10.1001/JAMA.1889.04440040008002]; KEIR M, 1927, MARCH COMMERCE, V4, P121; KNAPP P, 1888, BOSTON MED SURG J, V119, P421; MENDEL E, 1884, NEUROLOGISCHES  0515, P229; MULLEN JB, 1979, NEUROSURGERY, V5, P432, DOI 10.1227/00006123-197910000-00004; OPPENHEIM H, 1911, TXB NERVOUS DISEASES, V11, P1162; OPPENHEIM H, 1885, ARCH PSYCHIAT NERVEN, V16, P743; PAGE H, 1885, MED TIMES GAZ, P437; PAGE H, 1891, WOODS MED SEURGICAL, V10, P23; PAGE H, 1885, INJURIES SPINE SPINA, P14; PHILLIPS L, 1965, YONDER COMES TRAIN, P30; PUTNAM JJ, 1883, BOSTON MED SURG J, V104, P217; REED R, 1968, TRAIN WRECKS, P10; REYNOLDS JR, 1868, SYSTEM MED, V2, P640; RIGLER J, 1879, UEBER FOLGEN VERLETZ, P7; ROGERS L, 1944, BRIT J SURG, V32, P517; SCHNAID E, 1985, J TRAUMA, V25, P1099; SMITH HH, 1889, JAMA-J AM MED ASSOC, V13, P181; SPITZKA E, 1883, AM J NEUROL PSYCHIAT, V2, P541; STRUMPELL A, 1887, LEHRBUCH SPECIALLEN, V11, P161; THORBURN W, 1888, MED CHRONICLE MANCHE, V9, P265; THORBURN W, 1888, MED CHRONICLE MANCHE, V9, P198; TRAFTON PG, 1984, J TRAUMA, V24, P506, DOI 10.1097/00005373-198406000-00008; TRIMBLE MR, 1981, POST TRAUMATIC NEURO, P141; VONLEYDEN E, 1878, ARK PSYCH, V8, P21; Walton G. L., 1881, BOSTON MED SURG J, V109, P337, DOI 10.1056/NEJM188310111091501; WESTPHAL C, 1878, CHARITE ANN, V5, P379; WHITE J, 1880, BOSTON MED SURG J, V102, P132; 1858, HARPERS WEEKLY  0831, P483; 1890, INDEX LIBRARY SURGEO; 1862, LANCET, V1, P79; 1980, DIAGNOSTIC STATISTIC, P238; 1856, NY TIMES        0717, P1; 1871, NY TIMES        0827, P1; 1975, COLONIAL TIMES 1970, V2, P211; 1988, NY TIMES        1011, P1	66	15	16	0	1	J HIST MED ALLIED SCI INC	CANTON	 PO BOX 487, CANTON, MA 02021	0022-5045			J HIST MED ALL SCI	J. Hist. Med. Allied Sci.	OCT	1995	50	4					507	524		10.1093/jhmas/50.4.507			18	Health Care Sciences & Services; History & Philosophy Of Science	Health Care Sciences & Services; History & Philosophy of Science	TB616	WOS:A1995TB61600003	7594404				2021-06-18	
J	CAVALLO, MM; SAUCEDO, C				CAVALLO, MM; SAUCEDO, C			TRAUMATIC BRAIN INJURY IN FAMILIES FROM CULTURALLY DIVERSE POPULATIONS	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						CULTURAL DIVERSITY; SERVICE DELIVERY; TRAUMATIC BRAIN INJURY	REHABILITATION; ACCULTURATION; AMERICANS	This article presents information regarding the epidemiology of traumatic brain injury (TBI) in culturally diverse populations and factors that must be considered when providing services to these persons and their families (eg. language, level of acculturation, family values). Issues of assessment and treatment are also discussed. Recommendations for education and training of rehabilitation professionals and for providing effective clinical interventions to culturally diverse people with TBI and their families are provided.		CAVALLO, MM (corresponding author), ASSOC HELP RETARDED CHILDREN,TRAUMAT BRAIN INJURY COMMUNITY SUPPORT SERV,NEW YORK,NY, USA.						ACOSTA FX, 1982, EFFECTIVE PSYCHOTHER; Ardila A., 1994, NEUROPSYCHOLOGICAL E; AXELROD D, 1986, HEAD INJURY IN NEW Y; BARRINGER F, 1993, NY TIMES        0428, pA18; BAXTER B, 1993, NOV NAT HEAD INJ F S; BELGRAVE FZ, 1991, P NATIONAL C FUTURE; BROOKS DN, 1992, J CLIN EXP PSYCHOL, V13, P155; CHAVIRA JA, 1988, DISABILITY REHABILIT; COOPER KD, 1983, NEUROEPIDEMIOLOGY, V2, P70; CUELLAR I, 1988, J REHABIL, V54, P35; Del Castillo J. C., 1970, AM J PSYCHIAT, V127, P160; DIKENGIL A, 1993, J COGNITIVE REHABILI, V11, P10; ESTRADA AL, 1990, AM J PUBLIC HEALTH, V80, P27, DOI 10.2105/AJPH.80.Suppl.27; FITZGERALD MH, 1992, J REHABIL, V58, P38; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST; GARCIA PI, 1984, HISPANIC J BEHAV SCI, V6, P225, DOI 10.1177/07399863840063002; HAVILAND MG, 1983, J COUNS PSYCHOL, V30, P267, DOI 10.1037/0022-0167.30.2.267; HORAN K, 1990, ARIZONA COUNSEL J, V15, P6; Horan K.T., 1987, RURAL SPECIAL ED Q, V8, P19; KAY T, 1994, FAMILY SYSTEM IMPACT; LACALLE JJ, 1987, AM J FORENSIC PSYCH, V5, P29; MARSHALL CA, 1991, J COUNS DEV, V70, P225, DOI 10.1002/j.1556-6676.1991.tb01588.x; MARTINEZ C, 1988, CLIN GUIDELINES CROS; NEGY C, 1992, HISPANIC J BEHAV SCI, V14, P224, DOI 10.1177/07399863920142003; NEGY C, 1992, HISPANIC J BEHAV SCI, V14, P248, DOI 10.1177/07399863920142004; NIX L, 1993, NOV NAT HEAD INJ F S; Orlandi MA., 1992, CULTURAL COMPETENCE; PADILLA A, 1980, ACCULTURATION THEORY; PADILLA AM, 1992, CULTURAL COMPETENCE; PUENTE AE, 1990, HDB PSYCHOL ASSESSME; SMART JF, 1992, J REHABIL, V58, P29; SZAPOCZNIK J, 1993, AM PSYCHOL, V48, P400, DOI 10.1037/0003-066X.48.4.400; Szapocznik J, 1980, ACCULTURATION THEORY; Szapocznik J., 1980, INT J INTERCULT RELA, V4, P353, DOI [DOI 10.1016/0147-1767(80)90010-3, 10.1016/0147-1767(80)90010-3]; SZAPOCZNIK J, 1978, INTERAMERICAN J PSYC, V12, P113; *TASK FORC DEL SER, 1990, GUID PROV PSYCH SERV; VASQUEZ C, 1991, HOSP COMMUNITY PSYCH, V42, P163; WALKER S, 1993, NOV NAT HEAD INJ F S; WESTERMEYER J, 1980, HOSP COMMUNITY PSYCH, V137, P160; WILLIAMS J, 1993, STAFF DEV CLIN INTER; WILLIAMS J, 1991, HEAD INJURY FAMILY M; 1993, REHABIL BRIEF, V15, P1	42	15	15	0	0	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1995	10	2					66	77		10.1097/00001199-199504000-00008			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	QR039	WOS:A1995QR03900008					2021-06-18	
J	MINTZ, MC; VANHORN, KR; LEVINE, MJ				MINTZ, MC; VANHORN, KR; LEVINE, MJ			DEVELOPMENTAL MODELS OF SOCIAL COGNITION IN ASSESSING THE ROLE OF FAMILY STRESS IN RELATIVES PREDICTIONS FOLLOWING TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							HEAD-INJURY; ANXIETY	The present study extended the utilization of developmental models of social cognition to the investigation of stress and relatives' perception of traumatic brain injury (TBI) survivors. Structured interviews were conducted with 21 TBI survivors utilizing interpersonal negotiation strategies (INS) and self understanding (self) in the framework of Selman's model of social perspective-taking and Damon and Hart's multidimensional model of self understanding. A relative group composed of 21 participants was interviewed and their predictions of the responses of the TBI survivors to the action domain of the INS stories were obtained. The relative participant group was also administered the Beck Anxiety and Depression Inventories and Leeds Scales of Depression and Anxiety. The relationships among relative groups' predictive scores, INS and self domains and stress levels were analysed. The result of the survivor groups responses on INS and self were in agreement with the previous findings that TBI survivors respond at psychosocially immature levels. Comparison of INS action scores obtained by the survivor group and predicted by relative group were within one developmental level of each other in 87.4% of the cases. Fifty-two per cent of the relative group scored in mild to moderate or greater depression and 48% scored in the mild to moderate range of anxiety on the Beck scales. Pearson correlation coefficients indicated significant negative correlations between Beck scores and predictive INS scores. ANOVA indicated significantly higher Beck depression scores in relatives of TBI survivors living in residential facilities than relatives of TBI survivors in an outpatient treatment programme. The study supports the view that developmental social cognition methods appear to advance our understanding of psychosocial adjustments and relatives' perceptions of social cognition in TBI survivors.		MINTZ, MC (corresponding author), CENT MICHIGAN UNIV,DEPT PSYCHOL,SLOAN HALL 226,MT PLEASANT,MI 48859, USA.						BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; DAMON W, 1988, UNPUB SCORING MANUAL; Derogatis LR, 1975, BRIEF SYMPTOM INVENT; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; JENNETT B, 1975, LANCET, V3, P480; KAY T, 1988, HEAD INJURY FAMILY I; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEVINE M, 1993, 17TH POSTGR COURS RE; LEVINE MJ, 1993, BRAIN INJURY, V7, P153, DOI 10.3109/02699059309008169; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; McCubbin M.A., 1989, TREATING STRESS FAMI, P3; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; SELMAN RL, 1986, UNPUB INTERVIEW METH; SNAITH RP, 1976, BRIT J PSYCHIAT, V128, P156, DOI 10.1192/bjp.128.2.156; Van Horn K R, 1992, Brain Inj, V6, P15, DOI 10.3109/02699059209008118; WILLIAMS JM, 1987, COGNITIVE BEHAVIOR R	19	15	15	0	5	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB-MAR	1995	9	2					173	186		10.3109/02699059509008190			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	QN628	WOS:A1995QN62800006	7787837				2021-06-18	
J	HELLER, KD; FORST, J; FORST, R				HELLER, KD; FORST, J; FORST, R			RECOMMENDATIONS FOR THE TREATMENT OF PERSISTENT POSTERIOR DISLOCATION OF THE SHOULDER - A REVIEW OF THE LITERATURE	UNFALLCHIRURG			German	Article								Three-hundred and twenty-nine cases of posterior dislocation of the shoulder documented in 300 articles published in the international literature are reviewed. They included 130 cases in which the duration of the dislocation was longer than 6 weeks and the dislocation could be classified as persistent primary dislocation. This group is the second largest group following that with acute primary dislocation. The mechanism of injury may be direct or indirect force: trauma, convulsions or electrocution are usually responsible for this type of dislocation, which often persists for longer than 6 weeks. Anatomically, 97.5% of dislocations are classified as subacromial. Posterior dislocation of the shoulder is commonly misdiagnosed on plain antero-posterior radiographs, and in over 50% of cases the diagnosis was missed on first examination. The typical signs of primary traumatic posterior dislocation of the shoulder are described. Management of persistent traumatic posterior dislocation of the shoulder depends on the size of the anterior Hill-Sachs lesion, the precipitating mechanism and the duration of dislocation. The results of 109 surgically and 24 conservatively treated dislocations of this type that have been published in the international literature are reviewed. Closed reduction is indicated in carefully selected cases with an anterior Kill-Sachs lesion under 15% of the size of humeral head (measured in the axillary view) that has been dislocation for less than 2 months. In most due to convulsions there was a distinct anterior Hill-Sachs lesion, which led to recurrence. In 83% of cases of convulsive origin there was a recurrence, whereas in the traumatic group redislocation occurred in 43%. In the group of 109 operative treated shoulders, isolated soft-tissue procedures have not been shown to produce good long-term results. In the case of a small anterior Hill-Sachs lesion, posterior bone block combined with anterior capsulotomy and stripping of the subscapularis muscle, as described by Augereau et al., gave good results in 5 of 6 cases. When a defect of 15-25% of the humeral head is present, subscapularis transposition is indicated. This method gave good or excellent results in 63% of cases seen after a mean follow-up time of 42 months. In 89% of the cases treated with the transposition to the lesser tuberosity as described by Neer the treatment was successful. Alternative treatment options in this group include the use of an autogeneous corticocancellous bone graft to fill the defect (Ahlers and Ritter), combined with a rotational osteotomy of the humerus if necessary. A hemiarthroplasty or total arthroplasty is indicated where these surgical treatments have been unsuccessful and when degenerative arthritis is present.		HELLER, KD (corresponding author), RHEIN WESTFAL TH AACHEN,FAK MED,ORTHOPAD KLIN,PAUWELSSTR 30,D-52057 AACHEN,GERMANY.							0	15	15	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0177-5537			UNFALLCHIRURG	Unfallchirurg	JAN	1995	98	1					6	12					7	Emergency Medicine; Surgery	Emergency Medicine; Surgery	QD254	WOS:A1995QD25400002	7886466				2021-06-18	
J	ACHTEREEKTE, HAM; VANDERKRUIJK, RA; HEKSTER, REM; KEUNEN, RWM				ACHTEREEKTE, HAM; VANDERKRUIJK, RA; HEKSTER, REM; KEUNEN, RWM			DIAGNOSIS OF TRAUMATIC CAROTID-ARTERY DISSECTION BY TRANSCRANIAL DOPPLER ULTRASOUND - CASE-REPORT AND REVIEW OF THE LITERATURE	SURGICAL NEUROLOGY			English	Article						ANGIOGRAPHY; DUPLEX SONOGRAPHY; TRANSCRANIAL DOPPLER RECORDINGS; TRAUMATIC CAROTID ARTERY DISSECTION	CEREBRAL BLOOD-FLOW	The clinical course, transcranial Doppler ultrasound (TCD) findings, and angiographic outcome are reported for a patient with a traumatic carotid artery dissection. Transient asymmetrical decreased middle cerebral artery blood flow velocities led to the suspicion of an internal carotid artery (ICA) stenosis. Duplex scanning and angiography subsequently demonstrated an extracranial traumatic ICA dissection in combination with a traumatic saccular aneurysm. These data imply that TCD monitoring has a potential to diagnose not only well established complications of neurotrauma, such as vasospasm and intracranial hypertension, but may also suggest the presence of traumatic extracranial carotid obstructions.		ACHTEREEKTE, HAM (corresponding author), ZIEKENHUIS LEYENBURG,DEPT NEUROL & CLIN NEUROPHYSIOL,DEPT NEURORADIOL,LEYWEG 275,2545 CH THE HAGUE,NETHERLANDS.						GAWLOWSKI J, 1989, Neurosurgical Review, V12, P386, DOI 10.1007/BF01790679; KAECH D, 1990, UNFALLCHIRURG, V93, P6; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MOKRI B, 1988, J NEUROSURG, V68, P189, DOI 10.3171/jns.1988.68.2.0189; MULLGES W, 1992, J NEUROL NEUROSUR PS, V52, P98; SAUNDERS FW, 1988, SURG NEUROL, V29, P401, DOI 10.1016/0090-3019(88)90049-3; STURZENEGGER M, 1991, ARCH NEUROL-CHICAGO, V48, P1057, DOI 10.1001/archneur.1991.00530220079023; SUNDT TM, 1986, J NEUROSURG, V64, P169, DOI 10.3171/jns.1986.64.2.0169; WATRIDGE CB, 1989, J NEUROSURG, V71, P189; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; ZELENOCK GB, 1982, ARCH SURG-CHICAGO, V117, P425	11	15	15	0	0	ELSEVIER SCIENCE PUBL CO INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0090-3019			SURG NEUROL	Surg. Neurol.	SEP	1994	42	3					240	244		10.1016/0090-3019(94)90270-4			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	QB699	WOS:A1994QB69900009	7940112				2021-06-18	
J	WALKER, AE				WALKER, AE			THE PHYSIOLOGICAL-BASIS OF CONCUSSION - 50 YEARS LATER	JOURNAL OF NEUROSURGERY			English	Article						JOURNAL OF NEUROSURGERY; NEUROSURGICAL HISTORY		In this brief narrative, the author compares what is known today about the physiological basis of concussion with the results of studies described 50 years ago in the Journal of Neurosurgery. The author was a member of the team that originally reported these findings in the first volume of the Journal of Neurosurgery.								BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349; BRICOLO AP, 1990, HDB CLIN NEUROLOGY, V57, P207; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; ESCHUN G, 1992, SURG NEUROL, V37, P101, DOI 10.1016/0090-3019(92)90184-O; FOLTZ EL, 1956, J NEUROSURG, V13, P145, DOI 10.3171/jns.1956.13.2.0145; KOCHER T, 1901, SPECIELLE PATHOLOGIE, V9; MAGOUN HW, 1958, WAKING BRAIN; MEYER JS, 1955, ELECTROEN CLIN NEURO, V7, P529, DOI 10.1016/0013-4694(55)90078-X; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1966, HEAD INJURY, P260; Scott WW, 1940, ARCH NEURO PSYCHIATR, V43, P270, DOI 10.1001/archneurpsyc.1940.02280020078006; TOWER DB, 1948, J CLIN INVEST, V27, P558; VANDENPOL AN, 1990, J COMP NEUROL, V296, P654, DOI 10.1002/cne.902960410; von Haller A, 1753, COMMENTARII SOC REGI, VII, P114; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WARD AA, 1966, HEAD INJURY C P, P203; WEISEND M P, 1989, Society for Neuroscience Abstracts, V15, P69; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223	18	15	15	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	1994	81	3					493	494		10.3171/jns.1994.81.3.0493			2	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	PC762	WOS:A1994PC76200025	8057163				2021-06-18	
J	KONASIEWICZ, SJ; MOULTON, RJ; SHEDDEN, PM				KONASIEWICZ, SJ; MOULTON, RJ; SHEDDEN, PM			SOMATOSENSORY-EVOKED POTENTIALS AND INTRACRANIAL-PRESSURE IN SEVERE HEAD-INJURY	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							DIFFUSE AXONAL INJURY; INTRA-CRANICAL PRESSURE; NEUROFILAMENT SUBUNITS; AGGRESSIVE TREATMENT; COMATOSE CHILDREN; EARLY PREDICTION; CEREBRAL TRAUMA; SHORT-LATENCY; MANAGEMENT; DIAGNOSIS	The purpose of this study was to explore the relationship between neurologic function, using a quantitative measurement of continuous somatosensory evoked potentials (SSEPs), and intracranial pressure (ICP) following traumatic brain injury. During a 6 year period, severely head-injured patients with a Glascow Coma Scale less than or equal to 8 who were not moribund were monitored with SSEPs and ICP measurements. SSEPs from each hemisphere and ICP were recorded hourly for each patient. Neurologic outcomes were scored using the Glasgow Outcome Scale at three months post injury. Although initial SSEP amplitude did not correlate well with outcome, final SSEP summed peak to peak amplitude from both hemispheres (p = .0001), the best hemisphere (p = .0004), and the worst hemisphere (p = .0001) correlated well with the Glasgow Outcome Scale groups. Of a total of 72 patients, 40 had deteriorating SSEPs and 32 had stable or improving SSEPs. Peak ICP values were not statistically different in these groups (p = .6). Among patients with deteriorating SSEPs, 52.5% lost the greatest proportion of hemispheric electrical activity prior to ICP elevation. In the remaining patients, the percent reduction of SSEP activity after peak ICP levels was not statistically different from the percent reduction in SSEP activity prior to the peak ICP levels (p = .9). This data suggests that in a select group of patients with severe head injury, ICP does not cause SSEP deterioration, but rather is the consequence of deterioration of brain function.	UNIV TORONTO, ST MICHAELS HOSP, DIV NEUROSURG, TORONTO M5B 1A6, ON, CANADA							ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; AHMED I, 1988, CLIN ELECTROENCEPHAL, V19, P78, DOI 10.1177/155005948801900209; ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERTRAND O, 1990, NEW TRENDS ADV TEC S, V41, P51; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; BYRNES DP, 1980, INTRACRANIAL PRESSUR, V4, P73; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; DEWEERD AW, 1985, ACTA NEUROL SCAND, V72, P489; GARCIALARREA L, 1992, J NEUROL NEUROSUR PS, V55, P792, DOI 10.1136/jnnp.55.9.792; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GOODWIN SR, 1991, CRIT CARE MED, V19, P518, DOI 10.1097/00003246-199104000-00011; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; GRIMM G, 1988, LANCET, V2, P1392; GRIMM G, 1991, INTENS CARE MED, V17, P94, DOI 10.1007/BF01691430; GRIMM G, 1990, KIDNEY INT, V38, P480, DOI 10.1038/ki.1990.229; Guerit J. M., 1993, Neurophysiologie Clinique, V23, P209, DOI 10.1016/S0987-7053(05)80231-X; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; HUME AL, 1980, ANN NEUROL, V37, P630; Imhof H G, 1993, Aktuelle Traumatol, V23, P7; JENNETT B, 1975, LANCET, V1, P480; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; LINDSAY KW, 1981, J NEUROL NEUROSUR PS, V44, P796, DOI 10.1136/jnnp.44.9.796; MADL C, 1993, LANCET, V341, P855, DOI 10.1016/0140-6736(93)93061-5; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MENDELOW AD, 1983, BRIT J SURG, V70, P641, DOI 10.1002/bjs.1800701102; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MOULTON R, 1991, J TRAUMA, V31, P676, DOI 10.1097/00005373-199105000-00012; MOULTON RJ, IN PRESS CAN J NEURO; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NEWLON PG, 1982, J NEUROSURG, V57, P168, DOI 10.3171/jns.1982.57.2.0168; NEWLON PG, 1985, NEUROL CLIN, V3, P675, DOI 10.1016/S0733-8619(18)31029-6; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; SAHUQUILLOBARRIS J, 1988, J NEUROSURG, V68, P894, DOI 10.3171/jns.1988.68.6.0894; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SEYAL M, 1987, NEUROLOGY, V37, P650, DOI 10.1212/WNL.37.4.650; STUART GG, 1983, J NEUROSURG, V59, P601, DOI 10.3171/jns.1983.59.4.0601; TAYLOR MJ, 1989, PEDIATR NEUROL, V5, P145, DOI 10.1016/0887-8994(89)90063-5; Turner H B, 1988, J Neurosci Nurs, V20, P236; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YAMADA T, 1983, ARCH NEUROL-CHICAGO, V40, P215, DOI 10.1001/archneur.1983.04050040045007; YAMAKI T, 1992, ACTA NEUROCHIR, V119, P153, DOI 10.1007/BF01541800	48	15	15	0	2	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0317-1671	2057-0155		CAN J NEUROL SCI	Can. J. Neurol. Sci.	AUG	1994	21	3					219	226		10.1017/S0317167100041196			8	Clinical Neurology	Neurosciences & Neurology	PC596	WOS:A1994PC59600006	8000977	Bronze			2021-06-18	
J	KOSCIULEK, JF				KOSCIULEK, JF			DIMENSIONS OF FAMILY COPING WITH HEAD-INJURY	REHABILITATION COUNSELING BULLETIN			English	Article							TRAUMATIC BRAIN INJURY; STRESS; CHILDREN	Head injury affects not only the person who sustains the injury but also the individual's entire family. Although the negative consequences of head injuries on families have been well documented, little is known about family efforts to manage the demands of a member's injury. The purpose of this study was to examine the dimensions underlying family coping with head injury. The following three dimensions were identified: (a) individual-to-family versus family-to-community coping, (b) family-respite versus head-injury-focused coping, and (c) cognitive versus behavioral coping. Implications for family stress and coping theory advancement, family assessment and intervention, and future head injury family research are discussed.		KOSCIULEK, JF (corresponding author), UNIV GEORGIA,DEPT COUNSELING & HUMAN DEV SERV,REHABIL COUNSELING PROGRAM,ATHENS,GA 30602, USA.						Aldenderfer M.S., 1984, CLUSTER ANAL; Bishop DS, 1988, J HEAD TRAUMA REHAB, V3, P16; Boss P, 1987, HDB MARRIAGE FAMILY, P695; BOX GEP, 1976, J AM STAT ASSOC, V71, P791, DOI 10.2307/2286841; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROWN BW, 1988, FAM RELAT, V37, P300; Copeland AP, 1991, STUDYING FAMILIES; COZBY PC, 1993, METHODS BEHAVIORAL R; DAVISON M, 1992, MULTIDIMENSIONAL SCA; DeJong G., 1990, J HEAD TRAUMA REHAB, V5, P9, DOI [https://doi.org/10.1097/00001199-199003000-00004, DOI 10.1097/00001199-199003000-00004]; Filsinger E. E., 1990, FAMILY VARIABLES CON, P90; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Graffi S, 1989, J APPLIED SOCIAL SCI, V13, P293; HAIR JF, 1987, MULTIVARIATE DATA AN; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KAY T, 1991, HEAD INJURY FAMILY M, P121; KAY T, 1990, TRAUMATIC BRAIN INJU, P21; KOSCIULEK JF, 1993, J REHABIL, V59, P40; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; Kruscal J., 1977, CLASSIFICATION CLUST, P17; Kruskal Joseph B, 1978, MULTIDIMENSIONAL SCA, V11; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; Livingston M G, 1987, Brain Inj, V1, P33, DOI 10.3109/02699058709034442; Livingston MG., 1990, REHABILITATION ADULT, P225; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Mathis M, 1984, J Neurosurg Nurs, V16, P36; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; McCubbin H.I., 1983, SOCIAL STRESS FAMILY, P7, DOI DOI 10.1300/J002V06N01_02; MCCUBBIN HI, 1980, J MARRIAGE FAM, V42, P855, DOI 10.2307/351829; MCCUBBIN HI, 1979, J MARRIAGE FAM, V41, P237, DOI 10.2307/351693; MCCUBBIN HI, 1981, FCOPES FAMILY CRISIS; MCCUBBIN MA, 1988, FAM RELAT, V37, P203, DOI 10.2307/584321; McCubin M. A., 1991, FAMILY ASSESSMENT IN, P3; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; Moore A. D., 1991, J HEAD TRAUMA REHAB, V6, P83; *NAT HEAD INJ F, 1986, TRAUM SIL EP; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; PARKER RM, 1993, REHABIL COUNS BULL, V36, P130; Patterson J., 1988, FAMILY SYST MED, V6, P202, DOI DOI 10.1037/H0089739; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Schiffman S. S., 1981, INTRO MULTIDIMENSION; *SPSS INC, 1992, SPSS WIND BAS SYST U; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; Willer B., 1990, CANADIAN J REHABILIT, V3, P167; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Williams J.M., 1991, HEAD INJURY FAMILY M, P81; Young F.W., 1987, MULTIDIMENSIONAL SCA	53	15	15	0	1	AMER COUNSELING ASSOC	ALEXANDRIA	5999 STEVENSON AVE, ALEXANDRIA, VA 22304-3300	0034-3552			REHABIL COUNS BULL	Rehabil. Couns. Bull.	MAR	1994	37	3					244	258					15	Rehabilitation	Rehabilitation	NU899	WOS:A1994NU89900004					2021-06-18	
J	RIVARA, JB				RIVARA, JB			FAMILY FUNCTIONING FOLLOWING PEDIATRIC TRAUMATIC BRAIN INJURY	PEDIATRIC ANNALS			English	Article										RIVARA, JB (corresponding author), CHILDRENS HOSP & MED CTR,DEPT REHABIL MED,CH-71,4800 SAND POINT WAY NE,POB 5371,SEATTLE,WA 98105, USA.							0	15	15	0	0	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086	0090-4481			PEDIATR ANN	Pediatr. Annu.	JAN	1994	23	1					38	&		10.3928/0090-4481-19940101-09			0	Pediatrics	Pediatrics	MU563	WOS:A1994MU56300006	8152863				2021-06-18	
J	JORDAN, FM; MURDOCH, BE				JORDAN, FM; MURDOCH, BE			A PROSPECTIVE-STUDY OF THE LINGUISTIC SKILLS OF CHILDREN WITH CLOSED-HEAD INJURIES	APHASIOLOGY			English	Article								Little research in the paediatric closed-head injury (CHI) literature has attempted to follow the course of recovery of CHI children over a prolonged period, particularly in the area of linguistic recovery. The present study documented the course of recovery of the linguistic skills of a group of 11 CHI children over an 18-month period post-injury. All of the CHI children studied demonstrated measurable gains in a number of speech and language skills during the 18-month period post-injury. The results indicated that childhood CHI did not permanently disrupt the acquisition of any of the speech and language skills observed. A number of subjects did, however, continue to demonstrate measurable deficits in some language areas even at 18 months post-injury.		JORDAN, FM (corresponding author), UNIV QUEENSLAND, DEPT PSYCHOL, BRISBANE, QLD 4072, AUSTRALIA.		Murdoch, Bruce E/C-1397-2012				ALAJOUANINE T, 1965, BRAIN, V88, P653, DOI 10.1093/brain/88.4.653; BLOOM L, 1975, REV CHILD DEV RES, V4; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CARTER RL, 1982, SCIENCE, V218, P797, DOI 10.1126/science.7134973; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; ENDERBY PM, 1983, FRENCHAY DYSARTHRIA; Ewing-Cobbs L., 1985, SPEECH LANGUAGE EVAL, P97; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; GADDES WH, 1973, RES MONOGRAPH, V25; HAMMILL DD, 1982, TEST LANGUAGE DEV IN; HAMMILL DD, 1987, TEST ADOLESCENT LANG, P2; HECAEN H, 1976, BRAIN LANG, V3, P114, DOI 10.1016/0093-934X(76)90009-2; JORDAN F M, 1990, Brain Injury, V4, P27; JORDAN F M, 1990, Brain Injury, V4, P147, DOI 10.3109/02699059009026159; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; Kaplan E., 1983, BOSTON NAMING TEST; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; Newcomer P, 1982, TEST LANGUAGE DEV; OWENS RE, 1988, LANGUAGE DEV INTRO; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SATZ P, 1981, ACQUIRED APHASIA; SEMELMINTZ E, 1982, CLIN EVALUATION LANG; Spreen O, 1969, NEUROSENSORY CTR COM; TEASDALE G, 1974, LANCET, V2, P81; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; 1983, CELF UPDATE 3	29	15	15	0	2	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology	SEP-OCT	1993	7	5					503	512		10.1080/02687039308248626			10	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	LZ486	WOS:A1993LZ48600011					2021-06-18	
J	SOBUS, KML; ALEXANDER, MA; HARCKE, HT				SOBUS, KML; ALEXANDER, MA; HARCKE, HT			UNDETECTED MUSCULOSKELETAL TRAUMA IN CHILDREN WITH TRAUMATIC BRAIN INJURY OR SPINAL-CORD INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article										SOBUS, KML (corresponding author), ALFRED I DUPONT INST,1600 ROCKLAND RD,POB 269,WILMINGTON,DE 19899, USA.						CITTAPIETROLUNG.TJ, 1992, ARCH PHYS MED REHAB, V73, P289; DEUTSCH SD, 1983, SURG CLIN N AM, V63, P567; HARCKE HT, 1983, ANN RADIOL, V26, P675; MARTIN P, 1983, SEMIN NUCL MED, V13, P104; MOLNAR GE, 1985, PEDIATRIC REHABILITA, P207	5	15	15	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1993	74	9					902	904					3	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	LX551	WOS:A1993LX55100002	8379833				2021-06-18	
J	BULLOCK, R				BULLOCK, R			PATHOPHYSIOLOGICAL ALTERATIONS IN THE CENTRAL-NERVOUS-SYSTEM DUE TO TRAUMA	SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT			English	Article							SEVERE HEAD-INJURY; BRAIN; DAMAGE; TRIAL	Neurotrauma is the largest cause of death and severe disability in young adults. In this review, the pathophysiological processes which damage the brain and spinal cord, both acutely, and hours to days after injury, are discussed. Secondary, delayed damage is the major cause of bad outcome in at least 40% of patients, with severe head injury. Diffuse damage to axons, hypoxic-ischaemic damage to neurons and astrocytes, contusions, intracranial haematomas, and brain swelling are discussed. The prospect for improving outcome by pharmacological therapy, and the current status of head injury trials are presented.	UNIV GLASGOW, INST NEUROL SCI, DEPT NEUROSURG, GLASGOW G12 8QQ, SCOTLAND							Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ANDERSON DK, 1992, J NEUROTRAUM, V9, P113, DOI 10.1089/neu.1992.9.113; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; BULLOCK R, 1991, VINKEN BRUYNS HDB CL, V24, P249; CHEN MH, 1991, J NEUROSURG, V74, P944, DOI 10.3171/jns.1991.74.6.0944; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1978, INJURY, V10, P31; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169	15	15	15	0	0	E M H SWISS MEDICAL PUBLISHERS LTD	MUTTENZ	FARNSBURGERSTR 8, CH-4132 MUTTENZ, SWITZERLAND	0036-7672			SCHWEIZ MED WSCHR	Schweiz. Med. Wochenschr.	MAR 20	1993	123	11					449	458					10	Medicine, General & Internal	General & Internal Medicine	KT714	WOS:A1993KT71400002	8475352				2021-06-18	
J	CONFORTI, PJ; HAUG, RH; LIKAVEC, M				CONFORTI, PJ; HAUG, RH; LIKAVEC, M			MANAGEMENT OF CLOSED HEAD-INJURY IN THE PATIENT WITH MAXILLOFACIAL TRAUMA	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							INTRACRANIAL-PRESSURE; MANNITOL		ST RAPHAELS HOSP, DEPT ORAL & MAXILLOFACIAL SURG, NEW HAVEN, CT USA; METROHEALTH MED CTR CLEVELAND, CLEVELAND, OH USA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA							Bakay L, 1980, HEAD INJURY; BATES B, 1974, GUIDE PHYSICAL EXAMI; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; CHAMBERS IR, 1990, NEUROSURGERY, V26, P421, DOI 10.1227/00006123-199003000-00007; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; CRITCHLEY ER, 1988, NEUROLOGICAL EMERGEN; CUTLER RWP, 1968, BRAIN, V91, P707, DOI 10.1093/brain/91.4.707; DAVIDOFF G, 1988, ANN EMERG MED, V17, P6, DOI 10.1016/S0196-0644(88)80492-X; GADISSEUZ P, 1989, TXB HEAD INJURY, P241; GORDON E, 1970, BRIT J ANAESTH, V42, P2, DOI 10.1093/bja/42.1.2; HAUG HZ, 1992, J ORAL MAXIL SURG, V50, P218, DOI 10.1016/0278-2391(92)90315-Q; HOFFMAN WE, 1990, CLIN ANESTH, P819; JANE JA, 1982, CLIN NEUR, V29, P346; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; KADIS LB, 1981, ANESTHESIA UNCOMMON, P485; KEENAN RL, 1989, TXB HEAD INJURY, P182; LEE KF, 1987, J NEUROSURG, V66, P542, DOI 10.3171/jns.1987.66.4.0542; LEITMAN MW, 1988, MANUAL EYE EXAMINATI; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; MARSHALL SB, 1990, NEUROSCIENCE CRITICA; MCEVOY GK, 1989, AM HOSPITAL FORMULAR; MCGILLICUDDY JE, 1985, CHEST, V87, P85, DOI 10.1378/chest.87.1.85; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1984, GREENFIELDS NEUROPAT, P53; MOLLMAN HD, 1988, J NEUROSURG, V68, P737, DOI 10.3171/jns.1988.68.5.0737; MOSS E, 1979, BRIT J ANAESTH, V51, P757, DOI 10.1093/bja/51.8.757; OSTRUP RC, 1987, J NEUROSURG, V67, P206, DOI 10.3171/jns.1987.67.2.0206; POLLAY M, 1983, J NEUROSURG, V59, P945, DOI 10.3171/jns.1983.59.6.0945; ROCKOFF MA, 1988, NEUROLOGICAL NEUROSU; SAUL TG, 1988, CONNS CURRENT THERAP, P817; SIEBER FE, 1992, CRIT CARE MED, V20, P104, DOI 10.1097/00003246-199201000-00022; TEASDALE G, 1974, LANCET, V2, P81; TGRUNKEY D, 1991, NEW ENGL J MED, V324, P1259; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; WOSTER PS, 1990, CLIN PHARMACY, V9, P762; YOUMANS JR, 1990, NEUROLOGY SURGERY, V3	40	15	16	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	MAR	1993	51	3					298	303		10.1016/S0278-2391(10)80179-X			6	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	KQ334	WOS:A1993KQ33400019	8445472				2021-06-18	
J	XUE, ZY; GROSSFELD, RM				XUE, ZY; GROSSFELD, RM			STRESS PROTEIN-SYNTHESIS AND ACCUMULATION AFTER TRAUMATIC INJURY OF CRAYFISH CNS	NEUROCHEMICAL RESEARCH			English	Article						STRESS; PROTEIN; TRAUMA; CRAYFISH; CNS; WOUND	HEAT-SHOCK PROTEINS; CENTRAL NERVOUS-SYSTEM; FIBRILLARY ACIDIC PROTEIN; HYPERTHERMIA PROTECTS; GERBIL BRAIN; RAT; INDUCTION; HSP70; GENE; ISCHEMIA	By several days after a crush injury of crayfish CNS, the wound site heals. Changes in protein synthesis and accumulation occur at the lesion site and nearby. During the first few hours, synthesis of 35, 70, 90, and 150 kDa proteins is induced in the injured tissue. By one day, the relative amounts of 70-90 kDa proteins increase dramatically, particularly at the crush site and adjacent to it. The 70 kDa proteins, which are related to mammalian stress proteins (SPs), remain elevated for at least one month in the traumatized region or nearby. The crushed tissue contains an SP70 isoform not present in its uncrushed counterpart. These biochemical changes may reflect the cellular changes that accompany wound healing and/or a cellular stress response to compensate for the lesion. Since similar adaptations occur in the mammalian CNS, they may represent a phylogenetically conserved attempt to retard or repair CNS tissue deterioration.	N CAROLINA STATE UNIV,DEPT ZOOL,RALEIGH,NC 27695							AGUAYO AJ, 1981, J EXP BIOL, V95, P231; BARBE MF, 1988, SCIENCE, V241, P1817, DOI 10.1126/science.3175623; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; BITTNER GD, 1981, COMP BIOCHEM PHYS A, V68, P299, DOI 10.1016/0300-9629(81)90055-4; BITTNER GD, 1988, AM ZOOL, V28, P1165; BROCK TO, 1987, J NEUROSCI, V7, P931; BROWN IR, 1990, J NEUROSCI RES, V27, P247, DOI 10.1002/jnr.490270302; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; BURDON RH, 1986, BIOCHEM J, V240, P313, DOI 10.1042/bj2400313; CHOPP M, 1989, NEUROLOGY, V39, P1396, DOI 10.1212/WNL.39.10.1396; CLEMENTE CD, 1964, INT REV NEUROBIOL, V6, P257, DOI 10.1016/S0074-7742(08)60771-0; COTMAN CW, 1985, ANN NY ACAD SCI, V457, P83, DOI 10.1111/j.1749-6632.1985.tb20800.x; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; GOWER DJ, 1989, J NEUROSURG, V70, P605, DOI 10.3171/jns.1989.70.4.0605; GROSSFELD RM, 1987, NEUROCHEM RES, V12, P977, DOI 10.1007/BF00970926; HOY RR, 1973, DEV NEUROBIOLOGY ART, P203; HUGHES J, 1981, ANAL BIOCHEM, V117, P1, DOI 10.1016/0003-2697(81)90681-3; JOHNSTON RN, 1988, SCIENCE, V242, P1551, DOI 10.1126/science.3201244; KITAMURA T, 1972, J NEUROPATHOL EXP NE, V31, P5002; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LOOMIS WF, 1982, DEV BIOL, V90, P412, DOI 10.1016/0012-1606(82)90390-6; LOWENSTEIN DH, 1990, BRAIN RES, V531, P173, DOI 10.1016/0006-8993(90)90771-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marangos P. J., 1988, NEURONAL GLIAL PROTE, P339; MENDES M, 1980, J NEUROSURG, V53, P772; MEYER MR, 1978, BRAIN RES, V143, P213, DOI 10.1016/0006-8993(78)90565-6; MIZZEN LA, 1988, J CELL BIOL, V106, P1105, DOI 10.1083/jcb.106.4.1105; Nover L, 1991, HEAT SHOCK RESPONSE; NOWAK TS, 1985, J NEUROCHEM, V45, P1635, DOI 10.1111/j.1471-4159.1985.tb07236.x; NOWAK TS, 1991, J CEREBR BLOOD F MET, V11, P432, DOI 10.1038/jcbfm.1991.84; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PELHAM HRB, 1984, EMBO J, V3, P3095, DOI 10.1002/j.1460-2075.1984.tb02264.x; PILAR G, 1972, SCIENCE, V177, P1116, DOI 10.1126/science.177.4054.1116; RAISMAN G, 1973, DYNAMICS DEGENERATIO, V22, P373; Reier PJ, 1983, SPINAL CORD RECONSTR, P163; RIABOWOL KT, 1988, SCIENCE, V242, P433, DOI 10.1126/science.3175665; ROCHELLE JM, 1991, NEUROCHEM RES, V16, P533, DOI 10.1007/BF00974871; RUDGE JS, 1989, EXP NEUROL, V103, P1, DOI 10.1016/0014-4886(89)90180-5; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SUBJECK JR, 1986, AM J PHYSIOL, V250, pC1; VASS K, 1988, ACTA NEUROPATHOL, V77, P128; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; WELCH WJ, 1989, UCLA S MOL CELL BIOL, V96, P198	48	15	15	0	1	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013	0364-3190			NEUROCHEM RES	Neurochem. Res.	FEB	1993	18	2					209	218		10.1007/BF01474686			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	KF464	WOS:A1993KF46400015	8474563				2021-06-18	
J	NEISTADT, ME				NEISTADT, ME			THE RABIDEAU KITCHEN EVALUATION-REVISED - AN ASSESSMENT OF MEAL PREPARATION SKILL	OCCUPATIONAL THERAPY JOURNAL OF RESEARCH			English	Article						ACTIVITIES OF DAILY LIVING; INDEPENDENT LIVING SKILLS TRAUMATIC BRAIN INJURY	SCALE	This paper describes the Rabideau Kitchen Evaluation-Revised (RKE-R), an assessment of meal preparation skill for adults with traumatic brain injury (TBI) that yields information about client skill with component steps of an actual meal preparation activity-preparation of a sandwich and a hot beverage. Validity and reliability studies on this instrument are also described. An inter-rater reliability study yielded an 86% agreement among eight evaluators. A test-retest study with four adult men with TBI resulted in a Spearman rank order correlation coefficient of 0.80. Preliminary norms from a sample of 34 ambulatory men with TBI, ages 18 to 49, are reported, and suggest that the RKE-R may not be a useful evaluation tool for clients with subtle cognitive/perceptual deficits. Recommendations for modifying the RKE-R to increase the clinical information it can provide are discussed.	UNIV NEW HAMPSHIRE,SCH HLTH & HUMAN SERV,DEPT OCCUPAT THERAPY,DURHAM,NH 03824							BENSON J, 1982, AM J OCCUP THER, V36, P789, DOI 10.5014/ajot.36.12.789; DOW PW, 1989, OCCUPATIONAL THERAPY, P484; EAKIN P, 1989, BRIT J OCCUPATIONAL, V52, P11; INTAGLIATA S, 1991, OCCUP THER PRACT, V2, P26; KLEIN RM, 1982, ARCH PHYS MED REHAB, V63, P335; LAW M, 1989, AM J OCCUP THER, V43, P522, DOI 10.5014/ajot.43.8.522; LEZAK M, 1983, NEUROPSYUCHOLOGICAL; MCNENY R, 1983, REHABILITATION HEAD, P143; PANIKOFF LB, 1983, AM J OCCUP THER, V37, P735, DOI 10.5014/ajot.37.11.735; RABIDEAU GM, 1986, THESIS TUFTS U MEDFO; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROSENTHAL M, 1991, JUN PRAT STRAT SCI B; Trombly CA, 1989, OCCUPATIONAL THERAPY; TROMBLY CA, 1983, OCCUPATIONAL THERAPY; *UN DAT SYST MED R, 1990, GUID US UN DAT SET M; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th	16	15	15	0	4	AMER OCCUP THER FOUND INC	ROCKVILLE	1383 PICCARD DR, ROCKVILLE, MD 20849-1725	0276-1599			OCCUP THER J RES	Occup. Ther. J. Res.	JUL-AUG	1992	12	4					242	253		10.1177/153944929201200404			12	Rehabilitation	Rehabilitation	JX734	WOS:A1992JX73400004					2021-06-18	
J	THOMAIDES, TN; KEREZOUDI, EP; CHAUDHURI, KR; CHEROPOULOS, C				THOMAIDES, TN; KEREZOUDI, EP; CHAUDHURI, KR; CHEROPOULOS, C			STUDY OF EEGS FOLLOWING 24-HOUR SLEEP-DEPRIVATION IN PATIENTS WITH POSTTRAUMATIC EPILEPSY	EUROPEAN NEUROLOGY			English	Article						POSTTRAUMATIC EPILEPSY; ACTIVATION; SLEEP DEPRIVATION; HEAD INJURY	ACTIVATION; WAKING	Routine and awake EEGs following 24-hour sleep deprivation were studied in 119 patients with closed head injury, 64 epileptics without any history of head injury and 53 healthy controls. The results were compared to CT brain scan findings. There were no epileptic discharges in routine EEGs, while EEGs after 24-hour sleep deprivation showed considerable activation, ranging from 28 to 37.5 % in those with a history of head injury or epilepsy. No correlation was found between the period elapsed between the time of injury and the activation of the EEG. Most of the patients with EEG activation after sleep deprivation had abnormal CT scans. EEGs following 24-hour sleep deprivation therefore appear to be a useful adjunct to other methods used in detecting brain damage in patients with head injury or epilepsy.	GEN HOSP, ATHENS, GREECE; ROYAL FREE HOSP, SCH MED, DEPT NEUROL SCI, LONDON, ENGLAND; UCL NATL HOSP NEUROL & NEUROSURG, DEPT EEG, AUTONOM INVEST UNIT, LONDON, ENGLAND; NIMTS HOSP, ATHENS, GREECE							ARNEBES MC, 1982, SLEEP EPILEPSY, P441; BECHINGER D, 1976, ELECTROEN CLIN NEURO, V41, P654; BENNETT DR, 1969, NEUROLOGY, V19, P375, DOI 10.1212/WNL.19.4.375; DECKLERCK AC, 1982, SLEEP EPILEPSY, P453; DEGEN R, 1980, ELECTROEN CLIN NEURO, V49, P577, DOI 10.1016/0013-4694(80)90398-3; DEGEN R, 1984, EPILEPSY SLEEP SLEEP, P273; DELRIO MB, 1940, RIV SPER FRENIATR, V64, P159; GELLER MR, 1969, DEV MED CHILD NEUROL, V11, P771; Gibbs Frederic A., 1944, AMER JOUR PSYCHIATRY, V100, P738; GUNDERSO.CH, 1973, NEUROLOGY, V23, P678, DOI 10.1212/WNL.23.7.678; Heinemann L G, 1966, Arch Psychiatr Nervenkr (1970), V208, P177, DOI 10.1007/BF00343267; JENNETT WB, 1962, EPILEPSY BLUNT HEAD; JOHNSON IC, 1971, NMNP14 NAV MED NEUR, P37; JOVANIC VJ, 1971, ARCH PSYCHIAT NERVEN, V214, P183; KLINGLER D, 1982, WIEN MED WOCHENSCHR, V132, P253; LEVI L, 1972, STRESS DISTRESS RESP, P119; LOGOTHETIS J, 1986, EUR NEUROL, V25, P134, DOI 10.1159/000116094; MATTSON RH, 1965, ARCH NEUROL-CHICAGO, V13, P310, DOI 10.1001/archneur.1965.00470030090009; RODIN EA, 1962, ELECTROEN CLIN NEURO, V14, P544, DOI 10.1016/0013-4694(62)90060-3; Roth B, 1986, Schweiz Arch Neurol Psychiatr (1985), V137, P17; SCOLLOLAVIZZARI G, 1977, EUR NEUROL, V15, P121, DOI 10.1159/000114829; WALTON J N, 1963, Med Leg J, V31, P15; WELCH LK, 1971, AEROSPACE MED, V42, P349; WILLIAMS D, 1944, J NEUROL NEUROSUR PS, V7, P131; Zouhar A, 1981, Cesk Neurol Neurochir, V44, P210	25	15	15	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0014-3022			EUR NEUROL	Eur. Neurol.	MAR-APR	1992	32	2					79	82		10.1159/000116796			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	HH174	WOS:A1992HH17400004	1563465				2021-06-18	
J	PARKINSON, D				PARKINSON, D			CONCUSSION IS COMPLETELY REVERSIBLE - AN HYPOTHESIS	MEDICAL HYPOTHESES			English	Article								It is hypothesized that there is an entity properly called 'concussion', a transient loss of neuronal function without permanent neuronal damage, as defined years ago by Derek-Denny Brown (1). This implies that multiple concussions leave no deficit. n + 1 times zero is still zero. Arguments are presented indicating that there is a margin of safety between the acceleration inducing 1-10 s loss of function (concussion) and that inducing permanent damage (contusions, lacerations).		PARKINSON, D (corresponding author), UNIV MANITOBA,128 BASIC SCI BLDG,730 WILLIAM AVE,WINNIPEG R3E 0W3,MANITOBA,CANADA.						De Haven Hugh, 1942, WAR MED, V2, P586; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; ESCHUN G, UNPUB MR SPECTROSCOP; FROWEIN RA, 1976, ACTA NEUROCHIR, V34, P5, DOI 10.1007/BF01405858; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; LOMBARD CHARLES F., 1951, JOUR AVIATION MED, V22, P109; PARKINSON D, 1988, SURG NEUROL, V30, P102, DOI 10.1016/0090-3019(88)90094-8; PARKINSON D, 1978, NEUROSURGERY, V3, P176, DOI 10.1227/00006123-197809000-00008; PARKINSON D, 1989, UNPUB LIGHT EM STUDI; PARKINSON D, 1988, CHANGES NEUROTRANSMI, pA73; SUTHERLAND GR, 1991, IN PRESS NMR SPECTRO; WEST M, 1980, CAN FED BIOL SCI, V23, P141; WEST M, 1980, CAN J NEUROL SCI	13	15	15	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH, MIDLOTHIAN, SCOTLAND EH1 3AF	0306-9877			MED HYPOTHESES	Med. Hypotheses	JAN	1992	37	1					37	39		10.1016/0306-9877(92)90010-A			3	Medicine, Research & Experimental	Research & Experimental Medicine	HE576	WOS:A1992HE57600009	1569905				2021-06-18	
J	JANI, NN; LAURENO, R; MARK, AS; BREWER, CC				JANI, NN; LAURENO, R; MARK, AS; BREWER, CC			DEAFNESS AFTER BILATERAL MIDBRAIN CONTUSION - A CORRELATION OF MAGNETIC-RESONANCE-IMAGING WITH AUDITORY BRAIN-STEM EVOKED-RESPONSES	NEUROSURGERY			English	Article						AUDITORY BRAIN STEM EVOKED RESPONSE; CONVERSION DISORDER; DEAFNESS; INFERIOR COLLICULUS; MAGNETIC RESONANCE IMAGING; MIDBRAIN TRAUMA	MIDDLE-EAR REFLEX; HEARING-LOSS; NEURONAL ORGANIZATION; POTENTIALS; LESIONS; MR	A 46-year-old woman became deaf after a closed head injury. When a computed tomographic scan failed to disclose the cause, conversion disorder was suspected. Magnetic resonance imaging, however, showed bilateral contusions of the inferior colliculi, providing objective evidence for an organic cause of hearing loss. Auditory brain stem evoked responses and stapedial reflexes also provided objective evidence of brain stem injury. This case illustrates the phenomenon of dorsal midbrain injury after head trauma. It indicates the sensitivity of magnetic resonance imaging for small focal lesions after head trauma, and it demonstrates some difficulties in the diagnosis of "hysterical" deafness.	WASHINGTON HOSP CTR,DEPT NEUROL,2A-44,110 IRVING ST NW,WASHINGTON,DC 20010; GEORGE WASHINGTON UNIV,SCH MED,WASHINGTON,DC 20052; WASHINGTON HOSP CTR,DEPT RADIOL,WASHINGTON,DC 20010; WASHINGTON HOSP CTR,DEPT HEARING & SPEECH,WASHINGTON,DC 20010							BORG E, 1973, BRAIN RES, V49, P101, DOI 10.1016/0006-8993(73)90404-6; BRANTZAWADZKI M, 1986, AM J NEURORADIOL, V7, P781; DIX MR, 1973, ACTA OTO-LARYNGOL, V75, P165, DOI 10.3109/00016487309139692; FELDMANN H, 1987, ACTA OTO-LARYNGOL, V103, P379; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; HOWDE JR, 1975, NEUROLOGY, V25, P286; MARK AS, 1989, MRI DESICIONS, V13, P26; MOLLER AR, 1983, SCAND AUDIOL, V12, P125, DOI 10.3109/01050398309076235; MOLLER AR, 1982, ELECTROEN CLIN NEURO, V53, P612, DOI 10.1016/0013-4694(82)90137-7; MOLLER AR, ACOUSTIC REFLEX SCI, P1; MOMOSE KJ, 1983, AM J NEURORADIOL, V4, P781; ROPPER AH, 1985, ANN NEUROL, V18, P80, DOI 10.1002/ana.410180114	12	15	15	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	JUL	1991	29	1					106	109		10.1227/00006123-199107000-00018			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FT164	WOS:A1991FT16400018	1870669				2021-06-18	
J	JAEGER, CB; WINN, SR; TRESCO, PA; AEBISCHER, P				JAEGER, CB; WINN, SR; TRESCO, PA; AEBISCHER, P			REPAIR OF THE BLOOD-BRAIN-BARRIER FOLLOWING IMPLANTATION OF POLYMER CAPSULES	BRAIN RESEARCH			English	Article						RAT; MACROCAPSULE; ALBUMIN IMMUNOCYTOCHEMISTRY; NEURAL TRANSPLANTATION; EVANS BLUE	ENDOTHELIAL-CELLS; GROWTH-FACTOR; ASTROCYTES; IMMUNOFLUORESCENCE; VERTEBRATES; PATTERNS; INVITRO; TISSUE; RATS	Past studies of polymer-encapsulated cell lines implanted in the brain indicated their usefulness for transmitter replacement therapy in animal models. Such grafts may have potentially important clinical applications, but their placement into neural parenchyma may cause a traumatic injury resulting in a leaky blood-brain barrier around the implant. This study investigated whether or not injury repair and reformation of the barrier takes place near a polymer capsule implanted in the brain of Sprague-Dawley rats. The two methods used for detection of a leaky barrier were immunocytochemical localization of extravasated serum albumin and circulating Evans blue that binds to serum albumin. Immunocytochemical staining for glial filament protein provided a measure for evaluating injury associated gliosis. Polymer capsules implanted for 10, 16 and 18 days were surrounded by microvessels that leaked detectable quantities of serum albumin into interstitial spaces and, by secondary uptake, into some nearby neurons and reactive astrocytes. Reactive astroglia were observed within the outer regions of the capsule wall and in the near vicinity of the implant after these early survival times. In contrast, at post-implantation times of 46 and 54 days, serum albumin was no longer detected in the neural parenchyma near the macrocapsules and only few reactive astrocytes remained. These findings show that polymer capsules implanted within the cerebrum permit (a) reformation of the blood-brain barrier and (b) occurrence of repair processes that lead to minimal deposition of reactive astroglia near the implanted polymer capsule.	BROWN UNIV, ARTIFICIAL ORGAN LAB, PROVIDENCE, RI 02912 USA	JAEGER, CB (corresponding author), PURDUE UNIV, SCH VET MED, DEPT ANAT, CTR PARALYSIS RES, W LAFAYETTE, IN 47907 USA.		Aebischer, Patrick/E-1387-2013		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 27694] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027694] Funding Source: NIH RePORTER		AEBISCHER P, 1991, EXP NEUROL, V111, P269, DOI 10.1016/0014-4886(91)90093-R; AEBISCHER P, 1988, BRAIN RES, V448, P364, DOI 10.1016/0006-8993(88)91278-4; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; BLAKEMORE WF, 1969, J NEUROPATH EXP NEUR, V28, P139, DOI 10.1097/00005072-196901000-00008; Bradbury MWB, 1979, CONCEPT BLOOD BRAIN; CSERR HF, 1984, AM J PHYSIOL, V246, pR277; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FREEDMAN FB, 1969, AM J PHYSIOL, V216, P675; GOLDSTEIN GW, 1986, SCI AM, V255, P74, DOI 10.1038/scientificamerican0986-74; HYMER WC, 1981, NEUROENDOCRINOLOGY, V32, P339, DOI 10.1159/000123184; JAEGER CB, 1985, EXP BRAIN RES, V59, P615; JAEGER CB, 1985, J COMP NEUROL, V231, P121, DOI 10.1002/cne.902310110; JAEGER CB, 1986, ANN NY ACAD SCI, V481, P361; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KARNOVSKY MJ, 1967, J CELL BIOL, V35, P312; KRUM JM, 1988, J COMP NEUROL, V271, P331, DOI 10.1002/cne.902710304; MILICI AJ, 1985, P NATL ACAD SCI USA, V82, P6181, DOI 10.1073/pnas.82.18.6181; NITSCH C, 1983, J NEUROL SCI, V59, P305, DOI 10.1016/0022-510X(83)90016-3; POWELL EM, 1990, BRAIN RES, V515, P309, DOI 10.1016/0006-8993(90)90612-F; ROSENSTEIN JM, 1987, SCIENCE, V235, P772, DOI 10.1126/science.2433767; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; TAOCHENG JH, 1987, J NEUROSCI, V7, P3293; WILMES F, 1979, ACTA NEUROPATHOL, V45, P47, DOI 10.1007/BF00691804; WINN SR, 1989, J BIOMED MATER RES, V23, P31, DOI 10.1002/jbm.820230104; WINN SR, 1990, NEUR ABSTR, V16, P39; WOLMAN M, 1981, ACTA NEUROPATHOL, V54, P55, DOI 10.1007/BF00691332	28	15	15	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUN 14	1991	551	1-2					163	170		10.1016/0006-8993(91)90929-P			8	Neurosciences	Neurosciences & Neurology	FV304	WOS:A1991FV30400025	1913150				2021-06-18	
J	HAYES, KC; ALLATT, RD; WOLFE, DL; KASAI, T; HSIEH, J				HAYES, KC; ALLATT, RD; WOLFE, DL; KASAI, T; HSIEH, J			REINFORCEMENT OF MOTOR EVOKED-POTENTIALS IN PATIENTS WITH SPINAL-CORD INJURY	ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY			English	Article; Proceedings Paper	SYMP ON TRANSCRANIAL MAGNETIC STIMULATION AND THE MOTOR EVOKED POTENTIAL	AUG, 1989	CHICAGO, IL	E PARALYZED VET ASSOC, NATL PARALYSIS ASSOC, CHICAGO NEUROSURG CTR, FDN INVESTIGAT NEUROL DISORDERS, AMER PARALYSIS ASSOC		MOTOR EVOKED POTENTIALS; SPINAL CORD INJURY; ELECTROPHYSIOLOGY	MAGNETIC STIMULATION; HUMAN-BRAIN; TRANSCRANIAL STIMULATION; MULTIPLE-SCLEROSIS; CONDUCTION TIME; CORTEX; RESPONSES; MUSCLES; PATHWAYS; MECHANISMS	Transcranial magnetic stimulation of the motor cortex has been used to investigate the putative existence of spared motor pathways in spinal cord injured patients with clinically complete paralysis. Particular consideration was given to methods of neurological reinforcement likely to minimize the risk of false negative interpretation of absent motor evoked potentials (MEPs). The principal methods of reinforcement included target and remote muscle contractions and conditioning of MEPs with a brief (20 msec) train of cutaneous stimulation (500 Hz: duration 0.1 msec) delivered 20-150 msec prior to cortical stimulation, Twelve control subjects and 26 patients with severe traumatic spinal cord injury underwent cortical stimulation delivered from a Cadwell MES 10 (70-100% intensity) through a 9-cm focal point coil. Electromyographic responses were recorded from surface electrodes in bipolar configuration and amplified (3 dB down at 10 Hz-1 kHz) prior to storage, MEPs were recorded, following reinforcement, in muscles with clinically complete paralysis in 4/26 patients. In each case, MEPs were of low amplitude (< 0.5 mV), polyphasic, and with variable and prolonged latencies. MEPs were evoked in severely paretic (clinically incomplete paralysis) muscles in 6/8 patients only when neurological reinforcement was employed. Conditioning of MEPs in tibialis anterior with proceeding cutaneous stimulation to the plantar surface (subthreshold for evoking a flexion reflex) yielded a well-defined modulation of MEP amplitude in control subjects. An early (Conditioning-Test (C-T) intervals 20-45 msec) period of inhibition of MEPs (x = 60% of control) was followed by a period (C-T intervals 50-90 msec) of facilitation (x 345%) and a subsequent (C-T intervals 90-150 msec) period of inhibition (X 0%). In spinal cord injured patients the same conditioning paradigm failed to reveal MEPs. but did result in the appearance of suprathreshold flexion reflexes in 2 patients at 20-55 msec C-T intervals. This summation of convergent but subliminal cortical and cutaneous inputs to the target motoneuron pool provided additional evidence of preserved cortical influence on segmental structures that was not detectable by other means. These results extend previous reports of electrophysiological evidence of spared motor pathways in spinal cord injured patients with complete paralysis, and affirm the need for neurological reinforcement as a routine procedure in cortical stimulation studies of spinal cord injuries.	PARKWOOD HOSP,DEPT PHYS MED & REHABIL,LONDON,ONTARIO,CANADA; UNIV WESTERN ONTARIO,LONDON N6A 3K7,ONTARIO,CANADA							BARKER AT, 1985, LANCET, V1, P1106; BARKER AT, 1986, LANCET, V1, P1325; Barker AT, 1985, ELECTROENCEPHALOGR C, V61, P245; BARKER AT, 1988, NEUROLOGY NEUROBIOLO, V41, P231; BENECKE R, 1988, ELECTROEN CLIN NEURO, V69, P412, DOI 10.1016/0013-4694(88)90063-6; BERARDELLI A, 1988, NEUROLOGY NEUROBIOLO, V41, P219; BLIGHT AR, 1986, NEUROSCIENCE, V19, P321, DOI 10.1016/0306-4522(86)90025-4; CARAMIA MD, 1988, NEUROLOGY NEUROBIOLO, V41, P193; CARAMIA MD, 1990, MAGNETIC STIMULATION, P145; COWAN JMA, 1984, LANCET, V2, P304; DAY BL, 1988, J PHYSIOL-LONDON, V399, pP68; DAY BL, 1987, NEUROSCI LETT, V75, P101, DOI 10.1016/0304-3940(87)90083-8; DELETIS V, 1987, NEUROSURGERY, V20, P195; DELWAIDE PJ, 1984, J NEUROL NEUROSUR PS, V47, P190, DOI 10.1136/jnnp.47.2.190; DIMITRIJEVCIC MR, 1984, ANN NEUROL, V1644, P2169; DIMITRIJEVIC MR, 1984, ANN NEUROL, V16, P216, DOI 10.1002/ana.410160208; DIMITRIJEVIC MR, 1987, PARAPLEGIA, V25, P205, DOI 10.1038/sc.1987.35; DIMITRIJEVIC MR, 1988, NEUROLOGY NEUROBIOLO, V41, P243; EDMONDS HL, 1989, SPINE, V14, P683, DOI 10.1097/00007632-198907000-00006; GASSEL MM, 1964, NEUROLOGY, V14, P640, DOI 10.1212/WNL.14.7.640; GASSEL MM, 1964, NEUROLOGY, V14, P555, DOI 10.1212/WNL.14.6.555; GIANUTSOS J, 1987, EXP NEUROL, V98, P34, DOI 10.1016/0014-4886(87)90069-0; GOTTLIEB GL, 1970, J NEUROPHYSIOL, V33, P365; GOTTLIEB GL, 1971, J NEUROL NEUROSUR PS, V34, P226, DOI 10.1136/jnnp.34.3.226; HESS CW, 1986, NEUROSCI LETT, V71, P235, DOI 10.1016/0304-3940(86)90565-3; HORE J, 1976, J NEUROPHYSIOL, V39, P484; INGRAM DA, 1987, J NEUROL NEUROSUR PS, V50, P159, DOI 10.1136/jnnp.50.2.159; INGRAM DA, 1988, NEUROLOGY NEUROBIOLO, V41, P207; Jendrassik E., 1883, DTSCH ARCH KLIN MED, V33, P177; JONES EG, 1983, ADV NEUROL, V29, P263; Kakulas B A, 1984, Cent Nerv Syst Trauma, V1, P117; KAKULAS BA, 1987, PARAPLEGIA, V25, P212, DOI 10.1038/sc.1987.37; LANDAU WM, 1964, ARCH NEUROL-CHICAGO, V10, P117, DOI 10.1001/archneur.1964.00460140003001; LUCIER GE, 1975, J PHYSIOL-LONDON, V251, P833, DOI 10.1113/jphysiol.1975.sp011125; Meinck H. M., 1983, MOTOR CONTROL MECHAN, P787; MERTON PA, 1980, NATURE, V285, P227, DOI 10.1038/285227a0; MERTON PA, 1982, LANCET, V2, P597; MEYER DR, 1953, PSYCHOL BULL, V50, P204, DOI 10.1037/h0061173; MILLS KR, 1987, NEUROSURGERY, V20, P164; MILLS KR, 1985, ANN NEUROL, V18, P601, DOI 10.1002/ana.410180514; PORTER R, 1983, MOTOR CONTROL MECHAN; ROSSINI PM, 1988, NONINVASIVE STIMULAT, V41, P37; ROTHWELL JC, 1987, NEUROSURGERY, V20, P156; SHAHANI BT, 1971, J NEUROL NEUROSUR PS, V34, P616, DOI 10.1136/jnnp.34.5.616; THOMPSON PD, 1987, ANN NEUROL, V21, P389, DOI 10.1002/ana.410210412; TRONI W, 1988, NEUROLOGY NEUROBIOLO, V41, P73; WAXMAN SG, 1989, J NEUROL SCI, V91, P1, DOI 10.1016/0022-510X(89)90072-5; YORK DH, 1987, NEUROSURGERY, V20, P70	48	15	15	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0013-4694			ELECTROEN CLIN NEURO	Electroencephalogr. Clin. Neurophysiol.		1991				43			312	329					18	Engineering, Biomedical; Clinical Neurology	Engineering; Neurosciences & Neurology	HB515	WOS:A1991HB51500027	1773771				2021-06-18	
J	NORDBY, HK; URDAL, P; BJORNAES, H				NORDBY, HK; URDAL, P; BJORNAES, H			THE PROGNOSIS OF PATIENTS WITH CONCUSSION AND INCREASED CREATINE KINASE-BB IN THE CEREBROSPINAL-FLUID	ACTA NEUROCHIRURGICA			English	Article									UNIV OSLO,ULLEVAL HOSP,CENT LAB,OSLO,NORWAY	NORDBY, HK (corresponding author), UNIV OSLO,ULLEVAL HOSP,DEPT NEUROSURG,OSLO,NORWAY.						BURUMA OJS, 1981, J NEUROL NEUROSUR PS, V44, P144, DOI 10.1136/jnnp.44.2.144; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; INGHAM JG, 1979, J EPIDEMIOL COMMUN H, V33, P191, DOI 10.1136/jech.33.3.191; LIDVALL HF, 1974, ACTA NEUROL SCAND, V56, P50; NORDBY HK, 1982, ACTA NEUROCHIR, V65, P93, DOI 10.1007/BF01405445; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SEKINO H, 1981, Neurologia Medico-Chirurgica, V21, P677	7	15	15	0	0	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1984	71	3-4					205	215		10.1007/BF01401315			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	SV378	WOS:A1984SV37800004	6741637				2021-06-18	
J	RICHARDSON, JTE				RICHARDSON, JTE			MENTAL-IMAGERY, HUMAN-MEMORY, AND THE EFFECTS OF CLOSED HEAD-INJURY	BRITISH JOURNAL OF SOCIAL AND CLINICAL PSYCHOLOGY			English	Article										RICHARDSON, JTE (corresponding author), BRUNEL UNIV,DEPT PSYCHOL,UXBRIDGE UB8 3PH,MIDDLESEX,ENGLAND.			Richardson, John/0000-0002-6267-0603			BADDELEY AD, 1970, J VERB LEARN VERB BE, V9, P176, DOI 10.1016/S0022-5371(70)80048-2; BADDELEY AD, 1973, NEUROPSYCHOLOGIA, V11, P159, DOI 10.1016/0028-3932(73)90003-1; BLACK FW, 1973, J CLIN PSYCHOL, V29, P441; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; CLARK HH, 1973, J VERB LEARN VERB BE, V12, P335, DOI 10.1016/S0022-5371(73)80014-3; CONKEY RC, 1938, ARCH PSYCHOLOGY, V33; Courville CB, 1942, ARCH SURG-CHICAGO, V45, P19, DOI 10.1001/archsurg.1942.01220010022002; FODOR IE, 1972, J NEUROL NEUROSUR PS, V35, P818, DOI 10.1136/jnnp.35.6.818; GLANZER M, 1966, J VERB LEARN VERB BE, V5, P351, DOI 10.1016/S0022-5371(66)80044-0; GOLDSTEIN K, 1948, LANGUAGE LANGUAGE DI; GROHER M, 1977, J SPEECH HEAR RES, V20, P212, DOI 10.1044/jshr.2002.212; GRONWALL, 1974, LANCET, V2, P605; Gurdjian ES, 1943, SURGERY, V13, P333; JAMIESON KG, 1971, FIRST NOTEBOOK HEAD; JONES MK, 1974, NEUROPSYCHOLOGIA, V12, P21, DOI 10.1016/0028-3932(74)90023-2; LEVIN HS, 1976, CORTEX, V12, P175, DOI 10.1016/S0010-9452(76)80021-4; MAHER B, 1974, J CONSULT CLIN PSYCH, V42, P1; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1127, DOI 10.1136/jnnp.38.11.1127; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1976, HEAD INJURIES; PAIVIO A, 1972, FUNCTION NATURE IMAG; PAIVIO A, 1968, J EXPT PSYCHOLOGY  2, V76; Paivio A., 1971, IMAGERY VERBAL PROCE; PARKER SA, 1976, ACTA NEUROCHIR, V34, P71, DOI 10.1007/BF01405864; RICHARDSON JT, 1974, J VERB LEARN VERB BE, V13, P709, DOI 10.1016/S0022-5371(74)80057-5; RICHARDSON JTE, 1978, BRIT J SOC CLIN PSYC, V17, P261, DOI 10.1111/j.2044-8260.1978.tb00276.x; RICHARDSON JTE, 1975, BRIT J MATH STAT PSY, V28, P235; RICHARDSON JTE, 1978, Q J EXP PSYCHOL, V30, P471, DOI 10.1080/00335557843000061; RICHARDSON JTE, 1976, BRIT J PSYCHOL, V67, P487, DOI 10.1111/j.2044-8295.1976.tb01537.x; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUTHERFORD WH, 1977, LANCET, V1, P1; THOMSEN IV, 1977, SCAND J REHABIL MED, V9, P73; Thorndike EL., 1944, TEACHERS WORD BOOK 3; *UK OFF POP CENS S, 1970, 1970 CLASS OCC	41	15	15	0	0	BRITISH PSYCHOLOGICAL SOC	LEICESTER	ST ANDREWS HOUSE, 48 PRINCESS RD EAST, LEICESTER, LEICS, ENGLAND LE1 7DR	0007-1293			BRIT J SOC CLIN PSYC			1979	18	SEP					319	327		10.1111/j.2044-8260.1979.tb00342.x			9	Psychology, Clinical; Psychology; Psychology, Social	Psychology	HM221	WOS:A1979HM22100007	519141				2021-06-18	
J	LABAW, WL				LABAW, WL			DENIAL INSIDE OUT SUBJECTIVE EXPERIENCE WITH ANOSOGNOSIA IN CLOSED HEAD INJURY	PSYCHIATRY			English	Article																Babinski J., 1914, REV NEUROL-FRANCE, V27, P845; BRAZIER ME, 1967, INT J PSYCHIATRY, V3, P40; FREUD A, 1946, EGO MECHANISMS DEFEN; FULTON JF, 1929, J NERV MENT DIS, V69, P145; Goldstein K., 1939, ORGANISM; HEATH RG, 1964, J NEUROPSYCHIATRY, V5, P318; JAQUES E, 1965, INT J PSYCHOANAL, V46, P502; LaBaw W L, 1968, Med Times, V96, P821; LaBaw W L, 1966, Med Times, V94, P407; LABAW WL, IN PRESS; LABAW WL, UNPUBLISHED MANUSCRI; LABAW WL, 1967, RESIDENT PHYSICIAN, V13, P149; MACDONALD JM, 1964, AM J PSYCHIAT, V121, P366, DOI 10.1176/ajp.121.4.366; McLaurin R L, 1964, Clin Neurosurg, V12, P143; OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P419, DOI 10.1037/h0058775; Piaget J., 1951, PLAY DREAMS IMITATIO; SANDIFER PH, 1946, BRAIN, V69, P122, DOI 10.1093/brain/69.2.122; TABACHNICK N, 1966, ARCH GEN PSYCHIAT, V14, P60; WALSHE FMR, 1952, DISEASES NERVOUS SYS; WEINSTEIN EA, 1966, ARCH NEUROL-CHICAGO, V15, P545, DOI 10.1001/archneur.1966.00470170099012; Weinstein EA, 1955, DENIAL ILLNESS	21	15	15	0	1	GUILFORD PUBLICATIONS INC	NEW YORK	72 SPRING STREET, NEW YORK, NY 10012				PSYCHIATR			1969	32	2					174	&		10.1080/00332747.1969.11023582			0	Psychiatry	Psychiatry	D3835	WOS:A1969D383500005	5792492				2021-06-18	
J	CASSEN, B; NEFF, R				CASSEN, B; NEFF, R			BLOOD-BRAIN BARRIER BEHAVIOR DURING TEMPORARY CONCUSSION	AMERICAN JOURNAL OF PHYSIOLOGY			English	Article																BAKAY L, 1956, BLOOD BRAIN BARRIER, pCH5; Denny-Brown D, 1941, BRAIN, V64, P7; ROWBOTHAM GF, 1949, ACUTE INJURIES HEAD, P59	3	15	15	0	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0002-9513			AM J PHYSIOL	Am. J. Physiol.		1960	198	6					1296	1298					3	Physiology	Physiology	WE172	WOS:A1960WE17200035	13808217				2021-06-18	
J	FRIEDE, RL				FRIEDE, RL			SPECIFIC CORD DAMAGE AT THE ATLAS LEVEL AS A PATHOGENIC MECHANISM IN CEREBRAL CONCUSSION	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article																Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; GROAT R, 1950, J NEUROPATH EXP NEUR, V9, P150, DOI 10.1097/00005072-195004000-00003; HOLLISTER N, 1958, INVESTIGATIONS MECHA, V58, P130; MEESSEN H, 1949, CYTOARCHITECTONIC AT; WINDLE W. F., 1944, TRANS AMER NEUROL ASSOC, V70, P117; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561; WINDLE WF, 1945, ANAT REC, V93, P201, DOI 10.1002/ar.1090930210	7	15	15	0	0	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.		1960	19	2					266	279		10.1097/00005072-196004000-00007			14	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	WB087	WOS:A1960WB08700007	13825036				2021-06-18	
J	GURDJIAN, ES; WEBSTER, JE; LISSNER, HR				GURDJIAN, ES; WEBSTER, JE; LISSNER, HR			MECHANISM OF SCALP AND SKULL INJURIES, CONCUSSION, CONTUSION AND LACERATION	JOURNAL OF NEUROSURGERY			English	Article																BUTLER EG, 1945, J NEUROSURG, V2, P358, DOI 10.3171/jns.1945.2.4.0358; Scott WW, 1940, ARCH NEURO PSYCHIATR, V43, P270, DOI 10.1001/archneurpsyc.1940.02280020078006; ZUCKERMAN S, 1940, BRIT MED J, V2, P131	3	15	15	1	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1958	15	2					125	128		10.3171/jns.1958.15.2.0125			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	WG961	WOS:A1958WG96100001	13514509				2021-06-18	
J	GUTTMANN, E				GUTTMANN, E			LATE EFFECTS OF CLOSED HEAD INJURIES - PSYCHIATRIC OBSERVATIONS	JOURNAL OF MENTAL SCIENCE			English	Article																ADLER A, 1945, ARCH NEURO PSYCHIATR, V53, P34, DOI 10.1001/archneurpsyc.1945.02300010044003; Botterell EH, 1944, CAN MED ASSOC J, V51, P498; Brenner C, 1944, J NEUROSURG, V1, P379, DOI 10.3171/jns.1944.1.6.0379; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; Eysenck HJ, 1944, J MENT SCI, V90, P851; FRIEDMAN AP, 1945, J NEUROSURG, V2, P36, DOI 10.3171/jns.1945.2.1.0036; Guttmann E, 1944, J MENT SCI, V90, P328; Guttmann E, 1943, Br Med J, V1, P94; Guttmann E, 1943, LANCET, V1, P10; Lewis A. J., 1942, P ROY SOC MED, V35, P607; MERRITT HH, 1943, WAR MED, V4, P61; Russell W Ritchie, 1934, Edinb Med J, V41, P129; Symonds CP, 1943, LANCET, V1, P7	13	15	15	0	0	HEADLEY BROTHERS LTD	ASHFORD	INVICTA PRESS, ASHFORD TN24 8HH, KENT, ENGLAND				J MENT SCI	J. Mental Sci.		1946	92	386					1	18					18	Psychiatry	Psychiatry	YD845	WOS:A1946YD84500001	20984290				2021-06-18	
J	Rotter, R				Rotter, R			Organic brain process as late sequelae of concussions.	ZEITSCHRIFT FUR DIE GESAMTE NEUROLOGIE UND PSYCHIATRIE			German	Article																	0	15	15	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0303-4194			Z GESAMTE NEUROL PSY	Z. Gesamte Neurol. Psychiatr.		1929	119						97	108		10.1007/BF02863809			12	Psychiatry	Psychiatry	V39CB	WOS:000202641700006					2021-06-18	
J	Ovsiew, GP; Resch, ZJ; Nayar, K; Williams, CP; Soble, JR				Ovsiew, Gabriel P.; Resch, Zachary J.; Nayar, Kritika; Williams, Christopher P.; Soble, Jason R.			Not so fast! Limitations of processing speed and working memory indices as embedded performance validity tests in a mixed neuropsychiatric sample	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Performance validity; processing speed; working memory; psychometrics; assessment	TRAUMATIC BRAIN-INJURY; FALSE DISCOVERY RATE; TEST CUTOFF SCORES; CARD SORTING TEST; DIGIT SPAN; MALINGERING DETECTION; INVALID PERFORMANCE; RECOGNITION TRIAL; CROSS-VALIDATION; TEST-II	Introduction Validity indicators embedded within standard neuropsychological tests have received increasing attention as more efficient measures for sampling performance validity throughout an evaluation. This cross-sectional study examined multiple performance validity tests (PVTs) embedded in the Wechsler Adult Intelligence Scale-IV (WAIS-IV) Working Memory (WMI) and Processing Speed (PSI) Indices for detecting invalid test performance. Method This cross-sectional study examined data from a mixed clinical neuropsychiatric sample of 110 patients referred for outpatient evaluation. The sample was composed of 85 patients with valid neuropsychological performance and 25 with invalid performance based on multiple independent criterion PVTs. Among the patients with valid performance, 54% were cognitively impaired, whereas 46% were cognitively unimpaired. Results Among the overall sample, performance on WMI, PSI, and 3/4 constituent subtests (i.e., Digit Span, Symbol Search, Coding) was significantly worse among the invalid group compared to the valid group (eta(2)(p) =.06-.16) with areas under the curve (AUCs) of.67-.76 and 24-32% sensitivity (>= 88% specificity) for identifying invalid performance at cut-scores that maximized accuracy. When the sample was subdivided by cognitive impairment status, AUCs of.68-.87 and 36-56% sensitivity (>= 87% specificity) for detecting invalidity at cut-scores that maximized accuracy were found among those without cognitive impairment. In contrast, for patients with cognitive impairment, Digit Span, Arithmetic, WMI, and Coding were nonsignificant, and AUCs of.66-.67. Further, notably reduced sensitivities of 16-28% (>= 91% specificity) were found for the remaining significant indices. Conclusion Overall, results indicated that embedded WAIS-IV WMI and PSI are useful embedded PVTs in conditions in which cognitive impairment is not expected; however, these embedded PVTs demonstrated questionable utility among patients with cognitive impairment due to poor sensitivity, if adequate specificity is maintained, suggesting limited efficacy among patients with cognitive impairment due to risk of false-positive classification.	[Ovsiew, Gabriel P.; Resch, Zachary J.; Nayar, Kritika; Williams, Christopher P.; Soble, Jason R.] Univ Illinois, Dept Psychiat, Coll Med, 910 S Wood St,MC 913, Chicago, IL 60612 USA; [Resch, Zachary J.; Williams, Christopher P.] Rosalind Franklin Univ Med & Sci, Dept Psychol, N Chicago, IL USA; [Nayar, Kritika] Northwestern Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL USA; [Soble, Jason R.] Univ Illinois, Coll Med, Dept Neurol, Chicago, IL 60612 USA	Ovsiew, GP (corresponding author), Univ Illinois, Dept Psychiat, Coll Med, 910 S Wood St,MC 913, Chicago, IL 60612 USA.	Ovsiew@Outlook.com					Alverson WA, 2019, CLIN NEUROPSYCHOL, V33, P1420, DOI 10.1080/13854046.2019.1599071; Ashendorf L, 2017, CLIN NEUROPSYCHOL, V31, P857, DOI 10.1080/13854046.2017.1285961; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Bailey KC, 2018, ARCH CLIN NEUROPSYCH, V33, P895, DOI 10.1093/arclin/acx111; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bondi M. W., 2009, NEUROPSYCHOLOGICAL A, P159; Boone K., 2002, B TEST MANUAL; Boone K. B., 2002, DOT COUNTING TEST MA; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Busse M, 2012, CLIN NEUROPSYCHOL, V26, P675, DOI 10.1080/13854046.2012.679623; Chiaravalloti ND, 2008, LANCET NEUROL, V7, P1139, DOI 10.1016/S1474-4422(08)70259-X; Dean AC, 2009, CLIN NEUROPSYCHOL, V23, P133, DOI 10.1080/13854040701819050; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; DSM-V American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Etherton Joseph L, 2006, Spine J, V6, P61, DOI 10.1016/j.spinee.2005.05.382; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Fuermaier AB, 2017, TEST MANUAL GRONINGE; Gabel NM, 2019, BRAIN INJURY, V33, P377, DOI 10.1080/02699052.2018.1553311; Glassmire DM, 2019, PSYCHOL ASSESSMENT, V31, P120, DOI 10.1037/pas0000650; Glassmire DM, 2016, ASSESSMENT, V23, P292, DOI 10.1177/1073191115587551; Glickman ME, 2014, J CLIN EPIDEMIOL, V67, P850, DOI 10.1016/j.jclinepi.2014.03.012; Green P., 2003, GREENS WORD MEMORY T; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Gunzler SA, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P567, DOI 10.1007/978-0-387-76978-3_19; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Henry GK, 2013, CLIN NEUROPSYCHOL, V27, P864, DOI 10.1080/13854046.2013.786758; Hillary FG, 2010, BRAIN IMAGING BEHAV, V4, P141, DOI 10.1007/s11682-010-9094-z; Jasinski LJ, 2011, J CLIN EXP NEUROPSYC, V33, P300, DOI 10.1080/13803395.2010.516743; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1373, DOI 10.1080/13854046.2013.851740; Kanser RJ, 2019, CLIN NEUROPSYCHOL, V33, P90, DOI 10.1080/13854046.2018.1440006; King JH, 2002, CLIN NEUROPSYCHOL, V16, P506, DOI 10.1076/clin.16.4.506.13912; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Lippa SM, 2018, CLIN NEUROPSYCHOL, V32, P391, DOI 10.1080/13854046.2017.1406146; Loring DW, 2008, J INT NEUROPSYCH SOC, V14, P394, DOI 10.1017/S1355617708080582; Lu P. H., 2007, ASSESSMENT FEIGNED C, P128; Martin PK, 2020, CLIN NEUROPSYCHOL, V34, P88, DOI 10.1080/13854046.2019.1637027; Martin PK, 2015, CLIN NEUROPSYCHOL, V29, P741, DOI 10.1080/13854046.2015.1087597; Meyers JE, 2014, ARCH CLIN NEUROPSYCH, V29, P224, DOI 10.1093/arclin/acu001; Odland AP, 2015, PSYCHOL INJ LAW, V8, P46, DOI 10.1007/s12207-015-9216-4; Schutte C., 2013, MILD TRAUMATIC BRAIN, P159; Schwartz ES, 2016, J INT NEUROPSYCH SOC, V22, P851, DOI 10.1017/S1355617716000746; Shura RD, 2020, CLIN NEUROPSYCHOL, V34, P1025, DOI 10.1080/13854046.2019.1635209; Shura RD, 2016, APPL NEUROPSYCH-ADUL, V23, P94, DOI 10.1080/23279095.2015.1014556; Silk-Eglit GM, 2016, ARCH CLIN NEUROPSYCH, V31, P231, DOI 10.1093/arclin/acv108; Soble JR, 2019, APPL NEUROPSYCH-ADUL, V26, P311, DOI 10.1080/23279095.2017.1418744; Soble JR, 2017, PHYS MED REH CLIN N, V28, P339, DOI 10.1016/j.pmr.2016.12.009; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Stevens A, 2016, PSYCHIAT RES, V245, P74, DOI 10.1016/j.psychres.2016.08.022; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Webber TA, 2020, ASSESSMENT, V27, P1399, DOI 10.1177/1073191118804874; Webber TA, 2018, CLIN NEUROPSYCHOL, V32, P657, DOI 10.1080/13854046.2017.1415374; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Willcutt E. G., 2010, PEDIAT NEUROPSYCHOLO, P393; Young JC, 2016, CLIN NEUROPSYCHOL, V30, P497, DOI 10.1080/13854046.2016.1159730; Young JC, 2012, ARCH CLIN NEUROPSYCH, V27, P159, DOI 10.1093/arclin/acr109	66	14	14	1	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAY 27	2020	42	5					473	484		10.1080/13803395.2020.1758635		JUN 2020	12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	ME3AD	WOS:000542839500001	32498648				2021-06-18	
J	Czeiter, E; Amrein, K; Gravesteijn, BY; Lecky, F; Menon, DK; Mondello, S; Newcombe, VFJ; Richter, S; Steyerberg, EW; Vande Vyvere, T; Verheyden, J; Xu, HY; Yang, ZH; Maas, AIR; Wang, KKW; Buki, A				Czeiter, Endre; Amrein, Krisztina; Gravesteijn, Benjamin Y.; Lecky, Fiona; Menon, David K.; Mondello, Stefania; Newcombe, Virginia F. J.; Richter, Sophie; Steyerberg, Ewout W.; Vande Vyvere, Thijs; Verheyden, Jan; Xu, Haiyan; Yang, Zhihui; Maas, Andrew I. R.; Wang, Kevin K. W.; Buki, Andras		CENTER-TBI Participants	Blood biomarkers on admission in acute traumatic brain injury: Relations to severity, CT findings and care path in the CENTER-TBI study	EBIOMEDICINE			English	Article						Traumatic brain injury; Biomarkers; GFAP; Serum; Diagnostic; Computerized tomography; Clinical decision rule; Injury severity	COMPUTED-TOMOGRAPHY; IMPROVE	Background: Serum biomarkers may inform and improve care in traumatic brain injury (TBI). We aimed to correlate serum biomarkers with clinical severity, care path and imaging abnormalities in TBI, and explore their incremental value over clinical characteristics in predicting computed tomographic (CT) abnormalities. Methods: We analyzed six serum biomarkers (S100B, NSE, GFAP, UCH-L1, NFL and t-tau) obtained <24 h post-injury from 2867 patients with any severity of TBI in the Collaborative European NeuroTrauma Effectiveness Research (CENTER-TBI) Core Study, a prospective, multicenter, cohort study. Univariable and multivariable logistic regression analyses were performed. Discrimination was assessed by the area under the receiver operating characteristic curve (AUC) with 95% confidence intervals. Findings: All biomarkers scaled with clinical severity and care path (ER only, ward admission, or ICU), and with presence of CT abnormalities. GFAP achieved the highest discrimination for predicting CT abnormalities (AUC 0.89 [95%CI: 0.87-0.90]), with a 99% likelihood of better discriminating CT-positive patients than clinical characteristics used in contemporary decision rules. In patients with mild TBI, GFAP also showed incremental diagnostic value: discrimination increased from 0.84 [95%CI: 0.83-0.86] to 0.89 [95%CI: 0.87-0.90] when GFAP was included. Results were consistent across strata, and injury severity. Combinations of biomarkers did not improve discrimination compared to GFAP alone. Interpretation: Currently available biomarkers reflect injury severity, and serum GFAP, measured within 24 h after injury, outperforms clinical characteristics in predicting CT abnormalities. Our results support the further development of serum GFAP assays towards implementation in clinical practice, for which robust clinical assay platforms are required.(C) 2020 The Authors. Published by Elsevier B.V.	[Czeiter, Endre; Amrein, Krisztina; Buki, Andras] Univ Pecs, Med Sch, Dept Neurosurg, Ret U 2, H-7623 Pecs, Hungary; [Czeiter, Endre; Amrein, Krisztina; Buki, Andras] Univ Pecs, Szentagothai Res Ctr, Neurotrauma Res Grp, Ifjusag Utja 20, H-7624 Pecs, Hungary; [Czeiter, Endre] MTA PTE Clin Neurosci MR Res Grp, Ret U 2, H-7623 Pecs, Hungary; [Gravesteijn, Benjamin Y.; Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands; [Lecky, Fiona] Univ Sheffield, Sch Hlth & Related Res ScHARR, Hlth Serv Res Sect, Ctr Urgent & Emergency Care Res CURE, Sheffield S1 4DA, S Yorkshire, England; [Lecky, Fiona] Salford Royal Hosp, Emergency Dept, Salford M6 8HD, Lancs, England; [Menon, David K.; Newcombe, Virginia F. J.; Richter, Sophie] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Box 93,Hills Rd, Cambridge CB2 0QQ, England; [Mondello, Stefania] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Via Consolare Valeria 1, I-98125 Messina, Italy; [Steyerberg, Ewout W.] Leiden Univ, Med Ctr, Dept Biomed Data Sci, Leiden, Netherlands; [Vande Vyvere, Thijs; Verheyden, Jan] Icometrix, Res & Dev, Kolonel Begaultlaan 1b-12, B-3012 Leuven, Belgium; [Vande Vyvere, Thijs] Antwerp Univ Hosp, Dept Radiol, Wijlrijkstr 10, B-2650 Edegem, Belgium; [Vande Vyvere, Thijs; Maas, Andrew I. R.] Univ Antwerp, Wijlrijkstr 10, B-2650 Edegem, Belgium; [Xu, Haiyan; Yang, Zhihui; Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Program Neurotrauma Neuroprote & Biomarker Res, Dept Emergency Med, L4-100L 1149 South Newell Dr, Gainesville, FL 32611 USA; [Xu, Haiyan; Yang, Zhihui; Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Program Neurotrauma Neuroprote & Biomarker Res, Dept Psychiat & Neurosci, L4-100L 1149 South Newell Dr, Gainesville, FL 32611 USA; [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, Wijlrijkstr 10, B-2650 Edegem, Belgium; [Wang, Kevin K. W.] Malcom Randall Vet Affairs Med Ctr VAMC, Brain Rehabil Res Ctr, 1601 SW Archer Rd, Gainesville, FL 32608 USA	Czeiter, E (corresponding author), Univ Pecs, Szentagothai Res Ctr, Neurotrauma Res Grp, Ifjusag Utja 20, H-7624 Pecs, Hungary.	endre.czeiter@gmail.com	Castano-Leon, Ana M/ABF-6322-2020; Posti, Jussi P./Y-2908-2019; Mondello, Stefania/A-1813-2012	Castano-Leon, Ana M/0000-0002-7918-5049; Posti, Jussi P./0000-0002-5925-5193; Mondello, Stefania/0000-0002-8587-3614; Richter, Sophie/0000-0003-3272-484X; Czeiter, Endre/0000-0002-9578-6944; Newcombe, Virginia/0000-0001-6044-9035	European Union 7th Framework program (EC grant) [602150]; Hannelore Kohl Stiftung (Germany); OneMind (USA); Integra LifeSciences Corporation (USA); Neurotrauma Sciences (USA)	CENTER-TBI study supported by the European Union 7th Framework program (EC grant 602150). Additional funding was obtained from the Hannelore Kohl Stiftung (Germany), from OneMind (USA), from Integra LifeSciences Corporation (USA) and from Neurotrauma Sciences (USA).	Abdelhak A, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00280; Bazarian JJ, 2018, LANCET NEUROL, V17, P782, DOI 10.1016/S1474-4422(18)30231-X; Bossuyt PM, 2020, J CLIN EPIDEMIOL, V117, P29, DOI 10.1016/j.jclinepi.2019.09.017; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Foks KA, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3527; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Huie JR, 2020, J NEUROTRAUM, DOI 10.1089/neu.2019.6762; Maas AIR, 2018, LANCET NEUROL, V17, P737, DOI 10.1016/S1474-4422(18)30275-8; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Minkkinen M, 2019, J NEUROTRAUM, V36, P2904, DOI 10.1089/neu.2018.6351; Mondello Stefania, 2015, Handb Clin Neurol, V127, P245, DOI 10.1016/B978-0-444-52892-6.00016-7; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; National_Clinical_Guideline_C._National_Clinical_Guidance_Centre, 2014, 176 CG NAT CLIN GUID; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Rezaii PG, 2019, J NEUROTRAUM, V36, P2407, DOI 10.1089/neu.2018.6053; Rubin DB., 2004, MULTIPLE IMPUTATION; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Steyerberg EW, 2019, LANCET NEUROL, V18, P923, DOI 10.1016/S1474-4422(19)30232-7; Steyerberg EW, 2015, BIOMETRICAL J, V57, P556, DOI 10.1002/bimj.201300260; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Thelin E, 2019, J NEUROTRAUM, V36, P2850, DOI 10.1089/neu.2019.6375; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; US_Food_and_Drug_Administration, 2019, EV AUT CLASS 3 DES B; van Buuren S, 2018, FLEXIBLE IMPUTATION, V2nd; Wang KK, 2018, EXPERT REV MOL DIAGN, V18, P165, DOI 10.1080/14737159.2018.1428089; Welch RD, 2017, J NEUROTRAUM, V34, P1957, DOI 10.1089/neu.2016.4772; Yue JK, 2019, LANCET NEUROL, V18, P953, DOI 10.1016/S1474-4422(19)30282-0	31	14	14	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	2352-3964			EBIOMEDICINE	EBioMedicine	JUN	2020	56								102758	10.1016/j.ebiom.2020.102785			11	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	MM1OY	WOS:000549929200009	32464528	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Ashina, H; Iljazi, A; Al-Khazali, HM; Ashina, S; Jensen, RH; Amin, FM; Ashina, M; Schytz, HW				Ashina, Hakan; Iljazi, Afrim; Al-Khazali, Haidar Muhsen; Ashina, Sait; Jensen, Rigmor Hojland; Amin, Faisal Mohammad; Ashina, Messoud; Winther Schytz, Henrik			Persistent post-traumatic headache attributed to mild traumatic brain injury: Deep phenotyping and treatment patterns	CEPHALALGIA			English	Article						Concussion; head trauma; head injury; clinical management	CHRONIC PAIN; PREVALENCE; MIGRAINE	Objective To investigate clinical characteristics and treatment patterns in persistent post-traumatic headache attributed to mild traumatic brain injury. Methods A total of 100 individuals with persistent post-traumatic headache attributed to mild traumatic brain injury were enrolled between July 2018 and June 2019. Deep phenotyping was performed using a semi-structured interview while allodynia was assessed using the 12-item Allodynia Symptom Checklist. Results In 100 subjects with persistent post-traumatic headache, the mean headache frequency was 25.4 +/- 7.1 days per month. The most common headache phenotype was chronic migraine-like headache (n = 61) followed by combined episodic migraine-like and tension-type-like headache (n = 29) while nine subjects reported "pure" chronic tension-type-like headache. The most frequent trigger factors were stress, lack of sleep, and bright lights. A history of preventive medication use was reported by 63 subjects, of which 79% reported failure of at least one preventive drug, while 19% reported failure of at least four preventive drugs. Cutaneous allodynia was absent in 54% of the subjects, mild in 23%, moderate in 17%, and severe in 6%. Conclusions The headache profile of individuals with persistent post-traumatic headache most often resembled a chronic migraine-like phenotype or a combined episodic migraine-like and tension-type-like headache phenotype. Migraine-specific preventive medications were largely reported to be ineffective. Therefore, there is a pressing need for pathophysiological insights and disease-specific therapies.	[Ashina, Hakan; Iljazi, Afrim; Al-Khazali, Haidar Muhsen; Jensen, Rigmor Hojland; Amin, Faisal Mohammad; Ashina, Messoud; Winther Schytz, Henrik] Univ Copenhagen, Fac Hlth & Med Sci, Rigshosp Glostrup, Danish Headache Ctr,Dept Neurol, Copenhagen, Denmark; [Ashina, Sait] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Neurol, Comprehens Headache Ctr, Boston, MA 02115 USA; [Ashina, Sait] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Comprehens Headache Ctr, Boston, MA 02115 USA	Schytz, HW (corresponding author), Univ Copenhagen, Danish Headache Ctr, Dept Neurol, Fac Hlth & Med Sci,Rigshosp Glostrup, Valdemar Hansens Vej 5, DK-2600 Glostrup, Denmark.	henrik.winther.schytz.01@regionh.dk	Ashina, Sait/AAC-7681-2019; Ashina, Sait/I-1766-2019	Ashina, Sait/0000-0003-3973-6640; Amin, Faisal Mohammad/0000-0003-3803-3599; Schytz, Henrik Winther/0000-0002-6262-2986; Ashina, Hakan/0000-0002-6268-727X; Ashina, Messoud/0000-0003-0951-5804	Rigshospitalet Research Foundation [F-23340-02]	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was supported by a grant from the Rigshospitalet Research Foundation (F-23340-02).	Anthony Michael, 1993, P255; Ashina H, 2019, NAT REV NEUROL, V15, P607, DOI 10.1038/s41582-019-0243-8; Bergman S, 2001, J RHEUMATOL, V28, P1369; CELENTANO DD, 1990, J CLIN EPIDEMIOL, V43, P983, DOI 10.1016/0895-4356(90)90082-Z; Defrin R, 2010, EUR J PAIN, V14, P924, DOI 10.1016/j.ejpain.2010.03.004; Kelman L, 2007, CEPHALALGIA, V27, P394, DOI 10.1111/j.1468-2982.2007.01303.x; Kjeldgaard D, 2014, CEPHALALGIA, V34, P191, DOI 10.1177/0333102413505236; Larsen EL, 2019, J HEADACHE PAIN, V20, DOI 10.1186/s10194-019-1051-7; Levy D, 2020, CEPHALALGIA, V40, P675, DOI 10.1177/0333102419896368; Lieba-Samal D, 2011, CEPHALALGIA, V31, P1618, DOI 10.1177/0333102411428954; Lipton RB, 2008, ANN NEUROL, V63, P148, DOI 10.1002/ana.21211; Lipton RB, 2014, HEADACHE, V54, P1661, DOI 10.1111/head.12464; Lucas S, 2018, HEADACHE, V58, P873, DOI 10.1111/head.13311; Lucas S, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0520-1; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Mantyselka PT, 2003, JAMA-J AM MED ASSOC, V290, P2435, DOI 10.1001/jama.290.18.2435; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; OECD and European Observatory on Health Systems and Policies, STAT HLTH EU DENM CO; RASMUSSEN BK, 1992, NEUROLOGY, V42, P1225, DOI 10.1212/WNL.42.6.1225; Russell MB, 1996, CEPHALALGIA, V16, P239, DOI 10.1046/j.1468-2982.1996.1604239.x; Russell MB, 1996, CEPHALALGIA, V16, P156, DOI 10.1046/j.1468-2982.1996.1603156.x; Seifert TD, 2010, CURR PAIN HEADACHE R, V14, P292, DOI 10.1007/s11916-010-0117-7; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Voormolen DC, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111921; Wittchen HU, 2011, EUR NEUROPSYCHOPHARM, V21, P655, DOI 10.1016/j.euroneuro.2011.07.018; World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI DOI 10.1001/JAMA.2013.281053	27	14	14	1	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0333-1024	1468-2982		CEPHALALGIA	Cephalalgia	MAY	2020	40	6					554	564	0333102420909865	10.1177/0333102420909865		FEB 2020	11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	LN2BE	WOS:000516901700001	32102546				2021-06-18	
J	Dickstein, DL; De Gasperi, R; Sosa, MGA; Perez-Garcia, G; Short, JA; Sosa, H; Perez, GM; Tschiffely, AE; Dams-O'Connor, K; Pullman, MY; Knesaurek, K; Knutsen, A; Pham, DL; Soleimani, L; Jordan, BD; Gordon, WA; Delman, BN; Shumyatsky, G; Shahim, PP; DeKosky, ST; Stone, JR; Peskind, E; Blennow, K; Zetterberg, H; Chance, SA; Torso, M; Kostakoglu, L; Sano, M; Hof, PR; Ahlers, ST; Gandy, S; Elder, GA				Dickstein, Dara L.; De Gasperi, Rita; Gama Sosa, Miguel A.; Perez-Garcia, Georgina; Short, Jennifer A.; Sosa, Heidi; Perez, Gissel M.; Tschiffely, Anna E.; Dams-O'Connor, Kristen; Pullman, Mariel Y.; Knesaurek, Karin; Knutsen, Andrew; Pham, Dzung L.; Soleimani, Lale; Jordan, Barry D.; Gordon, Wayne A.; Delman, Bradley N.; Shumyatsky, Gleb; Shahim, Pashtun-Poh; DeKosky, Steven T.; Stone, James R.; Peskind, Elaine; Blennow, Kaj; Zetterberg, Henrik; Chance, Steven A.; Torso, Mario; Kostakoglu, Lale; Sano, Mary; Hof, Patrick R.; Ahlers, Stephen T.; Gandy, Sam; Elder, Gregory A.			Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes following blast exposure	MOLECULAR PSYCHIATRY			English	Article; Early Access							PERSISTENT POSTCONCUSSIVE SYMPTOMS; MILITARY SERVICE MEMBERS; PET TRACER F-18-AV-1451; DISORDER-RELATED TRAITS; COGNITIVE IMPAIRMENT; TAU; MODEL; EXPRESSION; DEMENTIA; DISEASE	Traumatic brain injury (TBI) is a risk factor for the later development of neurodegenerative diseases that may have various underlying pathologies. Chronic traumatic encephalopathy (CTE) in particular is associated with repetitive mild TBI (mTBI) and is characterized pathologically by aggregation of hyperphosphorylated tau into neurofibrillary tangles (NFTs). CTE may be suspected when behavior, cognition, and/or memory deteriorate following repetitive mTBI. Exposure to blast overpressure from improvised explosive devices (IEDs) has been implicated as a potential antecedent for CTE amongst Iraq and Afghanistan Warfighters. In this study, we identified biomarker signatures in rats exposed to repetitive low-level blast that develop chronic anxiety-related traits and in human veterans exposed to IED blasts in theater with behavioral, cognitive, and/or memory complaints. Rats exposed to repetitive low-level blasts accumulated abnormal hyperphosphorylated tau in neuronal perikarya and perivascular astroglial processes. Using positron emission tomography (PET) and the [F-18]AV1451 (flortaucipir) tau ligand, we found that five of 10 veterans exhibited excessive retention of [F-18]AV1451 at the white/gray matter junction in frontal, parietal, and temporal brain regions, a typical localization of CTE tauopathy. We also observed elevated levels of neurofilament light (NfL) chain protein in the plasma of veterans displaying excess [F-18]AV1451 retention. These findings suggest an association linking blast injury, tauopathy, and neuronal injury. Further study is required to determine whether clinical, neuroimaging, and/or fluid biomarker signatures can improve the diagnosis of long-term neuropsychiatric sequelae of mTBI.	[Dickstein, Dara L.] Uniformed Serv Univ Hlth Sci, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Dickstein, Dara L.; Knutsen, Andrew; Pham, Dzung L.; Shahim, Pashtun-Poh] Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [De Gasperi, Rita; Gama Sosa, Miguel A.; Perez-Garcia, Georgina; Sosa, Heidi; Perez, Gissel M.; Sano, Mary; Gandy, Sam] James J Peters Dept Vet Affairs Med Ctr, Res & Dev Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA; [De Gasperi, Rita; Gama Sosa, Miguel A.; Short, Jennifer A.; Sosa, Heidi; Pullman, Mariel Y.; Sano, Mary; Gandy, Sam; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave Levy Pl, New York, NY 10029 USA; [Perez-Garcia, Georgina; Dams-O'Connor, Kristen; Gandy, Sam; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, One Gustave Levy Pl, New York, NY 10029 USA; [Tschiffely, Anna E.; Ahlers, Stephen T.] Naval Med Res Ctr, Dept Neurotrauma, 503 Robert Grant Ave, Silver Spring, MD 20910 USA; [Dams-O'Connor, Kristen; Gordon, Wayne A.] Icahn Sch Med Mt Sinai, Dept Rehabil & Phys Med, One Gustave Levy Pl, New York, NY 10029 USA; [Knesaurek, Karin; Soleimani, Lale; Delman, Bradley N.; Kostakoglu, Lale] Icahn Sch Med Mt Sinai, Dept Mol & Intervent Radiol, One Gustave L Levy Pl, New York, NY 10029 USA; [Jordan, Barry D.] Burke Rehabil & Res, 785 Mamaroneck Ave, White Plains, NY 10605 USA; [Shumyatsky, Gleb] Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA; [Shahim, Pashtun-Poh] NINDS, NIH, Neurol Inst, POB 5081, Bethesda, MD 20824 USA; [DeKosky, Steven T.] Univ Florida, Dept Neurol, Gainesville, FL 32611 USA; [Stone, James R.] Univ Virginia, Dept Radiol & Med Imaging, Charlottesville, VA USA; [Peskind, Elaine] VA Northwest Network Mental Illness Res Educ & Cl, Seattle, WA 98195 USA; [Peskind, Elaine] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Sahlgrenska Acad, S-43180 Molndal, Sweden; [Blennow, Kaj; Zetterberg, Henrik] Sahlgrens Univ Hosp, Clin Neurochem Lab, S-43180 Molndal, Sweden; [Zetterberg, Henrik] UCL, UK Dementia Res Inst, London WC1E 6BT, England; [Zetterberg, Henrik] UCL Inst Neurol, Dept Neurodegenerat Dis, Queen Sq, London WC1N 3BG, England; [Chance, Steven A.; Torso, Mario] Univ Oxford, Nuffield Dept Clin Neurosci, Neuropathol, West Wing,Level 1, Oxford OX3 9DU, England; [Sano, Mary; Hof, Patrick R.; Gandy, Sam; Elder, Gregory A.] Mt Sinai Alzheimers Dis Res Ctr, New York, NY 10029 USA; [Sano, Mary; Hof, Patrick R.; Gandy, Sam; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Ronald M Loeb Ctr Alzheimers Dis, New York, NY 10029 USA; [Hof, Patrick R.] Icahn Sch Med Mt Sinai, Nash Family Dept Neurosci, One Gustave Levy, New York, NY 10029 USA; [Hof, Patrick R.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, One Gustave Levy, New York, NY 10029 USA; [Hof, Patrick R.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Care, New York, NY 10029 USA; [Gandy, Sam] Icahn Sch Med Mt Sinai, NFL Neurol Care Ctr, New York, NY 10029 USA; [Gandy, Sam; Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA; [Gandy, Sam] South Australian Hlth & Res Med Inst, Adelaide, SA 5000, Australia	Gandy, S (corresponding author), James J Peters Dept Vet Affairs Med Ctr, Res & Dev Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.; Gandy, S; Elder, GA (corresponding author), Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave Levy Pl, New York, NY 10029 USA.; Gandy, S; Elder, GA (corresponding author), Icahn Sch Med Mt Sinai, Dept Neurol, One Gustave Levy Pl, New York, NY 10029 USA.; Gandy, S; Elder, GA (corresponding author), Mt Sinai Alzheimers Dis Res Ctr, New York, NY 10029 USA.; Gandy, S; Elder, GA (corresponding author), Icahn Sch Med Mt Sinai, Ronald M Loeb Ctr Alzheimers Dis, New York, NY 10029 USA.; Gandy, S (corresponding author), Icahn Sch Med Mt Sinai, NFL Neurol Care Ctr, New York, NY 10029 USA.; Gandy, S; Elder, GA (corresponding author), James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.; Gandy, S (corresponding author), South Australian Hlth & Res Med Inst, Adelaide, SA 5000, Australia.	samuel.gandy@mssm.edu; gregory.elder@va.gov	Pham, Dzung/AAR-8263-2020	Torso, Mario/0000-0002-5284-9167; Delman, Bradley/0000-0002-9792-8942	Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service AwardsUS Department of Veterans Affairs [1I01RX000996, I01RX002660, 1I01BX004067, 1I01RX000684, 1I01RX002333, I21RX002069, I21RX002876]; Alzheimer's Disease Drug Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NINDS 5U01NS086625, NICHD K01HD074651-01A]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG11508]; Swedish Research CouncilSwedish Research CouncilEuropean Commission [2018-02532]; European Research CouncilEuropean Research Council (ERC)European Commission [681712]; Swedish State Support for Clinical Research [ALFGBG-720931]; Werber Family Foundation; Sara and Gideon Gartner Foundation; Louis B. Mayer Foundation; Jennifer and Scott Moskowitz Foundation; Jane Martin and Stuart Katz Foundation; Lady Va and Sir Deryck Maughan Foundation; Georgianne and Dr. Reza Khatib Foundation; George B. Link Foundation; Department of DefenseUnited States Department of Defense [0000B999.0000.000. A1503]	This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Awards 1I01RX000996 (GAE), I01RX002660 (GAE), 1I01BX004067 (GAE), 1I01RX000684 (SG), 1I01RX002333 (SG), I21RX002069 (MAGS) and I21RX002876 (MAGS), by Department of Defense work unit number 0000B999.0000.000. A1503, by the Alzheimer's Disease Drug Foundation (SG and DLD) and by NIH grants NINDS 5U01NS086625 (WAG and KD-O) and NICHD K01HD074651-01A (KD-O), NIA P50AG11508 (MS, SG, PRH). KB holds the Torsten Soderberg Professorship of Medicine. HZ is a Wallenberg Academy Fellow supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712) and Swedish State Support for Clinical Research (#ALFGBG-720931). The Werber Family Foundation, the Sara and Gideon Gartner Foundation, the Louis B. Mayer Foundation, the Jennifer and Scott Moskowitz Foundation, the Jane Martin and Stuart Katz Foundation, the Lady Va and Sir Deryck Maughan Foundation, the Georgianne and Dr. Reza Khatib Foundation, and the George B. Link Foundation provided additional support.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Ahmed F, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00114; Arun P, 2015, NEUROSCI LETT, V609, P152, DOI 10.1016/j.neulet.2015.10.036; Arun P, 2013, NEUROSCI LETT, V552, P87, DOI 10.1016/j.neulet.2013.07.047; Baker SL, 2017, DATA BRIEF, V15, P648, DOI 10.1016/j.dib.2017.10.024; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Barret O, 2017, J NUCL MED, V58, P1124, DOI 10.2967/jnumed.116.182881; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; Cao JQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11654-7; Chance SA, 2011, CEREB CORTEX, V21, P1870, DOI 10.1093/cercor/bhq264; Chase RP, 2015, J HEAD TRAUMA REHAB, V30, pE57, DOI 10.1097/HTR.0000000000000061; Chen ST, 2018, J ALZHEIMERS DIS, V65, P79, DOI 10.3233/JAD-171152; Clark CM, 2011, JAMA-J AM MED ASSOC, V305, P275, DOI 10.1001/jama.2010.2008; Cooper DB, 2015, BRAIN IMAGING BEHAV, V9, P403, DOI 10.1007/s11682-015-9440-2; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; DENENBERG VH, 1981, BEHAV BRAIN SCI, V4, P1, DOI 10.1017/S0140525X00007330; Dickstein DL, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.175; Diedrichsen J, 2011, NEUROIMAGE, V54, P1786, DOI 10.1016/j.neuroimage.2010.10.035; Du XP, 2017, FREE RADICAL BIO MED, V108, P627, DOI 10.1016/j.freeradbiomed.2017.04.343; Du XP, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4159357; Elder GA, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0591-8; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Farhang S, 2014, SYNAPSE, V68, P387, DOI 10.1002/syn.21746; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Gerson J, 2016, J NEUROTRAUM, V33, P2034, DOI 10.1089/neu.2015.4262; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hanes J, 2009, J NEUROCHEM, V108, P1167, DOI 10.1111/j.1471-4159.2009.05869.x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huber BR, 2016, PHYS MED REH CLIN N, V27, P503, DOI 10.1016/j.pmr.2015.12.007; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Ivanov I, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00127; Klur S, 2009, HIPPOCAMPUS, V19, P800, DOI 10.1002/hipo.20562; Kovacs GG, 2017, BRAIN PATHOL, V27, P675, DOI 10.1111/bpa.12536; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; Liu MD, 2014, CHIN J TRAUMATOL, V17, P317, DOI 10.3760/cma.j.issn.1008-1275.2014.06.003; Logsdon AF, 2017, ARCH NEUROSCI, V4, DOI 10.5812/archneurosci.44254; Lopes S, 2016, P NATL ACAD SCI USA, V113, pE3755, DOI 10.1073/pnas.1600953113; Lowe VJ, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0315-6; Lucke-Wold B, 2017, J NEUROL NEUROSUR PS, V4, P140; Lucke-Wold BP, 2015, TRANSL RES, V166, P509, DOI 10.1016/j.trsl.2015.08.005; Lucke-Wold BP, 2016, J NEUROSURG, V124, P687, DOI 10.3171/2015.3.JNS141802; Mac Donald CL, 2017, JAMA NEUROL, V74, P821, DOI 10.1001/jamaneurol.2017.0143; Mahan AL, 2012, TRENDS NEUROSCI, V35, P24, DOI 10.1016/j.tins.2011.06.007; Mammadova N, 2017, AM J PATHOL, V187, P1459, DOI 10.1016/j.ajpath.2017.03.005; Marquie M, 2017, ANN NEUROL, V81, P117, DOI 10.1002/ana.24844; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meabon JS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaa9585; MESSING RB, 1980, LIFE SCI, V26, P921, DOI 10.1016/0024-3205(80)90112-5; Mitsis EM, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.91; Mohamed AZ, 2019, EUR J NUCL MED MOL I, V46, P1139, DOI 10.1007/s00259-018-4241-7; Morissette SB, 2011, REHABIL PSYCHOL, V56, P340, DOI 10.1037/a0025462; National Research Council, 2008, GULF WAR HLTH, V7; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Omalu B, 2018, NEUROSURGERY, V82, P237, DOI 10.1093/neuros/nyx536; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Perez-Garcia G, 2018, ENEURO, V5, DOI 10.1523/ENEURO.0357-17.2018; Perez-Garcia G, 2018, BEHAV BRAIN RES, V340, P117, DOI 10.1016/j.bbr.2016.09.061; Perez-Garcia G, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00176; Perez-Polo JR, 2015, J NEUROSCI RES, V93, P549, DOI 10.1002/jnr.23513; Prigatano GP, 2011, CURR OPIN PSYCHIATR, V24, P243, DOI 10.1097/YCO.0b013e328344698b; Robinson ME, 2019, NEUROIMAGE-CLIN, V21, DOI 10.1016/j.nicl.2019.101651; Ryu J, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0153-3; Sajja VSSS, 2015, SCI REP-UK, V5, DOI 10.1038/srep15075; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Shcherbinin S, 2016, J NUCL MED, V57, P1535, DOI 10.2967/jnumed.115.170027; Shinohara Y, 2012, HIPPOCAMPUS, V22, P117, DOI 10.1002/hipo.20886; Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6; Sosa MAG, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-018-0647-5; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Sullivan RM, 2014, PROG NEURO-PSYCHOPH, V54, P59, DOI 10.1016/j.pnpbp.2014.05.002; Tanielian T, 2016, PSYCHIAT SERV, V67, P718, DOI 10.1176/appi.ps.201500237; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tsai RM, 2019, ALZHEIMERS RES THER, V11, DOI 10.1186/s13195-019-0470-7; Vincent AS, 2014, ALZHEIMERS DEMENT, V10, pS174, DOI 10.1016/j.jalz.2014.04.006; Wooten DW, 2019, J NEUROTRAUM, V36, P3233, DOI 10.1089/neu.2018.6178; Zetterberg H, 2018, J ALZHEIMERS DIS, V64, pS271, DOI 10.3233/JAD-179926	84	14	14	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1359-4184	1476-5578		MOL PSYCHIATR	Mol. Psychiatr.												10.1038/s41380-020-0674-z		FEB 2020	15	Biochemistry & Molecular Biology; Neurosciences; Psychiatry	Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry	KO3UQ	WOS:000515474300001	32094584	Green Published, Other Gold			2021-06-18	
J	Mangat, HS; Wu, X; Gerber, LM; Schwarz, JT; Fakhar, M; Murthy, SB; Stieg, PE; Ghajar, J; Hartl, R				Mangat, Halinder S.; Wu, Xian; Gerber, Linda M.; Schwarz, Justin T.; Fakhar, Malik; Murthy, Santosh B.; Stieg, Philip E.; Ghajar, Jamshid; Hartl, Roger			Hypertonic Saline is Superior to Mannitol for the Combined Effect on Intracranial Pressure and Cerebral Perfusion Pressure Burdens in Patients With Severe Traumatic Brain Injury	NEUROSURGERY			English	Article						Cerebral perfusion pressure; Hypertonic saline; Intracranial pressure; Mannitol; Traumatic brain injury	HEAD-INJURY; SODIUM-CHLORIDE; BLOOD-FLOW; HYPERTENSION; ICP; RESUSCITATION; GUIDELINES; MANAGEMENT	BACKGROUND Hypertonic saline (HTS) and mannitol are effective in reducing intracranial pressure (ICP) after severe traumatic brain injury (TBI). However, their simultaneous effect on the cerebral perfusion pressure (CPP) and ICP has not been studied rigorously. OBJECTIVE To determine the difference in effects of HTS and mannitol on the combined burden of high ICP and low CPP in patients with severe TBI. METHODS We performed a case-control study using prospectively collected data from the New York State TBI-trac (R) database (Brain Trauma Foundation, New York, New York). Patients who received only 1 hyperosmotic agent, either mannitol or HTS for raised ICP, were included. Patients in the 2 groups were matched (1:1 and 1:2) for factors associated with 2-wk mortality: age, Glasgow Coma Scale score, pupillary reactivity, hypotension, abnormal computed tomography scans, and craniotomy. Primary endpoint was the combined burden of ICPhigh (> 25 mm Hg) and CPPlow (< 60 mm Hg). RESULTS There were 25 matched pairs for 1:1 comparison and 24 HTS patients matched to 48 mannitol patients in 1:2 comparisons. Cumulative median osmolar doses in the 2 groups were similar. In patients treated with HTS compared to mannitol, total number of days (0.6 0.8 vs 2.4 +/- 2.3 d, P < .01), percentage of days with (8.8 +/- 10.6 vs 28.1 +/- 26.9%, P < .01), and the total duration of ICPhigh + CPPlow (11.12 +/- 14.11 vs 30.56 +/- 31.89 h, P = .01) were significantly lower. These results were replicated in the 1:2 match comparisons. CONCLUSION HTS bolus therapy appears to be superior to mannitol in reduction of the combined burden of intracranial hypertension and associated hypoperfusion in severe TBI patients.	[Mangat, Halinder S.; Fakhar, Malik; Murthy, Santosh B.] Weill Cornell Med, Dept Neurol, New York, NY 10065 USA; [Mangat, Halinder S.; Schwarz, Justin T.; Stieg, Philip E.; Hartl, Roger] Weill Cornell Med, Dept Neurol Surg, Weill Cornell Brain & Spine Inst, New York, NY 10065 USA; [Wu, Xian; Gerber, Linda M.] Weill Cornell Med, Dept Healthcare Policy & Res, New York, NY 10065 USA; [Schwarz, Justin T.] NewYork Presbyterian Hosp, New York, NY USA; [Ghajar, Jamshid] Stanford Univ, Dept Neurol Surg, Palo Alto, CA 94304 USA; [Ghajar, Jamshid] Brain Trauma Fdn, New York, NY USA	Mangat, HS (corresponding author), Weill Cornell Med, Dept Neurol, Div Stroke & Crit Care, 525 East 68 St,F-610, New York, NY 10065 USA.	hsm9001@med.cornell.edu	Murthy, Santosh/ABA-2883-2020; Mangat, HALINDER/AAN-9153-2020	Murthy, Santosh/0000-0002-4950-0992; Mangat, HALINDER/0000-0003-3426-2001	New York State Department of Health; Brain Trauma Foundation; New York-Presbyterian Hospital TBI fund	The authors thank the New York State Department of Health, the Brain Trauma Foundation and the New York-Presbyterian Hospital TBI fund for their financial support.	Asehnoune K, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1918-4; Bentsen G, 2006, CRIT CARE MED, V34, P2912, DOI 10.1097/01.CCM.0000245665.46789.7C; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock M Ross, 2006, Neurosurgery, V58, pS7; BURKE AM, 1981, J NEUROSURG, V55, P550, DOI 10.3171/jns.1981.55.4.0550; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cottenceau V, 2011, J NEUROTRAUM, V28, P2003, DOI 10.1089/neu.2011.1929; DEFELIPPE J, 1980, LANCET, V2, P1002; Eskandari R, 2013, J NEUROSURG, V119, P338, DOI 10.3171/2013.4.JNS121541; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276; Hartl R, 1997, ACT NEUR S, V70, P126; Hartl R, 1997, ACT NEUR S, V70, P40; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; JAMES HE, 1980, ACTA NEUROCHIR, V51, P161, DOI 10.1007/BF01406742; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; Koenig MA, 2008, NEUROLOGY, V70, P1023, DOI 10.1212/01.wnl.0000304042.05557.60; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mangat HS, 2015, J NEUROSURG, V122, P202, DOI 10.3171/2014.10.JNS132545; Marion DW, 2006, NEUROSURGERY, V58, P655; Mortazavi MM, 2012, J NEUROSURG, V116, P210, DOI 10.3171/2011.7.JNS102142; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; NATH F, 1986, J NEUROSURG, V65, P41, DOI 10.3171/jns.1986.65.1.0041; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Roquilly A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018035; ROSENBAUM PR, 1989, J AM STAT ASSOC, V84, P1024, DOI 10.2307/2290079; Schatzmann C, 1998, ACT NEUR S, V71, P31; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; Sheth KN, 2013, NEUROCRIT CARE, V18, P26, DOI 10.1007/s12028-012-9780-3; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wakai A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub5; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; WILLERSON JT, 1975, CIRCULATION, V51, P1095, DOI 10.1161/01.CIR.51.6.1095; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478	42	14	14	2	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2020	86	2					221	229		10.1093/neuros/nyz046			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	KN8UY	WOS:000515122000058	30877299				2021-06-18	
J	Williams, AM; Bhatti, UF; Brown, JF; Biesterveld, BE; Kathawate, RG; Graham, NJ; Chtraklin, K; Siddiqui, AZ; Dekker, SE; Andjelkovic, A; Higgins, GA; Buller, B; Alam, HB				Williams, Aaron M.; Bhatti, Umar F.; Brown, Jordana F.; Biesterveld, Ben E.; Kathawate, Ranganath G.; Graham, Nathan J.; Chtraklin, Kiril; Siddiqui, Ali Z.; Dekker, Simone E.; Andjelkovic, Anuska; Higgins, Gerald A.; Buller, Benjamin; Alam, Hasan B.			Early single-dose treatment with exosomes provides neuroprotection and improves blood-brain barrier integrity in swine model of traumatic brain injury and hemorrhagic shock	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	78th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST) / Clinical Congress of Acute Care Surgery	SEP 18-21, 2019	Dallas, TX	Amer Assoc Surg Trauma		Exosomes; mesenchymal stem cells; neuroprotection; traumatic brain injury; swine	VALPROIC ACID; EXTRACELLULAR VESICLES; STROMAL CELLS; RECOVERY; LIGHT	BACKGROUND Administration of human mesenchymal stem cell (MSC)-derived exosomes can enhance neurorestoration in models of traumatic brain injury (TBI) and hemorrhagic shock (HS). The impact of early treatment with MSC-derived exosomes on brain injury in a large animal model remains unknown. We sought to evaluate the impact of early single-dose exosome treatment on brain swelling and lesion size, blood-based cerebral biomarkers, and blood-brain barrier (BBB) integrity. METHODS Female Yorkshire swine were subjected to a severe TBI (12-mm cortical impact) and HS (40% estimated total blood volume). One hour into shock, animals were randomized (n = 5/cohort) to receive either lactated Ringer's (LR; 5 mL) or LR + exosomes (1 x 10(12) exosome particles in 5 mL LR). Animals then underwent additional shock (1 hour) followed by normal saline resuscitation. After 6 hours of observation, brain swelling (% increase compared with the uninjured side) and lesion size (mm(3)) were assessed. Cerebral hemodynamics and blood-based biomarkers of brain injury were compared. Immunofluorescence and RNA sequencing with differential gene expression and pathway analysis were used to assess the integrity of the perilesion BBB. RESULTS Exosome-treated animals had significantly less (p < 0.05) brain swelling and smaller lesion size. They also had significantly decreased (p < 0.05) intracranial pressures and increased cerebral perfusion pressures. Exosome-treated animals had significantly decreased (p < 0.05) albumin extravasation and significantly higher (p < 0.05) laminin, claudin-5, and zonula occludens 1 levels. Differential gene expression and pathway analysis confirmed these findings. Serum glial fibrillary acidic protein levels were also significantly lower (p < 0.05) in the exosome-treated cohort at the end of the experiment. CONCLUSION In a large animal model of TBI and HS, early treatment with a single dose of MSC-derived exosomes significantly attenuates brain swelling and lesion size, decreases levels of blood-based cerebral biomarkers, and improves BBB integrity.	[Williams, Aaron M.; Bhatti, Umar F.; Brown, Jordana F.; Biesterveld, Ben E.; Kathawate, Ranganath G.; Graham, Nathan J.; Chtraklin, Kiril; Siddiqui, Ali Z.; Dekker, Simone E.; Alam, Hasan B.] Univ Michigan, Dept Surg, 2920 Taubman Ctr 5331,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA; [Andjelkovic, Anuska] Univ Michigan, Dept Neuropathol, Ann Arbor, MI 48109 USA; [Higgins, Gerald A.] Univ Michigan, Dept Bioinformat & Computat Med, Ann Arbor, MI 48109 USA; [Buller, Benjamin] Henry Ford Hlth Syst, Dept Neurol, Neurol Res Educ & Res Bldg,Room 3013, Detroit, MI USA	Alam, HB (corresponding author), Univ Michigan, Dept Surg, 2920 Taubman Ctr 5331,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.; Buller, B (corresponding author), Henry Ford Hlth Syst, Dept Neurol, Neurol Res Educ & Res Bldg,Room 3013, Detroit, MI USA.	bbuller1@hfhs.org; alamh@med.umich.edu	Biesterveld, Ben/AAM-1087-2021	Higgins, Gerry/0000-0002-0434-1465	Massey TBI Research Grant; U.S. Army Medical Research Materiel Command grant [W81XWH-09-1-0520]	For all authors, no conflicts are declared. This study was supported by the Massey TBI Research Grant (to A.M.W. and H.B.A.) and the U.S. Army Medical Research Materiel Command grant W81XWH-09-1-0520 (to H.B.A.). The views, opinions, and/or findings contained in this report are those of the authors and should not be construed as an official Department of the Army position, policy, or decision unless so designated by other documentation.	Al Nimer F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132177; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chopp M, 2015, EXPERT OPIN EMERG DR, V20, P523, DOI 10.1517/14728214.2015.1061993; Frazee AC, 2015, NAT BIOTECHNOL, V33, P243, DOI 10.1038/nbt.3172; Gao WW, 2018, EXP NEUROL, V307, P99, DOI 10.1016/j.expneurol.2018.06.001; Georgoff PE, 2017, J NEUROTRAUM, V34, P2167, DOI 10.1089/neu.2016.4859; Gunzel D, 2013, PHYSIOL REV, V93, P525, DOI 10.1152/physrev.00019.2012; Halaweish I, 2016, J TRAUMA ACUTE CARE, V81, P1080, DOI 10.1097/TA.0000000000001204; Huang XJ, 2015, J NEUROTRAUM, V32, P1179, DOI 10.1089/neu.2015.3873; Huber W, 2015, NAT METHODS, V12, P115, DOI [10.1038/NMETH.3252, 10.1038/nmeth.3252]; Kanehisa M, 2019, NUCLEIC ACIDS RES, V47, pD590, DOI 10.1093/nar/gky962; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Korley FK, 2018, J NEUROTRAUM, V35, P1185, DOI 10.1089/neu.2017.5581; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Lin T, 2006, SURGERY, V139, P365, DOI 10.1016/j.surg.2005.08.022; Lu YH, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00209; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mi HY, 2019, NUCLEIC ACIDS RES, V47, pD419, DOI 10.1093/nar/gky1038; Moore TL, 2019, RESTOR NEUROL NEUROS, V37, P347, DOI 10.3233/RNN-190910; Ni HQ, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00014; Nikolian VC, 2019, J TRAUMA ACUTE CARE, V86, P232, DOI 10.1097/TA.0000000000002119; Nikolian VC, 2018, J TRAUMA ACUTE CARE, V84, P459, DOI 10.1097/TA.0000000000001765; Nikolian VC, 2018, CRIT CARE MED, V46, pE59, DOI 10.1097/CCM.0000000000002800; Nikolian VC, 2017, J TRAUMA ACUTE CARE, V83, P1066, DOI 10.1097/TA.0000000000001612; Otero-Ortega L, 2018, J CEREBR BLOOD F MET, V38, P767, DOI 10.1177/0271678X17708917; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Pearn ML, 2017, CELL MOL NEUROBIOL, V37, P571, DOI 10.1007/s10571-016-0400-1; Reinhold AK, 2017, PFLUG ARCH EUR J PHY, V469, P123, DOI 10.1007/s00424-016-1920-8; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125; Varet H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157022; Webb RL, 2018, STROKE, V49, P1248, DOI 10.1161/STROKEAHA.117.020353; Williams AM, 2019, J NEUROTRAUM, V36, P54, DOI 10.1089/neu.2018.5711; Xiong Y, 2017, NEURAL REGEN RES, V12, P19, DOI 10.4103/1673-5374.198966; Yang YX, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00055; Yuan XC, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00319; Zhang YL, 2017, NEUROCHEM INT, V111, P69, DOI 10.1016/j.neuint.2016.08.003; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhang ZG, 2019, NAT REV NEUROL, V15, P193, DOI 10.1038/s41582-018-0126-4	41	14	14	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2020	88	2					207	217		10.109711-A.0000000000002563			11	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	KJ3LI	WOS:000511958800026	31804413				2021-06-18	
J	Ye, XC; Hao, Q; Ma, WJ; Zhao, QC; Wang, WW; Yin, HH; Zhang, T; Wang, M; Zan, K; Yang, XX; Zhang, ZH; Shi, HJ; Zu, J; Raza, HK; Zhang, XL; Geng, DQ; Hu, JX; Cui, GY				Ye, Xin-Chun; Hao, Qi; Ma, Wei-Jing; Zhao, Qiu-Chen; Wang, Wei-Wei; Yin, Han-Han; Zhang, Tao; Wang, Miao; Zan, Kun; Yang, Xin-Xin; Zhang, Zuo-Hui; Shi, Hong-Juan; Zu, Jie; Raza, Hafiz Khuram; Zhang, Xue-Ling; Geng, De-Qin; Hu, Jin-Xia; Cui, Gui-Yun			Dectin-1/Syk signaling triggers neuroinflammation after ischemic stroke in mice	JOURNAL OF NEUROINFLAMMATION			English	Article						Dectin-1; Syk; inflammation; ischemic stroke	TYROSINE KINASE SYK; BETA-GLUCAN RECEPTOR; TOLL-LIKE RECEPTORS; NLRP3 INFLAMMASOME; BRAIN-INJURY; KAPPA-B; ACTIVATION; EXPRESSION; RECOGNITION; INHIBITION	Background Dendritic cell-associated C-type lectin-1 (Dectin-1) receptor has been reported to be involved in neuroinflammation in Alzheimer's disease and traumatic brain injury. The present study was designed to investigate the role of Dectin-1 and its downstream target spleen tyrosine kinase (Syk) in early brain injury after ischemic stroke using a focal cortex ischemic stroke model. Methods Adult male C57BL/6 J mice were subjected to a cerebral focal ischemia model of ischemic stroke. The neurological score, adhesive removal test, and foot-fault test were evaluated on days 1, 3, 5, and 7 after ischemic stroke. Dectin-1, Syk, phosphorylated (p)-Syk, tumor necrosis factor-alpha (TNF-alpha), and inducible nitric oxide synthase (iNOS) expression was analyzed via western blotting in ischemic brain tissue after ischemic stroke and in BV2 microglial cells subjected to oxygen-glucose deprivation/reoxygenation (OGD/R) injury in vitro. The brain infarct volume and Iba1-positive cells were evaluated using Nissl's and immunofluorescence staining, respectively. The Dectin-1 antagonist laminarin (LAM) and a selective inhibitor of Syk phosphorylation (piceatannol; PIC) were used for the intervention. Results Dectin-1, Syk, and p-Syk expression was significantly enhanced on days 3, 5, and 7 and peaked on day 3 after ischemic stroke. The Dectin-1 antagonist LAM or Syk inhibitor PIC decreased the number of Iba1-positive cells and TNF-alpha and iNOS expression, decreased the brain infarct volume, and improved neurological functions on day 3 after ischemic stroke. In addition, the in vitro data revealed that Dectin-1, Syk, and p-Syk expression was increased following the 3-h OGD and 0, 3, and 6 h of reperfusion in BV2 microglial cells. LAM and PIC also decreased TNF-alpha and iNOS expression 3 h after OGD/R induction. Conclusion Dectin-1/Syk signaling plays a crucial role in inflammatory activation after ischemic stroke, and further investigation of Dectin-1/Syk signaling in stroke is warranted.	[Ye, Xin-Chun; Ma, Wei-Jing; Yin, Han-Han; Zhang, Tao; Wang, Miao; Zan, Kun; Yang, Xin-Xin; Zhang, Zuo-Hui; Shi, Hong-Juan; Zu, Jie; Raza, Hafiz Khuram; Geng, De-Qin; Hu, Jin-Xia; Cui, Gui-Yun] Xuzhou Med Univ, Inst Stroke Ctr, Xuzhou, Jiangsu, Peoples R China; [Ye, Xin-Chun; Ma, Wei-Jing; Yin, Han-Han; Zhang, Tao; Wang, Miao; Zan, Kun; Yang, Xin-Xin; Zhang, Zuo-Hui; Shi, Hong-Juan; Zu, Jie; Raza, Hafiz Khuram; Geng, De-Qin; Hu, Jin-Xia; Cui, Gui-Yun] Xuzhou Med Univ, Dept Neurol, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China; [Hao, Qi] Xuzhou Med Univ, Dept Neurol, Affiliated Hosp 2, Xuzhou, Jiangsu, Peoples R China; [Zhao, Qiu-Chen] Nanjing Univ, Drum Tower Hosp, Dept Neurol, Med Sch, Nanjing, Peoples R China; [Wang, Wei-Wei] Linyi Canc Hosp, Dept Rehabil Med, Linyi, Shandong, Peoples R China; [Zhang, Xue-Ling] Nanjing Drum Tower Hosp Grp, Dept Neurol, Suqian Peoples Hosp, Suqian, Jiangsu, Peoples R China	Ye, XC; Hu, JX; Cui, GY (corresponding author), Xuzhou Med Univ, Inst Stroke Ctr, Xuzhou, Jiangsu, Peoples R China.; Ye, XC; Hu, JX; Cui, GY (corresponding author), Xuzhou Med Univ, Dept Neurol, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China.	xinchunye@xzhmu.edu.cn; jinxia0819@163.com; guiyuncui@foxmail.com	Zhang, Zuohui/AAQ-6728-2021; Raza, Hafiz Khuram/AAX-4308-2020	Zhang, Zuohui/0000-0002-8486-4767; Raza, Hafiz Khuram/0000-0002-1748-7359	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81971134, 81571155, 81571210, 81771282]; National Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BK20191152, BK20150209, BL2014031]; Natural Science Foundation of the Higher Education Institutions of Jiangsu Province [17KJB320017]; Jiangsu Provincial Medical Youth Talent [QNRC2016788]; Jiangsu Commission of Heath [LGY2019086]; Xuzhou Key Research and Development Program [KC18055, KC19131]; Xuzhou Innovation Capacity Building Program [KC19239]; Suqian Science and Technology Plan [S201714]; Summit of Six Top Talents Program of Jiangsu Province [2017-WSN-118]	The present study was supported by the National Natural Science Foundation of China (grant nos. 81971134 and 81571155 to Dr. Ye and grant nos. 81571210 and 81771282 to Dr. Cui), the National Natural Science Foundation of Jiangsu Province (grant nos. BK20191152, BK20150209 and BL2014031), the Natural Science Foundation of the Higher Education Institutions of Jiangsu Province (grant no. 17KJB320017), Jiangsu Provincial Medical Youth Talent (grant no. QNRC2016788), Jiangsu Commission of Heath (grant no. LGY2019086), Xuzhou Key Research and Development Program (grant nos. KC18055 and KC19131), Xuzhou Innovation Capacity Building Program (grant no. KC19239), Suqian Science and Technology Plan (grant no. S201714), and the Summit of Six Top Talents Program of Jiangsu Province (grant no. 2017-WSN-118).	Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Baldwin KT, 2015, P NATL ACAD SCI USA, V112, P2581, DOI 10.1073/pnas.1423221112; Benakis C, 2010, BRAIN BEHAV IMMUN, V24, P800, DOI 10.1016/j.bbi.2009.11.001; Bertuzzi M, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004413; Bhatia HS, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0615-6; Chamorro A, 2012, NAT REV NEUROL, V8, P401, DOI 10.1038/nrneurol.2012.98; Chaudhary A, 2007, IMMUNOL CELL BIOL, V85, P249, DOI 10.1038/sj.icb7100030; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Derecki NC, 2012, NATURE, V484, P105, DOI 10.1038/nature10907; Dhungana H, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-1010-7; Duta F, 2006, HISTOCHEM CELL BIOL, V126, P495, DOI 10.1007/s00418-006-0188-z; Eldahshan W, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104349; Friedrich V, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-103; Frontera JA, 2012, J THROMB HAEMOST, V10, P711, DOI 10.1111/j.1538-7836.2012.04651.x; Gao L, 2017, INFLAMM RES, V66, P17, DOI 10.1007/s00011-016-0981-7; GEAHLEN RL, 1994, ADV EXP MED BIOL, V365, P103; Gensel JC, 2015, J NEUROSCI, V35, P9966, DOI 10.1523/JNEUROSCI.0337-15.2015; Gringhuis SI, 2012, NAT IMMUNOL, V13, P246, DOI 10.1038/ni.2222; Gross O, 2009, NATURE, V459, P433, DOI 10.1038/nature07965; Guo GW, 2006, ANTIOXID REDOX SIGN, V8, P911, DOI 10.1089/ars.2006.8.911; Hise AG, 2009, CELL HOST MICROBE, V5, P487, DOI 10.1016/j.chom.2009.05.002; Huang C, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-129; Huysamen C, 2008, J BIOL CHEM, V283, P16693, DOI 10.1074/jbc.M709923200; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Ishizuka F, 2013, INVEST OPHTH VIS SCI, V54, P5807, DOI 10.1167/iovs.13-11932; Jeong D, 2013, J ETHNOPHARMACOL, V146, P205, DOI 10.1016/j.jep.2012.12.034; Jung JE, 2011, STROKE, V42, P3574, DOI 10.1161/STROKEAHA.111.626648; Kankkunen P, 2010, J IMMUNOL, V184, P6335, DOI 10.4049/jimmunol.0903019; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kim JY, 2014, CURR MED CHEM, V21, P2076, DOI 10.2174/0929867321666131228205146; Lamkanfi M, 2012, ANNU REV CELL DEV BI, V28, P137, DOI 10.1146/annurev-cellbio-101011-155745; Lech M, 2012, INT J MOL SCI, V13, P10113, DOI 10.3390/ijms130810113; Lugo-Villarino G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01123; Martin B, 2009, IMMUNITY, V31, P321, DOI 10.1016/j.immuni.2009.06.020; Mocsai A, 2010, NAT REV IMMUNOL, V10, P387, DOI 10.1038/nri2765; Pamuk ON, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3198; Pamuk ON, 2010, AM J PHYSIOL-GASTR L, V299, pG391, DOI 10.1152/ajpgi.00198.2010; Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Reid DM, 2004, J LEUKOCYTE BIOL, V76, P86, DOI 10.1189/jlb.0104031; Riccaboni M, 2010, DRUG DISCOV TODAY, V15, P517, DOI 10.1016/j.drudis.2010.05.001; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; Said-Sadier N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010008; Sancho D, 2009, NATURE, V458, P899, DOI 10.1038/nature07750; Shichita T, 2012, J NEUROCHEM, V123, P29, DOI 10.1111/j.1471-4159.2012.07941.x; Shichita T, 2012, NAT MED, V18, P911, DOI 10.1038/nm.2749; Sun WK, 2012, EUR J CLIN MICROBIOL, V31, P2755, DOI 10.1007/s10096-012-1624-8; Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; Willment JA, 2005, EUR J IMMUNOL, V35, P1539, DOI 10.1002/eji.200425725; Yamasaki S, 2008, NAT IMMUNOL, V9, P1179, DOI 10.1038/ni.1651; Yang CS, 2009, GLIA, V57, P1091, DOI 10.1002/glia.20832; Yang WS, 2012, J ETHNOPHARMACOL, V142, P287, DOI 10.1016/j.jep.2012.04.026; Ye XC, 2018, STROKE, V49, P165, DOI 10.1161/STROKEAHA.117.018115; Ye XC, 2017, EXP NEUROL, V292, P46, DOI 10.1016/j.expneurol.2017.03.002; Yin ZR, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00065; Yoon JY, 2013, J ETHNOPHARMACOL, V148, P999, DOI 10.1016/j.jep.2013.05.030; Ystgaard MB, 2015, NEONATOLOGY, V108, P211, DOI 10.1159/000437247; Yu T, 2012, J ETHNOPHARMACOL, V139, P566, DOI 10.1016/j.jep.2011.11.051; Zhao YJ, 2018, NEURON, V97, P1023, DOI 10.1016/j.neuron.2018.01.031	60	14	15	2	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	JAN 11	2020	17	1							17	10.1186/s12974-019-1693-z			16	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	KL9AE	WOS:000513708500003	31926564	DOAJ Gold, Green Published			2021-06-18	
J	Langer, L; Levy, C; Bayley, M				Langer, Laura; Levy, Charissa; Bayley, Mark			Increasing Incidence of Concussion: True Epidemic or Better Recognition?	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						administrative health databases; concussion; epidemiology; incidence; sex differences; urban rural differences	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; EXTERNAL CAUSES; UNITED-STATES; PREVALENCE; DIAGNOSIS; OUTCOMES; TRENDS; AREA	Objectives: To provide updated estimates of the incidence of concussion from all causes diagnosed by all physicians in a large jurisdiction, as previous studies have examined only single causes of injury or from smaller specific populations. Design: Physician Billing and National Ambulatory Care Reporting System (NACRS) databases were used to identify all Ontario residents with a diagnosis of concussion (ICD-9 850.0 and ICD-10 S06.0) made by physicians between 2008 and 2016, excluding those with moderate to severe traumatic brain injury. Results: In total, 1 330 336 people were diagnosed with a concussion between 2008 and 2016. The annual average was 147 815, and 79% were diagnosed in the emergency department. The average annual incidence was 1153 per 100 000 residents. Incidence varied by age, sex, and geography; children younger than 5 years had the highest incidence of concussion, more than 3600 per 100 000 individuals of that age group. Males had higher incidence than females except in older than 65 years age groups. There was a Pearson correlation (+0.669) between sustaining a concussion and living in rural locations. Conclusion: The annual incidence of approximately 1.2% of the population is the highest rate of concussion ever reported thorough sampling methods and may represent a closer estimate of the true picture of concussion. Findings may inform future concussion treatment and healthcare planning.	[Langer, Laura; Bayley, Mark] Univ Hlth Network, Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada; [Levy, Charissa] GTA Rehab Network, Toronto ABI Network, Toronto, ON, Canada; [Levy, Charissa] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Bayley, Mark] Univ Toronto, Div Physiatry, Toronto, ON, Canada	Langer, L (corresponding author), Univ Hlth Network, Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	laura.langer@uhn.ca		Langer, Laura/0000-0003-4408-355X	Institute for Clinical and Evaluative Sciences (ICES); Ontario Neurotrauma Foundation (ONF)	This study was supported through the provision of data from the Institute for Clinical and Evaluative Sciences (ICES) and through the funding support to ICES from an Ontario Neurotrauma Foundation (ONF) research grant. The authors acknowledge Dr Susan Jaglal, Jennifer Voth, Symron Bansal, and Refik Saskin, for their assistance and expertise with the ICES databases, and Sarah Cote and Andrew Ho, for manuscript editing assistance. The opinions, results, and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by ICES or ONF is intended or should be inferred.	Amaranath JE, 2014, ANZ J SURG, V84, P424, DOI 10.1111/ans.12445; Amoo-Achampong K, 2017, PHYSICIAN SPORTSMED, V45, P239, DOI 10.1080/00913847.2017.1327304; [Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Berrigan L, 2011, BRAIN INJURY, V25, P742, DOI 10.3109/02699052.2011.580317; Boutis K, 2018, J EMERG MED, V54, P757, DOI 10.1016/j.jemermed.2018.02.041; Burke MJ, 2012, CAN J NEUROL SCI, V39, P763, DOI 10.1017/S0317167100015584; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS278, DOI 10.1016/j.apmr.2013.08.295; Centers for Disease Control and Prevention, 2010, NAT HOSP AMB MED CAR; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Gordon KE, 2018, BRAIN INJURY, V32, P41, DOI 10.1080/02699052.2017.1403046; Kerr ZY, 2017, NEUROL CLIN, V35, P409, DOI 10.1016/j.ncl.2017.03.001; Kim H, 2006, NEUROREHABILITATION, V21, P269; Kontos AP, 2013, J PEDIATR-US, V163, P717, DOI 10.1016/j.jpeds.2013.04.011; KRAUS JF, 1985, J OCCUP ENVIRON MED, V27, P757; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; Laflamme L, 2009, SOCIOECONOMIC DIFFER; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Liu M, 2011, WORK, V39, P283, DOI 10.3233/WOR-2011-1176; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; Noble JM, 2013, NEUROPSYCHOL REV, V23, P273, DOI 10.1007/s11065-013-9239-0; Oddy M, 2012, BRAIN INJURY, V26, P1058, DOI 10.3109/02699052.2012.667595; Rona RJ, 2012, J HEAD TRAUMA REHAB, V27, P75, DOI 10.1097/HTR.0b013e31823029f6; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Statistics Canada, 2018, CENS CAN 2006 2011 2; Topolovec-Vranic Jane, 2014, CMAJ Open, V2, pE69, DOI 10.9778/cmajo.20130046; van Pelt ED, 2011, EUR J PAEDIATR NEURO, V15, P519, DOI 10.1016/j.ejpn.2011.05.005; Veliz P, 2017, JAMA-J AM MED ASSOC, V318, P1180, DOI 10.1001/jama.2017.9087; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; Zemek R, 2015, CAN J EMERG MED, V17, P115, DOI 10.1017/cem.2014.38; Zemek RL, 2017, J PEDIATR-US, V181, P222, DOI 10.1016/j.jpeds.2016.10.067	35	14	15	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2020	35	1			SI		E60	E66		10.1097/HTR.0000000000000503			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	KL0UE	WOS:000513147300013	31246881				2021-06-18	
J	Xiao, L; Wei, F; Zhou, YH; Anderson, GJ; Frazer, DM; Lim, YC; Liu, TQ; Xiao, Y				Xiao, Lan; Wei, Fei; Zhou, Yinghong; Anderson, Gregory J.; Frazer, David M.; Lim, Yi Chieh; Liu, Tianqing; Xiao, Yin			Dihydrolipoic Acid-Gold Nanoclusters Regulate Microglial Polarization and Have the Potential To Alter Neurogenesis	NANO LETTERS			English	Article						Gold nanoclusters; neuroinflammation; microglial polarization; neuronal regeneration; immunomodulation	NF-KAPPA-B; ALPHA-LIPOIC ACID; NEURONAL NUCLEAR ANTIGEN; CENTRAL-NERVOUS-SYSTEM; AUTOPHAGIC CELL-DEATH; PROTEIN-KINASE-C; IN-VITRO MODEL; OXIDATIVE STRESS; METAL NANOCLUSTERS; NITRIC-OXIDE	Microglia-mediated neuroinflammation is one of the most significant features in a variety of central nervous system (CNS) disorders such as traumatic brain injury, stroke, and many neurodegenerative diseases. Microglia become polarized upon stimulation. The two extremes of the polarization are the neuron-destructive proinflammatory M1-like and the neuron-regenerative M2-like phenotypes. Thus, manipulating microglial polarization toward the M2 phenotype is a promising therapeutic approach for CNS repair and regeneration. It has been reported that nanoparticles are potential tools for regulating microglial polarization. Gold nanoclusters (AuNCs) could penetrate the blood brain barrier and have neuroprotective effects, suggesting the possibility of utilizing AuNCs to regulate microglial polarization and improve neuronal regeneration in CNS. In the current study, AuNCs functionalized with dihydrolipoic acid (DHLA-AuNCs), an antioxidant with demonstrated neuroprotective roles, were prepared, and their effects on polarization of a microglial cell line (BV2) were examined. DHLA-AuNCs effectively suppressed proinflammatory processes in BV2 cells by inducing polarization toward the M2-like phenotype. This was associated with a decrease in reactive oxygen species and reduced NF-kB signaling and an improvement in cell survival coupled with enhanced autophagy and inhibited apoptosis. Conditioned medium from DHLA-AuNC-treated BV2 cells was able to enhance neurogenesis in both the neuronal cell line N2a and in an ex vivo brain slice stroke model. The direct treatment of brain slices with DHLA-AuNCs also ameliorated stroke-related tissue injury and reduced astrocyte activation (astrogliosis). This study suggests that by regulating neuroinflammation to improve neuronal regeneration, DHLA-AuNCs could be a potential therapeutic agent in CNS disorders.	[Xiao, Lan; Wei, Fei; Zhou, Yinghong; Xiao, Yin] Queensland Univ Technol, Inst Hlth & Biomed Innovat, 60 Musk Ave, Brisbane, Qld 4059, Australia; [Zhou, Yinghong; Xiao, Yin] Australia China Ctr Tissue Engn & Regenerat Med, Shanghai, Peoples R China; [Anderson, Gregory J.; Frazer, David M.; Lim, Yi Chieh; Liu, Tianqing] QIMR Berghofer Med Res Inst, 300 Herston Rd, Brisbane, Qld 4006, Australia	Xiao, Y (corresponding author), Queensland Univ Technol, Inst Hlth & Biomed Innovat, 60 Musk Ave, Brisbane, Qld 4059, Australia.; Xiao, Y (corresponding author), Australia China Ctr Tissue Engn & Regenerat Med, Shanghai, Peoples R China.; Liu, TQ (corresponding author), QIMR Berghofer Med Res Inst, 300 Herston Rd, Brisbane, Qld 4006, Australia.	michelle.liu@qimrberghofer.edu.au; yin.xiao@qut.edu.au	Xiao, Yin/AAM-4033-2020; Anderson, Gregory/G-4148-2013	Xiao, Yin/0000-0003-1785-3491; Lim, Yi Chieh/0000-0003-1261-5419; Liu, Tianqing/0000-0002-9058-2643; Anderson, Gregory/0000-0002-8814-5866; Zhou, Yinghong/0000-0001-9757-7735	National Health and Medical Research Council (NHMRC) Early Career FellowshipNational Health and Medical Research Council of Australia [1105035]	Dr. Tianqing Liu is supported by the National Health and Medical Research Council (NHMRC) Early Career Fellowship (Grant No. 1112258). Dr. Yinghong Zhou is supported by the National Health and Medical Research Council (NHMRC) Early Career Fellowship (Grant No. 1105035).	Allen CL, 2009, INT J STROKE, V4, P461, DOI 10.1111/j.1747-4949.2009.00387.x; Bae EA, 2006, PLANTA MED, V72, P627, DOI 10.1055/s-2006-931563; Belarbi K, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00145; Bhaskar S, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-3; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Biewenga GP, 1997, GEN PHARMACOL, V29, P315, DOI 10.1016/S0306-3623(96)00474-0; Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bookout A. L, 2003, NUCL RECEPT SIGNALIN, V1; Bundscherer A, 2013, ANTICANCER RES, V33, P3201; Bustamante J, 1998, FREE RADICAL BIO MED, V24, P1023, DOI 10.1016/S0891-5849(97)00371-7; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Cakatay U, 2006, MED HYPOTHESES, V66, P110, DOI 10.1016/j.mehy.2005.07.020; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chen K, 2008, J CELL BIOL, V181, P1129, DOI 10.1083/jcb.200709049; Chen ZT, 2017, ACS NANO, V11, P4494, DOI 10.1021/acsnano.6b07808; Chhor V, 2013, BRAIN BEHAV IMMUN, V32, P70, DOI 10.1016/j.bbi.2013.02.005; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cho S, 2007, CURR NEUROPHARMACOL, V5, P19, DOI 10.2174/157015907780077105; Cho SG, 2004, NEUROCHEM INT, V45, P117, DOI 10.1016/j.neuint.2003.11.012; Colonna M, 2017, ANNU REV IMMUNOL, V35, P441, DOI 10.1146/annurev-immunol-051116-052358; Colton CA, 2010, CNS NEUROL DISORD-DR, V9, P174, DOI 10.2174/187152710791012053; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; DACHARYPRIGENT J, 1993, BLOOD, V81, P2554; DAWSON VL, 1993, J NEUROSCI, V13, P2651; Dobrovolskaia MA, 2007, NAT NANOTECHNOL, V2, P469, DOI 10.1038/nnano.2007.223; Elliott EI, 2015, IMMUNOL REV, V265, P35, DOI 10.1111/imr.12286; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; Erta M, 2012, INT J BIOL SCI, V8, P1254, DOI 10.7150/ijbs.4679; Fan LW, 2017, NEURAL REGEN RES, V12, P366, DOI 10.4103/1673-5374.202926; Fernandez TD, 2015, BIOMATERIALS, V43, P1, DOI 10.1016/j.biomaterials.2014.11.045; Finley M, 2004, BRAIN RES, V1001, P125, DOI 10.1016/j.brainres.2003.12.009; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Forrester SJ, 2018, CIRC RES, V122, P877, DOI 10.1161/CIRCRESAHA.117.311401; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Gao GB, 2019, BIOMATERIALS, V194, P36, DOI 10.1016/j.biomaterials.2018.12.013; Ghibu S, 2009, J CARDIOVASC PHARM, V54, P391, DOI 10.1097/FJC.0b013e3181be7554; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011; Gloor SM, 2001, BRAIN RES REV, V36, P258, DOI 10.1016/S0165-0173(01)00102-3; Goraca A, 2011, PHARMACOL REP, V63, P849; GORCZYCA W, 1993, EXP CELL RES, V207, P202, DOI 10.1006/excr.1993.1182; Gosselin D, 2007, BRAIN BEHAV IMMUN, V21, P281, DOI 10.1016/j.bbi.2006.12.004; GREENAMYRE JT, 1994, NEUROSCI LETT, V171, P17, DOI 10.1016/0304-3940(94)90593-2; Guillemin GJ, 2004, J LEUKOCYTE BIOL, V75, P388, DOI 10.1189/jlb.0303114; Gusel'nikova VV, 2015, ACTA NATURAE, V7, P42, DOI 10.32607/20758251-2015-7-2-42-47; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; Henn A, 2009, ALTEX-ALTERN TIEREXP, V26, P83; Herculano-Houzel S, 2005, J NEUROSCI, V25, P2518, DOI 10.1523/JNEUROSCI.4526-04.2005; Hingorani R, 2011, DETECTION APOPTOSIS; Ho YS, 2007, BIOCHEM PHARMACOL, V73, P1786, DOI 10.1016/j.bcp.2006.12.006; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Humpel C, 2015, NEUROSCIENCE, V305, P86, DOI 10.1016/j.neuroscience.2015.07.086; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Ishaque A, 1998, J IMMUNOL METHODS, V221, P43, DOI 10.1016/S0022-1759(98)00166-5; JACQUE CM, 1978, J NEUROL SCI, V35, P147, DOI 10.1016/0022-510X(78)90107-7; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; KALTSCHMIDT C, 1994, J NEUROIMMUNOL, V55, P99, DOI 10.1016/0165-5728(94)90151-1; Kamenova Petya, 2006, Hormones (Athens), V5, P251; Kim YJ, 2006, J NEUROSCI RES, V84, P1037, DOI 10.1002/jnr.21011; Klionsky DJ, 2007, AUTOPHAGY, V3, P181, DOI 10.4161/auto.3678; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Koenig ML, 2003, NEUROTOX RES, V5, P265, DOI 10.1007/BF03033384; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Kuroda J, 2010, P NATL ACAD SCI USA, V107, P15565, DOI 10.1073/pnas.1002178107; Laake JH, 1999, BRAIN RES PROTOC, V4, P173, DOI 10.1016/S1385-299X(99)00021-5; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Lehnardt S, 2010, GLIA, V58, P253, DOI 10.1002/glia.20928; Leu JG, 2012, NANOMED-NANOTECHNOL, V8, P767, DOI 10.1016/j.nano.2011.08.013; Li JJ, 2014, TRAC-TREND ANAL CHEM, V58, P90, DOI 10.1016/j.trac.2014.02.011; Li QY, 2018, NAT REV IMMUNOL, V18, P225, DOI 10.1038/nri.2017.125; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Liesz A, 2011, BRAIN, V134, P704, DOI 10.1093/brain/awr008; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143; Liu Y, 2013, P NATL ACAD SCI USA, V110, P20364, DOI 10.1073/pnas.1319661110; Maczurek A, 2008, ADV DRUG DELIVER REV, V60, P1463, DOI 10.1016/j.addr.2008.04.015; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Mao AJ, 2000, J BIOL CHEM, V275, P34407, DOI 10.1074/jbc.M003917200; Margaritescu O, 2009, ROM J MORPHOL EMBRYO, V50, P327; Minami SS, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-22; MINANA MD, 1990, P NATL ACAD SCI USA, V87, P4335, DOI 10.1073/pnas.87.11.4335; Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149; Mizushima N, 2007, AUTOPHAGY, V3, P542; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Moini H, 2002, TOXICOL APPL PHARM, V182, P84, DOI 10.1006/taap.2002.9437; Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178; Moss DW, 2001, EUR J NEUROSCI, V13, P529, DOI 10.1046/j.1460-9568.2001.01418.x; Myhre O, 2003, BIOCHEM PHARMACOL, V65, P1575, DOI 10.1016/S0006-2952(03)00083-2; Nair LV, 2017, J MATER CHEM B, V5, P8314, DOI 10.1039/c7tb02247f; Nair LV, 2015, ACS NANO, V9, P5825, DOI 10.1021/acsnano.5b00406; Niemann A, 2001, J HISTOCHEM CYTOCHEM, V49, P177, DOI 10.1177/002215540104900205; Packer L, 1997, FREE RADICAL BIO MED, V22, P359, DOI 10.1016/S0891-5849(96)00269-9; Papa S, 2013, ACS NANO, V7, P9881, DOI 10.1021/nn4036014; Paradells-Navarro S, 2017, ACS CHEM NEUROSCI, V8, P569, DOI 10.1021/acschemneuro.6b00306; Park J, 2015, NEUROSCI LETT, V584, P191, DOI 10.1016/j.neulet.2014.10.016; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Ryu J, 2000, J BIOL CHEM, V275, P29955, DOI 10.1074/jbc.M001220200; Sanchez-Ramos JR, 2001, EXP NEUROL, V171, P109, DOI 10.1006/exnr.2001.7748; Sarnat HB, 1998, BRAIN DEV-JPN, V20, P88, DOI 10.1016/S0387-7604(97)00111-3; Sato C, 2002, J BIOL CHEM, V277, P45299, DOI 10.1074/jbc.M206046200; Seleverstov O, 2006, NANO LETT, V6, P2826, DOI 10.1021/nl0619711; Shahsavari S, 2016, J NANOMED RES, V3; Shaid S, 2013, CELL DEATH DIFFER, V20, P21, DOI 10.1038/cdd.2012.72; Shang L, 2013, ANGEW CHEM INT EDIT, V52, P11154, DOI 10.1002/anie.201306366; Shang L, 2012, NANOSCALE, V4, P4155, DOI 10.1039/c2nr30219e; Shang L, 2011, SMALL, V7, P2614, DOI 10.1002/smll.201100746; Shi JY, 2013, AUTOPHAGY, V9, P1591, DOI 10.4161/auto.26059; Shinto L, 2014, J ALZHEIMERS DIS, V38, P111, DOI 10.3233/JAD-130722; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577; Sirokmany G, 2016, TRENDS PHARMACOL SCI, V37, P318, DOI 10.1016/j.tips.2016.01.006; Smith JA, 2012, BRAIN RES BULL, V87, P10, DOI 10.1016/j.brainresbull.2011.10.004; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Song XR, 2016, ANALYST, V141, P3126, DOI 10.1039/c6an00773b; Stansley B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-115; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Sun Q, 2017, MOL MED, V23, P188, DOI 10.2119/molmed.2017.00077; Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5; Tasca CI, 2015, METHODS MOL BIOL, V1254, P197, DOI 10.1007/978-1-4939-2152-2_15; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; Tremblay RG, 2010, J NEUROSCI METH, V186, P60, DOI 10.1016/j.jneumeth.2009.11.004; Vazquez CL, 2009, METHOD ENZYMOL, V452, P85, DOI 10.1016/S0076-6879(08)03606-9; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Vidal PM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.466; Wei ZJ, 2015, MOL MED REP, V12, P63, DOI 10.3892/mmr.2015.3395; Wu CT, 2012, BIOMATERIALS, V33, P2076, DOI 10.1016/j.biomaterials.2011.11.042; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100; Xiao L, 2018, J BONE MINER RES, V33, P1090, DOI 10.1002/jbmr.3396; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XD, 2017, BRAIN BEHAV IMMUN, V64, P162, DOI 10.1016/j.bbi.2017.03.003; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Yuan L, 2014, MOL CELL BIOCHEM, V386, P153, DOI 10.1007/s11010-013-1854-9; Zabirnyk O, 2007, AUTOPHAGY, V3, P278, DOI 10.4161/auto.3916; Zhang CL, 2013, J MATER CHEM B, V1, P5045, DOI 10.1039/c3tb20784f; Zhang LB, 2014, NANO TODAY, V9, P132, DOI 10.1016/j.nantod.2014.02.010; Zhao CH, 2007, NEUROBIOL DIS, V26, P36, DOI 10.1016/j.nbd.2006.11.012; Zhao YF, 2016, ACS NANO, V10, P5959, DOI 10.1021/acsnano.6b01326; Zheng YK, 2017, ADV COLLOID INTERFAC, V242, P1, DOI 10.1016/j.cis.2017.02.005; Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051; Zhong ZY, 2016, CELL, V164, P896, DOI 10.1016/j.cell.2015.12.057; Zhou KR, 2018, STROKE, V49, P175, DOI 10.1161/STROKEAHA.117.018593; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	154	14	14	16	47	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1530-6984	1530-6992		NANO LETT	Nano Lett.	JAN	2020	20	1					478	495		10.1021/acs.nanolett.9b04216			18	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	KC4LO	WOS:000507151600062	31789044				2021-06-18	
J	Thibaut, A; Bodien, YG; Laureys, S; Giacino, JT				Thibaut, Aurore; Bodien, Yelena G.; Laureys, Steven; Giacino, Joseph T.			Minimally conscious state "plus": diagnostic criteria and relation to functional recovery	JOURNAL OF NEUROLOGY			English	Article						Minimally conscious state; Disorders of consciousness; Brain-injuries; Coma recovery scale-revised; Disability rating scale; Command-following; Intentional communication; Intelligible verbalization	DISORDERS; LANGUAGE; SCALE; COMA	Background We investigated the relationship between three language-dependent behaviors (i.e., command-following, intelligible verbalization, and intentional communication) and the functional status of patients with disorders of consciousness (DoC). We hypothesized that patients in minimally conscious state (MCS) who retain behavioral evidence of preserved language function would have similar levels of functional disability, while patients who lack these behaviors would demonstrate significantly greater disability. We reasoned that these results could then be used to establish empirically-based diagnostic criteria for MCS+. Methods In this retrospective cohort study we included rehabilitation inpatients diagnosed with DoC following severe-acquired brain injury (MCS = 57; vegetative state/unresponsive wakefulness syndrome [VS/UWS] = 63); women: 46; mean age: 47 +/- 19 years; traumatic etiology: 68; time post-injury: 40 +/- 23 days). We compared the scores of the Disability Rating Scale score (DRS) at time of transition from VS/UWS to MCS or from MCS- to MCS+, and at discharge between groups. Results Level of disability on the DRS was similar in patients with any combination of the three language-related behaviors. MCS patients with no behavioral evidence of language function (i.e., MCS-) were more functionally impaired than patients with MCS+ at time of transition and at discharge. Conclusions Command-following, intelligible verbalization, and intentional communication are not associated with different levels of functional disability. Thus, the MCS+ syndrome can be diagnosed based on the presence of any one of these language-related behaviors. Patients in MCS+ may evidence less functional disability compared to those in MCS who fail to demonstrate language function (i.e., MCS-).	[Thibaut, Aurore; Laureys, Steven] Univ Liege, Coma Sci Grp, GIGA Consciousness, Allee Hop 11-B34, B-4000 Liege, Belgium; [Thibaut, Aurore; Laureys, Steven] Univ Hosp Liege, Allee Hop 11-B34, B-4000 Liege, Belgium; [Bodien, Yelena G.] Harvard Med Sch, Ctr Neurotechnol & Neurorecovery, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA; [Bodien, Yelena G.; Giacino, Joseph T.] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02115 USA; [Giacino, Joseph T.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Thibaut, Aurore; Laureys, Steven] Univ Hosp Liege, Ctr Cerveau2, Liege, Belgium	Thibaut, A (corresponding author), Univ Liege, Coma Sci Grp, GIGA Consciousness, Allee Hop 11-B34, B-4000 Liege, Belgium.; Thibaut, A (corresponding author), Univ Hosp Liege, Allee Hop 11-B34, B-4000 Liege, Belgium.; Thibaut, A (corresponding author), Univ Hosp Liege, Ctr Cerveau2, Liege, Belgium.	athibaut@ulg.ac.be	Giacino, Joseph/AAF-1952-2021; Laureys, Steven/A-3349-2011; Laureys, Steven/AAN-2097-2021	Giacino, Joseph/0000-0002-7916-9698; Laureys, Steven/0000-0002-3096-3807; Bodien, Yelena/0000-0003-4858-2903	Wallonie Brussel International (WBI) scholarship; Belgian American Educational Foundation (BAEF); Leon Fredericq Foundation; National Institute on Disability, Independent Living and Rehabilitation Research (NIDILRR), Administration for Community Living (Spaulding-Harvard TBI Model System) [90DP0039]; NIDILRR (SpauldingHarvard TBI Model System) [90DP0039]; James S. McDonnell Foundation	Dr. Aurore Thibaut is a FNRS is a post-doctoral research fellow and has been supported by the Wallonie Brussel International (WBI) scholarship, the Belgian American Educational Foundation (BAEF), and the Leon Fredericq Foundation. Dr. Bodien is supported by the National Institute on Disability, Independent Living and Rehabilitation Research (NIDILRR), Administration for Community Living (90DP0039, Spaulding-Harvard TBI Model System). Dr. Giacino received support from NIDILRR (90DP0039, SpauldingHarvard TBI Model System) and the James S. McDonnell Foundation (Understanding Human Cognition-Collaborative). The authors thank the clinical staff at Spaulding Hospital Cambridge and Spaulding Rehabilitation Hospital for acquiring the clinical metrics used in this study.	Airenti G, 2010, COGN SYST RES, V11, P165, DOI 10.1016/j.cogsys.2009.03.002; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Aubinet C, 2018, HUM BRAIN MAPP, V39, P4519, DOI 10.1002/hbm.24303; Bara BG, 2001, BRAIN LANG, V77, P72, DOI 10.1006/brln.2000.2430; Bara BG, 2011, INTERCULT PRAGMAT, V8, P443, DOI 10.1515/IPRG.2011.020; Bruno MA, 2012, J NEUROL, V259, P1087, DOI 10.1007/s00415-011-6303-7; Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Davis MH, 2003, J NEUROSCI, V23, P3423; Demertzi A, 2011, J NEUROL, V258, P1058, DOI 10.1007/s00415-010-5882-z; Di Perri C, 2016, LANCET NEUROL, V15, P1115, DOI 10.1016/S1474-4422(16)30205-8; Estraneo A, 2016, CLIN NEUROPHYSIOL, V127, P2379, DOI 10.1016/j.clinph.2016.03.021; Gabrieli JDE, 1998, P NATL ACAD SCI USA, V95, P906, DOI 10.1073/pnas.95.3.906; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GOODWIN C, 1995, RES LANG SOC INTERAC, V28, P233, DOI 10.1207/s15327973rlsi2803_4; Gosseries O, 2014, BRAIN INJURY, V28, P1141, DOI 10.3109/02699052.2014.920522; Guldenmund P, 2016, BRAIN INJURY, V30, P343, DOI 10.3109/02699052.2015.1118765; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hickok G, 2007, NAT REV NEUROSCI, V8, P393, DOI 10.1038/nrn2113; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Longoni Francesca, 2005, Brain Cogn, V57, P131, DOI 10.1016/j.bandc.2004.08.032; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Riecker A, 2005, NEUROLOGY, V64, P700, DOI 10.1212/01.WNL.0000152156.90779.89; Schnakers C, 2015, NEUROLOGY CONSCIOUSN; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Stender J, 2014, LANCET, V384, P514, DOI 10.1016/S0140-6736(14)60042-8; Tomasello M, 2005, BEHAV BRAIN SCI, V28, P675, DOI 10.1017/S0140525X05000129; Tomasello M, 2008, JEAN NICOD LECT, P1; Vigneau M, 2006, NEUROIMAGE, V30, P1414, DOI 10.1016/j.neuroimage.2005.11.002; Willems RM, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00203; Zheng ZS, 2017, HUM BRAIN MAPP, V38, P431, DOI 10.1002/hbm.23370	31	14	14	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	MAY	2020	267	5					1245	1254		10.1007/s00415-019-09628-y		NOV 2019	10	Clinical Neurology	Neurosciences & Neurology	LH5IB	WOS:000520990100001	31773246				2021-06-18	
J	Sun, YX; Bai, LJ; Niu, X; Wang, ZN; Yin, B; Bai, GH; Zhang, DB; Gan, SQ; Sun, CZ; Wang, S; Zhu, F; Zhang, M				Sun, Yingxiang; Bai, Lijun; Niu, Xuan; Wang, Zhuonan; Yin, Bo; Bai, Guanghui; Zhang, Danbin; Gan, Shuoqiu; Sun, Chuanzhu; Wang, Shan; Zhu, Feng; Zhang, Ming			Elevated Serum Levels of Inflammation-Related Cytokines in Mild Traumatic Brain Injury Are Associated With Cognitive Performance	FRONTIERS IN NEUROLOGY			English	Article						inflammation-related cytokines; post-concussion symptoms; cognitive performance; mild traumatic brain injury; follow-up	WHITE-MATTER; MEMORY; PROFILES; INTERLEUKIN-1-BETA; NEUROINFLAMMATION; NEUROPROTECTION; ACTIVATION; SYMPTOMS; DISEASE	Mild traumatic brain injury (mTBI) is the most common neurological insult and leads to long-lasting cognitive impairments. The immune system modulates brain functions and plays a key role in cognitive deficits, however, the relationship between TBI-induced changes in inflammation-related cytokine levels and cognitive consequences is unclear. This was investigated in the present study in two cohorts of individuals within 1 week of mTBI (n = 52, n = 43) and 54 matched healthy control subjects. Patients with mTBI were also followed up at 1 and 3 months post-injury. Measures included cognitive assessments and a 9-plex panel of serum cytokines including interleukin (IL)-1 beta, IL-4, IL-6, IL-8, IL-10, IL-12, chemokine ligand 2 (CCL2), interferon-gamma (IFN-gamma), and tumor necrosis factor-alpha (TNF-alpha). The contribution of cytokine levels to cognitive function was evaluated by multivariate linear regression analysis. The results showed that serum levels of IL-1 beta, IL-6, and CCL2 were acutely elevated in mTBI patients relative to controls; CCL2 level was remained high over 3 months whereas IL-1 beta and IL-6 levels were declined by 3 months post-injury. A high level of CCL2 was associated with greater severity of post-concussion symptoms (which survived in the multiple testing correction); elevated IL-1 beta was associated with worse working memory in acute phase (which failed in correction); and acute high CCL2 level predicted higher information processing speed at 3 months post-injury (which failed in correction). Thus, acute serum cytokine levels are useful for evaluating post-concussion symptoms and predicting cognitive outcome in participants with mTBI.	[Sun, Yingxiang; Niu, Xuan; Wang, Zhuonan; Gan, Shuoqiu; Zhang, Ming] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Imaging, Xian, Shaanxi, Peoples R China; [Bai, Lijun; Gan, Shuoqiu; Sun, Chuanzhu; Wang, Shan] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Dept Biomed Engn, Key Lab Biomed Informat Engn,Minist Educ, Xian, Shaanxi, Peoples R China; [Yin, Bo] Wenzhou Med Univ, Affiliated Hosp 2, Dept Neurosurg, Wenzhou, Peoples R China; [Yin, Bo; Bai, Guanghui; Zhang, Danbin] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China; [Bai, Guanghui; Zhang, Danbin] Wenzhou Med Univ, Affiliated Hosp 2, Dept Radiol, Wenzhou, Peoples R China; [Zhu, Feng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Ctr Translat Med, Xian, Shaanxi, Peoples R China	Zhang, M (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Imaging, Xian, Shaanxi, Peoples R China.; Bai, LJ (corresponding author), Xi An Jiao Tong Univ, Sch Life Sci & Technol, Dept Biomed Engn, Key Lab Biomed Informat Engn,Minist Educ, Xian, Shaanxi, Peoples R China.; Zhu, F (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Ctr Translat Med, Xian, Shaanxi, Peoples R China.	bailijun@xjtu.edu.cn; zhufeng0714@163.com; zhangming01@mail.xjtu.edu.cn	Wang, Zhuonan/E-3691-2017; Bai, Lijun/C-5119-2015	Wang, Zhuonan/0000-0002-5745-4340; Bai, Lijun/0000-0001-8790-5424	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571752, 81771914, 81871331, 81571640]; Zhejiang Natural Science FoundationNatural Science Foundation of Zhejiang Province [LY15H090016]; Wenzhou Municipal Sci-Tech Bureau [Y20140577]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [xjj2018229, xzy022019045]	This research was supported by the National Natural Science Foundation of China (grant nos. 81571752, 81771914, 81871331, 81571752, and 81571640); Zhejiang Natural Science Foundation (grant nos. LY15H090016); Wenzhou Municipal Sci-Tech Bureau (grant no. Y20140577); and the Fundamental Research Funds for the Central Universities (grant nos. xjj2018229 and xzy022019045).	Amor S, 2014, IMMUNOLOGY, V142, P151, DOI 10.1111/imm.12233; Arfanakis K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073107; Arisi GM, 2014, EPILEPSY BEHAV, V38, P43, DOI 10.1016/j.yebeh.2014.01.017; ARNETT JA, 1995, PSYCHOL ASSESSMENT, V7, P220; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Briones TL, 2014, BRAIN BEHAV IMMUN, V35, P23, DOI 10.1016/j.bbi.2013.07.175; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Correia LCL, 2010, CLIN CHIM ACTA, V411, P540, DOI 10.1016/j.cca.2010.01.011; Deary IJ, 2002, NATURE, V418, P932, DOI 10.1038/418932a; Eisenberger NI, 2010, BRAIN BEHAV IMMUN, V24, P558, DOI 10.1016/j.bbi.2009.12.009; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Finnoff JT, 2011, PM&R, V3, pS452, DOI 10.1016/j.pmrj.2011.07.014; Goshen I, 2007, PSYCHONEUROENDOCRINO, V32, P1106, DOI 10.1016/j.psyneuen.2007.09.004; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Harman-Smith YE, 2013, J CLIN EXP NEUROPSYC, V35, P785, DOI 10.1080/13803395.2013.824554; Hoseth EZ, 2016, ACTA PSYCHIAT SCAND, V133, P53, DOI 10.1111/acps.12467; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Joy S, 2004, ARCH CLIN NEUROPSYCH, V19, P759, DOI 10.1016/j.acn.2003.09.009; Juengst SB, 2015, J HEAD TRAUMA REHAB, V30, P207, DOI 10.1097/HTR.0000000000000031; Kim YS, 2017, PSYCHOGERIATRICS, V17, P224, DOI 10.1111/psyg.12218; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kochunov P, 2017, JAMA PSYCHIAT, V74, P958, DOI 10.1001/jamapsychiatry.2017.2228; Kulesh A, 2018, J STROKE CEREBROVASC, V27, P1752, DOI 10.1016/j.jstrokecerebrovasdis.2018.02.004; Kumar RG, 2016, BRAIN BEHAV IMMUN, V53, P183, DOI 10.1016/j.bbi.2015.12.008; Kumar RG, 2015, J HEAD TRAUMA REHAB, V30, P369, DOI 10.1097/HTR.0000000000000067; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Lyon DE, 2016, J NEUROIMMUNOL, V301, P74, DOI 10.1016/j.jneuroim.2016.11.002; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; Mayer CL, 2013, HEADACHE, V53, P1523, DOI 10.1111/head.12173; Miller AH, 2009, BIOL PSYCHIAT, V65, P732, DOI 10.1016/j.biopsych.2008.11.029; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morris GP, 2013, NEUROBIOL LEARN MEM, V105, P40, DOI 10.1016/j.nlm.2013.07.002; Murray KN, 2013, MOL CELL NEUROSCI, V53, P14, DOI 10.1016/j.mcn.2012.09.004; Mustafa T, 2013, ADV PHARMACOL, V68, P445, DOI 10.1016/B978-0-12-411512-5.00021-X; Nilsson LG, 2006, NEUROPSYCHOLOGY, V20, P645, DOI 10.1037/0894-4105.20.6.645; Petrone AB, 2017, NEUROREHABILITATION, V40, P501, DOI 10.3233/NRE-171437; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; Russo MV, 2018, NAT IMMUNOL, V19, P442, DOI 10.1038/s41590-018-0086-2; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Santarsieri M, 2015, BRAIN BEHAV IMMUN, V45, P15, DOI 10.1016/j.bbi.2014.09.003; Schnabel RB, 2009, CIRC-CARDIOVASC GENE, V2, P229, DOI 10.1161/CIRCGENETICS.108.804245; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P459, DOI 10.1038/jcbfm.2009.240; Singh K, 2016, EXP NEUROL, V275, P427, DOI 10.1016/j.expneurol.2015.07.016; Stalnacke BM, 2007, J REHABIL MED, V39, P405, DOI 10.2340/16501977-0057; Su SH, 2014, BRAIN BEHAV IMMUN, V38, P111, DOI 10.1016/j.bbi.2014.01.009; Tasci A, 2003, NEUROL RES, V25, P871, DOI 10.1179/016164103771953998; Theadom A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191655; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015	53	14	15	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	OCT 23	2019	10								1120	10.3389/fneur.2019.01120			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	JK2IO	WOS:000494670900001	31708858	DOAJ Gold, Green Published			2021-06-18	
J	Muraoka, S; Jedrychowski, MP; Tatebe, H; DeLeo, AM; Ikezu, S; Tokuda, T; Gygi, SP; Stern, RA; Ikezu, T				Muraoka, Satoshi; Jedrychowski, Mark P.; Tatebe, Harutsugu; DeLeo, Annina M.; Ikezu, Seiko; Tokuda, Takahiko; Gygi, Steven P.; Stern, Robert A.; Ikezu, Tsuneya			Proteomic Profiling of Extracellular Vesicles Isolated From Cerebrospinal Fluid of Former National Football League Players at Risk for Chronic Traumatic Encephalopathy	FRONTIERS IN NEUROSCIENCE			English	Article						chronic traumatic encephalopathy; cerebrospinal fluid; extracellular vesicles; microtubule-associated protein tau; proteome; tauopathy; football	EXOSOMAL TAU; PATHOLOGY; CLEAVAGE; DISEASE; FRAGMENTS; BETA; CELL	Chronic Traumatic Encephalopathy (CTE) is a tauopathy that affects individuals with a history of repetitive mild traumatic brain injury, such as American football players. Initial neuropathologic changes in CTE include perivascular deposition of phosphorylated microtubule-associated protein tau (p-tau) neurofibrillary tangles and other aggregates in neurons, astrocytes and cell processes in an irregular pattern often at the depths of the cortical sulci. In later stages, the p-tau depositions become widespread and is associated with neurodegeneration. Extracellular vesicles (EVs) are known to carry neuropathogenic molecules, most notably p-tau. We therefore examined the protein composition of EVs isolated from the cerebrospinal fluid (CSF) of former National Football League (NFL) players with cognitive and neuropsychiatric dysfunction, and an age-matched control group (CTRL) with no history of contact sports or traumatic brain injury. EVs were isolated from the CSF samples using an affinity purification kit. Total tau (t-tau) and tau phosphorylated on threonine(181) (p-tau(181)) in CSF-derived EVs from former NFL players and CTRL participants were measured by ultrasensitive immunoassay. The t-tau and p-tau(181) levels of CSF-derived EV were positively correlated with the t-tau and p-tau(181) levels of total CSF in former NFL players, respectively, but not in the CTRL group. 429 unique proteins were identified from CSF-derived EVs and quantified by TMT-10 plex method. The identified protein molecules were significantly enriched for the extracellular exosome molecules, Alzheimer's disease pathway and Age/Telomere Length ontology as determined by DAVID Gene Ontology analysis. Ingenuity pathway analysis of the differentially expressed EV proteins revealed enrichment of canonical liver/retinoid X receptor activation pathway. Upstream effect analysis predicted MAPT (tau) as an upstream regulator in former NFL players. These data will be useful for understanding the EV-mediated disease spread and development of novel EV biomarkers for CTE and related disorders.	[Muraoka, Satoshi; DeLeo, Annina M.; Ikezu, Seiko; Ikezu, Tsuneya] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA; [Jedrychowski, Mark P.; Gygi, Steven P.] Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA; [Tatebe, Harutsugu] Kyoto Prefectural Univ Med, Dept Med Innovat & Translat Med Sci, Kyoto, Japan; [Tokuda, Takahiko] Kyoto Prefectural Univ Med, Dept Mol Pathobiol Brain Dis, Kyoto, Japan; [Stern, Robert A.; Ikezu, Tsuneya] Boston Univ, Sch Med, Dept Neurol, Alzheimers Dis Ctr,CTE Ctr, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg & Anat & Neurobiol, Boston, MA 02118 USA	Ikezu, T (corresponding author), Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA.; Ikezu, T (corresponding author), Boston Univ, Sch Med, Dept Neurol, Alzheimers Dis Ctr,CTE Ctr, Boston, MA 02118 USA.	tikezu@bu.edu	, Bob/ABA-8507-2020		Aethlon Medical, Inc.; Cure Alzheimer's Fund; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RF1AG054199, R56AG057469, R01NS078337, U01NS093334, P30AG13846]; AMED [17dk0207042s0101]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM067945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R56AG057469] Funding Source: NIH RePORTER	This work was in part funded by the Aethlon Medical, Inc. (TI), Cure Alzheimer's Fund (TI), NIH RF1AG054199 (TI), NIH R56AG057469 (TI), R01NS078337 (RS), U01NS093334 (RS), P30AG13846 (RS), and AMED 17dk0207042s0101 (TT).	Alosco ML, 2018, ALZHEIMERS DEMENT, V14, P1159, DOI 10.1016/j.jalz.2018.05.004; Alosco ML, 2017, J NEUROTRAUM, V34, P772, DOI 10.1089/neu.2016.4536; Asai H, 2015, NAT NEUROSCI, V18, P1584, DOI 10.1038/nn.4132; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Chen ZC, 2019, ALZHEIMERS DEMENT, V15, P487, DOI 10.1016/j.jalz.2018.09.010; Chiasserini D, 2014, J PROTEOMICS, V106, P191, DOI 10.1016/j.jprot.2014.04.028; Cicognola C, 2019, ACTA NEUROPATHOL, V137, P279, DOI 10.1007/s00401-018-1948-2; Dayon L, 2019, J PROTEOME RES, V18, P1162, DOI 10.1021/acs.jproteome.8b00809; Deleo AM, 2018, J NEUROIMMUNE PHARM, V13, P292, DOI 10.1007/s11481-017-9768-z; Delpech JC, 2019, TRENDS NEUROSCI, V42, P361, DOI 10.1016/j.tins.2019.02.007; Elias JE, 2007, NAT METHODS, V4, P207, DOI 10.1038/nmeth1019; Falcon B, 2019, NATURE, V568, P420, DOI 10.1038/s41586-019-1026-5; Ferreira A, 2011, MOL MED, V17, P676, DOI 10.2119/molmed.2010.00220; Galasko DR, 2017, NAT REV NEUROL, V13, P131, DOI 10.1038/nrneurol.2017.11; Garg S, 2011, NEUROBIOL AGING, V32, P1, DOI 10.1016/j.neurobiolaging.2010.09.008; Gill J, 2018, BRAIN INJURY, V32, P1277, DOI 10.1080/02699052.2018.1471738; Huttlin EL, 2010, CELL, V143, P1174, DOI 10.1016/j.cell.2010.12.001; Kim DK, 2015, BIOINFORMATICS, V31, P933, DOI 10.1093/bioinformatics/btu741; Ko J, 2018, LAB CHIP, V18, P3617, DOI 10.1039/c8lc00672e; Lee J, 2016, CLIN CHIM ACTA, V462, P118, DOI 10.1016/j.cca.2016.09.001; Ling H, 2017, NEUROPATH APPL NEURO, V43, P467, DOI 10.1111/nan.12425; Manek R, 2018, MOL NEUROBIOL, V55, P6112, DOI 10.1007/s12035-017-0821-y; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McAlister GC, 2014, ANAL CHEM, V86, P7150, DOI 10.1021/ac502040v; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Moutinho M, 2017, J LIPID RES, V58, P1937, DOI 10.1194/jlr.R075556; Nakai W, 2016, SCI REP-UK, V6, DOI 10.1038/srep33935; Nam KN, 2016, SCI REP-UK, V6, DOI 10.1038/srep24048; Paton D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067364; Paulo JA, 2018, PROTEOMICS, V18, DOI 10.1002/pmic.201700326; Perez-Gonzalez R, 2012, J BIOL CHEM, V287, P43108, DOI 10.1074/jbc.M112.404467; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Quek C, 2017, BIOCHEM BIOPH RES CO, V483, P1178, DOI 10.1016/j.bbrc.2016.09.090; Stern RA, 2019, NEW ENGL J MED, V380, P1716, DOI 10.1056/NEJMoa1900757; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; Street JM, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-5; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; Tatebe H, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0206-8; Wilhelmus MMM, 2009, BRAIN PATHOL, V19, P612, DOI 10.1111/j.1750-3639.2008.00197.x; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.11772/j.issn.1001-9081.2014.07.1929, 10.1523/JNEUROSCI.1860-14.2014]; Zhang ZT, 2014, NAT MED, V20, P1254, DOI 10.1038/nm.3700; Zhao XH, 2016, NAT MED, V22, P1268, DOI 10.1038/nm.4199	47	14	14	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-453X		FRONT NEUROSCI-SWITZ	Front. Neurosci.	OCT 9	2019	13								1059	10.3389/fnins.2019.01059			12	Neurosciences	Neurosciences & Neurology	JO4UZ	WOS:000497576800001	31649498	DOAJ Gold, Green Published			2021-06-18	
J	Rich, AM; Filben, TM; Miller, LE; Tomblin, BT; Van Gorkom, AR; Hurst, MA; Barnard, RT; Kohn, DS; Urban, JE; Stitzel, JD				Rich, Andrea M.; Filben, Tanner M.; Miller, Logan E.; Tomblin, Brian T.; Van Gorkom, Aaron R.; Hurst, Michael A.; Barnard, Ryan T.; Kohn, Dena S.; Urban, Jillian E.; Stitzel, Joel D.			Development, Validation and Pilot Field Deployment of a Custom Mouthpiece for Head Impact Measurement	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Mouthpiece; Soccer; Pediatric; Subconcussive impacts; Concussion; Instrumentation; Head impact exposure; Head kinematics	ACCELERATION MEASUREMENT; LABORATORY EVALUATION; SYSTEM; CONCUSSIONS; KINEMATICS; MOUTHGUARD; SCENARIO; DEVICE	The objective of this study was to develop a mouthpiece sensor with improved head kinematic measurement for use in non-helmeted and helmeted sports through laboratory validation and pilot field deployment in female youth soccer. For laboratory validation, data from the mouthpiece sensor was compared to standard sensors mounted in a headform at the center of gravity as the headform was struck with a swinging pendulum. Linear regression between peak kinematics measured from the mouthpiece and headform showed strong correlation, with r(2) values of 0.95 (slope = 1.02) for linear acceleration, 1.00 (slope = 1.00) for angular velocity, and 0.97 (slope = 0.96) for angular acceleration. In field deployment, mouthpiece data were collected from four female youth soccer players and time-synchronized with film. Film-verified events (n = 915) were observed over 9 practices and 5 games, and 632 were matched to a corresponding mouthpiece event. This resulted in an overall sensitivity of 69.2% and a positive predictive value of 80.3%. This validation and pilot field deployment data demonstrates that the mouthpiece provides highly accurate measurement of on-field head impact data that can be used to further study the effects of impact exposure in both helmeted and non-helmeted sports.	[Rich, Andrea M.; Filben, Tanner M.; Miller, Logan E.; Tomblin, Brian T.; Van Gorkom, Aaron R.; Barnard, Ryan T.; Kohn, Dena S.; Urban, Jillian E.; Stitzel, Joel D.] Wake Forest Sch Med, Dept Biomed Engn, 575 N Patterson Ave,Suite 120, Winston Salem, NC 27101 USA; [Rich, Andrea M.; Filben, Tanner M.; Miller, Logan E.; Tomblin, Brian T.; Van Gorkom, Aaron R.; Urban, Jillian E.; Stitzel, Joel D.] Wake Forest Univ, Sch Biomed Engn & Sci, Virginia Tech, 575 N Patterson Ave,Suite 120, Winston Salem, NC 27101 USA; [Barnard, Ryan T.] Wake Forest Sch Med, Dept Biostat & Data Sci, 525 Vine St, Winston Salem, NC 27101 USA; [Hurst, Michael A.] Hurst Dent Lab, 946 Brookstown Ave, Winston Salem, NC 27101 USA	Stitzel, JD (corresponding author), Wake Forest Sch Med, Dept Biomed Engn, 575 N Patterson Ave,Suite 120, Winston Salem, NC 27101 USA.	jstitzel@wakehealth.edu		Stitzel, Joel/0000-0001-9762-3033	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS091602-01A1, R01NS082453, R01NS094410]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS091602, R01NS082453, R01NS094410] Funding Source: NIH RePORTER	The authors thank the Virginia Tech Helmet Lab for their assistance in conducting the laboratory validation tests. They would also like to thank Konstantia Strates for her efforts in study coordination. Special thanks to the Childress Institute for Pediatric Trauma at Wake Forest Baptist Medical Center for providing support for this study. The National Institute of Neurological Disorders and Stroke of the National Institutes of Health, through Award Numbers R01NS091602-01A1, R01NS082453 and R01NS094410, supported members of the research team who contributed to this study. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The mouthpiece technology presented herein is patent pending.	Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Bartsch Adam, 2014, Stapp Car Crash J, V58, P1; Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Campbell KR, 2016, ANN BIOMED ENG, V44, P1246, DOI 10.1007/s10439-015-1391-7; Chrisman SPD, 2019, CLIN J SPORT MED, V29, P3, DOI 10.1097/JSM.0000000000000497; Chrisman SPD, 2016, J CHILD NEUROL, V31, P971, DOI 10.1177/0883073816634857; Covassin T, 2003, J ATHL TRAINING, V38, P238; Engineers S. O. A., 1995, INSTR IMP TEST 1; Federation Internationale de Football Association-FIFA, 2007, FIFA BIG COUNT 2006; Funk JR, 2011, ANN BIOMED ENG, V39, P766, DOI 10.1007/s10439-010-0183-3; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Harriss A, 2019, MUSCULOSKEL SCI PRAC, V40, P53, DOI 10.1016/j.msksp.2019.01.009; Higgins M, 2007, J ATHL TRAINING, V42, P5; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Kuo C, 2016, J BIOMECH, V49, P1845, DOI 10.1016/j.jbiomech.2016.04.017; Lamond LC, 2018, J ATHL TRAINING, V53, P115, DOI 10.4085/1062-6050-90-17; Lightman K, 2016, IEEE SPECTRUM, V53, P48, DOI 10.1109/MSPEC.2016.7420400; Mainwaring L, 2018, INT J PSYCHOPHYSIOL, V132, P39, DOI 10.1016/j.ijpsycho.2018.01.007; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Miller L., 2019, RES SPORTS MED, DOI [10.1080/15438627.2019.159083, DOI 10.1080/15438627.2019.159083]; Miller LE, 2018, J BIOMECH ENG-T ASME, V140, DOI 10.1115/1.4039165; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Nevins D, 2015, PROCEDIA ENGINEER, V112, P175, DOI 10.1016/j.proeng.2015.07.195; O'Kane JW, 2016, PHYSICIAN SPORTSMED, V44, P190, DOI 10.1080/00913847.2016.1149423; Press JN, 2017, CLIN J SPORT MED, V27, P104, DOI 10.1097/JSM.0000000000000313; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Rowson S., 2017, P I MECH ENG P-J SPO, DOI [10.1177/1754337, DOI 10.1177/1754337]; Rowson S, 2014, J NEUROSURG, V120, P919, DOI 10.3171/2014.1.JNS13916; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Self BP, 2006, ENG SPORT 6, V6, P81; Siegmund GP, 2016, ANN BIOMED ENG, V44, P1257, DOI 10.1007/s10439-015-1420-6; Stewart WF, 2017, NEUROLOGY, V88, P901, DOI 10.1212/WNL.0000000000003657; Triax Technologies, 2014, LAB VAL SIM G HEAD I; Tyson AM, 2018, J APPL BIOMECH, V34, P320, DOI 10.1123/jab.2017-0256; Wu LC, 2016, J BIOMECH, V49, P2918, DOI 10.1016/j.jbiomech.2016.07.004; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3; Wu LC, 2014, IEEE T BIO-MED ENG, V61, P2659, DOI 10.1109/TBME.2014.2320153; Yang YT, 2016, JAMA PEDIATR, V170, P413, DOI 10.1001/jamapediatrics.2016.0338; Yoganandan N, 2009, J BIOMECH, V42, P1177, DOI 10.1016/j.jbiomech.2009.03.029	42	14	14	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	OCT	2019	47	10			SI		2109	2121		10.1007/s10439-019-02313-1			13	Engineering, Biomedical	Engineering	JQ0HT	WOS:000498636800007	31297724				2021-06-18	
J	Wartenberg, KE; Hwang, DY; Haeusler, KG; Muehlschlegel, S; Sakowitz, OW; Madzar, D; Hamer, HM; Rabinstein, AA; Greer, DM; Hemphill, JC; Meixensberger, J; Varelas, PN				Wartenberg, Katja E.; Hwang, David Y.; Haeusler, Karl Georg; Muehlschlegel, Susanne; Sakowitz, Oliver W.; Madzar, Dominik; Hamer, Hajo M.; Rabinstein, Alejandro A.; Greer, David M.; Hemphill, J. Claude, III; Meixensberger, Juergen; Varelas, Panayiotis N.			Gap Analysis Regarding Prognostication in Neurocritical Care: A Joint Statement from the German Neurocritical Care Society and the Neurocritical Care Society	NEUROCRITICAL CARE			English	Article						Prognostication; Self-fulfilling prophecy; Outcome predictors; Comorbidities	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; HEMORRHAGE GRADING SCALE; CLINICAL-PREDICTION RULE; SHARED DECISION-MAKING; IN-HOSPITAL MORTALITY; ACUTE ISCHEMIC-STROKE; GLASGOW COMA SCALE; INTRACEREBRAL HEMORRHAGE; SUBARACHNOID HEMORRHAGE	Background/Objective Prognostication is a routine part of the delivery of neurocritical care for most patients with acute neurocritical illnesses. Numerous prognostic models exist for many different conditions. However, there are concerns about significant gaps in knowledge regarding optimal methods of prognostication. Methods As part of the Arbeitstagung NeuroIntensivMedizin meeting in February 2018 in Wurzburg, Germany, a joint session on prognostication was held between the German NeuroIntensive Care Society and the Neurocritical Care Society. The purpose of this session was to provide presentations and open discussion regarding existing prognostic models for eight common neurocritical care conditions (aneurysmal subarachnoid hemorrhage, intracerebral hemorrhage, acute ischemic stroke, traumatic brain injury, traumatic spinal cord injury, status epilepticus, Guillain-Barre Syndrome, and global cerebral ischemia from cardiac arrest). The goal was to develop a qualitative gap analysis regarding prognostication that could help inform a future framework for clinical studies and guidelines. Results Prognostic models exist for all of the conditions presented. However, there are significant gaps in prognostication in each condition. Furthermore, several themes emerged that crossed across several or all diseases presented. Specifically, the self-fulfilling prophecy, lack of accounting for medical comorbidities, and absence of integration of in-hospital care parameters were identified as major gaps in most prognostic models. Conclusions Prognostication in neurocritical care is important, and current prognostic models are limited. This gap analysis provides a summary assessment of issues that could be addressed in future studies and evidence-based guidelines in order to improve the process of prognostication.	[Wartenberg, Katja E.] Univ Leipzig, Dept Neurol, Neurocrit Care & Stroke Unit, Liebigstr 20, D-04103 Leipzig, Germany; [Hwang, David Y.] Yale Sch Med, Dept Neurol, POB 208018, New Haven, CT 06520 USA; [Haeusler, Karl Georg] Univ Klinikum Wurzburg, Dept Neurol, Josef Schneider Str 11, D-97080 Wurzburg, Germany; [Muehlschlegel, Susanne] Univ Massachusetts, Sch Med, Dept Neurol Anesthesiol & Surg, 55 Lake Ave North, Worcester, MA 01655 USA; [Sakowitz, Oliver W.] RKH Klinikum Ludwigsburg, Neurosurg Ctr Ludwigsburg Heilbronn, Posilipostr 4, D-71640 Ludwigsburg, Germany; [Madzar, Dominik; Hamer, Hajo M.] Univ Erlangen Nurnberg, Dept Neurol, Schwabachanlage 6, D-91054 Erlangen, Germany; [Rabinstein, Alejandro A.] Mayo Clin, Dept Neurol, 200 First St SW, Rochester, MN 55905 USA; [Greer, David M.] Boston Univ, Med Ctr, Dept Neurol, 72 East Concord St, Boston, MA 02118 USA; [Hemphill, J. Claude, III] Univ Calif San Francisco, Dept Neurol, 1001 Potrero Ave, San Francisco, CA 94110 USA; [Meixensberger, Juergen] Univ Leipzig, Dept Neurosurg, Liebigstr 20, D-04103 Leipzig, Germany; [Varelas, Panayiotis N.] Henry Ford Hosp, Dept Neurol & Neurosurg, 2799 W Grand Blvd Neurosurg K-11, Detroit, MI 48202 USA	Wartenberg, KE (corresponding author), Univ Leipzig, Dept Neurol, Neurocrit Care & Stroke Unit, Liebigstr 20, D-04103 Leipzig, Germany.	katja.wartenberg@medizin.uni-leipzig.de	Hwang, David/ABG-6957-2020	Hwang, David/0000-0002-2150-4289; Hamer, Hajo/0000-0003-1709-8617; Hemphill, Claude/0000-0003-4019-7525	National Institutes of Health/National Institute of Child Health and Human Development (NIH/NICHD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5K23HD080971]; UMass Memorial Medical Group (Prize for Academic Collaboration and Excellence (PACE Prize)); DARPAUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [HR001117S0032WASH-FP-031]; National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS102574-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD080971] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001863] Funding Source: NIH RePORTER	Susanne Muehlschlegel received Grant support from National Institutes of Health/National Institute of Child Health and Human Development (NIH/NICHD) Grant 5K23HD080971, UMass Memorial Medical Group (Prize for Academic Collaboration and Excellence (PACE Prize) and DARPA (HR001117S0032WASH-FP-031). David Greer received Grant support from National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) Grant (R01 NS102574-01A1).	[Anonymous], IMP PROGN CALC; [Anonymous], 2012, INJURY NCDE TB; Bar B, 2011, STROKE, V42, P2944, DOI 10.1161/STROKEAHA.111.617639; Belliveau T, 2016, ARCH PHYS MED REHAB, V97, P1663, DOI 10.1016/j.apmr.2016.04.014; Betjemann JP, 2015, LANCET NEUROL, V14, P615, DOI 10.1016/S1474-4422(15)00042-3; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Bruce SS, 2011, NEUROCRIT CARE, V15, P498, DOI 10.1007/s12028-011-9518-7; Callaway CW, 2015, CIRCULATION, V132, pS465, DOI 10.1161/CIR.0000000000000262; Cheung RTF, 2003, STROKE, V34, P1717, DOI 10.1161/01.STR.0000078657.22835.B9; Chu SY, 2016, SEMIN NEUROL, V36, P254, DOI 10.1055/s-0036-1581992; Claassen J, 2004, CRIT CARE MED, V32, P832, DOI 10.1097/01.CCM.0000114830.48833.8A; CRASH calculator, CRASH CALC; Cronberg T, 2013, RESUSCITATION, V84, P867, DOI 10.1016/j.resuscitation.2013.01.019; Degos V, 2012, STROKE, V43, P1253, DOI 10.1161/STROKEAHA.111.638197; Dengler NF, 2018, EUR J NEUROL, V25, P111, DOI 10.1111/ene.13471; Durand MC, 2006, LANCET NEUROL, V5, P1021, DOI 10.1016/S1474-4422(06)70603-2; Fagerlin A, 2005, MED DECIS MAKING, V25, P398, DOI 10.1177/0272989X05278931; Fahey M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0185402; Fallenius M, 2017, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-017-0448-z; Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0; Fonarow GC, 2014, STROKE, V45, P1589, DOI 10.1161/STR.0000000000000014; Gao Q, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1221-9; Garrett JS, 2013, NEUROCRIT CARE, V19, P329, DOI 10.1007/s12028-013-9926-y; Gonzalez-Cuevas M, 2016, EUR J NEUROL, V23, P1534, DOI 10.1111/ene.13073; Gotoh O, 1996, NEUROSURGERY, V39, P19, DOI 10.1097/00006123-199607000-00005; Greer DM, 2013, RESUSCITATION, V84, P1546, DOI 10.1016/j.resuscitation.2013.07.028; Griggs RC, 2012, NEUROLOGY, V79, P2293, DOI 10.1212/WNL.0b013e31827a3c0a; Gupta VP, 2017, WORLD NEUROSURG, V101, P577, DOI 10.1016/j.wneu.2017.02.082; Han JX, 2018, WORLD NEUROSURG, V109, pE601, DOI 10.1016/j.wneu.2017.10.039; Heeley E, 2015, INT J STROKE, V10, P1101, DOI 10.1111/ijs.12518; Hemphill JC, 2017, NEUROCRIT CARE, V26, P157, DOI 10.1007/s12028-017-0384-9; Hemphill JC, 2009, EMERG MED CLIN N AM, V27, P27, DOI 10.1016/j.emc.2008.08.009; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Hicks KE, 2017, SPINE J, V17, P1383, DOI 10.1016/j.spinee.2017.05.031; Hirai S, 1996, NEUROSURGERY, V39, P441, DOI 10.1097/00006123-199609000-00002; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Hwang BY, 2010, NEUROCRIT CARE, V13, P141, DOI 10.1007/s12028-010-9382-x; Hwang DY, 2016, NEUROLOGY, V86, P126, DOI 10.1212/WNL.0000000000002266; INGALL TJ, 1989, STROKE, V20, P718, DOI 10.1161/01.STR.20.6.718; Inoa V, 2014, CEREBROVASC DIS, V37, P251, DOI 10.1159/000358869; Jaja BNR, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5745; Jampathong N, 2018, BMC NEUROL, V18, DOI 10.1186/s12883-018-1032-5; Ji RJ, 2013, CRIT CARE, V17, DOI 10.1186/cc13130; Kelly AG, 2012, NEUROLOGY, V79, P941, DOI 10.1212/WNL.0b013e318266fc40; Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024; Khan MW, 2017, NEUROL CLIN, V35, P825, DOI 10.1016/j.ncl.2017.06.014; Lagares A, 2005, ACTA NEUROCHIR, V147, P5, DOI 10.1007/s00701-004-0417-y; Lagares A, 2001, ACTA NEUROCHIR, V143, P665, DOI 10.1007/s007010170044; Lawn ND, 2001, ARCH NEUROL-CHICAGO, V58, P893, DOI 10.1001/archneur.58.6.893; Lee VH, 2014, NEUROCRIT CARE, V21, P14, DOI 10.1007/s12028-013-9952-9; Leitinger M, 2015, NEUROCRIT CARE, V22, P273, DOI 10.1007/s12028-014-0080-y; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas MB, 2017, CEREBROVASC DIS, V43, P110, DOI 10.1159/000452679; Marino RJ, 2002, J SPINAL CORD MED S1, V26, pS50; Mascitelli JR, 2020, NEUROSURGERY, V86, P101, DOI 10.1093/neuros/nyy600; Masotti L, 2017, ACTA NEUROL BELG, V117, P325, DOI 10.1007/s13760-016-0609-2; Masotti L, 2015, J STROKE CEREBROVASC, V24, P1100, DOI 10.1016/j.jstrokecerebrovasdis.2015.01.013; Mattishent K, 2015, J CLIN NEUROL, V11, P339, DOI 10.3988/jcn.2015.11.4.339; Mikati AG, 2019, NEUROSURGERY, V85, pE872, DOI 10.1093/neuros/nyz127; Morgenstern LB, 2015, NEUROLOGY, V84, P1739, DOI 10.1212/WNL.0000000000001525; Moskowitz J, 2018, MDM POLICY PRACT, V3; Muehlschlegel S, 2016, NEUROLOGY, V87, P2244, DOI 10.1212/WNL.0000000000003355; Muehlschlegel S, 2015, NEUROCRIT CARE, V23, P127, DOI 10.1007/s12028-014-0097-2; Naval NS, 2014, J STROKE CEREBROVASC, V23, P902, DOI 10.1016/j.jstrokecerebrovasdis.2013.07.035; Naval NS, 2013, J CRIT CARE, V28, P182, DOI 10.1016/j.jcrc.2012.05.008; Nolan JP, 2015, INTENS CARE MED, V41, P2039, DOI 10.1007/s00134-015-4051-3; Pan K, 2017, J STROKE CEREBROVASC, V26, P2563, DOI 10.1016/j.jstrokecerebrovasdis.2017.06.005; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158; Quinn TJ, 2017, NEUROLOGY, V89, P997, DOI 10.1212/WNL.0000000000004332; Rajabally YA, 2012, J NEUROL NEUROSUR PS, V83, P711, DOI 10.1136/jnnp-2011-301882; Reindl C, 2018, SEIZURE-EUR J EPILEP, V56, P92, DOI 10.1016/j.seizure.2018.01.024; Rossetti AO, 2006, NEUROLOGY, V66, P1736, DOI 10.1212/01.wnl.0000223352.71621.97; Rost NS, 2008, STROKE, V39, P2304, DOI 10.1161/STROKEAHA.107.512202; Ruiz-Sandoval JL, 2007, STROKE, V38, P1641, DOI 10.1161/STROKEAHA.106.478222; Safatli Diaa A, 2016, Surg Neurol Int, V7, pS510, DOI 10.4103/2152-7806.187493; Sano H, 2015, WORLD NEUROSURG, V83, P801, DOI 10.1016/j.wneu.2014.12.032; Satopaa J, 2017, J NEUROL SCI, V379, P103, DOI 10.1016/j.jns.2017.05.034; Sembill JA, 2017, NEUROLOGY, V89, P423, DOI 10.1212/WNL.0000000000004174; Soliman F, 2017, NEUROHOSPITALIST, V7, P169, DOI 10.1177/1941874417708128; Spatz ES, 2017, JAMA-J AM MED ASSOC, V317, P1309, DOI 10.1001/jama.2017.0616; Starke RM, 2009, J CLIN NEUROSCI, V16, P894, DOI 10.1016/j.jocn.2008.10.010; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Strauss J, 2009, CRIT CARE MED, V37, P2436, DOI 10.1097/CCM.0b013e3181a0fdfc; Strbian D, 2012, NEUROLOGY, V78, P427, DOI 10.1212/WNL.0b013e318245d2a9; Sun H, 2016, J NEUROTRAUM, V33, P1535, DOI 10.1089/neu.2015.4164; Sutter R, 2014, NEUROLOGY, V82, P656, DOI 10.1212/WNL.0000000000000009; Sutter R, 2013, CRIT CARE MED, V41, pE475, DOI 10.1097/CCM.0b013e31829eca06; Takagi K, 1999, J NEUROSURG, V90, P680, DOI 10.3171/jns.1999.90.4.0680; Taylor CJ, 2011, NEUROCRIT CARE, V14, P341, DOI 10.1007/s12028-010-9377-7; Teale EA, 2012, CLIN REHABIL, V26, P771, DOI 10.1177/0269215511433068; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; Trinka E, 2015, EPILEPSIA, V56, P1515, DOI 10.1111/epi.13121; Turgeon AF, 2013, CRIT CARE MED, V41, P1086, DOI 10.1097/CCM.0b013e318275d046; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; van den Berg B, 2013, NEUROLOGY, V80, P1650, DOI 10.1212/WNL.0b013e3182904fcc; van Heuven AW, 2008, STROKE, V39, P1347, DOI 10.1161/STROKEAHA.107.498345; van Koningsveld R, 2007, LANCET NEUROL, V6, P589, DOI 10.1016/S1474-4422(07)70130-8; van Middendorp JJ, 2011, LANCET, V377, P1004, DOI 10.1016/S0140-6736(10)62276-3; Walgaard C, 2011, NEUROLOGY, V76, P968, DOI 10.1212/WNL.0b013e3182104407; Walgaard C, 2010, ANN NEUROL, V67, P781, DOI 10.1002/ana.21976; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Weimar C, 2006, J NEUROL NEUROSUR PS, V77, P601, DOI 10.1136/jnnp.2005.081117; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; Wijdicks EFM, 2011, NEUROLOGY, V77, P84, DOI 10.1212/WNL.0b013e318220ac06; Wilson JR, 2012, J NEUROSURG-SPINE, V17, P46, DOI 10.3171/2012.4.AOSPINE1246; Witsch J, 2016, ANN NEUROL, V80, P46, DOI 10.1002/ana.24675; Yogendrakumar V, 2018, CRIT CARE MED, V46, pE310, DOI 10.1097/CCM.0000000000002962; Zahuranec DB, 2016, NEUROLOGY, V86, P1864, DOI 10.1212/WNL.0000000000002676; Zeiler FA, 2017, NEUROCRIT CARE, V27, P381, DOI 10.1007/s12028-017-0396-5; Zis P, 2014, J STROKE CEREBROVASC, V23, P1928, DOI 10.1016/j.jstrokecerebrovasdis.2014.02.006	114	14	14	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2019	31	2					231	244		10.1007/s12028-019-00769-6			14	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	JA0OX	WOS:000487511700001	31368059	Other Gold, Green Published			2021-06-18	
J	Desai, N; Wiebe, DJ; Corwin, DJ; Lockyer, JE; Grady, MF; Master, CL				Desai, Natasha; Wiebe, Douglas J.; Corwin, Daniel J.; Lockyer, Julia E.; Grady, Matthew F.; Master, Christina L.			Factors Affecting Recovery Trajectories in Pediatric Female Concussion	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						pediatric concussion; sex differences; vestibular examination; vision examination; female concussion	SPORT; EPIDEMIOLOGY; SEVERITY; OUTCOMES	Objective: Up to one-third of children with concussion have persistent postconcussion symptoms lasting beyond 4 weeks. Females have been shown to have prolonged concussion recovery compared with males. This study examined characteristics in pediatric athletes with concussion to investigate the underlying factors that may contribute to this difference and their relation to recovery trajectories in females compared with males. Design: A retrospective cohort study of pediatric patients with sportsrelated concussion (SRC). Setting: A subspecialty pediatric concussion program. Subjects: One hundred ninety-two records were reviewed, 75 females and 117 males, ages 7 to 18 years old. Assessment of Risk Factors: Sex of patient, time to presentation to specialty care after injury, presence of vision, and vestibular deficits on initial clinical examination. Main Outcome Measures: The main outcome of interest was time to clinical recovery, defined by resolution of symptoms, recovery of physical examination deficits, including vision and vestibular examination, recovery of neurocognitive function, and return to school, exercise, and sport. Results: Pediatric females, on average, presented later to specialty care for evaluation after SRC than males. Females also took longer to recover on 5 markers of recovery: time to return to school without accommodations, time to return to noncontact exercise, time to return to full sport, time to recovery of neurocognitive function on computerized testing, and time to clinical recovery of vision and vestibular deficits on examination including smooth pursuits, saccades, gaze stability, near point of convergence, and balance. These sex-based differences in recovery disappeared when controlling for time to presentation to specialty care. Conclusions: In this cohort of pediatric patients, ages 7 to 18 years old with SRC, females took longer to recover than males. Our results indicate, however, that a modifiable extrinsic factor, time to presentation to specialty care, may contribute to this difference in recovery between the sexes.	[Desai, Natasha] Columbia Univ, Dept Orthoped, Div Sports Med, Med Ctr, New York, NY 10032 USA; [Wiebe, Douglas J.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Corwin, Daniel J.] Childrens Hosp Philadelphia, Div Emergency Med, Philadelphia, PA 19104 USA; [Lockyer, Julia E.; Grady, Matthew F.; Master, Christina L.] Childrens Hosp Philadelphia, Div Orthoped Surg & Sports Med, Philadelphia, PA 19104 USA; [Grady, Matthew F.; Master, Christina L.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA	Desai, N (corresponding author), Columbia Univ, Sch Med, 622 W 168th St,PH-11, New York, NY 10032 USA.	Nd2498@cumc.columbia.edu		Master, Christina/0000-0002-6717-4270			Babiss LA, 2009, J DEV BEHAV PEDIATR, V30, P376, DOI 10.1097/DBP.0b013e3181b33659; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Berz K, 2013, PHYSICIAN SPORTSMED, V41, P58, DOI 10.3810/psm.2013.05.2015; Bock S, 2015, CHILD NERV SYST, V31, P2111, DOI 10.1007/s00381-015-2846-8; Brook EM, 2016, PHYSICIAN SPORTSMED, V44, P20, DOI 10.1080/00913847.2016.1142834; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Davis-Hayes C, 2017, J AM ACAD ORTHOP SUR, V25, P818, DOI 10.5435/JAAOS-D-17-00276; Elbin RJ, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0910; Fehr SD, 2017, CLIN J SPORT MED; Haarbauer-Krupa J, 2018, J PEDIATR-US, V197, P241, DOI 10.1016/j.jpeds.2018.01.075; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Kerr ZY, 2017, AM J PREV MED, V53, P914, DOI 10.1016/j.amepre.2017.05.017; Lavrich JB, 2010, CURR OPIN OPHTHALMOL, V21, P356, DOI 10.1097/ICU.0b013e32833cf03a; Leddy J, 2016, PM&R, V8, pS91, DOI 10.1016/j.pmrj.2015.10.017; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Master CL, 2018, CLIN J SPORT MED, V28, P139, DOI 10.1097/JSM.0000000000000507; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Miller JH, 2016, J NEUROSURG-PEDIATR, V17, P491, DOI 10.3171/2015.8.PEDS14332; Nazeer A, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00046; Oler M J, 1994, Arch Fam Med, V3, P781, DOI 10.1001/archfami.3.9.781; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Sufrinko AM, 2017, CLIN J SPORT MED, V27, P133, DOI 10.1097/JSM.0000000000000324; Tanveer S, 2017, PEDIATR NEUROL, V70, P44, DOI 10.1016/j.pediatrneurol.2017.02.001; Thiagarajan P, 2013, OPTOMETRY VISION SCI, V90, P57, DOI 10.1097/OPX.0b013e31827a233e; Wu JT, 2015, COMMITTEE EVALUATE S	31	14	14	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2019	29	5					361	367		10.1097/JSM.0000000000000646			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	KG1HH	WOS:000509692100003	31460948				2021-06-18	
J	Wilhelmsson, U; Pozo-Rodrigalvarez, A; Kalm, M; de Pablo, Y; Widestrand, A; Pekna, M; Pekny, M				Wilhelmsson, Ulrika; Pozo-Rodrigalvarez, Andrea; Kalm, Marie; de Pablo, Yolanda; Widestrand, Asa; Pekna, Marcela; Pekny, Milos			The role of GFAP and vimentin in learning and memory	BIOLOGICAL CHEMISTRY			English	Article						astrocytes; hippocampus; hippocampal neurogenesis; intermediate filaments; nanofilaments; reactive gliosis	FIBRILLARY ACIDIC PROTEIN; ADULT HIPPOCAMPAL NEUROGENESIS; ASTROCYTE-SECRETED PROTEINS; INTERMEDIATE-FILAMENTS; MICE DEFICIENT; COGNITIVE FLEXIBILITY; REACTIVE ASTROCYTES; OBJECT RECOGNITION; RETINAL-DETACHMENT; MULLER CELLS	Intermediate filaments (also termed nanofilaments) are involved in many cellular functions and play important roles in cellular responses to stress. The upregulation of glial fibrillary acidic protein (GFAP) and vimentin (Vim), intermediate filament proteins of astrocytes, is the hallmark of astrocyte activation and reactive gliosis in response to injury, ischemia or neurodegeneration. Reactive gliosis is essential for the protective role of astrocytes at acute stages of neurotrauma or ischemic stroke. However, GFAP and Vim were also linked to neural plasticity and regenerative responses in healthy and injured brain. Mice deficient for GFAP and vimentin (GFAP(-/-)Vim(-/-)) exhibit increased post-traumatic synaptic plasticity and increased basal and post-traumatic hippocampal neurogenesis. Here we assessed the locomotor and exploratory behavior of GFAP(-/-)Vim(-/-) mice, their learning, memory and memory extinction, by using the open field, object recognition and Morris water maze tests, trace fear conditioning, and by recording reversal learning in IntelliCages. While the locomotion, exploratory behavior and learning of GFAP(-/-)Vim(-/-) mice, as assessed by object recognition, the Morris water maze, and trace fear conditioning tests, were comparable to wildtype mice, GFAP(-/-)Vim(-/-) mice showed more pronounced memory extinction when tested in IntelliCages, a finding compatible with the scenario of an increased rate of reorganization of the hippocampal circuitry.	[Wilhelmsson, Ulrika; Pozo-Rodrigalvarez, Andrea; de Pablo, Yolanda; Widestrand, Asa; Pekna, Marcela; Pekny, Milos] Univ Gothenburg, Sahlgrenska Acad, Lab Astrocyte Biol & CNS Regenerat, Ctr Brain Repair,Dept Clin Neurosci,Inst Neurosci, Box 440, S-40530 Gothenburg, Sweden; [Pekna, Marcela; Pekny, Milos] Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia; [Pekna, Marcela; Pekny, Milos] Univ Newcastle, Newcastle, NSW, Australia; [Kalm, Marie] Univ Gothenburg, Inst Neurosci & Physiol, Dept Pharmacol, Sahlgrenska Acad, S-40530 Gothenburg, Sweden	Pekny, M (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Lab Astrocyte Biol & CNS Regenerat, Ctr Brain Repair,Dept Clin Neurosci,Inst Neurosci, Box 440, S-40530 Gothenburg, Sweden.; Pekny, M (corresponding author), Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia.; Pekny, M (corresponding author), Univ Newcastle, Newcastle, NSW, Australia.	Milos.Pekny@neuro.gu.se	Pekna, Marcela/AAM-3249-2021; Pekna, Marcela/AAM-3261-2021; de Pablo, Yolanda/AAD-1642-2019	Pekna, Marcela/0000-0003-2734-8237; Pekna, Marcela/0000-0003-2734-8237; de Pablo, Yolanda/0000-0001-5208-2114; Kalm, Marie/0000-0002-0680-5040	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission [2017-02255]; ALF Gothenburg [146051]; AFA Research Foundation; Soderbergs Foundations; Sten A. Olsson Foundation for Research and Culture; Amlov's Foundation; E. Jacobson's Donation Fund; VINNOVAVinnova; Swedish Stroke Foundation; NanoNet COST ActionEuropean Cooperation in Science and Technology (COST) [BM1002]; EU FP 7 Program EduGlia [237956]; EU FP 7 Program TargetBraIn [279017]; Hjarnfonden; Hagstromer's Foundation Millennium; EuroCellNet COST ActionEuropean Cooperation in Science and Technology (COST)	This work was supported by Swedish Medical Research Council (2017-02255), ALF Gothenburg (146051), AFA Research Foundation, Soderbergs Foundations, Sten A. Olsson Foundation for Research and Culture, Hjarnfonden, Hagstromer's Foundation Millennium, Amlov's Foundation, E. Jacobson's Donation Fund, VINNOVA, the Swedish Stroke Foundation, NanoNet COST Action (BM1002), EuroCellNet COST Action, EU FP 7 Program EduGlia (237956), and EU FP 7 Program TargetBraIn (279017). We thank Dr. Leke for teaching Dr. Pozo-Rodrigalvarez the open field and object recognition tests.	Akers KG, 2014, SCIENCE, V344, P598, DOI 10.1126/science.1248903; Allen NJ, 2012, NATURE, V486, P410, DOI 10.1038/nature11059; Anacker C, 2017, NAT REV NEUROSCI, V18, P335, DOI 10.1038/nrn.2017.45; Berg A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079395; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Buccafusco JJ, 2009, FRONT NEUROSCI, P1; Burghardt NS, 2012, HIPPOCAMPUS, V22, P1795, DOI 10.1002/hipo.22013; Cho KS, 2005, J CELL SCI, V118, P863, DOI 10.1242/jcs.01658; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; Chung WS, 2013, NATURE, V504, P394, DOI 10.1038/nature12776; Colucci-Guyon E, 1999, GLIA, V25, P33, DOI 10.1002/(SICI)1098-1136(19990101)25:1<33::AID-GLIA4>3.0.CO;2-J; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; de Pablo Y, 2013, HISTOCHEM CELL BIOL, V140, P81, DOI 10.1007/s00418-013-1110-0; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Dragoi G, 2003, NEURON, V39, P843, DOI 10.1016/S0896-6273(03)00465-3; Dupret D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001959; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Engelmann M, 2011, NAT PROTOC, V6, P1152, DOI 10.1038/nprot.2011.353; Epp JR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10838; Eroglu C, 2010, NATURE, V468, P223, DOI 10.1038/nature09612; Eroglu C, 2009, CELL, V139, P380, DOI 10.1016/j.cell.2009.09.025; Galsworthy MJ, 2005, BEHAV BRAIN RES, V157, P211, DOI 10.1016/j.bbr.2004.06.021; Garber C, 2018, NAT IMMUNOL, V19, P151, DOI 10.1038/s41590-017-0021-y; Garthe A, 2016, HIPPOCAMPUS, V26, P261, DOI 10.1002/hipo.22520; Ge MY, 2019, CELL REP, V26, P2052, DOI 10.1016/j.celrep.2019.01.098; Goncalves JT, 2016, CELL, V167, P897, DOI 10.1016/j.cell.2016.10.021; Henneberger C, 2010, NATURE, V463, P232, DOI 10.1038/nature08673; Jarlestedt K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010397; Kalm M, 2013, EXP NEUROL, V247, P402, DOI 10.1016/j.expneurol.2013.01.006; Kamphuis W, 2015, GLIA, V63, P1036, DOI 10.1002/glia.22800; Karlsson N, 2011, RADIAT RES, V175, P336, DOI 10.1667/RR2231.1; Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088; Kraft AW, 2013, FASEB J, V27, P187, DOI 10.1096/fj.12-208660; Kucukdereli H, 2011, P NATL ACAD SCI USA, V108, pE440, DOI 10.1073/pnas.1104977108; Labrie V, 2009, LEARN MEMORY, V16, P28, DOI 10.1101/lm.1112209; Laplagne DA, 2006, PLOS BIOL, V4, P2349, DOI 10.1371/journal.pbio.0040409; Larsson A, 2004, NEUROCHEM RES, V29, P2069, DOI 10.1007/s11064-004-6880-2; Laterza C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192118; Lee HS, 2014, P NATL ACAD SCI USA, V111, pE3343, DOI 10.1073/pnas.1410893111; Li LZ, 2008, J CEREBR BLOOD F MET, V28, P468, DOI 10.1038/sj.jcbfm.9600546; Liauw J, 2008, J CEREBR BLOOD F MET, V28, P1722, DOI 10.1038/jcbfm.2008.65; Liu ZW, 2014, GLIA, V62, P2022, DOI 10.1002/glia.22723; Lu YB, 2011, FASEB J, V25, P624, DOI 10.1096/fj.10-163790; Lu ZJ, 2010, FASEB J, V24, P1925, DOI 10.1096/fj.09-150573; Lundkvist A, 2004, J CELL SCI, V117, P3481, DOI 10.1242/jcs.01221; Macauley SL, 2011, J NEUROSCI, V31, P15575, DOI 10.1523/JNEUROSCI.3579-11.2011; Nakazawa K, 2003, NEURON, V38, P305, DOI 10.1016/S0896-6273(03)00165-X; Nakazawa T, 2007, INVEST OPHTH VIS SCI, V48, P2760, DOI 10.1167/iovs.06-1398; Pekna M, 2012, STROKE, V43, P2819, DOI 10.1161/STROKEAHA.112.654228; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; Pekny M, 2007, EXP CELL RES, V313, P2244, DOI 10.1016/j.yexcr.2007.04.023; Pekny M, 2019, NEUROSCI LETT, V689, P45, DOI 10.1016/j.neulet.2018.07.021; Pekny M, 2016, BBA-MOL BASIS DIS, V1862, P483, DOI 10.1016/j.bbadis.2015.11.014; Pekny M, 2016, ACTA NEUROPATHOL, V131, P323, DOI 10.1007/s00401-015-1513-1; Pekny M, 2014, PHYSIOL REV, V94, P1077, DOI 10.1152/physrev.00041.2013; Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071; Perez-Alcazar M, 2014, EXP NEUROL, V253, P154, DOI 10.1016/j.expneurol.2013.12.013; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Santello M, 2019, NAT NEUROSCI, V22, P154, DOI 10.1038/s41593-018-0325-8; Shi QQ, 2015, J NEUROSCI, V35, P13029, DOI 10.1523/JNEUROSCI.1698-15.2015; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Stogsdill JA, 2017, NATURE, V551, P192, DOI 10.1038/nature24638; Sultan S, 2015, NEURON, V88, DOI 10.1016/j.neuron.2015.10.037; Suzuki A, 2011, CELL, V144, P810, DOI 10.1016/j.cell.2011.02.018; Swan AA, 2014, HIPPOCAMPUS, V24, P1581, DOI 10.1002/hipo.22337; Tashiro A, 2006, NATURE, V442, P929, DOI 10.1038/nature05028; Toni N, 2007, NAT NEUROSCI, V10, P727, DOI 10.1038/nn1908; Verardo MR, 2008, INVEST OPHTH VIS SCI, V49, P3659, DOI 10.1167/iovs.07-1474; Verkhratsky A, 2018, PHYSIOL REV, V98, P239, DOI 10.1152/physrev.00042.2016; Widestrand A, 2007, STEM CELLS, V25, P2619, DOI 10.1634/stemcells.2007-0122; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Wilhelmsson U, 2019, CEREB CORTEX, V29, P4050, DOI 10.1093/cercor/bhy284; Wilhelmsson U, 2012, STEM CELLS, V30, P2320, DOI 10.1002/stem.1196; Winters BD, 2008, NEUROSCI BIOBEHAV R, V32, P1055, DOI 10.1016/j.neubiorev.2008.04.004; Wunderlich KA, 2015, FASEB J, V29, P4815, DOI 10.1096/fj.15-272963	76	14	15	2	7	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1431-6730	1437-4315		BIOL CHEM	Biol. Chem.	SEP	2019	400	9					1147	1156		10.1515/hsz-2019-0199			10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	IN5AB	WOS:000478687200007	31063456	Bronze			2021-06-18	
J	Rosciszewski, G; Cadena, V; Auzmendi, J; Cieri, MB; Lukin, J; Rossi, AR; Murta, V; Villarreal, A; Reines, A; Gomes, FCA; Ramos, AJ				Rosciszewski, Gerardo; Cadena, Vanesa; Auzmendi, Jeronimo; Belen Cieri, Maria; Lukin, Jeronimo; Rossi, Alicia R.; Murta, Veronica; Villarreal, Alejandro; Reines, Analia; Gomes, Flavia C. A.; Javier Ramos, Alberto			Detrimental Effects of HMGB-1 Require Microglial-Astroglial Interaction: Implications for the Status Epilepticus -Induced Neuroinflammation	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						epilepsy; glia; inflammation; seizures; neuronal death	GROUP BOX 1; TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; MOBILITY GROUP BOX-1; TOLL-LIKE RECEPTOR; FEBRILE SEIZURES; RAT MODEL; ACTIVATION; RAGE; PROTEIN	Temporal Lobe Epilepsy (TLE) is the most common form of human epilepsy and available treatments with antiepileptic drugs are not disease-modifying therapies. The neuroinflammation, neuronal death and exacerbated plasticity that occur during the silent period, following the initial precipitating event (IPE), seem to be crucial for epileptogenesis. Damage Associated Molecular Patterns (DAMP) such as HMGB-1, are released early during this period concomitantly with a phenomenon of reactive gliosis and neurodegeneration. Here, using a combination of primary neuronal and glial cell cultures, we show that exposure to HMGB-1 induces dendrite loss and neurodegeneration in a glial-dependent manner. In glial cells, loss of function studies showed that HMGB-1 exposure induces NF-kappa B activation by engaging a signaling pathway that involves TLR2, TLR4, and RAGE. In the absence of glial cells, HMGB-1 failed to induce neurodegeneration of primary cultured cortical neurons. Moreover, purified astrocytes were unable to fully respond to HMGB-1 with NF-kappa B activation and required microglial cooperation. In agreement, in vivo HMGB-1 blockage with glycyrrhizin, immediately after pilocarpine-induced status epilepticus (SE), reduced neuronal degeneration, reactive astrogliosis and microgliosis in the long term. We conclude that microglial-astroglial cooperation is required for astrocytes to respond to HMGB-1 and to induce neurodegeneration. Disruption of this HMGB-1 mediated signaling pathway shows beneficial effects by reducing neuroinflammation and neurodegeneration after SE. Thus, early treatment strategies during the latency period aimed at blocking downstream signaling pathways activated by HMGB-1 are likely to have a significant effect in the neuroinflammation and neurodegeneration that are proposed as key factors in epileptogenesis.	[Rosciszewski, Gerardo; Cadena, Vanesa; Auzmendi, Jeronimo; Belen Cieri, Maria; Lukin, Jeronimo; Rossi, Alicia R.; Murta, Veronica; Villarreal, Alejandro; Javier Ramos, Alberto] UBA, Lab Neuropatol Mol, Inst Biol Celular & Neurociencia Prof E Robertis, Fac Med,CONICET, Buenos Aires, DF, Argentina; [Reines, Analia] UBA, Lab Neurofarmacol, Inst Biol Celular & Neurociencia Prof E Robertis, Fac Med,CONICET, Buenos Aires, DF, Argentina; [Gomes, Flavia C. A.] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Rio De Janeiro, Brazil	Ramos, AJ (corresponding author), UBA, Lab Neuropatol Mol, Inst Biol Celular & Neurociencia Prof E Robertis, Fac Med,CONICET, Buenos Aires, DF, Argentina.	jramos@fmed.uba.ar	Ramos, Alberto Javier/AAR-7796-2020	Ramos, Alberto Javier/0000-0003-4009-6337; Villarreal, Alejandro/0000-0001-8624-8119; Auzmendi, Jeronimo/0000-0002-4819-2713	ANPCYT-FONCYTANPCyTFONCyT [PICT 2015-1451, 2017-2203]; UBACYT; CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); DECIT/MS; IBRO-LARC;  [PICT 2014-2178]	This study was supported by grants from the ANPCYT-FONCYT PICT 2015-1451 and 2017-2203 (AJR), UBACYT (AJR), PICT 2014-2178 (JA), CNPq (FG), and DECIT/MS (FG). GR, VC, and JL are doctoral fellows from CONICET. MC is a doctoral fellow of UBACYT. GR received a research visit grant from IBRO-LARC. AJR, VM, JA, and AV are researchers from CONICET (Argentina).	Alaimo A, 2011, NEUROCHEM INT, V59, P297, DOI 10.1016/j.neuint.2011.06.001; Blume WT, 2006, EPILEPSIA, V47, P71, DOI 10.1111/j.1528-1167.2006.00665.x; Braun M, 2017, BBA-MOL BASIS DIS, V1863, P2614, DOI 10.1016/j.bbadis.2017.05.020; CENDES F, 1993, NEUROLOGY, V43, P1083, DOI 10.1212/WNL.43.6.1083; Choi JY, 2017, P NATL ACAD SCI USA, V114, pE4987, DOI 10.1073/pnas.1702035114; Crack PJ, 2007, IMMUNOL CELL BIOL, V85, P476, DOI 10.1038/sj.icb.7100103; Curia G, 2008, J NEUROSCI METH, V172, P143, DOI 10.1016/j.jneumeth.2008.04.019; Diniz LP, 2012, J BIOL CHEM, V287, P41432, DOI 10.1074/jbc.M112.380824; Ellwood KB, 2000, MOL CELL BIOL, V20, P4359, DOI 10.1128/MCB.20.12.4359-4370.2000; Festoff BW, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0670-z; Angelo MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107901; Fonken LK, 2016, J NEUROSCI, V36, P7946, DOI 10.1523/JNEUROSCI.1161-16.2016; FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604; Fu L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01325-y; Gao HM, 2011, J NEUROSCI, V31, P1081, DOI 10.1523/JNEUROSCI.3732-10.2011; Gao TL, 2012, J TRAUMA ACUTE CARE, V72, P643, DOI 10.1097/TA.0b013e31823c54a6; Gao TL, 2018, BIOCHEM BIOPH RES CO, V497, P430, DOI 10.1016/j.bbrc.2018.02.102; Hamati-Haddad A, 1998, NEUROLOGY, V50, P917, DOI 10.1212/WNL.50.4.917; Haruma J, 2016, SCI REP-UK, V6, DOI 10.1038/srep37755; Hayakawa K, 2008, STROKE, V39, P951, DOI 10.1161/STROKEAHA.107.495820; Kim ID, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0438-8; Kim SW, 2012, NEUROBIOL DIS, V46, P147, DOI 10.1016/j.nbd.2011.12.056; Koyama R, 2012, NAT MED, V18, P1271, DOI 10.1038/nm.2850; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Li YJ, 2019, J PHARM PHARMACOL, V71, P390, DOI 10.1111/jphp.13040; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Liesz A, 2015, J NEUROSCI, V35, P583, DOI 10.1523/JNEUROSCI.2439-14.2015; Luo L, 2014, CELL MOL NEUROBIOL, V34, P987, DOI 10.1007/s10571-014-0075-4; Luo Lidan, 2013, Exp Neurobiol, V22, P107, DOI 10.5607/en.2013.22.2.107; Majores M, 2007, EPILEPSIA, V48, P4, DOI 10.1111/j.1528-1167.2007.01062.x; Maroso M, 2010, NAT MED, V16, P413, DOI 10.1038/nm.2127; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Muhammad S, 2008, J NEUROSCI, V28, P12023, DOI 10.1523/JNEUROSCI.2435-08.2008; Ohnishi M, 2014, NEUROCHEM INT, V75, P32, DOI 10.1016/j.neuint.2014.05.007; Ohnishi M, 2011, NEUROPHARMACOLOGY, V61, P975, DOI 10.1016/j.neuropharm.2011.06.026; Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Parker TM, 2017, BRAIN INJURY, V31, P2, DOI 10.1080/02699052.2016.1217045; Paudel YN, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00628; Pedrazzi M, 2007, J IMMUNOL, V179, P8525, DOI 10.4049/jimmunol.179.12.8525; Qi L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142901; Qiu J, 2008, J CEREBR BLOOD F MET, V28, P927, DOI 10.1038/sj.jcbfm.9600582; Qiu JH, 2010, STROKE, V41, P2077, DOI 10.1161/STROKEAHA.110.590463; RACINE RJ, 1972, BRAIN RES, V47, P262, DOI 10.1016/0006-8993(72)90268-5; Rossi AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078516; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Rosciszewski G, 2018, MOL NEUROBIOL, V55, P3875, DOI 10.1007/s12035-017-0618-z; Rossi A, 2017, PHARMACEUTICALS-BASE, V10, DOI 10.3390/ph10040093; Santoro M, 2016, NEUROBIOL DIS, V91, P59, DOI 10.1016/j.nbd.2016.02.018; Sasaki T, 2016, EXP NEUROL, V275, P220, DOI 10.1016/j.expneurol.2015.11.003; Singh V, 2016, ANTIOXID REDOX SIGN, V24, P635, DOI 10.1089/ars.2015.6397; Sun Q, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-106; Tajalli-Nezhad S, 2019, CELL MOL LIFE SCI, V76, P523, DOI 10.1007/s00018-018-2953-2; Takizawa T, 2017, J CEREBR BLOOD F MET, V37, P890, DOI 10.1177/0271678X16647398; Terrando N, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00441; Theodore WH, 1999, NEUROLOGY, V52, P132, DOI 10.1212/WNL.52.1.132; Tian XD, 2017, CURR DRUG DELIV, V14, P785, DOI 10.2174/1567201813666160808111933; Venereau E, 2016, PHARMACOL RES, V111, P534, DOI 10.1016/j.phrs.2016.06.031; Verrijdt G, 2002, BIOCHEM J, V361, P97, DOI 10.1042/0264-6021:3610097; Villarreal A, 2014, J NEUROCHEM, V131, P190, DOI 10.1111/jnc.12790; Walker LE, 2017, BIOMARKERS, V22, P635, DOI 10.1080/1354750X.2016.1265003; Walker LE, 2017, J CLIN INVEST, V127, P2118, DOI 10.1172/JCI92001; Wang C, 2016, INFLAMMATION, V39, P1862, DOI 10.1007/s10753-016-0418-z; Wang DL, 2017, SCI REP-UK, V7, DOI 10.1038/srep46243; Wang W, 2016, NEUROSCIENCE, V316, P328, DOI 10.1016/j.neuroscience.2015.11.001; Weber MD, 2015, J NEUROSCI, V35, P316, DOI 10.1523/JNEUROSCI.3561-14.2015; Aviles-Reyes RX, 2010, J NEUROCHEM, V112, P854, DOI 10.1111/j.1471-4159.2009.06535.x; Xiong XX, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0705-5; Yang Qing-Wu, 2010, Front Biosci (Schol Ed), V2, P1081; Yang WH, 2017, NEUROCHEM RES, V42, P1179, DOI 10.1007/s11064-016-2153-0; Zurolo E, 2011, BRAIN, V134, P1015, DOI 10.1093/brain/awr032	71	14	15	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-5102		FRONT CELL NEUROSCI	Front. Cell. Neurosci.	AUG 27	2019	13								380	10.3389/fncel.2019.00380			19	Neurosciences	Neurosciences & Neurology	IT4PT	WOS:000482843700001	31507379	DOAJ Gold, Green Published			2021-06-18	
J	Cohen, E; Rodean, J; Diong, C; Hall, M; Freedman, SB; Aronson, PL; Simon, HK; Marin, JR; Samuels-Kalow, M; Alpern, ER; Morse, RB; Shah, SS; Peltz, A; Neuman, MI				Cohen, Eyal; Rodean, Jonathan; Diong, Christina; Hall, Matt; Freedman, Stephen B.; Aronson, Paul L.; Simon, Harold K.; Marin, Jennifer R.; Samuels-Kalow, Margaret; Alpern, Elizabeth R.; Morse, Rustin B.; Shah, Samir S.; Peltz, Alon; Neuman, Mark I.			Low-Value Diagnostic Imaging Use in the Pediatric Emergency Department in the United States and Canada	JAMA PEDIATRICS			English	Article							COMPUTED-TOMOGRAPHY; DEFENSIVE MEDICINE; CHILDREN; CARE; PHYSICIANS; MALPRACTICE; RADIOGRAPHY; YIELD	ImportanceDiagnostic imaging overuse in children evaluated in emergency departments (EDs) is a potential target for reducing low-value care. Variation in practice patterns across Canada and the United States stemming from organization of care, payment structures, and medicolegal environments may lead to differences in imaging overuse between countries. ObjectiveTo compare overall and low-value use of diagnostic imaging across pediatric ED visits in Ontario, Canada, and the United States. Design, Setting, and ParticipantsThis study used administrative health databases from 4 pediatric EDs in Ontario and 26 in the United States in calendar years 2006 through 2016. Individuals 18 years and younger who were discharged from the ED, including after visits for diagnoses in which imaging is not routinely recommended (eg, asthma, bronchiolitis, abdominal pain, constipation, concussion, febrile convulsion, seizure, and headache) were included. Data analysis occurred from April 2018 to October 2018. ExposuresDiagnostic imaging use. Main Outcome and MeasuresOverall and condition-specific low-value imaging use. Three-day and 7-day rates of hospital admission and those admissions resulting in intensive care, surgery, or in-hospital mortality were assessed as balancing measures. ResultsA total of 1783752 visits in Ontario and 21807332 visits in the United States were analyzed. Compared with visits in the United States, those in Canada had lower overall use of head computed tomography (Canada, 22942 [1.3%] vs the United States, 753270 [3.5%]; P<.001), abdomen computed tomography (5626 [0.3%] vs 211018 [1.0%]; P<.001), chest radiographic imaging (208843 [11.7%] vs 3408540 [15.6%]; P<.001), and abdominal radiographic imaging (77147 [4.3%] vs 3607141 [16.5%]; P<.001). Low-value imaging use was lower in Canada than the United States for multiple indications, including abdominal radiographic images for constipation (absolute difference, 23.7% [95% CI, 23.2%-24.3%]) and abdominal pain (20.6% [95% CI, 20.3%-21.0%]) and head computed tomographic scans for concussion (22.9% [95% CI, 22.3%-23.4%]). Abdominal computed tomographic use for constipation and abdominal pain, although low overall, were approximately 10-fold higher in the United States (0.1% [95% CI, 0.1%-0.2%] vs 1.2% [95% CI, 1.2%-1.2%]) and abdominal pain (0.8% [95% CI, 0.7%-0.9%] vs 7.0% [95% CI, 6.9%-7.1%]). Rates of 3-day and 7-day post-ED adverse outcomes were similar. Conclusions and RelevanceLow-value imaging rates were lower in pediatric EDs in Ontario compared with the United States, particularly those involving ionizing radiation. Lower use of imaging in Canada was not associated with higher rates of adverse outcomes, suggesting that usage may be safely reduced in the United States.	[Cohen, Eyal] Hosp Sick Children, Dept Pediat, Div Pediat Med, Toronto, ON, Canada; [Cohen, Eyal] Hosp Sick Children, Child Hlth Evaluat Sci, Toronto, ON, Canada; [Cohen, Eyal] Univ Toronto, Inst Hlth Policy Management & Evaluat, Dept Pediat, Toronto, ON, Canada; [Cohen, Eyal; Diong, Christina] ICES, Toronto, ON, Canada; [Rodean, Jonathan; Hall, Matt] Childrens Hosp Assoc, Lenexa, KS USA; [Freedman, Stephen B.] Univ Calgary, Alberta Childrens Hosp Res Inst, Alberta Childrens Hosp,Dept Pediat, Sect Pediat Emergency Med,Cumming Sch Med, Calgary, AB, Canada; [Freedman, Stephen B.] Univ Calgary, Alberta Childrens Hosp Res Inst, Alberta Childrens Hosp,Dept Pediat, Sect Gastroenterol,Cumming Sch Med, Calgary, AB, Canada; [Aronson, Paul L.] Yale Sch Med, Sect Pediat Emergency Med, Dept Pediat, New Haven, CT USA; [Aronson, Paul L.] Yale Sch Med, Dept Emergency Med, New Haven, CT USA; [Simon, Harold K.] Emory Univ, Sch Med, Dept Emergency Med, Div Emergency Med, Atlanta, GA USA; [Simon, Harold K.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; [Simon, Harold K.] Childrens Healthcare Atlanta, Atlanta, GA USA; [Marin, Jennifer R.] Childrens Hosp Pittsburgh, Div Pediat Emergency Med, Pittsburgh, PA 15213 USA; [Samuels-Kalow, Margaret] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Alpern, Elizabeth R.] Northwestern Univ, Dept Pediat, Ann & Robert H Lurie Childrens Hosp Chicago, Div Emergency Med,Feinberg Sch Med, Chicago, IL 60611 USA; [Morse, Rustin B.] Childrens Hlth Syst Texas, Dallas, TX USA; [Shah, Samir S.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Hosp Med, Cincinnati, OH 45229 USA; [Shah, Samir S.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Infect Dis, Cincinnati, OH 45229 USA; [Peltz, Alon] Yale Sch Med, New Haven, CT USA; [Neuman, Mark I.] Harvard Med Sch, Boston Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA	Cohen, E (corresponding author), Univ Toronto, Div Pediat Med, Hosp Sick Children, Dept Pediat, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	eyal.cohen@sickkids.ca	; Freedman, Stephen/H-9102-2012	Alpern, Elizabeth/0000-0001-7887-3563; Freedman, Stephen/0000-0003-2319-6192; Marin, Jennifer/0000-0003-3090-664X	Agency for Healthcare Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K08HS026006]; Alberta Children's Hospital Foundation Professorship in Child Health andWellness; Ontario Ministry of Health and Long-Term CareMinistry of Health and Long-Term Care, Ontario; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K08HS026006] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001863] Funding Source: NIH RePORTER	This study was supported by the Agency for Healthcare Research and Quality (grant K08HS026006 [Dr Aronson]) and the Alberta Children's Hospital Foundation Professorship in Child Health andWellness (Dr Freedman). In addition, ICES is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care. Parts of the data and/or information compiled were provided by the Canadian Institute for Health Information.	Allie EH, 2018, AM J EMERG MED, V36, P769, DOI 10.1016/j.ajem.2017.10.009; American Academy of Pediatrics, 2013, 10 THINGS PHYS PAT S; Bakel LA, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-0092; Berdahl CT, 2013, ANN EMERG MED, V62, P486, DOI 10.1016/j.annemergmed.2013.02.018; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Bourgeois FT, 2007, PEDIATR EMERG CARE, V23, P94, DOI 10.1097/PEC.0b013e3180302c22; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Canadian Association of Emergency Physicians, 2018, 10 THINGS PHYS PAT; Canadian Institute for Health Information, 2019, NAT AMB CAR REP SYST; Cheng AHY, 2017, CAN J EMERG MED, V19, pS9, DOI 10.1017/cem.2017.1; Chua KP, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-1809; DeAngelis J, 2017, WEST J EMERG MED, V18, P821, DOI 10.5811/westjem.2017.6.33685; Emil S, 2007, J PEDIATR SURG, V42, P878, DOI 10.1016/j.jpedsurg.2006.12.054; Ferguson CC, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2016-2290; Feudtner C, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-199; Gallagher TH, 2006, ARCH INTERN MED, V166, P1605, DOI 10.1001/archinte.166.15.1605; Gong C, 2017, PEDIATR EMERG CARE, DOI [10.1097/PEC.0000000000001145, DOI 10.1097/PEC.000000000000114528441240]; Health Quality Ontario The Emergency Department Return Visit Quality Program, 2018, EM DEP RET VIS QUAL; Horner KB, 2016, AM J EMERG MED, V34, P2320, DOI 10.1016/j.ajem.2016.08.041; Hudgins JD, 2019, PEDIATR EMERG CARE, DOI [10.1097/PEC.0000000000001706, DOI 10.1097/PEC.000000000000170630624420]; Ivers N, 2018, JAMA INTERN MED, V178, P1250, DOI 10.1001/jamainternmed.2018.3568; Kimia AA, 2012, PEDIATR EMERG CARE, V28, P316, DOI 10.1097/PEC.0b013e31824d8b0b; Knapp JF, 2010, PEDIATR EMERG CARE, V26, P364, DOI 10.1097/PEC.0b013e3181db2262; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Levinson W, 2018, JAMA-J AM MED ASSOC, V319, P1975, DOI 10.1001/jama.2018.2202; Li GH, 2007, ACAD EMERG MED, V14, P582, DOI 10.1197/j.aem.2007.02.030; Lyons TW, 2016, SEIZURE-EUR J EPILEP, V35, P4, DOI 10.1016/j.seizure.2015.12.009; Mafi JN, 2018, BMJ QUAL SAF, V27, P333, DOI 10.1136/bmjqs-2017-007477; Niles LM, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-0615; Papanicolas I, 2018, JAMA-J AM MED ASSOC, V319, P1024, DOI 10.1001/jama.2018.1150; Quinonez RA, 2013, J HOSP MED, V8, P479, DOI 10.1002/jhm.2064; Ralston SL, 2014, PEDIATRICS, V134, pE1474, DOI 10.1542/peds.2014-2742; Reuchlin-Vroklage LM, 2005, ARCH PEDIAT ADOL MED, V159, P671, DOI 10.1001/archpedi.159.7.671; Sharma S, 2003, PEDIATRICS, V111, P1, DOI 10.1542/peds.111.1.1; Steiner IP, 2003, CAN MED ASSOC J, V168, P1549; Studdert DM, 2005, JAMA-J AM MED ASSOC, V293, P2609, DOI 10.1001/jama.293.21.2609; Subcommittee on Febrile Seizures, 2011, Pediatrics, V127, P389, DOI 10.1542/peds.2010-3318; Tabbers MM, 2014, J PEDIATR GASTR NUTR, V58, P258, DOI 10.1097/MPG.0000000000000266; WILLIAMS JI, 1996, PATTERNS HLTH CARE O, P339; Wong AC, 2011, PEDIATR EMERG CARE, V27, P182, DOI 10.1097/PEC.0b013e31820d64f7; Woolhandler S, 2003, NEW ENGL J MED, V349, P768, DOI 10.1056/NEJMsa022033; Yan SC, 2016, WORLD NEUROSURG, V95, P53, DOI 10.1016/j.wneu.2016.07.069	42	14	14	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	AUG	2019	173	8							e191439	10.1001/jamapediatrics.2019.1439			10	Pediatrics	Pediatrics	IP8LG	WOS:000480297300016	31157877	Green Published, Bronze			2021-06-18	
J	Han, D; Zhou, YD				Han, Dong; Zhou, Yidong			YY1-induced upregulation of lncRNA NEAT1 contributes to OGD/R injury-induced inflammatory response in cerebral microglial cells via Wnt/beta-catenin signaling pathway	IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL			English	Article						YY1; lncRNA NEAT1; OGD; R injury; Microglial cells; Wnt; beta-catenin signaling pathway	NONCODING RNA NEAT1; TRAUMATIC BRAIN-INJURY; CANCER PROGRESSION; ISCHEMIC-STROKE; IN-VITRO; KAPPA-B; EXPRESSION; ACTIVATION; MECHANISMS; APOPTOSIS	Stroke can lead to the serious long-term neurological disability. The dysregulation of long non-coding RNAs (lncRNAs) has been proven to be a pivotal factor for the progression of ischemic stroke. However, it is largely unknown whether lncRNAs regulated the OGD/R injury of cerebral microglial cells. In this study, we designed experiments to reveal the role of lncRNA Nuclear Enriched Abundant Transcript 1 (NEAT1) in the OGD/R injury of microglial cells. We found that NEAT1 contributed to the OGD/R injury and neuroinflammation damage in microglial cells. Moreover, the molecular mechanism involved in the NEAT1-mediated OGD/R injury. Mechanism investigation revealed that NEAT1 was upregulated by the transcription factor YY1. Moreover, Western blot analysis suggested that NEAT1 enhance the protein levels of core factors of Wnt/beta-catenin signaling pathway, indicating that NEAT1 contributed to the activation of Wnt/beta-catenin signaling pathway. Rescue assays were carried out in the microglial cells treated with OGD/R. The results showed that NEAT1 regulated the OGD/R injury and neuroinflammation damage via Wnt/beta-catenin signaling pathway. In conclusion, our findings suggested that YY1-induced upregulation of NEAT1 contributed to the OGD/R injury and neuroinflammation damage of microglial cells via Wnt/beta-catenin signaling pathway.	[Han, Dong; Zhou, Yidong] Ningbo First Hosp, Dept Neurol, Ningbo 315010, Zhejiang, Peoples R China	Han, D (corresponding author), Ningbo First Hosp, Dept Neurol, Ningbo 315010, Zhejiang, Peoples R China.	DongHan3389@163.com					AGBOR LN, 2018, FASEB J S, V32; Baizabal-Aguirre VM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01396; Battistelli C, 2019, CELL DEATH DIFFER, V26, P890, DOI 10.1038/s41418-018-0170-z; Carniglia L, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/5048616; Chakravarty D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6383; Chen Q, 2018, CLIN CANCER RES, V24, P684, DOI 10.1158/1078-0432.CCR-17-0605; Chen XX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0962-6; Cheng L, 2018, BIOCHEM BIOPH RES CO, V495, P1890, DOI 10.1016/j.bbrc.2017.12.058; Choudhry H, 2015, ONCOGENE, V34, P4482, DOI 10.1038/onc.2014.378; Donnan GA, 2008, LANCET NEUROL, V7, P981, DOI 10.1016/S1474-4422(08)70230-8; Fancy SPJ, 2014, NAT NEUROSCI, V17, P506, DOI 10.1038/nn.3676; Gandhy SU, 2015, ONCOTARGET, V6, P26359, DOI 10.18632/oncotarget.4560; Gong W, 2016, ONCOTARGET, V7, P62208, DOI 10.18632/oncotarget.11403; Gu DM, 2015, BIOCHEM BIOPH RES CO, V457, P391, DOI 10.1016/j.bbrc.2015.01.002; Guo F, 2018, J CELL MOL MED, V22, P5062, DOI 10.1111/jcmm.13790; Hu ZP, 2016, BRAIN RES, V1644, P15, DOI 10.1016/j.brainres.2016.05.012; Huang MD, 2017, MOL THER, V25, P1014, DOI 10.1016/j.ymthe.2017.01.017; Huang W, 2017, INT IMMUNOPHARMACOL, V47, P134, DOI 10.1016/j.intimp.2017.03.030; Jang J.B., 2017, TANG, V7, pe14, DOI DOI 10.1038/srep41612; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Jiang L, 2018, BIOMED PHARMACOTHER, V107, P24, DOI 10.1016/j.biopha.2018.07.142; Jin R, 2013, J CARDIOVASC TRANSL, V6, P834, DOI 10.1007/s12265-013-9508-6; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Kiernan EA, 2016, J PHYSIOL-LONDON, V594, P1563, DOI 10.1113/JP271502; Knauss JL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0840-2; Lakhan SE, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-97; Li GY, 2018, THERANOSTICS, V8, P2846, DOI 10.7150/thno.23463; Li RP, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aao2387; Li WJ, 2017, J CLIN INVEST, V127, P3427, DOI 10.1172/JCI94233; Li X, 2018, CANCER RES, V78, P4138, DOI 10.1158/0008-5472.CAN-18-0688; Li Z, 2016, TUMOR BIOL, V37, P673, DOI 10.1007/s13277-015-3843-y; Liu F, 2017, ONCOTARGET, V8, P62927, DOI 10.18632/oncotarget.17757; Liu HT, 2018, CANCER RES, V78, P5877, DOI 10.1158/0008-5472.CAN-18-1011; Liu J, 2017, MOL NEUROBIOL, V54, P8179, DOI 10.1007/s12035-016-0270-z; Louro R, 2009, GENOMICS, V93, P291, DOI 10.1016/j.ygeno.2008.11.009; Lu ZL, 2018, CANCER LETT, V432, P156, DOI 10.1016/j.canlet.2018.06.013; Mehta SL, 2015, J NEUROSCI, V35, P16443, DOI 10.1523/JNEUROSCI.2943-15.2015; Micieli G, 2009, VASC HEALTH RISK MAN, V5, P397; Peng JH, 2017, SCI REP-UK, V7, DOI 10.1038/srep46577; Piccin D, 2011, STEM CELLS, V29, P528, DOI 10.1002/stem.589; Ponjavic J, 2007, GENOME RES, V17, P556, DOI 10.1101/gr.6036807; Ponting CP, 2010, HUM MOL GENET, V19, pR162, DOI 10.1093/hmg/ddq362; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Qi FZ, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0420-4; Qiu CW, 2018, EXP NEUROL, V309, P44, DOI 10.1016/j.expneurol.2018.07.011; Saura J, 2003, GLIA, V44, P183, DOI 10.1002/glia.10274; Suo T, 2018, BIOMED PHARMACOTHER, V108, P783, DOI 10.1016/j.biopha.2018.09.046; Taiana E, 2019, HAEMATOLOGICA, V104, pE72, DOI 10.3324/haematol.2018.201301; Tulsulkar J, 2017, BRAIN RES, V1662, P1, DOI 10.1016/j.brainres.2017.02.006; Wang CF, 2017, J NEUROTRAUM, V34, P2100, DOI 10.1089/neu.2016.4642; Wang JR, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00329; Wang X, 2016, J HEPATOL, V64, P1283, DOI 10.1016/j.jhep.2016.01.019; Wang YJ, 2017, ONCOTARGET, V8, P70156, DOI 10.18632/oncotarget.19596; White BD, 2010, STEM CELLS, V28, P297, DOI 10.1002/stem.268; Zeng CW, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0884-z; Zhang FF, 2016, J AUTOIMMUN, V75, P96, DOI 10.1016/j.jaut.2016.07.012; Zhang M, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0656-7; Zhang Q, 2013, MBIO, V4, DOI 10.1128/mBio.00596-12; Zhong JJ, 2017, BRAIN BEHAV IMMUN, V65, P183, DOI 10.1016/j.bbi.2017.05.001	59	14	14	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1071-2690	1543-706X		IN VITRO CELL DEV-AN	In Vitro Cell. Dev. Biol.-Anim.	AUG	2019	55	7					501	511		10.1007/s11626-019-00375-y			11	Cell Biology; Developmental Biology	Cell Biology; Developmental Biology	IM3JC	WOS:000477888500004	31286366				2021-06-18	
J	Volovici, V; Steyerberg, EW; Cnossen, MC; Haitsma, IK; Dirven, CMF; Maas, AIR; Lingsma, HF				Volovici, Victor; Steyerberg, Ewout W.; Cnossen, Maryse C.; Haitsma, Iain K.; Dirven, Clemens M. F.; Maas, Andrew I. R.; Lingsma, Hester F.			Evolution of Evidence and Guideline Recommendations for the Medical Management of Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						BTF Guidelines; evidence base; guidelines for severe TBI; survival of recommendations	CLINICAL-PRACTICE GUIDELINES	Brain Trauma Foundation (BTF) Guidelines for medical management of severe traumatic brain injury (TBI) have become a global standard for the treatment of TBI patients. We aim to explore the evolution of the guidelines for the management of severe TBI. We reviewed the four editions of the BTF guidelines published over the past 20 years. The 1996 and 2000 editions were merged because of minimal differences, and are referred to as the 1996 edition. We described changes in topics and recommendations over time, and analyzed predictors of survival of recommendations with logistical regression. The guidelines contained 27 recommendations on 18 topics in 2016, 35 recommendations on 15 topics in 2007, and 22 recommendations on 10 topics in 1996. Substantial delays were found between the search for evidence and the guideline publication, ranging from 18 to 34 months. The overall body of evidence comprised 189 studies on 18 topics in 2016, compared with 156 studies on 15 topics in 2007 and 180 studies on 10 topics in 1996. Over time, a total of 175 studies were discarded from the evidence base following more rigorous grading of evidence. A total of 15/23 (65%) of the 1996/2000 recommendations were discarded over time. Out of 12 new recommendations introduced in the 2007 edition, 8 (66%) were discarded in 2016. Survival of recommendations varied between 33% and 100% for level I recommendations and between 11% and 31% for level II and III recommendations. No predictors of survival of recommendations were found. Substantial delays exist between literature search and publication, and survival rate of TBI guideline recommendations is poor. These factors may adversely affect currency and adherence to guidelines. The TBI community should take responsibility for improving the quality of the evidence base and ensuring that the translation of the evidence into guidelines supports clinicians in daily clinical practice.	[Volovici, Victor; Haitsma, Iain K.; Dirven, Clemens M. F.] Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands; [Volovici, Victor; Steyerberg, Ewout W.; Cnossen, Maryse C.; Lingsma, Hester F.] Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; [Steyerberg, Ewout W.] Leiden Univ, Med Ctr, Dept Med Stat & Bioinformat, Leiden, Netherlands; [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium	Volovici, V (corresponding author), Erasmus MC Univ, Med Ctr, Erasmus MC Stroke Ctr, Dept Neurosurg & Med Decis Making, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands.	v.volovici@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Volovici, Victor/AAZ-8901-2020	Maas, Andrew IR/0000-0003-1612-1264; Volovici, Victor/0000-0002-5798-5360	European Union Framework 7 program - CENTER TBI [602150]	This work was supported by the European Union Framework 7 program (grant 602150) - CENTER TBI. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bragge P, 2016, J NEUROTRAUM, V33, P1461, DOI 10.1089/neu.2015.4233; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Cnossen MC, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1816-9; Elliott JH, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001603; Grilli R, 2000, LANCET, V355, P103, DOI 10.1016/S0140-6736(99)02171-6; Higgins J, 2011, COCHRANE COLLAB, V5, P1, DOI DOI 10.1002/9780470712184; Kuehn BM, 2011, JAMA-J AM MED ASSOC, V305, P1846, DOI 10.1001/jama.2011.597; Kung J, 2012, ARCH INTERN MED, V172, P1628, DOI 10.1001/2013.jamainternmed.56; Laine C, 2011, ANN INTERN MED, V154, DOI 10.7326/0003-4819-154-11-201106070-00011; Lenfant C, 2003, NEW ENGL J MED, V349, P868, DOI 10.1056/NEJMsa035507; Liu WM, 2018, NEUROSURG REV, V41, P55, DOI 10.1007/s10143-016-0742-7; Meyfroidt G, 2017, NEUROSURGERY, V81, pE1, DOI 10.1093/neuros/nyx144; Neuman MD, 2014, JAMA-J AM MED ASSOC, V311, P2092, DOI 10.1001/jama.2014.4949; Robin Graham M.M., 2011, CLIN PRACTICE GUIDEL; Shaneyfelt TM, 2009, JAMA-J AM MED ASSOC, V301, P868, DOI 10.1001/jama.2009.225; The Brain Trauma Foundation, 2000, METHODOLOGY J NEUROT, V17, P561; Thomas L, 2000, COCHRANE DB SYST REV; Volovici V, 2019, WORLD NEUROSURG; Volovici V, 2017, NEUROSURGERY, V81, pE21, DOI 10.1093/neuros/nyx183; Yarascavitch BA, 2012, NEUROSURGERY, V71, P1131, DOI 10.1227/NEU.0b013e318271bc99	21	14	14	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2019	36	22					3183	3189		10.1089/neu.2019.6474		JUL 2019	7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	JI6MG	WOS:000479787600001	31280663	Green Accepted, Bronze			2021-06-18	
J	Sufrinko, AM; Kegel, NE; Mucha, A; Collins, MW; Kontos, AP				Sufrinko, Alicia M.; Kegel, Nathan E.; Mucha, Anne; Collins, Michael W.; Kontos, Anthony P.			History of High Motion Sickness Susceptibility Predicts Vestibular Dysfunction Following Sport/Recreation-Related Concussion	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; motion sickness susceptibility; neurocognitive; vestibular; ocular motor	POSTTRAUMATIC MIGRAINE; BASE-LINE; RELIABILITY; IMPACT; SYSTEM; DISORDERS; CONSTRUCT; RECOVERY; VALIDITY; BATTERY	Objective: To compare vestibular dysfunction at 1 to 10 and 11 to 20 days following sport/recreation-related concussion (SRC) in athletes with and without history of motion sickness susceptibility. Secondary aims of this study were to investigate differences in neurocognitive performance and affective symptoms in these groups. Design: Cross-sectional. Setting: Concussion Specialty Clinic. Participants: One hundred twenty-four adolescents and adults (82 males, 42 females) aged 14 to 26 (16.3 +/- 62.10) years, diagnosed with SRC in the past 10 (4.56 +/- 2.54) days; 47 participants composed the sample for quartile analyses. Independent Variable: Motion sickness susceptibility questionnaire short form score. Main Outcome Measures: Computerized neurocognitive test scores, vestibular/oculomotor screening scores (VOMS), and symptom factor scores from a standardized concussion symptom inventory. Results: There was no association between history of motion sickness susceptibility and VOMS scores (above or below clinical cutoff) at 1 to 10 days after injury, although at 11 to 20 days after injury there was an association between high motion sickness susceptibility and symptoms above clinical cutoff on 5 of the 6 VOMS items (P values 0.01-0.04). The high motion sickness group had more affective symptoms on the symptom inventory than the no motion sickness group (P=0.002) at 1 to 10 days after injury. Groups did not differ on computerized neurocognitive testing (P = 0.11). Conclusion: Athletes with a preexisting history of motion sensitivity may exhibit more prolonged vestibular dysfunction following SRC, and may experience more affective symptoms early in recovery.	[Sufrinko, Alicia M.; Kegel, Nathan E.; Collins, Michael W.; Kontos, Anthony P.] Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, Pittsburgh, PA USA; [Mucha, Anne] UPMC Ctr Rehabil Serv, Pittsburgh, PA USA	Sufrinko, AM (corresponding author), UPMC Ctr Sports Med, 3200 South Water St, Pittsburgh, PA 15203 USA.	sufrinkoam@upmc.edu					Alhilali LM, 2014, RADIOLOGY, V272, P224, DOI 10.1148/radiol.14132670; Allen BJ, 2011, BRAIN INJURY, V25, P179, DOI 10.3109/02699052.2010.541897; Anzalone AJ, 2016, AM J SPORTS MED, V45, P36; Chen YC, 2013, GAIT POSTURE, V38, P795, DOI 10.1016/j.gaitpost.2013.03.023; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Cullen KE, 2012, TRENDS NEUROSCI, V35, P185, DOI 10.1016/j.tins.2011.12.001; Elbin R, 2015, PERSPECT NEUROPHYSIO, V25, P4, DOI DOI 10.1044/NNSLD25.1.4; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P709, DOI 10.3171/2015.5.PEDS15220; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Furman JM, 2011, J HEADACHE PAIN, V12, P81, DOI 10.1007/s10194-010-0250-z; Golding JF, 2006, PERS INDIV DIFFER, V41, P237, DOI 10.1016/j.paid.2006.01.012; Golding JF, 2015, CURR OPIN NEUROL, V28, P83, DOI 10.1097/WCO.0000000000000163; Gurvich C, 2013, BRAIN RES, V1537, P244, DOI 10.1016/j.brainres.2013.08.058; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Jeong SH, 2010, J NEUROL, V257, P905, DOI 10.1007/s00415-009-5435-5; Kolev OI, 2016, FUNCT NEUROL, V31, P75; Kontos AP, 2016, AM J SPORT MED, V44, P1400, DOI 10.1177/0363546516632754; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Mast FW, 2014, FRONT INTEGR NEUROSC, V8, DOI 10.3389/fnint.2014.00044; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Rajagopalan Archana, 2017, J Nat Sci Biol Med, V8, P11, DOI 10.4103/0976-9668.198350; Saman Yougan, 2012, Front Neurol, V3, P116, DOI 10.3389/fneur.2012.00116; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Scopaz KA, 2013, SPORTS HEALTH, V5, P537, DOI 10.1177/1941738112473059; Smith PF, 2017, CURR OPIN NEUROL, V30, P84, DOI 10.1097/WCO.0000000000000403; Sufrinko A, 2018, J HEAD TRAUMA REHAB, V33, P7, DOI 10.1097/HTR.0000000000000315; Yorke AM, 2017, SPORTS HEALTH, V9, P174, DOI 10.1177/1941738116678411	36	14	15	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2019	29	4					318	323		10.1097/JSM.0000000000000528			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	IQ4RL	WOS:000480737900012	31241535				2021-06-18	
J	Schroeder, RW; Olsen, DH; Martin, PK				Schroeder, Ryan W.; Olsen, Daniel H.; Martin, Phillip K.			Classification accuracy rates of four TOMM validity indices when examined independently and jointly	CLINICAL NEUROPSYCHOLOGIST			English	Article						TOMM; test of memory malingering; performance validity; sensitivity; specificity	ADVANCED CLINICAL SOLUTIONS; ALBANY CONSISTENCY INDEX; MEMORY MALINGERING TOMM; TRAUMATIC BRAIN-INJURY; TRIAL 1; DIGIT SPAN; PERFORMANCE; VALIDATION; INDICATORS; BELIEFS	Objective: This study investigated sensitivity and specificity rates of four Test of Memory Malingering (TOMM) indices (Trial 1, Trial 2, Retention, and Albany Consistency Index (ACI)) and examined how classification accuracy rates change when utilizing these indices in various combinations. Method: A sample of 202 neuropsychological outpatients was utilized. Patients were categorized as valid performers if they passed all criterion performance validity tests (PVTs) and were determined to be invalid performers if they failed two or more criterion PVTs. Classification accuracy statistics were obtained for individual TOMM indices as well as combinations of TOMM indices. Results: When using only Trial 1 as a validity indicator, the TOMM identified 57% of invalidly performing individuals. When all TOMM indices were examined, the ACI demonstrated the highest sensitivity value (63%) but it also demonstrated the lowest specificity value (91%). Allowing for failure of any of the four TOMM indices provided the best overall sensitivity value (67%) while maintaining adequate specificity (90%). Finally, it was determined that failure of three or more TOMM validity indices resulted in a specificity rate of 97% and failure of four of more TOMM validity indices resulted in a specificity rate of 98%. Conclusions: Classification accuracy of TOMM validity indices are discussed in relation to positive and negative predictive values. Results suggest that clinicians can examine all four TOMM validity indices concurrently, particularly in settings where high base rates of invalidity occur.	[Schroeder, Ryan W.; Olsen, Daniel H.; Martin, Phillip K.] Univ Kansas, Sch Med Wichita, Dept Psychiat & Behav Sci, 1010 N Kansas St, Wichita, KS 67214 USA	Schroeder, RW (corresponding author), Univ Kansas, Sch Med Wichita, Dept Psychiat & Behav Sci, 1010 N Kansas St, Wichita, KS 67214 USA.	rschroeder2@kumc.edu					[Anonymous], 2009, ADV CLIN SOL ADM SCO; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Boone K. B., 2002, DOT COUNTING TEST MA; Boone K. B., 2013, CLIN PRACTICE FORENS; Buddin WH, 2014, CLIN NEUROPSYCHOL, V28, P525, DOI 10.1080/13854046.2014.906658; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P1278, DOI 10.1080/13854046.2014.975844; Davis JJ, 2012, ARCH CLIN NEUROPSYCH, V27, P706, DOI 10.1093/arclin/acs078; Dean AC, 2008, CLIN NEUROPSYCHOL, V22, P705, DOI 10.1080/13854040701440493; Dean AC, 2009, CLIN NEUROPSYCHOL, V23, P133, DOI 10.1080/13854040701819050; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Fazio RL, 2017, CLIN NEUROPSYCHOL, V31, P251, DOI 10.1080/13854046.2016.1213316; Green P, 2011, APPL NEUROPSYCHOL, V18, P18, DOI 10.1080/09084282.2010.523365; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P1250, DOI 10.1080/13854040902828272; Gunner JH, 2012, ARCH CLIN NEUROPSYCH, V27, P1, DOI 10.1093/arclin/acr089; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; HOSMER DW, 2000, WILEY PS TX, P1; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Marshall P, 2010, CLIN NEUROPSYCHOL, V24, P1204, DOI 10.1080/13854046.2010.514290; Martin PK, 2018, ASSESSMENT, V25, P640, DOI 10.1177/1073191116656796; Martin PK, 2017, CLIN NEUROPSYCHOL, V31, P829, DOI 10.1080/13854046.2017.1284265; Martin PK, 2015, CLIN NEUROPSYCHOL, V29, P741, DOI 10.1080/13854046.2015.1087597; Meyers J E, 2001, Appl Neuropsychol, V8, P234, DOI 10.1207/S15324826AN0804_6; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; Odland AP, 2015, PSYCHOL INJ LAW, V8, P46, DOI 10.1007/s12207-015-9216-4; Olsen DH, 2019, CLIN NEUROPSYCHOL, V33, P732, DOI 10.1080/13854046.2018.1501096; Proto DA, 2014, ARCH CLIN NEUROPSYCH, V29, P614, DOI 10.1093/arclin/acu044; Schroeder RW, 2013, ARCH CLIN NEUROPSYCH, V28, P21, DOI 10.1093/arclin/acs094; Schroeder RW, 2019, CLIN NEUROPSYCHOL, V33, P466, DOI 10.1080/13854046.2018.1484517; Schroeder RW, 2016, CLIN NEUROPSYCHOL, V30, P515, DOI 10.1080/13854046.2016.1177118; Schroeder RW, 2012, ASSESSMENT, V19, P21, DOI 10.1177/1073191111428764; Schroeder RW, 2011, CLIN NEUROPSYCHOL, V25, P437, DOI 10.1080/13854046.2011.556668; Schroeder RW, 2010, CLIN NEUROPSYCHOL, V24, P326, DOI 10.1080/13854040903369441; Silk-Eglit GM, 2015, APPL NEUROPSYCH-ADUL, V22, P335, DOI 10.1080/23279095.2014.938809; Tombaugh TN, 1996, TEST MEMORY MALINGER; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682	44	14	14	1	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	NOV 17	2019	33	8			SI		1373	1387		10.1080/13854046.2019.1619839		JUN 2019	15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	JH1IM	WOS:000478424100001	31130071				2021-06-18	
J	Fraser, EE; Downing, MG; Biernacki, K; McKenzie, DP; Ponsford, JL				Fraser, Elinor E.; Downing, Marina G.; Biernacki, Kathryn; McKenzie, Dean P.; Ponsford, Jennie L.			Cognitive Reserve and Age Predict Cognitive Recovery after Mild to Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cognitive recovery; cognitive reserve; traumatic brain injury	GLASGOW COMA SCALE; NEUROPSYCHOLOGICAL RECOVERY; MULTIPLE IMPUTATION; CLINICAL UTILITY; OLDER-ADULTS; HEAD-INJURY; FOLLOW-UP; MODERATE; IMPACT; TRAJECTORIES	The persistence of injury-related cognitive impairments can have devastating consequences for everyday function after traumatic brain injury (TBI). This longitudinal study examined the association of long-term cognitive recovery in 109 adults (71% male) experiencing complicated mild-to-severe TBI with age, pre-morbid intelligence (IQ), and injury severity measured by post-traumatic amnesia (PTA) duration. Participants' twice completed measures of pre-morbid IQ (National Adult Reading Test), attention (Digit Symbol Coding Test), memory (Rey Auditory Verbal Learning Test), and executive function (Trail Making Test Part-B) at a mean of 43.73 days post-TBI and again at a mean of 3.70 years (range 23-72 months) post-injury. A healthy control group comprising 63 adults (59% male) completed the measures once. At initial assessment, TBI participants performed significantly worse on all measures compared with the healthy control group. Within the TBI group, shorter PTA duration, younger age, and higher pre-morbid IQ were associated with better initial cognitive performance. Cognitive task performance improved significantly in the TBI group at follow-up between two to five years later but remained significantly below control group means. Notably, higher pre-morbid IQ and younger age were associated with greater cognitive recovery at follow-up, whereas PTA duration was not. These findings support the role of cognitive reserve and age in cognitive recovery after TBI and may inform prognostication and rehabilitation. Additional research is needed to elucidate the biological mechanisms of cognitive reserve in cognitive recovery after TBI.	[Fraser, Elinor E.; Downing, Marina G.; Ponsford, Jennie L.] Monash Univ, Monash Epworth Rehabil Res Ctr, Monash Inst Cognit & Clin Neurosci, Melbourne, Vic, Australia; [Biernacki, Kathryn] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; [McKenzie, Dean P.] Rutgers State Univ, Ctr Mol & Behav Neurosci, Newark, NJ USA; [McKenzie, Dean P.] Epworth HealthCare, Melbourne, Vic, Australia	Ponsford, JL (corresponding author), Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu	Downing, Marina/AAX-2380-2020	Downing, Marina/0000-0002-3126-6632; Fraser, Elinor/0000-0001-5679-4362	Transport Accident Commission	This research was funded by the Transport Accident Commission. The authors also gratefully acknowledge the staff at the Monash-Epworth Rehabilitation Research Centre for their assistance with data collection.	[Anonymous], 2010, LANCET NEUROL, V9, P331, DOI 10.1016/S1474-4422(10)70069-7; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P139, DOI 10.1097/01.HTR.0000319930.69343.64; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bigler Erin D, 2015, Handb Clin Neurol, V128, P691, DOI 10.1016/B978-0-444-63521-1.00043-1; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; BROWN MB, 1974, J AM STAT ASSOC, V69, P364, DOI 10.2307/2285659; CALLAHAN CD, 1994, J CLIN PSYCHOL MED S, V1, P261, DOI 10.1007/BF01989627; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; Crawford J.R., 1992, HDB NEUROPSYCHOLOGIC; de Guise E, 2017, BRAIN INJURY, V31, P1061, DOI 10.1080/02699052.2017.1297485; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Donders J, 2019, ARCH CLIN NEUROPSYCH, V34, P206, DOI 10.1093/arclin/acy035; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Farbota KDM, 2012, J INT NEUROPSYCH SOC, V18, P1006, DOI 10.1017/S1355617712000835; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Griesbach GS, 2018, J NEUROTRAUM, V35, P17, DOI 10.1089/neu.2017.5103; Harel O, 2009, J APPL STAT, V36, P1109, DOI 10.1080/02664760802553000; Haut MW, 2007, BRAIN IMAGING BEHAV, V1, P83, DOI 10.1007/s11682-007-9008-x; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Howell DC., 2012, STAT METHODS PSYCHOL; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jeon IC, 2008, J KOREAN NEUROSURG S, V44, P295, DOI 10.3340/jkns.2008.44.5.295; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Kruskal W. H., 1960, TECHNOMETRICS, V2, P1, DOI [10.2307/1266526, DOI 10.2307/1266526]; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Lannoo E, 2001, BRAIN INJURY, V15, P1, DOI 10.1080/02699050150209084; Leary JB, 2018, J HEAD TRAUMA REHAB, V33, pE28, DOI 10.1097/HTR.0000000000000329; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Little R, 2002, STAT ANAL MISSING DA, V2nd; LITTLE RJA, 1992, J AM STAT ASSOC, V87, P1227, DOI 10.2307/2290664; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; MOSS AR, 1991, BRIT J CLIN PSYCHOL, V30, P179, DOI 10.1111/j.2044-8260.1991.tb00934.x; Narad ME, 2017, J HEAD TRAUMA REHAB, V32, P98, DOI 10.1097/HTR.0000000000000247; Nelson HE, 1982, NATL ADULT READING T; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pedersen AB, 2017, CLIN EPIDEMIOL, V9, P157, DOI 10.2147/CLEP.S129785; Pollet TV, 2017, ADAPT HUM BEHAV PHYS, V3, P43, DOI 10.1007/s40750-016-0050-z; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Rabinowitz AR, 2018, J INT NEUROPSYCH SOC, V24, P237, DOI 10.1017/S1355617717000996; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rassovsky Y, 2015, J CLIN EXP NEUROPSYC, V37, P354, DOI 10.1080/13803395.2015.1015498; Raz N, 2006, NEUROSCI BIOBEHAV R, V30, P730, DOI 10.1016/j.neubiorev.2006.07.001; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reitan R. M., 1992, TRAIL MAKING TEST MA; Riley GA, 2003, BRIT J CLIN PSYCHOL, V42, P319, DOI 10.1348/01446650360703410; Thais MERD, 2014, J NEUROPSYCHOL, V8, P125, DOI 10.1111/jnp.12000; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Schmidt M., 1996, REY AUDITORY VERBAL; Schneider EB, 2014, NEUROLOGY, V82, P1636, DOI 10.1212/WNL.0000000000000379; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schultz R, 2013, BRAIN IMPAIR, V14, P450, DOI 10.1017/BrImp.2013.24; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Sherer M, 2006, BRAIN INJURY, V20, P997, DOI 10.1080/02699050600677055; Sherer M, 2017, J HEAD TRAUMA REHAB, V32, pE17, DOI 10.1097/HTR.0000000000000290; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Sigurdardottir S, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000039; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Song M, 2008, NEUROIMAGE, V41, P1168, DOI 10.1016/j.neuroimage.2008.02.036; Spitz G, 2013, BRAIN COGNITION, V83, P34, DOI 10.1016/j.bandc.2013.06.007; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Stern Y, 2009, NEUROPSYCHOLOGIA, V47, P2015, DOI 10.1016/j.neuropsychologia.2009.03.004; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; Steward KA, 2018, J HEAD TRAUMA REHAB, V33, pE18, DOI 10.1097/HTR.0000000000000325; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Sumowski JF, 2013, ARCH PHYS MED REHAB, V94, P2562, DOI 10.1016/j.apmr.2013.07.023; Tabachnick B.G., 2013, USING MULTIVARIATE S; van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463; van den Heuvel MP, 2009, J NEUROSCI, V29, P7619, DOI 10.1523/JNEUROSCI.1443-09.2009; Vasquez BP, 2018, NEUROREHAB NEURAL RE, V32, P191, DOI 10.1177/1545968318760727; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Wardlaw C, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00563; Watt KJ, 1999, J NEUROL NEUROSUR PS, V66, P474, DOI 10.1136/jnnp.66.4.474; Wechsler D, 1997, WAIS 3 WECHSLER ADUL; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wood RLI, 2006, J NEUROL NEUROSUR PS, V77, P1180, DOI 10.1136/jnnp.2006.091553	89	14	14	4	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2019	36	19					2753	2761		10.1089/neu.2019.6430		JUN 2019	9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	JB8IG	WOS:000472104100001	31017049				2021-06-18	
J	Bari, S; Svaldi, DO; Jang, I; Shenk, TE; Poole, VN; Lee, T; Dydak, U; Rispoli, JV; Nauman, EA; Talavage, TM				Bari, Sumra; Svaldi, Diana O.; Jang, Ikbeom; Shenk, Trey E.; Poole, Victoria N.; Lee, Taylor; Dydak, Ulrike; Rispoli, Joseph V.; Nauman, Eric A.; Talavage, Thomas M.			Dependence on subconcussive impacts of brain metabolism in collision sport athletes: an MR spectroscopic study	BRAIN IMAGING AND BEHAVIOR			English	Article						MR spectroscopy; Concussion; Subconcussive injury; Football; Soccer	MAGNETIC-RESONANCE SPECTROSCOPY; CHRONIC TRAUMATIC ENCEPHALOPATHY; APPEARING WHITE-MATTER; DEFAULT MODE NETWORK; HIGH-SCHOOL; COGNITIVE IMPAIRMENT; HEAD IMPACTS; INJURY; CONCUSSION; REPRODUCIBILITY	Long term neurological impairments due to repetitive head trauma are a growing concern for collision sport athletes. American Football has the highest rate of reported concussions among male high school athletes, a position held by soccer for female high school athletes. Recent research has shown that subconcussive events experienced by collision sport athletes can be a further significant source of accrued damage. Collision sport athletes experience hundreds of subconcussive events in a single season, and these largely go uninvestigated as they produce no overt clinical symptoms. Continued participation by these seemingly uninjured athletes is hypothesized to increase susceptibility to diagnoseable brain injury. This study paired magnetic resonance spectroscopy with head impact monitoring to quantify the relationship between metabolic changes and head acceleration event characteristics in high school-aged male football and female soccer collision sport athletes. During the period of exposure to subconcussive events, asymptomatic male (football) collision sport athletes exhibited statistically significant changes in concentrations of glutamate+glutamine (Glx) and total choline containing compounds (tCho) in dorsolateral prefrontal cortex, and female (soccer) collision sport athletes exhibited changes in glutamate+glutamine (Glx) in primary motor cortex. Neurometabolic alterations observed in football athletes during the second half of the season were found to be significantly associated with the average acceleration per head acceleration events, being best predicted by the accumulation of events exceeding 50g. These marked deviations in neurometabolism, in the absence of overt symptoms, raise concern about the neural health of adolescent collision-sport athletes and suggest limiting exposure to head acceleration events may help to ameliorate the risk of subsequent cognitive impairment.	[Bari, Sumra; Jang, Ikbeom; Shenk, Trey E.; Rispoli, Joseph V.; Talavage, Thomas M.] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA; [Svaldi, Diana O.; Poole, Victoria N.; Rispoli, Joseph V.; Nauman, Eric A.; Talavage, Thomas M.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Svaldi, Diana O.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN 46202 USA; [Lee, Taylor; Nauman, Eric A.] Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA; [Dydak, Ulrike] Purdue Univ, Sch Hlth Sci, W Lafayette, IN 47907 USA; [Nauman, Eric A.] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Talavage, TM (corresponding author), Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA.; Talavage, TM (corresponding author), Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA.	tmt@purdue.edu	Rispoli, Joseph/AAB-1655-2019	Rispoli, Joseph/0000-0003-4514-3390; Poole, Victoria/0000-0003-0974-2564; Lee, Taylor/0000-0001-9218-9194	General Electric HealthcareGE Healthcare; BrainScope Company, GE-NFL Head Health Initiative	This study was funded in part by General Electric Healthcare and the BrainScope Company, as part of a grant obtained from the GE-NFL Head Health Initiative.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Abbas K, 2015, DEV NEUROPSYCHOL, V40, P51, DOI 10.1080/87565641.2014.990455; Alosco Michael L, 2017, Alzheimers Dement (Amst), V7, P33, DOI 10.1016/j.dadm.2016.11.003; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/neu.2004.21.1539; Auerbach PS, 2016, JAMA-J AM MED ASSOC, V316, P1260, DOI 10.1001/jama.2016.8184; Bailes J, 2015, DEV NEUROPSYCHOL, V40, P59, DOI 10.1080/87565641.2015.1018090; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Batra NA, 2008, BIOL PSYCHIAT, V63, P1178, DOI 10.1016/j.biopsych.2007.10.007; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Belson K, 2015, NY TIMES, pB12; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Breedlove KM., 2014, ATHLETIC TRAIN SPORT, V6, P119, DOI [10.3928/19425864-20140507-02, DOI 10.3928/19425864-20140507-02]; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chard DT, 2002, BRAIN, V125, P2342, DOI 10.1093/brain/awf240; Chun IY, 2015, DEV NEUROPSYCHOL, V40, P92, DOI 10.1080/87565641.2015.1020945; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Cummiskey B, 2017, P I MECH ENG P-J SPO, V231, P144, DOI 10.1177/1754337116658395; Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; DeLellis Stephen M, 2009, J Spec Oper Med, V9, P36; Ding XQ, 2015, MAGN RESON MED, V73, P921, DOI 10.1002/mrm.25208; Dou WQ, 2015, MAGN RESON MATER PHY, V28, P259, DOI 10.1007/s10334-014-0469-9; Endres D, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00367; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2001, J ATHL TRAINING, V36, P228; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Groger A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084081; Gujar SK, 2005, J NEURO-OPHTHALMOL, V25, P217, DOI 10.1097/01.wno.0000177307.21081.81; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hancu L, 2005, NMR BIOMED, V18, P352, DOI 10.1002/nbm.965; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Honaker J, 2011, J STAT SOFTW, V45, P1; Jang I, 2016, 22 ANN M ORG HUM BRA; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Lin Alexander, 2005, NeuroRx, V2, P197, DOI 10.1602/neurorx.2.2.197; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; Maudsley AA, 2010, NMR BIOMED, V23, P251, DOI 10.1002/nbm.1445; Maudsley AA, 2015, J NEUROTRAUM, V32, P1056, DOI 10.1089/neu.2014.3505; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Newsholme P, 2003, CELL BIOCHEM FUNCT, V21, P1, DOI 10.1002/cbf.1003; O'Gorman RL, 2011, J MAGN RESON IMAGING, V33, P1262, DOI 10.1002/jmri.22520; Oz G, 2014, RADIOLOGY, V270, P658, DOI 10.1148/radiol.13130531; Poole VN, 2015, DEV NEUROPSYCHOL, V40, P12, DOI 10.1080/87565641.2014.984810; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Rasgon NL, 2001, PSYCHIAT RES-NEUROIM, V106, P47, DOI 10.1016/S0925-4927(00)00085-8; Reynolds BB, 2018, BRAIN IMAGING BEHAV, V12, P1332, DOI 10.1007/s11682-017-9790-z; Ricci B, 1997, NEURORADIOLOGY, V39, P313, DOI 10.1007/s002340050415; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Schwarz A, 2011, NY TIMES, pD1; Shenk TE, 2015, DEV NEUROPSYCHOL, V40, P63, DOI 10.1080/87565641.2015.1014088; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Slobounov SM, 2017, NEUROIMAGE-CLIN, V14, P708, DOI 10.1016/j.nicl.2017.03.006; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Svaldi DO, 2017, BRAIN IMAGING BEHAV, V11, P98, DOI 10.1007/s11682-016-9509-6; Svaldi DO, 2015, DEV NEUROPSYCHOL, V40, P80, DOI 10.1080/87565641.2014.973959; Svaldi DO, 2016, CEREBROVASCULAR REAC; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; Talavage TM, 2016, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00273; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Wilde EA, 2015, BRAIN IMAGING BEHAV, V9, P367, DOI 10.1007/s11682-015-9444-y; Wilson M, 2011, MAGN RESON MED, V65, P1, DOI 10.1002/mrm.22579; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Zhang B, 2015, J NEUROIMAGING, V25, P269, DOI 10.1111/jon.12138; Zhu H, 2011, METHODS MOL BIOL, V711, P203, DOI 10.1007/978-1-61737-992-5_9; Zhu XP, 2006, ALZ DIS ASSOC DIS, V20, P77, DOI 10.1097/01.wad.0000213809.12553.fc; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	89	14	14	1	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2019	13	3					735	749		10.1007/s11682-018-9861-9			15	Neuroimaging	Neurosciences & Neurology	IA1VV	WOS:000469351500015	29802602				2021-06-18	
J	Rogers, JM; Duckworth, J; Middleton, S; Steenbergen, B; Wilson, PH				Rogers, Jeffrey M.; Duckworth, Jonathan; Middleton, Sandy; Steenbergen, Bert; Wilson, Peter H.			Elements virtual rehabilitation improves motor, cognitive, and functional outcomes in adult stroke: evidence from a randomized controlled pilot study	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article						Cognition; Motor activity; Rehabilitation; Stroke; Upper extremity; Virtual reality	TRAUMATIC BRAIN-INJURY; REALITY-BASED REHABILITATION; UPPER EXTREMITY FUNCTION; ARM FUNCTION; BLOCK TEST; INTERNATIONAL CLASSIFICATION; RECOVERY; IMPAIRMENT; VALIDITY; THERAPY	BackgroundVirtual reality technologies show potential as effective rehabilitation tools following neuro-trauma. In particular, the Elements system, involving customized surface computing and tangible interfaces, produces strong treatment effects for upper-limb and cognitive function following traumatic brain injury. The present study evaluated the efficacy of Elements as a virtual rehabilitation approach for stroke survivors.MethodsTwenty-one adults (42-94years old) with sub-acute stroke were randomized to four weeks of Elements virtual rehabilitation (three weekly 30-40min sessions) combined with treatment as usual (conventional occupational and physiotherapy) or to treatment as usual alone. Upper-limb skill (Box and Blocks Test), cognition (Montreal Cognitive Assessment and selected CogState subtests), and everyday participation (Neurobehavioral Functioning Inventory) were examined before and after inpatient training, and one-month later.ResultsEffect sizes for the experimental group (d=1.05-2.51) were larger compared with controls (d=0.11-0.86), with Elements training showing statistically greater improvements in motor function of the most affected hand (p=0.008), and general intellectual status and executive function (p0.001). Proportional recovery was two- to three-fold greater than control participants, with superior transfer to everyday motor, cognitive, and communication behaviors. All gains were maintained at follow-up.ConclusionA course of Elements virtual rehabilitation using goal-directed and exploratory upper-limb movement tasks facilitates both motor and cognitive recovery after stroke. The magnitude of training effects, maintenance of gains at follow-up, and generalization to daily activities provide compelling preliminary evidence of the power of virtual rehabilitation when applied in a targeted and principled manner.Trial registrationthis pilot study was not registered.	[Rogers, Jeffrey M.] Univ Sydney, Fac Hlth Sci, Sydney, NSW, Australia; [Duckworth, Jonathan] RMIT, Sch Design, Melbourne, Vic, Australia; [Middleton, Sandy] St Vincents Hlth Australia, Nursing Res Inst, Sydney, NSW, Australia; [Middleton, Sandy] Australian Catholic Univ, Sydney, NSW, Australia; [Steenbergen, Bert] Radboud Univ Nijmegen, Behav Sci Inst, Nijmegen, Netherlands; [Wilson, Peter H.] Australian Catholic Univ, Ctr Disabil & Dev Res CeDDR, Melbourne, Vic, Australia; [Wilson, Peter H.] Australian Catholic Univ, Sch Behav & Hlth Sci, Melbourne, Vic, Australia	Rogers, JM (corresponding author), Univ Sydney, Fac Hlth Sci, Sydney, NSW, Australia.	jeffrey.rogers@sydney.edu.au	Middleton, Sandy/J-5526-2015; Wilson, Peter H./E-2881-2018	Middleton, Sandy/0000-0002-7201-4394; Wilson, Peter H./0000-0003-3747-0287; Steenbergen, Bert/0000-0001-8863-2624	Prince of Wales Hospital Foundation Research Grant; Australian Catholic University Research Fund Program Grant	This research was supported by a Prince of Wales Hospital Foundation Research Grant awarded to JMR and an Australian Catholic University Research Fund Program Grant awarded to PHW.	Acosta AM, 2011, J REHABIL RES DEV, V48, P431, DOI 10.1682/JRRD.2010.04.0052; Adams ILJ, 2014, NEUROSCI BIOBEHAV R, V47, P225, DOI 10.1016/j.neubiorev.2014.08.011; Al Banna M, 2016, J NEUROL NEUROSUR PS, V87, P161, DOI 10.1136/jnnp-2015-310305; Aminov A, 2018, J NEUROENG REHABIL, V15, DOI 10.1186/s12984-018-0370-2; Aminov A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185841; [Anonymous], 2017, STROK AUSTR NO POSTC; Barker-Collo S, 2012, STROKE, V43, P50, DOI 10.1161/STROKEAHA.111.627182; Barsalou LW, 2010, TOP COGN SCI, V2, P716, DOI 10.1111/j.1756-8765.2010.01115.x; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Billinger SA, 2014, STROKE, V45, P2532, DOI 10.1161/STR.0000000000000022; Boyd LA, 2003, PHYS THER, V83, P976, DOI 10.1093/ptj/83.11.976; Broeren J, 2008, CEREBROVASC DIS, V26, P289, DOI 10.1159/000149576; Broeren J, 2008, STUD HEALTH TECHNOL, V136, P77; Burton L, 2015, J REHABIL MED, V47, P193, DOI 10.2340/16501977-1930; Cameirao MS, 2016, J NEUROENG REHABIL, V13, DOI 10.1186/s12984-016-0127-8; CameirAo MS, 2017, P 2017 INT C VIRT RE, V2017, P1, DOI DOI 10.1109/ICVR.2017.8007543; Chen C, 2013, NEUROLOGY, V80, pS27, DOI 10.1212/WNL.0b013e3182762569; Choi JH, 2014, ANN REHABIL MED-ARM, V38, P485, DOI 10.5535/arm.2014.38.4.485; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Crosbie JH, 2012, CLIN REHABIL, V26, P798, DOI 10.1177/0269215511434575; Cumming TB, 2016, INT J STROKE, V11, P968, DOI 10.1177/1747493016669861; Cumming TB, 2013, INT J STROKE, V8, P38, DOI 10.1111/j.1747-4949.2012.00972.x; Cumming TB, 2011, STROKE, V42, P2642, DOI 10.1161/STROKEAHA.111.619486; Cameirao MDS, 2011, RESTOR NEUROL NEUROS, V29, P287, DOI 10.3233/RNN-2011-0599; DESROSIERS J, 1994, ARCH PHYS MED REHAB, V75, P751; Dijkerman C, 2018, CORTEX, V104, P133, DOI 10.1016/j.cortex.2018.06.001; Palma GCD, 2017, TOP STROKE REHABIL, V24, P269, DOI 10.1080/10749357.2016.1250373; Douiri A, 2013, STROKE, V44, P138, DOI 10.1161/STROKEAHA.112.670844; Duckworth Jonathan, 2013, Design, User Experience, and Usability. Health, Learning, Playing, Cultural, and Cross-Cultural User Experience.Second International Conference, DUXU 2013 Held as Part of HCI International 2013. Proceedings. LNCS 8013, P391, DOI 10.1007/978-3-642-39241-2_43; Duckworth J, 2009, SUPERHUMAN REVOULTIO, P120; Duff M, 2013, NEUROREHAB NEURAL RE, V27, P306, DOI 10.1177/1545968312465195; Dunn LE, 2016, CEREBROVASC DIS EXTR, V6, P12, DOI 10.1159/000444149; Edmans JA, 2006, STROKE, V37, P2770, DOI 10.1161/01.STR.0000245133.50935.65; Falleti MG, 2006, J CLIN EXP NEUROPSYC, V28, P1095, DOI 10.1080/13803390500205718; Faria AL, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00854; Favate AS, 2016, NEUROL CLIN, V34, P967, DOI 10.1016/j.ncl.2016.06.013; Friedly J, 2014, ARCH PHYS MED REHAB, V95, P1419, DOI 10.1016/j.apmr.2014.03.022; Fritz NE, 2015, J NEUROL PHYS THER, V39, P142, DOI 10.1097/NPT.0000000000000090; Fu MJ, 2015, PHYS MED REH CLIN N, V26, P747, DOI 10.1016/j.pmr.2015.06.001; Gamito P, 2017, DISABIL REHABIL, V39, P385, DOI 10.3109/09638288.2014.934925; Green D, 2012, DISABIL REHABIL, V34, P593, DOI 10.3109/09638288.2011.613520; Harrison RA, 2015, CEREBROVASC DIS, V39, P190, DOI 10.1159/000375397; Hatem SM, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00442; Hawe R.L., 2018, STROKE, DOI 10.1161/STROKEAHA.118. 023006; Higgins JP, 2008, COCHRANE HDB SYSTEMA; Hope TMH, 2019, BRAIN, V142, P15, DOI 10.1093/brain/awy302; Housman SJ, 2009, NEUROREHAB NEURAL RE, V23, P505, DOI 10.1177/1545968308331148; Howard MC, 2017, COMPUT HUM BEHAV, V70, P317, DOI 10.1016/j.chb.2017.01.013; In TS, 2012, J PHYS THER SCI, V24, P339, DOI 10.1589/jpts.24.339; Jo K, 2012, J PHYS THER SCI, V24, P1205; Jokinen H, 2015, EUR J NEUROL, V22, P1288, DOI 10.1111/ene.12743; Kaelin-Lang A, 2005, J NEUROPHYSIOL, V93, P1099, DOI 10.1152/jn.00143.2004; Kalaria RN, 2016, BBA-MOL BASIS DIS, V1862, P915, DOI 10.1016/j.bbadis.2016.01.015; Kim BR, 2011, ANN REHABIL MED-ARM, V35, P450, DOI 10.5535/arm.2011.35.4.450; Kizony R, 2003, J VISUAL COMP ANIMAT, V14, P261, DOI 10.1002/vis.323; Kottink AIR, 2014, GAMES HEALTH J, V3, P184, DOI 10.1089/g4h.2014.0026; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; Kwon JS, 2012, NEUROREHABILITATION, V31, P379, DOI 10.3233/NRE-2012-00807; Lai SM, 2002, STROKE, V33, P1840, DOI 10.1161/01.STR.0000019289.15440.F2; LANGE K, 2010, P ICDVRAT CHIL AUG, P249, DOI DOI 10.1007/978-1-4419-5945-4_14; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Laugrand F, 2010, ARCTIC ANTHROPOL, V47, P1; Laver KE, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008349.pub4; Leisman G, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00094; Levin MF, 2012, NEUROL THER, V1, DOI 10.1007/s40120-012-0003-9; Lohse KR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093318; Maier M, 2019, NEUROREHAB NEURAL RE, V33, P112, DOI 10.1177/1545968318820169; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; MATHIOWETZ V, 1985, AM J OCCUP THER, V39, P386, DOI 10.5014/ajot.39.6.386; McDonald MW, 2018, FRONT BEHAV NEUROSCI, V12, DOI 10.3389/fnbeh.2018.00135; Merians AS, 2002, PHYS THER, V82, P898, DOI 10.1093/ptj/82.9.898; Meyer S, 2015, STROKE, V46, P1613, DOI 10.1161/STROKEAHA.115.009421; Mitchell AJ, 2017, GEN HOSP PSYCHIAT, V47, P48, DOI 10.1016/j.genhosppsych.2017.04.001; Mullick AA, 2015, RESTOR NEUROL NEUROS, V33, P389, DOI 10.3233/RNN-150510; Mumford N, 2012, BRAIN INJURY, V26, P166, DOI 10.3109/02699052.2011.648706; Mumford N, 2010, BRAIN INJURY, V24, P780, DOI 10.3109/02699051003652807; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nijenhuis SM, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0080-y; Platz T, 2005, CLIN REHABIL, V19, P404, DOI 10.1191/0269215505cr832oa; Prabhakaran S, 2008, NEUROREHAB NEURAL RE, V22, P64, DOI 10.1177/1545968307305302; Reeves M, 2013, STROKE, V44, P3211, DOI 10.1161/STROKEAHA.113.002881; Rizzo AA, 2004, NEUROPSYCHOL REHABIL, V14, P207, DOI 10.1080/09602010343000183; Rogers JM, 2018, NEUROPSYCHOL REV; Sakzewski L, 2013, PEDIATRICS; Saposnik G, 2016, LANCET NEUROL, V15, P1019, DOI 10.1016/S1474-4422(16)30121-1; Saposnik G, 2011, STROKE, V42, P1380, DOI 10.1161/STROKEAHA.110.605451; Saposnik G, 2010, STROKE, V41, P1477, DOI 10.1161/STROKEAHA.110.584979; Schultheis MT, 2001, J CLIN PSYCHIAT, V62, P617, DOI [10.4088/JCP.v62n0808, DOI 10.4088/JCP.V62N0808]; Shah N, 2014, GAMES HEALTH J, V3, P13, DOI 10.1089/g4h.2013.0044; Sin H, 2013, AM J PHYS MED REHAB, V92, P871, DOI 10.1097/PHM.0b013e3182a38e40; Standen PJ, 2017, CLIN REHABIL, V31, P340, DOI 10.1177/0269215516640320; Stolwyk RJ, 2018, TOP STROKE REHABIL, V25, P527, DOI 10.1080/10749357.2018.1499301; Stroke Foundation, 2017, CLIN GUID STROK MAN; Subramanian SK, 2015, 2015 INTERNATIONAL CONFERENCE ON VIRTUAL REHABILITATION PROCEEDINGS (ICVR), P38, DOI 10.1109/ICVR.2015.7358582; TATEMICHI TK, 1994, J NEUROL NEUROSUR PS, V57, P202, DOI 10.1136/jnnp.57.2.202; Thomas SA, 2006, BRIT J CLIN PSYCHOL, V45, P49, DOI 10.1348/014466505X34183; Tieri G, 2018, EXPERT REV MED DEVIC, V15, P107, DOI 10.1080/17434440.2018.1425613; Tse T, 2013, ARCH PHYS MED REHAB, V94, P177, DOI 10.1016/j.apmr.2012.09.002; Vargus-Adams JN, 2014, J CHILD NEUROL, V29, P1030, DOI 10.1177/0883073814533595; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; Vratsistas-Curto A, 2018, CLIN REHABIL, V32, P1098, DOI 10.1177/0269215518778316; Wagle J, 2011, DEMENT GERIATR COGN, V31, P379, DOI 10.1159/000328970; Weiss P, 2006, TXB NEURAL REPAIR RE, V51, P182; Wood RL, 2008, BRAIN INJURY, V22, P905, DOI 10.1080/02699050802491271; World Health Organization, 2017, INT CLASS FUNCT DIS; Yin CW, 2014, CLIN REHABIL, V28, P1107, DOI 10.1177/0269215514532851; Zimmerli L, 2013, ARCH PHYS MED REHAB, V94, P1737, DOI 10.1016/j.apmr.2013.01.029	109	14	15	3	17	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1743-0003		J NEUROENG REHABIL	J. NeuroEng. Rehabil.	MAY 15	2019	16								56	10.1186/s12984-019-0531-y			13	Engineering, Biomedical; Neurosciences; Rehabilitation	Engineering; Neurosciences & Neurology; Rehabilitation	HY3UZ	WOS:000468054200002	31092252	DOAJ Gold, Green Published			2021-06-18	
J	Churchill, NW; Caverzasi, E; Graham, SJ; Hutchison, MG; Schweizer, TA				Churchill, Nathan W.; Caverzasi, Eduardo; Graham, Simon J.; Hutchison, Michael G.; Schweizer, Tom A.			White matter during concussion recovery: Comparing diffusion tensor imaging (DTI) and neurite orientation dispersion and density imaging (NODDI)	HUMAN BRAIN MAPPING			English	Article						concussion; DTI; NODDI; white matter	TRAUMATIC BRAIN-INJURY; MICROSTRUCTURE; STABILITY; SPORT	Concussion pathophysiology in humans remains incompletely understood. Diffusion tensor imaging (DTI) has identified microstructural abnormalities in otherwise normal appearing brain tissue, using measures of fractional anisotropy (FA), axial diffusivity (AD), and radial diffusivity (RD). The results of prior DTI studies suggest that acute alterations in microstructure persist beyond medical clearance to return to play (RTP), but these measures lack specificity. To better understand the observed effects, this study combined DTI with neurite orientation dispersion and density imaging (NODDI), which employs a more sophisticated description of water diffusion in the brain. A total of 66 athletes were recruited, including 33 concussed athletes, scanned within 7 days after concussion and at RTP, along with 33 matched controls. Both univariate and multivariate methods identified DTI and NODDI parameters showing effects of concussion on white matter. Spatially extensive decreases in FA and increases in AD and RD were associated with reduced intra-neurite water volume, at both the symptomatic phase of injury and RTP, indicating that effects persist beyond medical clearance. Subsequent analyses also demonstrated that concussed athletes with higher symptom burden and a longer recovery time had greater reductions in FA and increased AD, RD, along with increased neurite dispersion. This study provides the first longitudinal evaluation of concussion from acute injury to RTP using combined DTI and NODDI, significantly enhancing our understanding of the effects of concussion on white matter microstructure.	[Churchill, Nathan W.; Schweizer, Tom A.] St Michaels Hosp, Neurosci Res Program, Toronto, ON, Canada; [Churchill, Nathan W.; Hutchison, Michael G.; Schweizer, Tom A.] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Caverzasi, Eduardo] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Graham, Simon J.] Sunnybrook Res Inst, Phys Sci Platform, Toronto, ON, Canada; [Graham, Simon J.] Univ Toronto, Dept Med Biophys, Fac Med, Toronto, ON, Canada; [Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Fac Med Neurosurg, Toronto, ON, Canada	Churchill, NW (corresponding author), 209 Victoria St, Toronto, ON M5B 1M8, Canada.	nchurchill.research@gmail.com	Caverzasi, Eduardo/P-1707-2019		Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [RN294001-367456]; Canadian Institute for Military and Veterans Health [W7714-145967]; Siemens Canada Ltd.	Canadian Institutes of Health Research, Grant/Award Number: RN294001-367456; Canadian Institute for Military and Veterans Health, Grant/Award Number: W7714-145967; Siemens Canada Ltd.	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bro R, 1996, J CHEMOMETR, V10, P47, DOI 10.1002/(SICI)1099-128X(199601)10:1<47::AID-CEM400>3.3.CO;2-3; Chang YS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123656; Churchill N, 2013, SPRINGER P MATH STAT, V56, P171, DOI 10.1007/978-1-4614-8283-3_11; Churchill NW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07742-3; Churchill NW, 2017, HUM BRAIN MAPP, V38, P4201, DOI 10.1002/hbm.23658; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Dean PJA, 2015, BRAIN INJURY, V29, P1211, DOI 10.3109/02699052.2015.1035334; Di Battista AP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159929; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Grussu F, 2017, ANN CLIN TRANSL NEUR, V4, P663, DOI 10.1002/acn3.445; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Hutchinson EB, 2017, MAGN RESON MED, V78, P1767, DOI 10.1002/mrm.26575; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Krishnan A, 2011, NEUROIMAGE, V56, P455, DOI 10.1016/j.neuroimage.2010.07.034; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Marmarou A, 2007, NEUROSURG FOCUS, V22, pE1, DOI DOI 10.3171/F0C.2007.22.5.2; Mayer AR, 2017, BRAIN IMAGING BEHAV, V11, P698, DOI 10.1007/s11682-016-9546-1; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrea M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097447; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meier TB, 2016, HUM BRAIN MAPP, V37, P833, DOI 10.1002/hbm.23072; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe V, 2009, BRIT J NEUROSURGERY, V21, P340; Owen JP, 2014, J NEUROSCI, V34, P6214, DOI 10.1523/JNEUROSCI.4495-13.2014; Patterson ZR, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00058; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wang Y, 2011, NEUROIMAGE, V55, P1577, DOI 10.1016/j.neuroimage.2011.01.038; Zhang H, 2012, NEUROIMAGE, V61, P1000, DOI 10.1016/j.neuroimage.2012.03.072	42	14	14	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	APR 15	2019	40	6					1908	1918		10.1002/hbm.24500			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	HO5SD	WOS:000460987100018	30585674	Bronze, Green Published			2021-06-18	
J	Das, N; Spence, JS; Aslan, S; Vanneste, S; Mudar, R; Rackley, A; Quiceno, M; Chapman, SB				Das, Namrafa; Spence, Jeffrey S.; Aslan, Sina; Vanneste, Sven; Mudar, Raksha; Rackley, Audette; Quiceno, Mary; Chapman, Sandra Bond			Cognitive Training and Transcranial Direct Current Stimulation in Mild Cognitive Impairment: A Randomized Pilot Trial	FRONTIERS IN NEUROSCIENCE			English	Article						mild cognitive impairment; Alzheimer's disease; transcranial direct current stimulation; cerebral blood flow; fMRI; cognitive training; strategic memory advanced reasoning training; brain modulation	TRAUMATIC BRAIN-INJURY; DISEASE; MEMORY; INHIBITION; ACTIVATION; DEMENTIA; RISK; TDCS	Background: Transcranial direct current stimulation (tDCS), a non-invasive stimulation, represents a potential intervention to enhance cognition across clinical populations including Alzheimer's disease and mild cognitive impairment (MCI). This randomized clinical trial in MCI investigated the effects of anodal tDCS (a-tDCS) delivered to left inferior frontal gyrus (IFG) combined with gist-reasoning training (SMART) versus sham tDCS (s-tDCS) plus SMART on measures of cognitive and neural changes in resting cerebral blood flow (rCBF). We were also interested in SMART effects on cognitive performance regardless of the tDCS group. Methods: Twenty-two MCI participants, who completed the baseline cognitive assessment (T1), were randomized into one of two groups: a-tDCS + SMART and s-tDCS + SMART. Of which, 20 participants completed resting pCASL MRI scan to measure rCBF. Eight SMART sessions were administered over 4 weeks with a-tDCS or s-tDCS stimulation for 20 min before each session. Participants were assessed immediately (T2) and 3-months after training (T3). Results: Significant group x time interactions showed cognitive gains at T2 in executive function (EF) measure of inhibition [DKEFS- Color word (p = 0.047)], innovation [TOSL (p = 0.01)] and on episodic memory [TOSL (p = 0.048)] in s-tDCS + SMART but not in a-tDCS + SMART group. Nonetheless, the gains did not persist for 3 months (T3) after the training. A voxel-based analysis showed significant increase in regional rCBF in the right middle frontal cortex (MFC) (cluster-wise p = 0.05, k = 1,168 mm(3)) in a-tDCS + SMART compared to s-tDCS + SMART. No significant relationship was observed between the increased CBF with cognition. Irrespective of group, the combined MCI showed gains at T2 in EF of conceptual reasoning [DKEFS card sort (p = 0.033)] and category fluency [COWAT (p = 0.055)], along with gains at T3 in EF of verbal fluency [COWAT (p = 0.009)]. Conclusion: One intriguing finding is a-tDCS to left IFG plus SMART increased blood flow to right MFC, however, the stimulation seemingly blocked cognitive benefits of SMART on EF (inhibition and innovation) and episodic memory compared to s-tDCS + SMART group. Although the sample size is small, this paper contributes to growing evidence that cognitive training provides a way to significantly enhance cognitive performance in adults showing memory loss, where the role of a-tDCS in augmenting these effects need further study.	[Das, Namrafa; Spence, Jeffrey S.; Aslan, Sina; Vanneste, Sven; Rackley, Audette; Chapman, Sandra Bond] Univ Texas Dallas, Ctr BrainHlth, Dallas, TX 75080 USA; [Aslan, Sina] Adv MRI LLC, Frisco, TX USA; [Mudar, Raksha] Univ Illinois, Dept Speech & Hearing Sci, Champaign, IL USA; [Quiceno, Mary] Univ North Texas, Hlth Sci Ctr, Ft Worth, TX USA; [Quiceno, Mary] Univ North Texas, Dept Internal Med & Geriatr, Ft Worth, TX USA; [Quiceno, Mary] Univ North Texas, TCU UNTHSC, Sch Med, Dept Med Educ, Ft Worth, TX USA	Chapman, SB (corresponding author), Univ Texas Dallas, Ctr BrainHlth, Dallas, TX 75080 USA.	schapman@utdallas.edu		Vanneste, Sven/0000-0003-1513-5752	BvB Dallas; Sammons Enterprises; Barbara Wallace and Kelly King Charitable Foundation Trust; Dallas Foundation; Golden Rule Family Foundation	This research project was supported by BvB Dallas, Sammons Enterprises, Barbara Wallace and Kelly King Charitable Foundation Trust, the AWARE fund of the Dallas Foundation, and the Golden Rule Family Foundation. ClinicalTrials.gov ID: NCT02588209.	Aisen PS, 2010, ALZHEIMERS DEMENT, V6, P239, DOI 10.1016/j.jalz.2010.03.006; Anand R, 2011, INT J GERIATR PSYCH, V26, P961, DOI 10.1002/gps.2633; Andrieu S, 2015, LANCET NEUROL, V14, P926, DOI 10.1016/S1474-4422(15)00153-2; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Aslan S, 2010, MAGN RESON MED, V63, P765, DOI 10.1002/mrm.22245; Belleville S, 2011, BRAIN, V134, P1623, DOI 10.1093/brain/awr037; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Benton A., 1994, MULTILINGUAL APHASIA; Biundo R, 2015, BRAIN STIMUL, V8, P1223, DOI 10.1016/j.brs.2015.07.043; Boggio PS, 2012, BRAIN STIMUL, V5, P223, DOI 10.1016/j.brs.2011.06.006; Cattaneo Z, 2011, NEUROSCIENCE, V183, P64, DOI 10.1016/j.neuroscience.2011.03.058; Chapman SB, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00314; Chapman SB, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00338; Chapman SB, 2015, CEREB CORTEX, V25, P396, DOI 10.1093/cercor/bht234; Chapman SB, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00069; Chapman SB, 2002, ALZ DIS ASSOC DIS, V16, P177, DOI 10.1097/00002093-200207000-00008; Cohen AD, 2014, NEUROBIOL DIS, V72, P117, DOI 10.1016/j.nbd.2014.05.001; Cook LG, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00087; Cotelli M, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00038; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Diamond EL, 2007, NEUROLOGY, V69, P1331, DOI 10.1212/01.wnl.0000277292.37292.69; Edwards Jerri D, 2017, Alzheimers Dement (N Y), V3, P603, DOI 10.1016/j.trci.2017.09.002; Elder GJ, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0074-1; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Ferrucci R, 2008, NEUROLOGY, V71, P493, DOI 10.1212/01.wnl.0000317060.43722.a3; Filbey FM, 2010, BRAIN IMAGING BEHAV, V4, P177, DOI 10.1007/s11682-010-9097-9; Floel A, 2012, NEUROBIOL AGING, V33, P1682, DOI 10.1016/j.neurobiolaging.2011.05.007; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gonzalez PC, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00416; Grady C, 2012, NAT REV NEUROSCI, V13, P491, DOI 10.1038/nrn3256; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Han K, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.687; Hanten G, 2007, DEV NEUROPSYCHOL, V32, P585, DOI 10.1080/87565640701361112; Harvey PD, 2018, BIOL PSYCHIAT-COGN N, V3, P907, DOI 10.1016/j.bpsc.2018.06.008; Heilman KM, 2003, NEUROCASE, V9, P369, DOI 10.1076/neur.9.5.369.16553; Iyer MB, 2005, NEUROLOGY, V64, P872, DOI 10.1212/01.WNL.0000152986.07469.E9; Japee S, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00023; Jean L, 2010, AM J GERIAT PSYCHIAT, V18, P281, DOI 10.1097/JGP.0b013e3181c37ce9; Lang N, 2003, SUPPL CLIN NEUROPHYS, V56, P277; Manenti R, 2016, MOVEMENT DISORD, V31, P715, DOI 10.1002/mds.26561; Manly JJ, 2008, ANN NEUROL, V63, P494, DOI 10.1002/ana.21326; Meinzer M, 2015, ALZHEIMERS DEMENT, V11, P1032, DOI 10.1016/j.jalz.2014.07.159; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Morris MC, 2009, EUR J NEUROL, V16, P1, DOI 10.1111/j.1468-1331.2009.02735.x; Motes MA, 2018, NEUROBIOL AGING, V62, P72, DOI 10.1016/j.neurobiolaging.2017.10.003; Mudar RA, 2019, BRAIN RES, V1704, P229, DOI 10.1016/j.brainres.2018.10.017; Mudar RA, 2017, INT J GERIATR PSYCH, V32, P548, DOI 10.1002/gps.4492; Murugaraja V, 2017, ASIAN J PSYCHIATR, V30, P135, DOI 10.1016/j.ajp.2017.09.001; Nitsche M. A., 2007, TRANSCRANIAL BRAIN S, V23; Peters MAK, 2013, NEUROPSYCHOLOGIA, V51, P1234, DOI 10.1016/j.neuropsychologia.2013.03.013; Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985; Polania R, 2011, HUM BRAIN MAPP, V32, P1236, DOI 10.1002/hbm.21104; Prehn K, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00355; Reinhart RMG, 2017, ATTEN PERCEPT PSYCHO, V79, P3, DOI 10.3758/s13414-016-1224-2; Roberts RO, 2014, NEUROLOGY, V82, P317, DOI 10.1212/WNL.0000000000000055; Rubia K, 2003, NEUROIMAGE, V20, P351, DOI 10.1016/S1053-8119(03)00275-1; Siddiqui Shazia Veqar, 2008, Indian J Psychiatry, V50, P202, DOI 10.4103/0019-5545.43634; Spreen O., 1998, COMPENDIUM NEUROPSYC; Troyer AK, 2002, J GERONTOL B-PSYCHOL, V57, pP19, DOI 10.1093/geronb/57.1.P19; Vas A, 2016, NEUROPSYCHOL REHABIL, V26, P502, DOI 10.1080/09602011.2015.1044013; Vas Asha K, 2015, Handb Clin Neurol, V128, P497, DOI 10.1016/B978-0-444-63521-1.00031-5; Vas AK, 2011, J HEAD TRAUMA REHAB, V26, P224, DOI 10.1097/HTR.0b013e318218dd3d; Venza EE, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01676; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Weiner M. W., 2013, ALZHEIMERS DEMENTI S, V9, P194, DOI [10.1016/j.jalz.2013.05, DOI 10.1016/J.JALZ.2013.05]; Wilkinson G.S., 2006, WRAT4 WIDE RANGE ACH; Wishart HA, 2006, AM J PSYCHIAT, V163, P1603, DOI 10.1176/appi.ajp.163.9.1603; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; Yun K, 2016, ALZHEIMERS RES THER, V8, DOI 10.1186/s13195-016-0218-6	70	14	15	1	19	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	APR 12	2019	13								307	10.3389/fnins.2019.00307			14	Neurosciences	Neurosciences & Neurology	HT3GB	WOS:000464451200001	31031581	DOAJ Gold, Green Published			2021-06-18	
J	Pham, L; Shultz, SR; Kim, HA; Brady, RD; Wortman, RC; Genders, SG; Hale, MW; O'Shea, RD; Djouma, E; van den Buuse, M; Church, JE; Christie, BR; Drummond, GR; Sobey, CG; McDonald, SJ				Pham, Louise; Shultz, Sandy R.; Kim, Hyun Ah; Brady, Rhys D.; Wortman, Ryan C.; Genders, Shannyn G.; Hale, Matthew W.; O'Shea, Ross D.; Djouma, Elvan; van den Buuse, Maarten; Church, Jarrod E.; Christie, Brian R.; Drummond, Grant R.; Sobey, Christopher G.; McDonald, Stuart J.			Mild Closed-Head Injury in Conscious Rats Causes Transient Neurobehavioral and Glial Disturbances: A Novel Experimental Model of Concussion	JOURNAL OF NEUROTRAUMA			English	Article						anesthesia; astrocytes; behavior; microglia; mild traumatic brain injury; neuroinflammation	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; ELEVATED PLUS-MAZE; ANIMAL-MODELS; ANXIETY; ADULT; NEUROINFLAMMATION; DEPRESSION; VULNERABILITY; THRESHOLD	Rodent models can provide insights into the most pertinent issues surrounding concussion. Nonetheless, the relevance of some existing models to clinical concussion can be questioned, particularly with regard to the use of surgery and anesthesia and the mechanism and severity of injury. Accordingly, we have co-developed an awake closed-head injury (ACHI) model in rats. Here, we aimed to create a temporal profile of the neurobehavioral and neuropathological effects of a single ACHI. Adolescent male rats were placed in a restraint bag and a steel helmet was positioned over the head such that the impact target was centered over the left parietal cortex. Once positioned on a foam platform, a cortical impactor was used to strike the helmet. Sham animals underwent the same procedure without impact. When compared with sham rats, those given a single ACHI displayed evidence of sensorimotor deficits and reduced exploratory behavior within the first 20 min post-injury; however, these effects were resolved after 24 h. A single ACHI impaired spatial memory on the Y-maze task at both 5 min and 24 h post-ACHI; however, no deficits were apparent at 48 h. Immunostaining revealed region-specific increases in ionized calcium-binding adaptor molecule 1 and glial fibrillary acidic protein expression at 3 days post-impact, with no differences found at either 1 or 14 days. Taken together, our findings indicate that a single ACHI results in transient neurobehavioral and glial disturbances and as such, this model may be a valuable tool for pre-clinical concussion research.	[Pham, Louise; Kim, Hyun Ah; Genders, Shannyn G.; O'Shea, Ross D.; Djouma, Elvan; Church, Jarrod E.; Drummond, Grant R.; Sobey, Christopher G.; McDonald, Stuart J.] La Trobe Univ, Dept Physiol Anat & Microbiol, Bundoora, Vic, Australia; [Hale, Matthew W.; van den Buuse, Maarten] La Trobe Univ, Dept Psychol & Counseling, Bundoora, Vic, Australia; [Shultz, Sandy R.; Brady, Rhys D.; Wortman, Ryan C.; McDonald, Stuart J.] Monash Univ, Dept Neurosci, Melbourne, Vic, Australia; [Shultz, Sandy R.; Brady, Rhys D.] Univ Melbourne, Dept Med, Melbourne, Vic, Australia; [van den Buuse, Maarten] Univ Melbourne, Dept Pharmacol, Melbourne, Vic, Australia; [van den Buuse, Maarten] James Cook Univ, Coll Publ Hlth Med & Vet Sci, Townsville, Qld, Australia; [Christie, Brian R.] Univ Victoria, Div Med Sci, Victoria, BC, Canada	McDonald, SJ (corresponding author), Monash Univ, Cent Clin Sch, Dept Neurosci, Melbourne, Vic 3004, Australia.	stuart.mcdonald@monash.edu	Christie, Brian/AAF-3766-2019; O'Shea, Ross D/B-5426-2012	O'Shea, Ross D/0000-0002-8178-8797; Hale, Matthew/0000-0003-1686-0972; McDonald, Stuart/0000-0001-5190-3179; Christie, Brian/0000-0002-6830-0160	Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Sport, Exercise, and Rehabilitation RFA of La Trobe University; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Natural Sciences and Engineering Research CouncilNatural Sciences and Engineering Research Council of Canada (NSERC)	CGS, SRS, and GRD acknowledge the Australian National Health and Medical Research Council for funding. SJM acknowledges funding from the Sport, Exercise, and Rehabilitation RFA of La Trobe University. BRC receives funding from the Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council. The authors also thank Karen Griggs for her continued assistance with this work.	Agoston DV, 2017, BRAIN INJURY, V31, P1195, DOI 10.1080/02699052.2017.1357836; Brady RD, 2016, J MUSCULOSKEL NEURON, V16, P369; Brady RD, 2016, J NEUROTRAUM, V33, P2154, DOI 10.1089/neu.2014.3836; Cao L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051431; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Davis G.A., 2017, BR J SPORTS MED, V5, P1, DOI DOI 10.1136/BJSPORTS-2017-097506; Dean O, 2009, BEHAV BRAIN RES, V198, P258, DOI 10.1016/j.bbr.2008.11.017; Dong YL, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0039386, 10.1371/journal.pone.0034435, 10.1371/journal.pone.0051643]; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Fehily B, 2017, CELL TRANSPLANT, V26, P1131, DOI 10.1177/0963689717714092; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Finch CF, 2013, MED J AUSTRALIA, V198, P427, DOI 10.5694/mja12.11217; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gururajan A, 2015, NEUROSCIENCE, V284, P297, DOI 10.1016/j.neuroscience.2014.10.009; Gururajana A, 2014, NEUROSCI LETT, V576, P6, DOI 10.1016/j.neulet.2014.05.041; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Iverson GL, 2015, NEUROSCI BIOBEHAV R, V56, P276, DOI 10.1016/j.neubiorev.2015.05.008; Jamnia N, 2017, J NEUROTRAUM, V34, P1351, DOI 10.1089/neu.2016.4517; Johnstone MR, 2018, BRAIN INJURY, V32, P257, DOI 10.1080/02699052.2017.1394492; Kamins J, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097464; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Luh C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019948; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Manley G, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097791; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097447; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; Meconi A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197187; Namjoshi DR, 2017, EXP NEUROL, V292, P80, DOI 10.1016/j.expneurol.2017.03.003; Namjoshi DR, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-55; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Peng M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29874; Petraglia Anthony L, 2014, Neurosurgery, V75 Suppl 4, pS34, DOI 10.1227/NEU.0000000000000472; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; Rowe RK, 2013, LAB ANIMAL, V42, P286, DOI 10.1038/laban.257; Shultz SR, 2017, NEUROSCI BIOBEHAV R, V76, P396, DOI 10.1016/j.neubiorev.2016.09.014; Shultz SR, 2015, J CEREBR BLOOD F MET, V35, P1339, DOI 10.1038/jcbfm.2015.56; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Sun MJ, 2017, BRAIN BEHAV IMMUN, V66, P359, DOI 10.1016/j.bbi.2017.08.005; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; Teel EF, 2017, J ATHL TRAINING, V52, P288, DOI 10.4085/1062-6050-52.1.12; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vink R, 2018, J NEUROSCI RES, V96, P527, DOI 10.1002/jnr.24079; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Wortman RC, 2018, J NEUROTRAUM, V35, pA199; Wright DK, 2017, ANN CLIN TRANSL NEUR, V4, P640, DOI 10.1002/acn3.441; Wright DK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28713; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang JZ, 2015, DEV NEUROPSYCHOL, V40, P18, DOI 10.1080/87565641.2014.973499; Yonezaki K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122118	61	14	15	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2019	36	14					2260	2271		10.1089/neu.2018.6169		APR 2019	12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	IH1NO	WOS:000464546500001	30843474				2021-06-18	
J	Dewan, MC; Rattani, A; Baticulon, RE; Faruque, S; Johnson, WD; Dempsey, RJ; Haglund, MM; Alkire, BC; Park, KB; Warf, BC; Shrime, MG				Dewan, Michael C.; Rattani, Abbas; Baticulon, Ronnie E.; Faruque, Serena; Johnson, Walter D.; Dempsey, Robert J.; Haglund, Michael M.; Alkire, Blake C.; Park, Kee B.; Warf, Benjamin C.; Shrime, Mark G.			Operative and consultative proportions of neurosurgical disease worldwide: estimation from the surgeon perspective	JOURNAL OF NEUROSURGERY			English	Article						burden; global; neurosurgery; surgeon; survey	GLOBAL NEUROSURGERY; BURDEN	OBJECTIVE The global magnitude of neurosurgical disease is unknown. The authors sought to estimate the surgical and consultative proportion of diseases commonly encountered by neurosurgeons, as well as surgeon case volume and perceived workload. METHODS An electronic survey was sent to 193 neurosurgeons previously identified via a global surgeon mapping initiative. The survey consisted of three sections aimed at quantifying surgical incidence of neurological disease, consultation incidence, and surgeon demographic data. Surgeons were asked to estimate the proportion of 11 neurological disorders that, in an ideal world, would indicate either neurosurgical operation or neurosurgical consultation. Respondent surgeons indicated their confidence level in each estimate. Demographic and surgical practice characteristics-including case volume and perceived workload-were also captured. RESULTS Eighty-five neurosurgeons from 57 countries, representing all WHO regions and World Bank income levels, completed the survey. Neurological conditions estimated to warrant neurosurgical consultation with the highest frequency were brain tumors (96%), spinal tumors (95%), hydrocephalus (94%), and neural tube defects (92%), whereas stroke (54%), central nervous system infection (58%), and epilepsy (40%) carried the lowest frequency. Similarly, surgery was deemed necessary for an average of 88% cases of hydrocephalus, 82% of spinal tumors and neural tube defects, and 78% of brain tumors. Degenerative spine disease (42%), stroke (31%), and epilepsy (24%) were found to warrant surgical intervention less frequently. Confidence levels were consistently high among respondents (lower quartile > 70/100 for 90% of questions), and estimates did not vary significantly across WHO regions or among income levels. Surgeons reported performing a mean of 245 cases annually (median 190). On a 100-point scale indicating a surgeon's perceived workload (0-not busy, 100-overworked), respondents selected a mean workload of 75 (median 79). CONCLUSIONS With a high level of confidence and strong concordance, neurosurgeons estimated that the vast majority of patients with central nervous system tumors, hydrocephalus, or neural tube defects mandate neurosurgical involvement. A significant proportion of other common neurological diseases, such as traumatic brain and spinal injury, vascular anomalies, and degenerative spine disease, demand the attention of a neurosurgeon-whether via operative intervention or expert counsel. These estimates facilitate measurement of the expected annual volume of neurosurgical disease globally.	[Dewan, Michael C.; Rattani, Abbas; Alkire, Blake C.; Park, Kee B.; Warf, Benjamin C.; Shrime, Mark G.] Dept Global Hlth & Social Med, Global Neurosurg Initiat, Program Global Surg & Social Change, Boston, MA USA; [Warf, Benjamin C.] Harvard Med Sch, Boston Childrens Hosp, Dept Neurol Surg, Boston, MA 02115 USA; [Alkire, Blake C.] Off Global Surg & Hlth, Boston, MA USA; [Shrime, Mark G.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA; [Faruque, Serena] Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA; [Dewan, Michael C.] Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN USA; [Rattani, Abbas] Meharry Med Coll, Sch Med, Nashville, TN 37208 USA; [Baticulon, Ronnie E.] Univ Philippines, Coll Med, Philippine Gen Hosp, Manila, Philippines; [Johnson, Walter D.] World Hlth Org, Emergency & Essential Surg Care Programme Lead, Geneva, Switzerland; [Dempsey, Robert J.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol Surg, Madison, WI USA; [Haglund, Michael M.] Duke Univ, Dept Neurosurg, Div Global Neurosurg & Neurol, Durham, NC USA; [Haglund, Michael M.] Duke Univ, Duke Global Hlth Inst, Durham, NC USA	Dewan, MC (corresponding author), Vanderbilt Univ, Med Ctr, Nashville, TN 37235 USA.	michael.dewan@vumc.org	Baticulon, Ronnie/AAW-7768-2020; Alkire, Blake/AAY-6463-2020	Baticulon, Ronnie/0000-0002-2781-1845; 	Vanderbilt Medical Scholars Program; NCATS/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000445]; GE Foundation Safe Surgery 2020; Steven and Carmella Kletjian Foundation	We thank Charles Howard for his assistance in identifying potential study participants. We acknowledge the Vanderbilt Medical Scholars Program for providing Abbas Rattani with support on this project.; Grant funding support from NCATS/NIH UL1 TR000445 for Vanderbilt REDCap (M.C.D.). Grant funding support from GE Foundation Safe Surgery 2020 and the Steven and Carmella Kletjian Foundation (M.G.S.).	Alkire BC, 2015, LANCET GLOB HEALTH, V3, pE316, DOI 10.1016/S2214-109X(15)70115-4; Anderson JE, 2014, WORLD J SURG, V38, P823, DOI 10.1007/s00268-013-2366-1; Aspinall W, 2010, NATURE, V463, P294, DOI 10.1038/463294a; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Haglund MM, 2011, WORLD J SURG, V35, P1175, DOI 10.1007/s00268-011-1080-0; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Lo A, 2014, J GLOB HEALTH, V4, DOI 10.7189/jogh.04.010402; Meara JG, 2015, LANCET, V386, P569, DOI 10.1016/S0140-6736(15)60160-X; Miranda-Filho A, 2017, NEURO-ONCOLOGY, V19, P270, DOI 10.1093/neuonc/now166; Nayar V, 2016, ANN THORAC SURG, V101, P190, DOI 10.1016/j.athoracsur.2015.07.042; Park KB, 2016, WORLD NEUROSURG, V88, P32, DOI 10.1016/j.wneu.2015.12.048; Pugely AJ, 2015, J BONE JOINT SURG AM, V97A, P1278, DOI 10.2106/JBJS.N.01260; Punchak M, 2016, NEUROSCI COLOMB, V23, P294; Punchak M, 2018, WORLD NEUROSURG, V112, pE240, DOI 10.1016/j.wneu.2018.01.029; Shrime MG, 2015, LANCET GLOB HEALTH, V3, pS8, DOI 10.1016/S2214-109X(14)70384-5; Warf BC, 2015, WORLD NEUROSURG, V84, P1547, DOI 10.1016/j.wneu.2015.07.052	16	14	14	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2019	130	4					1098	1106		10.3171/2017.10.JNS17347			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HR1CV	WOS:000462866700007	29749918	Bronze			2021-06-18	
J	Li, QZ; Wang, PC; Huang, CX; Chen, BZ; Liu, JB; Zhao, MM; Zhao, JN				Li, Qingzhi; Wang, Pengcheng; Huang, Chuixue; Chen, Baozhi; Liu, Jiabin; Zhao, Mingmei; Zhao, Jiannong			N-Acetyl Serotonin Protects Neural Progenitor Cells Against Oxidative Stress-Induced Apoptosis and Improves Neurogenesis in Adult Mouse Hippocampus Following Traumatic Brain Injury	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						N-acetyl serotonin; Neural progenitor cell; Apoptosis; Oxidative stress; Hippocampal neurogenesis; Traumatic brain injury	GLYCOGEN-SYNTHASE KINASE-3; ACTIVATION	In this study, with primary mouse neural progenitor cells (NPCs), we investigated the neuroprotective effect of a tropomyosin-related kinase receptor B (TrkB) agonist, N-acetyl serotonin (NAS), against hydrogen peroxide (H2O2)-induced toxicity. We found that pre-incubation with NAS not only ameliorates H2O2-induced cell viability loss, lactate dehydrogenase (LDH) release, and proliferative and migratory capacity impairments, but counteracts H2O2-triggered production of nitric oxide (NO), reactive oxygen species (ROS), malondialdehyde (MDA), and 8-hydroxy-deoxyguanosine (8-OHdG) in a dose-dependent manner. Additionally, pre-treatment with NAS was able to attenuate H2O2-induced apoptosis in NPCs, evidenced by the decreased percentage of apoptotic cells and altered expression of apoptosis-related factors. Furthermore, in differentiated NPCs, NAS improves H2O2-induced reduction in neurite growth. Mechanistic studies revealed that the protective effects of NAS in NPCs may be mediated by the TrkB/PI3K/Akt/ cAMP response element binding protein (CREB) signaling cascades. In a mouse traumatic brain injury (TBI) model, we found that systemic administration of 30mg/kg NAS could improve hippocampal neurogenesis, manifested by the increased number of SOX-2-positive cells and increased expression of phosphorylated CREB in the dentate gyrus (DG) area. Treatment with NAS also ameliorates cognitive impairments caused by TBI, as assessed by Y-maze and contextual and cued fear conditioning tests. Taken together, these results provide valuable insights into the neuroprotective and neuroregenerative effects of NAS, suggesting it may have therapeutic potential for the treatment of TBI.	[Li, Qingzhi; Wang, Pengcheng; Huang, Chuixue; Chen, Baozhi; Zhao, Jiannong] Hainan Gen Hosp, Dept Neurosurg, 19 Xiuhua Rd, Haikou 570311, Hainan, Peoples R China; [Liu, Jiabin] Southern Med Univ, Dept Radiotherapy, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China; [Zhao, Mingmei] Qingdao Univ, Coll Med, Affiliated Hosp, Dept Neurosurg, Qingdao, Shandong, Peoples R China	Zhao, JN (corresponding author), Hainan Gen Hosp, Dept Neurosurg, 19 Xiuhua Rd, Haikou 570311, Hainan, Peoples R China.	md.zhaojiannong@outlook.com					Atkins CM, 2009, NEUROSCI LETT, V459, P52, DOI 10.1016/j.neulet.2009.04.064; Bergmann O, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a018994; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Blaya MO, 2015, EXP NEUROL, V264, P67, DOI 10.1016/j.expneurol.2014.11.014; Chen L, 2015, J NEUROPATH EXP NEUR, V74, P557, DOI 10.1097/NEN.0000000000000199; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Fernandez-Gajardo R, 2014, CNS DRUGS, V28, P229, DOI 10.1007/s40263-013-0138-y; Guzowski JF, 1997, P NATL ACAD SCI USA, V94, P2693, DOI 10.1073/pnas.94.6.2693; Haddad SH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-12; Hammad A, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1066-z; He YB, 2014, NAT NEUROSCI, V17, P943, DOI 10.1038/nn.3732; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Hughes RN, 2004, NEUROSCI BIOBEHAV R, V28, P497, DOI 10.1016/j.neubiorev.2004.06.006; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Katagiri D, 2013, J AM SOC NEPHROL, V24, P2034, DOI 10.1681/ASN.2013020134; Lazarov O, 2016, PROG NEUROBIOL, V138, P1, DOI 10.1016/j.pneurobio.2015.12.006; Leaden PJ, 2007, PROSTAG LEUKOTR ESS, V77, P29, DOI 10.1016/j.plefa.2007.06.001; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Massa SM, 2010, J CLIN INVEST, V120, P1774, DOI 10.1172/JCI41356; Mayer CL, 2013, HEADACHE, V53, P1523, DOI 10.1111/head.12173; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P231, DOI 10.1017/S1355617712001506; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Ngwenya LB, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00102; Peltier J, 2007, DEV NEUROBIOL, V67, P1348, DOI 10.1002/dneu.20506; Pierini D, 2015, METHODS MOL BIOL, V1208, P63, DOI 10.1007/978-1-4939-1441-8_5; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shoji H, 2014, JOVE-J VIS EXP, DOI 10.3791/50871; Smith LK, 2015, NAT MED, V21, P932, DOI 10.1038/nm.3898; Stoleru Bogdan, 2013, Maedica (Bucur), V8, P43; Tanaka K, 2001, PROG NEUROBIOL, V65, P173, DOI 10.1016/S0301-0082(01)00002-8; Tullai JW, 2007, J BIOL CHEM, V282, P9482, DOI 10.1074/jbc.M700067200; Varghese F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096801; Wong AW, 2013, J NEUROSCI, V33, P4947, DOI 10.1523/JNEUROSCI.3990-12.2013; Yoo JM, 2017, REDOX BIOL, V11, P592, DOI 10.1016/j.redox.2016.12.034; Yoshii A, 2010, DEV NEUROBIOL, V70, P304, DOI 10.1002/dneu.20765	37	14	14	2	13	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	APR	2019	67	4					574	588		10.1007/s12031-019-01263-6			15	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	HS2OU	WOS:000463700900009	30684239				2021-06-18	
J	Hu, JN; Chen, LF; Huang, XJ; Wu, K; Ding, SD; Wang, WK; Wang, B; Smith, C; Ren, CH; Ni, HQ; ZhuGe, QC; Yang, JJ				Hu, Jiangnan; Chen, Lefu; Huang, Xujun; Wu, Ke; Ding, Saidan; Wang, Weikan; Wang, Brian; Smith, Charity; Ren, Changhong; Ni, Haoqi; ZhuGe, Qichuan; Yang, Jianjing			Calpain inhibitor MDL28170 improves the transplantation-mediated therapeutic effect of bone marrow-derived mesenchymal stem cells following traumatic brain injury	STEM CELL RESEARCH & THERAPY			English	Article						Traumatic brain injury; Bone marrow-derived mesenchymal stem cells; Preconditioning; Calpain inhibitor; MDL28170; Transplantation	SPINAL-CORD; STROMAL CELLS; INFLAMMATION; EXPRESSION; MDL-28170; ANGIOGENESIS; INVOLVEMENT; MECHANISMS; APOPTOSIS; SURVIVAL	BackgroundStudies have shown that transplantation of bone marrow-derived mesenchymal stem cells (BMSCs) protects against brain damage. However, the low survival number of transplanted BMSCs remains a pertinent challenge and can be attributed to the unfavorable microenvironment of the injured brain. It is well known that calpain activation plays a critical role in traumatic brain injury (TBI)-mediated inflammation and cell death; previous studies showed that inhibiting calpain activation is neuroprotective after TBI. Thus, we investigated whether preconditioning with the calpain inhibitor, MDL28170, could enhance the survival of BMSCs transplanted at 24h post TBI to improve neurological function.MethodsTBI rat model was induced by the weight-drop method, using the gravitational forces of a free falling weight to produce a focal brain injury. MDL28170 was injected intracranially at the lesion site at 30min post TBI, and the secretion levels of neuroinflammatory factors were assessed 24h later. BMSCs labeled with green fluorescent protein (GFP) were locally administrated into the lesion site of TBI rat brains at 24h post TBI. Immunofluorescence and histopathology were performed to evaluate the BMSC survival and the TBI lesion volume. Modified neurological severity scores were chosen to evaluate the functional recovery. The potential mechanisms by which MDL28170 is involved in the regulation of inflammation signaling pathway and cell apoptosis were determined by western blot and immunofluorescence staining.ResultsOverall, we found that a single dose of MDL28170 at acute phase of TBI improved the microenvironment by inhibiting the inflammation, facilitated the survival of grafted GFP-BMSCs, and reduced the grafted cell apoptosis, leading to the reduction of lesion cavity. Furthermore, a significant neurological function improvement was observed when BMSCs were transplanted into a MDL28170-preconditioned TBI brains compared with the one without MDL28170-precondition group.ConclusionsTaken together, our data suggest that MDL28170 improves BMSC transplantation microenvironment and enhances the neurological function restoration after TBI via increased survival rate of BMSCs. We suggest that the calpain inhibitor, MDL28170, could be pursued as a new combination therapeutic strategy to advance the effects of transplanted BMSCs in cell-based regenerative medicine.	[Hu, Jiangnan; Chen, Lefu; Wu, Ke; Ding, Saidan; Ni, Haoqi; ZhuGe, Qichuan; Yang, Jianjing] Wenzhou Med Univ, Affiliated Hosp 1, Zhejiang Prov Key Lab Aging & Neurol Disorder Res, Wenzhou 325000, Peoples R China; [Hu, Jiangnan; Wang, Weikan; Wang, Brian; Smith, Charity] Univ North Texas, Hlth Sci Ctr, Dept Pharmaceut Sci, Ft Worth, TX 76107 USA; [Huang, Xujun] Hengdian Wenrong Hosp, Dept Intens Care Unit ICU, Jinhua 322100, Peoples R China; [Ren, Changhong] Capital Med Univ, Beijing Key Lab Hypox Conditioning Translat Med, Xuanwu Hosp, Beijing, Peoples R China	Hu, JN; ZhuGe, QC; Yang, JJ (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Zhejiang Prov Key Lab Aging & Neurol Disorder Res, Wenzhou 325000, Peoples R China.; Hu, JN (corresponding author), Univ North Texas, Hlth Sci Ctr, Dept Pharmaceut Sci, Ft Worth, TX 76107 USA.	hu.jiangnan@hotmail.com; zhugeqichuan@vip.163.com; yangjianjing2@163.com	Hu, John/AAL-6376-2021	Hu, Jiangnan/0000-0002-0112-7578	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81771262]; Zhejiang Health Science and Technology Project [2016RCA022]; Zhejiang Key Research and Development Project [2017C03027]; American Heart Association Predoctoral FellowshipAmerican Heart Association [19PRE34380114]	This work was supported by the National Natural Science Foundation of China (No. 81771262), Zhejiang Health Science and Technology Project (2016RCA022), Zhejiang Key Research and Development Project (2017C03027) and American Heart Association Predoctoral Fellowship for Jiangnan Hu (19PRE34380114).	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; [Anonymous], 1999, JAMA, V282, P974; Arataki S, 2005, J NEUROTRAUM, V22, P398, DOI 10.1089/neu.2005.22.398; Bennett MH, 2012, COCHRANE DB SYST REV, V12; Bhang SH, 2007, BIOCHEM BIOPH RES CO, V359, P40, DOI 10.1016/j.bbrc.2007.05.046; Carrico KM, 2009, J NEUROTRAUM, V26, P1369, DOI [10.1089/neu.2008.0870, 10.1089/neu.2008-0870]; Chen G, 1999, LIFE SCI, V64, P1231, DOI 10.1016/S0024-3205(99)00055-7; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Fairless R, 2005, INT J BIOCHEM CELL B, V37, P693, DOI 10.1016/j.biocel.2004.10.010; Fillmore N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120257; Guyton MK, 2010, J NEUROSCI RES, V88, P2398, DOI 10.1002/jnr.22408; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hill CE, 2010, J NEUROTRAUM, V27, P1685, DOI 10.1089/neu.2010.1272; Iguchi-Hashimoto M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027020; Imam SA, 2007, J NEUROIMMUNOL, V190, P139, DOI 10.1016/j.jneuroim.2007.07.016; Kanelos SK, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199812000-00003; Kawamura M, 2005, BRAIN RES, V1037, P59, DOI 10.1016/j.brainres.2004.12.050; Kunz S, 2004, PAIN, V110, P409, DOI 10.1016/j.pain.2004.04.031; Laurer HL, 2001, CURR PHARM DESIGN, V7, P1505, DOI 10.2174/1381612013397285; Lee JP, 2007, NAT MED, V13, P439, DOI 10.1038/nm1548; Li XP, 2014, AM J PHYSIOL-HEART C, V306, pH833, DOI 10.1152/ajpheart.00893.2012; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Messer JS, 2017, CELL MOL LIFE SCI, V74, P1281, DOI 10.1007/s00018-016-2403-y; Napoli I, 2009, NEUROSCIENCE, V158, P1030, DOI 10.1016/j.neuroscience.2008.06.046; Nichols JE, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt151; Ray SK, 2003, CNS NEUROL DISORD-DR, V2, P173, DOI 10.2174/1568007033482887; Redmond DE, 2007, P NATL ACAD SCI USA, V104, P12175, DOI 10.1073/pnas.0704091104; Ren CH, 2018, AGING DIS, V9, P869, DOI 10.14336/AD.2017.1106; Ren CH, 2018, EXP NEUROL, V304, P30, DOI 10.1016/j.expneurol.2018.02.013; Rhodes J, 2011, CURR OPIN CRIT CARE, V17, P122, DOI 10.1097/MCC.0b013e3283447948; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Sakata H, 2012, J NEUROSCI, V32, P3462, DOI 10.1523/JNEUROSCI.5686-11.2012; Schallert T, 1997, ADV NEUROL, V73, P229; Schwab ME, 2002, SCIENCE, V295, P1029, DOI 10.1126/science.1067840; Shen Q, 2016, CELL PHYSIOL BIOCHEM, V38, P748, DOI 10.1159/000443031; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Skardelly M, 2011, J NEUROTRAUM, V28, P401, DOI 10.1089/neu.2010.1526; Tao XG, 2017, CHINESE MED J-PEKING, V130, P187, DOI 10.4103/0366-6999.198001; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Thompson SN, 2010, J NEUROTRAUM, V27, P2233, DOI 10.1089/neu.2010.1474; Uceyler N, 2007, BRAIN BEHAV IMMUN, V21, P553, DOI 10.1016/j.bbi.2006.10.003; Wang C, 2016, NEUROCHEM INT, V97, P15, DOI 10.1016/j.neuint.2016.04.015; Wang YB, 2018, EXPERT OPIN THER TAR, V22, P19, DOI 10.1080/14728222.2018.1409723; Xiong Y, 2012, ANN NY ACAD SCI, V1270, P51, DOI 10.1111/j.1749-6632.2012.06683.x; Xu XL, 2017, AGING DIS, V8, P590, DOI 10.14336/AD.2017.0430; Xu XL, 2017, AGING DIS, V8, P486, DOI 10.14336/AD.2017.0507; Yan FD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037948; Yang JJ, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00061; Yoshifuji H, 2005, INT IMMUNOL, V17, P1327, DOI 10.1093/intimm/dxh311; Yu CG, 2008, J NEUROTRAUM, V25, P833, DOI 10.1089/neu.2007.0490; Yu CG, 2007, NEUROCHEM RES, V32, P2046, DOI 10.1007/s11064-007-9347-4; Yu SP, 2013, TRANSL STROKE RES, V4, P76, DOI 10.1007/s12975-012-0251-0; Zhang H, 2017, BONE MARROW STEM CEL, P81, DOI DOI 10.1007/978-981-10-2929-5_4; Zhang ZX, 2008, CYTOTHERAPY, V10, P134, DOI 10.1080/14653240701883061; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	61	14	14	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-6512			STEM CELL RES THER	Stem Cell Res. Ther.	MAR 15	2019	10								96	10.1186/s13287-019-1210-4			13	Cell & Tissue Engineering; Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	HO9ZL	WOS:000461324500002	30876457	DOAJ Gold, Green Published			2021-06-18	
J	Gobatto, ALN; Link, MA; Solla, DJ; Bassi, E; Tierno, PF; Paiva, W; Taccone, FS; Malbouisson, LM				Gobatto, Andre L. N.; Link, Milena A.; Solla, Davi J.; Bassi, Estevao; Tierno, Paulo F.; Paiva, Wellingson; Taccone, Fabio S.; Malbouisson, Luiz M.			Transfusion requirements after head trauma: a randomized feasibility controlled trial	CRITICAL CARE			English	Article						Transfusion; Traumatic brain injury; Anemia	BRAIN-INJURY; ANEMIA; GUIDELINES; MANAGEMENT; VASOSPASM; STRATEGY; UPDATE	BackgroundAnemia is frequent among patients with traumatic brain injury (TBI) and is associated with an increased risk of poor outcome. The optimal hemoglobin concentration to trigger red blood cell (RBC) transfusion in patients with TBI is not clearly defined.MethodsAll eligible consecutive adult patients admitted to the intensive care unit (ICU) with moderate or severe TBI were randomized to a restrictive (hemoglobin transfusion threshold of 7g/dL), or a liberal (threshold 9g/dL) transfusion strategy. The transfusion strategy was continued for up to 14days or until ICU discharge. The primary outcome was the mean difference in hemoglobin between groups. Secondary outcomes included transfusion requirements, intracranial pressure management, cerebral hemodynamics, length of stay, mortality and 6-month neurological outcome.ResultsA total of 44 patients were randomized, 21 patients to the liberal group and 23 to the restrictive group. There were no baseline differences between the groups. The mean hemoglobin concentrations during the 14-day period were 8.41.0 and 9.31.3 (p<0.01) in the restrictive and liberal groups, respectively. Fewer RBC units were administered in the restrictive than in the liberal group (35 vs. 66, p=0.02). There was negative correlation (r=-0.265, p<0.01) between hemoglobin concentration and middle cerebral artery flow velocity as evaluated by transcranial Doppler ultrasound and the incidence of post-traumatic vasospasm was significantly lower in the liberal strategy group (4/21, 3% vs. 15/23, 65%; p<0.01). Hospital mortality was higher in the restrictive than in the liberal group (7/23 vs. 1/21; p=0.048) and the liberal group tended to have a better neurological status at 6months (p=0.06).Conclusions The trial reached feasibility criteria. The restrictive group had lower hemoglobin concentrations and received fewer RBC transfusions. Hospital mortality was lower and neurological status at 6 months favored the liberal group.Trial registration ClinicalTrials.gov, NCT02203292. Registered on 29 July 2014.	[Gobatto, Andre L. N.] Hosp Sao Rafael, Internal Med, Salvador, BA, Brazil; [Gobatto, Andre L. N.] Hosp Cidade, Intens Care Unit, Salvador, BA, Brazil; [Gobatto, Andre L. N.; Link, Milena A.; Malbouisson, Luiz M.] Univ Sao Paulo, Hosp Clin, Med Sch, Surg Intens Care Unit,Anesthesiol Div, Sao Paulo, Brazil; [Solla, Davi J.; Paiva, Wellingson] Univ Sao Paulo, Hosp Clin, Med Sch, Div Neurosurg, Sao Paulo, Brazil; [Bassi, Estevao; Tierno, Paulo F.; Malbouisson, Luiz M.] Univ Sao Paulo, Hosp Clin, Med Sch, Trauma Intens Care Unit,Surg Emergency Dept, Sao Paulo, Brazil; [Bassi, Estevao] Hosp Alemao Oswaldo Cruz, Intens Care Unit, Sao Paulo, Brazil; [Taccone, Fabio S.] Erasme Univ Hosp, Dept Intens Care, Brussels, Belgium	Malbouisson, LM (corresponding author), Univ Sao Paulo, Hosp Clin, Med Sch, Surg Intens Care Unit,Anesthesiol Div, Sao Paulo, Brazil.; Malbouisson, LM (corresponding author), Univ Sao Paulo, Hosp Clin, Med Sch, Trauma Intens Care Unit,Surg Emergency Dept, Sao Paulo, Brazil.	luiz.malbouisson@hc.fm.usp.br	Bassi, Estevao/AAN-5521-2020; Paiva, Wellingson S/G-5517-2013; Solla, Davi/E-6988-2013	Bassi, Estevao/0000-0002-3819-2699; Paiva, Wellingson S/0000-0002-5165-7040; Solla, Davi/0000-0002-5092-6595			Badenes R, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1748-4; Boutin A, 2016, TRANSFUS MED REV, V30, P15, DOI 10.1016/j.tmrv.2015.08.004; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Dellinger RP, 2013, CRIT CARE MED, V41, P580, DOI 10.1097/CCM.0b013e31827e83af; Ferreira Cesar Biselli, 2015, Rev Bras Ter Intensiva, V27, P315, DOI 10.5935/0103-507X.20150055; Lagunju I, 2014, J CLIN ULTRASOUND, V42, P89, DOI 10.1002/jcu.22099; McIntyre L, 2004, J TRAUMA, V57, P563, DOI 10.1097/01.TA.0000136158.93864.54; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; Mermel LA, 2009, CLIN INFECT DIS, V49, P1, DOI 10.1086/599376; Oddo M, 2012, INTENS CARE MED, V38, P1497, DOI 10.1007/s00134-012-2593-1; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Perrein A, 2015, MINERVA ANESTESIOL, V81, P1219; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Rossaint R, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1265-x; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Sena MJ, 2009, INTENS CARE MED, V35, P480, DOI 10.1007/s00134-008-1289-z; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thygesen K, 2012, CIRCULATION, V126, P2020, DOI 10.1161/CIR.0b013e31826e1058; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	22	14	14	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	MAR 12	2019	23								89	10.1186/s13054-018-2273-9			10	Critical Care Medicine	General & Internal Medicine	HP0LQ	WOS:000461357900001	30871608	DOAJ Gold, Green Published			2021-06-18	
J	Chen, ZH; Wang, H; Zhong, JJ; Yang, JQ; Darwazeh, R; Tian, XC; Huang, ZJ; Jiang, L; Cheng, CJ; Wu, Y; Guo, ZD; Sun, XC				Chen, Zhihao; Wang, Hong; Zhong, Jianjun; Yang, Junqing; Darwazeh, Rami; Tian, Xiaocui; Huang, Zhijian; Jiang, Li; Cheng, Chongjie; Wu, Yue; Guo, Zongduo; Sun, Xiaochuan			Significant changes in circular RNA in the mouse cerebral cortex around an injury site after traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						TBI; Circular RNA; miRNA; CXCR2; RNA-seq	SPINAL-CORD-INJURY; LONG NONCODING RNA; CXCR2; INFLAMMATION; EXPRESSION; NEUROPROTECTION; IDENTIFICATION; ACTIVATION; BEXAROTENE; INDUCTION	Background and objective: Circular RNA (circRNA) is an important type of non-coding RNA that has not been widely researched in traumatic brain injury (TBI). The present study aimd to detect the altered circRNA expression around an injury site in the mouse cerebral cortex after TBI and explore its potential functions. Method: C57BL/6 mice were used to construct a controlled cortical impact (CCI) model to simulate TBI. At 24 h post-TBI, the cortex around the injury site was collected, and the total RNA was extracted to perform RNA sequencing (RNA-seq). The differentially expressed circRNAs were determined according to the following criteria: vertical bar log(2)((fold) (change))vertical bar > 1, P < .05 and FDR < 0.05. Among them, circRNA chr8_87,859,283-87,904,548 was preliminarily explored to determine its function. Results: A total of 8036 altered circRNAs were discovered, and among them, 16 were significantly changed (5 up-regulated and 11 down-regulated). The circRNA chr8_87,859,283-87,904,548 significantly increased by approximately 4 times in the cerebral cortex around the injury site after TBI and promoted neuro-inflammation through increasing the CXCR2 protein by sponging mmu-let-7a-5p. As a result, the increased circRNA chr8_87,859,283-87,904,548 blocked the restoration of neurological function after TBI. Conclusion: Many circRNAs are significantly up-regulated or down-regulated in the traumatic cerebral penumbra cortex after TBI. Among them, the circRNA chr8_87,859,283-87,904,548 potentially plays a pro-inflammatory role, which may have a deleterious effect on neurological restoration after TBI.	[Chen, Zhihao; Wang, Hong; Yang, Junqing; Tian, Xiaocui] Chongqing Med Univ, Dept Pharmacol, Key Lab Biochem & Mol Pharmacol, Chongqing 400016, Peoples R China; [Zhong, Jianjun; Darwazeh, Rami; Huang, Zhijian; Jiang, Li; Cheng, Chongjie; Wu, Yue; Guo, Zongduo; Sun, Xiaochuan] Chongqing Med Univ, Dept Neurosurg, Affiliated Hosp 1, Chongqing 400016, Peoples R China	Zhong, JJ; Sun, XC (corresponding author), Chongqing Med Univ, Dept Neurosurg, Affiliated Hosp 1, Chongqing 400016, Peoples R China.	zjjcom682161@126.com; sunxch1445@qq.com	Darwazeh, Rami/AAT-7891-2020	Darwazeh, Rami/0000-0003-3099-8257; sun, xiao chuan/0000-0001-6992-332X; Huang, Zhijian/0000-0002-8241-0761	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571159]; Youth Fund of the National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81801230]	This work was supported by grants from the National Natural Science Foundation of China (grant No.: 81571159) and the Youth Fund of the National Natural Science Foundation of China (grant No.: 81801230). We express special acknowledgement to "Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology" for providing an experimental platform. We give special thanks to Rami Darwazeh from the First Affiliated Hospital of Chongqing Medical University for language modification.	Bai Y, 2018, J NEUROSCI, V38, P32, DOI 10.1523/JNEUROSCI.1348-17.2017; Bajrami B, 2016, J EXP MED, V213, P1999, DOI 10.1084/jem.20160393; Bhat SA, 2016, MOL NEUROBIOL, V53, P6950, DOI 10.1007/s12035-015-9584-5; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Donofrio G, 2006, MICROBES INFECT, V8, P898, DOI 10.1016/j.micinf.2005.10.016; Dubovicky Michal, 2014, Interdiscip Toxicol, V7, P201, DOI 10.2478/intox-2014-0029; Guo J, 2016, MOL NEUROBIOL, V53, P3154, DOI 10.1007/s12035-015-9222-2; Han B, 2018, AUTOPHAGY, V14, P1164, DOI 10.1080/15548627.2018.1458173; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Ho J, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1555-3; Hsieh CY, 2014, J IMMUNOL, V193, P3693, DOI 10.4049/jimmunol.1400692; Hu JZ, 2015, BRAIN RES, V1608, P191, DOI 10.1016/j.brainres.2015.02.036; Huang JH, 2016, BRAIN RES, V1648, P35, DOI 10.1016/j.brainres.2016.07.023; Jiang YJ, 2019, J NEUROTRAUM, V36, P1018, DOI 10.1089/neu.2018.5647; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Lerner CA, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2076.00391; Li JX, 2018, CELL PHYSIOL BIOCHEM, V45, P677, DOI 10.1159/000487161; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Lin SP, 2016, BIOCHEM BIOPH RES CO, V471, P52, DOI 10.1016/j.bbrc.2016.01.183; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lukiw Walter J., 2013, Frontiers in Genetics, V4, P77, DOI [10.3389/fgene.2013.00307, 10.3389/fgene.2013.00077]; Marchelletta RR, 2015, J INFECT DIS, V212, P128, DOI 10.1093/infdis/jiu829; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Qu SB, 2015, CANCER LETT, V365, P141, DOI 10.1016/j.canlet.2015.06.003; Ranganathan P, 2013, AM J PHYSIOL-RENAL, V305, pF1422, DOI 10.1152/ajprenal.00319.2013; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Salvi A, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5059043; Salzman J, 2016, TRENDS GENET, V32, P309, DOI 10.1016/j.tig.2016.03.002; Sharma A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112019; Song XF, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw075; Steele CW, 2015, J PATHOL, V237, P85, DOI 10.1002/path.4555; Szabo L, 2016, GENOME BIOL, V17, DOI [10.1186/s13059-016-1123-9, 10.1186/s13059-015-0690-5]; Teng ZP, 2016, STROKE, V47, P196, DOI 10.1161/STROKEAHA.115.011701; Tiwari N, 2016, AM J PHYSIOL-LUNG C, V310, pL496, DOI 10.1152/ajplung.00290.2015; Veno MT, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0801-3; Villapol S, 2012, NEUROPSYCHOPHARMACOL, V37, P2817, DOI 10.1038/npp.2012.152; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wilhelm BT, 2008, NATURE, V453, P1239, DOI 10.1038/nature07002; Wu FJ, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0316-6; Xia SY, 2017, BRIEF BIOINFORM, V18, P984, DOI 10.1093/bib/bbw081; Xie BS, 2018, J NEUROTRAUM, V35, P1659, DOI 10.1089/neu.2017.5468; You XT, 2015, NAT NEUROSCI, V18, P603, DOI 10.1038/nn.3975; Zhang Q, 2016, MOL NEUROBIOL, V53, P662, DOI 10.1007/s12035-014-9035-8; Zhang XJ, 2019, NEUROSCIENTIST, V25, P22, DOI 10.1177/1073858418769556; Zhang Y, 2013, MOL CELL, V51, P792, DOI 10.1016/j.molcel.2013.08.017; Zhong JJ, 2017, BRAIN BEHAV IMMUN, V65, P183, DOI 10.1016/j.bbi.2017.05.001; Zhong JJ, 2017, NEUROSCIENCE, V343, P434, DOI 10.1016/j.neuroscience.2016.05.033; Zhong JJ, 2016, BRAIN RES, V1646, P589, DOI 10.1016/j.brainres.2016.07.002; Zhou X, 2016, BRAIN RES, V1648, P136, DOI 10.1016/j.brainres.2016.07.034; Zhu LH, 2018, CELL PHYSIOL BIOCHEM, V49, P2264, DOI 10.1159/000493829	54	14	16	3	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2019	313						37	48		10.1016/j.expneurol.2018.12.003			12	Neurosciences	Neurosciences & Neurology	HK1HD	WOS:000457654700005	30529438				2021-06-18	
J	Pal, R; Ghosh, A; Kumar, R; Galwankar, S; Paul, SK; Pal, S; Sinha, D; Jaiswal, AK; Moscote-Salazar, LR; Agrawal, A				Pal, Ranabir; Ghosh, Amrita; Kumar, Raman; Galwankar, Sagar; Paul, Swapan Kumar; Pal, Shrayan; Sinha, Debashis; Jaiswal, A. K.; Rafael Moscote-Salazar, Luis; Agrawal, Amit			Public health crisis of road traffic accidents in India: Risk factor assessment and recommendations on prevention on the behalf of the Academy of Family Physicians of India	JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE			English	Article						Public health; road safety; road traffic injury; traumatic brain injury; vehicle		Roads are considered a sign of development bringing colossal benefits to community as socioeconomic and logistic facilitator. Yet, growth of road network has brought road crashes leading to civic pain from premature deaths of productive age group. In 2017, 16 citizens were killed and 53 injured every hour on Indian roads as per officially reported data, while a fair number go unreported. This is unacceptably high when compared with international standards. Risk correlates of road traffic injuries (RTIs) need to be redefined so as to form a continuum with other confounding factors that impact to take lives on road. Risk factors impacting RTIs vary from human components to the roles and responsibilities of healthcare stakeholders. We should have made roads safer for all citizens because a large percentage of population - children, pedestrians, cyclists, motorcyclists, and the elderly - are most vulnerable. A taskforce was set up by the Academy of Family Physicians of India to scientifically analyze the literature available to assess risks and put forward appropriate recommendations.	[Pal, Ranabir; Paul, Swapan Kumar] MGM Med Coll & LSK Hosp, Dept Community Med, Kishanganj 855107, Bihar, India; [Pal, Shrayan] MGM Med Coll & LSK Hosp, Dept Dermatol Venereol & Leprosy, Kishanganj, Bihar, India; [Ghosh, Amrita] Med Coll, Dept Biochem, Kolkata, W Bengal, India; [Kumar, Raman] Acad Family Phys India, New Delhi, India; [Sinha, Debashis] High Court Calcutta, New Delhi, India; [Sinha, Debashis] Supreme Court India, New Delhi, India; [Jaiswal, A. K.] All India Inst Med Sci, Dept Forens Med & Toxicol, New Delhi, India; [Agrawal, Amit] Narayana Med Coll Hosp, Dept Neurosurg, Nellore, Andhra Pradesh, India; [Galwankar, Sagar] Univ Florida, Dept Emergency Med, Jacksonville, FL USA; [Rafael Moscote-Salazar, Luis] Org Latinoamer Trauma & Cuidado, RED LATINO, Neurosurg Crit Care, Neurointens, Bogota, Colombia	Pal, R (corresponding author), MGM Med Coll & LSK Hosp, Dept Community Med, Kishanganj 855107, Bihar, India.	ranabirmon@yahoo.co.in					Agrawal A, 2018, NEUROL INDIA, V66, P976, DOI 10.4103/0028-3886.237027; Agrawal A, 2016, INDIAN J NEUROTRAUM, V13, P81, DOI 10.1055/s-0036-1586486; Agrawal Amit, 2016, Int J Crit Illn Inj Sci, V6, P65, DOI 10.4103/2229-5151.183025; Alam K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164362; [Anonymous], 2004, GLOBAL BURDEN DIS; Baluja A, 2018, INT J ACAD MED, V4, P119, DOI 10.4103/IJAM.IJAM_9_18; Bhandarkar P, 2018, J EMERG TRAUMA SHOCK, V11, P10, DOI 10.4103/JETS.JETS_70_17; Bhoi S, 2018, J EMERG TRAUMA SHOCK, V11, P160, DOI 10.4103/JETS.JETS_119_17; Biswas S., 2015, WHAT IS DELHIS NEW O; Citizen's Charter, 2013, CITIZENS CHARTER; Cummings P, 2002, BRIT MED J, V324, P1119, DOI 10.1136/bmj.324.7346.1119; Dandona R, 2006, J SAFETY RES, V37, P149, DOI 10.1016/j.jsr.2005.11.002; Dash DK, BOOMING SALE CARS BI; El-Menyar Ayman, 2016, J Emerg Trauma Shock, V9, P64, DOI 10.4103/0974-2700.179461; Elder R.W., 2002, TRAFFIC INJ PREV, V3, P266, DOI DOI 10.1080/15389580214623; Fildes B, 1994, 61 MON U ACC RES CTR; Ghosh A, 2019, INT J ACAD MED; Gupta Amit, 2009, Indian J Community Med, V34, P75, DOI 10.4103/0970-0218.45383; Gurung B., 2010, TELEGRAPH; Gururaj G, 2004, J Indian Med Assoc, V102, P157; Gururaj G, 2004, J Coll Physicians Surg Pak, V14, P713; Gururaj G., 2005, BACKGROUND PAPERS BU, P325; Jaiswal A. K., 2018, Al Ameen Journal of Medical Sciences, V11, P154; Joshipura MK, 2004, ACAD TRAUMATOL, V8, P93; Lahiri SK, 2005, INDIAN J PREV SOC ME, V36, P94, DOI 3 & 4; Liu BC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004333.pub3; Maheshwari R., HIGHWAY LIQUOR BAN S; McLean A, 1980, ALCOHOL DRUGS TRAFFI, P15; Mirkazemi Roksana, 2009, Indian J Community Med, V34, P301, DOI 10.4103/0970-0218.58387; Pal R, 2012, NEPAL J EPIDEMIOL, V2, P216, DOI 10.3126/nje.v2i4.7825; Pal R., 2012, INDIAN J PREV SOC ME, V43, P229; Pal Ranabir, 2017, J Family Med Prim Care, V6, P175, DOI 10.4103/jfmpc.jfmpc_221_15; Pal R, 2012, J KRISHNA INST MED S, V1, P4; Pal Ranabir, 2016, Int J Crit Illn Inj Sci, V6, P127; Pal R, 2016, J NEUROSCI RURAL PRA, V7, P483, DOI 10.4103/0976-3147.188633; Pal Ranabir, 2014, J Family Med Prim Care, V3, P295, DOI 10.4103/2249-4863.148086; Pal Ranabir, 2014, Int J Crit Illn Inj Sci, V4, P114, DOI 10.4103/2229-5151.134151; Peden M., 2008, WORLD REPORT CHILD I; Peden M., 2004, WORLD REPORT ROAD TR; SAID PZ, 2018, ARCH MENT HLTH, V19, P97; Satapathy Mani Charan, 2016, Int J Crit Illn Inj Sci, V6, P16, DOI 10.4103/2229-5151.177359; Sharma N, ROAD ACCIDENTS INDIA; Shekhar Chandra, 2015, J Emerg Trauma Shock, V8, P131, DOI 10.4103/0974-2700.160700; Sheriff Akbar, 2011, Indian J Public Health, V55, P125, DOI 10.4103/0019-557X.85248; Shults RA, 2002, AM J PREV MED, V23, P72; Singh Anil Kumar, 2018, Asian J Neurosurg, V13, P714, DOI 10.4103/ajns.AJNS_131_16; Sreedharan Jayadevan, 2010, J Inj Violence Res, V2, P49, DOI 10.5249/jivr.v2i1.26; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Sweedler BM, 1995, TRANSPORT RES CIRCUL, V437; Uc EY, 2009, NEUROLOGY, V73, P2112, DOI 10.1212/WNL.0b013e3181c67b77; UNECE, IT WORKS JOIN IT SER, pxi; Vyas D, 2016, J SURG RES, V203, P22, DOI 10.1016/j.jss.2016.03.026; Wadhwa N., ROAD ACCIDENTS INDIA	53	14	14	1	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	2249-4863	2278-7135		J FAM MED PRIM CARE	J. Fam. Med. Prim. Care	MAR	2019	8	3					775	783	PMID 31041200	10.4103/jfmpc.jfmpc_214_18			9	Primary Health Care	General & Internal Medicine	VJ9SP	WOS:000648425100002	31041200	DOAJ Gold, Green Published			2021-06-18	
J	Yoo, RE; Choi, SH; Oh, BM; Shin, SD; Lee, EJ; Shin, DJ; Jo, SW; Kang, KM; Yun, TJ; Kim, JH; Sohn, CH				Yoo, Roh-Eul; Choi, Seung Hong; Oh, Byung-Mo; Shin, Sang Do; Lee, Eun Jung; Shin, Dong Jae; Jo, Sang Won; Kang, Koung Mi; Yun, Tae Jin; Kim, Ji-hoon; Sohn, Chul-Ho			Quantitative dynamic contrast-enhanced MR imaging shows widespread blood-brain barrier disruption in mild traumatic brain injury patients with post-concussion syndrome	EUROPEAN RADIOLOGY			English	Article						Blood-brain barrier; Magnetic resonance imaging; Perfusion; Permeability; Post-concussion syndrome (PCS)	HEAD-INJURY; PERMEABILITY; DYSFUNCTION; PERFUSION; LEAKAGE; SERUM; PROGRESSION; BREAKDOWN; MODELS; HEALTH	ObjectivesTo explore the utility of dynamic contrast-enhanced (DCE) MR imaging for quantitative analysis of blood-brain barrier disruption in mild traumatic brain injury (mTBI) patients with post-concussion syndrome (PCS).MethodsForty-four consecutive patients with PCS after mTBI and 32 controls were included in this retrospective study. K-trans and v(e) from DCE MR imaging were analyzed at contrast-enhancing lesions, T2 hyperintense white matter (WM) lesions, normal-appearing white matter (NAWM), and predilection sites for diffuse axonal injury (Location(DAI)). The Mann-Whitney U-test was performed to compare the parameters between mTBI patients and controls and the parameters were correlated with neuropsychological tests using Mann-Whitney U-test and Spearman rank correlation.ResultsThe median v(e) of the T2 hyperintense WM lesions in mTBI patients (n=21) was higher than that of NAWM in controls (p=.027). Both median K-trans and v(e) at NAWM were also significantly higher in mTBI patients than in controls (p=.023 and p=.029, respectively). In addition, mTBI patients had higher K-trans and v(e) at Location(DAI) than controls (p=.008 and p=.015, respectively). VLT (delayed recall) scores were significantly correlated with v(e) values at T2 hyperintense WM lesions (p=-0.767, p=.044). The median v(e) at Location(DAI) was significantly higher in patients with atypical performance in the digit span test (forward) than in those with average or good performance (p=.043).ConclusionsmTBI patients with PCS had higher K-trans and v(e) values than controls not only at T2 hyperintense WM lesions but also at NAWM and Location(DAI). BBB disruption may be implicated in development of PCS in mTBI patients.Key Points center dot mTBI patients with PCS had higher permeability than controls at T2 hyperintense WM lesions on DCE MR imaging.center dot mTBI patients with PCS had higher permeability than controls also at NAWM and predilection sites for DAI.center dot BBB disruption may be implicated in the development of PCS in mTBI patients.	[Yoo, Roh-Eul; Choi, Seung Hong; Kang, Koung Mi; Yun, Tae Jin; Kim, Ji-hoon; Sohn, Chul-Ho] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Radiol, 28 Yongon Dong, Seoul 110744, South Korea; [Choi, Seung Hong] Seoul Natl Univ, IBS, Ctr Nanoparticle Res, Seoul 151742, South Korea; [Choi, Seung Hong] Seoul Natl Univ, Sch Chem & Biol Engn, Seoul 151742, South Korea; [Oh, Byung-Mo] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Rehabil Med, 28 Yongon Dong, Seoul 110744, South Korea; [Shin, Sang Do] Seoul Natl Univ, Coll Med, Dept Emergency Med, 28 Yongon Dong, Seoul 110744, South Korea; [Lee, Eun Jung] Chung Ang Univ Hosp, Dept Radiol, Seoul, South Korea; [Shin, Dong Jae] Seran Gen Hosp, Dept Radiol, Seoul, South Korea; [Jo, Sang Won] Kangbuk Samsung Hosp, Dept Radiol, Seoul, South Korea	Choi, SH (corresponding author), Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Radiol, 28 Yongon Dong, Seoul 110744, South Korea.; Choi, SH (corresponding author), Seoul Natl Univ, IBS, Ctr Nanoparticle Res, Seoul 151742, South Korea.; Choi, SH (corresponding author), Seoul Natl Univ, Sch Chem & Biol Engn, Seoul 151742, South Korea.	verocay@snuh.org			Bayer HealthcareBayer AGBayer Healthcare Pharmaceuticals; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare of South Korea [HI16C1111]; Ministry of Science, ICT & Future Planning [2016M3C7A1914002]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning [2017R1A2B2006526]; Ministry of Education [2017R1D1A1B04034838]; Creative-Pioneering Researchers Program through Seoul National University (SNU);  [IBS-R006-D1]	This study was supported by a grant from Bayer Healthcare, the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare of South Korea (HI16C1111), and by the Ministry of Science, ICT & Future Planning (2016M3C7A1914002), by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2017R1A2B2006526) and by the Ministry of Education (2017R1D1A1B04034838), by Creative-Pioneering Researchers Program through Seoul National University (SNU), and by Project Code (IBS-R006-D1).	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Adelson PD, 1998, ACT NEUR S, V71, P104; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; EVANS RW, 1992, NEUROL CLIN, V10, P815; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Haroon HA, 2004, J MAGN RESON IMAGING, V19, P527, DOI 10.1002/jmri.20045; Harrer JU, 2004, J MAGN RESON IMAGING, V20, P748, DOI 10.1002/jmri.20182; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Kassner A, 2009, AM J NEURORADIOL, V30, P1864, DOI 10.3174/ajnr.A1774; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Liu W, 2013, NMR BIOMED, V26, P651, DOI 10.1002/nbm.2910; Nag S, 2011, NEUROPATH APPL NEURO, V37, P3, DOI 10.1111/j.1365-2990.2010.01138.x; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Riedy G, 2015, RADIOLOGY, DOI [10.1148/radiol.2015150438:150438, DOI 10.1148/RADIOL.2015150438:150438]; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P295, DOI 10.1196/annals.1403.022; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Tofts PS, 1999, J MAGN RESON IMAGING, V10, P223, DOI 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; van Vliet EA, 2007, BRAIN, V130, P521, DOI 10.1093/brain/awl318; van Vliet EA, 2014, NEUROBIOL DIS, V63, P74, DOI 10.1016/j.nbd.2013.11.019; Wei XE, 2011, J TRAUMA, V71, P1645, DOI 10.1097/TA.0b013e31823498eb; Weissberg I, 2014, JAMA NEUROL, V71, P1453, DOI 10.1001/jamaneurol.2014.2682; Winter C, 2015, NEUROL RES, V37, P599, DOI 10.1179/1743132815Y.0000000018; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Yun TJ, 2015, RADIOLOGY, V274, P830, DOI 10.1148/radiol.14132632; Zhang CE, 2017, NEUROLOGY, V88, P426, DOI 10.1212/WNL.0000000000003556; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	36	14	15	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-7994	1432-1084		EUR RADIOL	Eur. Radiol.	MAR	2019	29	3					1308	1317		10.1007/s00330-018-5656-z			10	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	HJ7RX	WOS:000457396100026	30066251				2021-06-18	
J	Lazaridis, C				Lazaridis, Christos			Withdrawal of Life-Sustaining Treatments in Perceived Devastating Brain Injury: The Key Role of Uncertainty	NEUROCRITICAL CARE			English	Article						Brain injury; Decision-making; Disability; Chronic conditions and rehabilitation; End-of-life issues	TRAUMATIC BRAIN; DECISION-MAKING; HEALTH-CARE; DISABILITY PARADOX; NEUROCRITICAL CARE; DISORDERS; CONSCIOUSNESS; COMMUNICATION; SUPPORT; HEURISTICS	BackgroundWithdrawal of life-sustaining treatment (WOLST) is the leading proximate cause of death in patients with perceived devastating brain injury (PDBI). There are reasons to believe that a potentially significant proportion of WOLST decisions, in this setting, are premature and guided by a number of assumptions that falsely confer a sense of certainty.MethodThis manuscript proposes that these assumptions face serious challenges, and that we should replace unwarranted certainty with an appreciation for the great degree of multi-dimensional uncertainty involved. The article proceeds by offering a taxonomy of uncertainty in PDBI and explores the key role that uncertainty as a cognitive state, may play into how WOLST decisions are reached.ConclusionIn order to properly share decision-making with families and surrogates of patients with PDBI, we will have to acknowledge, understand, and be able to communicate the great degree of uncertainty involved.	[Lazaridis, Christos] Univ Chicago, Dept Neurol, Div Neurocrit Care, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Lazaridis, Christos] Univ Chicago, Dept Neurosurg, Div Neurocrit Care, Chicago, IL 60637 USA; [Lazaridis, Christos] Univ Chicago Med, 5841 S Maryland Ave, Chicago, IL 60637 USA	Lazaridis, C (corresponding author), Univ Chicago Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.	lazaridis@uchicago.edu		Lazaridis, Christos/0000-0003-1814-4830			Albrecht GL, 1999, SOC SCI MED, V48, P977, DOI 10.1016/S0277-9536(98)00411-0; Bayne T, 2017, ANN NEUROL, V82, P866, DOI 10.1002/ana.25088; Beauchamp TL., 2009, PRINCIPLES BIOMEDICA, V7; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Bernacki RE, 2014, JAMA INTERN MED, V174, P1994, DOI 10.1001/jamainternmed.2014.5271; Bernat J.L., 2016, AJOB NEUROSCI, V7, P46, DOI DOI 10.1080/21507740.2016.1146367; Bernat JL, 2006, LANCET, V367, P1181, DOI 10.1016/S0140-6736(06)68508-5; Blumenthal-Barby JS, 2016, AM J BIOETHICS, V16, P5, DOI 10.1080/15265161.2016.1159750; Blumenthal-Barby JS, 2015, MED DECIS MAKING, V35, P539, DOI 10.1177/0272989X14547740; Brownstein Michael, 2017, STANFORD ENCY PHILOS; Bruno MA, 2011, BMJ-BRIT MED J, V23; CAMERER C, 1992, J RISK UNCERTAINTY, V5, P325, DOI 10.1007/BF00122575; Chatfield DA, 2018, NURS CRIT CARE, V23, P82, DOI 10.1111/nicc.12290; Cochrane TI, 2009, AM J BIOETHICS, V9, P47, DOI 10.1080/15265160902718857; Cote N, 2013, NEUROCRIT CARE, V18, P154, DOI 10.1007/s12028-012-9787-9; Creutzfeldt CJ, 2012, STROKE, V43, P3405, DOI 10.1161/STROKEAHA.112.673376; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Dale CM, 2016, ANN AM THORAC SOC, V13, P1115, DOI 10.1513/AnnalsATS.201511-751OC; Edlow BL, 2017, BRAIN, V140, P2399, DOI 10.1093/brain/awx176; Etkind SN, 2016, POSTGRAD MED J, V92, P412, DOI 10.1136/postgradmedj-2015-133371; Feltz A, 2012, J BIOETHIC INQ, V9, P443, DOI 10.1007/s11673-012-9396-5; Fins JJ., 2015, RIGHTS COME MIND BRA; Fins JJ, 2018, BRAIN INJURY, V32, P670, DOI 10.1080/02699052.2018.1430377; Fins JJ, 2018, CAMB Q HEALTHC ETHIC, V27, P163, DOI 10.1017/S0963180117000329; Gendler TS, 2008, J PHILOS, V105, P634, DOI 10.5840/jphil20081051025; Geurts M, 2014, LANCET NEUROL, V13, P515, DOI 10.1016/S1474-4422(14)70030-4; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; Granger CV, 2009, AM J PHYS MED REHAB, V88, P755, DOI 10.1097/PHM.0b013e3181aa71a8; Han PKJ, 2011, MED DECIS MAKING, V31, P828, DOI 10.1177/0272989X11393976; Harvey D, 2018, BRIT J ANAESTH, V120, P138, DOI 10.1016/j.bja.2017.10.002; Hemphill JC, 2009, EMERG MED CLIN N AM, V27, P27, DOI 10.1016/j.emc.2008.08.009; Holloway RG, 2013, NEUROLOGY, V80, P764, DOI 10.1212/WNL.0b013e318282509c; Hwang DY, 2014, J NEUROSCI NURS, V46, P106, DOI 10.1097/JNN.0000000000000038; Izzy S, 2013, NEUROCRIT CARE, V19, P347, DOI 10.1007/s12028-013-9925-z; Johnson L. Syd, 2016, AJOB NEUROSCIENCE, V7, P35; Johnson LSM, 2013, AM J BIOETH NEUROSCI, V4, P24; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Kennedy Andrew D M, 2003, Health Expect, V6, P255, DOI 10.1046/j.1369-6513.2003.00240.x; KITZINGER J, 2013, SOCIOL HEALTH ILL, V35, P1095, DOI DOI 10.1111/1467-9566.12020; Klein A, 2012, NEUROCRIT CARE, V16, P456, DOI 10.1007/s12028-012-9677-1; Klein C, 2015, BR J PHILOS SCI, V68, P27; Koch PM, 2017, INTENS CARE MED, V43, P1518, DOI 10.1007/s00134-017-4819-8; Kondziella D, 2016, J NEUROL NEUROSUR PS, V87, P485, DOI 10.1136/jnnp-2015-310958; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Lind R, 2011, INTENS CARE MED, V37, P1143, DOI 10.1007/s00134-011-2253-x; Mayor SA, 1999, NEUROLOGY, V52, P1602, DOI 10.1212/WNL.52.8.1602; McMahan J, 2002, ETHICS KILLING PROBL, P2002; Mishel M H, 1988, Image J Nurs Sch, V20, P225, DOI 10.1111/j.1547-5069.1988.tb00082.x; MISHEL MH, 1984, RES NURS HEALTH, V7, P163, DOI 10.1002/nur.4770070304; Monti MM, 2012, ANNU REV CLIN PSYCHO, V8, P431, DOI 10.1146/annurev-clinpsy-032511-143050; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Muehlschlegel S, 2015, NEUROCRIT CARE, V23, P127, DOI 10.1007/s12028-014-0097-2; Naccache L, 2018, BRAIN, V141, P949, DOI 10.1093/brain/awx324; Nelson WL, 2007, MED DECIS MAKING, V27, P609, DOI 10.1177/0272989x07306780; Norton SA, 2003, AM J CRIT CARE, V12, P548, DOI 10.4037/ajcc2003.12.6.548; Pushkarskaya H, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00325; Relyea-Chew A, 2009, ARCH PHYS MED REHAB, V90, P413, DOI 10.1016/j.apmr.2008.07.031; Schiff ND, 2016, CURR BIOL, V26, pR572, DOI 10.1016/j.cub.2016.02.027; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Shepherd J, 2016, CONSCIOUSNESS SEVERE; Smithson M, 1999, ORGAN BEHAV HUM DEC, V79, P179, DOI 10.1006/obhd.1999.2844; Souter MJ, 2015, NEUROCRIT CARE, V23, P4, DOI 10.1007/s12028-015-0137-6; Steppacher I, 2016, ANN CLIN TRANSL NEUR, V3, P61, DOI 10.1002/acn3.269; Steppacher I, 2014, ANN CLIN TRANSL NEUR, V1, P401, DOI 10.1002/acn3.63; Turgeon AF, 2013, CRIT CARE MED, V41, P1086, DOI 10.1097/CCM.0b013e318275d046; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Ubel PA, 2005, HEALTH PSYCHOL, V24, pS57, DOI 10.1037/0278-6133.24.4.S57; Verkade MA, 2012, NEUROCRIT CARE, V16, P130, DOI 10.1007/s12028-011-9567-y; Watt D.F., 2004, TXB BIOL PSYCHIAT, P75; Whyte J, 2013, ARCH PHYS MED REHAB, V94, P1851, DOI 10.1016/j.apmr.2013.07.003; Wilkinson, 2013, DEATH DISABILITY CAR; Wilkinson D, 2018, MONASH BIOETH REV; Wilkinson D, 2009, THEOR MED BIOETH, V30, P401, DOI 10.1007/s11017-009-9120-6; Williams B., 1985, ETHICS LIMITS PHILOS; Zahuranec DB, 2010, NEUROLOGY, V75, P626, DOI 10.1212/WNL.0b013e3181ed9cc9; Zier LS, 2012, ANN INTERN MED, V156, P360, DOI 10.7326/0003-4819-156-5-201203060-00008	76	14	14	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	FEB	2019	30	1					33	41		10.1007/s12028-018-0595-8			9	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	HJ8LA	WOS:000457449700005	30143963				2021-06-18	
J	Kan, C; Ding, N; Yang, JZ; Tan, ZY; McGuire, TL; Lu, HM; Zhang, KQ; Berger, DMP; Kessler, JA; Kan, LX				Kan, Chen; Ding, Na; Yang, Jiazhao; Tan, Zhenya; McGuire, Tammy L.; Lu, Haimei; Zhang, Keqin; Berger, Diana M. Palila; Kessler, John A.; Kan, Lixin			BMP-dependent, injury-induced stem cell niche as a mechanism of heterotopic ossification	STEM CELL RESEARCH & THERAPY			English	Article						Heterotopic ossification (HO); Niche; Mesenchymal stem cells (MSCs); Niche supportive cells; Niche supportive molecules; Bone morphogenetic protein (BMP); Hedgehog (Hh)	TRAUMATIC BRAIN-INJURY; BONE-FORMATION; STEM/PROGENITOR CELLS; PROGENITOR CELLS; TRANSGENIC MICE; CONTRIBUTE; HETEROGENEITY; EXPRESSION; PREVENTS; MUSCLE	BackgroundHeterotopic ossification (HO), either acquired (aHO) or hereditary, such as fibrodysplasia ossificans progressiva (FOP), is a serious condition without effective treatment. Understanding of the core process of injury-induced HO is still severely limited.MethodsDouble-pulse thymidine analog labeling was used to explore the distinctive domains evolved in injury-induced lesions in an animal model of HO (Nse-BMP4). Histological studies were performed to see whether a similar zonal pattern is also consistently found in biopsies from patients with aHO and FOP. In vivo clonal analysis with Rainbow mice, genetic loss-of-function studies with diphtheria toxin A (DTA)-mediated depletion and lineage tracing with Zsgreen reporter mice were used to obtain further evidence that Tie2-cre-, Gli1-creERT-, and Glast-creERT-labeled cells contribute to HO as niche-dwelling progenitor/stem cells. Immunohistochemistry was used to test whether vasculature, neurites, macrophages, and mast cells are closely associated with the proposed niche and thus are possible candidate niche supportive cells. Similar methods also were employed to further understand the signaling pathways that regulate the niche and the resultant HO.ResultsWe found that distinctive domains evolved in injury-induced lesions, including, from outside-in, a mesenchymal stem cell (MSC) niche, a transient domain and an inner differentiated core in an animal model of HO (Nse-BMP4). A similar zonal structure was found in patients with aHO and FOP. In vivo clonal analysis with Rainbow mice and genetic loss-of-function studies with DTA provided evidence that Tie2-cre-, Gli1-creERT-, and Glast-creERT-labeled cells contribute to HO as niche-dwelling progenitor/stem cells; consistently, vasculature, neurites, macrophages, and mast cells are closely associated with the proposed niche and thus are possible candidate niche supportive cells. Further mechanistic study found that BMP and hedgehog (Hh) signaling co-regulate the niche and the resultant HO.ConclusionsAvailable data provide evidence of a potential core mechanism in which multiple disease-specific cellular and extracellular molecular elements form a unique local microenvironment, i.e., an injury-induced stem cell niche, which regulates the proliferation and osteogenic differentiation of mesenchymal stem cells (MSCs). The implication for HO is that therapeutic approaches must consider several different disease specific factors as parts of a functional unit, instead of treating one factor at a time.	[Kan, Chen; Ding, Na; Tan, Zhenya; Lu, Haimei; Kan, Lixin] Anhui Med Univ, Sch Basic Med Sci, 81 Meishan Rd, Hefei 230032, Anhui, Peoples R China; [Yang, Jiazhao] Chinese Univ Sci & Technol, Affiliated Hosp 1, Dept Traumat Orthoped, Anhui Prov Hosp, Hefei 233000, Anhui, Peoples R China; [McGuire, Tammy L.; Kessler, John A.; Kan, Lixin] Northwestern Univ, Dept Neurol, Ward Bldg 10-233,303 East Chicago Ave, Chicago, IL 60611 USA; [Zhang, Keqin] Tongji Univ, Sch Med, Tongji Hosp, Dept Endocrinol & Metab, Shanghai, Peoples R China; [Berger, Diana M. Palila] Northwestern Univ, Feinberg Med Sch, Ctr Comparat Med, Chicago, IL 60611 USA	Kan, LX (corresponding author), Anhui Med Univ, Sch Basic Med Sci, 81 Meishan Rd, Hefei 230032, Anhui, Peoples R China.; Kan, LX (corresponding author), Northwestern Univ, Dept Neurol, Ward Bldg 10-233,303 East Chicago Ave, Chicago, IL 60611 USA.	l-kan@northwestern.edu	zhang, ke/AAH-8217-2019		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81472087]; Natural Science Foundation of Anhui provinceNatural Science Foundation of Anhui Province [1508085MC45]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 AR066539]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR066539] Funding Source: NIH RePORTER	LK was supported in part by the National Natural Science Foundation of China (81472087) and Natural Science Foundation of Anhui province (1508085MC45). This work was supported by NIH grant RO1 AR066539 (JAK).	Agarwal S, 2017, STEM CELLS, V35, P705, DOI 10.1002/stem.2515; Agarwal S, 2016, P NATL ACAD SCI USA, V113, pE338, DOI 10.1073/pnas.1515397113; Ahn S, 2004, CELL, V118, P505, DOI 10.1016/j.cell.2004.07.023; Almangour W, 2016, ANN PHYS REHABIL MED, V59, P263, DOI 10.1016/j.rehab.2016.03.009; Birbrair A, 2016, ANN NY ACAD SCI, V1370, P82, DOI 10.1111/nyas.13016; Davies OG, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00194; Dey D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1090; Fu HD, 2017, EXP THER MED, V14, P5424, DOI 10.3892/etm.2017.5210; Gannon FH, 2001, HUM PATHOL, V32, P842, DOI 10.1053/hupa.2001.26464; Hojo H, 2013, J BIOL CHEM, V288, P9924, DOI 10.1074/jbc.M112.409342; Hsieh HHS, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00074; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Ivanova A, 2005, GENESIS, V43, P129, DOI 10.1002/gene.20162; Kan C, 2018, BONE, V109, P43, DOI 10.1016/j.bone.2017.04.014; Kan C, 2018, BONE, V109, P71, DOI 10.1016/j.bone.2017.06.014; Kan LX, 2014, INFLAMM RES, V63, P207, DOI 10.1007/s00011-013-0690-4; Kan LX, 2013, BONE, V53, P194, DOI 10.1016/j.bone.2012.12.008; Kan LX, 2011, J CELL BIOCHEM, V112, P2759, DOI 10.1002/jcb.23259; Kan LX, 2009, STEM CELLS, V27, P150, DOI 10.1634/stemcells.2008-0576; Kan LX, 2004, AM J PATHOL, V165, P1107, DOI 10.1016/S0002-9440(10)63372-X; Kazmers NH, 2015, BONE, V81, P524, DOI 10.1016/j.bone.2015.09.002; Kendler A, 1996, J NEUROPATH EXP NEUR, V55, P1253, DOI 10.1097/00005072-199612000-00009; Kiel MJ, 2007, NATURE, V449, P238, DOI 10.1038/nature06115; Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106; Kraft CT, 2016, J TRAUMA ACUTE CARE, V80, P156, DOI 10.1097/TA.0000000000000883; Livet J, 2007, NATURE, V450, P56, DOI 10.1038/nature06293; Llorens-Martin M, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00076; Lounev VY, 2009, J BONE JOINT SURG AM, V91A, P652, DOI 10.2106/JBJS.H.01177; Lv FJ, 2014, STEM CELLS, V32, P1408, DOI 10.1002/stem.1681; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Olmsted-Davis EA, 2017, STEM CELL TRANSL MED, V6, P1109, DOI 10.1002/sctm.16-0347; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Pignolo Robert J, 2013, Pediatr Endocrinol Rev, V10 Suppl 2, P437; Pluchino S, 2010, ARCH ITAL BIOL, V148, P173; Rinkevich Y, 2014, CELL REP, V7, P1270, DOI 10.1016/j.celrep.2014.04.018; Sakellariou VI, 2012, J MUSCULOSKEL NEURON, V12, P230; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; Snippert HJ, 2010, CELL, V143, P134, DOI 10.1016/j.cell.2010.09.016; Wang P, 2017, INT J BIOL SCI, V13, P996, DOI 10.7150/ijbs.19986; Wosczyna MN, 2012, J BONE MINER RES, V27, P1004, DOI 10.1002/jbmr.1562; Yu VWC, 2016, CURR OPIN HEMATOL, V23, P331, DOI 10.1097/MOH.0000000000000265; Zhang C, 2016, FEBS J, V283, P1275, DOI 10.1111/febs.13667	42	14	15	1	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-6512			STEM CELL RES THER	Stem Cell Res. Ther.	JAN 11	2019	10								14	10.1186/s13287-018-1107-7			17	Cell & Tissue Engineering; Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	HH2AK	WOS:000455520800003	30635039	DOAJ Gold, Green Published			2021-06-18	
J	Fang, J; Zhu, YH; Wang, HD; Cao, BL; Fei, MX; Niu, WH; Zhou, Y; Wang, XL; Li, X; Zhou, ML				Fang, Jiang; Zhu, Yihao; Wang, Handong; Cao, Bailu; Fei, Maoxing; Niu, Wenhao; Zhou, Yuan; Wang, Xiaoliang; Li, Xiang; Zhou, Mengliang			Baicalin Protects Mice Brain From Apoptosis in Traumatic Brain Injury Model Through Activation of Autophagy	FRONTIERS IN NEUROSCIENCE			English	Article						Baicalin; traumatic brain injury; autophagy; apoptosis; mitochondrial apoptosis	CLOSED-HEAD INJURY; OXIDATIVE STRESS; PATHWAY; NEUROPROTECTION; INFLAMMATION; INVOLVEMENT; MODULATION; MELATONIN; RAPAMYCIN; MOUSE	Autophagy is associated with secondary injury following traumatic brain injury (TBI) and is expected to be a therapeutic target. Baicalin, a neuroprotective agent, has been proven to exert multi-functional bioactive effects in brain injury diseases. However, it is unknown if Baicalin influences autophagy after TBI. In the present study, we aimed to explore the effects that Baicalin had on TBI in a mice model, focusing on autophagy as a potential mechanism. We found that Baicalin administration significantly improved motor function, reduced cerebral edema, and alleviated disruption of the blood-brain barrier (BBB) after TBI in mice. Besides, TBI-induced apoptosis was reversed by Baicalin evidenced by Nissl staining, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, and the level of cleaved caspase-3. More importantly, Baicalin enhanced autophagy by detecting the autophagy markers (LC3, Beclin 1, and p62) using western blot and LC3 immunofluorescence staining, ameliorating mitochondrial apoptotic pathway evidenced by restoration of the TBI-induced translocation of Bax and cytochrome C. However, simultaneous treatment with 3-MA inhibited Baicalin-induced autophagy and abolished its protective effects on mitochondrial apoptotic pathway. In conclusion, we demonstrated that Baicalin enhanced autophagy, ameliorated mitochondrial apoptosis and protected mice brain in TBI mice model.	[Fang, Jiang; Zhu, Yihao; Wang, Handong; Fei, Maoxing; Niu, Wenhao; Zhou, Yuan; Wang, Xiaoliang; Zhou, Mengliang] Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China; [Fang, Jiang; Wang, Handong; Niu, Wenhao] Southeast Univ, Sch Med, Nanjing, Jiangsu, Peoples R China; [Zhu, Yihao; Wang, Xiaoliang; Zhou, Mengliang] Nanjing Univ, Sch Med, Nanjing, Jiangsu, Peoples R China; [Cao, Bailu; Fei, Maoxing; Zhou, Yuan] Nanjing Med Univ, Jinling Clin Med Coll, Nanjing, Jiangsu, Peoples R China; [Cao, Bailu] Jinling Hosp, Dept Endocrinol, Nanjing, Jiangsu, Peoples R China; [Li, Xiang] Jiangsu Prov Second Chinese Med Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China	Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China.; Wang, HD (corresponding author), Southeast Univ, Sch Med, Nanjing, Jiangsu, Peoples R China.	njhdwang@hotmail.com		Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81672503, 81571162, 81401026]; Military Medical Youth Training Program [16QNP042]; Project of Hospital Management of Nanjing General Hospital of Nanjing Military Region [2017013]	This work was supported by the National Natural Science Foundation of China (Grant Nos. 81672503, 81571162, and 81401026), Military Medical Youth Training Program (Grant No. 16QNP042), and the Project of Hospital Management of Nanjing General Hospital of Nanjing Military Region (Grant No. 2017013).	Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Cao YG, 2011, BRAIN RES BULL, V85, P396, DOI 10.1016/j.brainresbull.2011.05.002; Cavallucci V, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.511; Chen XR, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1151-3; Chen XR, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00117; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Cortes CJ, 2019, NEUROBIOL DIS, V122, P83, DOI 10.1016/j.nbd.2018.05.012; Ding H, 2017, NEUROCHEM RES, V42, P337, DOI 10.1007/s11064-016-2077-8; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Fang J, 2018, DRUG DES DEV THER, V12, P2497, DOI 10.2147/DDDT.S163951; Fernandez A, 2015, J PINEAL RES, V59, P292, DOI 10.1111/jpi.12264; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fowler AJ, 2018, CNS DRUGS, V32, P1, DOI 10.1007/s40263-018-0497-5; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019; Hong C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10443-6; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kang JH, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.14; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Lee WS, 2015, CURR MOL MED, V15, P735, DOI 10.2174/1566524015666150921105453; Liang JW, 2018, DRUG DES DEV THER, V12, P845, DOI 10.2147/DDDT.S160046; Lin CJ, 2013, INT J ONCOL, V42, P993, DOI 10.3892/ijo.2013.1791; Lipinski MM, 2015, ANTIOXID REDOX SIGN, V23, P565, DOI 10.1089/ars.2015.6306; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo SQ, 2013, AUTOPHAGY, V9, P104, DOI 10.4161/auto.22399; Ma AT, 2009, AM J CHINESE MED, V37, P85, DOI 10.1142/S0192415X09006709; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mustafa AG, 2013, NEUROSCIENCES, V18, P222; Shi XQ, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1401790; Tan XM, 2018, CELL TRANSPLANT, V27, P1753, DOI 10.1177/0963689718760486; Tarrago T, 2008, BIOORGAN MED CHEM, V16, P7516, DOI 10.1016/j.bmc.2008.04.067; Tu XK, 2009, NEUROCHEM RES, V34, P1626, DOI 10.1007/s11064-009-9953-4; Viscomi MT, 2012, AUTOPHAGY, V8, P222, DOI 10.4161/auto.8.2.18599; Wang CQ, 2017, NEUROSCIENCE, V343, P30, DOI 10.1016/j.neuroscience.2016.11.029; Wang YQ, 2012, NEUROCHEM RES, V37, P1849, DOI 10.1007/s11064-012-0791-4; Wei WT, 2015, NEUROCHEM INT, V87, P85, DOI 10.1016/j.neuint.2015.06.003; Xu JG, 2014, BRAIN RES, V1582, P237, DOI 10.1016/j.brainres.2014.07.042; Zhang L, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00190; Zhang L, 2018, NEUROCHEM INT, V118, P304, DOI 10.1016/j.neuint.2018.05.011; Zhang L, 2016, CELL MOL NEUROBIOL, V36, P131, DOI 10.1007/s10571-015-0227-1; Zhang QW, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02142; Zhang XN, 2013, AUTOPHAGY, V9, P1321, DOI 10.4161/auto.25132; Zhang XJ, 2012, ONCOL REP, V27, P1128, DOI 10.3892/or.2011.1599; Zuo DY, 2016, NEUROTOX RES, V30, P159, DOI 10.1007/s12640-016-9611-y	52	14	16	1	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	JAN 9	2019	12								1006	10.3389/fnins.2018.01006			12	Neurosciences	Neurosciences & Neurology	HG9MO	WOS:000455333000001	30686973	DOAJ Gold, Green Published			2021-06-18	
J	LaRocca, D; Barns, S; Hicks, SD; Brindle, A; Williams, J; Uhlig, R; Johnson, P; Neville, C; Middleton, FA				LaRocca, Daria; Barns, Sarah; Hicks, Steven D.; Brindle, Andrew; Williams, Jeremy; Uhlig, Richard; Johnson, Paul; Neville, Christopher; Middleton, Frank A.			Comparison of serum and saliva miRNAs for identification and characterization of mTBI in adult mixed martial arts fighters	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID; BIOMARKERS; MICRORNAS; EXPRESSION; MIR-155; PLASMA; HEALTH; GENES	Traumatic brain injury (TBI) is a major cause of death and disability worldwide, with mild TBI (mTBI) accounting for 85% of cases. mTBI is also implicated in serious long-term sequelae including second impact syndrome and chronic traumatic encephalopathy. mTBI often goes undiagnosed due to delayed symptom onset and limited sensitivity of conventional assessment measures compared with severe TBI. Current efforts seek to identify accurate and reliable non-invasive biomarkers associated with functional measures relevant to long-term outcomes. Here we evaluated the utility of serum and salivary microRNAs (miRNAs) to serve as sensitive and specific peripheral biomarkers of possible mTBI. Our primary objectives were to establish the relationship between peripheral measures of miRNA, objective quantification of head impacts, and sensitive indices of balance and cognitive function in healthy young adult athletes. A secondary objective was to compare the sensitivity of miRNA versus commonly used blood-based protein biomarkers. 50 amateur mixed martial arts (MMA) fighters participated. 216 saliva and serum samples were collected at multiple time points, both pre- and post-fight. Levels of 10 serum proteins were compared in a subset of the fighters (n = 24). Levels of miRNAs were obtained by next generation sequencing. Functional outcomes were evaluated using a computerized assessment system that measured cognitive performance, body sway, and combined cognitive performance and body sway during dual task completion. Data were analyzed using multivariate logistic regression for predictive classification, analysis of variance, correlation analysis and principal component analysis. We identified a subset of salivary and serum miRNAs that showed robust utility at predicting TBI likelihood and demonstrated quantitative associations with head impacts as well as cognitive and balance measures. In contrast, serum proteins demonstrated far less utility. We also found that the timing of the responses varies in saliva and serum, which is a critical observation for biomarker studies to consider.	[LaRocca, Daria; Barns, Sarah; Middleton, Frank A.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA; [Barns, Sarah; Brindle, Andrew; Williams, Jeremy; Uhlig, Richard] Quadrant Biosci Inc, 405 Irving Ave, Syracuse, NY USA; [Hicks, Steven D.] Penn State Coll Med, Dept Pediat, Hershey, PA USA; [Johnson, Paul] SUNY Upstate Med Univ, Coll Hlth Profess Clin Lab Sci, Syracuse, NY 13210 USA; [Neville, Christopher] SUNY Upstate Med Univ, Dept Phys Therapy Educ, Syracuse, NY 13210 USA; [Middleton, Frank A.] SUNY Upstate Med Univ, Dept Psychiat & Behav Sci, Syracuse, NY 13210 USA; [Middleton, Frank A.] SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA; [Middleton, Frank A.] SUNY Upstate Med Univ, Dept Pediat, Syracuse, NY 13210 USA	Middleton, FA (corresponding author), SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA.; Middleton, FA (corresponding author), SUNY Upstate Med Univ, Dept Psychiat & Behav Sci, Syracuse, NY 13210 USA.; Middleton, FA (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA.; Middleton, FA (corresponding author), SUNY Upstate Med Univ, Dept Pediat, Syracuse, NY 13210 USA.	middletf@upstate.edu		Middleton, Frank/0000-0002-3107-7188; Hicks, Steven/0000-0002-9579-6798; Johnson, Paul/0000-0003-2661-9197; Neville, Christopher/0000-0002-8601-976X	Quadrant Biosciences, Inc.; Research Foundation of the State University of New York [RF1128143-1-72906]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR002015, UL1TR002014] Funding Source: NIH RePORTER	Part of the financial support for this work was funded by an award from Motion Intelligence, Inc. (now Quadrant Biosciences, Inc; https://quadrantbiosciences.com/).This award was issued to the corresponding author (F. Middleton) and administered through the Research Foundation of the State University of New York (grant number RF1128143-1-72906). The funder provided support in the form of salaries for authors SB, AB, JW and RU, who helped with data acquisition and project support, but did not have any additional role in the data analysis, decision to publish, or preparation of the initial manuscript. The specific roles of these authors are in the 'author contributions' section.	Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bhomia M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28148; Cardoso AL, 2012, IMMUNOLOGY, V135, P73, DOI 10.1111/j.1365-2567.2011.03514.x; Chandran R, 2017, BRAIN INJURY, V31, P106, DOI 10.1080/02699052.2016.1213420; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gaudet AD, 2016, J NEUROSCI, V36, P8516, DOI 10.1523/JNEUROSCI.0735-16.2016; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Harrison EB, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00228; Hayes J, 2014, TRENDS MOL MED, V20, P460, DOI 10.1016/j.molmed.2014.06.005; Hicks SD, 2018, J NEUROTRAUM, V35, P64, DOI 10.1089/neu.2017.5111; Hutchison MG, 2014, AM J SPORT MED, V42, P1352, DOI 10.1177/0363546514526151; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ignacio C, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0195-x; Jee MK, 2012, HUM GENE THER, V23, P508, DOI 10.1089/hum.2011.121; Johnson JJ, 2018, JAMA PEDIATR, V172, P65, DOI 10.1001/jamapediatrics.2017.3884; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Koval ED, 2013, HUM MOL GENET, V22, P4127, DOI 10.1093/hmg/ddt261; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Laterza OF, 2009, CLIN CHEM, V55, P1977, DOI 10.1373/clinchem.2009.131797; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; Lopez-Ramirez MA, 2016, FASEB J, V30, P2662, DOI 10.1096/fj.201600435RR; Lukiw WJ, 2007, NEUROREPORT, V18, P297, DOI 10.1097/WNR.0b013e3280148e8b; Moore CS, 2013, ANN NEUROL, V74, P709, DOI 10.1002/ana.23967; O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106; Pasinetti Giulio M, 2012, Am J Neurodegener Dis, V1, P88; Phay M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137461; Plog BA, 2018, ANNU REV PATHOL-MECH, V13, P379, DOI 10.1146/annurev-pathol-051217-111018; Puhakka N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172521; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Roncon P, 2015, SCI REP-UK, V5, DOI 10.1038/srep14143; Sajja VSSS, 2018, J NEUROTRAUM, V35, P353, DOI 10.1089/neu.2017.5009; Sharma A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112019; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Sullan MJ, 2018, NEUROSCI BIOBEHAV R, V84, P316, DOI 10.1016/j.neubiorev.2017.08.016; Tan L, 2015, MOL NEUROBIOL, V51, P1249, DOI 10.1007/s12035-014-8803-9; Thome AD, 2016, J NEUROSCI, V36, P2383, DOI 10.1523/JNEUROSCI.3900-15.2016; Woods DL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124345; Yeri A, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4726-6; You WD, 2016, CHIN J TRAUMATOL, V19, P11, DOI 10.1016/j.cjtee.2016.01.004; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	44	14	14	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 2	2019	14	1							e0207785	10.1371/journal.pone.0207785			38	Multidisciplinary Sciences	Science & Technology - Other Topics	HG1BB	WOS:000454683200004	30601825	DOAJ Gold, Green Published			2021-06-18	
J	Terry, DP; Brassil, M; Iverson, GL; Panenka, WJ; Silverberg, ND				Terry, Douglas P.; Brassil, Michelle; Iverson, Grant L.; Panenka, William J.; Silverberg, Noah D.			Effect of depression on cognition after mild traumatic brain injury in adults	CLINICAL NEUROPSYCHOLOGIST			English	Article						Mild traumatic brain injury; MTBI; depression; cognition; neuropsychological functioning	PATIENT HEALTH QUESTIONNAIRE-9; SYMPTOM VALIDITY TEST; NIH TOOLBOX; NEUROPSYCHOLOGICAL OUTCOMES; DIAGNOSTIC METAANALYSIS; CONCUSSION; SEVERITY; DISORDER; TESTS; PHQ-9	Objective: The current study examined the effect of depression on cognitive test performance in a sample of adults seeking treatment for a mild traumatic brain injury (MTBI). We hypothesized that patients with greater depressive symptoms would perform worse on tasks of fluid cognition compared to those without depression, after controlling for potential confounds. Method: Patients (N = 76) completed a brief cognitive test battery (NIH Toolbox Cognition Battery; NIHTB-CB) and a depression screening questionnaire (PHQ-9) at 11.7-weeks post injury (SD = 6.3 range 2-26). Cognitive scores were adjusted for age, education, gender, and race/ethnicity. Depressive symptoms were examined continuously and dichotomized as: (1) total PHQ-9 score of >= 10, the optimal cut-off for Major Depressive Disorder caseness from prior research, and (2) five or more symptoms of depression, including either depressed mood or anhedonia (i.e. DSM-5-based definition). Results: Twenty-seven patients (35.5%) met DSM-5-based criteria for depression and 42 (55.3%) met criteria based on PHQ-9 > 10. Depression symptom severity correlated with lower fluid cognition composite scores [r = -.22, p = .05] and contributed to the prediction of fluid cognition performance in a model that controlled for time since injury and crystallized cognitive abilities [F(3, 72) = 7.49, p R-2 = 20.6%]. Examining specific NIHTB-CB fluid subtests, the largest group differences were seen on processing speed (d = .40-.49), cognitive flexibility (d = .32-.36), and episodic memory (d = .20-.34). Depression severity was strongly associated with overall post-concussion symptom burden (r = .77, p < .001). Conclusion: Depression is a common comorbidity and an important factor to consider when interpreting neurocognitive test performance in adults with concussion in a clinical setting.	[Terry, Douglas P.; Brassil, Michelle; Iverson, Grant L.; Silverberg, Noah D.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA 02115 USA; [Terry, Douglas P.; Brassil, Michelle; Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Terry, Douglas P.; Iverson, Grant L.] Home Base, Boston, MA USA; [Terry, Douglas P.; Iverson, Grant L.] Massachusetts Gen Hosp Program, Boston, MA USA; [Terry, Douglas P.; Iverson, Grant L.] MassGen Hosp, Children Sport Concuss Program, Boston, MA USA; [Panenka, William J.] Univ British Columbia, British Columbia Neuropsychiat Program, Vancouver, BC, Canada; [Panenka, William J.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC, Canada; [Silverberg, Noah D.] GF Strong Rehab Ctr, Rehabil Res Program, Vancouver Coastal Hlth Res Inst, Vancouver, BC, Canada	Silverberg, ND (corresponding author), Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA 02115 USA.; Silverberg, ND (corresponding author), Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC, Canada.; Silverberg, ND (corresponding author), GF Strong Rehab Ctr, Rehabil Res Program, Vancouver Coastal Hlth Res Inst, Vancouver, BC, Canada.	noah.silverberg@vch.ca		Panenka, William/0000-0001-7143-6512; Iverson, Grant/0000-0001-7348-9570	Specific Priorities Research Grant from WorkSafeBC [RS2014-SP03]; Vancouver Coastal Health Research Institute; Michael Smith Foundation for Health ResearchMichael Smith Foundation for Health Research	This study was funded by a Specific Priorities Research Grant from WorkSafeBC [grant number #RS2014-SP03]. Noah Silverberg receives salary support from a Clinician-Scientist Career Development Award from the Vancouver Coastal Health Research Institute and a Health Professional Investigator Award from the Michael Smith Foundation for Health Research. Grant Iverson acknowledges unrestricted philanthropic support from the Mooney-Reed Charitable Foundation, ImPACT Applications, Inc., and the Heinz Family Foundation.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Barker-Collo S, 2015, BRAIN INJURY, V29, P1604, DOI 10.3109/02699052.2015.1075143; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2014, BRAIN INJURY, V28, P1623, DOI 10.3109/02699052.2014.947627; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Broshek DK, 2015, BRAIN INJURY, V29, P228, DOI 10.3109/02699052.2014.974674; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Casaletto KB, 2016, J INT NEUROPSYCH SOC, V22, P364, DOI 10.1017/S135561771500137X; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cook KF, 2011, ARCH PHYS MED REHAB, V92, P818, DOI 10.1016/j.apmr.2010.12.008; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Fox DD, 2011, CLIN NEUROPSYCHOL, V25, P488, DOI 10.1080/13854046.2011.554443; Gale CR, 2009, INTELLIGENCE, V37, P592, DOI 10.1016/j.intell.2008.09.002; Gale CR, 2008, ARCH GEN PSYCHIAT, V65, P1410, DOI 10.1001/archpsyc.65.12.1410; Gilbody S, 2007, J GEN INTERN MED, V22, P1596, DOI 10.1007/s11606-007-0333-y; Green, 2004, GREENS MED SYMPTOM V; Hammar A, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.026.2009; Henry JD, 2005, J CLIN EXP NEUROPSYC, V27, P78, DOI 10.1080/138033990513654; Holdnack JA, 2017, REHABIL PSYCHOL, V62, P474, DOI 10.1037/rep0000145; Holdnack JA, 2017, ARCH CLIN NEUROPSYCH, V32, P574, DOI 10.1093/arclin/acx032; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Howe L, 2009, CLIN NEUROPSYCHOL, V23, P329, DOI 10.1080/13854040801945060; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Koenen KC, 2009, AM J PSYCHIAT, V166, P50, DOI 10.1176/appi.ajp.2008.08030343; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LandrO N. I., NEUROPSYCHIATRY NEUR, V14, P233; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Lucas S, 2016, HEADACHE, V56, P323, DOI 10.1111/head.12762; Manea L, 2015, GEN HOSP PSYCHIAT, V37, P67, DOI 10.1016/j.genhosppsych.2014.09.009; McClintock SA, 2010, NEUROPSYCHOLOGY, V24, P9, DOI 10.1037/a0017336; Mitchell AJ, 2016, BJPSYCH OPEN, V2, P127, DOI 10.1192/bjpo.bp.115.001685; Panczykowski DM, 2014, PROG NEUROL SURG, V28, P195, DOI 10.1159/000358780; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Tulsky DS, 2017, REHABIL PSYCHOL, V62, P413, DOI 10.1037/rep0000174; van der Naalt J, 2017, LANCET NEUROL, V16, P532, DOI 10.1016/S1474-4422(17)30117-5; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745; Waljas M, 2014, J NEUROTRAUM, V31, P108, DOI 10.1089/neu.2013.2941; Weintraub S, 2014, J INT NEUROPSYCH SOC, V20, P567, DOI 10.1017/S1355617714000320; Weintraub S, 2013, NEUROLOGY, V80, pS54, DOI 10.1212/WNL.0b013e3182872ded; West LK, 2011, J NEUROPSYCHOL, V5, P114, DOI 10.1348/174866410X521434; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Zakzanis K. K., 1999, STUD NEUROPSYCHOL DE	48	14	14	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JAN 2	2019	33	1					124	136		10.1080/13854046.2018.1459853			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	HK9OC	WOS:000458320100008	29726314				2021-06-18	
J	Braeckman, K; Descamps, B; Pieters, L; Vral, A; Caeyenberghs, K; Vanhove, C				Braeckman, Kim; Descamps, Benedicte; Pieters, Leen; Vral, Anne; Caeyenberghs, Karen; Vanhove, Christian			Dynamic changes in hippocampal diffusion and kurtosis metrics following experimental mTBI correlate with glial reactivity	NEUROIMAGE-CLINICAL			English	Article						Mild traumatic brain injury; Diffusion magnetic resonance imaging; DTI; DKI; White matter model	TRAUMATIC BRAIN-INJURY; MATTER TRACT INTEGRITY; WHITE-MATTER; AXONAL INJURY; BIDIRECTIONAL CHANGES; COGNITIVE IMPAIRMENT; TENSOR; MRI; IMPACT; PARAMETERS	Diffusion magnetic resonance imaging biomarkers can provide quantifiable information of the brain tissue after a mild traumatic brain injury (mTBI). However, the commonly applied diffusion tensor imaging (DTI) model is not very specific to changes in the underlying cellular structures. To overcome these limitations, other diffusion models have recently emerged to provide a more complete view on the damage profile following TBI. In this study, we investigated longitudinal changes in advanced diffusion metrics following experimental mTBI, utilising three different diffusion models in a rat model of mTBI, including DTI, diffusion kurtosis imaging and a white matter model. Moreover, we investigated the association between the diffusion metrics with histological markers, including glial fibrillary acidic protein (GFAP), neurofilaments and synaptophysin in order to investigate specificity. Our results revealed significant decreases in mean diffusivity in the hippocampus and radial diffusivity and radial extra axonal diffusivity (RadEAD) in the cingulum one week post injury. Furthermore, correlation analysis showed that increased values of fractional anisotropy one day post injury in the hippocampus was highly correlated with GFAP reactivity three months post injury. Additionally, we observed a positive correlation between GFAP on one hand and the kurtosis parameters in the hippocampus on the other hand three months post injury. This result indicated that prolonged glial activation three months post injury is related to higher kurtosis values at later time points. In conclusion, our findings point out to the possible role of kurtosis metrics as well as metrics from the white matter model as prognostic biomarker to monitor prolonged glial reactivity and inflammatory responses after a mTBI not only at early timepoints but also several months after injury.	[Braeckman, Kim; Descamps, Benedicte; Vanhove, Christian] UGent, Infin Lab, Med Imaging & Signal Proc Grp, Ghent, Belgium; [Pieters, Leen; Vral, Anne] UGent, Dept Human Struct & Repair, Ghent, Belgium; [Caeyenberghs, Karen] Australian Catholic Univ, Mary MacKillop Inst Hlth Res, Melbourne, Vic, Australia; [Braeckman, Kim; Descamps, Benedicte] MEDISIP IBiTech, Infin Lab, Blok B-5,Ingang 36,Campus UZ Gent, B-9000 Ghent, Belgium; [Pieters, Leen; Vral, Anne] Dept Human Struct & Repair, Radiobiol Res Unit, 6B3,Ingang 46,Campus UZ Gent, B-9000 Ghent, Belgium; [Caeyenberghs, Karen] Mary MacKillop Insitute Hlth Res, Bldg 470,Level 5,Room 470-5-02,215 Spring St, Melbourne, Vic 3000, Australia	Braeckman, K (corresponding author), UGent, Infin Lab, Med Imaging & Signal Proc Grp, Ghent, Belgium.	kim.braeckman@ugent.be; benedicte.descamps@ugent.be; leen.pieters@ugent.be; anne.vral@ugent.be; karen.caeyenberghs@acu.edu.au; christian.vanhove@ugent.be	Vral, Anne/R-5778-2019	Descamps, Benedicte/0000-0001-8879-1772; Vanhove, Christian/0000-0002-3988-5980	Research Foundation - Flanders (FWO)FWO [G027815N]	This work was supported by the Research Foundation - Flanders (FWO) [grant number G027815N].	Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Asken BM, 2018, BRAIN IMAGING BEHAV, V12, P585, DOI 10.1007/s11682-017-9708-9; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Billiet T, 2015, NEUROBIOL AGING, V36, P2107, DOI 10.1016/j.neurobiolaging.2015.02.029; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Chung S, 2018, J NEUROTRAUM, V35, P1015, DOI 10.1089/neu.2017.5320; de Kouchkovsky I, 2016, J NEUROL, V263, P1146, DOI 10.1007/s00415-016-8118-z; De Santis S, 2014, NEUROIMAGE, V89, P35, DOI 10.1016/j.neuroimage.2013.12.003; Dewan MC, 2016, WORLD NEUROSURG, V91, P497, DOI 10.1016/j.wneu.2016.03.045; Duricki DA, 2016, NAT PROTOC, V11, P1112, DOI 10.1038/nprot.2016.048; Fieremans E, 2013, AM J NEURORADIOL, V34, P2105, DOI 10.3174/ajnr.A3553; Fieremans E, 2011, NEUROIMAGE, V58, P177, DOI 10.1016/j.neuroimage.2011.06.006; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Grossman EJ, 2015, NEUROIMAGE, V118, P334, DOI 10.1016/j.neuroimage.2015.05.061; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Guglielmetti C, 2016, NEUROIMAGE, V125, P363, DOI 10.1016/j.neuroimage.2015.10.052; Harris NG, 2016, NEUROIMAGE, V133, P129, DOI 10.1016/j.neuroimage.2016.03.012; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Hutchinson EB, 2018, J NEUROSCI RES, V96, P612, DOI 10.1002/jnr.24065; Jelescu IO, 2016, NEUROIMAGE, V132, P104, DOI 10.1016/j.neuroimage.2016.02.004; Jensen JH, 2010, NMR BIOMED, V23, P698, DOI 10.1002/nbm.1518; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Kelma ND, 2016, NEUROIMAGE, V124, P612, DOI 10.1016/j.neuroimage.2015.09.028; Lazar M, 2014, NEUROIMAGE-CLIN, V4, P417, DOI 10.1016/j.nicl.2014.01.014; Lebel C, 2012, NEUROIMAGE, V60, P340, DOI 10.1016/j.neuroimage.2011.11.094; Lebel C, 2019, NMR BIOMED, V32, DOI 10.1002/nbm.3778; Leemans A., 2009, P INT SOC MAG RESON, V17, P3537, DOI DOI 10.1093/occmed/kqr069; Li SX, 2013, INT J LEGAL MED, V127, P159, DOI 10.1007/s00414-012-0712-8; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Loening Andreas Markus, 2003, Mol Imaging, V2, P131, DOI 10.1162/153535003322556877; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McDonald JH, 2014, HDB BIOL STAT, P254; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Novikov DS, 2018, MAGN RESON MED, V79, P3172, DOI 10.1002/mrm.27101; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Qin Y, 2018, BEHAV BRAIN RES, V340, P41, DOI 10.1016/j.bbr.2016.08.008; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Siedler DG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00429; Singh K, 2016, EXP NEUROL, V275, P427, DOI 10.1016/j.expneurol.2015.07.016; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Szczepankiewicz F, 2013, NEUROIMAGE, V76, P145, DOI 10.1016/j.neuroimage.2013.02.078; Thurman DJ, 2016, J CHILD NEUROL, V31, P20, DOI 10.1177/0883073814544363; Tu TW, 2016, ANN NEUROL, V79, P907, DOI 10.1002/ana.24641; Veraart J, 2016, NEUROIMAGE, V142, P384, DOI 10.1016/j.neuroimage.2016.08.016; Veraart J, 2016, MAGN RESON MED, V76, P1582, DOI 10.1002/mrm.26059; Veraart J, 2013, NEUROIMAGE, V81, P335, DOI 10.1016/j.neuroimage.2013.05.028; Veraart J, 2011, MAGN RESON MED, V65, P138, DOI 10.1002/mrm.22603; Wallace EJ, 2018, BRAIN IMAGING BEHAV, V12, P1607, DOI 10.1007/s11682-018-9823-2; Yu FS, 2017, J NEUROTRAUM, V34, P1364, DOI 10.1089/neu.2016.4569; Zhang S, 2018, IRAN J RADIOL, V15, P1, DOI [10.5812/iranjradiol.56115.Research, DOI 10.5812/IRANJRADIOL.56115.RESEARCH]; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	56	14	14	1	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2019	21								101669	10.1016/j.nicl.2019.101669			12	Neuroimaging	Neurosciences & Neurology	HN6ZP	WOS:000460337700082	30658945	DOAJ Gold, Green Published			2021-06-18	
J	Chen, CH; Zhong, XL; Smith, DK; Tai, WJ; Yang, JJ; Zou, YH; Wang, LL; Sun, JH; Qin, S; Zhang, CL				Chen, Chunhai; Zhong, Xiaoling; Smith, Derek K.; Tai, Wenjiao; Yang, Jianjing; Zou, Yuhua; Wang, Lei-Lei; Sun, Jiahong; Qin, Song; Zhang, Chun-Li			Astrocyte-Specific Deletion of Sox2 Promotes Functional Recovery After Traumatic Brain Injury	CEREBRAL CORTEX			English	Article						brain repair; neural stem cell; reactive gliosis; SOX2; traumatic brain injury	NEURAL STEM-CELLS; CONTROLLED CORTICAL IMPACT; NUCLEAR RECEPTOR TLX; ADULT SPINAL-CORD; REACTIVE ASTROCYTES; SCAR FORMATION; GLIAL PROLIFERATION; SIGNALING PATHWAY; ACTIVATION; EXPRESSION	Injury to the adult brain induces activation of local astrocytes, which serves as a compensatory response that modulates tissue damage and recovery. However, the mechanism governing astrocyte activation during brain injury remains largely unknown. Here we provide in vivo evidence that SOX2, a transcription factor critical for stem cells and brain development, is also required for injury-induced activation of adult cortical astrocytes. Genome-wide chromatin immunoprecipitation-seq analysis of mouse cortical tissues reveals that SOX2 binds to regulatory regions of genes associated with signaling pathways that control glial cell activation, such as Nr2e1, Mmd2, Wnt7a, and Akt2. Astrocyte-specific deletion of Sox2 in adult mice greatly diminishes glial response to controlled cortical impact injury and, most unexpectedly, dampens injury-induced cortical loss and benefits behavioral recovery of mice after injury. Together, these results uncover an essential role of SOX2 in somatic cells under pathological conditions and indicate that SOX2-dependent astrocyte activation could be targeted for functional recovery after traumatic brain injury.	[Chen, Chunhai; Zhong, Xiaoling; Smith, Derek K.; Tai, Wenjiao; Yang, Jianjing; Zou, Yuhua; Wang, Lei-Lei; Sun, Jiahong; Qin, Song; Zhang, Chun-Li] Univ Texas Southwestern Med Ctr Dallas, Dept Mol Biol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA; [Chen, Chunhai; Zhong, Xiaoling; Smith, Derek K.; Tai, Wenjiao; Yang, Jianjing; Zou, Yuhua; Wang, Lei-Lei; Sun, Jiahong; Qin, Song; Zhang, Chun-Li] Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Regenerat Sci & Med, 6000 Harry Hines Blvd, Dallas, TX 75390 USA; [Chen, Chunhai] Third Mil Med Univ, Dept Occupat Hlth, Chongqing 400038, Peoples R China; [Qin, Song] Fudan Univ, Sch Basic Med Sci, Dept Anat Histol & Embryol, Shanghai 200032, Peoples R China; [Qin, Song] Tongji Univ, Shanghai Peoples Hosp 10, Ctr Neural Injury & Repair, Shanghai 200072, Peoples R China	Qin, S; Zhang, CL (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Regenerat Sci & Med, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.; Qin, S (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Anat Histol & Embryol, Shanghai 200032, Peoples R China.; Qin, S (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Ctr Neural Injury & Repair, Shanghai 200072, Peoples R China.	sqin@fudan.edu.cn; Chun-Li.Zhang@UTSouthwestern.edu	Qin, Song/AAK-5489-2021	Qin, Song/0000-0002-5569-4324; Zhang, Chun-Li/0000-0002-2639-4605; Zhong, Xiaoling/0000-0003-2963-4798; Chen, Chunhai/0000-0002-7549-213X	Welch FoundationThe Welch Foundation [I-1724]; Texas Institute for Brain Injury and Repair; Decherd Foundation; Kent Waldrep Foundation Center for Basic Research on Nerve Growth and Regeneration; Mobility Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS070981, NS099073, NS088095, NS092616, NS093502]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81528006]; National Key Basic Research Program of China (973 Program)National Basic Research Program of China [2014CB965001]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [1501219100]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS099073, R01NS092616, R21NS093502, R01NS088095, R01NS070981] Funding Source: NIH RePORTER	The work in the Zhang laboratory was supported by Welch Foundation (I-1724), Texas Institute for Brain Injury and Repair, Decherd Foundation, Kent Waldrep Foundation Center for Basic Research on Nerve Growth and Regeneration, Mobility Foundation, National Institutes of Health (NS070981, NS099073, NS088095, NS092616, and NS093502) and National Natural Science Foundation of China (No. 81528006). The work in the Qin laboratory was supported by grants from National Key Basic Research Program of China (973 Program, No. 2014CB965001), National Natural Science Foundation of China (No. 81528006), and Fundamental Research Funds for the Central Universities (No. 1501219100).	Adhikari A, 2011, NEURON, V71, P898, DOI 10.1016/j.neuron.2011.07.027; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Bani-Yaghoub M, 2006, DEV BIOL, V295, P52, DOI 10.1016/j.ydbio.2006.03.007; Benner EJ, 2013, NATURE, V497, P369, DOI 10.1038/nature12069; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Bylund M, 2003, NAT NEUROSCI, V6, P1162, DOI 10.1038/nn1131; Can A, 2012, JOVE-J VIS EXP, DOI 10.3791/3769; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen YC, 2012, NEUROL RES, V34, P390, DOI 10.1179/1743132812Y.0000000027; Chen YC, 2012, BIOCHEM BIOPH RES CO, V420, P397, DOI 10.1016/j.bbrc.2012.03.006; Choi I, 2013, GLIA, V61, P800, DOI 10.1002/glia.22475; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Endersby R, 2011, CANCER RES, V71, P4106, DOI 10.1158/0008-5472.CAN-10-3597; Episkopou V, 2005, TRENDS NEUROSCI, V28, P219, DOI 10.1016/j.tins.2005.03.003; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Ferri ALM, 2004, DEVELOPMENT, V131, P3805, DOI 10.1242/dev.01204; Ganat YM, 2006, J NEUROSCI, V26, P8609, DOI 10.1523/JNEUROSCI.2532-06.2006; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Gong SC, 2003, NATURE, V425, P917, DOI 10.1038/nature02033; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Gregorian C, 2009, J NEUROSCI, V29, P1874, DOI 10.1523/JNEUROSCI.3095-08.2009; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; Guo FZ, 2011, J NEUROSCI, V31, P11914, DOI 10.1523/JNEUROSCI.1759-11.2011; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Heinrich C, 2014, STEM CELL REP, V3, P1000, DOI 10.1016/j.stemcr.2014.10.007; Huang XT, 2013, J NEUROTRAUM, V30, P2080, DOI 10.1089/neu.2013.2996; Islam MM, 2015, STEM CELL REP, V5, P805, DOI 10.1016/j.stemcr.2015.09.015; Jeong SR, 2012, EXP NEUROL, V233, P312, DOI 10.1016/j.expneurol.2011.10.021; Jin T, 2012, CELL RES, V22, P661, DOI 10.1038/cr.2011.161; Kang P, 2012, NEURON, V74, P79, DOI 10.1016/j.neuron.2012.01.024; Kang WF, 2014, P NATL ACAD SCI USA, V111, pE2987, DOI 10.1073/pnas.1320401111; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Lang HN, 2015, SCI REP-UK, V5, DOI 10.1038/srep13383; Lang HN, 2011, JARO-J ASSOC RES OTO, V12, P151, DOI 10.1007/s10162-010-0244-1; LeComte MD, 2015, P NATL ACAD SCI USA, V112, P8726, DOI 10.1073/pnas.1501029112; Lee HJ, 2013, J NEUROSCI RES, V91, P196, DOI 10.1002/jnr.23151; Luukkainen S, 2012, PSYCHIAT RES, V200, P767, DOI 10.1016/j.psychres.2012.04.018; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Niu WZ, 2015, STEM CELL REP, V4, P780, DOI 10.1016/j.stemcr.2015.03.006; Niu WZ, 2013, NAT CELL BIOL, V15, P1164, DOI 10.1038/ncb2843; Niu WZ, 2011, J NEUROSCI, V31, P13816, DOI 10.1523/JNEUROSCI.1038-11.2011; Pardo L, 2016, GLIA, V64, P853, DOI 10.1002/glia.22969; Pekny M, 2014, PHYSIOL REV, V94, P1077, DOI 10.1152/physrev.00041.2013; Pevny LH, 2010, INT J BIOCHEM CELL B, V42, P421, DOI 10.1016/j.biocel.2009.08.018; Qin S, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00074; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Schildge S, 2013, JOVE-J VIS EXP, DOI 10.3791/50079; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Shaham O, 2009, DEVELOPMENT, V136, P2567, DOI 10.1242/dev.032888; Shi YH, 2004, NATURE, V427, P78, DOI 10.1038/nature02211; Shimozaki K, 2012, J BIOL CHEM, V287, P5969, DOI 10.1074/jbc.M111.290403; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Srinivasan K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11295; Su ZD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4338; Suh H, 2007, CELL STEM CELL, V1, P515, DOI 10.1016/j.stem.2007.09.002; Susarla BTS, 2014, ASN NEURO, V6, DOI 10.1042/AN20130034; Tanaka S, 2004, MOL CELL BIOL, V24, P8834, DOI 10.1128/MCB.24.20.8834-8846.2004; Tsai HH, 2012, SCIENCE, V337, P358, DOI 10.1126/science.1222381; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wang LL, 2016, CELL REP, V17, P891, DOI 10.1016/j.celrep.2016.09.038; Wang TW, 2006, J COMP NEUROL, V497, P88, DOI 10.1002/cne.20984; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Xie ZF, 2016, CELL MOL NEUROBIOL, V36, P93, DOI 10.1007/s10571-015-0223-5; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang CC, 2012, BRAIN INJURY, V26, P1185, DOI 10.3109/02699052.2012.666374; Yang JL, 2016, GLIA, V64, P1083, DOI 10.1002/glia.22984; Zhang CL, 2008, NATURE, V451, P1004, DOI 10.1038/nature06562; Zhao C, 2015, J NEUROSCI, V35, P11482, DOI 10.1523/JNEUROSCI.3655-14.2015	84	14	15	5	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	JAN	2019	29	1					54	69		10.1093/cercor/bhx303			16	Neurosciences	Neurosciences & Neurology	HM5LZ	WOS:000459518500005	29161339	Bronze, Green Published			2021-06-18	
J	Silva, PHR; Spedo, CT; Baldassarini, CR; Benini, CD; Ferreira, DA; Barreira, AA; Leoni, RF				Silva, P. H. R.; Spedo, C. T.; Baldassarini, C. R.; Benini, C. D.; Ferreira, D. A.; Barreira, A. A.; Leoni, R. F.			Brain functional and effective connectivity underlying the information processing speed assessed by the Symbol Digit Modalities Test	NEUROIMAGE			English	Article						Information processing speed; Functional connectivity; Effective connectivity; Dynamic causal modeling	COGNITIVE IMPAIRMENT; FMRI; PERFORMANCE; RELIABILITY; ATTENTION; NETWORK	Delayed Information Processing Speed (IPS) often underlies attention deficits and is particularly evident in patients with traumatic brain injury, Parkinson's disease, depression, dementia, and multiple sclerosis. Therefore, it is of interest to determine the brain network that is responsible for such essential cognitive function to understand IPS deficits and to develop effective rehabilitation programs. We assessed brain functional connectivity and effective connectivity during the performance of an adapted version of the Symbol Digit Modalities Test. Using dynamic causal modeling, we focused on obtaining a network model for IPS function in healthy subjects. Sixteen right-handed volunteers (seven women, age: 29.7 +/- 5.0 years) were included in the study after giving written consent for participating. Functional magnetic resonance images were acquired in a 3T scanner. According to our results, two systems interact during the IPS task performance. One is formed by frontoparietal and fronto-occipital networks, related to the control of goal-directed (top-down) selection for stimuli and response, while the second is composed of the temporoparietal and inferior frontal cortices, which are associated with stimulus-driven attention in the brain. Additionally, the default-mode network showed a significant correlation with networks positively associated with the task, mainly those related to visual detection and processing, indicating its relevant role in functional integration involving IPS. Therefore, an IPS-related network was proposed through a methodology that may be useful for future studies considering other cognitive functions and tasks, clinical groups, and longitudinal assessments.	[Silva, P. H. R.; Leoni, R. F.] Univ Sao Paulo, FFCLRP, Dept Phys, Av Bandeirantes 3900, BR-14040901 Ribeirao Preto, SP, Brazil; [Spedo, C. T.; Baldassarini, C. R.; Benini, C. D.; Ferreira, D. A.; Barreira, A. A.] Univ Sao Paulo, Med Sch Ribeirao Preto, Dept Neurosci & Behav Sci, Ribeirao Preto, SP, Brazil	Leoni, RF (corresponding author), Univ Sao Paulo, FFCLRP, Dept Phys, Av Bandeirantes 3900, BR-14040901 Ribeirao Preto, SP, Brazil.	leonirf@usp.br	Leoni, Renata Ferranti/J-3182-2012; da Silva, Pedro Henrique Rodrigues/AAR-8026-2020	Leoni, Renata Ferranti/0000-0002-4568-0746; da Silva, Pedro Henrique Rodrigues/0000-0002-0230-7474; Rossi Baldassarini, Caique/0000-0003-2362-9795	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [001]	This study was financed in part by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 001.	Anticevic A, 2012, TRENDS COGN SCI, V16, P584, DOI 10.1016/j.tics.2012.10.008; Archibald CJ, 2004, BRAIN, V127, P1526, DOI 10.1093/brain/awh167; Batista S, 2012, J NEUROL, V259, P139, DOI 10.1007/s00415-011-6147-1; BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129; Benedict RHB, 2017, MULT SCLER J, V23, P721, DOI 10.1177/1352458517690821; Buchel C, 1998, NEUROIMAGE, V8, P140, DOI 10.1006/nimg.1998.0351; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Chiaravalloti ND, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00067; Chiaravalloti ND, 2013, J CLIN EXP NEUROPSYC, V35, P180, DOI 10.1080/13803395.2012.760537; Christodoulou C, 2003, NEUROLOGY, V60, P1793, DOI 10.1212/01.WNL.0000072264.75989.B8; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; de Fockert J, 2004, J COGNITIVE NEUROSCI, V16, P751, DOI 10.1162/089892904970762; Feys P, 2017, MULT SCLER J, V23, P711, DOI 10.1177/1352458517690824; Fleisher AS, 2007, NEUROLOGY, V68, P1588, DOI 10.1212/01.wnl.0000258542.58725.4c; Forn C, 2013, BRAIN COGNITION, V82, P152, DOI 10.1016/j.bandc.2013.04.003; Forn C, 2013, EXP BRAIN RES, V225, P399, DOI 10.1007/s00221-012-3380-5; Forn C, 2009, NEUROSCI LETT, V456, P11, DOI 10.1016/j.neulet.2009.03.081; Friston KJ, 2010, NAT REV NEUROSCI, V11, P127, DOI 10.1038/nrn2787; Friston KJ, 1995, HUM BRAIN MAPP, V3, P56, DOI 10.1002/hbm.460030106; Friston KJ, 2003, NEUROIMAGE, V19, P1273, DOI 10.1016/S1053-8119(03)00202-7; Gorelick PB, 2011, STROKE, V42, P2672, DOI 10.1161/STR.0b013e3182299496; Grefkes C, 2008, NEUROIMAGE, V41, P1382, DOI 10.1016/j.neuroimage.2008.03.048; Grefkes C, 2014, LANCET NEUROL, V13, P206, DOI 10.1016/S1474-4422(13)70264-3; Hampshire A, 2010, NEUROIMAGE, V50, P1313, DOI 10.1016/j.neuroimage.2009.12.109; Hopfinger JB, 2000, NAT NEUROSCI, V3, P284; Huijbregts SCJ, 2004, NEUROLOGY, V63, P335, DOI 10.1212/01.WNL.0000129828.03714.90; Humphries C, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00406; Kiran S, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00316; Koster-Hale J, 2013, NEURON, V79, P836, DOI 10.1016/j.neuron.2013.08.020; Laird AR, 2005, HUM BRAIN MAPP, V25, P155, DOI 10.1002/hbm.20136; Langdon DW, 2012, MULT SCLER J, V18, P891, DOI 10.1177/1352458511431076; Laurienti PJ, 2002, NEUROIMAGE, V17, P751, DOI 10.1006/nimg.2002.1237; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Li Y, 2006, NANO TO MACRO 2006, P2; Maldjian J, 1994, HUM BRAIN MAPP, V63, P1; Marreiros AC, 2008, NEUROIMAGE, V39, P269, DOI 10.1016/j.neuroimage.2007.08.019; McDermott JH, 2008, CURR OPIN NEUROBIOL, V18, P452, DOI 10.1016/j.conb.2008.09.005; O'Brien CP, 2008, JAMA-J AM MED ASSOC, V300, P2054, DOI 10.1001/jama.2008.570; Peirce JW, 2007, J NEUROSCI METH, V162, P8, DOI 10.1016/j.jneumeth.2006.11.017; PFEFFER RI, 1981, AM J EPIDEMIOL, V114, P515, DOI 10.1093/oxfordjournals.aje.a113217; Plichta MM, 2012, NEUROIMAGE, V60, P1746, DOI 10.1016/j.neuroimage.2012.01.129; Poerio GL, 2017, SOC COGN AFFECT NEUR, V12, P1047, DOI 10.1093/scan/nsx041; Poggel DA, 2004, ACTA NEUROBIOL EXP, V64, P427; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Rachakonda S, 2007, COMPUTER LONG BEACH, V554, P304; Randolph JJ, 2001, CLIN NEUROPSYCHOL, V15, P357, DOI 10.1076/clin.15.3.357.10278; Rao SM, 2014, MULT SCLER INT, V2014, DOI 10.1155/2014/975803; Rodrigues Ana Carolina, 2010, Dement. neuropsychol., V4, P277, DOI 10.1590/S1980-57642010DN40400005; Schoonheim MM, 2015, NEUROLOGY, V84, P776, DOI 10.1212/WNL.0000000000001285; Silva PHR, 2018, MULT SCLER RELAT DIS, V20, P136, DOI 10.1016/j.msard.2018.01.014; Smith A., 1968, LEARNING DISORDERS, P83; Fittipaldi-Marquez MS, 2017, NEURODEGENER DIS, V17, P199, DOI 10.1159/000460252; STARKSTEIN SE, 1988, J NEUROL NEUROSUR PS, V51, P1259, DOI 10.1136/jnnp.51.10.1259; Tang R, 2015, BMC NEUROSCI, V16, pP247, DOI [10.1186/1471-2202-16-S1-P247, DOI 10.1186/1471-2202-16-S1-P247]; Vossel S, 2014, NEUROSCIENTIST, V20, P150, DOI 10.1177/1073858413494269; Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073; Zanto TP, 2014, NEUROIMAGE, V84, P443, DOI 10.1016/j.neuroimage.2013.08.063	57	14	14	1	25	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JAN 1	2019	184						761	770		10.1016/j.neuroimage.2018.09.080			10	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	GZ4RB	WOS:000449385000064	30292813	Bronze			2021-06-18	
J	Xu, ZM; Fouda, AY; Lemtalsi, T; Shosha, E; Rojas, M; Liu, F; Patel, C; Caldwell, RW; Narayanan, SP; Caldwell, RB				Xu, Zhimin; Fouda, Abdelrahman Y.; Lemtalsi, Tahira; Shosha, Esraa; Rojas, Modesto; Liu, Fang; Patel, Chintan; Caldwell, R. William; Narayanan, Subhadra Priya; Caldwell, Ruth B.			Retinal Neuroprotection From Optic Nerve Trauma by Deletion of Arginase 2	FRONTIERS IN NEUROSCIENCE			English	Article						arginase 2; retina; neuroprotection; optic nerve crush; brain derived neurotrophic factor; retinal ganglion cells	GANGLION-CELLS; FUNCTIONAL-CHANGES; GAP-43; EXPRESSION; INJURY; MARKER; BDNF; RNA	Our previous studies have implicated expression of the mitochondrial isoform of the arginase enzyme arginase 2 (A2) in neurovascular injury during ischemic retinopathies. The aim of this study was to characterize the specific involvement of A2 in retinal injury following optic nerve crush (ONC). To accomplish this, wild-type (WT) or A2 knockout (A2(-/-)) mice were subjected to ONC injury. The contralateral eye served as sham control. Quantitative RT-PCR and western blot were used to evaluate mRNA and protein expression. Retinal ganglion cell (RGC) survival was assessed in retinal whole mounts. Axonal sprouting was determined by anterograde transport of Cholera Toxin B (CTB). These analyses showed increased A2 expression following ONC. Numbers of NeuN-positive neurons as well as Brn3a- and RBPMS-positive RGC were decreased in the WT retinas at 14 days after ONC as compared to the sham controls. This ONC-induced neuronal loss was diminished in the A2(-/-) retinas. Similarly, axonal degeneration was ameliorated by A2 deletion whereas axon sprouting was enhanced. Significant retinal thinning was also seen in WT retinas at 21 days after ONC, and this was blocked in A2(-/-) mice. Cell death studies showed an increase in TUNEL positive cells in the RGC layer at 5 days after ONC in the WT retinas, and this was attenuated by A2 deletion. ONC increased glial cell activation in WT retinas, and this was significantly reduced by A2 deletion. Western blotting showed a marked increase in the neurotrophin, brain derived neurotrophic factor (BDNF) and its downstream signaling in A2(-/-) retinas vs. WT after ONC. This was associated with increases in the axonal regeneration marker GAP-43 in A2(-/-) retinas. Furthermore, A2(-/-) retinas showed decreased NLRP3 inflammasome activation and lower interleukin (IL-) 1 beta/IL-18 levels as compared to WT retinas subjected to ONC. Collectively, our results show that deletion of A2 limits ONC-induced neurodegeneration and glial activation, and enhances axonal sprouting by a mechanism involving increases in BDNF and decreases in retinal inflammation. These data demonstrate that A2 plays an important role in ONC-induced retinal damage. Blockade of A2 activity may offer a therapeutic strategy for preventing vision loss induced by traumatic retinal injury.	[Xu, Zhimin; Fouda, Abdelrahman Y.; Lemtalsi, Tahira; Shosha, Esraa; Rojas, Modesto; Liu, Fang; Narayanan, Subhadra Priya; Caldwell, Ruth B.] Charlie Norwood VA Med Ctr, Augusta, GA 30904 USA; [Xu, Zhimin; Fouda, Abdelrahman Y.; Lemtalsi, Tahira; Shosha, Esraa; Rojas, Modesto; Liu, Fang; Patel, Chintan; Narayanan, Subhadra Priya; Caldwell, Ruth B.] Augusta Univ, Vasc Biol Ctr, Augusta, GA 30904 USA; [Xu, Zhimin; Fouda, Abdelrahman Y.; Lemtalsi, Tahira; Shosha, Esraa; Rojas, Modesto; Liu, Fang; Caldwell, R. William; Narayanan, Subhadra Priya; Caldwell, Ruth B.] Augusta Univ, James & Jean Culver Vis Discovery Inst, Augusta, GA 30904 USA; [Rojas, Modesto; Caldwell, R. William] Augusta Univ, Dept Pharmacol & Toxicol, Augusta, GA USA; [Liu, Fang; Narayanan, Subhadra Priya] Univ Georgia, Coll Pharm, Program Clin & Expt Therapeut, Augusta, GA USA; [Caldwell, Ruth B.] Augusta Univ, Dept Cell Biol & Anat, Augusta, GA 30904 USA; [Caldwell, Ruth B.] Augusta Univ, Dept Ophthalmol, Augusta, GA 30904 USA	Caldwell, RB (corresponding author), Charlie Norwood VA Med Ctr, Augusta, GA 30904 USA.; Caldwell, RB (corresponding author), Augusta Univ, Vasc Biol Ctr, Augusta, GA 30904 USA.; Caldwell, RB (corresponding author), Augusta Univ, James & Jean Culver Vis Discovery Inst, Augusta, GA 30904 USA.; Caldwell, RB (corresponding author), Augusta Univ, Dept Cell Biol & Anat, Augusta, GA 30904 USA.; Caldwell, RB (corresponding author), Augusta Univ, Dept Ophthalmol, Augusta, GA 30904 USA.	rcaldwel@augusta.edu		Rojas, Modesto/0000-0002-9441-3302	National Institute of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R0I-EY11766]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and DevelopmentUS Department of Veterans Affairs [BX001233]; American Heart Association (AHA) postdoctoral fellowshipAmerican Heart Association [18POST34060036]; Culver Vision Discovery Institute at Augusta University; Department of Veterans AffairsUS Department of Veterans Affairs; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY011766] Funding Source: NIH RePORTER	This work was supported by grants from The National Institute of Health (NIH grant R0I-EY11766, the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development (BX001233) to RBC, American Heart Association (AHA) postdoctoral fellowship (18POST34060036) to AYF, and the Culver Vision Discovery Institute at Augusta University. RBC was the recipient of a Research Career Scientist Award from the Department of Veterans Affairs. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Caldwell RW, 2018, PHYSIOL REV, V98, P641, DOI 10.1152/physrev.00037.2016; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; Fouda AY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1051-6; Fournier AE, 1997, J NEUROSCI RES, V47, P561, DOI 10.1002/(SICI)1097-4547(19970315)47:6<561::AID-JNR1>3.3.CO;2-Q; Gupta SK, 2009, CELL DEATH DIFFER, V16, P624, DOI 10.1038/cdd.2008.188; Holahan MR, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00266; Klocker N, 2001, NEUROBIOL DIS, V8, P103, DOI 10.1006/nbdi.2000.0329; Li HY, 2014, NEURAL REGEN RES, V9, P565, DOI 10.4103/1673-5374.130093; Li Y, 1999, INVEST OPHTH VIS SCI, V40, P1004; Liu Y, 2014, INVEST OPHTH VIS SCI, V55, P3766, DOI 10.1167/iovs.14-13895; Mac Nair CE, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0558-y; Mesentier-Louro LA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010098; Mysona BA, 2017, EXPERT REV OPHTHALMO, V12, P69, DOI 10.1080/17469899.2017.1259566; Nadal-Nicolas FM, 2009, INVEST OPHTH VIS SCI, V50, P3860, DOI 10.1167/iovs.08-3267; Narayanan SP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022460; Nuschke AC, 2015, EXP EYE RES, V141, P111, DOI 10.1016/j.exer.2015.06.006; Ratican SE, 2018, NEURAL PLAST, V2018, DOI 10.1155/2018/7108948; Rodriguez AR, 2014, J COMP NEUROL, V522, P1411, DOI 10.1002/cne.23521; Shosha E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.295; TANG ZS, 2011, JOVE J VIS EXP APR, DOI DOI 10.3791/2685; Wang JX, 2018, MOL VIS, V24, P174; Weber AJ, 2008, J PHYSIOL-LONDON, V586, P4393, DOI 10.1113/jphysiol.2008.156729; Yukita M, 2015, DOC OPHTHALMOL, V130, P149, DOI 10.1007/s10633-014-9478-2; Zhen PY, 2016, SCI REP-UK, V6, DOI 10.1038/srep20998	24	14	14	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	DEC 20	2018	12								970	10.3389/fnins.2018.00970			13	Neurosciences	Neurosciences & Neurology	HF0YP	WOS:000453891800001	30618589	DOAJ Gold, Green Published			2021-06-18	
J	Howe, EI; Andelic, N; Perrin, PB; Roe, C; Sigurdardottir, S; Arango-Lasprilla, JC; Lu, J; Lovstad, M; Forslund, MV				Howe, Emilie I.; Andelic, Nada; Perrin, Paul B.; Roe, Cecilie; Sigurdardottir, Solrun; Arango-Lasprilla, Juan Carlos; Lu, Juan; Lovstad, Marianne; Forslund, Marit Vindal			Employment Probability Trajectories Up To 10 Years After Moderate-To-Severe Traumatic Brain Injury	FRONTIERS IN NEUROLOGY			English	Article						brain injury; outcome assessment; prospective studies; return to work; rehabilitation	WORKING-AGE INDIVIDUALS; RETURN; REHABILITATION; STABILITY; DISABILITY; PATTERNS	Aims: To examine trajectories of employment probability up to 10 years following moderate-to-severe traumatic brain injury (TBI) and identify significant predictors from baseline socio-demographic and injury characteristics. Methods: A longitudinal observational study followed 97 individuals with moderate-to-severe TBI for their employment status up to 10 years post injury. Participants were enrolled at the Trauma Referral Center in South-Eastern Norway between 2005 and 2007. Socio-demographic and injury characteristics were recorded at baseline. Employment outcomes were assessed at 1, 2, 5, and 10 years. Hierarchical linear modeling (HLM) was used to examine employment status over time and assess the predictors of time, gender, age, relationship status, education, employment pre-injury, occupation, cause of injury, acute Glasgow Coma Scale (GCS) score, duration of post-traumatic amnesia (PTA), CT findings, and injury severity score, as well as the interaction terms between significant predictors and time. Results: The linear trajectory of employment probabilities for the full sample remained at similar to 50% across 1, 2, 5, and 10-years post-injury. Gender (p = 0.016), relationship status (p = 0.002), employment (p < 0.001) and occupational status at injury (p = 0.005), and GCS (p = 0.006) yielded statistically significant effects on employment probability trajectories. Male gender, those in a partnered relationship at the time of injury, individuals who had been employed at the time of injury, those in a white-collar profession, and participants with a higher acute GCS score had significantly higher overall employment probability trajectories across the four time points. The time*gender interaction term was statistically significant (p = 0.002), suggesting that employment probabilities remained fairly stable over time for men, but showed a downward trend for women. The time*employment at injury interaction term was statistically significant (p = 0.003), suggesting that employment probabilities were fairly level over time for those who were employed at injury, but showed an upward trend over time for those who had been unemployed at injury. Conclusion: Overall employment probability trajectories remained relatively stable between 1 and 10 years. Baseline socio-demographic and injury characteristics were predictive of employment trajectories. Regular follow-up is recommended for patients at risk of long-term unemployment.	[Howe, Emilie I.; Andelic, Nada; Roe, Cecilie; Forslund, Marit Vindal] Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway; [Howe, Emilie I.; Roe, Cecilie] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway; [Andelic, Nada; Lu, Juan] Univ Oslo, Inst Hlth & Soc, Fac Med, Res Ctr Habilitat & Rehabil Models & Serv CHARM, Oslo, Norway; [Perrin, Paul B.] Virginia Commonwealth Univ, Dept Psychol, Box 2018, Richmond, VA 23284 USA; [Sigurdardottir, Solrun; Lovstad, Marianne] Sunnaas Rehabil Hosp Trust, Dept Res, Nesoddtangen, Norway; [Arango-Lasprilla, Juan Carlos] Cruces Univ Hosp Barakaldo, BioCruces Hlth Res Inst, Baracaldo, Spain; [Arango-Lasprilla, Juan Carlos] Basque Fdn Sci, Ikerbasque, Bilbao, Spain; [Lu, Juan] Virginia Commonwealth Univ, Dept Family Med & Populat Hlth, Div Epidemiol, Richmond, VA USA; [Lovstad, Marianne] Univ Oslo, Dept Psychol, Oslo, Norway	Howe, EI (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway.; Howe, EI (corresponding author), Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway.	emilie.howe@medisin.uio.no		Andelic, Nada/0000-0002-3719-4406; Arango-Lasprilla, Juan Carlos/0000-0002-7184-8311; Lu, Juan/0000-0002-5389-7603	Department of Physical Medicine and Rehabilitation, Oslo University Hospital; Institute of Health and Society, CHARM (Research Centre for Habilitation and Rehabilitation Models and Services), Faculty of Medicine, University of Oslo; Research Council of NorwayResearch Council of Norway; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR002649] Funding Source: NIH RePORTER	The authors would like to thank all the patients for their participation. Special thanks to Nini Hammergren and Svein A. Berntsen for assistance with patient registrations, and Tone Jerstad, neuroradiologist, for the CT assessments. This study was funded by the Department of Physical Medicine and Rehabilitation, Oslo University Hospital, The Institute of Health and Society, CHARM (Research Centre for Habilitation and Rehabilitation Models and Services), Faculty of Medicine, University of Oslo, and The Research Council of Norway.	Andelic N, 2012, BRAIN INJURY, V26, P261, DOI 10.3109/02699052.2012.654589; Arango-Lasprilla JC, 2009, PM&R, V1, P41, DOI 10.1016/j.pmrj.2008.07.001; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P1400, DOI 10.1016/j.apmr.2007.08.006; Cuthbert JP, 2015, ARCH PHYS MED REHAB, V96, P2128, DOI 10.1016/j.apmr.2015.07.020; Cuthbert JP, 2015, J HEAD TRAUMA REHAB, V30, P160, DOI 10.1097/HTR.0000000000000090; Dahm J, 2015, J REHABIL MED, V47, P932, DOI 10.2340/16501977-2016; Fadyl JK, 2009, J HEAD TRAUMA REHAB, V24, P195, DOI 10.1097/HTR.0b013e3181a0d458; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Forslund MV, 2014, BRAIN INJURY, V28, P980, DOI 10.3109/02699052.2014.888770; Forslund MV, 2013, J REHABIL MED, V45, P801, DOI 10.2340/16501977-1168; Fraser R, 2006, J VOCAT REHABIL, V25, P141; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Grauwmeijer E, 2017, J NEUROTRAUM, V34, P2575, DOI 10.1089/neu.2016.4846; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kjeldsberg M, 2013, SCAND J PRIM HEALTH, V31, P36, DOI 10.3109/02813432.2012.751697; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Olsen T, 2005, INT REV PSYCHIATR, V17, P375, DOI 10.1080/09540260500238579; Ose SO, 2013, SINTEF RAPPORT, P1; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Ponsford J, 2020, NEUROPSYCHOL REHABIL, V30, P85, DOI 10.1080/09602011.2018.1453367; Ponsford JL, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000033; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Saltychev M, 2013, BRAIN INJURY, V27, P1516, DOI 10.3109/02699052.2013.831131; Sandhaug M, 2015, BRAIN INJURY, V29, P1431, DOI 10.3109/02699052.2015.1063692; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sigurdardottir S, 2020, NEUROPSYCHOL REHABIL, V30, P281, DOI 10.1080/09602011.2018.1462719; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; TEASDALE G, 1974, LANCET, V2, P81; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335	36	14	14	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	DEC 5	2018	9								1051	10.3389/fneur.2018.01051			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	HC9SP	WOS:000452147400001	30568630	DOAJ Gold, Green Published			2021-06-18	
J	Ernst, G; Qeadan, F; Carlson, AP				Ernst, Griffin; Qeadan, Fares; Carlson, Andrew P.			Subcutaneous bone flap storage after emergency craniectomy: cost-effectiveness and rate of resorption	JOURNAL OF NEUROSURGERY			English	Article						subcutaneous pocket; cranioplasty; bone resorption; autologous bone	COMPLICATIONS FOLLOWING CRANIOPLASTY; DECOMPRESSIVE CRANIECTOMY; AUTOLOGOUS BONE; RISK-FACTORS; CRYOPRESERVED BONE; INFECTION; HEMICRANIECTOMY; EXPERIENCE; MANAGEMENT	OBJECTIVE Decompressive craniectomy is used for uncontrolled intracranial pressure in traumatic brain injury and malignant hemispheric stroke. Subcutaneous preservation of the autologous bone flap in the abdomen is a simple, portable technique but has largely been abandoned due to perceived concerns of resorption. The authors sought to characterize their experience with subcutaneous preservation of the bone flap and cranioplasty. METHODS The authors performed a retrospective single-institution review of subcutaneous preservation of the autologous bone flap after decompressive craniectomy from 2005 to 2015. The primary outcome was clinically significant bone resorption, defined as requiring a complete mesh implant at the time of cranioplasty, or delayed revision. The outcome also combined cases with any minor bone resorption to determine predictors of this outcome. Logistic regression modeling was used to determine the risk factors for predicting resorption. A cost comparison analysis was also used via the 2-sided t-test to compare the cost of cranioplasty using an autologous bone flap with standard custom implant costs. RESULTS A total of 193 patients with craniectomy were identified, 108 of whom received a cranioplasty. The mean time to cranioplasty was 104.31 days. Severe resorption occurred in 10 cases (9.26%): 4 were clinically significant (2 early and 2 late) and 6 demonstrated type II (severe) necrosis on CT, but did not require revision. Early resorption of any kind (mild or severe) occurred in 28 (25.93%) of 108 cases. Of the 108 patients, 26 (24.07%) required supplemental cranioplasty material. Late resorption of any kind (mild or severe) occurred in 6 (5.88%) of 102 cases. Of these, a clinically noticeable but nonoperative deformity was noted in 4 (3.92%) and minor (type I) necrosis on CT in 37 (37%) of 100. Bivariate analysis identified fragmentation of bone (OR 3.90, 95% CI 1.03-14.8), shunt-dependent hydrocephalus (OR 7.97, 95% CI 1.57-40.46), and presence of post-cranioplasty drain (OR 9.39, 95% CI 1.14-1000) to be significant risk factors for bone resorption. A binary logistic regression optimized using Fisher's scoring determined the optimal multivariable combination of factors. Fragmentation of bone (OR 5.84, 95% CI 1.38-28.78), diabetes (OR 7.61, 95% CI 1.37-44.56), and shunt-dependent hydrocephalus (OR 9.35, 95% CI 1.64-56.21) were found to be most predictive of resorption, with a C value of 0.78. Infections occurred in the subcutaneous pocket in 5 (2.60%) of the 193 cases and after cranioplasty in 10 (9.26%) of the 108 who underwent cranioplasty. The average cost of cranioplasty with autologous bone was $2156.28 +/- $ 1144.60 (n = 15), and of a custom implant was $35,118.60 +/- $2067.51 (3 different sizes; p < 0.0001). CONCLUSIONS Craniectomy with autologous bone cranioplasty using subcutaneous pocket storage is safe and compares favorably to cryopreservation in terms of resorption and favorably to a custom synthetic implant in terms of cost. While randomized data are required to definitively prove the superiority of one method, subcutaneous preservation has enough practical advantages with low risk to warrant routine use for most patients.	[Ernst, Griffin] Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA; [Qeadan, Fares] Univ New Mexico, Sch Med, Clin & Translat Sci Ctr, Albuquerque, NM 87131 USA; [Carlson, Andrew P.] Univ New Mexico, Sch Med, Dept Neurosurg, Albuquerque, NM 87131 USA	Carlson, AP (corresponding author), Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA.	andrewcarlson@salud.unm.edu	Qeadan, Fares/ABD-3131-2020; Carlson, Andrew P/B-4369-2012; Qeadan, Fares/B-9482-2014	Carlson, Andrew P/0000-0003-2189-3699; Qeadan, Fares/0000-0002-3376-220X			Agrawal D, 2005, EUR J CLIN MICROBIOL, V24, P772, DOI 10.1007/s10096-005-0017-7; Ashayeri K, 2016, NEUROSURGERY, V79, P525, DOI 10.1227/NEU.0000000000001366; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Bobinski L, 2013, CLIN NEUROL NEUROSUR, V115, P1788, DOI 10.1016/j.clineuro.2013.04.013; Bonda DJ, 2015, NEUROSURGERY, V77, P814, DOI 10.1227/NEU.0000000000000899; Bonfield CM, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.1.FOCUS13504; Bowers CA, 2013, J NEUROSURG-PEDIATR, V11, P526, DOI 10.3171/2013.1.PEDS12483; Cheng Cheng-Hsin, 2014, Clin Neurol Neurosurg, V124, P85, DOI 10.1016/j.clineuro.2014.06.029; Corliss B, 2016, WORLD NEUROSURG, V96, P510, DOI 10.1016/j.wneu.2016.09.025; Di Rienzo A, 2008, ACTA NEUROCHIR, V150, P1057, DOI 10.1007/s00701-008-0019-1; Dunisch P, 2013, J NEUROSURG, V118, P1141, DOI 10.3171/2013.1.JNS12860; Feroze AH, 2015, J NEUROSURG, V123, P1098, DOI 10.3171/2014.11.JNS14622; Ferro JM, 2011, STROKE, V42, P2825, DOI 10.1161/STROKEAHA.111.615393; FISHER CM, 1994, SURG NEUROL, V41, P65, DOI 10.1016/0090-3019(94)90210-0; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Harris DA, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13560; HAUPTLI J, 1980, HELV CHIR ACTA, V47, P121; Honeybul S, 2013, BRAIN INJURY, V27, P979, DOI 10.3109/02699052.2013.794974; Honeybul S, 2017, J NEUROSURG, V126, P81, DOI 10.3171/2015.12.JNS152004; Honeybul S, 2012, PLAST RECONSTR SURG, V130, P1110, DOI 10.1097/PRS.0b013e318267d4de; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Iaccarino C, 2015, J ORAL MAXIL SURG, V73, P2375, DOI 10.1016/j.joms.2015.07.008; Inamasu J, 2010, J TRAUMA, V68, P183, DOI 10.1097/TA.0b013e3181c45384; Jasielski Piotr, 2013, Acta Neurochir Suppl, V118, P125, DOI 10.1007/978-3-7091-1434-6_22; Malcolm JG, 2016, J CLIN NEUROSCI, V33, P39, DOI 10.1016/j.jocn.2016.04.017; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Morton RP, 2016, J NEUROSURG, V125, P766, DOI 10.3171/2015.8.JNS151390; Movassaghi K, 2006, PLAST RECONSTR SURG, V117, P202, DOI 10.1097/01.prs.0000187152.48402.17; Pasaoglu A, 1996, NEUROSURG REV, V19, P153, DOI 10.1007/BF00512044; Pepe MS, 2000, BIOMETRICS, V56, P352, DOI 10.1111/j.0006-341X.2000.00352.x; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Riordan MA, 2016, WORLD NEUROSURG, V87, P207, DOI 10.1016/j.wneu.2015.11.070; Schoekler B, 2014, CLIN NEUROL NEUROSUR, V120, P64, DOI 10.1016/j.clineuro.2014.02.014; Schuss P, 2013, J NEUROTRAUM, V30, P91, DOI 10.1089/neu.2012.2542; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Schwarz F, 2016, J NEUROSURG, V124, P710, DOI 10.3171/2015.4.JNS159; Scotter J, 2014, BRIT J NEUROSURG, V28, P534, DOI 10.3109/02688697.2013.841855; Shoakazemi A, 2009, NEUROSURGERY, V65, P505, DOI 10.1227/01.NEU.0000350870.69891.86; Sultan SM, 2011, PLAST RECONSTR SURG, V127, P1855, DOI 10.1097/PRS.0b013e31820e89a5; Sundseth J, 2014, ACTA NEUROCHIR, V156, P805, DOI 10.1007/s00701-013-1992-6; Takeuchi H, 2016, ACTA NEUROCHIR, V158, P571, DOI 10.1007/s00701-015-2679-y; Wachter D, 2013, CLIN NEUROL NEUROSUR, V115, P1293, DOI 10.1016/j.clineuro.2012.12.002; Zingale A, 2003, J Neurosurg Sci, V47, P137	43	14	15	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2018	129	6					1604	1610		10.3171/2017.6.JNS17943			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HE4YU	WOS:000453376800025	29303450	Bronze			2021-06-18	
J	Isokuortti, H; Iverson, GL; Silverberg, ND; Kataja, A; Brander, A; Ohman, J; Luoto, TM				Isokuortti, Harri; Iverson, Grant L.; Silverberg, Noah D.; Kataja, Anneli; Brander, Antti; Ohman, Juha; Luoto, Teemu M.			Characterizing the type and location of intracranial abnormalities in mild traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; head injury; computed tomography; neurodegenerative diseases; common data elements; trauma	CT HEAD RULE; COMMON DATA ELEMENTS; NEW-ORLEANS CRITERIA; COMPUTED-TOMOGRAPHY; COLLABORATING-CENTER; TASK-FORCE; MODERATE; EPIDEMIOLOGY; ADULTS; CLASSIFICATION	OBJECTIVE The incidence of intracranial abnormalities after mild traumatic brain injury (TBI) varies widely across studies. This study describes the characteristics of intracranial abnormalities (acute/preexisting) in a large representative sample of head-injured patients who underwent CT imaging in an emergency department. METHODS CT scans were systematically analyzed/coded in the TBI Common Data Elements framework. Logistic regression modeling was used to quantify risk factors for traumatic intracranial abnormalities in patients with mild TBIs. This cohort included all patients who were treated at the emergency department of the Tampere University Hospital (between 2010 and 2012) and who had undergone head CT imaging after suffering a suspected TBI (n = 3023), including 2766 with mild TBI and a reference group with moderate to severe TBI. RESULTS The most common traumatic lesions seen on CT scans obtained in patients with mild TBIs and those with moderate to severe TBIs were subdural hematomas, subarachnoid hemorrhages, and contusions. Every sixth patient (16.1%) with mild TBI had an intracranial lesion compared with 5 of 6 patients (85.6%) in the group with moderate to severe TBI. The distribution of different types of acute traumatic lesions was similar among mild and moderate/severe TBI groups. Preexisting brain lesions were a more common CT finding among patients with mild TBIs than those with moderate to severe TBIs. Having a past traumatic lesion was associated with increased risk for an acute traumatic lesion but neurodegenerative and ischemic lesions were not. A lower Glasgow Coma Scale score, male sex, older age, falls, and chronic alcohol abuse were associated with higher risk of acute intracranial lesion in patients with mild TBI. CONCLUSIONS These findings underscore the heterogeneity of neuropathology associated with the mild TBI classification. Preexisting brain lesions are common in patients with mild TBI, and the incidence of preexisting lesions increases with age. Acute traumatic lesions are fairly common in patients with mild TBI; every sixth patient had a positive CT scan. Older adults (especially men) who fall represent a susceptible group for acute CT-positive TBI.	[Isokuortti, Harri] Univ Tampere, Fac Med & Life Sci, Tampere, Finland; [Kataja, Anneli; Brander, Antti] Tampere Univ Hosp, Dept Radiol, Med Imaging Ctr, Tampere, Finland; [Ohman, Juha; Luoto, Teemu M.] Tampere Univ Hosp, Dept Neurosurg, Tampere, Finland; [Iverson, Grant L.; Silverberg, Noah D.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] MassGeneral Hosp Children, Sports Concuss Program, Boston, MA USA; [Iverson, Grant L.; Silverberg, Noah D.] Red Sox Fdn, Home Base, Boston, MA USA; [Iverson, Grant L.; Silverberg, Noah D.] Massachusetts Gen Hosp Program, Boston, MA USA; [Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Dept Med, Vancouver, BC, Canada; [Silverberg, Noah D.] GF Strong Rehab Ctr, Vancouver, BC, Canada	Isokuortti, H (corresponding author), Univ Tampere, Tampere, Finland.	isokuortti@gmail.com	Luoto, Teemu/W-6468-2018	Luoto, Teemu/0000-0002-7329-3284; Iverson, Grant/0000-0001-7348-9570			BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Chan V, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-97; Chun KA, 2010, J NEUROTRAUM, V27, P325, DOI 10.1089/neu.2009.1115; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Dams-O'Connor K, 2016, J AM GERIATR SOC, V64, P844, DOI 10.1111/jgs.14014; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Dunham CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109473; Easter JS, 2017, JAMA-J AM MED ASSOC, V317, P2021, DOI 10.1001/jama.2017.5136; Easter JS, 2013, ACAD EMERG MED, V20, P753, DOI 10.1111/acem.12184; Erly WK, 2002, AM J NEURORADIOL, V23, P103; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Huff JS, 2014, AM J EMERG MED, V32, P606, DOI 10.1016/j.ajem.2014.03.010; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Iverson GL, 2000, BRAIN INJURY, V14, P1057; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/415740; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Laalo JP, 2009, J NEUROTRAUM, V26, P2169, DOI 10.1089/neu.2009.1011; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Moore MM, 2012, J TRAUMA ACUTE CARE, V73, P126, DOI 10.1097/TA.0b013e31824b01af; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; Ono K, 2007, NEUROL MED-CHIR, V47, P291, DOI 10.2176/nmc.47.291; Pandor A, 2012, J NEUROTRAUM, V29, P707, DOI 10.1089/neu.2011.1967; Panenka WJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122746; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Raj R, 2014, NEUROSURGERY, V75, P632, DOI 10.1227/NEU.0000000000000533; Rathlev NK, 2006, ACAD EMERG MED, V13, P302, DOI 10.1197/j.aem.2005.10.015; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saboori M, 2007, CLIN NEUROL NEUROSUR, V109, P399, DOI 10.1016/j.clineuro.2007.01.013; Savola O, 2005, ALCOHOL ALCOHOLISM, V40, P269, DOI 10.1093/alcalc/agh159; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Thiruppathy SP, 2004, ACTA NEUROCHIR, V146, P1075, DOI 10.1007/s00701-004-0335-z; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wu MZ, 2014, RADIOLOGY, V270, P717, DOI 10.1148/radiol.13131114; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	64	14	14	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2018	129	6					1588	1597		10.3171/2017.7.JNS17615			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HE4YU	WOS:000453376800023	29328003	Bronze			2021-06-18	
J	Li, FY; Wang, XD; Deng, ZK; Zhang, XL; Gao, PF; Liu, HL				Li, Fayin; Wang, Xiaodong; Deng, Zhikui; Zhang, Xianlong; Gao, Pengfei; Liu, Hailin			Dexmedetomidine reduces oxidative stress and provides neuroprotection in a model of traumatic brain injury via the PGC-1 alpha signaling pathway	NEUROPEPTIDES			English	Article						Dexmedetomidine; Traumatic brain injury; PGC-1 alpha; Oxidative stress	ACUTE LUNG INJURY; RATS; EXPRESSION; MECHANISM; ANTIOXIDANTS; INVOLVEMENT; ACTIVATION	The protective effects of dexmedetomidine (DEX) mediated by reductions of oxidative stress, mitochondrial damage and disintegration have been demonstrated in many injury models. However, whether DEX has a beneficial effect on traumatic brain injury (TBI) remains unknown. In this study, the neuroprotective effect of DEX and its potential mechanism were assessed in a model of TBI. DEX treatment relieved encephala edema and neuron cell apoptosis and increased behavioral function. These protective effects were accompanied by upregulation of peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1 alpha) expression. These findings imply that DEX protects neurons following TBI, possibly by activating the PGC-1 alpha pathway. The data will help clarify the mechanisms responsible for the anti-apoptosis effect of DEX with possible involvement of the PGC-1 alpha pathway.	[Li, Fayin; Zhang, Xianlong; Gao, Pengfei; Liu, Hailin] Nanjing Med Univ, Affiliated Huaian Peoples Hosp 1, Dept Anesthesiol, Huaian 223002, Jiangsu, Peoples R China; [Wang, Xiaodong] Nanjing Med Univ, Affiliated Huaian Peoples Hosp 1, Dept Neurosurg, Huaian 223002, Jiangsu, Peoples R China; [Deng, Zhikui] Nanjing Med Univ, Affiliated Huaian Peoples Hosp 1, Dept Cent Lab, Huaian 223002, Jiangsu, Peoples R China	Liu, HL (corresponding author), Nanjing Med Univ, Affiliated Huaian Peoples Hosp 1, Dept Anesthesiol, Huaian 223002, Jiangsu, Peoples R China.	huaianniuhailin@126.com					Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Bouitbir J, 2012, EUR HEART J, V33, P1397, DOI 10.1093/eurheartj/ehr224; Butterfield DA, 2016, PROTEOM CLIN APPL, V10, P1191, DOI 10.1002/prca.201600003; Castillo LF, 2017, CELL SIGNAL, V34, P76, DOI 10.1016/j.cellsig.2017.03.003; Chen XR, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00117; Dahmani S, 2008, ANESTHESIOLOGY, V108, P457, DOI 10.1097/ALN.0b013e318164ca81; Di C. M. L., 2017, MINI-REV MED CHEM, V17, P95; Dobrovolny J, 2018, NEUROL SCI, V39, P989, DOI 10.1007/s10072-018-3398-y; Fan YW, 2012, BRAIN INJURY, V26, P1267, DOI 10.3109/02699052.2012.672789; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Hu HY, 2017, AM J TRANSL RES, V9, P5245; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Kokiko-Cochran ON, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00672; Li X, 2018, J CELL MOL MED, V22, P883, DOI 10.1111/jcmm.13313; Li X, 2016, AM J TRANSL RES, V8, P3558; Liang JW, 2018, DRUG DES DEV THER, V12, P845, DOI 10.2147/DDDT.S160046; Liu YC, 2017, CELL MOL NEUROBIOL, V37, P879, DOI 10.1007/s10571-016-0425-5; Lu ZB, 2010, ANTIOXID REDOX SIGN, V13, P1011, DOI 10.1089/ars.2009.2940; Meng L, 2018, MOL IMMUNOL, V94, P7, DOI 10.1016/j.molimm.2017.12.008; Rasouri S, 2007, M S-MED SCI, V23, P840, DOI 10.1051/medsci/20072310840; Robinson A, 2014, AGING CELL, V13, P263, DOI 10.1111/acel.12183; Sabella S. A., 2018, BRAIN INJURY, P1; Shen M, 2017, BIOMED PHARMACOTHER, V95, P885, DOI 10.1016/j.biopha.2017.08.125; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Szarka N, 2018, J NEUROTRAUM, V35, P930, DOI 10.1089/neu.2017.5056; Terry DP, 2018, CLIN NEUROPSYCHOL, V33, P1; Wu J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23003-3; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Yu LM, 2017, SCI REP-UK, V7, DOI 10.1038/srep41337; Zhang H, 2017, BIOMED PHARMACOTHER, V90, P914, DOI 10.1016/j.biopha.2017.04.047; Zhang MH, 2018, MOL MED REP, V17, P8079, DOI 10.3892/mmr.2018.8898; Zhang W, 2017, EXP THER MED, V14, P973, DOI 10.3892/etm.2017.4623; Zhang YL, 2017, J NEUROSURG, V126, P782, DOI 10.3171/2016.3.JNS152699; Zhao SF, 2012, NEUROL RES, V34, P400, DOI 10.1179/1743132812Y.0000000025	34	14	16	3	5	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0143-4179	1532-2785		NEUROPEPTIDES	Neuropeptides	DEC	2018	72						58	64		10.1016/j.npep.2018.10.004			7	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	HE0FT	WOS:000452942900007	30396595	Other Gold			2021-06-18	
J	Pijet, B; Stefaniuk, M; Kostrzewska-Ksiezyk, A; Tsilibary, PE; Tzinia, A; Kaczmarek, L				Pijet, Barbara; Stefaniuk, Marzena; Kostrzewska-Ksiezyk, Agnieszka; Tsilibary, Photini-Effie; Tzinia, Athina; Kaczmarek, Leszek			Elevation of MMP-9 Levels Promotes Epileptogenesis After Traumatic Brain Injury	MOLECULAR NEUROBIOLOGY			English	Article						Traumatic brain injury; Controlled cortical impact; Matrix metalloproteinase-9 (MMP-9); Extracellular matrix (ECM); Epileptogenesis; Posttraumatic epilepsy	CONTROLLED CORTICAL IMPACT; POSTTRAUMATIC EPILEPSY; MATRIX METALLOPROTEINASES; ELECTRICAL-STIMULATION; MATRIX-METALLOPROTEINASE-9; MICE; INHIBITORS; SEIZURE; RATS; HIPPOCAMPUS	Posttraumatic epilepsy (PTE) is a recurrent seizure disorder that often develops secondary to traumatic brain injury (TBI) that is caused by an external mechanical force. Recent evidence shows that the brain extracellular matrix plays a major role in the remodeling of neuronal connections after injury. One of the proteases that is presumably responsible for this process is matrix metalloproteinase-9 (MMP-9). The levels of MMP-9 are elevated in rodent brain tissue and human blood samples after TBI. However, no studies have described the influence of MMP-9 on the development of PTE. The present study used controlled cortical impact (CCI) as a mouse model of TBI. We examined the detailed kinetics of MMP-9 levels for 1month after TBI and observed two peaks after injury (30min and 6h after injury). We tested the hypothesis that high levels of MMP-9 predispose individuals to the development of PTE, and MMP-9 inhibition would protect against PTE. We used transgenic animals with either MMP-9 knockout or MMP-9 overexpression. MMP-9 overexpression increased the number of mice that exhibited TBI-induced spontaneous seizures, and MMP-9 knockout decreased the appearance of seizures. We also evaluated changes in responsiveness to a single dose of the chemoconvulsant pentylenetetrazol. MMP-9-overexpressing mice exhibited a significantly shorter latency between pentylenetetrazol administration and the first epileptiform spike. MMP-9 knockout mice exhibited the opposite response profile. Finally, we found that the occurrence of PTE was correlated with the size of the lesion after injury. Overall, our data emphasize the contribution of MMP-9 to TBI-induced structural and physiological alterations in brain circuitry that may lead to the development of PTE.	[Pijet, Barbara; Stefaniuk, Marzena; Kostrzewska-Ksiezyk, Agnieszka; Kaczmarek, Leszek] Nencki Inst Expt Biol, Neurobiol Lab, Dept Mol & Cellular Neurobiol, Pasteura 3, PL-02093 Warsaw, Poland; [Tsilibary, Photini-Effie] Univ Minnesota, Dept Neurosci, Minneapolis, MN 55405 USA; [Tsilibary, Photini-Effie] Brain Sci Ctr, Minneapolis, MN 55417 USA; [Tzinia, Athina] NCSR Demokritos, Lab Cell & Matrix Pathobiol, Inst Biosci & Applicat, Athens 15310, Greece	Pijet, B; Kaczmarek, L (corresponding author), Nencki Inst Expt Biol, Neurobiol Lab, Dept Mol & Cellular Neurobiol, Pasteura 3, PL-02093 Warsaw, Poland.	b.pijet@nencki.gov.pl; m.stefaniuk@nencki.gov.pl; a.kostrzewska@nencki.gov.pl; tsili001@umn.edu; atzin@bio.demokritos.gr; l.kaczmarek@nencki.gov.pl	Kaczmarek, Leszek/B-6171-2008; Pijet, Barbara/B-6559-2019	Kaczmarek, Leszek/0000-0002-7207-3490; Pijet, Barbara/0000-0002-9268-5208; Kostrzewska-Ksiezyk, Agnieszka/0000-0002-0033-4321	National Center of Research and Development (NCBiR) [NEURON/09/13, PBS/A8/36/2015]	This study was supported by National Center of Research and Development (NCBiR) grants (ERA-NET Neuron grant no. NEURON/09/13 and PBS/A8/36/2015).	Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Buckmaster PS., 2012, JASPERS BASIC MECH E; Chen W, 2017, NEUROPSYCH DIS TREAT, V13, P2301, DOI 10.2147/NDT.S141486; Czlonkowska A, 2011, J NEUROIMMUNOL, V231, P78, DOI 10.1016/j.jneuroim.2010.09.020; Dyhrfjeld-Johnsen J, 2007, J NEUROPHYSIOL, V97, P1566, DOI 10.1152/jn.00950.2006; Dziembowska M, 2012, J NEUROSCI, V32, P14538, DOI 10.1523/JNEUROSCI.6028-11.2012; Dzwonek J, 2004, FEBS LETT, V567, P129, DOI 10.1016/j.febslet.2004.03.070; Fragkouli A, 2012, J NEUROCHEM, V121, P239, DOI 10.1111/j.1471-4159.2011.07637.x; Guerriero RM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0545-1; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Huntley GW, 2012, NAT REV NEUROSCI, V13, P743, DOI 10.1038/nrn3320; Jain S, 2011, N-S ARCH PHARMACOL, V383, P385, DOI 10.1007/s00210-011-0606-1; Kim GW, 2009, NEUROBIOL DIS, V36, P169, DOI 10.1016/j.nbd.2009.07.008; Kim YH, 2012, J BIOL CHEM, V287, P38957, DOI 10.1074/jbc.M112.357863; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Konopka A, 2013, EPILEPSY RES, V104, P45, DOI 10.1016/j.eplepsyres.2012.09.018; Kowluru RA, 2011, DIABETES, V60, P3023, DOI 10.2337/db11-0816; Kuzniewska B, 2016, MOL NEUROBIOL, V53, P1478, DOI 10.1007/s12035-014-9089-7; LEMOS T, 1995, EXP BRAIN RES, V102, P423; Lu PF, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005058; Lukasiuk K, 2011, EPILEPSY RES, V96, P191, DOI 10.1016/j.eplepsyres.2011.08.002; Miszczuk D, 2016, MOL NEUROBIOL, V53, P7010, DOI 10.1007/s12035-015-9578-3; Mizoguchi H, 2011, J NEUROSCI, V31, P12963, DOI 10.1523/JNEUROSCI.3118-11.2011; NADLER JV, 1980, BRAIN RES, V182, P1; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Pitkanen A, 2012, JASPERS BASIC MECH E, P1; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rivera S, 2010, J NEUROSCI, V30, P15337, DOI 10.1523/JNEUROSCI.3467-10.2010; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Semple BD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143386; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stute J, 2003, J PROTEIN CHEM, V22, P509, DOI 10.1023/B:JOPC.0000005499.51466.50; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; Suenaga N, 2008, J NEUROL SCI, V266, P126, DOI 10.1016/j.jns.2007.09.011; Szklarczyk A, 2002, J NEUROSCI, V22, P920, DOI 10.1523/JNEUROSCI.22-03-00920.2002; Takacs E, 2010, NEUROCHEM INT, V56, P799, DOI 10.1016/j.neuint.2010.03.003; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Vafadari B, 2016, J NEUROCHEM, V139, P91, DOI 10.1111/jnc.13415; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wilczynski GM, 2008, J CELL BIOL, V180, P1021, DOI 10.1083/jcb.200708213; Zimowska M, 2013, BIOL CELL, V105, P334, DOI 10.1111/boc.201300020	44	14	16	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	DEC	2018	55	12					9294	9306		10.1007/s12035-018-1061-5			13	Neurosciences	Neurosciences & Neurology	GY3VF	WOS:000448483400037	29667129	Other Gold, Green Published			2021-06-18	
J	Dukhinova, M; Kuznetsova, I; Kopeikina, E; Veniaminova, E; Yung, AWY; Veremeyko, T; Levchuk, K; Barteneva, NS; Wing-Ho, KK; Yung, WH; Liu, JYH; Rudd, J; Yau, SSY; Anthony, DC; Strekalova, T; Ponomarev, ED				Dukhinova, Marina; Kuznetsova, Inna; Kopeikina, Ekaterina; Veniaminova, Ekaterina; Yung, Amanda W. Y.; Veremeyko, Tatyana; Levchuk, Kseniia; Barteneva, Natasha S.; Wing-Ho, Kenny Kam; Yung, Wing-Ho; Liu, Julia Y. H.; Rudd, John; Yau, Sonata S. Y.; Anthony, Daniel C.; Strekalova, Tatyana; Ponomarev, Eugene D.			Platelets mediate protective neuroinflammation and promote neuronal plasticity at the site of neuronal injury	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Neuronal plasticity; Dendritic spines; Serotonin; Neuroinflammation; Glycobiology; Platelets; Platelet-derived microparticles; Traumatic brain injury; CNS repair	TRAUMATIC BRAIN-INJURY; ACTIVATING-FACTOR; CEREBROSPINAL-FLUID; MOUSE MODEL; SEROTONIN; RECEPTOR; PROTEIN; MICE; BLOOD; PHOSPHORYLATION	It is generally accepted that inflammation within the CNS contributes to neurodegeneration after traumatic brain injury (TBI), but it is not clear how inflammation is initiated in the absence of infection and whether this neuroinflammation is predominantly beneficial or detrimental. We have previously found that brain-enriched glycosphingolipids within neuronal lipid rafts (NLR) induced platelet degranulation and secretion of neuro-transmitters and pro-inflammatory factors. In the present study, we compared TBI-induced inflammation and neurodegeneration in wild-type vs. St3gal5 deficient (ST3(-/-)) mice that lack major CNS-specific glycosphingolipids. After TBI, microglial activation and CNS macrophage infiltration were substantially reduced in ST3(-/-) animals. However, ST3(-/-) mice had a larger area of CNS damage with marked neuronal/axonal loss. The interaction of platelets with NLR stimulated neurite growth, increased the number of PSD95-positive dendritic spines, and intensified neuronal activity. Adoptive transfer and blocking experiments provide further that platelet-derived serotonin and platelet activating factor plays a key role in the regulation of sterile neuroinflammation,hemorrhage and neuronal plasticity after TBI.	[Dukhinova, Marina; Kuznetsova, Inna; Kopeikina, Ekaterina; Yung, Amanda W. Y.; Veremeyko, Tatyana; Levchuk, Kseniia; Wing-Ho, Kenny Kam; Yung, Wing-Ho; Liu, Julia Y. H.; Rudd, John; Ponomarev, Eugene D.] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China; [Veniaminova, Ekaterina; Strekalova, Tatyana] Maastricht Univ, Dept Neurosci, Maastricht, Netherlands; [Barteneva, Natasha S.] Harvard Med Sch, Childrens Hosp Boston, Program Cellular & Mol Med, Boston, MA USA; [Barteneva, Natasha S.] Harvard Med Sch, Dept Pediat, Boston, MA USA; [Rudd, John] Chinese Univ Hong Kong, Brain & Mind Inst, Shatin, Hong Kong, Peoples R China; [Yau, Sonata S. Y.] Hong Kong Polytech Univ, Dept Rehabil Sci, Hung Hom, Kowloon, Hong Kong, Peoples R China; [Anthony, Daniel C.] Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; [Ponomarev, Eugene D.] Kunming Inst Zool & Chinese Univ Hong Kong Joint, Kunmin, Hong Kong, Peoples R China	Ponomarev, ED (corresponding author), Chinese Univ Hong Kong, Shatin, 323A,3-F,Lo Kwee Seong Integrated Biomed Sci Bld, Hong Kong, Peoples R China.	eponomarev@cuhk.edu.hk	Ponomarev, Eugene D./K-1546-2013; Barteneva, Natalie/V-3826-2019; Anthony, Daniel C/F-7765-2010; Veniaminova, Ekaterina/Q-1704-2017; Yung, Ho/R-6161-2018; Levchuk, Ksenia/ABD-4642-2020; Dukhinova, Marina/P-8167-2019; Rudd, John A./R-6603-2018	Ponomarev, Eugene D./0000-0002-0871-8522; Barteneva, Natalie/0000-0002-8109-1754; Anthony, Daniel C/0000-0003-1380-6655; Veniaminova, Ekaterina/0000-0003-3477-7099; Yung, Ho/0000-0002-5542-8173; Dukhinova, Marina/0000-0001-8118-9439; Yung, Amanda WY/0000-0003-4265-9324; Yau, Sonata Suk Yu/0000-0002-7425-6741; Rudd, John A./0000-0002-8316-0792	Lo Kwee-Seong Biomedical Research fund (The Chinese University of Hong Kong), Health and Medical Research Fund Grant [02130636]; Research Grant Council-General Research Fund Grant (Hong Kong Government, Hong Kong) [14113316]	We wish to thank Ekaterina Biryukova and Yana Venerina for technical assistance for analysis of behaviour tests. The work was supported by the Lo Kwee-Seong Biomedical Research fund (The Chinese University of Hong Kong), Health and Medical Research Fund Grant, reference no. 02130636 (Hong Kong Government, Hong Kong), and the Research Grant Council-General Research Fund Grant, reference no 14113316 (Hong Kong Government, Hong Kong).	Barteneva NS, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-23; Bazan NG, 1997, NEUROCHEM INT, V30, P225, DOI 10.1016/S0197-0186(96)00020-4; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Boccuto L, 2014, HUM MOL GENET, V23, P418, DOI 10.1093/hmg/ddt434; Boilard E, 2010, SCIENCE, V327, P580, DOI 10.1126/science.1181928; Bonneh-Barkay D, 2009, BRAIN PATHOL, V19, P573, DOI 10.1111/j.1750-3639.2008.00195.x; Cacialli P, 2018, NEURAL REGEN RES, V13, P941, DOI 10.4103/1673-5374.233430; Cane M, 2014, J NEUROSCI, V34, P2075, DOI 10.1523/JNEUROSCI.3353-13.2014; Castejon OJ, 2004, DEV BRAIN RES, V151, P25, DOI 10.1016/j.devbrainres.2004.03.019; Chacon-Fernandez P, 2016, J BIOL CHEM, V291, P9872, DOI 10.1074/jbc.M116.720029; Chen ZH, 2012, J NEUROSCI, V32, P11706, DOI 10.1523/JNEUROSCI.0730-12.2012; Choudhri TF, 1997, STROKE, V28, P2296, DOI 10.1161/01.STR.28.11.2296; Collins JM, 2015, EXP NEUROL, V267, P219, DOI 10.1016/j.expneurol.2015.02.034; Cruz-Haces M, 2017, TRANSL NEURODEGENER, V6, DOI 10.1186/s40035-017-0088-2; Daneman R, 2010, NATURE, V468, P562, DOI 10.1038/nature09513; de las Casas-Engel M, 2013, J IMMUNOL, V190, P2301, DOI 10.4049/jimmunol.1201133; Doronin II, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-295; Dukhinova M, 2018, METHODS MOL BIOL, V1745, P167, DOI 10.1007/978-1-4939-7680-5_10; Elhusseiny A, 2001, BRIT J PHARMACOL, V132, P55, DOI 10.1038/sj.bjp.0703763; Fragaki K, 2013, EUR J HUM GENET, V21, P528, DOI 10.1038/ejhg.2012.202; Gill P, 2015, J ALLERGY CLIN IMMUN, V135, P1424, DOI 10.1016/j.jaci.2015.04.019; Graeber MB, 2011, FEBS LETT, V585, P3798, DOI 10.1016/j.febslet.2011.08.033; Haimovich B, 1999, THROMB HAEMOSTASIS, V81, P618; Han R, 2011, NEUROSCI MED, V2, P370, DOI [10.4236/nm.2011.24049, DOI 10.4236/NM.2011.24049]; Herr N, 2017, FRONT CARDIOVASC MED, V4, DOI 10.3389/fcvm.2017.00048; Huang M, 2009, SURG NEUROL, V72, P481, DOI 10.1016/j.surneu.2008.12.016; Itsekson-Hayosh Z, 2016, J NEUROTRAUM, V33, P1848, DOI 10.1089/neu.2015.4146; Iwamoto S, 1996, BIOCHEM BIOPH RES CO, V218, P940, DOI 10.1006/bbrc.1996.0166; Izikki M, 2007, AM J PHYSIOL-LUNG C, V293, pL1045, DOI 10.1152/ajplung.00082.2007; Jones KA, 2009, P NATL ACAD SCI USA, V106, P19575, DOI 10.1073/pnas.0905884106; Kellner Yves, 2014, Front Synaptic Neurosci, V6, P5, DOI 10.3389/fnsyn.2014.00005; Kim BK, 2013, NEUROCHEM INT, V63, P121, DOI 10.1016/j.neuint.2013.05.010; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Lai KC, 2003, J CELL PHYSIOL, V194, P206, DOI 10.1002/jcp.10222; Lai KO, 2012, NAT NEUROSCI, V15, P1506, DOI 10.1038/nn.3237; Law JKY, 2012, ANN BIOMED ENG, V40, P619, DOI 10.1007/s10439-011-0432-0; Lee JS, 2016, AM J MED GENET A, V170, P2200, DOI 10.1002/ajmg.a.37773; Li Q, 2016, MOL NEUROBIOL, V53, P4226, DOI 10.1007/s12035-015-9362-4; Louyeau A, 2015, TRENDS IMMUNOL, V36, P569, DOI 10.1016/j.it.2015.08.006; Martinowich K, 2008, NEUROPSYCHOPHARMACOL, V33, P73, DOI 10.1038/sj.npp.1301571; Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617; Mattugini N, 2018, GLIA, V66, P1644, DOI 10.1002/glia.23329; Mayo L, 2014, NAT MED, V20, P1147, DOI 10.1038/nm.3681; Mohammad-Zadeh LF, 2008, J VET PHARMACOL THER, V31, P187, DOI 10.1111/j.1365-2885.2008.00944.x; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Nagafuku M, 2012, P NATL ACAD SCI USA, V109, pE336, DOI 10.1073/pnas.1114965109; Nudo RJ, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00887; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Pearn ML, 2017, CELL MOL NEUROBIOL, V37, P571, DOI 10.1007/s10571-016-0400-1; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; Ponomarev ED, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00406; Ponomarev Eugene D, 2011, BMC Res Notes, V4, P517, DOI 10.1186/1756-0500-4-517; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Proia RL, 2004, NAT GENET, V36, P1147, DOI 10.1038/ng1104-1147; Quaegebeur A, 2010, NEURON, V68, P321, DOI 10.1016/j.neuron.2010.10.024; Ransohoff RM, 2012, NAT REV IMMUNOL, V12, P623, DOI 10.1038/nri3265; Rivera FJ, 2016, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00511; Ryan SD, 2007, J NEUROCHEM, V103, P88, DOI 10.1111/j.1471-4159.2007.04740.x; Shechter R, 2013, TRENDS MOL MED, V19, P135, DOI 10.1016/j.molmed.2012.11.007; Simpson MA, 2004, NAT GENET, V36, P1225, DOI 10.1038/ng1460; Sokolova E, 2008, THROMB HAEMOSTASIS, V100, P576, DOI 10.1160/TH08-03-0131; Sotnikov I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058979; Starossom SC, 2015, CIRC RES, V117, P779, DOI 10.1161/CIRCRESAHA.115.306847; Starossom SC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096256; Thomas MR, 2015, THROMB HAEMOSTASIS, V114, P449, DOI 10.1160/TH14-12-1067; Torres-Espin A, 2018, BRAIN, V141, P1946, DOI 10.1093/brain/awy128; Trakhtenberg EF, 2012, INT REV NEUROBIOL, V106, P105, DOI 10.1016/B978-0-12-407178-0.00005-3; Tsuda M, 2007, J NEUROCHEM, V102, P1658, DOI 10.1111/j.1471-4159.2007.04796.x; Veitinger M, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-65; Veremeyko T, 2012, JOVE-J VIS EXP, DOI 10.3791/4097; Veremeyko T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00050; Veremeyko T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081774; Wang H, 2016, CLIN GENET, V89, P625, DOI 10.1111/cge.12703; Wen FQ, 1999, ARTERIOSCL THROM VAS, V19, P519, DOI 10.1161/01.ATV.19.3.519; Winnubst J, 2015, NEURON, V87, P399, DOI 10.1016/j.neuron.2015.06.029; Wuescher LM, 2015, J THROMB HAEMOST, V13, P303, DOI 10.1111/jth.12795; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; Yoshikawa M, 2009, P NATL ACAD SCI USA, V106, P9483, DOI 10.1073/pnas.0903279106; Zhao Z, 2015, CELL, V163, P1064, DOI 10.1016/j.cell.2015.10.067; Zheng S, 2012, NAT NEUROSCI, V15, P381, DOI 10.1038/nn.3026	80	14	14	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	NOV	2018	74						7	27		10.1016/j.bbi.2018.09.009			21	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	HF4FB	WOS:000454187500003	30217533				2021-06-18	
J	Hwang, JH; Kumar, RV; Kang, SY; Jung, HW; Park, YK				Hwang, Ji Hye; Kumar, Vinoth R.; Kang, Seok Yong; Jung, Hyo Won; Park, Yong-Ki			Effects of Flower Buds Extract of Tussilago farfara on Focal Cerebral Ischemia in Rats and Inflammatory Response in BV2 Microglia	CHINESE JOURNAL OF INTEGRATIVE MEDICINE			English	Article						Tussilago farfara; focal cerebral ischemia; inflammation; microglia; tussilagone	TRAUMATIC BRAIN-INJURY; STROKE; CELLS; SESQUITERPENOIDS; NEURONS; DISEASE; NEUROTOXICITY; RECOGNITION; MECHANISMS; EXPRESSION	Objective: To investigate the effects of the flower buds extract of Tussilago farfara Linne (Farfarae Flos; FF) on focal cerebral ischemia through regulation of inflammatory responses in activated microglia. Methods: Brain ischemia was induced in Sprague-Dawley rats by a transient middle cerebral artery occlusion (tMCAO) for 90 min and reperfusion for 24 h. Twenty rats were randomly divided into 4 groups (n=5 per group): normal, tMCAO-induced ischemic control, tMCAO plus FF extract 300 mg/kg-treated, and tMCAO plus MK-801 1 mg/kg-treated as reference drug. FF extract (300 mg/kg, p.o.) or MK-801 (1 mg/kg, i.p.) was administered after reperfusion. Brain infarction was measured by 2,3,5,-triphenyltetrazolium chloride staining. Neuronal damage was observed by haematoxylin eosin, Nissl staining and immunohistochemistry using anti-neuronal nuclei (NeuN), anti-glial fibrillary acidic protein (GFAP), and anti-CD11b/c (OX42) antibodies in ischemic brain. The expressions of inducible nitric oxide synthase (iNOS), tumor necrosis factor (TNF- alpha ), and hypoxia-inducible factor-1 alpha (HIF-1 alpha) were determined by Western blot. BV2 microglial cells were treated with FF extract or its main bioactive compound, tussilagone with or without lipopolysaccharide (LPS). Nitric oxide (NO) production was measured in culture medium by Griess assay. The expressions of iNOS, COX-2 and pro-inflammatory cytokines mRNA were analyzed by reverse transcription-polymerase chain reaction. The expression of iNOS, and COX-2 proteins, the phosphorylation of ERK1/2, JNK, and p38 MAPK and the nuclear expression of NF-kappa B p65 in BV2 cells were determined by Western blot. Results: FF extract significantly decreased brain infarctions in ischemic rats (P<0.01). The neuronal death and the microglia/astrocytes activation in ischemic brains were inhibited by FF extract. FF extract also suppressed iNOS, TNF-alpha, and HIF-1 alpha expression in ischemic brains. FF extract (0.2 and 0.5 mg/mL, P<0.01) and tussilagone 20 and 50 mu mol/L, P<0.01) significantly decreased LPS-induced NO production in BV2 microglia through downregulation of iNOS mRNA and protein expression. FF extract and tussilagone significantly inhibited LPS-induced expression of TNF-alpha, IL-1 beta, and IL-6 mRNA, and also suppressed the phosphorylation of ERK1/2, JNK and p38 MAPK and the nuclear expression of NF- kappa B in a dose-dependent manner. Conclusion: FF extract has a neuroprotective effect in ischemic stroke by the decrease of brain infarction, and the inhibition of neuronal death and microglial activation-mediated inflammatory responses.	[Hwang, Ji Hye] Gachon Univ, Dept Acupuncture & Moxibust Med, Coll Korean Med, Seongnam 13120, South Korea; [Kumar, Vinoth R.; Kang, Seok Yong; Jung, Hyo Won; Park, Yong-Ki] Dongguk Univ, Dept Herbol, Coll Korean Med, Gyeongju 38066, South Korea	Park, YK (corresponding author), Dongguk Univ, Dept Herbol, Coll Korean Med, Gyeongju 38066, South Korea.	yongki@dongguk.ac.kr	Hwang, Ji Hye/R-9219-2017; Rethineswaran, Vinoth Kumar/AAE-5917-2019	Hwang, Ji Hye/0000-0002-6304-1972; 	Ministry of Food and Drug Safety, Republic of KoreaMinistry of Food & Drug Safety (MFDS) [12172MFDS989]	Supported by the grant from Ministry of Food and Drug Safety in 2014 (No. 12172MFDS989), Republic of Korea	Amantea D, 2014, CURR MED CHEM, V21, P2098, DOI 10.2174/0929867321666131227162634; Ayala GX, 2005, EUR J NEUROSCI, V22, P3067, DOI 10.1111/j.1460-9568.2005.04509.x; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Boje K.M., 1992, BRAIN RES, V853, P236; Bora KS, 2011, PHARM BIOL, V49, P175, DOI 10.3109/13880209.2010.506489; Cho JS, 2005, BIOL PHARM BULL, V28, P440; Cunningham C, 2005, J NEUROSCI, V25, P9275, DOI 10.1523/JNEUROSCI.2614-05.2005; Fluri F, 2015, DRUG DES DEV THER, V9, P3445, DOI 10.2147/DDDT.S56071; Gao HM, 2003, J NEUROSCI, V23, P1228; Garden GA, 2006, J NEUROIMMUNE PHARM, V1, P127, DOI 10.1007/s11481-006-9015-5; Han RZ, 2009, NEUROSCI BULL, V25, P367, DOI 10.1007/s12264-009-0608-x; Hoozemans JJM, 2003, CURR DRUG TARGETS, V4, P461, DOI 10.2174/1389450033490902; Hwangbo C, 2009, INT IMMUNOPHARMACOL, V9, P1578, DOI 10.1016/j.intimp.2009.09.016; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ip FCF, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1417-1; Jang H, 2016, ARCH PHARM RES, V39, P127, DOI 10.1007/s12272-015-0667-7; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Jordan J, 2008, CURR PHARM DESIGN, V14, P3549, DOI 10.2174/138161208786848766; Kaminska B, 2009, ANAT REC, V292, P1902, DOI 10.1002/ar.21047; Kim MS, 2016, J MED FOOD, V19, P196, DOI 10.1089/jmf.2015.3512; Kocaeli H, 2005, SURG NEUROL, V64, P22, DOI 10.1016/j.surneu.2005.07.034; Kokoska L, 2002, J ETHNOPHARMACOL, V82, P51, DOI 10.1016/S0378-8741(02)00143-5; Li H, 2014, BIOCHEM BIOPH RES CO, V443, P132, DOI 10.1016/j.bbrc.2013.11.062; Li W, 2012, FITOTERAPIA, V83, P318, DOI 10.1016/j.fitote.2011.11.011; Lim HJ, 2008, ARCH PHARM RES, V31, P645, DOI 10.1007/s12272-001-1207-4; Lim HJ, 2015, J ENZYM INHIB MED CH, V30, P852, DOI 10.3109/14756366.2014.965701; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Park Y, 2014, INT IMMUNOPHARMACOL, V22, P400, DOI 10.1016/j.intimp.2014.07.023; Rock RB, 2006, J NEUROIMMUNE PHARM, V1, P117, DOI 10.1007/s11481-006-9012-8; Scali C, 2003, NEUROSCIENCE, V117, P909, DOI 10.1016/S0306-4522(02)00839-4; Seo UM, 2015, CHEM PHARM BULL, V63, P546, DOI 10.1248/cpb.c15-00204; Svensson C, 2010, BRAIN RES, V1322, P1, DOI 10.1016/j.brainres.2010.01.082; Tzeng Shun-Fen, 2005, Current Drug Targets - Inflammation and Allergy, V4, P335, DOI 10.2174/1568010054022051; Zhi HJ, 2012, PHYTOCHEM ANALYSIS, V23, P492, DOI 10.1002/pca.2346	34	14	16	3	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1672-0415	1993-0402		CHIN J INTEGR MED	Chin. J. Integr. Med.	NOV	2018	24	11					844	852		10.1007/s11655-018-2936-4			9	Integrative & Complementary Medicine	Integrative & Complementary Medicine	GX5OG	WOS:000447797700008	30090976				2021-06-18	
J	Janulewicz, P; Krengel, M; Quinn, E; Heeren, T; Toomey, R; Killiany, R; Zundel, C; Ajama, J; O'Callaghan, J; Steele, L; Klimas, N; Sullivan, K				Janulewicz, Patricia; Krengel, Maxine; Quinn, Emily; Heeren, Timothy; Toomey, Rosemary; Killiany, Ronald; Zundel, Clara; Ajama, Joy; O'Callaghan, James; Steele, Lea; Klimas, Nancy; Sullivan, Kimberly			The Multiple Hit Hypothesis for Gulf War Illness: Self-Reported Chemical/Biological Weapons Exposure and Mild Traumatic Brain Injury	BRAIN SCIENCES			English	Article						Gulf War Illness; Gulf War; mild traumatic brain injury; chemical weapons; neurotoxicant exposures	MULTISYMPTOM ILLNESS; CYCLOSARIN EXPOSURE; RISK-FACTORS; VETERANS; SYMPTOMS; ETIOLOGY; HISTORY; SARIN; SENSE	The Gulf War Illness Consortium (GWIC) was designed to identify objective biomarkers of Gulf War Illness (GWI) in 1991 Gulf War veterans. The symptoms of GWI include fatigue, pain, cognitive problems, gastrointestinal, respiratory, and skin problems. Neurotoxicant exposures during deployment, such as pesticides, sarin, and pyridostigmine bromide pills have been identified as contributors to GWI. We have also found an association between mild traumatic brain injury (mTBI) and increased rates of GWI. However, the combined impact of these physical and chemical exposures has not yet been explored in GWI. The objective of this study was to examine both self-reported mTBI and exposure to chemical/biological weapons (CBW) as a multiple or two hit model for increased risk of GWI and other chronic health conditions. The study population included 125 Gulf War (GW) veterans from the Boston GWIC. Exposure to CBW was reported in 47.2% of the study population, and 35.2% reported sustaining a mTBI during the war. Results confirmed that those with both exposures (mTBI and CBW) had higher rates of comorbid chronic health conditions while rates of GWI were equivalent for mTBI and CBW or mTBI alone. The timing of exposure to mTBI was found to be strikingly different between those with GWI and those without it. Correspondingly, 42.3% of GWI cases reported experiencing a mTBI during military service while none of the controls did (p = 0.0002). Rates of mTBI before and after the war did not differ between the cases and controls. In addition, 54% of cases compared to 14.3% of controls (p = <0.001) reported being exposed to CBW during military service. The current study examined the relation of the separate and combined effects of exposure to mTBI and CBW in 1991 GW veterans. The findings from this study suggest that both exposure to mTBI and CBW are associated with the development of GWI and multiple chronic health conditions and that combined exposure appears to lead to higher risk of chronic health effects.	[Janulewicz, Patricia; Ajama, Joy; Sullivan, Kimberly] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA; [Krengel, Maxine] VA Boston Healthcare Syst, Res Serv, Boston, MA 02130 USA; [Krengel, Maxine] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Quinn, Emily] Boston Univ, Sch Publ Hlth, Biostat & Epidemiol Data Analyt Ctr, Boston, MA 02118 USA; [Heeren, Timothy] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA; [Toomey, Rosemary] Boston Univ, Dept Psychol & Brain Sci, Boston, MA 02215 USA; [Killiany, Ronald] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Zundel, Clara] Boston Univ, Sch Med, Dept Behav Neurosci, Boston, MA 02118 USA; [O'Callaghan, James] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA; [Steele, Lea] Baylor Coll Med, Dept Psychiat & Behav Sci, Div Neuropsychiat, Houston, TX 77030 USA; [Klimas, Nancy] Miami VA Healthcare Syst, Dept Med, Miami, FL 33125 USA; [Klimas, Nancy] Nova Southeastern Univ, Dept Clin Immunol, Miami, FL 33314 USA	Janulewicz, P (corresponding author), Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA.	paj@bu.edu; mhk@bu.edu; eq@bu.edu; tch@bu.edu; toomey@bu.edu; killiany@bu.edu; cgzundel@bu.edu; ajamajoy@bu.edu; jdo5@cdc.gov; Lea.Steele@bcm.edu; nklimas@nova.edu; tty@bu.edu	Zundel, Clara/AAV-5775-2020; Killiany, Ronald/Y-7251-2019	Zundel, Clara/0000-0002-1736-2695; Killiany, Ronald/0000-0003-4740-2181; Sullivan, Kimberly/0000-0001-7940-6123	Congressionally Directed Medical Research Program (CDMRP) through the Gulf War Illness Research Program (GWIRP) [W81XWH-13-2-0072]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	This work was supported by the Congressionally Directed Medical Research Program (CDMRP) through the Gulf War Illness Research Program (GWIRP) under Award No. W81XWH-13-2-0072 to Kimberly Sullivan.	Abou-Donia MB, 2017, NEUROTOXICOL TERATOL, V61, P36, DOI 10.1016/j.ntt.2017.03.002; Alhasson F, 2018, REDOX BIOL, V17, P1, DOI 10.1016/j.redox.2018.04.002; Banks CN, 2012, NEUROTOXICOLOGY, V33, P575, DOI 10.1016/j.neuro.2012.02.002; Barnett ML, 2018, NEUROIMAGE-CLIN, V17, P596, DOI 10.1016/j.nicl.2017.11.017; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Chao LL, 2018, MIL MED, V183, pE571, DOI 10.1093/milmed/usy109; Chao LL, 2016, NEUROTOXICOLOGY, V53, P246, DOI 10.1016/j.neuro.2016.02.009; Chao LDL, 2015, NEUROTOXICOLOGY, V48, P239, DOI 10.1016/j.neuro.2015.04.005; Corrigan F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0738-9; Feigenson KA, 2014, NEUROSCI BIOBEHAV R, V38, P72, DOI 10.1016/j.neubiorev.2013.11.006; Feng L., 2012, THESIS; First M.B., 1996, STRUCTURED CLIN INTE; Fukuda K, 1998, JAMA-J AM MED ASSOC, V280, P981, DOI 10.1001/jama.280.11.981; Georgopoulos AP, 2017, EXP BRAIN RES, V235, P3217, DOI 10.1007/s00221-017-5050-0; Haley RW, 2013, NEUROEPIDEMIOLOGY, V40, P178, DOI 10.1159/000345124; Institute of Medicine, 2014, CHRON MULT ILLN GULF; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Matzinger P, 2002, ANN NY ACAD SCI, V961, P341, DOI 10.1111/j.1749-6632.2002.tb03118.x; Miller KJ, 2013, J HEAD TRAUMA REHAB, V28, P31, DOI 10.1097/HTR.0b013e318255ceae; O'Callaghan JP, 2016, EBIOMEDICINE, V13, P5, DOI 10.1016/j.ebiom.2016.10.037; Proctor S.P., 2006, DEV STRUCTURED NEURO; Proctor SP, 1998, INT J EPIDEMIOL, V27, P1000, DOI 10.1093/ije/27.6.1000; Proctor SP, 2006, NEUROTOXICOLOGY, V27, P931, DOI 10.1016/j.neuro.2006.08.001; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; Rayhan RU, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0058493, 10.1371/journal.pone.0063903]; Research Advisory Committee on Gulf War Veterans Illness, 2014, GULF WAR ILLN HLTH G; Research Advisory Committee on Gulf War Veterans' Illnesses, 2008, GULF WAR ILLN HLTH G; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Seth RK, 2018, TOXICOL APPL PHARM, V350, P64, DOI 10.1016/j.taap.2018.05.006; Smith MA, 2004, NEUROBIOL AGING, V25, pS68, DOI 10.1016/S0197-4580(04)80231-8; Steele L, 2000, AM J EPIDEMIOL, V152, P992, DOI 10.1093/aje/152.10.992; Steele L, 2012, ENVIRON HEALTH PERSP, V120, P112, DOI 10.1289/ehp.1003399; Sullivan K, 2003, J PSYCHOPATHOL BEHAV, V25, P95, DOI 10.1023/A:1023342915425; Sullivan K, 2018, NEUROTOXICOL TERATOL, V65, P1, DOI 10.1016/j.ntt.2017.11.002; Sulzer D, 2007, TRENDS NEUROSCI, V30, P244, DOI 10.1016/j.tins.2007.03.009; Van Riper SM, 2017, PAIN, V158, P2364, DOI 10.1097/j.pain.0000000000001038; Vynorius KC, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00188; White RF, 2001, AM J IND MED, V40, P42, DOI 10.1002/ajim.1070; White RF, 2016, CORTEX, V74, P449, DOI 10.1016/j.cortex.2015.08.022; Wolfe J, 2002, J OCCUP ENVIRON MED, V44, P271, DOI 10.1097/00043764-200203000-00015; Yee MK, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7070079; Yee MK, 2016, J HEAD TRAUMA REHAB, V31, P320, DOI 10.1097/HTR.0000000000000173	45	14	14	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	2076-3425			BRAIN SCI	Brain Sci.	NOV	2018	8	11							198	10.3390/brainsci8110198			14	Neurosciences	Neurosciences & Neurology	HB8AS	WOS:000451306300008	30428552	DOAJ Gold, Green Published			2021-06-18	
J	McGuine, TA; Pfaller, AY; Post, EG; Hetzel, SJ; Brooks, A; Broglio, SP				McGuine, Timothy A.; Pfaller, Adam Y.; Post, Eric G.; Hetzel, Scott J.; Brooks, Alison; Broglio, Steven P.			The Influence of Athletic Trainers on the Incidence and Management of Concussions in High School Athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						adolescents; health care access; sport injury; epidemiology	SPORT-RELATED CONCUSSIONS; CONSENSUS STATEMENT; SECONDARY-SCHOOLS; FOOTBALL PLAYERS; KNOWLEDGE; INJURY; EPIDEMIOLOGY; BEHAVIORS	Context: In many US high schools, the athletic trainer (AT) has the responsibility to identify and manage athletes with concussions. Although the availability of ATs varies a great deal among schools, how the level of AT availability in high schools affects the reported incidence and management of sport-related concussions (SRCs) is unknown. Objective: To determine how the presence of an AT affects the reporting and management of SRCs. Design: Prospective cohort study. Patients or Other Participants: A total of 2459 (female = 37.5%, age = 16.1 +/- 1.2 years) athletes from 31 Wisconsin high schools were categorized as having low availability (LoAT), mid availability (MidAT), or high availability (HiAT) of ATs. Athletic trainers recorded the incidence, days lost from sport, and postconcussion management through return to sport. The incidence of SRC reporting among categories was examined using a multivariate Cox proportional hazards model. Fisher exact tests were used to determine if postconcussion management differed based on AT availability. Results: The incidence of reported SRCs was lower for the LoAT schools (2.4%) compared with the MidAT (5.6%, hazard ratio = 2.59, P = .043) and HiAT (7.0%, hazard ratio = 3.33, P = .002) schools. The median time before the first AT interaction was longer for LoAT schools (24.0 hours) than for MidAT (0.5 hours, post hoc P = .012) and HiAT (0.2 hours, post hoc P = .023) schools. The number of post-SRC interactions was different in all groups (LoAT = 2 interactions, MidAT = 3, and HiAT = 4; all post hoc P values < .05). Days lost were greater for MidAT and HiAT (both 14 days lost) schools compared with LoAT schools (11.5 days lost, post hoc P = .231 and P = .029, respectively). Athletes at LoAT schools were less likely to undergo a return-to-play protocol (9/18 SRCs, 50.0%) than athletes at MidAT (44/47 SRCs, 93.6%; post hoc P = .001) or HiAT (64/64 SRCs, 100%; post hoc P < .001) schools. Conclusions: The level of AT availability positively influenced the reported incidence of SRCs as well as postconcussion management activities in this sample of high schools.	[McGuine, Timothy A.; Pfaller, Adam Y.; Brooks, Alison] Univ Wisconsin, Dept Orthopaed & Rehabil, 1685 Highland Ave, Madison, WI 53705 USA; [Hetzel, Scott J.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA; [Post, Eric G.] San Diego State Univ, Sch Exercise & Nutr Sci, San Diego, CA 92182 USA; [Broglio, Steven P.] Univ Michigan, NeuroTrauma Res Lab, Ann Arbor, MI 48109 USA	McGuine, TA (corresponding author), Univ Wisconsin, Dept Orthopaed & Rehabil, 1685 Highland Ave, Madison, WI 53705 USA.	mcguine@ortho.wisc.edu			NATA Research & Education Foundation	We acknowledge Jacob E. Resch, PhD, ATC, at the University of Virginia for assistance with the study concept and design; R. Dawn Comstock, PhD, at the University of Colorado School of Medicine for assistance with the concept and design of the study as well as advice regarding the methods used to collect the data; and the NATA Research & Education Foundation for funding.	Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Courson R, 2014, J ATHL TRAINING, V49, P128, DOI 10.4085/1062-6050-49.1.06; de Lench B, ATHLETIC TRAINERS EV; Feuer J., STUDY RAISES CONCERN; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hotz RL, WALL STREET J; Kroshus E, 2017, CLIN J SPORT MED, V27, P542, DOI 10.1097/JSM.0000000000000409; Kroshus E, 2017, HEALTH COMMUN, V32, P963, DOI 10.1080/10410236.2016.1196417; Lynall RC, 2013, J ATHL TRAINING, V48, P844, DOI 10.4085/1062-6050-48.6.04; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; O'Connor KL, 2017, J ATHL TRAINING, V52, P175, DOI 10.4085/1062-6050-52.1.15; Pietrosimone B, 2015, MED SCI SPORT EXER, V47, P2366, DOI 10.1249/MSS.0000000000000684; Post EG, J ATHL TRAIN; Pryor RR, 2015, J ATHL TRAINING, V50, P156, DOI 10.4085/1062-6050-50.2.03; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Richardson LP, 2010, PEDIATRICS, V126, P1117, DOI 10.1542/peds.2010-0852; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Svoskos A, HUFFPOST NEWS; Swanik CB, 2007, AM J SPORT MED, V35, P943, DOI 10.1177/0363546507299532; McLeod TCV, 2008, CLIN J SPORT MED, V18, P235, DOI 10.1097/JSM.0b013e3181705756; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Wallace J, 2017, J ATHL TRAINING, V52, P682, DOI 10.4085/1062-6050-52.3.06; Wilkerson GB, 2012, INT J ATHL THER TRAI, V17, P4, DOI 10.1123/ijatt.17.6.4; Williams RM, 2015, J ATHL TRAINING, V50, P262, DOI 10.4085/1062-6050-49.3.81; Williams RM, 2014, SPORTS HEALTH, V6, P434, DOI 10.1177/1941738114545612	33	14	14	0	4	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	NOV	2018	53	11					1017	1024		10.4085/1062-6050-209-18			8	Sport Sciences	Sport Sciences	HH3VE	WOS:000455647200001	30403363	Green Published, Bronze			2021-06-18	
J	Samary, CS; Ramos, AB; Maia, LA; Rocha, NN; Santos, CL; Magalhaes, RF; Clevelario, AL; Pimentel-Coelho, PM; Mendez-Otero, R; Cruz, FF; Capelozzi, VL; Ferreira, TPT; Koch, T; de Abreu, MG; dos Santos, CC; Pelosi, P; Silva, PL; Rocco, PRM				Samary, Cynthia S.; Ramos, Alane B.; Maia, Ligia A.; Rocha, Nazareth N.; Santos, Cintia L.; Magalhaes, Raquel F.; Clevelario, Amanda L.; Pimentel-Coelho, Pedro M.; Mendez-Otero, Rosalia; Cruz, Fernanda F.; Capelozzi, Vera L.; Ferreira, Tatiana P. T.; Koch, Thea; de Abreu, Marcelo Gama; dos Santos, Claudia C.; Pelosi, Paolo; Silva, Pedro L.; Rocco, Patricia R. M.			Focal ischemic stroke leads to lung injury and reduces alveolar macrophage phagocytic capability in rats	CRITICAL CARE			English	Article						Focal ischemic stroke; Lung injury; Brain-lung interaction; Inflammation; Macrophages	TRAUMATIC BRAIN-INJURY; RESPIRATORY MECHANICS; INNATE IMMUNITY; TIDAL-VOLUME; INFLAMMATION; PULMONARY; COMPLICATIONS; POSTSTROKE; INFECTION; PNEUMONIA	Background: Ischemic stroke causes brain inflammation, which we postulate may result in lung damage. Several studies have focused on stroke-induced immunosuppression and lung infection; however, the possibility that strokes may trigger lung inflammation has been overlooked. We hypothesized that even focal ischemic stroke might induce acute systemic and pulmonary inflammation, thus altering respiratory parameters, lung tissue integrity, and alveolar macrophage behavior. Methods: Forty-eight Wistar rats were randomly assigned to ischemic stroke (Stroke) or sham surgery (Sham). Lung function, histology, and inflammation in the lung, brain, bronchoalveolar lavage fluid (BALF), and circulating plasma were evaluated at 24 h. In vitro, alveolar macrophages from naive rats (unstimulated) were exposed to serum or BALF from Sham or Stroke animals to elucidate possible mechanisms underlying alterations in alveolar macrophage phagocytic capability. Alveolar macrophages and epithelial and endothelial cells of Sham and Stroke animals were also isolated for evaluation of mRNA expression of interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha. Results: Twenty-four hours following ischemic stroke, the tidal volume, expiratory time, and mean inspiratory flow were increased. Compared to Sham animals, the respiratory rate and duty cycle during spontaneous breathing were reduced, but this did not affect lung mechanics during mechanical ventilation. Lungs from Stroke animals showed clear evidence of increased diffuse alveolar damage, pulmonary edema, and inflammation markers. This was associated with an increase in ultrastructural damage, as evidenced by injury to type 2 pneumocytes and endothelial cells, cellular infiltration, and enlarged basement membrane thickness. Protein levels of proinflammatory mediators were documented in the lung, brain, and plasma (TNF-alpha and IL-6) and in BALF (TNF-alpha). The phagocytic ability of macrophages was significantly reduced. Unstimulated macrophages isolated from naive rats only upregulated expression of TNF-alpha and IL-6 following exposure to serum from Stroke rats. Exposure to BALF from Stroke or Sham animals did not change alveolar macrophage behavior, or gene expression of TNF-alpha and IL-6. IL-6 expression was increased in macrophages and endothelial cells from Stroke animals. Conclusions: In rats, focal ischemic stroke is associated with brain-lung crosstalk, leading to increased pulmonary damage and inflammation, as well as reduced alveolar macrophage phagocytic capability, which seems to be promoted by systemic inflammation.	[Samary, Cynthia S.; Maia, Ligia A.; Rocha, Nazareth N.; Santos, Cintia L.; Magalhaes, Raquel F.; Clevelario, Amanda L.; Cruz, Fernanda F.; Silva, Pedro L.; Rocco, Patricia R. M.] Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Carlos Chagas Filho Biophys Inst, Lab Pulm Invest, Ave Carlos Chagas Filho S-N,Bloco G-014, BR-21941902 Rio De Janeiro, RJ, Brazil; [Ramos, Alane B.; Pimentel-Coelho, Pedro M.; Mendez-Otero, Rosalia] Univ Fed Rio de Janeiro, Carlos Chagas Filho Biophys Inst, Lab Cellular & Mol Neurobiol, Rio De Janeiro, RJ, Brazil; [Rocha, Nazareth N.] Fluminense Fed Univ, Dept Physiol & Pharmacol, Niteroi, RJ, Brazil; [Capelozzi, Vera L.] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, SP, Brazil; [Ferreira, Tatiana P. T.] Oswaldo Cruz Fdn FIOCRUZ, Oswaldo Cruz Inst, Lab Inflammat, Rio De Janeiro, SP, Brazil; [Koch, Thea; de Abreu, Marcelo Gama] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Anesthesiol & Intens Care Therapy, Pulm Engn Grp, Dresden, Germany; [dos Santos, Claudia C.] Univ Toronto, St Michaels Hosp, Keenan Res Ctr Biomed Sci, Interdept Div Crit Care, Toronto, ON, Canada; [Pelosi, Paolo] Univ Genoa, Dipartimento Sci Chirurg & Diagnost Integrate DIS, Genoa, Italy; [Pelosi, Paolo] IRCCS Osped Policlin San Martino, Genoa, Italy	Rocco, PRM (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Carlos Chagas Filho Biophys Inst, Lab Pulm Invest, Ave Carlos Chagas Filho S-N,Bloco G-014, BR-21941902 Rio De Janeiro, RJ, Brazil.	prmrocco@gmail.com	Silva, Pedro Leme/AAD-8236-2019; , Capelozzi/N-1737-2019; Pimentel-Coelho, Pedro Moreno/AAM-9106-2020; Pimentel-Coelho, Pedro M/K-1994-2015; Mendez-Otero, Rosalia/AAL-7551-2020	Silva, Pedro Leme/0000-0001-5838-4949; , Capelozzi/0000-0001-9732-5853; Pimentel-Coelho, Pedro M/0000-0002-2414-3386; Mendez-Otero, Rosalia/0000-0002-1798-9930; Pelosi, Paolo/0000-0001-5055-3023	Brazilian Council for Scientific and Technological Development (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Rio de Janeiro State Research Foundation (FAPERJ)Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ); Coordination for the Improvement of Higher Education Personnel (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Department of Science and Technology-Brazilian Ministry of Health (DECIT/MS); National Institute of Science and Technology for Regenerative Medicine/CNPq; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY026103] Funding Source: NIH RePORTER	This study was supported by the Brazilian Council for Scientific and Technological Development (CNPq), the Rio de Janeiro State Research Foundation (FAPERJ), Coordination for the Improvement of Higher Education Personnel (CAPES), the Department of Science and Technology-Brazilian Ministry of Health (DECIT/MS), and the National Institute of Science and Technology for Regenerative Medicine/CNPq.	Ansell TK, 2016, RESPIROLOGY, V21, P1041, DOI 10.1111/resp.12800; Bai W, 2018, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00755; Bar-Joseph G, 2009, J NEUROSURG-PEDIATR, V4, P40, DOI 10.3171/2009.1.PEDS08319; Ben Assayag E, 2010, MOL MED, V16, P278, DOI 10.2119/molmed.2010.00015; Chamorro A, 2007, STROKE, V38, P1097, DOI 10.1161/01.STR.0000258346.68966.9d; Chang LC, 2013, CNS NEUROSCI THER, V19, P390, DOI 10.1111/cns.12077; Chao MCM, 2010, RESP PHYSIOL NEUROBI, V173, P179, DOI 10.1016/j.resp.2010.08.005; Dai SS, 2013, J EXP MED, V210, P839, DOI 10.1084/jem.20122196; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; dos Santos AD, 2010, BRAIN RES, V1306, P149, DOI 10.1016/j.brainres.2009.09.094; Elmer J, 2013, CRIT CARE MED, V41, P1992, DOI 10.1097/CCM.0b013e31828a3f4d; Emsley HC, 2008, LANCET NEUROL, V7, P341, DOI 10.1016/S1474-4422(08)70061-9; Engel O, 2015, STROKE, V46, P3232, DOI 10.1161/STROKEAHA.115.008989; GAUTIER H, 1980, CLIN SCI, V58, P343, DOI 10.1042/cs0580343; Giraidi-Guimaraes A, 2009, BRAIN RES, V1266, P108, DOI 10.1016/j.brainres.2009.01.062; Guldner A, 2015, ANESTHESIOLOGY, V123, P692, DOI 10.1097/ALN.0000000000000754; Herre J, 2004, BLOOD, V104, P4038, DOI 10.1182/blood-2004-03-1140; Hilz MJ, 2008, STROKE, V39, P2421, DOI 10.1161/STROKEAHA.108.518613; Hoymann Heinz Gerd, 2007, Journal of Pharmacological and Toxicological Methods, V55, P16, DOI 10.1016/j.vascn.2006.04.006; Hu PJ, 2017, AM J PHYSIOL-LUNG C, V313, pL1, DOI 10.1152/ajplung.00485.2016; Jin W, 2009, EXP BIOL MED, V234, P181, DOI 10.3181/0807-RM-232; Johnston KC, 1998, STROKE, V29, P447, DOI 10.1161/01.STR.29.2.447; Kalra L, 2015, LANCET, V386, P1835, DOI 10.1016/S0140-6736(15)00126-9; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; Kerr NA, 2018, J NEUROTRAUM, V35, P2067, DOI 10.1089/neu.2017.5430; Koo BB, 2010, RESP PHYSIOL NEUROBI, V172, P129, DOI 10.1016/j.resp.2010.05.008; Koutsoukou A, 2006, INTENS CARE MED, V32, P1947, DOI 10.1007/s00134-006-0406-0; Lafargue M, 2012, FASEB J, V26, P2919, DOI 10.1096/fj.11-197384; LEE MC, 1976, STROKE, V7, P382, DOI 10.1161/01.STR.7.4.382; Marchal G, 1999, J CEREBR BLOOD F MET, V19, P467, DOI 10.1097/00004647-199905000-00001; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Mascia L, 2007, CRIT CARE MED, V35, P1815, DOI 10.1097/01.CCM.0000275269.77467.DF; Meisel A, 2015, NAT REV NEUROL, V11, DOI 10.1038/nrneurol.2015.220; Morgan EE, 2014, CARDIOVASC ULTRASOUN, V12, DOI 10.1186/1476-7120-12-37; Neumann S, 2015, INT J MOL SCI, V16, P29029, DOI 10.3390/ijms161226141; Olson BJ, 2007, CURR PROTOC PROTEIN, DOI [10.1002/hed.24713, DOI 10.1002/HED.24713]; Pelosi P, 2011, CRIT CARE MED, V39, P1482, DOI 10.1097/CCM.0b013e31821209a8; Piazza O, 2013, INT J IMMUNOPATH PH, V26, P383, DOI 10.1177/039463201302600211; Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098; Qin MZ, 2015, INT J CLIN EXP PATHO, V8, P12943; Renu A, 2015, STROKE, V46, P673, DOI 10.1161/STROKEAHA.114.008147; Riva DR, 2008, CRIT CARE MED, V36, P1900, DOI 10.1097/CCM.0b013e3181760e5d; Rocco PRM, 1997, RESP PHYSIOL, V110, P9, DOI 10.1016/S0034-5687(97)00067-4; Samary CS, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1573-1; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Seshadri S, 2006, STROKE, V37, P345, DOI 10.1161/01.STR.0000199613.38911.b2; Shim R, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010064; Silveira KSO, 2004, RESP PHYSIOL NEUROBI, V139, P167, DOI 10.1016/j.resp.2003.10.002; Stanley D, 2016, NAT MED, V22, P1277, DOI 10.1038/nm.4194; Szigeti K, 2015, J CEREBR BLOOD F MET, V35, P1921, DOI 10.1038/jcbfm.2015.174; Thrift AG, 2017, INT J STROKE, V12, P13, DOI 10.1177/1747493016676285; Toung TJK, 2005, CRIT CARE MED, V33, P203, DOI 10.1097/01.CCM.0000150659.15558.23; TRAUPE H, 1982, STROKE, V13, P615, DOI 10.1161/01.STR.13.5.615; Uhlig C, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-56; WARLOW CP, 1998, LANCET S3, V352, P1, DOI DOI 10.1016/S0140-6736(98)90086-1; Weber DJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009443; Westendorp WF, 2015, LANCET, V385, P1519, DOI 10.1016/S0140-6736(14)62456-9; Worthmann H, 2010, ANN NY ACAD SCI, V1207, P116, DOI 10.1111/j.1749-6632.2010.05738.x; Yildirim E, 2004, EUR J CARDIO-THORAC, V25, P523, DOI 10.1016/j.ejcts.2003.12.021	60	14	15	1	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	OCT 5	2018	22								249	10.1186/s13054-018-2164-0			11	Critical Care Medicine	General & Internal Medicine	GW0XK	WOS:000446593000001	30290827	DOAJ Gold, Green Published			2021-06-18	
J	Gerzanich, V; Stokum, JA; Ivanova, S; Woo, SK; Tsymbalyuk, O; Sharma, A; Akkentli, F; Imran, Z; Aarabi, B; Sahuquillo, J; Simard, JM				Gerzanich, Volodymyr; Stokum, Jesse A.; Ivanova, Svetlana; Woo, Seung Kyoon; Tsymbalyuk, Orest; Sharma, Amit; Akkentli, Fatih; Imran, Ziyan; Aarabi, Bizhan; Sahuquillo, Juan; Simard, J. Marc			Sulfonylurea Receptor 1, Transient Receptor Potential Cation Channel Subfamily M Member 4, and KIR6.2:Role in Hemorrhagic Progression of Contusion	JOURNAL OF NEUROTRAUMA			English	Article						brain contusion; brain swelling; glibenclamide; hemorrhagic progression of contusion; K-ATP; SUR1-TRPM4; traumatic brain injury	TRAUMATIC BRAIN-INJURY; K-ATP-CHANNELS; SENSITIVE POTASSIUM CHANNELS; PORE-FORMING SUBUNIT; COMPUTED-TOMOGRAPHY; REACTIVE ASTROCYTES; INSULIN-SECRETION; CEREBRAL EDEMA; DOUBLE-BLIND; GLIBENCLAMIDE	In severe traumatic brain injury (TBI), contusions often are worsened by contusion expansion or hemorrhagic progression of contusion (HPC), which may double the original contusion volume and worsen outcome. In humans and rodents with contusion-TBI, sulfonylurea receptor 1 (SUR1) is upregulated in microvessels and astrocytes, and in rodent models, blockade of SUR1 with glibenclamide reduces HPC. SUR1 does not function by itself, but must co-assemble with either KIR6.2 or transient receptor potential cation channel subfamily M member 4 (TRPM4) to form K-ATP (SUR1-KIR6.2) or SUR1-TRPM4 channels, with the two having opposite effects on membrane potential. Both KIR6.2 and TRPM4 are reportedly upregulated in TBI, especially in astrocytes, but the identity and function of SUR1-regulated channels post-TBI is unknown. Here, we analyzed human and rat brain tissues after contusion-TBI to characterize SUR1, TRPM4, and KIR6.2 expression, and in the rat model, to examine the effects on HPC of inhibiting expression of the three subunits using intravenous antisense oligodeoxynucleotides (AS-ODN). Glial fibrillary acidic protein (GFAP) immunoreactivity was used to operationally define core versus penumbral tissues. In humans and rats, GFAP-negative core tissues contained microvessels that expressed SUR1 and TRPM4, whereas GFAP-positive penumbral tissues contained astrocytes that expressed all three subunits. Forster resonance energy transfer imaging demonstrated SUR1-TRPM4 heteromers in endothelium, and SUR1-TRPM4 and SUR1-KIR6.2 heteromers in astrocytes. In rats, glibenclamide as well as AS-ODN targeting SUR1 and TRPM4, but not KIR6.2, reduced HPC at 24h post-TBI. Our findings demonstrate upregulation of SUR1-TRPM4 and K-ATP after contusion-TBI, identify SUR1-TRPM4 as the primary molecular mechanism that accounts for HPC, and indicate that SUR1-TRPM4 is a crucial target of glibenclamide.	[Gerzanich, Volodymyr; Stokum, Jesse A.; Ivanova, Svetlana; Woo, Seung Kyoon; Tsymbalyuk, Orest; Sharma, Amit; Akkentli, Fatih; Imran, Ziyan; Aarabi, Bizhan; Simard, J. Marc] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; [Sahuquillo, Juan] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Neurotraumatol & Neurosurg Res Unit, Barcelona, Spain; [Sahuquillo, Juan] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Dept Neurosurg, Barcelona, Spain	Simard, JM (corresponding author), Univ Maryland, Sch Med, 22 S Greene St,Suite S12D, Baltimore, MD 21201 USA.	msimard@som.umaryland.edu	Sahuquillo, Juan/B-3577-2008	Sahuquillo, Juan/0000-0003-0713-5875	Department of Veterans AffairsUS Department of Veterans Affairs [I01BX002889]; Department of DefenseUnited States Department of Defense [SCI170199]; National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL082517]; National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060801, R01NS102589, R01NS105633]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS061934]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL082517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060801, R01NS102589, R01NS105633, R01NS061934] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002889] Funding Source: NIH RePORTER	J.M.S is supported by grants from the Department of Veterans Affairs (I01BX002889), the Department of Defense (SCI170199), the National Heart, Lung and Blood Institute (R01HL082517) and the National Institute of Neurological Disorders and Stroke (NINDS) (R01NS060801; R01NS102589; R01NS105633); V.G. is supported by a grant from NINDS (NS061934).	Aarabi B, 2009, NEUROSURGERY, V64, P927, DOI 10.1227/01.NEU.0000341907.30831.D2; Abu Hamdeh S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25060-0; Aittoniemi J, 2009, PHILOS T R SOC B, V364, P257, DOI 10.1098/rstb.2008.0142; Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; AMMALA C, 1991, BIOCHIM BIOPHYS ACTA, V1092, P347; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; BOKVIST K, 1991, P ROY SOC B-BIOL SCI, V243, P139, DOI 10.1098/rspb.1991.0022; Bryan J, 2007, PFLUG ARCH EUR J PHY, V453, P703, DOI 10.1007/s00424-006-0116-z; Carnevale JA, 2018, J NEUROSURG, V129, P1305, DOI 10.3171/2017.7.JNS17988; Castro L, 2019, J NEUROTRAUM, V36, P165, DOI 10.1089/neu.2017.5619; Cepeda S, 2015, J NEUROTRAUM, V32, P1246, DOI 10.1089/neu.2014.3808; Chen MK, 2001, J NEUROSCI, V21, P6512; Cheng H, 2007, CELL CALCIUM, V41, P51, DOI 10.1016/j.ceca.2006.04.032; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dunn-Meynell AA, 1998, BRAIN RES, V814, P41, DOI 10.1016/S0006-8993(98)00956-1; Fujita A, 2000, PHARMACOL THERAPEUT, V85, P39, DOI 10.1016/S0163-7258(99)00050-9; Galderisi U, 1999, J CELL PHYSIOL, V181, P251, DOI 10.1002/(SICI)1097-4652(199911)181:2<251::AID-JCP7>3.0.CO;2-D; Gerzanich V, 2009, NAT MED, V15, P185, DOI 10.1038/nm.1899; Gorse K., 2018, J NEUROTRAUMA, pprint; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Griffith CM, 2016, NEUROSCIENCE, V336, P81, DOI 10.1016/j.neuroscience.2016.08.034; Hashiguchi H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184261; Heron-Milhavet L, 2004, MOL CELL NEUROSCI, V25, P585, DOI 10.1016/j.mcn.2003.10.012; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; Jansen-Olesen I, 2005, EUR J PHARMACOL, V523, P109, DOI 10.1016/j.ejphar.2005.08.028; Jayakumar AR, 2014, J NEUROTRAUM, V31, P1249, DOI 10.1089/neu.2013.3169; Jha R.M., 2018, J NEUROL NEUROSURG P; Jha RM, 2018, J NEUROTRAUM, V35, P2125, DOI 10.1089/neu.2016.4696; Jha RM, 2017, NEUROCRIT CARE, V26, P213, DOI 10.1007/s12028-016-0309-z; Jha Ruchira M, 2017, Crit Care Med, V45, pe255, DOI 10.1097/CCM.0000000000002079; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; Kawamata Tatsuro, 2007, Neurosurg Focus, V22, pE5, DOI 10.3171/foc.2007.22.5.6; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; Khalili H, 2017, WORLD NEUROSURG, V101, P130, DOI 10.1016/j.wneu.2017.01.103; Kochanek PM, 2018, MIL MED, V183, P303, DOI 10.1093/milmed/usx184; Konig P, 2006, LAB INVEST, V86, P853, DOI 10.1038/labinvest.3700443; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Kurland DB, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0599-2; Lamensdorf I, 1999, BRAIN RES, V818, P275, DOI 10.1016/S0006-8993(98)01290-6; Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7; Maegele M, 2017, LANCET NEUROL, V16, P630, DOI 10.1016/S1474-4422(17)30197-7; Makar TK, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0432-3; Marigo V, 2009, MOL CELL ENDOCRINOL, V299, P194, DOI 10.1016/j.mce.2008.11.011; MARMAROU A, 1987, J NEUROSURG, V66, P883, DOI 10.3171/jns.1987.66.6.0883; Martinez-Valverde T, 2015, J NEUROTRAUM, V32, P1478, DOI 10.1089/neu.2014.3706; Mehta RI, 2015, J NEUROPATH EXP NEUR, V74, P835, DOI 10.1097/NEN.0000000000000223; Mehta RI, 2013, J NEUROPATH EXP NEUR, V72, P871, DOI 10.1097/NEN.0b013e3182a32e40; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Ningaraj NS, 2003, CANCER RES, V63, P8899; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Ploug KB, 2006, EUR J PHARMACOL, V553, P254, DOI 10.1016/j.ejphar.2006.09.053; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Santa N, 2003, STROKE, V34, P1276, DOI 10.1161/01.STR.0000068171.01248.97; Sheth KN, 2016, LANCET NEUROL, V15, P1160, DOI 10.1016/S1474-4422(16)30196-X; Simard J.M., 2013, J SPINE S, P4; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Simard JM, 2012, TRANSL STROKE RES, V3, P286, DOI 10.1007/s12975-012-0149-x; Simard JM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000522; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Simard JM, 2009, STROKE, V40, P604, DOI 10.1161/STROKEAHA.108.522409; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Soundarapandian MM, 2007, J NEUROCHEM, V103, P1721, DOI 10.1111/j.1471-4159.2007.04963.x; Stokum JA, 2018, GLIA, V66, P108, DOI 10.1002/glia.23231; Sun HS, 2013, ACTA PHARMACOL SIN, V34, P24, DOI 10.1038/aps.2012.138; Sun HS, 2006, J NEUROPHYSIOL, V95, P2590, DOI 10.1152/jn.00970.2005; Szeto V, 2018, ACTA PHARMACOL SIN, V39, P683, DOI 10.1038/aps.2018.10; Thomzig A, 2001, MOL CELL NEUROSCI, V18, P671, DOI 10.1006/mcne.2001.1048; Tosun C, 2013, STROKE, V44, P3522, DOI 10.1161/STROKEAHA.113.002904; Uhlen M, 2016, NAT METHODS, V13, P823, DOI [10.1038/nmeth.3995, 10.1038/NMETH.3995]; Vinogradov SV, 2004, BIOCONJUGATE CHEM, V15, P50, DOI 10.1021/bc034164r; Woo SK, 2013, J BIOL CHEM, V288, P3655, DOI 10.1074/jbc.M112.428219; Xu ZM, 2017, J NEUROTRAUM, V34, P925, DOI 10.1089/neu.2016.4491; Yamada K, 2001, SCIENCE, V292, P1543, DOI 10.1126/science.1059829; Yan FF, 2005, AM J PHYSIOL-CELL PH, V289, pC1351, DOI 10.1152/ajpcell.00240.2005; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zhou M, 2002, MOL BRAIN RES, V101, P23, DOI 10.1016/S0169-328X(02)00137-7; Zhou M, 1999, MOL BRAIN RES, V74, P15, DOI 10.1016/S0169-328X(99)00232-6; Zweckberger K, 2014, NEUROSCIENCE, V272, P199, DOI 10.1016/j.neuroscience.2014.04.040	79	14	14	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2019	36	7					1060	1079		10.1089/neu.2018.5986		OCT 2018	20	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HR6CG	WOS:000446467400001	30160201	Other Gold, Green Published			2021-06-18	
J	Missault, S; Anckaerts, C; Blockx, I; Deleye, S; Van Dam, D; Barriche, N; De Pauw, G; Aertgeerts, S; Valkenburg, F; De Deyn, PP; Verhaeghe, J; Wyffels, L; Van der Linden, A; Staelens, S; Verhoye, M; Dedeurwaerdere, S				Missault, Stephan; Anckaerts, Cynthia; Blockx, Ines; Deleye, Steven; Van Dam, Debby; Barriche, Nora; De Pauw, Glenn; Aertgeerts, Stephanie; Valkenburg, Femke; De Deyn, Peter Paul; Verhaeghe, Jeroen; Wyffels, Leonie; Van der Linden, Annemie; Staelens, Steven; Verhoye, Marleen; Dedeurwaerdere, Stefanie			Neuroimaging of Subacute Brain Inflammation and Microstructural Changes Predicts Long-Term Functional Outcome after Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						diffusion tensor imaging; MRI; PET; positron emission tomography; post-traumatic epilepsy; TSPO	CONTROLLED CORTICAL IMPACT; TRANSLOCATOR PROTEIN TSPO; SPIKE-WAVE DISCHARGES; SPRAGUE-DAWLEY RATS; POSTTRAUMATIC EPILEPSY; BINDING-AFFINITY; NERVOUS-SYSTEM; DENTATE GYRUS; MODEL; SEIZURES	There is currently a lack of prognostic biomarkers to predict the different sequelae following traumatic brain injury (TBI). The present study investigated the hypothesis that subacute neuroinflammation and microstructural changes correlate with chronic TBI deficits. Rats were subjected to controlled cortical impact (CCI) injury, sham surgery, or skin incision (naive). CCI-injured (n=18) and sham-operated rats (n=6) underwent positron emission tomography (PET) imaging with the translocator protein 18kDa (TSPO) radioligand [F-18]PBR111 and diffusion tensor imaging (DTI) in the subacute phase (3 weeks post-injury) to quantify inflammation and microstructural alterations. CCI-injured, sham-operated, and naive rats (n=8) underwent behavioral testing in the chronic phase (5.5-10 months post-injury): open field and sucrose preference tests, two one-week video-electroencephalogram (vEEG) monitoring periods, pentylenetetrazole (PTZ) seizure susceptibility tests, and a Morris water maze (MWM) test. In vivo imaging revealed pronounced neuroinflammation, decreased fractional anisotropy, and increased diffusivity in perilesional cortex and ipsilesional hippocampus of CCI-injured rats. Behavioral analysis revealed disinhibition, anhedonia, increased seizure susceptibility, and impaired learning in CCI-injured rats. Subacute TSPO expression and changes in DTI metrics significantly correlated with several chronic deficits (Pearson's |r|=0.50-0.90). Certain specific PET and DTI parameters had good sensitivity and specificity (area under the receiver operator characteristic [ROC] curve=0.85-1.00) to distinguish between TBI animals with and without particular behavioral deficits. Depending on the investigated behavioral deficit, PET or DTI data alone, or the combination, could very well predict the variability in functional outcome data (adjusted R-2=0.54-1.00). Taken together, both TSPO PET and DTI seem promising prognostic biomarkers to predict different chronic TBI sequelae.	[Missault, Stephan; Barriche, Nora; De Pauw, Glenn; Aertgeerts, Stephanie] Univ Antwerp, Fac Med & Hlth Sci, Expt Lab Translat Neurosci & Otolaryngol, Antwerp, Belgium; [Missault, Stephan; Anckaerts, Cynthia; Blockx, Ines; Van der Linden, Annemie; Verhoye, Marleen] Univ Antwerp, Fac Pharmaceut Biomed & Vet Sci, Bioimaging Lab, Antwerp, Belgium; [Deleye, Steven; Verhaeghe, Jeroen; Wyffels, Leonie; Staelens, Steven] Univ Antwerp, Fac Med & Hlth Sci, Mol Imaging Ctr Antwerp, Antwerp, Belgium; [Dedeurwaerdere, Stefanie] Univ Antwerp, Fac Med & Hlth Sci, Lab Expt Hematol, Antwerp, Belgium; [Van Dam, Debby; Valkenburg, Femke; De Deyn, Peter Paul] Univ Antwerp, Inst Born Bunge, Lab Neurochem & Behav, Antwerp, Belgium; [Van Dam, Debby; Valkenburg, Femke; De Deyn, Peter Paul] Univ Groningen, Dept Neurol, Groningen, Netherlands; [Van Dam, Debby; Valkenburg, Femke; De Deyn, Peter Paul] Univ Groningen, Alzheimer Res Ctr, Groningen, Netherlands; [Van Dam, Debby; Valkenburg, Femke; De Deyn, Peter Paul] Univ Med Ctr Groningen, Groningen, Netherlands; [Wyffels, Leonie] Univ Hosp Antwerp, Dept Nucl Med, Edegem, Belgium	Missault, S (corresponding author), Univ Antwerp, Univ Pl 1, B-2610 Antwerp, Belgium.	stephan.missault@uantwerpen.be	Verhaeghe, Jeroen/I-1539-2016; Staelens, Steven/D-8385-2017; Van Dam, Debby/G-1666-2018	Verhaeghe, Jeroen/0000-0002-4493-1902; Staelens, Steven/0000-0003-3376-0519; Missault, Stephan/0000-0002-1141-4810; Van Dam, Debby/0000-0003-4739-6076; Verhoye, Marleen/0000-0002-6267-0611	ERA-NET NEURON/Research Foundation Flanders [GA00913N]; Research Foundation FlandersFWO [11K3714N/11K3716N]; Hercules Foundation (Belgium); Interuniversity Poles of Attraction of the Belgian Federal Science Policy Office [IAP7/16]	We thank Krystyna Szewczyk, Annemie Van Eetveldt, Philippe Joye, and Caroline Berghmans for their excellent technical assistance. This research was supported by ERA-NET NEURON/Research Foundation Flanders GA00913N. Stephan Missault has a PhD fellowship from the Research Foundation Flanders (11K3714N/11K3716N). The 7T PharmaScan MR system was purchased through Hercules Foundation funding (Belgium) under the promotership of Prof. Annemie Van der Linden. We also acknowledge the Interuniversity Poles of Attraction of the Belgian Federal Science Policy Office (IAP7/16), Belgian Alzheimer Research Foundation (SAO-FRA), agreement between Institute Born-Bunge and University of Antwerp, the Medical Research Foundation Antwerp, the Thomas Riellaerts Research Fund, the Alzheimer Research Center Groningen (UMCG), and Neurosearch Antwerp.	Albrecht DS, 2016, ACS CHEM NEUROSCI, V7, P470, DOI 10.1021/acschemneuro.6b00056; Amhaoul H, 2016, NEUROPHARMACOLOGY, V105, P175, DOI 10.1016/j.neuropharm.2016.01.018; Amhaoul H, 2015, NEUROBIOL DIS, V82, P526, DOI 10.1016/j.nbd.2015.09.004; [Anonymous], 2008, BMJ-BRIT MED J, V336, P425, DOI DOI 10.1136/bmj.39461.643438.25; Bertoglio D, 2017, BRAIN BEHAV IMMUN, V61, P69, DOI 10.1016/j.bbi.2016.12.015; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Bourdier T, 2012, APPL RADIAT ISOTOPES, V70, P176, DOI 10.1016/j.apradiso.2011.07.014; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Defrise M, 1997, IEEE T MED IMAGING, V16, P145, DOI 10.1109/42.563660; Donat CK, 2016, NEUROMOL MED, V18, P158, DOI 10.1007/s12017-016-8385-y; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Fisher RS, 2015, CURR OPIN NEUROL, V28, P130, DOI 10.1097/WCO.0000000000000174; Frey L, 2014, NEUROL RES, V36, P26, DOI 10.1179/1743132813Y.0000000269; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HUDSON HM, 1994, IEEE T MED IMAGING, V13, P601, DOI 10.1109/42.363108; Hunt RF, 2010, J NEUROPHYSIOL, V103, P1490, DOI 10.1152/jn.00957.2009; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Hutchinson EB, 2018, J NEUROSCI RES, V96, P612, DOI 10.1002/jnr.24065; Huusko N, 2015, BRAIN STRUCT FUNCT, V220, P153, DOI 10.1007/s00429-013-0644-1; Ikegaya Y, 2000, NEUROSCIENCE, V98, P647, DOI 10.1016/S0306-4522(00)00188-3; Immonen R, 2013, J NEUROTRAUM, V30, P1305, DOI 10.1089/neu.2012.2815; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; Irimia A, 2012, NEUROIMAGE-CLIN, V1, P1, DOI 10.1016/j.nicl.2012.08.002; James ML, 2012, ANESTHESIOLOGY, V116, P1299, DOI 10.1097/ALN.0b013e318253a02a; Johnstone VPA, 2015, J NEUROTRAUM, V32, P1333, DOI 10.1089/neu.2014.3785; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Juengst SB, 2015, J HEAD TRAUMA REHAB, V30, P207, DOI 10.1097/HTR.0000000000000031; Katsifis A, 2011, NUCL MED BIOL, V38, P137, DOI 10.1016/j.nucmedbio.2010.07.008; Kelly Kevin M, 2004, Epilepsy Curr, V4, P176, DOI 10.1111/j.1535-7597.2004.04503.x; Kelly KM, 2015, EPILEPSY RES, V117, P104, DOI 10.1016/j.eplepsyres.2015.09.009; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kim H, 2017, J NEUROSURG, V127, P23, DOI 10.3171/2016.7.JNS161263; Kocka A, 2014, BEHAV SCI, V4, P352, DOI 10.3390/bs4040352; Koerte I.K., 2016, TRANSLATIONAL RES TR; Li L, 2017, NEUROPHARMACOLOGY, V125, P117, DOI 10.1016/j.neuropharm.2017.06.023; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lyoo CH, 2015, J NUCL MED, V56, P701, DOI 10.2967/jnumed.114.146027; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Missault S, 2014, BRAIN BEHAV IMMUN, V42, P138, DOI 10.1016/j.bbi.2014.06.013; Missault S, 2017, EPILEPSIA, V58, P1615, DOI 10.1111/epi.13845; Mizrahi R, 2012, J CEREBR BLOOD F MET, V32, P968, DOI 10.1038/jcbfm.2012.46; Nissinen J, 2017, EPILEPSY RES, V136, P18, DOI 10.1016/j.eplepsyres.2017.07.005; Owen DR, 2012, J CEREBR BLOOD F MET, V32, P1, DOI 10.1038/jcbfm.2011.147; Pearce PS, 2014, EPILEPSY BEHAV, V32, P121, DOI 10.1016/j.yebeh.2014.01.004; Rodgers KM, 2015, J NEUROSCI, V35, P9194, DOI 10.1523/JNEUROSCI.0919-15.2015; Roncaroli F, 2016, CLIN TRANSL IMAGING, V4, P145, DOI 10.1007/s40336-016-0168-9; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rowe RK, 2016, DEV NEUROSCI-BASEL, V38, P195, DOI 10.1159/000446773; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Save E, 1996, BEHAV NEUROSCI, V110, P74; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shaw FZ, 2004, J NEUROPHYSIOL, V91, P63, DOI 10.1152/jn.00487.2003; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Sick T, 2017, J NEUROTRAUM, V34, P2467, DOI 10.1089/neu.2016.4826; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tu TW, 2014, J NEUROPATH EXP NEUR, V73, P1152, DOI 10.1097/NEN.0000000000000140; Tucker LB, 2017, J NEUROTRAUM, V34, P890, DOI 10.1089/neu.2016.4508; Van den Eynde K, 2014, BEHAV BRAIN RES, V258, P179, DOI 10.1016/j.bbr.2013.10.005; van der Werf IM, 2017, BEHAV BRAIN RES, V328, P218, DOI 10.1016/j.bbr.2017.04.014; Vonder Haar C, 2017, J NEUROTRAUM, V34, P2790, DOI 10.1089/neu.2016.4813; Wang SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063511; Wang Y, 2014, EUR J NUCL MED MOL I, V41, P1440, DOI 10.1007/s00259-014-2727-5; Webster KM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0786-1; Whiting MD, 2006, ANIMAL MODELCOGNIT; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002; Wright DK, 2017, J NEUROTRAUM, V34, P2109, DOI 10.1089/neu.2016.4730; Wright DK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28713; Young NH, 2008, PLOS MED, V5, P1186, DOI 10.1371/journal.pmed.0050168; Yu I, 2010, J NEUROTRAUM, V27, P1463, DOI 10.1089/neu.2009.1196	76	14	14	2	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2019	36	5					768	788		10.1089/neu.2018.5704		OCT 2018	21	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HR2BG	WOS:000446275000001	30032713	Green Accepted			2021-06-18	
J	Bharadwaj, VN; Rowe, RK; Harrison, J; Wu, C; Anderson, TR; Lifshitz, J; Adelson, PD; Kodibagkar, VD; Stabenfeldt, SE				Bharadwaj, Vimala N.; Rowe, Rachel K.; Harrison, Jordan; Wu, Chen; Anderson, Trent R.; Lifshitz, Jonathan; Adelson, P. David; Kodibagkar, Vikram D.; Stabenfeldt, Sarah E.			Blood-brainbarrier disruption dictates nanoparticle accumulation following experimental brain injury	NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE			English	Article						Nanoparticles; Traumatic brain injury; Blood-brain barrier; Mild closed head injury; Fluid percussion injury; Optimal therapeutic window; Drug delivery; Pharmacodynamics	FLUID PERCUSSION INJURY; BARRIER BREAKDOWN; SURFACE-CHARGE; MODEL; EPIDEMIOLOGY; PERMEABILITY; DIAPEDESIS; TRANSPORT; DELIVERY; MODERATE	Clinically, traumatic brain injury (TBI) results in complex heterogeneous pathology that cannot be recapitulated in single pre-clinical animal model. Therefore, we focused on evaluating utility of nanoparticle (NP)-based therapeutics following three diffuse-TBI models: mildclosed-head injury (mCHI), repetitive-mCHI and midline-fluid percussion injury (FPI). We hypothesized that NP accumulation after diffuse TBI correlates directly with blood-brainbarrier permeability. Mice received PEGylated-NP cocktail (20-500 nm) (intravenously) after single-or repetitive-(1 impact/day, 5 consecutive days) CHI (immediately) and midline-FPI (1 h, 3 h and 6 h). NPs circulated for 1 h before perfusion/brain extraction. NP accumulation was analyzed using fluorescent microscopy in brain regions vulnerable to neuropathology. Minimal/no NP accumulation after mCHI/RmCHI was observed. In contrast, midlineFPI resulted in significant peak accumulation of up to 500 nm NP at 3 h post-injury compared to sham, 1 h, and 6 h groups in the cortex. Therefore, our study provides the groundwork for feasibility of NP-delivery based on NPinjection time and NPsize after mCHI/RmCHI and midline-FPI. (c) 2018 Elsevier Inc. All rights reserved.	[Bharadwaj, Vimala N.; Kodibagkar, Vikram D.; Stabenfeldt, Sarah E.] Arizona State Univ, Sch Biol & Hlth Syst Engn, Tempe, AZ 85287 USA; [Rowe, Rachel K.; Wu, Chen; Lifshitz, Jonathan; Adelson, P. David] Univ Arizona, Dept Child Hlth, Coll Med, Phoenix, AZ USA; [Rowe, Rachel K.; Lifshitz, Jonathan; Adelson, P. David] Phoenix Childrens Hosp, BARROW Neurol Inst, Phoenix, AZ USA; [Rowe, Rachel K.; Lifshitz, Jonathan] Phoenix Vet Affairs Healthcare Syst, Phoenix, AZ USA; [Harrison, Jordan; Lifshitz, Jonathan] Arizona State Univ, Interdisciplinary Grad Program Neurosci, Tempe, AZ USA; [Anderson, Trent R.] Univ Arizona, Coll Med, Basic Med Sci, Phoenix, AZ USA	Stabenfeldt, SE (corresponding author), Arizona State Univ, Sch Biol & Hlth Syst Engn, Tempe, AZ 85287 USA.	sarah.stabenfeldt@asu.edu	Adelson, David/W-2083-2019	Rowe, Rachel/0000-0002-9034-3159	NIH NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1DP2HD084067]; Flinn Foundation [1976]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [DP2HD084067] Funding Source: NIH RePORTER	Authors declare no conflict of interest or disclosures. Authors would like to thank funding sources NIH NICHD (1DP2HD084067; SES), and Flinn Foundation (1976; VDK, SES, JL, PDA).	Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Ban Y, 1997, Mol Vis, V3, P18; Bharadwaj VN, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201700668; Bharadwaj VN, 2016, SCI REP-UK, V6, DOI 10.1038/srep29988; Bitner BR, 2012, ACS NANO, V6, P8007, DOI 10.1021/nn302615f; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Carman CV, 2009, J CELL SCI, V122, P3025, DOI 10.1242/jcs.047522; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Clond MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061819; Cruz LJ, 2016, J CONTROL RELEASE, V223, P31, DOI 10.1016/j.jconrel.2015.12.029; Cruz LJ, 2016, NANO RES, V9, P1276, DOI 10.1007/s12274-016-1023-z; De Bock M, 2016, GLIA, V64, P1097, DOI 10.1002/glia.22960; de Boer AG, 2007, ANNU REV PHARMACOL, V47, P323, DOI 10.1146/annurev.pharmtox.47.120505.105237; Feigin VL, 2010, BEST PRACT RES-CLIN, V24, P485, DOI 10.1016/j.bpa.2010.10.006; Gao X, 2017, NEUROTOXICITY OF NANOMATERIALS AND NANOMEDICINE, P59, DOI 10.1016/B978-0-12-804598-5.00003-9; Goddeyne C, 2015, J NEUROPHYSIOL, V113, P3268, DOI 10.1152/jn.00970.2014; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Jo DH, 2015, NANOMED-NANOTECHNOL, V11, P1603, DOI 10.1016/j.nano.2015.04.015; Johnson V. E., 2018, ACTA NEUROPATHOL, P1; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Khalin I, 2016, DRUG DELIV, V23, P3520, DOI 10.1080/10717544.2016.1199609; Knowland D, 2014, NEURON, V82, P603, DOI 10.1016/j.neuron.2014.03.003; Kwon EJ, 2016, ACS NANO, V10, P7926, DOI 10.1021/acsnano.6b03858; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levchenko TS, 2002, INT J PHARMACEUT, V240, P95, DOI 10.1016/S0378-5173(02)00129-1; Li SD, 2008, MOL PHARMACEUT, V5, P496, DOI 10.1021/mp800049w; Li XJ, 2013, NEURAL REGEN RES, V8, P338, DOI 10.3969/j.issn.1673-5374.2013.04.006; Lifshitz J, 2016, BRAIN INJURY, V30, P1293, DOI 10.1080/02699052.2016.1193628; Lin Y, 2012, LAB INVEST, V92, P1623, DOI 10.1038/labinvest.2012.118; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Main BS, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0249-5; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Martinelli R, 2014, J CELL SCI, V127, P3720, DOI 10.1242/jcs.148619; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Nag S, 2011, NEUROPATH APPL NEURO, V37, P3, DOI 10.1111/j.1365-2990.2010.01138.x; Nyul-Toth A, 2016, AM J PHYSIOL-HEART C, V310, pH1702, DOI 10.1152/ajpheart.00774.2015; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pardridge WM, 2012, J CEREBR BLOOD F MET, V32, P1959, DOI 10.1038/jcbfm.2012.126; Ping XJ, 2014, J NEUROTRAUM, V31, P1172, DOI 10.1089/neu.2013.3147; Rowe RK, 2016, METHODS MOL BIOL, V1462, P211, DOI 10.1007/978-1-4939-3816-2_13; Ruozi B, 2015, MOL NEUROBIOL, V52, P899, DOI 10.1007/s12035-015-9235-x; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Villasenor R, 2016, SCI REPORTER, P1; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wilhelm I, 2016, TISSUE BARRIERS, V4, DOI 10.1080/21688370.2016.1143544; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu JL, 2016, ADV FUNCT MATER, V26, P4124, DOI 10.1002/adfm.201504416; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Yardeni T, 2011, LAB ANIMAL, V40, P155, DOI 10.1038/laban0511-155; Yun X, 2013, J CEREBR BLOOD F MET, V33, P583, DOI 10.1038/jcbfm.2012.209; Zhang B, 2016, J NEUROTRAUM, V33, pA14	61	14	14	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1549-9634	1549-9642		NANOMED-NANOTECHNOL	Nanomed.-Nanotechnol. Biol. Med.	OCT	2018	14	7					2155	2166		10.1016/j.nano.2018.06.004			12	Nanoscience & Nanotechnology; Medicine, Research & Experimental	Science & Technology - Other Topics; Research & Experimental Medicine	GV9RF	WOS:000446496900017	29933022	Green Accepted			2021-06-18	
J	Gardner, RC; Rubenstein, R; Wang, KKW; Korley, FK; Yue, JK; Yuh, EL; Mukherje, P; Valadka, AB; Okonkwo, DO; Diaz-Arrastia, R; Manley, GT				Gardner, Raquel C.; Rubenstein, Richard; Wang, Kevin K. W.; Korley, Frederick K.; Yue, John K.; Yuh, Esther L.; Mukherje, Pratik; Valadka, Alex B.; Okonkwo, David O.; Diaz-Arrastia, Ramon; Manley, Geoffrey T.		TRACK-TBI Investigators	Age-Related Differences in Diagnostic Accuracy of Plasma Glial Fibrillary Acidic Protein and Tau for Identifying Acute Intracranial Trauma on Computed Tomography: A TRACK-TBI Study	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; CT; geriatric; traumatic brain injury	COMMON DATA ELEMENTS; C-TERMINAL HYDROLASE-L1; BRAIN-INJURY; TRANSFORMING RESEARCH; CLINICAL KNOWLEDGE; OLDER-ADULTS; HEAD RULE; LEVEL I; MILD; DISEASE	Plasma tau and glial fibrillary acidic protein (GFAP) are promising biomarkers for identifying traumatic brain injury (TBI) patients with intracranial trauma on computed tomography (CT). Accuracy in older adults with mild TBI (mTBI), the fastest growing TBI population, is unknown. Our aim was to assess for age-related differences in diagnostic accuracy of plasma tau and GFAP for identifying intracranial trauma on CT. Samples from 169 patients (age <40 years [n=79], age 40-59 years [n=60], age 60 years+ [n=30]), a subset of patients from the Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) Pilot study who presented with mTBI (Glasgow Coma Scale score of 13-15), received head CT, and consented to blood draw within 24h of injury, were assayed for hyperphosphorylated-tau (P-tau), total-tau (T-tau; both via amplification-linked enhanced immunoassay using multi-arrayed fiberoptics), and GFAP (via sandwich enzyme-linked immunosorbent assay). P-tau, T-tau, P-tau:T-tau ratio, and GFAP concentration were significantly associated with CT findings. Overall, discriminative ability declined with increasing age for all assays, but this decline was only statistically significant for GFAP (area under the receiver operating characteristic curve [AUC]: old 0.73 [reference group; ref] vs. young 0.93 [p=0.037] or middle-aged 0.92 [p=0.0497]). P-tau concentration consistently showed the highest diagnostic accuracy across all age-groups (AUC: old 0.84 [ref] vs. young 0.95 [p=0.274] or middle-aged 0.93 [p=0.367]). Comparison of models including P-tau alone versus P-tau plus GFAP revealed significant added value of GFAP. In conclusion, the GFAP assay was less accurate for identifying intracranial trauma on CT among older versus younger mTBI patients. Mechanisms of this age-related difference, including role of assay methodology, specific TBI neuroanatomy, pre-existing conditions, and anti-thrombotic use, warrant further study.	[Gardner, Raquel C.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA USA; [Gardner, Raquel C.] Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA 94143 USA; [Yue, John K.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Yuh, Esther L.; Mukherje, Pratik] Univ Calif San Francisco, Dept Radiol, 505 Parnassus Ave, San Francisco, CA USA; [Gardner, Raquel C.] San Francisco VA Med Ctr, Dept Neurol, San Francisco, CA USA; [Gardner, Raquel C.] San Francisco VA Med Ctr, Ctr Populat Brain Hlth, San Francisco, CA USA; [Rubenstein, Richard] Suny Downstate Med Ctr, Lab Neurodegenerat Dis, Dept Neurol, Brooklyn, NY 11203 USA; [Rubenstein, Richard] Suny Downstate Med Ctr, Lab Neurodegenerat Dis, Dept Physiol Pharmacol, Brooklyn, NY 11203 USA; [Rubenstein, Richard] Suny Downstate Med Ctr, CNS Biomarker Discovery, Brooklyn, NY 11203 USA; [Wang, Kevin K. W.] Univ Florida, Dept Emergency Med, Program Neurotrauma Neuroprote & Biomarker Res, Gainesville, FL USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Program Neurotrauma Neuroprote & Biomarker Res, Gainesville, FL 32611 USA; [Wang, Kevin K. W.] Univ Florida, Dept Neurosci, Program Neurotrauma Neuroprote & Biomarker Res, Gainesville, FL 32610 USA; [Wang, Kevin K. W.] Univ Florida, Dept Chem, Program Neurotrauma Neuroprote & Biomarker Res, Gainesville, FL 32611 USA; [Wang, Kevin K. W.] Malcom Randall VA Med Ctr, Brain Rehabil Res Ctr, Gainesville, FL USA; [Korley, Frederick K.] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Yue, John K.; Yuh, Esther L.; Mukherje, Pratik; Manley, Geoffrey T.] Zuckerberg San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA USA; [Valadka, Alex B.] Virginia Commonwealth Univ, Dept Neurol Surg, Richmond, VA USA; [Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA; [Diaz-Arrastia, Ramon] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA	Gardner, RC (corresponding author), Univ Calif San Francisco, Dept Neurol, Neurol 127, 4150 Clement St, San Francisco, CA 94121 USA.; Gardner, RC (corresponding author), San Francisco VA Med Ctr, Neurol 127, 4150 Clement St, San Francisco, CA 94121 USA.	raquel.gardner@ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Wang, Kevin/0000-0002-9343-6473	National Institutes of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS095755, RC2 NS069409, U01 NS086090, R21NS085455]; American Federation for Aging Research; Department of Defense (DoD)United States Department of Defense [W81XWH-13-1-0441, W81XWH-14-2-0176]; University of Florida McKnight Brain Institute BSCIRTF fund; SUNY Downstate Medical Center; Office of the Assistant Secretary of Defense for Health Affairs through the DoD Broad Agency Announcement [W81XWH-11-2-0069, W81XWH-14-2-0166]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090, K23NS095755] Funding Source: NIH RePORTER	This study was supported by the National Institutes of Neurological Disorders and Stroke (Beeson K23NS095755 to RCG, RC2 NS069409 to GTM, U01 NS086090 to GTM, and R21NS085455 to KWW), the American Federation for Aging Research (to RCG), the Department of Defense (DoD; W81XWH-13-1-0441 to GTM and W81XWH-14-2-0176 to GTM), the University of Florida McKnight Brain Institute BSCIRTF fund (to KWW), and the SUNY Downstate Medical Center (to RR). This study was also supported in part by the Office of the Assistant Secretary of Defense for Health Affairs through the DoD Broad Agency Announcement under award numbers W81XWH-11-2-0069 (RR) and W81XWH-14-2-0166 (RR).	Albrecht JS, 2016, J HEAD TRAUMA REHAB, V31, pE1, DOI 10.1097/HTR.0000000000000190; Altman J., 2015, ACAD EMERG MED, V22, pS255; Bogoslovsky T, 2017, J NEUROTRAUM, V34, P66, DOI 10.1089/neu.2015.4333; Braak H, 2006, ACTA NEUROPATHOL, V112, P389, DOI 10.1007/s00401-006-0127-z; Braak H, 2011, J NEUROPATH EXP NEUR, V70, P960, DOI 10.1097/NEN.0b013e318232a379; Calcagnile O, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-52; Dams-O'Connor K, 2016, J AM GERIATR SOC, V64, P844, DOI 10.1111/jgs.14014; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2001, DOI 10.1089/neu.2013.3047; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Faul M, 2016, PREHOSP EMERG CARE, V20, P594, DOI 10.3109/10903127.2016.1149651; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Garwe T, 2011, J TRAUMA, V70, P1118, DOI 10.1097/TA.0b013e3181e243b8; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Hawley C, 2017, EMERG MED J, V34, P509, DOI 10.1136/emermed-2016-206506; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Ikonomovic MD, 2017, AGEING RES REV, V34, P51, DOI 10.1016/j.arr.2016.11.003; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Katsanos AH, 2017, STROKE, V48, P2586, DOI 10.1161/STROKEAHA.117.018409; Kirkman MA, 2013, J NEUROTRAUM, V30, P1385, DOI 10.1089/neu.2013.2881; Liu H, 2017, AGEING RES REV, V34, P64, DOI 10.1016/j.arr.2016.11.006; Manley G.T., 2017, J NEUROTRAUMA; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Mattsson N, 2016, NEUROLOGY, V87, P1827, DOI 10.1212/WNL.0000000000003246; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Mehan ND, 2012, NEUROBIOL AGING, V33, P1857, DOI 10.1016/j.neurobiolaging.2011.09.029; Mondello S, 2021, J NEUROTRAUM, V38, P1086, DOI 10.1089/neu.2017.5182; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; National Institutes of Neurological Diseases and Stroke Common Data Elements, NAT I NEUR DIS STROK; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Posti JP, 2016, NEUROSURGERY, V79, P456, DOI 10.1227/NEU.0000000000001226; Rubenstein R, 2017, JAMA NEUROL, V74, P1063, DOI 10.1001/jamaneurol.2017.0655; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Shahim P, 2016, J NEUROTRAUM, V33, P1995, DOI 10.1089/neu.2014.3741; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Welch RD, 2017, J NEUROTRAUM, V34, P1957, DOI 10.1089/neu.2016.4772; Wolf H, 2014, J NEUROSURG, V120, P447, DOI 10.3171/2013.10.JNS13726; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zoltewicz JS, 2012, BIOMARK INSIGHTS, V7, P71, DOI 10.4137/BMI.S9873	47	14	14	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2018	35	20					2341	2350		10.1089/neu.2018.5694			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GV6DE	WOS:000446196600001	29717620	Green Published			2021-06-18	
J	Kinoshita, T; Hayashi, M; Yamakawa, K; Watanabe, A; Yoshimura, J; Hamasaki, T; Fujimi, S				Kinoshita, Takahiro; Hayashi, Motohisa; Yamakawa, Kazuma; Watanabe, Atsushi; Yoshimura, Jumpei; Hamasaki, Toshimitsu; Fujimi, Satoshi			Effect of the Hybrid Emergency Room System on Functional Outcome in Patients with Severe Traumatic Brain Injury	WORLD NEUROSURGERY			English	Article						Craniotomy; CT; Functional outcome; Traumatic brain injury; Trauma workflow	MULTISLICE COMPUTED-TOMOGRAPHY; ACUTE SUBDURAL-HEMATOMA; INTRACRANIAL HYPERTENSION; EXTERNAL VALIDATION; CT SCANNER; MANAGEMENT; PREDICTION; PROGNOSIS; MORTALITY; SURGERY	OBJECTIVE: The timely treatment of severe traumatic brain injury (TBI) is essential for limiting the effects of damage; however, there is no consensus regarding an effective method for early intervention. In August 2011, our hospital launched a novel trauma workflow using the hybrid emergency room (ER), consisting of an interventional radiology-computed tomography (CT) unit installed in the trauma resuscitation room to facilitate early interventions. The aim of this study was to evaluate effects of the hybrid ER system on functional outcomes in patients with severe TBI. METHODS: We conducted a retrospective historical control study of patients with severe TBI (Glasgow Coma Scale score <= 8) who received conventional treatment (August 2007-July 2011) or treatment in the hybrid ER (August 2011-July 2015). The primary end point was unfavorable outcome at 6 months after injury (death, vegetative state, or lower severe disability) as evaluated by the Glasgow Outcome Scale-Extended. Secondary end points included time from arrival to the start of CT examination and emergency intracranial operation. Potential confounders were adjusted with multivariable logistic regressions. RESULTS: Among 158 included patients, 88 were in the conventional group and 70 were in the hybrid ER group. After model adjustment, the hybrid ER group was significantly associated with a reduction in unfavorable outcomes. Times to CT examination and intracranial operation were significantly shorter in the hybrid ER group than that in the conventional group. CONCLUSIONS: The hybrid ER system is useful for realizing immediate CT examination and emergency surgery and improving functional outcomes in patients with severe TBI.	[Kinoshita, Takahiro; Hayashi, Motohisa; Yamakawa, Kazuma; Watanabe, Atsushi; Yoshimura, Jumpei; Fujimi, Satoshi] Osaka Gen Med Ctr, Div Trauma & Surg Crit Care, Sumiyoshi Ku, Osaka, Japan; [Hamasaki, Toshimitsu] Natl Cerebral & Cardiovasc Ctr, Dept Data Sci, Suita, Osaka, Japan	Yamakawa, K (corresponding author), Osaka Gen Med Ctr, Div Trauma & Surg Crit Care, Sumiyoshi Ku, Osaka, Japan.	k.yamakawa0911@gmail.com	Watanabe, Atsushi/AAU-8018-2020; Hamasaki, Toshimitsu/N-3851-2015	Hamasaki, Toshimitsu/0000-0002-4928-1160; Yamakawa, Kazuma/0000-0003-2999-4021			American College of Surgeons Committee on Trauma, 2012, ATLS ADV TRAUM LIF S; Bullock M Ross, 2006, Neurosurgery, V58, pS7; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Centers for Disease Control and Prevention, 2017, SEV TBI; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; Committee of the Japan Association of Traumatology, 2016, JAP ADV TRAUM EV CAR; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; Farahvar A, 2011, J NEUROSURG, V114, P1471, DOI 10.3171/2010.11.JNS101116; Fountain DM, 2017, ANN SURG, V265, P590, DOI 10.1097/SLA.0000000000001682; Guiza F, 2017, J NEUROTRAUM, V34, P2425, DOI 10.1089/neu.2016.4807; Harrison DA, 2015, J NEUROTRAUM, V32, P1522, DOI 10.1089/neu.2014.3628; Hilbert P, 2007, INJURY, V38, P552, DOI 10.1016/j.injury.2006.12.023; Huber-Wagner S, 2014, INJURY, V45, pS76, DOI 10.1016/j.injury.2014.08.022; Jin PHPFK, 2008, J TRAUMA, V64, P1320, DOI 10.1097/TA.0b013e318059b9ae; Kinoshita T, 2019, ANN SURG, V269, P370, DOI 10.1097/SLA.0000000000002527; Lee EJ, 1998, J TRAUMA, V45, P946, DOI 10.1097/00005373-199811000-00017; Lee KL, 2009, INJURY, V40, P873, DOI 10.1016/j.injury.2008.12.001; Marcoux J, 2016, J NEUROSURG, V125, P642, DOI 10.3171/2015.6.JNS15175; Marion DW, 2006, NEUROSURGERY, V58, P655; Matsushima K, 2015, J TRAUMA ACUTE CARE, V79, P838, DOI 10.1097/TA.0000000000000719; McMillan TM, 2012, J NEUROL NEUROSUR PS, V83, P1086, DOI 10.1136/jnnp-2012-302746; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Saltzherr TP, 2012, BRIT J SURG, V99, P105, DOI 10.1002/bjs.7705; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Tien HCN, 2011, ANN SURG, V253, P1178, DOI 10.1097/SLA.0b013e318217e339; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Wada D, 2018, SCAND J TRAUMA RESUS, V26, DOI 10.1186/s13049-018-0484-3; Wada D, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-52; Walcott BP, 2014, J CLIN NEUROSCI, V21, P2107, DOI 10.1016/j.jocn.2014.05.016; Weninger P, 2007, J TRAUMA, V62, P584, DOI 10.1097/01.ta.0000221797.46249.ee; Wulffeld S, 2017, ACTA ANAESTH SCAND, V61, P832, DOI 10.1111/aas.12927; Wurmb TE, 2009, J TRAUMA, V66, P658, DOI 10.1097/TA.0b013e31817de3f4	36	14	14	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	OCT	2018	118						E792	E799		10.1016/j.wneu.2018.07.053			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GU1NY	WOS:000445032000103	30026142				2021-06-18	
J	Sicard, V; Moore, RD; Ellemberg, D				Sicard, Veronik; Moore, Robert Davis; Ellemberg, Dave			Long-term cognitive outcomes in male and female athletes following sport-related concussions	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						Traumatic brain injury; Concussion; Sex differences; Computerized neuropsychological testing; Persistent deficits; Executive functions	TRAUMATIC BRAIN-INJURY; NEUROCOGNITIVE ASSESSMENT TOOLS; SEGMENT DYNAMIC STABILIZATION; SEX-DIFFERENCES; BASE-LINE; WORKING-MEMORY; NEUROPSYCHOLOGICAL FUNCTION; GENDER-DIFFERENCES; HEAD ACCELERATION; SOCCER PLAYERS	Despite concussion being a serious public health concern and the increasing participation of female athletes in sport, the comparative long-term outcomes of male and female athletes are poorly understood, potentially limiting the scientific understanding and clinical management of these injuries. We examined whether sex influences the long-term cognitive outcomes in athletes with a history of concussion (HOC; 6+ months from injury). Accordingly, 196 asymptomatic student-athletes participated in the study (98 with a HOC; 98 matched controls). The sample included both male (n = 98) and female athletes (n = 98). Participants completed the Cogstate brief battery, to which we added a 2-Back condition to increase cognitive load. As predicted, the results revealed sex differences on the N-back Task, a measure of executive functions, with female athletes having a HOC responding significantly more slowly than their male counterparts on the 2-Back condition (p = 0.02). Moreover, irrespective of sex, athletes with a HOC were slower and less accurate relative to controls on the N back Task (p = 0.01). Analyses failed to reveal any significant sex or group difference on tasks that measure lower-level cognition (ps > 0.05). The current results reaffirm the presence of subtle, yet long-term alterations in aspects of executive functions following a sport-related concussion. More importantly, our results highlight that female athletes exhibit alterations of greater magnitude than their male counterparts. Therefore, the sex difference observed in the days or weeks following a concussion may persist well into the chronic phase of injury.	[Sicard, Veronik; Ellemberg, Dave] Univ Montreal, Dept Kinesiol, 2100 Edouard Montpetit, Montreal, PQ H3T 1J4, Canada; [Sicard, Veronik; Ellemberg, Dave] Univ Montreal, Ctr Rech Neuropsychol & Cognit, 90 Rue Vincent dIndy, Montreal, PQ H2V 2S9, Canada; [Moore, Robert Davis] Univ South Carolina, Arnold Sch Publ Hlth, 921 Assembly St, Columbia, SC 29208 USA	Ellemberg, D (corresponding author), 2100 Edouard Montpetit, Montreal, PQ H3T 1J4, Canada.	veronik.sicard@umontreal.ca; moorerd3@mailbox.sc.edu; dave.ellemberg@umontreal.ca		Sicard, Veronik/0000-0003-2452-934X	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [CIHR MOP-102608]	This research was supported by a grant from the Canadian Institutes of Health Research (CIHR MOP-102608) to Dave Ellemberg.	Baker JG, 2016, CLIN PEDIATR, V55, P771, DOI 10.1177/0009922815606417; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown DA, 2015, SPORTS MED, V45, P1027, DOI 10.1007/s40279-015-0335-6; Bush G, 2006, NAT PROTOC, V1, P308, DOI 10.1038/nprot.2006.48; Catale C, 2009, J CLIN EXP NEUROPSYC, V31, P331, DOI 10.1080/13803390802134616; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Cole WR, 2013, ARCH CLIN NEUROPSYCH, V28, P732, DOI 10.1093/arclin/act040; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Cromer JA, 2015, CLIN NEUROPSYCHOL, V29, P542, DOI 10.1080/13854046.2015.1054437; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dougan BK, 2014, J INT NEUROPSYCH SOC, V20, P64, DOI 10.1017/S1355617712001464; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; EMERSON CS, 1992, NEUROREPORT, V3, P957, DOI 10.1097/00001756-199211000-00002; Fratti S, 2017, CLIN NEUROPSYCHOL, V31, P569, DOI 10.1080/13854046.2016.1256435; Gardner A, 2012, APPL NEUROPSYCH-ADUL, V19, P90, DOI 10.1080/09084282.2011.643945; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hammeke TA, 2013, J INT NEUROPSYCH SOC, V19, P863, DOI 10.1017/S1355617713000702; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Keightley ML, 2014, J NEUROTRAUM, V31, P437, DOI [10.1089/NEU.2013.3052, 10.1089/neu.2013.3052]; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Louey AG, 2014, ARCH CLIN NEUROPSYCH, V29, P432, DOI 10.1093/arclin/acu020; Luna B, 2009, ADV CHILD DEV BEHAV, V37, P233, DOI 10.1016/S0065-2407(09)03706-9; MacDonald J, 2015, CLIN J SPORT MED, V25, P367, DOI 10.1097/JSM.0000000000000139; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Manley G, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097791; Mansell J, 2005, J ATHL TRAINING, V40, P310; Mayr U, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091379; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Moore DR, 2016, INT J PSYCHOPHYSIOL, V99, P85, DOI 10.1016/j.ijpsycho.2015.11.010; Moore RD, 2014, J ATHL TRAINING, V49, P24, DOI 10.4085/1062-6050-49.1.01; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Ozen LJ, 2013, BRAIN INJURY, V27, P1244, DOI 10.3109/02699052.2013.804207; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Queen RM, 2003, MED SCI SPORT EXER, V35, P2069, DOI 10.1249/01.MSS.0000099081.20125.A5; Rice SM, 2018, SPORTS MED, V48, P447, DOI 10.1007/s40279-017-0810-3; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Sicard V, 2019, CLIN J SPORT MED, V29, P62, DOI 10.1097/JSM.0000000000000492; Tanveer S, 2017, PEDIAT NEUROL; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; Weiss E, 2003, NEUROSCI LETT, V344, P169, DOI 10.1016/S0304-3940(03)00406-3; Wunderle K, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000006; Zuckerman SL, 2013, J NEUROSURG-PEDIATR, V12, P103, DOI 10.3171/2013.5.PEDS12524	67	14	14	0	16	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	OCT	2018	132		A		SI		3	8		10.1016/j.ijpsycho.2018.03.011			6	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	GV7GC	WOS:000446289000002	29572188				2021-06-18	
J	Bauman, MD; Schumann, CM; Carlson, EL; Taylor, SL; Vazquez-Rosa, E; Cintron-Perez, CJ; Shin, MK; Williams, NS; Pieper, AA				Bauman, Melissa D.; Schumann, Cynthia M.; Carlson, Erin L.; Taylor, Sandra L.; Vazquez-Rosa, Edwin; Cintron-Perez, Coral J.; Shin, Min-Kyoo; Williams, Noelle S.; Pieper, Andrew A.			Neuroprotective efficacy of P7C3 compounds in primate hippocampus	TRANSLATIONAL PSYCHIATRY			English	Article							RETINAL GANGLION-CELLS; TRAUMATIC BRAIN-INJURY; ADULT NEUROGENESIS; DENTATE GYRUS; MACAQUE MONKEY; NEUROPSYCHIATRIC DISORDERS; AMINOPROPYL CARBAZOLES; MAJOR DEPRESSION; PROGENITOR CELLS; DRUG DEVELOPMENT	There is a critical need for translating basic science discoveries into new therapeutics for patients suffering from difficult to treat neuropsychiatric and neurodegenerative conditions. Previously, a target-agnostic in vivo screen in mice identified P7C3 aminopropyl carbazole as capable of enhancing the net magnitude of postnatal neurogenesis by protecting young neurons from death. Subsequently, neuroprotective efficacy of P7C3 compounds in a broad spectrum of preclinical rodent models has also been observed. An important next step in translating this work to patients is to determine whether P7C3 compounds exhibit similar efficacy in primates. Adult male rhesus monkeys received daily oral P7C3-A20 or vehicle for 38 weeks. During weeks 2-11, monkeys received weekly injection of 5'bromo- 2-deoxyuridine (BrdU) to label newborn cells, the majority of which would normally die over the following 27 weeks. BrdU+ cells were quantified using unbiased stereology. Separately in mice, the proneurogenic efficacy of P7C3-A20 was compared to that of NSI-189, a proneurogenic drug currently in clinical trials for patients with major depression. Orally-administered P7C3-A20 provided sustained plasma exposure, was well-tolerated, and elevated the survival of hippocampal BrdU+ cells in nonhuman primates without adverse central or peripheral tissue effects. In mice, NSI-189 was shown to be pro-proliferative, and P7C3-A20 elevated the net magnitude of hippocampal neurogenesis to a greater degree than NSI-189 through its distinct mechanism of promoting neuronal survival. This pilot study provides evidence that P7C3-A20 safely protects neurons in nonhuman primates, suggesting that the neuroprotective efficacy of P7C3 compounds is likely to translate to humans as well.	[Bauman, Melissa D.; Schumann, Cynthia M.; Carlson, Erin L.] Univ Calif Davis, Dept Psychiat & Behav Sci, Davis, CA 95616 USA; [Bauman, Melissa D.; Schumann, Cynthia M.] Univ Calif Davis, UC Davis MIND Inst, Davis, CA 95616 USA; [Bauman, Melissa D.] Calif Natl Primate Res Ctr, Davis, CA USA; [Bauman, Melissa D.; Taylor, Sandra L.] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA 95616 USA; [Vazquez-Rosa, Edwin; Cintron-Perez, Coral J.; Shin, Min-Kyoo; Pieper, Andrew A.] Case Western Reserve Univ, Dept Psychiat, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Vazquez-Rosa, Edwin; Cintron-Perez, Coral J.; Shin, Min-Kyoo; Pieper, Andrew A.] Harrington Discovery Inst, Louis Stokes Cleveland VAMC, Geriatr Res Educ Ctr, Cleveland, OH 44106 USA; [Vazquez-Rosa, Edwin; Cintron-Perez, Coral J.; Shin, Min-Kyoo; Pieper, Andrew A.] Harrington Discovery Inst, Louis Stokes Cleveland VAMC, Clin Ctr, Cleveland, OH 44106 USA; [Williams, Noelle S.] UT Southwestern Med Ctr, Dept Biochem, Dallas, TX USA	Pieper, AA (corresponding author), Case Western Reserve Univ, Dept Psychiat, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA.; Pieper, AA (corresponding author), Harrington Discovery Inst, Louis Stokes Cleveland VAMC, Geriatr Res Educ Ctr, Cleveland, OH 44106 USA.; Pieper, AA (corresponding author), Harrington Discovery Inst, Louis Stokes Cleveland VAMC, Clin Ctr, Cleveland, OH 44106 USA.	mdbauman@ucdavis.edu; Andrew.Pieper@HarringtonDiscovery.org		Pieper, Andrew/0000-0001-6299-6577	NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21 NS081487]; CNPRC [OD011107]; Hartwell Foundation; Brockman Medical Research Foundation; Calico LLC (California Life Company); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U54 HD079125]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD079125] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [T32CA078586] Funding Source: NIH RePORTER	This work was supported by NIMH R21 NS081487 to M.D.B. and A.A.P, the CNPRC base grant OD011107, funds from The Hartwell Foundation to A.A.P., funds from an anonymous donor to the Mary Alice Smith Fund for Neuropsychiatry Research to A.A.P, and funds from the Brockman Medical Research Foundation. Pathological analysis of tissue conducted by Abbvie Pharmaceuticals (North Chicago, Illinois, USA) was funded by Calico LLC (California Life Company). Special acknowledgements are due to Research Services and Primate Medicine staff at the California National Primate Research Center for care of the animals and in particular to T. Traill for her assistance with compound administration and to Dr. David Amaral for consultation on experimental design and use of microscopy equipment. Data analysis was supported by the NIH-funded MIND Institute Intellectual and Developmental Disabilities Research Center (U54 HD079125). We would like to thank Katherine Ku for her assistance in GCL volumetric data collection, Alicja Omanska for assistance with tissue processing and Casey Hogrefe for assistance with manuscript preparation. Finally, we thank Dr. Karl Murray for insightful comments on an early draft of the manuscript.	Allen KM, 2016, AUST NZ J PSYCHIAT, V50, P473, DOI 10.1177/0004867415589793; ALTMAN J, 1965, NATURE, V207, P953, DOI 10.1038/207953a0; Amaral DG, 2007, PROG BRAIN RES, V163, P3, DOI 10.1016/S0079-6123(07)63001-5; Bacchetti P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001628; Bauman MD, 2005, NEUROSCIENCE, V136, P193, DOI 10.1016/j.neuroscience.2005.07.040; Bergmann O, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a018994; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Boldrini M, 2018, CELL STEM CELL, V22, P589, DOI 10.1016/j.stem.2018.03.015; Boldrini M, 2013, NEUROPSYCHOPHARMACOL, V38, P1068, DOI 10.1038/npp.2013.5; Boldrini M, 2012, BIOL PSYCHIAT, V72, P562, DOI 10.1016/j.biopsych.2012.04.024; Boldrini M, 2009, NEUROPSYCHOPHARMACOL, V34, P2376, DOI 10.1038/npp.2009.75; Burke SN, 2012, FRONT AGING NEUROSCI, V4, DOI 10.3389/fnagi.2012.00015; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Cameron HA, 2015, ANNU REV PSYCHOL, V66, P53, DOI 10.1146/annurev-psych-010814-015006; Coe CL, 2003, BIOL PSYCHIAT, V54, P1025, DOI 10.1016/S0006-3223(03)00698-X; De Jesus-Cortes H, 2016, NEUROGENESIS AUSTIN, V3, pe1231160, DOI 10.1080/23262133.2016.1231160; De Jesus-Cortes H, 2012, P NATL ACAD SCI USA, V109, P17010, DOI 10.1073/pnas.1213956109; De Jesus-Cortest H, 2015, NPJ PARKINSON DIS, V1, DOI 10.1038/npjparkd.2015.10; Dutca LM, 2014, INVEST OPHTH VIS SCI, V55, P8330, DOI 10.1167/iovs.14-15468; Engle JR, 2012, FRONT AGING NEUROSCI, V4, DOI [10.3389/fnagi.2012.00036, 10.3389/fnagi.2012.00010]; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Esposito MS, 2005, J NEUROSCI, V25, P10074, DOI 10.1523/JNEUROSCI.3114-05.2005; Fava M, 2016, MOL PSYCHIATR, V21, P1483, DOI 10.1038/mp.2016.140; Galvan V, 2007, CLIN INTERV AGING, V2, P605; Gibbs RA, 2007, SCIENCE, V316, P222, DOI 10.1126/science.1139247; Glover LR, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2001154; Goetghebeur PJD, 2016, J PSYCHOPHARMACOL, V30, P586, DOI 10.1177/0269881116645269; Goncalves JT, 2016, CELL, V167, P897, DOI 10.1016/j.cell.2016.10.021; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; Gould E, 1999, P NATL ACAD SCI USA, V96, P5263, DOI 10.1073/pnas.96.9.5263; Gray DT, 2015, NEUROSCIENCE, V309, P17, DOI 10.1016/j.neuroscience.2015.08.001; Gribkoff VK, 2017, NEUROPHARMACOLOGY, V120, P11, DOI 10.1016/j.neuropharm.2016.03.021; Gu C, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.250; Hill AS, 2015, NEUROPSYCHOPHARMACOL, V40, P2368, DOI 10.1038/npp.2015.85; Jabes A, 2011, J COMP NEUROL, V519, P1051, DOI 10.1002/cne.22549; Jabes A, 2010, EUR J NEUROSCI, V31, P273, DOI 10.1111/j.1460-9568.2009.07061.x; Kemp SWP, 2015, NEUROSCIENCE, V284, P202, DOI 10.1016/j.neuroscience.2014.10.005; Kesselheim AS, 2015, NAT REV DRUG DISCOV, V14, P815, DOI 10.1038/nrd4793; Kohler SJ, 2011, P NATL ACAD SCI USA, V108, P10326, DOI 10.1073/pnas.1017099108; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Kronmuller KT, 2009, PSYCHIAT RES-NEUROIM, V174, P62, DOI 10.1016/j.pscychresns.2008.08.001; Laplagne DA, 2006, PLOS BIOL, V4, P2349, DOI 10.1371/journal.pbio.0040409; Lavenex P, 2000, HIPPOCAMPUS, V10, P420, DOI 10.1002/1098-1063(2000)10:4<420::AID-HIPO8>3.0.CO;2-5; Lavenex P, 2009, J COMP NEUROL, V512, P27, DOI 10.1002/cne.21906; Lee AS, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0006-16.2016; LoCoco PM, 2017, ELIFE, V6, DOI 10.7554/eLife.29626; Loris ZB, 2018, TRANSL STROKE RES, V9, P146, DOI 10.1007/s12975-017-0565-z; Loris ZB, 2017, EXP NEUROL, V290, P63, DOI 10.1016/j.expneurol.2017.01.006; Lucassen PJ, 2010, NEUROPHARMACOLOGY, V58, P940, DOI 10.1016/j.neuropharm.2010.01.012; MacMillan KS, 2011, J AM CHEM SOC, V133, P1428, DOI 10.1021/ja108211m; McAvoy KM, 2017, NEUROTHERAPEUTICS, V14, P630, DOI 10.1007/s13311-017-0539-6; McIntyre RS, 2017, EXPERT OPIN INV DRUG, V26, P767, DOI 10.1080/13543784.2017.1324847; Naidoo J, 2014, J MED CHEM, V57, P3746, DOI 10.1021/jm401919s; Nestler EJ, 2010, NAT NEUROSCI, V13, P1161, DOI 10.1038/nn.2647; Oku H, 2017, INVEST OPHTH VIS SCI, V58, P4877, DOI 10.1167/iovs.17-22179; Oku H, 2017, JPN J OPHTHALMOL, V61, P195, DOI 10.1007/s10384-016-0493-6; Pedraza O, 2004, J INT NEUROPSYCH SOC, V10, P664, DOI 10.1017/S1355617704105080; Perera TD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017600; Phillips KA, 2014, AM J PRIMATOL, V76, P801, DOI 10.1002/ajp.22281; Piatti VC, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00050; Pieper AA, 2017, NEUROTHERAPEUTICS, V14, P533, DOI 10.1007/s13311-017-0547-6; Pieper AA, 2014, CHEM SOC REV, V43, P6716, DOI 10.1039/c3cs60448a; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; Reif A, 2006, MOL PSYCHIATR, V11, P514, DOI 10.1038/sj.mp.4001791; Rosenzweig ES, 2018, NAT MED, V24, P484, DOI 10.1038/nm.4502; Rosenzweig ES, 2010, NAT NEUROSCI, V13, P1505, DOI 10.1038/nn.2691; Sahay A, 2007, NAT NEUROSCI, V10, P1110, DOI 10.1038/nn1969; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Schinder AF, 2004, PHYSIOLOGY, V19, P253, DOI 10.1152/physiol.00012.2004; Schoenfeld TJ, 2017, BIOL PSYCHIAT, V82, P914, DOI 10.1016/j.biopsych.2017.05.013; Schoenfeld TJ, 2015, NEUROPSYCHOPHARMACOL, V40, P113, DOI 10.1038/npp.2014.230; Serafini G, 2014, CNS NEUROL DISORD-DR, V13, P1708; Snyder JS, 2011, NATURE, V476, P458, DOI 10.1038/nature10287; Sorrells SF, 2018, NATURE, V555, P377, DOI 10.1038/nature25975; Spalding KL, 2013, CELL, V153, P1219, DOI 10.1016/j.cell.2013.05.002; Tajiri N, 2017, J CELL PHYSIOL, V232, P2731, DOI 10.1002/jcp.25847; Terrillion CE, 2017, NEUROPSYCHOPHARMACOL, V42, P2242, DOI 10.1038/npp.2017.129; Tesla R, 2012, P NATL ACAD SCI USA, V109, P17016, DOI 10.1073/pnas.1213960109; Voorhees JR, 2018, BIOL PSYCHIAT, V84, P488, DOI 10.1016/j.biopsych.2017.10.023; Walker AK, 2015, MOL PSYCHIATR, V20, P500, DOI 10.1038/mp.2014.34; Walter A, 2016, NEUROSCI BIOBEHAV R, V71, P680, DOI 10.1016/j.neubiorev.2016.10.007; Walton NM, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.56; Wang G, 2014, CELL, V158, P1324, DOI 10.1016/j.cell.2014.07.040; Wang SN, 2016, CNS NEUROSCI THER, V22, P782, DOI 10.1111/cns.12576; Watson KK, 2012, J NEURODEV DISORD, V4, DOI 10.1186/1866-1955-4-21; West M.J., 2012, BASIC STEREOLOGY BIO; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; Woolard AA, 2012, PSYCHIAT RES-NEUROIM, V201, P48, DOI 10.1016/j.pscychresns.2011.07.016; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030; Yun S, 2018, NAT MED, V24, P658, DOI 10.1038/s41591-018-0002-1; Yun S, 2016, NAT MED, V22, P1239, DOI 10.1038/nm.4218; Zhang LQ, 2018, AM J PATHOL, V188, P1640, DOI 10.1016/j.ajpath.2018.04.004	93	14	14	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	2158-3188			TRANSL PSYCHIAT	Transl. Psychiatr.	SEP 26	2018	8								202	10.1038/s41398-018-0244-1			11	Psychiatry	Psychiatry	GV6XU	WOS:000446264100001	30258178	DOAJ Gold, Green Published			2021-06-18	
J	Zhang, Z; Rasmussen, L; Saraswati, M; Koehler, RC; Robertson, C; Kannan, S				Zhang, Zhi; Rasmussen, Lindsey; Saraswati, Manda; Koehler, Raymond C.; Robertson, Courtney; Kannan, Sujatha			Traumatic Injury Leads to Inflammation and Altered Tryptophan Metabolism in the Juvenile Rabbit Brain	JOURNAL OF NEUROTRAUMA			English	Article						IDO; inflammation; microglia; serotonin; TBI	TUMOR-NECROSIS-FACTOR; CEREBROSPINAL-FLUID; QUINOLINIC ACID; MESSENGER-RNA; FACTOR-ALPHA; TNF-ALPHA; INDOLEAMINE 2,3-DIOXYGENASE; KYNURENINE PATHWAY; CYTOKINE EXPRESSION; SEROTONIN	Neuroinflammation after traumatic brain injury (TBI) contributes to widespread cell death and tissue loss. Here, we evaluated sequential inflammatory response in the brain, as well as inflammation-induced changes in brain tryptophan metabolism over time, in a rabbit pediatric TBI model. On post-natal days 5-7 (P5-P7), New Zealand white rabbit littermates were randomized into three groups: naive (no injury), sham (craniotomy alone), and TBI (controlled cortical impact). Animals were sacrificed at 6h and 1, 3, 7, and 21 days post-injury for evaluating levels of pro- and anti-inflammatory cytokines, as well as the major components in the tryptophan-kynurenine pathway. We found that 1) pro- and anti-inflammatory cytokine levels in the brain injury area were differentially regulated in a time-dependent manner post-injury; 2) indoleamine 2,3 dioxygeenase 1 (IDO1) was upregulated around the injury area in TBI kits that persisted at 21 days post-injury; 3) mean length of serotonin-staining fibers was significantly reduced in the injured brain region in TBI kits for at least 21 days post-injury; and 4) kynurenine level significantly increased at 7 days post-injury. A significant decrease in serotonin/tryptophan ratio and melatonin/tryptophan ratio at 21 days post-injury was noted, suggesting that tryptophan metabolism is altered after TBI. A better understanding of the temporal evolution of immune responses and tryptophan metabolism during injury and repair after TBI is crucial for the development of novel therapeutic strategies targeting these pathways.	[Zhang, Zhi; Rasmussen, Lindsey; Saraswati, Manda; Koehler, Raymond C.; Robertson, Courtney; Kannan, Sujatha] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Bloomberg Childrens Bldg,6318D-C4,1800 Orleans St, Baltimore, MD 21287 USA; [Zhang, Zhi] Univ Michigan, Dept Nat Sci, Dearborn, MI 48128 USA	Kannan, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Bloomberg Childrens Bldg,6318D-C4,1800 Orleans St, Baltimore, MD 21287 USA.	skannan3@jhmi.edu		Zhang, Zhi/0000-0001-6256-9516	Johns Hopkins Department of Anesthesiology and Critical Care StAAR grant;  [R01NS093416];  [R01NS092747]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092747] Funding Source: NIH RePORTER	This study was funded in part by R01NS093416 (SK), R01NS092747 (CR), and by Johns Hopkins Department of Anesthesiology and Critical Care StAAR grant.	Aarum J, 2003, P NATL ACAD SCI USA, V100, P15983, DOI 10.1073/pnas.2237050100; Balasingam V, 1996, J NEUROSCI, V16, P2945; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Bassani TB, 2014, BRAIN RES, V1593, P95, DOI 10.1016/j.brainres.2014.09.068; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; Bendz LM, 2010, ANN PHARMACOTHER, V44, P185, DOI 10.1345/aph.1M365; BennettClarke CA, 1997, SOMATOSENS MOT RES, V14, P27; BENVENISTE EN, 1995, INT J DEV NEUROSCI, V13, P341, DOI 10.1016/0736-5748(94)00061-7; Berger RP, 2004, J NEUROTRAUM, V21, P1123; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Bhutia YD, 2015, BBA-BIOMEMBRANES, V1848, P453, DOI 10.1016/j.bbamem.2014.10.021; BLIGHT AR, 1995, BRAIN, V118, P735, DOI 10.1093/brain/118.3.735; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Boutin H, 2001, J NEUROSCI, V21, P5528; BRENNER T, 1993, BRAIN RES, V608, P273, DOI 10.1016/0006-8993(93)91468-8; Brummelte S, 2017, NEUROSCIENCE, V342, P212, DOI 10.1016/j.neuroscience.2016.02.037; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Carmody DP, 2004, NEURORADIOLOGY, V46, P781, DOI 10.1007/s00234-004-1241-z; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Chollet F, 2011, LANCET NEUROL, V10, P123, DOI 10.1016/S1474-4422(10)70314-8; Ciurea A V, 2011, J Med Life, V4, P234; Connor TJ, 2008, NEUROSCI LETT, V441, P29, DOI 10.1016/j.neulet.2008.06.007; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; DAMATO RJ, 1987, P NATL ACAD SCI USA, V84, P4322, DOI 10.1073/pnas.84.12.4322; Damiani JM, 2014, AM J HEALTH-SYST PH, V71, P95, DOI 10.2146/ajhp130215; Daubert EA, 2010, TRENDS NEUROSCI, V33, P424, DOI 10.1016/j.tins.2010.05.005; Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800; Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; Elkhayat HA, 2010, PEDIATR NEUROL, V42, P249, DOI 10.1016/j.pediatrneurol.2009.11.002; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Fujigaki H, 2006, J BIOCHEM, V139, P655, DOI 10.1093/jb/mvj072; Gaspar P, 2003, NAT REV NEUROSCI, V4, P1002, DOI 10.1038/nrn1256; Gelman A., 2007, DATA ANAL USING REGR; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Grima NA, 2018, BMC MED, V16, DOI 10.1186/s12916-017-0995-1; Guillemin GJ, 2005, NEUROPATH APPL NEURO, V31, P395, DOI 10.1111/j.1365-2990.2005.00655.x; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Haynes RL, 2005, J COMP NEUROL, V484, P156, DOI 10.1002/cne.20453; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; Hide I, 2000, J NEUROCHEM, V75, P965, DOI 10.1046/j.1471-4159.2000.0750965.x; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Jorge RE, 2016, JAMA PSYCHIAT, V73, P1041, DOI 10.1001/jamapsychiatry.2016.2189; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Koizumi H, 2004, BRAIN DEV-JPN, V26, P434, DOI 10.1016/j.braindev.2003.09.011; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kozak M, 2007, J CELL BIOCHEM, V102, P280, DOI 10.1002/jcb.21464; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lauder J M, 1981, Adv Exp Med Biol, V133, P477; Lebrand C, 1996, NEURON, V17, P823, DOI 10.1016/S0896-6273(00)80215-9; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Lobo-Silva D, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0763-8; Lorente L, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0922-2; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Maddaloni G, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00202; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Marseglia L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051053; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; Mehra A, 2003, BIOTECHNOL BIOENG, V84, P822, DOI 10.1002/bit.10860; Meier TB, 2016, J NEUROTRAUM, V33, P1349, DOI 10.1089/neu.2015.4118; Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood-2003-11-3909; Miceli S, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00088; Michell-Robinson MA, 2015, BRAIN, V138, P1138, DOI 10.1093/brain/awv066; Miller E, 2015, CURR TOP MED CHEM, V15, P163, DOI 10.2174/1568026615666141209160556; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Moss DW, 2001, EUR J NEUROSCI, V13, P529, DOI 10.1046/j.1460-9568.2001.01418.x; Narboux-Neme N, 2008, NEUROPHARMACOLOGY, V55, P994, DOI 10.1016/j.neuropharm.2008.08.020; Nie L, 2006, GENETICS, V174, P2229, DOI 10.1534/genetics.106.065862; Ouellet MC, 2015, LANCET NEUROL, V14, P746, DOI 10.1016/S1474-4422(15)00068-X; Pardridge WM, 1998, NEUROCHEM RES, V23, P635, DOI 10.1023/A:1022482604276; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; PRATT OE, 1979, J NEURAL TRANSM, P29; Raimondi A, 1987, Chemioterapia, V6, P103; Rasouli J, 2011, Einstein J Biol Med, V27, P74; Regan T, 2018, J LEUKOCYTE BIOL, V103, P681, DOI 10.1002/JLB.3A0617-261R; REID TR, 1989, J BIOL CHEM, V264, P4583; Richard DM, 2009, INT J TRYPTOPHAN RES, V2, P45; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Rossignol DA, 2014, CURR CLIN PHARMACOL, V9, P326, DOI 10.2174/15748847113086660072; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Sarkhosh K, 2003, J CELL BIOCHEM, V90, P206, DOI 10.1002/jcb.10593; Sawada M, 1999, J NEUROCHEM, V72, P1466, DOI 10.1046/j.1471-4159.1999.721466.x; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Seifman MA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00237; SEMENZATO G, 1990, BRIT J CANCER, V61, P354, DOI 10.1038/bjc.1990.78; Shebl FM, 2010, CANCER EPIDEM BIOMAR, V19, P978, DOI 10.1158/1055-9965.EPI-10-0064; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Siepmann T, 2015, BRAIN BEHAV, V5, DOI 10.1002/brb3.373; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Sodhi MSK, 2004, INT REV NEUROBIOL, V59, P111; Stein DM, 2011, J TRAUMA, V70, P1096, DOI 10.1097/TA.0b013e318216930d; Streit WJ, 2002, E SCHERING RES FDN W, V39, P11; Sullivan PG, 1999, J NEUROSCI, V19, P6248; SUSEL Z, 1991, NEUROSCI LETT, V121, P234, DOI 10.1016/0304-3940(91)90693-N; Suzuki T, 2004, J NEUROSCI, V24, P1, DOI 10.1523/JNEUROSCI.3792-03.2004; Tang LL, 2011, NEUROL RES, V33, P1064, DOI 10.1179/016164110X12700393823651; Trakhtenberg EF, 2012, INT REV NEUROBIOL, V106, P105, DOI 10.1016/B978-0-12-407178-0.00005-3; Tsuchiyama R, 2010, ACTA NEUROCHIR SUPPL, V106, P155, DOI 10.1007/978-3-211-98811-4_28; Vahidy FS, 2016, J CEREBR BLOOD F MET, V36, P1012, DOI 10.1177/0271678X15607880; Vasquez-Vivar J, 2017, REDOX BIOL, V13, P594, DOI 10.1016/j.redox.2017.08.002; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williamson LM, 2002, J EPIDEMIOL COMMUN H, V56, P285, DOI 10.1136/jech.56.4.285; Wu HJ, 2016, J PINEAL RES, V61, P241, DOI 10.1111/jpi.12344; Yan EB, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0328-2; Yue JK, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7080093; Zhang Z, 2015, J NEUROTRAUM, V32, P1369, DOI 10.1089/neu.2014.3701; Zunszain PA, 2012, NEUROPSYCHOPHARMACOL, V37, P939, DOI 10.1038/npp.2011.277	120	14	14	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2019	36	1					74	86		10.1089/neu.2017.5450		SEP 2018	13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HF0PB	WOS:000444269100001	30019623				2021-06-18	
J	Nencka, AS; Meier, TB; Wang, Y; Muftuler, LT; Wu, YC; Saykin, AJ; Harezlak, J; Brooks, MA; Giza, CC; Difiori, J; Guskiewicz, KM; Mihalik, JP; LaConte, SM; Duma, SM; Broglio, S; McAllister, T; McCrea, MA; Koch, KM				Nencka, Andrew S.; Meier, Timothy B.; Wang, Yang; Muftuler, L. Tugan; Wu, Yu-Chien; Saykin, Andrew J.; Harezlak, Jaroslaw; Brooks, M. Alison; Giza, Christopher C.; Difiori, John; Guskiewicz, Kevin M.; Mihalik, Jason P.; LaConte, Stephen M.; Duma, Stefan M.; Broglio, Steven; McAllister, Thomas; McCrea, Michael A.; Koch, Kevin M.			Stability of MRI metrics in the advanced research core of the NCAA-DoD concussion assessment, research and education (CARE) consortium	BRAIN IMAGING AND BEHAVIOR			English	Article						MRI; Stability; Reproducibility; Quantitative imaging; Concussion; mTBI	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; COLLEGIATE FOOTBALL PLAYERS; SPORT-RELATED CONCUSSION; TENSOR IMAGING FINDINGS; DIFFUSION TENSOR; INTERNATIONAL-CONFERENCE; RELAXATION-TIMES; WHITE-MATTER; RECOVERY	The NCAA-DoD Concussion Assessment, Research, and Education (CARE) consortium is performing a large-scale, comprehensive study of sport related concussions in college student-athletes and military service academy cadets. The CARE "Advanced Research Core" (ARC), is focused on executing a cutting-edge investigative protocol on a subset of the overall CARE athlete population. Here, we present the details of the CARE ARC MRI acquisition and processing protocol along with preliminary analyzes of within-subject, between-site, and between-subject stability across a variety of MRI biomarkers. Two experimental datasets were utilized for this analysis. First, two "human phantom" subjects were imaged multiple times at each of the four CARE ARC imaging sites, which utilize equipment from two imaging vendors. Additionally, a control cohort of healthy athletes participating in non-contact sports were enrolled in the study at each CARE ARC site and imaged at four time points. Multiple morphological image contrasts were acquired in each MRI exam; along with quantitative diffusion, functional, perfusion, and relaxometry imaging metrics. As expected, the imaging markers were found to have varying levels of stability throughout the brain. Importantly, between-subject variance was generally found to be greater than within-subject and between-site variance. These results lend support to the expectation that cross-site and cross-vendor advanced quantitative MRI metrics can be utilized to improve analytic power in assessing sensitive neurological variations; such as those effects hypothesized to occur in sports-related-concussion. This stability analysis provides a crucial foundation for further work utilizing this expansive dataset, which will ultimately be freely available through the Federal Interagency Traumatic Brain Injury Research Informatics System.	[Nencka, Andrew S.; Wang, Yang; Koch, Kevin M.] Med Coll Wisconsin, Dept Radiol, 8700 W Wisconsin Ave, Milwaukee, WI 53226 USA; [Meier, Timothy B.; Muftuler, L. Tugan; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Wu, Yu-Chien; Saykin, Andrew J.] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Indianapolis, IN 46202 USA; [Harezlak, Jaroslaw] Indiana Univ, Dept Epidemiol & Biostat, Bloomington, IN USA; [Brooks, M. Alison] Univ Wisconsin, Sch Med & Publ Hlth, Dept Orthoped & Rehabil, Madison, WI USA; [Giza, Christopher C.] Univ Calif Los Angeles, Steve Tisch BrainSPORT Program, Dept Pediat & Neurosurg, Los Angeles, CA USA; [Difiori, John] Univ Calif Los Angeles, Dept Orthoped, Los Angeles, CA USA; [Guskiewicz, Kevin M.; Mihalik, Jason P.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [LaConte, Stephen M.] Virginia Tech, Carilon Res Inst, Blacksburg, VA USA; [Duma, Stefan M.] Virginia Tech, Inst Crit Technol & Appl Sci, Blacksburg, VA USA; [Broglio, Steven] Univ Michigan, Dept Kinesiol, Ann Arbor, MI 48109 USA; [McAllister, Thomas] Indiana Univ Sch Med, Dept Psychiat, Bloomington, IN USA	Nencka, AS (corresponding author), Med Coll Wisconsin, Dept Radiol, 8700 W Wisconsin Ave, Milwaukee, WI 53226 USA.	anencka@mcw.edu	Muftuler, L. Tugan/AAG-7539-2021; Koch, Kevin/AAD-6403-2021; Saykin, Andrew/A-1318-2007; Harezlak, Jaroslaw/P-8557-2014	Wu, Yu-Chien/0000-0003-1084-2634; Saykin, Andrew/0000-0002-1376-8532; Muftuler, L. Tugan/0000-0002-6635-5678; Harezlak, Jaroslaw/0000-0002-3070-7686	Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium; National Collegiate Athletic Association (NCAA); Department of Defense (DOD)United States Department of Defense; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG053993, P30AG010133] Funding Source: NIH RePORTER	This project was funded with support from the Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium, funded, in part by the National Collegiate Athletic Association (NCAA) and the Department of Defense (DOD). The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award NO W81XWH-14-2-0151. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense (DHP funds). The authors would like to thank Jenelle E. Fuller, Haley M. Cilliers, Martha Garcia, Sara John, Nana Asiedu, Liga Blyholder, Mike Powers, Morgan Shields, Briana Meyer, Sonal Singh, Zoey Wang, Mania Alexandria, Max Zeiger, Alma Martinez, Douglas Chan, Brennan Delattre, Jonathan Lisinski, Christopher Anzalone, Amber Leinwand, April 'Nikki' Jennings, Sharon Bryan, Victor Wright, Jennifer Franco, Issack Boru, Corey Rodrigo, Parker Traugot, Grant Cabell, Erin Grand, Aliza Nedimyer, and Tricia Combs for data acquisition and Brad Swearingen, Lezlie Espana, and Robin Karr for algorithm support.	Andersson JLR, 2016, NEUROIMAGE, V125, P1063, DOI 10.1016/j.neuroimage.2015.10.019; Andersson JLR, 2003, NEUROIMAGE, V20, P870, DOI 10.1016/S1053-8119(03)00336-7; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Chen YF, 2011, J MAGN RESON IMAGING, V33, P940, DOI 10.1002/jmri.22345; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Friedman L, 2006, NEUROIMAGE, V32, P1656, DOI 10.1016/j.neuroimage.2006.03.062; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Jarrett M, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00011; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; JUST M, 1988, RADIOLOGY, V169, P779, DOI 10.1148/radiology.169.3.3187000; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Lancaster MA, 2016, HUM BRAIN MAPP, V37, P3821, DOI 10.1002/hbm.23278; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liu W, 2016, RADIOLOGY, V278, P536, DOI 10.1148/radiol.2015150160; Lu HZ, 2006, NMR BIOMED, V19, P236, DOI 10.1002/nbm.1020; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; Mazziotta J, 2001, J AM MED INFORM ASSN, V8, P401, DOI 10.1136/jamia.2001.0080401; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Mori S., 2005, MRI ATLAS HUMAN WHIT; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; Palacios E.M., 2016, AM J NEURORADIOLOGY; Penny W.D., 2011, STAT PARAMETRIC MAPP; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Stevenson VL, 2000, J NEUROL SCI, V178, P81, DOI 10.1016/S0022-510X(00)00339-7; Tan CO, 2014, NEUROLOGY, V83, P1665, DOI 10.1212/WNL.0000000000000944; Vidorreta M, 2013, NEUROIMAGE, V66, P662, DOI 10.1016/j.neuroimage.2012.10.087; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072; Wansapura JP, 1999, JMRI-J MAGN RESON IM, V9, P531, DOI 10.1002/(SICI)1522-2586(199904)9:4<531::AID-JMRI4>3.0.CO;2-L; Wu WC, 2007, MAGN RESON MED, V58, P1020, DOI 10.1002/mrm.21403; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Zang YF, 2004, NEUROIMAGE, V22, P394, DOI 10.1016/j.neuroimage.2003.12.030; Zou QH, 2008, J NEUROSCI METH, V172, P137, DOI 10.1016/j.jneumeth.2008.04.012	49	14	14	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	AUG	2018	12	4					1121	1140		10.1007/s11682-017-9775-y			20	Neuroimaging	Neurosciences & Neurology	GO6HY	WOS:000440141800017	29064019	Green Accepted			2021-06-18	
J	Seal, KH; Bertenthal, D; Barnes, DE; Byers, AL; Gibson, CJ; Rife, TL; Yaffe, K				Seal, Karen H.; Bertenthal, Daniel; Barnes, Deborah E.; Byers, Amy L.; Gibson, Carolyn J.; Rife, Tessa L.; Yaffe, Kristine		Chronic Effects Neurotrauma Consor	Traumatic Brain Injury and Receipt of Prescription Opioid Therapy for Chronic Pain in Iraq and Afghanistan Veterans: Do Clinical Practice Guidelines Matter?	JOURNAL OF PAIN			English	Article						Traumatic brain injury; chronic pain; opioids; veterans; post-traumatic stress disorder	CHRONIC NONCANCER PAIN; POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH DISORDERS; SUBSTANCE USE; PRIMARY-CARE; LONG-TERM; US VETERANS; ASSOCIATION; RISK; PREVALENCE	Clinical practice guidelines admonish against prescribing opioids for individuals with chronic pain and traumatic brain injury (TBI) because of increased risk for adverse outcomes, yet no studies have described opioid prescribing patterns in these higher-risk patients. Between October 2007 and March 2015, 53,124 Iraq and Afghanistan veterans with chronic pain not prescribed opioids in the previous year were followed for 1 year after completing a Comprehensive TBI Evaluation within the Department of Veterans Affairs health care facilities. Veterans reporting the most severe TBI sequelae (eg, loss of consciousness >30 minutes) were significantly more likely to receive short-term and long-term opioid therapy than those with less severe or no TBI sequelae (P values < .001). In analyses adjusted for sociodemographic characteristics, military service, pain disability, and previous nonopioid treatment modalities, veterans with moderate to severe TBI had a significantly increased risk of receiving opioid therapy. Veterans with moderate to severe TBI and comorbid post-traumatic stress disorder and depression had an even greater risk of initiating long-term opioid therapy in the year after the Comprehensive TBI Evaluation (adjusted relative risk = 3.57 [95% confidence interval = 2.85-4.47]). Higher risk patients with chronic pain and TBI with mental health comorbidities may benefit from improved access to behavioral health and nonpharmacological therapies for chronic pain. Perspective: Paradoxically, veterans with greater TBI severity and comorbid mental health burden are more likely to be prescribed opioids for chronic pain. More vulnerable veterans may benefit from improved access to behavioral health and nonpharmacological modalities for chronic pain, because of the health and safety risks of opioids. (C) Published by Elsevier Inc. on behalf of the American Pain Society	[Seal, Karen H.; Bertenthal, Daniel; Barnes, Deborah E.; Byers, Amy L.; Gibson, Carolyn J.; Rife, Tessa L.; Yaffe, Kristine] San Francisco Vet Affairs Hlth Care Syst, San Francisco, CA USA; [Seal, Karen H.; Barnes, Deborah E.; Byers, Amy L.; Gibson, Carolyn J.; Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA	Seal, KH (corresponding author), Univ Calif San Francisco, San Francisco VA Hlth Care Syst, Dept Med, 4150 Clement St,Box 116-A, San Francisco, CA 94121 USA.; Seal, KH (corresponding author), Univ Calif San Francisco, San Francisco VA Hlth Care Syst, Dept Psychiat, 4150 Clement St,Box 116-A, San Francisco, CA 94121 USA.	Karen.Seal@va.gov		Rife, Tessa/0000-0002-5397-3012	U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC); U.S. Department of Veterans Affairs Chronic Effects of Neurotrauma Consortium [W81XWH-13-2-0095]	This work was supported by the U.S. Army Medical Research and Materiel Command and the U.S. Department of Veterans Affairs Chronic Effects of Neurotrauma Consortium under award number W81XWH-13-2-0095.	Anderson Daren, 2012, Qual Prim Care, V20, P421; Barry DT, 2015, PSYCHIAT RES, V227, P324, DOI 10.1016/j.psychres.2015.03.006; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Center for Disease Control and Prevention, 2016, WID RANG ONL DAT EP; Chang JS, 2017, SUBST USE MISUSE, V52, P251, DOI 10.1080/10826084.2016.1223138; Chaparro LE, 2014, SPINE, V39, P556, DOI 10.1097/BRS.0000000000000249; Department of Veterans Affairs and the Department of Defense, 2017, MAN OP THER OT CHRON; Department of Veterans Affairs Department of Defense, 2009, VA DOD CLIN PRACT GU; Dobscha SK, 2013, CLIN J PAIN, V29, P102, DOI 10.1097/AJP.0b013e3182490bdb; Edlund MJ, 2010, CLIN J PAIN, V26, P1, DOI 10.1097/AJP.0b013e3181b99f35; Frayne SM, 2005, ARCH INTERN MED, V165, P2631, DOI 10.1001/archinte.165.22.2631; Golub A, 2013, SUBST USE MISUSE, V48, P811, DOI 10.3109/10826084.2013.796988; Griffin ML, 2015, AM J ADDICTION, V24, P308, DOI 10.1111/ajad.12188; Gruber SA, 2007, NEUROPSYCHOL REV, V17, P299, DOI 10.1007/s11065-007-9041-y; Hawkins EJ, 2015, PAIN MED, V16, P1943, DOI 10.1111/pme.12787; Hendricks AM, 2013, BRAIN INJURY, V27, P125, DOI 10.3109/02699052.2012.729284; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hudson TJ, 2017, PAIN, V158, P1039, DOI 10.1097/j.pain.0000000000000874; Ilie G, 2015, J NEUROTRAUM, V32, P1130, DOI 10.1089/neu.2014.3619; Im JJ, 2015, J GEN INTERN MED, V30, P979, DOI 10.1007/s11606-015-3220-y; Jamison Robert N, 2014, J Opioid Manag, V10, P375, DOI 10.5055/jom.2014.0234; Kerns RD, 2003, J REHABIL RES DEV, V40, P371, DOI 10.1682/JRRD.2003.09.0371; Krebs EE, 2014, J PAIN, V15, P1148, DOI 10.1016/j.jpain.2014.08.006; LeResche L, 2015, J WOMENS HEALTH, V24, P629, DOI 10.1089/jwh.2015.5222; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lin LWA, 2017, PAIN, V158, P833, DOI 10.1097/j.pain.0000000000000837; Mathew N, 2016, COMMUNITY MENT HLT J, V52, P165, DOI 10.1007/s10597-015-9939-4; Matthias MS, 2010, PAIN MED, V11, P1688, DOI 10.1111/j.1526-4637.2010.00980.x; Morasco BJ, 2014, PAIN MED, V15, P1902, DOI 10.1111/pme.12472; Morasco BJ, 2013, DRUG ALCOHOL DEPEN, V127, P193, DOI 10.1016/j.drugalcdep.2012.06.032; Morasco BJ, 2010, PAIN, V151, P625, DOI 10.1016/j.pain.2010.08.002; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Outcalt SD, 2014, J REHABIL RES DEV, V51, P559, DOI 10.1682/JRRD.2013.06.0134; Ramirez S, 2017, AM J THER, V24, pE150, DOI 10.1097/MJT.0000000000000141; Reinecke H, 2015, BRIT J PHARMACOL, V172, P324, DOI 10.1111/bph.12634; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Salas J, 2017, PAIN, V158, P306, DOI 10.1097/j.pain.0000000000000763; Scherrer JF, 2016, J PAIN, V17, P473, DOI 10.1016/j.jpain.2015.12.012; Seal K, 2017, J GEN INTERN MED, V32, P931, DOI 10.1007/s11606-017-4047-5; Seal KH, 2012, JAMA-J AM MED ASSOC, V307, P940, DOI 10.1001/jama.2012.234; Sullivan MD, 2006, ARCH INTERN MED, V166, P2087, DOI 10.1001/archinte.166.19.2087; Sullivan MD, 2010, PAIN, V151, P567, DOI 10.1016/j.pain.2010.08.036; Sullivan MD, 2006, J GEN INTERN MED, V21, P360, DOI 10.1111/j.1525-1497.2006.00352.x; Trafton J, 2010, PAIN MED, V11, P575, DOI 10.1111/j.1526-4637.2010.00818.x	44	14	14	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	AUG	2018	19	8					931	941		10.1016/j.jpain.2018.03.005			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	GP9GZ	WOS:000441226800010	29597083				2021-06-18	
J	Bird, CW; Taylor, DH; Pinkowski, NJ; Chavez, GJ; Valenzuela, CF				Bird, Clark W.; Taylor, Devin H.; Pinkowski, Natalie J.; Chavez, G. Jill; Valenzuela, C. Fernando			Long-term Reductions in the Population of GABAergic Interneurons in the Mouse Hippocampus following Developmental Ethanol Exposure	NEUROSCIENCE			English	Article						interneuron; hippocampus; apoptosis; fetal; alcohol; development	PRENATAL ALCOHOL EXPOSURE; TRAUMATIC BRAIN-INJURY; SPECTRUM DISORDERS; DENTATE GYRUS; EXCITATORY ACTIONS; NEURONAL NETWORKS; FETAL; CHILDREN; GABA; MEMORY	Developmental exposure to ethanol leads to a constellation of cognitive and behavioral abnormalities known as Fetal Alcohol Spectrum Disorders (FASDs). Many cell types throughout the central nervous system are negatively impacted by gestational alcohol exposure, including inhibitory, GABAergic interneurons. Little evidence exists, however, describing the long-term impact of fetal alcohol exposure on survival of interneurons within the hippocampal formation, which is critical for learning and memory processes that are impaired in individuals with FASDs. Mice expressing Venus yellow fluorescent protein in inhibitory interneurons were exposed to vaporized ethanol during the third trimester equivalent of human gestation (postnatal days 2-9), and the longterm effects on interneuron numbers were measured using unbiased stereology at P90. In adulthood, interneuron populations were reduced in every hippocampal region examined. Moreover, we found that a single exposure to ethanol at P7 caused robust activation of apoptotic neurodegeneration of interneurons in the hilus, granule cell layer, CA1 and CA3 regions of the hippocampus. These studies demonstrate that developmental ethanol exposure has a long-term impact on hippocampal interneuron survivability, and may provide a mechanism partially explaining deficits in hippocampal function and hippocampus-dependent behaviors in those afflicted with FASDs. (C) 2018 IBRO. Published by Elsevier Ltd. All rights reserved.	[Bird, Clark W.; Taylor, Devin H.; Pinkowski, Natalie J.; Chavez, G. Jill; Valenzuela, C. Fernando] Univ New Mexico, Sch Med, Dept Neurosci, Hlth Sci Ctr, Albuquerque, NM 87131 USA	Valenzuela, CF (corresponding author), Dept Neurosci, MSC08 4740,1 Univ New Mexico, Albuquerque, NM 87131 USA.	fvalenzuela@salud.unm.edu		Bird, Clark/0000-0001-7712-6531	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R37-AA015614, P50-AA0022534]; UNM's Undergraduate Pipeline Network; University of New Mexico & Cancer Center Fluorescence Microscopy Shared Resource; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [P50AA022534, R37AA015614] Funding Source: NIH RePORTER	Supported by NIH grants R37-AA015614 and P50-AA0022534 (CFV), as well as UNM's Undergraduate Pipeline Network (NJP). Unbiased stereology and fluorescence microscopy was carried out at the University of New Mexico & Cancer Center Fluorescence Microscopy Shared Resource, funded as detailed on: http://hsc.unm.edu/crtc/microscopy/acknowledgement.shtml. We thank Dr. Yuchio Yanagawa at the Department of Genetic and Behavioral Neuroscience at the Gunma University School of Medicine (Maebashi, Japan) for generously providing Venus-VGAT mice.	ANDRADE JP, 1992, HIPPOCAMPUS, V2, P65, DOI 10.1002/hipo.450020109; Andrews-Zwilling Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040555; AUTTIRAMO I, 1991, NEUROPEDIATRICS, V22, P59, DOI 10.1055/s-2008-1071418; Ben-Ari Y, 2014, NEUROSCIENCE, V279, P187, DOI 10.1016/j.neuroscience.2014.08.001; Ben-Ari Y, 2012, NEUROSCIENTIST, V18, P467, DOI 10.1177/1073858412438697; Bering R, 1997, EXP BRAIN RES, V115, P423, DOI 10.1007/PL00005712; Berman RE, 2000, HIPPOCAMPUS, V10, P94, DOI 10.1002/(SICI)1098-1063(2000)10:1<94::AID-HIPO11>3.0.CO;2-T; Bird CW, 2017, BEHAV BRAIN RES, V320, P1, DOI 10.1016/j.bbr.2016.11.036; Cellot G, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00136; Chasnoff IJ, 2010, J DEV BEHAV PEDIATR, V31, P192, DOI 10.1097/DBP.0b013e3181d5a4e2; Chi P, 2016, BEHAV BRAIN RES, V305, P1, DOI 10.1016/j.bbr.2015.12.040; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cumming G., 2012, UNDERSTANDING NEW ST; D'Amelio M, 2010, CELL DEATH DIFFER, V17, P1104, DOI 10.1038/cdd.2009.180; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Erturk A, 2014, J NEUROSCI, V34, P1672, DOI 10.1523/JNEUROSCI.3121-13.2014; Ethen M, 2009, MATERN CHILD HLTH J, V13, P274, DOI 10.1007/s10995-008-0328-2; FREEDMAN R, 1993, J NEUROSCI, V13, P1965; Galindo R, 2005, J NEUROCHEM, V94, P1500, DOI 10.1111/j.1471-4159.2005.03294.x; Galindo R, 2006, ALCOHOL, V40, P111, DOI 10.1016/j.alcohol.2006.11.001; Gulyaeva NV, 2003, J NEUROSCI RES, V73, P853, DOI 10.1002/jnr.10730; Gundersen HJG, 1999, J MICROSC-OXFORD, V193, P199, DOI 10.1046/j.1365-2818.1999.00457.x; Hamilton DA, 2003, BEHAV BRAIN RES, V143, P85, DOI 10.1016/S0166-4328(03)00028-7; Hamilton GF, 2011, BRAIN RES, V1412, P88, DOI 10.1016/j.brainres.2011.07.027; Hedges L.V., 1985, STAT METHODS META AN; Hellemans KGC, 2010, ALCOHOL CLIN EXP RES, V34, P633, DOI 10.1111/j.1530-0277.2009.01132.x; Hochreiter-Hufford A, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008748; Huesmann GR, 2006, NEURON, V52, P1061, DOI 10.1016/j.neuron.2006.10.033; Ikonomidou C, 2000, SCIENCE, V287, P1056, DOI 10.1126/science.287.5455.1056; JOHANSEN FF, 1993, ACTA NEUROL SCAND, V88, P1; Kajimoto K, 2016, HIPPOCAMPUS, V26, P1078, DOI 10.1002/hipo.22588; Kajimoto K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073788; Klintsova AY, 2007, ALCOHOL CLIN EXP RES, V31, P2073, DOI 10.1111/j.1530-0277.2007.00528.x; Kodituwakku PW, 2007, NEUROSCI BIOBEHAV R, V31, P192, DOI 10.1016/j.neubiorev.2006.06.020; Kullmann DM, 2011, CURR OPIN NEUROBIOL, V21, P709, DOI 10.1016/j.conb.2011.05.006; Lakens D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00863; Le Magueresse C, 2013, NEURON, V77, P388, DOI 10.1016/j.neuron.2013.01.011; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lubke J, 1998, J NEUROPHYSIOL, V79, P1518, DOI 10.1152/jn.1998.79.3.1518; Maccaferri G, 2003, TRENDS NEUROSCI, V26, P564, DOI 10.1016/j.tins.2003.08.002; Mattson SN, 2013, ALCOHOL CLIN EXP RES, V37, P517, DOI 10.1111/j.1530-0277.2012.01952.x; Mattson SN, 1996, ALCOHOL CLIN EXP RES, V20, P810, DOI 10.1111/j.1530-0277.1996.tb05256.x; Mattson SN, 1999, J INT NEUROPSYCH SOC, V5, P462, DOI 10.1017/S1355617799555082; May PA, 2014, PEDIATRICS, V134, P855, DOI 10.1542/peds.2013-3319; Miguez HA, 2009, ACTA PSIQUIAT PSICOL, V55, P76; Miki T, 2000, HIPPOCAMPUS, V10, P284, DOI 10.1002/1098-1063(2000)10:3<284::AID-HIPO9>3.0.CO;2-K; Miller MW, 2006, NEUROSCIENCE, V138, P97, DOI 10.1016/j.neuroscience.2005.10.060; Moore DB, 1998, NEUROSCI LETT, V249, P25, DOI 10.1016/S0304-3940(98)00378-4; Moreno MC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180873; Morton RA, 2014, JOVE-J VIS EXP, DOI 10.3791/51839; Muller Christina, 2014, Front Synaptic Neurosci, V6, P23, DOI 10.3389/fnsyn.2014.00023; Myers CE, 2009, HIPPOCAMPUS, V19, P321, DOI 10.1002/hipo.20516; Thanh NX, 2014, J POPUL THER CLIN PH, V21, pE395; Nirgudkar P, 2016, NEUROSCI LETT, V632, P86, DOI 10.1016/j.neulet.2016.08.039; Noor S, 2017, BRAIN BEHAV IMMUN, V61, P80, DOI 10.1016/j.bbi.2016.12.016; Ogievetsky E, 2017, BIONANOSCIENCE, V7, P151, DOI 10.1007/s12668-016-0334-6; Ognjanovski N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15039; OLBRICH HG, 1985, ANAT EMBRYOL, V173, P105, DOI 10.1007/BF00707308; Olney JW, 2002, NEUROBIOL DIS, V9, P205, DOI 10.1006/nbdi.2001.0475; Paxinos G., 2013, PAXINOS FRANKLINS MO, V4th; Preibisch S, 2009, BIOINFORMATICS, V25, P1463, DOI 10.1093/bioinformatics/btp184; Ribak CE, 2007, PROG BRAIN RES, V163, P155, DOI 10.1016/S0079-6123(07)63009-X; Riley EP, 2011, NEUROPSYCHOL REV, V21, P73, DOI 10.1007/s11065-011-9166-x; Rodriguez CI, 2016, ALCOHOL CLIN EXP RES, V40, P2134, DOI 10.1111/acer.13175; Rodriguez CI, 2016, BEHAV BRAIN RES; Sadrian B, 2014, NEUROSCIENCE, V280, P204, DOI 10.1016/j.neuroscience.2014.09.008; Savanthrapadian S, 2014, J NEUROSCI, V34, P8197, DOI 10.1523/JNEUROSCI.5433-13.2014; Schiavone S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09202-4; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Shetty AK, 2001, EXP NEUROL, V169, P276, DOI 10.1006/exnr.2001.7668; Shetty AK, 2009, J CELL MOL MED, V13, P2408, DOI 10.1111/j.1582-4934.2009.00675.x; Simmons RW, 2010, ALCOHOL, V44, P371, DOI 10.1016/j.alcohol.2010.02.013; Smiley JF, 2015, ALCOHOL, V49, P571, DOI 10.1016/j.alcohol.2015.04.008; Staples MC, 2015, MOL CELL NEUROSCI, V65, P153, DOI 10.1016/j.mcn.2015.03.008; Stepanichev MY, 2005, NEUROSCIENCE, V136, P579, DOI 10.1016/j.neuroscience.2005.08.010; Topper LA, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0382-9; Tunc-Ozcan E, 2017, MOL PSYCHIAT; Uecker A, 1998, AM J MENT RETARD, V103, P12, DOI 10.1352/0895-8017(1998)103<0012:SBNOMI>2.0.CO;2; Uecker A, 1996, NEUROPSYCHOLOGIA, V34, P209, DOI 10.1016/0028-3932(95)00096-8; Valeeva G, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00020; Varaschin RK, 2010, J PHARMACOL EXP THER, V334, P191, DOI 10.1124/jpet.109.165027; Varlinskaya EI, 2014, BEHAV BRAIN RES, V261, P106, DOI 10.1016/j.bbr.2013.12.016; Viollet C, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00131; Wang Y, 2009, NEUROSCIENCE, V164, P1031, DOI 10.1016/j.neuroscience.2009.09.010; WEST JR, 1987, ALCOHOL DRUG RES, V7, P423; Wilson DA, 2011, ALCOHOL CLIN EXP RES, V35, P1974, DOI 10.1111/j.1530-0277.2011.01549.x; Wu JY, 1997, PEPTIDES, V18, P1131, DOI 10.1016/S0196-9781(97)00146-0	89	14	14	3	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUL 15	2018	383						60	73		10.1016/j.neuroscience.2018.05.003			14	Neurosciences	Neurosciences & Neurology	GI7RO	WOS:000434699900006	29753864	Green Accepted			2021-06-18	
J	Allen, RS; Motz, CT; Feola, A; Chesler, KC; Haider, R; Rao, SR; Skelton, LA; Fliesler, SJ; Pardue, MT				Allen, Rachael S.; Motz, Cara T.; Feola, Andrew; Chesler, Kyle C.; Haider, Raza; Rao, Sriganesh Ramachandra; Skelton, Lara A.; Fliesler, Steven J.; Pardue, Machelle T.			Long-Term Functional and Structural Consequences of Primary Blast Overpressure to the Eye	JOURNAL OF NEUROTRAUMA			English	Article						blast; electroretinogram; optomotor response; retina; visual function	TRAUMATIC BRAIN-INJURY; INDUCED OCULAR TRAUMA; FIBRILLARY ACIDIC PROTEIN; VISUAL FUNCTION; MOUSE MODEL; PROGESTERONE TREATMENT; RETINAL INJURY; DYSFUNCTION; ELECTRORETINOGRAM; DAMAGE	Acoustic blast overpressure (ABO) injury in military personnel and civilians is often accompanied by delayed visual deficits. However, most animal model studies dealing with blast-induced visual defects have focused on short-term (1 month) changes. Here, we evaluated long-term (8 months) retinal structure and function deficits in rats with ABO injury. Adult male Long-Evans rats were subjected to ABO from a single blast (approximately 190 dB SPL, approximate to 63kPa, @80 psi), generated by a shock tube device. Retinal function (electroretinography; ERG), visual function (optomotor response), retinal thickness (spectral domain-optical coherence tomography; SD-OCT), and spatial cognition/exploratory motor behavior (Y-maze) were measured at 2, 4, 6, and 8 months post-blast. Immunohistochemical analysis of glial fibrillary acidic protein (GFAP) in retinal sections was performed at 8 months post-blast. Electroretinogram a- and b-waves, oscillatory potentials, and flicker responses showed greater amplitudes with delayed implicit times in both eyes of blast-exposed animals, relative to controls. Contrast sensitivity (CS) was reduced in both eyes of blast-exposed animals, whereas spatial frequency (SF) was decreased only in ipsilateral eyes, relative to controls. Total retinal thickness was greater in both eyes of blast-exposed animals, relative to controls, due to increased thickness of several retinal layers. Age, but not blast exposure, altered Y-maze outcomes. GFAP was greatly increased in blast-exposed retinas. ABO exposure resulted in visual and retinal changes that persisted up to 8 months post-blast, mimicking some of the visual deficits observed in human blast-exposed patients, thereby making this a useful model to study mechanisms of injury and potential treatments.	[Allen, Rachael S.; Motz, Cara T.; Feola, Andrew; Haider, Raza; Pardue, Machelle T.] Atlanta VA Med Ctr, Ctr Visual & Neurocognit Rehabil, Atlanta, GA USA; [Allen, Rachael S.; Feola, Andrew; Chesler, Kyle C.; Pardue, Machelle T.] Georgia Inst Technol, Biomed Engn, Atlanta, GA 30332 USA; [Rao, Sriganesh Ramachandra; Fliesler, Steven J.] SUNY Univ Buffalo, Ophthalmol Biochem & Neurosci Program, Buffalo, NY USA; [Skelton, Lara A.; Fliesler, Steven J.] VA Western NY Healthcare Syst, Res Serv, Buffalo, NY USA	Pardue, MT (corresponding author), Atlanta VA Ctr Visual & Neurocognit Rehabil, Res Serv Oph 151, 1670 Clairmont Rd, Decatur, GA 30033 USA.	machelle.pardue@bme.gatech.edu	Fliesler, Steven J./AAE-9243-2020; Feola, Andrew/ABC-3476-2020	Feola, Andrew/0000-0002-7914-989X	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 EY006360]; NCATS Clinical and Translational Science Award [1UL1 TR001358]; Department of Veterans Affairs (BLR&D Service Merit Award)US Department of Veterans Affairs [1I01 BX002439]; BLR&D Service Research Career Scientist Award; RR&D Service Research Career Scientist Award [C9257]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30EY006360] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [IK1RX002111, I01BX002439] Funding Source: NIH RePORTER	This work was supported, in part, by grants from the National Institutes of Health (NIH) (P30 EY006360 to Emory University [MTP], and NCATS Clinical and Translational Science Award 1UL1 TR001358 to the University at Buffalo [SJF]), and from the Department of Veterans Affairs (BLR&D Service Merit Award 1I01 BX002439 [SJF& BLR&D Service Research Career Scientist Award [SJF]; and RR&D Service Research Career Scientist Award [C9257; MTP]).	Allen RS, 2016, RESTOR NEUROL NEUROS, V34, P947, DOI 10.3233/RNN-160672; Allen RS, 2015, INVEST OPHTH VIS SCI, V56, P2880, DOI 10.1167/iovs.14-16070; Almeida-Suhett CP, 2015, EXP NEUROL, V273, P11, DOI 10.1016/j.expneurol.2015.07.028; Almeida-Suhett CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102627; Aung MH, 2013, INVEST OPHTH VIS SCI, V54, P1370, DOI 10.1167/iovs.12-10927; Balcer LJ, 2010, NEUROLOGY, V74, pS16, DOI 10.1212/WNL.0b013e3181dbb664; Behrend K, 2007, VISUAL NEUROSCI, V24, P787, DOI 10.1017/S0952523807070691; Bricker-Anthony C, 2017, OPTOMETRY VISION SCI, V94, P20, DOI 10.1097/OPX.0000000000000898; Bricker-Anthony C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131921; Bricker-Anthony C, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0192-5; Bricker-Anthony C, 2014, INVEST OPHTH VIS SCI, V55, P4853, DOI 10.1167/iovs.14-14353; Chang B, 2007, VISION RES, V47, P624, DOI 10.1016/j.visres.2006.11.020; Choi JH, 2015, CLIN EXP OPHTHALMOL, V43, P239, DOI 10.1111/ceo.12407; Cockerham GC, 2011, NEW ENGL J MED, V364, P2172, DOI 10.1056/NEJMc1010683; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Coe CD, 2010, OPTOMETRY VISION SCI, V87, P604, DOI 10.1097/OPX.0b013e3181e61bc0; Cunha-Vaz J, 2017, OPHTHALMOLOGICA, V237, P1, DOI 10.1159/000455809; Daneshvar DH, 2015, MOL CELL NEUROSCI, V66, P81, DOI 10.1016/j.mcn.2015.03.007; Defense and Veterans Brain Injury Center, DOD WORLDW NUMB TBI; del Mar N, 2015, EXP NEUROL, V271, P53, DOI 10.1016/j.expneurol.2015.04.023; DeMar J, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00059; Douglas RM, 2005, VISUAL NEUROSCI, V22, P677, DOI 10.1017/S0952523805225166; Dutca LM, 2014, INVEST OPHTH VIS SCI, V55, P8330, DOI 10.1167/iovs.14-15468; Eggers ED, 2006, J PHYSIOL-LONDON, V572, P215, DOI 10.1113/jphysiol.2005.103648; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Fernandez-Bueno I, 2017, INVEST OPHTH VIS SCI, V58, P4925, DOI 10.1167/iovs.17-21742; Emberti Gialloreti L, 2014, J AUTISM DEV DISORD, V44, P873, DOI 10.1007/s10803-013-1939-z; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Goodrich GL, 2014, J REHABIL RES DEV, V51, P547, DOI 10.1682/JRRD.2013.02.0049; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Goodrich JA, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0395-3; Guerriero RM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0545-1; Guley N.M., 2016, THESIS; Guley NH, 2016, J NEUROTRAUM, V33, P403, DOI 10.1089/neu.2015.3886; Haan M, 2012, NEUROLOGY, V78, P942, DOI 10.1212/WNL.0b013e31824d9655; Hart S, 2013, INVEST OPHTH VIS SCI, V54; Hernandez-Ramirez E, 2017, CELL PHYSIOL BIOCHEM, V42, P2353, DOI 10.1159/000480007; HEYWOD CA, 1988, EXP BRAIN RES, V70, P513; Hines-Beard J, 2012, EXP EYE RES, V99, P63, DOI 10.1016/j.exer.2012.03.013; JENKINS TCA, 1990, BRIT J OPHTHALMOL, V74, P681, DOI 10.1136/bjo.74.11.681; Jiang YD, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-96; Jones K, 2016, J NEUROTRAUM, V33, P1194, DOI 10.1089/neu.2015.4022; Kallakuri S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169239; KAPLAN E, 1986, P NATL ACAD SCI USA, V83, P2755, DOI 10.1073/pnas.83.8.2755; Keret A, 2017, J NEUROSURG-PEDIATR, V20, P64, DOI 10.3171/2017.2.PEDS16585; Kupenova P, 2008, VISION RES, V48, P882, DOI 10.1016/j.visres.2008.01.003; Lavoie J, 2014, PROG NEURO-PSYCHOPH, V48, P129, DOI 10.1016/j.pnpbp.2013.09.020; Lee JY, 2014, J PARKINSON DIS, V4, P197, DOI 10.3233/JPD-130306; Lemke S, 2016, OPHTHALMOLOGY, V123, P415, DOI 10.1016/j.ophtha.2015.10.003; Lewis GP, 2003, INT REV CYTOL, V230, P263, DOI 10.1016/S0074-7696(03)30005-1; Magone MT, 2014, J REHABIL RES DEV, V51, P71, DOI 10.1682/JRRD.2013.01.0008; Mammadova N, 2017, AM J PATHOL, V187, P1459, DOI 10.1016/j.ajpath.2017.03.005; MAURICE T, 1995, BEHAV PHARMACOL, V6, P167; Mishra V, 2016, SCI REP-UK, V6, DOI 10.1038/srep26992; Mohan K, 2013, INVEST OPHTH VIS SCI, V54, P3440, DOI 10.1167/iovs.12-11522; Moller A, 2003, VISUAL NEUROSCI, V20, P535, DOI 10.1017/S0952523803205071; Moore-Dotson JM, 2016, INVEST OPHTH VIS SCI, V57, P1418, DOI 10.1167/iovs.15-17999; Newman AJ, 2015, J NEUROSCI METH, V242, P82, DOI 10.1016/j.jneumeth.2015.01.009; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Phillips MJ, 2010, INVEST OPHTH VIS SCI, V51, P6744, DOI 10.1167/iovs.10-5421; Polo V, 2017, EYE, V31, P1034, DOI 10.1038/eye.2017.23; POURCHO RG, 1983, J COMP NEUROL, V219, P25, DOI 10.1002/cne.902190104; Prusky GT, 2006, J NEUROSCI, V26, P11554, DOI 10.1523/JNEUROSCI.3396-06.2006; Prusky GT, 2004, INVEST OPHTH VIS SCI, V45, P4611, DOI 10.1167/iovs.04-0541; Reiner A, 2015, INT J MOL SCI, V16, P758, DOI 10.3390/ijms16010758; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Ritter AC, 2016, EPILEPSIA, V57, P1968, DOI 10.1111/epi.13582; Sakai T, 2009, INVEST OPHTH VIS SCI, V50, P4402, DOI 10.1167/iovs.09-3458; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Wang HCH, 2014, MIL MED, V179, P34, DOI 10.7205/MILMED-D-13-00504; WASSLE H, 1991, PHYSIOL REV, V71, P447; Weichel ED, 2008, OPHTHALMOLOGY, V115, P2235, DOI 10.1016/j.ophtha.2008.08.033; Yang ZH, 2015, TRENDS NEUROSCI, V38, P364, DOI 10.1016/j.tins.2015.04.003; Yin T.C., 2016, ENEURO, P3; Zou YY, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-79	78	14	14	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2018	35	17					2104	2116		10.1089/neu.2017.5394		JUL 2018	13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GQ7LU	WOS:000437229600001	29648979	Green Published			2021-06-18	
J	Bishop, SA; Neary, JP				Bishop, Scott A.; Neary, J. Patrick			Assessing prefrontal cortex oxygenation after sport concussion with near-infrared spectroscopy	CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING			English	Article						concussion; hypercapnia; near-infrared spectroscopy; pathophysiology	TEST-RETEST RELIABILITY; TRAUMATIC BRAIN-INJURY; CEREBRAL AUTOREGULATION; APPROXIMATE ENTROPY; SYMPTOM VALIDITY; HEART-RATE; REACTIVITY; MANAGEMENT; PERFORMANCE; COMPLEXITY	BackgroundClinicians typically rely on neuropsychological and balance tests to track concussion recovery. The aforementioned tests imply impairments that are based on performance, but these tests do not directly measure brain physiology throughout concussion recovery. Because of these issues, an objective biomarker that can index severity and the recovery timeline is needed. Moreover, the number of concussions occurring at a recreational level requires the biomarker to be easily administered in a cost effective manner, and the results easily interpreted. MethodsTo address these issues, near-infrared spectroscopy was used to assess the relative changes in oxy (HbO(2))- and deoxyhaemoglobin and the associated standard deviations (SD) in the prefrontal cortex. Resting haemoglobin, and haemoglobin changes in response to hypercapnia (five repeated 20s breath holds), was measured in all participants. Data were aggregated into healthy baselines (n=115), and concussed participants on days 1-3 (n=14), 4-6 (n=8), and 7-14 (n=11). The data were statistically compared using a 1x4 ANOVA. ResultsResting HbO(2) values progressively lowered from days 1-3 to 7-14 (with no differences compared to controls). The second major finding showed that hypercapnic HbO(2) SD was significantly lower than resting values on days 1-3 and 4-6, but reversed back towards the healthy control group on day 7-14. ConclusionMonitoring cerebral oxygenation changes is a viable biomarker to assess the physiological state of the brain following concussion.	[Bishop, Scott A.; Neary, J. Patrick] Univ Regina, Fac Kinesiol & Hlth Studies, 3737 Wascana Pkwy, Regina, SK S4S 0A2, Canada	Neary, JP (corresponding author), Univ Regina, Fac Kinesiol & Hlth Studies, 3737 Wascana Pkwy, Regina, SK S4S 0A2, Canada.	patrick.neary@uregina.ca		Neary, J. Patrick/0000-0003-2480-8031	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Saskatchewan Health Research Foundation (SHRF)	We wish to acknowledge all the volunteer subjects, who participated in this study, their dedication and time involved is greatly appreciated. We also wish to acknowledge the financial contribution from research grants provided by the Canadian Institutes of Health Research (CIHR) and the Saskatchewan Health Research Foundation (SHRF). Finally, we would like to acknowledge Drs Goodman, Bjornson, Bhambhani and Asmundsen for their contributions during the inception of this mild brain injury research programme.	[Anonymous], 2004, Paediatr Child Health, V9, P99; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bigler ED, 2012, NEUROSCI LETT, V509, P1, DOI 10.1016/j.neulet.2011.12.009; Bishop S, 2017, BRAIN INJURY, P1; Bishop S, 2015, CURRENT RES CONCUSSI, V2, P49; Blake T, 2015, BRIT J SPORT MED, V48, P569; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Buckley TA, 2016, J SPORT HEALTH SCI, V5, P61, DOI 10.1016/j.jshs.2016.01.007; Cerutti S, 2009, PHILOS T R SOC A, V367, P1337, DOI 10.1098/rsta.2008.0267; Costa M, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.021906; Coveney PV, 2003, PHILOS T R SOC A, V361, P1057, DOI 10.1098/rsta.2003.1191; Critchley HD, 2003, BRAIN, V126, P2139, DOI 10.1093/brain/awg216; Cui X, 2011, NEUROIMAGE, V54, P2808, DOI 10.1016/j.neuroimage.2010.10.069; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; Duncan A, 1996, PEDIATR RES, V39, P889, DOI 10.1203/00006450-199605000-00025; Eckner JT, 2010, CURR SPORT MED REP, V9, P8, DOI 10.1249/JSR.0b013e3181caa778; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Fabiani M, 2014, NEUROIMAGE, V85, P592, DOI 10.1016/j.neuroimage.2013.04.113; Ferrari M, 2012, NEUROIMAGE, V63, P921, DOI 10.1016/j.neuroimage.2012.03.049; Field A. P, 2009, DISCOVERING STAT USI; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Fox DD, 2011, CLIN NEUROPSYCHOL, V25, P488, DOI 10.1080/13854046.2011.554443; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Huppert TJ, 2006, NEUROIMAGE, V29, P368, DOI 10.1016/j.neuroimage.2005.08.065; Iverson GL, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/415740; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; Kainerstorfer JM, 2015, J CEREBR BLOOD F MET, V35, P959, DOI 10.1038/jcbfm.2015.5; Kennedy DO, 2011, BIOL PSYCHOL, V86, P298, DOI 10.1016/j.biopsycho.2010.12.010; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; Kontos AP, 2014, BRAIN IMAGING BEHAV, V8, P621, DOI 10.1007/s11682-014-9289-9; La Fountaine MF, 2009, AUTON NEUROSCI-BASIC, V148, P101, DOI 10.1016/j.autneu.2009.03.001; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Lee JK, 2009, STROKE, V40, P1820, DOI 10.1161/STROKEAHA.108.536094; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Len TK, 2013, BRAIN INJURY, V27, P346, DOI 10.3109/02699052.2012.743185; Len TK, 2011, MED SCI SPORT EXER, V43, P2241, DOI 10.1249/MSS.0b013e3182249539; Lovallo W.R., 2005, STRESS HLTH BIOL PSY; MacIntosh BJ, 2003, NEUROIMAGE, V20, P1246, DOI 10.1016/S1053-8119(03)00417-8; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Meier TB, 2015, JAMA NEUROL, V87106, P1; Militana AR, 2015, BRAIN IMAGING BEHAV, V1, P1; Molinari F, 2006, J NEUROENG REHABIL, V3, P1; Moody M, 2005, AM J PHYSIOL-REG I, V288, pR1581, DOI 10.1152/ajpregu.00837.2004; Mutch WAC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102181; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Onate JA, 2007, J ATHL TRAINING, V42, P446; Panerai RB, 2009, PHILOS T R SOC A, V367, P1319, DOI 10.1098/rsta.2008.0264; Papaioannou V, 2008, J CRIT CARE, V23, P380, DOI 10.1016/j.jcrc.2007.04.006; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297; Randolph C, 2005, J ATHL TRAINING, V40, P139; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Resch JE, 2013, NEUROPSYCHOL REV, V23, P335, DOI 10.1007/s11065-013-9242-5; Resch JE, 2013, CLIN NEUROPSYCHOL, V27, P1265, DOI 10.1080/13854046.2013.845247; Ryan ML, 2011, ANESTHESIOL RES PRAC, V2011, DOI 10.1155/2011/416590; Sakagami M, 2006, NEURAL NETWORKS, V19, P1255, DOI 10.1016/j.neunet.2006.05.040; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Starling A. J., 2015, CONCUSSION, V1, P1; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; Susco TM, 2004, J ATHL TRAINING, V39, P241; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Taylor AG, 2010, EXPLORE-NY, V6, P29, DOI 10.1016/j.explore.2009.10.004; Thayer JF, 2012, NEUROSCI BIOBEHAV R, V36, P747, DOI 10.1016/j.neubiorev.2011.11.009; Urban KJ, 2015, J NEUROTRAUM, V32, P833, DOI 10.1089/neu.2014.3577; Vernieri F, 2004, STROKE, V35, P64, DOI 10.1161/01.STR.0000106486.26626.E2; Wilkins JC, 2004, J ATHL TRAINING, V39, P156; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zweifel C, 2010, STROKE, V41, P1963, DOI 10.1161/STROKEAHA.109.577320; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	86	14	14	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1475-0961	1475-097X		CLIN PHYSIOL FUNCT I	Clin. Physiol. Funct. Imaging	JUL	2018	38	4					573	585		10.1111/cpf.12447			13	Physiology	Physiology	GJ0RJ	WOS:000434961600006	28626873	Green Published			2021-06-18	
J	Verhelst, H; Vander Linden, C; De Pauw, T; Vingerhoets, G; Caeyenberghs, K				Verhelst, Helena; Vander Linden, Catharine; De Pauw, Toon; Vingerhoets, Guy; Caeyenberghs, Karen			Impaired rich club and increased local connectivity in children with traumatic brain injury: Local support for the rich?	HUMAN BRAIN MAPPING			English	Article						diffusion-weighted imaging; graph theory; rich club; structural connectivity; traumatic brain injury	HUMAN CEREBRAL-CORTEX; STATE FUNCTIONAL CONNECTIVITY; STRUCTURAL CONNECTIVITY; DIFFUSION MRI; SPHERICAL-DECONVOLUTION; HUMAN CONNECTOME; SMALL-WORLD; ORGANIZATION; NETWORKS; IMAGES	Recent evidence has shown the presence of a rich club in the brain, which constitutes a core network of highly interconnected and spatially distributed brain regions, important for high-order cognitive processes. This study aimed to map the rich club organization in 17 young patients with moderate to severe TBI (15.71 +/- 1.75 years) in the chronic stage of recovery and 17 age- and gender-matched controls. Probabilistic tractography was performed on diffusion weighted imaging data to construct the edges of the structural connectomes using number of streamlines as edge weight. In addition, the whole-brain network was divided into a rich club network, a local network and a feeder network connecting the latter two. Functional outcome was measured with a parent questionnaire for executive functioning. Our results revealed a significantly decreased rich club organization (p values<.05) and impaired executive functioning (p<.001) in young patients with TBI compared with controls. Specifically, we observed reduced density values in all three subnetworks (p values<.005) and a reduced mean strength in the rich club network (p=.013) together with an increased mean strength in the local network (p=.002) in patients with TBI. This study provides new insights into the nature of TBI-induced brain network alterations and supports the hypothesis that the local subnetwork tries to compensate for the biologically costly subnetwork of rich club nodes after TBI.	[Verhelst, Helena; Vingerhoets, Guy] Univ Ghent, Fac Psychol & Educ Sci, Dept Expt Psychol, Henri Dunantlaan 2, B-9000 Ghent, Belgium; [Vander Linden, Catharine] Ghent Univ Hosp, Dept Phys Med & Rehabil, Child Rehabil Ctr, Ghent, Belgium; [De Pauw, Toon] Odisee Univ Coll, Dept Elect & ICT, Fac Ind Sci & Technol, Brussels, Belgium; [Caeyenberghs, Karen] Australian Catholic Univ, Fac Hlth Sci, Sch Psychol, Melbourne, Vic, Australia	Verhelst, H (corresponding author), Univ Ghent, Fac Psychol & Educ Sci, Dept Expt Psychol, Henri Dunantlaan 2, B-9000 Ghent, Belgium.	helena.verhelst@ugent.be		Verhelst, Helena/0000-0002-6861-0249; Caeyenberghs, Karen/0000-0001-7009-6843	Special Research Fund (BOF) from the University of Ghent [01N00214]	Special Research Fund (BOF) from the University of Ghent, Grant/Award Number: 01N00214	Andersson JLR, 2016, NEUROIMAGE, V125, P1063, DOI 10.1016/j.neuroimage.2015.10.019; Antonakakis M, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00416; Baggio HC, 2015, J COGNITIVE NEUROSCI, V27, P1801, DOI 10.1162/jocn_a_00821; Bassett DS, 2006, NEUROSCIENTIST, V12, P512, DOI 10.1177/1073858406293182; Benjamini Y, 2010, J R STAT SOC B, V72, P405, DOI 10.1111/j.1467-9868.2010.00746.x; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Caeyenberghs K, 2012, NEUROIMAGE-CLIN, V1, P106, DOI 10.1016/j.nicl.2012.09.011; Caeyenberghs K, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00726; Castellanos NP, 2011, NEUROIMAGE, V55, P1189, DOI 10.1016/j.neuroimage.2010.12.046; Collin G, 2014, CEREB CORTEX, V24, P2258, DOI 10.1093/cercor/bht064; Collin G, 2014, SCHIZOPHRENIA BULL, V40, P438, DOI 10.1093/schbul/sbt162; Connelly, 2010, P ISMRM, P1670; Crossley NA, 2014, BRAIN, V137, P2382, DOI 10.1093/brain/awu132; Dall'Acqua P, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00127; de Reus MA, 2013, NEUROIMAGE, V70, P402, DOI 10.1016/j.neuroimage.2012.12.066; Dennis EL, 2013, I S BIOMED IMAGING, P624; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Fagerholm ED, 2015, BRAIN, V138, P1696, DOI 10.1093/brain/awv075; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Galantucci S, 2017, RADIOLOGY, V283, P515, DOI 10.1148/radiol.2016160274; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hayes JP, 2016, J INT NEUROPSYCH SOC, V22, P120, DOI 10.1017/S1355617715000740; Hillary FG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104021; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Huizinga M, 2009, BRIEF VRAGENLIJST EX; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Kim J, 2014, J INT NEUROPSYCH SOC, V20, P887, DOI 10.1017/S1355617714000812; Konigs M, 2017, HUM BRAIN MAPP, V38, P3603, DOI 10.1002/hbm.23614; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; MCCOLGAN P, 2015, BRAIN 11, V138; Meier J, 2016, BRAIN CONNECT, V6, P298, DOI 10.1089/brain.2015.0408; Mitra J, 2016, NEUROIMAGE, V129, P247, DOI 10.1016/j.neuroimage.2016.01.056; Moenninghoff C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122329; Mohammadi Dara, 2015, Lancet Neurol, V14, P462, DOI 10.1016/S1474-4422(15)00005-8; Opsahl T, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.168702; Raffelt D, 2012, NEUROIMAGE, V59, P3976, DOI 10.1016/j.neuroimage.2011.10.045; Ray S, 2014, HUM BRAIN MAPP, V35, P6032, DOI 10.1002/hbm.22603; Reijmer YD, 2015, NEUROIMAGE, V117, P222, DOI 10.1016/j.neuroimage.2015.05.054; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Skudlarski P, 2008, NEUROIMAGE, V43, P554, DOI 10.1016/j.neuroimage.2008.07.063; Smith RE, 2013, NEUROIMAGE, V67, P298, DOI 10.1016/j.neuroimage.2012.11.049; Smith RE, 2012, NEUROIMAGE, V62, P1924, DOI 10.1016/j.neuroimage.2012.06.005; Solmaz B, 2017, HUM BRAIN MAPP, V38, P2913, DOI 10.1002/hbm.23561; Sporns O, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001049; Stellmann JP, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000375; Tournier JD, 2007, NEUROIMAGE, V35, P1459, DOI 10.1016/j.neuroimage.2007.02.016; Tournier JD, 2013, NMR BIOMED, V26, P1775, DOI 10.1002/nbm.3017; Tournier JD, 2012, INT J IMAG SYST TECH, V22, P53, DOI 10.1002/ima.22005; van den Heuvel MP, 2008, NEUROIMAGE, V43, P528, DOI 10.1016/j.neuroimage.2008.08.010; van den Heuvel MP, 2013, JAMA PSYCHIAT, V70, P783, DOI 10.1001/jamapsychiatry.2013.1328; van den Heuvel MP, 2012, P NATL ACAD SCI USA, V109, P11372, DOI 10.1073/pnas.1203593109; van den Heuvel MP, 2011, J NEUROSCI, V31, P15775, DOI 10.1523/JNEUROSCI.3539-11.2011; van den Heuvel MP, 2009, HUM BRAIN MAPP, V30, P3127, DOI 10.1002/hbm.20737; Veraart J, 2016, MAGN RESON MED, V76, P1582, DOI 10.1002/mrm.26059; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011; Yeh CH, 2016, NEUROIMAGE, V142, P150, DOI 10.1016/j.neuroimage.2016.05.047; Yuan WH, 2017, NEUROREHAB NEURAL RE, V31, P190, DOI 10.1177/1545968316675430; Yuan WH, 2015, HUM BRAIN MAPP, V36, P779, DOI 10.1002/hbm.22664; Zatorre RJ, 2012, NAT NEUROSCI, V15, P528, DOI 10.1038/nn.3045; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	65	14	14	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	JUL	2018	39	7					2800	2811		10.1002/hbm.24041			12	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	GL9TM	WOS:000437682100009	29528158	Green Published			2021-06-18	
J	Trotta, A; Annaidh, AN; Burek, RO; Pelgrims, B; Ivens, J				Trotta, Antonia; Annaidh, Aisling Ni; Burek, Roy Owen; Pelgrims, Bart; Ivens, Jan			Evaluation of the head-helmet sliding properties in an impact test	JOURNAL OF BIOMECHANICS			English	Article						Scalp; Friction; Head impact; Helmet; Rotational acceleration	TRAUMATIC BRAIN-INJURIES; DIFFUSE AXONAL INJURY; HUMAN SKIN; FRICTION; RECONSTRUCTIONS; AGE	The scalp plays a crucial role in head impact biomechanics, being the first tissue involved in the impact and providing a sliding interface between the impactor and/or helmet and the skull. It is important to understand both the scalp-skull and the scalp-helmet sliding in order to determine the head response due to an impact. However, experimental data on the sliding properties of the scalp is lacking. The aim of this work was to identify the sliding properties of the scalp using cadaver heads, in terms of scalp skull and scalp-liner (internal liner of the helmet) friction and to compare these values with that of widely used artificial headforms (Hill and magnesium EN960). The effect of the hair, the direction of sliding, the speed of the test and the normal load were considered. The experiments revealed that the sliding behaviour of the scalp under impact loading is characterised by three main phases: (1) the low friction sliding of the scalp over the skull (scalp-skull friction), (2) the tensioning effect of the scalp and (3) the sliding of the liner fabric over the scalp (scalp-liner friction). Results showed that the scalp-skull coefficient of friction (COF) is very low (0.06 0.048), whereas the scalp-liner COF is 0.29 0.07. The scalp-liner COF is statistically different from the value of the HIII-liner (0.75 0.06) and the magnesium EN960-liner (0.16 0.026). These data will lead to the improvement of current headforms for head impact standard tests, ultimately leading to more realistic head impact simulations and the optimization of helmet designs. (C) 2018 Elsevier Ltd. All rights reserved.	[Trotta, Antonia; Annaidh, Aisling Ni] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 4, Ireland; [Annaidh, Aisling Ni] Univ Coll Dublin, Sch Med & Med Sci, UCD Charles Inst Dermatol, Dublin 4, Ireland; [Burek, Roy Owen] Charles Owen & Co Bow Ltd, Croesfoel Ind Pk, Wrexham LL14 4BJ, Wales; [Burek, Roy Owen] Cardiff Univ, Sch Engn, Queens Bldg, Cardiff CF24 3AA, S Glam, Wales; [Pelgrims, Bart; Ivens, Jan] Katholieke Univ Leuven, Dept Mat Engn, Kasteelpk Arenberg 44, B-3001 Leuven, Belgium	Trotta, A (corresponding author), Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 4, Ireland.	antonia.trotta@ucd.ie	Ivens, Jan ID/I-4339-2016	Ivens, Jan ID/0000-0002-2766-1381; Trotta, Antonia/0000-0003-0973-6420; Ni Annaidh, Aisling/0000-0002-9929-4541	European Union's Horizon 2020 research programme under the Marie Sklodowska - Curie grant [642662]	Funding was provided by the European Union's Horizon 2020 research programme under the Marie Sklodowska - Curie grant agreement No. 642662. The authors wish to thank Bart Depreitere, the ethical committee of KU Leuven and the anatomy skills centre for their support and approval.	Aare Magnus, 2003, Traffic Inj Prev, V4, P240, DOI 10.1080/15389580309879; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Amoros E, 2012, INJURY PREV, V18, P27, DOI 10.1136/ip.2011.031815; Annaidh AN, 2012, ANN BIOMED ENG, V40, P1666, DOI 10.1007/s10439-012-0542-3; Attewell RG, 2001, ACCIDENT ANAL PREV, V33, P345, DOI 10.1016/S0001-4575(00)00048-8; Belingardi G, 2005, P 19 INT TECHN C ENH; Christensen M.S., 1983, FACIAL OILINESS DRYN; COMAISH S, 1971, BRIT J DERMATOL, V84, P37, DOI 10.1111/j.1365-2133.1971.tb14194.x; Connor TA, 2016, CURRENT STANDARDS SP; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; Derler S, 2012, TRIBOL LETT, V45, P1, DOI 10.1007/s11249-011-9854-y; Di Landro L, 2002, POLYM TEST, V21, P217, DOI 10.1016/S0142-9418(01)00073-3; Ebrahimi I, 2015, TRAFFIC INJ PREV, V16, P404, DOI 10.1080/15389588.2014.937804; Fahlstedt M, 2015, J BIOMECH, V48, P1331, DOI 10.1016/j.jbiomech.2015.02.057; Finan JD, 2008, TRAFFIC INJ PREV, V9, P483, DOI 10.1080/15389580802272427; Fotoh C, 2008, SKIN RES TECHNOL, V14, P327, DOI 10.1111/j.1600-0846.2008.00299.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1987, DIRECTIONAL DEPENDEN; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Gerhardt LC, 2008, SKIN RES TECHNOL, V14, P77, DOI 10.1111/j.1600-0846.2007.00264.x; Halldin P., 2013, P 1 INT C HELM PERF; Hasler RM, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.05.016; Holbourn AHS, 1943, LANCET, V2, P438; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Keng SH, 2005, ACCIDENT ANAL PREV, V37, P349, DOI 10.1016/j.aap.2004.09.006; Kleiven S., 2013, FRONT BIOENG BIOTECH, V1; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kondo S., 2002, J JPN RES ASS TEXT E, V43, P41; Langer K., 1861, BR J PLAST SURG, V17, P93; NOCSAE, 2018, STAND PNEUM RAM TEST; Ottenio M, 2015, J MECH BEHAV BIOMED, V41, P241, DOI 10.1016/j.jmbbm.2014.10.006; POCHI PE, 1979, J INVEST DERMATOL, V73, P108, DOI 10.1111/1523-1747.ep12532792; Povey LJ, 1999, ACCIDENT ANAL PREV, V31, P763, DOI 10.1016/S0001-4575(99)00033-0; Rueda MAF, 2011, COMPUT METHOD BIOMEC, V14, P1021, DOI 10.1080/10255842.2010.504922; Sivamani RK, 2003, SKIN RES TECHNOL, V9, P299, DOI 10.1034/j.1600-0846.2003.00034.x; Tang W, 2008, J BIONIC ENG, V5, P33, DOI 10.1016/S1672-6529(08)60004-9; Taylor CA, 2017, MMWR SURVEILL SUMM, P66; Thompson D.C., 1999, COCHR DATABASE SYST, V4; Thompson D. C., 1998, CYCLE HELMETS PREVEN; TOLHURST DE, 1991, PLAST RECONSTR SURG, V87, P603, DOI 10.1097/00006534-199104000-00001; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang M, 1999, PROSTHET ORTHOT INT, V23, P135	44	14	14	1	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	JUN 25	2018	75						28	34		10.1016/j.jbiomech.2018.05.003			7	Biophysics; Engineering, Biomedical	Biophysics; Engineering	GM3GQ	WOS:000437991500003	29784247	Green Published			2021-06-18	
J	Robinson, S; Winer, JL; Chan, LAS; Oppong, AY; Yellowhair, TR; Maxwell, JR; Andrews, N; Yang, YR; Sillerud, LO; Meehan, WP; Mannix, R; Brigman, JL; Jantzie, LL				Robinson, Shenandoah; Winer, Jesse L.; Chan, Lindsay A. S.; Oppong, Akosua Y.; Yellowhair, Tracylyn R.; Maxwell, Jessie R.; Andrews, Nicholas; Yang, Yirong; Sillerud, Laurel O.; Meehan, William P., III; Mannix, Rebekah; Brigman, Jonathan L.; Jantzie, Lauren L.			Extended Erythropoietin Treatment Prevents Chronic Executive Functional and Microstructural Deficits Following Early Severe Traumatic Brain Injury in Rats	FRONTIERS IN NEUROLOGY			English	Article						controlled cortical impact; diffusion tensor imaging; diffusivity; infant; touchscreen; cognition; cognitive flexibility	ABUSIVE HEAD TRAUMA; EXPRESSION PATTERNS; VENTRAL STRIATUM; TESTING METHOD; RECEPTOR; MICE; NEUROPROTECTION; PROGESTERONE; NEUROGENESIS; CHILDREN	Survivors of infant traumatic brain injury (TBI) are prone to chronic neurological deficits that impose lifelong individual and societal burdens. Translation of novel interventions to clinical trials is hampered in part by the lack of truly representative preclinical tests of cognition and corresponding biomarkers of functional outcomes. To address this gap, the ability of a high-dose, extended, post-injury regimen of erythropoietin (EPO, 3000U/kg/dose x 6d) to prevent chronic cognitive and imaging deficits was tested in a postnatal day 12 (P12) controlled-cortical impact (CCI) model in rats, using touch-screen operant chambers and regional analysis of diffusion tensor imaging (DTI). Results indicate that EPO prevents functional injury and MRI injury after infant TBI. Specifically, subacute DTI at P30 revealed widespread microstructural damage that is prevented by EPO. Assessment of visual discrimination on a touchscreen operant chamber platform demonstrated that all groups can performvisual discrimination. However, CCI rats treated with vehicle failed to pass reversal learning, and perseverated, in contrast to sham and CCI-EPO rats. Chronic DTI at P90 showed EPO treatment prevented contralateral white matter and ipsilateral lateral prefrontal cortex damage. This DTI improvement correlated with cognitive performance. Taken together, extended EPO treatment restores executive function and prevents microstructural brain abnormalities in adult rats with cognitive deficits in a translational preclinical model of infant TBI. Sophisticated testing with touchscreen operant chambers and regional DTI analyses may expedite translation and effective yield of interventions from preclinical studies to clinical trials. Collectively, these data support the use of EPO in clinical trials for human infants with TBI.	[Robinson, Shenandoah; Winer, Jesse L.; Chan, Lindsay A. S.; Oppong, Akosua Y.] Harvard Med Sch, Boston Childrens Hosp, Neurosurg, Boston, MA 02115 USA; [Robinson, Shenandoah] Harvard Med Sch, Boston Childrens Hosp, Neurol, Boston, MA 02115 USA; [Robinson, Shenandoah; Andrews, Nicholas] Harvard Med Sch, Boston Childrens Hosp, FM Kirby Ctr Neurobiol, Boston, MA 02115 USA; [Yellowhair, Tracylyn R.; Maxwell, Jessie R.; Jantzie, Lauren L.] Univ New Mexico, Dept Pediat, Albuquerque, NM 87131 USA; [Yang, Yirong] Univ New Mexico, Dept Pharmaceut Sci, Albuquerque, NM 87131 USA; [Sillerud, Laurel O.] Univ New Mexico, Dept Neurol, Albuquerque, NM 87131 USA; [Meehan, William P., III] Harvard Med Sch, Boston Childrens Hosp, Sports Med, Boston, MA USA; [Mannix, Rebekah] Harvard Med Sch, Boston Childrens Hosp, Emergency Med, Boston, MA USA; [Brigman, Jonathan L.; Jantzie, Lauren L.] Univ New Mexico, Dept Neurosci, Albuquerque, NM 87131 USA; [Robinson, Shenandoah] Johns Hopkins Univ, Pediat Neurosurg, Baltimore, MD 21218 USA	Robinson, S (corresponding author), Harvard Med Sch, Boston Childrens Hosp, Neurosurg, Boston, MA 02115 USA.; Robinson, S (corresponding author), Harvard Med Sch, Boston Childrens Hosp, Neurol, Boston, MA 02115 USA.; Robinson, S (corresponding author), Harvard Med Sch, Boston Childrens Hosp, FM Kirby Ctr Neurobiol, Boston, MA 02115 USA.; Jantzie, LL (corresponding author), Univ New Mexico, Dept Pediat, Albuquerque, NM 87131 USA.; Jantzie, LL (corresponding author), Univ New Mexico, Dept Neurosci, Albuquerque, NM 87131 USA.; Robinson, S (corresponding author), Johns Hopkins Univ, Pediat Neurosurg, Baltimore, MD 21218 USA.	srobin81@jhmi.edu; ljantzie@salud.unm.edu	Maxwell, Jessie R./N-1890-2019; Mannix, Rebekah/AAD-8702-2020	Maxwell, Jessie R./0000-0001-8990-7239; 	Dedicated Health Research funds from the University of New Mexico School of Medicine; University of New Mexico Brain and Behavioral Health Institute (BBHI); Center for Biomedical Research Excellence Pilot Award [CoBRE P30GM103400]; Department of Neurosurgery at Boston Children's Hospital; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM109089, P30GM103400] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [P50AA022534] Funding Source: NIH RePORTER	The authors are exceptionally grateful to Dave Fuller, Jessie Newville, Andrea Allan PhD for statistical expertise, and the generous funding provided by the Dedicated Health Research funds from the University of New Mexico School of Medicine, the University of New Mexico Brain and Behavioral Health Institute (BBHI), a Center for Biomedical Research Excellence Pilot Award to LJ (CoBRE P30GM103400/PI:Liu), and the Department of Neurosurgery at Boston Children's Hospital.	Aung Wint Yan, 2013, Imaging Med, V5, P427; Basar K, 2010, PROG NEUROBIOL, V92, P533, DOI 10.1016/j.pneurobio.2010.08.007; Bondi CO, 2015, NEUROSCI BIOBEHAV R, V58, P123, DOI 10.1016/j.neubiorev.2014.12.004; Bondi CO, 2014, J NEUROTRAUM, V31, P926, DOI 10.1089/neu.2013.3295; Bramlett HM, 2016, J NEUROTRAUM, V33, P538, DOI 10.1089/neu.2015.4116; Brigman JL, 2013, NAT NEUROSCI, V16, P1101, DOI 10.1038/nn.3457; Brigman JL, 2010, CEREB CORTEX, V20, P1955, DOI 10.1093/cercor/bhp266; Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Bussey TJ, 2012, NEUROPHARMACOLOGY, V62, P1191, DOI 10.1016/j.neuropharm.2011.04.011; Bussey TJ, 2008, LEARN MEMORY, V15, P516, DOI 10.1101/lm.987808; Chen C, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14040414; Chudasama Y, 2003, J NEUROSCI, V23, P8771; Dennis EL, 2015, NEUROIMAGE-CLIN, V7, P493, DOI 10.1016/j.nicl.2015.02.002; Dias RB, 2018, CEREB CORTEX, V28, P2795, DOI 10.1093/cercor/bhx159; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Egger K, 2016, NEUROIMAGE, V127, P1, DOI 10.1016/j.neuroimage.2015.10.091; Faber J, 2016, BRAIN INJURY, V30, P1635, DOI 10.1080/02699052.2016.1199910; Ferguson NM, 2017, CRIT CARE MED, V45, P1398, DOI 10.1097/CCM.0000000000002378; Ghezzi P, 2010, LANCET, V375, P2142, DOI 10.1016/S0140-6736(10)60992-0; Graybeal C, 2011, NAT NEUROSCI, V14, P1507, DOI 10.1038/nn.2954; Hasselblatt M, 2006, J NEUROSURG ANESTH, V18, P132, DOI 10.1097/00008506-200604000-00007; Hassouna I, 2016, MOL PSYCHIATR, V21, P1752, DOI 10.1038/mp.2015.212; Hellewell SC, 2018, CRIT CARE MED, V46, P554, DOI 10.1097/CCM.0000000000002938; Hellewell SC, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-156; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Iwai M, 2010, STROKE, V41, P1032, DOI 10.1161/STROKEAHA.109.570325; Izquierdo A, 2006, BEHAV BRAIN RES, V171, P181, DOI 10.1016/j.bbr.2006.03.029; Jantzie LL, 2014, MOL CELL NEUROSCI, V61, P152, DOI 10.1016/j.mcn.2014.06.009; Jantzie LL, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00233; Jantzie LL, 2016, DEV NEUROSCI-BASEL, V38, P15, DOI 10.1159/000441024; Jantzie LL, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00347; Jantzie LL, 2015, DEV NEUROSCI-BASEL, V37, P277, DOI 10.1159/000371721; Jantzie LL, 2013, PEDIATR RES, V74, P658, DOI 10.1038/pr.2013.155; Keller M, 2006, NEUROBIOL DIS, V24, P357, DOI 10.1016/j.nbd.2006.07.007; Knabe W, 2005, ANAT EMBRYOL, V210, P209, DOI 10.1007/s00429-005-0019-3; Knabe W, 2004, ANAT EMBRYOL, V207, P503, DOI 10.1007/s00429-003-0365-y; Leach PT, 2018, GENES BRAIN BEHAV, V17, DOI 10.1111/gbb.12452; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Mar AC, 2017, PSYCHOPHARMACOLOGY, V234, P2837, DOI 10.1007/s00213-017-4679-5; Marquardt K, 2014, ALCOHOL CLIN EXP RES, V38, P2962, DOI 10.1111/acer.12577; Mazur M, 2010, J NEUROSURG-PEDIATR, V6, P206, DOI 10.3171/2010.5.PEDS1032; Miller TR, 2014, PEDIATRICS, V134, pE1545, DOI 10.1542/peds.2014-1385; Miskowiak K, 2007, J NEUROSCI, V27, P2788, DOI 10.1523/JNEUROSCI.5013-06.2007; Nichols JN, 2017, J NEUROTRAUM, V34, P2481, DOI 10.1089/neu.2017.4998; Nithianantharajah J, 2013, NEUROBIOL LEARN MEM, V105, P13, DOI 10.1016/j.nlm.2013.06.006; Noguchi Constance Tom, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000860; O'Gorman RL, 2015, BRAIN, V138, P388, DOI 10.1093/brain/awu363; Ohls RK, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3859; Ohls RK, 2014, PEDIATRICS, V133, P1023, DOI 10.1542/peds.2013-4307; Ott C, 2015, MOL MED, V21, P803, DOI 10.2119/molmed.2015.00192; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Rajesh A, 2017, J NEUROTRAUM, V34, P3280, DOI 10.1089/neu.2017.5047; Rangarajan V, 2014, PEDIATR NEUROL, V51, P481, DOI 10.1016/j.pediatrneurol.2014.06.008; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Robinson S, 2018, EXP NEUROL, V302, P1, DOI 10.1016/j.expneurol.2017.12.010; Robinson S, 2016, J NEUROSURG-PEDIATR, V17, P739, DOI 10.3171/2015.10.PEDS15554; Ryan NP, 2018, PSYCHOL MED, V48, P679, DOI 10.1017/S0033291717002057; Schober ME, 2018, BRAIN DEV-JPN, V40, P367, DOI 10.1016/j.braindev.2018.01.003; Schober ME, 2014, BRAIN RES, V1574, P105, DOI 10.1016/j.brainres.2014.05.046; Schober ME, 2014, J NEUROTRAUM, V31, P358, DOI 10.1089/neu.2013.2922; Schumacher M, 2016, J STEROID BIOCHEM, V160, P53, DOI 10.1016/j.jsbmb.2015.11.010; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Shah S, 2012, BRAIN INJURY, V26, P201, DOI 10.3109/02699052.2012.654591; Shultz SR, 2017, NEUROSCI BIOBEHAV R, V76, P396, DOI 10.1016/j.neubiorev.2016.09.014; Simard F, 2011, CEREB CORTEX, V21, P1084, DOI 10.1093/cercor/bhq182; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Stein DG, 2015, BRAIN INJURY, V29, P1259, DOI 10.3109/02699052.2015.1065344; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; van de Looij Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095643; Vonder Haar C, 2017, J NEUROTRAUM, V34, P2790, DOI 10.1089/neu.2016.4813; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P404, DOI 10.1007/s11682-012-9150-y; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Xiong Y, 2010, J NEUROTRAUM, V27, P205, DOI 10.1089/neu.2009.1001; Yellowhair TR, 2018, EXP NEUROL, V301, P110, DOI 10.1016/j.expneurol.2017.11.002; Yu XB, 2002, DEVELOPMENT, V129, P505; Zhou ZW, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.827	78	14	15	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JUN 19	2018	9								451	10.3389/fneur.2018.00451			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	GK0TO	WOS:000435825000001	29971038	DOAJ Gold, Green Published			2021-06-18	
J	Di Battista, AP; Churchill, N; Schweizer, TA; Rhind, SG; Richards, D; Baker, AJ; Hutchison, MG				Di Battista, Alex P.; Churchill, Nathan; Schweizer, Tom A.; Rhind, Shawn G.; Richards, Doug; Baker, Andrew J.; Hutchison, Michael G.			Blood biomarkers are associated with brain function and blood flow following sport concussion	JOURNAL OF NEUROIMMUNOLOGY			English	Article							NEURON-SPECIFIC ENOLASE; MINOR HEAD-INJURY; RESTING-STATE FMRI; QUANTITATIVE-EVALUATION; COMPUTED-TOMOGRAPHY; TRAUMA PATIENTS; CT FINDINGS; S100B; SERUM; PROTEIN	Background: Secondary injury pathophysiology after sport-related concussion (SRC) is poorly understood. Blood biomarkers may be a useful tool for characterizing these processes, yet there are limitations in their application as a single modality. Combining blood biomarker analysis with advanced neuroimaging may help validate their continued utility in brain injury research by elucidating important secondary injury mechanisms. Hence, the purpose of this study was to evaluate co-modulation between peripheral blood biomarkers and advanced functional brain imaging after SRC. Methods: Forty-three university level athletes from 7 sports were recruited (16 recently concussed athletes; 15 healthy athletes with no prior history of concussion; 12 healthy athletes with a history of concussion). Seven blood biomarkers were evaluated: s100B, total tau (T-tau), von Willebrand factor (vWF), brain derived neurotrophic factor (BDNF), peroxiredoxin (PRDX)-6, monocyte chemoattractant protein (MCP)-1 and -4. Resting-state functional MRI was employed to assess global neural connectivity (Gconn), and arterial spin labelling was used to evaluate cerebral blood flow (CBF). We tested for concurrent alterations in blood biomarkers and MRI measures of brain function between athlete groups using a non-parametric, bootstrapped resampling framework. Results: Compared to healthy athletes, recently concussed athletes showed greater concurrent alterations in several peripheral blood biomarker and MRI measures: a decrease in T-Tau and Gconn, a decrease in T-Tau and CBF, a decrease in Gconn with elevated PRDX-6, a decrease in CBF with elevated PRDX-6, and a decrease in Gconn with elevated MCP-4. In addition, compared to healthy athletes with no concussion history, healthy athletes with a history of concussion displayed greater concurrent alterations in blood biomarkers and Gconn; lower GConn covaried with higher blood levels of s100B and MCP-4. Conclusion: We identified robust relationships between peripheral blood biomarkers and MRI measures in both recently concussed athletes and healthy athletes with a history of concussion. The results from this combinatorial approach further support that human concussion is associated with inflammation, oxidative stress, and cellular damage, and that physiological perturbations may extend chronically beyond recovery. Finally, our results support the continued implementation of blood biomarkers as a tool to investigate brain injury, particularly in a multimodal framework.	[Di Battista, Alex P.; Rhind, Shawn G.; Richards, Doug; Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Di Battista, Alex P.; Rhind, Shawn G.] Def Res & Dev Canada, Toronto Res Ctr, Toronto, ON, Canada; [Churchill, Nathan; Schweizer, Tom A.; Hutchison, Michael G.] St Michaels Hosp, Neurosci Program, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada; [Schweizer, Tom A.; Baker, Andrew J.; Hutchison, Michael G.] St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada; [Richards, Doug] Univ Toronto, Fac Kinesiol & Phys Educ, David L Macintosh Sport Med Clin, Toronto, ON, Canada; [Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Crit Care, Toronto, ON, Canada; [Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Anesthesia, Toronto, ON, Canada; [Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Surg, Toronto, ON, Canada	Di Battista, AP (corresponding author), Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada.	alex.dibattista@utoronto.ca; schweizerT@smh.ca; shawn.rhind@drdc-rddc.gc.ca; doug.richards@utoronto.ca; bakera@smh.ca; michael.hutchison@utoronto.ca		Di Battista, Alex/0000-0002-3325-6833; Rhind, Shawn/0000-0003-2300-0620	Canadian Institute of Military and Veteran Health Research [W7714-145967]	The authors would like to acknowledge Maria Shiu and Sarah Watling for their help with data collection during the study period. This study was funded by the Canadian Institute of Military and Veteran Health Research (W7714-145967) (CIMVHR) - Task 7.	Akhtar Javed I, 2003, Pediatr Crit Care Med, V4, P322; Baumann R, 2013, AM J RHINOL ALLERGY, V27, P266, DOI 10.2500/ajra.2013.27.3913; Becelewski Janusz, 2002, Neurol Neurochir Pol, V36, P1135; Breland UM, 2010, CARDIOVASC RES, V86, P265, DOI 10.1093/cvr/cvq044; Buonora JE, 2015, J NEUROTRAUM, V32, P1805, DOI 10.1089/neu.2014.3736; Buonora JE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00068; Catania A, 2009, BRAIN BEHAV IMMUN, V23, P877, DOI 10.1016/j.bbi.2009.04.006; Chrousos G P, 1997, Aging (Milano), V9, P25; Churchill N, 2017, J NEUROTRAUM, V34, P765, DOI 10.1089/neu.2016.4531; Churchill NW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07742-3; Churchill NW, 2017, NEUROIMAGE-CLIN, V14, P480, DOI 10.1016/j.nicl.2017.02.015; Cole MW, 2012, J NEUROSCI, V32, P8988, DOI 10.1523/JNEUROSCI.0536-12.2012; Dalgard C, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2016.285; Di Battista AP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159929; Di Battista AP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0500-3; Di Battista AP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00044; Elenkov I., 2000, NEUROENDOCRINE EFFEC; Elenkov IJ, 1999, BEST PRACT RES CL EN, V13, P583, DOI 10.1053/beem.1999.0045; Falcone T, 2015, J PSYCHIATR RES, V62, P14, DOI 10.1016/j.jpsychires.2014.12.002; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Gempp E, 2014, DIVING HYPERB MED, V44, P26; Gentili A, 2016, HORM METAB RES, V48, P847, DOI 10.1055/s-0042-108731; Gill J, 2017, NEUROLOGY, V88, P595, DOI 10.1212/WNL.0000000000003587; Gill J, 2016, J HEAD TRAUMA REHAB, V31, P269, DOI 10.1097/HTR.0000000000000191; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Iliff JJ, 2013, J NEUROSCI, V33, P18190, DOI 10.1523/JNEUROSCI.1592-13.2013; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Isgro MA, 2015, ADV EXP MED BIOL, V867, P125, DOI 10.1007/978-94-017-7215-0_9; Jaerve A, 2012, CELL TISSUE RES, V349, P229, DOI 10.1007/s00441-012-1427-3; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Jones Harlan P, 2012, Methods Mol Biol, V934, P77, DOI 10.1007/978-1-62703-071-7_4; Kamins J, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097464; Koh SXT, 2014, SPORTS MED, V44, P369, DOI 10.1007/s40279-013-0119-9; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Len TK, 2011, MED SCI SPORT EXER, V43, P2241, DOI 10.1249/MSS.0b013e3182249539; Liezmann C, 2012, DERM-ENDOCRINOL, V4, DOI 10.4161/derm.22023; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Menard C, 2017, NEUROPSYCHOPHARMACOL, V42, P62, DOI 10.1038/npp.2016.90; Merchant-Borna K, 2016, J NEUROTRAUM, V33, P1576, DOI 10.1089/neu.2015.4191; Mishra SK, 2017, MOL CELL NEUROSCI, V78, P25, DOI 10.1016/j.mcn.2016.11.008; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Okugawa Y, 2016, J SURG ONCOL, V114, P483, DOI 10.1002/jso.24335; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Petzold A, 2003, NEUROSCI LETT, V336, P167, DOI 10.1016/S0304-3940(02)01257-0; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Pradeep AR, 2013, CYTOKINE, V61, P772, DOI 10.1016/j.cyto.2012.12.022; Relster MM, 2017, APMIS, V125, P148, DOI 10.1111/apm.12636; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Sahu Seelora, 2017, World J Biol Chem, V8, P21, DOI 10.4331/wjbc.v8.i1.21; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P459, DOI 10.1038/jcbfm.2009.240; Shahim P, 2015, BRAIN INJURY, V29, P872, DOI 10.3109/02699052.2015.1018324; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Singh SP, 2016, AM J PHYSIOL-CELL PH, V310, pC1, DOI 10.1152/ajpcell.00229.2015; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Strothert SC, 2002, NEUROIMAGE, V15, P747, DOI 10.1006/nimg.2001.1034; Tolan NV, 2013, CLIN CHIM ACTA, V424, P216, DOI 10.1016/j.cca.2013.06.009; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072; Webster EL, 1997, MOL PSYCHIATR, V2, P368, DOI 10.1038/sj.mp.4000305; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x; Woda A, 2016, PSYCHONEUROENDOCRINO, V71, P127, DOI 10.1016/j.psyneuen.2016.05.017; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; ZHANG Z, 2014, SCI WORLD J, V2014, P9, DOI DOI 10.1155/2014/473651; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	74	14	14	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728	1872-8421		J NEUROIMMUNOL	J. Neuroimmunol.	JUN 15	2018	319						1	8		10.1016/j.jneuroim.2018.03.002			8	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	GG9JI	WOS:000433016400001	29685283	Other Gold			2021-06-18	
J	Einarsen, CE; van der Naalt, J; Jacobs, B; Follestad, T; Moen, KG; Vik, A; Haberg, AK; Skandsen, T				Einarsen, Cathrine Elisabeth; van der Naalt, Joukje; Jacobs, Bram; Follestad, Turid; Moen, Kent Goran; Vik, Anne; Haberg, Asta Kristine; Skandsen, Toril			Moderate Traumatic Brain Injury: Clinical Characteristics and a Prognostic Model of 12-Month Outcome	WORLD NEUROSURGERY			English	Article						Cohort studies; Comparative study; Craniocerebral trauma; Prognosis; Statistical models	GLASGOW COMA SCALE; ACUTE ALCOHOL-INTOXICATION; HEAD-INJURY; PROSPECTIVE MULTICENTER; STRUCTURED INTERVIEWS; EMERGENCY-DEPARTMENT; EARLY PREDICTORS; CARE; CLASSIFICATION; EPIDEMIOLOGY	BACKGROUND: Patients with moderate traumatic brain injury (TBI) often are studied together with patients with severe TBI, even though the expected outcome of the former is better. Therefore, we aimed to describe patient characteristics and 12-month outcomes, and to develop a prognostic model based on admission data, specifically for patients with moderate TBI. METHODS: Patients with Glasgow Coma Scale scores of 9-13 and age >= 16 years were prospectively enrolled in 2 level I trauma centers in Europe. Glasgow Outcome Scale Extended (GOSE) score was assessed at 12 months. A prognostic model predicting moderate disability or worse (GOSE score <= 6), as opposed to a good recovery, was fitted by penalized regression. Model performance was evaluated by area under the curve of the receiver operating characteristics curves. RESULTS: Of the 395 enrolled patients, 81% had intracranial lesions on head computed tomography, and 71% were admitted to an intensive care unit. At 12 months, 44% were moderately disabled or worse (GOSE score <= 6), whereas 8% were severely disabled and 6% died (GOSE score <= 4). Older age, lower Glasgow Coma Scale score, no day-of-injury alcohol intoxication, presence of a subdural hematoma, occurrence of hypoxia and/or hypotension, and preinjury disability were significant predictors of GOSE score <= 6 (area under the curve = 0.80). CONCLUSIONS: Patients with moderate TBI exhibit characteristics of significant brain injury. Although few patients died or experienced severe disability, 44% did not experience good recovery, indicating that follow-up is needed. The model is a first step in development of prognostic models for moderate TBI that are valid across centers.	[Einarsen, Cathrine Elisabeth; Skandsen, Toril] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Vik, Anne] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Neurosurg, Trondheim, Norway; [Haberg, Asta Kristine] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Radiol & Nucl Med, Trondheim, Norway; [Einarsen, Cathrine Elisabeth; Moen, Kent Goran; Vik, Anne; Haberg, Asta Kristine; Skandsen, Toril] Norwegian Univ Sci & Technol, NTNU, Fac Med & Hlth Sci, Dept Neuromed & Movement Sci, Trondheim, Norway; [Follestad, Turid] Norwegian Univ Sci & Technol, NTNU, Fac Med & Hlth Sci, Dept Publ Hlth & Nursing, Trondheim, Norway; [van der Naalt, Joukje; Jacobs, Bram] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol AB51, Groningen, Netherlands; [Moen, Kent Goran] Nord Trondelag Hosp Trust, Levanger Hosp, Dept Radiol, Levanger, Norway	Einarsen, CE (corresponding author), Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway.; Einarsen, CE (corresponding author), Norwegian Univ Sci & Technol, NTNU, Fac Med & Hlth Sci, Dept Neuromed & Movement Sci, Trondheim, Norway.	cathrine.einarsen@ntnu.no			Liaison Committee	This work was supported by funding from the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU).	Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Cnossen MC, 2017, J NEUROTRAUM, V34, P2396, DOI 10.1089/neu.2016.4819; Compagnone C, 2009, NEUROSURGERY, V64, P690, DOI 10.1227/01.NEU.0000340796.18738.F7; Cnossen MC, 2017, CRIT CARE MED, V45, P660, DOI 10.1097/CCM.0000000000002263; de Guise E, 2015, BRAIN INJURY, V29, P558, DOI 10.3109/02699052.2014.976593; de Koning ME, 2015, BRAIN INJURY, V29, P423, DOI 10.3109/02699052.2014.982188; Dezeure R, 2015, STAT SCI, V30, P533, DOI 10.1214/15-STS527; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P567, DOI 10.1136/jnnp.2007.120162; Fearnside M, 1998, AUST NZ J SURG, V68, P58, DOI 10.1111/j.1445-2197.1998.tb04638.x; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Gennarelli TA, 2006, INJURY, V37, P1083, DOI 10.1016/j.injury.2006.07.009; Gomez PA, 2014, NEUROCIRUGIA, V25, P199, DOI 10.1016/j.neucir.2014.05.001; Hosmer DW., 2013, APPL LOGISTIC REGRES, V3rd ed.; Mena JH, 2011, J TRAUMA, V71, P1185, DOI 10.1097/TA.0b013e31823321f8; Husson EC, 2010, J REHABIL MED, V42, P425, DOI 10.2340/16501977-0566; Jacobs B, 2013, NEUROCRIT CARE, V19, P79, DOI 10.1007/s12028-012-9795-9; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Lund SB, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0269-5; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Mahler SA, 2010, J EMERG MED, V39, P685, DOI 10.1016/j.jemermed.2009.05.016; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Puljula J, 2007, ALCOHOL ALCOHOLISM, V42, P474, DOI 10.1093/alcalc/agm003; R Development Core Team, 2016, R LANG ENV STAT COMP; Raj R, 2015, J NEUROTRAUM, V32, P95, DOI 10.1089/neu.2014.3488; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Roe C, 2015, BEHAV NEUROL, V2015, P845; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Rundhaug NP, 2015, J NEUROSURG, V122, P211, DOI 10.3171/2014.9.JNS14322; Scheenen ME, 2016, J NEUROTRAUM, V33, P339, DOI 10.1089/neu.2015.3926; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Tosetti P, 2013, J NEUROTRAUM, V30, P1211, DOI 10.1089/neu.2013.2896; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; van der Naalt J, 2017, LANCET NEUROL, V16, P532, DOI 10.1016/S1474-4422(17)30117-5; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilson JTL, 2007, NEUROSURGERY, V61, P123, DOI 10.1227/01.neu.0000279732.21145.9e; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910	51	14	14	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JUN	2018	114						E1199	E1210		10.1016/j.wneu.2018.03.176			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GG8PI	WOS:000432959600141	29614364	Green Published, Other Gold			2021-06-18	
J	Hogan, SR; Phan, JH; Alvarado-Velez, M; Wang, MD; Bellamkonda, RV; Fernandez, FM; LaPlaca, MC				Hogan, Scott R.; Phan, John H.; Alvarado-Velez, Melissa; Wang, May Dongmei; Bellamkonda, Ravi V.; Fernandez, Facundo M.; LaPlaca, Michelle C.			Discovery of Lipidome Alterations Following Traumatic Brain Injury via High-Resolution Metabolomics	JOURNAL OF PROTEOME RESEARCH			English	Article						biomarkers; traumatic brain injury; lipidomics; mass spectrometry; animal model	MITOCHONDRIAL OXIDATIVE DAMAGE; FREE FATTY-ACIDS; MASS-SPECTROMETRY; ARACHIDONIC-ACID; CEREBROSPINAL-FLUID; TIME-COURSE; RAT-BRAIN; MOUSE MODEL; BIOMARKERS; BLOOD	Traumatic brain injury (TBI) can occur across wide segments of the population, presenting in a heterogeneous manner that makes diagnosis inconsistent and management challenging. Biomarkers offer the potential to objectively relative concentrations of endogenous molecules in readily identify injury status, severity, and phenotype by measuring the accessible biofluids. Through a data-driven, discovery approach, novel biomarker candidates for TBI were identified in the serum lipidome of adult male Sprague-Dawley rats in the first week following moderate controlled cortical impact (CCI). Serum samples were analyzed in positive and negative modes by ultraperformance liquid chromatography-mass spectrometry (UPLC-MS). A predictive panel for the classification of injured and uninjured sera samples, consisting of 26 dysregulated species belonging to a variety of lipid classes, was developed with a cross-validated accuracy of 85.3% using omniClassifier software to optimize feature selection. Polyunsaturated fatty acids (PUFAs) and PUFA-containing diacylglycerols were found to be upregulated in sera from injured rats, while changes in sphingolipids and other membrane phospholipids were also observed, many of which map to known secondary injury pathways. Overall, the identified biomarker panel offers viable molecular candidates representing lipids that may readily cross the blood-brain barrier (BBB) and aid in the understanding of TBI pathophysiology.	[Hogan, Scott R.; Fernandez, Facundo M.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA; [Phan, John H.; Alvarado-Velez, Melissa; Wang, May Dongmei; Bellamkonda, Ravi V.; LaPlaca, Michelle C.] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; [Alvarado-Velez, Melissa; Bellamkonda, Ravi V.] Duke Univ, Pratt Sch Engn, Dept Biomed Engn, Fitzpatrick CIEMAS, Room 1427,101 Sci Dr,Campus Box 90281, Durham, NC 27708 USA	Fernandez, FM (corresponding author), Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA.; LaPlaca, MC (corresponding author), Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA.	facundo.fernandez@chemistry.gatech.edu; michelle.laplaca@bme.gatech.edu	Wang, May Dongmei/AAF-2065-2021; Fernandez, Facundo/B-7015-2008	Wang, May Dongmei/0000-0003-3961-3608; Fernandez, Facundo/0000-0002-0302-2534	National Institutes of Health (GT BioMAT Training Grant)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32EB006343-05, R01NS079739, R21NS091832, R01NS101909-01]; Vasser-Wooley endowed funds; Parker H. Petit Institute for Bioengineering & Bioscience (GT); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [T32EB006343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS101029, R21NS091832] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (GT BioMAT Training Grant Nos. T32EB006343-05, to S.R.H., R01NS079739 to R.V.B. and M.C.L., R21NS091832 to M.C.L., and R01NS101909-01 to F.M.F. and M.C.L.), Vasser-Wooley endowed funds to F.M.F., and Parker H. Petit Institute for Bioengineering & Bioscience (GT). We gratefully acknowledge access to instrumentation from the Center for Chemical Evolution at Georgia Tech.	Abdullah L, 2014, FASEB J, V28, P5311, DOI 10.1096/fj.14-258228; Adibhatla RM, 2007, FUTURE LIPIDOL, V2, P403, DOI 10.2217/17460875.2.4.403; Annesley TM, 2003, CLIN CHEM, V49, P1041, DOI 10.1373/49.7.1041; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Anthonymuthu TS, 2016, BRAIN RES, V1640, P57, DOI 10.1016/j.brainres.2016.02.006; BANERJEE RK, 1966, MOL PHARMACOL, V2, P56; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Betancur MI, 2017, ACS BIOMATER SCI ENG, V3, P420, DOI 10.1021/acsbiomaterials.6b00805; Blache D, 1996, J LIPID MEDIAT CELL, V13, P127, DOI 10.1016/0929-7855(95)00056-9; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boccard J, 2013, ANAL CHIM ACTA, V769, P30, DOI 10.1016/j.aca.2013.01.022; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cheng H, 2008, BIOCHEMISTRY-US, V47, P5869, DOI 10.1021/bi7023282; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; da Silva TF, 2012, BBA-MOL BASIS DIS, V1822, P1501, DOI 10.1016/j.bbadis.2012.05.014; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Dayson H., 1993, INTRO BLOOD BRAIN BA; Ding Chris, 2005, Journal of Bioinformatics and Computational Biology, V3, P185, DOI 10.1142/S0219720005001004; Fahy E, 2009, J LIPID RES, V50, pS9, DOI 10.1194/jlr.R800095-JLR200; Farias SE, 2011, J TRAUMA, V71, P1211, DOI 10.1097/TA.0b013e3182092c62; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FOLCH J, 1957, J BIOL CHEM, V226, P497; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gutowski SM, 2015, BIOMATERIALS, V44, P55, DOI 10.1016/j.biomaterials.2014.12.009; GUTTERIDGE JMC, 1995, CLIN CHEM, V41, P1819; Hankin JA, 2011, J AM SOC MASS SPECTR, V22, P1014, DOI 10.1007/s13361-011-0122-z; Hill RL, 2017, NEUROCHEM INT, V111, P45, DOI 10.1016/j.neuint.2017.03.015; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Homayoun P, 1997, J NEUROCHEM, V69, P199; Iannaccone PM, 2009, DIS MODEL MECH, V2, P206, DOI 10.1242/dmm.002733; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Ivanova PT, 2009, CURR OPIN CHEM BIOL, V13, P526, DOI 10.1016/j.cbpa.2009.08.011; JANERO DR, 1990, FREE RADICAL BIO MED, V9, P515, DOI 10.1016/0891-5849(90)90131-2; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Kimball BA, 2016, CHEM SENSES, V41, P407, DOI 10.1093/chemse/bjw014; Kliman M, 2011, BBA-MOL CELL BIOL L, V1811, P935, DOI 10.1016/j.bbalip.2011.05.016; Kobeissy F.H., 2015, BRAIN NEUROTRAUMA MO; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levine JS, 2002, NEW ENGL J MED, V346, P752, DOI 10.1056/NEJMra002974; Licastro F, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00189; Lippi G, 2012, SEMIN THROMB HEMOST, V38, P565, DOI 10.1055/s-0032-1315961; MARINETTI GV, 1958, J BIOL CHEM, V233, P562; May JC, 2016, ANNU REV ANAL CHEM, V9, P387, DOI 10.1146/annurev-anchem-071015-041734; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Mondello S, 2014, MED RES REV, V34, P503, DOI 10.1002/med.21295; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Osier N, 2016, METHODS MOL BIOL, V1462, P177, DOI 10.1007/978-1-4939-3816-2_11; Pardridge William M, 2005, NeuroRx, V2, P3; Parent BA, 2016, JAMA SURG, V151, DOI 10.1001/jamasurg.2016.0853; Parry RM, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S3-S7; Pasvogel AE, 2008, BIOL RES NURS, V10, P113, DOI 10.1177/1099800408323218; Pasvogel AE, 2010, BIOL RES NURS, V11, P325, DOI 10.1177/1099800409346056; Phan John H, 2014, ACM BCB, V2014, P514; Pilitsis JG, 2003, NEUROSCI LETT, V349, P136, DOI 10.1016/S0304-3940(03)00803-6; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pitkanen A, 2006, MODELS OF SEIZURES AND EPILEPSY, P1; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Robin X., 2013, TL PROTEOMICS, V1, P57, DOI [10.1016/j.trprot.2013.04.003, DOI 10.1016/J.TRPROT.2013.04.003]; Romisch-Margl W, 2012, METABOLOMICS, V8, P133, DOI 10.1007/s11306-011-0293-4; Roux A, 2016, J NEUROSCI METH, V272, P19, DOI 10.1016/j.jneumeth.2016.02.004; Sarafian MH, 2014, ANAL CHEM, V86, P5766, DOI 10.1021/ac500317c; Schiess R, 2009, MOL ONCOL, V3, P33, DOI 10.1016/j.molonc.2008.12.001; Schofield M, 1998, CHEM PHYS LIPIDS, V95, P23, DOI 10.1016/S0009-3084(98)00065-6; Semmes OJ, 2004, CANCER EPIDEM BIOMAR, V13, P1555; Sharp MK, 1998, ANN BIOMED ENG, V26, P788, DOI 10.1114/1.65; Sheth SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129735; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Smith CA, 2005, THER DRUG MONIT, V27, P747, DOI 10.1097/01.ftd.0000179845.53213.39; Soares HD, 1995, J NEUROSCI, V15, P8223; Sparvero LJ, 2010, J NEUROCHEM, V115, P1322, DOI 10.1111/j.1471-4159.2010.07055.x; Tang X, 2006, AM J PHYSIOL-HEART C, V290, pH37, DOI 10.1152/ajpheart.00491.2005; Thomale UW, 2002, ACTA NEUROCHIR SUPPL, V81, P229; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Viant MR, 2005, NMR BIOMED, V18, P507, DOI 10.1002/nbm.980; White TE, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-282; WIELOCH T, 1982, PATHOL BIOL, V30, P269; Wishart DS, 2013, NUCLEIC ACIDS RES, V41, pD801, DOI 10.1093/nar/gks1065; Woods AS, 2013, ACS CHEM NEUROSCI, V4, P594, DOI 10.1021/cn300216h; Worley B, 2013, CURR METABOL, V1, P92, DOI 10.2174/2213235X11301010092; Yang SG, 2012, J NEUROTRAUM, V29, P2696, DOI 10.1089/neu.2012.2442; Zalewski A, 2006, CLIN CHEM, V52, P1645, DOI 10.1373/clinchem.2006.070672; Zhang ZQ, 2010, METHODS MOL BIOL, V662, P317, DOI 10.1007/978-1-60761-800-3_16; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	98	14	14	1	22	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1535-3893	1535-3907		J PROTEOME RES	J. Proteome Res.	JUN	2018	17	6					2131	2143		10.1021/acs.jproteome.8b00068			13	Biochemical Research Methods	Biochemistry & Molecular Biology	GI4UT	WOS:000434367400013	29671324	Green Accepted			2021-06-18	
J	Martin, G; Shah, D; Elson, N; Boudreau, R; Hanseman, D; Pritts, TA; Makley, AT; Foreman, B; Goodman, MD				Martin, Grace; Shah, Dhavan; Elson, Nora; Boudreau, Ryan; Hanseman, Dennis; Pritts, Timothy A.; Makley, Amy T.; Foreman, Brandon; Goodman, Michael D.			Relationship of Coagulopathy and Platelet Dysfunction to Transfusion Needs After Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Coagulopathy; Platelet function assays; Thromboelastography; Transfusion	SEVERE HEAD-INJURY; INTRACRANIAL HEMORRHAGE; ANTIPLATELET THERAPY; FUNCTION TESTS; CLOPIDOGREL; ASPIRIN; RESPONSIVENESS; VARIABILITY; REVERSAL; ASSAY	Coagulopathy and platelet dysfunction commonly develop after traumatic brain injury (TBI). Thromboelastography (TEG) and platelet function assays (PFAs) are often performed at the time of admission; however, their roles in assessing post-TBI coagulopathy have not been investigated. We hypothesized that compared to blunt TBI, penetrating TBI would (1) demonstrate greater coagulopathy by TEG, (2) be associated with abnormal PFA results, and (3) require more blood product transfusions. We performed a retrospective study of patients admitted to the neuroscience intensive care unit of a level 1 trauma center from 2013 to 2015 with head Abbreviated Injury Scale ae<yen>3. Patients were compared by mechanism of injury (blunt vs. penetrating). Admission demographics, injury characteristics, and laboratory parameters were evaluated. VerifyNow(A (R)) Aspirin and P2Y12 tests were used for platelet function analysis. Five hundred and thirty-four patients were included in the analysis. There were no differences between groups in platelet count or international normalized ratio; however, patients with penetrating TBI were more coagulopathic by TEG, with all of the TEG parameters being significantly different except for R time. Patients with penetrating head trauma were not more likely than their blunt counterparts to have abnormal PFA results, and PFA results did not correlate with any TEG parameter in either group. The penetrating cohort received more units of blood products in the first 4 and 24 h than the blunt cohort. Patients presenting with penetrating TBI demonstrated increased coagulopathy compared to those with blunt TBI as measured by TEG and need for transfusion. PFA results did not correlate with TEG findings in this population.	[Martin, Grace; Shah, Dhavan; Elson, Nora; Boudreau, Ryan; Hanseman, Dennis; Pritts, Timothy A.; Makley, Amy T.; Goodman, Michael D.] Univ Cincinnati, Div Trauma Crit Care, Dept Surg, Coll Med, 231 Albert Sabin Way,ML 0558, Cincinnati, OH 45267 USA; [Foreman, Brandon] Univ Cincinnati, Div Neurocrit Care, Dept Neurol, Coll Med, 231 Albert Sabin Way,ML 0558, Cincinnati, OH 45267 USA	Goodman, MD (corresponding author), Univ Cincinnati, Div Trauma Crit Care, Dept Surg, Coll Med, 231 Albert Sabin Way,ML 0558, Cincinnati, OH 45267 USA.	goodmamd@ucmail.uc.edu		Pritts, Timothy/0000-0003-2495-3255; Foreman, Brandon/0000-0002-5418-674X; Elson, Nora/0000-0001-6038-4761			Abdelfattah K, 2016, INT J SURG, V33, P196, DOI 10.1016/j.ijsu.2015.09.036; Bachelani AM, 2011, SURGERY, V150, P836, DOI 10.1016/j.surg.2011.07.059; Bansal V, 2011, J TRAUMA, V70, P65, DOI 10.1097/TA.0b013e318204fdae; Ben-Dor I, 2009, AM J CARDIOL, V104, P227, DOI 10.1016/j.amjcard.2009.03.022; Boto GR, 2006, J NEUROL NEUROSUR PS, V77, P1054, DOI 10.1136/jnnp.2005.087056; Briggs A, 2015, J SURG RES, V193, P802, DOI 10.1016/j.jss.2014.08.016; Campbell PG, 2010, WORLD NEUROSURG, V74, P279, DOI 10.1016/j.wneu.2010.05.030; Centers for Disease Control and Prevention, TRAUMATIC BRAIN INJU; Folkerson LE, 2015, SURGERY, V158, P655, DOI 10.1016/j.surg.2015.02.029; Hans GA, 2016, BRIT J HAEMATOL, V173, P37, DOI 10.1111/bjh.13930; Harrison P, 2005, STROKE, V36, P1001, DOI 10.1161/01.STR.0000162719.11058.bd; Jeong YH, 2012, AM HEART J, V164, P35, DOI 10.1016/j.ahj.2012.03.022; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P990, DOI 10.1097/TA.0b013e3182a96591; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; Massaro AM, 2015, NEUROCRIT CARE, V22, P45, DOI 10.1007/s12028-014-0051-3; Nishijima DK, 2012, J TRAUMA ACUTE CARE, V72, P1658, DOI 10.1097/TA.0b013e318256dfc5; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Oestreich JH, 2009, CORONARY ARTERY DIS, V20, P207, DOI 10.1097/MCA.0b013e328329924b; Paniccia R, 2015, VASC HEALTH RISK MAN, V11, P133, DOI 10.2147/VHRM.S44469; Schochl H, 2010, CRIT CARE, V14, DOI 10.1186/cc8948; Serebruany VL, 2005, J AM COLL CARDIOL, V45, P246, DOI 10.1016/j.jacc.2004.09.067; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Taylor G, 2013, J TRAUMA ACUTE CARE, V74, P1367, DOI 10.1097/TA.0b013e31828cca61; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050	28	14	14	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2018	28	3					330	337		10.1007/s12028-017-0485-5			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	GK8EB	WOS:000436449800010	29313313				2021-06-18	
J	Rostami, E; Engquist, H; Howells, T; Johnson, U; Ronne-Engstrom, E; Nilsson, P; Hillered, L; Lewen, A; Enblad, P				Rostami, Elham; Engquist, Henrik; Howells, Timothy; Johnson, Ulf; Ronne-Engstrom, Elisabeth; Nilsson, Pelle; Hillered, Lars; Lewen, Anders; Enblad, Per			Early low cerebral blood flow and high cerebral lactate: prediction of delayed cerebral ischemia in subarachnoid hemorrhage	JOURNAL OF NEUROSURGERY			English	Article						xenon-CT; lactate; CBF; cerebral blood flow; lactate/pyruvate ratio; SAH; subarachnoid hemorrhage; DCI; delayed cerebral ischemia; vasospasm; vascular disorders	POSITRON-EMISSION-TOMOGRAPHY; TRAUMATIC BRAIN-INJURY; INTRACEREBRAL MICRODIALYSIS; SYMPTOMATIC VASOSPASM; BEDSIDE MICRODIALYSIS; NEUROINTENSIVE CARE; ENERGY-METABOLISM; XE-CT; DISTURBANCES; MANAGEMENT	OBJECTIVE Delayed cerebral ischemia (DCI) following subarachnoid hemorrhage (SAH) is one of the major contributors to poor outcome. It is crucial to be able to detect early signs of DCI to prevent its occurrence. The objective of this study was to determine if low cerebral blood flow (CBF) measurements and pathological microdialysis parameters measured at the bedside can be observed early in patients with SAH who later developed DCI. METHODS The authors included 30 patients with severe SAH. The CBF measurements were performed at Day 0-3 after disease onset, using bedside xenon-CT. Interstitial glucose, lactate, pyruvate, glycerol, and glutamate were measured using microdialysis. RESULTS Nine of 30 patients developed DCI. Patients with DCI showed significantly lower global and regional CBF, and lactate was significantly increased in these patients. A high lactate/pyruvate ratio was also detected in patients with DCI. CONCLUSIONS Early low CBF measurements and a high lactate and lactate/pyruvate ratio may be early warning signs of the risk of developing DCI. The clinical value of these findings needs to be confirmed in larger studies.	[Rostami, Elham; Engquist, Henrik; Howells, Timothy; Johnson, Ulf; Ronne-Engstrom, Elisabeth; Nilsson, Pelle; Hillered, Lars; Lewen, Anders; Enblad, Per] Uppsala Univ, Sect Neurosurg, Dept Neurosci, Uppsala, Sweden; [Engquist, Henrik] Uppsala Univ, Anesthesiol & Intens Care, Dept Surg Sci, Uppsala, Sweden; [Johnson, Ulf] Uppsala Univ, Dept Surg Sci & Radiol, Uppsala, Sweden	Rostami, E (corresponding author), Uppsala Univ Hosp, Sect Neurosurg, Dept Neurosci, SE-75185 Uppsala, Sweden.	elham.rostami@neuro.uu.se	Lewen, Anders/A-5156-2013; Engquist, Henrik/S-1890-2016	Lewen, Anders/0000-0003-4925-1348; Engquist, Henrik/0000-0002-9826-1422			BERGVALL U, 1973, NEURORADIOLOGY, V5, P24, DOI 10.1007/BF02464626; Cesarini KG, 2002, ACTA NEUROCHIR, V144, P1121, DOI 10.1007/s00701-002-1011-9; Chen HI, 2011, NEUROSURGERY, V69, P53, DOI 10.1227/NEU.0b013e3182191451; De Micheli E, 2001, ACT NEUR S, V77, P149; Diringer MN, 2011, NEUROCRIT CARE, V15, P211, DOI 10.1007/s12028-011-9605-9; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; Frykholm P, 2004, ACTA NEUROL SCAND, V109, P25, DOI 10.1034/j.1600-0404.2003.00174.x; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KETY SS, 1951, PHARMACOL REV, V3, P1; MEYER JS, 1988, NEURORADIOLOGY, V30, P283, DOI 10.1007/BF00328177; Nyberg C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099904; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; Qureshi AI, 2000, CRIT CARE MED, V28, P984, DOI 10.1097/00003246-200004000-00012; Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397; Rostami E, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00089; Ryttlefors M, 2007, NEUROSURGERY, V61, P704, DOI 10.1227/01.NEU.0000298898.38979.E3; Samuelsson C, 2009, ACTA NEUROCHIR, V151, P437, DOI 10.1007/s00701-009-0265-x; Sarrafzadeh A, 2005, J NEURORADIOLOGY, V32, P348, DOI 10.1016/S0150-9861(05)83168-2; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Sarrafzadeh AS, 2004, STROKE, V35, P638, DOI 10.1161/01.STR.0000116101.66624.F1; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Schmidt JM, 2011, STROKE, V42, P1351, DOI 10.1161/STROKEAHA.110.596874; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Skoglund K, 2014, NEUROCRIT CARE, V20, P413, DOI 10.1007/s12028-013-9876-4; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; Sturnegk P, 2007, BRIT J NEUROSURG, V21, P332, DOI 10.1080/02688690701411574; Ungerstedt U, 2004, CURR PHARM DESIGN, V10, P2145, DOI 10.2174/1381612043384105; van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; WEIR B, 1978, J NEUROSURG, V48, P173, DOI 10.3171/jns.1978.48.2.0173; Yonas H, 1996, NEUROSURG CLIN N AM, V7, P605; YONAS H, 1991, J CEREBR BLOOD F MET, V11, P716, DOI 10.1038/jcbfm.1991.128; YONAS H, 1984, LANCET, V1, P1357; YONAS H, 1989, NEUROSURGERY, V24, P368, DOI 10.1227/00006123-198903000-00010	36	14	15	1	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2018	128	6					1762	1770		10.3171/2016.11.JNS161140			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GP2IM	WOS:000440653000023	28574309				2021-06-18	
J	Singer, W; Kasini, K; Manthey, M; Eckert, P; Armbruster, P; Vogt, MA; Jaumann, M; Dotta, M; Yamahara, K; Harasztosi, C; Zimmermann, U; Knipper, M; Ruttiger, L				Singer, Wibke; Kasini, Kamyar; Manthey, Marie; Eckert, Philipp; Armbruster, Philipp; Vogt, Miriam Annika; Jaumann, Mirko; Dotta, Michela; Yamahara, Kohei; Harasztosi, Csaba; Zimmermann, Ulrike; Knipper, Marlies; Ruettiger, Lukas			The glucocorticoid antagonist mifepristone attenuates sound-induced long-term deficits in auditory nerve response and central auditory processing in female rats	FASEB JOURNAL			English	Article						glucocorticoid receptors; mineralocorticoid receptors; hidden hearing loss; synaptic ribbon; auditory trauma	SENSORINEURAL HEARING-LOSS; TRAUMATIC BRAIN-INJURY; OUTER HAIR-CELLS; RESTRAINT STRESS; ACOUSTIC TRAUMA; GUINEA-PIG; MINERALOCORTICOID RECEPTOR; COCHLEAR SYNAPTOPATHY; INTRATYMPANIC DEXAMETHASONE; INNER-EAR	Systemic corticosteroids have been the mainstay of treatment for various hearing disorders for more than 30 yr. Accordingly, numerous studies have described glucocorticoids (GCs) and stressors to be protective in the auditory organ against damage associated with a variety of health conditions, including noise exposure. Conversely, stressors are also predictive risk factors for hearing disorders. How both of these contrasting stress actions are linked has remained elusive. Here, we demonstrate that higher corticosterone levels during acoustic trauma in female rats is highly correlated with a decline of auditory fiber responses in high-frequency cochlear regions, and that hearing thresholds and the outer hair cell functions (distortion products of otoacoustic emissions) are left unaffected. Moreover, when GC receptor (GR) or mineralocorticoid receptor (MR) activation was antagonized by mifepristone or spironolactone, respectively, GR, but not MR, inhibition significantly and permanently attenuated trauma-induced effects on auditory fiber responses, including inner hair cell ribbon loss and related reductions of early and late auditory brainstem responses. These findings strongly imply that higher corticosterone stress levels profoundly impair auditory nerve processing, which may influence central auditory acuity. These changes are likely GR mediated as they are prevented by mifepristone.	[Singer, Wibke; Kasini, Kamyar; Manthey, Marie; Eckert, Philipp; Armbruster, Philipp; Vogt, Miriam Annika; Jaumann, Mirko; Dotta, Michela; Yamahara, Kohei; Zimmermann, Ulrike; Knipper, Marlies; Ruettiger, Lukas] Univ Tubingen, Tubingen Hearing Res Ctr, Dept Otolaryngol, Mol Physiol Hearing, Tubingen, Germany; [Harasztosi, Csaba] Univ Tubingen, Tubingen Hearing Res Ctr, Dept Otolaryngol, Sect Physiol Acoust & Commun, Tubingen, Germany; [Yamahara, Kohei] Kyoto Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Kyoto, Japan	Knipper, M (corresponding author), Univ Tubingen, Dept Otolaryngol, Tubingen Hearing Res Ctr, Elfriede Aulhorn Str 5, D-72076 Tubingen, Germany.	marlies.knipper@uni-tuebingen.de	aa, a·a/AAC-7392-2019	aa, a·a/0000-0002-3281-7547; Vogt, Miriam Annika/0000-0002-3400-5067	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [DFG-Kni-316-10-1, SPP 1608 RU 316/12-1, KN 316/12-1]	This work was supported by the Deutsche Forschungsgemeinschaft (Grants DFG-Kni-316-10-1, SPP 1608 RU 316/12-1, and KN 316/12-1). The authors thank Michael Paolillo (Interfaculty Institute of Biochemistry, University of Tubingen) for reading the manuscript. The authors declare no conflicts of interest.	Adamec R, 2007, BEHAV BRAIN RES, V179, P192, DOI 10.1016/j.bbr.2007.02.001; Perez MA, 2013, NEUROSCIENCE, V246, P94, DOI 10.1016/j.neuroscience.2013.04.044; Ashmore J, 2008, PHYSIOL REV, V88, P173, DOI 10.1152/physrev.00044.2006; Bharadwaj HM, 2015, J NEUROSCI, V35, P2161, DOI 10.1523/JNEUROSCI.3915-14.2015; Boudaba C, 2006, AM J PHYSIOL-REG I, V291, pR102, DOI 10.1152/ajpregu.00795.2005; Buran BN, 2010, J NEUROSCI, V30, P7587, DOI 10.1523/JNEUROSCI.0389-10.2010; Burkard R.F., 2007, AUDITORY EVOKED POTE, P229; Canlon B, 2007, HEARING RES, V226, P61, DOI 10.1016/j.heares.2006.05.009; Chavez CM, 2009, NEUROBIOL LEARN MEM, V91, P382, DOI 10.1016/j.nlm.2008.10.010; Dagnino-Subiabre A, 2009, BEHAV BRAIN RES, V203, P88, DOI 10.1016/j.bbr.2009.04.024; DALLOS P, 1978, J NEUROPHYSIOL, V41, P365; de Kloet ER, 2013, EUR J PHARMACOL, V719, P53, DOI 10.1016/j.ejphar.2013.04.053; de Kloet ER, 2014, ENDOCRINOLOGY, V155, P2754, DOI 10.1210/en.2014-1048; El Sabbagh NG, 2017, LARYNGOSCOPE, V127, P1897, DOI 10.1002/lary.26394; El-Badry MM, 2007, BRAIN RES, V1134, P122, DOI 10.1016/j.brainres.2006.11.078; Engel J, 2006, NEUROSCIENCE, V143, P837, DOI 10.1016/j.neuroscience.2006.08.060; Felmingham KL, 2012, BIOL PSYCHOL, V90, P224, DOI 10.1016/j.biopsycho.2012.03.011; Fetoni AR, 2016, FREE RADICAL BIO MED, V101, P211, DOI 10.1016/j.freeradbiomed.2016.10.014; Fox LC, 2016, BEHAV BRAIN RES, V312, P362, DOI 10.1016/j.bbr.2016.06.048; Furman AC, 2013, J NEUROPHYSIOL, V110, P577, DOI 10.1152/jn.00164.2013; Griesbach GS, 2012, NEUROSCIENCE, V210, P393, DOI 10.1016/j.neuroscience.2012.03.005; Groeneweg FL, 2011, J ENDOCRINOL, V209, P153, DOI 10.1530/JOE-10-0472; Hickox AE, 2017, HEARING RES, V349, P164, DOI 10.1016/j.heares.2016.12.010; Hobson CE, 2016, CURR OPIN OTOLARYNGO, V24, P407, DOI 10.1097/MOO.0000000000000288; Howland RH, 2013, J PSYCHOSOC NURS MEN, V51, P11, DOI 10.3928/02793695-20121219-01; Jaumann M, 2012, NAT MED, V18, P252, DOI 10.1038/nm.2634; Jia H, 2016, NEUROSCIENCE, V316, P261, DOI 10.1016/j.neuroscience.2015.12.031; Joels M, 2017, J ENDOCRINOL, V234, pT49, DOI 10.1530/JOE-16-0660; JOHNSON DH, 1976, BIOPHYS J, V16, P719, DOI 10.1016/S0006-3495(76)85724-4; Karst H, 2010, P NATL ACAD SCI USA, V107, P14449, DOI 10.1073/pnas.0914381107; Kil SH, 2013, HEARING RES, V299, P63, DOI 10.1016/j.heares.2013.01.020; Kobel M, 2017, HEARING RES, V349, P148, DOI 10.1016/j.heares.2016.12.008; KORTE SM, 1995, PSYCHONEUROENDOCRINO, V20, P385, DOI 10.1016/0306-4530(94)00069-7; Kujawa SG, 2009, J NEUROSCI, V29, P14077, DOI 10.1523/JNEUROSCI.2845-09.2009; Kurabi A, 2017, HEARING RES, V349, P129, DOI 10.1016/j.heares.2016.11.013; Lee HY, 2017, EUR ARCH OTO-RHINO-L, V274, P143, DOI 10.1007/s00405-016-4276-y; Ma LL, 2017, STRESS, V20, P312, DOI 10.1080/10253890.2017.1323861; Marcon S, 2008, HEARING RES, V237, P76, DOI 10.1016/j.heares.2007.12.011; McLean WJ, 2009, JARO-J ASSOC RES OTO, V10, P37, DOI 10.1007/s10162-008-0152-9; Melcher JR, 1996, HEARING RES, V93, P52, DOI 10.1016/0378-5955(95)00200-6; Meltser I, 2011, HEARING RES, V281, P47, DOI 10.1016/j.heares.2011.06.003; Muller M, 2017, HNO, V65, pS59, DOI 10.1007/s00106-016-0266-z; MULLER M, 1991, HEARING RES, V57, P63, DOI 10.1016/0378-5955(91)90075-K; Niedermeier K, 2012, ACTA OTO-LARYNGOL, V132, P1252, DOI 10.3109/00016489.2012.701017; O'Byrne PM, 1998, J ALLERGY CLIN IMMUN, V102, P879, DOI 10.1016/S0091-6749(98)70322-7; O'Leary SJ, 2013, HEARING RES, V298, P27, DOI 10.1016/j.heares.2013.01.012; Oitzl MS, 2010, NEUROSCI BIOBEHAV R, V34, P853, DOI 10.1016/j.neubiorev.2009.07.006; Plontke SK, 2014, OTOL NEUROTOL, V35, P1168, DOI 10.1097/MAO.0000000000000434; RAREY KE, 1995, HEARING RES, V82, P135, DOI 10.1016/0378-5955(94)00171-L; Ruttiger L, 2017, ORL J OTO-RHINO-LARY, V79, P93, DOI 10.1159/000455705; Ruttiger L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057247; Safieddine S, 2012, ANNU REV NEUROSCI, V35, P509, DOI 10.1146/annurev-neuro-061010-113705; Schmiedt RA, 1996, J NEUROPHYSIOL, V76, P2799; Sergeyenko Y, 2013, J NEUROSCI, V33, P13686, DOI 10.1523/JNEUROSCI.1783-13.2013; Sha SH, 2017, EXPERT OPIN INV DRUG, V26, P85, DOI 10.1080/13543784.2017.1269171; Shera CA, 1999, J ACOUST SOC AM, V105, P782, DOI 10.1121/1.426948; Singer W, 2016, METHODS MOL BIOL, V1427, P263, DOI 10.1007/978-1-4939-3615-1_15; Singer W, 2013, MOL NEUROBIOL, V47, P261, DOI 10.1007/s12035-012-8372-8; Tahera Y, 2006, J NEUROSCI RES, V83, P1066, DOI 10.1002/jnr.20795; Tahera Y, 2007, NEUROBIOL DIS, V25, P189, DOI 10.1016/j.nbd.2006.09.004; Tahera Y, 2006, ENDOCRINOLOGY, V147, P4430, DOI 10.1210/en.2006-0260; Terakado M, 2011, HEARING RES, V280, P148, DOI 10.1016/j.heares.2011.05.006; Trune DR, 2012, ANAT REC, V295, P1928, DOI 10.1002/ar.22576; Trune DR, 2006, HEARING RES, V212, P22, DOI 10.1016/j.heares.2005.10.006; Tsigos C., 2000, ENDOTEXT; Wang Y, 2002, JARO, V3, P248, DOI 10.1007/s101620020028; Wang Y, 2002, HEARING RES, V165, P96, DOI 10.1016/S0378-5955(02)00289-7; Yao XF, 1996, ACTA OTO-LARYNGOL, V116, P493, DOI 10.3109/00016489609137879; Yoshida N, 2000, HEARING RES, V148, P213, DOI 10.1016/S0378-5955(00)00161-1; Yoshida N, 1999, HEARING RES, V131, P29, DOI 10.1016/S0378-5955(99)00008-8	70	14	14	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2018	32	6					3005	3019		10.1096/fj.201701041RRR			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GG2TP	WOS:000432546000010	29401591				2021-06-18	
J	Terry, DP; Miller, LS				Terry, Douglas P.; Miller, L. Stephen			Repeated mild traumatic brain injuries is not associated with volumetric differences in former high school football players	BRAIN IMAGING AND BEHAVIOR			English	Article						Concussion; Mild traumatic brain injury; MRI; Brain volume; Atrophy; Cognition	HEAD-INJURY; NEUROCOGNITIVE PERFORMANCE; INTRACRANIAL VOLUME; ALZHEIMERS-DISEASE; AXONAL DAMAGE; CONCUSSION; ABNORMALITIES; ATROPHY; SEGMENTATION; DISORDER	We investigated potential brain volumetric differences in a sample of former high school football players many years after these injuries. Forty community-dwelling males ages 40-65 who played high school football, but not college or professional sports, were recruited. The experimental group (n = 20) endorsed experiencing two or more mTBIs on an empirically validated mTBI assessment tool (median = 3, range = 2-15). The control group (n = 20) denied ever experiencing an mTBI. Participants completed a self-report index of current mTBI symptomatology and underwent high-resolution T1-weighted MRI scanning, which were analyzed using the Freesurfer software package. A priori regions of interest (ROIs) included total intracranial volume (ICV), total gray matter, total white matter, bilateral anterior cingulate cortex, bilateral hippocampi, and lateral ventricles. ROIs were corrected for head size using a normalization method that took ICV into account. Despite an adequate sample size and being matched on age, education, estimated premorbid IQ, current concussive symptomatology, there were no statistically significant volumetric group differences across all of the ROIs. These data suggest that multiple mTBIs from high school football may not be associated with measurable brain atrophy later in life. Accounting for the severity of injury and chronicity of sport exposure may be especially important when measuring long-term neuroanatomical differences.	[Terry, Douglas P.] Harvard Med Sch, Dept Phys Med & Rehabil, Spaulding Rehabil Network, Boston, MA USA; [Terry, Douglas P.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA USA; [Miller, L. Stephen] Univ Georgia, Dept Psychol, 110 Hooper St,Psychol Bldg,Room 163, Athens, GA 30602 USA; [Miller, L. Stephen] Univ Georgia, Biomed & Hlth Sci Inst, BioImaging Res Ctr, Athens, GA 30602 USA	Miller, LS (corresponding author), Univ Georgia, Dept Psychol, 110 Hooper St,Psychol Bldg,Room 163, Athens, GA 30602 USA.; Miller, LS (corresponding author), Univ Georgia, Biomed & Hlth Sci Inst, BioImaging Res Ctr, Athens, GA 30602 USA.	dterry@mgh.harvard.edu; lsmiller@uga.edu			John and Mary Franklin Foundation; University of Georgia BioImaging Research Center	This study was funded by partial support to D.P. Terry by the John and Mary Franklin Foundation and the University of Georgia BioImaging Research Center.	Arciniegas D, 2000, J NEUROPSYCH CLIN N, V12, P77, DOI 10.1176/jnp.12.1.77; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Buckner RL, 2004, NEUROIMAGE, V23, P724, DOI 10.1016/j.neuroimage.2004.06.018; Canu E, 2010, J ALZHEIMERS DIS, V19, P963, DOI 10.3233/JAD-2010-1295; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control, 2010, INJ PREV CONTR TRAUM; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Du AT, 2006, NEUROBIOL AGING, V27, P733, DOI 10.1016/j.neurobiolaging.2005.03.021; Erickson KI, 2009, HIPPOCAMPUS, V19, P1030, DOI 10.1002/hipo.20547; Faul M, 2010, TRAUMATIC BRAIN INJU, P2; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Gioia G.A., 2006, ACUTE CONCUSSION EVA; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Head D, 2008, NEUROPSYCHOLOGY, V22, P491, DOI 10.1037/0894-4105.22.4.491; Henry LC, 2017, NEUROSCIENTIST, V23, P567, DOI 10.1177/1073858416651034; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Jarrett M, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00011; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kendler KS, 2008, PSYCHOL MED, V38, P1001, DOI 10.1017/S0033291707001821; Kramer JH, 2007, NEUROPSYCHOLOGY, V21, P412, DOI 10.1037/0894-4105.21.4.412; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; List J, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00228; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Moffitt TE, 2007, ARCH GEN PSYCHIAT, V64, P651, DOI 10.1001/archpsyc.64.6.651; Monti JM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00041; Morey RA, 2009, NEUROIMAGE, V45, P855, DOI 10.1016/j.neuroimage.2008.12.033; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Piland SG, 2010, J ATHL TRAINING, V45, P273, DOI 10.4085/1062-6050-45.3.273; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Ross DE, 2014, NEUROIMAGE, V102, P565, DOI 10.1016/j.neuroimage.2014.07.043; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; Sanfilipo MP, 2004, NEUROIMAGE, V22, P1732, DOI 10.1016/j.neuroimage.2004.03.037; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Terribilli D, 2011, NEUROBIOL AGING, V32, P354, DOI 10.1016/j.neurobiolaging.2009.02.008; Terry D. P., 2016, NAT AC NEUR ANN C OC; Terry DP, 2015, ARCH CLIN NEUROPSYCH, V30, P341, DOI 10.1093/arclin/acv020; Tremblay S, 2014, BRAIN, V137, P2997, DOI 10.1093/brain/awu236; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Wierenga CE, 2007, NEUROPSYCHOL REV, V17, P127, DOI 10.1007/s11065-007-9025-y; Wilde EA, 2016, BRAIN INJURY, V30, P1442, DOI 10.1080/02699052.2016.1219063; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	57	14	14	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2018	12	3					631	639		10.1007/s11682-017-9719-6			9	Neuroimaging	Neurosciences & Neurology	GI6PB	WOS:000434491400002	28434160				2021-06-18	
J	Zhang, MH; Zhou, XM; Cui, JZ; Wang, KJ; Feng, Y; Zhang, HA				Zhang, Man-He; Zhou, Xiu-Min; Cui, Jian-Zhong; Wang, Kai-Jie; Feng, Yan; Zhang, Hong-Ao			Neuroprotective effects of dexmedetomidine on traumatic brain injury: Involvement of neuronal apoptosis and HSP70 expression	MOLECULAR MEDICINE REPORTS			English	Article						traumatic brain injury; dexmedetomidine; apoptosis; heat shock proteins; hippocampus; neuron	ISCHEMIA/REPERFUSION INJURY; RATS; ISCHEMIA; PATHOPHYSIOLOGY; HIPPOCAMPUS; PROTECTION; PROPOFOL; MODEL	The aim of the present study was to investigate the protective effect of dexmedetomidine (Dex) on traumatic brain injury (TBI), and further evaluate whether the underlying neuroprotective mechanisms are associated with neurological apoptosis and the expression of 70 kDa heat shock protein (HSP70) in the hippocampus. A total of 90 adult male Sprague-Dawley rats were randomly assigned into 3 groups (n=30/group): Sham, TBI and Dex groups. The rat models of TBI were established using a modified weight-drop device and Dex (15 mu g/kg) was intravenously administered immediately following TBI. The brain edema and neurological function outcomes of TBI were assessed using wet-dry weight analysis and the Neurological Severity Score method. The expression levels of B-cell lymphoma-2 (Bcl-2) and Bcl-2-associated X protein (Bax) in the rat hippocampus were evaluated using immunohistochemical staining and western blot analysis. The protein levels of HSP70 in the hippocampal region were analyzed using western blot analysis. The results of the present study revealed that administration of Dex post-TBI improved brain edema and neurological outcomes, due to the attenuation of the TBI-induced reduction of Bax expression and increase of Bcl-2 and HSP70 expression. In conclusion, the results of the present study suggested that administration of Dex may serve as a neuroprotective agent against brain injury, at least partially via the inhibition of neuronal apoptosis and upregulation of HSP70 expression in the hippocampus.	[Zhang, Man-He; Cui, Jian-Zhong; Feng, Yan] Hebei Med Univ, Dept Surg, 361 East Zhongshan Rd, Shijiazhuang 050017, Hebei, Peoples R China; [Zhou, Xiu-Min; Wang, Kai-Jie; Zhang, Hong-Ao] Tangshan Workers Hosp, Dept Neurosurg, Tangshan 063000, Hebei, Peoples R China	Cui, JZ (corresponding author), Hebei Med Univ, Dept Surg, 361 East Zhongshan Rd, Shijiazhuang 050017, Hebei, Peoples R China.	jzcdoctor@163.com			Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2012401071, 2014105079]	The present study was supported by a grant from the Natural Science Foundation of Hebei Province (grant nos. H2012401071 and 2014105079).	Anderson MA, 2014, SEMIN HEMATOL, V51, P219, DOI 10.1053/j.seminhematol.2014.05.008; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Cai Y, 2014, MOL MED REP, V9, P1542, DOI 10.3892/mmr.2014.2034; Cheng G, 2013, MED HYPOTHESES, V80, P115, DOI 10.1016/j.mehy.2012.11.004; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Fanselow MS, 2010, NEURON, V65, P7, DOI 10.1016/j.neuron.2009.11.031; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; Goyagi T, 2014, BRAIN RES, V1566, P24, DOI 10.1016/j.brainres.2014.04.013; Guler L, 2014, ADV CLIN EXP MED, V23, P683, DOI 10.17219/acem/37214; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Harvey LA, 2012, INJURY, V43, P1821, DOI 10.1016/j.injury.2012.07.188; James ML, 2012, ANAESTH INTENS CARE, V40, P949, DOI 10.1177/0310057X1204000605; Jiang LL, 2014, MOL MED REP, V9, P419, DOI 10.3892/mmr.2013.1867; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Liao ZX, 2014, BRAIN RES BULL, V107, P69, DOI 10.1016/j.brainresbull.2014.07.001; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Mangat Halinder S, 2012, Continuum (Minneap Minn), V18, P532, DOI 10.1212/01.CON.0000415426.76524.e1; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Nasrallah N A, 2016, CHEST, V150, p228A, DOI [10.1016/j.chest.2016.08.241, DOI 10.1016/J.CHEST.2016.08.241]; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Sato A, 2017, YAKUGAKU ZASSHI, V137, P1315, DOI 10.1248/yakushi.17-00131; Shamas-Din A, 2011, BBA-MOL CELL RES, V1813, P508, DOI 10.1016/j.bbamcr.2010.11.024; Shen M, 2017, BIOMED PHARMACOTHER, V95, P885, DOI 10.1016/j.biopha.2017.08.125; Si YN, 2014, EUR REV MED PHARMACO, V18, P1843; Smania N, 2013, J HEAD TRAUMA REHAB, V28, P131, DOI 10.1097/HTR.0b013e31823c0127; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Wang XM, 2013, BRAIN INJURY, V27, P1617, DOI 10.3109/02699052.2013.831130; Wang Z, 2014, NEUROREHABILITATION, V35, P825, DOI 10.3233/NRE-141177; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; Xiong B, 2014, BRAIN INJURY, V28, P1003, DOI 10.3109/02699052.2014.888765; Xu XD, 2018, METAB BRAIN DIS, V33, P115, DOI 10.1007/s11011-017-0129-7; Yang NL, 2010, PRACT PREV MED, V17, P243; Zhang JN, 2012, J NEUROTRAUM, V29, P2597, DOI 10.1089/neu.2012.2348; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhua YM, 2013, BRAIN RES, V1494, P1, DOI 10.1016/j.brainres.2012.11.047; Zink BJ, 2010, PSYCHIAT CLIN N AM, V33, P741, DOI 10.1016/j.psc.2010.08.005	41	14	16	0	2	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	JUN	2018	17	6					8079	8086		10.3892/mmr.2018.8898			8	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	GJ5AQ	WOS:000435394000076	29693126	Other Gold, Green Published			2021-06-18	
J	Huang, TQ; Zhao, JJ; Guo, D; Pang, HG; Zhao, YL; Song, JN				Huang, Tingqin; Zhao, Junjie; Guo, Dan; Pang, Honggang; Zhao, Yonglin; Song, Jinning			Curcumin mitigates axonal injury and neuronal cell apoptosis through the PERK/Nrf2 signaling pathway following diffuse axonal injury	NEUROREPORT			English	Article						curcumin; diffuse axonal injury; endoplasmic reticulum stress; nuclear factor-erythroid 2-related factor 2; unfolded protein response	ENDOPLASMIC-RETICULUM-STRESS; TRAUMATIC BRAIN-INJURY; UNFOLDED PROTEIN RESPONSE; ACTIVATING TRANSCRIPTION FACTOR-4; INDUCED ER STRESS; OXIDATIVE STRESS; CLINICOPATHOLOGICAL ENTITY; DEPENDENT ACTIVATION; HEME OXYGENASE-1; RAT	Diffuse axonal injury (DAI) accounts for more than 50% of all traumatic brain injury. In response to the mechanical damage associated with DAI, the abnormal proteins produced in the neurons and axons, namely, -APP and p-tau, induce endoplasmic reticulum (ER) stress. Curcumin, a major component extracted from the rhizome of Curcuma longa, has shown potent anti-inflammatory, antioxidant, anti-infection, and antitumor activity in previous studies. Moreover, curcumin is an activator of nuclear factor-erythroid 2-related factor 2 (Nrf2) and promotes its nuclear translocation. In this study, we evaluated the therapeutic potential of curcumin for the treatment of DAI and investigated the mechanisms underlying the protective effects of curcumin against neural cell death and axonal injury after DAI. Rats subjected to a model of DAI by head rotational acceleration were treated with vehicle or curcumin to evaluate the effect of curcumin on neuronal and axonal injury. We observed that curcumin (20 mg/kg intraperitoneal) administered 1h after DAI induction alleviated the aggregation of p-tau and beta-APP in neurons, reduced ER-stress-related cell apoptosis, and ameliorated neurological deficits. Further investigation showed that the protective effect of curcumin in DAI was mediated by the PERK/Nrf2 pathway. Curcumin promoted PERK phosphorylation, and then Nrf2 dissociated from Keap1 and was translocated to the nucleus, which activated ATF4, an important bZIP transcription factor that maintains intracellular homeostasis, but inhibited the CHOP, a hallmark of ER stress and ER-associated programmed cell death. In summary, we demonstrate for the first time that curcumin confers protection against abnormal proteins and neuronal apoptosis after DAI, that the process is mediated by strengthening of the unfolded protein response to overcome ER stress, and that the protective effect of curcumin against DAI is dependent on the activation of Nrf2. Copyright (C) 2018 The Author(s). Published by Wolters Kluwer Health, Inc.	[Huang, Tingqin; Zhao, Junjie; Guo, Dan; Pang, Honggang; Zhao, Yonglin; Song, Jinning] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Neurosurg, 277 West Yanta Rd, Xian 710061, Shaanxi, Peoples R China	Song, JN (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Neurosurg, 277 West Yanta Rd, Xian 710061, Shaanxi, Peoples R China.	jinningsong@126.com					Aydin Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10087-6; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Boone DR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127287; Chen FY, 2015, J MOL NEUROSCI, V55, P995, DOI 10.1007/s12031-014-0456-7; Chen WJ, 2013, INT J ONCOL, V42, P963, DOI 10.3892/ijo.2013.1774; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Cong XQ, 2016, BIOL TRACE ELEM RES, V173, P390, DOI 10.1007/s12011-016-0668-5; Cui QL, 2016, MOL MED REP, V13, P1381, DOI 10.3892/mmr.2015.4657; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Cullinan SB, 2006, INT J BIOCHEM CELL B, V38, P317, DOI 10.1016/j.biocel.2005.09.018; Cullinan SB, 2004, J BIOL CHEM, V279, P20108, DOI 10.1074/jbc.M314219200; Dash PK, 2015, J NEUROTRAUM, V32, P1608, DOI 10.1089/neu.2014.3772; Davceva N, 2012, J FORENSIC LEG MED, V19, P413, DOI 10.1016/j.jflm.2012.04.011; Davceva N, 2015, AM J FOREN MED PATH, V36, P127, DOI 10.1097/PAF.0000000000000168; Duan ZQ, 2014, NEUROTOXICOLOGY, V44, P149, DOI 10.1016/j.neuro.2014.06.005; Ehren JL, 2013, BIOCHEM PHARMACOL, V85, P1816, DOI 10.1016/j.bcp.2013.04.010; Fan Xiao-Fang, 2012, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V28, P561; GERMANO AF, 1994, J NEUROTRAUM, V11, P345, DOI 10.1089/neu.1994.11.345; GIUFFRIDA AM, 1975, J NEUROCHEM, V24, P749; Hayashi Takahito, 2009, Leg Med (Tokyo), V11 Suppl 1, pS171, DOI 10.1016/j.legalmed.2009.01.076; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; He XS, 2010, ACTA NEUROL BELG, V110, P49; He XS, 2000, J NEUROSURG, V93, P626, DOI 10.3171/jns.2000.93.4.0626; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Hoozemans JJM, 2012, NEURODEGENER DIS, V10, P212, DOI 10.1159/000334536; Huang TQ, 2017, MOL MED REP, V15, P3001, DOI 10.3892/mmr.2017.6350; Imaizumi Kazunori, 2013, Clin Calcium, V23, P1759, DOI CliCa131217591766; Jiang H, 2011, BIOL PHARM BULL, V34, P1194, DOI 10.1248/bpb.34.1194; Kaur B, 1999, J CLIN PATHOL, V52, P203, DOI 10.1136/jcp.52.3.203; Kim JK, 2014, INT J MOL SCI, V15, P12149, DOI 10.3390/ijms150712149; Kim KM, 2007, CIRC RES, V101, P919, DOI 10.1161/CIRCRESAHA.107.154781; King MK, 2014, PHARMACOL THERAPEUT, V141, P1, DOI 10.1016/j.pharmthera.2013.07.010; Krajewska M, 2011, BRAIN RES, V1370, P227, DOI 10.1016/j.brainres.2010.11.015; Kuo CP, 2011, ANESTHESIOLOGY, V115, P1229, DOI 10.1097/ALN.0b013e31823306f0; Lee BW, 2011, TOXICOL APPL PHARM, V252, P47, DOI 10.1016/j.taap.2011.01.018; Li W, 2016, MICROVASC RES, V106, P117, DOI 10.1016/j.mvr.2015.12.008; Li Y, 2013, BRAIN RES, V1495, P95, DOI 10.1016/j.brainres.2012.12.005; Liu CL, 2014, INT J MOL MED, V33, P499, DOI 10.3892/ijmm.2013.1603; Logsdon AE, 2016, BRAIN RES, V1643, P140, DOI 10.1016/j.brainres.2016.04.063; Lu M, 2003, J NEUROSCI METH, V128, P183, DOI 10.1016/S0165-0270(03)00188-2; Luis A, 2014, FREE RADICAL BIO MED, V77, P217, DOI 10.1016/j.freeradbiomed.2014.09.008; Ma JW, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/9746313; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Miller DM, 2015, EXP NEUROL, V264, P103, DOI 10.1016/j.expneurol.2014.11.008; Mohajeri M, 2015, NEUROPHARMACOLOGY, V99, P156, DOI 10.1016/j.neuropharm.2015.07.013; Oakes SA, 2015, ANNU REV PATHOL-MECH, V10, P173, DOI 10.1146/annurev-pathol-012513-104649; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Pahl HL, 1999, PHYSIOL REV, V79, P683; Pang H., 2016, MEDIAT INFLAMM, V2016; Patel S, 2017, NEUROSCI BIOBEHAV R, V83, P589, DOI 10.1016/j.neubiorev.2017.08.025; Peidis P, 2011, CELL DEATH DIFFER, V18, P145, DOI 10.1038/cdd.2010.76; Periyasamy P, 2017, PROG RETIN EYE RES, V60, P1, DOI 10.1016/j.preteyeres.2017.08.003; Pluquet O, 2015, AM J PHYSIOL-CELL PH, V308, pC415, DOI 10.1152/ajpcell.00334.2014; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rao JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065568; RAVINDRANATH V, 1980, TOXICOLOGY, V16, P259, DOI 10.1016/0300-483X(80)90122-5; Rozpedek W, 2016, CURR MOL MED, V16, P533, DOI 10.2174/1566524016666160523143937; Ryu J, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0153-3; Sato Y, 2017, MOL GENET METAB REP, V10, P56, DOI 10.1016/j.ymgmr.2017.01.006; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Sprenkle NT, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0183-y; Su E, 2016, TRANSLATIONAL RES TR, P41; Su Q, 2008, J BIOL CHEM, V283, P469, DOI 10.1074/jbc.M704612200; Taniguchi M, 2015, CURR OPIN NEPHROL HY, V24, P345, DOI 10.1097/MNH.0000000000000141; Tao TQ, 2015, APOPTOSIS, V20, P285, DOI 10.1007/s10495-014-1081-1; Tenkerian C, 2015, MOL CANCER RES, V13, P1377, DOI 10.1158/1541-7786.MCR-15-0184-T; Urra H, 2013, BBA-MOL CELL RES, V1833, P3507, DOI 10.1016/j.bbamcr.2013.07.024; Vajtr D, 2012, Soud Lek, V57, P7; Wang JC, 2016, INT J CARDIOL, V203, P779, DOI 10.1016/j.ijcard.2015.11.033; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu G, 2016, MED SCI MONITOR, V22, P2161, DOI 10.12659/MSM.896568; Yang CH, 2009, BRAIN RES, V1282, P133, DOI 10.1016/j.brainres.2009.05.009; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Yuruker V, 2015, METAB BRAIN DIS, V30, P223, DOI 10.1007/s11011-014-9623-3; Zhang C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101523; Zhang HY, 2015, MOL NEUROBIOL, V51, P1343, DOI 10.1007/s12035-014-8813-7; Zhang P, 2016, J PROTEOMICS, V133, P93, DOI 10.1016/j.jprot.2015.12.014; Zhang RR, 2017, MOL NEUROBIOL, V54, P6006, DOI 10.1007/s12035-016-0111-0; Zhao YL, 2016, NEURAL REGEN RES, V11, P944, DOI 10.4103/1673-5374.184493; Zhao YL, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/1570917; Zhao YL, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/4706915; Zhao ZW, 2017, BIOMED PHARMACOTHER, V92, P1103, DOI 10.1016/j.biopha.2017.05.099; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59; Zhu YF, 2015, EUR J PHARMACOL, V762, P239, DOI 10.1016/j.ejphar.2015.06.002; Zong ZH, 2012, BBA-MOL CELL RES, V1823, P1395, DOI 10.1016/j.bbamcr.2012.06.001	89	14	14	2	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	MAY 23	2018	29	8					661	677		10.1097/WNR.0000000000001015			17	Neurosciences	Neurosciences & Neurology	GE5YR	WOS:000431301100009	29570500	Green Published, Other Gold			2021-06-18	
J	Sauerbeck, AD; Fanizzi, C; Kim, JH; Gangolli, M; Bayly, PV; Wellington, CL; Brody, DL; Kummer, TT				Sauerbeck, A. D.; Fanizzi, C.; Kim, J. H.; Gangolli, M.; Bayly, P. V.; Wellington, C. L.; Brody, D. L.; Kummer, T. T.			modCHIMERA: a novel murine closed-head model of moderate traumatic brain injury	SCIENTIFIC REPORTS			English	Article							IMPACT MODEL; MILD; EPIDEMIOLOGY; BIOMECHANICS; HEMORRHAGE; DISORDERS; PATHOLOGY; TIME	Traumatic brain injury is a major source of global disability and mortality. Preclinical TBI models are a crucial component of therapeutic investigation. We report a tunable, monitored model of murine non-surgical, diffuse closed-head injury-modCHIMERA-characterized by impact as well as linear and rotational acceleration. modCHIMERA is based on the Closed-Head Impact Model of Engineered Rotational Acceleration (CHIMERA) platform. We tested this model at 2 energy levels: 1.7 and 2.1 Joules-substantially higher than previously reported for this system. Kinematic analysis demonstrated linear acceleration exceeding injury thresholds in humans, although outcome metrics tracked impact energy more closely than kinematic parameters. Acute severity metrics were consistent with a complicated-mild or moderate TBI, a clinical population characterized by high morbidity but potentially reversible pathology. Axonal injury was multifocal and bilateral, neuronal death was detected in the hippocampus, and microglial neuroinflammation was prominent. Acute functional analysis revealed prolonged post-injury unconsciousness, and decreased spontaneous behavior and stimulated neurological scores. Neurobehavioral deficits were demonstrated in spatial learning/memory and socialization at 1-month. The overall injury profile of modCHIMERA corresponds with the range responsible for a substantial portion of TBI-related disability in humans. modCHIMERA should provide a reliable platform for efficient analysis of TBI pathophysiology and testing of treatment modalities.	[Sauerbeck, A. D.; Fanizzi, C.; Kim, J. H.; Brody, D. L.; Kummer, T. T.] Washington Univ St Louis, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Fanizzi, C.] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Neurosurg, Milan, Italy; [Gangolli, M.] Washington Univ St Louis, Sch Med, Dept Biomed Engn, St Louis, MO USA; [Bayly, P. V.] Washington Univ St Louis, Mech Engn & Mat Sci, St Louis, MO USA; [Wellington, C. L.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada	Kummer, TT (corresponding author), Washington Univ St Louis, Sch Med, Dept Neurol, St Louis, MO 63110 USA.	kummert@wustl.edu	Fanizzi, Claudia/AAI-4342-2021	Fanizzi, Claudia/0000-0001-5560-036X; Kummer, Terrance/0000-0001-8938-8280	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5K08NS094760-02, T32NS007205]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007205, K08NS094760] Funding Source: NIH RePORTER	The authors would like to thank Richard Davenport, Samuel Kim, Maverick Salyards, Dhananjay R. Namjoshi, and Asma Bashir for technical support and advice. This work was supported by the National Institutes of Health [5K08NS094760-02, TTK; T32NS007205, ADS].	Godoy DA, 2016, NEUROCRIT CARE, V25, P306, DOI 10.1007/s12028-016-0253-y; [Anonymous], 2016, INJURY MODELS CENTRA; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA, P1; Centers for Disease Control and Prevention National Center for Injury Prevention and Control, 2016, TRAUM BRAIN INJ CONC; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; COLOHAN ART, 1992, J NEUROTRAUM, V9, pS259; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Hasan KM, 2001, J MAGN RESON IMAGING, V13, P769, DOI 10.1002/jmri.1107; Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880; Hessen E, 2009, BRAIN INJURY, V23, P234, DOI 10.1080/02699050902748349; Hong S, 2016, SCIENCE, V352, P712, DOI 10.1126/science.aad8373; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Iverson GL, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/415740; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Kaidanovich-Beilin O, 2011, JOVE-J VIS EXP, DOI 10.3791/2473; Kalish BT, 2016, METHODS MOL BIOL, V1462, P193, DOI 10.1007/978-1-4939-3816-2_12; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Lifshitz J., 2016, METHOD MOL BIOL, V1462, P369; M. o. C. M. T. W. G., 2009, CLIN PRACT GUID MAN, P1; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; McIntosh AS, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005078; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Moy SS, 2004, GENES BRAIN BEHAV, V3, P287, DOI 10.1111/j.1601-1848.2004.00076.x; Namjoshi DR, 2017, EXP NEUROL, V292, P80, DOI 10.1016/j.expneurol.2017.03.003; Namjoshi DR, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-55; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Ommaya AK, 1967, P 11 STAPP CAR CRASH, P670906; Panzer MB, 2014, EXP NEUROL, V261, P120, DOI 10.1016/j.expneurol.2014.07.002; Parikh U, 2016, J NEUROPATH EXP NEUR, V75, P731, DOI 10.1093/jnen/nlw045; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P306, DOI 10.1017/S1355617709991342; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Sauerbeck A, 2012, EXP NEUROL, V234, P85, DOI 10.1016/j.expneurol.2011.12.012; Sauerbeck AD, 2015, J NEUROTRAUM, V32, P159, DOI 10.1089/neu.2014.3497; Schoch KM, 2016, NEURON, V90, P941, DOI 10.1016/j.neuron.2016.04.042; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Spitz G, 2017, J NEUROTRAUM, V34, P807, DOI 10.1089/neu.2016.4527; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Tayim FM, 2016, J CLIN EXP NEUROPSYC, V38, P1005, DOI 10.1080/13803395.2016.1182968; TEASDALE G, 1974, LANCET, V2, P81; Titova E, 2009, NEUROL RES, V31, P568, DOI 10.1179/174313209X382412; Toyama M, 2017, CEPHALALGIA, V37, P1317, DOI 10.1177/0333102416678387; Veeramuthu V, 2015, J NEUROTRAUM, V32, P1497, DOI 10.1089/neu.2014.3750; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Wassenbergh S. V., 2007, BUTTERWORTH FILTER M; Wenk Gary L, 2004, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0805as26; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407	65	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	MAY 16	2018	8								7677	10.1038/s41598-018-25737-6			17	Multidisciplinary Sciences	Science & Technology - Other Topics	GF9CS	WOS:000432274300002	29769541	DOAJ Gold, Green Published			2021-06-18	
J	Amyot, F; Kenney, K; Moore, C; Haber, M; Turtzo, LC; Shenouda, C; Silverman, E; Gong, YH; Qu, BX; Harburg, L; Lu, HZY; Wassermann, EM; Diaz-Arrastia, R				Amyot, Franck; Kenney, Kimbra; Moore, Carol; Haber, Margalit; Turtzo, L. Christine; Shenouda, Christian; Silverman, Erika; Gong, Yunhua; Qu, Bao-Xi; Harburg, Leah; Lu, Hanzhang Y.; Wassermann, Eric M.; Diaz-Arrastia, Ramon			Imaging of Cerebrovascular Function in Chronic Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; cerebrovascular reactivity; hypercapnia; magnetic resonance imaging-blood oxygen level dependent; neurovascular unit; traumatic brain injury; traumatic cerebrovascular injury	CEREBRAL-BLOOD-FLOW; BIOGENIC-AMINE CONTENT; TRANSCRANIAL DOPPLER; UNITED-STATES; REACTIVITY; CONSEQUENCES; RECOVERY; EPIDEMIOLOGY; HYPOTHERMIA; HYPERCAPNIA	Traumatic cerebrovascular injury (TCVI) is a common pathologic mechanism of traumatic brain injury (TBI) and presents an attractive target for intervention. The aims of this study were to assess cerebral blood flow (CBF) and cerebrovascular reactivity (CVR) using magnetic resonance imaging (MRI) to assess their value as biomarkers of TCVI in chronic TBI, characterize the spatial distribution of TCVI, and assess the relationships between each biomarker and neuropsychological and clinical assessments. Forty-two subjects (27 chronic TBI, 15 age- and gender-matched healthy volunteers) were studied cross-sectionally. CBF was measured by arterial spin labeling and CVR by assessing the MRI-blood oxygen level-dependent signal with hypercapnia challenge. A focused neuropsychological battery adapted from the TBI Common Data Elements and neurobehavioral symptom questionnaires were administered at the time of the imaging session. Chronic TBI subjects showed a significant reduction in mean global, gray matter (GM), and white matter (WM) CVR, compared with healthy volunteers (p<0.001). Mean GM CVR had the greatest effect size (Cohen's d=0.9). CVR maps in chronic TBI subjects showed patchy, multifocal CVR deficits. CBF discriminated poorly between TBI subjects and healthy volunteers and did not correlate with CVR. Mean global CVR correlated best with chronic neurobehavioral symptoms among TBI subjects. Global, GM, and WM CVR are reliable and potentially useful biomarkers of TCVI in the chronic stage after moderate-to-severe TBI. CBF is less useful as biomarker of TCVI. CVR correlates best with chronic TBI symptoms. CVR has potential as a predictive and pharmacodynamic biomarker for interventions targeting TCVI.	[Amyot, Franck; Kenney, Kimbra; Moore, Carol; Qu, Bao-Xi; Harburg, Leah] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Haber, Margalit; Silverman, Erika; Gong, Yunhua; Diaz-Arrastia, Ramon] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Turtzo, L. Christine; Shenouda, Christian] NINDS, Ctr Neurosci & Regenerat Med, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Lu, Hanzhang Y.] Johns Hopkins Univ, Dept Radiol & Radiol Sci, Baltimore, MD USA; [Wassermann, Eric M.] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA	Diaz-Arrastia, R (corresponding author), Univ Penn, Dept Neurol, Perelman Sch Med, Penn Presbyterian Med Ctr, 51 North 39th St, Philadelphia, PA 19104 USA.	Ramon.Diaz-Arrastia@uphs.upenn.edu	Wassermann, Eric M./AAC-9064-2020	Wassermann, Eric M./0000-0003-0628-0210	Center for Neuroscience and Regenerative Medicine (CNRM), Uniformed Services University of the Health Sciences (USUHS), Bethesda, MD; Military Clinical Neuroscience Center of Excellence (MCNCoE), Department of Neurology, USUHS; Intramural Research Program of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS002977] Funding Source: NIH RePORTER	Work in the authors' laboratory was supported by the Center for Neuroscience and Regenerative Medicine (CNRM), Uniformed Services University of the Health Sciences (USUHS), Bethesda, MD, by the Military Clinical Neuroscience Center of Excellence (MCNCoE), Department of Neurology, USUHS, and by the Intramural Research Program of the National Institutes of Health. The contents of this paper are solely the responsibility of the authors and do not represent the official views of the Department of Defense, CNRM, MCNCoE, or the National Institutes of Health.	[Anonymous], 2008, GULF WAR HLTH, V7; Bailey DM, 2013, CLIN SCI, V124, P177, DOI 10.1042/CS20120259; Baranova AI, 2008, J NEUROSURG, V109, P502, DOI 10.3171/JNS/2008/109/9/0502; Besancon E, 2008, TRENDS PHARMACOL SCI, V29, P268, DOI 10.1016/j.tips.2008.02.003; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Diomedi M, 2005, NEUROLOGY, V65, P919, DOI 10.1212/01.wnl.0000173835.12308.bb; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Ellis MJ, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00061; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Furuya Y, 2003, NEUROSURGERY, V52, P340, DOI 10.1227/01.NEU.0000043931.83041.AA; Gao GY, 2010, J CEREBR BLOOD F MET, V30, P628, DOI 10.1038/jcbfm.2009.235; Gardner AJ, 2015, BRIT J SPORT MED, V49, P1050, DOI 10.1136/bjsports-2014-093901; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; INOUE M, 1991, J CEREBR BLOOD F MET, V11, P242, DOI 10.1038/jcbfm.1991.56; Kassner Andrea, 2004, Top Magn Reson Imaging, V15, P58, DOI 10.1097/00002142-200402000-00006; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P187, DOI 10.1097/00001199-200505000-00001; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lu H., 2014, JOVE-J VIS EXP, P17; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Menon DK, 2006, CURR OPIN CRIT CARE, V12, P85, DOI 10.1097/01.ccx.0000216572.19062.8f; Mutch WAC, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00107; Mutch WAC, 2016, J NEUROSURG, V125, P648, DOI 10.3171/2015.6.JNS15972; Mutch WAC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102181; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nicolakakis N, 2011, J CEREBR BLOOD F MET, V31, P1354, DOI 10.1038/jcbfm.2011.43; Nicolakakis N, 2011, J CEREBR BLOOD F MET, V31, P200, DOI 10.1038/jcbfm.2010.78; Oda Y, 2011, J CEREBR BLOOD F MET, V31, P1143, DOI 10.1038/jcbfm.2010.208; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; PAPPIUS HM, 1988, J CEREBR BLOOD F MET, V8, P324, DOI 10.1038/jcbfm.1988.67; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Wang JY, 2014, NEUROBIOL DIS, V68, P91, DOI 10.1016/j.nbd.2014.04.014; Wei EP, 2009, J NEUROTRAUM, V26, P527, DOI 10.1089/neu.2008.0797; Yezhuvath US, 2012, NEUROBIOL AGING, V33, P75, DOI 10.1016/j.neurobiolaging.2010.02.005; Yezhuvath US, 2009, NMR BIOMED, V22, P779, DOI 10.1002/nbm.1392; Zhu YS, 2013, J CEREBR BLOOD F MET, V33, P1190, DOI 10.1038/jcbfm.2013.66	41	14	14	2	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2018	35	10					1116	1123		10.1089/neu.2017.5114			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GF8DL	WOS:000432198500002	29065769	Green Published			2021-06-18	
J	Thurman, DJ; Begley, CE; Carpio, A; Helmers, S; Hesdorffer, DC; Mu, J; Toure, K; Parko, KL; Newton, CR				Thurman, David J.; Begley, Charles E.; Carpio, Arturo; Helmers, Sandra; Hesdorffer, Dale C.; Mu, Jie; Toure, Kamadore; Parko, Karen L.; Newton, Charles R.			The primary prevention of epilepsy: A report of the Prevention Task Force of the International League Against Epilepsy	EPILEPSIA			English	Article						central nervous system infection; epidemiology; etiology; perinatal brain injury; prevalence; stroke; traumatic brain injury	ACTIVE CONVULSIVE EPILEPSY; NEW-ONSET EPILEPSY; LONG-TERM RISK; GLOBAL LEVELS; RURAL AREA; PREVALENCE; POPULATION; SEIZURES; NEUROCYSTICERCOSIS; ETIOLOGY	Among the causes of epilepsy are several that are currently preventable. In this review, we summarize the public health burden of epilepsy arising from such causes and suggest priorities for primary epilepsy prevention. We conducted a systematic review of published epidemiologic studies of epilepsy of 4 preventable etiologic categoriesperinatal insults, traumatic brain injury (TBI), central nervous system (CNS) infection, and stroke. Applying consistent criteria, we assessed the quality of each study and extracted data on measures of risk from those with adequate quality ratings, summarizing findings across studies as medians and interquartile ranges. Among higher-quality population-based studies, the median prevalence of active epilepsy across all ages was 11.1 per 1000 population in lower- and middle-income countries (LMIC) and 7.0 per 1000 in high-income countries (HIC). Perinatal brain insults were the largest attributable fraction of preventable etiologies in children, with median estimated fractions of 17% in LMIC and 15% in HIC. Stroke was the most common preventable etiology among older adults with epilepsy, both in LMIC and in HIC, accounting for half or more of all new onset cases. TBI was the attributed cause in nearly 5% of epilepsy cases in HIC and LMIC. CNS infections were a more common attributed cause in LMIC, accounting for about 5% of all epilepsy cases. Among some rural LMIC communities, the median proportion of epilepsy cases attributable to endemic neurocysticercosis was 34%. A large proportion of the overall public health burden of epilepsy is attributable to preventable causes. The attributable fraction for perinatal causes, infections, TBI, and stroke in sum reaches nearly 25% in both LMIC and HIC. Public health interventions addressing maternal and child health care, immunizations, public sanitation, brain injury prevention, and stroke prevention have the potential to significantly reduce the burden of epilepsy.	[Thurman, David J.; Helmers, Sandra] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Begley, Charles E.] Univ Texas Houston, Sch Publ Hlth, Hlth Sci Ctr Houston, Houston, TX USA; [Carpio, Arturo] Univ Cuenca, Fac Med Sci, Cuenca, Ecuador; [Hesdorffer, Dale C.] Columbia Univ, Med Ctr, Gertrude H Sergievsky Ctr, New York, NY USA; [Hesdorffer, Dale C.] Columbia Univ, Med Ctr, Dept Epidemiol, New York, NY USA; [Mu, Jie] Sichuan Univ, Dept Neurol, West China Hosp, Chengdu, Sichuan, Peoples R China; [Toure, Kamadore] Fann Univ Hosp, Dept Neurol, Dakar, Senegal; [Parko, Karen L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Newton, Charles R.] Kenya Govt Med Res Ctr, Wellcome Trust Collaborat Program, Kilifi, Kenya; [Newton, Charles R.] Univ Oxford, Dept Psychiat, Oxford, England	Thurman, DJ (corresponding author), Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.	david.j.thurman@emory.edu	Newton, Charles/V-7872-2019; Newton, Charles RJC/B-7578-2014	Newton, Charles/0000-0002-6999-5507; Newton, Charles RJC/0000-0002-6999-5507; Thurman, David/0000-0002-0533-7062; Carpio, Arturo/0000-0002-5821-6379	UCBUCB Pharma SA; Patient-Centered Outcomes Research InstitutePatient-Centered Outcomes Research Institute - PCORI; U.S. National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Epilepsy Study Consortium; Wellcome Trust, UKWellcome Trust; Epilepsia; Mount Sinai Injury Control Research Center	D.J.T. receives consultant fees under contract with UCB. D.C.H. serves as an associate editor of Epilepsia (paid), is on the editorial board of Epilepsy and Behavior (unpaid), and is a consultant to the Mount Sinai Injury Control Research Center (paid); she receives grant support from the Patient-Centered Outcomes Research Institute, the U.S. National Institutes of Health, and the Epilepsy Study Consortium. C.R.N. is funded by the Wellcome Trust, UK. None of the other authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.	Ablah E, 2014, EPILEPSY RES, V108, P792, DOI 10.1016/j.eplepsyres.2014.01.001; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Cansu A, 2007, SEIZURE-EUR J EPILEP, V16, P338, DOI 10.1016/j.seizure.2007.02.003; Carpio A, 1998, EPILEPSIA, V39, P1025, DOI 10.1111/j.1528-1157.1998.tb01287.x; Carter JA, 2004, EPILEPSIA, V45, P978, DOI 10.1111/j.0013-9580.2004.65103.x; Chung TT, 2013, EPILEPSY BEHAV, V29, P374, DOI 10.1016/j.yebeh.2013.08.013; Cruz ME, 1999, INT J EPIDEMIOL, V28, P799, DOI 10.1093/ije/28.4.799; Del Brutto OH, 2005, EPILEPSIA, V46, P583, DOI 10.1111/j.0013-9580.2005.36504.x; Ehrenstein V, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-23; Ehrenstein V, 2007, PEDIATRICS, V119, pE554, DOI 10.1542/peds.2006-1308; Feigin VL, 2017, LANCET NEUROL, V16, P877, DOI 10.1016/S1474-4422(17)30299-5; Fernandez-Suarez E, 2015, REV NEUROLOGIA, V60, P535, DOI 10.33588/rn.6012.2015038; Fiest KM, 2017, NEUROLOGY, V88, P296, DOI 10.1212/WNL.0000000000003509; Garcia HH, 2016, NEW ENGL J MED, V374, P2335, DOI 10.1056/NEJMoa1515520; Gething PW, 2016, NEW ENGL J MED, V375, P2435, DOI 10.1056/NEJMoa1606701; Goel D, 2011, NEUROL INDIA, V59, P37, DOI 10.4103/0028-3886.76855; Guekht A, 2010, EPILEPSY RES, V92, P209, DOI 10.1016/j.eplepsyres.2010.09.011; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; Hesdorffer DC, 2004, ARCH GEN PSYCHIAT, V61, P731, DOI 10.1001/archpsyc.61.7.731; Hussain SA, 2006, EPILEPSY RES, V71, P195, DOI 10.1016/j.eplepsyres.2006.06.018; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Imfeld P, 2013, EPILEPSIA, V54, P700, DOI 10.1111/epi.12045; Josipovic-Jelic Z, 2011, EPILEPSY BEHAV, V20, P686, DOI 10.1016/j.yebeh.2011.02.008; Kaiser C, 1998, EPILEPSY RES, V30, P247, DOI 10.1016/S0920-1211(98)00007-2; Kannoth S, 2009, EPILEPSY BEHAV, V16, P58, DOI 10.1016/j.yebeh.2009.07.019; Khedr EM, 2013, EPILEPSY RES, V103, P294, DOI 10.1016/j.eplepsyres.2012.08.006; Krishnamurthi RV, 2013, LANCET GLOB HEALTH, V1, pE259, DOI 10.1016/S2214-109X(13)70089-5; Lee ACC, 2013, PEDIATR RES, V74, P50, DOI 10.1038/pr.2013.206; Li XH, 1997, EPILEPSIA, V38, P1216, DOI 10.1111/j.1528-1157.1997.tb01219.x; Ma GY, 2004, CHIN J CLIN REHAB, V8, P3178; Mahendran M, 2017, EPILEPSY BEHAV, V75, P102, DOI 10.1016/j.yebeh.2017.02.034; Mani R, 2011, NEUROSCI LETT, V497, P251, DOI 10.1016/j.neulet.2011.03.010; Martin RC, 2014, EPILEPSIA, V55, P1120, DOI 10.1111/epi.12649; Matuja WBP, 2001, NEUROEPIDEMIOLOGY, V20, P242, DOI 10.1159/000054797; Medina MT, 2011, EPILEPSIA, V52, P1177, DOI 10.1111/j.1528-1167.2010.02945.x; Medina MT, 2005, EPILEPSIA, V46, P124, DOI 10.1111/j.0013-9580.2005.11704.x; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Moller AB, 2017, LANCET GLOB HEALTH, V5, pE977, DOI 10.1016/S2214-109X(17)30325-X; Moyano LM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002692; Murphy DJ, 2004, AM J OBSTET GYNECOL, V191, P392, DOI 10.1016/j.ajog.2004.03.020; Mwape KE, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003972; Ngoungou EB, 2006, EPILEPSIA, V47, P2147, DOI 10.1111/j.1528-1167.2006.00890.x; Ngugi AK, 2013, LANCET NEUROL, V12, P253, DOI 10.1016/S1474-4422(13)70003-6; Ngugi AK, 2010, EPILEPSIA, V51, P883, DOI 10.1111/j.1528-1167.2009.02481.x; Njamnshi AK, 2007, AFR J NEUROL SCI, V26, P18; Norrving B, 2015, NEUROEPIDEMIOLOGY, V45, P215, DOI 10.1159/000441104; Pugh MJV, 2009, J AM GERIATR SOC, V57, P237, DOI 10.1111/j.1532-5415.2008.02124.x; Rajshekhar V, 2006, NEUROLOGY, V67, P2135, DOI 10.1212/01.wnl.0000249113.11824.64; Ruwe M, 2010, SOC WORK PUBLIC HLTH, V25, P550, DOI 10.1080/19371910903344217; Scheffer IE, 2017, EPILEPSIA, V58, P512, DOI 10.1111/epi.13709; Sen Wu C, 2008, PEDIATRICS, V122, P1072, DOI 10.1542/peds.2007-3666; Singh G, 2012, EPILEPSIA, V53, P2203, DOI 10.1111/epi.12005; Staton C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0144971; Su CL, 1998, ACTA NEUROL TAIWAN, V7, P75; Sun YL, 2006, EPIDEMIOLOGY, V17, P296, DOI 10.1097/01.ede.0000208478.47401.b6; Syvertsen M, 2015, EPILEPSIA, V56, P699, DOI 10.1111/epi.12972; Tabatabaei SS, 2013, NEUROL SCI, V34, P1441, DOI 10.1007/s10072-012-1261-0; Tchalla AE, 2011, EPILEPSIA, V52, P2203, DOI 10.1111/j.1528-1167.2011.03320.x; Tekle AH, 2016, INFECT DIS POVERTY, V5, DOI 10.1186/s40249-016-0160-7; Tellez-Zenteno JF, 2017, EPILEPSY BEHAV, V16, P30770; Thompson K, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009900.pub2; Thurman DJ, 2007, BRAIN INJURY MED PRI, P45; Vestergaard M, 2007, AM J EPIDEMIOL, V165, P911, DOI 10.1093/aje/kwk086; Wagner RG, 2014, EPILEPSY RES, V108, P782, DOI 10.1016/j.eplepsyres.2014.01.004; Whitehead E, 2006, PEDIATRICS, V117, P1298, DOI 10.1542/peds.2005-1660; World Health Organization, 2006, NEUR DIS PUBL HLTH C; World Health Organization, 2015, GLOB BURD EP NEED CO; World Health Organization, 2007, WHO GLOB REP FALLP; World Health Organization, 2008, WORLD REPORT CHILD I; World Health Organization [WHO], 1998, HLTH PROM GLOSS; Wright J, 2000, SEIZURE-EUR J EPILEP, V9, P309, DOI 10.1053/seiz.2000.0422	71	14	14	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	MAY	2018	59	5					905	914		10.1111/epi.14068			10	Clinical Neurology	Neurosciences & Neurology	GE8QB	WOS:000431495200004	29637551	Green Accepted			2021-06-18	
J	Woodruff, SI; Galarneau, MR; McCabe, CT; Sack, DI; Clouser, MC				Woodruff, Susan I.; Galarneau, Michael R.; McCabe, Cameron T.; Sack, Daniel I.; Clouser, Mary C.			Health-related quality of life among US military personnel injured in combat: findings from the Wounded Warrior Recovery Project	QUALITY OF LIFE RESEARCH			English	Article						Health-related quality of life; Mental health; Injury; Military	POSTTRAUMATIC-STRESS-DISORDER; WELL-BEING SCALE; TRAUMATIC BRAIN-INJURY; ADMINISTERED VERSION; SEVERITY SCORE; QWB-SA; VETERANS; DEPRESSION; IRAQ; COMORBIDITY	Little is known about the long-term, health-related quality of life (HRQOL) of those wounded in combat during Operations Enduring Freedom, Iraqi Freedom, and New Dawn. The present study described the overall HRQOL for a large group of US service members experiencing mild-to-severe combat-related injuries, and assessed the unique contribution of demographics, service- and injury-related characteristics, and mental health factors on long-term HRQOL. The Wounded Warrior Recovery Project examines patient-reported outcomes in a cohort of US military personnel wounded in combat. Participants were identified from the Expeditionary Medical Encounter Database, a US Navy-maintained deployment health database, and invited to complete a web-based survey. At the time of this study, 3245 service members consented and completed the survey. Hierarchical linear regression analyses were conducted to assess the unique contribution of each set of antecedents on HRQOL scores. HRQOL was uniquely associated with a number of demographics, and service- and injury-related characteristics. Nevertheless, screening positive for posttraumatic stress disorder (B = - .09; P < .001), depression (B = - .10; P < .001), or both as a set (B = - .19; P < .001) were the strongest predictors of lower long-term HRQOL. Postinjury HRQOL among service members wounded in combat was associated with service and injury experience, and demographic factors, but was most strongly linked with current mental health status. These findings underscore the significance of mental health issues long after injury. Further, findings reinforce that long-term mental health screening, services, and treatment are needed for those injured in combat.	[Woodruff, Susan I.; McCabe, Cameron T.; Clouser, Mary C.] Leidos Inc, San Diego, CA 92121 USA; [Galarneau, Michael R.] Naval Hlth Res Ctr, Med Modeling Simulat & Mission Support, 140 Sylvester Rd, San Diego, CA 92106 USA; [Sack, Daniel I.] Axiom, San Diego, CA USA	McCabe, CT (corresponding author), Leidos Inc, San Diego, CA 92121 USA.	cameron.t.mccabe.ctr@mail.mil			Bureau of Medicine and Surgery, under the Wounded, Ill, and Injured Psychological Health and Traumatic Brain Injury Program [17-XX, 60808]	Report No. 17-XX was supported by Bureau of Medicine and Surgery, under the Wounded, Ill, and Injured Psychological Health and Traumatic Brain Injury Program, under work unit No. 60808.	Andresen EM, 1998, MED CARE, V36, P1349, DOI 10.1097/00005650-199809000-00007; Asano M, 2008, PROSTHET ORTHOT INT, V32, P231, DOI 10.1080/03093640802024955; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barrett DH, 2003, MIL MED, V168, P941; Bilmes L., 2007, SOLDIERS RETURNING I; Blanchard EB, 1998, J ANXIETY DISORD, V12, P21, DOI 10.1016/S0887-6185(97)00047-9; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brickell TA, 2014, MIL MED, V179, P827, DOI 10.7205/MILMED-D-13-00506; Browne T, 2007, BRIT J PSYCHIAT, V190, P484, DOI 10.1192/bjp.bp.106.030544; Chiu S, 2011, PUBLIC HEALTH REP, V126, P201, DOI 10.1177/003335491112600211; Christensen J, 2016, DISABIL REHABIL, V38, P2345, DOI 10.3109/09638288.2015.1129446; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Daggett V, 2009, J NEUROSCI NURS, V41, P59, DOI 10.1097/JNN.0b013e31819a7133; Defense Casualty Analysis System, 2017, US MIL CAS OP NEW DA; Defense Casualty Analysis System, 2017, US MIL CAS OP END FR; Defense Casualty Analysis System, 2017, US MIL CAS OP IR FRE; Forman-Hoffman VL, 2005, QUAL LIFE RES, V14, P2303, DOI 10.1007/s11136-005-6540-2; Frosch DL, 2004, ARTHRIT RHEUM-ARTHR, V51, P28, DOI 10.1002/art.20071; Fryback DG, 2007, MED CARE, V45, P1162, DOI 10.1097/MLR.0b013e31814848f1; Fryback DG, 1997, MED DECIS MAKING, V17, P1, DOI 10.1177/0272989X9701700101; Galarneau MR, 2006, MIL MED, V171, P691, DOI 10.7205/MILMED.171.8.691; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gennarelli TA, 2005, ABBREVIATED INJURY S; Gold Matthew K, 2016, DEBATES DIGITAL HUMA, P1; Institute of Medicine of the National Academies, 2010, RET HOM IR AFGH PREL; Kaplan RM, 1997, PSYCHOL HEALTH, V12, P783, DOI 10.1080/08870449708406739; Le QA, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-59; Mancino MJ, 2006, J NERV MENT DIS, V194, P877, DOI 10.1097/01.nmd.0000244686.79689.21; McAndrew LM, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-73; Melcer T, 2013, J ORTHOP TRAUMA, V27, pE31, DOI 10.1097/BOT.0b013e3182517e1c; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Moergeli H, 2012, PSYCHOTHER PSYCHOSOM, V81, P305, DOI 10.1159/000330887; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P1390, DOI 10.1176/appi.ajp.161.8.1390; Pittman JOE, 2012, QUAL LIFE RES, V21, P99, DOI 10.1007/s11136-011-9918-3; Power M, 1998, SOC SCI MED, V46, P1569, DOI 10.1016/s0277-9536(98)00009-4; Pyne JM, 2003, J AFFECT DISORDERS, V76, P237, DOI 10.1016/S0165-0327(03)00106-X; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Richmond TS, 2011, GEN HOSP PSYCHIAT, V33, P327, DOI 10.1016/j.genhosppsych.2011.05.003; Riviere LA, 2011, J NERV MENT DIS, V199, P199, DOI 10.1097/NMD.0b013e31820caee4; Rosen PN, 2005, J CATARACT REFR SURG, V31, P369, DOI 10.1016/j.jcrs.2004.04.043; Schnurr PP, 2006, J CONSULT CLIN PSYCH, V74, P707, DOI 10.1037/0022-006X.74.4.707; Schok ML, 2005, MIL PSYCHOL, V17, P89, DOI 10.1207/s15327876mp1702_2; Sieber W, 2008, QUALITY WELL BEING S; Sieber WJ, 2000, HEADACHE, V40, P662, DOI 10.1046/j.1526-4610.2000.040008662.x; Singh JA, 2005, J AM GERIATR SOC, V53, P108, DOI 10.1111/j.1532-5415.2005.53020.x; Smith BM, 2008, SPINAL CORD, V46, P507, DOI 10.1038/sc.2008.2; Spertus JA, 2002, CIRCULATION, V106, P43, DOI 10.1161/01.CIR.0000020688.24874.90; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; Sullivan Gail M, 2012, J Grad Med Educ, V4, P279, DOI 10.4300/JGME-D-12-00156.1; Taft CT, 1999, J TRAUMA STRESS, V12, P3, DOI 10.1023/A:1024786030358; van Delft-Schreurs CCHM, 2014, QUAL LIFE RES, V23, P1353, DOI 10.1007/s11136-013-0546-y; van Delft-Schreurs CCHM, 2014, INJURY, V45, P320, DOI 10.1016/j.injury.2013.02.025; Vasterling JJ, 2010, J TRAUMA STRESS, V23, P41, DOI 10.1002/jts.20487; Voelker MD, 2002, AM J EPIDEMIOL, V155, P899, DOI 10.1093/aje/155.10.899; Woodruff SI, 2014, MIL MED, V179, P265, DOI 10.7205/MILMED-D-13-00444	56	14	14	0	5	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0962-9343	1573-2649		QUAL LIFE RES	Qual. Life Res.	MAY	2018	27	5					1393	1402		10.1007/s11136-018-1806-7			10	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	GC1QK	WOS:000429556500026	29450855				2021-06-18	
J	Herman, P; Stein, A; Gibbs, K; Korsunsky, I; Gregersen, P; Bloom, O				Herman, Paige; Stein, Adam; Gibbs, Katie; Korsunsky, Ilya; Gregersen, Peter; Bloom, Ona			Persons with Chronic Spinal Cord Injury Have Decreased Natural Killer Cell and Increased Toll-Like Receptor/Inflammatory Gene Expression	JOURNAL OF NEUROTRAUMA			English	Article						genomics; human studies; inflammation; spinal cord injury	ELEVATED CIRCULATING LEVELS; MIGRATION INHIBITORY FACTOR; TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID; SYSTEMIC INFLAMMATION; IMMUNE SUPPRESSION; INNATE IMMUNITY; NK CELLS; DEFICIENCY; BIOMARKERS	Infections are the leading cause of death for individuals with traumatic spinal cord injury (SCI). Along with increased infection rates, inflammation is often also observed in persons with chronic SCI. Together, immunological changes post-SCI are also poised to impede neurological recovery and mediate common medical consequences of SCI, including atherogenesis and neuropathic pain. The molecular mechanisms contributing to increased infection susceptibility and inflammation in persons living with SCI are poorly understood. Here, we used tools of functional genomics to perform a pilot study to compare whole-blood gene expression in individuals with chronic SCI (1 year from initial injury; N=31) and uninjured individuals (N=26). We identified 1815 differentially expressed genes in all SCI participants and 2226 differentially expressed genes in persons with SCI rostral to thoracic level 5, compared to uninjured participants. This included marked downregulation of natural killer cell genes and upregulation of the proinflammatory Toll-like receptor signaling pathway. These data provide novel mechanistic insights into the causes underlying the symptoms of immune dysfunction in individuals living with SCI.	[Herman, Paige; Gibbs, Katie; Bloom, Ona] Northwell Hlth, Feinstein Inst Med Res, Hempstead, NY USA; [Stein, Adam; Gibbs, Katie; Bloom, Ona] Northwell Hlth, Zucker Sch Med, Dept Phys Med & Rehabil, Hempstead, NY USA; [Korsunsky, Ilya; Gregersen, Peter] Feinstein Inst Med Res, Robert S Boas Ctr Genom & Human Genet, Manhasset, NY USA; [Gregersen, Peter; Bloom, Ona] Northwell Hlth, Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Mol Med, Hempstead, NY USA; [Herman, Paige] SUNY Downstate Sch Med, Brooklyn, NY USA; [Korsunsky, Ilya] Harvard Med Sch, Broad Inst, Brigham & Womens Hosp, Dept Med, Cambridge, MA USA	Bloom, O (corresponding author), Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Phys Med & Rehabil Mol Med, Feinstein Inst Med Res, 350 Community Dr, Manhasset, NY 11030 USA.	obloom@northwell.edu		BLOOM, ONA/0000-0002-8340-2392	Craig H. Neilsen Foundation; NY State Empire Clinical Research Program; NY State Spinal Cord Injury Research Board; Northwell Health	We thank the participants for enabling this study. We thank Cassandra Pond for outstanding technical assistance. Support was provided by the Craig H. Neilsen Foundation, the NY State Empire Clinical Research Program (grants to O.B.), the NY State Spinal Cord Injury Research Board (grants to OB), and Northwell Health.	Adib-Conquy M, 2014, IMMUNOL CELL BIOL, V92, P256, DOI 10.1038/icb.2013.99; Ardura MI, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005446; Banchereau R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034390; Bank M, 2015, ARCH PHYS MED REHAB, V96, P633, DOI 10.1016/j.apmr.2014.10.021; Bauman W A, 2000, Phys Med Rehabil Clin N Am, V11, P109; BAUMAN WA, 1994, METABOLISM, V43, P749, DOI 10.1016/0026-0495(94)90126-0; Bauman WA, 1999, SPINAL CORD, V37, P601, DOI 10.1038/sj.sc.3100911; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247; Brommer B, 2016, BRAIN, V139, P692, DOI 10.1093/brain/awv375; Campagnolo DI, 2008, SPINAL CORD, V46, P477, DOI 10.1038/sc.2008.4; CAMPAGNOLO DI, 1994, AM J PHYS MED REHAB, V73, P387, DOI 10.1097/00002060-199411000-00003; Cardenas DD, 2004, ARCH PHYS MED REHAB, V85, P1757, DOI 10.1016/j.apmr.2004.03.016; Chaussabel D, 2008, IMMUNITY, V29, P150, DOI 10.1016/j.immuni.2008.05.012; Chaussabel D, 2014, NAT REV IMMUNOL, V14, P271, DOI 10.1038/nri3642; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Church JS, 2016, J NEUROSCI, V36, P6352, DOI 10.1523/JNEUROSCI.0353-16.2016; Darwiche SS, 2013, J TRAUMA ACUTE CARE, V74, P1454, DOI 10.1097/TA.0b013e3182905ed2; Davies AL, 2007, ARCH PHYS MED REHAB, V88, P1384, DOI 10.1016/j.apmr.2007.08.004; DeJong G, 2013, ARCH PHYS MED REHAB, V94, pS87, DOI 10.1016/j.apmr.2012.10.037; DEVIVO MJ, 1993, ARCH PHYS MED REHAB, V74, P248; Didangelos A, 2016, SCI REP-UK, V6, DOI 10.1038/srep21607; Failli V, 2012, BRAIN, V135, P3238, DOI 10.1093/brain/aws267; Frost F, 2005, ARCH PHYS MED REHAB, V86, P312, DOI 10.1016/j.apmr.2004.02.009; Gao M, 2011, SHOCK, V36, P228, DOI 10.1097/SHK.0b013e318225b29a; Garshick E, 2011, PM&R, V3, P433, DOI 10.1016/j.pmrj.2011.02.003; Gaujoux R, 2013, BIOINFORMATICS, V29, P2211, DOI 10.1093/bioinformatics/btt351; Gleeson M, 2011, NAT REV IMMUNOL, V11, P607, DOI 10.1038/nri3041; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589; Kesinger MR, 2015, J TRAUMA ACUTE CARE, V78, P396, DOI 10.1097/TA.0000000000000526; Kidd BA, 2014, NAT IMMUNOL, V15, P118, DOI 10.1038/ni.2787; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kigerl KA, 2018, BRAIN BEHAV IMMUN, V72, P22, DOI 10.1016/j.bbi.2017.11.018; Kigerl KA, 2009, CURR TOP MICROBIOL, V336, P121, DOI 10.1007/978-3-642-00549-7_7; Kopp MA, 2017, NEUROLOGY, V88, P892, DOI [10.1212/WNL.0000000000003652, 10.1212/wnl.0000000000003652]; Kopp MA, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-168; Kumar RG, 2015, J HEAD TRAUMA REHAB, V30, P369, DOI 10.1097/HTR.0000000000000067; Kwon BK, 2017, J NEUROTRAUM, V34, P567, DOI 10.1089/neu.2016.4435; Kwon BK, 2010, J NEUROTRAUM, V27, P669, DOI 10.1089/neu.2009.1080; Leicht CA, 2013, EXERC IMMUNOL REV, V19, P144; Li P, 2015, SCI REP-UK, V5, DOI 10.1038/srep10229; Li XQ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-62; Lustig A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01027; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; NASH MS, 1994, MED SCI SPORT EXER, V26, P164, DOI 10.1249/00005768-199402000-00006; National Spinal Cord Injury Statistical Center, 2017, FACTS FIG GLANC; National Spinal Cord Injury Statistical Center, 2016, COMPL PUBL VERS; Obermoser G, 2013, IMMUNITY, V38, P831, DOI 10.1016/j.immuni.2012.12.008; Papatheodorou A, 2017, J NEUROTRAUM, V34, P746, DOI 10.1089/neu.2016.4596; Pavlov VA, 2017, NAT NEUROSCI, V20, P156, DOI 10.1038/nn.4477; Pavlov VA, 2012, NAT REV ENDOCRINOL, V8, P743, DOI 10.1038/nrendo.2012.189; Popovich P, 2009, NAT MED, V15, P736, DOI 10.1038/nm0709-736; Pouw MH, 2014, SPINAL CORD, V52, P428, DOI 10.1038/sc.2014.26; Pruss H, 2017, NAT NEUROSCI, V20, P1549, DOI 10.1038/nn.4643; Riegger T, 2009, NEUROSCIENCE, V158, P1194, DOI 10.1016/j.neuroscience.2008.08.021; Riegger T, 2007, EUR J NEUROSCI, V25, P1743, DOI 10.1111/j.1460-9568.2007.05447.x; Sabharwal L, 2014, J BIOCHEM, V156, P299, DOI 10.1093/jb/mvu057; Saltzman JW, 2013, J NEUROTRAUM, V30, P434, DOI 10.1089/neu.2012.2501; Satzer D, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0212-0; Schwab JM, 2014, EXP NEUROL, V258, P121, DOI 10.1016/j.expneurol.2014.04.023; Segal JL, 1997, ARCH PHYS MED REHAB, V78, P44, DOI 10.1016/S0003-9993(97)90008-3; Shen-Orr SS, 2013, CURR OPIN IMMUNOL, V25, P571, DOI 10.1016/j.coi.2013.09.015; Souza-Fonseca-Guimaraes F, 2012, CRIT CARE, V16, DOI 10.1186/cc11838; Stein A, 2013, ARCH PHYS MED REHAB, V94, P1498, DOI 10.1016/j.apmr.2013.04.004; Stirling DP, 2014, BRAIN, V137, P707, DOI 10.1093/brain/awt341; Stivers NS, 2017, EXP NEUROL, V294, P1, DOI 10.1016/j.expneurol.2017.04.012; Streijger F, 2017, J NEUROTRAUM, V34, P2054, DOI 10.1089/neu.2016.4879; Watkins NA, 2009, BLOOD, V113, pE1, DOI 10.1182/blood-2008-06-162958; Yuan ZQ, 2016, CELL SIGNAL, V28, P158, DOI 10.1016/j.cellsig.2015.12.013; Zhang Y, 2013, J NEUROSCI, V33, P12970, DOI 10.1523/JNEUROSCI.1974-13.2013; Zimmer P, 2017, EXERC IMMUNOL REV, V23, P66	72	14	14	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2018	35	15					1819	1829		10.1089/neu.2017.5519		APR 2018	11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GL8IW	WOS:000429203100001	29310515	Bronze, Green Published			2021-06-18	
J	Thibeault, CM; Thorpe, S; O'Brien, MJ; Canac, N; Ranjbaran, M; Patanam, I; Sarraf, A; LeVangie, J; Scalzo, F; Wilk, SJ; Diaz-Arrastia, R; Hamilton, RB				Thibeault, Corey M.; Thorpe, Samuel; O'Brien, Michael J.; Canac, Nicolas; Ranjbaran, Mina; Patanam, Ilyas; Sarraf, Artin; LeVangie, James; Scalzo, Fabien; Wilk, Seth J.; Diaz-Arrastia, Ramon; Hamilton, Robert B.			A Cross-Sectional Study on Cerebral Hemodynamics After Mild Traumatic Brain Injury in a Pediatric Population	FRONTIERS IN NEUROLOGY			English	Article						traumatic brain injury; vascular reactivity; cerebral blood flow autoregulation; blood flow; cerebral blood flow velocity	SPORTS-RELATED CONCUSSION; NITRIC-OXIDE SYNTHASE; BLOOD-FLOW ALTERATIONS; TRANSCRANIAL DOPPLER; HEAD-INJURY; VASCULAR INJURY; REACTIVITY; PATHOPHYSIOLOGY; PULSATILITY; EXPRESSION	The microvasculature is prominently affected by traumatic brain injury (TBI), including mild TBI (concussion). Assessment of cerebral hemodynamics shows promise as biomarkers of TBI, and may help inform development of therapies aimed at promoting neurologic recovery. The objective of this study was to assess the evolution in cerebral hemodynamics observable with transcranial Doppler (TCD) ultrasound in subjects suffering from a concussion at different intervals during recovery. Pediatric subjects between the ages of 14 and 19 years clinically diagnosed with a concussion were observed at different points post-injury. Blood flow velocity in the middle cerebral artery was measured with TCD. After a baseline period, subjects participated in four breath holding challenges. Pulsatility index (PI), resistivity index (RI), the ratio of the first two pulse peaks (P2R), and the mean velocity (MV) were computed from the baseline section. The breath hold index (BHI) was computed from the challenge sections. TCD detected two phases of hemodynamic changes after concussion. Within the first 48 h, PI, RI, and P2R show a significant difference from the controls (U = -3.10; P < 0.01, U = -2.86; P < 0.01, and U = 2.62; P < 0.01, respectively). In addition, PI and P2R were not correlated (rp = -0.36; P = 0.23). After 48 h, differences in pulsatile features were no longer observable. However, BHI was significantly increased when grouped as 2-3, 4-5, and 6-7 days post-injury (U = 2.72; P < 0.01, U = 2.46; P = 0.014, and U = 2.38; P = 0.018, respectively). To our knowledge, this is the first longitudinal study of concussions using TCD. In addition, these results are the first to suggest the multiple hemodynamic changes after a concussion are observable with TCD and could ultimately lead to a better understanding of the underlying pathophysiology. In addition, the different hemodynamic responses to a concussion as compared to severe traumatic brain injuries highlight the need for specific diagnostic and therapeutic treatments of mild head injuries in adolescents.	[Thibeault, Corey M.; Thorpe, Samuel; O'Brien, Michael J.; Canac, Nicolas; Ranjbaran, Mina; Patanam, Ilyas; LeVangie, James; Wilk, Seth J.; Hamilton, Robert B.] Neural Analyt Inc, Los Angeles, CA 90064 USA; [Sarraf, Artin] Citadel LLC, Greenwich, CT USA; [Scalzo, Fabien] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Scalzo, Fabien] Univ Calif Los Angeles, Dept Comp Sci, Los Angeles, CA 90024 USA; [Diaz-Arrastia, Ramon] Univ Penn Hosp, Penn Presbyterian Med Ctr, Philadelphia, PA USA	Thibeault, CM (corresponding author), Neural Analyt Inc, Los Angeles, CA 90064 USA.	corey@neuralanalytics.com	Scalzo, Fabien/AAM-6328-2020	Scalzo, Fabien/0000-0001-9755-8104	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R43NS092209-01, 2R44NS092209-02]; Neural Analytics, Inc.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R43NS092209, R44NS092209] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health grants 1R43NS092209-01 and 2R44NS092209-02, as well as internal funding from Neural Analytics, Inc. The NIH had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	Bailey DM, 2013, CLIN SCI, V124, P177, DOI 10.1042/CS20120259; Barkhoudarian G, 2016, PHYS MED REH CLIN N, V27, P373, DOI 10.1016/j.pmr.2016.01.003; Bouzat P, 2016, ANESTHESIOLOGY, V125, P346, DOI 10.1097/ALN.0000000000001165; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; de Riva N, 2012, NEUROCRIT CARE, V17, P58, DOI 10.1007/s12028-012-9672-6; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Gahm C, 2000, NEUROSURGERY, V46, P169; GILLER CA, 1990, J NEUROSURG, V72, P901, DOI 10.3171/jns.1990.72.6.0901; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Hamilton R, 2012, J APPL PHYSIOL, V113, P1560, DOI 10.1152/japplphysiol.00357.2012; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Kim S, 2013, IEEE T BIO-MED ENG, V60, P1126, DOI 10.1109/TBME.2012.2227477; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; Len TK, 2013, BRAIN INJURY, V27, P346, DOI 10.3109/02699052.2012.743185; Len TK, 2011, MED SCI SPORT EXER, V43, P2241, DOI 10.1249/MSS.0b013e3182249539; Lim MH, 2009, STROKE, V40, P3216, DOI 10.1161/STROKEAHA.109.558403; Mandera M, 2002, CHILD NERV SYST, V18, P124, DOI 10.1007/s00381-002-0572-5; MARKUS HS, 1992, STROKE, V23, P668, DOI 10.1161/01.STR.23.5.668; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Metting Z, 2009, ANN NEUROL, V66, P809, DOI 10.1002/ana.21785; Militana AR, 2016, BRAIN IMAGING BEHAV, V10, P559, DOI 10.1007/s11682-015-9407-3; Mutch WAC, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00107; Oliphant TE, 2007, COMPUT SCI ENG, V9, P10, DOI 10.1109/MCSE.2007.58; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Settakis G, 2002, J NEUROIMAGING, V12, P252, DOI 10.1177/10528402012003007; Tegeler CH, 2013, J NEUROIMAGING, V23, P466, DOI 10.1111/j.1552-6569.2012.00711.x; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Zaaroor M, 2007, INDIAN J NEUROTRAUM, V4, P25, DOI 10.1016/S0973-0508(07)80007-4; Zweifel C, 2012, NEUROSURGERY, V71, P853, DOI 10.1227/NEU.0b013e3182675b42	35	14	14	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	APR 5	2018	9								200	10.3389/fneur.2018.00200			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	GB7PQ	WOS:000429267000001	29674994	DOAJ Gold, Green Published			2021-06-18	
J	Chen, XL; Gestring, ML; Rosengart, MR; Billiar, TR; Peitzman, AB; Sperry, JL; Brown, JB				Chen, Xilin; Gestring, Mark L.; Rosengart, Matthew R.; Billiar, Timothy R.; Peitzman, Andrew B.; Sperry, Jason L.; Brown, Joshua B.			Speed is not everything: Identifying patients who may benefit from helicopter transport despite faster ground transport	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	76th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST) / Clinical Congress of Acute Care Surgery	SEP 13-16, 2017	Baltimore, MD	Amer Assoc Surg Trauma		Helicopter; air medical; emergency medical services; prehospital; triage	TRAUMATIC BRAIN-INJURY; EMERGENCY MEDICAL-SERVICES; RAPID-SEQUENCE INTUBATION; PREHOSPITAL TRIAGE SCORE; BLOOD-CELL TRANSFUSION; ENDOTRACHEAL INTUBATION; REDUCED MORTALITY; SCENE; SURVIVAL; IMPACT	BACKGROUND: Helicopter emergency medical services (HEMS) have demonstrated survival benefits over ground emergency medical services (GEMS) for trauma patient transport. While HEMS speed is often-cited, factors such as provider experience and level of care may also play a role. Our objective was to identify patient groups that may benefit from HEMS even when prehospital time for helicopter utilization is longer than GEMS transport. METHODS: Adult patients transported by HEMS or GEMS from the scene of injury in the Pennsylvania State Trauma Registry were included. Propensity score matching was used to match HEMS and GEMS patients for likelihood of HEMS, keeping only pairs in which the HEMS patient had longer total prehospital time than the matched GEMS patient. Mixed-effects logistic regression evaluated the effect of transport mode on survival while controlling for demographics, admission physiology, transfusions, and procedures. Interaction testing between transport mode and existing trauma triage criteria was conducted and models stratified across significant interactions to determine which criteria identify patients with a significant survival benefit when transported by HEMS even when slower than GEMS. RESULTS: From 153,729 eligible patients, 8,307 pairs were matched. Helicopter emergency medical services total prehospital time was a median of 13 minutes (interquartile range, 6-22) longer than GEMS. Patients with abnormal respiratory rate (odds ratio [OR], 2.39; 95% confidence interval [CI], 1.26-4.55; p = 0.01), Glasgow Coma Scale score of 8 or less (OR, 1.61; 95% CI, 1.16-2.22; p < 0.01), and hemo/pneumothorax (OR, 2.25; 95% CI, 1.06-4.78; p = 0.03) had a significant survival advantage when transported by HEMS even with longer prehospital time than GEMS. Conversely, there was no association between transport mode and survival in patients without these factors (p > 0.05). CONCLUSION: Patients with abnormal respiratory rate, Glasgow Coma Scale score of 8 or less, and hemo/pneumothorax benefit from HEMS transport even when GEMS transport was faster. This may indicate that these patients benefit primarily from HEMS care, such as advanced airway and chest trauma management, rather than simply faster transport to a trauma center. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.	[Chen, Xilin; Rosengart, Matthew R.; Billiar, Timothy R.; Peitzman, Andrew B.; Sperry, Jason L.; Brown, Joshua B.] Univ Pittsburgh, Dept Surg, Med Ctr, Div Trauma & Gen Surg, 200 Lothrop St, Pittsburgh, PA 15213 USA; [Gestring, Mark L.] Univ Rochester, Med Ctr, Dept Surg, Div Acute Care Surg, Rochester, NY 14642 USA	Brown, JB (corresponding author), Univ Pittsburgh, Dept Surg, Med Ctr, Div Trauma & Gen Surg, 200 Lothrop St, Pittsburgh, PA 15213 USA.	brownjb@upmc.edu					Abe T, 2014, CRIT CARE, V18, DOI 10.1186/cc13981; Andruszkow H, 2013, CRIT CARE, V17, DOI 10.1186/cc12796; Bekelis K, 2014, ANN SURG; Blumen IJ, 2006, PRINCIPLES DIRECTION, P519; Brathwaite CEM, 1998, J TRAUMA, V45, P140, DOI 10.1097/00005373-199807000-00029; Brown JB, 2017, J TRAUMA ACUTE CARE, V82, P270, DOI 10.1097/TA.0000000000001326; Brown JB, 2016, ANN SURG, V264, P378, DOI 10.1097/SLA.0000000000001496; Brown JB, 2016, J TRAUMA ACUTE CARE, V81, P93, DOI 10.1097/TA.0000000000000999; Brown JB, 2016, SURGERY, V159, P947, DOI 10.1016/j.surg.2015.09.015; Brown JB, 2015, J AM COLL SURGEONS, V220, P797, DOI 10.1016/j.jamcollsurg.2015.01.006; Brown JB, 2015, ANN SURG, V261, P997, DOI 10.1097/SLA.0000000000000674; Brown JB, 2012, J TRAUMA ACUTE CARE, V73, P319, DOI 10.1097/TA.0b013e3182572bee; Brown JB, 2011, J TRAUMA, V70, P310, DOI 10.1097/TA.0b013e3182032b4f; Brown JB, 2010, J TRAUMA, V69, P263, DOI 10.1097/TA.0b013e3181e5d72e; Bulger EM, 2012, J TRAUMA ACUTE CARE, V72, P567, DOI 10.1097/TA.0b013e31824baddf; Bulger EM, 2012, J TRAUMA ACUTE CARE, V72, P573, DOI DOI 10.1097/TA.0B013E31824BADDF; Butler DP, 2010, EMERG MED J, V27, P692, DOI 10.1136/emj.2009.087486; Chou D, 2016, J TRAUMA ACUTE CARE, V80, P278, DOI 10.1097/TA.0000000000000901; Cudnik MT, 2008, PREHOSP EMERG CARE, V12, P459, DOI 10.1080/10903120802290745; Cunningham P, 1997, J TRAUMA, V43, P940, DOI 10.1097/00005373-199712000-00013; Davis DP, 2010, J TRAUMA, V69, P294, DOI 10.1097/TA.0b013e3181dc6c7f; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Delgado MK, 2013, ANN EMERG MED, V62, P351, DOI 10.1016/j.annemergmed.2013.02.025; Fakhry SM, 2006, J TRAUMA, V60, P997, DOI 10.1097/01.ta.0000217285.94057.5e; Galvagno SM, 2013, CRIT CARE, V17, DOI 10.1186/cc12779; Galvagno SM, 2012, JAMA-J AM MED ASSOC, V307, P1602, DOI 10.1001/jama.2012.467; Holcomb JB, 2015, PREHOSP EMERG CARE, V19, P1, DOI 10.3109/10903127.2014.923077; Hosmer DW, 2000, APPL LOGISTRIC REGRE; Meizoso JP, 2015, J TRAUMA ACUTE CARE, V79, P227, DOI 10.1097/TA.0000000000000748; Mitra R, 2012, STAT METHODS MED RES; Moore Lynne, 2009, J Emerg Trauma Shock, V2, P73, DOI 10.4103/0974-2700.44774; Moore L, 2009, J AM COLL SURGEONS, V209, P572, DOI 10.1016/j.jamcollsurg.2009.07.004; Nirula R, 2010, J TRAUMA, V69, P595, DOI 10.1097/TA.0b013e3181ee6e32; Pike N, 2011, METHODS ECOL EVOL, V2, P278, DOI 10.1111/j.2041-210X.2010.00061.x; Ringburg A, 2009, PREHOSP EMERG CARE, V13, P28, DOI 10.1080/10903120802472012; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Rubin DB., 1987, MULTIPLE IMPUTATION; Shatney CH, 2002, J TRAUMA, V53, P817, DOI 10.1097/00005373-200211000-00002; Shaw JJ, 2015, ANN SURG; Smith Bryce D., 2012, Morbidity and Mortality Weekly Report, V61, P1; Sonne A, 2017, DAN MED J, V64; StataCorp, 2013, STAT MULT MIX EFF RE; Stewart KE, 2011, ACAD EMERG MED, V18, P1208, DOI 10.1111/j.1553-2712.2011.01207.x; Sullivent EE, 2011, PREHOSP EMERG CARE, V15, P295, DOI 10.3109/10903127.2011.569849; Thomas SH, 2014, PREHOSP EMERG CARE, V18, P35, DOI 10.3109/10903127.2013.844872; Tsuchiya A, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0335-z; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Yang D, UNIFIED APPROACH MEA	50	14	14	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	APR	2018	84	4					549	557		10.1097/TA.0000000000001769			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	GE4IT	WOS:000431179700001	29251708				2021-06-18	
J	Galindo, LT; Mundim, MTVV; Pinto, AS; Chiarantin, GMD; Almeida, MES; Lamers, ML; Horwitz, AR; Santos, MF; Porcionatto, M				Galindo, Layla T.; Mundim, Mayara T. V. V.; Pinto, Agnes S.; Chiarantin, Gabrielly M. D.; Almeida, Maira E. S.; Lamers, Marcelo L.; Horwitz, Alan R.; Santos, Marinilce F.; Porcionatto, Marimelia			Chondroitin Sulfate Impairs Neural Stem Cell Migration Through ROCK Activation	MOLECULAR NEUROBIOLOGY			English	Article						Neural stem cell; Cell migration; Chondroitin sulfate; Traumatic brain injury; RhoA; Rock	SPINAL-CORD-INJURY; FOCAL CEREBRAL-ISCHEMIA; FUNCTIONAL RECOVERY; NEURITE OUTGROWTH; RHO/ROCK PATHWAY; NERVOUS-SYSTEM; GLIAL SCAR; REGENERATION; PROTEOGLYCANS; PHOSPHATASE	Brain injuries such as trauma and stroke lead to glial scar formation by reactive astrocytes which produce and secret axonal outgrowth inhibitors. Chondroitin sulfate proteoglycans (CSPG) constitute a well-known class of extracellular matrix molecules produced at the glial scar and cause growth cone collapse. The CSPG glycosaminoglycan side chains composed of chondroitin sulfate (CS) are responsible for its inhibitory activity on neurite outgrowth and are dependent on RhoA activation. Here, we hypothesize that CSPG also impairs neural stem cell migration inhibiting their penetration into an injury site. We show that DCX+ neuroblasts do not penetrate a CSPG-rich injured area probably due to Nogo receptor activation and RhoA/ROCK signaling pathway as we demonstrate in vitro with neural stem cells cultured as neurospheres and pull-down for RhoA. Furthermore, CS-impaired cell migration in vitro induced the formation of large mature adhesions and altered cell protrusion dynamics. ROCK inhibition restored migration in vitro as well as decreased adhesion size.	[Galindo, Layla T.; Mundim, Mayara T. V. V.; Pinto, Agnes S.; Chiarantin, Gabrielly M. D.; Porcionatto, Marimelia] Univ Fed Sao Paulo, Dept Biochem, Neurobiol Lab, Rua Pedro de Toledo 669,3 Andar, BR-04039032 Sao Paulo, SP, Brazil; [Almeida, Maira E. S.] Butantan Inst, Physiopathol Lab, BR-05503900 Sao Paulo, Brazil; [Lamers, Marcelo L.] Univ Fed Rio Grande do Sul, Dept Morphol Sci, BR-90050170 Porto Alegre, RS, Brazil; [Horwitz, Alan R.] Univ Virginia, Dept Cell Biol, Sch Med, Charlottesville, VA 22903 USA; [Santos, Marinilce F.] Univ Sao Paulo, Inst Biomed Sci, Dept Cell & Dev Biol, BR-05508000 Sao Paulo, Brazil	Porcionatto, M (corresponding author), Univ Fed Sao Paulo, Dept Biochem, Neurobiol Lab, Rua Pedro de Toledo 669,3 Andar, BR-04039032 Sao Paulo, SP, Brazil.	marimelia.porcionatto@unifesp.br	LAMERS, MARCELO/A-5291-2013; Santos, Marinilce F/G-9548-2011; Porcionatto, Marimelia/C-3322-2012; Mundim, Mayara V/N-9985-2015	LAMERS, MARCELO/0000-0001-5296-5662; Santos, Marinilce F/0000-0002-3257-3327; Porcionatto, Marimelia/0000-0001-6287-916X; Mundim, Mayara/0000-0002-9771-977X	Fundacao de Amparo a Pesquisa de Sao Paulo - FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/00526-7, 2012/00652]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [404,646/2012-3]; National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM23244]	This work was supported by Fundacao de Amparo a Pesquisa de Sao Paulo - FAPESP (2011/00526-7; 2012/00652 to MP), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq (404,646/2012-3 to MP), and National Institute of General Medical Sciences (GM23244 to ARH).	Akbik F, 2012, EXP NEUROL, V235, P43, DOI 10.1016/j.expneurol.2011.06.006; Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Ayoub E, 2013, J BIOL CHEM, V288, P25739, DOI 10.1074/jbc.M113.501007; Bartus K, 2014, J NEUROSCI, V34, P4822, DOI 10.1523/JNEUROSCI.4369-13.2014; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Busch SA, 2007, CURR OPIN NEUROBIOL, V17, P120, DOI 10.1016/j.conb.2006.09.004; Chiba S, 2004, J NEUROL SCI, V219, P107, DOI 10.1016/j.jns.2004.01.006; Coulson-Thomas YA, 2008, J NEUROSCI METH, V171, P19, DOI 10.1016/j.jneumeth.2008.01.030; Dickendesher TL, 2012, NAT NEUROSCI, V15, P703, DOI 10.1038/nn.3070; Dyck SM, 2015, STEM CELLS, V33, P2550, DOI 10.1002/stem.1979; Filippo TRM, 2013, STEM CELL RES, V11, P913, DOI 10.1016/j.scr.2013.06.003; Fisher D, 2011, J NEUROSCI, V31, P14051, DOI 10.1523/JNEUROSCI.1737-11.2011; Fonseca AV, 2010, J BIOL CHEM, V285, P31661, DOI 10.1074/jbc.M110.145037; Fournier AE, 2003, J NEUROSCI, V23, P1416; Fry EJ, 2010, GLIA, V58, P423, DOI 10.1002/glia.20934; Galindo LT, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/564089; Galtrey CM, 2007, BRAIN RES REV, V54, P1, DOI 10.1016/j.brainresrev.2006.09.006; Gandham VD, 2013, CLIN EXP DERMATOL, V38, P782, DOI 10.1111/ced.12067; Garcia-Alias G, 2009, NAT NEUROSCI, V12, P1145, DOI 10.1038/nn.2377; Garwood J, 2003, J BIOL CHEM, V278, P24164, DOI 10.1074/jbc.M211721200; Garwood J, 1999, J NEUROSCI, V19, P3888; Goetsch KP, 2014, J CELL BIOCHEM, V115, P1299, DOI 10.1002/jcb.24784; Gu WL, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-128; Hinz B, 1999, EXP CELL RES, V251, P234, DOI 10.1006/excr.1999.4541; Houle JD, 2006, J NEUROSCI, V26, P7405, DOI 10.1523/JNEUROSCI.1166-06.2006; Jaerve A, 2012, CELL TISSUE RES, V349, P229, DOI 10.1007/s00441-012-1427-3; Kantor DB, 2004, NEURON, V44, P961, DOI 10.1016/j.neuron.2004.12.002; Kojima T, 2010, STEM CELLS, V28, P545, DOI 10.1002/stem.306; Laabs T, 2005, CURR OPIN NEUROBIOL, V15, P116, DOI 10.1016/j.conb.2005.01.014; Leong SY, 2011, NEUROCHEM INT, V59, P382, DOI 10.1016/j.neuint.2010.12.024; Leong SY, 2011, STEM CELLS, V29, P332, DOI 10.1002/stem.577; Li X, 2011, NEUROCHEM RES, V36, P2363, DOI 10.1007/s11064-011-0562-7; Lin R, 2008, J NEUROCHEM, V104, P400, DOI 10.1111/j.1471-4159.2007.05066.x; Llorens F, 2011, FASEB J, V25, P463, DOI 10.1096/fj.10-162792; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; Monnier PP, 2003, MOL CELL NEUROSCI, V22, P319, DOI 10.1016/S1044-7431(02)00035-0; Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Rhodes KE, 2004, J ANAT, V204, P33, DOI 10.1111/j.1469-7580.2004.00261.x; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Robin AM, 2006, J CEREBR BLOOD F MET, V26, P125, DOI 10.1038/sj.jcbfm.9600172; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Schweigreiter R, 2004, MOL CELL NEUROSCI, V27, P163, DOI 10.1016/j.mcn.2004.06.004; Shen YJ, 2009, SCIENCE, V326, P592, DOI 10.1126/science.1178310; Siebert JR, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/845323; Siebzehnrubl FA, 2011, METHODS MOL BIOL, V750, P61, DOI 10.1007/978-1-61779-145-1_4; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith A, 2003, J CELL SCI, V116, P3123, DOI 10.1242/jcs.00606; Takeuchi H, 2007, NEUROSCI LETT, V426, P69, DOI 10.1016/j.neulet.2007.08.048; Tanaka M, 2003, J NEUROSCI, V23, P2804, DOI 10.1523/jneurosci.23-07-02804.2003; Vicente-Manzanares M, 2011, J CELL BIOL, V193, P381, DOI 10.1083/jcb.201012159; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Wang D, 2014, NEURAL REGEN RES, V9, P2189, DOI 10.4103/1673-5374.147952; Wang F, 2008, NEUROSCIENCE, V151, P74, DOI 10.1016/j.neuroscience.2007.10.034; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Yan YP, 2007, J CEREBR BLOOD F MET, V27, P1213, DOI 10.1038/sj.jcbfm.9600432; Zhou CX, 2010, CELL MOL BIOENG, V3, P76, DOI 10.1007/s12195-010-0106-2	60	14	15	0	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	APR	2018	55	4					3185	3195		10.1007/s12035-017-0565-8			11	Neurosciences	Neurosciences & Neurology	FY8EX	WOS:000427097500037	28477140	Green Published, Other Gold			2021-06-18	
J	Latifi, R; Olldashi, F; Dogjani, A; Dasho, E; Boci, A; El-Menyar, A				Latifi, Rifat; Olldashi, Fatos; Dogjani, Agron; Dasho, Erion; Boci, Arian; El-Menyar, Ayman			Telemedicine for Neurotrauma in Albania: Initial Results from Case Series of 146 Patients	WORLD NEUROSURGERY			English	Article						Albania; Low- and middle-income countries; Neurotrauma; Spinal cord injuries; Telemedicine; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; DIGITAL OBSERVATION CAMERA; DEVELOPING-COUNTRIES; MEDICAL SYSTEMS; NEUROSURGERY; GUIDELINES; EXPERIENCE; MANAGEMENT; ARIZONA; CARE	BACKGROUND: Use of telemedicine for neurotrauma when performed by neurosurgeons is an innovative care option for traumatic brain injury patients, particularly in countries with limited neurosurgery expertise resources. In recent years, Albania has developed a robust telemedicine program and teleneurotrauma is the flagship of the program. We aimed to evaluate the outcomes of the first neurotrauma patients managed via telemedicine in Albania. METHODS: A retrospective analysis of prospectively collected data on all telemedicine consultations for isolated neurotrauma was performed from 2014 through 2016. Patient demographics, mechanism of injury, modes of teleneurotrauma consultation (store-and-forward vs. live video consultation), outcomes of teleconsultation (whether the patient was transferred or kept at the regional hospital), operative procedures for those transferred, length of hospital stay, and discharge status were analyzed. RESULTS: Of the 146 teleconsultations for neurotrauma, asynchronous technology (store-and-forward) accounted for the majority of teleconsultations (84%), while the live plus store-and-forward technique was employed in 15% of cases. Median time of response to teleconsultation was 20 minutes. Sixty-six percent of patients remained at the referring hospital for further observation and did not require transfer to a trauma center. Of the patients transferred to the tertiary care, 91% were treated nonoperatively, 85% percent were discharged to home, 9% were transferred to another hospital, and 6% died in the hospital. CONCLUSION: Telemedicine for neurotrauma, when structured appropriately and led by neurosurgeons, is a valuable service for the entire country, prevents unnecessary transfers to trauma center, and saves resources, particularly in low- and middle-income countries.	[Latifi, Rifat; El-Menyar, Ayman] Westchester Med Ctr Hlth Network, Dept Surg, Valhalla, NY 10595 USA; [Latifi, Rifat; El-Menyar, Ayman] New York Med Coll, Valhalla, NY 10595 USA; [Latifi, Rifat; Dogjani, Agron; Dasho, Erion; Boci, Arian] Int Virtual Hosp Fdn, Tucson, AZ USA; [Olldashi, Fatos] Univ Hosp Trauma, Dept Neurosurg, Tirana, Albania; [Dogjani, Agron] Univ Hosp Trauma, Dept Trauma Surg, Tirana, Albania; [Latifi, Rifat; Boci, Arian] Integrated Telemed & E Hlth Program Albania, Tirana, Albania	Latifi, R (corresponding author), Westchester Med Ctr Hlth Network, Dept Surg, Valhalla, NY 10595 USA.; Latifi, R (corresponding author), New York Med Coll, Valhalla, NY 10595 USA.; Latifi, R (corresponding author), Int Virtual Hosp Fdn, Tucson, AZ USA.; Latifi, R (corresponding author), Integrated Telemed & E Hlth Program Albania, Tirana, Albania.	Rifat.Latifi@wmchealth.org	El-Menyar, Ayman/F-6734-2015	El-Menyar, Ayman/0000-0003-2584-953X; Latifi, Rifat/0000-0003-1091-3682	United States Agency for International Development in Albania, Integrated Telemedicine and e-Health ProjectUnited States Agency for International Development (USAID) [182-A-00-09-00101-00]	The study is part of the project funded from the United States Agency for International Development in Albania, Integrated Telemedicine and e-Health Project (Contract 182-A-00-09-00101-00).	Agha RA, 2016, INT J SURG, V36, P319, DOI 10.1016/j.ijsu.2016.10.025; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Boer C, 2012, CURR OPIN ANESTHESIO, V25, P556, DOI 10.1097/ACO.0b013e328357225c; Demaerschalk BM, 2012, TELEMED E-HEALTH, V18, P230, DOI 10.1089/tmj.2011.0116; Demaerschalk BM, 2010, STROKE, V41, P1251, DOI 10.1161/STROKEAHA.109.574509; El Khamlichi Abdeslam, NEUROSURGERY AFRICA; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Joseph B, 2014, J TRAUMA ACUTE CARE, V77, P984, DOI 10.1097/TA.0000000000000428; Kahn EN, 2016, WORLD NEUROSURG, V89, P133, DOI 10.1016/j.wneu.2016.01.075; Latifi R., TELEMEDICINE TRAUMA; Latifi R, TELEMED J E-HEALTH, DOI [10.1089/tmj.2014.0026.8, DOI 10.1089/TMJ.2014.0026.8]; Latifi R, 2006, TELEMED J E-HEALTH, V12, P332, DOI 10.1089/tmj.2006.12.332; Latifi R, 2016, TELEMED E-HEALTH, V22, P1024, DOI 10.1089/tmj.2016.0050; Latifi R, 2016, INT J EMERG MED, V9, DOI 10.1186/s12245-016-0124-5; Latifi R, 2015, TELEMED E-HEALTH, V21, P503, DOI 10.1089/tmj.2014.0138; Latifi R, 2014, WORLD J SURG, V38, P1898, DOI 10.1007/s00268-014-2538-7; Latifi Rifat, 2014, Am J Disaster Med, V9, P25, DOI 10.5055/ajdm.2014.0139; Latifi Rifat, 2009, Am J Surg, V198, P905, DOI 10.1016/j.amjsurg.2009.08.011; Lewis ER, 2012, TELEMED E-HEALTH, V18, P434, DOI 10.1089/tmj.2011.0199; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Migliaretti G, 2013, J TELEMED TELECARE, V19, P33, DOI 10.1177/1357633X12474738; Mrak G, 2009, J TELEMED TELECARE, V15, P142, DOI 10.1258/jtt.2009.003012; Puvanachandra P., 2009, PAK J NEUROL SCI, V4, P27; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206	24	14	14	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	APR	2018	112						E747	E753		10.1016/j.wneu.2018.01.146			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GG8FH	WOS:000432932700088	29410169				2021-06-18	
J	Lin, L; Wang, QZ; Qian, K; Cao, ZY; Xiao, J; Wang, XY; Li, XK; Yu, ZY				Lin, Li; Wang, Qingzhi; Qian, Kenny; Cao, Zeyuan; Xiao, Jian; Wang, Xiaoying; Li, Xiaokun; Yu, Zhanyang			bFGF Protects Against Oxygen Glucose Deprivation/Reoxygenation-Induced Endothelial Monolayer Permeability via S1PR1-Dependent Mechanisms	MOLECULAR NEUROBIOLOGY			English	Article						Basic fibroblast growth factor (bFGF); Endothelial cell monolayer permeability; Oxygen-glucose deprivation and reoxygenation (OGD/R); Junction protein; FGF receptor 1 (FGFR1); Sphingosine-1-phosphate receptor 1 (S1PR1)	BLOOD-BRAIN-BARRIER; FIBROBLAST-GROWTH-FACTOR; FOCAL CEREBRAL INFARCTION; CENTRAL-NERVOUS-SYSTEM; FUNCTIONAL RECOVERY; STROKE; INJURY; DYSFUNCTION; INTEGRITY; HEPARIN	Blood-brain barrier (BBB) disruption is a common pathological feature of many neurological disorders including stroke and brain trauma, therefore is an important therapeutic target for treatment of these diseases. Basic fibroblast growth factor (bFGF) as a member of FGF superfamily plays critical roles in angiogenesis, neurogenesis, and neuron survival. We recently showed that recombinant bFGF protects against BBB disruption in traumatic brain injury in mice. In this study, we further investigated the mechanisms of recombinant bFGF in BBB protection by measuring the permeability of cultured endothelial cell monolayer induced by oxygen-glucose deprivation and reoxygenation (OGD/R). We found that recombinant bFGF significantly decreased OGD/R-induced permeability of primary human brain microvascular endothelial cell (HBMEC) monolayer and preserved OGD/R-induced decreases of trans-endothelial electrical resistance (TEER). Western blot and immunocytochemistry showed that bFGF significantly rescued OGD/R-induced downregulation of junction proteins ZO-1, occludin, and VE-cadherin. We further show that the BBB protective effect of bFGF is via FGF receptor 1 (FGFR1) activation as FGFR1 inhibitor can block this protection effect. Moreover, we revealed that the BBB protection effect of bFGF is at least partially through rescuing the OGD/R-induced downregulation of sphingosine-1- phosphate receptor 1 (S1PR1) protein, as S1PR1 inhibitor or SIPR1 small interfering RNA blocked the BBB protective effect of bFGF, whereas S1PR1 agonist alone has comparable BBB protection effect of bFGF. These findings will improve our understanding of the protective effect and mechanisms of bFGF on BBB and propose bFGF as a potential therapeutic agent against BBB damage in neurological disorders.	[Lin, Li; Xiao, Jian; Li, Xiaokun] Wenzhou Med Univ, Sch Pharmaceut Sci, Key Lab Biotechnol & Pharmaceut Engn, Wenzhou 325035, Zhejiang, Peoples R China; [Lin, Li; Wang, Qingzhi; Qian, Kenny; Cao, Zeyuan; Wang, Xiaoying; Yu, Zhanyang] Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, 149 13th St,Room 2401, Charlestown, MA 02129 USA; [Lin, Li; Wang, Qingzhi; Qian, Kenny; Cao, Zeyuan; Wang, Xiaoying; Yu, Zhanyang] Massachusetts Gen Hosp, Dept Neurol, Neuroprotect Res Lab, 149 13th St,Room 2401, Charlestown, MA 02129 USA; [Lin, Li; Wang, Qingzhi; Qian, Kenny; Cao, Zeyuan; Wang, Xiaoying; Yu, Zhanyang] Harvard Med Sch, 149 13th St,Room 2401, Charlestown, MA 02129 USA; [Wang, Qingzhi] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou 450000, Henan, Peoples R China	Li, XK (corresponding author), Wenzhou Med Univ, Sch Pharmaceut Sci, Key Lab Biotechnol & Pharmaceut Engn, Wenzhou 325035, Zhejiang, Peoples R China.; Yu, ZY (corresponding author), Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, 149 13th St,Room 2401, Charlestown, MA 02129 USA.; Yu, ZY (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Neuroprotect Res Lab, 149 13th St,Room 2401, Charlestown, MA 02129 USA.; Yu, ZY (corresponding author), Harvard Med Sch, 149 13th St,Room 2401, Charlestown, MA 02129 USA.	linliwz@hotmail.com; qwang15@mgh.harvard.edu; keninqian2018@u.northwestern.edu; caozeyuan1230@126.com; xfxj2000@126.com; wangxi@helix.mgh.harvard.edu; xiaokunli@163.net; Yu.Zhanyang@mgh.harvard.edu		Qian, Kenin/0000-0003-0296-6207	AHA Scientist Development Grant (SDG) [15SDG25550035]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81470999]	This study was in part supported by the National Natural Science Foundation of China 81470999 (X. L.) and AHA Scientist Development Grant (SDG) 15SDG25550035 (Z.Y.).	Abe K, 2001, PHARMACOL RES, V43, P307, DOI 10.1006/phrs.2000.0794; Alluri H, 2015, METAB BRAIN DIS, V30, P1093, DOI 10.1007/s11011-015-9651-7; Ephstein Y, 2013, J BIOL CHEM, V288, P2191, DOI 10.1074/jbc.M112.404780; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985; Fernandez-Lopez D, 2012, J NEUROSCI, V32, P9588, DOI 10.1523/JNEUROSCI.5977-11.2012; Ford-Perriss M, 2001, CLIN EXP PHARMACOL P, V28, P493, DOI 10.1046/j.1440-1681.2001.03477.x; Gaengel K, 2012, DEV CELL, V23, P587, DOI 10.1016/j.devcel.2012.08.005; Jin R, 2010, NEUROBIOL DIS, V38, P376, DOI 10.1016/j.nbd.2010.03.008; Kassner A, 2015, STROKE, V46, P3310, DOI 10.1161/STROKEAHA.115.008861; Kawamata T, 1996, J CEREBR BLOOD F MET, V16, P542, DOI 10.1097/00004647-199607000-00003; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; Khatri R, 2012, NEUROLOGY, V79, pS52, DOI 10.1212/WNL.0b013e3182697e70; Matakidou A, 2007, BRIT J CANCER, V96, P1904, DOI 10.1038/sj.bjc.6603816; Nacer A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002982; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; Prakash R, 2015, CURR OPIN NEUROL, V28, P556, DOI 10.1097/WCO.0000000000000248; Raballo R, 2000, J NEUROSCI, V20, P5012; Rosen L, 2000, Oncologist, V5 Suppl 1, P20; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Singh S, 2016, KIDNEY INT, V90, P985, DOI 10.1016/j.kint.2016.05.019; Stamatovic SM, 2016, TISSUE BARRIERS, V4, DOI 10.1080/21688370.2016.1154641; Sun N, 2016, STROKE, V47, P1899, DOI 10.1161/STROKEAHA.115.012236; Wang Z, 2015, ADV MATER SCI ENG, V2015, DOI 10.1155/2015/165631; Weiss N, 2009, BBA-BIOMEMBRANES, V1788, P842, DOI 10.1016/j.bbamem.2008.10.022; Xuan YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108182; Ye LB, 2016, NEUROTHERAPEUTICS, V13, P844, DOI 10.1007/s13311-016-0437-3; Zhao Z, 2015, CELL, V163, P1064, DOI 10.1016/j.cell.2015.10.067; Zuo SL, 2017, MOL NEUROBIOL, V54, P1213, DOI 10.1007/s12035-016-9732-6	29	14	16	1	12	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	APR	2018	55	4					3131	3142		10.1007/s12035-017-0544-0			12	Neurosciences	Neurosciences & Neurology	FY8EX	WOS:000427097500033	28466272				2021-06-18	
J	Nogueira, ML; Hamraz, M; Abolhassani, M; Bigan, E; Lafitte, O; Steyaert, JM; Dubois, B; Schwartz, L				Nogueira, Marcel Levy; Hamraz, Minoo; Abolhassani, Mohammad; Bigan, Erwan; Lafitte, Olivier; Steyaert, Jean-Marc; Dubois, Bruno; Schwartz, Laurent			Mechanical stress increases brain amyloid beta, tau, and alpha-synuclein concentrations in wild-type mice	ALZHEIMERS & DEMENTIA			English	Article						Alzheimer's disease; Parkinson's disease; Animal models; Mechanical stress; Repetitive mild traumatic brain injury; Amyloid; Tau; alpha-synuclein	CHRONIC TRAUMATIC ENCEPHALOPATHY; CONTROLLED CORTICAL IMPACT; LONG-TERM ACCUMULATION; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; MOUSE MODEL; NEURODEGENERATIVE DISEASES; COGNITIVE IMPAIRMENT; INJURY MODEL; HEAD-INJURY	Introduction: Exposure to traumatic brain injury is a core risk factor that predisposes an individual to sporadic neurodegenerative diseases. We provide evidence that mechanical stress increases brain levels of hallmark proteins associated with neurodegeneration. Methods: Wild-type mice were exposed to multiple regimens of repetitive mild traumatic brain injury, generating a range of combinations of impact energies, frequencies, and durations of exposure. Brain concentrations of amyloid beta 1-42 (A beta(1-42)), total tau, and alpha-synuclein were measured by sandwich enzyme-linked immunosorbent assay. Results: There was a highly significant main effect of impact energy, frequency, and duration of exposure on A beta(1-42), tau, and alpha-synuclein levels (P<.001), and a significant interaction between impact energy and duration of exposure for A beta(1-42) and tau (P<.001), but not for alpha-synuclein. Discussion: Dose-dependent and cumulative influence of repetitive mild traumatic brain injury-induced mechanical stress may trigger and/or accelerate neurodegeneration by pushing protein concentration over the disease threshold. (C) 2017 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.	[Nogueira, Marcel Levy; Dubois, Bruno] Hop La Pitie Salpetriere, AP HP, Dept Neurol, IM2A, Paris, France; [Nogueira, Marcel Levy; Dubois, Bruno] Inst Cerveau & Moelle Epiniere ICM, Inst Rech Translat Neurosci IHU A ICM, Paris, France; [Hamraz, Minoo; Abolhassani, Mohammad] Nosco Pharmaceut, Paris, France; [Bigan, Erwan; Steyaert, Jean-Marc] Univ Paris Saclay, Lab Informat LIX, Ecole Polytech, UMR 7161, Palaiseau, France; [Lafitte, Olivier] Univ Paris 13, LAGA, UMR 7539, Sorbonne Paris Cite, Villetaneuse, France; [Dubois, Bruno] Inst Cerveau & Moelle Epiniere ICM, CNRS, INSERM, UMR S975, Paris, France; [Schwartz, Laurent] AP HP, Paris, France	Nogueira, ML (corresponding author), Hop La Pitie Salpetriere, AP HP, Dept Neurol, IM2A, Paris, France.; Nogueira, ML (corresponding author), Inst Cerveau & Moelle Epiniere ICM, Inst Rech Translat Neurosci IHU A ICM, Paris, France.	marcel.levy@psl.aphp.fr					Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Arun P, 2013, NEUROSCI LETT, V552, P87, DOI 10.1016/j.neulet.2013.07.047; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Budde MD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00154; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chetelat G, 2013, NAT REV NEUROL, V9, P123, DOI [10.1038/nrneurol.2013.21, 10.1038/nrneurol.2013.21-c2]; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Duyckaerts C, 2008, ACTA NEUROPATHOL, V115, P5, DOI 10.1007/s00401-007-0312-8; Emmanouilidou E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022225; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; Higuchi M, 2002, NEUROMOL MED, V2, P131, DOI 10.1385/NMM:2:2:131; Houpt TA, 2013, AM J PHYSIOL-REG I, V305, pR793, DOI 10.1152/ajpregu.00549.2012; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mondello S, 2013, NEUROLOGY, V80, P1662, DOI 10.1212/WNL.0b013e3182904d43; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Nadler Y, 2008, GLIA, V56, P552, DOI 10.1002/glia.20638; Nogueira ML, 2016, ALZHEIMERS DEMENT, V12, P324, DOI 10.1016/j.jalz.2015.10.005; Nogueira ML, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00197; Pannuzzo M, 2013, PHYS CHEM CHEM PHYS, V15, P8940, DOI 10.1039/c3cp44539a; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Surgucheva I, 2014, MOL CELL NEUROSCI, V63, P114, DOI 10.1016/j.mcn.2014.10.005; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tsitsopoulos PP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00079; Turner RC, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00223; Turner RC, 2013, EXP NEUROL, V248, P520, DOI 10.1016/j.expneurol.2013.07.008; Tyler WJ, 2012, NAT REV NEUROSCI, V13, P867, DOI 10.1038/nrn3383; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; van Raaij ME, 2008, BIOPHYS J, V95, P4871, DOI 10.1529/biophysj.107.127464; Washington PM, 2016, EXP NEUROL, V275, P381, DOI 10.1016/j.expneurol.2015.06.015; Xu LY, 2016, EXP NEUROL, V275, P436, DOI 10.1016/j.expneurol.2014.11.004; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	51	14	14	1	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	APR	2018	14	4					444	453		10.1016/j.jalz.2017.11.003			10	Clinical Neurology	Neurosciences & Neurology	GC6LN	WOS:000429903200002	29244999				2021-06-18	
J	Xu, Z; Lv, XA; Dai, Q; Lu, M; Jin, Z				Xu, Zhen; Lv, Xiao-Ai; Dai, Qun; Lu, Man; Jin, Zhang			Exogenous BDNF Increases Mitochondrial pCREB and Alleviates Neuronal Metabolic Defects Following Mechanical Injury in a MPTP-Dependent Way	MOLECULAR NEUROBIOLOGY			English	Article						TBI; Metabolic defects; BDNF; Mitochondria; CREB; Complex V	TRAUMATIC BRAIN-INJURY; ELEMENT-BINDING PROTEIN; NEUROTROPHIC FACTOR; CYCLOSPORINE-A; CREB; TRANSCRIPTION; SURVIVAL; CRISIS; RATS; DYSFUNCTION	Metabolic defects are common pathological phenomena following traumatic brain injury (TBI) which contribute to poor prognosis. Brain-derived neurotrophic factor (BDNF) is an important regulator of neuronal survival, development, function, and plasticity. This study was designed to investigate the potential effects of BDNF on TBI-induced metabolic defects and their underlying molecular mechanisms. BDNF was added into cultured neurons to a concentration of 25, 50, and 100 ng/ml, respectively, right after mechanical injury and metabolite levels were analyzed 4 h post injury. The mitochondrial phosphorylated cAMP response element-binding protein (pCREB) distribution and complex V synthesis, as well as their roles in metabolic defects, were evaluated. We found that exogenous BDNF improved metabolic defects, especially the uncoupling of oxidative phosphorylation. BDNF increased pCREB in mitochondrial inner membrane and matrix and promoted mitochondrial complex V synthesis. We also found that these results were negatively regulated by the mitochondrial permeability transition pore (MPTP) antagonist CsA and positively regulated by the MPTP agonist atractyloside. BDNF's protectional effects on metabolic defects were abolished by CREB knockout. When administrated in a dominant interfering CREB mutant (A-CREB) model, mitochondrial pCREB accumulation could still be observed, but the synthesis of complex V and alleviation of metabolic defects were repressed. Our data demonstrate that exogenous BDNF mitigates neuronal metabolic defects following mechanical injury by promoting the pCREB accumulation in mitochondrial inner membrane and matrix, which is regulated by MPTP opening, thus facilitating the synthesis of mitochondrial complex V.	[Xu, Zhen] Zhejiang Chinese Med Univ, Dept Neurosurg, Affiliated Hosp 1, 54 Youdian Lane, Hangzhou 310006, Zhejiang, Peoples R China; [Lv, Xiao-Ai] Zhejiang Chinese Med Univ, Dept Surg, Affiliated Hosp 1, 54 Youdian Lane, Hangzhou 310006, Zhejiang, Peoples R China; [Dai, Qun] Zhejiang Chinese Med Univ, Cent Lab, Affiliated Hosp 1, 54 Youdian Lane, Hangzhou 310006, Zhejiang, Peoples R China; [Lu, Man] Zhejiang Chinese Med Univ, Dept Anesthesiol, Affiliated Hosp 1, 54 Youdian Lane, Hangzhou 310006, Zhejiang, Peoples R China; [Jin, Zhang] Peoples Hosp Lishui, Dept Spine Surg, 15 Dazong Rd, Lishui 323000, Peoples R China	Xu, Z (corresponding author), Zhejiang Chinese Med Univ, Dept Neurosurg, Affiliated Hosp 1, 54 Youdian Lane, Hangzhou 310006, Zhejiang, Peoples R China.	xuzhenhangzhou@yeah.net			Zhejiang Provincial Medical Health and Science and Technology Project Foundation [2016KYB213]; Zhejiang Provincial Natural Science FoundationNatural Science Foundation of Zhejiang Province [LY16H090014]	This work was supported by Zhejiang Provincial Natural Science Foundation (LY16H090014) and Zhejiang Provincial Medical Health and Science and Technology Project Foundation (2016KYB213).	Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; Bijur GN, 2003, J NEUROCHEM, V87, P1427, DOI 10.1046/j.1471-4159.2003.02113.x; Binder DK, 2004, GROWTH FACTORS, V22, P123, DOI 10.1080/08977190410001723308; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; Cammarota M, 1999, J NEUROCHEM, V72, P2272, DOI 10.1046/j.1471-4159.1999.0722272.x; Carre E, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00146; Cox LJ, 2008, NAT CELL BIOL, V10, P149, DOI 10.1038/ncb1677; De Rasmo D, 2009, FEBS J, V276, P4325, DOI 10.1111/j.1742-4658.2009.07133.x; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Khalin I, 2016, DRUG DELIV, V2016, P1; Lee J, 2005, J BIOL CHEM, V280, P40398, DOI 10.1074/jbc.C500140200; Luo CL, 2013, J NEUROTRAUM, V30, P597, DOI 10.1089/neu.2012.2425; Milon L, 2000, J BIOL CHEM, V275, P14264, DOI 10.1074/jbc.275.19.14264; Oliveira MD, 2014, J NEUROTRAUM, V31, P1750, DOI 10.1089/neu.2014.3386; Puehringer D, 2013, NAT NEUROSCI, V16, P407, DOI 10.1038/nn.3333; Readnower RD, 2011, J NEUROTRAUM, V28, P1845, DOI 10.1089/neu.2011.1755; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Sakamoto K, 2011, J NEUROCHEM, V116, P1, DOI 10.1111/j.1471-4159.2010.07080.x; Sharov VG, 2005, HEART FAIL REV, V10, P305, DOI 10.1007/s10741-005-7545-1; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SIESJO BK, 1984, J NEUROSURG, V60, P883, DOI 10.3171/jns.1984.60.5.0883; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; Stein NR, 2012, NEUROCRIT CARE, V17, P49, DOI 10.1007/s12028-012-9708-y; SZABO I, 1991, J BIOL CHEM, V266, P3376; Veech RL, 2012, IUBMB LIFE, V64, P203, DOI 10.1002/iub.590; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Wender R, 2000, J NEUROSCI, V20, P6804, DOI 10.1523/JNEUROSCI.20-18-06804.2000; Wright MJ, 2013, BRAIN IMAGING BEHAV, V7, P307, DOI 10.1007/s11682-013-9231-6; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xu Z, 2016, MOL BRAIN, V9, DOI 10.1186/s13041-016-0257-8; Yan Q, 1997, J COMP NEUROL, V378, P135; Yang JL, 2014, NEUROMOL MED, V16, P161, DOI 10.1007/s12017-013-8270-x; Yang JY, 2013, J MOL CELL CARDIOL, V59, P167, DOI 10.1016/j.yjmcc.2013.02.016; Zhang H., 2014, MATH PROBL ENG, V2014, P9, DOI DOI 10.1371/J0URNAL.P0NE.0088909	42	14	14	1	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	APR	2018	55	4					3499	3512		10.1007/s12035-017-0576-5			14	Neurosciences	Neurosciences & Neurology	FY8EX	WOS:000427097500059	28508150				2021-06-18	
J	Wright, AD; Smirl, JD; Bryk, K; Fraser, S; Jakovac, M; van Donkelaar, P				Wright, Alexander D.; Smirl, Jonathan D.; Bryk, Kelsey; Fraser, Sarah; Jakovac, Michael; van Donkelaar, Paul			Sport-Related Concussion Alters Indices of Dynamic Cerebral Autoregulation	FRONTIERS IN NEUROLOGY			English	Article						cerebral blood flow; autoregulation; blood pressure; autonomic dysfunction; transfer function analysis; repetitive head impact exposure	TRAUMATIC BRAIN-INJURY; TRANSCRANIAL DOPPLER ULTRASOUND; ARTERIAL-BLOOD GASES; SUBARACHNOID HEMORRHAGE; VASCULAR INJURY; FLOW VELOCITY; HEAD-INJURY; PRESSURE; REACTIVITY; RESPONSES	Sport-related concussion is known to affect a variety of brain functions. However, the impact of this brain injury on cerebral autoregulation (CA) is poorly understood. Thus, the goal of the current study was to determine the acute and cumulative effects of sport-related concussion on indices of dynamic CA. Toward this end, 179 elite, junior-level (age 19.6 +/- 1.5 years) contact sport (ice hockey, American football) athletes were recruited for preseason testing, 42 with zero prior concussions and 31 with three or more previous concussions. Eighteen athletes sustained a concussion during that competitive season and completed follow-up testing at 72 h, 2 weeks, and 1 month post injury. Beat-bybeat arterial blood pressure (BP) and middle cerebral artery blood velocity (MCAv) were recorded using finger photoplethysmography and transcranial Doppler ultrasound, respectively. Five minutes of repetitive squat-stand maneuvers induced BP oscillations at 0.05 and 0.10 Hz (20- and 10-s cycles, respectively). The BP-MCAv relationship was quantified using transfer function analysis to estimate Coherence (correlation), Gain (amplitude ratio), and Phase (timing offset). At a group level, repeated-measures ANOVA indicated that 0.10 Hz Phase was significantly reduced following an acute concussion, compared to preseason, by 23% (-0.136 +/- 0.033 rads) at 72 h and by 18% (-0.105 +/- 0.029 rads) at 2 weeks post injury, indicating impaired autoregulatory functioning; recovery to preseason values occurred by 1 month. Athletes were cleared to return to competition after a median of 14 days (range 7-35), implying that physiologic dysfunction persisted beyond clinical recovery in many cases. When comparing dynamic pressure buffering between athletes with zero prior concussions and those with three or more, no differences were observed. Sustaining an acute sport-related concussion induces transient impairments in the capabilities of the cerebrovascular pressure-buffering system that may persist beyond 2 weeks and may be due to a period of autonomic dysregulation. Athletes with a history of three or more concussions did not exhibit impairments relative to those with zero prior concussions, suggesting recovery of function over time. Findings from this study support the potential need to consider physiological recovery in deciding when patients should return to play following a concussion.	[Wright, Alexander D.] Univ British Columbia, MD PhD Program, Vancouver, BC, Canada; [Wright, Alexander D.; Fraser, Sarah; Jakovac, Michael] Univ British Columbia Okanagan, Southern Med Program, Reichwald Hlth Sci Ctr, Kelowna, BC, Canada; [Wright, Alexander D.] Univ British Columbia, Expt Med Program, Fac Med, Vancouver, BC, Canada; [Wright, Alexander D.; Smirl, Jonathan D.; Bryk, Kelsey; van Donkelaar, Paul] Univ British Columbia Okanagan, Sch Hlth & Exercise Sci, Kelowna, BC, Canada	van Donkelaar, P (corresponding author), Univ British Columbia Okanagan, Sch Hlth & Exercise Sci, Kelowna, BC, Canada.	paul.vandonkelaar@ubc.ca		Smirl, Jonathan/0000-0003-1054-0038	CIHRCanadian Institutes of Health Research (CIHR) [183304]; CFICanada Foundation for Innovation [30979]; Vanier Canada Graduate Scholarships program; Vancouver Coastal Health-CIHR-UBC MD/PhD Studentship; O'Brien Foundation Fellowship; Innovations in Wellness post-doctoral fellowship	This research was funded by grants from CIHR (183304) and CFI (30979) awarded to PD. AW was supported by the Vanier Canada Graduate Scholarships program, a Vancouver Coastal Health-CIHR-UBC MD/PhD Studentship, and an O'Brien Foundation Fellowship. JS was supported by the Innovations in Wellness post-doctoral fellowship.	Abaji JP, 2016, J NEUROTRAUM, V33, P811, DOI 10.1089/neu.2015.3989; Ainslie PN, 2007, EXP PHYSIOL, V92, P769, DOI 10.1113/expphysiol.2006.036814; Ainslie PN, 2014, J APPL PHYSIOL, V117, P1081, DOI 10.1152/japplphysiol.00854.2014; Allen B, 2015, PSYCHOPHYSIOLOGY, V52, P277, DOI 10.1111/psyp.12321; Aries MJH, 2010, STROKE, V41, P2697, DOI 10.1161/STROKEAHA.110.594168; Bailey DM, 2013, CLIN SCI, V124, P177, DOI 10.1042/CS20120259; Barlow KM, 2017, J NEUROTRAUM, V34, P996, DOI 10.1089/neu.2016.4634; Becelewski Janusz, 2003, Neurol Neurochir Pol, V37, P339; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Brothers RM, 2016, J PHYSIOL-LONDON, V594, P4077, DOI 10.1113/JP271884; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Budohoski KP, 2015, NEUROCRIT CARE, V22, P65, DOI 10.1007/s12028-014-0032-6; Budohoski KP, 2012, NEUROSURGERY, V71, P652, DOI 10.1227/NEU.0b013e318260feb1; Churchill N, 2017, J NEUROTRAUM, V34, P765, DOI 10.1089/neu.2016.4531; Claassen JAHR, 2016, J CEREBR BLOOD F MET, V36, P665, DOI 10.1177/0271678X15626425; Covassin T, 2016, J ATHL TRAINING, V51, P189, DOI 10.4085/1062-6050-51.3.05; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Doshi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118061; Edvinsson L, 1975, Acta Physiol Scand Suppl, V427, P1; Gabler LF, 2018, J BIOMECH ENG-T ASME, V140, DOI 10.1115/1.4038357; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Gardner AJ, 2015, BRIT J SPORT MED, V49, P1050, DOI 10.1136/bjsports-2014-093901; Ghajari M, 2017, BRAIN, V140, P333, DOI 10.1093/brain/aww317; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hamner JW, 2014, STROKE, V45, P1771, DOI 10.1161/STROKEAHA.114.005293; Hamner JW, 2012, J PHYSIOL-LONDON, V590, P6343, DOI 10.1113/jphysiol.2012.245100; Hamner JW, 2010, STROKE, V41, P102, DOI 10.1161/STROKEAHA.109.557132; Hamner JW, 2004, J PHYSIOL-LONDON, V559, P965, DOI 10.1113/jphysiol.2004.066969; Hilz MJ, 2016, J NEUROL SCI, V365, P181, DOI 10.1016/j.jns.2016.04.022; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; Hilz MJ, 2004, J NEUROL, V251, P564, DOI 10.1007/s00415-004-0364-9; Hlatky R, 2004, NEUROCRIT CARE, V1, P69, DOI 10.1385/NCC:1:1:69; Hoiland RL, 2016, J PHYSIOL-LONDON, V594, P4073, DOI 10.1113/JP271981; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; KAWAI Y, 1993, J APPL PHYSIOL, V74, P3046; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Kirkness C J, 2001, Biol Res Nurs, V2, P175, DOI 10.1177/109980040100200303; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; List J, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00228; Liu W, 2013, NMR BIOMED, V26, P651, DOI 10.1002/nbm.2910; Mandera M, 2002, CHILD NERV SYST, V18, P124, DOI 10.1007/s00381-002-0572-5; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; OPPENHEIMER S, 1993, STROKE, V24, pI3; OPPENHEIMER SM, 1992, BRAIN RES, V581, P133, DOI 10.1016/0006-8993(92)90352-A; Otite F, 2014, STROKE, V45, P677, DOI 10.1161/STROKEAHA.113.002630; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Purkayastha S, 2014, J CEREBR BLOOD F MET, V34, P228, DOI 10.1038/jcbfm.2013.180; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; Santos GA, 2016, NEUROLOGY, V86, P1950, DOI 10.1212/WNL.0000000000002696; Shultz SR, 2017, NEUROSCI BIOBEHAV R, V76, P396, DOI 10.1016/j.neubiorev.2016.09.014; Smirl JD, 2015, J APPL PHYSIOL, V119, P487, DOI 10.1152/japplphysiol.00264.2015; Sorond FA, 2010, J ULTRAS MED, V29, P1017, DOI 10.7863/jum.2010.29.7.1017; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; Sviri GE, 2009, J NEUROSURG, V111, P695, DOI 10.3171/2008.10.17686; Tan CO, 2014, NEUROLOGY, V83, P1665, DOI 10.1212/WNL.0000000000000944; Thayer JF, 2009, NEUROSCI BIOBEHAV R, V33, P81, DOI 10.1016/j.neubiorev.2008.08.004; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Willie CK, 2014, J PHYSIOL-LONDON, V592, P841, DOI 10.1113/jphysiol.2013.268953; Wright AD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150215; ZAMRINI EY, 1990, NEUROLOGY, V40, P1408, DOI 10.1212/WNL.40.9.1408; Zhang R, 1998, J APPL PHYSIOL, V85, P1113	68	14	14	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	MAR 27	2018	9								196	10.3389/fneur.2018.00196			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	GA6EQ	WOS:000428426100001	29636724	DOAJ Gold, Green Published			2021-06-18	
J	Busquets, O; Ettcheto, M; Verdaguer, E; Castro-Torres, RD; Auladell, C; Beas-Zarate, C; Folch, J; Camins, A				Busquets, Oriol; Ettcheto, Miren; Verdaguer, Ester; Castro-Torres, Ruben D.; Auladell, Carme; Beas-Zarate, Carlos; Folch, Jaume; Camins, Antoni			JNK1 inhibition by Licochalcone A leads to neuronal protection against excitotoxic insults derived of kainic acid	NEUROPHARMACOLOGY			English	Article						Kainic acid; Epilepsy; Neurodegeneration; Licochalcone A; Hippocampus	N-TERMINAL KINASE; TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; C-JUN; CEREBRAL-ISCHEMIA; STATUS EPILEPTICUS; KAINATE MODEL; SEIZURES; DEGENERATION; PHOSPHORYLATION	The mitogen-activated protein kinase family (MAPK) is an important group of enzymes involved in cellular responses to diverse external stimuli. One of the members of this family is the c-Jun-N-terminal kinase (JNK). The activation of the JNK pathway has been largely associated with the pathogenesis that occurs in epilepsy and neurodegeneration. Kainic acid (KA) administration in rodents is an experimental approach that induces status epilepticus (SE) and replicates many of the phenomenological features of human temporal lobe epilepsy (TLE). Recent studies in our group have evidenced that the absence of the JNK1 gene has neuroprotective effects against the damage induced by MA, as it occurs with the absence of JNK3. The aim of the present study was to analyse whether the pharmacological inhibition of JNK1 by Licochalcone A (Lic-A) had similar effects and if it may be considered as a new molecule for the treatment of SE. In order to achieve this objective, animals were pre-treated with Lic-A and posteriorly administered with KA as a model for TLE. In addition, a comparative study with MA was performed between wild type pre-treated with Lic-A and single knock-out transgenic mice for the Jnk1(-/-) gene. Our results showed that JNK1 inhibition by Lic-A, previous to KA administration, caused a reduction in the convulsive pattern. Furthermore, it reduced phosphorylation levels of the JNK, as well as its activity. In addition, Lic-A prevented hippocampal neuronal degeneration, increased pro-survival anti-apoptotic mechanisms, reduced pro-apoptotic biomarkers, decreased cellular stress and neuroinflammatory processes. Thus, our results suggest that inhibition of the JNK1 by Lic-A has neuroprotective effects and that; it could be a new potential approach for the treatment of SE and neurodegeneration. (C) 2017 Elsevier Ltd. All rights reserved.	[Busquets, Oriol; Ettcheto, Miren; Folch, Jaume] Univ Rovira & Virgili, Fac Med & Ciencies Salut, Dept Bioquim & Biotecnol, Tarragona, Spain; [Busquets, Oriol; Ettcheto, Miren; Castro-Torres, Ruben D.; Camins, Antoni] Univ Barcelona, Fac Farm & Ciencies Alimentacio, Dept Farmacol Toxicol & Quim Terapeut, Barcelona, Spain; [Busquets, Oriol; Ettcheto, Miren; Verdaguer, Ester; Auladell, Carme; Folch, Jaume; Camins, Antoni] Biomed Res Networking Ctr Neurodegenerat Dis CIBE, Madrid, Spain; [Busquets, Oriol; Ettcheto, Miren; Verdaguer, Ester; Auladell, Carme; Camins, Antoni] Univ Barcelona, Inst Neurociencias, Barcelona, Spain; [Verdaguer, Ester; Castro-Torres, Ruben D.; Auladell, Carme] Univ Barcelona, Fac Biol, Dept Biol Cellular Fisiol & Immunol, Barcelona, Spain; [Castro-Torres, Ruben D.; Beas-Zarate, Carlos] Univ Guadalajara, Dept Biol Celular & Mol, CUCBA, Sierra Mojada 800, Guadalajara 44340, Jalisco, Mexico; [Castro-Torres, Ruben D.; Beas-Zarate, Carlos] Div Neurociencias, Sierra Mojada 800, Guadalajara 44340, Jalisco, Mexico	Camins, A (corresponding author), Univ Barcelona, Fac Farm & Ciencies Alimentacio, Dept Farmacol Toxicol & Quim Terapeut, Barcelona, Spain.; Folch, J (corresponding author), Biomed Res Networking Ctr Neurodegenerat Dis CIBE, Madrid, Spain.	camins@ub.edu	Camins, Antonio/J-5126-2019; Figueras, Oriol Busquets/L-2624-2017	Camins, Antonio/0000-0002-1229-5956; Figueras, Oriol Busquets/0000-0002-1372-9699; Ettcheto, Miren/0000-0002-4301-7297	Spanish Ministry of Science and InnovationSpanish Government [PI2016/01, CB06/05/0024]; European Regional Development Founds; CONACyT MexicoConsejo Nacional de Ciencia y Tecnologia (CONACyT) [0177594]; CONACYTConsejo Nacional de Ciencia y Tecnologia (CONACyT) [298337, 000091]	This work was supported by grants from the Spanish Ministry of Science and Innovation P12016/01, CB06/05/0024 (CIBERNED) and the European Regional Development Founds. Research team from UB and URV belongs to 2014SGR-525 from Generalitat de Catalunya. CBZ is supported by grants from CONACyT Mexico (No. 0177594) and RDCT from Postdoctoral fellowship CONACYT No. 298337 and the Doctoral Program in Sciences in Molecular Biology in Medicine, LGAC Molecular Bases of Chronic Diseases Degenerative and its Applications (000091, PNPC, CONACyT). The authors are grateful to Roxanne Rowles for the English revision of the manuscript.	Auladell C, 2017, FRONT BIOSCI-LANDMRK, V22, P795, DOI 10.2741/4517; BENARI Y, 1979, BRAIN RES, V163, P176, DOI 10.1016/0006-8993(79)90163-X; Benito E, 2010, TRENDS NEUROSCI, V33, P230, DOI 10.1016/j.tins.2010.02.001; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Borsello T, 2003, NAT MED, V9, P1180, DOI 10.1038/nm911; Brecht S, 2005, EUR J NEUROSCI, V21, P363, DOI 10.1111/j.1460-9568.2005.03857.x; Carboni S, 2008, BRIT J PHARMACOL, V153, P157, DOI 10.1038/sj.bjp.0707574; de Lemos L, 2017, MOL NEUROBIOL; de Lemos L, 2010, J NEUROCHEM, V114, P1315, DOI 10.1111/j.1471-4159.2010.06853.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Dunleavy M, 2013, J MOL NEUROSCI, V49, P202, DOI 10.1007/s12031-012-9927-x; Ettcheto M, 2015, MOL NEUROBIOL, V52, P120, DOI 10.1007/s12035-014-8836-0; Fernandez-Espejo E, 1996, Rev Neurol, V24, P779; Franklin Paxinos, 2012, MOUSE BRAIN STEREOTA; FRENCH ED, 1982, NEUROSCIENCE, V7, P2525, DOI 10.1016/0306-4522(82)90212-3; Funakoshi-Tago M, 2010, INT IMMUNOPHARMACOL, V10, P562, DOI 10.1016/j.intimp.2010.02.003; Hammer J, 2008, GLIA, V56, P856, DOI 10.1002/glia.20659; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Jefferys J, 2016, J NEUROSCI METH, V260, P53, DOI 10.1016/j.jneumeth.2015.04.011; Jeon SH, 2000, EXP MOL MED, V32, P227, DOI 10.1038/emm.2000.37; Jessberger S, 2007, J NEUROSCI, V27, P9400, DOI 10.1523/JNEUROSCI.2002-07.2007; Junyent F, 2009, J NEUROSCI RES, V87, P1500, DOI 10.1002/jnr.21950; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kuan CY, 2003, P NATL ACAD SCI USA, V100, P15184, DOI 10.1073/pnas.2336254100; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lerma J, 2013, NEURON, V80, P292, DOI 10.1016/j.neuron.2013.09.045; Levesque M, 2013, NEUROSCI BIOBEHAV R, V37, P2887, DOI 10.1016/j.neubiorev.2013.10.011; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Lucke-Wold BP, 2015, SEIZURE-EUR J EPILEP, V33, P13, DOI 10.1016/j.seizure.2015.10.002; MATHERN GW, 1993, ELECTROEN CLIN NEURO, V87, P326, DOI 10.1016/0013-4694(93)90186-Y; Mechanisms B., 2002, PATHOPHYSIOLOGY SEIZ, P9; Morrison R. S., 1996, LOSS P53 TUMOR SUPPR, V76, P1337; NADLER JV, 1980, BRAIN RES, V195, P47; NADLER JV, 1980, J COMP NEUROL, V192, P333, DOI 10.1002/cne.901920209; Olloquequi J, 2010, RESP MED, V104, P1310, DOI 10.1016/j.rmed.2010.03.002; Parent JM, 2008, EPILEPSIA, V49, P19, DOI 10.1111/j.1528-1167.2008.01634.x; Park MJ, 2015, MATH PROBL ENG, V2015, P1, DOI DOI 10.1007/S13592-015-0383-9; Repici M, 2007, NEUROSCIENCE, V150, P40, DOI 10.1016/j.neuroscience.2007.08.021; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Sabapathy K., 2012, PROGR MOL BIOL TRANS; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shibata S, 2000, YAKUGAKU ZASSHI, V120, P849, DOI 10.1248/yakushi1947.120.10_849; Spigolon G, 2010, EUR J NEUROSCI, V31, P1261, DOI 10.1111/j.1460-9568.2010.07158.x; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Tai TY, 2017, NEUROSCIENCE, V349, P35, DOI 10.1016/j.neuroscience.2017.02.024; Verdaguer E, 2003, ANN NY ACAD SCI, V1010, P671, DOI 10.1196/annals.1299.122; Yao K, 2014, CANCER PREV RES, V7, P139, DOI 10.1158/1940-6207.CAPR-13-0117; Zhao Y, 2012, MOL CELL NEUROSCI, V49, P300, DOI 10.1016/j.mcn.2011.12.005; Zheng YF, 2004, J BIOL CHEM, V279, P42898, DOI 10.1074/jbc.M403193200	53	14	15	1	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	MAR 15	2018	131						440	452		10.1016/j.neuropharm.2017.10.030			13	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	FZ1DK	WOS:000427316000039	29111385				2021-06-18	
J	Khan, M; Dhammu, TS; Baarine, M; Kim, J; Paintlia, MK; Singh, I; Singh, AK				Khan, Mushfiquddin; Dhammu, Tajinder S.; Baarine, Mauhamad; Kim, Jinsu; Paintlia, Manjeet K.; Singh, Inderjit; Singh, Avtar K.			GSNO promotes functional recovery in experimental TBI by stabilizing HIF-1 alpha	BEHAVIOURAL BRAIN RESEARCH			English	Article						TBI; GSNO; HIF-1 alpha; VEGF; Neurobehavioral function; Neurorepair; S-nitrosylation	TRAUMATIC BRAIN-INJURY; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; RECEPTOR AGONIST 8-OH-DPAT; S-NITROSOGLUTATHIONE; NITRIC-OXIDE; RAT MODEL; CEREBRAL-ISCHEMIA; STROKE; PROTECTS; DEFICITS	Traumatic brain injury (TBI) causes sustained disability due to compromised neurorepair mechanisms. Crucial to neurorepair and functional recovery following both TBI and stroke is hypoxia-inducible factor 1 alpha (HIF-1 alpha). Based on reports that HIF-1 alpha could be stabilized via S-nitrosylation, we tested the hypothesis that the S-nitrosylating agent S-nitrosoglutathione (GSNO) would stabilize HIF-1 alpha, thereby stimulating neurorepair mechanisms and aiding in functional recovery. TBI was induced by controlled cortical impact (CCI) in adult rats. GSNO (0.05 mg/kg) was administered at two hours after CCI. The treatment was repeated daily until the 14th day after CCI. Functional recovery was assessed by motor and cognitive functions, and the recovery was compared with the expression of HIF-1 alpha. The mechanisms of GSNO-mediated S-nitrosylation of HIF-1 alpha were determined using brain endothelial cells. While non-treated TBI animals showed sustained neurobehavioral deficits, GSNO treatment of TBI improved neurobehavioral functions. GSNO also increased the expression of HIF-1 alpha and VEGF. The beneficial effects of GSNO on neurobehavioral functions in TBI animals were blocked by treatment with the HIF-1 alpha inhibitor 2-methoxyestradiol (2-ME). The stimulatory effect of GSNO on VEGF was reversed not only by 2-ME but also by the denitrosylating agent dithiothreitol, confirming our hypothesis that GSNO's benefits are mediated by the stabilization of HIF-1 alpha via S-nitrosylation. GSNO's S-nitrosylation of HIF-1 alpha was further confirmed using a biotin switch assay in endothelial cells. The data provide evidence that GSNO treatment of TBI aids functional recovery through stabilizing HIF-1 alpha via S-nitrosylation. GSNO is a natural component of the human brain/body, and its exogenous administration has not shown adverse effects in humans. Therefore, the translational potential of GSNO therapy in TBI is high. (C) 2016 Elsevier B.V. All rights reserved.	[Khan, Mushfiquddin; Dhammu, Tajinder S.; Kim, Jinsu; Paintlia, Manjeet K.; Singh, Inderjit] Med Univ South Carolina, Dept Pediat, Charleston, SC 29425 USA; [Baarine, Mauhamad; Singh, Avtar K.] Med Univ South Carolina, Dept Pathol & Lab Med, 508 Childrens Res Inst,173 Ashley Ave, Charleston, SC 29425 USA; [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA	Khan, M (corresponding author), Med Univ South Carolina, Dept Pediat, Charleston, SC 29425 USA.; Singh, AK (corresponding author), Med Univ South Carolina, Dept Pathol & Lab Med, 508 Childrens Res Inst,173 Ashley Ave, Charleston, SC 29425 USA.	khanm@musc.edu; Dhammu@musc.edu; baarine@musc.edu; kimji@musc.edu; kaurm@musc.edu; singhi@musc.edu; singha@musc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-72511]; VA merit awardUS Department of Veterans Affairs [RX2090]; NIH from the Extramural Research Facilities Program of the National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [C06 RR018823, C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR015455, C06RR018823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072511] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX003401, I01RX002090] Funding Source: NIH RePORTER	This work was supported by grants from NIH (NS-72511) and VA merit award (RX2090). This work was also supported by the NIH, Grants C06 RR018823 and No C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We thank Ms. Joyce Bryan for her technical help. We also acknowledge Dr. Tom Smith from the MUSC Writing Center for his valuable suggestions and editing of the manuscript.	Baarine M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143238; Baarine M, 2015, J NEUROCHEM, V133, P380, DOI 10.1111/jnc.12992; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; Carbonaro M, 2012, J BIOL CHEM, V287, P11859, DOI 10.1074/jbc.M112.345587; Chen CH, 2007, J NEUROCHEM, V102, P1831, DOI 10.1111/j.1471-4159.2007.04652.x; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Chistiakov DA, 2016, EXP MOL PATHOL, V100, P409, DOI 10.1016/j.yexmp.2016.03.012; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Dhawan J, 2011, FUTUR NEUROL, V6, P823, DOI 10.2217/FNL.11.55; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gao Y, 2016, MOL CELL BIOCHEM, V414, P77, DOI 10.1007/s11010-016-2660-y; Hess DT, 2012, J BIOL CHEM, V287, P4411, DOI 10.1074/jbc.R111.285742; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Hornyak I, 2011, CURR PHARM BIOTECHNO, V12, P1368, DOI 10.2174/138920111798280983; Huang TN, 2014, NAT NEUROSCI, V17, P240, DOI 10.1038/nn.3626; Ke XJ, 2013, J HUAZHONG U SCI-MED, V33, P433, DOI 10.1007/s11596-013-1137-4; Khan M, 2015, DRUG DES DEV THER, V9, P2233, DOI 10.2147/DDDT.S77115; Khan M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-78; Kimura H, 2002, BIOCHEM BIOPH RES CO, V296, P976, DOI 10.1016/S0006-291X(02)02029-6; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Li F, 2007, MOL CELL, V26, P63, DOI 10.1016/j.molcel.2007.02.024; Lima B, 2009, P NATL ACAD SCI USA, V106, P6297, DOI 10.1073/pnas.0901043106; Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.E02-12-0791; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; Monville C, 2006, J NEUROSCI METH, V158, P219, DOI 10.1016/j.jneumeth.2006.06.001; Mooberry SL, 2003, DRUG RESIST UPDATE, V6, P355, DOI 10.1016/j.drup.2003.10.001; Palmer LA, 2000, MOL PHARMACOL, V58, P1197; Privratsky JR, 2014, CELL TISSUE RES, V355, P607, DOI 10.1007/s00441-013-1779-3; Quaegebeur A, 2016, CELL METAB, V23, P280, DOI 10.1016/j.cmet.2015.12.007; RADOMSKI MW, 1992, BRIT J PHARMACOL, V107, P745, DOI 10.1111/j.1476-5381.1992.tb14517.x; Sen T, 2016, NEUROPHARMACOLOGY, V107, P79, DOI 10.1016/j.neuropharm.2016.03.009; Shunmugavel A, 2015, NEUROUROL URODYNAM, V34, P519, DOI 10.1002/nau.22619; Shunmugavel Anandakumar, 2012, Neurosci Med, V3, P294; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Thelin E. P., 2016, BRAIN INJURY FRONT N, V7, P23, DOI [10.3389/fneur.2016.0002327014178, DOI 10.3389/FNEUR.2016.0002327014178]; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang ZF, 2012, STROKE, V43, P2430, DOI 10.1161/STROKEAHA.112.652545; Wellman TL, 2003, FASEB J, V17, P379, DOI 10.1096/fj.03-0143fje; Yasinska IM, 2003, FEBS LETT, V549, P105, DOI 10.1016/S0014-5793(03)00807-X; Zhou DC, 2008, NEUROL RES, V30, P268, DOI 10.1179/016164107X229920	41	14	14	0	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	MAR 15	2018	340				SI		63	70		10.1016/j.bbr.2016.10.037			8	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	FU9JY	WOS:000424173400007	27780722	Green Accepted			2021-06-18	
J	Beck, B; Gantner, D; Cameron, PA; Braaf, S; Saxena, M; Cooper, DJ; Gabbe, BJ				Beck, Ben; Gantner, Dashiell; Cameron, Peter A.; Braaf, Sandra; Saxena, Manoj; Cooper, D. James; Gabbe, Belinda J.			Temporal Trends in Functional Outcomes after Severe Traumatic Brain Injury: 2006-2015	JOURNAL OF NEUROTRAUMA			English	Article						disability; epidemiology; head injury; trauma; trends over time	MAJOR TRAUMA; HEAD-INJURY; DECOMPRESSIVE CRANIECTOMY; COMORBIDITY INDEX; EPIDEMIOLOGY; TRIAL; MANAGEMENT; AUSTRALIA; VICTORIA; MODERATE	Severe traumatic brain injury (TBI) is associated with poor outcomes; however, little is known about whether these outcomes are improving over time. This study examined temporal trends in functional outcomes of severe TBI at six months post-injury. We conducted a retrospective cohort study (January 1, 2006 to December 31, 2015) of hospitalized adult (16 years) patients with severe TBI using data from the population-based Victorian State Trauma Registry. The primary outcome was the Glasgow Outcome Scale-Extended (GOS-E) at six months post-injury, dichotomized as upper severe disability or worse (GOS-E <= 4, termed "unfavorable outcome") and lower moderate disability or better (GOS-E >= 5; termed "favorable outcome"). Multivariable logistic regression was used to investigate temporal trends in functional outcomes at six months post-injury. Of the 1966 patients with severe TBI who were followed up at six months post-injury (median age, 42 years (interquartile range [IQR]: 25-68); male, 73%), a majority of patients had an unfavorable outcome (GOS-E <= 4; n = 1372, 70%). After adjusting for confounders, there was no change in functional outcomes over time (adjusted odds ratio [AOR] = 1.02, 95% confidence interval [CI]: 0.98,1.06; p = 0.35). Similarly, there was no change in the adjusted odds of death (GOS-E = 1) at six months post-injury (AOR = 1.04, 95% CI: 1.00,1.08; p = 0.08). Using a population-wide, high quality, comprehensive registry, we demonstrated no change in death or functional outcomes after severe TBI between 2006 and 2015 in a mature trauma system. There is a clear need to identify targeted improvements in the treatment of these patients with the aim of reducing in-hospital death and improving long-term outcomes.	[Beck, Ben; Cameron, Peter A.; Braaf, Sandra; Gabbe, Belinda J.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; [Gantner, Dashiell; Cooper, D. James] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; [Gantner, Dashiell; Cooper, D. James] Alfred, Dept Intens Care & Hyperbar Med, Melbourne, Vic, Australia; [Cameron, Peter A.] Alfred Hosp, Emergency & Trauma Ctr, Melbourne, Vic, Australia; [Saxena, Manoj] St George Hosp, Intens Care Unit, Sydney, NSW, Australia; [Saxena, Manoj] Univ New South Wales, George Inst Global Hlth, Crit Care & Trauma Div, Sydney, NSW, Australia; [Gabbe, Belinda J.] Swansea Univ, Med Sch, Farr Inst, Swansea, W Glam, Wales	Beck, B (corresponding author), Monash Univ, Dept Epidemiol & Prevent Med, Sch Publ Hlth & Prevent Med, 553 St Kilda Rd, Melbourne, Vic 3004, Australia.	ben.beck@monash.edu	Beck, Ben/ABD-5556-2020; Cooper, D. James/G-7961-2013	Beck, Ben/0000-0003-3262-5956; Cooper, D. James/0000-0002-5872-9051; Braaf, Sandra/0000-0001-7942-0179; Cameron, Peter/0000-0002-1443-557X; Saxena, Manoj/0000-0002-0385-6731	Victorian State Trauma Registry (VSTR) is a Department of Health and Human Services, State Government of Victoria; Transport Accident Commission; National Health and Medical Research Council (NHRMC) Australian Resuscitation Outcomes Consortium (Aus-ROC) Centre of Research ExcellenceNational Health and Medical Research Council of Australia [1029983]; Practitioner Fellowship from the NHMRCNational Health and Medical Research Council of Australia [545926]; Career Development Fellowship from the NHMRCNational Health and Medical Research Council of Australia [GNT1048731]	The Victorian State Trauma Registry (VSTR) is a Department of Health and Human Services, State Government of Victoria and Transport Accident Commission funded project. The Victorian State Trauma Outcome Registry and Monitoring (VSTORM) group is thanked for the provision of VSTR data. The authors also thank Sue McLellan for her assistance with the data and Pam Simpson for statistical advice.; Ben Beck received salary support from the National Health and Medical Research Council (NHRMC) Australian Resuscitation Outcomes Consortium (Aus-ROC) Centre of Research Excellence (#1029983). Peter Cameron and Belinda Gabbe were supported by a Practitioner Fellowship (#545926), and a Career Development Fellowship (GNT1048731), from the NHMRC, respectively.	Ackland HM, 2016, INJURY, V47, P1109, DOI 10.1016/j.injury.2015.12.016; Andelic N, 2012, NEUROEPIDEMIOLOGY, V38, P259, DOI 10.1159/000338032; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; [Anonymous], 2008, BMJ-BRIT MED J, V336, P425, DOI DOI 10.1136/bmj.39461.643438.25; Association for the Advancement of Automotive Medicine, 2008, ABBR INJ SCAL 2005 U; Beck B, 2016, MED J AUSTRALIA, V204, P407, DOI 10.5694/mja15.01369; Bragge P, 2016, J NEUROTRAUM, V33, P1461, DOI 10.1089/neu.2015.4233; Cameron PA, 2004, ANZ J SURG, V74, P424, DOI 10.1111/j.1445-1433.2004.03029.x; Cameron PA, 2008, MED J AUSTRALIA, V189, P546, DOI 10.5694/j.1326-5377.2008.tb02176.x; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Edwards P, 2005, LANCET, V365, P1957; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Fountain DM, 2017, ANN SURG, V265, P590, DOI 10.1097/SLA.0000000000001682; Fu TS, 2015, J TRAUMA ACUTE CARE, V79, P449, DOI 10.1097/TA.0000000000000733; Fuller G, 2011, BRIT J NEUROSURG, V25, P414, DOI 10.3109/02688697.2011.570882; Gabbe BJ, 2015, ANN SURG, V261, P565, DOI 10.1097/SLA.0000000000000522; Gabbe BJ, 2012, ANN SURG, V255, P1009, DOI 10.1097/SLA.0b013e31824c4b91; Gabbe BJ, 2010, J TRAUMA, V69, P532, DOI 10.1097/TA.0b013e3181e5125b; Gabbe BJ, 2005, ACAD EMERG MED, V12, P751, DOI 10.1197/j.aem.2005.03.527; Gabbe BJ, 2005, ACAD EMERG MED, V12, P318, DOI 10.1197/j.aem.2004.12.002; Helps Y., 2008, INJURY RES STAT SERI, V45; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Kupas DF, 2016, ANN EMERG MED, V68, P744, DOI 10.1016/j.annemergmed.2016.06.017; Lefering R, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0476-2; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Palmer CS, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-29; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; TEASDALE G, 1974, LANCET, V2, P81; Udy AA, 2017, CRIT CARE MED, V45, pE138, DOI 10.1097/CCM.0000000000002059; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; Van Essen TA, 2016, J NEUROTRAUM, V33, pA20; Williamson OD, 2011, J TRAUMA, V71, P63, DOI 10.1097/TA.0b013e31820e898d; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; World Health Organization, 2006, NEUR DIS PUBL HLTH C; Zygun DA, 2005, CAN J NEUROL SCI, V32, P87, DOI 10.1017/S0317167100016930	49	14	14	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2018	35	8					1021	1029		10.1089/neu.2017.5287		MAR 2018	9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GC0DM	WOS:000426658100001	29256832				2021-06-18	
J	Clark, MD; Varangis, EML; Champagne, AA; Giovanello, KS; Shi, F; Kerr, ZY; Smith, JK; Guskiewicz, KM				Clark, Michael D.; Varangis, Eleanna M. L.; Champagne, Allen A.; Giovanello, Kelly S.; Shi, Feng; Kerr, Zachary Y.; Smith, J. Keith; Guskiewicz, Kevin M.			Effects of Career Duration, Concussion History, and Playing Position on White Matter Microstructure and Functional Neural Recruitment in Former College and Professional Football Athletes	RADIOLOGY			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; SUBCONCUSSIVE HEAD TRAUMA; LIFE COGNITIVE IMPAIRMENT; LEAGUE PLAYERS; RECURRENT CONCUSSION; BRAIN-FUNCTION; OLDER-ADULTS; NFL PLAYERS; DEPRESSION; ASSOCIATION	Purpose: To better understand the relationship between exposure to concussive and subconcussive head impacts, white matter integrity, and functional task-related neural activity in former U.S. football athletes. Materials and Methods: Between 2011 and 2013, 61 cognitively unimpaired former collegiate and professional football players (age range, 52-65 years) provided informed consent to participate in this cross-sectional study. Participants were stratified across three crossed factors: career duration, concussion history, and primary playing position. Fractional anisotropy (FA) and blood oxygen level-dependent (BOLD) percent signal change (PSC) were measured with diffusion-weighted and task-related functional magnetic resonance imaging, respectively. Analyses of variance of FA and BOLD PSC were used to determine main or interaction effects of the three factors. Results: A significant interaction between career duration and concussion history was observed; former college players with more than three concussions had lower FA in a broadly distributed area of white matter compared with those with zero to one concussion (t29 = 2.774; adjusted P =.037), and the opposite was observed for former professional players (t29 = 3.883; adjusted P =.001). A separate interaction between concussion history and position was observed: Nonspeed players with more than three concussions had lower FA in frontal white matter compared with those with zero to one concussion (t25 = 3.861; adjusted P =.002). Analysis of working memory-task BOLD PSC revealed a similar interaction between concussion history and position (all adjusted P<.004). Overall, former players with lower FA tended to have lower BOLD PSC across three levels of a working memory task. Conclusion: Career duration and primary playing position seem to modify the effects of concussion history on white matter structure and neural recruitment. The differences in brain structure and function were observed in the absence of clinical impairment, which suggested that multimodal imaging may provide early markers of onset of traumatic neurodegenerative disease. (C) RSNA, 2017	[Clark, Michael D.; Kerr, Zachary Y.; Guskiewicz, Kevin M.] Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, 209 Fetzer Hall,CB 8700, Chapel Hill, NC 27599 USA; [Varangis, Eleanna M. L.; Giovanello, Kelly S.] Univ North Carolina Chapel Hill, Dept Psychol & Neurosci, 209 Fetzer Hall,CB 8700, Chapel Hill, NC 27599 USA; [Smith, J. Keith] Univ North Carolina Chapel Hill, Dept Radiol, 209 Fetzer Hall,CB 8700, Chapel Hill, NC 27599 USA; [Champagne, Allen A.] Queens Univ, Ctr Neurosci Studies, Kingston, ON, Canada; [Shi, Feng] Cedars Sinai Med Ctr, Biomed Imaging Res Inst, Los Angeles, CA 90048 USA	Guskiewicz, KM (corresponding author), Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, 209 Fetzer Hall,CB 8700, Chapel Hill, NC 27599 USA.	gus@email.unc.edu	Smith, J Keith/AAD-3968-2021	Smith, J Keith/0000-0001-7588-3520; Varangis, Eleanna/0000-0002-2688-2297; Clark, Michael/0000-0002-5019-0290	National Institute of Neurologic Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F30NS090816]; National Football League Charities; National Football League Players' Association; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F30NS090816] Funding Source: NIH RePORTER	M.D.C. supported by National Institute of Neurologic Disorders and Stroke (F30NS090816). Study supported by the National Football League Charities and the National Football League Players' Association.	Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Cabeza R, 2002, NEUROIMAGE, V17, P1394, DOI 10.1006/nimg.2002.1280; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Ford JH, 2013, J NEUROTRAUM, V30, P1683, DOI 10.1089/neu.2012.2535; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Goswami R, 2016, BRAIN STRUCT FUNCT, V221, P1911, DOI 10.1007/s00429-015-1012-0; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hakun JG, 2015, NEUROPSYCHOLOGIA, V71, P225, DOI 10.1016/j.neuropsychologia.2015.04.008; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Kerr ZY, 2015, J NEUROTRAUM, V32, P1083, DOI 10.1089/neu.2014.3666; KIRCHNER WK, 1958, J EXP PSYCHOL, V55, P352, DOI 10.1037/h0043688; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2016, JAMA NEUROL, V73, P353, DOI 10.1001/jamaneurol.2015.3998; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; O'Conaill CR, 2015, J NEURODEV DISORD, V7, DOI 10.1186/s11689-015-9106-9; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Persson J, 2006, CEREB CORTEX, V16, P907, DOI 10.1093/cercor/bhj036; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Solomon GS, 2016, AM J SPORT MED, V44, P1106, DOI 10.1177/0363546515626164; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Tremblay S, 2014, BRAIN, V137, P2997, DOI 10.1093/brain/awu236; Wechsler D., 1997, TECHNICAL MANUAL WEC; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P371	38	14	14	0	17	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	MAR	2018	286	3					975	985		10.1148/radiol.2017170539			11	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	FW8LC	WOS:000425583200027	29087238	Green Published, Bronze			2021-06-18	
J	Clevenger, AC; Kim, H; Salcedo, E; Yonchek, JC; Rodgers, KM; Orfila, JE; Dietz, RM; Quillinan, N; Traystman, RJ; Herson, PS				Clevenger, Amy C.; Kim, Hoon; Salcedo, Ernesto; Yonchek, Joan C.; Rodgers, Krista M.; Orfila, James E.; Dietz, Robert M.; Quillinan, Nidia; Traystman, Richard J.; Herson, Paco S.			Endogenous Sex Steroids Dampen Neuroinflammation and Improve Outcome of Traumatic Brain Injury in Mice	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Traumatic brain injury; sex differences; Sex steroids; Stereology; Neuroinflammation	GENDER-DIFFERENCES; ESTROGEN; MODERATE; PREDICTORS; DIFFERENCE; IMPACT; NEUROPROTECTION; PROGESTERONE; DIMORPHISM; SEVERITY	The role of biological sex in short-term and long-term outcome after traumatic brain injury (TBI) remains controversial. The observation that exogenous female sex steroids (progesterone and estrogen) reduce brain injury coupled with a small number of clinical studies showing smaller injury in women suggest that sex steroids may play a role in outcome from TBI. We used the controlled cortical impact (CCI) model of TBI in mice to test the hypothesis that after CCI, female mice would demonstrate less injury than male mice, related to the protective role of endogenous steroids. Indeed, adult females exhibit histological protection (3.7 +/- 0.5 mm(3)) compared to adult male mice (6.8 +/- 0.6 mm(3)), and females that lacked sex steroids (ovex) showed increased injury compared to intact females. Consistent with histology, sensorimotor deficits measured as reduced contralateral limb use were most pronounced in male mice (31.9 +/- 6.9% reduced limb use) compared to a 12.7 +/- 3.8% reduction in female mice. Ovex mice exhibited behavioral deficits similar to males (31.5 +/- 3.9% reduced limb use). Ovex females demonstrated increased microglial activation relative to intact females in both the peri-injury cortex and the reticular thalamic nucleus. Ovex females also demonstrated increased astrogliosis in comparison to both females and males in the peri-injury cortex. These data indicate that female sex steroids reduce brain sensitivity to TBI and that reduced acute neuroinflammation may contribute to the relative protection observed in females.	[Clevenger, Amy C.; Dietz, Robert M.] Childrens Hosp Colorado, Dept Pediat, Anschutz Med Campus,13121 E 17th Ave, Aurora, CO 80045 USA; [Clevenger, Amy C.; Dietz, Robert M.] Univ Colorado Denver, Anschutz Med Campus,13121 E 17th Ave, Aurora, CO 80045 USA; [Kim, Hoon] Chungbuk Natl Univ Hosp, Dept Emergency Med, Coll Med, Chung Dae Ro1, Cheongju, South Korea; [Salcedo, Ernesto] Univ Colorado Denver, Dept Cell & Dev Biol, Anschutz Med Campus,12801 E 17th Ave, Aurora, CO 80045 USA; [Yonchek, Joan C.; Rodgers, Krista M.; Orfila, James E.; Quillinan, Nidia; Traystman, Richard J.; Herson, Paco S.] Univ Colorado Denver, Dept Anesthesiol, Anschutz Med Campus,12800 E 19th Ave, Aurora, CO 80045 USA	Herson, PS (corresponding author), Univ Colorado Denver, Dept Anesthesiol, Anschutz Med Campus,12800 E 19th Ave, Aurora, CO 80045 USA.	Amy.Clevenger@childrenscolorado.org; nichekh2000@hanmail.net; Ernesto.Salcedo@ucdenver.edu; joan.yonchek@ucdenver.edu; krista.rodgers@ucdenver.edu; james.orfila@ucdenver.edu; Robert.Dietz@childrenscolorado.org; nidia.quillinan@ucdenver.edu; richard.traystman@ucdenver.edu; paco.herson@ucdenver.edu	Rodgers, Krista/AAC-5063-2020	RODGERS, KRISTA/0000-0003-4393-6389	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS046072, R01NS092645]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092645, R01NS046072] Funding Source: NIH RePORTER	We would like to acknowledge Frank Strnad, who completed a portion of the animal perfusions post-injury. We would also like to acknowledge Myriam Moreno Garcia who managed the animal colonies. Funding provided by National Institutes of Health, R01NS046072 (RJT) and R01NS092645 (PSH).	Acaz-Fonseca E, 2015, GLIA, V63, P1966, DOI 10.1002/glia.22867; Albrecht JS, 2016, J TRAUMA ACUTE CARE, V81, P486, DOI 10.1097/TA.0000000000001118; Allen D, 2011, J CEREBR BLOOD F MET, V31, P2302, DOI 10.1038/jcbfm.2011.90; Baum J, 2016, WORLD NEUROSURG, V90, P525, DOI 10.1016/j.wneu.2015.12.012; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Bland ST, 2000, STROKE, V31, P1144, DOI 10.1161/01.STR.31.5.1144; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Brotfain E, 2016, CURR NEUROPHARMACOL, V14, P641, DOI 10.2174/1570159X14666160309123554; Bruce-Keller AJ, 2000, ENDOCRINOLOGY, V141, P3646, DOI 10.1210/en.141.10.3646; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; CUTOLO M, 1995, CLIN EXP RHEUMATOL, V13, P217; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2014, DOI 10.1089/neu.2013.3049; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; Deng GY, 2017, CELL REP, V18, P1109, DOI 10.1016/j.celrep.2017.01.011; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Halassa MM, 2016, TRENDS NEUROSCI, V39, P680, DOI 10.1016/j.tins.2016.08.001; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Herson PS, 2009, SEMIN REPROD MED, V27, P229, DOI 10.1055/s-0029-1216276; Hurn PD, 2003, STROKE, V34, P338, DOI 10.1161/01.STR.0000054051.88378.25; Huusko N, 2014, NEUROSCIENCE, V267, P30, DOI 10.1016/j.neuroscience.2014.02.026; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Maghool F, 2013, BRAIN RES, V1497, P61, DOI 10.1016/j.brainres.2012.12.014; Moore DW, 2010, NEUROPSYCHOL REHABIL, V20, P340, DOI 10.1080/09602010903250928; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Ng I, 2006, BRIT J NEUROSURG, V20, P73, DOI 10.1080/02688690600682259; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; Ottochian M, 2009, AM J SURG, V197, P155, DOI 10.1016/j.amjsurg.2008.09.008; PARENT A, 1995, BRAIN RES REV, V20, P91, DOI 10.1016/0165-0173(94)00007-C; Ponsford JL, 2008, INJURY, V39, P67, DOI 10.1016/j.injury.2007.08.028; Renner C, 2012, BRAIN INJURY, V26, P1360, DOI 10.3109/02699052.2012.667592; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sarajuuri JM, 2005, ARCH PHYS MED REHAB, V86, P2296, DOI 10.1016/j.apmr.2005.06.018; Scholten AC, 2015, INJURY, V46, P616, DOI 10.1016/j.injury.2014.10.064; Seifert J., 2007, J EPIDEMIOL COMMUNIT, V61, P926, DOI DOI 10.1136/JECH.2007.059717; Semple BD, 2017, BEHAV BRAIN RES, V319, P48, DOI 10.1016/j.bbr.2016.10.045; Shimizu K, 2016, EXP NEUROL, V275, P78, DOI 10.1016/j.expneurol.2015.10.014; Slewa-Younan S, 2008, J NEUROL NEUROSUR PS, V79, P1197, DOI 10.1136/jnnp.2008.147983; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Stein Donald G, 2011, Dialogues Clin Neurosci, V13, P352; Suzuki T, 2003, EXP NEUROL, V184, P1017, DOI 10.1016/S0014-4886(03)00389-3; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Tsushima WT, 2009, BRAIN INJURY, V23, P809, DOI 10.1080/02699050903200530; Tucker LB, 2017, J NEUROTRAUM, V34, P890, DOI 10.1089/neu.2016.4508; Tucker LB, 2016, J NEUROTRAUM, V33, P880, DOI 10.1089/neu.2015.3977; Villapol S, 2017, GLIA, V65, P1423, DOI 10.1002/glia.23171; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Xing GQ, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00173; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052	60	14	14	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	MAR	2018	64	3					410	420		10.1007/s12031-018-1038-x			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	GA8HD	WOS:000428579400009	29450697	Green Accepted			2021-06-18	
J	Deng, QJ; Xu, XF; Ren, J				Deng, Quan-Jun; Xu, Xiao-Feng; Ren, Jing			Effects of SDF-1/CXCR4 on the Repair of Traumatic Brain Injury in Rats by Mediating Bone Marrow Derived Mesenchymal Stem Cells	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						SDF-1; CXCR4; Traumatic brain injury; Bone mesenchymal stem cells and cell transplantation	GASTRIC-CANCER; AXIS; MIGRATION; CXCR4; TRANSPLANTATION; BDNF; ANGIOGENESIS; CONTRIBUTES; INHIBITION; SECRETION	Our study aims to investigate the effects of the SDF-1/CXCR4 axis on the repair of traumatic brain injury (TBI) in rats by mediating bone marrow derived from mesenchymal stem cells (BMSCs). Healthy male SD rats were collected, their tibiofibulars were removed, cultured, and BMSCs were collected. The expression of cell-surface molecular proteins was examined using flow cytometry. The mRNA and protein expression of CXCR4 in cells were tested using qRT-PCR and western blotting analysis. An electronic brain injury instrument was utilized to build TBI rat models and each rat was assigned into the experiment, positive control and control groups (10 rats in each group). The morris water maze was used to calculate the escape latency and number of times rats in each group crossed the platform. Neurological severity scores (NSS) was calculated to evaluate the recovery of neurological functioning. The distribution of neuronal nuclear antigens was detected using double-labeling immunohistochemistry. The morphological changes in the hippocampal neuronal and the number of BrdU-positive cells were observed through Nissl's staining and high magnification. The mRNA and protein expressions of CXCR4 were gradually increased as SDF-1 concentration increased. NGF and BDNF positive cells were expressed in each group. The distribution of neuronal nuclear antigens in the experiment group was elevated compared to the control and positive control groups. Among the three groups, the experimental group had the shortest escape latency and the highest number platform crossings. The difference in NSS among the three groups was significant. The experimental group had better cell morphology and a higher number of BrdU-positive cells than the other groups. The present study demonstrates that transplanting BMSCs with SDF-1-induced CXCR4 expression can promote the repair of TBI. This is expected to become a new treatment regimen for TBI.	[Deng, Quan-Jun] Tianjin Med Univ Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Xu, Xiao-Feng] Fudan Univ, Dept Clin Lab, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Xu, Xiao-Feng] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200032, Peoples R China; [Ren, Jing] Tianjin Med Univ Gen Hosp, Dept Med Lab, 154 Anshan Rd, Tianjin 300052, Peoples R China	Ren, J (corresponding author), Tianjin Med Univ Gen Hosp, Dept Med Lab, 154 Anshan Rd, Tianjin 300052, Peoples R China.	renjingzyy@126.com					Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Cencioni C, 2012, CARDIOVASC RES, V94, P400, DOI 10.1093/cvr/cvs132; Clift IC, 2014, MOL PHARMACOL, V85, P542, DOI 10.1124/mol.113.089714; Crowley MG, 2016, J NEUROSURG SCI; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Du ZY, 2013, LIVER TRANSPLANT, V19, P215, DOI 10.1002/lt.23577; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Hu CJ, 2013, J SURG RES, V183, P427, DOI 10.1016/j.jss.2013.01.019; Huang MZ, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-80; Jiang JD, 2012, NEURAL REGEN RES, V7, P46, DOI 10.3969/j.issn.1673-5374.2012.01.008; Johnson Victoria E, 2015, Handb Clin Neurol, V127, P115, DOI 10.1016/B978-0-444-52892-6.00008-8; Jones GN, 2012, STEM CELL TRANSL MED, V1, P70, DOI 10.5966/sctm.2011-0007; Kawakami Y, 2015, J BONE MINER RES, V30, P95, DOI 10.1002/jbmr.2318; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Kioi M, 2010, J CLIN INVEST, V120, P694, DOI 10.1172/JCI40283; Lavezzi AM, 2013, J NEUROL SCI, V329, P45, DOI 10.1016/j.jns.2013.03.012; Lee HJ, 2012, HISTOL HISTOPATHOL, V27, P1155, DOI 10.14670/HH-27.1155; Lee HJ, 2011, EXP THER MED, V2, P499, DOI 10.3892/etm.2011.228; Lewin Gary R, 2014, Handb Exp Pharmacol, V220, P251, DOI 10.1007/978-3-642-45106-5_10; Liu NM, 2013, J CELL BIOCHEM, V114, P2677, DOI 10.1002/jcb.24615; Liu XL, 2011, PROTEIN CELL, V2, P845, DOI 10.1007/s13238-011-1097-z; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maleki Masoud, 2014, International Journal of Stem Cells, V7, P118, DOI 10.15283/ijsc.2014.7.2.118; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Park SA, 2011, INT J ONCOL, V38, P97, DOI 10.3892/ijo_00000828; Penn MS, 2012, GENE THER, V19, P583, DOI 10.1038/gt.2012.32; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rostami E, 2014, BRAIN RES, V1542, P195, DOI 10.1016/j.brainres.2013.10.047; Shi W, 2012, BIOMATERIALS, V33, P3119, DOI 10.1016/j.biomaterials.2012.01.009; Vanden Berg-Foels WS, 2014, TISSUE ENG PART B-RE, V20, P28, DOI 10.1089/ten.TEB.2013.0100; Wang Y, 2008, BRAIN RES, V1195, P104, DOI 10.1016/j.brainres.2007.11.068; Wang YL, 2014, BRAIN RES, V1575, P78, DOI 10.1016/j.brainres.2014.05.035; Wei L, 2012, NEUROBIOL DIS, V46, P635, DOI 10.1016/j.nbd.2012.03.002; Xia GZ, 2010, J PERINAT MED, V38, P215, DOI [10.1515/JPM.2010.021, 10.1515/jpm.2010.021]; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xiong Y, 2011, J NEUROSURG, V114, P102, DOI 10.3171/2010.4.JNS10118; Xuan WJ, 2015, J BIOPHOTONICS, V8, P502, DOI 10.1002/jbio.201400069; Yang DY, 2010, NEUROL RES, V32, P1041, DOI 10.1179/016164110X12807570510013; Zhao BC, 2011, WORLD J GASTROENTERO, V17, P2389, DOI 10.3748/wjg.v17.i19.2389	42	14	14	1	11	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	MAR	2018	38	2					467	477		10.1007/s10571-017-0490-4			11	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	FX4WL	WOS:000426079300007	28484859				2021-06-18	
J	Micay, R; Richards, D; Hutchison, MG				Micay, Rachel; Richards, Doug; Hutchison, Michael G.			Feasibility of a postacute structured aerobic exercise intervention following sport concussion in symptomatic adolescents: a randomised controlled study	BMJ OPEN SPORT & EXERCISE MEDICINE			English	Article								Objective The utility of structured exercise for rehabilitation purposes early in the postacute phase (ie, beyond the initial 24-48 hours of advised rest) following sport-related concussion (SRC) remains largely unexplored. This study examined the feasibility of implementing a standardised aerobic exercise (AE) intervention in the postacute stage of SRC recovery in a sample of adolescent students with SRC compared with usual care. Methods Symptomatic adolescents with SRC were randomised to one of two groups: Aerobic Exercise (n=8) or Usual Care (n=7). The AE intervention, beginning on day 6 postinjury, comprised eight sessions with progressive increases in intensity and duration on a cycle ergometer. Usual care consisted of rest followed by physician-advised progressions in activity levels in an unsupervised setting. All participants were evaluated by physician at weeks 1, 2, 3 and 4 postconcussion. Outcome measures included: (1) Intervention feasibility: symptom status pre-post exercise sessions and completion of intervention and (2) Clinical recovery: symptom status at weeks 1, 2, 3 and 4 postinjury and medical clearance date. Results All participants completed the exercise sessions as part of the AE intervention and symptom exacerbation was not associated with any exercise session. The AE group experienced greater symptom resolution compared with the Usual Care Group across the recovery timeline. Conclusion A structured AE protocol appears to be safe and feasible to administer in the postacute stage of SRC recovery in adolescents and should be explored as part of a full Phase III Clinical Trial.	[Micay, Rachel; Richards, Doug; Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada	Micay, R (corresponding author), Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada.	rachel.micay@mail.utoronto.ca			Steve Moore Foundation (Toronto, ON, Canada) [501044]	This study was funded by the Steve Moore Foundation (Toronto, ON, Canada), grant number 501044.	Albert S, 2012, J NEUROL, V259, P817, DOI 10.1007/s00415-011-6247-y; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; Cumming TB, 2008, J REHABIL MED, V40, P609, DOI 10.2340/16501977-0226; Dahm KT, 1996, ADVICE REST BED VERS, P1; Di Battista AP, 2018, BRAIN INJURY, V32, P575, DOI 10.1080/02699052.2018.1432892; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Hagen KB, 2005, SPINE, V30, P542, DOI 10.1097/01.brs.0000154625.02586.95; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hutchison MG, 2017, J HEAD TRAUMA REHAB, V32, pE38, DOI 10.1097/HTR.0000000000000252; Itoh T, 2011, J NEURAL TRANSM, V118, P193, DOI 10.1007/s00702-010-0495-3; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Jacotte-Simancas A, 2015, J NEUROTRAUM, V32, P739, DOI 10.1089/neu.2014.3502; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Neeper SA, 1996, BRAIN RES, V726, P49, DOI 10.1016/0006-8993(96)00273-9; Ono KE, 2016, AM J SPORT MED, V44, P748, DOI 10.1177/0363546515617746; Schnabel M, 2004, EMERG MED J, V21, P306, DOI 10.1136/emj.2003.010165; Soderlund A, 2000, CLIN REHABIL, V14, P457, DOI 10.1191/0269215500cr348oa; Stern RA, 2017, J NEUROTRAUM, V34, P861, DOI 10.1089/neu.2016.4475; Teasell RW, 2010, PAIN RES MANAG, V15, P313, DOI 10.1155/2010/487279; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Waddell G, 1997, BRIT J GEN PRACT, V47, P647	27	14	15	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2398-9459	2055-7647		BMJ OPEN SPORT EXERC	BMJ Open Sport Exerc. Med.	MAR	2018	4	1							e000404	10.1136/bmjsem-2018-000404			6	Sport Sciences	Sport Sciences	VJ4QA	WOS:000596798200103	30018795	DOAJ Gold, Green Published			2021-06-18	
J	Sauvigny, T; Gotsche, J; Czorlich, P; Vettorazzi, E; Westphal, M; Regelsberger, J				Sauvigny, Thomas; Goetsche, Jennifer; Czorlich, Patrick; Vettorazzi, Eik; Westphal, Manfred; Regelsberger, Jan			Intracranial pressure in patients undergoing decompressive craniectomy: new perspective on thresholds	JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure; decompressive craniectomy; stroke; traumatic brain injury; neurocritical care; diagnostic technique	TRAUMATIC BRAIN-INJURY; MIDDLE-CEREBRAL-ARTERY; AGITATION-SEDATION SCALE; GLASGOW COMA SCALE; CARE-UNIT PATIENTS; SEVERE HEAD-INJURY; MALIGNANT INFARCTION; CLINICAL ARTICLE; TRIAL; HEMICRANIECTOMY	OBJECTIVE Decompressive craniectomy (DC) is an established part of treatment in patients suffering from malignant infarction of the middle cerebral artery (MCA) or traumatic brain injury (TBI). However, no clear evidence for intracranial pressure (ICP)-guided therapy after DC exists. The lack of this evidence might be due to the frequently used, but simplified threshold for ICP of 20 mm Hg, which determines further therapy. Therefore, the objective of this study was to evaluate this threshold's accuracy and to investigate the course of ICP values with respect to neurological outcome. METHODS Data on clinical characteristics and parameters of the ICP course on the intensive care unit were collected retrospectively in 102 patients who underwent DC between December 2007 and April 2014 at the authors' institution. The postoperative ICP course in the first 168 hours was recorded and analyzed. From these findings, ICP thresholds discriminating favorable from unfavorable outcome were calculated using conditional inference tree analysis. Additionally, survival analysis was performed using the Kaplan-Meier method. Prognostic factors were assessed via univariate analysis and multivariate logistic regression. Favorable outcome was defined as a score of 0-4 on the modified Rankin Scale. RESULTS Multivariate logistic regression revealed that anisocoria, diagnosis, and ICP values differed significantly between the outcome groups. ICP values in the favorable and unfavorable outcome groups differed significantly (p < 0.001), while the mean ICP of both groups lay below the limit of 20 mm Hg (17.5 and 11.5 mm Hg, respectively). These findings were reproduced when analyzing the underlying pathologies of TBI and MCA infarction separately. Based on these findings, optimized time-dependent threshold values were calculated and found to be between 10 and 17 mm Hg. These values significantly distinguished favorable from unfavorable outcome and predicted 30-day mortality (p < 0.001). CONCLUSIONS This study systematically evaluated ICP levels in a long-term analysis after DC and provides new, surprisingly low, time-dependent ICP thresholds for these patients. Future trials investigating the benefit of ICP-guided therapy should take these thresholds into consideration and validate them in further patient cohorts.	[Sauvigny, Thomas; Goetsche, Jennifer; Czorlich, Patrick; Westphal, Manfred; Regelsberger, Jan] Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, Martinistr 52, D-20246 Hamburg, Germany; [Vettorazzi, Eik] Univ Med Ctr Hamburg Eppendorf, Dept Med Biometry & Epidemiol, Hamburg, Germany	Sauvigny, T (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, Martinistr 52, D-20246 Hamburg, Germany.	t.sauvigny@uke.de	Czorlich, Patrick/H-8934-2019; Vettorazzi, Eik/B-8130-2019	Vettorazzi, Eik/0000-0002-3737-6402			Al-Tamimi YZ, 2009, NEUROSURGERY, V64, P94, DOI 10.1227/01.NEU.0000328392.98602.5A; Poca MA, 2010, J NEUROSURG, V112, P648, DOI 10.3171/2009.7.JNS081677; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Chesnut R, 2014, NEUROCRIT CARE, V21, P64, DOI 10.1007/s12028-014-0048-y; Chesnut RM, 2015, J NEUROTRAUM, V32, P1722, DOI 10.1089/neu.2015.3976; Chesnut RM, 2013, INTENS CARE MED, V39, P771, DOI 10.1007/s00134-013-2852-9; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Dunisch P, 2013, J NEUROSURG, V118, P1141, DOI 10.3171/2013.1.JNS12860; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Firsching R, 2015, AWMF LEITLINIE SCHAD; Handschu R, 2005, J NEUROL, V252, P1249, DOI 10.1007/s00415-005-0853-5; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Hothorn T, 2006, J COMPUT GRAPH STAT, V15, P651, DOI 10.1198/106186006X133933; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Huttner HB, 2009, LANCET NEUROL, V8, P949, DOI 10.1016/S1474-4422(09)70224-8; Johnson RD, 2011, J CLIN NEUROSCI, V18, P1023, DOI 10.1016/j.jocn.2010.12.025; Juttler E, 2014, NEW ENGL J MED, V370, P1091, DOI 10.1056/NEJMoa1311367; Juttler E, 2012, AWMF LEITLINIE INTRA; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Kocher E, 1901, HIRNERSCHUTTERUNG HI, P255; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Marion DW, 2006, NEUROSURGERY, V58, P655; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Munch E, 2000, NEUROSURGERY, V47, P315; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Paldor I, 2015, J CLIN NEUROSCI, V22, P79, DOI 10.1016/j.jocn.2014.07.006; Potts MB, 2008, ACTA NEUROCHIR SUPPL, V102, P109, DOI 10.1007/978-3-211-85578-2_22; Raj R, 2014, CRIT CARE, V18, DOI 10.1186/cc13814; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Sakr Y, 2012, J EVAL CLIN PRACT, V18, P231, DOI 10.1111/j.1365-2753.2010.01559.x; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Sharda Priya, 2014, Asian J Neurosurg, V9, P203, DOI 10.4103/1793-5482.146605; Stocchetti N, 2014, ACTA NEUROCHIR, V156, P1615, DOI 10.1007/s00701-014-2127-4; Suistomaa M, 2002, INTENS CARE MED, V28, P479, DOI 10.1007/s00134-002-1214-9; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Zacchetti L, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1137-9	41	14	16	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2018	128	3					819	827		10.3171/2016.11.JNS162263			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FX7WD	WOS:000426301400020	28409728	Bronze			2021-06-18	
J	Turkstra, LS; Norman, RS; Mutlu, B; Duff, MC				Turkstra, L. S.; Norman, R. S.; Mutlu, B.; Duff, M. C.			Impaired theory of mind in adults with traumatic brain injury: A replication and extension of findings	NEUROPSYCHOLOGIA			English	Article						Adult; Brain injuries; Cognition; Female; Theory of mind; Human	EMOTION RECOGNITION TASK; RADIAL-ARM MAZE; SOCIAL COGNITION; SEX-DIFFERENCES; NORMATIVE DATA; IMPAIRMENTS; DEFICITS; COMPREHENSION; EXPRESSIONS; PERSPECTIVE	Objective: To replicate a previous study of Theory of Mind (ToM) task performance in adults with traumatic brain injury (TBI) under different working memory (WM) demands, and determine if there are sex-based differences in effects of WM load on ToM task performance. Method: 58 adults with moderate-severe TBI (24 females) and 66 uninjured adults (34 females) matched group wise for age, sex, and education viewed a series of video vignettes from the Video Social Inference Task (VSIT) (Turkstra, 2008) and answered ToM questions. Vignette presentation format required updating and maintenance of information, and WM load was manipulated by varying presence of distracters. Results: There were main effects of group and WM load, no significant effect of sex, and a marginal interaction of group by WM load, with larger between-group differences in conditions with higher WM load. VSIT scores for the condition with the highest WM load were significantly correlated with scores on the first trial of the California Verbal Learning Test. Conclusions: We replicated findings of lower scores in adults with TBI on a video-based ToM task, and provided additional evidence of the effect of WM load on social cognition task performance. There were no significant accuracy differences between men and women, inconsistent with prior evidence including our own data using the same test. There is strong evidence of a female advantage on other social cognition tasks, and the parameters of this advantage remain to be discovered.	[Turkstra, L. S.; Norman, R. S.] Univ Wisconsin Madison, Dept Commun Sci & Disorders, Madison, WI USA; [Turkstra, L. S.] Univ Wisconsin Madison, Neurosci Training Program, Madison, WI USA; [Turkstra, L. S.] Univ Wisconsin Madison, Dept Surg, Madison, WI USA; [Mutlu, B.] Univ Wisconsin Madison, Dept Comp Sci, Madison, WI USA; [Duff, M. C.] Vanderbilt Univ, Dept Hearing & Speech Sci, 221 Kirkland Hall, Nashville, TN 37235 USA	Turkstra, LS (corresponding author), McMaster Univ, Sch Rehabil Sci, Inst Appl Hlth Sci, Room 403 G,1400 Main St West, Hamilton, ON L8S 1C7, Canada.	turkstrl@mcmaster.ca			NIH NICHD/NCMRR awardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD071089]; NIH/NIGMS award [R25GMO83252]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD071089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R25GM083252] Funding Source: NIH RePORTER	This work was supported by NIH NICHD/NCMRR award number R01 HD071089 and NIH/NIGMS award number R25GMO83252. The authors thank Dr. Erica Richmond, Eva Bernstein, and staff and students in the Turkstra and Duff labs for work on data collection and management, and Dr. Jee-Seon Kim for assistance with statistical analysis. The authors have no conflicts of interest to report.	Apperly IA, 2004, J COGNITIVE NEUROSCI, V16, P1773, DOI 10.1162/0898929042947928; Astur RS, 2004, BEHAV BRAIN RES, V151, P103, DOI 10.1016/j.bbr.2003.08.024; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bosco FM, 2015, INT J LANG COMM DIS, V50, P63, DOI 10.1111/1460-6984.12114; Bradford EEF, 2015, COGNITION, V138, P21, DOI 10.1016/j.cognition.2015.02.001; Byom Lindsey J, 2013, Front Hum Neurosci, V7, P413, DOI 10.3389/fnhum.2013.00413; Carpenter PA, 1989, COMPLEX INFORMATION, P31; Channon S, 2010, NEUROPSYCHOL REHABIL, V20, P739, DOI 10.1080/09602011003794583; Delis DC, 2000, CALIFORNIA VERBAL LE; Dennis M, 2013, DEV COGN NEUROS-NETH, V5, P25, DOI 10.1016/j.dcn.2012.11.006; Duff MC, 2012, SEMIN SPEECH LANG, V33, P44, DOI 10.1055/s-0031-1301162; Duran ND, 2011, COGNITION, V121, P22, DOI 10.1016/j.cognition.2011.06.009; Evans KL, 2015, BRAIN COGNITION, V93, P42, DOI 10.1016/j.bandc.2014.11.006; Flanagan S., 1998, AWARENESS SOCIAL INF; Flavell JH, 2004, MERRILL PALMER QUART, V50, P274, DOI 10.1353/mpq.2004.0018; FLAVELL JH, 1968, DEV ROLE TAKING COMM; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; Greenfield PM, 2003, ANNU REV PSYCHOL, V54, P461, DOI 10.1146/annurev.psych.54.101601.145221; Haut KM, 2006, NEUROIMAGE, V32, P411, DOI 10.1016/j.neuroimage.2006.01.044; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Honan CA, 2015, BRAIN LANG, V150, P69, DOI 10.1016/j.bandl.2015.08.007; Kertesz A, 2006, W APHASIA BATTERY; Kessels RPC, 2014, J NEUROPSYCHOL, V8, P75, DOI 10.1111/jnp.12009; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Martin I, 2005, APHASIOLOGY, V19, P712, DOI 10.1080/02687030500172203; Matsuoka K, 2012, BRAIN INJURY, V26, P1723, DOI 10.3109/02699052.2012.698789; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P231, DOI 10.1017/S1355617712001506; Meulenbroek P, 2016, DISABIL REHABIL, V38, P452, DOI 10.3109/09638288.2015.1044621; Montagne B, 2007, PERCEPT MOTOR SKILL, V104, P589, DOI 10.2466/PMS.104.2.589-598; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; Rahman Q, 2005, BRAIN COGNITION, V58, P312, DOI 10.1016/j.bandc.2005.03.001; Rahman Q, 2004, BRAIN COGNITION, V54, P179, DOI 10.1016/j.bandc.2004.01.002; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Rigon A, 2016, COGN AFFECT BEHAV NE, V16, P866, DOI 10.3758/s13415-016-0437-0; Russell TA, 2012, COG EMOT, V21, P1554; Rutherford HJV, 2012, PERSONAL DISORD, V3, P393, DOI 10.1037/a0028938; Sabers DL, 1996, LANG SPEECH HEAR SER, V27, P102, DOI 10.1044/0161-1461.2702.102; Schilbach L, 2013, BEHAV BRAIN SCI, V36, P393, DOI 10.1017/S0140525X12000660; Spikman JM, 2013, NEUROPSYCHOL REHABIL, V23, P824, DOI 10.1080/09602011.2013.826138; Spikman JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065581; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Taylor SJ, 2013, DEV PSYCHOL, V49, P1253, DOI 10.1037/a0029871; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Turkstra L, 2005, J MED SPEECH-LANG PA, V13, pIX; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Turkstra LS, 2000, APHASIOLOGY, V14, P349, DOI 10.1080/026870300401405; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; YLVISAKER M, 1989, TOP LANG DISORD, V9, P34, DOI 10.1097/00011363-198903000-00005; Zhang D., 2015, NEUROPSYCHOL REHABIL, P1, DOI DOI 10.1007/978-94-017-9753-5_1	54	14	14	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	MAR	2018	111						117	122		10.1016/j.neuropsychologia.2018.01.016			6	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	GD6UQ	WOS:000430644300015	29366949	Green Accepted, Bronze			2021-06-18	
J	Woolcott, CR; Torrey, S; Turner, PV; Serpa, L; Schwean-Lardner, K; Widowski, TM				Woolcott, Caitlin R.; Torrey, Stephanie; Turner, Patricia V.; Serpa, Lilia; Schwean-Lardner, Karen; Widowski, Tina M.			Evaluation of Two Models of Non-Penetrating Captive Bolt Devices for On-Farm Euthanasia of Turkeys	ANIMALS			English	Article						animal welfare; euthanasia; turkey; insensibility; brain death	TRAUMATIC BRAIN-INJURY; MECHANICAL CERVICAL DISLOCATION; CARBON-DIOXIDE; BLUNT TRAUMA; BROILER-CHICKENS; POULTRY; RESPONSES; ELECTROENCEPHALOGRAM; UNCONSCIOUSNESS; ACCELEROMETERS	On-farm euthanasia is a critical welfare issue in the poultry industry and can be particularly difficult to perform on mature turkeys due to their size. We evaluated the efficacy of two commercially available non-penetrating captive bolt devices, the Zephyr-EXL and the Turkey Euthanasia Device (TED), on 253 turkeys at three stages of production: 4-5, 10, and 15-20 weeks of age. Effectiveness of each device was measured using both ante-and post-mortemmeasures. Application of the Zephyr-EXL resulted in a greater success rate (immediate abolishment of brainstem reflexes) compared to the TED (97.6% vs. 89.3%, p = 0.0145). Times to last movement (p = 0.102) and cardiac arrest (p = 0.164) did not differ between devices. Ante-and post-mortem measures of trauma and hemorrhage were highly correlated. Skull fractures and gross subdural hemorrhage (SDH) were present in 100% of birds euthanized with both the Zephyr-EXL and TED devices. Gross SDH scores were greater in birds killed with the Zephyr-EXL than the TED (p < 0.001). Microscopic SDH scores indicated moderate to severe hemorrhage in 92% of turkeys for the Zephyr-EXL and 96% of turkeys for the TED, with no difference between devices (p = 0.844). Overall, both devices were highly effective inducing immediate insensibility through traumatic brain injury and are reliable, single-step methods for on-farm euthanasia of turkeys.	[Woolcott, Caitlin R.; Torrey, Stephanie; Serpa, Lilia; Widowski, Tina M.] Univ Guelph, Dept Anim Biosci, Guelph, ON N1G 2W1, Canada; [Woolcott, Caitlin R.; Torrey, Stephanie; Turner, Patricia V.; Serpa, Lilia; Widowski, Tina M.] Univ Guelph, Campbell Ctr Study Anim Welf, Guelph, ON N1G 2W1, Canada; [Turner, Patricia V.] Univ Guelph, Dept Pathobiol, Guelph, ON N1G 2W1, Canada; [Schwean-Lardner, Karen] Univ Saskatchewan, Dept Anim & Poultry Sci, Saskatoon, SK S7N 5A8, Canada	Widowski, TM (corresponding author), Univ Guelph, Dept Anim Biosci, Guelph, ON N1G 2W1, Canada.; Widowski, TM (corresponding author), Univ Guelph, Campbell Ctr Study Anim Welf, Guelph, ON N1G 2W1, Canada.	caitwoolcott@gmail.com; storrey@uoguelph.ca; pvturner@uoguelph.ca; lilia.serpa20@gmail.com; karen.schwean@usask.ca; twidowsk@uoguelph.ca		Woolcott, Caitlin/0000-0002-3336-5060; Turner, Patricia/0000-0003-1547-0139; Torrey, Stephanie/0000-0002-8157-9207	Chicken Farmers of Saskatchewan; Egg Farmers of Canada; Hybrid Turkeys; Natural Sciences and Engineering Research Council (NSERC) of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC); Ontario Ministry of Agriculture and Rural Affairs (OMAFRA); Turkey Farmers of Canada through the Canadian Poultry Research Council; Turkey Farmers of Ontario through the Poultry Industry Council	This research is part of a large, multi-species project collectively funded by Chicken Farmers of Saskatchewan, Egg Farmers of Canada, Hybrid Turkeys, Natural Sciences and Engineering Research Council (NSERC) of Canada, the Ontario Ministry of Agriculture and Rural Affairs (OMAFRA), Turkey Farmers of Canada through the Canadian Poultry Research Council, and Turkey Farmers of Ontario through the Poultry Industry Council. Bock Industries, Inc., provided in-kind support.	Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; AVMA, 2013, AVMA GUIDELINES EUTH; Bader S, 2014, J APPL POULTRY RES, V23, P546, DOI 10.3382/japr.2014-00977; Benson ER, 2012, RES VET SCI, V93, P960, DOI 10.1016/j.rvsc.2011.12.008; BLACKMORE DK, 1979, VET REC, V105, P372, DOI 10.1136/vr.105.16.372; Bock Industries Inc, 2016, CAPT BOLT DEV HUM LI; Brennan LK, 2009, J NEUROS-PEDIATR, V3, P232, DOI 10.3171/2008.11.PEDS0835; Cartner SC, 2007, COMPARATIVE MED, V57, P570; Casey-Trott TM, 2014, J ANIM SCI, V92, P5166, DOI 10.2527/jas.2014-7980; Casey-Trott TM, 2013, J ANIM SCI, V91, P5477, DOI 10.2527/jas.2013-6320; Casey-Trott TM, 2012, THESIS; Cors JC, 2015, POULTRY SCI, V94, P147, DOI 10.3382/ps/peu038; Dalton HA, 2013, WORLD POULTRY SCI J, V69, P865, DOI 10.1017/S004393391300086X; Dawson MD, 2007, J APPL POULTRY RES, V16, P583, DOI 10.3382/japr.2007-00023; Dawson MD, 2009, J APPL POULTRY RES, V18, P135, DOI 10.3382/japr.2008-00072; Duggan G, 2014, J APPL POULTRY RES, V23, P280, DOI 10.3382/japr.2013-00860; Erasmus MA, 2010, VET REC, V167, P850, DOI 10.1136/vr.c5051; Erasmus MA, 2010, J APPL POULTRY RES, V19, P288, DOI 10.3382/japr.2009-00103; Erasmus MA, 2010, POULTRY SCI, V89, P1345, DOI 10.3382/ps.2009-00445; Erasmus M. A., 2009, THESIS; Finnie JW, 2003, AUST VET J, V81, P153, DOI 10.1111/j.1751-0813.2003.tb11078.x; Finnie JW, 2001, AUST VET J, V79, P628, DOI 10.1111/j.1751-0813.2001.tb10785.x; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gerritzen MA, 2004, POULTRY SCI, V83, P1294, DOI 10.1093/ps/83.8.1294; Gerritzen M, 2007, APPL ANIM BEHAV SCI, V108, P179, DOI 10.1016/j.applanim.2006.11.014; Gibson TJ, 2018, BRIT POULTRY SCI, V59, P13, DOI 10.1080/00071668.2017.1401215; GREGORY NG, 1990, VET REC, V126, P570; Grist A, 2017, ANIM WELFARE, V26, P111, DOI 10.7120/09627286.26.1.111; Heard D, 2000, Vet Clin North Am Exot Anim Pract, V3, P587; Martin JE, 2016, ANIM WELFARE, V25, P227, DOI 10.7120/09627286.25.2.227; Martin J.E., 2015, THESIS; Merskey H, 1994, CLASSIF CHRONIC PAIN, P209; National Farm Animal Care Council, 2016, COD PRACT CAR HANDL; National Turkey Federation, 2016, AN CAR GUID; RAJ ABM, 1992, BRIT VET J, V148, P147, DOI 10.1016/0007-1935(92)90106-B; Raj ABM, 2001, BRIT POULTRY SCI, V42, P295, DOI 10.1080/00071660120055232; Sandercock DA, 2014, PHYSIOL BEHAV, V133, P252, DOI 10.1016/j.physbeh.2014.05.030; Sparrey J, 2014, WORLD POULTRY SCI J, V70, P737, DOI 10.1017/S0043933914000816; Tseng WC, 2011, J TRAUMA, V71, P1611, DOI 10.1097/TA.0b013e31823a8a60; Turner PV, 2012, POULTRY SCI, V91, P1558, DOI 10.3382/ps.2012-02139; Veltri CJ, 2005, J FIELD ORNITHOL, V76, P127, DOI 10.1648/0273-8570-76.2.127; Verhoeven MTW, 2015, ANIMAL, V9, P320, DOI 10.1017/S1751731114002596; Walsh JL, 2017, ANIMALS, V7, DOI 10.3390/ani7120100; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407	45	14	15	0	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	2076-2615			ANIMALS	Animals	MAR	2018	8	3							42	10.3390/ani8030042			17	Agriculture, Dairy & Animal Science; Veterinary Sciences	Agriculture; Veterinary Sciences	GA7GC	WOS:000428502800012	29558419	DOAJ Gold, Green Published			2021-06-18	
J	Fischer, JT; Hannay, HJ; Alfano, CA; Swank, PR; Ewing-Cobbs, L				Fischer, Jesse T.; Hannay, H. Julia; Alfano, Candice A.; Swank, Paul R.; Ewing-Cobbs, Linda			Sleep Disturbances and Internalizing Behavior Problems Following Pediatric Traumatic Injury	NEUROPSYCHOLOGY			English	Article						injury; internalizing problems; outcome; sleep; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; SCHOOL-AGE-CHILDREN; QUALITY-OF-LIFE; 1ST 6 MONTHS; BRAIN-INJURY; ANXIETY DISORDERS; YOUNG-CHILDREN; HEAD-INJURY; LONGITUDINAL ASSOCIATIONS; PSYCHIATRIC-DISORDERS	Objective: This prospective longitudinal study investigated sleep disturbance (SD) and internalizing problems after traumatic injury, including traumatic brain injury (TBI) or extracranial/bodily injury (EI) in children and adolescents, relative to typically developing (TD) children. We also examined longitudinal relations between SD and internalizing problems postinjury. Method: Participants (N = 87) ages 8-15 included youth with TBI, EI, and TD children. Injury groups were recruited from a Level 1 trauma center after sustaining vehicle-related injuries. Parent-reported SD and internalizing problems were assessed at preinjury/baseline, and 6 and 12 months postinjury. Linear mixed models evaluated the relation of group and time of assessment on outcomes. Results: Controlling for age, the combined traumatic injury group experienced significantly higher postinjury levels of SD (p = .042) and internalizing problems (p = .024) than TD children; however, TBI and EI injury groups did not differ from each other. Injury severity was positively associated with SD in the EI group only, but in both groups SD was associated with additional postinjury sequelae, including fatigue and externalizing behavior problems. Internalizing problems predicted subsequent development of SD but not vice versa. The relation between injury and SD 1 year later was consistent with mediation by internalizing problems at 6 months postinjury. Conclusions: Children with both types of traumatic injury demonstrated higher SD and internalizing problems than healthy children. Internalizing problems occurring either prior to or following pediatric injury may be a risk factor for posttraumatic SD. Consequently, internalizing problems may be a promising target of intervention to improve both SD and related adjustment concerns.	[Fischer, Jesse T.; Alfano, Candice A.] Univ Houston, Dept Psychol, Houston, TX 77004 USA; [Hannay, H. Julia] Univ Houston, Texas Inst Measurement Evaluat & Stat, Houston, TX 77004 USA; [Swank, Paul R.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX 77030 USA; [Ewing-Cobbs, Linda] Univ Texas Hlth Sci Ctr Houston, Dept Pediat, 7000 Fannin St Suite 2401, Houston, TX 77030 USA; [Ewing-Cobbs, Linda] Univ Texas Hlth Sci Ctr Houston, Childrens Learning Inst, 7000 Fannin St Suite 2401, Houston, TX 77030 USA	Ewing-Cobbs, L (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Pediat, 7000 Fannin St Suite 2401, Houston, TX 77030 USA.; Ewing-Cobbs, L (corresponding author), Univ Texas Hlth Sci Ctr Houston, Childrens Learning Inst, 7000 Fannin St Suite 2401, Houston, TX 77030 USA.	linda.ewing-cobbs@uth.tmc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS046308]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046308] Funding Source: NIH RePORTER	This work was funded by National Institutes of Health Grant R01 NS046308 awarded to Linda Ewing-Cobbs. The content is solely the responsibility of the authors and does not necessarily represent the official views of the granting institute.	Aaronson L S, 1999, Image J Nurs Sch, V31, P45; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Alfano CA, 2007, J AM ACAD CHILD PSY, V46, P224, DOI 10.1097/01.chi.0000242233.06011.8e; Alfano CA, 2006, SLEEP MED, V7, P467, DOI 10.1016/j.sleep.2006.05.002; Alfano CA, 2009, CHILD YOUTH CARE FOR, V38, P327, DOI 10.1007/s10566-009-9081-y; Amin RS, 2002, AM J RESP CRIT CARE, V165, P1395, DOI 10.1164/rccm.2105118; Anderson V, 2012, DISABIL REHABIL, V34, P1639, DOI 10.3109/09638288.2012.656789; Arbogast KB, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0294; Beebe DW, 2008, J CHILD PSYCHOL PSYC, V49, P915, DOI 10.1111/j.1469-7610.2008.01885.x; Beebe DW, 2007, J PEDIATR PSYCHOL, V32, P845, DOI 10.1093/jpepsy/jsm003; Beebe DW, 2011, PEDIATR CLIN N AM, V58, P649, DOI 10.1016/j.pcl.2011.03.002; Borse NN, 2008, CDC childhood injury report: patterns of unintentional injuries among 0-19 year olds in the United States, 2000-2006; Bruni O, 1996, J SLEEP RES, V5, P251, DOI 10.1111/j.1365-2869.1996.00251.x; BUCKLEY SL, 1994, J PEDIATR ORTHOPED, V14, P449, DOI 10.1097/01241398-199407000-00005; Calhoun SL, 2017, J ABNORM CHILD PSYCH, V45, P337, DOI 10.1007/s10802-016-0166-4; Cohen R, 2013, PEDIATR NEUROL, V49, P465, DOI 10.1016/j.pediatrneurol.2013.06.010; Crichton AJ, 2017, J HEAD TRAUMA REHAB, V32, P107, DOI 10.1097/HTR.0000000000000248; Ding R, 2006, J PEDIATR ORTHOPED, V26, P157, DOI 10.1097/01.bpo.0000218521.98244.7e; El-Sheikh M, 2015, MONOGR SOC RES CHILD, V80, P15, DOI 10.1111/mono.12142; Ewing-Cobbs L, 2017, PSYCHONEUROENDOCRINO, V84, P66, DOI 10.1016/j.psyneuen.2017.06.003; Ewing-Cobbs L, 2014, J PEDIATR PSYCHOL, V39, P653, DOI 10.1093/jpepsy/jsu018; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; Gagner C, 2015, J NEUROTRAUM, V32, P1539, DOI 10.1089/neu.2014.3753; Gilchrist Julie, 2012, Morbidity and Mortality Weekly Report, V61, P270; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Gozal D, 2008, CURR OPIN PEDIATR, V20, P654, DOI 10.1097/MOP.0b013e328316ec2d; Gregory AM, 2005, J ABNORM CHILD PSYCH, V33, P157, DOI 10.1007/s10802-005-1824-0; Gregory AM, 2004, J AM ACAD CHILD PSY, V43, P744, DOI 10.1097/01.chi/0000122798.47863.a5; Gregory AM, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200208000-00015; Hayes AF, 2014, BRIT J MATH STAT PSY, V67, P451, DOI 10.1111/bmsp.12028; Hollingshead AA, 1975, 4 FACTOR INDEX UNPUB; IBM Corp, 2019, IBM SPSS STAT WIND V; Johnson EO, 2000, PSYCHIAT RES, V94, P93, DOI 10.1016/S0165-1781(00)00145-1; Kelly RJ, 2014, DEV PSYCHOL, V50, P1137, DOI 10.1037/a0034501; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; Koulouglioti C, 2008, PUBLIC HEALTH NURS, V25, P106, DOI 10.1111/j.1525-1446.2008.00687.x; Kovachy B, 2013, J CLIN SLEEP MED, V9, P503, DOI 10.5664/jcsm.2678; Kravitz Melva, 1993, Journal of Burn Care and Rehabilitation, V14, P83, DOI 10.1097/00004630-199301000-00018; Langeland W, 2008, NEUROSCI BIOBEHAV R, V32, P161, DOI 10.1016/j.neubiorev.2007.07.002; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; Max JE, 2015, J PEDIATR REHAB MED, V8, P345, DOI 10.3233/PRM-150352; Max JE, 2014, PSYCHIAT CLIN N AM, V37, P125, DOI 10.1016/j.psc.2013.11.003; Max JE, 2012, J NEUROPSYCH CLIN N, V24, P427, DOI 10.1176/appi.neuropsych.12060149; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; Mayes T, 2013, J BURN CARE RES, V34, pE15, DOI 10.1097/BCR.0b013e318272178e; McMakin DL, 2015, CURR OPIN PSYCHIATR, V28, P483, DOI 10.1097/YCO.0000000000000204; Mellman TA, 2001, DEPRESS ANXIETY, V14, P226, DOI 10.1002/da.1071; Milroy G, 2008, J PEDIATR PSYCHOL, V33, P242, DOI 10.1093/jpepsy/jsm099; Mindell JA, 1999, CHILD ADOL PSYCH CL, V8, P695; Necajauskaite Olga, 2005, Medicina (Kaunas), V41, P457; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Ong SH, 2006, J AFFECT DISORDERS, V96, P1, DOI 10.1016/j.jad.2006.05.025; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Osorio MB, 2013, PM&R, V5, P554, DOI 10.1016/j.pmrj.2012.11.006; Ouellet MC, 2004, ARCH PHYS MED REHAB, V85, P1298, DOI 10.1016/j.apmr.2003.11.036; Owens J.A., 2009, DEV BEHAV PEDIAT, P619; Owens Judith A, 2005, Behav Sleep Med, V3, P18, DOI 10.1207/s15402010bsm0301_4; PETERSEN AC, 1988, J YOUTH ADOLESCENCE, V17, P117, DOI 10.1007/BF01537962; Peterson RL, 2013, J HEAD TRAUMA REHAB, V28, pE1, DOI 10.1097/HTR.0b013e318263f5ba; Pillar G, 2003, PEDIATR NEUROL, V29, P131, DOI 10.1016/S0887-8994(03)00149-8; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2015, J HEAD TRAUMA REHAB, V30, P277, DOI 10.1097/HTR.0000000000000049; Ponsford JL, 2014, PSYCHIAT CLIN N AM, V37, P77, DOI 10.1016/j.psc.2013.10.001; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879; Reynolds KC, 2016, J PEDIATR PSYCHOL, V41, P971, DOI 10.1093/jpepsy/jsw014; Romeo DM, 2013, EUR J PAEDIATR NEURO, V17, P374, DOI 10.1016/j.ejpn.2012.12.009; Roth-Isigkeit A, 2005, PEDIATRICS, V115, pE152, DOI 10.1542/peds.2004-0682; Ruff Robert L, 2016, F1000Res, V5, DOI 10.12688/f1000research.9017.1; Sadeh A, 2002, CHILD DEV, V73, P405, DOI 10.1111/1467-8624.00414; Sadeh A, 2000, DEV PSYCHOL, V36, P291, DOI 10.1037/0012-1649.36.3.291; Sadeh A, 2009, SLEEP, V32, P1602, DOI 10.1093/sleep/32.12.1602; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; SAS Institute Incorporated, 2013, BAS SAS 9 4 PROC GUI; Shanahan L, 2014, J AM ACAD CHILD PSY, V53, P550, DOI 10.1016/j.jaac.2013.12.029; Shay N, 2014, J NEUROTRAUM, V31, P1305, DOI 10.1089/neu.2013.3275; Shirtcliff EA, 2008, DEV PSYCHOBIOL, V50, P690, DOI 10.1002/dev.20336; Spruyt K, 2004, SLEEP, V27, P495, DOI 10.1093/sleep/27.3.495; Stancin T, 2001, J TRAUMA, V51, P69, DOI 10.1097/00005373-200107000-00011; Sumpter RE, 2013, J INT NEUROPSYCH SOC, V19, P829, DOI 10.1017/S1355617713000465; TEASDALE G, 1974, LANCET, V2, P81; Tham SW, 2015, J NEUROTRAUM, V32, P847, DOI 10.1089/neu.2014.3559; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; Theadom A, 2016, BRAIN INJURY, V30, P1243, DOI 10.1080/02699052.2016.1183171; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Willis TA, 2015, SLEEP MED CLIN, V10, P125, DOI 10.1016/j.jsmc.2015.02.002; Zatzick D, 2008, ANN SURG, V248, P429, DOI 10.1097/SLA.0b013e318185a6b8; Zatzick DF, 2008, ARCH PEDIAT ADOL MED, V162, P642, DOI 10.1001/archpedi.162.7.642; Zatzick DF, 2006, J AM ACAD CHILD PSY, V45, P1188, DOI 10.1097/01.chi.0000231975.21096.45	94	14	14	1	13	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	FEB	2018	32	2					161	175		10.1037/neu0000420			15	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	FY7LU	WOS:000427044500004	29528681	Bronze, Green Accepted			2021-06-18	
J	Hughes, JM; Ulmer, CS; Gierisch, JM; Hastings, SN; Howard, MO				Hughes, Jaime M.; Ulmer, Christi S.; Gierisch, Jennifer M.; Hastings, S. Nicole; Howard, Matthew O.			Insomnia in United States military veterans: An integrated theoretical model	CLINICAL PSYCHOLOGY REVIEW			English	Article						Insomnia; Sleep; Stress; Coping; Resilience; Veterans	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS; SLEEP-DEPRIVATION; PSYCHIATRIC-DISORDERS; BEHAVIORAL TREATMENT; LIFE-COURSE; HEALTH; RESILIENCE; DISTURBANCE; DEPRESSION	Marked by difficulty falling or staying asleep and/or poor sleep leading to daytime dysfunction, insomnia contributes to functional impairment, poor health, and increased healthcare utilization when left untreated. As many as two-thirds of Iraq and Afghanistan military veterans complain of insomnia. Older veterans of prior conflicts report insomnia occurring since initial service, suggesting a chronic nature to insomnia in this population. Despite insomnia's high prevalence and severe consequences, there is no theoretical model to explain either the onset or chronicity of insomnia in this growing patient population. Existing theories view insomnia as an acute, unidirectional phenomenon and do little to elucidate long-term consequences of such problems. Existing theories also fail to address mechanisms by which acute insomnia becomes chronic. This paper presents an original, integrated theoretical model that draws upon constructs from several prominent behavioral medicine theories to reconceptualize insomnia as a chronic, cyclical problem that is both a consequence and predictor of stress. Additional research examining the relationships between stress, sleep, resilience, and outcomes of interest could inform clinical and research practices. Addressing sleep problems early could potentially enhance adaptive capacity, thereby reducing the risk for subsequent negative outcomes.	[Hughes, Jaime M.; Ulmer, Christi S.; Gierisch, Jennifer M.; Hastings, S. Nicole] Durham VA Hlth Care Syst, Hlth Serv Res & Dev, 508 Fulton St 152, Durham, NC 27705 USA; [Ulmer, Christi S.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA; [Gierisch, Jennifer M.] Duke Univ, Dept Populat Hlth Sci, Durham, NC USA; [Hastings, S. Nicole] Durham VA Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Durham, NC USA; [Hastings, S. Nicole] Duke Univ, Dept Med, Durham, NC USA; [Hastings, S. Nicole] Duke Univ, Ctr Study Aging & Human Dev, Durham, NC USA; [Howard, Matthew O.] Univ North Carolina Chapel Hill, Sch Social Work, Chapel Hill, NC USA	Hughes, JM (corresponding author), Durham VA Hlth Care Syst, Hlth Serv Res & Dev, 508 Fulton St 152, Durham, NC 27705 USA.	jane.hughes@va.gov		Hughes, Jaime/0000-0001-6410-0068	Office of Academic Affiliations, VA Health Services Research Development [TPH 21-000]; VA Research Career Development Award Program [CDA 09-218]; University of North Carolina Program on Integrative Medicine [NIH/NCCIH T32AT003378]; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32AT003378] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [IK2HX000845] Funding Source: NIH RePORTER	This work was supported by facilities and resources at the Center of Innovation for Health Services Research in Primary Care at the Durham VAMC (CIN 13-410); Office of Academic Affiliations, VA Health Services Research & Development (Hughes: TPH 21-000); VA Research Career Development Award Program (Ulmer: CDA 09-218); and University of North Carolina Program on Integrative Medicine (Hughes: NIH/NCCIH T32AT003378). None of the funding sources had a role in developing this material, writing the manuscript, or the decision to submit the paper for publication.	Ahn S, 2014, FAM COMMUNITY HEALTH, V37, P327, DOI 10.1097/FCH.0000000000000045; American Psychiatric Association, 2013, DESK REF DIAGN CRIT; Amin MM, 2010, MIL MED, V175, P155; [Anonymous], 2009, DEPRESS ANXIETY, V26, P493, DOI 10.1002/da.20581; Baglioni C, 2011, J AFFECT DISORDERS, V135, P10, DOI 10.1016/j.jad.2011.01.011; Benight CC, 2004, BEHAV RES THER, V42, P1129, DOI 10.1016/j.brat.2003.08.008; Blosnich JR, 2014, JAMA PSYCHIAT, V71, P1041, DOI 10.1001/jamapsychiatry.2014.724; Bramoweth AD, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0401-4; Breslau N, 1996, BIOL PSYCHIAT, V39, P411, DOI 10.1016/0006-3223(95)00188-3; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cabrera OA, 2007, AM J PREV MED, V33, P77, DOI 10.1016/j.amepre.2007.03.019; Campbell J, 2015, 29 ANN M ASS PROF SL; Castro C. A., 2015, TRAUMATOLOGY, V221, P299; Charles ST, 2013, PSYCHOL SCI, V24, P733, DOI 10.1177/0956797612462222; DeLongis A., 1982, HEALTH PSYCHOL, V1, P119, DOI [10.1037/0278-6133.1.2.119, DOI 10.1037/0278-6133.1.2.119]; Dement W.C, 1999, PROMISE SLEEP PIONEE; Dew MA, 2003, PSYCHOSOM MED, V65, P63, DOI 10.1097/01.PSY.0000039756.23250.7C; Drake C, 2004, SLEEP, V27, P285, DOI 10.1093/sleep/27.2.285; Drake CL, 2014, SLEEP, V37, P1295, DOI 10.5665/sleep.3916; Drake CL, 2011, SLEEP, V34, P1179, DOI 10.5665/SLEEP.1234; Fernandez-Mendoza J, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0418-8; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; Ford ES, 2015, SLEEP MED, V16, P372, DOI 10.1016/j.sleep.2014.12.008; GARMEZY N, 1971, AM J ORTHOPSYCHIAT, V41, P101, DOI 10.1111/j.1939-0025.1971.tb01111.x; Gehrman P, 2013, SLEEP, V36, P1009, DOI 10.5665/sleep.2798; Germain A, 2007, BEHAV RES THER, V45, P627, DOI 10.1016/j.brat.2006.04.009; Glanz K., 2008, HLTH BEHAV HLTH ED T, P211; Hamilton NA, 2007, HEALTH PSYCHOL, V26, P288, DOI 10.1037/0278-6133.26.3.288; Haynes P. L., 2013, SLEEP S, V36, pA232; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge EA, 2007, DEPRESS ANXIETY, V24, P139, DOI 10.1002/da.20175; Hughes JM, 2015, BEHAV SLEEP MED, V13, P197, DOI 10.1080/15402002.2013.855212; Ilgen M. A., 2013, VETERAN SUICIDE PUBL, P278; Institute of Medicine, 2013, RET HOM IRAQ AFGH AS; Irwin MR, 2014, INTERFACE FOCUS, V4, DOI 10.1098/rsfs.2014.0009; Juster RP, 2010, NEUROSCI BIOBEHAV R, V35, P2, DOI 10.1016/j.neubiorev.2009.10.002; Karlin BE, 2015, INT J GERIATR PSYCH, V30, P308, DOI 10.1002/gps.4143; Katz DA, 2002, J FAM PRACTICE, V51, P229; Killgore WDS, 2006, J SLEEP RES, V15, P7, DOI 10.1111/j.1365-2869.2006.00487.x; Killgore WDS, 2008, SLEEP MED, V9, P517, DOI 10.1016/j.sleep.2007.07.003; Koffel E., 2015, SLEEP S, V38, pA326; Kripke DF, 2002, ARCH GEN PSYCHIAT, V59, P131, DOI 10.1001/archpsyc.59.2.131; Lavretsky H, 2014, Resilience and Aging: Research and Practice, P1; Lohr JB, 2015, AM J GERIAT PSYCHIAT, V23, P709, DOI 10.1016/j.jagp.2015.04.001; Macera CA, 2013, SLEEP, V36, P83, DOI 10.5665/sleep.2306; Manber R, 2005, CLIN PSYCHOL REV, V25, P535, DOI 10.1016/J.CPR.2005.04.002; Marmar CR, 2015, JAMA PSYCHIAT, V72, P875, DOI 10.1001/jamapsychiatry.2015.0803; Masten AS, 2007, DEV PSYCHOPATHOL, V19, P921, DOI 10.1017/S0954579407000442; Masten AS, 2001, AM PSYCHOL, V56, P227, DOI 10.1037/0003-066X.56.3.227; McAlister A.L., 2008, HLTH BEHAV HLTH ED T, P167; McEwen B. S, 2006, METABOLISM CLIN E S2, V55; McEwen BS, 2015, SLEEP MED CLIN, V10, P1, DOI 10.1016/j.jsmc.2014.11.007; MONROE SM, 1991, PSYCHOL BULL, V110, P406, DOI 10.1037/0033-2909.110.3.406; Morin C, 1993, INSOMNIA PYSCHOL ASS; Morin CM, 2006, SLEEP, V29, P1398, DOI 10.1093/sleep/29.11.1398; Morin CM, 2003, PSYCHOSOM MED, V65, P259, DOI 10.1097/01.PSY.0000030391.09558.A3; Mysliwiec V, 2013, SLEEP, V36, P167, DOI 10.5665/sleep.2364; National Institutes of Health, 2005, NIH STAT SCI C STAT; Ong JC, 2014, SLEEP, V37, P1553, DOI 10.5665/sleep.4010; Pearlin LI, 1996, GERONTOLOGIST, V36, P239, DOI 10.1093/geront/36.2.239; Pearlin LI, 2005, J HEALTH SOC BEHAV, V46, P205, DOI 10.1177/002214650504600206; Perlis Michael L, 2006, Behav Sleep Med, V4, P104, DOI 10.1207/s15402010bsm0402_3; Perlis ML, 1997, J SLEEP RES, V6, P179, DOI 10.1046/j.1365-2869.1997.00045.x; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Pigeon WR, 2008, SLEEP, V31, P481, DOI 10.1093/sleep/31.4.481; Pigeon Wilfred R, 2012, J Clin Psychiatry, V73, pe1160, DOI 10.4088/JCP.11r07586; Pilcher JJ, 1996, SLEEP, V19, P318, DOI 10.1093/sleep/19.4.318; Qaseem A, 2016, ANN INTERN MED, V165, P125, DOI 10.7326/M15-2175; Roth Thomas, 2007, J Clin Sleep Med, V3, pS7; Ryden A. M., 2015, SLEEP S, V38, pA396; Schnurr PP, 2000, HEALTH PSYCHOL, V19, P91, DOI 10.1037/0278-6133.19.1.91; Seelig AD, 2016, SLEEP, V39, P1111, DOI 10.5665/sleep.5766; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Seeman TE, 1997, ARCH INTERN MED, V157, P2259; Sharma M, 2014, J EVID-BASED INTEGR, V19, P271, DOI 10.1177/2156587214543143; Shippee ND, 2012, J CLIN EPIDEMIOL, V65, P1041, DOI 10.1016/j.jclinepi.2012.05.005; Southwick SM, 2014, EUR J PSYCHOTRAUMATO, V5, DOI 10.3402/ejpt.v5.25338; Spielman AJ, 1991, CASE STUDIES INSOMNI; Stanley EA, 2011, COGN BEHAV PRACT, V18, P566, DOI 10.1016/j.cbpra.2010.08.002; Taylor DJ, 2007, SLEEP, V30, P213, DOI 10.1093/sleep/30.2.213; Trockel M, 2014, BEHAV RES THER, V53, P41, DOI 10.1016/j.brat.2013.11.006; Troxel W.M., 2015, SLEEP MILITARY PROMO; Ulmer CS, 2015, J CLIN SLEEP MED, V11, P995, DOI 10.5664/jcsm.5012; WERNER EE, 1995, CURR DIR PSYCHOL SCI, V4, P81, DOI 10.1111/1467-8721.ep10772327; Wolf EJ, 2016, PSYCHONEUROENDOCRINO, V63, P155, DOI 10.1016/j.psyneuen.2015.09.020; Wright KM, 2011, J CLIN PSYCHOL, V67, P1240, DOI 10.1002/jclp.20845; Yoon J, 2011, POPUL HEALTH MANAG, V14, P293, DOI 10.1089/pop.2010.0079; Young-McCaughan S., 2011, ROLE SLEEP HLTH RESI; Yu W, 2003, MED CARE RES REV, V60, p146S, DOI 10.1177/1077558703257000; Zullig LL, 2016, J GEN INTERN MED, V31, P329, DOI 10.1007/s11606-015-3512-2	90	14	14	0	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0272-7358	1873-7811		CLIN PSYCHOL REV	Clin. Psychol. Rev.	FEB	2018	59						118	125		10.1016/j.cpr.2017.11.005			8	Psychology, Clinical	Psychology	FT9VD	WOS:000423499600009	29180102	Green Accepted, Bronze			2021-06-18	
J	Shi, S; Gupta, R; Moore, JM; Griessenauer, CJ; Adeeb, N; Motiei-Langroudi, R; Thomas, AJ; Ogilvy, CS				Shi, Siyu; Gupta, Raghav; Moore, Justin M.; Griessenauer, Christoph J.; Adeeb, Nimer; Motiei-Langroudi, Rouzbeh; Thomas, Ajith J.; Ogilvy, Christopher S.			De novo AVM formation following venous sinus thrombosis and prior AVM resection in adults: report of 2 cases	JOURNAL OF NEUROSURGERY			English	Article						de novo AVM; venous sinus thrombosis; adult; angiogenesis; vascular disorders	CEREBRAL ARTERIOVENOUS-MALFORMATION; MOYAMOYA-DISEASE; CHILD	Brain arteriovenous malformations (AVMs) are traditionally considered congenital lesions, arising from aberrant vascular development during the intrauterine period. Rarely, however, AVMs develop in the postnatal period. Individual case reports of de novo AVM formation in both pediatric and adult patients have challenged the traditional dogma of a congenital origin. Instead, for these cases, a dynamic picture is emerging of AVM growth and development, initially triggered by ischemic and/or traumatic events, coupled with genetic predispositions. A number of pathophysiological descriptions involving aberrant angiogenic responses following trauma, hemorrhage, or inflammation have been proposed, although the exact etiology of these lesions remains to be elucidated. Here, the authors present 2 cases of de novo AVM formation in adult patients. The first case involves the development of an AVM following a venous sinus thrombosis and to the authors' knowledge is the first of its kind to be reported in the literature. They also present a case in which an elderly patient with a previously ruptured AVM developed a second AVM in the contralateral hemisphere 11 years later. In addition to presenting these cases, the authors propose a possible mechanism for de novo AVM development in adult patients following ischemic injury.	[Shi, Siyu; Gupta, Raghav; Moore, Justin M.; Griessenauer, Christoph J.; Adeeb, Nimer; Motiei-Langroudi, Rouzbeh; Thomas, Ajith J.; Ogilvy, Christopher S.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Surg, Div Neurosurg, 110 Francis St, Boston, MA 02215 USA	Ogilvy, CS (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Surg, Div Neurosurg, 110 Francis St, Boston, MA 02215 USA.	cogilvy@bidmc.harvard.edu	Thomas, Ajith/AAX-9054-2020	Thomas, Ajith/0000-0003-4412-3152			Aboian MS, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.8.FOCUS09161; Akimoto H, 2003, NEUROSURGERY, V52, P228, DOI 10.1097/00006123-200301000-00030; Ali MJ, 2003, PEDIATR NEUROSURG, V39, P32, DOI 10.1159/000070878; Alvarez H, 2012, J NEUROSURG-PEDIATR, V9, P327, DOI 10.3171/2011.12.PEDS11312; Bulsara KR, 2002, NEUROSURGERY, V50, P1137, DOI 10.1097/00006123-200205000-00036; Friedman JA, 2000, J NEUROSURG, V93, P1058, DOI 10.3171/jns.2000.93.6.1058; Fujimura M, 2014, J NEUROSURG-PEDIATR, V13, P647, DOI 10.3171/2014.3.PEDS13610; Gonzalez LF, 2005, J NEUROSURG, V102, P726, DOI 10.3171/jns.2005.102.4.0726; Hao Q, 2010, TRANSL STROKE RES, V1, P197, DOI 10.1007/s12975-010-0020-x; Hashimoto T, 2000, NEUROSURGERY, V47, P910, DOI 10.1097/00006123-200010000-00022; Jeffree RL, 2009, PEDIATR NEUROSURG, V45, P296, DOI 10.1159/000235604; Kilbourn KJ, 2014, NEUROSURG REV, V37, P685, DOI 10.1007/s10143-014-0557-3; Koch MJ, 2016, J CLIN NEUROSCI, V28, P162, DOI 10.1016/j.jocn.2015.11.021; Lasjaunias P., 2007, SURG NEUROANGIOGRAPH, V3; Lawton MT, 1997, J NEUROSURG, V87, P267, DOI 10.3171/jns.1997.87.2.0267; Mahajan A, 2010, NEUROSURG REV, V33, P115, DOI 10.1007/s10143-009-0227-z; Mathon B, 2013, NEUROLOGY, V81, P398, DOI 10.1212/WNL.0b013e31829c5cd5; Morales-Valero SF, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.6.FOCUS14234; Morales-Valero SF, 2014, NEUROSURG FOCUS, V39, pE14; Mullan S, 1996, J NEUROSURG, V85, P1, DOI 10.3171/jns.1996.85.1.0001; Neil Jayson A, 2014, Surg Neurol Int, V5, P148, DOI 10.4103/2152-7806.142796; O'Shaughnessy BA, 2005, J NEUROSURG, V102, P238, DOI 10.3171/jns.2005.102.2.0238; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Ozsarac Murat, 2012, J Emerg Med, V43, pe17, DOI 10.1016/j.jemermed.2009.05.035; SALCMAN M, 1992, SURG NEUROL, V38, P121, DOI 10.1016/0090-3019(92)90089-6; Schmit BP, 1996, J NEUROSURG, V84, P677, DOI 10.3171/jns.1996.84.4.0677; Stevens J, 2009, AM J NEURORADIOL, V30, P111, DOI 10.3174/ajnr.A1255; Yeo JJY, 2015, CHILD NERV SYST, V31, P609, DOI 10.1007/s00381-014-2609-y	28	14	14	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2018	128	2					506	510		10.3171/2016.9.JNS161710			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FU4JX	WOS:000423820500022	28186446	Bronze			2021-06-18	
J	Taylor, AN; Tio, DL; Paydar, A; Sutton, RL				Taylor, Anna N.; Tio, Delia L.; Paydar, Afshin; Sutton, Richard L.			Sex Differences in Thermal, Stress, and Inflammatory Responses to Minocycline Administration in Rats with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cytokines; hyperthermia; minocycline; stress; TBI	IMMUNE FUNCTION; HYPERTHERMIA; CYTOKINES; INCREASE; FEMALE; MODEL; IL-6	Persistent inflammation, mediated in part by increases in cytokines, is a hallmark of traumatlc brain injury (TBI). Minocycline has been shown to inhibit post-TBI neuroinflammation in male rats and mice, but has not been tested in females. Here, we studied sex differences in thermal, stress, and inflammatory responses to TBI and minocycline. Female rats were ovariectomized under isoflurane anesthesia at 33-36 days of age. At 45-55 days of age, male and female rats were implanted intraperitoneally (i.p.) with calibrated transmitters for monitoring body temperature. Moderate cortical contusion injury (CCI) or sham surgery was performed when the rats attained 60-70 days of age. One hour after surgery, rats were injected i.p. with minocycline (50mg/kg) or saline (0.3mL); injections were repeated once daily for the next 3 days. At 28 days after CCI or sham surgery, 30min restraint stress was initiated and blood samples were obtained by tail venipuncture before the onset of restraint and at 30, 60, and 90min after stress onset. At 35 days after CCI or sham surgery, rats were decapitated and blood was collected for corticosterone (CORT) and cytokine analysis. The brains were removed and ipsilateral cortical tissue and hippocampus were dissected and subsequently assayed for interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-. Hyperthermia occurred during days 1-6 post-CCI in male rats, but only on the day of CCI in female rats, and minocycline prevented its occurrence in both sexes. Minocycline facilitated suppression of the CORT response to restraint stress in both sexes. In females, but not males, hippocampal IL-6 content increased post-CCI compared with sham-injured controls, whereas IL-1 content was augmented by minocycline. Hippocampal TNF- was unaffected by CCI and minocycline. These results demonstrate sex differences in immediate thermal and long-lasting stress and cytokine responses to CCI, and only short-term protective effects of minocycline on hyperthermia.	[Taylor, Anna N.; Tio, Delia L.] UCLA, David Geffen Sch Med, Dept Neurobiol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA; [Paydar, Afshin; Sutton, Richard L.] UCLA, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA	Taylor, AN (corresponding author), UCLA, David Geffen Sch Med, Dept Neurobiol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	ataylor@mednet.ucla.edu					Acaz-Fonseca E, 2015, GLIA, V63, P1966, DOI 10.1002/glia.22867; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Barreto GE, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00132; Bedi SS, 2013, STEM CELL TRANSL MED, V2, P953, DOI 10.5966/sctm.2013-0100; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Caplan HW, 2017, J NEUROSCI RES, V95, P509, DOI 10.1002/jnr.23854; Engler H, 2016, BRAIN BEHAV IMMUN, V52, P18, DOI 10.1016/j.bbi.2015.08.013; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; HANDA RJ, 1994, HORM BEHAV, V28, P464, DOI 10.1006/hbeh.1994.1044; KITAY JI, 1961, ENDOCRINOLOGY, V68, P818, DOI 10.1210/endo-68-5-818; Kovesdi E., 2012, FRONT NEUROL, V3, P1; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Levkovitz Y, 2015, EUR NEUROPSYCHOPHARM, V25, P124, DOI 10.1016/j.euroneuro.2014.11.012; McEwen BS, 1997, BRAIN RES REV, V23, P79, DOI 10.1016/S0165-0173(96)00012-4; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Scharfman HE, 2017, J NEUROSCI RES, V95, P563, DOI 10.1002/jnr.23927; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Sorrells SF, 2014, NEUROENDOCRINOLOGY, V100, P129, DOI 10.1159/000367849; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; Taylor AN, 2006, J NEUROTRAUM, V23, P1802, DOI 10.1089/neu.2006.23.1802; Villapol S, 2017, GLIA, V65, P1423, DOI 10.1002/glia.23171; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	32	14	16	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2018	35	4					630	638		10.1089/neu.2017.5238		JAN 2018	9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FV3OH	WOS:000419868000001	29179648				2021-06-18	
J	Bathke, AC; Friedrich, S; Pauly, M; Konietschke, F; Staffen, W; Strobl, N; Holler, Y				Bathke, Arne C.; Friedrich, Sarah; Pauly, Markus; Konietschke, Frank; Staffen, Wolfgang; Strobl, Nicolas; Hoeller, Yvonne			Testing Mean Differences among Groups: Multivariate and Repeated Measures Analysis with Minimal Assumptions	MULTIVARIATE BEHAVIORAL RESEARCH			English	Article						Bootstrap; closed testing; factorial designs; MANOVA; repeated measures	BEHRENS-FISHER PROBLEM; TRAUMATIC BRAIN-INJURY; NORMAL YOUNG-ADULTS; ONE-WAY MANOVA; CLINICAL-TRIALS; FACTORIAL-DESIGNS; DIAGNOSTIC UTILITY; ALZHEIMERS-DISEASE; PHOTIC-STIMULATION; BOOTSTRAP	To date, there is a lack of satisfactory inferential techniques for the analysis of multivariate data in factorial designs, when only minimal assumptions on the data can be made. Presently available methods are limited to very particular study designs or assume either multivariate normality or equal covariance matrices across groups, or they do not allow for an assessment of the interaction effects across within-subjects and between-subjects variables. We propose and methodologically validate a parametric bootstrap approach that does not suffer from any of the above limitations, and thus provides a rather general and comprehensive methodological route to inference for multivariate and repeated measures data. As an example application, we consider data from two different Alzheimer's disease (AD) examination modalities that may be used for precise and early diagnosis, namely, single-photon emission computed tomography (SPECT) and electroencephalogram (EEG). These data violate the assumptions of classical multivariate methods, and indeed classical methods would not have yielded the same conclusions with regards to some of the factors involved.	[Bathke, Arne C.] Univ Salzburg, Dept Math, A-5020 Salzburg, Austria; [Friedrich, Sarah; Pauly, Markus] Univ Kentucky, Dept Stat, Lexington, KY 40536 USA; [Konietschke, Frank] Univ Texas Dallas, Dept Math Sci, Dallas, TX USA; [Staffen, Wolfgang; Strobl, Nicolas; Hoeller, Yvonne] Paracelsus Med Univ, Christian Doppler Med Ctr, Dept Neurol, Salzburg, Austria; [Staffen, Wolfgang; Strobl, Nicolas; Hoeller, Yvonne] Paracelsus Med Univ, Ctr Cognit Neurosci, Salzburg, Austria	Bathke, AC (corresponding author), Univ Salzburg, Dept Math, A-5020 Salzburg, Austria.; Bathke, AC (corresponding author), Univ Kentucky, Dept Stat, Lexington, KY 40536 USA.	Arne.Bathke@sbg.ac.at	Friedrich, Sarah/AAF-9038-2020; Holler, Yvonne/I-8928-2017	Friedrich, Sarah/0000-0003-0291-4378; Holler, Yvonne/0000-0002-1727-8557; Pauly, Markus/0000-0002-0976-7190	Austrian Science Fund (FWF)Austrian Science Fund (FWF) [I 2697-N31, KLI 12-B00]; German Research Foundation (DFG)German Research Foundation (DFG) [DFG-PA 2409/3-1]	This work was supported by Grants I 2697-N31 and KLI 12-B00 from the Austrian Science Fund (FWF) and by Grant DFG-PA 2409/3-1 from the German Research Foundation (DFG).	Allignol A, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-86; Anderson MJ, 2001, AUSTRAL ECOL, V26, P32, DOI 10.1111/j.1442-9993.2001.01070.pp.x; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Barnes DE, 2011, LANCET NEUROL, V10, P819, DOI 10.1016/S1474-4422(11)70072-2; Bartlett MS, 1939, P CAMB PHILOS SOC, V35, P180; Bateman R, 2015, LANCET NEUROL, V14, P4, DOI 10.1016/S1474-4422(14)70301-1; Bathke AC, 2008, J STAT PLAN INFER, V138, P588, DOI 10.1016/j.jspi.2006.11.004; Bathke AC, 2008, COMPUT STAT DATA AN, V52, P4951, DOI 10.1016/j.csda.2008.04.006; Bathke AC, 2016, SPRINGER P MATH STAT, V168, P121, DOI 10.1007/978-3-319-39065-9_7; Bellon A, 2008, ANN STAT, V36, P2377, DOI 10.1214/07-AOS528; DEMPSTER AP, 1958, ANN MATH STAT, V29, P995, DOI 10.1214/aoms/1177706437; DEMPSTER AP, 1960, BIOMETRICS, V16, P41, DOI 10.2307/2527954; Ellis AR, 2017, J STAT SOFTW, V76, P1, DOI 10.18637/jss.v076.i04; Friedrich S., 2016, MANOVA RM ANAL MULTI; Hahn S, 2017, STAT PAP, V58, P123, DOI 10.1007/s00362-015-0690-2; Harrar SW, 2012, ANN I STAT MATH, V64, P135, DOI 10.1007/s10463-010-0299-0; Harrar SW, 2008, AM J MATH MANAGEMENT, V28, P309, DOI [10.1080/01966324.2008.10737731, DOI 10.1080/01966324.2008.10737731]; Hotelling H., 1951, P 2 BERK S MATH STAT, P23; Hotelling H., 1947, TECHNIQUES STAT ANAL, P111; Huang P, 2009, MOVEMENT DISORD, V24, P1732, DOI 10.1002/mds.22645; Giron FJ, 2010, J MULTIVARIATE ANAL, V101, P2091, DOI 10.1016/j.jmva.2010.04.008; Kawasaki T, 2015, COMMUN STAT-SIMUL C, V44, P1850, DOI 10.1080/03610918.2013.824587; Konietschke F, 2015, J MULTIVARIATE ANAL, V140, P291, DOI 10.1016/j.jmva.2015.05.001; Krishnamoorthy K, 2004, STAT PROBABIL LETT, V66, P161, DOI 10.1016/j.spl.2003.10.012; Krishnamoorthy K, 2012, J MULTIVARIATE ANAL, V105, P141, DOI 10.1016/j.jmva.2011.08.019; Krishnamoorthy K, 2010, J STAT COMPUT SIM, V80, P873, DOI 10.1080/00949650902822564; Lawley DN, 1938, BIOMETRIKA, V30, P180, DOI 10.1093/biomet/30.1-2.180; Liu CX, 2011, STAT PROBABIL LETT, V81, P1502, DOI 10.1016/j.spl.2011.04.012; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; MARCUS R, 1976, BIOMETRIKA, V63, P655, DOI 10.1093/biomet/63.3.655; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Micanovic C, 2014, J NEURAL TRANSM, V121, P59, DOI 10.1007/s00702-013-1070-5; Moretti DV, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00031; NANDA DN, 1950, ANN MATH STAT, V21, P432, DOI 10.1214/aoms/1177729802; NEL DG, 1986, COMMUN STAT THEORY, V15, P3719, DOI 10.1080/03610928608829342; Pauly M, 2015, J R STAT SOC B, V77, P461, DOI 10.1111/rssb.12073; Pesarin F., 2010, PERMUTATION TESTS CO; Pesarin F, 2012, STAT COMPUT, V22, P639, DOI 10.1007/s11222-011-9261-0; PILLAI KCS, 1955, ANN MATH STAT, V26, P117, DOI 10.1214/aoms/1177728599; Prince M, 2013, ALZHEIMERS DEMENT, V9, P63, DOI 10.1016/j.jalz.2012.11.007; Vallejo G, 2012, BEHAV RES METHODS, V44, P471, DOI 10.3758/s13428-011-0152-2; Van Aelst S, 2013, J STAT SOFTW, V53, P1; Van Aelst S, 2011, J AM STAT ASSOC, V106, P706, DOI 10.1198/jasa.2011.tm09748; Vecchio Fabrizio, 2013, Suppl Clin Neurophysiol, V62, P223; Vester J, 2014, COMMUNICATION; Wada Y, 1996, INT J PSYCHOPHYSIOL, V22, P45, DOI 10.1016/0167-8760(96)00011-6; WADA Y, 1994, CLIN ELECTROENCEPHAL, V25, P81, DOI 10.1177/155005949402500209; Whitehead J, 2010, STAT MED, V29, P521, DOI 10.1002/sim.3822; WILKS SS, 1946, ANN MATH STAT, V17, P257, DOI 10.1214/aoms/1177730940; Xu LW, 2013, J MULTIVARIATE ANAL, V115, P172, DOI 10.1016/j.jmva.2012.10.008; Yeo JM, 2013, EUR ARCH PSY CLIN N, V263, P539, DOI 10.1007/s00406-013-0426-z; Zhang J. Q., 2013, ADV MATER SCI ENG, V2013, P2, DOI DOI 10.1371/J0URNAL.P0NE.0057251; Zhang JN, 2012, PROTEOME SCI, V10, DOI 10.1186/1477-5956-10-63; Zhang JT, 2013, METRIKA, V76, P135, DOI 10.1007/s00184-011-0379-z; Zhang JT, 2011, TECHNOMETRICS, V53, P426, DOI 10.1198/TECH.2011.10128	55	14	14	2	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0027-3171	1532-7906		MULTIVAR BEHAV RES	Multivariate Behav. Res.		2018	53	3					348	359		10.1080/00273171.2018.1446320			12	Mathematics, Interdisciplinary Applications; Social Sciences, Mathematical Methods; Psychology, Experimental; Statistics & Probability	Mathematics; Mathematical Methods In Social Sciences; Psychology	GF1PO	WOS:000431707100004	29565679	Green Published, Other Gold			2021-06-18	
J	Chen, W; Guo, YJ; Yang, WJ; Chen, L; Ren, DB; Wu, CX; He, B; Zheng, P; Tong, W				Chen, Wei; Guo, Yijun; Yang, Wenjin; Chen, Lei; Ren, Dabin; Wu, Chenxing; He, Bin; Zheng, Ping; Tong, Wusong			Phosphorylation of connexin 43 induced by traumatic brain injury promotes exosome release	JOURNAL OF NEUROPHYSIOLOGY			English	Article						connexin 43; ERK; exosome-based therapy; hippocampus; traumatic brain injury	GAP-JUNCTIONAL COMMUNICATION; FIBRILLARY ACIDIC PROTEIN; NEUROVASCULAR PLASTICITY; REACTIVE ASTROCYTES; FUNCTIONAL RECOVERY; STROMAL CELLS; DEATH; REDUCTION; ISCHEMIA; MODEL	Traumatic brain injury (TBI) caused by the external force leads to the neuronal dysfunction and even death. TBI has been reported to significantly increase the phosphorylation of glial gap junction protein connexin 43 (Cx43), which in turn propagates damages into surrounding brain tissues. However, the neuroprotective and anti-apoptosis effects of glia-derived exosomes have also been implicated in recent studies. Therefore, we detected whether TBI-induced phosphorylation of Cx43 would promote exosome release in rat brain. To generate TBI model, adult male Sprague-Dawley rats were subjected to lateral fluid percussion injury. Phosphorylated Cx43 protein levels and exosome activities were quantified using Western blot analysis following TBI. Long-term potentiation (LTP) was also tested in rat hippocampal slices. TBI significantly increased the phosphorylated Cx43 and exosome markers expression in rat ipsilateral hippocampus, but not cortex. Blocking the activity of Cx43 or ERK, but not JNK, significantly suppressed TBI-induced exosome release in hippocampus. Furthermore, TBI significantly inhibited the induction of LTP in hippocampal slices, which could be partially but significantly restored by pretreatment with exosomes. The results imply that TBI-activated Cx43 could mediate a nociceptive effect by propagating the brain damages, as well as a neuroprotective effect by promoting exosome release. NEW & NOTEWORTHY We have demonstrated in rat traumatic brain injury (TBI) models that both phosphorylated connexin 43 (p-Cx43) expression and exosome release were elevated in the hippocampus following TBI. The promoted exosome release depends on the phosphorylation of Cx43 and requires ERK signaling activation. Exosome treatment could partially restore the attenuated long-term potentiation. Our results provide new insight for future therapeutic direction on the functional recovery of TBI by promoting p-Cx43-dependent exosome release but limiting the gap junction-mediated bystander effect.	[Chen, Wei; Guo, Yijun; Yang, Wenjin; Chen, Lei; Ren, Dabin; Wu, Chenxing; He, Bin; Zheng, Ping; Tong, Wusong] Peoples Hosp Pu Dong New Area, 490 South Chuanhuan Rd, Shanghai 201299, Peoples R China	Tong, W (corresponding author), Peoples Hosp Pu Dong New Area, 490 South Chuanhuan Rd, Shanghai 201299, Peoples R China.	wstong3@sina.com			Outstanding Medical Talent Training Project of Health System of Pudong New Area, Shanghai [PWRq2015-16]; Science and Technology Committee Project of Pu dong New Area, Shanghai [PKJ2016-Y31]; Construction Specialty Project of Health and Family Planning Commission of Pudong New Area, Shanghai [PWZz2013-13]	This work was funded by Outstanding Medical Talent Training Project of Health System of Pudong New Area, Shanghai (PWRq2015-16); The Science and Technology Committee Project of Pu dong New Area, Shanghai (PKJ2016-Y31); and Construction Specialty Project of Health and Family Planning Commission of Pudong New Area, Shanghai (PWZz2013-13).	Bennett MVL, 2004, NEURON, V41, P495, DOI 10.1016/S0896-6273(04)00043-1; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; Contreras JE, 2004, BRAIN RES REV, V47, P290, DOI 10.1016/j.brainresrev.2004.08.002; Cottrell GT, 2003, AM J PHYSIOL-CELL PH, V284, pC511, DOI 10.1152/ajpcell.00214.2002; Danesh-Meyer HV, 2008, J CLIN NEUROSCI, V15, P1253, DOI 10.1016/j.jocn.2008.08.002; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196; Frantseva MV, 2002, J NEUROSCI, V22, P644, DOI 10.1523/JNEUROSCI.22-03-00644.2002; Giaume C, 1996, TRENDS NEUROSCI, V19, P319, DOI 10.1016/0166-2236(96)10046-1; Gyorgy B, 2015, ANNU REV PHARMACOL, V55, P439, DOI 10.1146/annurev-pharmtox-010814-124630; Hao L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/468748; Ji H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110314; Lai CPK, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00228; Lai RC, 2010, STEM CELL RES, V4, P214, DOI 10.1016/j.scr.2009.12.003; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; Li LZ, 2008, J CEREBR BLOOD F MET, V28, P468, DOI 10.1038/sj.jcbfm.9600546; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nagy JI, 2000, BRAIN RES REV, V32, P29, DOI 10.1016/S0165-0173(99)00066-1; Nakase T, 2004, AM J PATHOL, V164, P2067, DOI 10.1016/S0002-9440(10)63765-0; Naus CCG, 1997, J NEUROSCI RES, V49, P528, DOI 10.1002/(SICI)1097-4547(19970901)49:5<528::AID-JNR3>3.0.CO;2-D; Ohsumi A, 2006, ACTA NEUROCHIR SUPPL, V96, P148; Ohsumi A, 2010, J NEUROTRAUM, V27, P1255, DOI 10.1089/neu.2009.1234; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; Rami A, 2000, EXP NEUROL, V170, P297, DOI 10.1006/exnr.2001.7712; Siushansian R, 2001, J COMP NEUROL, V440, P387, DOI 10.1002/cne.1392; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Xin HQ, 2013, J CEREBR BLOOD F MET, V33, P1711, DOI 10.1038/jcbfm.2013.152; Xiong Y, 2017, NEURAL REGEN RES, V12, P19, DOI 10.4103/1673-5374.198966; Zhang YL, 2017, NEUROCHEM INT, V111, P69, DOI 10.1016/j.neuint.2016.08.003; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhao ZQ, 2004, EXP NEUROL, V190, P356, DOI 10.1016/j.expneurol.2004.06.015	34	14	18	1	11	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077	1522-1598		J NEUROPHYSIOL	J. Neurophysiol.	JAN	2018	119	1					305	311		10.1152/jn.00654.2017			7	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	FU7RV	WOS:000424051300025	29046426				2021-06-18	
J	Cheng, XX; Zheng, YY; Bu, P; Qi, XB; Fan, CL; Li, FQ; Kim, DH; Cao, QL				Cheng, Xiaoxin; Zheng, Yiyan; Bu, Ping; Qi, Xiangbei; Fan, Chunling; Li, Fengqiao; Kim, Dong H.; Cao, Qilin			Apolipoprotein E as a novel therapeutic neuroprotection target after traumatic spinal cord injury	EXPERIMENTAL NEUROLOGY			English	Article						Apolipoprotein E; Spinal cord-blood-barrier; Neuroprotection; Treatment; Spinal cord injury	BLOOD-BRAIN-BARRIER; E-DEFICIENT MICE; IMPROVES COGNITIVE PERFORMANCE; GLOBAL CEREBRAL-ISCHEMIA; E-MIMETIC PEPTIDE; APOE GENOTYPE; AXONAL REGENERATION; FUNCTIONAL RECOVERY; MULTIPLE-SCLEROSIS; NEURONAL DAMAGE	Apolipoprotein E (apoE), a plasma lipoprotein well known for its important role in lipid and cholesterol metabolism, has also been implicated in many neurological diseases. In this study, we examined the effect of apoE on the pathophysiology of traumatic spinal cord injury (SCI). ApoE-deficient mutant (apoE(-/-)) and wild-type mice received a T9 moderate contusion SCI and were evaluated using histological and behavioral analyses after injury. At 3 days after injury, the permeability of spinal cord-blood-barrier, measured by extravasation of Evans blue dye, was significantly increased in apoE(-/-) mice compared to wild type. The inflammation and spared white matter was also significantly increased and decreased, respectively, in apoE(-/-) mice compared to the wild type ones. The apoptosis of both neurons and oligodendrocytes was also significantly increased in apoE(-/-) mice. At 42 days after injury, the inflammation was still robust in the injured spinal cord in apoE(-/-) but not wild type mice. CD45 + leukocytes from peripheral blood persisted in the injured spinal cord of apoE(-/-) mice. The spared white matter was significantly decreased in apoE(-/-) mice compared to wild type ones. Locomotor function was significantly decreased in apoE(-/-) mice compared to wild type ones from week 1 to week 8 after contusion. Treatment of exogenous apoE mimetic peptides partially restored the permeability of spinal cord blood-barrier in apoE(-/-) mice after SCI. Importantly, the exogenous apoE peptides decreased inflammation, increased spared white matter and promoted locomotor recovery in apoE(-/-) mice after SCI. Our results indicate that endogenous apoE plays important roles in maintaining the spinal cord-blood-barrier and decreasing inflammation and spinal cord tissue loss after SCI, suggesting its important neuroprotective function after SCI. Our results further suggest that exogenous apoE mimetic peptides could be a novel and promising neuroprotective reagent for SCI.	[Cheng, Xiaoxin; Zheng, Yiyan; Bu, Ping; Qi, Xiangbei; Fan, Chunling; Kim, Dong H.; Cao, Qilin] Univ Texas Hlth Sci Ctr Houston, Vivian L Smith Dept Neurosurg, Houston, TX 77030 USA; [Cheng, Xiaoxin; Zheng, Yiyan; Bu, Ping; Kim, Dong H.; Cao, Qilin] Univ Texas Hlth Sci Ctr Houston, Brown Fdn, Inst Mol Med Prevent Human Dis, Ctr Stem Cell & Regenerat Med, Houston, TX 77030 USA; [Cheng, Xiaoxin] Dalian Med Univ, Dept Cell Biol, 25 Tinxin Rd, Dalian 116033, Liaoning, Peoples R China; [Qi, Xiangbei] Hebei Med Univ, Hosp 3, Dept Orthopaed Trauma Ctr, Shijiazhuang 050051, Hebei, Peoples R China; [Fan, Chunling] Cent S Univ, Xiangya Sch Med, Dept Anat & Neurobiol, Changsha 410011, Hunan, Peoples R China; [Li, Fengqiao] Cognosci Inc, Res Triangle Pk, NC USA	Cao, QL (corresponding author), UT Med Sch Houston, Dept Neurosurg, 1825 Pressler St, Houston, TX 77030 USA.	qi-lin.cao@uth.tmc.edu		Kim, Dong/0000-0002-1523-6396	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS099635]; Staman Ogilvie Fund for Spinal Cord Injury Recovery; Craig H. Neilsen Foundation [385446]; Mission Connect-a project of The TIRR Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS099635] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (R01 NS099635), the Staman Ogilvie Fund for Spinal Cord Injury Recovery, Craig H. Neilsen Foundation (385446), and Mission Connect-a project of The TIRR Foundation.	ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Badaut J, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-132; Bart RD, 1998, NEUROREPORT, V9, P2615, DOI 10.1097/00001756-199808030-00035; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Cao F, 2016, J NEUROTRAUM, V33, P175, DOI 10.1089/neu.2015.3887; Cao QL, 2005, EXP NEUROL, V191, pS3, DOI 10.1016/j.expneurol.2004.08.026; Chapman J, 2001, NEUROLOGY, V56, P312, DOI 10.1212/WNL.56.3.312; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Cohen DM, 2009, NMR BIOMED, V22, P332, DOI 10.1002/nbm.1343; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Fan CL, 2014, NEURAL REGEN RES, V9, P119, DOI 10.4103/1673-5374.125339; Fan CL, 2013, INT J BIOL SCI, V9, P78, DOI 10.7150/ijbs.5626; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fazekas F, 2000, J NEUROL NEUROSUR PS, V69, P25, DOI 10.1136/jnnp.69.1.25; Fazekas F, 2001, NEUROLOGY, V57, P853, DOI 10.1212/WNL.57.5.853; Fullerton SM, 2001, EXP NEUROL, V169, P13, DOI 10.1006/exnr.2001.7631; Gordon I, 1996, MOL CHEM NEUROPATHOL, V28, P97, DOI 10.1007/BF02815210; Grinberg LT, 2010, ACTA NEUROPATHOL, V119, P277, DOI 10.1007/s00401-010-0652-7; Gu Zhen, 2013, J Neurol Neurophysiol, V2014, P10; Guptill JT, 2017, J CLIN PHARMACOL, V57, P770, DOI 10.1002/jcph.853; Hafezi-Moghadam A, 2007, AM J PHYSIOL-CELL PH, V292, pC1256, DOI 10.1152/ajpcell.00563.2005; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Han SH, 2000, ANN NY ACAD SCI, V903, P357, DOI 10.1111/j.1749-6632.2000.tb06387.x; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Hill RL, 2009, J NEUROTRAUM, V26, P1, DOI 10.1089/neu.2008.0543; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Huang YWA, 2017, CELL, V168, P427, DOI 10.1016/j.cell.2016.12.044; Hulsebosch CE, 2002, ADV PHYSIOL EDUC, V26, P238, DOI 10.1152/advan.00039.2002; Jha A, 2008, J SPINAL CORD MED, V31, P171, DOI 10.1080/10790268.2008.11760708; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kakinuma Y, 1998, NAT MED, V4, P1078, DOI 10.1038/2070; Karussis D, 2003, MULT SCLER, V9, P476, DOI 10.1191/1352458503ms950oa; Kaufman NA, 2010, BEHAV BRAIN RES, V214, P395, DOI 10.1016/j.bbr.2010.06.017; Kim J, 2009, NEURON, V63, P287, DOI 10.1016/j.neuron.2009.06.026; Laskowitz DT, 2006, ACTA NEUROL SCAND, V114, P15, DOI 10.1111/j.1600-0404.2006.00680.x; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Laskowitz DT, 2017, SCI REP-UK, V7, DOI 10.1038/srep46461; Laskowitz DT, 2012, NEUROCRIT CARE, V16, P316, DOI 10.1007/s12028-011-9641-5; Laskowitz DT, 2010, J NEUROTRAUM, V27, P1983, DOI 10.1089/neu.2010.1396; Laskowitz DT, 2000, J LIPID RES, V41, P613; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; Lei BL, 2016, SCI REP-UK, V6, DOI 10.1038/srep34834; Li FQ, 2006, J PHARMACOL EXP THER, V318, P956, DOI 10.1124/jpet.106.103671; Li FQ, 2010, J PHARMACOL EXP THER, V334, P106, DOI 10.1124/jpet.110.167882; Lill CM, 2012, J MED GENET, V49, P558, DOI 10.1136/jmedgenet-2012-101175; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Lomnitski L, 1999, BBA-MOL BASIS DIS, V1453, P359, DOI 10.1016/S0925-4439(99)00010-1; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Mahley RW, 2006, ACTA NEUROL SCAND, V114, P8, DOI 10.1111/j.1600-0404.2006.00679.x; Mahley RW, 2016, J MOL MED, V94, P739, DOI 10.1007/s00109-016-1427-y; Masliah E, 1997, BRAIN RES, V751, P307, DOI 10.1016/S0006-8993(96)01420-5; McCarron MO, 1999, NEUROLOGY, V53, P2176, DOI 10.1212/WNL.53.9.2176; Methia N, 2001, MOL MED, V7, P810, DOI 10.1007/BF03401973; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; Nishitsuji K, 2011, J BIOL CHEM, V286, P17536, DOI 10.1074/jbc.M111.225532; Oitzl MS, 1997, BRAIN RES, V752, P189, DOI 10.1016/S0006-8993(96)01448-5; Pang JW, 2017, TRANSL STROKE RES, V8, P257, DOI 10.1007/s12975-016-0507-1; Patel CB, 2009, J NEUROTRAUM, V26, P1005, DOI 10.1089/neu.2008.0860; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Qiu Z, 2003, NEUROSCIENCE, V122, P291, DOI 10.1016/j.neuroscience.2003.08.017; Sahni V, 2010, J NEUROSCI, V30, P1839, DOI 10.1523/JNEUROSCI.4459-09.2010; Sarantseva S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008191; Schmitt Caroline, 2006, Spine J, V6, P113, DOI 10.1016/j.spinee.2005.05.379; Schwab ME, 1996, PHYSIOL REV, V76, P319; Seitz A, 2003, J NEUROSCI RES, V71, P417, DOI 10.1002/jnr.10482; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; Shi J, 2011, COGN BEHAV NEUROL, V24, P128, DOI 10.1097/WNN.0b013e31823380b5; Singh K, 2008, J BIOL CHEM, V283, P16752, DOI 10.1074/jbc.M710530200; Tai LM, 2016, ACTA NEUROPATHOL, V131, P709, DOI 10.1007/s00401-016-1547-z; Teng ZP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06932-3; Tenger C, 2003, IMMUNOLOGY, V109, P392, DOI 10.1046/j.1365-2567.2003.01665.x; Tlaskowitz D, 2007, PHARMACOGENOMICS, V8, P959, DOI 10.2217/14E22416.8.8.959; Toops KA, 2016, ADV EXP MED BIOL, V854, P3, DOI 10.1007/978-3-319-17121-0_1; Tu TM, 2017, ANN CLIN TRANSL NEUR, V4, P246, DOI 10.1002/acn3.399; Van Giau V, 2015, NEUROPSYCH DIS TREAT, V11, P1723, DOI 10.2147/NDT.S84266; Wang H, 2007, NEUROSCIENCE, V144, P1324, DOI 10.1016/j.neuroscience.2006.11.017; Wang H, 2013, EXP NEUROL, V241, P67, DOI 10.1016/j.expneurol.2012.11.027; Wang H, 2014, TRENDS ENDOCRIN MET, V25, P8, DOI 10.1016/j.tem.2013.10.003; Wang RH, 2014, J NEUROSCI RES, V92, P884, DOI 10.1002/jnr.23371; Wang YP, 2011, J NEUROSCI, V31, P6053, DOI 10.1523/JNEUROSCI.5524-09.2011; Wei JJ, 2013, NEUROBIOL DIS, V56, P59, DOI 10.1016/j.nbd.2013.04.009; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; Yin YW, 2012, GENE, V511, P12, DOI 10.1016/j.gene.2012.09.010; Zhang W, 2010, CLIN DEV IMMUNOL, DOI [10.1155/2010/186813, 10.1155/2010/459143]; Zhong JJ, 2017, NEUROSCIENCE, V343, P434, DOI 10.1016/j.neuroscience.2016.05.033; Zhu L, 2015, P NATL ACAD SCI USA, V112, P11965, DOI 10.1073/pnas.1510011112; Zlokovic BV, 2013, JAMA NEUROL, V70, P440, DOI 10.1001/jamaneurol.2013.2152	98	14	14	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.		2018	299		A				97	108		10.1016/j.expneurol.2017.10.014			12	Neurosciences	Neurosciences & Neurology	FR7PD	WOS:000419261500009	29056364	Green Accepted			2021-06-18	
J	Cnossen, MC; van Essen, TA; Ceyisakar, IE; Polinder, S; Andriessen, TM; van der Naalt, J; Haitsma, L; Horn, J; Franschman, G; Vos, PE; Peul, WC; Menon, DK; Maas, AIR; Steyerberg, EW; Lingsma, HF				Cnossen, Maryse C.; van Essen, Thomas A.; Ceyisakar, Iris E.; Polinder, Suzanne; Andriessen, Teuntje M.; van der Naalt, Joukje; Haitsma, Lain; Horn, Janneke; Franschman, Gaby; Vos, Pieter E.; Peul, Wilco C.; Menon, David K.; Maas, Andrew I. R.; Steyerberg, Ewout W.; Lingsma, Hester F.			Adjusting for confounding by indication in observational studies: a case study in traumatic brain injury	CLINICAL EPIDEMIOLOGY			English	Article						confounding; observational studies; traumatic brain injury; instrumental variable analysis; comparative effectiveness research	ACUTE SUBDURAL-HEMATOMA; PROPENSITY SCORE; HEAD-INJURY; MORTALITY; MANAGEMENT; CARE; BIAS; CLASSIFICATION; HEMORRHAGE; GUIDELINES	Introduction: Observational studies of interventions are at risk for confounding by indication. The objective of the current study was to define the circumstances for the validity of methods to adjust for confounding by indication in observational studies. Patients and methods: We performed post hoc analyses of data prospectively collected from three European and North American traumatic brain injury studies including 1,725 patients. The effects of three interventions (intracranial pressure [ICP] monitoring, intracranial operation and primary referral) were estimated in a proportional odds regression model with the Glasgow Outcome Scale as ordinal outcome variable. Three analytical methods were compared: classical covariate adjustment, propensity score matching and instrumental variable (IV) analysis in which the percentage exposed to an intervention in each hospital was added as an independent variable, together with a random intercept for each hospital. In addition, a simulation study was performed in which the effect of a hypothetical beneficial intervention (OR 1.65) was simulated for scenarios with and without unmeasured confounders. Results: For all three interventions, covariate adjustment and propensity score matching resulted in negative estimates of the treatment effect (OR ranging from 0.80 to 0.92), whereas the IV approach indicated that both ICP monitoring and intracranial operation might be beneficial (OR per 10% change 1.17, 95% CI 1.01-1.42 and 1.42, 95% CI 0.95-1.97). In our simulation study, we found that covariate adjustment and propensity score matching resulted in an invalid estimate of the treatment effect in case of unmeasured confounders (OR ranging from 0.90 to 1.03). The IV approach provided an estimate in the similar direction as the simulated effect (OR per 10% change 1.04-1.05) but was statistically inefficient. Conclusion: The effect estimation of interventions in observational studies strongly depends on the analytical method used. When unobserved confounding and practice variation are expected in observational multicenter studies, IV analysis should be considered.	[Cnossen, Maryse C.; Ceyisakar, Iris E.; Polinder, Suzanne; Steyerberg, Ewout W.; Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands; [van Essen, Thomas A.; Peul, Wilco C.] Leiden Univ, Med Ctr, Dept Neurosurg, Neurosurg Cooperat Holland, Leiden, Netherlands; [van Essen, Thomas A.; Peul, Wilco C.] Haaglanden Med Ctr, Dept Neurosurg, The Hague, Netherlands; [Andriessen, Teuntje M.] RIVAS Healthcare Grp, Dept Psychol, Gorinchem, Netherlands; [van der Naalt, Joukje] Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands; [Haitsma, Lain] Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands; [Horn, Janneke] Univ Amsterdam, Acad Med Ctr, Dept Intens Care Med, Amsterdam, Netherlands; [Franschman, Gaby] VU Univ Med Ctr Amsterdam, Dept Anesthesiol, Amsterdam, Netherlands; [Vos, Pieter E.] Slingeland Hosp, Dept Neurol, Doetinchem, Netherlands; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England; [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium; [Steyerberg, Ewout W.] Leiden Univ, Med Ctr, Dept Med Stat & Bioinformat, Leiden, Netherlands	Cnossen, MC (corresponding author), Erasmus MC, Dept Publ Hlth, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands.	m.c.cnossen@erasmusmc.nl	Maas, Andrew IR/C-5584-2013	Maas, Andrew IR/0000-0003-1612-1264	European Union PF 7th Framework Program [602150]; Dutch Brain Foundation (Hersenstichting Nederland)	This work was funded by the European Union PF 7th Framework Program (grant 602150) - CENTER TBI. In addition, the author TvE was funded by a grant from the Dutch Brain Foundation (Hersenstichting Nederland) for the Neurotraumatology Quality Registry (Net-QuRe) study. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Agoritsas T, 2017, JAMA-J AM MED ASSOC, V317, P748, DOI 10.1001/jama.2016.20029; Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Arthur KR, 2013, AM SURGEON, V79, P909; Austin PC, 2005, STAT MED, V24, P1563, DOI 10.1002/sim.2053; Basch E, 2012, JAMA-J AM MED ASSOC, V307, P1636, DOI 10.1001/jama.2012.466; Bates DM, 2015, PACKAGE VERSION 1 18; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Bosco JLF, 2010, J CLIN EPIDEMIOL, V63, P64, DOI 10.1016/j.jclinepi.2009.03.001; Brain Trauma Foundation, 2007, GUID MAN SEV TRAUM B; Brookhart M.A., 2007, INT J BIOSTAT, V3, P14; Brookhart MA, 2010, PHARMACOEPIDEM DR S, V19, P537, DOI 10.1002/pds.1908; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock M Ross, 2006, Neurosurgery, V58, pS7; Bullock MR, 2006, NEUROSURGERY S, V58, pSi; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chesnut RM, 2015, J NEUROTRAUM, V32, P1722, DOI 10.1089/neu.2015.3976; Cnossen MC, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1816-9; Davies NM, 2013, EPIDEMIOLOGY, V24, P363, DOI 10.1097/EDE.0b013e31828abafb; Dawes AJ, 2015, JAMA SURG, V150, P965, DOI 10.1001/jamasurg.2015.1678; Frieden TR, 2017, NEW ENGL J MED, V377, P465, DOI 10.1056/NEJMra1614394; Greenland S, 2017, EUR J EPIDEMIOL, V32, P3, DOI 10.1007/s10654-017-0230-6; Gregson BA, 2015, HEALTH TECHNOL ASSES, V19, DOI 10.3310/hta19700; Halpern EF, 2014, RADIOLOGY, V271, P625, DOI 10.1148/radiol.14140035; Harrell Jr FE, 2017, PACKAGE RMS; Hartings JA, 2014, J NEUROSURG, V120, P434, DOI 10.3171/2013.9.JNS13581; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Heinze G, 2011, EUR HEART J, V32, P1704, DOI 10.1093/eurheartj/ehr031; Hernan MA, 2006, EPIDEMIOLOGY, V17, P360, DOI 10.1097/01.ede.0000222409.00878.37; Hlatky MA, 2013, HEART FAIL CLIN, V9, P29, DOI 10.1016/j.hfc.2012.09.007; Ioannidis JPA, 2011, SCIENCE, V334, P1230, DOI 10.1126/science.1211811; Laborde-Casterot H, 2015, J CLIN EPIDEMIOL, V68, P1232, DOI 10.1016/j.jclinepi.2015.04.003; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Marion DW, 2006, NEUROSURGERY, V58, P655; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mendelow AD, 2015, J NEUROTRAUM, V32, P1312, DOI 10.1089/neu.2014.3644; Moodie EEM, 2011, INT J PUBLIC HEALTH, V56, P117, DOI 10.1007/s00038-010-0198-4; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; National Institute for Health and Care Excellence (NICE), 2014, HEAD INJ ASS MAN CLI; Normand SLT, 2010, STAT MED, V29, P1985, DOI 10.1002/sim.3933; Pezzin LE, 2015, MED CARE, V53, P1033, DOI 10.1097/MLR.0000000000000439; Rayan N, 2012, J TRAUMA ACUTE CARE, V72, P585, DOI 10.1097/TA.0b013e318243da4d; Roozenbeek B, 2011, CRIT CARE, V15, DOI 10.1186/cc10240; Roozenbeek B, 2009, CRIT CARE MED, V37, P2683, DOI 10.1097/CCM.0b013e3181ab85ec; Sanwald A, 2017, HEALTH SERV RES, V52, P16, DOI 10.1111/1475-6773.12509; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Signorello Lisa B, 2002, Am J Ther, V9, P199, DOI 10.1097/00045391-200205000-00005; Sjoding MW, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0923-8; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stukel TA, 2007, JAMA-J AM MED ASSOC, V297, P278, DOI 10.1001/jama.297.3.278; Van Essen TA, 2016, J NEUROTRAUM, V33, pA20; van Essen TA, 2017, J NEUROTRAUM, V34, P881, DOI 10.1089/neu.2016.4495; Williamson E, 2012, STAT METHODS MED RES, V21, P273, DOI 10.1177/0962280210394483; Xu JC, 2016, BRAIN INJURY, V30, P1054, DOI 10.3109/02699052.2016.1170882; Yuan Q, 2015, J NEUROSURG, V122, P574, DOI 10.3171/2014.10.JNS1460	58	14	14	0	4	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1179-1349			CLIN EPIDEMIOL	Clin. Epidemiol.		2018	10						841	852		10.2147/CLEP.S154500			12	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	GN6LN	WOS:000439196400001	30050328	DOAJ Gold, Green Published			2021-06-18	
J	Fridman, L; Scolnik, M; Macpherson, A; Rothman, L; Guttmann, A; Grool, AM; Duque, DR; Zemek, RL				Fridman, Liraz; Scolnik, Michal; Macpherson, Alison; Rothman, Linda; Guttmann, Astrid; Grool, Anne M.; Duque, Daniel Rodriguez; Zemek, Roger L.			Annual Trends in Follow-Up Visits for Pediatric Concussion in Emergency Departments and Physicians' Offices	JOURNAL OF PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; DISCHARGE; CHILDREN; SPORT; STATEMENT; SYMPTOMS	Objective To assess whether children and youth with concussion receive follow-up visits in accordance with the recommended guidelines. Study design We conducted a retrospective, population-based study using linked health administrative data from all concussion-related visits to emergency department and physician offices by children aged 5 through 18 years (range, 5.00-18.99) in Ontario between 2003 and 2013. We analyzed the percentage of children and youth seen for follow-up. The Mann-Kendall test for trends was used to assess a monotonic increasing trend over time in concussion follow-up visits. Results A total of 126 654 children and youth were evaluated for an index concussion visit. The number of children and youth assessed for concussion follow-up (N = 45 155) has increased significantly over time (P < .001). In 2003, 781 of 7126 patients (11.0%; 95% CI, 10.3-11.7) with an index visit for concussion had a follow-up assessment. By 2013, 6526 of 21 681 (30.1%; 95% CI, 29.5-30.7) patients received follow-up care. Conclusions The proportion of children and youth receiving follow-up after an acute concussion has significantly increased between 2003 and 2013. Nevertheless, more than two-thirds of all patients do not seek medical follow-up or clearance as recommended by current concussion guidelines, suggesting that ongoing efforts to improve and monitor compliance with recommended guidelines by patients and physicians are important.	[Fridman, Liraz; Macpherson, Alison; Rothman, Linda] York Univ, Toronto, ON, Canada; [Scolnik, Michal] Technion Amer Med Sch, Haifa, Israel; [Macpherson, Alison; Guttmann, Astrid; Duque, Daniel Rodriguez] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Guttmann, Astrid] Univ Toronto, Hosp Sick Children, Dept Pediat, Toronto, ON, Canada; [Grool, Anne M.; Zemek, Roger L.] Childrens Hosp, Eastern Ontario Res Inst, Toronto, ON, Canada; [Zemek, Roger L.] Univ Ottawa, Dept Pediat & Emergency Med, Ottawa, ON, Canada	Fridman, L (corresponding author), 4700 Keele St, Toronto, ON M3J1P3, Canada.	liraz@yorku.ca			Ontario Child Health SPOR Support Unit (OCHSU); Institute for Clinical Evaluative Sciences (ICES)University of Toronto; Ontario Ministry of Health and Long-Term Care (MOHLTC)Ministry of Health and Long-Term Care, Ontario; Canadian Institutes of Health Research (CIHR) Chairs in Reproductive and Child Health Services and Policy Research [126341]; Clinical Research Chair in Pediatric Concussion by the University of Ottawa	Supported by the Ontario Child Health SPOR Support Unit (OCHSU) and the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). Parts of this material are based on data and information compiled and provided by the Canadian Institute for Health Information (CIHI). A.M. and A.G. are supported by Canadian Institutes of Health Research (CIHR) Chairs in Reproductive and Child Health Services and Policy Research (# 126341). R.Z. is supported by a Clinical Research Chair in Pediatric Concussion by the University of Ottawa. The other authors declare no conflicts of interest.	American Academy of Neurology, 2013, SUMM EV BAS GUID CLI; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Brener I, 2004, J HEAD TRAUMA REHAB, V19, P405, DOI 10.1097/00001199-200409000-00005; Crandall M, 2014, BRAIN INJURY, V28, P1359, DOI 10.3109/02699052.2014.919533; Faul M, 2010, BRAIN INJURY; Fung M, 2006, BRAIN INJURY, V20, P889, DOI 10.1080/02699050600831934; Grool AM, 2016, JAMA-J AM MED ASSOC, V316, P2504, DOI 10.1001/jama.2016.17396; Haran HP, 2016, J SCI MED SPORT, V19, P194, DOI 10.1016/j.jsams.2015.02.009; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Henry LC, 2017, NEUROSCIENTIST, V23, P567, DOI 10.1177/1073858416651034; Hesselink G, 2013, INT J QUAL HEALTH C, V25, P66, DOI 10.1093/intqhc/mzs066; Macpherson A, 2014, PAED CHILD HEALT-CAN, V19, P543, DOI 10.1093/pch/19.10.543; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McLeod A. I., 2011, KENDALL KENDALL RANK; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Ontario Neurotrauma Foundation, 2014, GUID DIAGN MAN PED C, V1, P1; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Schneider KJ, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097475; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Upchurch C, 2015, CLIN J SPORT MED, V25, P297, DOI 10.1097/JSM.0000000000000123; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Zemek R, 2016, J PEDIAT, V181, pe2; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zemek RL, 2017, J PEDIATR-US, V181, P222, DOI 10.1016/j.jpeds.2016.10.067	24	14	14	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	JAN	2018	192						184	188		10.1016/j.jpeds.2017.09.018			5	Pediatrics	Pediatrics	FT7ST	WOS:000423353900035	29150146				2021-06-18	
J	Jiang, Y; Xie, H; Tu, W; Fang, H; Ji, CX; Yan, TF; Huang, HM; Yu, C; Hu, Q; Gao, ZY; Lv, SG				Jiang, Yuan; Xie, Huan; Tu, Wei; Fang, Hua; Ji, Chenxing; Yan, Tengfeng; Huang, Hongming; Yu, Cong; Hu, Qing; Gao, Ziyun; Lv, Shigang			Exosomes secreted by HUVECs attenuate hypoxia/reoxygenation-induced apoptosis in neural cells by suppressing miR-21-3p	AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH			English	Article						ATG12; autophagy; exosome; hypoxia/reoxygenation; microarray; miR-21-3p	TRAUMATIC BRAIN-INJURY; INHIBITION; REPERFUSION; MYOCARDIUM; ISCHEMIA; PROTECTS; DAMAGE	Background: Remote ischemic postconditioning (RIPostC) is an effective strategy for preventing key organs from becoming impaired due to an ischemia/reperfusion injury. In the current study, we investigated how remote exosome transfer of microRNAs (miRs) may contribute to the treatment effect of RIPostC on the central nerve system (CNS). Methods: Human umbilical vein endothelial cells (HUVECs) were subjected to hypoxia/reoxygenation (H/R) and their miR expression profiles were investigated using the microarray method. The pathways associated with dysregulated miRs were analyzed by gene ontology (GO) annotation of the target genes and a Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. The role played by the most significantly down-regulated miR (miR-21-3p) in the protective effect of HUVEC-derived exosomes on H/R-treated neural cells was further investigated. The pathway mediating the effect of miR-21-3p was then explored by focusing on activity of autophagy-related 12 (ATG12) protein. Results: The miR expression profile of HUVECs significantly changed after H/R administration, with 104 miRs becoming upregulated and 249 miRs becoming downregulated. Based on the GO and KEGG analyses, the target genes of 8 selected miRs were involved in multiple biological pathways, including the hippo signaling pathway and longevity regulating pathway. Further studies showed that inhibition of miR-21-3p by HUVEC-derived exosomes or a specific inhibitor could the block apoptotic process in H/R-treated neural cells. Molecular level studies showed that the effect of miR-21-3p inhibition depended on the restored function of ATG12, which resulted in the activation of autophagy and suppression of apoptosis. Conclusion: Taken together, these results suggest that H/R caused significant changes of miR expression in exosomes derived from H/R-treated HUVECs, and the exosomes protect neurons against H/R-induced injuries by suppressing miR-21-3p.	[Jiang, Yuan; Xie, Huan; Tu, Wei; Fang, Hua; Ji, Chenxing; Yan, Tengfeng; Huang, Hongming; Yu, Cong; Hu, Qing; Gao, Ziyun; Lv, Shigang] Nanchang Univ, Affiliated Hosp 2, Dept Neurosurg, 1 Minde Rd, Nanchang 330006, Jiangxi, Peoples R China	Gao, ZY; Lv, SG (corresponding author), Nanchang Univ, Affiliated Hosp 2, Dept Neurosurg, 1 Minde Rd, Nanchang 330006, Jiangxi, Peoples R China.	gaozy999@qq.com; lvsg1982@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81660420]; Construction Plan of the Superior Science and Technology Innovation Team of Jiangxi Province [20161BCB24-009]; Foreign Science and Technology Cooperation Plan of Jiangxi Province [20151BDH80009]; Key Projects of Natural Science Foundation of Jiangxi Province [20171ACB20035]	This work was supported by the National Natural Science Foundation of China (No. 81660420), the Construction Plan of the Superior Science and Technology Innovation Team of Jiangxi Province (No. 20161BCB24-009), the Foreign Science and Technology Cooperation Plan of Jiangxi Province (No. 20151BDH80009), and the Key Projects of Natural Science Foundation of Jiangxi Province (No. 20171ACB20035).	Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Barteneva NS, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00049; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Ge XT, 2014, SCI REP, V4, P1; Hess DC, 2013, STROKE, V44, P1191, DOI 10.1161/STROKEAHA.112.678482; Kalani A, 2014, MOL NEUROBIOL, V49, P590, DOI 10.1007/s12035-013-8544-1; Kerendi F, 2005, BASIC RES CARDIOL, V100, P404, DOI 10.1007/s00395-005-0539-2; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Pan JR, 2016, REV NEUROSCIENCE, V27, P501, DOI 10.1515/revneuro-2015-0043; Peng B, 2012, BRAIN RES, V1445, P92, DOI 10.1016/j.brainres.2012.01.033; PRZYKLENK K, 1993, CIRCULATION, V87, P893, DOI 10.1161/01.CIR.87.3.893; Ren CH, 2011, NEUROL RES, V33, P514, DOI 10.1179/016164111X13007856084241; Ren CC, 2009, BRAIN RES, V1288, P88, DOI 10.1016/j.brainres.2009.07.029; Rubinstein AD, 2011, MOL CELL, V44, P698, DOI 10.1016/j.molcel.2011.10.014; Slagsvold KH, 2014, CIRC RES, V114, P851, DOI 10.1161/CIRCRESAHA.114.302751; Sun F, 2010, CURR OPIN NEUROBIOL, V20, P510, DOI 10.1016/j.conb.2010.03.013; Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017; Yamaguchi T, 2015, INT J CARDIOL, V178, P239, DOI 10.1016/j.ijcard.2014.10.144; Yang JL, 2017, MOL THER-NUCL ACIDS, V7, P278, DOI 10.1016/j.omtn.2017.04.010; Zhao ZQ, 2003, AM J PHYSIOL-HEART C, V285, pH579, DOI 10.1152/ajpheart.01064.2002; Zong YH, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0235-6	24	14	15	1	5	E-CENTURY PUBLISHING CORP	MADISON	40 WHITE OAKS LN, MADISON, WI 53711 USA	1943-8141			AM J TRANSL RES	Am. J. Transl. Res.		2018	10	11					3529	+					16	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	HC2VM	WOS:000451660000019	30662605				2021-06-18	
S	Leinonen, V; Vanninen, R; Rauramaa, T		Kovacs, GG; Alafuzoff, I		Leinonen, Ville; Vanninen, Ritva; Rauramaa, Tuomas			Raised intracranial pressure and brain edema	NEUROPATHOLOGY	Handbook of Clinical Neurology		English	Article; Book Chapter							APPARENT DIFFUSION-COEFFICIENT; AQUAPORIN-4 EXPRESSION; MOLECULAR-MECHANISMS; CYTOTOXIC EDEMA; CEREBRAL EDEMA; BARRIER; INJURY; PATHOGENESIS; DISRUPTION; HEMORRHAGE	Acutely increased intracranial pressure (ICP) is a life-threatening neurosurgical emergency. Optimal management strategy is selected according to the causative process. Typical causes are intracranial bleeds like traumatic subdural, epidural, or intracerebral hematoma (ICH); spontaneous ICH, intraventricular hemorrhage, subarachnoid hemorrhage, and hydrocephalus. When occurring without significant brain injury and treated effectively before herniation, a full recovery can be expected. In intraparenchymal injuries a full recovery is unlikely since dead cells in the central nervous systemleave an "empty hole," to be replaced by cerebrospinal fluid. The clinical recovery is based on the surviving cells that are able to make new synapses. Surgery may decrease ICP by removing significant mass effect. In all conditions, when notable injury of brain parenchyma occurs, brain edema may gradually increase ICP and further worsen the clinical condition. This is seen typically in large brain infarctions when the formation of brain edema may lead to increased ICP for hours and days. Brain edema is traditionally classified as vasogenic or cytotoxic but according to current knowledge is rather a continuum, starting with cytotoxic cell swelling followed by ionic edema and then vasogenic edema. Here we review the causes of increased ICP, including mechanisms of brain edema, with clinical examples.	[Leinonen, Ville] Univ Eastern Finland, Inst Clin Med, Dept Neurosurg, Kuopio, Finland; [Leinonen, Ville] Kuopio Univ Hosp, NeuroCtr, Dept Neurosurg, Kuopio, Finland; [Vanninen, Ritva] Univ Eastern Finland, Inst Clin Med, Dept Radiol, Kuopio, Finland; [Vanninen, Ritva] Kuopio Univ Hosp, Dept Radiol, Kuopio, Finland; [Rauramaa, Tuomas] Univ Eastern Finland, Inst Clin Med, Dept Pathol, Kuopio, Finland; [Rauramaa, Tuomas] Kuopio Univ Hosp, Dept Pathol, Kuopio, Finland	Leinonen, V (corresponding author), Kuopio Univ Hosp, NeuroCtr, Dept Neurosurg, POB 100, Kys 70029, Finland.	ville.leinonen@kuh.fi					Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Argaw AT, 2012, J CLIN INVEST, V122, P2454, DOI 10.1172/JCI60842; Argaw AT, 2009, P NATL ACAD SCI USA, V106, P1977, DOI 10.1073/pnas.0808698106; Badaut J, 2007, PEDIATR RES, V62, P248, DOI 10.1203/PDR.0b013e3180db291b; Bartsch P, 2013, NEW ENGL J MED, V368, P2294, DOI 10.1056/NEJMcp1214870; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Bloch O, 2005, J NEUROCHEM, V95, P254, DOI 10.1111/j.1471-4159.2005.03362.x; Cahill J, 2006, STROKE, V37, P1868, DOI 10.1161/01.STR.0000226995.27230.96; Caner B, 2012, J NEUROCHEM, V123, P12, DOI 10.1111/j.1471-4159.2012.07939.x; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Dimitrijevic OB, 2007, STROKE, V38, P1345, DOI 10.1161/01.STR.0000259709.16654.8f; Hofmeijer J, 2004, STROKE, V35, P1476, DOI 10.1161/01.STR.0000128415.31274.3a; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Ishihara H, 2008, J NEUROPATH EXP NEUR, V67, P435, DOI 10.1097/NEN.0b013e31816fd622; Kahle KT, 2009, PHYSIOLOGY, V24, P257, DOI 10.1152/physiol.00015.2009; Kiviniemi V, 2016, J CEREBR BLOOD F MET, V36, P1033, DOI 10.1177/0271678X15622047; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Kuramatsu JB, 2013, J NEURAL TRANSM, V120, pS35, DOI 10.1007/s00702-013-1040-y; Leasure A, 2016, CURR TREAT OPTION NE, V18, DOI 10.1007/s11940-015-0392-z; Lee DJ, 2012, EPILEPSY RES, V98, P264, DOI 10.1016/j.eplepsyres.2011.09.016; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Liu YW, 2007, RADIOLOGY, V242, P518, DOI 10.1148/radiol.2422051698; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Mendelow AD, 2016, FRONT NEUROL NEUROSC, V37, P148, DOI 10.1159/000437119; Mendelow AD, 2005, LANCET, V365, P387; Michinaga S, 2015, INT J MOL SCI, V16, P9949, DOI 10.3390/ijms16059949; Mracsko E, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00388; Nakano T, 2002, CLIN IMAG, V26, P243, DOI 10.1016/S0899-7071(02)00433-3; Nedergaard M, 2005, GLIA, V50, P281, DOI 10.1002/glia.20205; Nico B, 2009, EUR J CANCER, V45, P3315, DOI 10.1016/j.ejca.2009.09.023; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Papadopoulos MC, 2013, NAT REV NEUROSCI, V14, P265, DOI 10.1038/nrn3468; Papadopoulos MC, 2004, NEUROSCIENCE, V129, P1011, DOI 10.1016/j.neuroscience.2004.05.044; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8; Rabinstein AA, 2010, CURR TREAT OPTION NE, V12, P129, DOI 10.1007/s11940-010-0062-0; Rickard AC, 2014, EMERG MED J, V31, P679, DOI 10.1136/emermed-2013-202679; Rumpel H, 1998, AM J NEURORADIOL, V19, P1636; Saadoun S, 2003, J CLIN PATHOL, V56, P972, DOI 10.1136/jcp.56.12.972; Saadoun S, 2010, NEUROSCIENCE, V168, P1036, DOI 10.1016/j.neuroscience.2009.08.019; Saadoun S, 2002, J NEUROL NEUROSUR PS, V72, P262, DOI 10.1136/jnnp.72.2.262; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Song TT, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0528-4; Stokum JA, 2016, J CEREBR BLOOD F MET, V36, P513, DOI 10.1177/0271678X15617172; Tait MJ, 2010, NEUROSCIENCE, V167, P60, DOI 10.1016/j.neuroscience.2010.01.053; Thrane AS, 2014, TRENDS NEUROSCI, V37, P620, DOI 10.1016/j.tins.2014.08.010; Thrane AS, 2011, P NATL ACAD SCI USA, V108, P846, DOI 10.1073/pnas.1015217108; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Urday S, 2016, CRIT CARE MED, V44, P790, DOI 10.1097/CCM.0000000000001553; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987; Weiss N, 2009, BBA-BIOMEMBRANES, V1788, P842, DOI 10.1016/j.bbamem.2008.10.022; Wendon J, 2008, NEUROCRIT CARE, V9, P97, DOI 10.1007/s12028-008-9123-6; Wilson MH, 2009, LANCET NEUROL, V8, P175, DOI 10.1016/S1474-4422(09)70014-6; Wolburg H, 2009, CELL TISSUE RES, V335, P75, DOI 10.1007/s00441-008-0658-9; Wolburg H, 2012, MOL ASPECTS MED, V33, P579, DOI 10.1016/j.mam.2012.02.003; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Yao XM, 2015, J NEUROTRAUM, V32, P1458, DOI 10.1089/neu.2014.3675	60	14	14	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0072-9752		978-0-12-802615-1; 978-0-12-802395-2	HAND CLINIC			2018	145						25	37		10.1016/B978-0-12-802395-2.00004-3			13	Clinical Neurology	Neurosciences & Neurology	BM3UR	WOS:000462710900006					2021-06-18	
J	Soliman, I; Johnson, GGRJ; Gillman, LM; Zeiler, FA; Faqihi, F; Aletreby, WT; Balhamar, A; Mahmood, NN; Mumtaz, SA; Alharthy, A; Lazaridis, C; Karakitsos, D				Soliman, Ibrahim; Johnson, Garrett G. R. J.; Gillman, Lawrence M.; Zeiler, Frederick A.; Faqihi, Fahad; Aletreby, Waleed Tharwat; Balhamar, Abdullah; Mahmood, Nasir Nasim; Mumtaz, Shahzad Ahmad; Alharthy, Abdulrahman; Lazaridis, Christos; Karakitsos, Dimitrios			New Optic Nerve Sonography Quality Criteria in the Diagnostic Evaluation of Traumatic Brain Injury	CRITICAL CARE RESEARCH AND PRACTICE			English	Article							RAISED INTRACRANIAL-PRESSURE; SHEATH DIAMETER; UNIQUE MODEL; ULTRASONOGRAPHY; MANAGEMENT	Background. New sonographic quality criteria to optimize optic nerve sheath diameter (ONSD) measurements were suggested. The latter were correlated to elevated intracranial pressure (ICP) in traumatic brain injury (TBI). Aim. We investigated whether ONSD measurements were correlated to simultaneous ICP measurements in severe TBI. Methods. Forty patients with severe TBI (Marshall Scale >= II and GCS <= 8) participated in the study. All patients had an intraparenchymal ICP catheter inserted, while ONSD was measured bilaterally, upon admission and over the next 48 hours, based on the new sonographic criteria. A total of 400 ONSD measurements were performed, while mean ONSD values of both eyes were used in the analysis. Results. ONSD measurements were strongly correlated to ICP values (r = 0.74, p < 0.0001). Receiver operator curve (ROC) analysis revealed that the ONSD cutoff value for predicting elevated ICP was 6.4mm when using the mean of both eyes (AUC = 0.88, 95% CI = 0.80 to 0.95; sensitivity = 85.3%, specificity = 82.6%). Linear regression analysis nested models revealed that sex (p = 0.006) and height (p = 0.04) were significant predictors of ONSD values. Conclusion. When applying the new sonographic quality criteria, ONSD is strongly correlated to ICP in severe TBI. Whether to use such criteria to monitor ONSD as a proxy for ICP trend in TBI remains to be further explored.	[Soliman, Ibrahim; Faqihi, Fahad; Aletreby, Waleed Tharwat; Balhamar, Abdullah; Mahmood, Nasir Nasim; Mumtaz, Shahzad Ahmad; Alharthy, Abdulrahman; Karakitsos, Dimitrios] King Saud Med City, Crit Care Dept, Neurocrit Care Unit, Riyadh, Saudi Arabia; [Johnson, Garrett G. R. J.] Univ Manitoba, Rady Fac Hlth Sci, Undergrad Med Educ, Winnipeg, MB, Canada; [Gillman, Lawrence M.; Zeiler, Frederick A.] Univ Manitoba, Rady Fac Hlth Sci, Dept Surg, Winnipeg, MB, Canada; [Zeiler, Frederick A.] Univ Manitoba, Rady Fac Hlth Sci, Clinician Investigator Program, Winnipeg, MB, Canada; [Zeiler, Frederick A.] Univ Cambridge, Addenbrookes Hosp, Div Anesthesia, Cambridge, England; [Lazaridis, Christos] Baylor Coll Med, Dept Neurol, Div Neurocrit Care, Houston, TX 77030 USA; [Lazaridis, Christos] Baylor Coll Med, Dept Neurosurg, Div Neurocrit Care, Houston, TX 77030 USA; [Karakitsos, Dimitrios] USC, Keck Sch Med, Dept Crit Care, Los Angeles, CA USA	Soliman, I (corresponding author), King Saud Med City, Crit Care Dept, Neurocrit Care Unit, Riyadh, Saudi Arabia.	ibrahimrefaat@hotmail.com	Aletreby, Waleed/AAH-7349-2019	Aletreby, Waleed/0000-0001-8387-1829; Zeiler, Frederick/0000-0003-1737-0510; Johnson, Garrett/0000-0001-5507-9543			Asghar A, 2015, ANAESTH PAIN INTENSI, V19, P282; Attaallah A. F., 2013, TRAUMA, P125; Badri S, 2012, INTENS CARE MED, V38, P1800, DOI 10.1007/s00134-012-2655-4; Blaivas M, 2003, ACAD EMERG MED, V10, P376, DOI 10.1197/aemj.10.4.376; Bratton S.L., 2007, J NEUROTRAUM, V24, pS37; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Dubourg J, 2011, INTENS CARE MED, V37, P1059, DOI 10.1007/s00134-011-2224-2; Geeraerts T, 2008, INTENS CARE MED, V34, P2062, DOI 10.1007/s00134-008-1149-x; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; Geeraerts T, 2008, CRIT CARE, V12, DOI 10.1186/cc7006; Goeres P, 2016, J CRIT CARE, V31, P168, DOI 10.1016/j.jcrc.2015.10.009; Johnson GGRJ, 2016, CRIT ULTRASOUND J, V8, DOI 10.1186/s13089-016-0053-9; Karakitsos D, 2006, TRANSPL P, V38, P3700, DOI 10.1016/j.transproceed.2006.10.185; Killer HE, 2003, BRIT J OPHTHALMOL, V87, P777, DOI 10.1136/bjo.87.6.777; Kimberly HH, 2008, ACAD EMERG MED, V15, P201, DOI 10.1111/j.1553-2712.2007.00031.x; Lee SH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002439; Maude RR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081013; O'Dwyer L. M., 2014, 2015046 REL US DEP E; Ohle R, 2015, J ULTRAS MED, V34, P1285, DOI 10.7863/ultra.34.7.1285; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845; Raffiz M, 2017, AM J EMERG MED, V35, P150, DOI 10.1016/j.ajem.2016.09.044; Sargsyan AE, 2014, CRITICAL CARE ULTRAS; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Wang LJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117939; Zeiler FA, 2014, CAN J NEUROL SCI, V41, P430, DOI 10.1017/S0317167100018448; Zeiler FA, 2016, CRIT ULTRASOUND J, V8, DOI 10.1186/s13089-016-0044-x; Zeiler FA, 2013, CAN J NEUROL SCI, V40, P225, DOI 10.1017/S0317167100013779	30	14	14	0	4	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-1305	2090-1313		CRIT CARE RES PRACT	Crit. Care Res. Pract.		2018	2018								3589762	10.1155/2018/3589762			7	Critical Care Medicine	General & Internal Medicine	GH0AO	WOS:000433064000001	29854448	DOAJ Gold, Green Published			2021-06-18	
J	Tao, JL; Yang, MH; Wu, H; Ma, T; He, CJ; Chai, ML; Zhang, XS; Zhang, JL; Ding, FR; Wang, ST; Deng, SL; Zhu, KF; Song, YK; Ji, PY; Liu, HJ; Lian, ZX; Liu, GS				Tao, Jingli; Yang, Minghui; Wu, Hao; Ma, Teng; He, Changjiu; Chai, Menglong; Zhang, Xiaosheng; Zhang, Jinlong; Ding, Fangrong; Wang, Sutian; Deng, Shoulong; Zhu, Kuanfeng; Song, Yukun; Ji, Pengyun; Liu, Haijun; Lian, Zhengxing; Liu, Guoshi			Effects of AANAT overexpression on the inflammatory responses and autophagy activity in the cellular and transgenic animal levels	AUTOPHAGY			English	Article						AANAT; autophagy; goat; inflammation; melatonin; PBMCs; somatic cell nuclear transfer	TRAUMATIC BRAIN-INJURY; ARYLALKYLAMINE-N-ACETYLTRANSFERASE; NUCLEAR TRANSFER; IN-VITRO; OXIDATIVE STRESS; PRONUCLEAR MICROINJECTION; EMBRYONIC-DEVELOPMENT; MELATONIN PROMOTES; SHEEP; MILK	To explore the anti-inflammatory activity of endogenous produced melatonin, a melatonin-enriched animal model (goat) with AANAT transfer was successfully generated with somatic cell nuclear transfer (SCNT) technology. Basically, a pIRES2-EGFP-AANAT expression vector was constructed and was transferred into the female fetal fibroblast cells (FFCs) via electrotransfection and then the nuclear of the transgenic FFC was transferred to the eggs of the donor goats. The peripheral blood mononuclear cells (PBMCs) of the transgenic offspring expressed significantly higher levels of AANAT and melatonin synthetic function than those PBMCs from the wild-type (WT) animals. After challenge with lipopolysaccharide (LPS), the transgenic PBMCs had increased autophagosomes and LC3B expression while they exhibited suppressed production of the proinflammatory cytokines, IL1B and IL12 (IL12A-IL12B/p70), compared to their WT. The mechanistic analysis indicated that the anti-inflammatory activity of endogenous melatonin was mediated by MTNR1B (melatonin receptor 1B). MTNR1B stimulation activated the MAPK14 signaling pathway to promote cellular macroautophagy/autophagy, thus, suppressing the excessive inflammatory response of cellular. However, when the intact animals challenged with LPS, the serum proinflammatory cytokines were significantly higher in the transgenic goats than that in the WT. The results indicated that endogenous melatonin inhibited the MAPK1/3 signaling pathway and ROS production, subsequently downregulated gene expression of BECN1, ATG5 in PMBCs and then suppressed the autophagy activity of PBMCs and finally elevated levels of serum proinflammatory cytokines in transgenic animals, Herein we provided a novel melatonin-enriched animal model to study the potential effects of endogenously produced melatonin on inflammatory responses and autophagy activity.	[Tao, Jingli; Yang, Minghui; Wu, Hao; Ma, Teng; He, Changjiu; Chai, Menglong; Wang, Sutian; Zhu, Kuanfeng; Song, Yukun; Ji, Pengyun; Lian, Zhengxing; Liu, Guoshi] China Agr Univ, Coll Anim Sci & Technol, Beijing Key Lab Anim Genet Improvement, Minist Agr,Natl Engn Lab Anim Breeding,Key Lab An, Beijing 100193, Peoples R China; [He, Changjiu] Huazhong Agr Univ, Coll Anim Sci & Technol, Wuhan, Hubei, Peoples R China; [Zhang, Xiaosheng; Zhang, Jinlong; Liu, Haijun] Acad Agr Sci Tianjin, Inst Anim Husb & Vet, Tianjin, Peoples R China; [Ding, Fangrong] China Agr Univ, Coll Biol Sci, State Key Lab Agrobiotechnol, Beijing, Peoples R China; [Deng, Shoulong] Chinese Acad Sci, Inst Zool, State Key Lab Stem Cell & Reprod Biol, Beijing, Peoples R China	Liu, GS (corresponding author), China Agr Univ, Coll Anim Sci & Technol, Beijing Key Lab Anim Genet Improvement, Minist Agr,Natl Engn Lab Anim Breeding,Key Lab An, Beijing 100193, Peoples R China.	gshliu@cau.edu.cn	Changjiu, He/AAG-3308-2021	deng, shou-long/0000-0003-1187-3037; he, changjiu/0000-0002-0350-9799	Genetically Modified Organisms Breeding Major Projects of China [2014ZX08008002B, 2016ZX08008003]	This work was supported by the Genetically Modified Organisms Breeding Major Projects of China [2014ZX08008002B, 2016ZX08008003].	Abdelaziz DHA, 2015, IMMUNOL REV, V265, P194, DOI 10.1111/imr.12288; Abecia JA, 2002, VET RES COMMUN, V26, P151, DOI 10.1023/A:1014099719034; Agarwal A, 2006, FERTIL STERIL, V86, P503, DOI 10.1016/j.fertnstert.2006.02.088; Auldist MJ, 2007, J DAIRY RES, V74, P52, DOI 10.1017/S0022029906002160; Blomeke B, 2008, J TOXICOL ENV HEAL A, V71, P874, DOI 10.1080/15287390801988020; Carrillo-Vico A, 2013, INT J MOL SCI, V14, P8638, DOI 10.3390/ijms14048638; Chen JY, 2014, J PINEAL RES, V56, P12, DOI 10.1111/jpi.12086; Chen YN, 2016, CELL PHYSIOL BIOCHEM, V40, P1094, DOI 10.1159/000453164; Cho SJ, 2010, THERIOGENOLOGY, V73, P848, DOI 10.1016/j.theriogenology.2009.09.008; Choi J, 2008, MOL REPROD DEV, V75, P1127, DOI 10.1002/mrd.20861; Choi SI, 2013, J PINEAL RES, V54, P361, DOI 10.1111/jpi.12039; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Cornetta K, 2013, TRANSGENIC RES, V22, P737, DOI 10.1007/s11248-012-9674-3; Damak S, 1996, BIO-TECHNOL, V14, P185, DOI 10.1038/nbt0296-185; Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532; Deretic V, 2012, J IMMUNOL, V189, P15, DOI 10.4049/jimmunol.1102108; Deretic V, 2012, CURR OPIN IMMUNOL, V24, P21, DOI 10.1016/j.coi.2011.10.006; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; Ding K, 2014, NEUROCHEM INT, V76, P23, DOI 10.1016/j.neuint.2014.06.015; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Effenberger-Neidnicht K, 2014, INFLAMMATION, V37, P738, DOI 10.1007/s10753-013-9792-y; Eriksson L, 1998, ACTA VET SCAND, V39, P301; EYESTONE WH, 1994, REPROD FERT DEVELOP, V6, P647, DOI 10.1071/RD9940647; Farez MF, 2015, CELL, V162, P1338, DOI 10.1016/j.cell.2015.08.025; Feng DY, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12395; Feng XJ, 2015, TRANSGENIC RES, V24, P73, DOI 10.1007/s11248-014-9818-8; Forman K, 2010, J PINEAL RES, V49, P312, DOI 10.1111/j.1600-079X.2010.00800.x; Francois A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138326; Galano A, 2013, J PINEAL RES, V54, P245, DOI 10.1111/jpi.12010; Gao C, 2012, J PINEAL RES, V52, P305, DOI 10.1111/j.1600-079X.2011.00944.x; Gomez-Florit M, 2013, BIOCHEM PHARMACOL, V86, P1784, DOI 10.1016/j.bcp.2013.10.009; Guo YC, 2010, J HUAZHONG U SCI-MED, V30, P1, DOI 10.1007/s11596-010-0101-9; HAMMER RE, 1985, NATURE, V315, P680, DOI 10.1038/315680a0; Han D, 2016, J PINEAL RES, V60, P178, DOI 10.1111/jpi.12299; Hevia D, 2015, J PINEAL RES, V58, P234, DOI 10.1111/jpi.12210; Huang YJ, 2007, P NATL ACAD SCI USA, V104, P13603, DOI 10.1073/pnas.0702756104; Ishizuka B, 2000, J PINEAL RES, V28, P48, DOI 10.1034/j.1600-079x.2000.280107.x; Ivics Z, 2014, NAT PROTOC, V9, P773, DOI 10.1038/nprot.2014.008; Jeong JK, 2012, J PINEAL RES, V53, P138, DOI 10.1111/j.1600-079X.2012.00980.x; Kalinichenko LS, 2014, B EXP BIOL MED+, V156, P627, DOI 10.1007/s10517-014-2411-6; Kang K, 2010, J PINEAL RES, V49, P176, DOI 10.1111/j.1600-079X.2010.00783.x; Kim HJ, 2013, J IMMUNOL, V191, P2657, DOI 10.4049/jimmunol.1300358; Kimata H, 2007, J PSYCHOSOM RES, V62, P699, DOI 10.1016/j.jpsychores.2006.12.007; Kirik D, 2003, P NATL ACAD SCI USA, V100, P2884, DOI 10.1073/pnas.0536383100; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; Lan GC, 2006, MOL REPROD DEV, V73, P834, DOI 10.1002/mrd.20443; Lapaquette P, 2017, M S-MED SCI, V33, P305, DOI 10.1051/medsci/20173303018; Lee GS, 2005, THERIOGENOLOGY, V63, P973, DOI 10.1016/j.theriogenology.2004.04.017; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Li X, 2014, INFLAMMATION, V37, P1317, DOI 10.1007/s10753-014-9859-4; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lissoni P, 1997, J BIOL REG HOMEOS AG, V11, P157; Ma T, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12406; Manchester LC, 2015, J PINEAL RES, V59, P403, DOI 10.1111/jpi.12267; Marh J, 2012, P NATL ACAD SCI USA, V109, P19184, DOI 10.1073/pnas.1216473109; McCreath KJ, 2000, NATURE, V405, P1066, DOI 10.1038/35016604; MELCHIORRI D, 1994, LIFE SCI, V56, P83, DOI 10.1016/0024-3205(94)00928-7; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; Nopparat C, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12407; Okazaki M, 2009, J PINEAL RES, V46, P373, DOI 10.1111/j.1600-079X.2009.00673.x; Pang YW, 2013, J PINEAL RES, V54, P389, DOI 10.1111/jpi.12024; Papis K, 2007, J PINEAL RES, V43, P321, DOI 10.1111/j.1600-079X.2007.00479.x; Permpoonputtana K, 2013, NEUROTOX RES, V23, P189, DOI 10.1007/s12640-012-9350-7; Peschke E, 2015, J PINEAL RES, V59, P1, DOI 10.1111/jpi.12240; Proikas-Cezanne T, 2015, J CELL SCI, V128, P207, DOI 10.1242/jcs.146258; Qi YL, 2014, CANCER RES, V74, P3740, DOI 10.1158/0008-5472.CAN-13-3182; Ren WK, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12394; Ritchie WA, 2009, MOL REPROD DEV, V76, P61, DOI 10.1002/mrd.20930; Rodriguez-Osorio N, 2007, J PINEAL RES, V43, P283, DOI 10.1111/j.1600-079X.2007.00475.x; Rosales-Corral SA, 2012, J PINEAL RES, V52, P167, DOI 10.1111/j.1600-079X.2011.00937.x; Rosas-Ballina M, 2015, BRAIN BEHAV IMMUN, V44, P19, DOI 10.1016/j.bbi.2014.07.010; Rowe SA, 2002, AM J PHYSIOL-REG I, V282, pR797, DOI 10.1152/ajpregu.00228.2001; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215; Stefanova NA, 2015, J PINEAL RES, V59, P163, DOI 10.1111/jpi.12248; Su JM, 2015, J PINEAL RES, V59, P455, DOI 10.1111/jpi.12275; Sun TJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10159; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; Tsuyuki S, 2014, AUTOPHAGY, V10, P497, DOI 10.4161/auto.27419; Valtonen M, 2005, NORD J PSYCHIAT, V59, P217, DOI 10.1080/08039480510023034; Vilar A, 2014, FREE RADICAL RES, V48, P119, DOI 10.3109/10715762.2013.845295; Wall R J, 2001, Cloning and stem cells, V3, P209, DOI 10.1089/15362300152725936; Wall RJ, 2005, NAT BIOTECHNOL, V23, P445, DOI 10.1038/nbt1078; Wang F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093641; Wang F, 2014, J PINEAL RES, V56, P333, DOI 10.1111/jpi.12126; Wang F, 2013, J PINEAL RES, V55, P267, DOI 10.1111/jpi.12069; Wang L, 2014, J PINEAL RES, V56, P134, DOI 10.1111/jpi.12105; Wang P, 2015, J PINEAL RES, V58, P479, DOI 10.1111/jpi.12233; Wang P, 2013, J PINEAL RES, V55, P424, DOI 10.1111/jpi.12091; Wang YS, 2015, THERIOGENOLOGY, V84, P608, DOI 10.1016/j.theriogenology.2015.04.016; Xin ZL, 2015, J PINEAL RES, V58, P375, DOI 10.1111/jpi.12227; Yang Y, 2014, J PINEAL RES, V57, P357, DOI 10.1111/jpi.12175; Yin XJ, 2008, BIOL REPROD, V78, P425, DOI 10.1095/biolreprod.107.065185; Yuan S, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.01289; Yuk JM, 2013, MOL CELLS, V36, P393, DOI 10.1007/s10059-013-0298-0; Zhang HM, 2014, J PINEAL RES, V57, P131, DOI 10.1111/jpi.12162; Zhang WL, 2016, ONCOTARGET, V7, P52179, DOI 10.18632/oncotarget.10538; Zheng WP, 2001, CHEM BIOL, V8, P379, DOI 10.1016/S1074-5521(01)00020-5	100	14	15	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1554-8627	1554-8635		AUTOPHAGY	Autophagy		2018	14	11					1850	1869		10.1080/15548627.2018.1490852			20	Cell Biology	Cell Biology	GU2BH	WOS:000445072900002	29985091	Green Published, Bronze			2021-06-18	
J	Guglielmetti, C; Chou, A; Krukowski, K; Najac, C; Feng, X; Riparip, LK; Rosi, S; Chaumeil, MM				Guglielmetti, Caroline; Chou, Austin; Krukowski, Karen; Najac, Chloe; Feng, Xi; Riparip, Lara-Kirstie; Rosi, Susanna; Chaumeil, Myriam M.			In vivo metabolic imaging of Traumatic Brain Injury	SCIENTIFIC REPORTS			English	Article							C-13-LABELED MICRODIALYSIS; MACROPHAGE POLARIZATION; CEREBRAL METABOLISM; LACTATE; NEUROINFLAMMATION; INHIBITION; INCREASE	Complex alterations in cerebral energetic metabolism arise after traumatic brain injury (TBI). To date, methods allowing for metabolic evaluation are highly invasive, limiting our understanding of metabolic impairments associated with TBI pathogenesis. We investigated whether C-13 MRSI of hyperpolarized (HP) [1-C-13] pyruvate, a non-invasive metabolic imaging method, could detect metabolic changes in controlled cortical injury (CCI) mice (n = 57). Our results show that HP [1-C-13] lactate-to-pyruvate ratios were increased in the injured cortex at acute (12/24 hours) and sub-acute (7 days) time points after injury, in line with decreased pyruvate dehydrogenase (PDH) activity, suggesting impairment of the oxidative phosphorylation pathway. We then used the colony-stimulating factor-1 receptor inhibitor PLX5622 to deplete brain resident microglia prior to and after CCI, in order to confirm that modulations of HP [1-C-13] lactate-to-pyruvate ratios were linked to microglial activation. Despite CCI, the HP [1-C-13] lactate-to-pyruvate ratio at the injury cortex of microglia-depleted animals at 7 days post-injury remained unchanged compared to contralateral hemisphere, and PDH activity was not affected. Altogether, our results demonstrate that HP [1-C-13] pyruvate has great potential for in vivo non-invasive detection of cerebral metabolism post-TBI, providing a new tool to monitor the effect of therapies targeting microglia/macrophages activation after TBI.	[Guglielmetti, Caroline; Chou, Austin; Krukowski, Karen; Feng, Xi; Riparip, Lara-Kirstie; Rosi, Susanna; Chaumeil, Myriam M.] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, San Francisco, CA 94143 USA; [Guglielmetti, Caroline; Najac, Chloe; Chaumeil, Myriam M.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, Surbeck Lab Adv Imaging, San Francisco, CA 94143 USA; [Chou, Austin; Krukowski, Karen; Feng, Xi; Riparip, Lara-Kirstie; Rosi, Susanna] Univ Calif San Francisco, Brain & Spinal Injury Ctr, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA; [Rosi, Susanna] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Rosi, Susanna] Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA 94143 USA; [Rosi, Susanna] Univ Calif San Francisco, Kavli Inst Fundamental Neurosci, San Francisco, CA 94143 USA	Rosi, S; Chaumeil, MM (corresponding author), Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, San Francisco, CA 94143 USA.; Chaumeil, MM (corresponding author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, Surbeck Lab Adv Imaging, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Kavli Inst Fundamental Neurosci, San Francisco, CA 94143 USA.	susanna.rosi@ucsf.edu; myriam.chaumeil@ucsf.edu	; Feng, Xi/N-7160-2016	Chou, Austin/0000-0003-4328-5811; Najac, Chloe/0000-0002-7804-2281; Chaumeil, Myriam/0000-0002-2110-4613; Feng, Xi/0000-0002-6920-1519	NMSSNational Multiple Sclerosis Society [FG-1507-05297]; NIH Hyperpolarized MRI Technology Resource CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P41EB013598]; NIH/NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA172845, R01CA1972254];  [ABTA BRF1700006];  [NIH/NINDS R21NS096718];  [NIH/NINDS R01NS102156];  [Cal-BRAIN349087]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA172845] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB013598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS102156, R21NS096718] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F32AG054126] Funding Source: NIH RePORTER	This work was supported by research grants: NIH/NINDS R21NS096718, NIH/NINDS R01NS102156, Cal-BRAIN349087, NIH Hyperpolarized MRI Technology Resource Center #P41EB013598, fellowship from the NMSS (FG-1507-05297), NIH/NCI R01CA172845, NIH/NCI R01CA1972254, ABTA BRF1700006.	Ardenkjaer-Larsen JH, 2003, P NATL ACAD SCI USA, V100, P10158, DOI 10.1073/pnas.1733835100; Carpenter KLH, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00112; Carpenter KLH, 2014, EUR J PHARM SCI, V57, P87, DOI 10.1016/j.ejps.2013.12.012; Chaumeil MM, 2015, METHOD ENZYMOL, V561, P1, DOI 10.1016/bs.mie.2015.04.001; Chou A, 2017, P NATL ACAD SCI USA, V114, pE6420, DOI 10.1073/pnas.1707661114; Daniels CJ, 2016, NMR BIOMED, V29, P387, DOI 10.1002/nbm.3468; DeVience SJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01736-x; Dienel GA, 2014, J CEREBR BLOOD F MET, V34, P1736, DOI 10.1038/jcbfm.2014.153; Edlow BL, 2012, SEMIN NEUROL, V32, P374, DOI 10.1055/s-0032-1331810; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Feng X, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0671-y; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Galvan-Pena S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00420; Guglielmetti C, 2016, NEUROIMAGE, V125, P363, DOI 10.1016/j.neuroimage.2015.10.052; Guglielmetti C, 2017, P NATL ACAD SCI USA, V114, pE6982, DOI 10.1073/pnas.1613345114; Hanrahan F., 2016, TRANSLATIONAL RES TR; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hillary FG, 2007, BRAIN INJURY, V21, P981, DOI 10.1080/02699050701426964; Jalloh I, 2013, J NEUROTRAUM, V30, P2031, DOI 10.1089/neu.2013.2947; Jha MK, 2015, J NEUROSCI, V35, P14353, DOI 10.1523/JNEUROSCI.1910-15.2015; Kettunen MI, 2010, MAGN RESON MED, V63, P872, DOI 10.1002/mrm.22276; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kurhanewicz J, 2011, NEOPLASIA, V13, P81, DOI 10.1593/neo.101102; Lama S, 2014, J BIOL CHEM, V289, P20200, DOI 10.1074/jbc.M114.570978; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Morganti JM, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0547-1; Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Nelson SJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006070; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Orihuela R, 2016, BRIT J PHARMACOL, V173, P649, DOI 10.1111/bph.13139; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Tan Z, 2015, J IMMUNOL, V194, P6082, DOI 10.4049/jimmunol.1402469; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Tisdall MM, 2007, BRIT J ANAESTH, V99, P61, DOI 10.1093/bja/aem143; Vallez Garcia D, 2016, J NEUROTRAUM, V33, P1855, DOI 10.1089/neu.2015.4230; Ward CS, 2010, CANCER RES, V70, P1296, DOI 10.1158/0008-5472.CAN-09-2251; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	45	14	14	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	DEC 13	2017	7								17525	10.1038/s41598-017-17758-4			10	Multidisciplinary Sciences	Science & Technology - Other Topics	FP7FR	WOS:000417796000045	29235509	DOAJ Gold, Green Published			2021-06-18	
J	Caswell, SV; Lincoln, AE; Stone, H; Kelshaw, P; Putukian, M; Hepburn, L; Higgins, M; Cortes, N				Caswell, Shane V.; Lincoln, Andrew E.; Stone, Hannah; Kelshaw, Patricia; Putukian, Margot; Hepburn, Lisa; Higgins, Michael; Cortes, Nelson			Characterizing Verified Head Impacts in High School Girls' Lacrosse	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						head impacts; female; lacrosse; wearable sensors; verification; video analysis	ICE HOCKEY PLAYERS; COLLEGIATE FOOTBALL PLAYERS; WOMENS LACROSSE; EYE INJURIES; EPIDEMIOLOGY; CONCUSSION; SOCCER; MENS; BIOMECHANICS; EXPOSURE	Background: Girls' high school lacrosse players have higher rates of head and facial injuries than boys. Research indicates that these injuries are caused by stick, player, and ball contacts. Yet, no studies have characterized head impacts in girls' high school lacrosse. Purpose: To characterize girls' high school lacrosse game-related impacts by frequency, magnitude, mechanism, player position, and game situation. Study Design: Descriptive epidemiology study. Methods: Thirty-five female participants (mean age, 16.2 +/- 1.2 years; mean height, 1.66 +/- 0.05 m; mean weight, 61.2 +/- 6.4 kg) volunteered during 28 games in the 2014 and 2015 lacrosse seasons. Participants wore impact sensors affixed to the right mastoid process before each game. All game-related impacts recorded by the sensors were verified using game video. Data were summarized for all verified impacts in terms of frequency, peak linear acceleration (PLA), and peak rotational acceleration (PRA). Descriptive statistics and impact rates were calculated. Results: Fifty-eight verified game-related impacts >= 20g were recorded (median PLA, 33.8g; median PRA, 6151.1 rad/s(2)) during 467 player-games. The impact rate for all game-related verified impacts was 0.12 per athlete-exposure (AE) (95% CI, 0.09-0.16), equivalent to 2.1 impacts per team game, indicating that each athlete suffered fewer than 2 head impacts per season 20g. Of these impacts, 28 (48.3%) were confirmed to directly strike the head, corresponding with an impact rate of 0.05 per AE (95% CI, 0.00-0.10). Overall, midfielders (n = 28, 48.3%) sustained the most impacts, followed by defenders (n = 12, 20.7%), attackers (n = 11, 19.0%), and goalies (n = 7, 12.1%). Goalies demonstrated the highest median PLA and PRA (38.8g and 8535.0 rad/s(2), respectively). The most common impact mechanisms were contact with a stick (n = 25, 43.1%) and a player (n = 17, 29.3%), followed by the ball (n = 7, 12.1%) and the ground (n = 7, 12.1%). One hundred percent of ball impacts occurred to goalies. Most impacts occurred to field players within the attack area of the field (n = 32, 55.2%) or the midfield (n = 18, 31.0%). Most (95%) impacts did not result in a penalty. Conclusion: The incidence of verified head impacts in girls' high school lacrosse was quite low. Ball to head impacts were associated with the highest impact magnitudes. While stick and body contacts are illegal in girls' high school lacrosse, rarely did such impacts to the head result in a penalty. The verification of impact mechanisms using video review is critical to collect impact sensor data.	[Caswell, Shane V.; Lincoln, Andrew E.; Stone, Hannah; Kelshaw, Patricia; Putukian, Margot; Hepburn, Lisa; Higgins, Michael; Cortes, Nelson] George Mason Univ, SMART Lab, Sports Med Assessment Res & Testing, 10900 Univ Blvd,MS4E5, Manassas, VA 20110 USA; [Lincoln, Andrew E.; Hepburn, Lisa] MedStar Sports Med, Baltimore, MD USA; [Putukian, Margot] Princeton Univ, Princeton, NJ 08544 USA; [Higgins, Michael] Univ Virginia, Charlottesville, VA USA	Caswell, SV (corresponding author), George Mason Univ, SMART Lab, Sports Med Assessment Res & Testing, 10900 Univ Blvd,MS4E5, Manassas, VA 20110 USA.	scaswell@gmu.edu	Kelshaw, Patricia/AAC-7220-2021	/0000-0001-8762-3144			[Anonymous], 2013 14 HIGH SCH ATH; ASTM International, F313715 ASTM; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Belanger HG, 2016, J HEAD TRAUMA REHAB, V31, P159, DOI 10.1097/HTR.0000000000000138; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Brennan JH, 2017, SPORTS MED, V47, P469, DOI 10.1007/s40279-016-0582-1; Carter EA, 2010, INT J INJ CONTROL SA, V17, P111, DOI 10.1080/17457300903524888; Caswell SV, 2012, AM J SPORT MED, V40, P756, DOI 10.1177/0363546512436647; Clark JM, 2016, AM J SPORT MED, V44, P1047, DOI 10.1177/0363546515623272; Cortes N, 2017, AM J SPORT MED, V45, P2379, DOI 10.1177/0363546517706703; Crisco JJ, 2015, J APPL BIOMECH, V31, P122, DOI [10.1123/jab.2014-0102, 10.1123/JAB.2014-0102]; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; De Lench B, ASTM STANDARD WOMENS; Diamond PT, 2001, BRAIN INJURY, V15, P537, DOI 10.1080/02699050010007362; Dick R, 2007, J ATHL TRAINING, V42, P262; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hall C, 2013, RES SPORTS MED, V21, P229, DOI 10.1080/15438627.2013.792085; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; Lincoln AE, 2007, AM J SPORT MED, V35, P207, DOI 10.1177/0363546506293900; Lincoln AE, 2012, AM J SPORT MED, V40, P611, DOI 10.1177/0363546511428873; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; Mihalik JP, 2012, ANN BIOMED ENG, V40, P141, DOI 10.1007/s10439-011-0405-3; Mihalik JP, 2011, CLIN J SPORT MED, V21, P416, DOI 10.1097/JSM.0B013E31822C8A5C; Miyashita T., 2016, ATHL TRAIN SPORTS HL, V8, P202, DOI DOI 10.3928/19425864-20160503-01; Morse JD, 2014, ANN BIOMED ENG, V42, P2501, DOI 10.1007/s10439-014-1091-8; O'Connor KL, 2017, J ATHL TRAINING, V52, P206, DOI 10.4085/1062-6050.52.2.05; Otago L, 2007, Int J Inj Contr Saf Promot, V14, P259, DOI 10.1080/17457300701602381; Press JN, 2017, CLIN J SPORT MED, V27, P104, DOI 10.1097/JSM.0000000000000313; Reed N, 2010, INT J SPORTS MED, V31, P826, DOI 10.1055/s-0030-1263103; Reynolds BB, 2016, AM J SPORT MED, V44, P2947, DOI 10.1177/0363546516648442; Rodowicz KA, 2015, ANN BIOMED ENG, V43, P949, DOI 10.1007/s10439-014-1154-x; Siegmund GP, 2016, ANN BIOMED ENG, V44, P1257, DOI 10.1007/s10439-015-1420-6; Svaldi DO, 2017, BRAIN IMAGING BEHAV, V11, P98, DOI 10.1007/s11682-016-9509-6; US Lacrosse, 2016 WOM RUL; Xiang J, 2014, AM J SPORT MED, V42, P2082, DOI 10.1177/0363546514539914	39	14	14	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	DEC	2017	45	14					3374	3381		10.1177/0363546517724754			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	FO4OH	WOS:000416823600023	28918649				2021-06-18	
J	Gu, F; Parada, I; Shen, F; Li, J; Bacci, A; Graber, K; Taghavi, RM; Scalise, K; Schwartzkroin, P; Wenzel, J; Prince, DA				Gu, Feng; Parada, Isabel; Shen, Fran; Li, Judith; Bacci, Alberto; Graber, Kevin; Taghavi, Reza Moein; Scalise, Karina; Schwartzkroin, Philip; Wenzel, Jurgen; Prince, David A.			Structural alterations in fast-spiking GABAergic interneurons in a model of posttraumatic neocortical epileptogenesis	NEUROBIOLOGY OF DISEASE			English	Article						Epilepsy; Parvalbumin; Axonal boutons; BDNF; TrkB; Trophic; GABA; Traumatic injury; Inhibitory synapses	TEMPORAL-LOBE EPILEPSY; V PYRAMIDAL NEURONS; ACTIVITY-DEPENDENT REGULATION; CAT VISUAL-CORTEX; NEUROTROPHIC FACTOR; LAYER-V; IN-VIVO; FUNCTIONAL ALTERATIONS; SYNAPTIC CONNECTIVITY; CORTICOSPINAL NEURONS	Electrophysiological experiments in the partial cortical isolation ("undercut" or "UC") model of injury-induced neocortical epileptogenesis have shown alterations in GABAergic synaptic transmission attributable to abnormalities in presynaptic terminals. To determine whether the decreased inhibition was associated with structural abnormalities in GABAergic interneurons, we used immunocytochemical techniques, confocal microscopy and EM in UC and control sensorimotor rat cortex to analyze structural alterations in fast-spiking parvalbumin-containing interneurons and pyramidal (Pyr) cells of layer V. Principle findings were: 1) there were no decreases in counts of parvalbumin (PV)- or GABA-immunoreactive interneurons in UC cortex, however there were significant reductions in expression of VGAT and GAD-65 and-67 in halos of GABAergic terminals around Pyr somata in layer V. 2) Consistent with previous results, somatic size and density of Pyr cells was decreased in infragranular layers of UC cortex. 3) Dendrites of biocytin-filled FS interneurons were significantly decreased in volume. 4) There were decreases in the size and VGAT content of GABAergic boutons in axons of biocytin-filled FS cells in the UC, together with a decrease in colocalization with postsynaptic gephyrin, suggesting a reduction in GABAergic synapses. Quantitative EM of layer V Pyr somata confirmed the reduction in inhibitory synapses. 5) There were marked and lasting reductions in brain derived neurotrophic factor (BDNF)-IR and-mRNA in Pyr cells and decreased TrkB-IR on PV cells in UC cortex. 6) Results lead to the hypothesis that reduction in trophic support by BDNF derived from Pyr cells may contribute to the regressive changes in axonal terminals and dendrites of FS cells in the UC cortex and decreased GABAergic inhibition. Significance: Injury to cortical structures is a major cause of epilepsy, accounting for about 20% of cases in the general population, with an incidence as high as-50% among brain-injured personnel in wartime. Loss of GABAergic inhibitory intemeurons is a significant pathophysiological factor associated with epileptogenesis following brain trauma and other etiologies. Results of these experiments show that the largest population of cortical interneurons, the parvalbumin-containing fast-spiking (FS) interneurons, are preserved in the partial neocortical isolation model of partial epilepsy. However, axonal terminals of these cells are structurally abnormal, have decreased content of GABA synthetic enzymes and vesicular GABA transporter and make fewer synapses onto pyramidal neurons. These structural abnormalities underlie defects in GABAergic neurotransmission that are a key pathophysiological factor in epileptogenesis found in electrophysiological experiments. BDNF, and its TrkB receptor, key factors for maintenance of interneurons and pyramidal neurons, are decreased in the injured cortex. Results suggest that supplying BDNF to the injured epileptogenic brain may reverse the structural and functional abnormalities in the parvalbumin FS interneurons and provide an antiepileptogenic therapy. (C) 2017 Elsevier Inc. All rights reserved.	[Gu, Feng; Parada, Isabel; Shen, Fran; Li, Judith; Graber, Kevin; Taghavi, Reza Moein; Scalise, Karina; Prince, David A.] Stanford Univ, Sch Med, Epilepsy Res Labs, Stanford, CA 94305 USA; [Bacci, Alberto] ICM Hop Pitie Salpetriere, 7 Bd Hop, F-75013 Paris, France; [Schwartzkroin, Philip; Wenzel, Jurgen] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA	Prince, DA (corresponding author), Stanford Univ, Sch Med, Epilepsy Res Labs, Stanford, CA 94305 USA.	daprince@stanford.edu		Bacci, Alberto/0000-0002-3355-5892; Moein Taghavi, Reza/0000-0001-7583-9079	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS06477, NS12151, NS39579]; Edward and Irene Thiele Pimley Research Fund; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS006477, R56NS039579, P50NS012151, R01NS039579, P01NS012151] Funding Source: NIH RePORTER	Supported by Grants NS06477; NS12151; NS39579 from the NINDS (DAP) and the Edward and Irene Thiele Pimley Research Fund.	ALCANTARA S, 1993, ANAT EMBRYOL, V188, P63; Avramescu S, 2009, J NEUROTRAUM, V26, P799, DOI 10.1089/neu.2008.0739; Bacci A, 2003, J NEUROSCI, V23, P9664; Bausch SB, 2005, EPILEPSY BEHAV, V7, P390, DOI 10.1016/j.yebeh.2005.07.019; Beierlein M, 2003, J NEUROPHYSIOL, V90, P2987, DOI 10.1152/jn.00283.2003; Berg A, 2012, EXP NEUROL, V237, P8, DOI 10.1016/j.expneurol.2012.06.008; Bergami M, 2013, J NEUROSCI, V33, P11464, DOI 10.1523/JNEUROSCI.4812-12.2013; BERGMANN M, 1991, NEUROSCIENCE, V42, P569, DOI 10.1016/0306-4522(91)90399-9; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; Brock JH, 2010, J NEUROSCI, V30, P9728, DOI 10.1523/JNEUROSCI.1924-10.2010; Buckmaster PS, 2016, J NEUROSCI, V36, P3295, DOI 10.1523/JNEUROSCI.4049-15.2016; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Chattopadhyaya B, 2004, J NEUROSCI, V24, P9598, DOI 10.1523/JNEUROSCI.1851-04.2004; Chattopadhyaya B, 2007, NEURON, V54, P889, DOI 10.1016/j.neuron.2007.05.015; Chaudhry FA, 1998, J NEUROSCI, V18, P9733; Chauvette S, 2016, J NEUROSCI METH, V260, P185, DOI 10.1016/j.jneumeth.2015.08.030; CHEN DH, 1978, J COMP NEUROL, V177, P635, DOI 10.1002/cne.901770407; Chen HX, 2003, J NEUROPHYSIOL, V89, P150, DOI 10.1152/jn.00325.2002; Chen ZH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5486; Chu Y, 2009, NEUROSCIENCE, V162, P339, DOI 10.1016/j.neuroscience.2009.04.003; De Gois S, 2005, J NEUROSCI, V25, P7121, DOI 10.1523/JNEUROSCI.5221-04.2005; DeFelipe J, 1999, BRAIN, V122, P1807, DOI 10.1093/brain/122.10.1807; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; DELGADOGARCIA JM, 1988, NEUROSCIENCE, V24, P143, DOI 10.1016/0306-4522(88)90319-3; Elmariah SB, 2004, J NEUROSCI, V24, P2380, DOI 10.1523/JNEUROSCI.4112-03.2004; Faria LC, 2012, NEUROBIOL DIS, V45, P821, DOI 10.1016/j.nbd.2011.11.006; Faria LC, 2010, J NEUROPHYSIOL, V104, P280, DOI 10.1152/jn.00351.2010; Galarreta M, 1999, NATURE, V402, P72; Georgiev D, 2016, SCHIZOPHRENIA BULL, V42, P992, DOI 10.1093/schbul/sbw022; Gibson JR, 1999, NATURE, V402, P75; Giehl KM, 1998, J NEUROSCI, V18, P7351; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; Graber KD, 2006, MODELS OF SEIZURES AND EPILEPSY, P477, DOI 10.1016/B978-012088554-1/50040-2; GRUNER JE, 1974, J COMP NEUROL, V154, P1, DOI 10.1002/cne.901540102; Hanno-Iijima Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134296; HARRIS KM, 1995, NEUROPHARMACOLOGY, V34, P1387, DOI 10.1016/0028-3908(95)00142-S; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762; Hong EJ, 2008, NEURON, V60, P610, DOI 10.1016/j.neuron.2008.09.024; Houser CR, 2014, ADV EXP MED BIOL, V813, P151, DOI 10.1007/978-94-017-8914-1_12; HOUSER CR, 1986, BRAIN RES, V383, P129, DOI 10.1016/0006-8993(86)90014-4; Houser CR, 1996, EPILEPSY RES, V26, P207, DOI 10.1016/S0920-1211(96)00054-X; Jiao YY, 2006, J NEUROSCI, V26, P8691, DOI 10.1523/JNEUROSCI.2478-06.2006; Jiao YY, 2011, P NATL ACAD SCI USA, V108, P12131, DOI 10.1073/pnas.1105296108; Jin X, 2003, J NEUROSCI, V23, P5662; Jin XM, 2014, J NEUROPHYSIOL, V112, P1703, DOI 10.1152/jn.00854.2013; Jin XM, 2011, CEREB CORTEX, V21, P1094, DOI 10.1093/cercor/bhq181; Jin XM, 2006, J NEUROSCI, V26, P4891, DOI 10.1523/JNEUROSCI.4361-05.2006; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Kohara K, 2007, J NEUROSCI, V27, P7234, DOI 10.1523/JNEUROSCI.1943-07.2007; Kron M, 2014, DIS MODEL MECH, V7, P1047, DOI 10.1242/dmm.016030; Kumar SS, 2006, J NEUROSCI, V26, P4613, DOI 10.1523/JNEUROSCI.0064-06.2006; KUNO M, 1970, J PHYSIOL-LONDON, V210, P823, DOI 10.1113/jphysiol.1970.sp009244; Li HF, 2002, J NEUROPHYSIOL, V88, P2, DOI 10.1152/jn.00507.2001; Li HF, 2012, NEUROBIOL DIS, V48, P429, DOI 10.1016/j.nbd.2012.06.019; Lin YX, 2008, NATURE, V455, P1198, DOI 10.1038/nature07319; Ma YY, 2012, NEUROBIOL DIS, V47, P102, DOI 10.1016/j.nbd.2012.03.027; Magloczky Z, 2005, TRENDS NEUROSCI, V28, P334, DOI 10.1016/j.tins.2005.04.002; Marco P, 1996, BRAIN, V119, P1327, DOI 10.1093/brain/119.4.1327; Marty S, 1996, J NEUROSCI, V16, P675; Massa SM, 2010, J CLIN INVEST, V120, P1774, DOI 10.1172/JCI41356; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nita DA, 2007, CEREB CORTEX, V17, P272, DOI 10.1093/cercor/bhj145; Peng ZC, 2013, J NEUROSCI, V33, P14392, DOI 10.1523/JNEUROSCI.2045-13.2013; PIERCE JP, 1994, NEUROSCIENCE, V58, P441, DOI 10.1016/0306-4522(94)90071-X; Ping XJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158231; Ping XJ, 2016, J NEUROTRAUM, V33, P354, DOI 10.1089/neu.2015.3913; Prince D. A., 2012, JASPERS BASIC MECH E, V4, P315; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; RIBAK CE, 1982, J NEUROSCI, V2, P1725; RIBAK CE, 1982, CAN J PHYSIOL PHARM, V60, P864, DOI 10.1139/y82-122; RIBAK CE, 1985, BRAIN RES, V326, P251, DOI 10.1016/0006-8993(85)90034-4; Rosen GD, 1998, CEREB CORTEX, V8, P753, DOI 10.1093/cercor/8.8.753; Rutherford LC, 1997, J NEUROSCI, V17, P4527; Sakata K, 2009, P NATL ACAD SCI USA, V106, P5942, DOI 10.1073/pnas.0811431106; Salin P, 1995, J NEUROSCI, V15, P8234; Schmid DA, 2012, J NEUROSCI, V32, P1803, DOI 10.1523/JNEUROSCI.0865-11.2012; SHARPLESS SK, 1962, ELECTROEN CLIN NEURO, V14, P244, DOI 10.1016/0013-4694(62)90034-2; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; Snapyan M, 2009, J NEUROSCI, V29, P4172, DOI 10.1523/JNEUROSCI.4956-08.2009; Takahashi DK, 2016, NEUROBIOL DIS, V91, P166, DOI 10.1016/j.nbd.2016.03.003; TAKATA M, 1981, BRAIN RES, V224, P165, DOI 10.1016/0006-8993(81)91127-6; Tamas G, 1997, J NEUROSCI, V17, P6352; Tamas G, 1997, J PHYSIOL-LONDON, V500, P715, DOI 10.1113/jphysiol.1997.sp022054; Timofeev I, 2010, NEUROSCIENTIST, V16, P19, DOI 10.1177/1073858409333545; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; Tseng GF, 1996, J NEUROPHYSIOL, V75, P248; Uematsu M, 2008, CEREB CORTEX, V18, P315, DOI 10.1093/cercor/bhm056; Villa KL, 2016, NEURON, V90, P662, DOI 10.1016/j.neuron.2016.03.035; Wenzel HJ, 2001, J NEUROSCI, V21, P983; Wyeth MS, 2010, J NEUROSCI, V30, P8993, DOI 10.1523/JNEUROSCI.1183-10.2010; Xiang ZX, 2002, J NEUROPHYSIOL, V88, P740, DOI 10.1152/jn.2002.88.2.740; Xiang ZX, 1998, J PHYSIOL-LONDON, V506, P715, DOI 10.1111/j.1469-7793.1998.715bv.x; Yamada J, 2011, NEUROSCIENCE, V182, P1, DOI 10.1016/j.neuroscience.2011.03.030	95	14	16	1	18	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	DEC	2017	108						100	114		10.1016/j.nbd.2017.08.008			15	Neurosciences	Neurosciences & Neurology	FM1GU	WOS:000414723000009	28823934	Green Accepted			2021-06-18	
J	Howell, DR; Brilliant, A; Berkstresser, B; Wang, F; Fraser, J; Meehan, WP				Howell, David R.; Brilliant, Anna; Berkstresser, Brant; Wang, Francis; Fraser, Joana; Meehan, William P., III			The Association between Dual-Task Gait after Concussion and Prolonged Symptom Duration	JOURNAL OF NEUROTRAUMA			English	Article						attention; mild traumatic brain injury; postural balance; sports; symptoms	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; EXECUTIVE FUNCTION; BALANCE CONTROL; HIGH-SCHOOL; POSTCONCUSSION SYNDROME; HOCKEY PLAYERS; RECOVERY; ADOLESCENTS; PREDICTORS	Quantitative gait measurements can identify persistent postconcussion impairments. However, their prognostic utility after injury to identify the likelihood of prolonged concussion symptoms remains unknown. Our objective was to examine if dual-task gait performance measures are independently associated with persistent (> 28 days) concussion symptoms among a sample of athletes. Sixty individuals diagnosed with a sport-related concussion were assessed within 10 days of their injury. Each participant completed a postconcussion symptom scale, an injury history questionnaire, and a single/dual-task gait examination. They were followed until they no longer reported symptoms, and the duration of time required for symptom resolution was calculated. A binary multivariable logistic regression model determined the independent association between dual-task gait and symptom duration (<= 28 days vs. >28 days) while controlling for the effect of gender, age, symptom severity, injury-to-examination time, and history of concussion. Seventeen (28%) participants reported a symptom duration > 28 days. The dual-task cost for average gait speed (-25.9 +/- 9.5% vs. -19.8 +/- 8.9%; p = 0.027) and cadence (-18.0 +/- 2.9% vs. -12.0 +/- 7.7%; p = 0.029) was significantly greater among participants who experienced symptoms for > 28 days. After adjusting for potential confounding variables, greater dual-task average gait speed costs were independently associated with prolonged symptom duration (aOR = 0.908; 95% CI = 0.835-0.987). Examinations of dual-task gait may provide useful information during multifaceted concussion examinations. Quantitative assessments that simultaneously test multiple domains, such as dual tasks, may be clinically valuable after a concussion to identify those more likely to experience symptoms for >28 days after injury.	[Howell, David R.] Univ Colorado, Sch Med, Childrens Hosp Colorado, Sports Med Ctr, Aurora, CO 80045 USA; [Howell, David R.; Brilliant, Anna; Fraser, Joana; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Howell, David R.; Brilliant, Anna; Fraser, Joana; Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, Dept Orthopaed, Boston, MA USA; [Berkstresser, Brant; Wang, Francis] Harvard Univ, Hlth Serv, Cambridge, MA 02138 USA; [Meehan, William P., III] Harvard Med Sch, Dept Pediat, Boston, MA USA; [Meehan, William P., III] Harvard Med Sch, Dept Orthopaed Surg, Boston, MA USA	Howell, DR (corresponding author), Univ Colorado, Sch Med, Colorado Childrens Hosp, Dept Orthopaed,Sports Med Ctr, 13123 E 16th Ave,B060, Aurora, CO 80045 USA.	David.Howell@ucdenver.edu			ElMinda Ltd.; National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament; Football Players Health Study at Harvard University - NFL Players Association	This research was funded, in part, by ElMinda Ltd. Dr. Howell and Ms. Brilliant received research support from ElMinda Ltd. Dr. Meehan receives royalties from (1) ABC-Clio publishing for the sale of his books, Kids, Sports, and Concussion: A Guide for Coaches and Parents, and Concussions; (2) Springer International for the book Head and Neck Injuries in the Young Athlete; and (3) Wolters Kluwer for working as an author for UpToDate. His research is funded, in part, by philanthropic support from the National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament and by a grant from the Football Players Health Study at Harvard University, which is funded by the NFL Players Association. The remaining authors have no disclosures related to this study.	Al-Yahya E, 2011, NEUROSCI BIOBEHAV R, V35, P715, DOI 10.1016/j.neubiorev.2010.08.008; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Benedict PA, 2015, J NEUROL SCI, V353, P111, DOI 10.1016/j.jns.2015.04.029; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Cossette I, 2016, BRAIN INJURY, V30, P1648, DOI 10.1080/02699052.2016.1200143; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Fino PC, 2016, J BIOMECH, V49, P1983, DOI 10.1016/j.jbiomech.2016.05.004; Gordon KE, 2006, BRIT J SPORT MED, V40, P184, DOI 10.1136/bjsm.2005.022251; Heyer GL, 2016, J PEDIATR-US, V174, P33, DOI 10.1016/j.jpeds.2016.03.014; Howel DR, 2017, J APPL BIOMECH, V33, P24, DOI 10.1123/jab.2015-0323; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2017, GAIT POSTURE, V54, P284, DOI 10.1016/j.gaitpost.2017.03.034; Howell DR, 2017, J NEUROTRAUM, V34, P838, DOI 10.1089/neu.2016.4609; Howell DR, 2016, ACTA PAEDIATR, V105, pE426, DOI 10.1111/apa.13486; Howell DR, 2016, AM J SPORT MED, V44, P1040, DOI 10.1177/0363546515625045; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kriz PK, 2016, J PEDIATR-US, V171, P234, DOI 10.1016/j.jpeds.2015.12.006; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lax ID, 2015, BRAIN INJURY, V29, P1409, DOI 10.3109/02699052.2015.1043344; Mancini Martina, 2011, J Bioeng Biomed Sci, VSuppl 1, P007; Mannix R, 2014, ANN CLIN TRANSL NEUR, V1, P433, DOI 10.1002/acn3.70; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2017, BR J SPORTS MED; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Meehan WP, 2016, J SCI MED SPORT, V19, P722, DOI 10.1016/j.jsams.2015.12.002; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Mihalik JP, 2013, AM J SPORT MED, V41, P1490, DOI 10.1177/0363546513487982; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Nishiguchi S, 2012, TELEMED E-HEALTH, V18, P292, DOI 10.1089/tmj.2011.0132; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Plummer P, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00225; Resch JE, 2015, J ATHL TRAINING, V50, P1292, DOI 10.4085/1062-6050-50.12.03; Sambasivan K, 2015, J PEDIATR REHAB MED, V8, P335, DOI 10.3233/PRM-150351; Sufrinko AM, 2017, AM J SPORT MED, V45, P1187, DOI 10.1177/0363546516685061; Tator CH, 2016, J NEUROSURG, V125, P1206, DOI 10.3171/2015.6.JNS15664; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	50	14	14	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2017	34	23					3288	3294		10.1089/neu.2017.5191			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FN9HM	WOS:000416341700010	28895490				2021-06-18	
J	Kornguth, S; Rutledge, N; Perlaza, G; Bray, J; Hardin, A				Kornguth, Steven; Rutledge, Neal; Perlaza, Gabe; Bray, James; Hardin, Allen			A Proposed Mechanism for Development of CTE Following Concussive Events: Head Impact, Water Hammer Injury, Neurofilament Release, and Autoimmune Processes	BRAIN SCIENCES			English	Article						chronic traumatic encephalopathy; brain structure and function; concussion; water hammer effect; neurofilament release from brain; autoimmune disease	TRAUMATIC BRAIN-INJURY; LIGHT PROTEIN; FOOTBALL; CATS; ANTINEUROFILAMENT; ENCEPHALOPATHY; MINOCYCLINE; ANTIBODIES; INDUCTION; SYMPTOMS	During the past decade, there has been an increasing interest in early diagnosis and treatment of traumatic brain injuries (TBI) that lead to chronic traumatic encephalopathy (CTE). The subjects involved range from soldiers exposed to concussive injuries from improvised explosive devices (IEDs) to a significant number of athletes involved in repetitive high force impacts. Although the forces from IEDs are much greater by a magnitude than those from contact sports, the higher frequency associated with contact sports allows for more controlled assessment of the mechanism of action. In our study, we report findings in university-level women soccer athletes followed over a period of four and a half years from accession to graduation. Parameters investigated included T1-, T2-, and susceptibility-weighted magnetic resonance images (SWI), IMPACT (Immediate Post-Concussion Assessment and Cognitive Testing), and C3 Logix behavioral and physiological assessment measures. The MRI Studies show several significant findings: first, a marked increase in the width of sulci in the frontal to occipital cortices; second, an appearance of subtle hemorrhagic changes at the base of the sulci; third was a sustained reduction in total brain volume in several soccer players at a developmental time when brain growth is generally seen. Although all of the athletes successfully completed their college degree and none exhibited long term clinical deficits at the time of graduation, the changes documented by MRI represent a clue to the pathological mechanism following an injury paradigm. The authors propose that our findings and those of prior publications support a mechanism of injury in CTE caused by an autoimmune process associated with the release of neural proteins from nerve cells at the base of the sulcus from a water hammer injury effect. As evidence accumulates to support this hypothesis, there are pharmacological treatment strategies that may be able to mitigate the development of long-term disability from TBI.	[Kornguth, Steven] Univ Texas Austin, Dept Kinesiol & Hlth Educ, Austin, TX 78712 USA; [Kornguth, Steven] Univ Texas Austin, Dept Neurol, Dell Med Sch, Austin, TX 78712 USA; [Rutledge, Neal] Austin Radiol Assoc, Res Imaging Ctr, Austin, TX 78705 USA; [Perlaza, Gabe; Bray, James; Hardin, Allen] Univ Texas Austin, Dept Intercollegiate Athlet, Austin, TX 78712 USA; [Bray, James] Univ Texas Austin, Dept Populat Hlth, Austin, TX 78712 USA	Kornguth, S (corresponding author), Univ Texas Austin, Dept Kinesiol & Hlth Educ, Austin, TX 78712 USA.; Kornguth, S (corresponding author), Univ Texas Austin, Dept Neurol, Dell Med Sch, Austin, TX 78712 USA.	steve_kornguth@utexas.edu; nrutledge@austin.rr.com; gabe.perlaza@athletics.utexas.edu; james.bray@athletics.utexas.edu; allen.hardin@athletics.utexas.edu					Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Babbs C F, 2001, ScientificWorldJournal, V1, P281; Bargerstock E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101477; BELL CL, 1991, ARTHRITIS RHEUM, V34, P432, DOI 10.1002/art.1780340408; Bernick C., 2017, P AM AC NEUR SPORTS; Budday S, 2015, J MECH BEHAV BIOMED, V46, P318, DOI 10.1016/j.jmbbm.2015.02.024; Byrne LM, 2017, LANCET NEUROL, V16, P601, DOI 10.1016/S1474-4422(17)30124-2; Centers for Disease Control and Prevention, 2011, MMWR-MORBID MORTAL W, V60, P1137; CRABTREE JW, 1986, J NEUROSCI, V6, P1199; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Deshpande SK, 2017, JAMA NEUROL, V74, P909, DOI 10.1001/jamaneurol.2017.1317; Dretsch MN, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.392; Elewa HF, 2006, PHARMACOTHERAPY, V26, P515, DOI 10.1592/phco.26.4.515; Fagan SC, 2010, STROKE, V41, P2283, DOI 10.1161/STROKEAHA.110.582601; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Ghidaoui M. S., 2005, Applied Mechanics Review, V58, P49, DOI 10.1115/1.1828050; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; GRUNWALD GB, 1985, LANCET, V1, P658; Hedman AM, 2012, HUM BRAIN MAPP, V33, P1987, DOI 10.1002/hbm.21334; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Institute of Medicine, 2011, COGN REH THER TRAUM; Jarrett M, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00011; Joy J. E., 2002, IS SOCCER BAD CHILDR; Kantarci OH, 2008, ARCH NEUROL-CHICAGO, V65, P349, DOI 10.1001/archneurol.2007.66; Kochanek PM, 1998, SEMIN CLIN NEUROPSYC, P176; KORNGUTH S, 1991, BIOCHEM BIOPH RES CO, V179, P102, DOI 10.1016/0006-291X(91)91340-I; KORNGUTH S, 1995, SCIENCE, V270, P720; KORNGUTH SE, 1986, CANCER RES, V46, P2588; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Mansell JL, 2010, BRAIN INJURY, V24, P1070, DOI 10.3109/02699052.2010.494589; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McCluskey LP, 2000, J NEUROPATH EXP NEUR, V59, P177, DOI 10.1093/jnen/59.3.177; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Neselius S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081249; Neumann H, 1997, J EXP MED, V185, P305, DOI 10.1084/jem.185.2.305; NEUMANN H, 1995, SCIENCE, V269, P549, DOI 10.1126/science.7624779; Neumann H, 1996, EUR J NEUROSCI, V8, P2582, DOI 10.1111/j.1460-9568.1996.tb01552.x; Nizamutdinov D, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7010011; Oliver JM, 2016, J NEUROTRAUM, V33, P1784, DOI 10.1089/neu.2015.4295; Ottum PA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00539; Poldrack RA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9885; Puvenna V, 2016, BRAIN RES, V1630, P225, DOI 10.1016/j.brainres.2015.11.007; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; ROBBINS ML, 1988, ARTHRITIS RHEUM, V31, P623, DOI 10.1002/art.1780310507; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Rubenstein R, 2017, JAMA NEUROL, V74, P1063, DOI 10.1001/jamaneurol.2017.0655; Seifert HA, 2014, J NEUROIMMUNE PHARM, V9, P679, DOI 10.1007/s11481-014-9560-2; Shahim P, 2016, JAMA NEUROL, V73, P1308, DOI 10.1001/jamaneurol.2016.2038; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Sironi L., 2003, THROMB VASC BIOL, V23, P322, DOI [10.1161/01.ATV.0000044458.23905.3B12588778, DOI 10.1161/01.ATV.0000044458.23905.3B12588778]; SPEAR PD, 1986, BRAIN RES, V368, P154, DOI 10.1016/0006-8993(86)91053-X; Turner RC, 2013, INT J MOL SCI, V14, P1890, DOI 10.3390/ijms14011890; Vedantam S., 2015, J NEUROL STROKE, V2, P73, DOI DOI 10.15406/JNSK.2015.02.00073; Wang KKW, 2016, J NEUROTRAUM, V33, P1270, DOI 10.1089/neu.2015.3881; WILLIAMS RW, 1985, BRAIN RES, V336, P57, DOI 10.1016/0006-8993(85)90415-9; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Yard EE, 2008, AM J SPORT MED, V36, P1930, DOI 10.1177/0363546508318047; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang J., 2016, BIOMARKERS TRAUMATIC; Zhang T. G., 2013, P ASME INT MECH ENG; Zhao Q, 2017, J IMMUNOL, V199, P312, DOI 10.4049/jimmunol.1700171	62	14	14	0	19	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-3425		BRAIN SCI	Brain Sci.	DEC	2017	7	12							164	10.3390/brainsci7120164			15	Neurosciences	Neurosciences & Neurology	FR6PC	WOS:000419187000009	29257064	DOAJ Gold, Green Published			2021-06-18	
J	Lee, SH; Choi, BY; Lee, SH; Kho, AR; Jeong, JH; Hong, DK; Suh, SW				Lee, Sang Hwon; Choi, Bo Young; Lee, Song Hee; Kho, A. Ra; Jeong, Jeong Hyun; Hong, Dae Ki; Suh, Sang Won			Administration of Protocatechuic Acid Reduces Traumatic Brain Injury-Induced Neuronal Death	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						traumatic brain injury; protocatechuic acid; neuron death; oxidative injury; microglial activation	OXIDATIVE STRESS; SUPEROXIDE-PRODUCTION; BARRIER DISRUPTION; LIPID-PEROXIDATION; DAMAGE; GLUTATHIONE; INHIBITION; IMPAIRMENT; RADICALS; RATS	Protocatechuic acid (PCA) was first purified from green tea and has shown numerous biological activities, including anti-apoptotic, anti-inflammatory, and anti-atherosclerotic effects. The effect of PCA on traumatic brain injury (TBI)-induced neuronal death has not previously been evaluated. TBI is defined as damage to the brain resulting from external mechanical force, such as rapid acceleration or deceleration, impact, blast waves, or penetration by a projectile. TBI causes neuronal death in the hippocampus and cerebral cortex. The present study aimed to evaluate the therapeutic potential of PCA on TBI-induced neuronal death. Here, TBI was induced by a controlled cortical impact model using rats. PCA (30 mg/kg) was injected into the intraperitoneal (ip) space immediately after TBI. Neuronal death was evaluated with Fluoro Jade-B (FJB) staining at 24 h after TBI. Oxidative injury was detected by 4-hydroxy-2-nonenal (4HNE), glutathione (GSH) concentration was analyzed by glutathione adduct with N-ethylmaleimide (GS-NEM) staining at 24 h after TBI, and microglial activation in the hippocampus was detected by CD11b immunohistochemistry at one week after TBI. We found that the proportion of degenerating neurons, oxidative injury, GSH depletion, and microglia activation in the hippocampus and cortex were all reduced by PCA treatment following TBI. Therefore, our study suggests that PCA may have therapeutic potential in preventing TBI-induced neuronal death.	[Lee, Sang Hwon; Choi, Bo Young; Lee, Song Hee; Kho, A. Ra; Jeong, Jeong Hyun; Hong, Dae Ki; Suh, Sang Won] Hallym Univ, Coll Med, Dept Physiol, Chunchon 24252, South Korea	Suh, SW (corresponding author), Hallym Univ, Coll Med, Dept Physiol, Chunchon 24252, South Korea.	bluesea3616@naver.com; bychoi@hallym.ac.kr; sshlee@hallym.ac.kr; rnlduadkfk136@hallym.ac.kr; jd1422@hanmail.net; zxnm01220@gmail.com; swsuh@hallym.ac.kr		Choi, Bo Young/0000-0002-9579-3503; Hong, Dae-Ki/0000-0003-3769-3456	National Research Foundation of Korea (NRF)National Research Foundation of Korea [NRF-2017R1C1B1004226]; Brain Research Program through the NRF - Ministry of Science, information and communication technology (ICT), and Future Planning [NRF-2017M3C7A1028937]	This study was supported by the National Research Foundation of Korea (NRF) (NRF-2017R1C1B1004226) to Bo Young Choi. This work was also supported by the Brain Research Program through the NRF funded by the Ministry of Science, information and communication technology (ICT), and Future Planning (NRF-2017M3C7A1028937) to Sang Won Suh.	ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; Bains JS, 1997, BRAIN RES REV, V25, P335, DOI 10.1016/S0165-0173(97)00045-3; Chao CY, 2009, FOODBORNE PATHOG DIS, V6, P201, DOI 10.1089/fpd.2008.0187; CHENG Y, 1994, NEUROCHEM RES, V19, P1557, DOI 10.1007/BF00969006; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Choi BY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102189; Choi BY, 2014, INT J MOL SCI, V15, P19444, DOI 10.3390/ijms151119444; Choi BY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081523; Ciftci O, 2013, TOXICOL IND HEALTH, V29, P806, DOI 10.1177/0748233712442735; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Guan S, 2009, TOXICOL IN VITRO, V23, P201, DOI 10.1016/j.tiv.2008.11.008; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; KIHARA T, 1995, J NEUROCHEM, V65, P282; Klein JA, 2003, J CLIN INVEST, V111, P785, DOI 10.1172/JCI200318182; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Krzysztoforska Kinga, 2019, Nutr Neurosci, V22, P72, DOI 10.1080/1028415X.2017.1354543; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Lee HM, 2017, INT J BIOCHEM CELL B, V90, P81, DOI 10.1016/j.biocel.2017.07.019; Lende Amol B., 2011, Inflammopharmacology, V19, P255, DOI 10.1007/s10787-011-0086-4; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Li CM, 2012, PHARM BIOL, V50, P413, DOI 10.3109/13880209.2011.608193; Li XC, 2012, MOLECULES, V17, P13457, DOI 10.3390/molecules171113457; Liu JZ, 2010, SEIZURE-EUR J EPILEP, V19, P165, DOI 10.1016/j.seizure.2010.01.010; Love S, 1999, BRAIN PATHOL, V9, P119; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Parikh S, 2007, INT ANESTHESIOL CLIN, V45, P119, DOI 10.1097/AIA.0b013e318078cfe7; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; Pompella A, 2003, BIOCHEM PHARMACOL, V66, P1499, DOI 10.1016/S0006-2952(03)00504-5; Scazzocchio B, 2011, DIABETES, V60, P2234, DOI 10.2337/db10-1461; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shi GF, 2006, NEUROSCI LETT, V403, P206, DOI 10.1016/j.neulet.2006.02.057; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Singh P, 2003, NEUROL INDIA, V51, P215; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Suh SW, 2007, J CLIN INVEST, V117, P910, DOI 10.1172/JCI30077; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suh SW, 2003, J NEUROSCI, V23, P10681; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Tang XAN, 2010, J NEUROSCI METH, V190, P240, DOI 10.1016/j.jneumeth.2010.05.004; Wang HY, 2015, NEUROCHEM RES, V40, P1655, DOI 10.1007/s11064-015-1646-6; Wang Z, 2015, NEUROL RES, V37, P159, DOI 10.1179/1743132814Y.0000000421; Wei MM, 2013, INT IMMUNOPHARMACOL, V15, P780, DOI 10.1016/j.intimp.2013.01.010; WINTER AN, 2017, OXID MED CELL LONGEV, V2017, DOI DOI 10.1155/2017/6297080; Yin X, 2015, SCI REP-UK, V5, DOI 10.1038/srep14507; Zhang HN, 2009, BIOL PHARM BULL, V32, P1866, DOI 10.1248/bpb.32.1866	50	14	14	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		1422-0067		INT J MOL SCI	Int. J. Mol. Sci.	DEC	2017	18	12							2510	10.3390/ijms18122510			13	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	FR2KU	WOS:000418896700014	29168791	DOAJ Gold, Green Published			2021-06-18	
J	Mei, ZR; Zheng, PY; Tan, XP; Wang, Y; Situ, B				Mei, Zhengrong; Zheng, Peiying; Tan, Xiangping; Wang, Ying; Situ, Bing			Huperzine A alleviates neuroinflammation, oxidative stress and improves cognitive function after repetitive traumatic brain injury	METABOLIC BRAIN DISEASE			English	Article						Traumatic brain injury; Huperzine A; Nueroprotection; Neuroinflammation; Oxidative stress	AMYLOID PRECURSOR PROTEIN; DEFICITS; EXPRESSION; PATHWAY	Traumatic brain injury (TBI) may trigger secondary injury cascades including endoplasmic reticulum stress, oxidative stress, and neuroinflammation. Unfortunately, there are no effective treatments targeting either primary or secondary injuries that result in long-term detrimental consequences. Huperzine A (HupA) is a potent acetylcholinesterase inhibitor (AChEI) that has been used treatment of Alzheimer's disease (AD). This study aimed to explore the neuroprotective effects of HupA in TBI and its possible mechanisms. Repetitive mild closed head injury (CHI) model was used to mimic concussive TBI. Mice were randomly assigned into three groups including sham, vehicle-treated and HupA-treated injured mice. The HupA was given at dose of 1.0 mg/kg/day and was initiated 30 min after the first injury, then administered daily for a total of 30 days. The neuronal functions including motor functions, emotion-like behaviors, learning and memory were tested. Axonal injury, reactive oxygen species (ROS), and neuroinflammation were examined as well. The results showed that injured mice treated with HupA had significant improvement in Morris water maze performance compared with vehicle-treated injured mice. HupA treatment significantly attenuated markers of neuroinflammation and oxidative stress in the injured mice. Taken together, HupA was effective in reducing neuroinflammation, oxidative stress and behavioral recovery after TBI. HupA is a promising candidate for treatment of TBI.	[Mei, Zhengrong; Zheng, Peiying; Tan, Xiangping; Wang, Ying; Situ, Bing] Guangzhou Med Univ, Affiliated Hosp 3, Dept Pharm, Guangzhou 510150, Guangdong, Peoples R China	Situ, B (corresponding author), Guangzhou Med Univ, Affiliated Hosp 3, Dept Pharm, Guangzhou 510150, Guangdong, Peoples R China.	646133313@qq.com			Guangzhou Education Bureau [1201421151]	This work is supported by a grant from Guangzhou Education Bureau (1201421151).	Acosta SA, 2017, J CELL PHYSIOL, V232, P665, DOI 10.1002/jcp.25629; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Cheng T, 2016, FREE RADICAL BIO MED, V92, P15, DOI 10.1016/j.freeradbiomed.2015.12.027; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Hayes JP, 2017, BRAIN, V140, P813, DOI 10.1093/brain/aww344; Johnson MW, 2011, J FORENSIC SCI, V56, P1198, DOI 10.1111/j.1556-4029.2011.01814.x; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kobeissy FH, 2016, PLOS ONE, V11; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee DJ, 2015, J NEUROTRAUM, V32, P1822, DOI 10.1089/neu.2014.3744; Lin C, 2017, EXP NEUROL, V290, P115, DOI 10.1016/j.expneurol.2017.01.005; Mannix R, 2017, J NEUROTRAUM, V34, P495, DOI 10.1089/neu.2016.4457; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Mao XY, 2016, CELL MOL NEUROBIOL, V36, P915, DOI 10.1007/s10571-015-0276-5; Mei ZR, 2018, BEHAV BRAIN RES, V340, P195, DOI 10.1016/j.bbr.2017.04.017; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Ruan QW, 2013, MECH AGEING DEV, V134, P89, DOI 10.1016/j.mad.2012.12.005; Scherer RW, 2013, PLOS ONE, V8; Schumann J, 2008, J NEUROTRAUM, V25, P945, DOI 10.1089/neu.2008.0521; Shu LF, 2016, NEUROSCI LETT, V611, P74, DOI 10.1016/j.neulet.2015.11.012; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Tabas I, 2013, SCIENCE, V339, P166, DOI 10.1126/science.1230720; Tu TM, 2017, ANN CLIN TRANSL NEUR, V4, P246, DOI 10.1002/acn3.399; Velosky AG, 2017, BEHAV BRAIN RES, V324, P115, DOI 10.1016/j.bbr.2017.02.017; Wang CY, 2011, NEUROPSYCHOPHARMACOL, V36, P1073, DOI 10.1038/npp.2010.245; Wang Y, 2012, J NEUROSCI RES, V90, P508, DOI 10.1002/jnr.22775; Wheaton P, 2011, J CLIN PSYCHOPHARM, V31, P745, DOI 10.1097/JCP.0b013e318235f4ac; Yang L, 2017, METAB BRAIN DIS, V32, P1395, DOI 10.1007/s11011-017-9991-6; Zhu D, 2015, PLOS ONE, V10	30	14	14	0	18	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0885-7490	1573-7365		METAB BRAIN DIS	Metab. Brain Dis.	DEC	2017	32	6					1861	1869		10.1007/s11011-017-0075-4			9	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	FM7CC	WOS:000415225800010	28748496				2021-06-18	
J	O'Connor, S; Warrington, G; McGoldrick, A; Cullen, S				O'Connor, Siobhan; Warrington, Giles; McGoldrick, Adrian; Cullen, SarahJane			Epidemiology of Injury Due to Race-Day Jockey Falls in Professional Flat and Jump Horse Racing in Ireland, 2011-2015	JOURNAL OF ATHLETIC TRAINING			English	Article						National Hunt; injury incidence; injury rate; high-risk sport; concussions; head injury; fractures; bone	GREAT-BRITAIN; BONE HEALTH; AUSTRALIA; INDUSTRY; CONSENSUS; FRANCE	Context: Professional horse racing is considered a high-risk sport, yet the last analysis of fall and injury incidence in this sport in Ireland was completed between 1999 and 2006. Objective: To provide an updated analysis of the fall and injury incidence in professional flat and jump horse racing in Ireland from 2011 through 2015, compare it with the previous analysis, and detail the specific types and locations of injuries. Design: Descriptive epidemiology study. Setting: A medical doctor recorded all injuries that occurred at every official flat and jump race meeting for the 2011 through 2015 seasons using standardized injury-report forms. Main Outcome Measure(s): Injury and fall rates and their 95% confidence intervals (CIs) were reported for flat and jump racing. Incidence rate ratios and 95% CIs were calculated between flat and jump racing, between the 1999-2006 analysis and the current results, and between 2011 and 2015. The distribution of injuries for type and location of injury was reported. Results: Compared with flat racing, jump racing had significantly more falls per 1000 rides (49.5 versus 3.8), injuries per 1000 rides (10.1 versus 1.4), and injuries per 1000 meetings 776.0 versus 94.1). However, the rate of injuries per 1000 falls was significantly higher in flat racing (352.8 versus 203.8). An increase in injuries per 1000 falls between 2011 and 2015 was found in flat racing (P = .005). Since the previous analysis, a significant increase in injuries per 1000 rides and falls was noted in jump racing. Soft tissue injuries were predominant in flat and jump racing (61.54% and 68.80%, respectively), with fractures the second most common injury (15.38% and 18.06%, respectively). Concussions were more prevalent from flat-racing falls (incidence rate ratio = 0.30; 95% CI = 0.15, 0.61). The lower limb was the most frequent location of injury (32.89%) in flat racing; however, in jump racing, upper limb injuries (34.97%) were predominant. Conclusions: An update on professional flat-and jumpracing fall and injury epidemiology is provided. Further research to identify risk factors for injury, design and investigate the feasibility of injury-prevention strategies, and document their effects on fall and injury incidence is required.	[O'Connor, Siobhan] Dublin City Univ, Sch Hlth & Human Performance, Dublin 9, Ireland; [Warrington, Giles] Univ Limerick, Dept Phys Educ & Sport Sci, Limerick, Ireland; [McGoldrick, Adrian] Turf Club, Curragh, Kildare, Ireland; [Cullen, SarahJane] Waterford Inst Technol, Dept Hlth Sport & Exercise Sci, Waterford, Ireland	O'Connor, S (corresponding author), Dublin City Univ, Sch Hlth & Human Performance, Dublin 9, Ireland.	siobhan.oconnor@dcu.ie	O'Connor, Siobhan/Q-8568-2018	O'Connor, Siobhan/0000-0002-2001-0746; Warrington, Giles/0000-0001-6473-3607	Irish Turf Club	This research was supported by the Irish Turf Club. We acknowledge the support of the Turf Club medical officers who gathered the valuable data at the various race meetings.	Bolwell C, 2014, COMP EXERC PHYSIOL, V10, P49, DOI 10.3920/CEP13036; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Cowley S, 2007, BRIT J SPORT MED, V41, P639, DOI 10.1136/bjsm.2006.032888; Curry BA, 2016, OCCUP MED-OXFORD, V66, P222, DOI 10.1093/occmed/kqv150; Hitchens P, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000142; Hitchens P, 2011, ACCIDENT ANAL PREV, V43, P840, DOI 10.1016/j.aap.2010.11.003; Hitchens PL, 2016, EQUINE VET J, V48, P50, DOI 10.1111/evj.12392; Hitchens PL, 2015, INJURY PREV, V21, P109, DOI 10.1136/injuryprev-2014-041223; Hitchens PL, 2012, INJURY PREV, V18, P385, DOI 10.1136/injuryprev-2011-040255; Hitchens PL, 2009, MED J AUSTRALIA, V190, P83, DOI 10.5694/j.1326-5377.2009.tb02284.x; Hitchens PL, 2010, OCCUP ENVIRON MED, V67, P693, DOI 10.1136/oem.2009.050567; McCrory P, 2006, BRIT J SPORT MED, V40, P614, DOI 10.1136/bjsm.2006.028449; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Rueda MAF, 2010, INJURY, V41, P533, DOI 10.1016/j.injury.2009.05.009; Turner M, 2012, BRIT J SPORT MED, V46, P704, DOI 10.1136/bjsports-2011-090312; Turner M, 2002, BRIT J SPORT MED, V36, P403, DOI 10.1136/bjsm.36.6.403; Walden M, 2005, BRIT J SPORT MED, V39, P542, DOI 10.1136/bjsm.2004.014571; Waller AE, 2000, JAMA-J AM MED ASSOC, V283, P1326, DOI 10.1001/jama.283.10.1326; Warrington G, 2009, J SPORT SCI, V27, P543, DOI 10.1080/02640410802702863; Wilson G, 2013, INT J SPORTS MED, V34, P453, DOI 10.1055/s-0032-1321898; Wilson G, 2014, SPORTS MED, V44, P785, DOI 10.1007/s40279-014-0169-7; Zasa M, 2016, SPORTS ORTHOP TRAUMA, V32, P289	22	14	15	0	8	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	DEC	2017	52	12					1140	1146		10.4085/1062-6050-52.12.17			7	Sport Sciences	Sport Sciences	FR9BQ	WOS:000419368900007	29154693	Bronze, Green Published			2021-06-18	
J	Tetlow, AM; Edwards, JD				Tetlow, Amber M.; Edwards, Jerri D.			Systematic Literature Review and Meta-Analysis of Commercially Available Computerized Cognitive Training Among Older Adults	JOURNAL OF COGNITIVE ENHANCEMENT			English	Article						Aging; Cognitive training; Brain fitness; Brain games		Researchers have explored a variety of interventions to improve cognition among older adults. One of which is computerized cognitive training programs. The number of commercially available, cognitive training programs has increased greatly, but scientists debate their value. The purposes of this systematic literature review and meta-analysis were to (1) evaluate the efficacy of commercially available, computerized cognitive training programs to improve cognition in older adults and (2) examine far transfer of training to untrained tasks relevant to everyday functioning. Articles were reviewed if the study (a) included a sample of adults aged 55 and older, (b) used a commercially available, computerized cognitive training program, (c) was a randomized controlled trial, (d) measured cognition as an outcome, and (e) included a sample that was free from health conditions affecting cognitive function (e.g., cancer, stroke, psychiatric conditions, or traumatic brain injury). Effect sizes were calculated using random effect models to determine cognitive training effects for various cognitive domains and far transfer tasks. There were significant small to medium training effects for the cognitive domains of attention (d = 0.651, p < .001), processing speed (d = 0.294, p = .002), and visuospatial memory (d = 0.252, p = 0.016). There was also evidence of far transfer to self-reported measures of everyday function (d = 0.277, p < 0.001). Commercially available computerized cognitive training programs may improve certain cognitive abilities among older adults, who also report improvement on tasks relevant to their everyday lives.	[Tetlow, Amber M.; Edwards, Jerri D.] Univ S Florida, Sch Aging Studies, 13301 Bruce B Downs Blvd,MHC 1300, Tampa, FL 33612 USA	Tetlow, AM (corresponding author), Univ S Florida, Sch Aging Studies, 13301 Bruce B Downs Blvd,MHC 1300, Tampa, FL 33612 USA.	ambertetlow@mail.usf.edu					ABIKOFF H, 1987, J CLIN EXP NEUROPSYC, V9, P435, DOI 10.1080/01688638708405063; Anderson S, 2013, P NATL ACAD SCI USA, V110, P4357, DOI 10.1073/pnas.1213555110; ARENBERG D, 1978, J GERONTOL, V33, P534, DOI 10.1093/geronj/33.4.534; Axelrod Bradley N, 1992, Clin Neuropsychol, V6, P143, DOI 10.1080/13854049208401851; Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; Ball K, 2007, J GERONTOL B-PSYCHOL, V62, P19, DOI 10.1093/geronb/62.special_issue_1.19; Ballesteros S, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00277; Barnett SM, 2002, PSYCHOL BULL, V128, P612, DOI 10.1037//0033-2909.128.4.612; Berry AS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011537; Berry D.T., 1991, CLIN NEUROPSYCHOL, V5, P143, DOI [10.1080/13854049108403298, DOI 10.1080/13854049108403298, https://doi.org/10.1080/13854049108403298]; Birren J. E., 1979, BRAIN FUNCTION OLD A, P10, DOI [DOI 10.1007/978-3-642-67304-7_3, 10.1007/978-3-642-67304-7_3]; Boman IL, 2004, BRAIN INJURY, V18, P985, DOI 10.1080/02699050410001672396; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Braak H, 2011, J NEUROPATH EXP NEUR, V70, P960, DOI 10.1097/NEN.0b013e318232a379; Brehmer Y., 2012, TRAINING INDUCED COG, V72; Brehmer Y, 2011, NEUROIMAGE, V58, P1110, DOI 10.1016/j.neuroimage.2011.06.079; Bridger RS, 2013, ERGONOMICS, V56, P1515, DOI 10.1080/00140139.2013.821172; Buitenweg JIV, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00183; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Centers for Disease Control and Prevention Trends in aging--United States and worldwide MMWR, 2003, MMWR-MORBID MORTAL W, V52, P101; Chein JM, 2010, PSYCHON B REV, V17, P193, DOI 10.3758/PBR.17.2.193; Cohen J, 1988, STAT POWER ANAL BEHA; Coull JT, 1996, NEUROPSYCHOLOGIA, V34, P1085, DOI 10.1016/0028-3932(96)00029-2; Covinsky KE, 2003, J AM GERIATR SOC, V51, P451, DOI 10.1046/j.1532-5415.2003.51152.x; Deouell LY, 2005, J INT NEUROPSYCH SOC, V11, P697, DOI 10.1017/S13556177050824; Deshpande Prasanna R, 2011, Perspect Clin Res, V2, P137, DOI 10.4103/2229-3485.86879; DIEHL M, 1995, PSYCHOL AGING, V10, P478, DOI 10.1037/0882-7974.10.3.478; Djernes JK, 2006, ACTA PSYCHIAT SCAND, V113, P372, DOI 10.1111/j.1600-0447.2006.00770.x; DUJOVNE BE, 1971, J CLIN PSYCHOL, V27, P351, DOI 10.1002/1097-4679(197107)27:3<351::AID-JCLP2270270313>3.0.CO;2-4; Dulay MF, 2002, CLIN NEUROPSYCHOL, V16, P452, DOI 10.1076/clin.16.4.452.13915; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Edwards J. D., 2013, J GERONTOL B-PSYCHOL; Edwards JD, 2005, J CLIN EXP NEUROPSYC, V27, P529, DOI 10.1080/13803390490515432; Edwards JD, 2005, AGING MENT HEALTH, V9, P262, DOI 10.1080/13607860412331336788; Edwards JD, 2002, GERONTOLOGY, V48, P329, DOI 10.1159/000065259; Ekstrom R.B., 1976, MANUAL KIT FACTOR RE; Emery L, 2007, PSYCHOL AGING, V22, P75, DOI 10.1037/0882-7974.22.1.75; FABRIGOULE C, 1995, J AM GERIATR SOC, V43, P485, DOI 10.1111/j.1532-5415.1995.tb06093.x; File Thom, 2014, COMPUTER INTERNET US; Finn M, 2011, BRAIN IMPAIR, V12, P187; Fowler KS, 2002, J INT NEUROPSYCH SOC, V8, P58, DOI 10.1017/S1355617701020069; Franzen M D, 1987, Arch Clin Neuropsychol, V2, P265, DOI 10.1016/0887-6177(87)90014-X; Gooding AL, 2016, NEUROPSYCHOL REHABIL, V26, P810, DOI 10.1080/09602011.2015.1118389; Greenwood PM, 2016, NEUROPSYCHOLOGY, V30, P742, DOI 10.1037/neu0000235; Groth-Marnat G, 2000, PERCEPT MOTOR SKILL, V90, P522, DOI 10.2466/PMS.90.2.522-526; Haimov I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061390; Hall CB, 2009, NEUROLOGY, V73, P356, DOI 10.1212/WNL.0b013e3181b04ae3; Hambrick D. Z., 2014, BRAIN TRAINING DOESN; Hardy RJ, 1998, STAT MED, V17, P841, DOI 10.1002/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO;2-D; Harris Y, 2006, J AM GERIATR SOC, V54, P593, DOI 10.1111/j.1532-5415.2006.00687.x; Heaton RK, 1999, J CLIN EXP NEUROPSYC, V21, P571, DOI 10.1076/jcen.21.4.572.882; Hertzog Christopher, 2008, Psychol Sci Public Interest, V9, P1, DOI 10.1111/j.1539-6053.2009.01034.x; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hill NTM, 2017, AM J PSYCHIAT, V174, P329, DOI 10.1176/appi.ajp.2016.16030360; Hyer L, 2016, CLIN GERONTOLOGIST, V39, P410, DOI 10.1080/07317115.2015.1120257; Jaeggi SM, 2008, P NATL ACAD SCI USA, V105, P6829, DOI 10.1073/pnas.0801268105; Joy S, 2004, ARCH CLIN NEUROPSYCH, V19, P759, DOI 10.1016/j.acn.2003.09.009; Karbach J, 2009, DEVELOPMENTAL SCI, V12, P978, DOI 10.1111/j.1467-7687.2009.00846.x; Kelly ME, 2014, AGEING RES REV, V15, P28, DOI 10.1016/j.arr.2014.02.004; Kessels R P, 2000, Appl Neuropsychol, V7, P252, DOI 10.1207/S15324826AN0704_8; Kimbler KJ, 2013, BEHAV SCI-BASEL, V3, P170, DOI 10.3390/bs3010170; LARRABEE GJ, 1983, J CLIN NEUROPSYCHOL, V5, P159, DOI 10.1080/01688638308401162; Lee Y, 2000, J EPIDEMIOL COMMUN H, V54, P123, DOI 10.1136/jech.54.2.123; Lezak M. D., 1976, NEUROPSYCHOLOGICAL A; Lo AHY, 2012, J NEUROPSYCHOL, V6, P212, DOI 10.1111/j.1748-6653.2011.02023.x; Lustig C, 2009, NEUROPSYCHOL REV, V19, P504, DOI 10.1007/s11065-009-9119-9; Mahncke HW, 2006, PROG BRAIN RES, V157, P81, DOI 10.1016/S0079-6123(06)57006-2; Mahncke HW, 2006, P NATL ACAD SCI USA, V103, P12523, DOI 10.1073/pnas.0605194103; MASUR DM, 1989, J CLIN EXP NEUROPSYC, V11, P615, DOI 10.1080/01688638908400920; Mayas J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092269; MCCARTY SM, 1982, J GERONTOL, V37, P169, DOI 10.1093/geronj/37.2.169; MEFFERD RB, 1966, PSYCHOL REP, V18, P3, DOI 10.2466/pr0.1966.18.1.3; Melby-Lervag M, 2016, PERSPECT PSYCHOL SCI, V11, P512, DOI 10.1177/1745691616635612; Miller KJ, 2013, AM J GERIAT PSYCHIAT, V21, P655, DOI 10.1016/j.jagp.2013.01.077; Millis SR, 1999, J CLIN EXP NEUROPSYC, V21, P87, DOI 10.1076/jcen.21.1.87.937; Monsell S, 2003, TRENDS COGN SCI, V7, P134, DOI 10.1016/S1364-6613(03)00028-7; Morrison AB, 2011, PSYCHON B REV, V18, P46, DOI 10.3758/s13423-010-0034-0; Newburger E. C., 2001, HOME COMPUTERS INTER; Neylan TC, 2004, J TRAUMA STRESS, V17, P41, DOI 10.1023/B:JOTS.0000014675.75686.ee; Nieboer A, 2005, SOC INDIC RES, V73, P313, DOI 10.1007/s11205-004-0988-2; O'Brien J, 2011, J VIS, V11, P203, DOI [10.1167/11.11.203, DOI 10.1167/11.11.203]; O'Brien JL, 2013, CLIN NEUROPHYSIOL, V124, P2198, DOI 10.1016/j.clinph.2013.05.012; Oh A, 2014, BRAIN COGNITION, V86, P90, DOI 10.1016/j.bandc.2014.02.006; OWEN AM, 1995, NEUROPSYCHOLOGIA, V33, P1, DOI 10.1016/0028-3932(94)00098-A; Owsley C, 2002, GERONTOLOGY, V48, P254, DOI 10.1159/000058360; Park DC, 2014, PSYCHOL SCI, V25, P103, DOI 10.1177/0956797613499592; Peres K, 2008, J AM GERIATR SOC, V56, P37, DOI 10.1111/j.1532-5415.2007.01499.x; Peretz C, 2011, NEUROEPIDEMIOLOGY, V36, P91, DOI 10.1159/000323950; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; Powell J B, 1991, Arch Clin Neuropsychol, V6, P241, DOI 10.1016/0887-6177(91)90001-P; Ratner E, 2015, J AM GERIATR SOC, V63, P2614, DOI 10.1111/jgs.2_13825; Raven J, 2000, COGNITIVE PSYCHOL, V41, P1, DOI 10.1006/cogp.1999.0735; Rebok GW, 2014, J AM GERIATR SOC, V62, P16, DOI 10.1111/jgs.12607; Richardson JTE, 2002, BEHAV RES METH INS C, V34, P69, DOI 10.3758/BF03195425; Roenker DL, 2003, HUM FACTORS, V45, P218, DOI 10.1518/hfes.45.2.218.27241; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Sanchez-Cubillo I, 2009, J INT NEUROPSYCH SOC, V15, P438, DOI 10.1017/S1355617709090626; Scarmeas N, 2001, NEUROLOGY, V57, P2236, DOI 10.1212/WNL.57.12.2236; Schaie KW, 1985, MANUAL SCHAIE THURST; Schmiedek F, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00027; Shah T, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.122; Shatil E, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00008; Sheridan LK, 2006, ARCH CLIN NEUROPSYCH, V21, P23, DOI 10.1016/j.acn.2005.07.003; Simons DJ, 2016, PSYCHOL SCI PUBL INT, V17, P103, DOI 10.1177/1529100616661983; Smith GE, 2009, J AM GERIATR SOC, V57, P594, DOI 10.1111/j.1532-5415.2008.02167.x; Standford Center on Longevity & Berlin Max Planck Institute for Human Development, 2014, CONS BRAIN TRAIN IND; Steer RA, 1997, PSYCHOL REP, V80, P443, DOI 10.2466/pr0.1997.80.2.443; Steffens DC, 2006, ARCH GEN PSYCHIAT, V63, P130, DOI 10.1001/archpsyc.63.2.130; Stine-Morrow EAL, 2008, PSYCHOL AGING, V23, P778, DOI 10.1037/a0014341; Strenziok M, 2014, NEUROIMAGE, V85, P1027, DOI 10.1016/j.neuroimage.2013.07.069; Talebi M., 2013, INT RES J APPL BASIC, V4, P31, DOI DOI 10.1177/0266242612465454; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Tombaugh TN, 2006, ARCH CLIN NEUROPSYCH, V21, P53, DOI 10.1016/j.acn.2005.07.006; Toril P, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00206; Tun PA, 1997, J AGING MENTAL HLTH, V18, P47; Uttl B, 2002, ARCH CLIN NEUROPSYCH, V17, P567, DOI 10.1016/S0887-6177(01)00135-4; Valenzuela M, 2009, AM J GERIAT PSYCHIAT, V17, P179, DOI 10.1097/JGP.0b013e3181953b57; Vance D, 2007, REHABIL PSYCHOL, V52, P89, DOI 10.1037/0090-5550.52.1.89; Verghese J, 2003, NEW ENGL J MED, V348, P2508, DOI 10.1056/NEJMoa022252; Wecker NS, 2005, NEUROPSYCHOLOGY, V19, P345, DOI 10.1037/0894-4105.19.3.345; WEINBERGER M, 1986, AM J PUBLIC HEALTH, V76, P457, DOI 10.2105/AJPH.76.4.457; Wilde NJ, 2004, J CLIN EXP NEUROPSYC, V26, P539, DOI 10.1080/13803390490496605; Willis SL, 2006, JAMA-J AM MED ASSOC, V296, P2805, DOI 10.1001/jama.296.23.2805; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; Wolinsky FD, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000225; ZELINSKI EM, 2009, NEUROSCIENCE, V27, P455, DOI DOI 10.3233/RNN-2009-0495	127	14	14	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	2509-3290	2509-3304		J COGN ENHANCE	J. Cogn. Enhance.	DEC	2017	1	4			SI		559	575		10.1007/s41465-017-0051-2			17	Neurosciences	Neurosciences & Neurology	VJ8HE	WOS:000635180900015					2021-06-18	
J	Sosa, MAG; De Gasperi, R; Garcia, GSP; Sosa, H; Searcy, C; Vargas, D; Janssen, PL; Perez, GM; Tschiffely, AE; Janssen, WG; McCarron, RM; Hof, PR; Haghighi, FG; Ahlers, ST; Elder, GA				Sosa, Miguel A. Gama; De Gasperi, Rita; Garcia, Georgina S. Perez; Sosa, Heidi; Searcy, Courtney; Vargas, Danielle; Janssen, Pierce L.; Perez, Gissel M.; Tschiffely, Anna E.; Janssen, William G.; McCarron, Richard M.; Hof, Patrick R.; Haghighi, Fatemeh G.; Ahlers, Stephen T.; Elder, Gregory A.			Lack of chronic neuroinflammation in the absence of focal hemorrhage in a rat model of low-energy blast-induced TBI	ACTA NEUROPATHOLOGICA COMMUNICATIONS			English	Article							TRAUMATIC BRAIN-INJURY; PROTEIN-KINASE PATHWAYS; MICROGLIAL ACTIVATION; EXPLOSIVE BLAST; INFLAMMATION; INVOLVEMENT; IMPAIRMENT; THROMBIN; DISEASE; SINGLE	Blast-related traumatic brain injury (TBI) has been a common cause of injury in the recent conflicts in Iraq and Afghanistan. Blast waves can damage blood vessels, neurons, and glial cells within the brain. Acutely, depending on the blast energy, blast wave duration, and number of exposures, blast waves disrupt the blood-brain barrier, triggering microglial activation and neuroinflammation. Recently, there has been much interest in the role that ongoing neuroinflammation may play in the chronic effects of TBI. Here, we investigated whether chronic neuroinflammation is present in a rat model of repetitive low-energy blast exposure. Six weeks after three 74.5-kPa blast exposures, and in the absence of hemorrhage, no significant alteration in the level of microglia activation was found. At 6 weeks after blast exposure, plasma levels of fractalkine, interleukin-1 beta, lipopolysaccharide-inducible CXC chemokine, macrophage inflammatory protein 1 alpha, and vascular endothelial growth factor were decreased. However, no differences in cytokine levels were detected between blast-exposed and control rats at 40 weeks. In brain, isolated changes were seen in levels of selected cytokines at 6 weeks following blast exposure, but none of these changes was found in both hemispheres or at 40 weeks after blast exposure. Notably, one animal with a focal hemorrhagic tear showed chronic microglial activation around the lesion 16 weeks post-blast exposure. These findings suggest that focal hemorrhage can trigger chronic focal neuroinflammation following blast-induced TBI, but that in the absence of hemorrhage, chronic neuroinflammation is not a general feature of low-level blast injury.	[Sosa, Miguel A. Gama] James J Peters Dept Vet Affairs Med Ctr, Gen Med Res Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA; [De Gasperi, Rita; Garcia, Georgina S. Perez; Sosa, Heidi; Searcy, Courtney; Vargas, Danielle; Janssen, Pierce L.; Perez, Gissel M.; Haghighi, Fatemeh G.] James J Peters Dept Vet Affairs Med Ctr, Res & Dev Serv, Bronx, NY USA; [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY USA; [Sosa, Miguel A. Gama; De Gasperi, Rita; Sosa, Heidi; Searcy, Courtney; Vargas, Danielle] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Garcia, Georgina S. Perez; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Janssen, Pierce L.; Janssen, William G.; Hof, Patrick R.; Haghighi, Fatemeh G.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA; [Hof, Patrick R.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Care, New York, NY 10029 USA; [Sosa, Miguel A. Gama; De Gasperi, Rita; Garcia, Georgina S. Perez; Janssen, William G.; Hof, Patrick R.; Haghighi, Fatemeh G.; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA; [Tschiffely, Anna E.; McCarron, Richard M.; Ahlers, Stephen T.] Naval Med Res Ctr, Operat & Undersea Med Directorate, Silver Spring, MD USA; [McCarron, Richard M.] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA	Sosa, MAG (corresponding author), James J Peters Dept Vet Affairs Med Ctr, Gen Med Res Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.; Sosa, MAG (corresponding author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Sosa, MAG (corresponding author), Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.	miguel.gama-sosa@mssm.edu		Vargas, Danielle/0000-0003-4409-9391	Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development ServiceUS Department of Veterans Affairs [1I01RX000996-01, I21RX002069]; General Medical Research Service, James J. Peters VA Medical Center; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P50 AG005138]; Uniformed Services University of the Health Sciences [601152 N.0000.000.A1308]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005138] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000996, I21RX002069] Funding Source: NIH RePORTER	The authors would like to thank the anonymous reviewers for their helpful suggestions and independent statistical analyses of the data provided that strengthened considerably the conclusions of this manuscript. The research described here was supported by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Awards 1I01RX000996-01 and I21RX002069. MAGS was supported in part by the General Medical Research Service, James J. Peters VA Medical Center. PRH is supported in part by NIH grant P50 AG005138. RMM, AET and STA were supported in part by work unit number (WUN) 601152 N.0000.000. A1308 from the Uniformed Services University of the Health Sciences. PLJ was a Carolyn L. Kuckein Student Research Fellow of the Alpha Omega Alpha Honor Medical Society. MAGS, RDG, GMP, GE, AET and STA are employees of the U.S. government. This work was prepared as part of their official duties. Title 17 U.S.C. 105 provides that 'Copyright protection under this title is not available for any work of the United States Government.' Title 17 U.S.C. 101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person's official duties. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, Department of Veterans Affairs, nor the U.S. Government.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Alford PW, 2011, P NATL ACAD SCI USA, V108, P12705, DOI 10.1073/pnas.1105860108; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Eftaxiopoulou T, 2016, INJURY, V47, P625, DOI 10.1016/j.injury.2016.01.017; Elali A, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00072; Elder GA, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0591-8; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Fatemifar F, 2016, J BIOMECH ENG-T ASME, V138, DOI 10.1115/1.4034785; Fujimoto S, 2007, NEUROSCIENCE, V144, P694, DOI 10.1016/j.neuroscience.2006.09.049; Gill J, 2017, BRAIN BEHAV IMMUN, V65, P90, DOI 10.1016/j.bbi.2017.02.015; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hald ES, 2014, TRANSL STROKE RES, V5, P385, DOI 10.1007/s12975-013-0300-3; Han HC, 2012, J VASC RES, V49, P185, DOI 10.1159/000335123; Huber BR, 2016, NEUROSCIENCE, V319, P206, DOI 10.1016/j.neuroscience.2016.01.022; Hulse RE, 2004, J NEUROSCI METH, V136, P87, DOI 10.1016/j.jneumeth.2003.12.023; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kabu S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127971; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kawoos U, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167510; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Li YS, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-52; Ling G, 2007, J TRAUMA, V62, pS102, DOI 10.1097/TA.0b013e318065b442; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Morgan JT, 2010, BIOL PSYCHIAT, V68, P368, DOI 10.1016/j.biopsych.2010.05.024; Ohnishi M, 2007, EXP NEUROL, V206, P43, DOI 10.1016/j.expneurol.2007.03.030; Ohnishi M, 2011, NEUROPHARMACOLOGY, V61, P975, DOI 10.1016/j.neuropharm.2011.06.026; Ohsawa K, 2000, J CELL SCI, V113, P3073; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Sajja Venkata Siva Sai S, 2012, Biomed Sci Instrum, V48, P374; Schwulst SJ, 2013, J TRAUMA ACUTE CARE, V75, P780, DOI 10.1097/TA.0b013e318299616a; Sheng JG, 1997, ACTA NEUROPATHOL, V94, P1, DOI 10.1007/s004010050664; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Taylor RA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/746068; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; Torres-Platas SG, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-12; Valiyaveettil M, 2012, NEUROSCI LETT, V506, P141, DOI 10.1016/j.neulet.2011.10.067; Wang JM, 2016, CHIN J TRAUMATOL, V19, P125, DOI 10.1016/j.cjtee.2016.03.001; Wang WY, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.03.49; Zhou JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092828	58	14	14	1	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2051-5960			ACTA NEUROPATHOL COM	Acta Neuropathol. Commun.	NOV 10	2017	5								80	10.1186/s40478-017-0483-z			12	Neurosciences	Neurosciences & Neurology	FM4TI	WOS:000415014600001	29126430	DOAJ Gold, Green Published			2021-06-18	
J	Feng, DD; Xia, Z; Zhou, J; Lu, HM; Zhang, CH; Fan, R; Xiong, XG; Cui, HJ; Gan, PP; Huang, W; Peng, WJ; He, F; Wang, ZM; Wang, Y; Tang, T				Feng, Dandan; Xia, Zian; Zhou, Jing; Lu, Hongmei; Zhang, Chunhu; Fan, Rong; Xiong, Xingui; Cui, Hanjin; Gan, Pingping; Huang, Wei; Peng, Weijun; He, Feng; Wang, Zhiming; Wang, Yang; Tang, Tao			Metabolomics reveals the effect of Xuefu Zhuyu Decoction on plasma metabolism in rats with acute traumatic brain injury	ONCOTARGET			English	Article						metabolomics; acute traumatic brain injury; traditional Chinese medicine; Xuefu Zhuyu Decoction; gas chromatography/mass spectrometry	SUCCINATE; GLUTAMATE; STRATEGIES; POTASSIUM; PATHWAY; IMPACT; SERUM; ACID; MICE	Xuefu Zhuyu Decoction (XFZY), an important traditional Chinese herbal formula, has been reported effective on traumatic brain injury (TBI) in rats. However, its cerebral protection mechanism has not been clarified at the metabolic level. This work aims to explore the global metabolic characteristics of XFZY in rats during the acute phase of TBI on days 1 and 3. A plasma metabolomics method based on gas chromatography-mass spectrometry coupled with univariate analysis and multivariate statistical analysis was performed in three groups (Sham, Vehicle, XFZY). Then, a pathway analysis using MetaboAnalyst 3.0 was performed to illustrate the pathways of therapeutic action of XFZY in TBI. XFZY treatment attenuates neurological dysfunction and cortical lesion volume post-injury on day 3, and reverses the plasma metabolite abnormalities (glutamic acid, lactic acid, 3-hydroxybutyric acid, and ribitol, etc.). These differential metabolites are mainly involved in D-glutamine and D-glutamate metabolism, alanine, aspartate and glutamate metabolism, and inositol phosphate metabolism. Our study reveals potential biomarkers and metabolic networks of acute TBI and neuroprotection effects of XFZY, and shows this metabolomics approach with MetaboAnalyst would be a feasible way to systematically study therapeutic effects of XFZY on TBI.	[Feng, Dandan; Xia, Zian; Zhou, Jing; Zhang, Chunhu; Fan, Rong; Xiong, Xingui; Cui, Hanjin; Huang, Wei; Wang, Yang; Tang, Tao] Cent S Univ, Xiangya Hosp, Inst Integrat Chinese Med, Changsha 410008, Hunan, Peoples R China; [Lu, Hongmei] Cent S Univ, Coll Chem & Chem Engn, Res Ctr Modernizat Tradit Chinese Med, Changsha 410083, Hunan, Peoples R China; [Gan, Pingping] Cent S Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China; [Peng, Weijun] Cent S Univ, Xiangya Hosp 2, Dept Integrated Chinese & Western Med, Changsha 410011, Hunan, Peoples R China; [He, Feng; Wang, Zhiming] Cent S Univ, Xiangya Hosp, Dept Hepatobiliary Surg, Changsha 410008, Hunan, Peoples R China	Wang, Y; Tang, T (corresponding author), Cent S Univ, Xiangya Hosp, Inst Integrat Chinese Med, Changsha 410008, Hunan, Peoples R China.	wangyang_xy87@csu.edu.cn; falcontang@126.com			Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81673719, 81473573, 81403259, 81303074]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2016M600639, 2017T100614]; Natural Science Foundation of Science and Technology Department of Hunan Province [2014SK3035]	This work was supported by the Natural Science Foundation of China (Grant Nos. 81673719, 81473573, 81403259, and 81303074), China Postdoctoral Science Foundation (Nos. 2016M600639 and 2017T100614), and the Natural Science Foundation of Science and Technology Department of Hunan Province (Grant No. 2014SK3035).	[Anonymous], 2010, LANCET NEUROL, V9, P331, DOI 10.1016/S1474-4422(10)70069-7; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Carpenter KLH, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00112; Chen J, 2015, J CHROMATOGR B; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Cheng T, 2016, FREE RADICAL BIO MED, V92, P15, DOI 10.1016/j.freeradbiomed.2015.12.027; Chouchani ET, 2014, NATURE, V515, P431, DOI 10.1038/nature13909; Chu H, 2016, J CHROMATOGR B, V1015, P50, DOI 10.1016/j.jchromb.2016.02.007; David Y, 2009, J NEUROSCI, V29, P10588, DOI 10.1523/JNEUROSCI.2323-09.2009; Deng-Bryant Y, 2011, J NEUROTRAUM, V28, P1813, DOI 10.1089/neu.2011.1822; Dunn WB, 2011, NAT PROTOC, V6, P1060, DOI 10.1038/nprot.2011.335; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fernandez-Gajardo R, 2014, CNS DRUGS, V28, P229, DOI 10.1007/s40263-013-0138-y; Gu Y, 2016, MED SCI MONITOR, V22, P4894, DOI 10.12659/MSM.898185; Guluma K, 2002, SEMIN RESP CRIT CARE, V23, P37, DOI 10.1055/s-2002-20587; Hu ZP, 2012, MOL BIOSYST, V8, P1979, DOI 10.1039/c2mb25061f; Jo YY, 2016, J ANESTH, V30, P637, DOI 10.1007/s00540-016-2169-2; Kierans AS, 2014, NEUROLOGY, V82, P521, DOI 10.1212/WNL.0000000000000105; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P187, DOI 10.1097/00001199-200505000-00001; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee JJ, 2011, J ETHNOPHARMACOL, V134, P824, DOI 10.1016/j.jep.2011.01.033; Leibowitz A, 2012, ACTA NEUROBIOL EXP, V72, P385; Lenz EM, 2007, J PROTEOME RES, V6, P443, DOI 10.1021/pr0605217; Liu JR, 2014, J NEW CHINESE MED, V46, P206; Ma X, 2016, FRONT PHARMACOL, V7, DOI [10.3339/fphar.2016.00014, 10.3389/fphar.2016.00014]; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mills E, 2014, TRENDS CELL BIOL, V24, P313, DOI 10.1016/j.tcb.2013.11.008; Moro N, 2016, BRAIN RES, V1642, P270, DOI 10.1016/j.brainres.2016.04.005; Nageli M, 2014, CRIT CARE, V18, DOI 10.1186/cc13962; Okorie ON, 2011, CRIT CARE CLIN, V27, P299, DOI 10.1016/j.ccc.2010.12.013; Pell VR, 2016, CARDIOVASC RES, V111, P134, DOI 10.1093/cvr/cvw100; Pfeuffer M, 2016, ADV NUTR, V7, P730, DOI 10.3945/an.115.011387; Shen YC, 2015, J ETHNOPHARMACOL, V173, P370, DOI 10.1016/j.jep.2015.07.018; Sheth SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129735; Song XF, 2013, J PHARMACEUT BIOMED, V78-79, P202, DOI 10.1016/j.jpba.2013.02.014; Streijger F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078765; Venkatesh B, 2010, CRIT CARE MED, V38, pS630, DOI 10.1097/CCM.0b013e3181f24406; Viant MR, 2005, NMR BIOMED, V18, P507, DOI 10.1002/nbm.980; WANG PQ, 2015, MEDICINE BALTIMORE, V94; Wang W, 2015, MOL NEUROBIOL; Wolahan S. M., 2015, BRAIN NEUROTRAUMA MO; Xing ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep20040; Yan EB, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0328-2; Yang B, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1076-2; Yang SG, 2012, J NEUROTRAUM, V29, P2696, DOI 10.1089/neu.2012.2442; Zhang AH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/257909; Zhou XY, 2016, TALANTA, V147, P82, DOI 10.1016/j.talanta.2015.09.040; Zhu H, 2015, SCI REP-UK, V5, DOI 10.1038/srep17536; Zhu Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep17068	50	14	14	1	28	IMPACT JOURNALS LLC	ORCHARD PARK	6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA		1949-2553		ONCOTARGET	Oncotarget	NOV 7	2017	8	55					94692	94710		10.18632/oncotarget.21876			19	Oncology; Cell Biology	Oncology; Cell Biology	FL9VQ	WOS:000414608400120		Green Published, Other Gold			2021-06-18	
J	Springer, JE; Visavadiya, NP; Sullivan, PG; Hall, ED				Springer, Joe E.; Visavadiya, Nishant P.; Sullivan, Patrick G.; Hall, Edward D.			Post-Injury Treatment with NIM811 Promotes Recovery of Function in Adult Female Rats after Spinal Cord Contusion: A Dose-Response Study	JOURNAL OF NEUROTRAUMA			English	Article						locomotor function; mitochondria; spinal cord injury	MITOCHONDRIAL PERMEABILITY TRANSITION; TRAUMATIC BRAIN-INJURY; CYCLOSPORINE-A; CYCLOPHILIN-D; CYTOCHROME-C; CELL-DEATH; LIPID-PEROXIDATION; ENDONUCLEASE-G; PORE; INHIBITION	Mitochondrial homeostasis is essential for maintaining cellular function and survival in the central nervous system (CNS). Mitochondrial function is significantly compromised after spinal cord injury (SCI) and is associated with accumulation of high levels of calcium, increased production of free radicals, oxidative damage, and eventually mitochondrial permeability transition (mPT). The formation of the mPT pore (mPTP) and subsequent mPT state are considered to be end stage events in the decline of mitochondrial integrity, and strategies that inhibit mPT can limit mitochondrial demise. Cyclosporine A (CsA) is thought to inhibit mPT by binding to cyclophilin D and has been shown to be effective in models of CNS injury. CsA, however, also inhibits calcineurin, which is responsible for its immunosuppressive properties. In the present study, we conducted a dose-response examination of NIM811, a nonimmunosuppressive CsA analog, on recovery of function and tissue sparing in a rat model of moderate to severe SCI. The results of our experiments revealed that NIM811 (10 mg/kg) significantly improved open field locomotor performance, while the two higher doses tested (20 and 40 mg/kg) significantly improved return of reflexive bladder control and significantly decreased the rostral-caudal extent of the lesion. Taken together, these results demonstrate the ability of NIM811 to improve recovery of function in SCI and support the role of protecting mitochondrial function as a potential therapeutic target.	[Springer, Joe E.; Visavadiya, Nishant P.; Sullivan, Patrick G.; Hall, Edward D.] Univ Kentucky, Med Ctr, Dept Neurosci, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone,BBSRB B443, Lexington, KY 40536 USA	Springer, JE (corresponding author), Univ Kentucky, Med Ctr, Dept Neurosci, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone,BBSRB B443, Lexington, KY 40536 USA.	jspring@uky.edu	Hall, Edward D/F-8930-2013		PHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U01-NS066915, P30 NS051220]; Craig H. Neilsen Foundation	This work was supported by PHS grant U01-NS066915, P30 NS051220, and the Craig H. Neilsen Foundation.	Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; Bernardi P, 1998, BIOFACTORS, V8, P273, DOI 10.1002/biof.5520080315; Blight A R, 2001, Curr Opin Investig Drugs, V2, P801; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Christensen MD, 1997, J NEUROTRAUM, V14, P517, DOI 10.1089/neu.1997.14.517; David BT, 2010, EXP NEUROL, V226, P128, DOI 10.1016/j.expneurol.2010.08.014; Diaz-Ruiz A, 1999, NEUROSCI LETT, V266, P61, DOI 10.1016/S0304-3940(99)00255-4; Diaz-Ruiz A, 2000, NEUROREPORT, V11, P1765, DOI 10.1097/00001756-200006050-00033; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hansson MJ, 2004, J BIOENERG BIOMEMBR, V36, P407, DOI 10.1023/B:JOBB.0000041776.31885.45; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; Hou SP, 2016, EXP NEUROL, V285, P136, DOI 10.1016/j.expneurol.2015.12.001; Hulsebosch CE, 2009, BRAIN RES REV, V60, P202, DOI 10.1016/j.brainresrev.2008.12.010; Ibarra A, 1996, J NEUROTRAUM, V13, P267, DOI 10.1089/neu.1996.13.267; Ibarra A, 2003, BRAIN RES, V979, P165, DOI 10.1016/S0006-8993(03)02898-1; Ibarra A, 1996, J NEUROTRAUM, V13, P569, DOI 10.1089/neu.1996.13.569; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOEWY AD, 1979, BRAIN RES, V172, P533, DOI 10.1016/0006-8993(79)90584-5; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; McEwen ML, 2007, J NEUROTRAUM, V24, P613, DOI 10.1089/neu.2006.9969; McEwen ML, 2011, NEUROTHERAPEUTICS, V8, P168, DOI 10.1007/s13311-011-0031-7; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314; Ravikumar R, 2007, J NEUROTRAUM, V24, P1618, DOI 10.1089/neu.2007.0329; Readnower RD, 2011, J NEUROTRAUM, V28, P1845, DOI 10.1089/neu.2011.1755; Reed JC, 2000, CELL DEATH DIFFER, V7, P1145, DOI 10.1038/sj.cdd.4400777; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Scorrano L, 1997, MOL CELL BIOCHEM, V174, P181, DOI 10.1023/A:1006887921810; Springer JE, 2010, J NEUROTRAUM, V27, P139, DOI 10.1089/neu.2009.0952; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; Visavadiya NP, 2016, REDOX BIOL, V8, P59, DOI 10.1016/j.redox.2015.12.011; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Waldmeier PC, 2003, CURR MED CHEM, V10, P1485, DOI 10.2174/0929867033457160; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	57	14	14	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 1	2018	35	3					492	499		10.1089/neu.2017.5167		NOV 2017	8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FU4BP	WOS:000414641200001	28967329	Green Published			2021-06-18	
J	Kennedy, E; Cohen, M; Munafo, M				Kennedy, Eleanor; Cohen, Miriam; Munafo, Marcus			Childhood Traumatic Brain Injury and the Associations With Risk Behavior in Adolescence and Young Adulthood: A Systematic Review	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						antisocial behavior; child; conduct disorder; head injury; pediatric; risk behavior; substance use; systematic review; traumatic brain injury	MILD HEAD-INJURY; POST-CONCUSSIVE SYMPTOMS; POSTCONCUSSIVE SYMPTOMS; CHILDREN; OUTCOMES; PREDICTORS; PRESCHOOL; POSTINJURY; SEQUELAE; PARENTS	Objective: To systematically review the evidence that childhood traumatic brain injury (TBI) is associated with risk behavior in adolescence and young adulthood. Risk behavior included one or more of the following: use of substances, including alcohol, tobacco, and illicit substances; involvement in criminal behavior; and behavioral issues with conduct. Methods: A literature search was conducted using these terms: child, pediatric, traumatic brain injury, head injury, adolescent, psychosocial, antisocial, conduct, substance use. Studies describing original research were included if they reported outcomes over the age of 13 years in participants who sustained a TBI between birth and age 13 years. Results: Six journal articles were reviewed based on 4 separate studies. Three articles indicated a relationship between childhood TBI and increased problematic substance use in adolescence and young adulthood. Three articles supported an association between childhood TBI and later externalizing behavior; however, 2 articles did not support this link. Conclusion: More research is warranted to explore the association between childhood TBI and later risk behavior as the relationship is not currently understood. Future research should build on existing longitudinal research with continued use of medical records for identifying TBI and inclusion of a non-brain-related trauma group to control for general injury effects.	[Kennedy, Eleanor; Munafo, Marcus] Univ Bristol, MRC Integrat Epidemiol Unit, UK Ctr Tobacco & Alcohol Studies, Sch Expt Psychol, 12a Priory Rd, Bristol BS8 1TU, Avon, England; [Cohen, Miriam] Univ Exeter, Coll Life & Environm Sci, Exeter, Devon, England; [Munafo, Marcus] UK Ctr Tobacco & Alcohol Studies, Bristol, Avon, England	Kennedy, E (corresponding author), Univ Bristol, MRC Integrat Epidemiol Unit, UK Ctr Tobacco & Alcohol Studies, Sch Expt Psychol, 12a Priory Rd, Bristol BS8 1TU, Avon, England.	e.kennedy@bristol.ac.uk	Munafo, Marcus/AAE-2306-2020	Munafo, Marcus/0000-0002-4049-993X	University of Bristol [MC_UU_12013/6]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission; British Heart FoundationBritish Heart Foundation; Cancer Research UKCancer Research UK; Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC); National Institute for Health Research under the UK Clinical Research Collaboration; Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [1564726] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_UU_12013/6] Funding Source: researchfish	This study was supported in part by the Medical Research Council and the University of Bristol (MC_UU_12013/6).; MM is a member of the UK Centre for Tobacco and Alcohol Studies, a UKCRC Public Health Research: Centre of Excellence. Funding from British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, and the National Institute for Health Research, under the auspices of the UK Clinical Research Collaboration, is gratefully acknowledged.	ACHENBACH TM, 1987, PSYCHOL BULL, V101, P213, DOI 10.1037/0033-2909.101.2.213; Anderson V., 1997, J INT NEUROPSYCH SOC, V3, P553; Anderson VA, 2014, DEV MED CHILD NEUROL, V56, P329, DOI 10.1111/dmcn.12387; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; [Anonymous], 2009, STAT STAT SOFTW COMP; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BABCOCK L, 2013, PEDIATRICS, V167, P156; Babikian T, 2013, J INT NEUROPSYCH SOC, V19, P145, DOI 10.1017/S135561771200104X; Barlow KM, 2016, J CHILD NEUROL, V31, P57, DOI 10.1177/0883073814543305; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Batty RA, 2013, BRAIN IMPAIR, V14, P21, DOI 10.1017/BrImp.2013.10; Bernard C, 2016, J INT NEUROPSYCH SOC, V22, P1; BIJUR PE, 1990, PEDIATRICS, V86, P337; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Bracken BA, 2004, CLIN ASSESSMENT BEHA; Brooks BL, 2014, ARCH CLIN NEUROPSYCH, V29, P186, DOI 10.1093/arclin/act083; Brown H, 2015, APPL MIXED MODELS ME; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Gioia GA, 2015, BRAIN INJURY, V29, P195, DOI 10.3109/02699052.2014.965210; Gioia GA, 2012, PEDIATRIC AND ADOLESCENT CONCUSSION: DIAGNOSIS, MANAGEMENT AND OUTCOMES, P151, DOI 10.1007/978-0-387-89545-1_12; Guo S., 2015, PROPENSITY SCORE ANA, V2nd; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Hosmer DW., 2013, APPL LOGISTIC REGRES, V3rd ed.; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kirk RE, 1996, EDUC PSYCHOL MEAS, V56, P746, DOI 10.1177/0013164496056005002; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; Kolb B, 1999, CAN J EXP PSYCHOL, V53, P62, DOI 10.1037/h0087300; Kolb B, 2012, DEV PSYCHOBIOL, V54, P311, DOI 10.1002/dev.20515; Lagattuta KH, 2012, J EXP CHILD PSYCHOL, V113, P211, DOI 10.1016/j.jecp.2012.04.001; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P3, DOI 10.1111/j.1365-2214.2009.01006.x; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; McKinlay A, 2014, AUST PSYCHOL, V49, P323, DOI 10.1111/ap.12084; McKinlay A, 2014, J HEAD TRAUMA REHAB, V29, P233, DOI 10.1097/HTR.0b013e3182a2dd7f; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Myers R., 1990, CLASSICAL MODERN REG; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2014, UNDERSTANDING TRAUMA, P190; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Ponsford JL, 2014, PSYCHIAT CLIN N AM, V37, P77, DOI 10.1016/j.psc.2013.10.001; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Scott C, 2015, NEUROPSYCHOLOGY, V29, P501, DOI 10.1037/neu0000074; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Stevens Penelope K, 2010, J Trauma Nurs, V17, P178, DOI 10.1097/JTN.0b013e3181ff2789; Tabachnick B.G., 2013, USING MULTIVARIATE S; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79	59	14	14	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2017	32	6					425	432		10.1097/HTR.0000000000000289			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FQ8BO	WOS:000418588100098	28092286	Green Published			2021-06-18	
J	Shan, HY; Chu, Y; Chang, P; Yang, LJ; Wang, Y; Zhu, SH; Zhang, MY; Tao, LY				Shan, Haiyan; Chu, Yang; Chang, Pan; Yang, Lijun; Wang, Yi; Zhu, Shaohua; Zhang, Mingyang; Tao, Luyang			Neuroprotective effects of hydrogen sulfide on sodium azide-induced autophagic cell death in PC12 cells	MOLECULAR MEDICINE REPORTS			English	Article						hydrogen sulfide; sodium azide; autophagic cell death	TRAUMATIC BRAIN-INJURY; CYTOCHROME-C-OXIDASE; PATHWAY; RAT; MITOCHONDRIA; ACTIVATION; EXPRESSION; APOPTOSIS; SYNTHASE; STRESS	Sodium azide (NaN3) is a chemical of rapidly growing commercial importance. It is very acutely toxic and inhibits cytochrome oxidase (COX) by binding irreversibly to the heme cofactor. A previous study from our group demonstrated that hydrogen sulfide (H2S), the third endogenous gaseous mediator identified, had protective effects against neuronal damage induced by traumatic brain injury (TBI). It is well-known that TBI can reduce the activity of COX and have detrimental effects on the central nervous system metabolism. Therefore, in the present study, it was hypothesized that H2S may provide neuroprotection against NaN3 toxicity. The current results revealed that NaN3 treatment induced non-apoptotic cell death, namely autophagic cell death, in PC12 cells. Expression of the endogenous H2S-producing enzymes, cystathionine-beta-synthase and 3-mercaptopyruvate sulfurtransferase, decreased in a dose-dependent manner following NaN3 treatment. Pretreatment with H2S markedly attenuated the NaN3-induced cell viability loss and autophagic cell death in a dose-dependent manner. The present study suggests that H2S-based strategies may have future potential in the prevention and/or therapy of neuronal damage following NaN3 exposure.	[Shan, Haiyan; Zhang, Mingyang] Minist Justice, Inst Forens Sci, Shanghai Key Lab Forens Med, Shanghai 200063, Peoples R China; [Shan, Haiyan] North Suzhou Municipal Hosp, Dept Obstet & Gynecol, Suzhou 215008, Jiangsu, Peoples R China; [Chu, Yang; Yang, Lijun; Wang, Yi; Zhu, Shaohua; Zhang, Mingyang; Tao, Luyang] Soochow Univ, Inst Forens Sci, 178 Ganjiang East Rd, Suzhou 215123, Jiangsu, Peoples R China; [Chang, Pan] Xian Med Coll, Cent Lab, Affiliated Hosp 2, Xian 710038, Shaanxi, Peoples R China	Zhang, MY; Tao, LY (corresponding author), Soochow Univ, Inst Forens Sci, 178 Ganjiang East Rd, Suzhou 215123, Jiangsu, Peoples R China.	mingyangzhang@suda.edu.cn; taoluyang@suda.edu.cn	Mingyang, Zhang/J-7412-2019	Mingyang, Zhang/0000-0001-7084-6237; Zhang, Mingyang/0000-0003-1612-0763	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81601306, 81301039, 81530062, 81271379, 81172911]; China Postdoctoral Science Foundation Funded ProjectChina Postdoctoral Science Foundation [2015M570476]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Jiangsu Talent Youth Medical Program [QNRC2016245]; Shanghai Key Lab of Forensic Medicine [KF1502]; Key Laboratory of Evidence Science (China University of Political Science and Law), Ministry of Education [2016KFKT05]; Suzhou Science and Technology Development Project [SYSD2015119]	The present study was supported by the National Natural Science Foundation of China (grant nos. 81601306, 81301039, 81530062, 81271379 and 81172911); China Postdoctoral Science Foundation Funded Project (grant no. 2015M570476); the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Jiangsu Talent Youth Medical Program (grant no. QNRC2016245); Shanghai Key Lab of Forensic Medicine (grant no. KF1502); Key Laboratory of Evidence Science (China University of Political Science and Law), Ministry of Education (grant no. 2016KFKT05); and the Suzhou Science and Technology Development Project (grant no. SYSD2015119).	Amador FC, 2004, NEUROTOXICOL TERATOL, V26, P387, DOI 10.1016/j.ntt.2003.12.007; Bennett MC, 1996, J NEUROCHEM, V66, P2606; Bhatia M, 2012, SCIENTIFICA, V2012, DOI 10.6064/2012/159680; Calvert JW, 2009, CIRC RES, V105, P365, DOI 10.1161/CIRCRESAHA.109.199919; Chang SJ, 2003, INT J TOXICOL, V22, P175, DOI 10.1080/10915810305109; Chen WL, 2015, REV NEUROSCIENCE, V26, P129, DOI 10.1515/revneuro-2014-0051; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Fayaz SM, 2014, CNS NEUROL DISORD-DR, V13, P42, DOI 10.2174/18715273113126660189; Gotor C, 2013, AUTOPHAGY, V9, P609, DOI 10.4161/auto.23460; Grammatopoulos TN, 2004, BRAIN RES BULL, V62, P297, DOI 10.1016/j.brainresbull.2003.09.018; Gu YL, 2014, NEUROSCI LETT, V570, P86, DOI 10.1016/j.neulet.2014.04.004; Han M, 2008, ARCH PHARM RES, V31, P749, DOI 10.1007/s12272-001-1222-5; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; Huang CW, 2015, HANDB EXP PHARMACOL, V230, P3, DOI 10.1007/978-3-319-18144-8_1; Huttemann M, 2008, NEUROSCIENCE, V151, P148, DOI 10.1016/j.neuroscience.2007.09.029; Inomata K, 2003, J PHARMACOL SCI, V93, P163, DOI 10.1254/jphs.93.163; Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191; Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001; Kimura H, 2015, HANDB EXP PHARMACOL, V230, P61, DOI 10.1007/978-3-319-18144-8_3; Kimura H, 2014, MOLECULES, V19, P16146, DOI 10.3390/molecules191016146; Kimura Hideo, 2012, Folia Pharmacologica Japonica, V139, P6; Kimura H, 2011, AMINO ACIDS, V41, P113, DOI 10.1007/s00726-010-0510-x; Kimura Y, 2010, ANTIOXID REDOX SIGN, V12, P1, DOI 10.1089/ars.2008.2282; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Lipinski MM, 2015, ANTIOXID REDOX SIGN, V23, P565, DOI 10.1089/ars.2015.6306; Liu JQ, 2016, CELL BIOSCI, V6, DOI 10.1186/s13578-016-0099-1; Liu LP, 2017, ALCOHOL ALCOHOLISM, V52, P12, DOI 10.1093/alcalc/agw077; Lutton JD, 1996, EXP PHYSIOL, V81, P251, DOI 10.1113/expphysiol.1996.sp003929; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Nagpure BV, 2015, HANDB EXP PHARMACOL, V230, P193, DOI 10.1007/978-3-319-18144-8_10; Ott M, 2007, APOPTOSIS, V12, P913, DOI 10.1007/s10495-007-0756-2; Park Y, 2015, J NEUROTRAUM, V32, P1449, DOI 10.1089/neu.2014.3694; Ryu JR, 2016, MOL BRAIN, V9, DOI 10.1186/s13041-016-0224-4; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Sato E, 2008, MED MOL MORPHOL, V41, P211, DOI 10.1007/s00795-008-0414-y; Satpute R, 2012, IRAN J PHARM RES, V11, P303; Selvatici R, 2009, NEUROCHEM RES, V34, P909, DOI 10.1007/s11064-008-9852-0; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; Shen HM, 2011, AUTOPHAGY, V7, P457, DOI 10.4161/auto.7.5.14226; Smith CM, 2011, NEUROBIOL DIS, V43, P52, DOI 10.1016/j.nbd.2010.09.014; Whiteman M, 2004, J NEUROCHEM, V90, P765, DOI 10.1111/j.1471-4159.2004.02617.x; Yin F, 2014, ANTIOXID REDOX SIGN, V20, P353, DOI 10.1089/ars.2012.4774; Zhang Li, 2011, Chinese Journal of Natural Medicines, V9, P450, DOI 10.3724/SP.J.1009.2011.00450; Zhang MY, 2017, CELL MOL NEUROBIOL, V37, P291, DOI 10.1007/s10571-016-0369-9; Zhang MY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087241; Zhang MY, 2013, J MOL NEUROSCI, V51, P57, DOI 10.1007/s12031-012-9948-5; Zhang ZY, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2012.2758	47	14	15	0	10	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	NOV	2017	16	5					5938	5946		10.3892/mmr.2017.7363			9	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	FM0ZU	WOS:000414698900026	28849152	Green Published, Other Gold			2021-06-18	
J	Zhou, ZW; Li, F; Zheng, ZT; Li, YD; Chen, TH; Gao, WW; Chen, JL; Zhang, JN				Zhou, Zi-wei; Li, Fei; Zheng, Zhi-tong; Li, Ya-dan; Chen, Tong-heng; Gao, Wei-wei; Chen, Jie-li; Zhang, Jian-ning			Erythropoietin regulates immune/inflammatory reaction and improves neurological function outcomes in traumatic brain injury	BRAIN AND BEHAVIOR			English	Article						erythropoietin; neuroimmune; neuroinflammation; regulatory T cell (Treg); traumatic brain injury	RECOMBINANT-HUMAN-ERYTHROPOIETIN; CEREBRAL-ISCHEMIA; COGNITIVE IMPAIRMENT; RECEPTOR EXPRESSION; NEURONAL APOPTOSIS; BARRIER DISRUPTION; WHITE-MATTER; HEAD-INJURY; T-CELLS; MODEL	IntroductionTraumatic brain injury (TBI) remains a leading cause of disability and death among young people in China. Unfortunately, no specific pharmacological agents to block the progression of secondary brain injury have been approved for clinical treatment. Recently, neuroprotective effects of erythropoietin (EPO) have been demonstrated in addition to its principal function in erythropoiesis, and hence it is viewed as a potential drug for TBI. In this study, we have investigated the neuroprotective effects of EPO associated with immune/inflammatory modulation in a mouse experimental TBI model. MethodsEPO (5000U/kg body weight, i.p.) was injected at 1hr, 1, 2, and 3days after TBI, and its effect on cognitive function, brain edema, immune/inflammatory cells including regulatory T cells (Tregs), neutrophils, CD3(+) T cells, and microglia, cytokines including interleukin-10 (IL-10), transforming growth factor- (TGF-), interleukin-1 (IL-1), and tumor necrosis factor- (TNF-) were evaluated at different time points after treatment. ResultsEPO treatment significantly decreased brain edema and improved cognitive function when compared to Saline-treated mice (p<.05). EPO treatment also significantly increased Tregs level in spleen and injured brain tissue as well as significantly reduced the infiltration and activation of immune/inflammatory cells (neutrophils, CD3(+)T cells, and microglia) in the injured hemisphere compared to Saline-treated control animals (p<.05). In addition, ELISA analysis demonstrated that EPO treatment increased the expression of anti-inflammatory cytokine IL-10, but decreased the expression of proinflammatory cytokine IL-1 and TNF- in the injured brain tissue (p<.05). ConclusionsThese findings suggest that EPO could improve neurological and cognitive functional outcomes as well as regulate immune/inflammatory reaction in TBI.	[Zhou, Zi-wei; Li, Fei; Zheng, Zhi-tong; Gao, Wei-wei; Zhang, Jian-ning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China; [Zhou, Zi-wei; Gao, Wei-wei; Zhang, Jian-ning] Tianjin Neurol Inst, Tianjin, Peoples R China; [Zhou, Zi-wei; Gao, Wei-wei; Zhang, Jian-ning] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin, Peoples R China; [Zhou, Zi-wei; Gao, Wei-wei; Zhang, Jian-ning] Tianjin Key Lab Injuries Variat & Regenerat Nervo, Tianjin, Peoples R China; [Li, Ya-dan] Tianjin Huanhu Hosp, Intens Care Units, Tianjin, Peoples R China; [Chen, Tong-heng] Tianjin Med Univ, Hosp 2, Dept Neurosurg, Tianjin, Peoples R China; [Chen, Jie-li] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA	Zhou, ZW; Zhang, JN (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China.	ziweizhou2009@hotmail.com; jianningzhang@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271361, 81330029]; Natural Science Foundations of TianjinNatural Science Foundation of Tianjin [13JCZDJC30800]; Incubation project of Natural Science Foundations of Tianjin Medical University General Hospital [303071901401]	National Natural Science Foundation of China, Grant/Award Number: 81271361 and 81330029; Natural Science Foundations of Tianjin, Grant/Award Number: 13JCZDJC30800; Incubation project of Natural Science Foundations of Tianjin Medical University General Hospital, Grant/Award Number: 303071901401	Acheson A, 2007, PHYSIOL BEHAV, V91, P579, DOI 10.1016/j.physbeh.2007.03.020; Assaraf MI, 2007, J NEUROPATH EXP NEUR, V66, P389, DOI 10.1097/nen.0b013e3180517b28; Atalay B, 2007, BRIT J NEUROSURG, V21, P281, DOI 10.1080/02688690701364781; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Barichello T, 2014, TRANSL RES, V163, P503, DOI 10.1016/j.trsl.2013.12.008; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Chen X, 2014, NEUROSCIENCE, V266, P235, DOI 10.1016/j.neuroscience.2013.11.036; Cianferotti L, 2014, ENDOCRINE, V45, P165, DOI 10.1007/s12020-013-0026-8; Cunningham TL, 2014, J NEUROTRAUM, V31, P505, DOI 10.1089/neu.2013.2965; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Fujiki M, 2008, J CLIN NEUROSCI, V15, P791, DOI 10.1016/j.jocn.2007.07.002; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Hellewell SC, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-156; Kertesz N, 2004, DEV BIOL, V276, P101, DOI 10.1016/j.ydbio.2004.08.025; Kumral A, 2011, BRAIN DEV-JPN, V33, P632, DOI 10.1016/j.braindev.2010.10.014; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Okutan O, 2008, SURG NEUROL, V70, P498, DOI 10.1016/j.surneu.2007.07.061; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Roberts DJ, 2013, J NEUROTRAUM, V30, P1727, DOI 10.1089/neu.2012.2842; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Schneider DF, 2007, J BURN CARE RES, V28, P365, DOI 10.1097/BCR.0B013E318053D40B; Tada H, 2006, CARDIOVASC RES, V71, P466, DOI 10.1016/j.cardiores.2006.05.010; TAN CC, 1991, KIDNEY INT, V40, P69, DOI 10.1038/ki.1991.181; Tang ZH, 2013, NEUROPHARMACOLOGY, V67, P8, DOI 10.1016/j.neuropharm.2012.10.017; Teixeira AM, 2010, RENAL FAILURE, V32, P1073, DOI 10.3109/0886022X.2010.509897; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Walsh JT, 2011, TRENDS MOL MED, V17, P541, DOI 10.1016/j.molmed.2011.05.012; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wright GL, 2004, FASEB J, V18, P1031, DOI 10.1096/fj.03-1289fje; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Xu F, 2012, EXP THER MED, V4, P977, DOI 10.3892/etm.2012.723; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yi CL, 2012, INJURY, V43, P402, DOI 10.1016/j.injury.2010.12.011; Yuan RR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001924	42	14	17	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	2162-3279			BRAIN BEHAV	Brain Behav.	NOV	2017	7	11							e00827	10.1002/brb3.827			10	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	FN5QR	WOS:000416063200004	29201540	DOAJ Gold, Green Published			2021-06-18	
J	van der Horn, HJ; Scheenen, ME; de Koning, ME; Liemburg, EJ; Spikman, JM; van der Naalt, J				van der Horn, Harm J.; Scheenen, Myrthe E.; de Koning, Myrthe E.; Liemburg, Edith J.; Spikman, Jacoba M.; van der Naalt, Joukje			The Default Mode Network as a Biomarker of Persistent Complaints after Mild Traumatic Brain Injury: A Longitudinal Functional MRI Study	JOURNAL OF NEUROTRAUMA			English	Article						brain networks; fMRI; functional connectivity; mTBI; persistent complaints	HEAD-INJURY; INDEPENDENT COMPONENTS; EARLY PREDICTORS; CONNECTIVITY; SYMPTOMS; ANXIETY; FMRI; INFERENCES; UPFRONT; RETURN	The objective of this study was to examine longitudinal functional connectivity of resting-state networks in patients with and without complaints after uncomplicated mild traumatic brain injury (mTBI). Second, we aimed to determine the value of network connectivity in predicting persistent complaints, anxiety, depression and long-term outcome. Thirty mTBI patients with three or more post-traumatic complaints at 2 weeks post-injury, 19 without complaints, and 20 matched healthy controls were selected for this study. Resting-state functional MRI (fMRI) was performed in patients at 1 month and 3 months post-injury, and once in healthy controls. Independent component analysis (ICA) was used to investigate the default mode, executive and salience networks. Persistent post-traumatic complaints, anxiety, and depression were measured at 3 months post-injury, and outcome was determined at 1 year post-injury. Within the group with complaints, higher functional connectivity between the anterior and posterior components of the default mode network at 1 month post-injury was associated with a greater number of complaints at 3 months post-injury (p=0.59, p=0.001). Minor longitudinal changes in functional connectivity were found for patients with and without complaints after mTBI, which were limited to connectivity within the precuneus component of the default mode network. No significant results were found for the executive and salience networks. Current results suggest that the default mode network may serve as a biomarker of persistent complaints in patients with uncomplicated mTBI.	[van der Horn, Harm J.; de Koning, Myrthe E.; van der Naalt, Joukje] Univ Groningen, Dept Neurol, Groningen, Netherlands; [Scheenen, Myrthe E.; Spikman, Jacoba M.] Univ Med Ctr Groningen, Dept Neuropsychol, Groningen, Netherlands; [Liemburg, Edith J.] Univ Med Ctr Groningen, NeuroImaging Ctr, Dept Neurosci, Groningen, Netherlands	van der Horn, HJ (corresponding author), Univ Groningen, Dept Neurol, Univ Med Ctr Groningen, Hanzepl 1,POB 30-001, NL-9700 RB Groningen, Netherlands.	h.j.van.der.horn@umcg.nl	Leemans, Alexander/A-1784-2011	Leemans, Alexander/0000-0002-9306-6126; Spikman, Jacoba/0000-0002-6477-0763	Dutch Brain Foundation [Ps2012-06]	The authors thank Dr. Jan Cees de Groot for his assistance in the assessment of structural MRI scans. The study was funded by the Dutch Brain Foundation (grant no. Ps2012-06).	Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Andrews-Hanna JR, 2014, ANN NY ACAD SCI, V1316, P29, DOI 10.1111/nyas.12360; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Anticevic A, 2012, TRENDS COGN SCI, V16, P584, DOI 10.1016/j.tics.2012.10.008; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cole MW, 2014, NEUROSCIENTIST, V20, P652, DOI 10.1177/1073858414525995; Cole MW, 2010, NEUROIMAGE, V49, P3132, DOI 10.1016/j.neuroimage.2009.11.001; de Koning ME, 2016, INJURY, V47, P2041, DOI 10.1016/j.injury.2016.04.036; DeYoung CG, 2010, PSYCHOL SCI, V21, P820, DOI 10.1177/0956797610370159; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Eklund A, 2016, P NATL ACAD SCI USA, V113, P7900, DOI 10.1073/pnas.1602413113; Ettenhofer ML, 2012, J INT NEUROPSYCH SOC, V18, P451, DOI 10.1017/S1355617711001895; Fisher RA, 1914, BIOMETRIKA, V10, P507; Fox KCR, 2015, NEUROIMAGE, V111, P611, DOI 10.1016/j.neuroimage.2015.02.039; Himberg J, 2004, NEUROIMAGE, V22, P1214, DOI 10.1016/j.neuroimage.2004.03.027; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Li WJ, 2014, HUM BRAIN MAPP, V35, P238, DOI 10.1002/hbm.22168; Li YO, 2007, HUM BRAIN MAPP, V28, P1251, DOI 10.1002/hbm.20359; Linley PA, 2004, J TRAUMA STRESS, V17, P11, DOI 10.1023/B:JOTS.0000014671.27856.7e; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; MCGRAW KO, 1992, PSYCHOL BULL, V111, P361, DOI 10.1037/0033-2909.111.2.361; Meier TB, 2017, BRAIN IMAGING BEHAV, V11, P129, DOI 10.1007/s11682-016-9520-y; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Mulders PC, 2015, NEUROSCI BIOBEHAV R, V56, P330, DOI 10.1016/j.neubiorev.2015.07.014; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Scheenen M. E., 2017, J NEUROTRAUMA NEU, V2016, P4885; Scheenen ME, 2017, CLIN REHABIL, V31, P1019, DOI 10.1177/0269215516687101; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Servaas MN, 2014, HUM BRAIN MAPP, V35, P4303, DOI 10.1002/hbm.22476; Skup M, 2010, STAT INTERFACE, V3, P235; Sours C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134019; Sours C, 2015, BRAIN IMAGING BEHAV, V9, P190, DOI 10.1007/s11682-014-9295-y; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Sylvester CM, 2012, TRENDS NEUROSCI, V35, P527, DOI 10.1016/j.tins.2012.04.012; Termenon M, 2016, NEUROIMAGE, V142, P172, DOI 10.1016/j.neuroimage.2016.05.062; van der Horn HJ, 2016, J NEUROTRAUM, V33, P1, DOI 10.1089/neu.2015.3905; van der Horn HJ, 2013, ARCH PHYS MED REHAB, V94, P867, DOI 10.1016/j.apmr.2012.11.039; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Naalt J, 2017, LANCET NEUROL, V16, P532, DOI 10.1016/S1474-4422(17)30117-5; Verhage F., 1964, INTELLIGENCE AGE STU; Whitfield-Gabrieli S, 2012, ANNU REV CLIN PSYCHO, V8, P49, DOI 10.1146/annurev-clinpsy-032511-143049; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	60	14	14	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2017	34	23					3262	3269		10.1089/neu.2017.5185		OCT 2017	8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FN9HM	WOS:000414459100001	28882089				2021-06-18	
J	Barbacci, DC; Roux, A; Muller, L; Jackson, SN; Post, J; Baldwin, K; Hoffer, B; Balaban, CD; Schultz, JA; Gouty, S; Cox, BM; Woods, AS				Barbacci, Damon C.; Roux, Aurelie; Muller, Ludovic; Jackson, Shelley N.; Post, Jeremy; Baldwin, Kathrine; Hoffer, Barry; Balaban, Carey D.; Schultz, J. Albert; Gouty, Shawn; Cox, Brian M.; Woods, Amina S.			Mass Spectrometric Imaging of Ceramide Biomarkers Tracks Therapeutic Response in Traumatic Brain Injury	ACS CHEMICAL NEUROSCIENCE			English	Article						Traumatic brain injury; controlled cortical impact; lipids; sphingomyelin; ceramides; mass spectrometry imaging; silver nanoparticles implantation; diffuse axonal injury	EXCITATORY AMINO-ACIDS; FREE FATTY-ACIDS; SPINAL-CORD; RAT-BRAIN; UP-REGULATION; CELL-DEATH; DYNORPHIN; NEUROTOXICITY; MECHANISM; PEPTIDES	Traumatic brain injury (TBI) is a serious public health problem and the leading cause of death in children and young adults. It also contributes to a substantial number of cases of permanent disability. As lipids make up over 50% of the brain mass and play a key role in both membrane structure and cell signaling, their profile is of particular interest. In this study, we show that advanced mass spectrometry imaging (MSI) has sufficient technical accuracy and reproducibility to demonstrate the anatomical distribution of 50 mu m diameter microdomains that show changes in brain ceramide levels in a rat model of controlled cortical impact (CCI) 3 days post injury with and without treatment. Adult male Sprague-Dawley rats received one strike and were euthanized 3 days post trauma. Brain MS images showed increase in ceramides in CCI animals compared to control as well as significant reduction in ceramides in CCI treated animals, demonstrating therapeutic effect of a peptide agonist. The data also suggests the presence of diffuse changes outside of the injured area. These results shed light on the extent of biochemical and structural changes in the brain after traumatic brain injury and could help to evaluate the efficacy of treatments.	[Roux, Aurelie; Muller, Ludovic; Jackson, Shelley N.; Post, Jeremy; Baldwin, Kathrine; Woods, Amina S.] NIH, Struct Biol Unit, Integrat Neurosci Branch, NIDA IRP, Baltimore, MD 21224 USA; [Gouty, Shawn; Cox, Brian M.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Dept Pharmacol, Bethesda, MD 20814 USA; [Barbacci, Damon C.; Schultz, J. Albert] Ionwerks Inc, Houston, TX 77002 USA; [Balaban, Carey D.] Univ Pittsburgh, Dept Otolaryngol Neurobiol Commun Sci & Disorders, Pittsburgh, PA 15213 USA; [Balaban, Carey D.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15213 USA; [Hoffer, Barry] Univ Hosp Cleveland, Cleveland, OH 44106 USA	Woods, AS (corresponding author), NIH, Struct Biol Unit, Integrat Neurosci Branch, NIDA IRP, Baltimore, MD 21224 USA.		Balaban, Carey/I-3467-2017; Balaban, Carey/O-6586-2019	Balaban, Carey/0000-0002-3570-3844; Balaban, Carey/0000-0002-3570-3844	Department of Defense, Center for Neuroscience and Regenerative Medicine (CNRM), Rockville, MD; National Institute on Drug Abuse, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); NIH SBIRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R44DA030853-03 5R44DA036263-03]; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [ZIADA000593, ZIADA000589, R44DA036263, R44DA030853, ZIADA000594] Funding Source: NIH RePORTER	This work was supported in part by grants from Department of Defense, Center for Neuroscience and Regenerative Medicine (CNRM), Rockville, MD and the Intramural Research Program of the National Institute on Drug Abuse, NIH. Ionwerks gratefully acknowledges support of this work through NIH SBIR Phase II Grants R44DA030853-03 5R44DA036263-03.	Armstead WM, 2011, NEUROL RES, V33, P726, DOI 10.1179/016164110X12807570509853; Aureli M, 2014, GLYCOCONJUGATE J, V31, P449, DOI 10.1007/s10719-014-9541-y; BAETHMANN A, 1989, J NEUROSURG, V70, P578, DOI 10.3171/jns.1989.70.4.0578; BAKSHI R, 1990, J NEUROSCI, V10, P3793; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Bjorneras J, 2013, BIOCHEMISTRY-US, V52, P4157, DOI 10.1021/bi4004205; CAUDLE RM, 1988, BRAIN RES, V443, P329, DOI 10.1016/0006-8993(88)91628-9; CONE RI, 1983, J NEUROSCI, V3, P2146; Crowley NA, 2016, CELL REP, V14, P2774, DOI 10.1016/j.celrep.2016.02.069; FADEN AI, 1992, J NEUROSCI, V12, P425; FALLON JH, 1986, J COMP NEUROL, V249, P293, DOI 10.1002/cne.902490302; Gatson JW, 2014, J NEUROSURG, V121, P1232, DOI 10.3171/2014.7.JNS132474; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hannun YA, 2011, J BIOL CHEM, V286, P27855, DOI 10.1074/jbc.R111.254359; Hauser KF, 1999, EXP NEUROL, V160, P361, DOI 10.1006/exnr.1999.7235; Hauser KF, 2005, FRONT BIOSCI-LANDMRK, V10, P216, DOI 10.2741/1522; HerreraMarschitz M, 1996, J NEUROCHEM, V66, P1726; Hussain ZM, 2012, J NEUROTRAUM, V29, P1785, DOI 10.1089/neu.2011.2286; Iremonger KJ, 2009, J NEUROSCI, V29, P7349, DOI 10.1523/JNEUROSCI.0381-09.2009; Kim JH, 2011, NEUROSCIENCE, V185, P125, DOI 10.1016/j.neuroscience.2011.04.018; Koetzner L, 2004, J NEUROSCI, V24, P1451, DOI 10.1523/JNEUROSCI.1517-03.2004; Kubota M, 1996, NEUROL RES, V18, P337; Kulkarni M, 2002, J NEUROTRAUM, V19, P965, DOI 10.1089/089771502320317113; Land BB, 2008, J NEUROSCI, V28, P407, DOI 10.1523/JNEUROSCI.4458-07.2008; LEE CH, 1991, J NEUROCHEM, V56, P370, DOI 10.1111/j.1471-4159.1991.tb08161.x; LONG JB, 1994, J PHARMACOL EXP THER, V269, P358; MacFarlane MP, 2015, BRAIN INJURY, V29, P139, DOI 10.3109/02699052.2014.965208; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Mickley GA, 2006, J AM ASSOC LAB ANIM, V45, P48; Muller L, 2017, J AM SOC MASS SPECTR, V28, P1716, DOI 10.1007/s13361-017-1665-4; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Romine J, 2014, JOVE-J VIS EXP, DOI 10.3791/51781; Roux A, 2016, J NEUROSCI METH, V272, P19, DOI 10.1016/j.jneumeth.2016.02.004; Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; SKILLING SR, 1992, BRAIN RES, V575, P272, DOI 10.1016/0006-8993(92)90090-V; Solin AV, 2013, B EXP BIOL MED+, V155, P324, DOI 10.1007/s10517-013-2144-y; Sparaco M, 2006, J NEUROSCI RES, V83, P256, DOI 10.1002/jnr.20729; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Tang QB, 2000, J NEUROPHYSIOL, V83, P2610; Taniguchi M, 2014, BBA-MOL CELL BIOL L, V1841, P692, DOI 10.1016/j.bbalip.2013.12.003; Team RC, 2016, R LANG ENV STAT COMP; Thon L, 2005, FASEB J, V19, P1945, DOI 10.1096/fj.05-3726com; Tulley JM, 2008, SHOCK, V29, P269, DOI 10.1097/shk.0b013e31811ff60c; WAGNER JJ, 1993, NATURE, V363, P451, DOI 10.1038/363451a0; WANG JQ, 1994, SYNAPSE, V18, P343, DOI 10.1002/syn.890180410; WATSON SJ, 1982, SCIENCE, V218, P1134, DOI 10.1126/science.6128790; Whitehead SN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020808; Woodcock J, 2006, IUBMB LIFE, V58, P462, DOI 10.1080/15216540600871118; Woods A, 2001, NEUROCHEM RES, V26, P395, DOI 10.1023/A:1010903215566; Woods AS, 2006, J PROTEOME RES, V5, P1017, DOI 10.1021/pr060016+; Yatsu FM, 1971, STROKE, V2, P587, DOI 10.1161/01.STR.2.6.587; Zhang L, 1997, J NEUROPHYSIOL, V78, P582	55	14	15	0	13	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	OCT	2017	8	10					2266	2274		10.1021/acschemneuro.7b00189			9	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	FK4YA	WOS:000413502700021	28745861				2021-06-18	
J	Bonow, RH; Friedman, SD; Perez, FA; Ellenbogen, RG; Browd, SR; Mac Donald, CL; Vavilala, MS; Rivara, FP				Bonow, Robert H.; Friedman, Seth D.; Perez, Francisco A.; Ellenbogen, Richard G.; Browd, Samuel R.; Mac Donald, Christine L.; Vavilala, Monica S.; Rivara, Frederick P.			Prevalence of Abnormal Magnetic Resonance Imaging Findings in Children with Persistent Symptoms after Pediatric Sports-Related Concussion	JOURNAL OF NEUROTRAUMA			English	Article						brain concussion; magnetic resonance imaging; post-concussion syndrome	TRAUMATIC BRAIN-INJURY; RETURN-TO-PLAY; NATURAL-HISTORY; INCIDENTAL FINDINGS; OUTCOME PREDICTION; CLINICAL ARTICLE; ARACHNOID CYSTS; PINEAL CYSTS; YOUNG-ADULTS; HEAD-INJURY	A subset of patients experience persistent symptoms after pediatric concussion, and magnetic resonance imaging (MRI) is commonly used to evaluate for pathology. The utility of this practice is unclear. We conducted a retrospective cohort study to describe the MRI findings in children with concussion. A registry of all patients seen at our institution from January 2010 through March 2016 with pediatric sports-related concussion was cross-referenced with a database of radiographical studies. Radiology reports were reviewed for abnormal findings. Patients with abnormal computed tomographies or MRI scans ordered for reasons other than concussion were excluded. Among 3338 children identified with concussion, 427 underwent MRI. Only 2 (0.5%) had findings compatible with traumatic injury, consisting in both of microhemorrhage. Sixty-one patients (14.3%) had abnormal findings unrelated to trauma, including 24 nonspecific T-2 changes, 15 pineal cysts, eight Chiari I malformations, and five arachnoid cysts. One child underwent craniotomy for a cerebellar hemangioblastoma after presenting with ataxia; another had cortical dysplasia resected after seizure. The 2 patients with microhemorrhage each had three previous concussions, significantly more than patients whose scans were normal (median, 1) or abnormal without injury (median, 1.5; p = 0.048). MRI rarely revealed intracranial injuries in children post-concussion, and the clinical relevance of these uncommon findings remains unclear. Abnormalities unrelated to trauma are usually benign. However, MRI should be thoughtfully considered in children who present with concerning or atypical symptoms.	[Bonow, Robert H.; Vavilala, Monica S.; Rivara, Frederick P.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent Res Ctr, 325 9Th Ave, Seattle, WA 98104 USA; [Bonow, Robert H.; Ellenbogen, Richard G.; Browd, Samuel R.; Mac Donald, Christine L.] Univ Washington, Dept Neurol Surg, 325 9th Ave,Box 359924, Seattle, WA 98104 USA; [Bonow, Robert H.; Perez, Francisco A.; Ellenbogen, Richard G.; Browd, Samuel R.; Mac Donald, Christine L.; Rivara, Frederick P.] Seattle Childrens Hosp, Seattle, WA USA; [Friedman, Seth D.] Seattle Childrens Hosp, Ctr Clin & Translat Res, Radiol Clin Res Imaging Core, Seattle, WA USA; [Perez, Francisco A.] Univ Washington, Seattle Childrens Hosp, Dept Radiol, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Harborview Med Ctr, Dept Anesthesia & Pain Med, 325 9Th Ave, Seattle, WA 98104 USA; [Rivara, Frederick P.] Univ Washington, Seattle Childrens Hosp, Dept Pediat, Seattle, WA 98195 USA	Bonow, RH (corresponding author), Univ Washington, Dept Neurol Surg, 325 9th Ave,Box 359924, Seattle, WA 98104 USA.	rbonow@uw.edu		friedman, seth/0000-0001-8785-7215	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD057822] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD057822] Funding Source: Medline		Al-Holou WN, 2013, J NEUROSURG, V118, P222, DOI 10.3171/2012.10.JNS12548; Al-Holou WN, 2010, J NEUROSURG-PEDIATR, V5, P578, DOI 10.3171/2010.2.PEDS09464; Al-Holou WN, 2010, J NEUROSURG-PEDIATR, V5, P162, DOI 10.3171/2009.9.PEDS09297; Al-Holou WN, 2009, J NEUROSURG-PEDIATR, V4, P230, DOI 10.3171/2009.4.PEDS0951; BERGMAN AB, 1967, NEW ENGL J MED, V276, P1008, DOI 10.1056/NEJM196705042761804; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Cantu RC, 2011, PM&R, V3, pS440, DOI 10.1016/j.pmrj.2011.07.013; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P241, DOI 10.3171/2015.1.PEDS14510; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Katzman GL, 1999, JAMA-J AM MED ASSOC, V282, P36, DOI 10.1001/jama.282.1.36; Kim BS, 2002, AM J NEURORADIOL, V23, P1674; Kokotos Faye, 2009, Pediatr Rev, V30, P193, DOI 10.1542/pir.30-5-193; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; LEVY JC, 1980, PEDIATRICS, V65, P956; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Morgan CD, 2015, CHILD NERV SYST, V31, P2305, DOI 10.1007/s00381-015-2916-y; Pulsipher DT, 2011, CURR SPORT MED REP, V10, P14, DOI 10.1249/JSR.0b013e31820711b8; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Swartz RH, 2004, ARCH NEUROL-CHICAGO, V61, P1366, DOI 10.1001/archneur.61.9.1366; Tator CH, 2016, J NEUROSURG, V125, P1206, DOI 10.3171/2015.6.JNS15664; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wintermark M, 2015, AM J NEURORADIOL, V36, pE12, DOI 10.3174/ajnr.A4254; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	34	14	15	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2017	34	19					2706	2712		10.1089/neu.2017.4970			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FI1DZ	WOS:000411672700005	28490224	Green Published			2021-06-18	
J	Dennis, EL; Babikian, T; Giza, CC; Thompson, PM; Asarnow, RF				Dennis, Emily L.; Babikian, Talin; Giza, Christopher C.; Thompson, Paul M.; Asarnow, Robert F.			Diffusion MRI in pediatric brain injury	CHILDS NERVOUS SYSTEM			English	Article						Traumatic brain injury; Diffusion MRI; Diffuse axonal injury; Pediatric; Concussion	WHITE-MATTER ABNORMALITIES; HEAD IMPACT EXPOSURE; CORPUS-CALLOSUM; BEHAVIOR RELATIONSHIPS; LONGITUDINAL CHANGES; EARLY-CHILDHOOD; CHILDREN; INTEGRITY; MICROSTRUCTURE; METAANALYSIS	Traumatic brain injury (TBI) is a major public health issue around the world and can be especially devastating in children as TBI can derail cognitive and social development. White matter (WM) is particularly vulnerable to disruption post-TBI, as myelination is ongoing during this period. Diffusion magnetic resonance imaging (dMRI) is a versatile modality for identifying and quantifying WM disruption and can detect diffuse axonal injury (DAI or TAI (traumatic axonal injury)). This review covers dMRI studies of pediatric TBI, including mild to severe injuries, and covering all periods post-injury. While there have been considerable advances in our understanding of pediatric TBI through the use of dMRI, there are still large gaps in our knowledge, which will be filled in by larger studies and more longitudinal studies. Heterogeneity post-injury is an obstacle in all TBI studies, but we expect that larger better-characterized samples will aid in identifying clinically meaningful subgroups within the pediatric TBI patient population.	[Dennis, Emily L.; Thompson, Paul M.] USC, Keck Sch Med, Imaging Genet Ctr, Mark & Mary Stevens Neuroimaging & Informat Inst, Marina Del Rey, CA 90292 USA; [Babikian, Talin; Asarnow, Robert F.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA; [Giza, Christopher C.] Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Neurosurg, Los Angeles, CA USA; [Giza, Christopher C.] Mattel Childrens Hosp, Div Pediat Neurol, Los Angeles, CA USA; [Thompson, Paul M.] USC, Dept Neurol, Los Angeles, CA USA; [Thompson, Paul M.] USC, Dept Pediat, Los Angeles, CA USA; [Thompson, Paul M.] USC, Dept Psychiat, Los Angeles, CA USA; [Thompson, Paul M.] USC, Dept Radiol, Los Angeles, CA USA; [Thompson, Paul M.] USC, Dept Engn, Los Angeles, CA USA; [Thompson, Paul M.] USC, Dept Ophthalmol, Los Angeles, CA USA; [Asarnow, Robert F.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA USA; [Asarnow, Robert F.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA USA	Dennis, EL (corresponding author), USC, Keck Sch Med, Imaging Genet Ctr, Mark & Mary Stevens Neuroimaging & Informat Inst, Marina Del Rey, CA 90292 USA.	emily.dennis@ini.usc.edu	Dennis, Emily/AAD-5223-2021; Thompson, Paul M/C-4194-2018	Thompson, Paul M/0000-0002-4720-8867; Dennis, Emily/0000-0001-7112-4009	NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD061504]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K99 NS096116]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U54 EB020403, R01 AG040060, R01 NS080655]; UCLA BIRC [R01 NS027544]; NCAA; US Dept of Defense; UCLA Steve Tisch BrainSPORT Program; Easton Foundation; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [U54EB020403, P41EB015922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K99NS096116, R01NS027544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG040060] Funding Source: NIH RePORTER	Researchers were supported by the NICHD (R01 HD061504). ELD is supported by a grant from the NINDS (K99 NS096116). ELD and PT are also supported by NIH grants to PT: U54 EB020403, R01 AG040060, and R01 NS080655. CCG is supported by the UCLA BIRC, R01 NS027544, NCAA, US Dept of Defense, UCLA Steve Tisch BrainSPORT Program, and Easton Foundation.	Adamson C, 2013, BRAIN INJURY, V27, P454, DOI 10.3109/02699052.2012.750756; Babcock L, 2015, J PEDIATR REHAB MED, V8, P285, DOI 10.3233/PRM-150347; Babikian T, 2009, PEDIATR NEUROL, V41, P406, DOI 10.1016/j.pediatrneurol.2009.06.002; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bearden CE, 2017, NEURON, V94, P232, DOI 10.1016/j.neuron.2017.03.033; Borich M, 2013, J NEUROTRAUM, V30, P1243, DOI 10.1089/neu.2012.2818; Broglio SP, 2017, SPORTS MED, DOI 10.1007/s40279-017-0707-1; Bruce D, 1979, MECH TIME COURSE CLE, P155; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2011, J NEUROTRAUM, V28, P897, DOI 10.1089/neu.2010.1721; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Dennis E. L., 2015, NEUROIMAGE CLIN; Dennis EL, 2017, NEUROLOGY, V88, P1392, DOI 10.1212/WNL.0000000000003808; Dennis EL, 2015, J NEUROSCI, V35, P10202, DOI 10.1523/JNEUROSCI.1595-15.2015; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Ewing-Cobbs L, 2016, HUM BRAIN MAPP, V37, P3929, DOI 10.1002/hbm.23286; Faber J, 2016, BRAIN INJURY, V30, P1635, DOI 10.1080/02699052.2016.1199910; Galloway NR, 2008, J NEUROTRAUM, V25, P1153, DOI 10.1089/neu.2007.0494; Genc S, 2017, J NEUROTRAUM, V34, P798, DOI 10.1089/neu.2016.4584; Hulkower M. B., 2013, AJNR AM J NEURORADIO; Insel T., 2013, DSM 5 RDOC SHARED IN; Jiang Q, 2010, STROKE, V41, pS112, DOI 10.1161/STROKEAHA.110.595629; Johnson CP, 2011, J INT NEUROPSYCH SOC, V17, P663, DOI 10.1017/S1355617711000464; Johnson CP, 2015, NEUROIMAGE-CLIN, V9, P668, DOI 10.1016/j.nicl.2015.10.009; Juranek J, 2012, BRAIN IMAGING BEHAV, V6, P36, DOI 10.1007/s11682-011-9140-5; Konigs M, 2017, BRAIN IMAGING BEHAV; Kurowski B, 2009, J PEDIATR REHAB MED, V2, P273, DOI 10.3233/PRM-2009-0093; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Thompson P. M., 2015, NEUROIMAGE; Thompson PM, 2014, BRAIN IMAGING BEHAV, V8, P153, DOI 10.1007/s11682-013-9269-5; Tlustos SJ, 2015, J PEDIATR REHAB MED, V8, P321, DOI 10.3233/PRM-150350; Treble A, 2013, J NEUROTRAUM, V30, P1609, DOI 10.1089/neu.2013.2934; Van Beek L, 2015, BRAIN INJURY, V29, P1701, DOI 10.3109/02699052.2015.1075172; Van Beek L, 2015, J NEUROTRAUM, V32, P1567, DOI 10.1089/neu.2014.3809; van der Zijden JP, 2008, EXP NEUROL, V212, P207, DOI 10.1016/j.expneurol.2008.03.027; Vu JA, 2011, EXCEPT CHILDREN, V77, P263, DOI 10.1177/001440291107700301; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P404, DOI 10.1007/s11682-012-9150-y; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, DEV NEUROSCI; Wunderle K, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000006; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Yuan WH, 2017, NEUROREHAB NEURAL RE, V31, P190, DOI 10.1177/1545968316675430; Yuan WH, 2015, HUM BRAIN MAPP, V36, P779, DOI 10.1002/hbm.22664; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216; Zhan L, 2010, NEUROIMAGE, V49, P1357, DOI 10.1016/j.neuroimage.2009.09.057	63	14	15	0	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	OCT	2017	33	10					1683	1692		10.1007/s00381-017-3522-y			10	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	FG1LZ	WOS:000409558900011	29149383	Green Accepted			2021-06-18	
J	Maclean, FL; Wang, Y; Walker, R; Horne, MK; Williams, RJ; Nisbet, DR				Maclean, Francesca L.; Wang, Yi; Walker, Rohan; Horne, Malcolm K.; Williams, Richard J.; Nisbet, David R.			Reducing Astrocytic Scarring after Traumatic Brain Injury with a Multifaceted Anti-Inflammatory Hydrogel System	ACS BIOMATERIALS SCIENCE & ENGINEERING			English	Article						hydrogels; fucoidan; astrocyte; phenotype; central nervous system	SPINAL-CORD-INJURY; CENTRAL-NERVOUS-SYSTEM; GLIAL SCAR; ELECTROSPUN SCAFFOLDS; EXTRACELLULAR-MATRIX; REACTIVE ASTROCYTES; STEM-CELLS; DUAL ROLE; REGENERATION; REPAIR	Traumatic brain injury results in devastating long-term functional damage due to the growth inhibition of the inflammatory response, and in particular, the complex response of astrocytes. Sustained, nonsteroidal anti-inflammatory approaches that can attenuate this response are of interest to improve therapeutic outcomes, particularly when combined with a tissue engineering construct that recapitulates the physiological microenvironment to facilitate functional repair. Here, we present a multifaceted, therapeutic extracellular-matrix mimic consisting of a coassembled scaffold with a laminin-inspired self-assembling peptide hydrogel, Fmoc-DIKVAV, and the anti-inflammatory macromolecule, fucoidan. At 7 days post-injury, our novel multicomponent hydrogel system presenting biologically relevant nanofibers and the anti-inflammatory fucoidan attenuated the primary glial scar to half that of a stab (control) injury. Further, the presentation of fucoidan increased the organization of astrocytes within the glial scar, while also significantly changing the morphology of astrocytes distal from the administered hydrogel and further into the parenchyma. This demonstrates that the anti-inflammatory fucoidan, present on the surface of the Fmoc-DIKVAV nanofibers, causes a change in astrocyte phenotype post-injury attenuating "reactive" astrocytosis. For the first time, we present a multicomponent tissue engineering construct to promote a growth-permissive environment in vivo and, thus, increase the potential for repair and regeneration after traumatic brain injury.	[Maclean, Francesca L.; Wang, Yi; Nisbet, David R.] Australian Natl Univ, Res Sch Engn, Lab Adv Biomat, Canberra, ACT, Australia; [Walker, Rohan] Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW, Australia; [Walker, Rohan] Hunter Med Res Inst, Ctr Brain & Mental Hlth Res, New Lambton Hts, Australia; [Horne, Malcolm K.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia; [Horne, Malcolm K.] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic, Australia; [Williams, Richard J.] RMIT Univ, Sch Engn, Melbourne, Vic, Australia; [Williams, Richard J.] St Vincents Hosp, BioFab3D, Fitzroy, Vic, Australia	Nisbet, DR (corresponding author), Australian Natl Univ, Res Sch Engn, Lab Adv Biomat, Canberra, ACT, Australia.; Williams, RJ (corresponding author), RMIT Univ, Sch Engn, Melbourne, Vic, Australia.; Williams, RJ (corresponding author), St Vincents Hosp, BioFab3D, Fitzroy, Vic, Australia.	richard.williams@rmit.edu.au; david.nisbet@anu.edu.au	Horne, Malcolm/AAL-5214-2020	Horne, Malcolm/0000-0001-9427-2100; Nisbet, David/0000-0002-1343-0769; Williams, Richard/0000-0003-3831-8738	NHMRCNational Health and Medical Research Council of Australia [APP1020332, APP1020401, APP1050684]; Australian Postgraduate AwardAustralian Government; Alfred Deakin Research Fellowship; Australian Microscopy and Microanalysis Research Facility (AMMRF)	This research was supported by funding from an NHMRC project grant (APP1020332). F.L.M. was supported by an Australian Postgraduate Award. M.K.H. was supported by an NHMRC Research Fellowship APP1020401. R.J.W. was supported by an Alfred Deakin Research Fellowship. D.R.N. was supported by an NHMRC Career Development Fellowship (APP1050684). Access to the facilities of the Australian National University Centre for Advanced Microscopy (CAM) with funding through the Australian Microscopy and Microanalysis Research Facility (AMMRF) is gratefully acknowledged, as is A/Prof Colin Jackson for the HPLC. The Florey Institute of Neuroscience and Mental Health receives infrastructure support from the Victorian State Government (Australia).	Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Baiguera S, 2014, BIOMATERIALS, V35, P1205, DOI 10.1016/j.biomaterials.2013.10.060; Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034; Busch SA, 2007, CURR OPIN NEUROBIOL, V17, P120, DOI 10.1016/j.conb.2006.09.004; Cregg JM, 2014, EXP NEUROL, V253, P197, DOI 10.1016/j.expneurol.2013.12.024; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; FLACH CR, 1994, BIOPHYS J, V67, P402, DOI 10.1016/S0006-3495(94)80495-3; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Koh HS, 2008, BIOMATERIALS, V29, P3574, DOI 10.1016/j.biomaterials.2008.05.014; Kwon BK, 2002, P NATL ACAD SCI USA, V99, P3246, DOI 10.1073/pnas.052308899; Lau CL, 2014, J NEUROCHEM, V130, P215, DOI 10.1111/jnc.12702; Li R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04643-3; Li R, 2016, NANOMED-NANOTECHNOL, V12, P1397, DOI 10.1016/j.nano.2016.01.009; Li R, 2015, RSC ADV, V5, P301, DOI 10.1039/c4ra13266a; Maclean FL, 2016, STEM CELLS DEV, V25, P214, DOI 10.1089/scd.2015.0314; Moshayedi P, 2014, BIOMATERIALS, V35, P3919, DOI 10.1016/j.biomaterials.2014.01.038; Muccigrosso MM, 2016, BRAIN BEHAV IMMUN, V54, P95, DOI 10.1016/j.bbi.2016.01.009; Nisbet DR, 2012, BIOINTERPHASES, V7, DOI 10.1007/s13758-011-0002-x; O'Shea RD, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00050; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Park HY, 2011, FOOD CHEM TOXICOL, V49, P1745, DOI 10.1016/j.fct.2011.04.020; Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071; Ramon, 1928, DEGENERATION REGENER; Rodriguez AL, 2014, J MATER CHEM B, V2, P7771, DOI 10.1039/c4tb01391c; Rodriguez AL, 2016, NANO RES, V9, P674, DOI 10.1007/s12274-015-0946-0; Rodriguez AL, 2013, SOFT MATTER, V9, P3915, DOI 10.1039/c3sm27758e; Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591; Shi W, 2016, ACTA BIOMATER, V45, P247, DOI 10.1016/j.actbio.2016.09.001; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Tom VJ, 2004, J NEUROSCI, V24, P6531, DOI 10.1523/JNEUROSCI.0994-04.2004; Wang TY, 2012, BIOMATERIALS, V33, P9188, DOI 10.1016/j.biomaterials.2012.09.013; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013	32	14	14	3	28	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	2373-9878			ACS BIOMATER SCI ENG	ACS Biomater. Sci. Eng.	OCT	2017	3	10					2542	2549		10.1021/acsbiomaterials.7b00524			8	Materials Science, Biomaterials	Materials Science	FJ6KO	WOS:000412866900034	33465910				2021-06-18	
J	Jiang, WW; Wang, QH; Liao, YJ; Peng, P; Xu, M; Yin, LX				Jiang, Wan-Wei; Wang, Qing-Hui; Liao, Ya-Jing; Peng, Pai; Xu, Min; Yin, Li-Xin			Effects of dexmedetomidine on TNF-alpha and interleukin-2 in serum of rats with severe craniocerebral injury	BMC ANESTHESIOLOGY			English	Article						Dexmedetomidine; Severe craniocerebral injury; TNF-alpha; Il-2	TRAUMATIC BRAIN-INJURY; INFLAMMATORY RESPONSE; ISCHEMIA-REPERFUSION; HEAD-INJURY; CELLS; NEUROPROTECTION; ANESTHESIA; IMPACT; DAMAGE; IL-6	Background: Dexmedetomidine is a highly selective adrenergic receptor agonist, which has a dose-dependent sedative hypnotic effect. Furthermore, it also has pharmacological properties, and the ability to inhibit sympathetic activity and improve cardiovascular stability during an operation. However, its protective effect on patients with severe craniocerebral injury in the perioperative period remains unclear. Method: Eighty adult male SD rats were used and divided into two groups (n = 40, each group): dexmedetomidine injury group (experimental group), and sodium chloride injury group (control group). Models of severe craniocerebral injury were established in these two groups using the modified Feeney's free-fall method. As soon as the establishment of models was succeed, rat in the experimental group received 1 mu g of dexmedetomidine (0.1 ml), while each rat in the control group was given 0.1 ml of 0.9% sodium chloride. Blood was sampled from an incision at the femoral vein to detect TNF-alpha and IL-2 levels at 1, 12, 24,36,48 and 72 h after establishing the model in the two groups. Results: After severe craniocerebral injury, TNF-alpha levels of rats were lower in every stage and at different degrees in the experimental group than in the control group (P < 0.05), while IL-2 levels were lower in the experimental group to different extents (P < 0.05). Conclusion: Dexmedetomidine protects the brain of rats with severe craniocerebral injury by reducing the release of inflammatory mediators.	[Jiang, Wan-Wei; Wang, Qing-Hui; Liao, Ya-Jing; Peng, Pai; Xu, Min; Yin, Li-Xin] Dalian Univ, Affiliated Zhongshan Hosp, Dept Anesthesiol 2, 6 Jiefang St, Dalian 116001, Peoples R China	Jiang, WW (corresponding author), Dalian Univ, Affiliated Zhongshan Hosp, Dept Anesthesiol 2, 6 Jiefang St, Dalian 116001, Peoples R China.	wanweijdoc@163.com					Aleksandrova E V, 2014, Zh Vopr Neirokhir Im N N Burdenko, V78, P53; Alipour E, 2016, J SOLID STATE ELECTR, V20, P1645, DOI 10.1007/s10008-016-3168-9; Aronowski J, 2011, STROKE, V42, P1781, DOI 10.1161/STROKEAHA.110.596718; Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156; Cakir M, 2015, RENAL FAILURE, V37, P704, DOI 10.3109/0886022X.2015.1011550; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; De Los Rios JA, 2009, NEUROCIRUGIA, V20, P433; Farag E, 2012, CURR PHARM DESIGN, V18, P6257, DOI 10.2174/138161212803832272; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Foley K, 2009, MED HYPOTHESES, V72, P150, DOI 10.1016/j.mehy.2008.08.024; Inoue S, 2016, SHOCK, V45, P63; Lee JS, 2009, ARCH ORTHOP TRAUM SU, V129, P711, DOI 10.1007/s00402-008-0632-8; Liao W, 2013, IMMUNITY, V38, P13, DOI 10.1016/j.immuni.2013.01.004; Lin Y, 2013, INT J MED SCI, V10, P515, DOI 10.7150/ijms.5423; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Mengel J, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00675; Mussack T, 2001, RESUSCITATION, V49, P193, DOI 10.1016/S0300-9572(00)00346-4; Riha H, 2012, PHYSIOL RES, V61, P63, DOI 10.33549/physiolres.932224; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; Sanders RD, 2010, ACTA ANAESTH SCAND, V54, P710, DOI 10.1111/j.1399-6576.2009.02177.x; Sanders RD, 2009, CRIT CARE CLIN, V25, P551, DOI 10.1016/j.ccc.2009.05.001; Sato K, 2010, ACTA ANAESTH SCAND, V54, P377, DOI 10.1111/j.1399-6576.2009.02139.x; Shi QQ, 2012, SAUDI MED J, V33, P375; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Tang XP, 2008, NEURAL REGEN RES, V3, P867; Waldmann TA, 2006, NAT REV IMMUNOL, V6, P595, DOI 10.1038/nri1901; Wang H, 2016, HYPERTENSION, V68, P114, DOI 10.1161/HYPERTENSIONAHA.116.07084; Wang QH, 2000, J TRAUMA SURG, V22, P24; Wu XJ, 2013, J TRAUMA ACUTE CARE, V74, P524, DOI 10.1097/TA.0b013e31827d5de3; Zhang XB, 2014, INFLAMMATION, V37, P942, DOI 10.1007/s10753-014-9814-4; Zhang XY, 2012, ANESTHESIOLOGY, V116, P1035, DOI 10.1097/ALN.0b013e3182503964	33	14	21	0	0	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	SEP 20	2017	17								130	10.1186/s12871-017-0410-7			5	Anesthesiology	Anesthesiology	FH7QB	WOS:000411384200001	28931374	DOAJ Gold, Green Published			2021-06-18	
J	Bailly, N; Llari, M; Donnadieu, T; Masson, C; Arnoux, PJ				Bailly, N.; Llari, M.; Donnadieu, T.; Masson, C.; Arnoux, P. J.			Head impact in a snowboarding accident	SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS			English	Article						Snowboard; ski; head injury; helmet; biomechanics	INJURIES; CONCUSSION; HELMETS; SKIERS; RISK	To effectively prevent sport traumatic brain injury (TBI), means of protection need to be designed and tested in relation to the reality of head impact. This study quantifies head impacts during a typical snowboarding accident to evaluate helmet standards. A snowboarder numerical model was proposed, validated against experimental data, and used to quantify the influence of accident conditions (speed, snow stiffness, morphology, and position) on head impacts (locations, velocities, and accelerations) and injury risk during snowboarding backward falls. Three hundred twenty-four scenarios were simulated: 70% presented a high risk of mild TBI (head peak acceleration >80g) and 15% presented a high risk of severe TBI (head injury criterion >1000). Snow stiffness, speed, and snowboarder morphology were the main factors influencing head impact metrics. Mean normal head impact speed (28 +/- 6km/h) was higher than equivalent impact speed used in American standard helmet test (ASTM F2040), and mean tangential impact speed, not included in standard tests, was 13.8 (+/- 7km/h). In 97% of simulated impacts, the peak head acceleration was below 300g, which is the pass/fail criteria used in standard tests. Results suggest that initial speed, impacted surface, and pass/fail criteria used in helmet standard performance tests do not fully reflect magnitude and variability of snowboarding backward-fall impacts.	[Bailly, N.; Llari, M.; Masson, C.; Arnoux, P. J.] Univ Mediterranee, IFSTTAR UMRT24, Lab Biomecan Appl, Marseille 20, France; [Bailly, N.; Donnadieu, T.] Salomon SAS, Annecy 9, France	Bailly, N (corresponding author), Univ Mediterranee, IFSTTAR UMRT24, Lab Biomecan Appl, Fac Med Sect Nord, Bd P Dramard, F-13916 Marseille 20, France.	nicolas.bailly@ifsttar.fr	ARNOUX, Pierre Jean/AAK-6652-2021	ARNOUX, Pierre Jean/0000-0002-0311-560X			Aare Magnus, 2003, Traffic Inj Prev, V4, P240, DOI 10.1080/15389580309879; Association des Medecin de Montagne, 2013, DOSS PRESS ACC SPORT; Bourdet N, 2014, INT J CRASHWORTHINES, V19, P222, DOI 10.1080/13588265.2013.805293; Cavallero C, 1983, IMPROVEMENT PEDESTRI; Di Landro L, 2002, POLYM TEST, V21, P217, DOI 10.1016/S0142-9418(01)00073-3; Domaines skiables de France, 2013, IND AN 2013; Dressler D, 2012, AM SOC TEST MATER, V1553, P235, DOI 10.1520/STP104525; Emily Sun R.S, 1998, DEV IMPROVED INJURY; European Committee for Standardization, 2007, 10772007 EUR COMM ST; European Committee for Standardization, 2006, 9602006 BS EN, V960; F08 Committee, 2011, F 2040 SPEC HELM US; Fierz C, 2009, J ECOL, V12, P111; Fournier E., 2000, IRCOBI INT RES COUNC, V2000, P223; Fukuda O, 2001, AM J SPORT MED, V29, P437, DOI 10.1177/03635465010290040901; Funk James R, 2008, Biomed Sci Instrum, V44, P207; Giordano Chiara, 2014, Stapp Car Crash J, V58, P29; Glasson E, 2000, IMECHE CONF TRANS, V2000, P79; Hansen K, 2013, ACCIDENT ANAL PREV, V59, P109, DOI 10.1016/j.aap.2013.05.019; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; King A.I., 2003, IRCOBI C LISB PORT, P1; Koyama S, 2011, AM J SPORT MED, V39, P2656, DOI 10.1177/0363546511422331; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; McIntosh AS, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005078; McIntosh AS, 2013, TRAFFIC INJ PREV, V14, P501, DOI 10.1080/15389588.2012.727217; McIntosh AS, 2011, BRIT J SPORT MED, V45, P1258, DOI 10.1136/bjsports-2011-090509; Meijer R., 2012, IRCOBI C SEPT 12 14, P622; Meyers MC, 2007, SPORTS MED, V37, P485, DOI 10.2165/00007256-200737060-00003; Nakaguchi H, 1999, J TRAUMA, V46, P1066, DOI 10.1097/00005373-199906000-00017; Nakaguchi H, 2002, J NEUROSURG, V97, P542, DOI 10.3171/jns.2002.97.3.0542; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Richards Darrin, 2008, Journal of ASTM International, V5, DOI 10.1520/JAI101406; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Ruedl G, 2013, WILD ENVIRON MED, V24, P118, DOI 10.1016/j.wem.2012.11.021; Scher I., 2006, Journal of ASTM International (JAI), V3, pJAI14203, DOI 10.1520/JAI14203; Serre T, 2007, INT J CRASHWORTHINES, V12, P227, DOI 10.1080/13588260701441050; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; Xiang HY, 2005, J TRAUMA, V58, P112, DOI 10.1097/01.TA.0000151270.26634.DD; Yang JK., 2000, J CRASH PREV INJ CON, V2, P131, DOI DOI 10.1080/10286580008902559; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	40	14	14	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0905-7188	1600-0838		SCAND J MED SCI SPOR	Scand. J. Med. Sci. Sports	SEP	2017	27	9					964	974		10.1111/sms.12699			11	Sport Sciences	Sport Sciences	FC8DJ	WOS:000407071700007	27185578				2021-06-18	
J	Cadena, R; Shoykhet, M; Ratcliff, JJ				Cadena, Rhonda; Shoykhet, Michael; Ratcliff, Jonathan J.			Emergency Neurological Life Support: Intracranial Hypertension and Herniation	NEUROCRITICAL CARE			English	Article						Intracranial pressure; Emergency Neurological Life Support; Neurocritical care; Intracranial hypertension	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; CEREBRAL-BLOOD-FLOW; DECOMPRESSIVE CRANIECTOMY; PERFUSION-PRESSURE; HYPERTONIC SALINE; RANDOMIZED-TRIAL; TRANSTENTORIAL HERNIATION; INTRACEREBRAL HEMORRHAGE; DIABETIC-KETOACIDOSIS	Sustained intracranial hypertension and acute brain herniation are "brain codes,'' signifying catastrophic neurological events that require immediate recognition and treatment to prevent irreversible injury and death. As in cardiac arrest, a brain code mandates the organized implementation of a stepwise management algorithm. The goal of this Emergency Neurological Life Support protocol is to implement an evidence-based, standardized approach to the evaluation and management of patients with intracranial hypertension and/or herniation.	[Cadena, Rhonda] Univ N Carolina, Sch Med, Dept Neurol, Chapel Hill, NC 27599 USA; [Cadena, Rhonda] Univ N Carolina, Sch Med, Dept Neurosurg, Chapel Hill, NC 27599 USA; [Cadena, Rhonda] Univ N Carolina, Sch Med, Dept Emergency Med, Chapel Hill, NC 27599 USA; [Shoykhet, Michael] Washington Univ, Sch Med, Dept Pediat, Pediat Crit Care Med, St Louis, MO 63110 USA; [Ratcliff, Jonathan J.] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA; [Ratcliff, Jonathan J.] Emory Univ, Dept Neurol, Atlanta, GA USA	Cadena, R (corresponding author), Univ N Carolina, Sch Med, Dept Neurol, Chapel Hill, NC 27599 USA.; Cadena, R (corresponding author), Univ N Carolina, Sch Med, Dept Neurosurg, Chapel Hill, NC 27599 USA.; Cadena, R (corresponding author), Univ N Carolina, Sch Med, Dept Emergency Med, Chapel Hill, NC 27599 USA.	rhonda.cadena@unc.edu; jonathan.ratcliff@emoryhealthcare.org					Allen BB, 2014, PEDIATR CRIT CARE ME, V15, P62, DOI 10.1097/PCC.0b013e3182a556ea; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Brady K, 2010, STROKE, V41, P1951, DOI 10.1161/STROKEAHA.109.575159; Brain Trauma F American Association of Neurological S Congress of Neurological S, 2016, GUID MAN SERV TRAUM; Brain Trauma Foundation, 2016, GUID MAN SERV TRAUM; Bulger EM, 2012, JAMA-J AM MED ASSOC, V304, P1455; Bullock MR, 1996, J NEUROTRAUM, V13, P711; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Chen HI, 2011, NEUROSURGERY, V69, P53, DOI 10.1227/NEU.0b013e3182191451; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cushing H, 1901, B J HOPKINS HOSP, V126, P289; DUBICK MA, 1994, J TRAUMA, V36, P323, DOI 10.1097/00005373-199403000-00007; Eberle BM, 2010, INJURY, V41, P894, DOI 10.1016/j.injury.2010.02.023; Edge JA, 2001, ARCH DIS CHILD, V85, P16, DOI 10.1136/adc.85.1.16; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; Fong JJ, 2008, CRIT CARE MED, V36, P2281, DOI 10.1097/CCM.0b013e318180c1eb; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; GALICICH JH, 1961, J LANCET, V81, P46; Glaser N, 2001, NEW ENGL J MED, V344, P264, DOI 10.1056/NEJM200101253440404; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Johnson RD, 2011, J CLIN NEUROSCI, V18, P1018, DOI 10.1016/j.jocn.2010.12.021; Kellie George, 1824, Trans Med Chir Soc Edinb, V1, P84; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; Kernohan JW, 1929, ARCH NEURO PSYCHIATR, V21, P274, DOI 10.1001/archneurpsyc.1929.02210200030004; Kerr ME, 2000, J NEUROSURG ANESTH, V12, P324, DOI 10.1097/00008506-200010000-00005; Khoshyomn Sami, 2004, Semin Pediatr Surg, V13, P80, DOI 10.1053/j.sempedsurg.2004.01.003; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Koenig MA, 2008, NEUROLOGY, V70, P1023, DOI 10.1212/01.wnl.0000304042.05557.60; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Mendelow AD, 2005, LANCET, V365, P387; Meyer A, 1920, ARCH NEURO PSYCHIATR, V4, P387, DOI 10.1001/archneurpsyc.1920.02180220036003; Monro Alexander, 1783, OBSERVATIONS STRUCTU; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Ng I, 2004, NEUROSURGERY, V54, P593, DOI 10.1227/01.NEU.0000108639.16783.39; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Perez-Barcena J, 2008, CRIT CARE, V12, DOI 10.1186/cc6999; Pfefferkorn T, 2009, STROKE, V40, P3045, DOI 10.1161/STROKEAHA.109.550871; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; QUARTEY GRC, 1976, J NEUROSURG, V45, P301, DOI 10.3171/jns.1976.45.3.0301; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Raco A, 2003, NEUROSURGERY, V53, P1061, DOI 10.1227/01.NEU.0000088766.34559.3E; Roberts RJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8145; ROPPER AH, 1986, NEW ENGL J MED, V314, P953, DOI 10.1056/NEJM198604103141504; Schmidt B, 2003, STROKE, V34, P84, DOI 10.1161/01.STR.0000047849.01376.AE; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Skoglund TS, 2005, ACTA ANAESTH SCAND, V49, P337, DOI 10.1111/j.1399-6576.2005.00624.x; Sperling M., 2014, PEDIAT ENDOCRINOLOGY; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012	59	14	14	0	10	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	SEP	2017	27			1			S82	S88		10.1007/s12028-017-0454-z			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	FU8HO	WOS:000424094100006	28913634				2021-06-18	
J	Hurstak, E; Johnson, JK; Tieu, L; Guzman, D; Ponath, C; Lee, CT; Jamora, CW; Kushel, M				Hurstak, Emily; Johnson, Julene K.; Tieu, Lina; Guzman, David; Ponath, Claudia; Lee, Christopher T.; Jamora, Christina Weyer; Kushel, Margot			Factors associated with cognitive impairment in a cohort of older homeless adults: Results from the HOPE HOME study	DRUG AND ALCOHOL DEPENDENCE			English	Article						Cognitive impairment; Homeless persons; Alcohol misuse	TRAUMATIC BRAIN-INJURY; ALCOHOL-USE DISORDERS; EXECUTIVE FUNCTION; GERIATRIC SYNDROMES; GENERAL-POPULATION; RISK DRINKING; HEALTH; MEMORY; PERFORMANCE; VALIDATION	Background: We evaluated cognitive function and factors associated with cognitive impairment in a cohort of older homeless adults. We hypothesized that substance use and a history of traumatic brain injury would be associated with cognitive impairment. Methods: We recruited 350 homeless individuals aged >= 50 years using population-based sampling and conducted structured interviews and neuropsychological testing. We evaluated alcohol use with the Alcohol Use Disorder Identification Test, defining high-severity alcohol use as a total score >= 16 or >= 4 on the alcohol dependency sub-scale. We assessed global cognition with the Modified Mini-Mental State Test (3MS) and processing speed and executive function with the Trail Making Test (TMTB), defining impairment as performing 1.5 standard deviations below the standardized mean. We used multivariable logistic regression to examine the association between alcohol use and cognition. Results: Participants had a median age of 58 years [IQR 54-61], 76.7% were men, and 79.9% were African American. A quarter (25.1%) of participants met criteria for impairment on the 3MS; 32.9% met criteria for impairment on TMTB. In models adjusted for sociodemographic variables and health conditions, high-severity alcohol use was associated with global cognitive impairment (AOR 2.39, CI 1.19-4.79) and executive dysfunction (AOR 3.09, CI 1.61-5.92). Conclusions: Older homeless adults displayed a prevalence of cognitive impairment 3-4 times higher than has been observed in general population adults aged 70 and older. Impaired cognition in older homeless adults could impact access to housing programs and the treatment of health conditions, including the treatment of alcohol use disorders.	[Hurstak, Emily; Tieu, Lina; Guzman, David; Ponath, Claudia; Lee, Christopher T.; Kushel, Margot] Univ Calif San Francisco, Div Gen Internal Med, Zuckerberg San Francisco Gen Hosp & Trauma Ctr, San Francisco, CA 94143 USA; [Johnson, Julene K.] Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA USA; [Johnson, Julene K.; Jamora, Christina Weyer] Univ Calif San Francisco, Ctr Aging Diverse Communities, San Francisco, CA 94143 USA; [Tieu, Lina; Guzman, David; Lee, Christopher T.; Kushel, Margot] Univ Calif San Francisco, Ctr Vulnerable Populat, Zuckerberg San Francisco Gen Hosp & Trauma Ctr, San Francisco, CA 94143 USA; [Jamora, Christina Weyer] Univ Calif San Francisco, Dept Psychiat, Zuckerberg San Francisco Gen Hosp & Trauma Ctr, San Francisco, CA 94143 USA	Hurstak, E; Kushel, M (corresponding author), UCSF ZSFG, Box 1364, San Francisco, CA 94143 USA.	Emily.hurstak@ucsf.edu; Margot.kushel@ucsf.edu		Kushel, Margot/0000-0002-1361-6889; Lee, Christopher/0000-0001-7957-1524; Tieu, Lina/0000-0002-9980-0774	National Institute on Aging (NIA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG041860, K24AG046372, P30AG15272, P30AG044281]; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32HP19025]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG015272, K24AG046372, R01AG041860, P30AG044281] Funding Source: NIH RePORTER	This study was funded by grants from the National Institute on Aging (NIA): R01AG041860 [Kushel, Ponath, Guzman], K24AG046372 [Kushel, Guzman and Tieu], P30AG15272 [Johnson], and P30AG044281 [Kushel]. These funding sources had no role in the preparation, review, or approval of the manuscript and do not necessarily represent the official views of the NIH or AHRQ.; Dr. Hurstak receives fellowship support from National Institute of HealthT32HP19025.	Al Hazzouri AZ, 2017, AM J PREV MED, V52, P1, DOI 10.1016/j.amepre.2016.08.009; Alvarez JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI 10.1007/s11065-006-9002-x; Andersen J, 2014, DISABIL REHABIL, V36, P2210, DOI 10.3109/09638288.2014.895870; Arias F, 2016, ADDICT BEHAV, V60, P137, DOI 10.1016/j.addbeh.2016.03.018; Babor T., 2001, ALCOHOL USE DISORDER, V2nd ed.; Backer Thomas Earl, 2007, J Prim Prev, V28, P375, DOI 10.1007/s10935-007-0100-1; Bates ME, 2005, ALCOHOL CLIN EXP RES, V29, P367, DOI 10.1097/01.ALC.0000156131.88125.2A; Bland RC, 2001, CAN J PSYCHIAT, V46, P506, DOI 10.1177/070674370104600604; Bommersbach TJ, 2015, MAYO CLIN PROC, V90, P659, DOI 10.1016/j.mayocp.2015.03.012; Bousman CA, 2010, J NERV MENT DIS, V198, P790, DOI 10.1097/NMD.0b013e3181f97dff; BRANDT J, 1983, ARCH GEN PSYCHIAT, V40, P435; Bravo G, 1997, INT J GERIATR PSYCH, V12, P1008, DOI 10.1002/(SICI)1099-1166(199710)12:10<1008::AID-GPS676>3.0.CO;2-A; Brown R.T., 2016, GERONTOLOGIST; Brown RT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155065; Brown RT, 2013, J HEALTH CARE POOR U, V24, P456, DOI 10.1353/hpu.2013.0077; Brown RT, 2012, J GEN INTERN MED, V27, P16, DOI 10.1007/s11606-011-1848-9; Buhrich N, 2000, PSYCHIATR SERV, V51, P520, DOI 10.1176/appi.ps.51.4.520; BURNAM MA, 1988, EVALUATION REV, V12, P117, DOI 10.1177/0193841X8801200202; Burra TA, 2009, CAN J PSYCHIAT, V54, P123, DOI 10.1177/070674370905400210; Burt MarthaR., 1999, HOMELESSNESS PROGRAM; Cantor J, 2014, ARCH PHYS MED REHAB, V95, P1, DOI 10.1016/j.apmr.2013.08.005; Carpenter WT, 2000, ARCH GEN PSYCHIAT, V57, P533, DOI 10.1001/archpsyc.57.6.533; Chen YJ, 2017, ALZHEIMERS DEMENT, V13, P399, DOI 10.1016/j.jalz.2016.07.151; Cimino T, 2015, JAMA INTERN MED, V175, P1237, DOI 10.1001/jamainternmed.2015.1562; CONIGRAVE KM, 1995, ADDICTION, V90, P1479, DOI 10.1111/j.1360-0443.1995.tb02810.x; Connelly R., 2016, METHOD INNOV, V9; Cossette I, 2014, ARCH PHYS MED REHAB, V95, P1594, DOI 10.1016/j.apmr.2014.03.019; Crews FT, 2005, ALCOHOL CLIN EXP RES, V29, P1504, DOI 10.1097/01.alc.0000175013.50644.61; Culhane Dennis P., 2013, ANAL SOCIAL ISSUES P, V13, P1; Darke S, 2000, ADDICTION, V95, P687, DOI 10.1046/j.1360-0443.2000.9556874.x; Department of Housing and Urban Development, 2011, HOM EM ASS RAP TRANS; Depp CA, 2015, J NERV MENT DIS, V203, P126, DOI 10.1097/NMD.0000000000000248; Ennis N., 2014, MEMORY, P1; Ersche KD, 2006, NEUROPSYCHOPHARMACOL, V31, P1036, DOI 10.1038/sj.npp.1300889; Fazel S, 2014, LANCET, V384, P1529, DOI 10.1016/S0140-6736(14)61132-6; Gabrielian S, 2015, J CLIN PSYCHIAT, V76, pE469, DOI 10.4088/JCP.14m09229; Gardner RC, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002246; Garibaldi B, 2005, J GEN INTERN MED, V20, P726, DOI 10.1111/j.1525-1497.2005.0142.x; GELBERG L, 1990, J AM GERIATR SOC, V38, P1220, DOI 10.1111/j.1532-5415.1990.tb01503.x; Gonzalez EA, 2001, J NERV MENT DIS, V189, P176, DOI 10.1097/00005053-200103000-00006; Hagen E, 2016, J SUBST ABUSE TREAT, V66, P1, DOI 10.1016/j.jsat.2016.02.010; Heaton RK, 2004, REVISED COMPREHENSIV; Humeniuk R, 2010, ALCOHOL SMOKING SUBS; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; Inozemtseva O., 2016, SUBST USE MISUSE, P1; Johnson JK, 2007, J GERONTOL A-BIOL, V62, P1134, DOI 10.1093/gerona/62.10.1134; KATZ S, 1983, J AM GERIATR SOC, V31, P721, DOI 10.1111/j.1532-5415.1983.tb03391.x; Koedam ELGE, 2008, DEMENT GERIATR COGN, V26, P147, DOI 10.1159/000149585; Kril JJ, 1997, NEUROSCIENCE, V79, P983, DOI 10.1016/S0306-4522(97)00083-3; Langa KM, 2008, ALZHEIMERS DEMENT, V4, P134, DOI 10.1016/j.jalz.2008.01.001; Lee CT, 2016, SOC SCI MED, V153, P131, DOI 10.1016/j.socscimed.2016.02.004; Lee CM, 2017, AM J GERIAT PSYCHIAT, V25, P107, DOI 10.1016/j.jagp.2016.07.019; Lundin A, 2015, ALCOHOL CLIN EXP RES, V39, P158, DOI 10.1111/acer.12593; Lundqvist T, 2005, PHARMACOL BIOCHEM BE, V81, P319, DOI 10.1016/j.pbb.2005.02.017; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; McTeague L.M., 2017, AM J PSYCHIAT; Montgomery AE, 2015, PSYCHIAT SERV, V66, P317, DOI 10.1176/appi.ps.201400014; Nishio A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138052; Pluck G, 2011, BRIT J CLIN PSYCHOL, V50, P33, DOI 10.1348/014466510X490253; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RITCHEY FJ, 1990, AM J PUBLIC HEALTH, V80, P1384, DOI 10.2105/AJPH.80.11.1384; Rumpf HJ, 2002, ALCOHOL ALCOHOLISM, V37, P261, DOI 10.1093/alcalc/37.3.261; Sabia S, 2014, NEUROLOGY, V82, P332, DOI 10.1212/WNL.0000000000000063; Sanchez-Cubillo I, 2009, J INT NEUROPSYCH SOC, V15, P438, DOI 10.1017/S1355617709090626; Seidman LJ, 2003, PSYCHIAT SERV, V54, P905, DOI 10.1176/appi.ps.54.6.905; Seidman LJ, 1997, J NERV MENT DIS, V185, P3, DOI 10.1097/00005053-199701000-00002; Shih RA, 2011, AM J PUBLIC HEALTH, V101, P1721, DOI 10.2105/AJPH.2011.300169; SOLARZ A, 1990, J COMMUNITY PSYCHOL, V18, P79, DOI 10.1002/1520-6629(199001)18:1<79::AID-JCOP2290180112>3.0.CO;2-B; Solliday-McRoy C, 2004, J NERV MENT DIS, V192, P471, DOI 10.1097/01.nmd.0000131962.30547.26; Spence S, 2004, J ROY SOC MED, V97, P375, DOI 10.1258/jrsm.97.8.375; Stergiopoulos V, 2015, ACTA PSYCHIAT SCAND, V131, P256, DOI 10.1111/acps.12391; Sullivan G, 2001, PSYCHIATR SERV, V52, P1097, DOI 10.1176/appi.ps.52.8.1097; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Topolovec-Vranic J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1059; Tsemberis S, 2007, J COMMUNITY PSYCHOL, V35, P29, DOI 10.1002/jcop.20132; Verdejo-Garcia A, 2007, PSYCHOPHARMACOLOGY, V190, P517, DOI 10.1007/s00213-006-0632-8; Virag M, 2015, EXP BRAIN RES, V233, P2081, DOI 10.1007/s00221-015-4279-8; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; Wilcox CE, 2014, REV NEUROSCIENCE, V25, P1, DOI 10.1515/revneuro-2013-0054; Wong S, 2016, J ALZHEIMERS DIS, V51, P889, DOI 10.3233/JAD-151016; Wong YLI, 2000, PSYCHOL ASSESSMENT, V12, P69, DOI 10.1037/1040-3590.12.1.69; Woods AJ, 2016, ALCOHOL CLIN EXP RES, V40, P2435, DOI 10.1111/acer.13211; Yarborough BJH, 2016, DRUG ALCOHOL DEPEN, V167, P49, DOI 10.1016/j.drugalcdep.2016.07.024	86	14	14	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	SEP 1	2017	178						562	570		10.1016/j.drugalcdep.2017.06.002			9	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	FF6UK	WOS:000409152300077	28738314	Green Accepted			2021-06-18	
J	Perez-Urrutia, N; Mendoza, C; Alvarez-Ricartes, N; Oliveros-Matus, P; Echeverria, F; Grizzell, JA; Barreto, GE; Iarkov, A; Echeverria, V				Perez-Urrutia, Nelson; Mendoza, Cristhian; Alvarez-Ricartes, Nathalie; Oliveros-Matus, Patricia; Echeverria, Florencia; Alex Grizzell, J.; Barreto, George E.; Iarkov, Alexandre; Echeverria, Valentina			Intranasal cotinine improves memory, and reduces depressive-like behavior, and GFAP plus cells loss induced by restraint stress in mice	EXPERIMENTAL NEUROLOGY			English	Article						Astrocytes; Stress; Cotinine; Depression; Memory	FIBRILLARY ACIDIC PROTEIN; NICOTINIC ACETYLCHOLINE-RECEPTORS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; AMYOTROPHIC-LATERAL-SCLEROSIS; COMBAT-RELATED PTSD; ALZHEIMERS-DISEASE; MOUSE MODEL; FLUOXETINE TREATMENT; HUNTINGTONS-DISEASE	Posttraumatic stress disorder (PTSD), chronic psychological stress, and major depressive disorder have been found to be associated with a significant decrease in glial fibrillary acidic protein (GFAP) immunoreactivity in the hippocampus of rodents. Cotinine is an alkaloid that prevents memory impairment, depressive-like behavior and synaptic loss when co-administered during restraint stress, a model of PTSD and stress-induced depression, in mice. Here, we investigated the effects of post-treatment with intranasal cotinine on depressive- and anxiety like behaviors, visual recognition memory as well as the number and morphology of GFAP+ immunoreactive cells, in the hippocampus and frontal cortex of mice subjected to prolonged restraint stress. The results revealed that in addition to the mood and cognitive impairments, restraint stress induced a significant decrease in the number and arborization of GFAP+ cells in the brain of mice. Intranasal cotinine prevented these stress-derived symptoms and the morphological abnormalities GFAP+ cells in both of these brain regions which are critical to resilience to stress. The significance of these findings for the therapy of PTSD and depression is discussed. (C) 2017 Elsevier Inc. All rights reserved.	[Perez-Urrutia, Nelson; Mendoza, Cristhian; Alvarez-Ricartes, Nathalie; Oliveros-Matus, Patricia; Echeverria, Florencia; Iarkov, Alexandre; Echeverria, Valentina] Univ San Sebastian, Fac Ciencias Salud, Lientur 1457, Concepcion 4030000, Chile; [Alex Grizzell, J.] Univ Tennessee, NeuroNET Res Ctr, Dept Psychol, Knoxville, TN 37996 USA; [Barreto, George E.] Pontificia Univ Javeriana, Fac Ciencias, Dept Nutr & Bioquim, Bogota, DC, Colombia; [Barreto, George E.; Echeverria, Valentina] Univ Autonoma Chile, Inst Ciencias Biomed, Santiago, Chile; [Echeverria, Valentina] Bay Pines VA Healthcare Syst Res & Dev, Bay Pines, FL 33744 USA	Iarkov, A; Echeverria, V (corresponding author), Fac Cs Salud, Lientur 1457, Concepcion 4080871, Chile.; Echeverria, V (corresponding author), 10,000 Bay Pines Blvd, Bay Pines, FL 33744 USA.	Alexandre.larkov@uss.cl; valentina.echeverria@uss.cl	Grizzell, J. Alex/AAF-3845-2019; Valentina Echeverria Moran, BCh/E-7765-2013; Barreto, George E./AAD-7420-2020	Valentina Echeverria Moran, BCh/0000-0003-2393-5418; Barreto, George E./0000-0002-6644-1971; Perez Urrutia, Nelson/0000-0001-9009-671X; Mendoza, Cristhian/0000-0002-5038-0991	Fondo de Ciencia y Tecnologia (FONDECYT) de Chile [1150149]	This material is the result of work supported with resources and the use of facilities at the Bay Pines VA Healthcare System. The contents do not necessarily represent the views of the Department of Veterans Affairs or the United States Government. Also, we thank Dr. William Fray and Dr. Leha Hanson from the Alzheimer's Research Center at Regions Hospital, HealthPartners Research Foundation for providing training and guidance with the implementation of intranasal delivery of drugs to mice. We would also like to thank Drs. Lowell Gaertner and Matthew Cooper from the University of Tennessee for advice on statistical analyses. Funding: This work was supported by the Fondo de Ciencia y Tecnologia (FONDECYT) de Chile, grant 1150149.	Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Babb T L, 1996, Epilepsy Res Suppl, V12, P343; Balsera B, 2014, EUR J MED CHEM, V86, P724, DOI 10.1016/j.ejmech.2014.09.039; Barreto GE, 2015, CURR PHARM DESIGN, V21, P3589, DOI 10.2174/1381612821666150710145250; Benarroch EE, 2005, MAYO CLIN PROC, V80, P1326, DOI 10.4065/80.10.1326; Bencherif M, 2014, CNS NEUROL DISORD-DR, V13, P836, DOI 10.2174/1871527313666140711094525; Broide RS, 1999, MOL NEUROBIOL, V20, P1, DOI 10.1007/BF02741361; Cobb JA, 2016, NEUROSCIENCE, V316, P209, DOI 10.1016/j.neuroscience.2015.12.044; Colquhoun L M, 1997, Adv Pharmacol, V39, P191, DOI 10.1016/S1054-3589(08)60072-1; Colvonen PJ, 2017, NEUROSCI BIOBEHAV R, V75, P140, DOI 10.1016/j.neubiorev.2017.01.027; Crotti A, 2015, TRENDS IMMUNOL, V36, P364, DOI 10.1016/j.it.2015.04.007; Czeh B, 2007, NEUROPSYCHOPHARMACOL, V32, P1490, DOI 10.1038/sj.npp.1301275; Czeh B, 2006, NEUROPSYCHOPHARMACOL, V31, P1616, DOI 10.1038/sj.npp.1300982; d'Incamps BL, 2014, J PHYSIOL-LONDON, V592, P4131, DOI 10.1113/jphysiol.2014.273128; Day JR, 1998, J APPL PHYSIOL, V85, P716; de Aguiar RB, 2013, NEUROPHARMACOLOGY, V71, P292, DOI 10.1016/j.neuropharm.2013.03.032; Dienel GA, 2017, NEUROSCI LETT, V637, P18, DOI 10.1016/j.neulet.2015.02.052; Diniz DG, 2016, BEHAV BRAIN FUNCT, V12, DOI 10.1186/s12993-016-0111-2; Echeverria V, 2017, CURR MED CHEM, V24, P411, DOI 10.2174/0929867323666161101140908; Echeverria V, 2016, PROG NEUROBIOL, V144, P142, DOI 10.1016/j.pneurobio.2016.01.002; Echeverria V, 2016, CURR PHARM DESIGN, V22, P1324, DOI 10.2174/138161282210160304112511; Exley R, 2008, BRIT J PHARMACOL, V153, pS283, DOI 10.1038/sj.bjp.0707510; Feng DY, 2015, EUR NEUROPSYCHOPHARM, V25, P1287, DOI 10.1016/j.euroneuro.2015.04.020; Ferraz AC, 2011, BEHAV BRAIN RES, V219, P116, DOI 10.1016/j.bbr.2010.12.028; Forster D, 2016, NEUROCHEM INT, V94, P57, DOI 10.1016/j.neuint.2016.02.006; Franklin KBJ, 2001, MOUSE BRAIN STEREOTA; Fuchs E, 2006, FRONT BIOSCI-LANDMRK, V11, P2746, DOI 10.2741/2004; Fuller S, 2010, MUTAT RES-FUND MOL M, V690, P40, DOI 10.1016/j.mrfmmm.2009.08.016; Gao J, 2014, BIOORG MED CHEM LETT, V24, P1472, DOI 10.1016/j.bmcl.2014.02.008; Gibbs ME, 2006, GLIA, V54, P214, DOI 10.1002/glia.20377; Grayson B, 2015, BEHAV BRAIN RES, V285, P176, DOI 10.1016/j.bbr.2014.10.025; Grizzell JA, 2017, PROG NEURO-PSYCHOPH, V78, P75, DOI 10.1016/j.pnpbp.2017.05.010; Grizzell JA, 2015, NEUROCHEM RES, V40, P2032, DOI 10.1007/s11064-014-1359-2; Grizzell JA, 2014, BEHAV NEUROSCI, V128, P713, DOI 10.1037/bne0000021; Grizzell JA, 2014, BEHAV BRAIN RES, V268, P55, DOI 10.1016/j.bbr.2014.03.047; Grizzell JA, 2014, NEUROCHEM RES; Guo-Ross SX, 1999, J NEUROCHEM, V73, P1609, DOI 10.1046/j.1471-4159.1999.0731609.x; Hanson LR, 2007, J NEUROIMMUNE PHARM, V2, P81, DOI 10.1007/s11481-006-9039-x; Hanson LR, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S3-S5; Heinrichs SC, 2013, NEUROSCI LETT, V552, P108, DOI 10.1016/j.neulet.2013.07.035; Hennessy E, 2015, J NEUROSCI, V35, P8411, DOI 10.1523/JNEUROSCI.2745-14.2015; Iarkov A, 2016, CANCER CHEMOTH PHARM, V78, P1033, DOI 10.1007/s00280-016-3161-0; Imbe H, 2012, NEUROSCIENCE, V223, P209, DOI 10.1016/j.neuroscience.2012.08.007; Jak A.J, 2016, CURR TOP BEHAV NEURO; Javidi H, 2012, INT J OCCUP ENV MED, V3, P2; Kabadi SV, 2014, J CEREBR BLOOD F MET, V34, P502, DOI 10.1038/jcbfm.2013.228; Karl T, 2003, EXP TOXICOL PATHOL, V55, P69, DOI 10.1078/0940-2993-00301; Karperien A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00003; Karperien AL, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00051; Kim J, 2015, J NEUROCHEM, V134, P927, DOI 10.1111/jnc.13178; KRETZSCHMAR HA, 1985, J NEUROPATH EXP NEUR, V44, P459, DOI 10.1097/00005072-198509000-00002; Laughame J., 2016, J NEUROPSYCHIATR CLI; Lee HS, 2014, P NATL ACAD SCI USA, V111, pE3343, DOI 10.1073/pnas.1410893111; Lee J. D., 2017, BR J PHARM; Li CY, 2011, CURR ALZHEIMER RES, V8, P67; Liu Y, 2015, NEUROPHARMACOLOGY, V91, P87, DOI 10.1016/j.neuropharm.2014.11.028; Lucassen Paul J., 2006, CNS & Neurological Disorders-Drug Targets, V5, P531, DOI 10.2174/187152706778559273; McHugh T, 2012, CLIN PSYCHOL REV, V32, P93, DOI 10.1016/j.cpr.2011.07.013; Meng LH, 2016, SCI REP-UK, V6, DOI 10.1038/srep33748; Moller HJ, 2015, WORLD J BIOL PSYCHIA, V16, P483, DOI 10.3109/15622975.2014.989261; Nagai M, 2007, NAT NEUROSCI, V10, P615, DOI 10.1038/nn1876; Naitoh H, 1992, Yakubutsu Seishin Kodo, V12, P105; Nestler EJ, 2002, NEURON, V34, P13, DOI 10.1016/S0896-6273(02)00653-0; Niranjan R, 2014, MOL NEUROBIOL, V49, P28, DOI 10.1007/s12035-013-8483-x; North CS, 2016, ANN CLIN PSYCHIATRY, V28, P197; Orlovsky MA, 2014, BRAIN RES, V1593, P83, DOI 10.1016/j.brainres.2014.09.059; Otani N, 2006, J CLIN NEUROSCI, V13, P934, DOI 10.1016/j.jocn.2005.10.018; Patel S, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00162; Perrine SA, 2016, BEHAV BRAIN RES, V303, P228, DOI 10.1016/j.bbr.2016.01.056; Pichon Y, 2004, EUR BIOPHYS J BIOPHY, V33, P211, DOI 10.1007/s00249-003-0373-0; Radford RA, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00414; Rehani K, 2008, BBA-MOL CELL RES, V1783, P375, DOI 10.1016/j.bbamcr.2007.12.003; Rotaru TS, 2016, INT J CLIN EXP HYP, V64, P116, DOI 10.1080/00207144.2015.1099406; Sanacora G, 2013, BIOL PSYCHIAT, V73, P1172, DOI 10.1016/j.biopsych.2013.03.032; Santha P, 2016, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00088; Saur L, 2016, NEUROCHEM RES, V41, P892, DOI 10.1007/s11064-015-1770-3; Schaaf KPW, 2013, RESUSCITATION, V84, P873, DOI 10.1016/j.resuscitation.2012.11.021; Schaffner AE, 2001, METHODS, V24, P323, DOI 10.1006/meth.2001.1202; Sheynin J, 2016, NEUROSCI LETT; Spence RD, 2011, P NATL ACAD SCI USA, V108, P8867, DOI 10.1073/pnas.1103833108; Stander VA, 2014, CLIN PSYCHOL REV, V34, P87, DOI 10.1016/j.cpr.2013.12.002; Stobart JL, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00038; Szczepanik J, 2016, PSYCHIAT RES-NEUROIM, V254, P67, DOI 10.1016/j.pscychresns.2016.06.005; Terry AV, 2015, J PHARMACOL EXP THER, V352, P405, DOI 10.1124/jpet.114.219881; Trevizol Alisson Paulino, 2016, Trends Psychiatry Psychother., V38, P50, DOI 10.1590/2237-6089-2015-0072; Ugbode C, 2017, BIOCHEM J, V474, P333, DOI 10.1042/BCJ20160505; Verkhratsky A, 2013, FUTUR NEUROL, V8, P149, DOI 10.2217/fnl.12.90; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Wang L, 2015, PSYCHOPHARMACOLOGY, V232, P4303, DOI 10.1007/s00213-015-4058-z; WATANABE Y, 1992, BRAIN RES, V588, P341, DOI 10.1016/0006-8993(92)91597-8; Webster KM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0786-1; Webster MJ, 2005, NEUROSCIENCE, V133, P453, DOI 10.1016/j.neuroscience.2005.02.037; WEINSTEIN DE, 1991, J CELL BIOL, V112, P1205, DOI 10.1083/jcb.112.6.1205; Wildeboer-Andrud KM, 2014, PHARMACOL BIOCHEM BE, V117, P144, DOI 10.1016/j.pbb.2013.12.005; Williams SG, 2015, SLEEP BREATH, V19, P175, DOI 10.1007/s11325-014-0984-y; Winkler EA, 2015, NAT NEUROSCI, V18, P521, DOI 10.1038/nn.3966; Xia L, 2013, BEHAV BRAIN RES, V256, P472, DOI 10.1016/j.bbr.2013.08.048; Yamanaka K, 2008, NAT NEUROSCI, V11, P251, DOI 10.1038/nn2047; Yang SS, 2015, PROG NEURO-PSYCHOPH, V61, P30, DOI 10.1016/j.pnpbp.2015.03.007; Yoon S, 2017, NEUROPSYCHOPHARMACOL, V42, P454, DOI 10.1038/npp.2016.136; Zeitlin R, 2012, BEHAV BRAIN RES, V228, P284, DOI 10.1016/j.bbr.2011.11.023; Zhu X., 2016, DEPRESS ANXIETY	102	14	14	3	25	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2017	295						211	221		10.1016/j.expneurol.2017.06.016			11	Neurosciences	Neurosciences & Neurology	FC4OS	WOS:000406820900021	28625590				2021-06-18	
J	Rosene, JM; Raksnis, B; Silva, B; Woefel, T; Visich, PS; Dompier, TP; Kerr, ZY				Rosene, John M.; Raksnis, Bryan; Silva, Brie; Woefel, Tyler; Visich, Paul S.; Dompier, Thomas P.; Kerr, Zachary Y.			Comparison of Concussion Rates Between NCAA Division I and Division III Men's and Women's Ice Hockey Players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						ice hockey; division differences; concussions; collegiate athletics; NCAA	INJURY SURVEILLANCE SYSTEM; STATES HIGH-SCHOOL; UNITED-STATES; EPIDEMIOLOGY; HELMETS; MECHANISMS; SPORT	Background: Examinations related to divisional differences in the incidence of sports-related concussions (SRC) in collegiate ice hockey are limited. Purpose: To compare the epidemiologic patterns of concussion in National Collegiate Athletic Association (NCAA) ice hockey by sex and division. Study Design: Descriptive epidemiology study. Methods: A convenience sample of men's and women's ice hockey teams in Divisions I and III provided SRC data via the NCAA Injury Surveillance Program during the 2009-2010 to 2014-2015 academic years. Concussion counts, rates, and distributions were examined by factors including injury activity and position. Injury rate ratios (IRRs) and injury proportion ratios (IPRs) with 95% confidence intervals (CIs) were used to compare concussion rates and distributions, respectively. Results: Overall, 415 concussions were reported for men's and women's ice hockey combined. The highest concussion rate was found in Division I men (0.83 per 1000 athlete-exposures [AEs]), followed by Division III women (0.78/1000 AEs), Division I women (0.65/1000 AEs), and Division III men (0.64/1000 AEs). However, the only significant IRR was that the concussion rate was higher in Division I men than Division III men (IRR = 1.29; 95% CI, 1.02-1.65). The proportion of concussions from checking was higher in men than women (28.5% vs 9.4%; IPR = 3.02; 95% CI, 1.63-5.59); however, this proportion was higher in Division I women than Division III women (18.4% vs 1.8%; IPR = 10.47; 95% CI, 1.37-79.75). The proportion of concussions sustained by goalkeepers was higher in women than men (14.2% vs 2.9%; IPR = 4.86; 95% CI, 2.19-10.77), with findings consistent within each division. Conclusion: Concussion rates did not vary by sex but differed by division among men. Checking-related concussions were less common in women than men overall but more common in Division I women than Division III women. Findings highlight the need to better understand the reasons underlying divisional differences within men's and women's ice hockey and the need to develop concussion prevention strategies specific to each athlete population.	[Rosene, John M.; Raksnis, Bryan; Silva, Brie; Woefel, Tyler; Visich, Paul S.; Dompier, Thomas P.; Kerr, Zachary Y.] Univ New England, Biddeford, ME USA; [Rosene, John M.; Raksnis, Bryan; Silva, Brie; Woefel, Tyler; Visich, Paul S.; Dompier, Thomas P.; Kerr, Zachary Y.] Datalys Ctr Sports Injury Res & Prevent, Indianapolis, IN USA; [Rosene, John M.; Raksnis, Bryan; Silva, Brie; Woefel, Tyler; Visich, Paul S.; Dompier, Thomas P.; Kerr, Zachary Y.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA	Rosene, JM (corresponding author), Westbrook Coll Hlth Profess, Dept Exercise & Sport Performance, 11 Hills Beach Rd, Biddeford, ME 04005 USA.	jrosene@une.edu			NCAA	One or more of the authors has declared the following potential conflict of interest or source of funding: The National Collegiate Athletic Association (NCAA) Injury Surveillance Program data were provided by the Datalys Center for Sports Injury Research and Prevention. The Injury Surveillance Program was funded by the NCAA. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NCAA.	Abbott K, 2014, CURR SPORT MED REP, V13, P377, DOI 10.1249/JSR.0000000000000102; Agel J, 2007, J ATHL TRAINING, V42, P272; Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2010, CAN J SURG, V53, P319; Bonfield CM, 2015, PHYSICIAN SPORTSMED, V43, P236, DOI 10.1080/00913847.2015.1039922; Clark JM, 2016, ANN BIOMED ENG, V44, P3693, DOI 10.1007/s10439-016-1686-3; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Hynes LM, 2006, BRAIN INJURY, V20, P179, DOI 10.1080/02699050500443707; Kerr ZY, 2016, AM J SPORT MED, V44, P220, DOI 10.1177/0363546515612082; Kerr ZY, 2015, MMWR-MORBID MORTAL W, V64, P1330, DOI 10.15585/mmwr.mm6448a2; Kerr ZY, 2015, J ATHL TRAINING, V50, P1174, DOI 10.4085/1062-6050-50.11.11; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Kroshus E, 2016, HEALTH COMMUN, P1; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Matic GT, 2015, PHYSICIAN SPORTSMED, V43, P119, DOI 10.1080/00913847.2015.1035210; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Peterson BJ, 2015, J STRENGTH COND RES, V29, P1191, DOI 10.1519/JSC.0000000000000754; Ruhe A, 2014, BRIT J SPORT MED, V48, P102, DOI 10.1136/bjsports-2012-091609; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Wasserman EB, 2016, AM J SPORT MED, V44, P226, DOI 10.1177/0363546515610537; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	27	14	14	0	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	SEP	2017	45	11					2622	2629		10.1177/0363546517710005			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	FF3NP	WOS:000408809800022	28622025				2021-06-18	
J	Subotic, A; Ting, WKC; Cusimano, MD				Subotic, Arsenije; Ting, Windsor Kwan-Chun; Cusimano, Michael D.			Characteristics of the King-Devick test in the assessment of concussed patients in the subacute and later stages after injury	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; VISUAL SCREENING TOOL; BASE-LINE ASSOCIATIONS; AMATEUR RUGBY UNION; ICE HOCKEY PLAYERS; EYE-MOVEMENTS; SLEEP-DEPRIVATION; YOUTH; INTERFERENCE; ATTENTION	Although the King-Devick (K-D) test has been used frequently in assessing sports related concussion early after injury, its characteristics over time after injury and in patients with prolonged persistent symptoms are unknown. The purpose of this paper was to: evaluate the ability of the K-D Test to distinguish patients seen early after concussion from those with symptoms persisting more than 3 months compared to controls, assess changes in the K-D test times over time after concussion, and determine the relationship of K-D times to the Stroop Color and Word Test scores. We performed cross-sectional comparisons of patients with recent concussive brain injury (acute group) and those with symptoms persisting more than 3 months to healthy controls on the K-D test, the Sports Concussion Assessment Tool 3 (SCAT3), and the Stroop Color and Word Test. Longitudinal comparisons of the acute group over time within the first month after injury were also made. Post-concussive syndrome (PCS) patients had significantly higher K-D times compared to controls (p = 0.01), while the acute group did not differ from controls(p = 0.33). K-D times at the second visit for the acute group were similar to those of controls (54.7 vs. 49.6, p = 0.31). While SCAT3 scores improved over time in the acute group, the K-D scores did not change between the first and second visit (55.2 vs. 54.7, p = 0.94). K-D scores correlated significantly with the Stroop scores for all three participant groups. The K-D test is likely useful very early after concussion in conjunction with baseline scores, and while scores in PCS patients remain elevated, they can be confounded by factors such as pre-morbid depression and medication use. High correlations with Stroop scores also suggest that performance on the K-D test can by proxy provide additional insight about cognitive function and predict performance on more cognitively demanding tasks.	[Subotic, Arsenije; Ting, Windsor Kwan-Chun; Cusimano, Michael D.] St Michaels Hosp, Div Neurosurg, Dept Surg, Injury Prevent Res Off, Toronto, ON, Canada; [Cusimano, Michael D.] Univ Toronto, Toronto, ON, Canada	Cusimano, MD (corresponding author), St Michaels Hosp, Div Neurosurg, Dept Surg, Injury Prevent Res Off, Toronto, ON, Canada.; Cusimano, MD (corresponding author), Univ Toronto, Toronto, ON, Canada.	injuryprevention@smh.ca	Cusimano, Michael/X-4059-2019; Ting, Windsor Kwan-Chun/I-4013-2014	Ting, Windsor Kwan-Chun/0000-0003-4293-9617	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP 123371]	We would like to thank the Canadian Institutes of Health Research MOP 123371 for the study funding. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Benedict PA, 2015, J NEUROL SCI, V353, P111, DOI 10.1016/j.jns.2015.04.029; Broshek DK, 2015, BRAIN INJURY, V29, P228, DOI 10.3109/02699052.2014.974674; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Davies EC, 2012, NEUROLOGY, V78, pE103, DOI 10.1212/WNL.0b013e318251833d; Duenas Matthew, 2014, Surg Neurol Int, V5, P91, DOI 10.4103/2152-7806.134364; Fransson PA, 2008, J VESTIBUL RES-EQUIL, V18, P209; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2015, J NEURO-OPHTHALMOL, V35, P235, DOI 10.1097/WNO.0000000000000226; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; Hoshizaki B, 2013, J NEUROL NEUROPHYSIO; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; King D, 2015, J NEUROL SCI, V351, P58, DOI 10.1016/j.jns.2015.02.035; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Leong Danielle F, 2015, J Optom, V8, P131, DOI 10.1016/j.optom.2014.12.005; MacLeod CM, 2000, TRENDS COGN SCI, V4, P383, DOI 10.1016/S1364-6613(00)01530-8; Marinides Z, 2015, NEUROL CLIN PRACT, V5, P25, DOI DOI 10.1212/CPJ.000000000; Matuszak JM, 2016, SPORTS HEALTH, V8, P260, DOI 10.1177/1941738116641394; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Munce TA, 2014, J CHILD NEUROL, V29, P1601, DOI 10.1177/0883073813509887; Naber M, PSYCHOL, V7, P822; Olk B, 2013, PSYCHOL RES-PSYCH FO, V77, P106, DOI 10.1007/s00426-011-0405-9; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Post A, 2012, P I MECH ENG P-J SPO, V226, P290, DOI 10.1177/1754337112436629; Reilly JL, 2008, BRAIN COGNITION, V68, P415, DOI 10.1016/j.bandc.2008.08.026; Rizzo JR, 2016, ANN CLIN TRANSL NEUR, V3, P801, DOI 10.1002/acn3.345; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seidman DH, 2015, J NEUROL SCI, V356, P97, DOI 10.1016/j.jns.2015.06.021; Silverberg ND, 2014, BRAIN INJURY, V28, P1590, DOI 10.3109/02699052.2014.943287; STROOP JR, 1992, J EXP PSYCHOL GEN, V121, P15; Tjarks BJ, 2013, J NEUROL SCI, V334, P148, DOI 10.1016/j.jns.2013.08.015; Vernau BT, 2015, DEV NEUROPSYCHOL, V40, P7, DOI 10.1080/87565641.2014.971955; Wright RM, J NEUROTRAUMA, V30, P102	39	14	14	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2017	12	8							e0183092	10.1371/journal.pone.0183092			13	Multidisciplinary Sciences	Science & Technology - Other Topics	FF2PY	WOS:000408740500010	28859119	DOAJ Gold, Green Published			2021-06-18	
J	Wada, T; Gando, S; Maekaw, K; Katabami, K; Sageshima, H; Hayakawa, M; Sawamura, A				Wada, Takeshi; Gando, Satoshi; Maekaw, Kunihiko; Katabami, Kenichi; Sageshima, Hisako; Hayakawa, Mineji; Sawamura, Atsushi			Disseminated intravascular coagulation with increased fibrinolysis during the early phase of isolated traumatic brain injury	CRITICAL CARE			English	Article						Disseminated intravascular coagulation; Fibrinolysis; Fibrinogenolysis; Isolated traumatic brain injury; Outcome	CRITICALLY-ILL PATIENTS; HEAD-INJURY; EARLY COAGULOPATHY; HYPOPERFUSION; HEMOSTASIS; THROMBOSIS; CRITERIA; SYSTEM; MICE	Background: There is evidence to demonstrate that the coagulopathy which occurs in patients with traumatic brain injury coincides with disseminated intravascular coagulation (DIC). We hypothesized that DIC with increased fibrinolysis during the early stage of isolated traumatic brain injury (iTBI) affects the outcome of the patients and that hypoperfusion contributes to hyperfibrinolysis in the DIC. Methods: This retrospective study included 92 patients with iTBI who were divided into DIC and non-DIC groups according to the Japanese Association Acute Medicine DIC scoring system. The DIC patients were subdivided into those with and without hyperfibrinolysis. The platelet counts and global markers of coagulation and fibrinolysis were measured. Systemic inflammatory response syndrome (SIRS), organ dysfunction (assessed by the Sequential Organ Failure Assessment score), tissue hypoperfusion (assessed by the lactate levels) and the transfusion volume were also evaluated. The outcome measure was all-cause hospital mortality. Results: DIC patients showed consumption coagulopathy, lower antithrombin levels and higher fibrin/fibrinogen degradation products (FDP) and D-dimer levels than non-DIC patients. All of the DIC patients developed SIRS accompanied by organ dysfunction and required higher blood transfusion volumes, leading to a worse outcome than non-DIC patients. These changes were more prominent in DIC with hyperfibrinolysis. A higher FDP/D-dimer ratio suggests that DIC belongs to the fibrinolytic phenotype and involves fibrin(ogen)olysis. The mean blood pressures of the patients with and without DIC on arrival were identical. Hypoperfusion and the lactate levels were not identified as independent predictors of hyperfibrinolysis. Conclusions: DIC, especially DIC with hyperfibrinolysis, affects the outcome of patients with iTBI. Low blood pressure-induced tissue hypoperfusion does not contribute to hyperfibrinolysis in this type of DIC.	[Wada, Takeshi; Gando, Satoshi; Maekaw, Kunihiko; Katabami, Kenichi; Sageshima, Hisako; Hayakawa, Mineji; Sawamura, Atsushi] Hokkaido Univ, Grad Sch Med, Div Acute & Crit Care Med, Dept Anesthesiol & Crit Care Med,Kita Ku, N15W7, Sapporo, Hokkaido 0608638, Japan	Gando, S (corresponding author), Hokkaido Univ, Grad Sch Med, Div Acute & Crit Care Med, Dept Anesthesiol & Crit Care Med,Kita Ku, N15W7, Sapporo, Hokkaido 0608638, Japan.	gando@med.hokudai.ac.jp	Gando, Satoshi/T-7407-2019	Gando, Satoshi/0000-0002-3525-0750	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15K15658] Funding Source: KAKEN		Asakura H, 2014, J INTENSIVE CARE, V2, DOI 10.1186/2052-0492-2-20; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Dellinger RP, 2013, CRIT CARE MED, V41, P580, DOI 10.1097/CCM.0b013e31827e83af; Dewan Y, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-87; Di Battista AP, 2016, SHOCK, V46, P96, DOI 10.1097/SHK.0000000000000642; Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754; Gando S., 2016, TRAUMA INDUCED COAGU, P195; Gando S, 2008, CRIT CARE MED, V36, P145, DOI 10.1097/01.CCM.0000295317.97245.2D; Gando S, 2015, SEMIN THROMB HEMOST, V41, P26, DOI 10.1055/s-0034-1398378; Hijazi N, 2015, BLOOD, V125, P2558, DOI 10.1182/blood-2014-08-588442; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; Lemarchant S, 2012, NEUROPHARMACOLOGY, V62, P749, DOI 10.1016/j.neuropharm.2011.10.020; Lin HL, 2011, J TRAUMA, V70, P765, DOI 10.1097/TA.0b013e318206d12a; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; MARDER VJ, 2006, HEMOSTASIS THROMBOSI, P1571; Medcalf RL, 2015, BLOOD, V125, P2457, DOI 10.1182/blood-2015-02-629808; Melchor JP, 2005, THROMB HAEMOSTASIS, V93, P655, DOI 10.1160/TH04-12-0838; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; Nakae R, 2016, J NEUROTRAUM, V33, P688, DOI 10.1089/neu.2015.4039; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Sahindranath M, 2011, LAB INVEST, V91, P1079; Sawamura A, 2009, THROMB RES, V124, P608, DOI 10.1016/j.thromres.2009.06.034; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327; Tian HL, 2010, NEUROSURG REV, V33, P359, DOI 10.1007/s10143-010-0251-z; TOVI D, 1973, ACTA NEUROL SCAND, V49, P152; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929	33	14	15	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	AUG 22	2017	21								219	10.1186/s13054-017-1808-9			10	Critical Care Medicine	General & Internal Medicine	FE2KE	WOS:000408044400001	28826407	DOAJ Gold, Green Published			2021-06-18	
J	Wylie, GR; Dobryakova, E; DeLuca, J; Chiaravalloti, N; Essad, K; Genova, H				Wylie, G. R.; Dobryakova, E.; DeLuca, J.; Chiaravalloti, N.; Essad, K.; Genova, H.			Cognitive fatigue in individuals with traumatic brain injury is associated with caudate activation	SCIENTIFIC REPORTS			English	Article							WORKING-MEMORY LOAD; MULTIPLE-SCLEROSIS; BASAL GANGLIA; PREFRONTAL CORTEX; MENTAL FATIGUE; NEURAL-NETWORK; REWARD; RESPONSES; TASK; CONSCIOUSNESS	We investigated differences in brain activation associated with cognitive fatigue between persons with traumatic brain injury (TBI) and healthy controls (HCs). Twenty-two participants with moderatesevere TBI and 20 HCs performed four blocks of a difficult working memory task and four blocks of a control task during fMRI imaging. Cognitive fatigue, assessed before and after each block, was used as a covariate to assess fatigue-related brain activation. The TBI group reported more fatigue than the HCs, though their performance was comparable. Regarding brain activation, the TBI group showed a Task X Fatigue interaction in the caudate tail resulting from a positive correlation between fatigue and brain activation for the difficult task and a negative relationship for the control task. The HC group showed the same Task X Fatigue interaction in the caudate head. Because we had prior hypotheses about the caudate, we performed a confirmatory analysis of a separate dataset in which the same subjects performed a processing speed task. A relationship between Fatigue and brain activation was evident in the caudate for this task as well. These results underscore the importance of the caudate nucleus in relation to cognitive fatigue.	[Wylie, G. R.; Dobryakova, E.; DeLuca, J.; Chiaravalloti, N.; Genova, H.] Kessler Fdn, 120 Eagle Rock Ave,Suite 100, E Hanover, NJ 07936 USA; [Wylie, G. R.; Dobryakova, E.; DeLuca, J.; Chiaravalloti, N.; Genova, H.] Rutgers State Univ, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07101 USA; [Wylie, G. R.] New Jersey Healthcare Syst, Dept Vet Affairs, War Related Illness & Injury Study Ctr, East Orange Campus, E Orange, NJ 07018 USA; [DeLuca, J.] Rutgers State Univ, New Jersey Med Sch, Dept Neurol, Newark, NJ 07101 USA; [Essad, K.] Dartmouth Coll Med Sch, Dartmouth Coll, Hanover, NH 03755 USA	Wylie, GR (corresponding author), Kessler Fdn, 120 Eagle Rock Ave,Suite 100, E Hanover, NJ 07936 USA.; Wylie, GR (corresponding author), Rutgers State Univ, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07101 USA.; Wylie, GR (corresponding author), New Jersey Healthcare Syst, Dept Vet Affairs, War Related Illness & Injury Study Ctr, East Orange Campus, E Orange, NJ 07018 USA.	gwylie@kesslerfoundation.org		Chiaravalloti, Nancy/0000-0003-2943-7567	New Jersey Commission for Brain Injury Research [10.005.BIR1]; Kessler Foundation Research Center	The authors would like to acknowledge grant support from The New Jersey Commission for Brain Injury Research (10.005.BIR1 to GW and HG), and The Kessler Foundation Research Center.	Akhlaghpour H, 2016, ELIFE, V5, DOI 10.7554/eLife.19507; [Anonymous], 2005, FATIGUE WINDOW BRAIN; Blockmans Daniel, 2006, Am J Med, V119, DOI 10.1016/j.amjmed.2005.07.047; Boksem MAS, 2006, BIOL PSYCHOL, V72, P123, DOI 10.1016/j.biopsycho.2005.08.007; Carlozzi NE, 2015, CLIN NEUROPSYCHOL, V29, P21, DOI 10.1080/13854046.2015.1005677; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Coronado VG, 2010, TRAUMATIC BRAIN INJU, P891, DOI [10.1016/B978-0-444-52910-7.00011-8, DOI 10.1016/B978-0-444-52910-7.00011-8]; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Das A, 2012, NEUROLOGY, V79, P2146, DOI 10.1212/WNL.0b013e3182752cdb; Delano-Wood L, 2015, BRAIN IMAGING BEHAV, V9, P500, DOI 10.1007/s11682-015-9432-2; Delgado MR, 2003, COGN AFFECT BEHAV NE, V3, P27, DOI 10.3758/CABN.3.1.27; Delgado MR, 2000, J NEUROPHYSIOL, V84, P3072; DeLuca J, 2009, PHYS MED REH CLIN N, V20, P325, DOI 10.1016/j.pmr.2008.12.007; Dobryakova E., 2013, J INT NEUROPSYCH SOC, V19, P1; Dobryakova E, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00052; Dobryakova E, 2013, COGN AFFECT BEHAV NE, V13, P725, DOI 10.3758/s13415-013-0182-6; Dobryakova E, 2013, J INT NEUROPSYCH SOC, V19, P849, DOI 10.1017/S1355617713000684; Genova HM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078811; Gibbs SEB, 2005, COGN AFFECT BEHAV NE, V5, P212, DOI 10.3758/CABN.5.2.212; Gillis MM, 2015, BRAIN IMAGING BEHAV, V9, P801, DOI 10.1007/s11682-014-9337-5; Harel Y, 2009, J NEUROL SCI, V276, P38, DOI 10.1016/j.jns.2008.08.025; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Hillary FG, 2011, BRAIN, V134, P1555, DOI 10.1093/brain/awr043; Johansson B, 2014, BRAIN INJURY, V28, P304, DOI 10.3109/02699052.2013.865267; Kluger BM, 2013, NEUROLOGY, V80, P409, DOI 10.1212/WNL.0b013e31827f07be; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; LEE KA, 1991, PSYCHIAT RES, V36, P291, DOI 10.1016/0165-1781(91)90027-M; Lewis SJG, 2004, EUR J NEUROSCI, V19, P755, DOI 10.1111/j.1460-9568.2004.03108.x; Lorist MM, 2009, BRAIN RES, V1270, P95, DOI 10.1016/j.brainres.2009.03.015; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; MCCORMACK HM, 1988, PSYCHOL MED, V18, P1007, DOI 10.1017/S0033291700009934; Mendonca DA, 2007, MOVEMENT DISORD, V22, P2070, DOI 10.1002/mds.21656; Middleton FA, 2000, BRAIN RES REV, V31, P236, DOI 10.1016/S0165-0173(99)00040-5; Moen KG, 2014, J NEUROTRAUM, V31, P1486, DOI 10.1089/neu.2013.3258; NAKAGAWA S, 2016, SCI REP UK, V6; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pardini M, 2015, MULT SCLER J, V21, P442, DOI 10.1177/1352458514546791; Pardini M, 2010, BEHAV NEUROSCI, V124, P329, DOI 10.1037/a0019585; Pardini M, 2010, NEUROLOGY, V74, P749, DOI 10.1212/WNL.0b013e3181d25b6b; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Power JD, 2015, NEUROIMAGE, V105, P536, DOI 10.1016/j.neuroimage.2014.10.044; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Ryan NP, 2016, CORTEX, V83, P222, DOI 10.1016/j.cortex.2016.07.020; Sandry J., 2014, FRONT NEUROL, V5, P1; Schneider W., 2002, E PRIME USERS GUIDE; Schoedel ALA, 2008, PAIN, V135, P131, DOI 10.1016/j.pain.2007.05.014; Schonberger M, 2017, NEUROPSYCHOL REHABIL, V27, P1056, DOI 10.1080/09602011.2016.1154875; SCHULTZ W, 1993, J NEUROSCI, V13, P900; TEASDALE G, 1974, LANCET, V2, P81; Tricomi E, 2008, NEUROIMAGE, V41, P1154, DOI 10.1016/j.neuroimage.2008.02.066; Wanger AK, 2009, J NEUROCHEM, V110, P801, DOI 10.1111/j.1471-4159.2009.06155.x; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wylie GR, 2014, HUM BRAIN MAPP, V35, P1, DOI 10.1002/hbm.22150	57	14	15	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	AUG 21	2017	7								8973	10.1038/s41598-017-08846-6			12	Multidisciplinary Sciences	Science & Technology - Other Topics	FE3HM	WOS:000408107000107	28827779	DOAJ Gold, Green Published			2021-06-18	
J	Gul, SS; Huesgen, KW; Wang, KK; Mark, K; Tyndall, JA				Gul, S. S.; Huesgen, K. W.; Wang, K. K.; Mark, K.; Tyndall, J. A.			Prognostic utility of neuroinjury biomarkers in post out-of-hospital cardiac arrest (OHCA) patient management	MEDICAL HYPOTHESES			English	Article						Out-of-hospital cardiac arrest; Prognostication; Neurologic outcome; Biomarkers	NEURON-SPECIFIC-ENOLASE; TRAUMATIC BRAIN-INJURY; ALPHA-II-SPECTRIN; FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE-L1; MYELIN BASIC-PROTEIN; SOMATOSENSORY-EVOKED POTENTIALS; EUROPEAN RESUSCITATION COUNCIL; AMERICAN-HEART-ASSOCIATION; ADULT COMATOSE SURVIVORS	Despite aggressive intervention, patients who survive an out-of-hospital cardiac arrest (OHCA) generally have very poor prognoses, with nationwide survival rates of approximately 10-20%. Approximately 90% of survivors will have moderate to severe neurological injury ranging from moderate cognitive impairment to brain death. Currently, few early prognostic indicators are considered reliable enough to support patients' families and clinicians' in their decisions regarding medical futility. Blood biomarkers of neurological injury after OHCA may be of prognostic value in these cases. When most bodily tissues are oxygen deprived, cellular metabolism switches from aerobic to anaerobic respiration. Neurons are a notable exception, however, being dependent solely upon aerobic respiration. Thus, after several minutes without circulating oxygen, neurons sustain irreversible damage, and certain measurable biomarkers are released into the circulation. Prior studies have demonstrated value in blood biomarkers in prediction of survival and neurologic impairment after OHCA. We hypothesize that understanding peptide biomarker kinetics in the early return of spontaneous circulation (ROSC) period, especially in the setting of refractory cardiac arrest, may assist clinicians in determining prognosis earlier in acute resuscitation. Specifically, during and after immediate resuscitation and return of ROSC, clinicians and families face a series of important questions regarding patient prognosis, futility of care and allocation of scarce resources such as the early initiation of extracorporeal cardiopulmonary resuscitation (ECPR). The ability to provide early prognostic information in this setting is highly valuable. Currently available, as well as potential biomarkers that could be good candidates in prognostication of neurological outcomes after OHCA or in the setting of refractory cardiac arrest will be reviewed and discussed. (C) 2017 The Authors. Published by Elsevier Ltd.	[Gul, S. S.; Huesgen, K. W.; Mark, K.; Tyndall, J. A.] Univ Florida, Dept Emergency Med, 1329 SW 16th St,Suite 5270, Gainesville, FL 32608 USA; [Wang, K. K.] Univ Florida, McKnight Brain Inst, Dept Psychiat, Program Neurotrauma Neuroprote & Biomarker Res, 1149 Newell Dr, Gainesville, FL 32610 USA	Tyndall, JA (corresponding author), Univ Florida, Dept Emergency Med, 1329 SW 16th St,Suite 5270, Gainesville, FL 32608 USA.	tyndall@ufl.edu		Wang, Kevin/0000-0002-9343-6473			Adrie C, 2002, CIRCULATION, V106, P562, DOI 10.1161/01.CIR.0000023891.80661.AD; Albrecht-Schgoer K, 2012, CIRCULATION, V126, P2491, DOI 10.1161/CIRCULATIONAHA.111.076950; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Annborn M, 2014, ACTA ANAESTH SCAND, V58, P428, DOI 10.1111/aas.12282; Arnaoutakis GJ, 2011, J THORAC CARDIOVASC, V142, P902; Avila J, 2004, PHYSIOL REV, V84, P361, DOI 10.1152/physrev.00024.2003; Balanescu S, 2011, J CLIN ENDOCR METAB, V96, P1046, DOI 10.1210/jc.2010-2499; BARBARESE E, 1988, J NEUROCHEM, V51, P1737, DOI 10.1111/j.1471-4159.1988.tb01153.x; Bel MS, 2003, REV ESP CARDIOL, V56, P703; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Berger RP., 2011, CHILD ABUSE NEGLECT, P429; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Bitsch A, 2002, EUR NEUROL, V47, P45, DOI 10.1159/000047946; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Boggs JM, 2006, CELL MOL LIFE SCI, V63, P1945, DOI 10.1007/s00018-006-6094-7; Broessner G, 2015, RESUSCITATION, V89, P75, DOI 10.1016/j.resuscitation.2015.01.013; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Callaway CW, 2015, CIRCULATION, V132, pS465, DOI 10.1161/CIR.0000000000000262; Chan PS, 2014, CIRCULATION, V130, P1876, DOI 10.1161/CIRCULATIONAHA.114.009711; Chen SY, 2016, EXP THER MED, V11, P2049, DOI 10.3892/etm.2016.3153; Choi S, 2016, EMERG MED J; Chou SHY, 2014, NEUROCRIT CARE, V21, P187, DOI 10.1007/s12028-014-0039-z; Claassen J, 2013, INTENS CARE MED, V39, P1337, DOI 10.1007/s00134-013-2938-4; Cronberg T, 2011, NEUROLOGY, V77, P623, DOI 10.1212/WNL.0b013e31822a276d; Cronberg T, 2013, RESUSCITATION, V84, P867, DOI 10.1016/j.resuscitation.2013.01.019; Daubin C, 2011, BMC CARDIOVASC DISOR, V11, DOI 10.1186/1471-2261-11-48; Day INM, 2010, PROG NEUROBIOL, V90, P327, DOI 10.1016/j.pneurobio.2009.10.020; Dennis M, 2017, INT J CARDIOL, V231, P131, DOI 10.1016/j.ijcard.2016.12.003; Derwall M, 2009, CRIT CARE, V13, DOI 10.1186/cc7785; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Diaz-Romero J, 2014, J CELL PHYSIOL, V229, P1106, DOI 10.1002/jcp.24547; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Dong XQ, 2011, J TRAUMA, V71, P1194, DOI 10.1097/TA.0b013e31821283f2; Eikelenboom MJ, 2011, MULT SCLER INT, V2011, DOI 10.1155/2011/823176; Einav S, 2013, RESUSCITATION, V84, P1083, DOI 10.1016/j.resuscitation.2013.01.031; Einav S, 2012, J AM COLL CARDIOL, V60, P304, DOI 10.1016/j.jacc.2012.04.020; Elmer J, 2016, RESUSCITATION, V102, P127, DOI 10.1016/j.resuscitation.2016.01.016; Fink EL, 2014, CRIT CARE MED, V42, P664, DOI 10.1097/01.ccm.0000435668.53188.80; FISCHERCOLBRIE R, 1995, PROG NEUROBIOL, V46, P49, DOI 10.1016/0301-0082(94)00060-U; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gao JX, 2015, INT J CLIN EXP MED, V8, P19881; GARCIA JH, 1977, VIRCHOWS ARCH B, V25, P191; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; Greer DM, 2017, SEMIN NEUROL, V37, P66, DOI 10.1055/s-0036-1594253; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; Hasslacher J, 2014, INTENS CARE MED, V40, P1518, DOI 10.1007/s00134-014-3423-4; Hayashida H, 2010, NEUROCRIT CARE, V12, P252, DOI 10.1007/s12028-009-9318-5; Huang CH, 2016, SCI REP-UK, V6, DOI 10.1038/srep27187; Huntgeburth M, 2014, NEUROCRIT CARE, V20, P358, DOI 10.1007/s12028-013-9848-8; Jain P, 2014, PEDIATR CRIT CARE ME, V15, P229, DOI 10.1097/PCC.0000000000000059; Jensen HA, 2011, CIRCULATION, V123, P714, DOI 10.1161/CIRCULATIONAHA.110.986497; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kaneko T, 2009, RESUSCITATION, V80, P790, DOI 10.1016/j.resuscitation.2009.04.003; Katan M, 2009, ANN NEUROL, V66, P799, DOI 10.1002/ana.21783; Kawata K, 2016, NEUROSCI BIOBEHAV R, V68, P460, DOI 10.1016/j.neubiorev.2016.05.009; KOHLSCHUTTER A, 1978, EUR J PEDIATR, V127, P155, DOI 10.1007/BF00442056; Larsson IM, 2014, RESUSCITATION, V85, P1654, DOI 10.1016/j.resuscitation.2014.09.007; Laver S, 2004, INTENS CARE MED, V30, P2126, DOI 10.1007/s00134-004-2425-z; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; Mailliot C, 2000, J CEREBR BLOOD F MET, V20, P543, DOI 10.1097/00004647-200003000-00013; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Marty MC, 2002, P NATL ACAD SCI USA, V99, P8856, DOI 10.1073/pnas.122079599; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Missler U, 1999, CLIN CHEM, V45, P138; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Morgenthaler NG, 2006, CLIN CHEM, V52, P112, DOI 10.1373/clinchem.2005.060038; Morgenthaler NG, 2007, SHOCK, V28, P219, DOI 10.1097/SHK.0b013e318033e5da; Mortberg E, 2011, ACTA ANAESTH SCAND, V55, P1132, DOI 10.1111/j.1399-6576.2011.02505.x; Mortberg E, 2011, RESUSCITATION, V82, P26, DOI 10.1016/j.resuscitation.2010.10.011; Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350; Muller B, 2007, EUR J CLIN INVEST, V37, P145, DOI 10.1111/j.1365-2362.2007.01762.x; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Oda Y, 2012, RESUSCITATION, V83, P1006, DOI 10.1016/j.resuscitation.2012.01.030; Oliver JM, 2016, J NEUROTRAUM, V33, P1784, DOI 10.1089/neu.2015.4295; Ostadal P, 2012, CRIT CARE, V16, DOI 10.1186/cc11671; Ottesen AH, 2015, J AM COLL CARDIOL, V65, P339, DOI 10.1016/j.jacc.2014.10.065; Panickar KS, 2005, GLIA, V50, P287, DOI 10.1002/glia.20181; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2004, SHOCK, V22, P88, DOI 10.1097/01.shk.0000130157.34382.3f; PETITO CK, 1982, ANN NEUROL, V11, P510, DOI 10.1002/ana.410110511; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Pfeifer R, 2014, ACTA ANAESTH SCAND, V58, P1093, DOI 10.1111/aas.12386; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Rana OR, 2013, INT J CARDIOL, V168, P1322, DOI 10.1016/j.ijcard.2012.12.016; Rana OR, 2011, J NEUROL SCI, V305, P80, DOI 10.1016/j.jns.2011.03.007; Randall J, 2013, RESUSCITATION, V84, P351, DOI 10.1016/j.resuscitation.2012.07.027; Ray P, 2010, ANESTHESIOLOGY, V112, P1023, DOI 10.1097/ALN.0b013e3181d47604; Rech TH, 2006, CRIT CARE, V10, DOI 10.1186/cc5046; Ren CH, 2013, BRAIN RES, V1540, P84, DOI 10.1016/j.brainres.2013.09.051; Ristagno G, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0831-y; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; Rosen H, 2004, J NEUROL SCI, V221, P19, DOI 10.1016/j.jns.2004.03.003; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Rossetti AO, 2016, LANCET NEUROL, V15, P597, DOI 10.1016/S1474-4422(16)00015-6; Rundgren M, 2012, CRIT CARE, V16, DOI 10.1186/cc11244; Rundgren M, 2009, RESUSCITATION, V80, P784, DOI 10.1016/j.resuscitation.2009.03.025; Sandroni C, 2017, SEMIN NEUROL, V37, P40, DOI 10.1055/s-0036-1593857; Sandroni C, 2015, CURR OPIN CRIT CARE, V21, P209, DOI 10.1097/MCC.0000000000000202; Sandroni C, 2014, RESUSCITATION, V85, P1779, DOI 10.1016/j.resuscitation.2014.08.011; Sandroni C, 2013, RESUSCITATION, V84, P1324, DOI 10.1016/j.resuscitation.2013.06.020; Sandroni C, 2013, RESUSCITATION, V84, P1310, DOI 10.1016/j.resuscitation.2013.05.013; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; Scolletta S, 2012, EXPERT REV CLIN PHAR, V5, P687, DOI [10.1586/ECP.12.64, 10.1586/ecp.12.64]; Sharma HS, 2011, J NEURAL TRANSM, V118, P87, DOI 10.1007/s00702-010-0486-4; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Shinozaki K, 2009, CRIT CARE, V13, DOI 10.1186/cc7973; Shinozaki K, 2009, RESUSCITATION, V80, P870, DOI 10.1016/j.resuscitation.2009.05.005; Siman R, 2005, J CEREBR BLOOD F MET, V25, P1433, DOI 10.1038/sj.jcbfm.9600138; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Siman R, 2015, J NEUROTRAUM, V32, P1294, DOI 10.1089/neu.2014.3698; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Stammet P, 2015, J AM COLL CARDIOL, V65, P2104, DOI 10.1016/j.jacc.2015.03.538; Stammet P, 2013, J AM COLL CARDIOL, V62, P851, DOI 10.1016/j.jacc.2013.04.039; Stern P, 2007, TUMOR BIOL, V28, P84, DOI 10.1159/000098441; Storm C, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-6; Taccone FS, 2014, CRIT CARE, V18, DOI 10.1186/cc13696; Tapiola T, 2009, ARCH NEUROL-CHICAGO, V66, P382, DOI 10.1001/archneurol.2008.596; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Voors AA, 2009, EUR HEART J, V30, P1187, DOI 10.1093/eurheartj/ehp098; Wang KIM, 2013, SYSTEMS BIOMARKERS A, V8723; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Weiss ES, 2009, ANN THORAC SURG, V88, P543, DOI 10.1016/j.athoracsur.2009.04.016; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; Wiedermann CJ, 1999, ACTA PHARMACOL SIN, V20, P789; Wiesmann M, 1998, CLIN CHEM, V44, P1056; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; Wu AHB, 1999, CLIN CHIM ACTA, V284, P161, DOI 10.1016/S0009-8981(99)00078-9; Wunderlich MT, 2006, CLIN NEUROL NEUROSUR, V108, P558, DOI 10.1016/j.clineuro.2005.12.006; Youn CS, 2017, RESUSCITATION, V110, P120, DOI 10.1016/j.resuscitation.2016.10.024; Zellner T, 2013, RESUSCITATION, V84, P1382, DOI 10.1016/j.resuscitation.2013.03.021; Zhang ZQ, 2011, TRANSL STROKE RES, V2, P455, DOI 10.1007/s12975-011-0137-6; Zulfikaroglu E, 2011, J OBSTET GYNAECOL RE, V37, P1198, DOI 10.1111/j.1447-0756.2010.01498.x	145	14	15	0	3	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses	AUG	2017	105						34	47		10.1016/j.mehy.2017.06.016			14	Medicine, Research & Experimental	Research & Experimental Medicine	FD6SA	WOS:000407657000009	28735650	Other Gold			2021-06-18	
J	Olkowski, BF; Shah, SO				Olkowski, Brian F.; Shah, Syed Omar			Early Mobilization in the Neuro-ICU: How Far Can We Go?	NEUROCRITICAL CARE			English	Article						Early mobilization; Rehabilitation; Acute ischemic stroke; Aneurysmal subarachnoid hemorrhage; Intracerebral hemorrhage; Neurotrauma	INTENSIVE-CARE-UNIT; ACUTE ISCHEMIC-STROKE; RANDOMIZED CONTROLLED-TRIAL; BLOOD-FLOW-VELOCITY; EARLY REHABILITATION; SUBARACHNOID HEMORRHAGE; CRITICALLY-ILL; ORTHOSTATIC HYPOTENSION; INTRACRANIAL-PRESSURE; PHASE-II	Immobility that is frequently encountered in the intensive care unit (ICU) can lead to patient complications. Early mobilization of patients in the ICU has been shown to reduce the complications associated with critical illness; however, early mobilization in the neurological intensive care unit (NICU) presents a unique challenge for the multidisciplinary team. The early mobilization of patients with acute neurologic injuries such as acute ischemic stroke, aneurysmal subarachnoid hemorrhage, intracerebral hemorrhage, and neurotrauma varies because of differing disease processes and management. When developing an early mobility program in the NICU, the following should be considered: the effect of positional changes and exercise, the time from symptom onset to the initiation of early mobilization, and the type and intensity of the exercise prescribed.	[Olkowski, Brian F.] Capital Hlth Reg Med Ctr, Dept Rehabil, Trenton, NJ 08638 USA; [Shah, Syed Omar] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA; [Shah, Syed Omar] Jefferson Hosp Neurosci, Div Crit Care & Neurotrauma, Philadelphia, PA USA	Olkowski, BF (corresponding author), Capital Hlth Reg Med Ctr, Dept Rehabil, Trenton, NJ 08638 USA.	bolkowski@capitalhealth.org	Shah, Syed/E-4083-2013	Shah, Syed/0000-0003-4760-5229			[Anonymous], 2016, CER HEM ORTH RESP UP; Arnold SM, 2015, J STROKE CEREBROVASC, V24, P1168, DOI 10.1016/j.jstrokecerebrovasdis.2015.01.007; Awad AJ, 2016, WORLD NEUROSURG, V87, P474, DOI 10.1016/j.wneu.2016.01.043; Balas MC, 2013, CRIT CARE MED, V41, pS116, DOI 10.1097/CCM.0b013e3182a17064; Baltz MJ, 2013, J NEUROL PHYS THER, V37, P9, DOI 10.1097/NPT.0b013e318282a1f0; Barer D, 2015, LANCET, V386, P1734, DOI 10.1016/S0140-6736(15)00691-1; Bartolo M, 2016, EUR J PHYS REHAB MED, V52, P90; Bernhardt J, 2008, STROKE, V39, P390, DOI 10.1161/STROKEAHA.107.492363; Bernhardt J, 2015, LANCET, V386, P46, DOI 10.1016/S0140-6736(15)60690-0; Bernhardt J, 2015, STROKE, V46, P1141, DOI 10.1161/STROKEAHA.114.007434; Brimioulle S, 1997, PHYS THER, V77, P1682, DOI 10.1093/ptj/77.12.1682; Brunser AM, 2016, INT J STROKE, V11, P253, DOI 10.1177/1747493015620808; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Burtin C, 2009, CRIT CARE MED, V37, P2499, DOI 10.1097/CCM.0b013e3181a38937; Claydon VE, 2006, SPINAL CORD, V44, P341, DOI 10.1038/sj.sc.3101855; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; Consortium Spinal Cord Med, 2008, J SPINAL CORD MED, V31, P403; Cumming TB, 2008, J REHABIL MED, V40, P609, DOI 10.2340/16501977-0226; Cumming TB, 2011, STROKE, V42, P153, DOI 10.1161/STROKEAHA.110.594598; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; Desai SV, 2011, CRIT CARE MED, V39, P371, DOI 10.1097/CCM.0b013e3181fd66e5; Diringer MN, 2011, NEUROCRIT CARE, V15, P211, DOI 10.1007/s12028-011-9605-9; Dubb R, 2016, ANN AM THORAC SOC, V13, P724, DOI 10.1513/AnnalsATS.201509-586CME; Fletcher SN, 2003, CRIT CARE MED, V31, P1012, DOI 10.1097/01.CCM.0000053651.38421.D9; Frazzitta G, 2015, J HEAD TRAUMA REHAB, V30, P290, DOI 10.1097/HTR.0000000000000135; Guidelines for the Management of Cervical Spine and Spinal Cord Injuries, 2002, CLIN NEUROSURG, V49, P407; Hanekom S, 2011, CLIN REHABIL, V25, P771, DOI 10.1177/0269215510397677; Hawryluk G, 2015, J NEUROTRAUM, V32, P1958, DOI 10.1089/neu.2014.3778; Helbok R, 2012, CRIT CARE, V16, DOI 10.1186/cc11880; Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Herter KR, 2016, ARCH PHYS MED REHAB, V97, P1620, DOI 10.1016/j.apmr.2016.05.009; Hester JM, 2015, NEUROCRIT CARE, V23, pS63; Hodgson CL, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0658-y; Hopkins RO, 2006, CHEST, V130, P869, DOI 10.1378/chest.130.3.869; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Kamdar BB, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1433-z; Karic T, 2016, J NEUROSURG, P1; Karic T, 2016, J REHABIL MED, V48, P676, DOI 10.2340/16501977-2121; Karic T, 2015, DISABIL REHABIL, V37, P1446, DOI 10.3109/09638288.2014.966162; Kawamoto S, 2004, J NEUROSURG, V100, P236, DOI 10.3171/jns.2004.100.2.0236; Kayambu G, 2013, CRIT CARE MED, V41, P1543, DOI 10.1097/CCM.0b013e31827ca637; Klein K, 2015, CRIT CARE MED, V43, P865, DOI 10.1097/CCM.0000000000000787; Klein KE, 2015, NEUROCRIT CARE, V23, pS269; Koch SM, 1996, J CRIT CARE, V11, P176, DOI 10.1016/S0883-9441(96)90028-3; Krassioukov A, 2009, ARCH PHYS MED REHAB, V90, P876, DOI 10.1016/j.apmr.2009.01.009; Kuznetsov AN, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/946056; Langhorne P, 2010, CEREBROVASC DIS, V29, P352, DOI 10.1159/000278931; Lantigua H, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1036-0; Li ZQ, 2013, ARCH PHYS MED REHAB, V94, P551, DOI 10.1016/j.apmr.2012.10.023; Liu N, 2014, STROKE, V45, P3502, DOI 10.1161/STROKEAHA.114.005661; Lord RK, 2013, CRIT CARE MED, V41, P717, DOI 10.1097/CCM.0b013e3182711de2; Luft AR, 2016, STROKE, V47, P291, DOI 10.1161/STROKEAHA.115.010483; Ma ZX, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008346.pub2; Martin Niels D, 2015, J Emerg Trauma Shock, V8, P94, DOI 10.4103/0974-2700.155507; Mills PB, 2015, ARCH PHYS MED REHAB, V96, P366, DOI 10.1016/j.apmr.2014.09.028; Morris PE, 2008, CRIT CARE MED, V36, P2238, DOI 10.1097/CCM.0b013e318180b90e; Nakagomi T, 2011, ACTA NEUROCHIR SUPPL, V110, P105, DOI 10.1007/978-3-7091-0356-2_19; Needham DM, 2008, JAMA-J AM MED ASSOC, V300, P1685, DOI 10.1001/jama.300.14.1685; Needham DM, 2012, CRIT CARE MED, V40, P502, DOI 10.1097/CCM.0b013e318232da75; Needham DM, 2010, ARCH PHYS MED REHAB, V91, P536, DOI 10.1016/j.apmr.2010.01.002; Oddo M, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1294-5; Olavarria VV, 2014, CEREBROVASC DIS, V37, P401, DOI 10.1159/000362533; Olkowski BF, 2015, J ACUTE CARE PHYS TH, V6, P47, DOI 10.1097/JAT.0000000000000008; Olkowski BF, 2013, PHYS THER, V93, P208, DOI 10.2522/ptj.20110334; Pandharipande P, 2010, CRIT CARE, V14, DOI 10.1186/cc8999; Riordan MA, 2014, ACTA NEUROCHIR, V120, pS55; Saciri BM, 2002, J NEUROL NEUROSUR PS, V72, P334, DOI 10.1136/jnnp.72.3.334; Schmidt A, 2014, STROKE, V45, P239, DOI 10.1161/STROKEAHA.113.002048; Schwarz S, 2002, STROKE, V33, P497, DOI 10.1161/hs0202.102376; Schweickert WD, 2007, CHEST, V131, P1541, DOI 10.1378/chest.06-2065; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Shimamura N, 2014, WORLD NEUROSURG, V81, P330, DOI 10.1016/j.wneu.2012.12.007; Sundseth A, 2012, STROKE, V43, P2389, DOI 10.1161/STROKEAHA.111.646687; SUZUKI I, 1991, SURG CEREB STROKE, V19, P295; Tay-Teo K, 2008, CEREBROVASC DIS, V26, P475, DOI 10.1159/000155984; Thomsen GE, 2008, CRIT CARE MED, V36, P1119, DOI 10.1097/CCM.0b013e318168f986; Titsworth WL, 2012, J NEUROSURG, V116, P1379, DOI 10.3171/2012.2.JNS111881; Tyedin K, 2010, DISABIL REHABIL, V32, P875, DOI 10.3109/09638280903349552; Winstein CJ, 2016, STROKE, V47, pE98, DOI 10.1161/STR.0000000000000098; Wojner-Alexander AW, 2005, NEUROLOGY, V64, P1354, DOI 10.1212/01.WNL.0000158284.41705.A5; Zhang Y, 2011, NEUROCRIT CARE, V14, P73, DOI 10.1007/s12028-010-9444-0	83	14	16	4	25	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2017	27	1					141	150		10.1007/s12028-016-0338-7			10	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	FB7GX	WOS:000406310200020	28000130				2021-06-18	
J	Radabaugh, HL; LaPorte, MJ; Greene, AM; Bondi, CO; Lajud, N; Kline, AE				Radabaugh, Hannah L.; LaPorte, Megan J.; Greene, Anna M.; Bondi, Corina O.; Lajud, Naima; Kline, Anthony E.			Refining environmental enrichment to advance rehabilitation based research after experimental traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Behavioral outcome; Controlled cortical impact; Environmental enrichment; Functional recovery; Learning and memory; Morris water maze; Traumatic brain injury	CONTROLLED CORTICAL IMPACT; RANDOMIZED CONTROLLED-TRIAL; RECEPTOR AGONIST 8-OH-DPAT; COGNITIVE FLEXIBILITY; HISTOLOGICAL BENEFITS; TREATMENT REGIMEN; CLINICAL-TRIALS; FEMALE RATS; RECOVERY; DEFICITS	The typical environmental enrichment (EE) paradigm, which consists of continuous exposure after experimental traumatic brain injury (TBI), promotes behavioral and histological benefits. However, rehabilitation is often abbreviated in the clinic and administered in multiple daily sessions. While recent studies have demonstrated that a once daily 6-hr bout of EE confers benefits comparable to continuous EE, breaking the therapy into two shorter sessions may increase novelty and ultimately enhance recovery. Hence, the aim of the study was to test the hypothesis that functional and histological outcomes will be significantly improved by daily preclinical neurorehabilitation consisting of two 3-hr periods of EE vs. a single 6-hr session. Anesthetized adult male rats received a controlled cortical impact of moderate-to-severe injury (2.8 mm tissue deformation at 4 m/s) or sham surgery and were then randomly assigned to groups receiving standard (STD) housing, a single 6-hr session of EE, or two 3-hr sessions of EE daily for 3 weeks. Motor function (beam-balance/traversal) and acquisition of spatial learning/memory retention (Morris water maze) were assessed on post-operative days 1-5 and 14-19, respectively. Cortical lesion volume was quantified on day 21. Both EE conditions improved motor function and acquisition of spatial learning, and reduced cortical lesion volume relative to STD housing (p < 0.05), but did not differ from one another in any endpoint (p > 0.05). The findings replicate previous work showing that 6-hr of EE daily is sufficient to confer behavioral and histological benefits after TBI and extend the findings by demonstrating that the benefits are comparable regardless of how the 6-hrs of EE are accrued. The relevance of the finding is that it can be extrapolated to the clinic and may benefit patients who cannot endure a single extended period of neurorehabilitation. (C) 2017 Elsevier Inc. All rights reserved.	[Radabaugh, Hannah L.; LaPorte, Megan J.; Greene, Anna M.; Bondi, Corina O.; Lajud, Naima; Kline, Anthony E.] Univ Pittsburgh, Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Radabaugh, Hannah L.; LaPorte, Megan J.; Greene, Anna M.; Bondi, Corina O.; Lajud, Naima; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Bondi, Corina O.] Univ Pittsburgh, Neurobiol, Pittsburgh, PA 15213 USA; [Bondi, Corina O.; Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Bondi, Corina O.; Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA; [Lajud, Naima] Inst Mexicano Seguro Social Morelia, Ctr Invest Biomed Michoacan, Div Neurociencias, Morelia, Michoacan, Mexico; [Kline, Anthony E.] Univ Pittsburgh, Crit Care Med, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Psychol, Pittsburgh, PA 15213 USA	Kline, AE (corresponding author), Univ Pittsburgh, John G Rangos Res Ctr, Childrens Hosp Pittsburgh, Psychol,Phys Med & Rehabil,Crit Care Med,Sch Med, Room 6126,4401 Penn Ave, Pittsburgh, PA 15224 USA.; Kline, AE (corresponding author), Univ Pittsburgh, Ctr Neurosci, Sch Med, Childrens Hosp Pittsburgh,John G Rangos Res Ctr, Room 6126,4401 Penn Ave, Pittsburgh, PA 15224 USA.	klineae@upmc.edu	Lajud, Naima/B-4605-2018	Lajud, Naima/0000-0003-3905-798X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD069620, HD069620-S1, NS060005, NS084967, NS094950, NS099683]; University of Pittsburgh Physicians/UPMC Academic Foundation; UMPC Rehabilitation Institute; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005, R21NS099683, R03NS094950, R01NS084967] Funding Source: NIH RePORTER	This work was supported, in part, by NIH grants HD069620, HD069620-S1, NS060005, NS084967 (AEK), NS094950, NS099683 (COB), the University of Pittsburgh Physicians/UPMC Academic Foundation, and the UMPC Rehabilitation Institute (COB).	Adelson PD, 1998, ACT NEUR S, V71, P104; Barry NC, 2015, J CLIN EXP NEUROPSYC, V37, P994, DOI 10.1080/13803395.2015.1038981; Bayir H, 2009, CRIT CARE MED, V37, P689, DOI 10.1097/CCM.0b013e318194abf2; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; Bondi CO, 2015, NEUROSCI BIOBEHAV R, V58, P123, DOI 10.1016/j.neubiorev.2014.12.004; Bondi CO, 2014, J NEUROTRAUM, V31, P873, DOI 10.1089/neu.2014.3328; Bramlett HM, 2016, J NEUROTRAUM, V33, P538, DOI 10.1089/neu.2015.4116; Carlson SW, 2017, EXP NEUROL, V289, P55, DOI 10.1016/j.expneurol.2016.12.006; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cheng JP, 2016, BRAIN RES, V1640, P5, DOI 10.1016/j.brainres.2015.11.026; Cheng JP, 2012, J NEUROTRAUM, V29, P2684, DOI 10.1089/neu.2012.2560; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; De Bartolo P, 2008, NEUROSCIENCE, V154, P444, DOI 10.1016/j.neuroscience.2008.03.069; de Witt BW, 2011, NEUROREHAB NEURAL RE, V25, P343, DOI 10.1177/1545968310390520; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hart T, 2016, ARCH PHYS MED REHAB, V97, P2045, DOI 10.1016/j.apmr.2016.07.012; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Homeman G., 2009, BRAIN INJURY, V23, P907; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2016, PROG NEUROBIOL, V142, P45, DOI 10.1016/j.pneurobio.2016.05.002; Kline AE, 2012, J NEUROTRAUM, V29, P1960, DOI 10.1089/neu.2012.2385; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Leary JB, 2017, J NEUROTRAUM, V34, P444, DOI 10.1089/neu.2016.4438; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Monaco CM, 2014, J NEUROTRAUM, V31, P1934, DOI 10.1089/neu.2014.3541; Monaco CM, 2013, EXP NEUROL, V247, P410, DOI 10.1016/j.expneurol.2013.01.007; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Olsen AS, 2012, J NEUROTRAUM, V29, P1898, DOI 10.1089/neu.2012.2358; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Radabaugh HL, 2016, EXP NEUROL, V286, P61, DOI 10.1016/j.expneurol.2016.09.015; Richter KM, 2015, J CLIN EXP NEUROPSYC, V37, P571, DOI 10.1080/13803395.2015.1030358; Shear DA, 2016, J NEUROTRAUM, V33, P523, DOI 10.1089/neu.2015.4115; Shiel A, 2001, CLIN REHABIL, V15, P501, DOI 10.1191/026921501680425225; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015; Zeleznikow-Johnston A, 2017, NEUROPHARMACOLOGY, V117, P219, DOI 10.1016/j.neuropharm.2017.02.009; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941	50	14	14	1	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	AUG	2017	294						12	18		10.1016/j.expneurol.2017.04.013			7	Neurosciences	Neurosciences & Neurology	EY6FA	WOS:000404076700002	28457905	Green Accepted			2021-06-18	
J	Baricich, A; de Sire, A; Antoniono, E; Gozzerino, F; Lamberti, G; Cisari, C; Invernizzi, M				Baricich, Alessio; de Sire, Alessandro; Antoniono, Elena; Gozzerino, Francesca; Lamberti, Gianfranco; Cisari, Carlo; Invernizzi, Marco			Recovery from vegetative state of patients with a severe brain injury: a 4-year real-practice prospective cohort study	FUNCTIONAL NEUROLOGY			English	Article						brain injury; minimally conscious state; rehabilitation; vegetative state	MINIMALLY CONSCIOUS STATE; STATUS EPILEPTICUS; BEHAVIORAL-ASSESSMENT; CLINICAL-PRACTICE; NATURAL-HISTORY; DISORDERS; EMERGENCE; REHABILITATION; RECOMMENDATIONS; MANAGEMENT	Patients who have suffered severe traumatic or non-traumatic brain injuries can show a progressive recovery, transitioning through a range of clinical conditions. They may progress from coma to a vegetative state (VS) and/or a minimally conscious state (MCS). A longer duration of the VS is known to be related to a lower probability of emergence from it; furthermore, the literature seems to lack evidence of late improvements in these patients. This real-practice prospective cohort study was conducted in inpatients in a VS following a severe brain injury, consecutively admitted to a vegetative state unit (VSU). The aim of the study was to assess their recovery in order to identify variables that might increase the probability of a VS patient transitioning to MCS. Rehabilitation treatment included passive joint mobilisation and helping/placing patients into an upright sitting position on a tilt table. All the patients underwent a specific assessment protocol every month to identify any emergence, however late, from the VS. Over a 4-year period, 194 patients suffering sequelae of a severe brain injury, consecutively seen, had an initial Glasgow Coma Scale score <= 8. Of these, 63 (32.5%) were in a VS, 84 (43.3%) in a MCS, and 47 (24.2%) in a coma; of the 63 patients admitted in a VS, 49 (57.1% males and 42.9% females, mean age 25.34 +/- 19.12 years) were transferred to a specialist VSU and put on a slow-to-recover brain injury programme. Ten of these 49 patients were still in a VS after 36 months; of these 10, 3 recovered consciousness, transitioning to a MCS, 2 died, and 5 remained in a VS during the last 12 months of the observation. Univariate analysis identified male sex, youth, a shorter time from onset of the VS, diffuse brain injury, and the presence of status epilepticus as variables increasing the likelihood of transition to a MCS. Long-term monitoring of patients with chronic disorders of consciousness should be adequately implemented in order to optimise their access to rehabilitation services.	[Baricich, Alessio; Cisari, Carlo] Univ Hosp Maggiore Carita, Phys Med & Rehabil, Novara, Italy; [Baricich, Alessio; Cisari, Carlo; Invernizzi, Marco] Univ Piemonte Orientale, Dept Hlth Sci, Phys & Rehabil Med, Novara, Italy; [de Sire, Alessandro] Univ Campania Luigi Vanvitelli, Dept Med & Surg Specialties & Dent, Naples, Italy; [Antoniono, Elena; Gozzerino, Francesca; Lamberti, Gianfranco] Azienda Sanit Locale CN, Neurorehabil & Vegetat State Unit, Cuneo, Italy	de Sire, A (corresponding author), Univ Campania Luigi Vanvitelli, Dept Med & Surg Specialties & Dent, Naples, Italy.	alessandro.desire@gmail.com	Baricich, Alessio/ABG-7696-2020; Invernizzi, Marco/I-9635-2019	Invernizzi, Marco/0000-0001-5141-0681; BARICICH, Alessio/0000-0001-8440-6283			ALEXANDER E, 1982, SURG NEUROL, V17, P107, DOI 10.1016/S0090-3019(82)80031-1; Andrews K, 1993, RECOVERY PATIENTS 4, V306, P1597; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Avesani R, 2006, BRAIN INJURY, V20, P333, DOI 10.1080/02699050500487605; Baricich A, 2017, AM J PHYS MED REHAB, V96, pS80, DOI 10.1097/PHM.0000000000000573; Bartolo M, 2016, EUR J PHYS REHAB MED, V52, P90; Bernat JL, 2010, NEUROLOGY, V75, P206, DOI 10.1212/WNL.0b013e3181e8e960; Bernat JL, 2009, ANNU REV MED, V60, P381, DOI 10.1146/annurev.med.60.060107.091250; Cesarini KG, 1999, J NEUROSURG, V90, P664, DOI 10.3171/jns.1999.90.4.0664; Childs NL, 1996, NEW ENGL J MED, V334, P24, DOI 10.1056/NEJM199601043340105; de Jong BM, 2012, J HEAD TRAUMA REHABI; De Tanti A, 2015, EUR J PHYS REHAB MED, V51, P89; DeFina PA, 2010, RESTOR NEUROL NEUROS, V28, P769, DOI 10.3233/RNN-2010-0548; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Faran S, 2006, J NEUROL NEUROSUR PS, V77, P998, DOI 10.1136/jnnp.2005.076554; Fins JJ, 2007, NEUROLOGY, V68, P304, DOI 10.1212/01.wnl.0000252376.43779.96; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino JT, 2007, CURR OPIN NEUROL, V20, P614, DOI 10.1097/WCO.0b013e3282f189ef; Giacino JT, 2009, PROG BRAIN RES, V177, P33, DOI 10.1016/S0079-6123(09)17704-X; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GILLIES JD, 1980, DEV MED CHILD NEUROL, V22, P642; Hagen C, 1979, REHABILITATION HEAD; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Khot S, 2006, SEMIN NEUROL, V26, P422, DOI 10.1055/s-2006-948323; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; LOWENSTEIN DH, 1992, NEUROLOGY, V42, P100, DOI 10.1212/WNL.42.1.100; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Lupi A, 2014, CURR RADIOPHARM, V7, P57, DOI 10.2174/1874471007666140411103819; Machado C, 2010, NEUROLOGY, V74, P1156, DOI 10.1212/WNL.0b013e3181d5df0d; McMillan TM, 2004, BRAIN INJURY, V18, P935, DOI 10.1080/02699050410001675915; Nakase-Richardson R, 2009, NEUROLOGY, V73, P1120, DOI 10.1212/WNL.0b013e3181bacf34; Picelli A, 2015, EUR J PHYS REHAB MED, V51, P849; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; PRIVITERA M, 1994, EPILEPSY RES, V18, P155, DOI 10.1016/0920-1211(94)90008-6; Rosanova M, 2012, BRAIN, V135, P1308, DOI 10.1093/brain/awr340; Sara M, 2007, BRAIN INJURY, V21, P101, DOI 10.1080/02699050601151761; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Singh R, 2008, BRAIN INJURY, V22, P103, DOI 10.1080/02699050701829704; Taricco M, 2006, Eura Medicophys, V42, P73; Taylor CM, 2007, ARCH PHYS MED REHAB, V88, P521, DOI 10.1016/j.apmr.2007.01.013; Thibaut A, 2012, J REHABIL MED   0319; Towne A, 1998, EPILIPSIA, V39, P3; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; VUILLEUMIER P, 1995, NEUROCHIRURGIE, V41, P98; Whyte J, 2009, PROG BRAIN RES, V177, P63, DOI 10.1016/S0079-6123(09)17706-3; Wilson SL, 2000, BRAIN INJURY, V14, P319	53	14	14	0	4	C I C-EDIZIONI INT SRL	ROME	CORSO TRIESTE, 42, 00198 ROME, ITALY	0393-5264	1971-3274		FUNCT NEUROL	Funct. Neurol.	JUL-SEP	2017	32	3					131	136					6	Clinical Neurology	Neurosciences & Neurology	FI4PG	WOS:000411954000004	29042001				2021-06-18	
J	Lavaur, J; Le Nogue, D; Lemaire, M; Pype, J; Farjot, G; Hirsch, EC; Michel, PP				Lavaur, Jeremie; Le Nogue, Deborah; Lemaire, Marc; Pype, Jan; Farjot, Geraldine; Hirsch, Etienne C.; Michel, Patrick P.			The noble gas xenon provides protection and trophic stimulation to midbrain dopamine neurons	JOURNAL OF NEUROCHEMISTRY			English	Article						astroglial cells; dopamine neurons; glutamate; neurodegeneration; NMDA; xenon	D-ASPARTATE RECEPTOR; MITOCHONDRIAL CALCIUM HOMEOSTASIS; TRAUMATIC BRAIN-INJURY; PARKINSONS-DISEASE; NMDA RECEPTOR; COMPETITIVE-INHIBITION; SUBSTANTIA-NIGRA; GLYCINE SITE; SUBTHALAMIC NUCLEUS; HYPOXIA-ISCHEMIA	Despite its low chemical reactivity, the noble gas xenon possesses a remarkable spectrum of biological effects. In particular, xenon is a strong neuroprotectant in preclinical models of hypoxic-ischemic brain injury. In this study, we wished to determine whether xenon retained its neuroprotective potential in experimental settings that model the progressive loss of midbrain dopamine (DA) neurons in Parkinson's disease. Using rat midbrain cultures, we established that xenon was partially protective for DA neurons through either direct or indirect effects on these neurons. So, when DA neurons were exposed to l-trans-pyrrolidine-2,4-dicarboxylic acid so as to increase ambient glutamate levels and generate slow and sustained excitotoxicity, the effect of xenon on DA neurons was direct. The vitamin E analog Trolox also partially rescued DA neurons in this setting and enhanced neuroprotection by xenon. However, in the situation where DA cell death was spontaneous, the protection of DA neurons by xenon appeared indirect as it occurred through the repression of a mechanism mediated by proliferating glial cells, presumably astrocytes and their precursor cells. Xenon also exerted trophic effects for DA neurons in this paradigm. The effects of xenon were mimicked and improved by the N-methyl-d-aspartate glutamate receptor antagonist memantine and xenon itself appeared to work by antagonizing N-methyl-d-aspartate receptors. Note that another noble gas argon could not reproduce xenon effects. Overall, present data indicate that xenon can provide protection and trophic support to DA neurons that are vulnerable in Parkinson's disease. This suggests that xenon might have some therapeutic value for this disorder.	[Lavaur, Jeremie; Le Nogue, Deborah; Hirsch, Etienne C.; Michel, Patrick P.] UPMC Univ Paris 06, Sorbonne Univ, INSERM, Hop Pitie Salpetriere,CNRS,Inst Cerveau & Moelle, Paris, France; [Lemaire, Marc; Pype, Jan; Farjot, Geraldine] Air Liquide Sante Int, Med R&D Paris, Saclay Res Ctr, Jouy En Josas, France	Michel, PP (corresponding author), Hop La Pitie Salpetriere, ICM, 47 Bd Hop, F-75013 Paris, France.	patrick-pierre.michel@upmc.fr	Hirsch, Etienne/AAC-7655-2019; Michel, Patrick Pierre/J-5248-2019	Hirsch, Etienne/0000-0003-4823-276X; Michel, Patrick Pierre/0000-0001-5607-3119	programs 'Investissements d'Avenir'French National Research Agency (ANR) [ANR-10-IAIHU-06, ANR-11-INBS-0011-NeurATRIS]; CIFRE doctoral fellowship; Association Nationale de la Recherche et de la Technologie (ANRT)French National Research Agency (ANR) [2014/0589]; Air Liquide Sante International	This study was funded by a grant from Air Liquide Sante International. The research leading to these results also received support from the programs 'Investissements d'Avenir' ANR-10-IAIHU- 06 and ANR-11-INBS-0011-NeurATRIS: Translational Research Infrastructure for Biotherapies in Neurosciences. This work benefited from equipment and services from the CELIS cell culture facility, at ICM. More specifically, we thank David Akbar for assistance regarding automated fluorescence microscopy. ML, JP, and GF are Air Liquide employees. DLN was supported by a CIFRE doctoral fellowship co-funded by Association Nationale de la Recherche et de la Technologie (ANRT, 2014/0589) and Air Liquide Sante International. We also wish to mention the contribution of other Air Liquide staff members, Aude Milet and Matthieu Chalopin for project management and Francois Gilles for technical support with gas delivery systems. Air Liquide has filed patent applications for the use of xenon as therapeutic agent for Parkinson's disease. E. Hirsch is an editor of JNC.	Aoyama K, 2015, MOLECULES, V20, P8742, DOI 10.3390/molecules20058742; Armstrong SP, 2012, ANESTHESIOLOGY, V117, P38, DOI 10.1097/ALN.0b013e31825ada2e; Assous M, 2014, NEUROBIOL DIS, V65, P69, DOI 10.1016/j.nbd.2014.01.011; Banks P, 2010, ANESTHESIOLOGY, V112, P614, DOI 10.1097/ALN.0b013e3181cea398; Bantel C, 2010, ANESTHESIOLOGY, V112, P623, DOI 10.1097/ALN.0b013e3181cf894a; Berman AE, 2011, ANN NEUROL, V69, P509, DOI 10.1002/ana.22162; Blandini F, 2001, ANN NEUROL, V49, P525, DOI 10.1002/ana.104.abs; Blitzblau R, 1996, EUR J NEUROSCI, V8, P1840, DOI 10.1111/j.1460-9568.1996.tb01328.x; Brennan-Minnella AM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.111; Brucken A, 2013, BRIT J ANAESTH, V110, P106, DOI 10.1093/bja/aes509; Campos-Pires R, 2015, CRIT CARE MED, V43, P149, DOI 10.1097/CCM.0000000000000624; Charles PD, 2008, NAT CLIN PRACT NEURO, V4, P424, DOI 10.1038/ncpneuro0848; CILIAX BJ, 1995, J NEUROSCI, V15, P1714; Coburn M, 2012, EUR J ANAESTH, V29, P549, DOI 10.1097/EJA.0b013e328357bfdd; Damier P, 1999, BRAIN, V122, P1421, DOI 10.1093/brain/122.8.1421; David HN, 2008, FASEB J, V22, P1275, DOI 10.1096/fj.07-9420com; de Chaumont F, 2012, NAT METHODS, V9, P690, DOI [10.1038/NMETH.2075, 10.1038/nmeth.2075]; Deng J, 2014, PROG NEUROBIOL, V115, P210, DOI 10.1016/j.pneurobio.2014.01.001; Dickinson R, 2007, ANESTHESIOLOGY, V107, P756, DOI 10.1097/01.anes.0000287061.77674.71; Gouix E, 2009, MOL CELL NEUROSCI, V40, P463, DOI 10.1016/j.mcn.2009.01.002; Gruss M, 2004, MOL PHARMACOL, V65, P443, DOI 10.1124/mol.65.2.443; Guerreiro S, 2015, MOL PHARMACOL, V87, P525, DOI 10.1124/mol.114.095703; Guerreiro S, 2009, J NEUROCHEM, V109, P1118, DOI 10.1111/j.1471-4159.2009.06040.x; Harris K, 2013, ANESTHESIOLOGY, V119, P1137, DOI 10.1097/ALN.0b013e3182a2a265; Janc OA, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00056; Jellinger KA, 2012, MOVEMENT DISORD, V27, P8, DOI 10.1002/mds.23795; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jimenez-Blasco D, 2015, CELL DEATH DIFFER, V22, P1877, DOI 10.1038/cdd.2015.49; Kotermanski SE, 2009, J NEUROSCI, V29, P2774, DOI 10.1523/JNEUROSCI.3703-08.2009; Kramer ER, 2015, FEBS LETT, V589, P3760, DOI 10.1016/j.febslet.2015.11.006; Lavaur J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.18; Lavaur J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.86; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Lipton SA, 2007, CURR DRUG TARGETS, V8, P621, DOI 10.2174/138945007780618472; Liu LT, 2010, J PHYS CHEM B, V114, P9010, DOI 10.1021/jp101687j; Ma DQ, 2005, ANN NEUROL, V58, P182, DOI 10.1002/ana.20547; Ma SY, 1997, J NEUROL SCI, V151, P83, DOI 10.1016/S0022-510X(97)00100-7; MAKI R, 1994, J NEUROSCI, V14, P6754; Michel PP, 2016, NEURON, V90, P675, DOI 10.1016/j.neuron.2016.03.038; Michel PP, 2013, FASEB J, V27, P3414, DOI 10.1096/fj.12-220418; Michel PP, 1997, J NEUROCHEM, V69, P1499; Mourlevat S, 2003, MOL PHARMACOL, V64, P578, DOI 10.1124/mol.64.3.578; Nafia I, 2008, J NEUROCHEM, V105, P484, DOI 10.1111/j.1471-4159.2007.05146.x; Petzelt C, 2003, LIFE SCI, V72, P1909, DOI 10.1016/S0024-3205(02)02439-6; Petzelt C, 1999, LIFE SCI, V65, P901, DOI 10.1016/S0024-3205(99)00320-3; Piallat B, 1999, J NEURAL TRANSM-SUPP, P71; Ramaswamy P, 2014, NEUROL SCI, V35, P823, DOI 10.1007/s10072-013-1604-5; Rasband W. S, 2012, IMAGEJ; Rousseau E, 2013, MOL PHARMACOL, V84, P888, DOI 10.1124/mol.113.087965; Salazar J, 2008, P NATL ACAD SCI USA, V105, P18578, DOI 10.1073/pnas.0804373105; Sanders RD, 2003, BRIT J ANAESTH, V91, P709, DOI 10.1093/bja/aeg232; Sauguet L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149795; Sepulveda-Diaz JE, 2016, GLIA, V64, P1912, DOI 10.1002/glia.23032; Spaggiari S, 2013, CELL CYCLE, V12, P2636, DOI 10.4161/cc.25650; Thomas C, 2009, REDOX REP, V14, P102, DOI 10.1179/135100009X392566; Thoresen M, 2009, J CEREBR BLOOD F MET, V29, P707, DOI 10.1038/jcbfm.2008.163; Toulorge D, 2011, FASEB J, V25, P2563, DOI 10.1096/fj.11-182824; Toulorge D, 2010, J NEUROCHEM, V114, P553, DOI 10.1111/j.1471-4159.2010.06785.x; Toyomoto M, 2005, NEUROSCI LETT, V379, P185, DOI 10.1016/j.neulet.2004.12.063; Vaarmann A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.194; Verkhratsky A, 2007, NEUROSCIENTIST, V13, P28, DOI 10.1177/1073858406294270; Waagepetersen HS, 2001, NEUROCHEM RES, V26, P661, DOI 10.1023/A:1010939304104; Wallace BA, 2007, BRAIN, V130, P2129, DOI 10.1093/brain/awm137; Wu HM, 2009, NEUROPSYCHOPHARMACOL, V34, P2344, DOI 10.1038/npp.2009.64; Yamamoto Y, 2010, ACTA ANAESTH SCAND, V54, P337, DOI 10.1111/j.1399-6576.2009.02111.x; Yang T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037020; ZHANG YX, 1995, AM MINERAL, V80, P670; Zhao HL, 2016, ONCOTARGET, V7, P25640, DOI 10.18632/oncotarget.8241	68	14	18	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUL	2017	142	1					14	28		10.1111/jnc.14041			15	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	EY3UE	WOS:000403899000002	28398653	Green Published, Other Gold			2021-06-18	
J	Modi, AC; Schmidt, M; Smith, AW; Turnier, L; Glaser, N; Wade, SL				Modi, Avani C.; Schmidt, Matthew; Smith, Aimee W.; Turnier, Luke; Glaser, Noah; Wade, Shari L.			Development of a web-based executive functioning intervention for adolescents with epilepsy: The Epilepsy Journey	EPILEPSY & BEHAVIOR			English	Article						Technology; Teenagers; Attention; Seizures; Treatment	TRAUMATIC BRAIN-INJURY; PROBLEM-SOLVING INTERVENTION; RANDOMIZED CLINICAL-TRIAL; SYMPTOMATIC EPILEPSY; PRELIMINARY EFFICACY; CHILDHOOD EPILEPSY; ABSENCE EPILEPSY; CHILDREN; DEFICITS; DYSFUNCTION	Introduction: Youth with epilepsy exhibit significant deficits in executive functioning (EF), yet there are few interventions to improve EF for adolescents. The aims of the current study were to develop an individuallytailored intervention, called Epilepsy Journey, to improve aspects of EF through an iterative, patient-centered process including focus groups and usability testing. Methods: Five adolescents and caregivers participated in focus groups. This input was used to develop ten learning modules based on subscales of the Behavioral Rating Inventory of Executive Functions and key issues that may impact EF in adolescents. Six adolescents participated in usability testing and a usability expert conducted a heuristic evaluation. Demographic information, chart reviews and measures of EF were also completed. Results: Focus group participants and their parents reported difficulties with memory, attention, organization, monitoring, initiation, impulsivity, emotional control, sleep, awareness in schools and managing stress. They also identified successful strategies to address memory and organizational difficulties. Usability testing of the resultant Epilepsy Journey modules revealed problems with navigation and identified features that promoted usability, including progress bars and interactivemodules. Programmodificationsweremade after each usability trial resulting in a relatively brief, interactive and readily navigable program. Perceived utility was high with all but one participant. Participants rated the content as helpful and indicated they would recommend Epilepsy Journey to others. Conclusions: Feedback from the focus group and usability testing yielded a feasible, acceptable, relevant and user-friendly web-based intervention for adolescents with epilepsy. The Epilepsy Journey program will be further tested in an open pilot with adolescents with epilepsy and associated EF deficits. (C) 2017 Elsevier Inc. All rights reserved.	[Modi, Avani C.; Smith, Aimee W.; Turnier, Luke] Cincinnati Childrens Hosp Med Ctr, Div Behav Med & Clin Psychol, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Schmidt, Matthew; Glaser, Noah] Univ Cincinnati, Coll Educ Criminal Justice & Human Serv, Cincinnati, OH 45221 USA; [Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Div Rehabil Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA	Modi, AC (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Behav Med & Clin Psychol, Ctr Adherence & Self Management, 3333 Burnet Ave,MLC 7039, Cincinnati, OH 45229 USA.	avani.modi@cchmc.org		Modi, Avani/0000-0002-7580-3751	National Institutes of Health-Eunice Kennedy Shriver, National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD083335-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD083335] Funding Source: NIH RePORTER	This research was funded by the National Institutes of Health-Eunice Kennedy Shriver, National Institute of Child Health and Human Development (R21HD083335-01).	Bailet LL, 2000, EPILEPSIA, V41, P426, DOI 10.1111/j.1528-1157.2000.tb00184.x; Fuentes A, 2017, EPILEPSY BEHAV, V67, P51, DOI 10.1016/j.yebeh.2016.12.016; Gaudieri PA, 2008, DIABETES CARE, V31, P1892, DOI 10.2337/dc07-2132; Gioia G.A., 2000, PSYCHOL ASSESSMENT R; Goggins S, 2010, 43 HAW INT C SYST SC; Goggins Sean P., 2011, International Journal of Social and Organizational Dynamics in IT, V1, P30, DOI 10.4018/ijsodit.2011010103; Hermann BP, 2008, EPILEPSIA, V49, P1847, DOI 10.1111/j.1528-1167.2008.01735.x; Hijmans CT, 2011, PEDIATR BLOOD CANCER, V56, P783, DOI 10.1002/pbc.22879; Hoie B, 2008, DEV MED CHILD NEUROL, V50, P530, DOI 10.1111/j.1469-8749.2008.03015.x; Hoie B, 2005, SEIZURE-EUR J EPILEP, V14, P223, DOI 10.1016/j.seizure.2004.10.006; Jackson DC, 2013, J PEDIATR-US, V162, P1047, DOI 10.1016/j.jpeds.2012.10.046; Jones JE, 2010, EPILEPSY BEHAV, V18, P211, DOI 10.1016/j.yebeh.2010.03.015; Kerr EN, 2015, EPILEPSIA, V56, P1784, DOI 10.1111/epi.13195; Kurowski BG, 2014, JAMA PEDIATR, V168, P523, DOI 10.1001/jamapediatrics.2013.5070; Kurowski BG, 2013, PEDIATRICS, V132, pE158, DOI 10.1542/peds.2012-4040; Lenhart A, 2015, TEEN SOCIAL MEDIA TE; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Macallister WS, 2014, APPL NEUROPSYCHOL CH; Madden M., 2013, TEENS AND TECHNOLOGY; Masur D, 2013, NEUROLOGY, V81, P1572, DOI 10.1212/WNL.0b013e3182a9f3ca; Parrish J, 2007, DEV MED CHILD NEUROL, V49, P412, DOI 10.1111/j.1469-8749.2007.00412.x; Pavone P, 2001, NEUROLOGY, V56, P1047, DOI 10.1212/WNL.56.8.1047; Piccinelli P, 2010, SEIZURE-EUR J EPILEP, V19, P540, DOI 10.1016/j.seizure.2010.07.014; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2011, PEDIATRICS, V128, pE947, DOI 10.1542/peds.2010-3721; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Wade SL, 2013, J HEAD TRAUMA REHABI; Winter AL, 2014, J CLIN EXP NEUROPSYC, V36, P818, DOI 10.1080/13803395.2014.943695	31	14	14	2	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	JUL	2017	72						114	121		10.1016/j.yebeh.2017.04.009			8	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	FB7LE	WOS:000406321300019	28575759	Green Accepted			2021-06-18	
J	Ren, HX; Yang, Z; Luo, CM; Zeng, HT; Li, P; Kang, JX; Wan, JB; He, CW; Su, HX				Ren, Huixia; Yang, Zhen; Luo, Chuanming; Zeng, Haitao; Li, Peng; Kang, Jing X.; Wan, Jian-Bo; He, Chengwei; Su, Huanxing			Enriched Endogenous Omega-3 Fatty Acids in Mice Ameliorate Parenchymal Cell Death After Traumatic Brain Injury	MOLECULAR NEUROBIOLOGY			English	Article						Traumatic brain injury; Omega-3 polyunsaturated fatty acids; Neuroprotection; Two-photon laser scanning microscopy; DHA	SPINAL-CORD-INJURY; DOCOSAHEXAENOIC ACID; NEUROPROTECTIN D1; ANTIOXIDANT THERAPIES; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; TRANSGENIC MICE; FATTY-ACIDS; SURVIVAL; SUPPLEMENTATION	Currently no effective therapies are available for the treatment of traumatic brain injury (TBI). Early intervention that specifically provides neuroprotection is of most importance which profoundly influences the outcome of TBI. In the present study, we adopted a closed-skull mild TBI model to investigate potential roles of omega-3 polyunsaturated fatty acids (omega-3 PUFAs) in protecting against TBI. Using two-photon laser scanning microscopy (2PLSM), parenchymal cell death and reactive oxidative species (ROS) expression were directly observed and recorded after TBI through a thinned skull bone window. Fat-1 mice with high endogenous omega-3 PUFAs significantly inhibited ROS expression and attenuated parenchymal cell death after compression injury during the early injury phase. Elevated generation of glutathione (GSH) and neuroprotectin D1 (NPD1) in the parenchyma of fat-1 mice could be the contributor to the beneficial role of omega-3 PUFAs in TBI. The results of the study suggest that omega-3 PUFAs is an effective neuroprotectant as an early pharmacological intervention for TBI and the information derived from this study may help guide dietary advice for those who are susceptible to repetitive mild TBI.	[Ren, Huixia; Luo, Chuanming; Li, Peng; Wan, Jian-Bo; He, Chengwei; Su, Huanxing] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Macau, Peoples R China; [Yang, Zhen] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Cardiol, Guangzhou 510080, Guangdong, Peoples R China; [Zeng, Haitao] Sun Yat Sen Univ, Affiliated Hosp 6, Ctr Reprod Med, Guangzhou, Guangdong, Peoples R China; [Kang, Jing X.] Massachusetts Gen Hosp, Dept Med, Lab Lipid Med & Technol, Boston, MA 02114 USA; [Kang, Jing X.] Harvard Med Sch, Boston, MA USA	Su, HX (corresponding author), Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.	huanxingsu@umac.mo	Su, Huanxing/X-3980-2019; He, Chengwei/J-7090-2015; Su, Huanxing/X-3954-2019; Wan, Jian-Bo/D-8368-2014	Su, Huanxing/0000-0002-0513-4943; Su, Huanxing/0000-0003-3254-825X; Wan, Jian-Bo/0000-0002-6750-2617	Macao Science and Technology Development Fund [063/2015/A1]; multi-year research grant, University of Macau [MYRG122 (Y1-L3)-ICMS12-SHX, MYRG110 (Y1-L2)-ICMS13-SHX]; National Natural Scientific Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31270992, 30800215]; Zhu Jiang Science and Technology New Star of Guangzhou City [2013 J2200019]; Guangdong Province Science and Technology Plan [2013B021800275]; Fundamental Research Funds for the Central Universities in Sun Yat-Sen University [13ykpy24]	This study was supported by the Macao Science and Technology Development Fund (063/2015/A1), multi-year research grant, University of Macau, MYRG122 (Y1-L3)-ICMS12-SHX and MYRG110 (Y1-L2)-ICMS13-SHX, the National Natural Scientific Foundation of China (31270992 and 30800215), Zhu Jiang Science and Technology New Star of Guangzhou City (2013 J2200019), Guangdong Province Science and Technology Plan (2013B021800275), and the Fundamental Research Funds for the Central Universities in Sun Yat-Sen University (13ykpy24).	Antony R, 2010, J BIOL CHEM, V285, P18301, DOI 10.1074/jbc.M109.095232; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005; Bazan NG, 2014, MOL NEUROBIOL, V50, P1, DOI 10.1007/s12035-014-8897-0; Bazan NG, 2012, MOL NEUROBIOL, V46, P221, DOI 10.1007/s12035-012-8322-5; Bazan NG, 2010, J LIPID RES, V51, P2018, DOI 10.1194/jlr.R001131; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Casanas-Sanchez V, 2014, J NEUROCHEM, V131, P470, DOI 10.1111/jnc.12833; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Das UN, 2009, LIPIDS HEALTH DIS, V8, DOI 10.1186/1476-511X-8-61; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hong SH, 2014, J NEUROL SCI, V338, P135, DOI 10.1016/j.jns.2013.12.033; Jennings JS, 2008, MINI-REV MED CHEM, V8, P689, DOI 10.2174/138955708784567377; Kanemaru K, 2013, P NATL ACAD SCI USA, V110, P11612, DOI 10.1073/pnas.1300378110; Kang JX, 2004, NATURE, V427, P504, DOI 10.1038/427504a; Kelly L, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.04.001; Kohli P, 2009, BRIT J PHARMACOL, V158, P960, DOI 10.1111/j.1476-5381.2009.00290.x; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Lalancette-Hebert M, 2011, STROKE, V42, P2903, DOI 10.1161/STROKEAHA.111.620856; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lim SN, 2013, NEUROBIOL DIS, V51, P104, DOI 10.1016/j.nbd.2012.10.021; Lim SN, 2013, EXP NEUROL, V239, P13, DOI 10.1016/j.expneurol.2012.09.015; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420; Luo CM, 2014, J LIPID RES, V55, P1288, DOI 10.1194/jlr.M046466; Michael-Titus AT, 2014, TRENDS NEUROSCI, V37, P30, DOI 10.1016/j.tins.2013.10.005; Mills JD, 2011, NEUROSURGERY, V68, P474, DOI 10.1227/NEU.0b013e3181ff692b; Moraes LA, 2006, PHARMACOL THERAPEUT, V110, P371, DOI 10.1016/j.pharmthera.2005.08.007; Nikolenko V, 2007, NAT METHODS, V4, P943, DOI 10.1038/NMETH1105; Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041; Orr SK, 2013, J NEUROCHEM, V127, P378, DOI 10.1111/jnc.12392; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Schaffer CB, 2006, PLOS BIOL, V4, P258, DOI 10.1371/journal.pbio.0040022; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Shi Z, 2015, MOL NEUROBI IN PRESS; Shih AY, 2012, J CEREBR BLOOD F MET, V32, P1277, DOI 10.1038/jcbfm.2011.196; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Vreugdenhil M, 1996, P NATL ACAD SCI USA, V93, P12559, DOI 10.1073/pnas.93.22.12559; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002; Wolf S, 2015, NAT METHODS, V12, P379, DOI 10.1038/nmeth.3371; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Yang R., 2011, CURR PROTOC IMMUNOL; Zhang WT, 2010, STROKE, V41, P2341, DOI 10.1161/STROKEAHA.110.586081	49	14	15	1	17	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JUL	2017	54	5					3317	3326		10.1007/s12035-016-9931-1			10	Neurosciences	Neurosciences & Neurology	EV9IQ	WOS:000402100100020	27167127				2021-06-18	
J	Turner-Stokes, L				Turner-Stokes, Lynne			A matter of life and death: controversy at the interface between clinical and legal decision-making in prolonged disorders of consciousness	JOURNAL OF MEDICAL ETHICS			English	Article							NEUROTRAUMA; FUTILITY	Best interests decision-making and end-of-life care for patients in permanent vegetative or minimally conscious states (VS/MCS) is a complex area of clinical and legal practice, which is poorly understood by most clinicians, lawyers and members of the public. In recent weeks, the Oxford Shrieval lecture by Mr Justice Baker ('A Matter of Life and Death', 11 October 2016) and its subsequent reporting in the public press has sparked debate on the respective roles of clinicians, the Court of Protection and the Mental Capacity Act 2005 in decisions to withhold or withdraw life-sustaining treatments from patients with disorders of consciousness. The debate became polarised and confused by misquotation and inaccurate terminology, and highlighted a lack of knowledge about how patients in VS/MCS die in the absence of court approval. This article sets out the background and discussion and attempts to give a more accurate representation of the facts. In the spirit of transparency, I present a mortality review of all the patients in VS/MCS who have died under the care of my own unit in the last decade-with or without referral to the court, but always in accordance with the law. These data demonstrate that clinicians regularly undertake best interests decision-making in conjunction with families that may include life and death decisions (sometimes even the withdrawal or withholding of clinically assisted nutrition and hydration); and that these can be made within the current legal framework without necessarily involving the court in all cases. This is the first published case series of its kind.	[Turner-Stokes, Lynne] Kings Coll London, Fac Life Sci & Med, Dept Palliat Care Policy & Rehabil, London, England; [Turner-Stokes, Lynne] Northwick Pk Hosp & Clin Res Ctr, Reg Hyper Acute Rehabil Unit, Harrow, Middx, England	Turner-Stokes, L (corresponding author), Northwick Pk Hosp & Clin Res Ctr, Reg Rehabil Unit, Watford Rd, Harrow HA1 3UJ, Middx, England.	lynne.turner-stokes@doctors.org.uk	Turner-Stokes, Lynne/F-4418-2012	Turner-Stokes, Lynne/0000-0002-3302-9462	Dunhill Medical TrustDunhill Medical Trust; National Institute for Health ResearchNational Institute for Health Research (NIHR) [RP-PG-0407-10185] Funding Source: researchfish	Financial support for the preparation of this manuscript was provided by the Dunhill Medical Trust.	[Anonymous], 2005, MENT CAP ACT; [Anonymous], 2013, PROLONGED DISORDERS; [Anonymous], 2016, ADV DECISIONS ARE LE; Baker J., 2016, OXFORD SHRIEVAL LECT; Bunn S, 2015, VEGETATIVE MINIMALLY; Formby A., 2015, COST ANAL LEGAL DECL; Giacino JT, 2005, NEUROPSYCHOL REHABIL, V15, P166, DOI 10.1080/09602010443000498; Gillett GR, 2010, J MED ETHICS, V36, P727, DOI 10.1136/jme.2010.037424; Honeybul S, 2011, J MED ETHICS, V37, P707, DOI 10.1136/medethics-2011-100081; Honeybul S, 2016, ACTA NEUROCHIR, V158, P1251, DOI 10.1007/s00701-016-2818-0; Honeybul S, 2013, NEUROSURGERY, V73, P917, DOI 10.1227/NEU.0000000000000014; Honeybul S, 2012, J MED ETHICS, V38, P657, DOI 10.1136/medethics-2012-100672; Jackson P., 2014, EWHC, V342; Kitzinger C, 2015, LEGITIMACY MED TREAT; Kitzinger C, 2015, J MED ETHICS, V41, DOI 10.1136/medethics-2013-101799; Kitzinger J, 2017, J MED ETHICS, V43, P459, DOI 10.1136/medethics-2016-103853; Laurie GT, 2016, MASON MCCALL SMITHS; NINDS, 2015, COM INF PAG; Ruck-Keene A., 2017, J MED ETHICS, V43, P435; Ruck-Keene A., 2016, MENTAL CAPACITY LAW; Strauss DJ, 1999, PEDIATR NEUROL, V21, P626, DOI 10.1016/S0887-8994(99)00051-X	21	14	15	1	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-6800	1473-4257		J MED ETHICS	J. Med. Ethics	JUL	2017	43	7					469	475		10.1136/medethics-2016-104057			7	Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical	Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences	EZ2ND	WOS:000404545100010	27986800	Green Published, Other Gold			2021-06-18	
J	Yates, NJ; Lydiard, S; Fehily, B; Weir, G; Chin, A; Bartlett, CA; Alderson, J; Fitzgerald, M				Yates, Nathanael J.; Lydiard, Stephen; Fehily, Brooke; Weir, Gillian; Chin, Aaron; Bartlett, Carole A.; Alderson, Jacqueline; Fitzgerald, Melinda			Repeated mild traumatic brain injury in female rats increases lipid peroxidation in neurons	EXPERIMENTAL BRAIN RESEARCH			English	Article						Repeated mild traumatic brain injury; Oxidative stress; Lipid peroxidation; Closed head; Weight drop model; Concussion; Female	CLOSED-HEAD INJURY; OXIDATIVE STRESS; MOUSE MODEL; TEMPORAL WINDOW; CELL-DEATH; PROFESSIONAL FOOTBALL; SYNAPTIC PROTEINS; AXONAL INJURY; TIME-COURSE; CONCUSSION	Negative outcomes of mild traumatic brain injury (mTBI) can be exacerbated by repeated insult. Animal models of repeated closed-head mTBI provide the opportunity to define acute pathological mechanisms as the number of mTBI increases. Furthermore, little is known about the effects of mTBI impact site, and how this may affect brain function. We use a closed head, weight drop model of mTBI that allows head movement following impact, in adult female rats to determine the role of the number and location of mTBI on brain pathology and behaviour. Biomechanical assessment of two anatomically well-defined mTBI impact sites were used, anterior (bregma) and posterior (lambda). Location of the impact had no significant effect on impact forces (450 N), and the weight impact locations were on average 5.4 mm from the desired impact site. No between location vertical linear head kinematic differences were observed immediately following impact, however, in the 300 ms post-impact, significantly higher mean vertical head displacement and velocity were observed in the mTBI lambda trials. Breaches of the blood brain barrier were observed with three mTBI over bregma, associated with immunohistochemical indicators of damage. However, an increased incidence of hairline fractures of the skull and macroscopic haemorrhaging made bregma an unsuitable impact location to model repeated mTBI. Repeated mTBI over lambda did not cause skull fractures and were examined more comprehensively, with outcomes following one, two or three mTBI or sham, delivered at 1 day intervals, assessed on days 1-4. We observe a mild behavioural phenotype, with subtle deficits in cognitive function, associated with no identifiable neuroanatomical or inflammatory changes. However, an increase in lipid peroxidation in a subset of cortical neurons following two mTBI indicates increasing oxidative damage with repeated injury in female rats, supported by increased amyloid precursor protein immunoreactivity with three mTBI. This study of acute events following closed head mTBI identifies lipid peroxidation in neurons at the same time as cognitive deficits. Our study adds to existing literature, providing biomechanics data and demonstrating mild cognitive disturbances associated with diffuse injury, predominantly to grey matter, acutely following repeated mTBI.	[Yates, Nathanael J.; Lydiard, Stephen; Fehily, Brooke; Bartlett, Carole A.; Fitzgerald, Melinda] Univ Western Australia, Sch Biol Sci, Expt & Regenerat Neurosci, Perth, WA, Australia; [Weir, Gillian; Chin, Aaron; Alderson, Jacqueline] Univ Western Australia, Sch Sport Sci Exercise & Hlth, Perth, WA 6009, Australia; [Alderson, Jacqueline] Auckland Univ Technol, SPRINZ, Auckland, New Zealand; [Fitzgerald, Melinda] Curtin Univ, Curtin Hlth Innovat Res Inst, Bentley, WA, Australia; [Fitzgerald, Melinda] Sarich Neurosci Res Inst, Perron Inst Nerurol & Translat Sci, Verdun St, Nedlands, WA 6009, Australia	Fitzgerald, M (corresponding author), Univ Western Australia, Sch Biol Sci, Expt & Regenerat Neurosci, Perth, WA, Australia.; Fitzgerald, M (corresponding author), Curtin Univ, Curtin Hlth Innovat Res Inst, Bentley, WA, Australia.; Fitzgerald, M (corresponding author), Sarich Neurosci Res Inst, Perron Inst Nerurol & Translat Sci, Verdun St, Nedlands, WA 6009, Australia.	lindy.fitzgerald@uwa.edu.au	Yates, Nathanael J/K-8358-2018; Alderson, Jacqueline/V-3491-2019; Fitzgerald, Melinda/C-4235-2011	Yates, Nathanael J/0000-0003-2742-6952; Alderson, Jacqueline/0000-0002-8866-0913; Fitzgerald, Melinda/0000-0002-4823-8179; Fehily, Brooke/0000-0002-8432-4621	Department of Health Western Australia Merit Award; NHMRCNational Health and Medical Research Council of Australia [APP1087114]	We acknowledge financial support from the Department of Health Western Australia Merit Award. MF is supported by an NHMRC Career Development Fellowship (APP1087114). We thank Dr Caitlin Wyrwoll for kindly allowing us to use her ANY-Maze software and Dr Jeremy Smith for providing selected antibodies.	Angoa-Perez M, 2014, J NEUROCHEM, V129, P916, DOI 10.1111/jnc.12690; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Bolouri H, 2012, ACTA NEUROL SCAND, V125, P241, DOI 10.1111/j.1600-0404.2011.01614.x; Bolton AN, 2014, J NEUROPATH EXP NEUR, V73, P933, DOI 10.1097/NEN.0000000000000115; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Buchele F, 2016, J NEUROTRAUM, V33, P1171, DOI 10.1089/neu.2015.4001; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Doig RLO, 2014, EXP NEUROL, V261, P136, DOI 10.1016/j.expneurol.2014.06.007; Fehily B, 2016, CELL TRANSPLANT, DOI [10.3727/096368916x692807, DOI 10.3727/096368916X692807]; Fitzgerald M, 2010, J NEUROTRAUM, V27, P439, DOI 10.1089/neu.2009.1112; Fuss B, 2000, DEV BIOL, V218, P259, DOI 10.1006/dbio.1999.9574; Gao LM, 2006, DEV BIOL, V290, P277, DOI 10.1016/j.ydbio.2005.11.007; Gregersen R, 2001, EXP BRAIN RES, V138, P384, DOI 10.1007/s002210100715; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Higgins GC, 2010, J ALZHEIMERS DIS, V20, pS453, DOI 10.3233/JAD-2010-100321; Hohl A, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.06.007; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Itoh T, 2010, NEUROCHEM RES, V35, P348, DOI 10.1007/s11064-009-0061-2; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kozlowski P, 2008, J NEUROTRAUM, V25, P653, DOI 10.1089/neu.2007.0462; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Mychasiuk R, 2016, J NEUROSCI METH, V257, P168, DOI 10.1016/j.jneumeth.2015.10.002; Payne SC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065710; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Psachoulia K, 2009, NEURON GLIA BIOL, V5, P57, DOI 10.1017/S1740925X09990354; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Ramos-Zuniga R, 2014, WORLD NEUROSURG, V82, P828, DOI 10.1016/j.wneu.2013.09.018; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Saunders NR, 2015, FRONT NEUROSCI-SWITZ, V9, DOI [10.3339/fnins.2015.00385, 10.3389/fnins.2015.00385]; Schneider C, 2008, J BIOL CHEM, V283, P15539, DOI 10.1074/jbc.R800001200; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Szymanski CR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066448; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Valavanidis A, 2009, J ENVIRON SCI HEAL C, V27, P120, DOI 10.1080/10590500902885684; Wells J, 2012, J NEUROSCI RES, V90, P606, DOI 10.1002/jnr.22784; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yamada KH, 2012, J BIOL CHEM, V287, P13182, DOI 10.1074/jbc.M111.302612; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	66	14	14	0	3	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	JUL	2017	235	7					2133	2149		10.1007/s00221-017-4958-8			17	Neurosciences	Neurosciences & Neurology	EY1IC	WOS:000403718600014	28417146				2021-06-18	
J	Yeates, KO; Beauchamp, M; Craig, W; Doan, Q; Zemek, R; Bjornson, BH; Gravel, J; Mikrogianakis, A; Goodyear, B; Abdeen, N; Beaulieu, C; Dehaes, M; Deschenes, S; Harris, A; Lebel, C; Lamont, R; Williamson, T; Barlow, KM; Bernier, F; Brooks, BL; Emery, C; Freedman, SB; Kowalski, K; Mrklas, K; Tomfohr-Madsen, L; Schneider, KJ				Yeates, Keith Owen; Beauchamp, Miriam; Craig, William; Doan, Quynh; Zemek, Roger; Bjornson, Bruce H.; Gravel, Jocelyn; Mikrogianakis, Angelo; Goodyear, Bradley; Abdeen, Nishard; Beaulieu, Christian; Dehaes, Mathieu; Deschenes, Sylvain; Harris, Ashley; Lebel, Catherine; Lamont, Ryan; Williamson, Tyler; Barlow, Karen Maria; Bernier, Francois; Brooks, Brian L.; Emery, Carolyn; Freedman, Stephen B.; Kowalski, Kristina; Mrklas, Kelly; Tomfohr-Madsen, Lianne; Schneider, Kathryn J.		Pediat Emergency Res Canada PERC	Advancing Concussion Assessment in Pediatrics (A-CAP): a prospective, concurrent cohort, longitudinal study of mild traumatic brain injury in children: study protocol	BMJ OPEN			English	Article							FUNCTIONAL DISABILITY INVENTORY; FAMILY ASSESSMENT DEVICE; SERIOUS MENTAL-ILLNESS; SYMPTOM VALIDITY TEST; EMERGENCY-DEPARTMENT; POSTCONCUSSIVE SYMPTOMS; POSTURAL STABILITY; GENERAL-POPULATION; OUTCOME SCALE; HEAD TRAUMA	Introduction Paediatric mild traumatic brain injury (mTBI) is a public health burden. Clinicians urgently need evidence-based guidance to manage mTBI, but gold standards for diagnosing and predicting the outcomes of mTBI are lacking. The objective of the Advancing Concussion Assessment in Pediatrics (A-CAP) study is to assess a broad pool of neurobiological and psychosocial markers to examine associations with postinjury outcomes in a large sample of children with either mTBI or orthopaedic injury (OI), with the goal of improving the diagnosis and prognostication of outcomes of paediatric mTBI. Methods and analysis A-CAP is a prospective, longitudinal cohort study of children aged 8.00-16.99 years with either mTBI or OI, recruited during acute emergency department (ED) visits at five sites from the Pediatric Emergency Research Canada network. Injury information is collected in the ED; follow-up assessments at 10 days and 3 and 6 months postinjury measure a variety of neurobiological and psychosocial markers, covariates/confounders and outcomes. Weekly postconcussive symptom ratings are obtained electronically. Recruitment began in September 2016 and will occur for approximately 24 months. Analyses will test the major hypotheses that neurobiological and psychosocial markers can: (1) differentiate mTBI from OI and (2) predict outcomes of mTBI. Models initially will focus within domains (eg, genes, imaging biomarkers, psychosocial markers), followed by multivariable modelling across domains. The planned sample size (700 mTBI, 300 OI) provides adequate statistical power and allows for internal cross-validation of some analyses. Ethics and dissemination The ethics boards at all participating institutions have approved the study and all participants and their parents will provide informed consent or assent. Dissemination will follow an integrated knowledge translation plan, with study findings presented at scientific conferences and in multiple manuscripts in peer-reviewed journals.	[Yeates, Keith Owen; Kowalski, Kristina; Tomfohr-Madsen, Lianne] Univ Calgary, Dept Psychol, Calgary, AB, Canada; [Yeates, Keith Owen; Goodyear, Bradley; Harris, Ashley; Emery, Carolyn; Schneider, Kathryn J.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Yeates, Keith Owen; Mikrogianakis, Angelo; Harris, Ashley; Lebel, Catherine; Lamont, Ryan; Barlow, Karen Maria; Bernier, Francois; Brooks, Brian L.; Emery, Carolyn; Freedman, Stephen B.; Kowalski, Kristina; Tomfohr-Madsen, Lianne; Schneider, Kathryn J.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada; [Beauchamp, Miriam] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Beauchamp, Miriam; Gravel, Jocelyn; Dehaes, Mathieu; Deschenes, Sylvain] Ste Justine Hosp, Montreal, PQ, Canada; [Craig, William] Univ Alberta, Dept Pediat, Edmonton, AB, Canada; [Craig, William] Stollery Childrens Hosp, Edmonton, AB, Canada; [Doan, Quynh; Bjornson, Bruce H.] Univ British Columbia, Dept Pediat, Vancouver, BC, Canada; [Doan, Quynh; Bjornson, Bruce H.] BC Childrens Hosp, Vancouver, BC, Canada; [Zemek, Roger] Univ Ottawa, Childrens Hosp Eastern Ontario, Dept Pediat & Emergency Med, Ottawa, ON, Canada; [Gravel, Jocelyn] Univ Montreal, Dept Pediat, Montreal, PQ, Canada; [Goodyear, Bradley; Harris, Ashley; Lebel, Catherine] Univ Calgary, Dept Radiol, Calgary, AB, Canada; [Abdeen, Nishard] Univ Ottawa, Dept Radiol, Ottawa, ON, Canada; [Abdeen, Nishard] Childrens Hosp Eastern Ontario, Ottawa, ON, Canada; [Beaulieu, Christian] Univ Alberta, Dept Biomed Engn, Edmonton, AB, Canada; [Dehaes, Mathieu; Deschenes, Sylvain] Univ Montreal, Dept Radiol Radiooncol & Nucl Med, Montreal, PQ, Canada; [Lamont, Ryan] Univ Calgary, Dept Med Genet, Calgary, AB, Canada; [Lamont, Ryan; Barlow, Karen Maria; Bernier, Francois; Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada; [Williamson, Tyler] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Barlow, Karen Maria; Brooks, Brian L.; Freedman, Stephen B.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Barlow, Karen Maria; Brooks, Brian L.] Univ Calgary, Dept Pediat, Calgary, AB, Canada; [Bernier, Francois] Univ Calgary, Dept Med Genet, Calgary, AB, Canada; [Emery, Carolyn; Schneider, Kathryn J.] Univ Calgary, Fac Kinesiol, Calgary, AB, Canada; [Mrklas, Kelly] Alberta Hlth Serv, Res Innovat & Analyt, Calgary, AB, Canada	Yeates, KO (corresponding author), Univ Calgary, Dept Psychol, Calgary, AB, Canada.; Yeates, KO (corresponding author), Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada.; Yeates, KO (corresponding author), Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada.	kyeates@ucalgary.ca	Bjornson, Bruce Hal/A-8616-2010; Bernier, Francois/V-7150-2018; Barlow, Karen/I-6492-2019; Zemek, Roger/H-1039-2018; Bernier, Francois/AAP-2174-2020; Yeates, Keith/AAJ-4223-2020; Beaulieu, Christian/E-9796-2011; Doan, Quynh/AAJ-6023-2021; Emery, Carolyn/AAI-2761-2020; Barlow, Karen/C-1323-2014; Freedman, Stephen/H-9102-2012; Lebel, Catherine/B-4298-2015	Bjornson, Bruce Hal/0000-0002-1465-6196; Beaulieu, Christian/0000-0002-2342-3298; Doan, Quynh/0000-0002-8435-7837; Schneider, Kathryn/0000-0002-5951-5899; Barlow, Karen/0000-0003-2612-8507; Tomfohr-Madsen, Lianne/0000-0002-0860-5392; Freedman, Stephen/0000-0003-2319-6192; Lebel, Catherine/0000-0002-0344-4032; Craig, William/0000-0002-4804-194X; Yeates, Keith/0000-0001-7680-2892	Canadian Institute of Health Research (CIHR) Foundation Grant [FDN143304]; Alberta Children's Hospital Foundation; Alberta Children's Hospital Research Institute	This work is supported by a Canadian Institute of Health Research (CIHR) Foundation Grant (FDN143304) to KY, as well as by funds from the Alberta Children's Hospital Foundation and Alberta Children's Hospital Research Institute.	Allen JL, 2012, J PSYCHOPATHOL BEHAV, V34, P204, DOI 10.1007/s10862-011-9270-5; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; ANDERSEN MB, 1988, J SPORT EXERCISE PSY, V10, P294, DOI 10.1123/jsep.10.3.294; ASHER SR, 1984, CHILD DEV, V55, P1456, DOI 10.2307/1130015; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2016, J CHILD NEUROL, V31, P57, DOI 10.1177/0883073814543305; Becker SP, 2015, SLEEP MED, V16, P79, DOI 10.1016/j.sleep.2014.09.008; Beers SR, 2012, J NEUROTRAUM, V29, P1126, DOI 10.1089/neu.2011.2272; Bonanno GA, 2004, AM PSYCHOL, V59, P20, DOI 10.1037/0003-066X.59.1.20; Bornbaum CC, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0351-9; Brooks BL, 2016, J NEUROTRAUM, V33, P2091, DOI 10.1089/neu.2015.4301; Brooks BL, 2016, J INT NEUROPSYCH SOC, V22, P379, DOI 10.1017/S1355617715001368; Brooks BL, 2014, J NEUROTRAUM, V31, P1744, DOI 10.1089/neu.2014.3356; BURCHINAL MR, 1994, J EARLY INTERVENTION, V18, P403, DOI 10.1177/105381519401800409; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; *CAN HLTH SERV RES, 2003, THEOR PRACT KNOWL BR; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; CARSKADON MA, 1993, J ADOLESCENT HEALTH, V14, P190, DOI 10.1016/1054-139X(93)90004-9; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chevignard M, 2015, ANN PHYS REHABIL MED, V58, pe138; Claar RL, 2006, PAIN, V121, P77, DOI 10.1016/j.pain.2005.12.002; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Dunning J, 2004, ARCH DIS CHILD, V89, P653, DOI 10.1136/adc.2003.027722; Ebesutani C, 2012, J PERS ASSESS, V94, P427, DOI 10.1080/00223891.2012.662188; Ewing-Cobbs L, 2014, J PEDIATR PSYCHOL, V39, P653, DOI 10.1093/jpepsy/jsu018; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Goodman R, 1999, J CHILD PSYCHOL PSYC, V40, P791, DOI 10.1111/1469-7610.00494; Gorelick MH, 2008, ACAD EMERG MED, V15, P812, DOI 10.1111/j.1553-2712.2008.00206.x; Green P., 2004, MANUAL GREENS MED SY; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Haug E, 2009, INT J PUBLIC HEALTH, V54, P167, DOI 10.1007/s00038-009-5408-6; Hewitt PL, 2002, PERS INDIV DIFFER, V32, P1049, DOI 10.1016/S0191-8869(01)00109-X; Hu FB, 1998, AM J EPIDEMIOL, V147, P694; Kessler RC, 2003, ARCH GEN PSYCHIAT, V60, P184, DOI 10.1001/archpsyc.60.2.184; Kessler RC, 2010, INT J METH PSYCH RES, V19, P4, DOI 10.1002/mpr.310; Khetani AM, PED EMERG C IN PRESS; Kirkwood MW, 2012, PSYCHOL ASSESSMENT, V24, P36, DOI 10.1037/a0024628; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; LeBourgeois MK, 2005, PEDIATRICS, V115, P257, DOI 10.1542/peds.2004-0815H; Lukow HR, 2015, J HEAD TRAUMA REHAB, V30, P241, DOI 10.1097/HTR.0000000000000137; Malecki CK, 2002, PSYCHOL SCHOOLS, V39, P1; McAllister TW, 2010, PM&R, V2, pS241, DOI 10.1016/j.pmrj.2010.10.005; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McCrea M, 2015, BRAIN INJURY, V29, P276, DOI 10.3109/02699052.2014.965216; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Moran LM, 2011, J HEAD TRAUMA REHAB, V26, P348, DOI 10.1097/HTR.0b013e3181f8d32e; Moran LM, 2009, J NEUROTRAUM, V26, P1489, DOI 10.1089/neu.2008.0767; Moriarty David G, 2003, Health Qual Life Outcomes, V1, P37, DOI 10.1186/1477-7525-1-37; Noel M, 2015, J PAIN, V16, P31, DOI 10.1016/j.jpain.2014.10.005; Novak Z, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.2900; Psychological Corporation, 1999, WECHSLER ABBREVIATED; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Reynolds C.R., 2004, BEHAV ASSESSMENT SYS; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Sinharay S, 2001, PSYCHOL METHODS, V6, P317, DOI 10.1037//1082-989X.6.4.317; Speranza M, 2012, CAN J PSYCHIAT, V57, P570, DOI 10.1177/070674371205700908; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-1; Varni JW, 2009, PEDIATR CLIN N AM, V56, P843, DOI 10.1016/j.pcl.2009.05.016; von Baeyer CL, 2009, PAIN, V143, P223, DOI 10.1016/j.pain.2009.03.002; WALKER LS, 1991, J PEDIATR PSYCHOL, V16, P39, DOI 10.1093/jpepsy/16.1.39; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 2012, ARCH PEDIAT ADOLESC, V166, P585; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zemek R, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003550	76	14	14	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open	JUL	2017	7	7							e017012	10.1136/bmjopen-2017-017012			14	Medicine, General & Internal	General & Internal Medicine	FG4HQ	WOS:000410203700218	28710227	DOAJ Gold, Green Published			2021-06-18	
J	Yeh, CY; Bulas, AM; Moutal, A; Saloman, JL; Hartnett, KA; Anderson, CT; Tzounopoulos, T; Sun, DD; Khanna, R; Aizenman, E				Yeh, Chung-Yang; Bulas, Ashlyn M.; Moutal, Aubin; Saloman, Jami L.; Hartnett, Karen A.; Anderson, Charles T.; Tzounopoulos, Thanos; Sun, Dandan; Khanna, Rajesh; Aizenman, Elias			Targeting a Potassium Channel/Syntaxin Interaction Ameliorates Cell Death in Ischemic Stroke	JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; ischemia; neuroprotection; potassium channel; syntaxin; zinc	RAT CORTICAL-NEURONS; RECEPTOR-MEDIATED NEUROTOXICITY; TRAUMATIC BRAIN-INJURY; IN-VITRO; NMDA RECEPTOR; HIPPOCAMPAL-NEURONS; K+ CURRENTS; INTRACELLULAR ZINC; APOPTOTIC SURGE; KV2.1 CHANNEL	The voltage-gated K+ channel Kv2.1 has been intimately linked with neuronal apoptosis. After ischemic, oxidative, or inflammatory insults, Kv2.1 mediates a pronounced, delayed enhancement of K+ efflux, generating an optimal intracellular environment for caspase and nuclease activity, key components of programmed cell death. This apoptosis-enabling mechanism is initiated via Zn2+-dependent dual phosphorylation of Kv2.1, increasing the interaction between the channel's intracellular C-terminus domain and the SNARE(soluble N-ethylmaleimide-sensitive factor activating protein receptor) protein syntaxin 1A. Subsequently, an upregulation of de novo channel insertion into the plasma membrane leads to the critical enhancement of K+ efflux in damaged neurons. Here, we investigated whether a strategy designed to interfere with the cell death-facilitating properties of Kv2.1, specifically its interaction with syntaxin 1A, could lead to neuroprotection following ischemic injury in vivo. The minimal syntaxin 1A-binding sequence of Kv2.1 C terminus (C1aB) was first identified via a far-Western peptide screen and used to create a protherapeutic product by conjugating C1aB to a cell-penetrating domain. The resulting peptide (TAT-C1aB) suppressed enhanced whole-cell K+ currents produced by a mutated form of Kv2.1 mimicking apoptosis in a mammalian expression system, and protected cortical neurons from slow excitotoxic injury in vitro, without influencing NMDA-induced intracellular calcium responses. Importantly, intraperitoneal administration of TAT-C1aB in mice following transient middle cerebral artery occlusion significantly reduced ischemic stroke damage and improved neurological outcome. These results provide strong evidence that targeting the proapoptotic function of Kv2.1 is an effective and highly promising neuroprotective strategy.	[Yeh, Chung-Yang; Bulas, Ashlyn M.; Saloman, Jami L.; Hartnett, Karen A.; Tzounopoulos, Thanos; Aizenman, Elias] Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15261 USA; [Yeh, Chung-Yang; Bulas, Ashlyn M.; Hartnett, Karen A.; Sun, Dandan; Aizenman, Elias] Univ Pittsburgh, Sch Med, Pittsburgh Inst Neurodegenerat Dis, Pittsburgh, PA 15261 USA; [Anderson, Charles T.; Tzounopoulos, Thanos] Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15261 USA; [Sun, Dandan] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; [Moutal, Aubin; Khanna, Rajesh] Univ Arizona, Coll Med, Dept Pharmacol, Dept Anesthesiol, Tucson, AZ 85724 USA; [Moutal, Aubin; Khanna, Rajesh] Univ Arizona, Coll Med, Dept Grad Interdisciplinary Program Neuro, Tucson, AZ 85724 USA	Aizenman, E (corresponding author), Dept Neurobiol, 3501 Fifth Ave,BST3-7020, Pittsburgh, PA 15261 USA.; Aizenman, E (corresponding author), Pittsburgh Inst Neurodegenerat Dis, 3501 Fifth Ave,BST3-7020, Pittsburgh, PA 15261 USA.	redox@pitt.edu		Saloman, Jami/0000-0001-6093-6511; Aizenman, Elias/0000-0001-9610-4194; Anderson, Charles/0000-0003-3353-0182; Tzounopoulos, Thanos/0000-0003-4583-145X; Yeh, Chung-Yang/0000-0002-0970-1300; Khanna, Rajesh/0000-0002-9066-2969; Moutal, Aubin/0000-0003-4268-1206	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS043277, DC007905, 5T32NS007433-18]; American Heart AssociationAmerican Heart Association [16PRE29170009]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS043277, R01NS043277, T32NS007433] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC007905] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grants NS043277 (E.A.) and DC007905 (T.T.). C-Y.Y. was supported by the National Institutes of Health Training Grant 5T32NS007433-18 and the American Heart Association individual predoctoral Fellowship 16PRE29170009. We thank J. Trimmer (University of California Davis) for providing the WT Kv2.1 plasmid and R. Di Maio (University of Pittsburgh) and J. Justice (University of Pittsburgh) for expert advice. We also thank E. Levitan (University of Pittsburgh) and I. Lotan (Tel Aviv University, Israel) for encouragement and advice throughout this project, as well as B. Davis (University of Pittsburgh) for allowing us access to his equipment to complete this work.	Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Aizenman E, 2000, J NEUROCHEM, V75, P1878, DOI 10.1046/j.1471-4159.2000.0751878.x; AIZENMAN E, 1990, NEURON, V5, P841, DOI 10.1016/0896-6273(90)90343-E; Aras M. A., 2008, CURR PROTOC NEUROSCI; Aras MA, 2005, NEUROSCI LETT, V387, P136, DOI 10.1016/j.neulet.2005.06.024; Aras MA, 2009, J NEUROCHEM, V110, P106, DOI 10.1111/j.1471-4159.2009.06106.x; Bach A, 2012, P NATL ACAD SCI USA, V109, P3317, DOI 10.1073/pnas.1113761109; Batey AJ, 2002, BRIT J PHARMACOL, V135, P1003, DOI 10.1038/sj.bjp.0704550; Bierbower SM, 2015, J NEUROSCI, V35, P2101, DOI 10.1523/JNEUROSCI.3805-14.2015; Blitzblau R, 1996, EUR J NEUROSCI, V8, P1840, DOI 10.1111/j.1460-9568.1996.tb01328.x; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Breton RR, 2012, ACUTE ISCHEMIC STROK, P29; Brittain JM, 2011, J BIOL CHEM, V286, P37778, DOI 10.1074/jbc.M111.255455; Brittain JM, 2011, NAT MED, V17, P822, DOI 10.1038/nm.2345; Brittain MK, 2012, NEUROBIOL DIS, V46, P109, DOI 10.1016/j.nbd.2011.12.051; Cook DJ, 2012, NATURE, V483, P213, DOI 10.1038/nature10841; FUETA Y, 1993, DEV BRAIN RES, V72, P51, DOI 10.1016/0165-3806(93)90158-7; GRAHAM AJP, 1950, BMJ-BRIT MED J, V2, P321, DOI 10.1136/bmj.2.4674.321; Granzotto A, 2015, NEUROBIOL DIS, V81, P25, DOI 10.1016/j.nbd.2015.04.010; Hartnett KA, 1997, J NEUROCHEM, V68, P1836; He K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129498; Hill MD, 2012, LANCET NEUROL, V11, P942, DOI 10.1016/S1474-4422(12)70225-9; Hughes FM, 1999, ADV ENZYME REGUL, V39, P157, DOI 10.1016/S0065-2571(98)00010-7; IWAKI M, 1987, CARDIOVASC RES, V21, P130, DOI 10.1093/cvr/21.2.130; Joshi CN, 2004, BRAIN RES PROTOC, V13, P11, DOI 10.1016/j.brainresprot.2003.12.001; Kikuchi K, 2014, CNS DRUGS, V28, P929, DOI 10.1007/s40263-014-0199-6; Kilic E, 2006, FRONT BIOSCI-LANDMRK, V11, P1716, DOI 10.2741/1917; Knoch ME, 2008, GLIA, V56, P89, DOI 10.1002/glia.20592; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Krosl J, 2003, NAT MED, V9, P1428, DOI 10.1038/nm951; Leary S, 2013, AVMA GUIDELINES EUTH; Leist M, 1998, EXP CELL RES, V239, P183, DOI 10.1006/excr.1997.4026; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; McCord MC, 2014, J PHYSIOL-LONDON, V592, P3511, DOI 10.1113/jphysiol.2014.276964; McCord MC, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00077; McCord MC, 2013, P NATL ACAD SCI USA, V110, P13988, DOI 10.1073/pnas.1306238110; McLaughlin B, 2001, J NEUROSCI, V21, P3303, DOI 10.1523/JNEUROSCI.21-10-03303.2001; Medvedeva YV, 2017, J NEUROSCI, V37, P726, DOI [10.1523/JNEUROSCI.3270-16.2016, 10.1523/JNEUROSCI.3270-16.2017]; MELDRUM BS, 1987, MED BIOL, V65, P153; Michaelevski I, 2003, J BIOL CHEM, V278, P34320, DOI 10.1074/jbc.M304943200; Murakoshi H, 1999, J NEUROSCI, V19, P1728; Nattel S, 2008, J PHYSIOL-LONDON, V586, P5849, DOI 10.1113/jphysiol.2008.163089; Pal S, 2003, J NEUROSCI, V23, P4798; Pal SK, 2006, CELL DEATH DIFFER, V13, P661, DOI 10.1038/sj.cdd.4401792; Pologruto TA, 2003, BIOMED ENG ONLINE, V2, DOI 10.1186/1475-925X-2-13; Quillinan Nidia, 2016, Anesthesiol Clin, V34, P453, DOI 10.1016/j.anclin.2016.04.011; Redman PT, 2006, NEUROSCIENCE, V143, P1, DOI 10.1016/j.neuroscience.2006.08.039; Redman PT, 2007, P NATL ACAD SCI USA, V104, P3568, DOI 10.1073/pnas.0610159104; Redman PT, 2009, J PHYSIOL-LONDON, V587, P4393, DOI 10.1113/jphysiol.2009.176321; REYNOLDS IJ, 1990, BRIT J PHARMACOL, V101, P178, DOI 10.1111/j.1476-5381.1990.tb12109.x; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Sesti F, 2016, AGING DIS, V7, P130, DOI 10.14336/AD.2015.0901; Shah NH, 2014, TRANSL STROKE RES, V5, P38, DOI 10.1007/s12975-013-0297-7; Shen QJ, 2009, J NEUROSCI RES, V87, P3153, DOI 10.1002/jnr.22136; Shepherd AJ, 2012, J NEUROSCI, V32, P17725, DOI 10.1523/JNEUROSCI.3029-12.2012; Singer-Lahat D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001381; Singer-Lahat D, 2007, J NEUROSCI, V27, P1651, DOI 10.1523/JNEUROSCI.4006-06.2007; Sinor JD, 2000, J NEUROSCI, V20, P8831; Speca DJ, 2014, GENES BRAIN BEHAV, V13, P394, DOI 10.1111/gbb.12120; Stalmans S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139652; Stas JI, 2016, SCI REP-UK, V6, DOI 10.1038/srep35080; Thrift AG, 2017, INT J STROKE, V12, P13, DOI 10.1177/1747493016676285; Tymianski M, 2014, NAT REV NEUROL, V10, P66, DOI 10.1038/nrneurol.2013.271; Tymianski M, 2013, STROKE, V44, P2942, DOI 10.1161/STROKEAHA.113.000731; Wang GJ, 1998, EUR J NEUROSCI, V10, P2523, DOI 10.1046/j.1460-9568.1998.t01-1-00256.x; Wang MZ, 2016, APPL MICROBIOL BIOT, V100, P5353, DOI 10.1007/s00253-015-7251-4; Wei L, 2003, STROKE, V34, P1281, DOI 10.1161/01.STR.0000065828.18661.FE; Wolf-Goldberg T, 2006, MOL PHARMACOL, V70, P818, DOI 10.1124/mol.105.021717; Wu KW, 2015, NEUROSCIENCE, V298, P94, DOI 10.1016/j.neuroscience.2015.04.015; Xia CF, 2006, HYPERTENSION, V47, P752, DOI 10.1161/01.HYP.0000214867.35632.0e; Yao HL, 2009, J NEUROCHEM, V108, P909, DOI 10.1111/j.1471-4159.2008.05834.x; Yu SP, 2003, PROG NEUROBIOL, V70, P363, DOI 10.1016/S0301-0082(03)00090-X; Yu SP, 1998, J NEUROSCI RES, V52, P612, DOI 10.1002/(SICI)1097-4547(19980601)52:5<612::AID-JNR13>3.0.CO;2-3; Yu W, 2016, J NEUROSCI, V36, P11084, DOI 10.1523/JNEUROSCI.2273-16.2016; Yuan H, 2011, EUR J PHARMACOL, V657, P76, DOI 10.1016/j.ejphar.2011.01.054; Zou LL, 2013, CURR NEUROPHARMACOL, V11, P197, DOI 10.2174/1570159X11311020006	77	14	14	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 7	2017	37	23					5648	5658		10.1523/JNEUROSCI.3811-16.2017			11	Neurosciences	Neurosciences & Neurology	EX0JS	WOS:000402907200008	28483976	Bronze, Green Published			2021-06-18	
J	Osier, ND; Pham, L; Pugh, BJ; Puccio, A; Ren, DX; Conley, YP; Alexander, S; Dixon, CE				Osier, Nicole D.; Pham, Lan; Pugh, Bunny J.; Puccio, Ava; Ren, Dianxu; Conley, Yvette P.; Alexander, Sheila; Dixon, C. Edward			Brain injury results in lower levels of melatonin receptors subtypes MT1 and MT2	NEUROSCIENCE LETTERS			English	Article						Traumatic brain injury (TBI); Brain trauma; Controlled cortical impact (CCI); Rat; Melatonin; Receptors	INDUCED OXIDATIVE STRESS; FREE-RADICAL SCAVENGER; CIRCADIAN-RHYTHM; SLEEP DISORDERS; DEPENDENT RESPONSE; AGONIST; RATS; ACTIVATION; EXPRESSION; APOPTOSIS	Background: Traumatic brain injury (TBI) is a devastating and costly acquired condition that affects individuals of all ages, races, and geographies via a number of mechanisms. The effects of TBI on melatonin receptors remain unknown. Purpose: The purpose of this study is to explore whether endogenous changes in two melatonin receptor subtypes (MT1 and MT2) occur after experimental TBI. Sample: A total of 25 adult male Sprague Dawley rats were used with 6 or 7 rats per group. Methods: Rats were randomly assigned to receive either TBI modeled using controlled cortical impact or sham surgery and to be sacrificed at either 6- or 24-h post-operatively. Brains were harvested, dissected, and flash frozen until whole cell lysates were prepared, and the supernatant fluid aliquoted and used for western blotting. Primary antibodies were used to probe for melatonin receptors (MT1 and MT2), and beta actin, used for a loading control. Image) and Image Lab software were used to quantify the data which was analyzed using t-tests to compare means. Results: Melatonin receptor levels were reduced in a brain region- and time point- dependent manner. Both MT1 and MT2 were reduced in the frontal cortex at 24 h and in the hippocampus at both 6 h and 24 h. Discussion: MT1 and MT2 are less abundant after injury, which may alter response to MEL therapy. Studies characterizing MT1 and MT2 after TBI are needed, including exploration of the time course and regional patterns, replication in diverse samples, and use of additional variables, especially sleep-related outcomes. Conclusion: TBI in rats resulted in lower levels of MT1 and MT2; replication of these findings is necessary as is evaluation of the consequences of lower receptor levels. (C) 2017 Elsevier B.V. All rights reserved.	[Osier, Nicole D.; Pham, Lan; Puccio, Ava; Ren, Dianxu; Conley, Yvette P.; Alexander, Sheila] Univ Pittsburgh, Sch Nursing, Victoria Bldg,3500 Victoria St, Pittsburgh, PA 15213 USA; [Osier, Nicole D.; Pugh, Bunny J.; Dixon, C. Edward] Childrens Hosp Pittsburgh UPMC, Safar Ctr Resuscitat Res, John G Rangos Res, Ctr 6th Floor,4401 Penn Ave, Pittsburgh, PA 15224 USA; [Puccio, Ava; Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Brain Trauma Res Ctr, UPMC Presbyterian, Suite B-400,200 Lothrop St, Pittsburgh, PA 15213 USA; [Conley, Yvette P.] Univ Pittsburgh, Dept Human Genet, Crabtree Hall,130 De Soto St, Pittsburgh, PA 15261 USA; [Alexander, Sheila] Univ Pittsburgh, Sch Med, M240 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA; [Dixon, C. Edward] VA Pittsburgh Healthcare Syst, 4100 Allequippa St, Pittsburgh, PA 15261 USA	Dixon, CE (corresponding author), Childrens Hosp Pittsburgh UPMC, Safar Ctr Resuscitat Res, John G Rangos Res, Ctr 6th Floor,4401 Penn Ave, Pittsburgh, PA 15224 USA.	ndo8@pitt.edu; lhp4@pitt.edu; bjp80@pitt.edu; puccam@upmc.edu; dir8@pitt.edu; yconley@pitt.edu; salexand@pitt.edu; dixoec@upmc.edu	Osier, Nicole/Q-7913-2017	Osier, Nicole/0000-0002-2903-6774; Conley, Yvette/0000-0002-1784-6067	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32NR009759, F31NR014957]; Copeland Award of The Pittsburgh Foundation; International Society of Nurses in Genetics; Neurotrauma Nursing Foundation/American Association of Neuroscience Nursing; Sigma Theta Tau International Eta Chapter; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32NR009759, F31NR014957] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health [T32NR009759, F31NR014957]; The Copeland Award of The Pittsburgh Foundation; the International Society of Nurses in Genetics; The Neurotrauma Nursing Foundation/American Association of Neuroscience Nursing; and Sigma Theta Tau International Eta Chapter. In addition, we would like to thank Michael Farmer for his assistance with the figures, and Marilyn Farmer for her continued editorial support.	Ates O, 2006, INT J DEV NEUROSCI, V24, P357, DOI 10.1016/j.ijdevneu.2006.08.003; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Babaee A, 2015, IRAN J BASIC MED SCI, V18, P867; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Boran MS, 2007, J NEUROCHEM, V102, P216, DOI 10.1111/j.1471-4159.2007.04464.x; Budinich CS, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/378307; Campolo M, 2013, J ENDOCRINOL, V217, P291, DOI 10.1530/JOE-13-0022; Carrillo-Vico A, 2003, CELL MOL LIFE SCI, V60, P2272, DOI 10.1007/s00018-003-3207-4; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chambers JC, 2009, DIABETES, V58, P2703, DOI 10.2337/db08-1805; Cirak B, 1999, PEDIATR NEUROSURG, V31, P298, DOI 10.1159/000028879; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Coronado V., 2012, EPIDEMIOLOGY PREVENT; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dehghan F, 2013, ARCH MED RES, V44, P251, DOI 10.1016/j.arcmed.2013.04.002; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Dubocovich ML, 2003, FRONT BIOSCI-LANDMRK, V8, pD1093, DOI 10.2741/1089; Duclos C, 2014, PATHOL BIOL, V62, P252, DOI 10.1016/j.patbio.2014.05.014; Farrell-Carnahan L, 2015, BRAIN INJURY, V29, P1400, DOI 10.3109/02699052.2015.1063161; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fisher SP, 2009, NEUROSCI LETT, V457, P93, DOI 10.1016/j.neulet.2009.04.005; Gold EM, 2013, REGEN MED, V8, P483, DOI 10.2217/rme.13.41; Grima NA, 2016, NEUROREHAB NEURAL RE, V30, P972, DOI 10.1177/1545968316650279; HARRINGTON M, 2012, LAB ANIMAL, V41, P31; Hou LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076087; Kelestemur T, 2016, NEUROSCI LETT, V612, P92, DOI 10.1016/j.neulet.2015.11.043; Kelso ML, 2011, NEUROSCI LETT, V488, P60, DOI 10.1016/j.neulet.2010.11.003; Kennaway DJ, 1998, J CLIN ENDOCR METAB, V83, P1013, DOI 10.1210/jc.83.3.1013; Kline AE, 2016, PROG NEUROBIOL, V142, P45, DOI 10.1016/j.pneurobio.2016.05.002; Kokkola T, 2007, J PINEAL RES, V43, P255, DOI 10.1111/j.1600-079X.2007.00470.x; LEBARS D, 1991, NUCL MED BIOL, V18, P357; Lee S, 2009, J PINEAL RES, V46, P43, DOI 10.1111/j.1600-079X.2008.00607.x; Lin C, 2016, J PINEAL RES, V61, P177, DOI 10.1111/jpi.12337; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; Masana MI, 2000, J PINEAL RES, V28, P185, DOI 10.1034/j.1600-079X.2001.280309.x; Miranda-Anaya M, 2002, J BIOL RHYTHM, V17, P526, DOI 10.1177/0748730402238235; Miyamoto M, 2009, CNS NEUROSCI THER, V15, P32, DOI 10.1111/j.1755-5949.2008.00066.x; Moeller Donald R, 2014, J Spec Oper Med, V14, P64; Murakami N, 2001, BRAIN RES, V889, P220, DOI 10.1016/S0006-8993(00)03205-4; Natarajan R, 2012, J NEUROIMMUNOL, V250, P106, DOI 10.1016/j.jneuroim.2012.05.014; Nau R, 2010, CLIN MICROBIOL REV, V23, P858, DOI 10.1128/CMR.00007-10; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; Ochoa-Sanchez R, 2011, J NEUROSCI, V31, P18439, DOI 10.1523/JNEUROSCI.2676-11.2011; Osier N., 2014, J NEUROTRAUM, V1882, P1; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Pandi-Perumal SR, 2006, FEBS J, V273, P2813, DOI 10.1111/j.1742-4658.2006.05322.x; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; REITER RJ, 1993, EXPERIENTIA, V49, P654, DOI 10.1007/BF01923947; Roth T, 2005, SLEEP, V28, P303; Sandhir R, 2010, NEUROCHEM INT, V56, P188, DOI 10.1016/j.neuint.2009.10.002; Seifman MA, 2008, J CEREBR BLOOD F MET, V28, P684, DOI 10.1038/sj.jcbfm.9600603; Senol N, 2014, NEURAL REGEN RES, V9, P1112, DOI 10.4103/1673-5374.135312; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Solis-Chagoyan H, 2008, COMP BIOCHEM PHYS A, V149, P373, DOI 10.1016/j.cbpa.2008.01.040; Steele DL, 2005, CHRONOBIOL INT, V22, P89, DOI 10.1081/CBI-200042428; Tamura H, 2013, ENDOCR J, V60, P1; Taylor SR, 2013, J NEUROSURG-PEDIATR, V12, P545, DOI 10.3171/2013.8.PEDS13154; Theadom A, 2015, SLEEP MED, V16, P926, DOI 10.1016/j.sleep.2015.04.013; Wang GS, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-170; Wang SX, 2012, PAIN, V153, P2448, DOI 10.1016/j.pain.2012.08.016; WETTERBERG L, 1987, CHRONOBIOLOGIA, V14, P377; Wiechmann AF, 2008, EXP EYE RES, V86, P241, DOI 10.1016/j.exer.2007.10.015; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Yanagihara M, 2014, TOHOKU J EXP MED, V234, P123, DOI 10.1620/tjem.234.123; YELLON SM, 1982, ENDOCRINOLOGY, V111, P488, DOI 10.1210/endo-111-2-488; Yuruker V, 2015, METAB BRAIN DIS, V30, P223, DOI 10.1007/s11011-014-9623-3	67	14	14	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAY 22	2017	650						18	24		10.1016/j.neulet.2017.03.053			7	Neurosciences	Neurosciences & Neurology	EW2XK	WOS:000402359100004	28377323	Green Accepted			2021-06-18	
J	Badachhape, AA; Okamoto, RJ; Durham, RS; Efron, BD; Nadell, SJ; Johnson, CL; Bayly, PV				Badachhape, Andrew A.; Okamoto, Ruth J.; Durham, Ramona S.; Efron, Brent D.; Nadell, Sam J.; Johnson, Curtis L.; Bayly, Philip V.			The Relationship of Three-Dimensional Human Skull Motion to Brain Tissue Deformation in Magnetic Resonance Elastography Studies	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article						magnetic resonance elastography; mechanical characterization; brain deformation; tissue	MR ELASTOGRAPHY; INJURY; STIFFNESS; VISCOELASTICITY; ANISOTROPY; INVERSION; HEAD	In traumatic brain injury (TBI), membranes such as the dura mater, arachnoid mater, and pia mater play a vital role in transmitting motion from the skull to brain tissue. Magnetic resonance elastography (MRE) is an imaging technique developed for noninvasive estimation of soft tissue material parameters. In MRE, dynamic deformation of brain tissue is induced by skull vibrations during magnetic resonance imaging (MRI); however, skull motion and its mode of transmission to the brain remain largely uncharacterized. In this study, displacements of points in the skull, reconstructed using data from an array of MRI-safe accelerometers, were compared to displacements of neighboring material points in brain tissue, estimated from MRE measurements. Comparison of the relative amplitudes, directions, and temporal phases of harmonic motion in the skulls and brains of six human subjects shows that the skull-brain interface significantly attenuates and delays transmission of motion from skull to brain. In contrast, in a cylindrical gelatin "phantom," displacements of the rigid case (reconstructed from accelerometer data) were transmitted to the gelatin inside (estimated from MRE data) with little attenuation or phase lag. This quantitative characterization of the skull-brain interface will be valuable in the parameterization and validation of computer models of TBI.	[Badachhape, Andrew A.; Durham, Ramona S.; Bayly, Philip V.] Washington Univ, Biomed Engn, St Louis, MO 63105 USA; [Okamoto, Ruth J.; Efron, Brent D.; Nadell, Sam J.; Bayly, Philip V.] Washington Univ, Mech Engn & Mat Sci, St Louis, MO 63105 USA; [Johnson, Curtis L.] Univ Delaware, Biomed Engn, Newark, DE 19716 USA	Badachhape, AA (corresponding author), Washington Univ, Biomed Engn, St Louis, MO 63105 USA.	abadachhape@wustl.edu	Johnson, Curtis/U-8372-2019	Badachhape, Andrew/0000-0002-5857-9495; Okamoto, Ruth/0000-0002-3085-3878	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS055951]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055951] Funding Source: NIH RePORTER	Financial support for this study was provided by National Institutes of Health (NIH) Grant No. R01 NS055951.	Arani A, 2015, NEUROIMAGE, V111, P59, DOI 10.1016/j.neuroimage.2015.02.016; Atay SM, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2899575; Barnhill E, 2015, MAGN RESON MED, V73, P2321, DOI 10.1002/mrm.25332; Clayton EH, 2012, J R SOC INTERFACE, V9, P2899, DOI 10.1098/rsif.2012.0325; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; GINSBERG G, 1995, DYNAMICS; Giordano C, 2014, J BIOMECH, V47, P1052, DOI 10.1016/j.jbiomech.2013.12.036; Guo J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071807; GURDJIAN ES, 1970, J BIOMECH, V3, P239, DOI 10.1016/0021-9290(70)90025-4; Hutson M, 2011, SPORTS INJURIES; Johnson CL, 2016, HUM BRAIN MAPP, V37, P4221, DOI 10.1002/hbm.23314; Johnson CL, 2013, MAGN RESON MED, V70, P404, DOI 10.1002/mrm.24473; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kruse SA, 2000, PHYS MED BIOL, V45, P1579, DOI 10.1088/0031-9155/45/6/313; Kruse SA, 2008, NEUROIMAGE, V39, P231, DOI 10.1016/j.neuroimage.2007.08.030; Manduca A, 2001, MED IMAGE ANAL, V5, P237, DOI 10.1016/S1361-8415(00)00039-6; Mazumder MMG, 2013, ACTA BIOENG BIOMECH, V15, P3, DOI 10.5277/abb130201; McGarry MDJ, 2012, MED PHYS, V39, P6388, DOI 10.1118/1.4754649; McGarry MDJ, 2011, PHYS MED BIOL, V56, pN153, DOI 10.1088/0031-9155/56/13/N02; Murphy MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081668; Murphy MC, 2011, J MAGN RESON IMAGING, V34, P494, DOI 10.1002/jmri.22707; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Okamoto RJ, 2011, PHYS MED BIOL, V56, P6379, DOI 10.1088/0031-9155/56/19/014; Oliphant TE, 2001, MAGNET RESON MED, V45, P299, DOI 10.1002/1522-2594(200102)45:2<299::AID-MRM1039>3.0.CO;2-O; Romano A, 2014, MAGN RESON MED, V72, P1755, DOI 10.1002/mrm.25067; Sack I, 2008, NMR BIOMED, V21, P265, DOI 10.1002/nbm.1189; Scharnhorst K, 2001, ACTA APPL MATH, V69, P95, DOI 10.1023/A:1012692601098; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Steen RG, 2007, AM J NEURORADIOL, V28, P1119, DOI 10.3174/ajnr.A0537; Streitberger KJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029888; Streitberger KJ, 2011, NMR BIOMED, V24, P385, DOI 10.1002/nbm.1602; Wang HF, 2011, PHYS MED BIOL, V56, P3935, DOI 10.1088/0031-9155/56/13/012; Woolsey T. A., 2013, BRAIN ATLAS VISUAL G	36	14	14	0	11	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	MAY	2017	139	5							051002	10.1115/1.4036146			12	Biophysics; Engineering, Biomedical	Biophysics; Engineering	ES2XB	WOS:000399390100002	28267188	Green Published			2021-06-18	
J	Cnossen, MC; Lingsma, HF; Tenovuo, O; Maas, AIR; Menon, D; Steyerberg, EW; Ribbers, GM; Polinder, S				Cnossen, Maryse C.; Lingsma, Hester F.; Tenovuo, Olli; Maas, Andrew I. R.; Menon, David; Steyerberg, Ewout. W.; Ribbers, Gerard M.; Polinder, Suzanne		CENTER-TBI Investigators	REHABILITATION AFTER TRAUMATIC BRAIN INJURY: A SURVEY IN 70 EUROPEAN NEUROTRAUMA CENTRES PARTICIPATING IN THE CENTER-TBI STUDY	JOURNAL OF REHABILITATION MEDICINE			English	Article						brain injuries; rehabilitation; health services research; survey; Europe	INPATIENT REHABILITATION; OUTCOMES; DISPARITIES; CHALLENGES; GUIDELINES; DISCHARGE; CARE	Objective: To describe variation in structural and process characteristics of acute in-hospital rehabilitation and referral to post-acute care for patients with traumatic brain injury across Europe. Design: Survey study, of neurotrauma centres. Methods: A 14-item survey about in-hospital rehabilitation and referral to post-acute care was sent to 71 neurotrauma centres participating in a European multicentre study (CENTER-TBI). The questionnaire was developed based on literature and expert opinion and was pilot-tested before sending out to the centres. Results: Seventy (99%) centres in 20 countries completed the survey. The included centres were predominately academic level I trauma centres. Among the 70 centres, a multidisciplinary rehabilitation team can be consulted at 41% (n = 29) of the intensive care units and 49% (n = 34) of the wards. Only 13 (19%) centres used rehabilitation guidelines in patients with traumatic brain injury. Age was reported as a major determinant of referral decisions in 32 (46%) centres, with younger patients usually referred to specialized rehabilitation centres, and patients = 65 years also referred to nursing homes or local hospitals. Conclusion: Substantial variation exists in structural and process characteristics of in-hospital acute rehabilitation and referral to post-acute rehabilitation facilities among neurotrauma centres across Europe.	[Cnossen, Maryse C.; Lingsma, Hester F.; Steyerberg, Ewout. W.; Polinder, Suzanne] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Sci, NL-3015CN Rotterdam, Netherlands; [Tenovuo, Olli] Turku Univ Hosp, Div Clin Neurosci, Dept Rehabil & Brain Trauma, Turku, Finland; [Tenovuo, Olli] Univ Turku, Dept Neurol, Turku, Finland; [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium; [Menon, David] Univ Cambridge, Div Anaesthesia, Addenbrookes Hosp, Cambridge, England; [Ribbers, Gerard M.] Erasmus MC, Rijndam Rehabil Ctr, Rotterdam, Netherlands; [Ribbers, Gerard M.] Erasmus MC, Dept Rehabil Med, Rotterdam, Netherlands	Cnossen, MC (corresponding author), Erasmus MC, Dept Publ Hlth, Ctr Med Decis Sci, NL-3015CN Rotterdam, Netherlands.	m.c.cnossen@erasmusmc.nl	Ribbers, Gerard/N-3623-2019; Badenes, Rafael/K-6628-2019; Maas, Andrew IR/C-5584-2013; Ribbers, Gerard M/C-1454-2014	Badenes, Rafael/0000-0001-7017-0150; Maas, Andrew IR/0000-0003-1612-1264; Ribbers, Gerard M/0000-0002-6114-349X	European Commission 7th Framework program [602150]	Data used in preparation of this manuscript were obtained in the context of CENTER-TBI, a large collaborative project with the support of the European Commission 7th Framework program (602150).	Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; Asemota AO, 2013, J NEUROTRAUM, V30, P2057, DOI 10.1089/neu.2013.3091; Borg J, 2011, AM J PHYS MED REHAB, V90, P65, DOI 10.1097/PHM.0b013e3181fc80e7; Brown AW, 2015, PM&R, V7, P3, DOI 10.1016/j.pmrj.2014.06.016; Carney N, 2016, NEUROSURGERY; Chan V, 2013, CAN J AGING, V32, P278, DOI 10.1017/S0714980813000317; Checkley W, 2014, CRIT CARE MED, V42, P344, DOI 10.1097/CCM.0b013e3182a275d7; Choi JH, 2008, J TRAUMA, V65, P1028, DOI 10.1097/TA.0b013e31815eba9b; Cnossen MC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161367; Cnossen MC, 2015, J NEUROTRAUMA; Dijkers M, 2013, NEUROREHABILITATION, V32, P233, DOI 10.3233/NRE-130841; Englum BR, 2011, J AM COLL SURGEONS, V213, P699, DOI 10.1016/j.jamcollsurg.2011.08.017; European Comission, 2007, REM RES PUBL PRIV SE; Francisco GE, 2007, BRAIN INJURY, V21, P1007, DOI 10.1080/02699050701559558; Hart T, 2014, ARCH PHYS MED REHAB, V95, pS66, DOI 10.1016/j.apmr.2013.03.033; Hasenbein U, 2003, DISABIL REHABIL, V25, P136, DOI 10.1080/0963828021000024889; Heffernan DS, 2011, J TRAUMA, V70, P527, DOI 10.1097/TA.0b013e31820d0ed7; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Meagher AD, 2015, J NEUROSURG, V122, P595, DOI 10.3171/2014.10.JNS14187; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Pisa FE, 2015, BRAIN INJURY, V29, P508, DOI 10.3109/02699052.2014.992474; Ribbers GM, 2007, J HEAD TRAUMA REHAB, V22, P234, DOI 10.1097/01.HTR.0000281839.07968.32; Servadei F, 2016, WORLD NEUROSURG, V90, P657, DOI 10.1016/j.wneu.2016.02.013; Turner-Stokes L, 2008, J REHABIL MED, V40, P691, DOI 10.2340/16501977-0265	25	14	15	1	11	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	MAY	2017	49	5					395	401		10.2340/16501977-2216			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	EV7YI	WOS:000401997100004	28440841	DOAJ Gold, Green Published			2021-06-18	
J	Eckner, JT; Seifert, T; Pescovitz, A; Zeiger, M; Kutcher, JS				Eckner, James T.; Seifert, Tad; Pescovitz, Allison; Zeiger, Max; Kutcher, Jeffrey S.			Is Migraine Headache Associated With Concussion in Athletes? A Case-Control Study	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						athlete; concussion; headache; migraine	SPORTS-RELATED CONCUSSION; MILD TRAUMATIC BRAIN; CHRONIC POSTTRAUMATIC HEADACHE; WHITE-MATTER INTEGRITY; HIGH-SCHOOL FOOTBALL; RISK-FACTORS; INJURY; PAIN; COHORT; IMPAIRMENT	Objective: The purpose of this study was to investigate the association between migraine headache and concussion in athletes. Design: Case-control observational study. Setting: A university-associated combined sports neurology and orthopedic sports medicine clinic. Participants: A total of 221 male (n = 140) and female (n = 81) athletes aged 12 to 24 years, including 115 concussion cases (52%) and 106 orthopedic controls (48%), were included in this study. Interventions: Participants completed a one-page questionnaire that recorded their age, sex, reason for visit (concussion vs any other injury), concussion history, and self/immediate family member migraine headache history. Main Outcome Measures: The odds of having a previous history of migraine headache were compared in the concussion group versus orthopedic controls. Results: Controlling for between-group differences in age and sex, there was a significant positive association between concussion group status and history of migraine headache [adjusted odds ratio (OR), 1.90; 95% confidence interval (CI), 1.03-3.50. P = 0.039]. However, when including a previous concussion history in the statistical model, this relationship failed to reach significance [adjusted OR, 1.68; 95% CI, 0.89-3.16. P = 0.107]. Conclusions: These results suggest that there is an association between migraine headache and concussion in athletes, but the cause-effect nature of this relationship cannot be determined. Migraine headache should be considered a modifying factor when caring for concussed athletes.	[Eckner, James T.] Univ Michigan, Dept Phys Med & Rehabil, 325 E Eisenhower Pkwy, Ann Arbor, MI 48108 USA; [Eckner, James T.; Pescovitz, Allison; Zeiger, Max; Kutcher, Jeffrey S.] Univ Michigan, Michigan NeuroSport, Ann Arbor, MI 48109 USA; [Seifert, Tad] Norton Healthcare, Dept Neurol, Louisville, KY USA; [Seifert, Tad] Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA; [Kutcher, Jeffrey S.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA; [Pescovitz, Allison] Maimonides Hosp, Dept Gen Surg, Brooklyn, NY 11219 USA; [Zeiger, Max] Univ Calif Los Angeles, Div Pediat Neurol, Los Angeles, CA USA; [Kutcher, Jeffrey S.] Sports Neurol Clin, Ann Arbor, MI USA	Eckner, JT (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, 325 E Eisenhower Pkwy, Ann Arbor, MI 48108 USA.	jeckner@med.umich.edu			Rehabilitation Medicine Scientist Training Program; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1 K23 HD078502]; National Collegiate Athletics Association; United States Department of DefenseUnited States Department of Defense [14132004]; University of Michigan Injury Center; Foundation for Physical Medicine and Rehabilitation; National Headache Foundation; American Headache Society; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD078502] Funding Source: NIH RePORTER	Dr Eckner received partial effort support during this project from the Rehabilitation Medicine Scientist Training Program and the National Institutes of Health (1 K23 HD078502). His active research funding includes the National Institutes of Health (1 K23 HD078502), the National Collegiate Athletics Association, the United States Department of Defense (14132004), the University of Michigan Injury Center, and the Foundation for Physical Medicine and Rehabilitation. Dr Seifert is a member of the Kentucky State Boxing Commission and has served as a consultant for the United States Department of Defense. He has received personal compensation as a speaker for the National Headache Foundation and the American Headache Society. Dr Kutcher is a consultant for the National Basketball Association and ElmindA, Ltd. The other authors report no conflicts of interest.	Anselmi Bruno, 1997, Recenti Progressi in Medicina, V88, P321; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Conidi F., 2015, AM AC NEUR 2015 ANN; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; de Tommaso M, 2012, CNS NEUROL DISORD-DR, V11, P110, DOI 10.2174/187152712800269759; Defrin R, 2015, J NEUROTRAUM, V32, P28, DOI 10.1089/neu.2014.3359; Defrin R, 2014, J MAN MANIP THER, V22, P36, DOI 10.1179/2042618613Y.0000000053; Finnoff JT, 2011, PM&R, V3, pS452, DOI 10.1016/j.pmrj.2011.07.014; Gilkey SJ, 1997, HEADACHE, V37, P583, DOI 10.1046/j.1526-4610.1997.3709583.x; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gordon KE, 2006, BRIT J SPORT MED, V40, P184, DOI 10.1136/bjsm.2005.022251; Heyer GL, 2014, PEDIATR NEUROL, V50, P464, DOI 10.1016/j.pediatrneurol.2014.01.040; Hussain A, 2010, HEADACHE, V50, P669, DOI 10.1111/j.1526-4610.2009.01436.x; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; Lipton RB, 2003, NEUROLOGY, V61, P375, DOI 10.1212/01.WNL.0000078940.53438.83; Lucas S, 2011, PM&R, V3, pS406, DOI 10.1016/j.pmrj.2011.07.016; MATTHEWS WB, 1972, BRIT MED J, V2, P326, DOI 10.1136/bmj.2.5809.326; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Misra UK, 2013, CEPHALALGIA, V33, P316, DOI 10.1177/0333102412473372; Nahman-Averbuch H, 2013, HEADACHE, V53, P1104, DOI 10.1111/head.12117; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; Piovesan Elcio J, 2003, Curr Pain Headache Rep, V7, P377, DOI 10.1007/s11916-003-0037-x; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Sabin MJ, 2011, CLIN J SPORT MED, V21, P411, DOI 10.1097/JSM.0b013e318223f3a4; Schneider KJ, 2013, CLIN J SPORT MED, V23, P267, DOI 10.1097/JSM.0b013e318281f09f; Seifert T, 2015, AM HEAD SOC 57 ANN S; Seifert T, AM J SPORTS IN PRESS; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; TAYLOR AR, 1966, LANCET, V2, P178; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x	40	14	14	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2017	27	3					266	270		10.1097/JSM.0000000000000346			5	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	ET9NV	WOS:000400635100005	27428679	Green Accepted			2021-06-18	
J	Iacono, D; Shively, SB; Edlow, BL; Perl, DP				Iacono, Diego; Shively, Sharon B.; Edlow, Brian L.; Perl, Daniel P.			Chronic Traumatic Encephalopathy Known Causes, Unknown Effects	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; Chronic traumatic encephalopathy; Tau; beta-Amyloid; Diffuse axonal injury; Acute and long-term effects; Neurodegeneration; Neuropsychiatric disorders	POSTTRAUMATIC-STRESS-DISORDER; AMYLOID PRECURSOR PROTEIN; LONG-TERM CONSEQUENCES; BRAIN-INJURY; AXONAL INJURY; DEMENTIA-PUGILISTICA; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; MAGNETIC-RESONANCE; FOOTBALL PLAYERS	Chronic traumatic encephalopathy (CTE) is a neuropathologic diagnosis typically made in human brains with a history of repetitive traumatic brain injury (rTBI). It remains unknown whether CTE occurs exclusively after rTBI, or whether a single TBI (sTBI) can cause CTE. Similarly, it is unclear whether impact (eg, motor vehicle accidents) and non -impact (eg, blasts) types of energy transfer trigger divergent or common pathologies. While it is established that a history of rTBI increases the risk of multiple neurodegenerative diseases (eg, dementia, parkinsonism, and CTE), the possible pathophysiologic and molecular mechanisms underlying these risks have yet to be elucidated.	[Iacono, Diego; Shively, Sharon B.; Perl, Daniel P.] Uniformed Serv Univ Hlth Sci, CNRM, Brain Tissue Repository & Neuropathol Core, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Iacono, Diego; Shively, Sharon B.] Henry M Jackson Fdn Adv Mil Med HJF, 6720A Rockledge Dr 100, Bethesda, MD 20817 USA; [Shively, Sharon B.; Perl, Daniel P.] Uniformed Serv Univ Hlth Sci, Dept Pathol, F Edward Hebert Sch Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Edlow, Brian L.] Massachusetts Gen Hosp, Dept Neurol, 175 Cambridge St Suite 300, Boston, MA 02114 USA; [Edlow, Brian L.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, 149 13th St, Charlestown, MA 02129 USA	Perl, DP (corresponding author), Uniformed Serv Univ Hlth Sci, CNRM, Brain Tissue Repository & Neuropathol Core, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.; Perl, DP (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pathol, F Edward Hebert Sch Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	daniel.perl@usuhs.edu	Iacono, Diego/K-8203-2016	Iacono, Diego/0000-0001-5511-0950			Absinta M, 2014, J NEUROPATH EXP NEUR, V73, P780, DOI 10.1097/NEN.0000000000000096; Acosta SA, 2015, J CELL PHYSIOL, V230, P1024, DOI 10.1002/jcp.24830; Alexander E Jr, 1991, Br J Neurosurg, V5, P183, DOI 10.3109/02688699108998465; Altmeyer W, 2016, MAGN RESON IMAGING C, V24, P305, DOI 10.1016/j.mric.2015.11.011; American Psychiatric Association, 2015, DIAGN STAT MAN MENT, P271; Aotsuka A, 1990, Rinsho Shinkeigaku, V30, P1243; Bandak F A, 2015, Handb Clin Neurol, V127, P89, DOI 10.1016/B978-0-444-52892-6.00006-4; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bogoslovsky T, 2017, J NEUROTRAUM, V34, P66, DOI 10.1089/neu.2015.4333; Bouzier-Sore AK, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00179; BRANDENBURG W, 1954, Virchows Arch Pathol Anat Physiol Klin Med, V325, P680, DOI 10.1007/BF00955101; Byrnes Kimberly R, 2014, Front Neuroenergetics, V5, P13, DOI 10.3389/fnene.2013.00013; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carron SF, 2016, J COMP NEUROL, V524, P3530, DOI 10.1002/cne.24014; Cassasa CB, 1924, P NEW YORK PATH SOC, P101; Casson IR, 2014, SPORTS HEALTH, V6, P384, DOI 10.1177/1941738114540270; Chio A, 2009, AMYOTROPH LATERAL SC, V10, P205, DOI 10.1080/17482960902721634; Chuang PY, 2010, J NEUROTRAUM, V27, P999, DOI 10.1089/neu.2009.1129; Cifu DX, 2013, J REHABIL RES DEV, V50, P1169, DOI 10.1682/JRRD.2013.01.0006; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CORSELLIS JAN, 1959, J MENT SCI, V105, P714; Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Daneshvar DH, 2015, MOL CELL NEUROSCI, V66, P81, DOI 10.1016/j.mcn.2015.03.007; Dart RA, 1949, AM J PHYS ANTHROP-NE, V7, P1, DOI 10.1002/ajpa.1330070103; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; del Zoppo GJ, 2013, STROKE, V44, P263, DOI 10.1161/STROKEAHA.112.653618; DENST J, 1959, ARCH PATHOL, V67, P134; DePalma RG., 2015, SOURCEBRAIN NEUROTRA, P5; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Doherty CP, 2016, J NEUROPATH EXP NEUR, V75, P656, DOI 10.1093/jnen/nlw036; Edlow BL, 2012, SEMIN NEUROL, V32, P374, DOI 10.1055/s-0032-1331810; Erichsen JE, 1875, CONCUSION SPINE NERV, P15; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Eulion JF, 1942, NEW ENGL J MED, V226, P1; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Finkbeiner NWB, 2016, CAN J PSYCHIAT, V61, P270, DOI 10.1177/0706743716644953; Forsyth D, 1915, LANCET, V186, P1399; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Fulton JJ, 2015, J ANXIETY DISORD, V31, P98, DOI 10.1016/j.janxdis.2015.02.003; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; GRAHMANN H, 1957, Psychiatr Neurol (Basel), V134, P261; Gross CG, 2003, TREPANATION: HISTORY, DISCOVERY, THEORY, P307; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Hetherington H, 2015, Handb Clin Neurol, V127, P309, DOI 10.1016/B978-0-444-52892-6.00020-9; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Iacono D, 2015, NEUROLOGY, V85, P1670, DOI 10.1212/WNL.0000000000002102; Jellinger KA, 2015, J NEURAL TRANSM, V122, P505, DOI 10.1007/s00702-014-1288-x; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2011, ACTA NEUROPATHOL, V122, P715, DOI 10.1007/s00401-011-0909-9; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jokl E, 1933, MUNCH MED WOCH, V15, P560; Jones E, 2002, BMJ-BRIT MED J, V324, P321, DOI 10.1136/bmj.324.7333.321; Jones Edgar, 2005, MAUDSLEY MONOGRAPHS, V47; Jungner M, 2016, MINERVA ANESTESIOL, V82, P525; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Kaur B, 1999, J CLIN PATHOL, V52, P203, DOI 10.1136/jcp.52.3.203; King A, 2010, NEUROPATHOLOGY, V30, P408, DOI 10.1111/j.1440-1789.2009.01085.x; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; Kovacs GG, 2013, ACTA NEUROPATHOL, V126, P365, DOI 10.1007/s00401-013-1157-y; Kshettry Varun R, 2007, Neurosurg Focus, V23, pE8; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Lambri M, 2001, CLIN NEUROPATHOL, V20, P263; Lazarus C, 2015, BIOPHYS J, V109, P231, DOI 10.1016/j.bpj.2015.06.029; Lepreux S, 2015, CLIN NEUROPATHOL, V34, P193, DOI 10.5414/NP300838; Li LZ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002028; Ling G, 2015, Handb Clin Neurol, V127, P173, DOI 10.1016/B978-0-444-52892-6.00011-8; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; MARTLAND HS, 1928, JAMA-J AM MED ASSOC, V91, P1103, DOI DOI 10.1001/JAMA.1928.02700150029009; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MAWDSLEY C, 1963, LANCET, V2, P795; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McNab JA, 2013, NEUROIMAGE, V80, P234, DOI 10.1016/j.neuroimage.2013.05.074; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Mez J, 2016, JAMA NEUROL, V73, P353, DOI 10.1001/jamaneurol.2015.3998; Michaelson DM, 2014, ALZHEIMERS DEMENT, V10, P861, DOI 10.1016/j.jalz.2014.06.015; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Minshall D, 2014, J R Nav Med Serv, V100, P252; Missios Symeon, 2007, Neurosurg Focus, V23, pE11; Mohanty AF, 2015, MED CARE, V53, pS143, DOI 10.1097/MLR.0000000000000314; Mortimer JA, 2009, ALZ DIS ASSOC DIS, V23, P152, DOI 10.1097/WAD.0b013e318190a855; Mott F W, 1917, Br Med J, V2, P612; Mott FW, 1916, LANCET, V1, P331; Myers CS, 1915, LANCET, V1, P316; Myrga JM, 2016, NEUROREHAB NEURAL RE, V30, P920, DOI 10.1177/1545968316648409; NEUBUERGER KT, 1959, ARCH NEURO PSYCHIATR, V81, P403, DOI 10.1001/archneurpsyc.1959.02340160001001; Neve RL, 2000, BRAIN RES, V886, P54, DOI 10.1016/S0006-8993(00)02869-9; Niess C, 2002, ACTA NEUROPATHOL, V104, P79, DOI 10.1007/s00401-002-0525-9; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Oppenheim H, 1889, NACH NERVENKLINIK CH; Osier ND, 2017, J NEUROTRAUM, V34, P86, DOI 10.1089/neu.2015.4343; Osnato M, 1927, ARCH NEURO PSYCHIATR, V18, P181, DOI 10.1001/archneurpsyc.1927.02210020025002; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Panourias IG, 2005, NEUROSURGERY, V57, P181, DOI 10.1227/01.NEU.0000163416.66374.48; Parker HL, 1934, J NEUROL PSYCHOPATHO, V15, P20; PAYNE EE, 1968, NEUROCHIRURGIA, V11, P173; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Peskind ER, 2013, J CLIN PSYCHIAT, V74, P180, DOI 10.4088/JCP.12011co1c; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Plummer S, 2016, AGING DIS, V7, P163, DOI 10.14336/AD.2015.0907; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Reams N, 2016, JAMA NEUROL, V73, P743, DOI 10.1001/jamaneurol.2015.5015; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; Riedy G, 2016, RADIOLOGY, V279, P207, DOI 10.1148/radiol.2015150438; Ritter AC, 2016, EPILEPSIA, V57, P984, DOI 10.1111/epi.13397; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Rose F C, 1997, J Hist Neurosci, V6, P154; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; RYAN GA, 1994, J TRAUMA, V36, P469; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; Selkoe DJ, 2016, EMBO MOL MED, V8, P595, DOI 10.15252/emmm.201606210; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Shively SB, 2016, LANCET NEUROL, V15, P944, DOI 10.1016/S1474-4422(16)30057-6; Singh AK, 2016, RADIOGRAPHICS, V36, P295, DOI 10.1148/rg.2016150114; Smith C, 2013, NEUROPATH APPL NEURO, V39, P35, DOI 10.1111/nan.12006; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Southborough Lord, 1922, REPORT WAR OFFICE CO; SPILLANE J D, 1962, Br Med J, V2, P1205; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Tanzi E, 1914, TRATTATO MALATTIE ME, V2, P325; Tartaglia MC, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00030; Tay T.L., 2016, J PHYSL; Trotter BB, 2015, BRAIN, V138, P2278, DOI 10.1093/brain/awv139; Turner RC, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00223; Vick Karl, 2014, Time, V184, P46; Washington PM, 2016, EXP NEUROL, V275, P381, DOI 10.1016/j.expneurol.2015.06.015; West TA, 2014, J NEUROTRAUM, V31, P159, DOI 10.1089/neu.2013.3031; WOLOWSKA J, 1960, Neurol Neurochir Psychiatr Pol, V10, P787; Young L, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00089	157	14	14	1	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	MAY	2017	28	2					301	+		10.1016/j.pmr.2016.12.007			23	Rehabilitation	Rehabilitation	EU5AJ	WOS:000401043700009	28390515				2021-06-18	
J	Stocker, RPJ; Khan, H; Henry, L; Germain, A				Stocker, Ryan P. J.; Khan, Hassen; Henry, Luke; Germain, Anne			Effects of Sleep Loss on Subjective Complaints and Objective Neurocognitive Performance as Measured by the Immediate Post-Concussion Assessment and Cognitive Testing	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Sleep; Sleep Loss; ImPACT; Neurocognitive Performance; Subjective Symptoms	TRAUMATIC BRAIN-INJURY; TEST-RETEST RELIABILITY; COMPUTERIZED NEUROPSYCHOLOGICAL ASSESSMENT; BRIEF BEHAVIORAL TREATMENT; DEFAULT-MODE NETWORK; IMPACT TEST BATTERY; FUNCTIONAL CONNECTIVITY; RESPONSE-INHIBITION; CHRONIC INSOMNIA; ONLINE VERSION	Objective: This study examined the effects of total and partial sleep deprivation on subjective symptoms and objective neurocognitive performance, as measured by the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) in a sample of healthy adults. Method: One-hundred and two, right-handed, healthy participants (between ages 18 and 30 years old) completed three consecutive nights in the sleep laboratory with concurrent continuous polysomnography monitoring. Night 1 served as a baseline night. Prior to Night 2, they were randomly assigned to one of three sleep conditions: undisrupted normal sleep (N = 34), sleep restriction (50% of habitual sleep, N = 37), or total sleep deprivation (N = 31). Participants slept undisturbed on Night 3. ImPACT was administered on three separate occasions. Results: Sleep loss was associated with increased severity of subjectively reported affective, cognitive, physical, and sleep symptoms. Although objective neurocognitive task scores derived from the ImPACT battery did not corroborate subjective complaints, sleep loss was associated with significant differences on tasks of visual memory, reaction time, and visual motor speed over time. Conclusions: While self-report measures suggested marked impairments following sleep loss, deficits in neurocognitive performance were observed only on three domains measured with ImPACT. ImPACT may capture subtle changes in neurocognitive performance following sleep loss; however, independent and larger validation studies are needed to determine its sensitivity to acute sleep loss and recovery sleep. Neurocognitive screening batteries may be useful for detecting the effects of more severe or chronic sleep loss under high-stress conditions that mimic high-risk occupations.	[Stocker, Ryan P. J.; Germain, Anne] Univ Pittsburgh, Sch Med, Dept Psychiat, 3811 OHara St, Pittsburgh, PA 15213 USA; [Khan, Hassen] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; [Henry, Luke] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA	Stocker, RPJ (corresponding author), Univ Pittsburgh, Sch Med, Dept Psychiat, 3811 OHara St, Pittsburgh, PA 15213 USA.	stockerrp@upmc.edu			Department of DefenseUnited States Department of Defense [11293006]	This work was supported by the Department of Defense as this was an ancillary study included in a larger sleep study focused on the effects of sleep loss of positive and negative affect in healthy individuals (Log#11293006).	Allen BJ, 2011, BRAIN INJURY, V25, P179, DOI 10.3109/02699052.2010.541897; American Academy of Sleep Medicine, 2014, INT CLASSIFICATION S, Vthird; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Banks Martha E, 2002, Adolesc Med, V13, P643; Barr T, 2015, ANNU REV NURS RES-SE, V33, P249, DOI 10.1891/0739-6686.33.249; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Bauer RM, 2012, CLIN NEUROPSYCHOL, V26, P177, DOI 10.1080/13854046.2012.663001; Benitez A, 2012, CLIN NEUROPSYCHOL, V26, P214, DOI 10.1080/13854046.2012.658439; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bressler SL, 2010, TRENDS COGN SCI, V14, P277, DOI 10.1016/j.tics.2010.04.004; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Buysse DJ, 2011, ARCH INTERN MED, V171, P887, DOI 10.1001/archinternmed.2010.535; Buysse DJ, 2008, SLEEP, V31, P1673, DOI 10.1093/sleep/31.12.1673; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chee MWL, 2007, P NATL ACAD SCI USA, V104, P9487, DOI 10.1073/pnas.0610712104; Coldren RL, 2012, MIL MED, V177, P179, DOI 10.7205/MILMED-D-11-00278; Cole WR, 2013, ARCH CLIN NEUROPSYCH, V28, P732, DOI 10.1093/arclin/act040; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Dinges DF, 1997, SLEEP, V20, P267; Dinges DF, 1992, SLEEP AROUSAL PERFOR, P177; Drake CL, 2001, PSYCHOPHYSIOLOGY, V38, P979, DOI 10.1111/1469-8986.3860979; Drummond SPA, 2006, J SLEEP RES, V15, P261, DOI 10.1111/j.1365-2869.2006.00535.x; Drummond SPA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035653; Drummond SPA, 2005, PSYCHIAT RES-NEUROIM, V140, P211, DOI 10.1016/j.pscychresns.2005.06.007; Drummond SPA, 2004, SLEEP, V27, P445; Drummond SPA, 2000, NATURE, V403, P655, DOI 10.1038/35001068; Drummond SPA, 2001, J SLEEP RES, V10, P85, DOI 10.1046/j.1365-2869.2001.00245.x; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; First M.B., 1996, STRUCTURED CLIN INTE; Fortier-Brochu E, 2012, SLEEP MED REV, V16, P83, DOI 10.1016/j.smrv.2011.03.008; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Friedl KE, 2007, ARCH CLIN NEUROPSYCH, V22, pS7, DOI 10.1016/j.acn.2006.10.002; Germain A, 2005, J ANXIETY DISORD, V19, P233, DOI 10.1016/j.janxdis.2004.02.001; Germain A, 2006, J CLIN SLEEP MED, V2, P403; Germain A, 2012, J PSYCHOSOM RES, V72, P89, DOI 10.1016/j.jpsychores.2011.11.010; Goel N, 2009, SEMIN NEUROL, V29, P320, DOI 10.1055/s-0029-1237117; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Greicius MD, 2008, HUM BRAIN MAPP, V29, P839, DOI 10.1002/hbm.20537; Hampson M, 2010, MAGN RESON IMAGING, V28, P1051, DOI 10.1016/j.mri.2010.03.021; Harrison Y, 2000, J EXP PSYCHOL-APPL, V6, P236, DOI 10.1037//1076-898X.6.3.236; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horovitz SG, 2009, P NATL ACAD SCI USA, V106, P11376, DOI 10.1073/pnas.0901435106; Iverson G.L., 2003, IMMEDIATE POSTCONCUS; Iverson G. L., 2003, 23 ANN M NAT AC NEUR; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kelly AMC, 2008, NEUROIMAGE, V39, P527, DOI 10.1016/j.neuroimage.2007.08.008; Kertzman S, 2008, ISR J PSYCHIATR REL, V45, P114; Kleitman N., 1963, SLEEP WAKEFULNESS; Kribbs N.B., 1994, SLEEP ONSET MECH, P113, DOI 10.1037/10166-007; Leposavic I, 2010, PSYCHIAT DANUB, V22, P149; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lupien SJ, 2007, BRAIN COGNITION, V65, P209, DOI 10.1016/j.bandc.2007.02.007; Lynch WJ, 2002, J HEAD TRAUMA REHAB, V17, P66, DOI 10.1097/00001199-200202000-00009; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McClure DJ, 2014, AM J SPORT MED, V42, P472, DOI 10.1177/0363546513510389; Menon V, 2011, TRENDS COGN SCI, V15, P483, DOI 10.1016/j.tics.2011.08.003; Mihalik JP, 2013, CLIN J SPORT MED, V23, P343, DOI 10.1097/JSM.0b013e318295a834; Nakayama Y, 2014, AM J SPORT MED, V42, P2000, DOI 10.1177/0363546514535901; Patrick GT., 1896, PSYCHOL REV, V3, P469; Pilcher J.J., 1996, SLEEP J SLEEP RES SL; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Ridderinkhof KR, 2004, BRAIN COGNITION, V56, P129, DOI 10.1016/j.bandc.2004.09.016; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2006, APPL NEUROPSYCHOL, V13, P151, DOI 10.1207/s15324826an1303_2; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schmaal L, 2013, BIOL PSYCHIAT, V73, P789, DOI 10.1016/j.biopsych.2012.12.025; Schwab KA, 2006, NEUROLOGY, V66, pA235; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; SPIELMAN AJ, 1987, SLEEP, V10, P45; Spreng RN, 2010, NEUROIMAGE, V53, P303, DOI 10.1016/j.neuroimage.2010.06.016; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; Tanielian TL, 2008, INVISIBLE WOUNDS WAR, V720; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Troyanskaya M, 2015, MIL MED, V180, P285, DOI 10.7205/MILMED-D-14-00256; Van Dongen HPA, 2003, SLEEP, V26, P117, DOI 10.1093/sleep/26.2.117; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wesensten NJ, 2012, DRUG DISCOV TODAY, V8, P139; WILKINSON RT, 1968, PROGRESS CLINICAL PS, V8, P28; Zhou J, 2010, BRAIN, V133, P1352, DOI 10.1093/brain/awq075	89	14	14	0	18	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2017	32	3					349	368		10.1093/arclin/acx003			20	Psychology, Clinical; Psychology	Psychology	EU2WN	WOS:000400890700010	28431034	Bronze			2021-06-18	
J	Tanveer, S; Zecavati, N; Delasobera, EB; Oyegbile, TO				Tanveer, Sarah; Zecavati, Nassim; Delasobera, Elizabeth Bronson; Oyegbile, Temitayo Oyefunmike			Gender Differences in Concussion and Postinjury Cognitive Findings in an Older and Younger Pediatric Population	PEDIATRIC NEUROLOGY			English	Article						gender; concussion; cognitive testing; pediatric	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; STATES HIGH-SCHOOL; SEX-DIFFERENCES; NEUROPSYCHOLOGICAL FUNCTION; SYMPTOMS; MANAGEMENT; IMPACT; RECOVERY	BACKGROUND: Studies have documented gender differences associated with concussion. The purpose of this study was to determine if these gender differences are also noted within a pediatric population. METHODS: This prospective study analyzed 1971 patients who had completed preconcussion and postconcussion neuropsychological testing within the Washington, DC, area. RESULTS: Our results showed that children and adolescents with concussion exhibit gender differences with respect to risk factors, recovery, and symptomatology. Females are more likely to preent with a concussion (P < 0.001), experience more discomfort from a concussion (P < 0.001),, and seek treatment for postconcussive headaches (P < 0.001). On the other hand, males are more likely to sustain a concussion from a contact sport (P < 0.001) and experience loss of consciousness, confusion, and amnesia with a concussion more frequently than females (P < 0.001). Postconcussive cognitive function also differs by gender. Both males and females exhibit a decline in cognitive testing compared with baseline (P < 0.001); however, visual memory (P = 0.02) is more affected in females than in males. These findings remain unchanged among pediatric patients aged >= 14 years; however, no gender differences were noted in individuals aged <= 13 years. CONCLUSION: It is important for health care providers, schools, athletic trainers, and coaches to be aware of these gender differences associated with concussion in order to provide adequate surveillance and appropriate monitoring and support during the recovery period.	[Oyegbile, Temitayo Oyefunmike] MedStar Georgetown Univ Hosp, Pediat Neurol Sleep Med & Epilepsy, 4200 Wisconsin Ave NW, Washington, DC 20016 USA	Oyegbile, TO (corresponding author), MedStar Georgetown Univ Hosp, Pediat Neurol Sleep Med & Epilepsy, 4200 Wisconsin Ave NW, Washington, DC 20016 USA.	Temitayo.O.Oyegbile@gunetzeorgetown.edu	Tanveer, Sarah/F-9639-2018; Tanveer, Sarah/AAK-1470-2020	Tanveer, Sarah/0000-0002-6408-9855; Tanveer, Sarah/0000-0002-6408-9855			[Anonymous], 2007, MMWR MORB MORTAL WKL, V56, P733; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Benedict PA, 2015, J NEUROL SCI, V353, P111, DOI 10.1016/j.jns.2015.04.029; Berz K, 2013, PHYSICIAN SPORTSMED, V41, P58, DOI 10.3810/psm.2013.05.2015; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Grubenhoff JA, 2011, BRAIN INJURY, V25, P943, DOI 10.3109/02699052.2011.597043; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Lee YM, 2013, J NEUROSURG-PEDIATR, V12, P537, DOI 10.3171/2013.7.PEDS12572; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Moser RS, 2007, PROF PSYCHOL-RES PR, V38, P699, DOI 10.1037/0735-7028.38.6.699; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Rose SC, 2015, PEDIATR NEUROL, V53, P108, DOI 10.1016/j.pediatrneurol.2015.04.003; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Wiebe DJ, 2011, INJURY PREV, V17, P69, DOI 10.1136/ip.2010.031211	28	14	14	2	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	MAY	2017	70						44	49		10.1016/j.pediatrneurol.2017.02.001			6	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	EV1FW	WOS:000401493100009	28320567				2021-06-18	
J	Kraus, N; Lindley, T; Colegrove, D; Krizman, J; Otto-Meyer, S; Thompson, EC; White-Schwoch, T				Kraus, Nina; Lindley, Tory; Colegrove, Danielle; Krizman, Jennifer; Otto-Meyer, Sebastian; Thompson, Elaine C.; White-Schwoch, Travis			The neural legacy of a single concussion	NEUROSCIENCE LETTERS			English	Article						Concussion; Mild traumatic brain injury; Sports medicine; Auditory processing; Neurophysiology; FFR	INDIVIDUALS	It has been hypothesized that concussions impart lasting brain damage, even after a patient has ostensibly recovered. This hypothesis is based largely upon neuropathological studies in deceased athletes, however, leaving open the question of whether it can be detected in vivo. We measured neural responses to speech in collegiate student-athletes with a history of a single concussion from which they had recovered. These student-athletes had weaker responses to speech than age- and position-matched peers. This group difference suggests that concussions engender small, but detectable, changes in brain function prior to the emergence of frank behavioral indications. (C) 2017 Elsevier B.V. All rights reserved.	[Kraus, Nina; Krizman, Jennifer; Otto-Meyer, Sebastian; Thompson, Elaine C.; White-Schwoch, Travis] Northwestern Univ, Dept Commun Sci, Auditory Neurosci Lab, Evanston, IL USA; [Kraus, Nina] Northwestern Univ, Dept Neurobiol, Evanston, IL USA; [Kraus, Nina] Northwestern Univ, Dept Otolaryngol, Evanston, IL USA; [Lindley, Tory; Colegrove, Danielle] Northwestern Univ, Sports Med Unit, Dept Athlet, Evanston, IL USA	Kraus, N (corresponding author), 2240 Campus Dr, Evanston, IL 60208 USA.	nkraus@northwestern.edu			Knowles Hearing Center	This work was supported by the Knowles Hearing Center.	Carman AJ, 2015, NAT REV NEUROL, V11, P230, DOI 10.1038/nrneurol.2015.30; Gallun FJ, 2012, J REHABIL RES DEV, V49, P1005, DOI 10.1682/JRRD.2012.03.0038; Kraus N., 2016, NAT SCI REP, V6; Kraus N, 2015, TRENDS COGN SCI, V19, P642, DOI 10.1016/j.tics.2015.08.017; Maro II, 2014, EAR HEARING, V35, P306, DOI 10.1097/01.aud.0000439101.07257.ed; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Skoe E, 2015, CEREB CORTEX, V25, P1415, DOI 10.1093/cercor/bht311; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Wilson MJ, 2014, DEV NEUROPSYCHOL, V39, P113, DOI 10.1080/87565641.2013.870177	9	14	14	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	APR 12	2017	646						21	23		10.1016/j.neulet.2017.03.008			3	Neurosciences	Neurosciences & Neurology	EV3SO	WOS:000401679600004	28279706				2021-06-18	
J	Catroppa, C; Hearps, S; Crossley, L; Yeates, K; Beauchamp, M; Fusella, J; Anderson, V				Catroppa, Cathy; Hearps, Stephen; Crossley, Louise; Yeates, Keith; Beauchamp, Miriam; Fusella, Jessica; Anderson, Vicki			Social and Behavioral Outcomes following Childhood Traumatic Brain Injury: What Predicts Outcome at 12 Months Post-Insult?	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; behavioral; children; predictors; social	FAMILY ASSESSMENT DEVICE; FUNCTIONAL RECOVERY; SELF-ESTEEM; HEAD-INJURY; CHILDREN; ADOLESCENTS; PARTICIPATION; FRIENDSHIP; SCHOOL; RELIABILITY	This study sought to investigate social and behavioral outcomes 12 months following childhood traumatic brain injury (TBI) and to identify predictors of these outcomes. The study also compared rates of impairment in social and behavioral outcomes at 12 months post-injury between children with TBI and a typically developing (TD) control group. The study comprised 114 children ages 5.5 to 16.0 years, 79 with mild, moderate, or severe TBI and 35 TD children, group-matched for age, sex and socio-economic status. Children with TBI were recruited via consecutive hospital admissions and TD children from the community. Social and behavioral outcomes were measured via parent-rated questionnaires. Analysis of covariance models identified a significant mean difference between the mild and moderate groups for social problems only, but the moderate and severe TBI groups showed a higher rate of impairment, particularly in externalizing problems. Pre-injury function, injury severity, parent mental health, and child self-esteem all contributed significantly to predicting social and behavioral outcomes. Both injury and non-injury factors should be considered when identifying children at risk for long-term difficulties in social and behavioral domains.	[Catroppa, Cathy; Hearps, Stephen; Crossley, Louise] Murdoch Childrens Res Inst, 4th Floor West,50 Flemington Rd, Parkville, Vic 3052, Australia; [Yeates, Keith] Alberta Childrens Prov Gen Hosp, Res Inst, Calgary, AB, Canada; [Beauchamp, Miriam] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Fusella, Jessica] Royal Melbourne Hosp, Melbourne, Vic, Australia; [Anderson, Vicki] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Anderson, Vicki] Univ Melbourne, Dept Psychol Sci & Pediat, Melbourne, Vic, Australia	Catroppa, C (corresponding author), Murdoch Childrens Res Inst, 4th Floor West,50 Flemington Rd, Parkville, Vic 3052, Australia.	cathy.catroppa@mcri.edu.au	Hearps, Stephen/L-6853-2016; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	Victorian Neurotrauma Initiative; Victorian Government Operational Infrastructure Scheme	The Victorian Neurotrauma Initiative funded this research, and it also was supported by the Victorian Government Operational Infrastructure Scheme.	Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Anaby D, 2012, DEV MED CHILD NEUROL, V54, P339, DOI 10.1111/j.1469-8749.2011.04204.x; Anderson V., 2013, J INT PSYCHOL SOC, V19, P1; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Bedell G, 2008, J HEAD TRAUMA REHAB, V23, P341, DOI 10.1097/01.HTR.0000336850.29574.7a; Bedell GM, 2004, NEUROREHABILITATION, V19, P191; Bohnert AM, 1997, DEV NEUROPSYCHOL, V13, P477, DOI 10.1080/87565649709540688; Catroppa C, 2015, J NEUROTRAUM, V32, P109, DOI 10.1089/neu.2013.3276; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; COFFEY CE, 1991, AM PSYCHOP, P243; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Di Battista A, 2014, J REHABIL MED, V46, P975, DOI 10.2340/16501977-1883; Di Battista A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101842; Emery CA, 2016, CAN J PSYCHIAT, V61, P259, DOI 10.1177/0706743716643741; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Galvin J, 2010, AUST OCCUP THER J, V57, P118, DOI 10.1111/j.1440-1630.2009.00822.x; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Harter S., 1985, MANUAL SELF PERCEPTI; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Hawley CA, 2012, NEUROREHABILITATION, V30, P173, DOI 10.3233/NRE-2012-0742; Heverly-Fitt S, 2014, J INT NEUROPSYCH SOC, V20, P684, DOI 10.1017/S1355617714000393; Jackson C, 2007, OCCUP MED-OXFORD, V57, P79, DOI 10.1093/occmed/kql169; Keightley Michelle L, 2014, Arch Phys Med Rehabil, V95, pS192, DOI 10.1016/j.apmr.2013.12.018; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; McMillan J, 2009, J SOCIOL, V45, P123, DOI 10.1177/1440783309103342; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Muris P, 2003, PERS INDIV DIFFER, V35, P1791, DOI 10.1016/S0191-8869(03)00004-7; Pastore V, 2015, BRAIN INJURY, V29, P937, DOI 10.3109/02699052.2015.1008045; Prigatano G.P., 2010, PED HLTH, V4, P447; Prigatano GP, 2006, J HEAD TRAUMA REHAB, V21, P505, DOI 10.1097/00001199-200611000-00005; Prigatano GP, 2008, J HEAD TRAUMA REHAB, V23, P378, DOI 10.1097/01.HTR.0000341433.67251.01; Rosema S, 2014, SOCIAL CARE NEURODIS, V5, DOI [10.1108/SCN-06-2013-0022, DOI 10.1108/SCN-06-2013-0022]; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Ross KA, 2011, BRAIN INJURY, V25, P1206, DOI 10.3109/02699052.2011.609519; Ryan NP, 2013, INT J DEV NEUROSCI, V31, P811, DOI 10.1016/j.ijdevneu.2013.10.002; Schmidt AT, 2010, BRAIN INJURY, V24, P1550, DOI 10.3109/02699052.2010.523047; Sharp NL, 2006, DISABIL REHABIL, V28, P767, DOI 10.1080/09638280500386668; Sonnenberg LK, 2010, BRAIN INJURY, V24, P1003, DOI 10.3109/02699052.2010.489033; Tabachnick B.G., 2000, USING MULTIVARIATE S, V4th; Taylor HG, 2015, J HEAD TRAUMA REHAB, V30, P302, DOI 10.1097/HTR.0000000000000106; TEASDALE G, 1974, LANCET, V2, P81; Thaler NS, 2012, APPL NEUROPSYCH-CHIL, V1, P30, DOI 10.1080/21622965.2012.665776; Thompson H, 2012, J NEUROTRAUM, V29, pA189; UCLA: Academic Technology Services, 2012, STAT DAT AN EX TOB A; van Tol E, 2011, BRAIN INJURY, V25, P1279, DOI 10.3109/02699052.2011.613089; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; Warschausky S, 1997, Pediatr Rehabil, V1, P77; WECHSLER D, 1990, WECHSLER ABBREVIATED; Wells R, 2009, DEV NEUROREHABIL, V12, P12, DOI 10.1080/17518420902773109; Yeates K. O., 2013, J INT NEUROPSYCH SOC, V19, P1; Yeates KO, 2014, CLIN PSYCHOL SCI, V2, P97, DOI 10.1177/2167702613499734; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Ylvisaker Mark, 2007, Phys Med Rehabil Clin N Am, V18, P133, DOI 10.1016/j.pmr.2006.11.007	56	14	14	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	7					1439	1447		10.1089/neu.2016.4594			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ER0FB	WOS:000398461600013	27809667				2021-06-18	
J	Krieg, SM; Trabold, R; Plesnila, N				Krieg, Sandro M.; Trabold, Raimund; Plesnila, Nikolaus			Time-Dependent Effects of Arginine-Vasopressin V1 Receptor Inhibition on Secondary Brain Damage after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						AVP; brain edema; ICP; secondary brain damage; TBI	CONTROLLED CORTICAL IMPACT; SUBARACHNOID HEMORRHAGE; VOLUME REGULATION; V-2 RECEPTORS; EXTRAHYPOTHALAMIC VASOPRESSIN; CEREBROSPINAL-FLUID; V-1A RECEPTORS; EDEMA; RATS; MICE	Arginine-vasopressin (AVP) V-1 receptors are known to mediate brain edema formation after traumatic brain injury (TBI). So far, however, AVP V-1 receptors were only inhibited by genetic deletion or prior to trauma. Therefore, the current study aimed to determine the therapeutic window of AVP V-1 receptor antagonization after TBI. Male C57BL/6 mice (n = 7 per group) were subjected to controlled cortical impact (CCI), and 500 ng of a selective peptide V-1 receptor antagonist (V1880) were applied by intracerebroventricular injection 5 min, and 1, 3, and 6 h thereafter. After 24 h, brain water content (BWC), intracranial pressure (ICP), and secondary contusion expansion volume were assessed. Neurological function was assessed daily for 7 days after trauma. Inhibition of AVP V-1 receptors within 1 h after TBI significantly reduced BWC from 81.6 +/- 0.7 to 80.6 +/- 0.7% (means +/- SD; p < 0.05). Reduction of brain edema resulted in a significant decrease in ICP from 25.9 +/- 1.8 mm Hg to 21.0 +/- 1.5 mm Hg (p < 0.05) and a reduction in contusion volume (26.1 +/- 2.5mm(3) vs. 30.1 +/- 2.0mm(3) in controls; p < 0.05). This reduction of brain injury resulted in a significantly improved neurological function 7 days after trauma. Treatments initiated 6 h after TBI had no effect. The results of the current study demonstrate that inhibition of AVP V-1 receptors improve outcome after experimental TBI when given within a clinically relevant time window. Therefore, AVP V-1 receptors may represent a therapeutic target with clinical potential.	[Krieg, Sandro M.; Trabold, Raimund; Plesnila, Nikolaus] Ludwig Maximilians Univ Munchen, Lab Expt Neurosurg, Munich, Germany; [Trabold, Raimund] Ludwig Maximilians Univ Munchen, Dept Neurosurg, Munich, Germany; [Plesnila, Nikolaus] Ludwig Maximilians Univ Munchen, Inst Stroke & Dementia Res, Munich, Germany; [Plesnila, Nikolaus] Ludwig Maximilians Univ Munchen, Munich Cluster Syst Neurol, Munich, Germany	Plesnila, N (corresponding author), Inst Stroke & Dementia Res, Feodor Lynen Str 17, D-81377 Munich, Germany.	nikolaus.plesnila@med.uni-muenchen.de	Krieg, Sandro M./W-2389-2019; Plesnila, Nikolaus/T-7522-2019	Krieg, Sandro M./0000-0003-4050-1531; 	research and medical education (Forderprogramm for Forschung und Lehre) of the Faculty of Medicine; LudwigMaximilians-University, Munich, Germany	This study was supported by grants of the sponsoring program for research and medical education (Forderprogramm for Forschung und Lehre) of the Faculty of Medicine, LudwigMaximilians-University, Munich, Germany. We apologize to all those colleagues whose work could not be cited because of space limitations.	Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Amiry-Moghaddam M, 2004, NEUROSCIENCE, V129, P999, DOI 10.1016/j.neuroscience.2004.08.049; Armstead WM, 2001, BRAIN RES, V910, P19, DOI 10.1016/S0006-8993(01)02716-0; Barreca T, 2001, CEREBROVASC DIS, V11, P113, DOI 10.1159/000047622; Bemana I, 1999, NEUROSURGERY, V44, P148, DOI 10.1097/00006123-199901000-00091; Ben Borgens R, 2012, Q REV BIOL, V87, P89, DOI 10.1086/665457; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BUIJS RM, 1980, J HISTOCHEM CYTOCHEM, V28, P357, DOI 10.1177/28.4.6989899; BUIJS RM, 1978, CELL TISSUE RES, V186, P423, DOI 10.1007/BF00224932; CHEN Y, 1992, CAN J PHYSIOL PHARM, V70, pS367, DOI 10.1139/y92-285; Chodobski A, 1997, MOL BRAIN RES, V48, P67, DOI 10.1016/S0169-328X(97)00079-X; Cintra ED, 2000, ARQ NEURO-PSIQUIAT, V58, P181; de Vries GJ, 1998, PROG BRAIN RES, V119, P3; DELBIGIO MR, 1990, ACT NEUR S, V51, P14; DEPASQUALE M, 1989, AM J PHYSIOL, V256, pF1059; DICKINSON LD, 1992, J CEREBR BLOOD F MET, V12, P681, DOI 10.1038/jcbfm.1992.93; DOCZI T, 1993, ACTA NEUROCHIR, V121, P1, DOI 10.1007/BF01405174; DOCZI T, 1982, NEUROSURGERY, V11, P402; FARACI FM, 1990, AM J PHYSIOL, V258, pR94; Fernandez N, 2001, BRIT J PHARMACOL, V132, P1837, DOI 10.1038/sj.bjp.0704034; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hockel K, 2012, STROKE, V43, P227, DOI 10.1161/STROKEAHA.111.626168; Holmes CL, 2003, CRIT CARE, V7, P427, DOI 10.1186/cc2337; Huang WD, 2008, J ENDOCRINOL INVEST, V31, P996, DOI 10.1007/BF03345638; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; Kleindienst A, 2013, ACTA NEUROCHIR, V155, P151, DOI 10.1007/s00701-012-1558-z; Krieg SM, 2015, J NEUROTRAUM, V32, P221, DOI 10.1089/neu.2013.3274; Laszlo FA, 1999, EUR J PHARMACOL, V364, P115, DOI 10.1016/S0014-2999(98)00836-X; Lee JC, 2015, INJURY, V46, P854, DOI 10.1016/j.injury.2014.12.023; LIU XF, 1991, CHINESE MED J-PEKING, V104, P480; Marmarou A, 2005, ACT NEUR S, V95, P277; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MATHER HM, 1981, J NEUROL NEUROSUR PS, V44, P216, DOI 10.1136/jnnp.44.3.216; Maybauer MO, 2008, BEST PRACT RES-CLIN, V22, P253, DOI 10.1016/j.bpa.2008.03.003; MOHRING J, 1978, CIRC RES, V42, P17, DOI 10.1161/01.RES.42.1.17; NAGAO S, 1994, ACTA NEUROCHIR, P502; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Pascale CL, 2006, J PHYSIOL PHARMACOL, V57, P161; Pearl GS, 1998, CLIN LAB MED, V18, P39; RAICHLE ME, 1978, BRAIN RES, V143, P191, DOI 10.1016/0006-8993(78)90766-7; Rauen K, 2013, J NEUROTRAUM, V30, P1442, DOI 10.1089/neu.2012.2807; ROSENBERG GA, 1992, STROKE, V23, P1767, DOI 10.1161/01.STR.23.12.1767; Shuaib A, 2002, STROKE, V33, P3033, DOI 10.1161/01.STR.0000039405.31526.06; SORENSEN PS, 1984, ANN NEUROL, V15, P435, DOI 10.1002/ana.410150506; Szmydynger-Chodobska J, 2004, J NEUROTRAUM, V21, P1090, DOI 10.1089/0897715041651033; Terpolilli NA, 2009, J NEUROTRAUM, V26, P1963, DOI 10.1089/neu.2008.0853; Trabold R, 2008, J NEUROTRAUM, V25, P1459, DOI 10.1089/neu.2008.0597; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; ZLOKOVIC BV, 1990, BIOCHIM BIOPHYS ACTA, V1025, P191, DOI 10.1016/0005-2736(90)90097-8; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	51	14	14	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	7					1329	1336		10.1089/neu.2016.4514			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ER0FB	WOS:000398461600004	27762660				2021-06-18	
J	Kroshus, E; Kerr, ZY; Lee, JGL				Kroshus, Emily; Kerr, Zachary Y.; Lee, Joseph G. L.			Community-Level Inequalities in Concussion Education of Youth Football Coaches	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; HEALTH INEQUALITIES; NEIGHBORHOOD; DISPARITIES; RATES	Introduction: USA Football has made the Heads Up Football (HUF) concussion education program available for coaches of youth football players. Existing evidence about the effectiveness of the HUF coach education program is equivocal. For HUF and other programs, there is growing concern that even effective interventions can increase inequalities if there is different uptake or impact by SES or other demographic factors. Understanding how adoption is patterned along these lines is important for understanding equity issues in youth football. This study tested the hypothesis that there will be lower adoption of HUF among coaches of youth football players in lower-SES communities. Methods: The authors conducted a cross-sectional study of the association between communitylevel characteristics and number of USA Football youth league coaches who have completed HUF. Data were collected in 2014 and analyzed in 2015-2016. Results: Implementation of the HUF program was patterned by community-level socioeconomic characteristics. Leagues located in communities with a higher percentage of families with children aged o18 years living below the poverty line and a smaller percentage of non-Hispanic white residents tended to have leagues with smaller percentages of HUF-certified coaches. Conclusions: As interventions are developed that reduce the risks of youth football, it is important to consider not just the effectiveness of these interventions, but also whether they reduce or exacerbate health inequities. These results suggest that relying on voluntary adoption of coach education may result in inequitable implementation. Further study is required to identify and remedy organizational and contextual barriers to implementation of coach education in youth sport. (C) 2017 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.	[Kroshus, Emily] Univ Washington, Dept Pediat, 2001 8th Ave,Suite 400, Seattle, WA 98121 USA; [Kroshus, Emily] Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, Seattle, WA USA; [Kroshus, Emily] Harborview Injury Prevent & Res Ctr, Seattle, WA USA; [Kerr, Zachary Y.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Lee, Joseph G. L.] East Carolina Univ, Dept Hlth Educ & Promot, Greenville, NC USA	Kroshus, E (corresponding author), Univ Washington, Dept Pediat, 2001 8th Ave,Suite 400, Seattle, WA 98121 USA.	ekroshus@uw.edu		Kroshus, Emily/0000-0002-7484-2601	USA Football	As a former employee of the Datalys Center, Zack Kerr served as Principal Investigator on Datalys Center projects funded by USA Football. USA Football had no role in the design and conduct of the study; management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Findings do not reflect the official opinions of USA Football.	Aspen Institute/ espnW, PROJ PLAY SURV PAR Y; Bain-Selbo E., 2009, GAME DAY GOD FOOTBAL; Bernard P, 2007, SOC SCI MED, V65, P1839, DOI 10.1016/j.socscimed.2007.05.037; Brown JC, 2016, INT J SPORTS SCI COA, V11, P637, DOI 10.1177/1747954116667100; Drewnowski A, 2007, SOC SCI MED, V65, P2458, DOI 10.1016/j.socscimed.2007.07.001; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; ESPN, YOUTH FOOTB PART DRO; Foraker RE, 2011, ANN EPIDEMIOL, V21, P580, DOI 10.1016/j.annepidem.2011.03.004; Frohlich KL, 2008, AM J PUBLIC HEALTH, V98, P216, DOI 10.2105/AJPH.2007.114777; Graham R., 2014, SPORTS RELATED CONCU; Grubesic T.H., 2008, SOCIOECON PLAN SCI, V42, P129, DOI DOI 10.1016/j.seps.2006.09.001; Hill S, 2014, TOB CONTROL, V23, DOI 10.1136/tobaccocontrol-2013-051110; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3; Lin AC, 2015, SPORTS HEALTH, V7, P124, DOI 10.1177/1941738115571570; Lorenc T, 2013, J EPIDEMIOL COMMUN H, V67, P190, DOI 10.1136/jech-2012-201257; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; National Council of Youth Sports, 2008, REP TRENDS PART ORG; National Federation of State High School Associations, 2011 12 HIGH SCH ATH; Nutbeam D, 2000, HEALTH PROMOT INT, V15, P259, DOI 10.1093/heapro/15.3.259; Phelan JC, 2010, J HEALTH SOC BEHAV, V51, pS28, DOI 10.1177/0022146510383498; Prins ML, 2012, INT J DEV NEUROSCI, V30, P185, DOI 10.1016/j.ijdevneu.2011.05.009; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Sorensen K, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-80; U. S. Census Bureau, GEOGR TERMS CONC CEN; U. S. Census Bureau, 2009, KEY FACTS; USA Football, HEADS FOOTB NEW STAN; Williams DR, 2001, PUBLIC HEALTH REP, V116, P404, DOI 10.1016/S0033-3549(04)50068-7	27	14	14	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0749-3797	1873-2607		AM J PREV MED	Am. J. Prev. Med.	APR	2017	52	4					476	482		10.1016/j.amepre.2016.12.021			7	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	EU5MZ	WOS:000401077200011	28209280				2021-06-18	
J	McCredie, VA; Piva, S; Santos, M; Xiong, W; Manoel, ALD; Rigamonti, A; Hare, GMT; Chapman, MG; Baker, AJ				McCredie, Victoria A.; Piva, Simone; Santos, Marlene; Xiong, Wei; Manoel, Airton Leonardo de Oliveira; Rigamonti, Andrea; Hare, Gregory M. T.; Chapman, Martin G.; Baker, Andrew J.			The Impact of Red Blood Cell Transfusion on Cerebral Tissue Oxygen Saturation in Severe Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Transfusion; Oximetry; Brain tissue oxygenation	NEAR-INFRARED SPECTROSCOPY; METABOLISM	There are a range of opinions on the benefits and thresholds for the transfusion of red blood cells in critically ill patients with traumatic brain injury (TBI) and an urgent need to understand the neurophysiologic effects. The aim of this study was to examine the influence of red blood cell transfusions on cerebral tissue oxygenation (SctO(2)) in critically ill TBI patients. This prospective observational study enrolled consecutive TBI patients with anemia requiring transfusion. Cerebral tissue oxygen saturation (SctO(2)) was measured noninvasively with bilateral frontal scalp probes using near-infrared spectroscopy (NIRS) technology. Data were collected at baseline and for 24 h after transfusion. The primary outcome was the applicability of a four-wavelength near-infrared spectrometer to monitor SctO(2) changes during a transfusion. Secondary outcomes included the correlation of SctO(2) with other relevant physiological variables, the dependence of SctO(2) on baseline hemoglobin and transfusion, and the effect of red blood cell transfusion on fractional tissue oxygen extraction. We enrolled 24 patients with severe TBI, of which five patients (21 %) were excluded due to poor SctO(2) signal quality from large subdural hematomas and bifrontal decompressive craniectomies. Twenty transfusions were monitored in 19 patients. The mean pre- and post-transfusion hemoglobin concentrations were significantly different [74 g/L (SD 8 g/L) and 84 g/L (SD 9 g/L), respectively; p value < 0.0001]. Post-transfusion SctO(2) was not significantly greater than pre-transfusion SctO(2) [left-side pre-transfusion 69 % (SD 7) vs. post-transfusion 70 % (SD 10); p = 0.68, and right-side pre-transfusion 69 % (SD 5) vs. post-transfusion 71 % (SD 7); p = 0.11]. In a multivariable mixed linear analysis, mean arterial pressure was the only variable significantly associated with a change in SctO(2). The bifrontal method of recording changes in NIRS signal was not able to detect a measurable impact on SctO(2) in this sample of patients receiving red blood cell transfusion therapy in a narrow but conventionally relevant, range of anemia.	[McCredie, Victoria A.; Chapman, Martin G.] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, 2075 Bayview Ave,Room D108, Toronto, ON M4N 3M5, Canada; [Piva, Simone] Univ Brescia Spedali Civili, Div Neuroanesthesia & Neurointens Care, Dept Anesthesia Intens Care & Perioperat Med, Brescia, Italy; [Santos, Marlene; Hare, Gregory M. T.; Baker, Andrew J.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Xiong, Wei] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON M4N 3M5, Canada; [Manoel, Airton Leonardo de Oliveira] St Michaels Hosp, Dept Med Imaging, Intervent Neuroradiol, Toronto, ON, Canada; [Rigamonti, Andrea; Hare, Gregory M. T.; Chapman, Martin G.; Baker, Andrew J.] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada; [Rigamonti, Andrea; Baker, Andrew J.] St Michaels Hosp, Dept Crit Care Med, Toronto, ON, Canada; [Hare, Gregory M. T.] Univ Toronto, Dept Physiol, Toronto, ON, Canada	McCredie, VA (corresponding author), Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, 2075 Bayview Ave,Room D108, Toronto, ON M4N 3M5, Canada.	Victoria.McCredie@sunnybrook.ca; pivadoc@gmail.com; SantosMar@smh.ca; wei.xiong@sunnybrook.com; airtonleo@bol.com.br; rigamontia@smh.ca; hareg@smh.ca; Martin.Chapman@sunnybrook.ca; BakerA@smh.ca	de Oliveira Manoel, Airton Leonardo/C-4724-2018; Hare, Greg/AAM-5599-2021; Piva, Simone/E-1902-2014	de Oliveira Manoel, Airton Leonardo/0000-0002-9593-1013; Piva, Simone/0000-0002-5483-8007; McCredie, Victoria/0000-0002-1590-2846	Physicians' Services Incorporated Foundation; St. Michael's Trauma-Neuro Research Group	This work was supported by grants from the Physicians' Services Incorporated Foundation and St. Michael's Trauma-Neuro Research Group. Caster Medical Systems supplied the foresight cerebral tissue oximetry monitors during the study period. We separately purchased all the probes for study use. Rainbow (R) pulse co-oximetry monitors were provided by Masimo Canada, and probes were purchased for each study patient. All funding and support sources were not involved in the collection, analysis, and interpretation of data.	BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Boutin A, 2016, TRANSFUS MED REV, V30, P15, DOI 10.1016/j.tmrv.2015.08.004; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Colquhoun DA, 2012, J CLIN MONIT COMPUT, V26, P91, DOI 10.1007/s10877-012-9338-0; Davies DJ, 2015, J NEUROTRAUM, V32, P933, DOI 10.1089/neu.2014.3748; Kenward MG, 1997, BIOMETRICS, V53, P983, DOI 10.2307/2533558; Kiraly LN, 2009, J TRAUMA, V67, P29, DOI 10.1097/TA.0b013e3181af6a8c; Kurtz P, 2016, NEUROCRIT CARE, V24, P118, DOI 10.1007/s12028-015-0180-3; Leal-Noval SR, 2006, INTENS CARE MED, V32, P1733, DOI 10.1007/s00134-006-0376-2; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Rosenthal G, 2009, CRIT CARE MED, V37, P379, DOI 10.1097/CCM.0b013e318193265f; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Sekhon MS, 2015, NEUROCRIT CARE, V23, P210, DOI 10.1007/s12028-015-0141-x; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Topolovec-Vranic J, 2014, CAN RESPIR J, V21, P293, DOI 10.1155/2014/719270; von Elm E, 2007, BMJ-BRIT MED J, V335, P806; Wardle SP, 2000, J CEREBR BLOOD F MET, V20, P272, DOI 10.1097/00004647-200002000-00008; Warner MA, 2010, J NEUROSURG, V113, P539, DOI 10.3171/2009.12.JNS091337; Watzman HM, 2000, ANESTHESIOLOGY, V93, P947, DOI 10.1097/00000542-200010000-00012; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	26	14	14	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2017	26	2					247	255		10.1007/s12028-016-0310-6			9	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	EN5EV	WOS:000396029300013	27757915				2021-06-18	
J	Nelson, LD; Furger, RE; Gikas, P; Lerner, EB; Barr, WB; Hammeke, TA; Randolph, C; Guskiewicz, K; McCrea, MA				Nelson, Lindsay D.; Furger, Robyn E.; Gikas, Peter; Lerner, E. Brooke; Barr, William B.; Hammeke, Thomas A.; Randolph, Christopher; Guskiewicz, Kevin; McCrea, Michael A.			Prospective, Head-to-Head Study of Three Computerized Neurocognitive Assessment Tools Part 2: Utility for Assessment of Mild Traumatic Brain Injury in Emergency Department Patients	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Mild traumatic brain injury; Concussion; Emergency department; Neurocognitive testing; Neuropsychological testing	SPORT-RELATED CONCUSSION; HIGH-SCHOOL; TEST-PERFORMANCE; SYMPTOMS; RECOVERY; PREDICTORS; RELIABILITY; POPULATION; PREVALENCE; MANAGEMENT	Objectives: The aim of this study was to evaluate the reliability and validity of three computerized neurocognitive assessment tools (CNTs; i.e., ANAM, DANA, and ImPACT) for assessing mild traumatic brain injury (mTBI) in patients recruited through a level I trauma center emergency department (ED). Methods: mTBI (n = 94) and matched trauma control (n = 80) subjects recruited from a level I trauma center emergency department completed symptom and neurocognitive assessments within 72 hr of injury and at 15 and 45 days post-injury. Concussion symptoms were also assessed via phone at 8 days post-injury. Results: CNTs did not differentiate between groups at any time point (e.g., M 72-hr Cohen's d = -.16, .02, and .00 for ANAM, DANA, and ImPACT, respectively; negative values reflect greater impairment in the mTBI group). Roughly a quarter of stability coefficients were over .70 across measures and test-retest intervals in controls. In contrast, concussion symptom score differentiated mTBI vs. control groups acutely), with this effect size diminished over time (72-hr and day 8, 15, and 45 Cohen's d = -.78, -.60, -.49, and -.35, respectively). Conclusions: The CNTs evaluated, developed and widely used to assess sport-related concussion, did not yield significant differences between patients with mTBI versus other injuries. Symptom scores better differentiated groups than CNTs, with effect sizes weaker than those reported in sport-related concussion studies. Nonspecific injury factors, and other characteristics common in ED settings, likely affect CNT performance across trauma patients as a whole and thereby diminish the validity of CNTs for assessing mTBI in this patient population.	[Nelson, Lindsay D.; Furger, Robyn E.; Gikas, Peter; Lerner, E. Brooke; Hammeke, Thomas A.; McCrea, Michael A.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Barr, William B.] NYU, Sch Med, New York, NY USA; [Randolph, Christopher] Loyola Univ, Sch Med, Maywood, IL 60153 USA; [Guskiewicz, Kevin] Univ North Carolina Chapel Hill, Chapel Hill, NC USA	Nelson, LD (corresponding author), Med Coll Wisconsin, Milwaukee, WI 53226 USA.; Nelson, LD (corresponding author), Neurosci Res Ctr, Dept Neurosurg, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA.	linelson@mcw.edu			U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-12-1-0004]; National Center for Advancing Translational Sciences (National Institutes of Health)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001436]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001436] Funding Source: NIH RePORTER	We thank David Gray, Ashley LaRoche, and Adam Pfaller for their contributions to data collection. This work was supported by the U.S. Army Medical Research and Materiel Command (M.M., award number W81XWH-12-1-0004) and the National Center for Advancing Translational Sciences (National Institutes of Health Grant Number UL1TR001436). Opinions, interpretations, conclusions, and recommendations expressed in the manuscript are those of the authors and are not necessarily endorsed by the U.S. Army or representative of the official views of the NIH. The authors have no conflicts of interest to report.	Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BRUERA E, 1989, PAIN, V39, P13, DOI 10.1016/0304-3959(89)90169-3; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention, 2015, C TRAUM BRAIN INJ US; Chin EY, 2016, AM J SPORT MED, V44, P2276, DOI 10.1177/0363546516648141; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Delaney JS, 2005, J EMERG MED, V29, P189, DOI 10.1016/j.jemermed.2005.01.020; Derogatis LR, 2001, BRIEF SYMPTOM INVENT; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Eastvold AD, 2012, CLIN NEUROPSYCHOL, V26, P520, DOI 10.1080/13854046.2012.663000; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Furger R. E., 2016, CONCUSSION, V1, pCNC11, DOI 10.2217/cnc.15.11; Green P, 2003, GREENS MED SYMPTOM V; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Helmick K, 2006, DEFENSE VETERANS BRA; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lichtenstein JD, 2014, AM J SPORT MED, V42, P479, DOI 10.1177/0363546513509225; Luoto TM, 2013, J NEUROTRAUM, V30, P11, DOI 10.1089/neu.2012.2611; Macciocchi SN, 2013, ARCH CLIN NEUROPSYCH, V28, P684, DOI 10.1093/arclin/act049; Mathias JL, 2014, J NEUROTRAUM, V31, P658, DOI 10.1089/neu.2013.3160; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Nelson LD, 2015, AM J SPORT MED, V43, P2018, DOI 10.1177/0363546515587714; Peterson SE, 2009, ANN EMERG MED, V53, P796, DOI 10.1016/j.annemergmed.2008.10.015; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Rabinowitz AR, 2015, J NEUROTRAUM, V32, P1488, DOI 10.1089/neu.2014.3555; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Vincent AS, 2012, MIL MED, V177, P248, DOI 10.7205/MILMED-D-11-00156; Weathers J. W., 1994, PTSD CHECKLIST CIVIL; Wechsler D., 2001, WECHSLER TEST ADULT	43	14	14	0	5	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	APR	2017	23	4					293	303		10.1017/S1355617717000157			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	ES2YO	WOS:000399394000001	28343463	Green Accepted			2021-06-18	
J	Erdodi, LA; Nussbaum, S; Sagar, S; Abeare, CA; Schwartz, ES				Erdodi, Laszlo A.; Nussbaum, Shayna; Sagar, Sanya; Abeare, Christopher A.; Schwartz, Eben S.			Limited English Proficiency Increases Failure Rates on Performance Validity Tests with High Verbal Mediation	PSYCHOLOGICAL INJURY & LAW			English	Article						Cross-cultural neuropsychology; Performance validity testing; Bilingualism; Word Choice Test; Complex Ideational Material	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; CLASSIFICATION ACCURACY; RECOGNITION TRIAL; SYMPTOM VALIDITY; SUSPECT EFFORT; MEMORY TEST; SCORES; SAMPLE; ACCULTURATION	This study was designed to examine the effect of language proficiency and level of verbal mediation on failure rates on performance validity tests (PVTs). PVTs with high and low verbal mediation were administered to 80 healthy community-dwelling English-Arabic bilinguals. Digit Span and Animal Fluency were administered in both English and Arabic, in counterbalanced order, as part of a brief battery of neuropsychological tests. Participants with Arabic as their dominant language were 2 to 16 times more likely to fail PVTs with high verbal mediation compared to native speakers of English. When Digit Span and Animal Fluency were administered in the nondominant language, participants were 2 to 18 times more likely to fail the validity cutoffs. Language dominance explained between 6 and 31% of variance in dichotomized outcomes (pass/fail) on PVTs with high verbal mediation. None of the participants failed any PVTs with low verbal mediation. Limited language proficiency may result in dramatic increases in false positive rates on PVTs with high verbal mediation. Failure on a PVT administered in English to an examinee with a different linguistic background should be interpreted with great caution.	[Erdodi, Laszlo A.; Nussbaum, Shayna; Sagar, Sanya; Abeare, Christopher A.] Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada; [Schwartz, Eben S.] Waukesha Mem Hosp, Waukesha, WI USA	Erdodi, LA (corresponding author), Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com		Abeare, Christopher/0000-0002-7163-7434; Sagar, Sanya/0000-0001-7381-0803			An KY, 2017, CLIN NEUROPSYCHOL, V31, P193, DOI 10.1080/13854046.2016.1217046; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Barhon LI, 2015, APPL NEUROPSYCH-ADUL, V22, P114, DOI 10.1080/23279095.2013.863775; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Boone, 2007, ASSESSMENT FEIGNED C; Boone K., 2002, DOT COUNTING TEST; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone KB, 2007, ARCH CLIN NEUROPSYCH, V22, P355, DOI 10.1016/j.acn.2007.01.010; Borod JC, 1980, J CLIN NEUROPSYCHOLO, V2, P209, DOI DOI 10.1080/01688638008403793; Burton V, 2012, ARCH CLIN NEUROPSYCH, V27, P262, DOI 10.1093/arclin/acs026; Bush SS, 2014, PSYCHOL INJ LAW, V7, P197, DOI 10.1007/s12207-014-9198-7; Coffey DM, 2005, ARCH CLIN NEUROPSYCH, V20, P795, DOI 10.1016/j.acn.2005.04.009; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P1278, DOI 10.1080/13854046.2014.975844; Erdodi L, 2017, APPL NEUROPSYCH-ADUL, V24, P264, DOI 10.1080/23279095.2016.1154856; Erdodi L, 2012, HUMOR, V25, P459, DOI 10.1515/humor-2012-0024; Erdodi LA, 2017, J CLIN EXP NEUROPSYC, V39, P369, DOI 10.1080/13803395.2016.1230181; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Goodglass H., 2001, BOSTON DIAGNOSTIC AP; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; HAYWARD L, 1987, AUST NZ J PSYCHIAT, V21, P87, DOI 10.3109/00048678709160904; Heaton RK, 2004, REVISED COMPREHENSIV; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Larrabee G.J., 2012, FORENSIC NEUROPSYCHO; Leighton A, 2014, J INT NEUROPSYCH SOC, V20, P873, DOI 10.1017/S135561771400085X; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lichtenstein JD, 2018, CHILD NEUROPSYCHOL, V24, P247, DOI 10.1080/09297049.2016.1259402; Lichtenstein JD, 2014, AM J SPORT MED, V42, P479, DOI 10.1177/0363546513509225; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Mitrushina M., 1999, HDB NORMATIVE DATA N; Moreno EM, 2005, COGNITIVE BRAIN RES, V22, P205, DOI 10.1016/j.cogbrainres.2004.08.010; Morse CL, 2013, CLIN NEUROPSYCHOL, V27, P1395, DOI 10.1080/13854046.2013.832385; O'Bryant SE, 2003, CLIN NEUROPSYCHOL, V17, P69, DOI 10.1076/clin.17.1.69.15624; Pearson, 2009, ADV CLIN SOL WAIS WM; Razani J, 2007, CLIN NEUROPSYCHOL, V21, P776, DOI 10.1080/13854040701437481; Razani J, 2007, ARCH CLIN NEUROPSYCH, V22, P333, DOI 10.1016/j.acn.2007.01.008; Rey A, 1964, EXAMEN CLIN PSYCHOL; Reznek L, 2005, BRAIN INJURY, V19, P539, DOI 10.1080/02699050400005242; Russeler J, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-37; Salazar X. F., 2007, ASSESSMENT FEIGNED C, P405; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; Trueblood W., 1994, J CLIN EXPT NEUROPSY, V4, P697, DOI DOI 10.1080/01688639408402671; Vilar-Lopez R, 2008, J CLIN EXP NEUROPSYC, V30, P710, DOI 10.1080/13803390701684562; Youngjohn JR, 1999, ARCH CLIN NEUROPSYCH, V14, P511, DOI 10.1016/S0887-6177(98)00049-3	49	14	14	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1938-971X	1938-9728		PSYCHOL INJ LAW	Psychol. Inj. Law	MAR	2017	10	1					96	103		10.1007/s12207-017-9282-x			8	Psychology, Clinical	Psychology	FG6NF	WOS:000410497200004					2021-06-18	
J	Kelly, M; McDonald, S; Frith, MHJ				Kelly, Michelle; McDonald, Skye; Frith, Matthew H. J.			Assessment and Rehabilitation of Social Cognition Impairment after Brain Injury: Surveying Practices of Clinicians	BRAIN IMPAIRMENT			English	Article						Traumatic brain injury; survey; clinician; staff; social cognition; social function; assessment; assessment practices; evidence-based practice	SPEECH-LANGUAGE PATHOLOGISTS; BLUNT HEAD-INJURY; HIGH-FUNCTIONING AUTISM; EMOTION RECOGNITION; COMMUNICATION PARTNERS; INDIVIDUAL-DIFFERENCES; ASPERGER-SYNDROME; BEHAVIOR; ADULTS; VALIDITY	Objectives: This study examined the current assessment practices of clinicians working with people with social cognition impairment following traumatic brain injury. Method: Two hundred and sixty clinicians completed an on-line survey that was disseminated through professional brain injury organisations. Of respondents around 90% were allied health clinicians, with the remainder comprising medical, nursing and academia. Main outcomes: The four areas of social cognition that were routinely assessed across the disciplines were insight, disinhibition, anger and social adjustment. The least routinely assessed areas were theory of mind and alexithymia. The test suggested most likely to identify social cognition impairments was The Awareness of Social Inference Test, although only 8% of clinicians responded to this question. Clinicians preferred informal assessment methods over standardised assessment methods for identifying social cognition rehabilitation goals. Higher levels of education were associated with greater use of standardised assessment modalities. Whilst there was paucity of responses overall, TBI Express was most commonly used for social cognition rehabilitation. Conclusions: Considering the high prevalence of social cognition impairments in this population, formal assessment is extremely limited. The under-utilisation of assessment tools is problematic for the assessment and rehabilitation initiatives offered to people with TBI. These results have implications for the training of clinicians working in brain injury rehabilitation.	[Kelly, Michelle] Univ Newcastle, Sch Psychol, Univ Dr Callaghan, Newcastle, NSW 2308, Australia; [Kelly, Michelle; McDonald, Skye] Univ New South Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Kelly, Michelle; McDonald, Skye] Ctr Res Excellence Brain Recovery, Sydney, NSW 2052, Australia; [Kelly, Michelle; Frith, Matthew H. J.] Hunter New England Hlth, Children Young People & Families, Newcastle, NSW, Australia	Kelly, M (corresponding author), Univ Newcastle, Sch Psychol, Univ Dr Callaghan, Newcastle, NSW 2308, Australia.; Kelly, M (corresponding author), Univ New South Wales, Sch Psychol, Sydney, NSW 2052, Australia.; Kelly, M (corresponding author), Ctr Res Excellence Brain Recovery, Sydney, NSW 2052, Australia.; Kelly, M (corresponding author), Hunter New England Hlth, Children Young People & Families, Newcastle, NSW, Australia.	Michelle.Kelly@newcastle.edu.au	Kelly, Michelle/J-9739-2019	Kelly, Michelle/0000-0003-0375-816X	Lifetime Care and Support Authority	This research was funded by Lifetime Care and Support Authority.	Addis ME, 2002, CLIN PSYCHOL-SCI PR, V9, P367, DOI 10.1093/clipsy/9.4.367; Agresti A, 2013, CATEGORICAL DATA ANA; Alpern G., 2007, DEV PROFILE; Australasian Faculty of Rehabilitation Medicine, 2011, STAND PROV INP AD RE; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; Baron-Cohen S, 2004, J AUTISM DEV DISORD, V34, P163, DOI 10.1023/B:JADD.0000022607.19833.00; BaronCohen S, 1997, CHILD DEV, V68, P48; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; Bayley N., 2005, BAYLEY SCALES INFANT, VThird; Beidas RS, 2010, CLIN PSYCHOL-SCI PR, V17, P1, DOI 10.1111/j.1468-2850.2009.01187.x; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bishop DVM, 1998, J CHILD PSYCHOL PSYC, V39, P879, DOI 10.1111/1469-7610.00388; Bornhofen C, 2009, READING SMILE OTHER; Bowers D., 1991, FLORIDA AFFECT BATTE; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Carter A. S., 2006, INFANT TODDLER SOCIA; Cassel A, 2019, NEUROPSYCHOL REHABIL, V29, P22, DOI 10.1080/09602011.2016.1257435; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; CORCORAN R, 1995, SCHIZOPHR RES, V17, P5, DOI 10.1016/0920-9964(95)00024-G; Corrigan JD, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000020; D'Zurilla T., 2007, SOCIAL PROBLEM SOLVI; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; de Sousa A, 2012, J CLIN EXP NEUROPSYC, V34, P606, DOI 10.1080/13803395.2012.667067; Dodge KA, 2002, PSYCHOL ASSESSMENT, V14, P60, DOI 10.1037//1040-3590.14.1.60; DODGE KA, 1980, CHILD DEV, V51, P162, DOI 10.2307/1129603; DONAHOE CP, 1990, PSYCHIATRY, V53, P329; Douglas J, 2000, TROBE COMMUNICATION; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Dyck MJ, 2001, EUR CHILD ADOLES PSY, V10, P105, DOI 10.1007/s007870170033; Elliott S.N., 2008, SOCIAL SKILLS RATING; Embling S, 1995, BRIT J THERAPY REHAB, V2, P142; FARRELL AD, 1985, BEHAV ASSESS, V7, P155; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; Frith M, 2014, BRAIN INJURY, V28, P1657, DOI 10.3109/02699052.2014.947619; Gilliam J.E., 2013, GILLIAM AUTISM RATIN, V3rd; Gioa GA., 2000, BEHAV RATING INVENTO; Golan O, 2006, DEV PSYCHOPATHOL, V18, P591, DOI 10.1017/S0954579406060305; Goldstein S., 2009, AUTISM SPECTRUM RATI; Grace J., 2001, FRSBE FRONTAL SYSTEM; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Greenspan SI, 2004, GREENSPAN SOCIAL EMO; Gresham F. M., 1990, SOCIAL SKILLS RATING; Gresham F. M., 2008, SOCIAL SKILLS IMPROV; Guercio JM, 2004, BRAIN INJURY, V18, P593, DOI 10.1080/02699050310001646116; Holland A, 1999, COMMUNICATION ACTIVI; Howell D.C., 2007, STAT METHODS PSYCHOL, V6th ed.; HUGHES JN, 1989, J ABNORM CHILD PSYCH, V17, P633, DOI 10.1007/BF00917727; Hughes JN, 2004, J CLIN CHILD ADOLESC, V33, P292, DOI 10.1207/s15374424jccp3302_11; Hynes CA, 2011, SOC NEUROSCI-UK, V6, P599, DOI 10.1080/17470919.2011.584447; Jackson H.F., 1995, BRIT J THERAPY REHAB, V2, P65; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kamphaus R. W, 2008, BEHAV EMOTIONAL SCRE; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; Kelly A, 2016, TALKABOUT SOCIAL COM; Kelly G, 2010, OVERT BEHAV SCALE; Kelly M, 2017, J HEAD TRAUMA REHAB, V32, pE55, DOI 10.1097/HTR.0000000000000269; Korkman M., 2007, NEPSY; Linscott RJ, 2003, PROFILE PRAGMA UNPUB; Loeb P. A., 1996, INDEPENDENT LIVING S; Lord, 2003, SOCIAL COMMUNICATION; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Lord C., 2012, AUTISM DIAGNOSTIC 1; LOWE MR, 1985, BEHAV MODIF, V9, P193, DOI 10.1177/01454455850092004; MAGILLEVANS J, 1995, J NONVERBAL BEHAV, V19, P151, DOI 10.1007/BF02175502; Matsumoto D, 2000, J NONVERBAL BEHAV, V24, P179, DOI 10.1023/A:1006668120583; Matsumoto D., 1988, JAPANESE CAUCASIAN F; McDonald S, 2013, NEUROPSYCHOL REHABIL, V23, P267, DOI 10.1080/09602011.2012.751340; McDonald S., 2011, AWARENESS SOCIAL INF; McDonald S., 2013, SOCIAL COMMUNICATION, P119; McDonald S., 2008, IMPROVING 1 IMPRESSI; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P231, DOI 10.1017/S1355617712001506; McDonald S, 2009, NEUROPSYCHOL REHABIL, V19, P321, DOI 10.1080/09602010802193989; McGann W, 1997, BRAIN INJURY, V11, P621, DOI 10.1080/026990597123179; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Mehrabian A., 2000, MANUAL BALANCED EMOT; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; MunroeBlum H, 1996, SCHIZOPHR RES, V20, P211, DOI 10.1016/0920-9964(96)88527-6; National Institute of Health, 1999, JAMA; Nelson LD, 1998, ARCH CLIN NEUROPSYCH, V13, P549, DOI 10.1016/S0887-6177(97)00052-8; Neumann D, 2015, J HEAD TRAUMA REHAB, V30, pE12, DOI 10.1097/HTR.0000000000000054; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Newman AC, 2000, BRAIN INJURY, V14, P333; Nott MT, 2008, AUST OCCUP THER J, V55, P188, DOI 10.1111/j.1440-1630.2007.00685.x; NOWICKI S, 1994, J NONVERBAL BEHAV, V18, P9, DOI 10.1007/BF02169077; Osborne-Crowley K, 2016, J INT NEUROPSYCH SOC, V22, P303, DOI 10.1017/S1355617715001277; Pagan E, 2015, BRAIN IMPAIR, V16, P173, DOI 10.1017/BrImp.2015.34; PARKER JG, 1993, DEV PSYCHOL, V29, P611, DOI 10.1037/0012-1649.29.4.611; Radice-Neumann D, 2009, J HEAD TRAUMA REHAB, V24, P313, DOI 10.1097/HTR.0b013e3181b09160; Ratner NB, 2006, LANG SPEECH HEAR SER, V37, P257, DOI 10.1044/0161-1461(2006/029); Rust J. O., 2004, J PSYCHOEDUCATIONAL, V22, P367; Rutter M, 2003, COMMUNICATION; Sander AM, 2009, CLIN NEUROPSYCHOL, V23, P1196, DOI 10.1080/13854040902845706; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; SHARPE D, 2015, PRACT ASSESS RES EVA, V0020, P00002, DOI DOI 10.HTTP://PARE0NLINE.NET/GETVN.ASP?; Sherer M., 2004, The Awareness Questionnaire. The center for outcome measurement in brain injury; Sim P, 2013, BRAIN INJURY, V27, P717, DOI 10.3109/02699052.2013.775485; Sloane S, 2002, COMMUNICATE CONFIDEN; Sparrow S, 2005, VINELAND ADAPTIVE BE; Sparrow S.S., 2005, VINELAND SOCIAL EMOT; Spence S., 1995, SPENCE SOCIAL SKILLS; Spikman J.M., 2016, IBIA 11 WORLD C BRA; Starkstein SE, 2014, PSYCHIAT CLIN N AM, V37, P103, DOI 10.1016/j.psc.2013.10.002; STOIBER KC, 2004, FUNCTIONAL ASSESSMEN; Stone VE, 2003, NEUROPSYCHOLOGIA, V41, P209, DOI 10.1016/S0028-3932(02)00151-3; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Tate R., 2011, MANUAL SYDNEY PSYCHO; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Togher L., 2010, AUSTR COMMUNICATION, V12, P82; Togher L, 2013, J REHABIL MED, V45, P637, DOI 10.2340/16501977-1173; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; United States Surgeon General, 1999, MENT HLTH REP SURG G; Vorst HCM, 2001, PERS INDIV DIFFER, V30, P413, DOI 10.1016/S0191-8869(00)00033-7; Wechsler D., 2009, ADV CLIN SOLUTIONS W; WEISSMAN MM, 1976, ARCH GEN PSYCHIAT, V33, P1111; Wertheimer JC, 2008, J HEAD TRAUMA REHAB, V23, P273, DOI 10.1097/01.HTR.0000336840.76209.a1; Whitehouse A. J. O., 2009, COMMUNICATION CHECKL; Williams KR, 2001, BRAIN INJURY, V15, P349, DOI 10.1080/026990501750111319; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Winegardner J., 2015, INS ASSBI 5 PAC RIM; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P471, DOI 10.1017/S1355617707070518; Yates D, 1999, PRACTICE STAT; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104; YOUNG AW, 2002, FACIAL EXPRESSION EM	128	14	14	1	17	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1443-9646	1839-5252		BRAIN IMPAIR	Brain Impair.	MAR	2017	18	1					11	35		10.1017/BrImp.2016.34			25	Clinical Neurology; Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EQ3SZ	WOS:000397994400003		Bronze			2021-06-18	
J	Langdon, R; DiSabella, MT				Langdon, Raquel; DiSabella, Marc T.			Pediatric Headache: An Overview	CURRENT PROBLEMS IN PEDIATRIC AND ADOLESCENT HEALTH CARE			English	Article							IDIOPATHIC INTRACRANIAL HYPERTENSION; PSEUDOTUMOR CEREBRI SYNDROME; MEDICATION-OVERUSE HEADACHE; TRAUMATIC BRAIN-INJURY; QUALITY STANDARDS SUBCOMMITTEE; TENSION-TYPE HEADACHE; ACADEMY-OF-NEUROLOGY; POSTTRAUMATIC HEADACHES; DIAGNOSTIC-CRITERIA; DOUBLE-BLIND	Headache represents the most common neurologic disorder in the general population including children and is increasingly being recognized as a major source of morbidity in youth related to missed school days and activities. In this article, we take a holistic approach to the child presenting with headache with a focus on the detailed headache history, physical and neurologic examinations, and diagnostic evaluation of these patients. Clinical presentations and classification schema of multiple primary and secondary headache types in children are discussed using the International Headache Criteria (IHCD-3) as a guide, and a summary provided of the various treatment modalities employed for pediatric headache including lifestyle modifications, behavioral techniques, and abortive and preventive medications.	[Langdon, Raquel; DiSabella, Marc T.] Childrens Natl Med Ctr, Ctr Neurosci & Behav Hlth, Washington, DC 20010 USA	Langdon, R (corresponding author), Childrens Natl Med Ctr, Ctr Neurosci & Behav Hlth, Washington, DC 20010 USA.						Abend NS, 2010, SEMIN PEDIATR NEUROL, V17, P123, DOI 10.1016/j.spen.2010.04.001; Aitken LA, 2009, PEDIATR NEUROL, V40, P449, DOI 10.1016/j.pediatrneurol.2009.01.003; Arbogast KB, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0294; Arnautovic A, 2015, J NEUROSURG-PEDIATR, V15, P161, DOI 10.3171/2014.10.PEDS14295; Babcock L, 2012, ARCH PEDIAT ADOLESC, V167, P156; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Blume HK, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0516-x; Blume HK, 2012, PEDIATR REV, V33, P562, DOI 10.1542/pir.33-12-562; Boukje de Vries, 2015, CEPHALALGIA; Brousseau DC, 2004, ANN EMERG MED, V43, P256, DOI 10.1016/S0196-0644(03)00716-9; Cady RK, 2002, NEUROLOGY, V58, pS10, DOI 10.1212/WNL.58.9_suppl_6.S10; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Chiang CC, 2016, CEPHALALGIA, V36, P371, DOI 10.1177/0333102415593088; Condo M, 2009, J HEADACHE PAIN, V10, P361, DOI 10.1007/s10194-009-0142-2; Cuvellier JC, 2008, ARCH PEDIATRIE, V15, P1805, DOI 10.1016/j.arcped.2008.09.017; DiFazio M, 2015, CLIN PEDIAT PHILA; Dipasquale V, 2015, J PEDIATR NEUROL, V13, P58, DOI 10.1055/s-0035-1555157; Dooley JM, 2009, PAED CHILD HEALT-CAN, V14, P24, DOI 10.1093/pch/14.1.24; Fokoloros C, 2015, J PEDIATR NEUROL, V13, P16, DOI 10.1055/s-0035-1555147; Friedman DI, 2013, NEUROLOGY, V81, P1159, DOI 10.1212/WNL.0b013e3182a55f17; Friedman DI, 2004, J NEURO-OPHTHALMOL, V24, P138, DOI 10.1097/00041327-200406000-00009; Gallelli Luca, 2005, J Headache Pain, V6, P277, DOI 10.1007/s10194-005-0206-x; Gelfand AA, 2012, NEUROLOGY, V79, P1392, DOI 10.1212/WNL.0b013e31826c1b7b; Gini G, 2014, HEADACHE, V54, P976, DOI 10.1111/head.12344; Gioia GA, 2016, J CHILD NEUROL, V31, P93, DOI 10.1177/0883073814555604; Giza Christopher C, 2014, Continuum (Minneap Minn), V20, P1545, DOI 10.1212/01.CON.0000458975.78766.11; Goadsby PJ, 1997, NEUROL CLIN, V15, P27, DOI 10.1016/S0733-8619(05)70293-0; Goh KY, 1997, J NEURO-OPHTHALMOL, V17, P86; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Hamalainen ML, 1997, NEUROLOGY, V48, P103, DOI 10.1212/WNL.48.1.103; Hamel E, 1999, CAN J NEUROL SCI, V26, pS2; Hering-Hanit R, 2003, CEPHALALGIA, V23, P332, DOI 10.1046/j.1468-2982.2003.00576.x; Hershey AD, 2001, NEUROLOGY, V57, P2034, DOI 10.1212/WNL.57.11.2034; Hershey AD, 2005, HEADACHE, V45, P1288, DOI 10.1111/j.1526-4610.2005.00260.x; Hershey AD, 2000, HEADACHE, V40, P539, DOI 10.1046/j.1526-4610.2000.00085.x; Hershey AD, 2014, SINUS HEADACHE NASAL, P172; Hershey AD, 2013, HEADACHE, V53, P799, DOI 10.1111/head.12105; Heyer GL, 2014, PEDIATR NEUROL, V50, P464, DOI 10.1016/j.pediatrneurol.2014.01.040; Hirshkowitz M, 2015, SLEEP HEALTH, V1, P40, DOI 10.1016/j.sleh.2014.12.010; Holroyd KA, 2006, SEMIN NEUROL, V26, P199, DOI 10.1055/s-2006-939920; Jensen R, 1999, CEPHALALGIA, V19, P602, DOI 10.1046/j.1468-2982.1999.019006602.x; Johnson KJ, 2014, CANCER EPIDEM BIOMAR, V23, P2716, DOI 10.1158/1055-9965.EPI-14-0207; Kabbouche MA, 2009, DIAGNOSTIC TESTING C; Kacperski J, 2016, HEADACHE, V56, P36, DOI 10.1111/head.12737; Kesler A, 2002, J CHILD NEUROL, V17, P745, DOI 10.1177/08830738020170101401; Kirkwood MW, 2012, NEUROPSYCHOLOGY, V26, P304; Klapper J, 2001, HEADACHE, V41, P981, DOI 10.1046/j.1526-4610.2001.01192.x; Kristoffersen ES, 2014, J PAIN RES, V7, P367, DOI 10.2147/JPR.S46071; Kroner-Herwig B, 2012, HEADACHE, V52, P1387, DOI 10.1111/j.1526-4610.2012.02210.x; Kroner-Herwig B, 2010, EUR J PAIN, V14, P951, DOI 10.1016/j.ejpain.2010.02.010; Krogh AB, 2015, CEPHALALGIA; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Kutcher Jeffrey S, 2014, Continuum (Minneap Minn), V20, P1552, DOI 10.1212/01.CON.0000458974.78766.58; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lee MJ, 2016, J HEADACHE PAIN, V17, DOI [10.1186/s10194-016-0662-5, 10.1186/s10194-016-0615-z]; Lewis D, 2004, NEUROLOGY, V63, P2215, DOI 10.1212/01.WNL.0000147332.41993.90; Lewis DW, 2009, NEUROL CLIN, V27, P481, DOI 10.1016/j.ncl.2008.11.003; Lewis DW, 2002, NEUROLOGY, V59, P490, DOI 10.1212/WNL.59.4.490; Lim M, 2005, ARCH DIS CHILD, V90, P206, DOI 10.1136/adc.2003.039305; Limbrick DD, 2014, J NEUROSURG-PEDIATR, V14, P30, DOI 10.3171/2014.7.PEDS14324; Linder SL, 2005, PEDIATR ANN, V34, P442, DOI 10.3928/0090-4481-20050601-08; Lipton R. B., 2015, NEUROLOGY, V21, P1118, DOI [10.1212/CON.000000000000021626252595, DOI 10.1212/CON.0000000000000216]; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McVige JW, 2014, NEUROL CLIN, V32, P95, DOI 10.1016/j.ncl.2013.07.002; Medina LS, 1997, RADIOLOGY, V202, P819, DOI 10.1148/radiology.202.3.9051039; Mokri Bahram, 2015, Continuum (Minneap Minn), V21, P1086, DOI 10.1212/CON.0000000000000193; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; OLESEN J, 1990, ANN NEUROL, V28, P791, DOI 10.1002/ana.410280610; Orr SL, 2014, CEPHALALGIA, V34, P568, DOI 10.1177/0333102413519512; Pacheva I, 2012, INT J CLIN PRACT, V66, P1168, DOI 10.1111/ijcp.12024; Papetti L, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0480-5; Persico AM, 2015, NEUROGENETICS, V16, P77, DOI 10.1007/s10048-014-0433-x; Piazza F, 2012, HEADACHE, V52, P1506, DOI 10.1111/j.1526-4610.2012.02221.x; Pinchefsky E, 2015, PEDIATR NEUROL, V52, P263, DOI 10.1016/j.pediatrneurol.2014.10.013; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Reiter PD, 2005, HEADACHE, V45, P899, DOI 10.1111/j.1526-4610.2005.05158.x; Rogers DL, 2014, PEDIATR CLIN N AM, V61, P579, DOI 10.1016/j.pcl.2014.03.004; Romanello S, 2013, JAMA-J AM MED ASSOC, V309, P1607, DOI 10.1001/jama.2013.747; Schobitz Erik, 2006, Curr Pain Headache Rep, V10, P391, DOI 10.1007/s11916-006-0066-3; Schwedt TJ, 2006, HEADACHE, V46, P387, DOI 10.1111/j.1526-4610.2006.00371.x; Schwedt Todd J, 2015, Continuum (Minneap Minn), V21, P1058, DOI 10.1212/CON.0000000000000201; Seeger TA, 2015, J CHILD NEUROL, V30, P1142, DOI 10.1177/0883073814553973; Serdaroglu G, 2002, HEADACHE, V42, P819, DOI 10.1046/j.1526-4610.2002.02186.x; Sheldon CA, 2015, J PEDIATR NEUROL, V13, P8, DOI 10.1055/s-0035-1555145; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Soiberman U, 2011, CHILD NERV SYST, V27, P1913, DOI 10.1007/s00381-011-1470-5; Stafstrom CE, 2002, PEDIATRICS, V109, P460, DOI 10.1542/peds.109.3.460; Standridge SM, 2010, PEDIATR NEUROL, V43, P377, DOI 10.1016/j.pediatrneurol.2010.08.001; Straube A, 2013, DTSCH ARZTEBL INT, V110, P811, DOI 10.3238/arztebl.2013.0811; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; Vinchon M, 2012, FLUIDS BARRIERS CNS, V9, DOI 10.1186/2045-8118-9-18; Watanabe TK, 2012, PM&R, V4, P129, DOI 10.1016/j.pmrj.2011.06.003; Wilson Maria-Carmen B, 2006, Curr Pain Headache Rep, V10, P387, DOI 10.1007/s11916-006-0065-4; Winner P, 2005, HEADACHE, V45, P1304, DOI 10.1111/j.1526-4610.2005.00262.x; Wu YW, 1999, NEUROLOGY, V53, P1271, DOI 10.1212/WNL.53.6.1271	99	14	14	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1538-5442	1538-3199		CURR PROB PEDIATR AD	Curr. Probl. Pediatr. Adolesc. Health Care	MAR	2017	47	3					44	65		10.1016/j.cppeds.2017.01.002			22	Pediatrics	Pediatrics	ER8JI	WOS:000399065400002	28366491				2021-06-18	
J	Li, G; Ma, K; Sun, J; Jin, G; Qin, MX; Feng, H				Li, Gen; Ma, Ke; Sun, Jian; Jin, Gui; Qin, Mingxin; Feng, Hua			Twenty-Four-Hour Real-Time Continuous Monitoring of Cerebral Edema in Rabbits Based on a Noninvasive and Noncontact System of Magnetic Induction	SENSORS			English	Article						cerebral edema; noncontact; magnetic induction; intracranial pressure; real-time monitoring	TRAUMATIC BRAIN-INJURY; INTRACRANIAL-PRESSURE; PHASE-SHIFT; HEMORRHAGE; TOMOGRAPHY; RATS; SPECTROSCOPY; ISCHEMIA; TISSUE	Cerebral edema is a common disease, secondary to craniocerebral injury, and real-time continuous monitoring of cerebral edema is crucial for treating patients after traumatic brain injury. This work established a noninvasive and noncontact system by monitoring the magnetic induction phase shift (MIPS) which is associated with brain tissue conductivity. Sixteen rabbits (experimental group n = 10, control group, n = 6) were used to perform a 24 h MIPS and intracranial pressure (ICP) simultaneously monitored experimental study. For the experimental group, after the establishment of epidural freeze-induced cerebral edema models, the MIPS presented a downward trend within 24 h, with a change magnitude of -13.1121 +/- 2.3953 degrees; the ICP presented an upward trend within 24 h, with a change magnitude of 12-41 mmHg. The ICP was negatively correlated with the MIPS. In the control group, the MIPS change amplitude was -0.87795 +/- 1.5146 without obvious changes; the ICP fluctuated only slightly at the initial value of 12 mmHg. MIPS had a more sensitive performance than ICP in the early stage of cerebral edema. These results showed that this system is basically capable of monitoring gradual increases in the cerebral edema solution volume. To some extent, the MIPS has the potential to reflect the ICP changes.	[Li, Gen; Ma, Ke; Sun, Jian; Jin, Gui; Qin, Mingxin] Third Mil Med Univ, Coll Biomed Engn, Chongqing 400038, Peoples R China; [Li, Gen] Chongqing Univ, Coll Bioengn, Chongqing 400030, Peoples R China; [Sun, Jian; Feng, Hua] Southwest Hosp, Dept Neurosurg, Chongqing 400038, Peoples R China	Sun, J; Qin, MX (corresponding author), Third Mil Med Univ, Coll Biomed Engn, Chongqing 400038, Peoples R China.; Sun, J (corresponding author), Southwest Hosp, Dept Neurosurg, Chongqing 400038, Peoples R China.	calvin_gen@163.com; ywqmk@sohu.com; nksunj@126.com; tjjingui@126.com; qmingxin@tmmu.edu.cn; fenghua_swh@sina.com			973 National Key Basic Research Program of ChinaNational Basic Research Program of China [2014cb541606]; Foundation of the Third Military Medical University [2014XZH03]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [61372065, 61501472, 51607181]	This work was supported by the 973 National Key Basic Research Program of China (2014cb541606), the Foundation of the Third Military Medical University (2014XZH03) and the National Natural Science Foundation of China (61372065, 61501472 and 51607181). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barai A, 2012, MEAS SCI TECHNOL, V23, DOI 10.1088/0957-0233/23/8/085501; Bigdeli MR, 2007, BRAIN RES, V1152, P228, DOI 10.1016/j.brainres.2007.03.068; Blixt J, 2015, BRAIN RES, V1611, P18, DOI 10.1016/j.brainres.2015.03.004; Chen S., 2008, CHIN J NEUROSURG DIS, V7, P725; Gonzalez CA, 2009, PHYSIOL MEAS, V30, P809, DOI 10.1088/0967-3334/30/8/006; Gonzalez CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063223; Griffiths H, 2001, MEAS SCI TECHNOL, V12, P1126, DOI 10.1088/0957-0233/12/8/319; Griffiths H, 1999, ANN NY ACAD SCI, V873, P335, DOI 10.1111/j.1749-6632.1999.tb09481.x; Heiss WD, 2016, CEREBROVASC DIS, V41, P1, DOI 10.1159/000441627; Horstmann S, 2009, J NEUROL SCI, V276, P75, DOI 10.1016/j.jns.2008.08.038; Huang YC, 2013, MAGN RESON IMAGING, V31, P1174, DOI 10.1016/j.mri.2013.03.026; Jin G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097179; Jin G, 2014, BIOSENS BIOELECTRON, V52, P374, DOI 10.1016/j.bios.2013.09.019; Kao HP, 1999, IEEE T BIO-MED ENG, V46, P1121, DOI 10.1109/10.784144; Kawai N, 2003, J NEUROTRAUM, V20, P649, DOI 10.1089/089771503322144563; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Laufer S., 2015, PHYSIOL MEAS, V33, P997, DOI [10.1088/0967-3334/33/6/99722561199, DOI 10.1088/0967-3334/33/6/99722561199]; Liu L., 2013, NEUROL RES, V28, P31, DOI [10.1179/016164106X9184316464360, DOI 10.1179/016164106X9184316464360]; Maciel CB, 2015, CURR ATHEROSCLER REP, V17, DOI 10.1007/s11883-015-0519-4; McBride DW, 2014, J NEUROTRAUM, V31, P1948, DOI 10.1089/neu.2014.3439; Melhem S., 2012, NEW ENGL J MED, V367, P2471, DOI [10.1186/cc13713, DOI 10.1186/CC13713]; O'Toole MD, 2015, MEAS SCI TECHNOL, V26, DOI 10.1088/0957-0233/26/3/035102; Pan WC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128127; Park KJ, 2010, J NEUROSURG, V112, P73, DOI 10.3171/2009.4.JNS09158; Rolland WB, 2013, EXP NEUROL, V241, P45, DOI 10.1016/j.expneurol.2012.12.009; Salci K, 2004, J NEUROTRAUM, V21, P317, DOI 10.1089/089771504322972103; Scharfetter H, 2003, IEEE T BIO-MED ENG, V50, P870, DOI 10.1109/TBME.2003.813533; Stocchetti N, 2014, ACTA NEUROCHIR, V156, P1615, DOI 10.1007/s00701-014-2127-4; Sun J, 2014, BRAZ J MED BIOL RES, V47, P144, DOI 10.1590/1414-431X20132978; Sun J, 2012, J PHYS CONF SER, V407, DOI 10.1088/1742-6596/407/1/012014; Thal SC, 2009, J NEUROSURG, V111, P988, DOI 10.3171/2009.3.JNS08412; Thrane AS, 2015, TRENDS NEUROSCI, V38, P333, DOI 10.1016/j.tins.2015.04.009; Wijdicks EFM, 2014, STROKE, V45, P1222, DOI 10.1161/01.str.0000441965.15164.d6; Wykes V., 2015, SURG OXFORD, V33, P355, DOI [10.1016/j.mpsur.2015.06.001, DOI 10.1016/J.MPSUR.2015.06.001]; Yan Q., 2016, BIOMED ENG, V62, P23, DOI [10.1515/bmt-2015-012926982603, DOI 10.1515/BMT-2015-012926982603]; Zolgharni M, 2009, PHYSIOL MEAS, V30, pS187, DOI 10.1088/0967-3334/30/6/S13	36	14	15	0	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		1424-8220		SENSORS-BASEL	Sensors	MAR	2017	17	3							537	10.3390/s17030537			12	Chemistry, Analytical; Engineering, Electrical & Electronic; Instruments & Instrumentation	Chemistry; Engineering; Instruments & Instrumentation	ER5CJ	WOS:000398818700110	28282851	DOAJ Gold, Green Published			2021-06-18	
J	Merritt, VC; Meyer, JE; Cadden, MH; Roman, CAF; Ukueberuwa, DM; Shapiro, MD; Arnett, PA				Merritt, Victoria C.; Meyer, Jessica E.; Cadden, Margaret H.; Roman, Cristina A. F.; Ukueberuwa, Dede M.; Shapiro, Michael D.; Arnett, Peter A.			Normative Data for a Comprehensive Neuropsychological Test Battery used in the Assessment of Sports-Related Concussion	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Assessment; Head injury; Traumatic brain injury; Norms/normative studies	TEST-RETEST RELIABILITY; TRAUMATIC BRAIN-INJURY; PROFESSIONAL ICE HOCKEY; VERBAL-LEARNING TEST; HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; SEX-DIFFERENCES; IMPACT; SYMPTOMS; VALIDITY	Objective: The use of normative data is a hallmark of the neuropsychological assessment process. Within the context of sports-related concussion, utilizing normative data is especially essential when individualized baseline data are unavailable for comparison. The primary purpose of this study was to establish normative data for a comprehensive neuropsychological test battery used in the assessment of sports-related concussion. A secondary aim was to provide normative data for pertinent demographic variables relevant to the assessment of college athletes, including sex, previous head injuries (PHI), and history of attention deficit hyperactivity disorder (ADHD)/learning disability (LD). Method: Participants included male and female college athletes (N = 794) who were involved in a concussion management program at an NCAA Division I university between 2002 and 2015. Athletes were administered a comprehensive neuropsychological test battery at baseline designed to assess the following cognitive domains: learning and memory, attention and concentration, processing speed, and executive functioning. The test battery primarily comprises paper-and-pencil measures. Results: Normative data are presented for the overall athlete sample. Additional sub-norms are then provided for specified demographic populations (i.e., sex, PHIs, and history of ADHD/LD). Findings indicate that there are mild cognitive differences between men and women, as well as between those athletes with and without a history of ADHD/LD. Given these findings, additional norms are provided for men and women with and without a history of ADHD/LD. Conclusions: In the absence of baseline testing, the normative data presented here can be used clinically to assess athletes' cognitive functioning post-concussion.	[Merritt, Victoria C.; Meyer, Jessica E.; Cadden, Margaret H.; Roman, Cristina A. F.; Ukueberuwa, Dede M.; Shapiro, Michael D.; Arnett, Peter A.] Penn State Univ, Dept Psychol, 372 Moore Bldg, University Pk, PA 16802 USA	Merritt, VC (corresponding author), Penn State Univ, Dept Psychol, 372 Moore Bldg, University Pk, PA 16802 USA.	vcabarnes@gmail.com		Merritt, Victoria/0000-0001-5683-4168	Wayne Sebastianelli and Penn State Sports Medicine	The authors would like to thank Wayne Sebastianelli and Penn State Sports Medicine for their generous support of our research. We would also like to thank Gray Vargas, Amanda Rabinowitz, Fiona Barwick, Aaron Rosenbaum, and Chris Bailey for their help as project coordinators of the program over the years.	Arnett P., 2014, CONCUSSION ATHLETICS, P35; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barth JT, 1989, MILD HEAD INJURY SPO; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Benedict RHB, 1996, PSYCHOL ASSESSMENT, V8, P145, DOI 10.1037/1040-3590.8.2.145; Brandt J., 2001, HOPKINS VERBAL LEARN; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Bruce J, 2016, APPL NEUROPSYCH-ADUL, V23, P336, DOI 10.1080/23279095.2015.1064002; Bruce J, 2014, CLIN NEUROPSYCHOL, V28, P14, DOI 10.1080/13854046.2013.866272; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; Cegalis J.A., 1994, VIGIL W CONTINUOUS P; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Conder RL, 2015, APPL NEUROPSYCH-CHIL, V4, P141, DOI 10.1080/21622965.2013.816849; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Crawford JR, 1998, J CLIN EXP NEUROPSYC, V20, P755, DOI 10.1076/jcen.20.5.755.1132; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Echemendia RJ, 2016, CLIN NEUROPSYCHOL, V30, P311, DOI 10.1080/13854046.2016.1158320; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Gray R., 2006, J PSYCHOEDUCATIONAL, V24, P88; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; IBM Corp, 2015, IBM SPSS STAT WIND V; ImPACT Applications Inc., 2012, IMPACT TEST TECHN MA; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Lovell MR., 2000, IMPACT IMMEDIATE POS; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meyer J. E., 2016, CLIN SENSITIVI UNPUB; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Nelson LD, 2015, AM J SPORT MED, V43, P2018, DOI 10.1177/0363546515587714; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Rabinowitz AR, 2012, J INT NEUROPSYCH SOC, V18, P139, DOI 10.1017/S1355617711001275; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Rao S., 1990, MANUAL BRIEF REPEATA; Reynolds C.R., 2002, COMPREHENSIVE TRAIL; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749; Smith A., 1991, SYMBOL DIGIT MODALIT; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; The Psychological Corporation, 1997, WAIS 3 WMS 3 TECHNIC; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Tsushima WT, 2016, ARCH CLIN NEUROPSYCH, V31, P105, DOI 10.1093/arclin/acv066; Wechsler D, 1997, WAIS 3 ADM SCORING M; Zuckerman SL, 2013, J NEUROSURG-PEDIATR, V12, P103, DOI 10.3171/2013.5.PEDS12524	58	14	16	0	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2017	32	2					168	183		10.1093/arclin/acw090			16	Psychology, Clinical; Psychology	Psychology	EQ4EG	WOS:000398026400004	28365744	Bronze			2021-06-18	
J	Ramirez, S; Bebarta, VS; Varney, SM; Ganem, V; Zarzabal, LA; Potter, JS				Ramirez, Sasha; Bebarta, Vikhyat S.; Varney, Shawn M.; Ganem, Victoria; Zarzabal, Lee A.; Potter, Jennifer S.			Misuse of Prescribed Pain Medication in a Military Population-A Self-Reported Survey to Assess a Correlation With Age, Deployment, Combat Illnesses, or Injury?	AMERICAN JOURNAL OF THERAPEUTICS			English	Article						military; army; opioid misuse; emergency department; toxicology; opioid abuse	PERSONNEL; IRAQ; CONSEQUENCES; AFGHANISTAN; BEHAVIORS; OPIOIDS; ABUSE	Opioid misuse is a growing epidemic among the civilian and military communities. Five hundred prospective, anonymous surveys were collected in the emergency department waiting room of a military tertiary care hospital over 3 weeks. Demographics, medical and military characteristics were investigated for association with opioid use. Univariate logistic models were used to characterize the probability of misuse in relation to the demographic, medical, and military-specific variables. Traumatic brain injury (TBI) and posttraumatic stress disorder were investigated within different age cohorts with adjustment for deployment. The opioid misuse rate disclosed by the subject was 31%. Subjects with TBI were less likely to misuse opioids. We found a trend among younger cohorts to have a higher likelihood for misusing opioids when diagnosed with TBI or posttraumatic stress disorder with history of deployment in the past 5 years. The most common form of misuse was using a previously prescribed medication for a new pain. Traumatic brain injury and/ or enrollment in post-deployment recovery programs maybe protective against opioid misuse. Chronic opioid use among young soldiers maybe viewed as a weakness that could influence opioid misuse. Younger cohorts of active duty service members could be at higher risk for misuse. Efforts to enhance close monitoring of misuse should address these at- risk populations.	[Ramirez, Sasha] San Antonio Mil Med Ctr, Emergency Med, SAUSHEC, San Antonio, TX USA; [Bebarta, Vikhyat S.; Ganem, Victoria; Zarzabal, Lee A.] US Air Force, Enroute Care Res Ctr, San Antonio Mil Med Ctr, San Antonio, TX USA; [Bebarta, Vikhyat S.] Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO 80045 USA; [Varney, Shawn M.] San Antonio Mil Med Ctr, Dept Emergency Med, San Antonio, TX USA; [Potter, Jennifer S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Anesthesiol, Dept Psychiat, Res Program, San Antonio, TX 78229 USA; [Potter, Jennifer S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Anesthesiol, Dept Psychiat, Student Program, San Antonio, TX 78229 USA	Bebarta, VS (corresponding author), Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO 80045 USA.	Vikhyat.Bebarta@ucdenver.edu	Bebarta, Vikhyat S/M-1513-2015; Potter, Jennifer Sharpe/C-6720-2008	Potter, Jennifer Sharpe/0000-0002-7250-4422	NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [U10DA020024] Funding Source: NIH RePORTER		Adams LL, 2004, J PAIN SYMPTOM MANAG, V27, P440, DOI 10.1016/j.jpainsymman.2003.10.009; Assistant Secretary of Defense (Health Affairs), 2006, DEP DEF SURV HLTH RE; Bebarta VS, 2012, N AM C CLIN TOX OCT; Bray RM, 2010, MIL MED, V175, P390, DOI 10.7205/MILMED-D-09-00132; Centers for Disease Control and Prevention (CDC), 2012, MMWR MORB MORTAL WKL, V61, P10; Chou R, 2009, J PAIN, V10, P131, DOI 10.1016/j.jpain.2008.10.009; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Golub A, 2013, SUBST USE MISUSE, V48, P811, DOI 10.3109/10826084.2013.796988; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Jeffery DD, 2013, MIL MED, V178, P180, DOI 10.7205/MILMED-D-12-00192; Levy BS, 2013, LANCET, V381, P949, DOI 10.1016/S0140-6736(13)60254-8; Office of the Army Surgeon General, 2010, PAIN MAN TASK FORC F; Seal KH, 2012, JAMA-J AM MED ASSOC, V307, P940, DOI 10.1001/jama.2012.234; Substance Abuse and Mental Health Services Administration, 2012, SURV NAT DRUG US HLT; Volkow ND, 2011, JAMA-J AM MED ASSOC, V305, P1346, DOI 10.1001/jama.2011.369; Volkow ND, 2011, JAMA-J AM MED ASSOC, V305, P1299, DOI 10.1001/jama.2011.401	16	14	14	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1075-2765	1536-3686		AM J THER	Am. J. Ther.	MAR-APR	2017	24	2					E150	E156		10.1097/MJT.0000000000000141			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	EP8LJ	WOS:000397626600007	26963723				2021-06-18	
J	Ray, B; Richardson, NJ				Ray, Bradley; Richardson, Nicholas J.			TRAUMATIC BRAIN INJURY AND RECIDIVISM AMONG RETURNING INMATES	CRIMINAL JUSTICE AND BEHAVIOR			English	Article						recidivism; traumatic brain injury; mental illness; returning inmate; TBI	TBI IDENTIFICATION METHOD; FRONTAL-LOBE INJURIES; HEAD-INJURY; PSYCHIATRIC-DISORDERS; SUBSTANCE-ABUSE; MENTAL-ILLNESS; NEIGHBORHOOD CONTEXT; VIOLENT BEHAVIOR; NORTHERN FINLAND; DECISION-MAKING	In recent years, there has been a surge in research that examines the relationship between traumatic brain injury (TBI) and involvement in the criminal justice system. However, the bulk of this research has been largely retrospective and descriptive, comparing rates of TBI in the offending population with the rates of TBI in the general population. Although findings from these studies indicate a higher prevalence of TBI in the offending population, virtually no studies have examined whether those with TBI are more likely to recidivate. To address this gap, the present study examined rearrest post release from prison among a cohort sample of Indiana inmates who were screened using the Ohio State University Traumatic Brain Injury Identification (OSU-TBI-ID) instrument. Findings indicate that, net of control variables, those with TBI were more likely to recidivate sooner than those without TBI. Policy implications and directions for future research are discussed.	[Ray, Bradley] Indiana Univ Purdue Univ, Sch Publ & Environm Affairs, Business SPEA Bldg,801 West Michigan St, Indianapolis, IN 46202 USA; [Richardson, Nicholas J.] RTI Int, Res Triangle Pk, NC USA	Ray, B (corresponding author), Indiana Univ Purdue Univ, Sch Publ & Environm Affairs, Business SPEA Bldg,801 West Michigan St, Indianapolis, IN 46202 USA.	bradray@iupui.edu		Richardson, Nicholas/0000-0001-8378-4557			BARKLEY RA, 1992, J ABNORM CHILD PSYCH, V20, P163, DOI 10.1007/BF00916547; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Bechara A, 2005, CURR OPIN NEUROL, V18, P734, DOI 10.1097/01.wco.0000194141.56429.3c; Beck, 1989, RECIDIVISM PRISONERS; BLAKE PY, 1995, NEUROLOGY, V45, P1641, DOI 10.1212/WNL.45.9.1641; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Box-Steffensmeier J., 2004, EVENT HIST MODELING; Bufkin JL, 2005, TRAUMA VIOLENCE ABUS, V6, P176, DOI 10.1177/1524838005275089; Chayer C, 2001, Curr Neurol Neurosci Rep, V1, P547, DOI 10.1007/s11910-001-0060-4; Cole WR, 2008, BRAIN INJURY, V22, P932, DOI 10.1080/02699050802454808; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Corrigan JD, 2012, BRAIN INJURY, V26, P139, DOI 10.3109/02699052.2011.648705; DelBello MP, 1999, PSYCHIAT RES, V89, P281, DOI 10.1016/S0165-1781(99)00112-2; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Dinn WM, 2009, CRIM JUSTICE BEHAV, V36, P117, DOI 10.1177/0093854808327507; Eghwrudjakpor PO, 2008, LIBYAN J MED, V3, P192, DOI 10.4176/080908; Fabian JM, 2010, AGGRESS VIOLENT BEH, V15, P209, DOI 10.1016/j.avb.2009.12.004; Farrer TJ, 2013, CHILD NEUROPSYCHOL, V19, P225, DOI 10.1080/09297049.2011.647901; Farrer TJ, 2011, PROG NEURO-PSYCHOPH, V35, P390, DOI 10.1016/j.pnpbp.2011.01.007; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fazel S, 2002, LANCET, V359, P545, DOI 10.1016/S0140-6736(02)07740-1; Fazel S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001150; Fellows LK, 2006, BRAIN, V129, P944, DOI 10.1093/brain/awl017; Ferguson PL, 2012, J HEAD TRAUMA REHAB, V27, pE11, DOI 10.1097/HTR.0b013e31824e5f47; Fisher WH, 2014, CRIME DELINQUENCY, V60, P811, DOI 10.1177/0011128714541204; Freedman D, 2000, SOC SCI MED, V50, P1757, DOI 10.1016/S0277-9536(99)00417-7; Frost RB, 2013, NEUROEPIDEMIOLOGY, V40, P154, DOI 10.1159/000343275; Gendreau P, 1996, CRIMINOLOGY, V34, P575, DOI 10.1111/j.1745-9125.1996.tb01220.x; Gerring JP, 2009, BRAIN INJURY, V23, P944, DOI 10.3109/02699050903285531; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Gottfredson M.R., 1990, GEN THEORY CRIME, DOI DOI 10.2307/1964276; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Hartwell SW, 2004, PSYCHIAT SERV, V55, P145, DOI 10.1176/appi.ps.55.2.145; Hawley CA, 2003, BRAIN INJURY, V17, P743, DOI 10.1080/0269905031000089341; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hirschi T., 1969, CAUSES DELINQUENCY; Huebner BM, 2011, JUSTICE Q, V28, P146, DOI 10.1080/07418820903365213; Ilie G, 2013, JAMA-J AM MED ASSOC, V309, P2550, DOI 10.1001/jama.2013.6750; Kaufman JM, 2005, JUSTICE Q, V22, P224, DOI 10.1080/07418820500088986; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Koponen S, 2005, EUR PSYCHIAT, V20, pS203; Kubrin CE, 2006, CRIMINOLOGY, V44, P165, DOI 10.1111/j.1745-9125.2006.00046.x; Kurlychek MC, 2007, CRIME DELINQUENCY, V53, P64, DOI 10.1177/0011128706294439; Langan P. A., 2002, RECIDIVISM PRISONERS; Langevin R, 2006, BRAIN COGNITION, V60, P206; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; Luukkainen S, 2012, PSYCHIAT RES, V200, P767, DOI 10.1016/j.psychres.2012.04.018; Martell D. A., 1996, EXPLORATIONS CRIMINA, P66; MARTELL DA, 1992, J FORENSIC SCI, V37, P878; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; National Data and Statistical Center, 2016, TRAUM BRAIN INJ MOD; National Institute of Neurological Disorders and Stroke Common Data Elements, 2016, COMM DAT EL; Pardini M, 2011, NEUROLOGY, V76, P1038, DOI 10.1212/WNL.0b013e318211c33e; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243, DOI 10.1002/cbm.702; Pickelsimer E. E., 2014, INT J OFFENDER THER, V60, P65; Raine A, 2002, J ABNORM CHILD PSYCH, V30, P311, DOI 10.1023/A:1015754122318; Raine A., 2014, ANATOMY VIOLENCE BIO; RANTAKALLIO P, 1992, ARCH DIS CHILD, V67, P1459, DOI 10.1136/adc.67.12.1459; Ray B, 2014, J FORENSIC SCI, V59, P1248, DOI 10.1111/1556-4029.12466; Reisig MD, 2007, JUSTICE Q, V24, P408, DOI 10.1080/07418820701485387; Sacks AL, 2009, J DUAL DIAGN, V5, P404, DOI 10.1080/15504260903182755; Sampson R. J., 1993, CRIME MAKING PATHWAY; Shiroma EJ, 2012, J HEAD TRAUMA REHAB, V27, pE1, DOI 10.1097/HTR.0b013e3182571c14; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Steadman HJ, 2009, PSYCHIAT SERV, V60, P761, DOI 10.1176/ps.2009.60.6.761; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; Ulmer JT, 2001, SOCIOL INQ, V71, P164, DOI 10.1111/j.1475-682X.2001.tb01107.x; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Vickery CD, 2008, ARCH PHYS MED REHAB, V89, P48, DOI 10.1016/j.apmr.2007.07.047; Visher CA, 2003, ANNU REV SOCIOL, V29, P89, DOI 10.1146/annurev.soc.29.010202.095931; Walker R, 2003, J PSYCHOACTIVE DRUGS, V35, P343, DOI 10.1080/02791072.2003.10400017; Walker R, 2001, SUBST USE MISUSE, V36, P757, DOI 10.1081/JA-100104089; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613	80	14	14	0	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0093-8548	1552-3594		CRIM JUSTICE BEHAV	Crim. Justice Behav.	MAR	2017	44	3					472	486		10.1177/0093854816686631			15	Psychology, Clinical; Criminology & Penology	Psychology; Criminology & Penology	EL7GV	WOS:000394790000008					2021-06-18	
J	Dretsch, MN; Silverberg, N; Gardner, AJ; Panenka, WJ; Emmerich, T; Crynen, G; Ait-Ghezala, G; Chaytow, H; Mathura, V; Crawford, FC; Iverson, GL				Dretsch, Michael N.; Silverberg, Noah; Gardner, Andrew J.; Panenka, William J.; Emmerich, Tanja; Crynen, Gogce; Ait-Ghezala, Ghania; Chaytow, Helena; Mathura, Venkat; Crawford, Fiona C.; Iverson, Grant L.			Genetics and Other Risk Factors for Past Concussions in Active-Duty Soldiers	JOURNAL OF NEUROTRAUMA			English	Article						APOE; BDNF; concussion; DRD2; genetics; mild traumatic brain injury; military; personality	TRAUMATIC BRAIN-INJURY; NEUROTROPHIC FACTOR; APOE PROMOTER; PSYCHIATRIC-DISORDERS; AGGRESSIVE-BEHAVIOR; META-REGRESSION; SPONTANEOUS SAH; HEAD-INJURY; ALCOHOL-USE; ASSOCIATION	Risk factors for concussion in active-duty military service members are poorly understood. The present study examined the association between self-reported concussion history and genetics (apolipoprotein E [APOE], brain-derived neurotrophic factor [BDNF], and D2 dopamine receptor genes [DRD2]), trait personality measures (impulsive-sensation seeking and trait aggression-hostility), and current alcohol use. The sample included 458 soldiers who were preparing to deploy for Operation Iraqi Freedom/Operation Enduring Freedom. For those with the BDNFMet/Met genotype, 57.9% (11/19) had a history of one or more prior concussions, compared with 35.6% (154/432) of those with other BDNF genotypes (p = 0.049, odds ratio [OR] = 2.48). APOE and DRD2 genotypes were not associated with risk for past concussions. Those with the BDNF Met/Met genotype also reported greater aggression and hostility personality characteristics. When combined in a predictive model, prior military deployments, being male, and having the BDNF Met/Met genotype were independently associated with increased lifetime history of concussions in active-duty soldiers. Replication in larger independent samples is necessary to have more confidence in both the positive and negative genetic associations reported in this study.	[Dretsch, Michael N.] US Army Aeromed Res Lab, Ft Rucker, AL USA; [Dretsch, Michael N.] Headquarters Army Training & Doctrine Command HQ, Human Dimens Div, Ft Eustis, VA USA; [Silverberg, Noah] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC, Canada; [Panenka, William J.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Silverberg, Noah] GF Strong Rehabil Ctr, Vancouver, BC, Canada; [Silverberg, Noah; Emmerich, Tanja; Crynen, Gogce; Ait-Ghezala, Ghania; Chaytow, Helena; Mathura, Venkat; Crawford, Fiona C.] Roskamp Inst, Sarasota, FL USA; [Gardner, Andrew J.] Univ Newcastle, Sch Med & Publ Hlth, Hunter New England Local Hlth Dist Sports Concuss, Newcastle, NSW, Australia; [Gardner, Andrew J.] Univ Newcastle, Sch Med & Publ Hlth, Ctr Stroke & Brain Injury, Newcastle, NSW, Australia; [Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Spaulding Rehabil Hosp & Home Base, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Iverson, Grant L.] Def & Vet Brain Injury Ctr, Bethesda, MD USA	Dretsch, MN (corresponding author), Headquarters Training & Doctrine Command, Army Capabil Integrat Ctr, Human Dimens Div, 950 Jefferson Ave, Ft Eustis, VA 23604 USA.	michael.n.dretsch.mil@mail.mil		Crynen, Gogce/0000-0001-6066-9900; Emmerich, Tanja/0000-0001-5064-7150; Ait-Ghezala, Ghania/0000-0002-9836-8617; Chaytow, Helena/0000-0003-2257-7620; Panenka, William/0000-0001-7143-6512; Iverson, Grant/0000-0001-7348-9570	INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium - Department of Defense Psychological Health/Traumatic Brain Injury Research Program [X81XWH-07-CC-CSDoD]; New South Wales Sporting Injuries Committee-Sports Research & Injury Prevention; Brain Foundation; Australia-Brain Injury Award; Hunter Medical Research Institute (HMRI); Australian Football League (AFL)	Grant L. Iverson acknowledges support from the INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium funded by the Department of Defense Psychological Health/Traumatic Brain Injury Research Program (X81XWH-07-CC-CSDoD). Andrew J. Gardner acknowledges funding from the New South Wales Sporting Injuries Committee-Sports Research & Injury Prevention Scheme, the Brain Foundation, Australia-Brain Injury Award, Hunter Medical Research Institute (HMRI) early career funding through Anne Greaves, and research fellowship funding from Jennie Thomas, Life Governor of the HMRI. Grant L. Iverson has been reimbursed by the government, professional scientific bodies, and commercial organizations for discussing or presenting research relating to mild TBI and sport-related concussion at meetings, scientific conferences, and symposiums. He has a clinical practice in forensic neuropsychology involving individuals who have sustained mild TBIs (including athletes). He has received honoraria for serving on research panels that provide scientific peer review of programs. He is a co-investigator, collaborator, or consultant on grants relating to mild TBI funded by several organizations. Andrew J. Gardner has a clinical practice in neuropsychology involving the assessment and management of individuals who have sustained sport-related concussion (including current and former athletes). He received travel funding from the Australian Football League (AFL) to present at the Concussion in Football Conference in 2013. He also serves in a unremunerated capacity as a member of the Concussion Advisory Group for the Australian Rugby Union (ARU). The other authors have nothing to disclose.	Babor T., 2001, ALCOHOL USE DISORDER, V2nd ed.; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Bergman O, 2011, INT J NEUROPSYCHOPH, V14, P1367, DOI 10.1017/S1461145711000502; Bogner J, 2015, BRAIN INJURY, V29, P905, DOI 10.3109/02699052.2015.1005136; Chen A, 2013, BIOMED REP, V1, P167, DOI 10.3892/br.2012.48; Cohen-Cory S, 2010, DEV NEUROBIOL, V70, P271, DOI 10.1002/dneu.20774; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Cusimano MD, 2014, J HEAD TRAUMA REHAB, V29, P172, DOI 10.1097/HTR.0b013e31827c7d15; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Dretsch MN, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.392; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; Ganti L, 2014, INT J EMERG MED, V7, DOI 10.1186/s12245-014-0031-6; Goswami R, 2016, BRAIN STRUCT FUNCT, V221, P1911, DOI 10.1007/s00429-015-1012-0; Greenwald MK, 2013, ADDICT BIOL, V18, P836, DOI 10.1111/j.1369-1600.2011.00431.x; Harvey AR, 2015, BRAIN RES, V1619, P36, DOI 10.1016/j.brainres.2014.10.049; Hehar H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139842; Isokuortti H, 2016, J NEUROTRAUM, V33, P232, DOI 10.1089/neu.2015.3888; Ito W, 2011, GENES BRAIN BEHAV, V10, P365, DOI 10.1111/j.1601-183X.2010.00676.x; Kassam I, 2016, J NEUROL NEUROSUR PS, V87, P433, DOI 10.1136/jnnp-2015-310500; Kazemi DM, 2014, J PSYCHOSOC NURS MEN, V52, P38, DOI 10.3928/02793695-20140310-01; Kocka A, 2014, BEHAV SCI, V4, P352, DOI 10.3390/bs4040352; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Lambert JC, 1998, HUM MOL GENET, V7, P1511, DOI 10.1093/hmg/7.9.1511; Lange RT, 2007, NEUROPSYCHOLOGY, V21, P590, DOI 10.1037/0894-4105.21.5.590; Lawrence DW, 2015, BRAIN INJURY, V29, P1018, DOI 10.3109/02699052.2015.1005131; Lendon CL, 2003, NEUROLOGY, V61, P683, DOI 10.1212/01.WNL.0000078033.81925.80; Logrip ML, 2015, BRAIN RES, V1628, P60, DOI 10.1016/j.brainres.2015.03.025; Lyons WE, 1999, P NATL ACAD SCI USA, V96, P15239, DOI 10.1073/pnas.96.26.15239; Miller SC, 2013, AM J PSYCHIAT, V170, P383, DOI 10.1176/appi.ajp.2012.12010126; Neumann D, 2015, REHABIL PSYCHOL, V60, P155, DOI 10.1037/rep0000036; Popoli M, 2015, INT J NEUROPSYCHOPHA, V18; Riggio S, 2009, MT SINAI J MED, V76, P163, DOI 10.1002/msj.20097; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schwab KA, 2006, NEUROLOGY, V66, pA235; Su H, 2014, NEUROSCI LETT, V582, P16, DOI 10.1016/j.neulet.2014.08.030; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Terrell TR, 2012, CLIN J SPORT MED, V22, P172; Thomson CJ, 2015, J SPORT SCI, V33, P1861, DOI 10.1080/02640414.2015.1020841; Tierney RT, 2010, CLIN J SPORT MED, V20, P464, DOI 10.1097/JSM.0b013e3181fc0a81; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Wu CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113397; Wu HT, 2010, BRAIN RES, V1362, P112, DOI 10.1016/j.brainres.2010.09.013; Yin C, 2015, GENE, V563, P52, DOI 10.1016/j.gene.2015.03.009; Zeng S, 2014, GENET TEST MOL BIOMA, V18, P202, DOI 10.1089/gtmb.2013.0421; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489; ZUCKERMAN M, 1993, J PERS SOC PSYCHOL, V65, P757, DOI 10.1037/0022-3514.65.4.757; Zuckerman M, 2002, BIG FIVE ASSESSMENT, P377	48	14	14	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2017	34	4					869	875		10.1089/neu.2016.4480			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EL0XD	WOS:000394344200014	27396498				2021-06-18	
J	Polimanti, R; Chen, CY; Ursano, RJ; Heeringa, SG; Jain, S; Kessler, RC; Nock, MK; Smoller, JW; Sun, XY; Gelernter, J; Stein, MB				Polimanti, Renato; Chen, Chia-Yen; Ursano, Robert J.; Heeringa, Steven G.; Jain, Sonia; Kessler, Ronald C.; Nock, Matthew K.; Smoller, Jordan W.; Sun, Xiaoying; Gelernter, Joel; Stein, Murray B.		Army STARRS Collaborators	Cross-Phenotype Polygenic Risk Score Analysis of Persistent Post-Concussive Symptoms in US Army Soldiers with Deployment-Acquired Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; concussion; genetic correlation; military personnel; US Army	GENOME-WIDE ASSOCIATION; MILITARY SERVICE MEMBERS; METAANALYSIS; INDIVIDUALS; DISEASE; BLAST; SCHIZOPHRENIA; VARIANTS; ALLELE; LOCI	Traumatic brain injury (TBI) contributes to the increased rates of suicide and post-traumatic stress disorder in military personnel and veterans, and it is also associated with the risk for neurodegenerative and psychiatric disorders. A cross-phenotype high-resolution polygenic risk score (PRS) analysis of persistent post-concussive symptoms (PCS) was conducted in 845 U.S. Army soldiers who sustained TBI during their deployment. We used a prospective longitudinal survey of three brigade combat teams to assess deployment-acquired TBI and persistent physical, cognitive, and emotional PCS. PRS was derived from summary statistics of large genome-wide association studies of Alzheimer's disease, Parkinson's disease, schizophrenia, bipolar disorder, and major depressive disorder (MDD); and for years of schooling, college completion, childhood intelligence, infant head circumference (IHC), and adult intracranial volume. Although our study had more than 95% of statistical power to detect moderate-to-large effect sizes, no association was observed with neurodegenerative and psychiatric disorders, suggesting that persistent PCS does not share genetic components with these traits to a moderate-to-large degree. We observed a significant finding: subjects with high IHC PRS recovered better from cognitive/emotional persistent PCS than the other individuals (R-2 = 1.11%; p = 3.37 x 10(-3)). Enrichment analysis identified two significant Gene Ontology (GO) terms related to this result: GO: 0050839 similar to Cell adhesion molecule binding (p = 8.9 x 10(-6)) and GO: 0050905 similar to Neuromuscular process (p = 9.8 x 10(-5)). In summary, our study indicated that the genetic predisposition to persistent PCS after TBI does not have substantial overlap with neurodegenerative and psychiatric diseases, but mechanisms related to early brain growth may be involved.	[Polimanti, Renato] Yale Sch Med, Dept Psychiat, West Haven, CT USA; [Gelernter, Joel] Yale Sch Med, Dept Psychiat, West Haven, CT USA; [Gelernter, Joel] Yale Sch Med, Dept Genet, West Haven, CT USA; [Gelernter, Joel] Yale Sch Med, Dept Neurosci, West Haven, CT USA; [Gelernter, Joel] VA CT Healthcare Ctr, West Haven, CT USA; [Chen, Chia-Yen; Smoller, Jordan W.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Chen, Chia-Yen; Smoller, Jordan W.] Harvard Med Sch, Boston, MA USA; [Chen, Chia-Yen; Smoller, Jordan W.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA USA; [Ursano, Robert J.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Ctr Study Traumat Stress, Bethesda, MD 20814 USA; [Heeringa, Steven G.] Univ Michigan, Inst Social Res, Ann Arbor, MI USA; [Jain, Sonia; Sun, Xiaoying] Univ Calif La Jolla, Dept Family Med & Publ Hlth, La Jolla, CA USA; [Stein, Murray B.] Univ Calif La Jolla, Dept Psychiat, La Jolla, CA USA; [Kessler, Ronald C.] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA USA; [Nock, Matthew K.] Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA; [Stein, Murray B.] VA San Diego Healthcare Syst, San Diego, CA USA	Stein, MB (corresponding author), Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr,Mailcode 0855, La Jolla, CA 92093 USA.	mstein@ucsd.edu	Nock, Matthew/AAE-8330-2019; Ursano, Robert/ABE-6533-2020	Gelernter, Joel/0000-0002-4067-1859; Chen, Chia-Yen/0000-0001-9548-5597; Polimanti, Renato/0000-0003-0745-6046; Ursano, Robert/0000-0002-1861-9173	GWAS consortia IGAP (International Genomics of Alzheimer's Project); PDGene, PGC (Psychiatric Genomics Consortium); SSGAC (Social Science Genetic Association Consortium); CHIC (Childhood Intelligence Consortium); EGG (Early Growth Genetics); ENIGMA (Enhancing Neuro Imaging Genetics through Meta-Analysis); French National Foundation on Alzheimer's Disease and Related Disorders; LABEX (Laboratory Of Excellence Program Investment for the Future) DISTALZ grant; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [503480]; Alzheimer's Research UKAlzheimer's Research UK (ARUK) [503176]; Wellcome TrustWellcome TrustEuropean Commission [082604/2/07/Z]; German Federal Ministry of Education and Research (BMBF) Competence Network Dementia (CND)Federal Ministry of Education & Research (BMBF) [01GI0102, 01GI0711, 01GI0420]; NIH/NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG033193, AG081220, U01 AG032984, U24 AG021886, U01 AG016976]; AGES [N01-AG-12100]; NHLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL105756]; Icelandic Heart Association; Erasmus Medical Center; Erasmus University; Alzheimer's AssociationAlzheimer's Association [ADGC 10 196728]; Department of the Army; U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health (NIH/ NIMH) [U01MH087981]; National Institutes of Health, National Institute of Alcoholism and Alcohol Abuse (NIH/NIAAA) [R21 AA024404]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [U01MH087981, K24MH094614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R21AA024404] Funding Source: NIH RePORTER	We thank the GWAS consortia IGAP (International Genomics of Alzheimer's Project), PDGene, PGC (Psychiatric Genomics Consortium), SSGAC (Social Science Genetic Association Consortium), CHIC (Childhood Intelligence Consortium), EGG (Early Growth Genetics), and ENIGMA (Enhancing Neuro Imaging Genetics through Meta-Analysis) and their funding agencies for providing summary results data for these analyses. The investigators who contributed to the design and implementation of these previous GWAS did not participate in analysis or writing of this report. IGAP and its participants were supported by the French National Foundation on Alzheimer's Disease and Related Disorders, LABEX (Laboratory Of Excellence Program Investment for the Future) DISTALZ grant, Medical Research Council (Grant no. 503480), Alzheimer's Research UK (Grant no. 503176), Wellcome Trust (Grant no. 082604/2/07/Z), German Federal Ministry of Education and Research (BMBF) Competence Network Dementia (CND) (Grant no. 01GI0102, 01GI0711, 01GI0420), NIH/NIA Grants (R01 AG033193, AG081220, U01 AG032984, U24 AG021886, U01 AG016976) and AGES contract N01-AG-12100, NHLBI Grant R01 HL105756, Icelandic Heart Association, Erasmus Medical Center and Erasmus University, and Alzheimer's Association Grant ADGC 10 196728.; Army STARRS was sponsored by the Department of the Army and funded under cooperative agreement number U01MH087981 with the U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health (NIH/ NIMH). Additional support was provided by the grant R21 AA024404 from the National Institutes of Health, National Institute of Alcoholism and Alcohol Abuse (NIH/NIAAA). The contents are solely the responsibility of the authors and do not necessarily represent the views of the Department of Health and Human Services, NIMH, Veterans Administration, Department of the Army, or Department of Defense.	Agerbo E, 2015, JAMA PSYCHIAT, V72, P635, DOI 10.1001/jamapsychiatry.2015.0346; Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Altshuler DM, 2010, NATURE, V467, P52, DOI 10.1038/nature09298; Bailey ZS, 2015, NEUROSCI LETT, V604, P119, DOI 10.1016/j.neulet.2015.07.035; Benyamin B, 2014, MOL PSYCHIATR, V19, P253, DOI 10.1038/mp.2012.184; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Bulik-Sullivan B, 2015, NAT GENET, V47, P1236, DOI 10.1038/ng.3406; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang CC, 2016, QUAL LIFE RES, V25, P2009, DOI 10.1007/s11136-015-1215-0; Cuthbert BN, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-126; Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]; Dretsch MN, 2015, J NEUROTRAUM, V32, P1301, DOI 10.1089/neu.2014.3810; Dretsch MN, 2015, J NEUROTRAUM, V32, P1217, DOI 10.1089/neu.2014.3637; Escott-Price V, 2015, ANN NEUROL, V77, P582, DOI 10.1002/ana.24335; Euesden J, 2015, BIOINFORMATICS, V31, P1466, DOI 10.1093/bioinformatics/btu848; French LM, 2014, J NEUROTRAUM, V31, P1607, DOI 10.1089/neu.2014.3401; Hibar DP, 2015, NATURE, V520, P224, DOI 10.1038/nature14101; Howie B, 2011, G3-GENES GENOM GENET, V1, P457, DOI 10.1534/g3.111.001198; Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415; Kiss JZ, 2014, CURR OPIN NEUROL, V27, P133, DOI 10.1097/WCO.0000000000000068; Kiss JZ, 2001, BRAIN RES REV, V36, P175, DOI 10.1016/S0165-0173(01)00093-5; Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lange RT, 2013, J NEUROTRAUM, V30, P237, DOI 10.1089/neu.2012.2685; Lill CM, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002548; Loh PR, 2015, NAT GENET, V47, P1385, DOI 10.1038/ng.3431; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Mavaddat N, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv036; Merritt VC, 2016, J INT NEUROPSYCH SOC, V22, P89, DOI 10.1017/S1355617715001022; Mychasiuk R, 2015, NEUROSCIENCE, V288, P145, DOI 10.1016/j.neuroscience.2014.12.034; Nalls MA, 2014, NAT GENET, V46, P989, DOI 10.1038/ng.3043; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Pers TH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6890; Polimanti R., 2016, NEUROPSYCHOPHARMACOL; Rietveld CA, 2013, SCIENCE, V340, P1467, DOI 10.1126/science.1235488; Ripke S, 2014, NATURE, V511, P421, DOI 10.1038/nature13595; Santarsieri M, 2015, BRAIN BEHAV IMMUN, V45, P15, DOI 10.1016/j.bbi.2014.09.003; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Simonti CN, 2016, SCIENCE, V351, P737, DOI 10.1126/science.aad2149; Sklar P, 2011, NAT GENET, V43, P977, DOI 10.1038/ng.943; Smyth K, 2014, DEV MED CHILD NEUROL, V56, P73, DOI 10.1111/dmcn.12263; Stein M. B., 2016, J NEUROTRAUMA; Stein MB, 2016, JAMA PSYCHIAT, V73, P695, DOI 10.1001/jamapsychiatry.2016.0350; Sullivan PF, 2013, MOL PSYCHIATR, V18, P497, DOI 10.1038/mp.2012.21; Taal HR, 2012, NAT GENET, V44, P532, DOI 10.1038/ng.2238; Ursano RJ, 2014, PSYCHIATRY, V77, P107, DOI 10.1521/psyc.2014.77.2.107; Vanderploeg RD, 2015, J HEAD TRAUMA REHAB, V30, P1, DOI 10.1097/HTR.0000000000000009; Wolfsgruber S., 2016, ALZHEIMERS DEMENT; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Zheng J., 2016, LD HUB CENTRALIZED D	50	14	14	2	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2017	34	4					781	789		10.1089/neu.2016.4550			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EL0XD	WOS:000394344200004	27439997	Green Published			2021-06-18	
J	Fogang, Y; Legros, B; Depondt, C; Mavroudakis, N; Gaspard, N				Fogang, Yannick; Legros, Benjamin; Depondt, Chantal; Mavroudakis, Nicolas; Gaspard, Nicolas			Yield of repeated intermittent EEG for seizure detection in critically ill adults	NEUROPHYSIOLOGIE CLINIQUE-CLINICAL NEUROPHYSIOLOGY			English	Article						Non-convulsive seizures; Continuous EEG monitoring; Critical care EEG; Electroencephalography; Health resources	NONCONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; ELECTROGRAPHIC SEIZURES; CONSENSUS STATEMENT; RECOMMENDATIONS; CHILDREN	Introduction. - Seizures are common in critically ill patients and prevalence can exceed 30% in the neuro-intensive care unit (ICU). Continuous EEG monitoring (cEEG) is the gold standard for seizure detection in critically ill patients. Objectives. - To determine the yield of intermittent EEG (iEEG) to detect critically ill adult patients with seizures and to identify the factors that affect this yield. Methods. - We retrospectively analyzed cEEG data and medical records from 977 consecutive critically ill patients undergoing cEEG. We included those presenting at least one electrographic seizure during the first 24 hours of cEEG. Patients with hypoxic-ischemic encephalopathy were excluded. For seizure detection, we reviewed six 30-minute epochs on cEEG selected at H0, H3, H6, H12, H18 and H24. Results. - Seizures occurred in 10.75% (105/977) of patients. Level of consciousness was impaired in 79 (75%) of patients, with 42 (40%) in coma. Review of the HO epoch on cEEG permitted to detect seizures in 61 (58%) patients. These figures increased to 70 (67%), 75 (71%), 91 (87%) and 97 (92%) patients for a sampling every 24, 12, 6 and 3 hours, respectively (P = 0.02). Frequency of seizures on cEEG was the only factor significantly affecting the probability of seizure detection. Sampling every 6 hours revealed seizures in all patients with more than six seizures per 24 hours. Conclusions. - iEEG repeated every 6 hours can accurately detect patients presenting seizures, especially when seizure frequency is greater than six per 24 hours. These findings have practical implications for electrographic seizure detection in critically ill patients in settings lacking cEEG. (C) 2016 Elsevier Masson SAS. All rights reserved.	[Fogang, Yannick; Legros, Benjamin; Depondt, Chantal; Mavroudakis, Nicolas; Gaspard, Nicolas] Univ Libre Bruxelles, Hop Erasme, Neurol Dept, Route Lennik 808, B-1070 Brussels, Belgium; [Fogang, Yannick] Cheikh Anta Diop Univ, Fann Teaching Hosp, Neurol Dept, Dakar, Senegal; [Gaspard, Nicolas] Yale Univ, Neurol Dept, New Haven, CT USA	Gaspard, N (corresponding author), Univ Libre Bruxelles, Hop Erasme, Neurol Dept, Route Lennik 808, B-1070 Brussels, Belgium.	Nicolas.Gaspard@erasme.ulb.ac.be			Fonds Erasme pour la Recherche Medicate	NG is a Master Clinician Scientist of the Belgian Fund for Scientific Research (FNRS); receives research funding from the Fonds Erasme pour la Recherche Medicate.	Aarli JA, 2007, NEUROLOGY, V69, P1715, DOI 10.1212/01.wnl.0000285102.47543.02; Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; Alvarez V, 2013, CRIT CARE, V17, DOI 10.1186/cc12879; Andre-Obadia N, 2015, NEUROPHYSIOL CLIN, V45, P39, DOI 10.1016/j.neucli.2014.11.003; Andre-Obadia N, 2015, NEUROPHYSIOL CLIN, V45, P1, DOI 10.1016/j.neucli.2014.11.002; Andre-Obadia N, 2014, NEUROPHYSIOL CLIN, V44, P515, DOI 10.1016/j.neucli.2014.10.001; BLECK TP, 1993, CRIT CARE MED, V21, P98, DOI 10.1097/00003246-199301000-00019; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Claassen J, 2013, INTENS CARE MED, V39, P1337, DOI 10.1007/s00134-013-2938-4; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Friedman D, 2009, ANESTH ANALG, V109, P506, DOI 10.1213/ane.0b013e3181a9d8b5; Gaspard N, 2014, EPILEPSIA, V55, P1366, DOI 10.1111/epi.12653; Herman ST, 2015, J CLIN NEUROPHYSIOL, V32, P87, DOI 10.1097/WNP.0000000000000166; Herman ST, 2015, J CLIN NEUROPHYSIOL, V32, P96, DOI 10.1097/WNP.0000000000000165; Hirsch LJ, 2013, J CLIN NEUROPHYSIOL, V30, P1, DOI 10.1097/WNP.0b013e3182784729; Husain AM, 2003, J NEUROL NEUROSUR PS, V74, P189, DOI 10.1136/jnnp.74.2.189; Jordan KG, 1999, J CLIN NEUROPHYSIOL, P1614; Payne ET, 2014, BRAIN, V137, P1429, DOI 10.1093/brain/awu042; PRIVITERA M, 1994, EPILEPSY RES, V18, P155, DOI 10.1016/0920-1211(94)90008-6; Shafi MM, 2012, NEUROLOGY, V79, P1796, DOI 10.1212/WNL.0b013e3182703fbc; Shneker BF, 2003, NEUROLOGY, V61, P1066, DOI 10.1212/01.WNL.0000082653.40257.0B; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Trinka E, 2015, EPILEPSIA, V56, P1515, DOI 10.1111/epi.13121; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Westover MB, 2015, CLIN NEUROPHYSIOL, V126, P463, DOI 10.1016/j.clinph.2014.05.037; Wittman JJ, 2005, NEUROCRIT CARE, V2, P330, DOI 10.1385/NCC:2:3:330; Young GB, 1996, NEUROLOGY, V47, P83	31	14	14	0	3	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0987-7053	1769-7131		NEUROPHYSIOL CLIN	Neurophysiol. Clin.-Clin. Neurophysiol.	FEB	2017	47	1					5	12		10.1016/j.neucli.2016.09.001			8	Clinical Neurology; Neurosciences; Physiology	Neurosciences & Neurology; Physiology	ET0NT	WOS:000399959800002	27771198				2021-06-18	
J	Martin, M; Cook, F; Lobo, D; Vermersch, C; Attais, A; Ait-Mamar, B; Plaud, B; Mounier, R; Dhonneur, G				Martin, Mathieu; Cook, Fabrice; Lobo, David; Vermersch, Charlotte; Attais, Arie; Ait-Mamar, Bouziane; Plaud, Benoit; Mounier, Roman; Dhonneur, Gilles			Secondary Insults and Adverse Events During Intrahospital Transport of Severe Traumatic Brain-Injured Patients	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Head computed tomography; Intrahospital transport	CRITICALLY-ILL PATIENTS; HEAD COMPUTED-TOMOGRAPHY; HEMORRHAGE; UTILITY; SAFETY	Our aim was to assess the occurrence of secondary insults (SIs) or adverse events (AEs) during intrahospital transport (IHT) of severe traumatic brain injury (TBI) patients for head computed tomography (CT) scanning. A prospective study based on severe TBI patients admitted from June 2011 through June 2013 in a level I trauma center. Patients received an IHT to perform a control CT scan in the first 3 days following trauma. The occurrence of SIs and AEs was assessed during the IHT for a control CT scan. The frequency of SIs was compared to the periods "before," "during," and "after" IHT. SI was defined by an intracranial pressure (ICP) > 30 mmHg, a cerebral perfusion pressure (CPP) < 50 mmHg, systolic blood pressure (SBP) < 90 mmHg, or saturation pulse O-2 (SpO(2)) < 90 % for more than five consecutive minutes. An AE was defined as failures of hardware or ventilator asynchrony requiring therapeutic intervention during transport. In addition, we assessed the therapeutic benefit of a CT scan control. The final analysis included 31 patients and 31 IHTs. The median duration of IHT was 29 min [25;37]. SIs occurred in 16 patients (52 %) during transport, whereas it was observed in 4 patients (13 %) before (p = 0.002) and 4 patients (13 %) after IHT (p = 0.001). Twenty-four AEs occurred during transport of 19 patients (61 %). One patient benefited from hematoma evacuation after implementation of control CT. IHT carries significant SIs and AEs in severe TBI patients. To improve a risk/benefit ratio favorable for patients, a program focusing on IHT complications regarding therapeutic impact of control CT scan is needed.	[Martin, Mathieu; Cook, Fabrice; Lobo, David; Vermersch, Charlotte; Attais, Arie; Ait-Mamar, Bouziane; Mounier, Roman; Dhonneur, Gilles] Paris Est Creteil Univ, Dept Anaesthesiol & Crit Care Med, Ctr Trauma, Surg Intens Care Unit, Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France; [Martin, Mathieu; Cook, Fabrice; Lobo, David; Vermersch, Charlotte; Attais, Arie; Ait-Mamar, Bouziane; Mounier, Roman; Dhonneur, Gilles] Henri Mondor Univ Hosp, AP HP, Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France; [Plaud, Benoit] Paris Diderot Univ, Dept Anaesthesiol & Surg Intens Care, 1 Ave Claude Vellefaux, F-75010 Paris, France; [Plaud, Benoit] St Louis Univ Hosp, AP HP, 1 Ave Claude Vellefaux, F-75010 Paris, France	Martin, M (corresponding author), Paris Est Creteil Univ, Dept Anaesthesiol & Crit Care Med, Ctr Trauma, Surg Intens Care Unit, Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France.; Martin, M (corresponding author), Henri Mondor Univ Hosp, AP HP, Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France.	mathieu.martin@hmn.aphp.fr		Lobo, David/0000-0002-7906-6023			ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; Beckmann U, 2004, INTENS CARE MED, V30, P1579, DOI 10.1007/s00134-004-2177-9; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Cuschieri J, 2012, ANN SURG, V255, P993, DOI 10.1097/SLA.0b013e31824f1ebc; Damm C, 2005, ANN FR ANESTH, V24, P24, DOI 10.1016/j.annfar.2004.10.026; Evans A, 1995, Am J Crit Care, V4, P106; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mathe JF, 2005, ANN FR ANESTH, V24, P688, DOI 10.1016/j.annfar.2005.03.029; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Park HK, 2009, BRIT J NEUROSURG, V23, P617, DOI 10.3109/02688690902999302; Schwebel C, 2013, CRIT CARE MED, V41, P1919, DOI 10.1097/CCM.0b013e31828a3bbd; Shackford SR, 2004, J TRAUMA, V56, P480; Sherren PB, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/s13049-014-0041-7; Sinson G, 2001, J TRAUMA, V51, P875; SMITH I, 1990, CRIT CARE MED, V18, P278, DOI 10.1097/00003246-199003000-00006; Stippler M, 2012, EMERG MED J, V29, P528, DOI 10.1136/emermed-2011-200162; SZEM JW, 1995, CRIT CARE MED, V23, P1660, DOI 10.1097/00003246-199510000-00009; Thomas BW, 2010, J AM COLL SURGEONS, V210, P824, DOI 10.1016/j.jamcollsurg.2009.12.039; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; WAYDHAS C, 1995, INTENS CARE MED, V21, P784, DOI 10.1007/BF01700959	22	14	15	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	FEB	2017	26	1					87	95		10.1007/s12028-016-0291-5			9	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	EI2AI	WOS:000392287900013	27601068				2021-06-18	
J	Matthieu, MM; Lawrence, KA; Robertson-Blackmore, E				Matthieu, Monica M.; Lawrence, Karen A.; Robertson-Blackmore, Emma			The impact of a civic service program on biopsychosocial outcomes of post 9/11 US military veterans	PSYCHIATRY RESEARCH			English	Article						Veterans; Health; Volunteer; Mental health; Depression; Brain injury; Stress disorders; Post-traumatic; Loneliness; Social support; Self-efficacy; Reintegration	MENTAL-HEALTH PROBLEMS; AFGHANISTAN VETERANS; IRAQ; PTSD; DEPRESSION; VALIDITY; ADULTS	Volunteering as a health promotion intervention, improves physical health, mental health, and social outcomes particularly in older adults, yet limited research exists for veterans. We conducted a preliminary study to explore whether volunteering impacts a variety of biopsychosocial outcomes, including symptoms of post-traumatic stress disorder (PTSD) and depression, among returning military veterans from Iraq and Afghanistan. A survey enrolling a prospective cohort of United States (U.S.) veterans who served in the military after 11 September 2001 and who participated in a national civic service program was conducted. A total of 346 veterans completed standardized health, mental health, and psychosocial self-report measures before and after the program. Statistically significant differences were detected in overall health rating, level of emotional difficulty, PTSD and depression symptoms, purpose in life, self-efficacy, social isolation, and the perceived availability of social support at program completion. Screening positive for probable PTSD predicted improved perceived self efficacy while probable depression predicted a decrease in loneliness, an increase in purpose in life, and an increase in perceived social support, at program completion. Volunteering was associated with significant improvements in health, mental health and social outcomes in returning veterans.	[Matthieu, Monica M.] St Louis Univ, Coll Publ Hlth & Social Justice, Sch Social Work, Tegeler Hall,Room 325,3500 Lindell Blvd, St Louis, MO 63103 USA; [Lawrence, Karen A.] Univ Kentucky, Sch Social Work, Lexington, KY USA; [Robertson-Blackmore, Emma] Halifax Hlth, Family Med Residency, Daytona Beach, FL USA; [Lawrence, Karen A.] Washington Univ, George Warren Brown Sch Social Work, St Louis, MO 63130 USA	Matthieu, MM (corresponding author), St Louis Univ, Coll Publ Hlth & Social Justice, Sch Social Work, Tegeler Hall,Room 325,3500 Lindell Blvd, St Louis, MO 63103 USA.	mmatthie@slu.edu		Lawrence, Karen/0000-0002-7235-5594	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019960] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32 MH019960, L30 MH108084] Funding Source: Medline		American Psychiatric Association [APA], 2000, DIAGN STAT MAN TEXT; Benight CC, 2004, BEHAV RES THER, V42, P1129, DOI 10.1016/j.brat.2003.08.008; Bliese PD, 2007, PSYCHOL SERV, V4, P141, DOI DOI 10.1037/1541-1559.4.3.141; Brewin CR, 2005, J TRAUMA STRESS, V18, P53, DOI 10.1002/jts.20007; Cohen BE, 2010, J GEN INTERN MED, V25, P18, DOI 10.1007/s11606-009-1117-3; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cooperation for National and Community Service [CNCS], 2007, HLTH BEN VOL REV REC; Crawford EF, 2015, J TRAUMA STRESS, V28, P118, DOI 10.1002/jts.21993; Department of Defense [DoD], 2008, POSTD HLTH REASS DD; Fulton JJ, 2015, J ANXIETY DISORD, V31, P98, DOI 10.1016/j.janxdis.2015.02.003; Hawkley LC, 2010, ANN BEHAV MED, V40, P218, DOI 10.1007/s12160-010-9210-8; IBM Corp, 2019, IBM SPSS STAT WIND V; Jenkinson CE, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-773; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lum TY, 2005, RES AGING, V27, P31, DOI 10.1177/0164027504271349; Matthieu K.M., 2017, BEST PRACTICES MENTA; Matthieu M.M., 2016, J VETERAN STUDIES, V1, P205, DOI DOI 10.1097/AOG.0B013E31826AF3D1; McBride A.M., 2007, CIVIC SERVICE WORLDW; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Morrow-Howell Nancy, 2003, J Gerontol B Psychol Sci Soc Sci, V58, pS137; Musick MA, 1999, J GERONTOL B-PSYCHOL, V54, pS173, DOI 10.1093/geronb/54B.3.S173; Musick MA, 2003, SOC SCI MED, V56, P259, DOI 10.1016/S0277-9536(02)00025-4; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Ramchand R, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0575-z; Russell DW, 1996, J PERS ASSESS, V66, P20, DOI 10.1207/s15327752jpa6601_2; RYFF CD, 1989, J PERS SOC PSYCHOL, V57, P1069, DOI 10.1037/0022-3514.57.6.1069; Sarason, 1985, SOCIAL SUPPORT THEOR, P73, DOI DOI 10.1007/978-94-009-5115-0_5; Sayer NA, 2010, PSYCHIAT SERV, V61, P589, DOI 10.1176/ps.2010.61.6.589; Schnurr P P, 1999, Semin Clin Neuropsychiatry, V4, P295; Schwarzer R, 1995, MEASURES HLTH PSYCHO, P35; Sloan DM, 2015, J CONTEMP PSYCHOTHER, V45, P215, DOI 10.1007/s10879-014-9292-x; Sundin J, 2010, PSYCHOL MED, V40, P367, DOI 10.1017/S0033291709990791; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Thoits PA, 2001, J HEALTH SOC BEHAV, V42, P115, DOI 10.2307/3090173; Vaughan CA, 2014, PSYCHIAT SERV, V65, P833, DOI 10.1176/appi.ps.201300111; ZUBIN J, 1977, J ABNORM PSYCHOL, V86, P103, DOI 10.1037/0021-843X.86.2.103	38	14	14	3	14	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	FEB	2017	248						111	116		10.1016/j.psychres.2016.12.028			6	Psychiatry	Psychiatry	EK1XO	WOS:000393721300018	28039802	Green Accepted			2021-06-18	
J	McDonald, V; Hauner, KK; Chau, A; Krueger, F; Grafman, J				McDonald, Valerie; Hauner, Katherina K.; Chau, Aileen; Krueger, Frank; Grafman, Jordan			Networks underlying trait impulsivity: Evidence from voxel-based lesion-symptom mapping	HUMAN BRAIN MAPPING			English	Article						impulsivity; motor impulsivity; prefrontal cortex; traumatic brain injury; voxel-based lesion-symptom mapping	TRAUMATIC BRAIN-INJURY; RESPONSE-INHIBITION; PREFRONTAL CORTEX; SELF-AWARENESS; HEALTHY-ADULTS; PERSONALITY; BEHAVIOR; REGISTRATION; SOFTWARE; DOMAINS	Impulsivity is considered a multidimensional construct that encompasses a range of behaviors, including poor impulse control, premature decision-making, and the inability to delay gratification. In order to determine the extent to which impulsivity and its components share a common network, a voxel-based lesion-symptom mapping (VLSM) analysis was performed in a large sample of patients (N=131) with focal, penetrating traumatic brain injuries (pTBI). Impulsivity was assessed using the Barratt Impulsiveness Scale (BIS-11), a standard self-report measure that allows for unique estimates of global impulsivity and its factor analysis-derived components (e.g., motor impulsivity). Heightened global impulsivity was associated with damage to multiple areas in bilateral prefrontal cortex (PFC), left superior, middle and inferior temporal gyrus, and left hippocampus. Moreover, a cluster was identified within the left PFC associated specifically with motor impulsivity (defined as acting without thinking). The results were consistent with the existing literature on bilateral prefrontal cortical involvement in behavioral impulsivity, but also provided new evidence for a more complex neuroanatomical representation of this construct, characterized by left-lateralized temporal and hippocampal involvement, as well as a left-lateralized prefrontal network specifically associated with motor impulsivity. Hum Brain Mapp 38:656-665, 2017. (c) 2016 Wiley Periodicals, Inc.	[McDonald, Valerie; Hauner, Katherina K.; Chau, Aileen; Grafman, Jordan] Rehabil Inst Chicago, Cognit Neurosci Lab, 345 East Super St,Suite 1796, Chicago, IL 60611 USA; [Hauner, Katherina K.; Grafman, Jordan] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Hauner, Katherina K.; Grafman, Jordan] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA; [Krueger, Frank] George Mason Univ, Mol Neurosci Dept, Fairfax, VA 22030 USA; [Krueger, Frank] George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA	Grafman, J (corresponding author), Rehabil Inst Chicago, Cognit Neurosci Lab, 345 East Super St,Suite 1796, Chicago, IL 60611 USA.	jgraf-man@northwestern.edu			Agency for Healthcare Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K12 HS023011]; National Institute of Neurological Disorders and Stroke intramural research programUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Brain Injury Research Program; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K12HS023011] Funding Source: NIH RePORTER	Contract grant sponsor: Agency for Healthcare Research and Quality to K. K. H.; Contract grant number: K12 HS023011; Contract grant sponsor: National Institute of Neurological Disorders and Stroke intramural research program; Contract grant sponsor: Brain Injury Research Program.	Aichert DS, 2012, J CLIN EXP NEUROPSYC, V34, P1016, DOI 10.1080/13803395.2012.706261; [Anonymous], 1960, DEP DEFENSE 1293; Asahi S, 2004, EUR ARCH PSY CLIN N, V254, P245, DOI 10.1007/s00406-004-0488-z; BARRATT ES, 1987, PERS INDIV DIFFER, V8, P43, DOI 10.1016/0191-8869(87)90009-2; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BROTHERS L, 2002, SO NEUROSCI SER, P367; Buss A. H., 1975, TEMPERAMENT THEORY P; Caswell AJ, 2015, PERS INDIV DIFFER, V76, P68, DOI 10.1016/j.paid.2014.11.059; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Dalley JW, 2011, NEURON, V69, P680, DOI 10.1016/j.neuron.2011.01.020; Daruna J. H., 1993, IMPULSIVE CLIENT THE, P23, DOI [10.1037/10500-002, DOI 10.1037/10500-002]; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Depue BE, 2016, CEREB CORTEX, V26, P1634, DOI 10.1093/cercor/bhu324; DICKMAN SJ, 1990, J PERS SOC PSYCHOL, V58, P95, DOI 10.1037/0022-3514.58.1.95; Diekhof EK, 2012, BRAIN RES, V1473, P63, DOI 10.1016/j.brainres.2012.07.010; Dom G, 2006, ADDICT BEHAV, V31, P298, DOI 10.1016/j.addbeh.2005.05.009; EYSENCK SBG, 1985, PERS INDIV DIFFER, V6, P613, DOI 10.1016/0191-8869(85)90011-X; EYSENCK SBG, 1977, BRIT J SOC CLIN PSYC, V16, P57, DOI 10.1111/j.2044-8260.1977.tb01003.x; Farr OM, 2012, NEUROIMAGE, V63, P1070, DOI 10.1016/j.neuroimage.2012.07.049; GERBING DW, 1987, MULTIVAR BEHAV RES, V22, P357, DOI 10.1207/s15327906mbr2203_6; Ghashghaei H, 2007, NEUROIMAGE, V34, P905, DOI 10.1016/j.neuroimage.2006.09.046; Goswami R, 2016, BRAIN STRUCT FUNCT, V221, P1911, DOI 10.1007/s00429-015-1012-0; Hogeveen J, 2016, EFFECTS HIGH DEFINIT; Kelley E, 2014, J HEAD TRAUMA REHAB, V29, P147, DOI 10.1097/HTR.0b013e31826db6b9; Lawrence NS, 2003, J COGNITIVE NEUROSCI, V15, P1028, DOI 10.1162/089892903770007416; Le K, 2014, AM J SPEECH-LANG PAT, V23, P271, DOI 10.1044/2014_AJSLP-13-0095; Logan Gordon D., 1994, P189; Lynam D., 2007, UPPSP MULTIDIM UNPUB; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Matsuo K, 2009, HUM BRAIN MAPP, V30, P1188, DOI 10.1002/hbm.20588; McNeil M. M., 1994, REVISED TOKEN TEST; Moeller FG, 2001, J SUBST ABUSE TREAT, V21, P193, DOI 10.1016/S0740-5472(01)00202-1; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; PARKER JDA, 1993, PERS INDIV DIFFER, V15, P267, DOI 10.1016/0191-8869(93)90216-P; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; Peluso MAM, 2007, J AFFECT DISORDERS, V100, P227, DOI 10.1016/j.jad.2006.09.037; Piguet O, 2011, LANCET NEUROL, V10, P162, DOI 10.1016/S1474-4422(10)70299-4; Revelle William, 1997, EXTRAVERSION IMPULSI, V189; Reynolds B, 2006, PERS INDIV DIFFER, V40, P305, DOI 10.1016/j.paid.2005.03.024; Robertson K, 2015, BRAIN INJURY, V29, P848, DOI 10.3109/02699052.2015.1005135; Schalling D, 1985, BIOL BASES PERSONALI; Schilling C, 2012, NEUROIMAGE, V59, P824, DOI 10.1016/j.neuroimage.2011.07.058; Snowden JS, 2001, J NEUROL NEUROSUR PS, V70, P323, DOI 10.1136/jnnp.70.3.323; Snowden RJ, 2011, PSYCHIAT RES, V187, P414, DOI 10.1016/j.psychres.2011.02.003; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Stahl C, 2014, J EXP PSYCHOL GEN, V143, P850, DOI 10.1037/a0033981; Stanford MS, 2009, PERS INDIV DIFFER, V47, P385, DOI 10.1016/j.paid.2009.04.008; Swann AC, 2008, J AFFECT DISORDERS, V106, P241, DOI 10.1016/j.jad.2007.07.011; Szczepanski SM, 2014, NEURON, V83, P1002, DOI 10.1016/j.neuron.2014.08.011; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Williams GB, 2005, NEUROIMAGE, V24, P1042, DOI 10.1016/j.neuroimage.2004.10.023; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027	53	14	14	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	FEB	2017	38	2					656	665		10.1002/hbm.23406			10	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EK2WC	WOS:000393786500005	27667777	Green Published, Green Accepted			2021-06-18	
J	Sprissler, RS; Wagnon, JL; Bunton-Stasyshyn, RK; Meisler, MH; Hammer, MF				Sprissler, Ryan S.; Wagnon, Jacy L.; Bunton-Stasyshyn, Rosie K.; Meisler, Miriam H.; Hammer, Michael F.			Altered gene expression profile in a mouse model of SCN8A encephalopathy	EXPERIMENTAL NEUROLOGY			English	Article						RNA-seq; Transcriptome; Seizure; Epileptic encephalopathy; Astrocyte; Gene expression; Sodium channel	CONTROLLED CORTICAL IMPACT; TRAUMATIC BRAIN-INJURY; EPILEPTIC ENCEPHALOPATHY; REACTIVE ASTROCYTES; NEURONAL DEGENERATION; ANTIEPILEPTIC DRUGS; MEDIATED EXPRESSION; RAT HIPPOCAMPUS; PROGRESS REPORT; SEIZURES	SCN8A encephalopathy is a severe, early-onset epilepsy disorder resulting from de novo gain-of-function mutations in the voltage-gated sodium channel Na(v)1.6. To identify the effects of this disorder on mRNA expression, RNA-seq was performed on brain tissue from a knock-in mouse expressing the patient mutation p.Asn1768Asp (N1768D). RNA was isolated from forebrain, cerebellum, and brainstem both before and after seizure onset, and from age-matched wildtype littermates. Altered transcript profiles were observed only in forebrain and only after seizures. The abundance of 50 transcripts increased more than 3-fold and 15 transcripts decreased more than 3 fold after seizures. The elevated transcripts included two anti-convulsant neuropeptides and more than a dozen genes involved in reactive astrocytosis and response to neuronal damage. There was no change in the level of transcripts encoding other voltage-gated sodium, potassium or calcium channels. Reactive astrocytosis was observed in the hippocampus of mutant mice after seizures. There is considerable overlap between the genes affected in this genetic model of epilepsy and those altered by chemically induced seizures, traumatic brain injury, ischemia, and inflammation. The data support the view that gain-of-function mutations of SCN8A lead to pathogenic alterations in brain function contributing to encephalopathy. (C) 2016 Elsevier Inc. All rights reserved.	[Sprissler, Ryan S.; Hammer, Michael F.] Univ Arizona, ARL Div Biotechnol, 1657 E Helen St, Tucson, AZ 85721 USA; [Wagnon, Jacy L.; Bunton-Stasyshyn, Rosie K.; Meisler, Miriam H.] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; [Meisler, Miriam H.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; [Hammer, Michael F.] Univ Arizona, Dept Neurol, Tucson, AZ 85721 USA	Hammer, MF (corresponding author), Univ Arizona, ARL Div Biotechnol, 1657 E Helen St, Tucson, AZ 85721 USA.; Meisler, MH (corresponding author), Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.	meislerm@umich.edu; mth@email.arizona.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS34509]; Dravet Syndrome Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034509] Funding Source: NIH RePORTER	Support is acknowledged from research grant NIH R01 NS34509 to MHM and a Postdoctoral Fellowship from the Dravet Syndrome Foundation to JLW. We would like to thank Branden Lau and Alexander Tchourbanov for excellent assistance with the RNAseq and biological pathway analyses.	Almeida-Suhett CP, 2014, J NEUROTRAUM, V31, P683, DOI 10.1089/neu.2013.3029; BANKER GA, 1980, SCIENCE, V209, P809, DOI 10.1126/science.7403847; Barker B., 2016, EPILEPSIA IN PRESS; Beaumont TL, 2012, J NEUROSCI, V32, P14389, DOI 10.1523/JNEUROSCI.3408-12.2012; Bialer M, 2015, EPILEPSY RES, V111, P85, DOI 10.1016/j.eplepsyres.2015.01.001; Bialer M, 2013, EPILEPSY RES, V103, P2, DOI 10.1016/j.eplepsyres.2012.10.001; Blanchard MG, 2015, J MED GENET, V52, P330, DOI 10.1136/jmedgenet-2014-102813; Boer K, 2010, BRAIN PATHOL, V20, P704, DOI 10.1111/j.1750-3639.2009.00341.x; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Crunelli V, 2015, NEUROSCIENTIST, V21, P62, DOI 10.1177/1073858414523320; Deng L, 2015, BRAIN RES, V1622, P186, DOI 10.1016/j.brainres.2015.06.027; Elliott RC, 2003, J NEUROSCI, V23, P2218; Estacion M, 2014, NEUROBIOL DIS, V69, P117, DOI 10.1016/j.nbd.2014.05.017; Fan X, 2009, BRAIN RES REV, V62, P99, DOI 10.1016/j.brainresrev.2009.09.006; Green BR, 2011, ACS CHEM NEUROSCI, V2, P51, DOI 10.1021/cn1000974; Haberman RP, 2003, NAT MED, V9, P1076, DOI 10.1038/nm901; Hammer MF, 2016, GENEREVIEWS R; Henneberger C., 2016, J PHYSL; Howell KB, 2016, EPILEPSIA, V57, P343, DOI 10.1111/epi.13306; Jones JM, 2014, GENESIS, V52, P141, DOI 10.1002/dvg.22731; Kokaia M, 2001, P NATL ACAD SCI USA, V98, P14006, DOI 10.1073/pnas.231496298; Larsen J, 2015, NEUROLOGY, V84, P480, DOI 10.1212/WNL.0000000000001211; Lin EJD, 2003, EUR J NEUROSCI, V18, P2087, DOI 10.1046/j.1460-9568.2003.02926.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lopez-Santiago L. F., 2015, AM EP SOC ANN M; Makinson CD, 2014, NEUROBIOL DIS, V68, P16, DOI 10.1016/j.nbd.2014.03.014; Mazarati AM, 2002, NEUROSCI LETT, V331, P123, DOI 10.1016/S0304-3940(02)00847-9; Mazarati AM, 1998, J NEUROSCI, V18, P10070; Mazarati AM, 2000, J NEUROSCI, V20, P6276, DOI 10.1523/JNEUROSCI.20-16-06276.2000; McCown TJ, 2006, MOL THER, V14, P63, DOI 10.1016/j.ymthe.2006.04.004; Meisler MH, 2016, EPILEPSIA, V57, P1027, DOI 10.1111/epi.13422; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Okamoto OK, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-230; Ortinski PI, 2010, NAT NEUROSCI, V13, P584, DOI 10.1038/nn.2535; Pekny M, 2016, ACTA NEUROPATHOL, V131, P323, DOI 10.1007/s00401-015-1513-1; Rakhade SN, 2005, ANN NEUROL, V58, P736, DOI 10.1002/ana.20633; Ravizza T, 2001, NEUROSCIENCE, V105, P43, DOI 10.1016/S0306-4522(01)00177-4; Robel S, 2015, J NEUROSCI, V35, P3330, DOI 10.1523/JNEUROSCI.1574-14.2015; Rubinstein M, 2001, J NEUROSCI, V21, P3756, DOI 10.1523/JNEUROSCI.21-11-03756.2001; Sakaida M, 2013, J PSYCHOPHARMACOL, V27, P1058, DOI 10.1177/0269881113497612; Samal BB, 2015, J MOL NEUROSCI, V57, P282, DOI 10.1007/s12031-015-0626-2; Schlifke I, 2006, EXP NEUROL, V200, P398, DOI 10.1016/j.expneurol.2006.02.124; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Tang Y, 2002, EUR J NEUROSCI, V15, P1937, DOI 10.1046/j.1460-9568.2002.02030.x; Veeramah KR, 2012, AM J HUM GENET, V90, P502, DOI 10.1016/j.ajhg.2012.01.006; Wagnon JL, 2016, ANN CLIN TRANSL NEUR, V3, P114, DOI 10.1002/acn3.276; Wagnon JL, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00104; Wagnon JL, 2015, HUM MOL GENET, V24, P506, DOI 10.1093/hmg/ddu470; Wetherington J, 2008, NEURON, V58, P168, DOI 10.1016/j.neuron.2008.04.002; Wilson DN, 2005, J MOL NEUROSCI, V25, P285, DOI 10.1385/JMN:25:3:285; Yang JL, 2016, GLIA, V64, P1083, DOI 10.1002/glia.22984; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhang Y, 2016, NEURON, V89, P37, DOI 10.1016/j.neuron.2015.11.013	53	14	14	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2017	288						134	141		10.1016/j.expneurol.2016.11.002			8	Neurosciences	Neurosciences & Neurology	EI4JY	WOS:000392461100013	27836728	Green Accepted, Green Published			2021-06-18	
J	Steward, KA; Novack, TA; Kennedy, R; Crowe, M; Marson, DC; Triebel, KL				Steward, Kayla A.; Novack, Thomas A.; Kennedy, Richard; Crowe, Michael; Marson, Daniel C.; Triebel, Kristen L.			The Wechsler Test of Adult Reading as a Measure of Premorbid Intelligence Following Traumatic Brain Injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Traumatic brain injury; Intelligence; Neuropsychological assessment; Rehabilitation	IQ; PERFORMANCE; VALIDITY; BATTERY; WAIS	Objective: The current study sought to determine whether the Wechsler Test of Adult Reading (WTAR) provides a stable estimate of premorbid intellectual ability in acutely injured patients recovering from traumatic brain injury (TBI). Method: A total of 135 participants (43 mild TBI [mTBI], 40 moderate/severe TBI [msevTBI], 52 healthy controls) were administered the WTAR at 1 and 12 months post-injury. Results: Despite similar demographic profiles, participants with msevTBI performed significantly worse than controls on the WTAR at both time points. Moreover, the msevTBI group had a significant improvement in WTAR performance over the 1-year period. In contrast, those participants with mTBI did not significantly differ from healthy controls and both the mTBI and control groups demonstrated stability on the WTAR over time. Conclusions: Results indicate that word-reading tests may underestimate premorbid intelligence during the immediate recovery period for patients with msevTBI. Clinicians should consider alternative estimation measures in this TBI subpopulation.	[Steward, Kayla A.; Crowe, Michael] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA; [Novack, Thomas A.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Kennedy, Richard] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Marson, Daniel C.; Triebel, Kristen L.] Univ Alabama Birmingham, Dept Neurol, UAB Stn, Birmingham, AL 35294 USA	Marson, DC (corresponding author), Univ Alabama Birmingham, Dept Neurol, Sparks Ctr 650, 1720 7th Ave South, Birmingham, AL 35294 USA.	dmarson@uabmc.edu	triebel, kristen/A-6569-2019	triebel, kristen/0000-0001-9161-7847	National Institute on Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1R01HD053074]	This work was supported by the National Institute on Child Health and Human Development [grant no. 1R01HD053074].	Brasure M., 2012, COMP EFFECTIVENESS R, V72, pES1; Bushnik T, 2008, ARCH PHYS MED REHAB, V89, P894, DOI 10.1016/j.apmr.2008.03.001; Crawford JR, 1997, CLIN NEUROPSYCHOL, V11, P192, DOI 10.1080/13854049708407050; Delis D. C., 2000, CVLT 2 CALIFORNIA VE; Dwan TM, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00056; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Kalmar K, 2008, ARCH PHYS MED REHAB, V89, P942, DOI 10.1016/j.apmr.2008.01.008; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Mathias JL, 2007, BRIT J CLIN PSYCHOL, V46, P457, DOI 10.1348/014466507X190197; McGurn B, 2004, NEUROLOGY, V62, P1184, DOI 10.1212/01.WNL.0000103169.80910.8B; Orme DR, 2004, REHABIL PSYCHOL, V49, P250, DOI 10.1037/0090-5550.49.3.250; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Riley GA, 2003, BRIT J CLIN PSYCHOL, V42, P319, DOI 10.1348/01446650360703410; RUSSELL EW, 1980, PERCEPT MOTOR SKILL, V51, P121, DOI 10.2466/pms.1980.51.1.121; Spreen O, 2006, COMPENDIUM NEUROPSYC; Triebel KL, 2012, NEUROLOGY, V78, P1472, DOI 10.1212/WNL.0b013e3182553c38; Wechsler D, 1997, WAIS 3 WECHSLER ADUL; Wechsler D., 2001, WECHSLER TEST ADULT; Wolfson D., 1993, HALSTEAD REITAN NEUR	20	14	14	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2017	32	1					98	103		10.1093/arclin/acw081			6	Psychology, Clinical; Psychology	Psychology	EO9KJ	WOS:000397007300012	27799224	Bronze			2021-06-18	
J	Tapper, A; Gonzalez, D; Roy, E; Niechwiej-Szwedo, E				Tapper, Anthony; Gonzalez, Dave; Roy, Eric; Niechwiej-Szwedo, Ewa			Executive function deficits in team sport athletes with a history of concussion revealed by a visual-auditory dual task paradigm	JOURNAL OF SPORTS SCIENCES			English	Article						Concussions; athletes; mild traumatic brain injury; dividing attention	WORKING-MEMORY; NEUROPSYCHOLOGICAL FUNCTION; NEUROCOGNITIVE PERFORMANCE; SEX-DIFFERENCES; GAIT STABILITY; HIGH-SCHOOL; ATTENTION; SYMPTOMS; LOCOMOTOR; RECOVERY	The purpose of this study was to examine executive functions in team sport athletes with and without a history of concussion. Executive functions comprise many cognitive processes including, working memory, attention and multi-tasking. Past research has shown that concussions cause difficulties in vestibular-visual and vestibular-auditory dual-tasking, however, visual-auditory tasks have been examined rarely. Twenty-nine intercollegiate varsity ice hockey athletes (age=19.13, SD=1.56; 15 females) performed an experimental dual-task paradigm that required simultaneously processing visual and auditory information. A brief interview, event description and self-report questionnaires were used to assign participants to each group (concussion, no-concussion). Eighteen athletes had a history of concussion and 11 had no concussion history. The two tests involved visuospatial working memory (i.e., Corsi block test) and auditory tone discrimination. Participants completed both tasks individually, then simultaneously. Two outcome variables were measured, Corsi block memory span and auditory tone discrimination accuracy. No differences were shown when each task was performed alone; however, athletes with a history of concussion had a significantly worse performance on the tone discrimination task in the dual-task condition. In conclusion, long-term deficits in executive functions were associated with a prior history of concussion when cognitive resources were stressed. Evaluations of executive functions and divided attention appear to be helpful in discriminating participants with and without a history concussion.	[Tapper, Anthony; Gonzalez, Dave; Roy, Eric; Niechwiej-Szwedo, Ewa] Univ Waterloo, Dept Kinesiol, Waterloo, ON, Canada	Tapper, A (corresponding author), Univ Waterloo, Dept Kinesiol, Waterloo, ON, Canada.	atapper@uwaterloo.ca			PROPEL Centre for Population Health Impact, University of Waterloo	This research was supported by funding from the PROPEL Centre for Population Health Impact, University of Waterloo.	Anderson V, 2010, STUD NEUROPSYCHOL NE, P1; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Berch DB, 1998, BRAIN COGNITION, V38, P317, DOI 10.1006/brcg.1998.1039; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Beurskens R, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/131608; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Chan RCK, 2008, ARCH CLIN NEUROPSYCH, V23, P201, DOI 10.1016/j.acn.2007.08.010; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Chein JM, 2003, J NEUROLINGUIST, V16, P315, DOI 10.1016/S0911-6044(03)00021-6; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Corsi P. M, 1972, HUMAN MEMORY MEDIAL; Cossette I, 2014, ARCH PHYS MED REHAB, V95, P1594, DOI 10.1016/j.apmr.2014.03.019; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Dougan BK, 2014, J INT NEUROPSYCH SOC, V20, P64, DOI 10.1017/S1355617712001464; Dziemianowicz MS, 2012, CURR NEUROL NEUROSCI, V12, P547, DOI 10.1007/s11910-012-0299-y; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Friedman NP, 2008, J EXP PSYCHOL GEN, V137, P201, DOI 10.1037/0096-3445.137.2.201; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kessels R P, 2000, Appl Neuropsychol, V7, P252, DOI 10.1207/S15324826AN0704_8; Kleffelgaard I, 2012, DISABIL REHABIL, V34, P788, DOI 10.3109/09638288.2011.619624; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Locklin J, 2010, SPORTS MED, V40, P183, DOI 10.2165/11319440-000000000-00000; Lovell M. R, 2011, IMMEDIATE POSTCONCUS; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Petersen SE, 2012, ANNU REV NEUROSCI, V35, P73, DOI 10.1146/annurev-neuro-062111-150525; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Sauseng P, 2005, INT J PSYCHOPHYSIOL, V57, P97, DOI 10.1016/j.ijpsycho.2005.03.018; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Vandierendonck A, 2004, BRIT J PSYCHOL, V95, P57, DOI 10.1348/000712604322779460; Vestberg T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034731; Voss MW, 2010, APPL COGNITIVE PSYCH, V24, P812, DOI 10.1002/acp.1588; Wager TD, 2003, COGN AFFECT BEHAV NE, V3, P255, DOI 10.3758/CABN.3.4.255	45	14	14	2	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0264-0414	1466-447X		J SPORT SCI	J. Sports Sci.	FEB	2017	35	3					231	240		10.1080/02640414.2016.1161214			10	Sport Sciences	Sport Sciences	EG2BT	WOS:000390848200004	26999459				2021-06-18	
J	Adams, J; Alipio-Jocson, V; Inoyama, K; Bartlett, V; Sandhu, S; Oso, J; Barry, JJ; Loring, DW; Meador, K				Adams, Jesse; Alipio-Jocson, Valerie; Inoyama, Katherine; Bartlett, Victoria; Sandhu, Saira; Oso, Jemima; Barry, John J.; Loring, David W.; Meador, Kimford			Methylphenidate, cognition, and epilepsy A double-blind, placebo-controlled, single-dose study	NEUROLOGY			English	Article							DEFICIT-HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; ATTENTION-DEFICIT; PEDIATRIC-PATIENTS; PERFORMANCE; SEIZURES; INDIVIDUALS; EFFICACY; SAFETY; RISK	Objective: To evaluate the potential efficacy of immediate-release methylphenidate (MPH) for treating cognitive deficits in epilepsy. Methods: This was a double-blind, randomized, single-dose, 3-period crossover study in patients with epilepsy and chronic cognitive complaints comparing the effects of placebo and MPH 10 and 20 mg given 1 week apart. Cognitive outcome was evaluated on the basis of an omnibus z score calculated from performance on the Conners Continuous Performance Test 3 (ability to discriminate between target and nontarget stimuli [d'] and hit reaction time standard deviation), Symbol-Digit Modalities Test, and Medical College of Georgia Paragraph Memory Test. Adverse events and seizure frequency were monitored. An open-label follow-up is reported elsewhere. Results: Thirty-five adult patients with epilepsy participated, of whom 31 finished. Demographics included the following: mean age = 35.3 years (range 20-62 years), 13 men and 18 women, and baseline seizure frequency of 2.8 per month. Epilepsy types were focal (n = 24), generalized (n = 6), or unclassified (n = 1). Mean epilepsy duration was 12.5 years. A statistically significant performance benefit was present at both 10-mg (p = 0.030) and 20-mg (p = 0.034) MPH doses. No seizures were associated with either MPH dose. Adverse effects leading to withdrawal included cognitive "fogginess" (n = 1 on 20 mg), anxiety/agitation (n = 1 on 10 mg), and tachycardia (n = 1). One participant was lost to follow-up after one 20-mg dose without side effect. Conclusions: This single-dose study suggests that MPH may be effective in ameliorating some cognitive deficits in patients with epilepsy. Additional studies are required.	[Adams, Jesse; Alipio-Jocson, Valerie; Sandhu, Saira; Oso, Jemima; Barry, John J.] Stanford Univ, Psychiat & Behav Sci, Stanford, CA 94305 USA; [Inoyama, Katherine; Bartlett, Victoria; Meador, Kimford] Stanford Univ, Neurol & Neurol Sci, Stanford, CA 94305 USA; [Loring, David W.] Emory Univ, Neurol, Atlanta, GA 30322 USA	Adams, J (corresponding author), Stanford Univ, Psychiat & Behav Sci, Stanford, CA 94305 USA.	jadamsmd@uw.edu	Meador, Kimford/W-6167-2019	Loring, David/0000-0003-2497-1074	Stanford University's Department of Neurology	This study was funded entirely by Stanford University's Department of Neurology.	Advokat C, 2010, NEUROSCI BIOBEHAV R, V34, P1256, DOI 10.1016/j.neubiorev.2010.03.006; Aldenkamp AP, 2001, J CHILD NEUROL, V16, P119, DOI 10.1177/088307380101600210; Aldenkamp AP, 1999, J CHILD NEUROL, V14, P795, DOI 10.1177/088307389901401205; [Anonymous], 2004, EP COGN FUNCT SURV; [Anonymous], 2007, PHYS DESK REFERENCE; BABINGTON R G, 1973, Pharmacology Biochemistry and Behavior, V1, P461, DOI 10.1016/0091-3057(73)90013-0; Baptista-Neto L, 2008, EXPERT OPIN INV DRUG, V17, P77, DOI 10.1517/13543784.17.1.77; Ben-Itzhak R, 2008, J AM GERIATR SOC, V56, P695, DOI 10.1111/j.1532-5415.2007.01623.x; BRUERA E, 1992, PAIN, V48, P163, DOI 10.1016/0304-3959(92)90053-E; CHAMBERL.RW, 1974, PEDIATRICS, V54, P658; Coghill DR, 2014, BIOL PSYCHIAT, V76, P603, DOI 10.1016/j.biopsych.2013.10.005; Conners CK., 2014, CONNERS CONTINUOUS P, V3rd; Epstein JN, 2003, J ABNORM CHILD PSYCH, V31, P543, DOI 10.1023/A:1025405216339; Feeney DJ, 1997, J AM ACAD CHILD PSY, V36, P1018, DOI 10.1097/00004583-199708000-00007; Gonzalez-Heydrich J, 2010, EPILEPSY BEHAV, V18, P229, DOI 10.1016/j.yebeh.2010.02.022; GrossTsur V, 1997, J PEDIATR-US, V130, P670, DOI 10.1016/S0022-3476(97)70258-0; Gucuyener K, 2003, J CHILD NEUROL, V18, P109, DOI 10.1177/08830738030180020601; Harel Y, 2009, J NEUROL SCI, V276, P38, DOI 10.1016/j.jns.2008.08.025; Hinkin CH, 2001, J NEUROPSYCH CLIN N, V13, P248, DOI 10.1176/appi.neuropsych.13.2.248; Holtmann M, 2003, EPILEPSIA, V44, P1241, DOI 10.1046/j.1528-1157.2003.13403.x; Kim YH, 2006, CLIN REHABIL, V20, P24, DOI 10.1191/0269215506cr927oa; Klein-Schwartz W, 2002, CURR OPIN PEDIATR, V14, P219, DOI 10.1097/00008480-200204000-00013; Koneski JAS, 2010, ARQ NEURO-PSIQUIAT, V68, P107, DOI 10.1590/S0004-282X2010000100023; Koneski JAS, 2011, EPILEPSY BEHAV, V21, P228, DOI 10.1016/j.yebeh.2011.02.029; MEADOR KJ, 1993, EPILEPSIA, V34, pS34, DOI 10.1111/j.1528-1157.1993.tb05914.x; Mendonca DA, 2007, MOVEMENT DISORD, V22, P2070, DOI 10.1002/mds.21656; Meyers CA, 1998, J CLIN ONCOL, V16, P2522, DOI 10.1200/JCO.1998.16.7.2522; Moore JL, 2002, EPILEPSY BEHAV, V3, P92, DOI 10.1006/ebeh.2001.0313; Perrine K, 1999, NEUROLOGY, V53, pS39; Repantis D, 2010, PHARMACOL RES, V62, P187, DOI 10.1016/j.phrs.2010.04.002; Rhodes SM, 2006, J CHILD PSYCHOL PSYC, V47, P1184, DOI 10.1111/j.1469-7610.2006.01633.x; Smith A., 1982, SYMBOL DIGIT MODALIT; Swanson J, 2011, NEUROPSYCHOPHARMACOL, V36, P207, DOI 10.1038/npp.2010.160; Tan M, 2005, ARCH DIS CHILD, V90, P57, DOI 10.1136/adc.2003.048504; Tavakoli SA, 2003, PSYCHOSOMATICS, V44, P262, DOI 10.1176/appi.psy.44.3.262; Torres AR, 2008, EPILEPSY BEHAV, V12, P217, DOI 10.1016/j.yebeh.2007.08.001; Van der Feltz-Cornelis CM, 2006, EPILEPSY BEHAV, V8, P659, DOI 10.1016/j.yebeh.2006.01.015; Wernicke JF, 2007, DEV MED CHILD NEUROL, V49, P498, DOI 10.1111/j.1469-8749.2007.00498.x; Willmott C, 2009, J NEUROL NEUROSUR PS, V80, P552, DOI 10.1136/jnnp.2008.159632; Wolraich ML, 2004, CNS DRUGS, V18, P243, DOI 10.2165/00023210-200418040-00004	40	14	14	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JAN 31	2017	88	5					470	476		10.1212/WNL.0000000000003564			7	Clinical Neurology	Neurosciences & Neurology	EP4HE	WOS:000397340800013	28031390	Green Published			2021-06-18	
J	Nizamutdinov, D; DeMorrow, S; McMillin, M; Kain, J; Mukherjee, S; Zeitouni, S; Frampton, G; Bricker, PCS; Hurst, J; Shapiro, LA				Nizamutdinov, Damir; DeMorrow, Sharon; McMillin, Matthew; Kain, Jessica; Mukherjee, Sanjib; Zeitouni, Suzanne; Frampton, Gabriel; Bricker, Paul Clint S.; Hurst, Jacob; Shapiro, Lee A.			Hepatic alterations are accompanied by changes to bile acid transporter-expressing neurons in the hypothalamus after traumatic brain injury	SCIENTIFIC REPORTS			English	Article							TUMOR-NECROSIS-FACTOR; ACUTE-PHASE RESPONSE; CIRCADIAN-RHYTHMS; LIVER-INJURY; RAT MODEL; HPA AXIS; INFLAMMATION; SERUM; MECHANISMS; PROTEINS	Annually, there are over 2 million incidents of traumatic brain injury (TBI) and treatment options are non-existent. While many TBI studies have focused on the brain, peripheral contributions involving the digestive and immune systems are emerging as factors involved in the various symptomology associated with TBI. We hypothesized that TBI would alter hepatic function, including bile acid system machinery in the liver and brain. The results show activation of the hepatic acute phase response by 2 hours after TBI, hepatic inflammation by 6 hours after TBI and a decrease in hepatic transcription factors, Gli 1, Gli 2, Gli 3 at 2 and 24 hrs after TBI. Bile acid receptors and transporters were decreased as early as 2 hrs after TBI until at least 24 hrs after TBI. Quantification of bile acid transporter, ASBT-expressing neurons in the hypothalamus, revealed a significant decrease following TBI. These results are the first to show such changes following a TBI, and are compatible with previous studies of the bile acid system in stroke models. The data support the emerging idea of a systemic influence to neurological disorders and point to the need for future studies to better define specific mechanisms of action.	[Nizamutdinov, Damir; Kain, Jessica; Mukherjee, Sanjib; Zeitouni, Suzanne; Bricker, Paul Clint S.; Hurst, Jacob; Shapiro, Lee A.] Texas A&M Univ, Hlth Sci Ctr, Dept Surg, Coll Med, Temple, TX 76504 USA; [Nizamutdinov, Damir; Shapiro, Lee A.] Baylor Scott & White Hlth, Neurosci Res Inst, Dept Neurosurg, Temple, TX 76504 USA; [DeMorrow, Sharon; McMillin, Matthew; Frampton, Gabriel] Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Internal Med, Temple, TX 76504 USA; [DeMorrow, Sharon; McMillin, Matthew; Frampton, Gabriel] Cent Texas Vet Hlth Care Syst, Temple, TX 76504 USA	Shapiro, LA (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Surg, Coll Med, Temple, TX 76504 USA.; Shapiro, LA (corresponding author), Baylor Scott & White Hlth, Neurosci Res Inst, Dept Neurosurg, Temple, TX 76504 USA.	lshapiro@medicine.tamhsc.edu	McMillin, Matthew/I-3090-2019	McMillin, Matthew/0000-0002-5980-0921; Kain, Jessica/0000-0003-1285-5690	BLRD VA [IK2 BX003486] Funding Source: Medline		Alrefai WA, 2007, PHARM RES-DORDR, V24, P1803, DOI 10.1007/s11095-007-9289-1; Anderson GD, 2015, AAPS J, V17, P1255, DOI 10.1208/s12248-015-9792-y; Angeletti RH, 1997, P NATL ACAD SCI USA, V94, P283, DOI 10.1073/pnas.94.1.283; Anthony DC, 2012, BRAIN BEHAV IMMUN, V26, P534, DOI 10.1016/j.bbi.2011.10.011; Arvin B, 1995, ANN NY ACAD SCI, V765, P62, DOI 10.1111/j.1749-6632.1995.tb16561.x; Arvin B., 1995, ANN NY ACAD SCI, V765, P98; BAUMANN H, 1987, J IMMUNOL, V139, P4122; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BEUTLER B, 1986, IMMUNOL RES, V5, P281, DOI 10.1007/BF02935501; Bookout AL, 2006, CELL, V126, P789, DOI 10.1016/j.cell.2006.06.049; Brough D, 2015, EXP PHYSIOL, V100, P1488, DOI 10.1113/EP085135; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; Chen F, 2003, J BIOL CHEM, V278, P19909, DOI 10.1074/jbc.M207903200; Chou TC, 2003, J NEUROSCI, V23, P10691; Cortez LM, 2015, J VIROL, V89, P7660, DOI 10.1128/JVI.01165-15; Crompton T, 2007, NAT REV IMMUNOL, V7, P726, DOI 10.1038/nri2151; De Morrow S, 2008, AM J PHYSIOL-GASTR L, V294, pG506, DOI 10.1152/ajpgi.00304.2007; DECKER T, 1985, INFECT IMMUN, V50, P358, DOI 10.1128/IAI.50.2.358-364.1985; Dimopoulou L, 2004, CRIT CARE MED, V32, P404, DOI 10.1097/01.CCM.0000108885.37811.CA; Foley C, 2009, J VET EMERG CRIT CAR, V19, P269, DOI 10.1111/j.1476-4431.2009.00409.x; Fox A, 2014, J REHABIL RES DEV, V51, P869, DOI 10.1682/JRRD.2013.10.0233; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gaddam Samson Sujit Kumar, 2015, Handb Clin Neurol, V127, P205, DOI 10.1016/B978-0-444-52892-6.00014-3; Gao P, 1999, J HISTOCHEM CYTOCHEM, V47, P1255, DOI 10.1177/002215549904701005; Gao WM, 2014, PEDIATR RES, V76, P280, DOI 10.1038/pr.2014.86; Gooley JJ, 2006, NAT NEUROSCI, V9, P398, DOI 10.1038/nn1651; Gorojankina T, 2016, CELL MOL LIFE SCI, V73, P1317, DOI 10.1007/s00018-015-2127-4; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Gruys E, 2005, J Zhejiang Univ Sci B, V6, P1045, DOI 10.1631/jzus.2005.B1045; Hegde GV, 2008, MOL CANCER RES, V6, P1928, DOI 10.1158/1541-7786.MCR-08-0142; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Hylemon PB, 2009, J LIPID RES, V50, P1509, DOI 10.1194/jlr.R900007-JLR200; Isaksson J, 1997, ACTA NEUROPATHOL, V94, P16, DOI 10.1007/s004010050666; Jain S, 2011, J PHARM BIOALLIED SC, V3, P118, DOI 10.4103/0975-7406.76489; Kawamata Y, 2003, J BIOL CHEM, V278, P9435, DOI 10.1074/jbc.M209706200; Keitel V, 2010, GLIA, V58, P1794, DOI 10.1002/glia.21049; Koniaris LG, 2001, J IMMUNOL, V167, P399, DOI 10.4049/jimmunol.167.1.399; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Lang MF, 2011, J NEUROENDOCRINOL, V23, P1194, DOI 10.1111/j.1365-2826.2011.02216.x; Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; Maier B, 2006, SHOCK, V26, P122, DOI 10.1097/01.shk.0000223127.41641.f4; McColl BW, 2007, J NEUROSCI, V27, P4403, DOI 10.1523/JNEUROSCI.5376-06.2007; McMillin M, 2016, AM J PATHOL, V186, P312, DOI 10.1016/j.ajpath.2015.10.005; McMillin M, 2015, MOL ENDOCRINOL, V29, P1720, DOI 10.1210/me.2015-1087; McMillin M, 2015, J NEUROCHEM, V135, P565, DOI 10.1111/jnc.13243; McNeilly AD, 2010, J HEPATOL, V52, P705, DOI 10.1016/j.jhep.2009.10.037; Miova B, 2015, J CELL BIOCHEM, V116, P2365, DOI 10.1002/jcb.25187; Mukherjee S, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00028; Mukherjee S, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00021; Okuda H, 2016, NEUROCHEM RES, V41, P278, DOI 10.1007/s11064-015-1791-y; Omenetti A, 2011, J HEPATOL, V54, P366, DOI 10.1016/j.jhep.2010.10.003; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; Quinn M, 2014, DIGEST LIVER DIS, V46, P527, DOI 10.1016/j.dld.2014.01.159; Quinn M, 2012, AM J PHYSIOL-GASTR L, V302, pG182, DOI 10.1152/ajpgi.00205.2011; Rodrigues CMP, 2003, P NATL ACAD SCI USA, V100, P6087, DOI 10.1073/pnas.1031632100; Rodrigues TMP, 2002, J CEREBR BLOOD F MET, V22, P463, DOI 10.1097/00004647-200204000-00010; Schubring SR, 2012, NEUROSCI LETT, V506, P322, DOI 10.1016/j.neulet.2011.11.036; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; St-Pierre MV, 2001, J EXP BIOL, V204, P1673; Szymusiak R, 2008, ANN NY ACAD SCI, V1129, P275, DOI 10.1196/annals.1417.027; Tabe-Bordbar S, 2016, FRONT COMPUT NEUROSC, V10, DOI 10.3389/fncom.2016.00027; Tobin RP, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0143-5; Tzirogiannis KN, 2004, ARCH TOXICOL, V78, P321, DOI 10.1007/s00204-004-0549-0; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Venetsanou K, 2007, EUR CYTOKINE NETW, V18, P206, DOI 10.1684/ecn.2007.0112; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; WILMS GE, 1986, RADIOLOGY, V160, P713, DOI 10.1148/radiology.160.3.3526406; Wittmann G, 2015, ENDOCRINOLOGY, V156, P1552, DOI 10.1210/en.2014-1830; Yang AH, 2002, BBA-MOL CELL BIOL L, V1582, P197, DOI 10.1016/S1388-1981(02)00172-5; Yu PP, 2017, MOL NEUROBIOL, V54, P212, DOI 10.1007/s12035-015-9639-7; ZAHEDI K, 1989, J IMMUNOL, V143, P2880; Zhou HP, 2014, STEROIDS, V86, P62, DOI 10.1016/j.steroids.2014.04.016; Zindler E, 2010, BEST PRACT RES-CLIN, V24, P551, DOI 10.1016/j.bpa.2010.11.001	77	14	14	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JAN 20	2017	7								40112	10.1038/srep40112			10	Multidisciplinary Sciences	Science & Technology - Other Topics	EI2TW	WOS:000392342300001	28106051	DOAJ Gold, Green Published			2021-06-18	
J	Cobbs, L; Hasanaj, L; Amorapanth, P; Rizzo, JR; Nolan, R; Serrano, L; Raynowska, J; Rucker, JC; Jordan, BD; Galetta, SL; Balcer, LJ				Cobbs, Lucy; Hasanaj, Lisena; Amorapanth, Prin; Rizzo, John-Ross; Nolan, Rachel; Serrano, Liliana; Raynowska, Jenelle; Rucker, Janet C.; Jordan, Barry D.; Galetta, Steven L.; Balcer, Laura J.			Mobile Universal Lexicon Evaluation System (MULES) test: A new measure of rapid picture naming for concussion	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Concussion; Sports; King-Devick test; Mobile Universal Lexicon Evaluation System; Saccades; Vision	QUALITY-OF-LIFE; PERIRHINAL CORTEX; EYE-MOVEMENTS; REPRESENTATION; HIPPOCAMPUS; KNOWLEDGE; MEMORY	Objective: This study introduces a rapid picture naming test, the Mobile Universal Lexicon Evaluation System (MULES), as a novel, vision-based performance measure for concussion screening. The MULES is a visual-verbal task that includes 54 original photographs of fruits, objects and animals. We piloted MULES in a cohort of volunteers to determine feasibility, ranges of picture naming responses, and the relation of MULES time scores to those of King-Devick (K-D), a rapid number naming test. Methods: A convenience sample (n = 20, age 34 10) underwent MULES and K-D (spiral bound, iPad versions). Administration order was randomized; MULES tests were audio-recorded to provide objective data on temporal variability and ranges of picture naming responses. Results: Scores for the best of two trials for all tests were 40-50 s; average times required to name each MULES picture (0.72 +/- 0.14 s) was greater than those needed for each K-D number ((spiral: 0.33 +/- 0.05 s, iPad: 0.36 +/- 0.06 s, 120 numbers), p < 0.0001, paired t-test). MULES scores showed the greatest degree of improvement between trials (9.4 +/- 4.8 s, p < 0.0001 for trials 1 vs. 2), compared to K-D (spiral 1.5 +/- 3.3 s, iPad 1.8 +/- 3.4 s). Shorter MULES times demonstrated moderate and significant correlations with shorter iPad but not spiral K-D times (r = 0.49, p = 0.03). Conclusion: The MULES test is a rapid picture naming task that may engage more extensive neural systems than more commonly used rapid number naming tasks. Rapid picture naming may require additional processing devoted to color perception, object identification, and categorization. Both tests rely on initiation and sequencing of saccadic eye movements. (C) 2016 Elsevier B.V. All rights reserved.	[Cobbs, Lucy; Hasanaj, Lisena; Nolan, Rachel; Serrano, Liliana; Raynowska, Jenelle; Rucker, Janet C.; Galetta, Steven L.; Balcer, Laura J.] NYU, Dept Neurol, Sch Med, 240 East 38th St,20th Floor, New York, NY 10016 USA; [Balcer, Laura J.] NYU, Sch Med, Dept Populat Hlth, New York, NY USA; [Rucker, Janet C.; Galetta, Steven L.; Balcer, Laura J.] NYU, Dept Ophthalmol, Sch Med, 550 1st Ave, New York, NY 10016 USA; [Amorapanth, Prin; Rizzo, John-Ross] NYU, Sch Med, Dept Phys Med & Rehabil, New York, NY USA; [Jordan, Barry D.] Burke Rehabil Hosp, White Plains, NY USA	Balcer, LJ (corresponding author), NYU, Dept Neurol, Sch Med, 240 East 38th St,20th Floor, New York, NY 10016 USA.	lucy.cobbs@nyumc.org; lisena.hasanaj@nyumc.org; prin.amorapanth@nyumc.org; johnross.rizzo@nyumc.org; rachel.nolan@nyumc.org; liliana.serrano2@nyumc.org; jenelle.raynowska@nyumc.org; janet.rucker@nyumc.org; bjordan@burke.org; steven.galetta@nyumc.org; laura.balcer@nyumc.org		Amorapanth, Prin/0000-0002-4260-7826; Rucker, Janet/0000-0002-0397-0999; Rizzo, John-Ross/0000-0002-4084-0085	NYU School of Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097, R01HD071978] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001073] Funding Source: NIH RePORTER	This study was supported in part by the NYU School of Medicine.	Aggleton JP, 2010, BEHAV NEUROSCI, V124, P55, DOI 10.1037/a0018320; Albasser MM, 2009, BEHAV NEUROSCI, V123, P115, DOI 10.1037/a0013829; Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Cummine J, 2014, BEHAV BRAIN RES, V275, P157, DOI 10.1016/j.bbr.2014.08.038; Dhawan P., 2015, J OPT, V8, P131; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta K.M., 2016, CONCUSSION, V2; Galetta K. M., 2016, ALZHEIMER DIS ASS DI; Galetta KM, 2015, J NEURO-OPHTHALMOL, V35, P235, DOI 10.1097/WNO.0000000000000226; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Grotheer M, 2016, J NEUROSCI, V36, P88, DOI 10.1523/JNEUROSCI.2129-15.2016; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hammond RS, 2004, NEUROBIOL LEARN MEM, V82, P26, DOI 10.1016/j.nlm.2004.03.005; Hargreaves IS, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00022; Heitger MH, 2002, PROG BRAIN RES, V140, P433; Kandel Eric, 2012, THE AGE OF INSIGHT; Kellenbach ML, 2005, CORTEX, V41, P121, DOI 10.1016/S0010-9452(08)70887-6; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; Kourtzi Z, 2011, ANNU REV NEUROSCI, V34, P45, DOI 10.1146/annurev-neuro-060909-153218; Lee ACH, 2006, J NEUROSCI, V26, P5198, DOI 10.1523/JNEUROSCI.3157-05.2006; Lin TP, 2014, PARKINSONISM RELAT D, V20, P226, DOI 10.1016/j.parkreldis.2013.10.009; Marinides Z, 2015, NEUROL CLIN PRACT, V5, P25, DOI DOI 10.1212/CPJ.000000000; Mayhew SD, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00075; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; Moster S, 2014, J NEUROL SCI, V343, P105, DOI 10.1016/j.jns.2014.05.047; Nardone A, 1997, ELECTROMYOGR MOTOR C, V105, P309, DOI 10.1016/S0924-980X(97)00040-4; Parrish RK, 1997, ARCH OPHTHALMOL-CHIC, V115, P1447, DOI 10.1001/archopht.1997.01100160617016; Pierrot-Deseilligny C, 2003, BRAIN, V126, P1460, DOI 10.1093/brain/awg148; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Raynowska J., 2016, NEUROLOGY S1, V86; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Roy JE, 2014, J COGNITIVE NEUROSCI, V26, P1283, DOI 10.1162/jocn_a_00568; Seymour KJ, 2016, CEREB CORTEX, V26, P1997, DOI 10.1093/cercor/bhv021; Shum J, 2013, J NEUROSCI, V33, P6709, DOI 10.1523/JNEUROSCI.4558-12.2013; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5; Watson HC, 2013, J NEUROSCI, V33, P4192, DOI 10.1523/JNEUROSCI.2075-12.2013; White OB, 2012, J NEURO-OPHTHALMOL, V32, P266, DOI 10.1097/WNO.0b013e3182688230	39	14	14	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	JAN 15	2017	372						393	398		10.1016/j.jns.2016.10.044			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EJ1WZ	WOS:000393002500074	27856005	Green Accepted			2021-06-18	
J	Cernak, I; Stein, DG; Elder, GA; Ahlers, S; Curley, K; DePalma, RG; Duda, J; Ikonomovic, M; Iverson, GL; Kobeissy, F; Koliatsos, VE; Leggieri, MJ; Pacifico, AM; Smith, DH; Swanson, R; Thompson, FJ; Tortella, FC				Cernak, Ibolja; Stein, Donald G.; Elder, Gregory A.; Ahlers, Stephn; Curley, Kenneth; DePalma, Ralph G.; Duda, John; Ikonomovic, Milos; Iverson, Grant L.; Kobeissy, Firas; Koliatsos, Vassilis E.; Leggieri, Michael J., Jr.; Pacifico, Anthony M.; Smith, Douglas H.; Swanson, Raymond; Thompson, Floyd J.; Tortella, Frank C.			Preclinical modelling of militarily relevant traumatic brain injuries: Challenges and recommendations for future directions	BRAIN INJURY			English	Article						United States Department of Veterans Affairs; conference; traumatic brain injury; blast-induced neurotrauma; preclinical research; experimental models	LONG-TERM CONSEQUENCES; COMMON DATA ELEMENTS; MITOCHONDRIAL DYSFUNCTION; CONCUSSION; PERSONNEL; UPDATE; PATHOPHYSIOLOGY; PROGESTERONE; EPIDEMIOLOGY; INFLAMMATION	As a follow-up to the 2008 state-of-the-art (SQTA) conference on traumatic brain injuries (TBIs); the 2015 event organized by the United States Department of Veterans Affairs (VA) Office of Research and Development (ORD) analysed the knowledge gained Over the last 7 years as it relates to basic scientific methods, experimental findings, diagnosis. therapy, and rehabilitation of TBIs and blast-induced neurotraumas (BINTs). The current article summarizes the discussions and recommendations of the scientific panel attending the Preclinical Modeling and Therapeutic Development Workshop of the conference; with special emphasis on factors slowing research,progress and recommendations for ways of addressing the most significant pitfalls.	[Cernak, Ibolja] Univ Alberta, Fac Rehabil Med, Mil & Vet Clin Rehabil Res, Edmonton, AB, Canada; [Stein, Donald G.] Emory Sch Med, Dept Emergency Med, Brain Res Lab, Atlanta, GA USA; [Elder, Gregory A.] James J Peters VA Med Ctr, Bronx, NY USA; [Elder, Gregory A.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Ahlers, Stephn] Naval Med Res Ctr, Operat & Undersea Med, Silver Spring, MD USA; [Curley, Kenneth] Latrikos Res & Dev Strategies LLC, Tampa, FL USA; [Curley, Kenneth] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA; [DePalma, Ralph G.] Uniformed Serv Univ Hlth Sci, Off Res & Dev, VA ORD, Washington, DC USA; [DePalma, Ralph G.] Uniformed Serv Univ Hlth Sci, Off Res & Dev, Dept Surg, Washington, DC USA; [Duda, John] Univ Penn, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA; [Duda, John] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; [Ikonomovic, Milos] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; [Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Neuropsychol Outcome Assessment Lab, Boston, MA USA; [Kobeissy, Firas] Univ Florida, Evelyn F & William L McKnight Brain Inst, Dept Psychiat, Psychoprote & Nanotechnol Res Ctr, Gainesville, FL USA; [Koliatsos, Vassilis E.] Johns Hopkins Sch Med, Dept Pathol Neuropathol & Neurol, Baltimore, MD USA; [Leggieri, Michael J., Jr.] US Army, Med Res & Mat Command, DoD Blast Injury Res Program Coordinating Off, Ft Detrick, MD USA; [Pacifico, Anthony M.] Alzheimers & Epilepsy Res Programs, Congressionally Directed Med Res Programs, Ft Detrick, MD USA; [Pacifico, Anthony M.] US Dept Hlth & Human Serv, Telemed & Adv Technol Res Ctr, Ft Detrick, MD USA; [Smith, Douglas H.] Univ Penn, PENNs Ctr Brain Injury & Repair, Robert A Groff Prof Neurosurg Res & Educ, Dept Neurosurg, Philadelphia, PA 19104 USA; [Swanson, Raymond] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Swanson, Raymond] SFVAMC, Neurol Serv, San Francisco, CA USA; [Thompson, Floyd J.] Univ Florida, Malcom Randall VAMC, Brain Rehabil Res Ctr, Gainesville, FL USA; [Thompson, Floyd J.] Univ Florida, Neurosci, Gainesville, FL USA; [Tortella, Frank C.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Branch Brain Trauma Neuroprotect & Neurorestorat, Silver Spring, MD USA	Cernak, I (corresponding author), Univ Alberta, Fac Rehabil Med, Corbett Hall 3-48, Edmonton, AB T6M 2J9, Canada.	cernak@ualberta.ca	DePalma, Ralph/P-1733-2019; Stein, Donald/AAJ-5139-2020	Iverson, Grant/0000-0001-7348-9570; Ibolja, Cernak/0000-0003-3214-698X	RRD VA [I01 RX000996] Funding Source: Medline; Veterans AffairsUS Department of Veterans Affairs [I01RX000996] Funding Source: NIH RePORTER		Ahmed F, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00114; Arun P, 2013, J NEUROTRAUM, V30, P1645, DOI 10.1089/neu.2012.2834; Barkhoudarian G, 2016, PHYS MED REH CLIN N, V27, P373, DOI 10.1016/j.pmr.2016.01.003; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Elder GA, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0591-8; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Giannotti M, 2010, INJURY, V41, P907, DOI 10.1016/j.injury.2009.09.040; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Gubata ME, 2014, J HEAD TRAUMA REHAB, V29, P65, DOI 10.1097/HTR.0b013e318295f590; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; Hicks R, 2013, J NEUROTRAUM, V30, P1852, DOI 10.1089/neu.2013.2938; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Holtkamp MD, 2016, CURR PAIN HEADACHE R, V20, DOI 10.1007/s11916-016-0572-x; Howard RB, 2017, J NEUROTRAUM, V34, P1915, DOI 10.1089/neu.2015.4179; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jeter CB, 2013, J NEUROTRAUM, V30, P671, DOI 10.1089/neu.2012.2491; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; MacGregor AJ, 2011, J REHABIL RES DEV, V48, P1269, DOI 10.1682/JRRD.2011.01.0013; McGinn Melissa J, 2015, Handb Clin Neurol, V127, P67, DOI 10.1016/B978-0-444-52892-6.00005-2; Nelson C, 2011, MIL MED, V176, P156, DOI 10.7205/MILMED-D-10-00252; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; Patel HDL, 2012, J TRAUMA ACUTE CARE, V73, P276, DOI 10.1097/TA.0b013e318256dd80; Peskind ER, 2013, J CLIN PSYCHIAT, V74, P180, DOI 10.4088/JCP.12011co1c; Pryor James, 2016, J Lifestyle Med, V6, P7, DOI 10.15280/jlm.2016.6.1.7; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Smith DH, 2015, J NEUROTRAUM, V32, P1725, DOI 10.1089/neu.2014.3861; Stein DG, 2011, NEUROSCIENCE, V191, P101, DOI 10.1016/j.neuroscience.2011.04.013; Stein DG, 2015, BRAIN INJURY, V29, P1259, DOI 10.3109/02699052.2015.1065344; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Voss JD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0506-z; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002	40	14	14	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	9			SI		1168	1176		10.1080/02699052.2016.1274779			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FK0NN	WOS:000413176600002	28981339	Other Gold			2021-06-18	
J	Cicuendez, M; Castano-Leon, A; Ramos, A; Hilario, A; Gomez, PA; Lagares, A				Cicuendez, Marta; Castano-Leon, Ana; Ramos, Ana; Hilario, Amaya; Gomez, Pedro A.; Lagares, Alfonso			Prognostic value of corpus callosum injuries in severe head trauma	ACTA NEUROCHIRURGICA			English	Article						Traumatic axonal injury; Corpus callosum injury; Traumatic brain injury; Severe head trauma; Magnetic resonance imaging	DIFFUSE AXONAL INJURY; BRAIN-INJURY; MAGNETIC-RESONANCE; MRI; IMPACT; STEM; CLASSIFICATION; VALIDATION; INTEGRITY; DIAGNOSIS	Background This study was performed to investigate the relationship between corpus callosum (CC) injury and prognosis in traumatic axonal injury (TAI). Method We retrospectively reviewed 264 patients with severe head trauma who underwent a conventional MR imaging in the first 60 days after injury. They were selected from a prospectively collected database of 1048 patients with severe head trauma admitted in our hospital. TAI lesions were defined as areas of increased signal intensity on T2 and FLAIR or areas of decreased signal on gradient-echo T2. We attempted to determine whether any MR imaging findings of TAI lesions at CC could be related to prognosis. Neurological impairment was assessed at 1 year after injury by means of GOS-E (good outcome being GOS-E 4/5 and bad outcome being GOS-E < 4). We adjusted the multivariable analysis for the prognostic factors according to the IMPACT studies: the Core model (age, motor score at admission, and pupillary reactivity) and the Extended model (including CT information and second insults). Results We found 97 patients (37 %) with TAI at CC and 167 patients (63 %) without CC lesions at MR. A total of 62 % of the patients with CC lesions had poor outcome, whereas 38% showed good prognosis. The presence of TAI lesions at the corpus callosum was associated with poor outcome 1 year after brain trauma (p < 0.001, OR 3.8, 95 % CI: 2.04-7.06). The volume of CC lesions measured on T2 and FLAIR sequences was negatively correlated with the GOS-E after adjustment for independent prognostic factors (p = 0.01, OR 2.23, 95 % CI: 1.17-4.26). Also the presence of lesions at splenium was statistically related to worse prognosis (p = 0.002, OR 8.1, 95 % CI: 2.2-29.82). We did not find statistical significance in outcome between hemorrhagic and non-hemorrhagic CC lesions. Conclusions The presence of CC is associated with a poor outcome. The total volume of the CC lesion is an independent prognostic factor for poor outcome in severe head trauma.	[Cicuendez, Marta] Hosp Univ Vall dHebron, Dept Neurosurg, Barcelona, Spain; [Castano-Leon, Ana; Gomez, Pedro A.; Lagares, Alfonso] Univ Complutense Madrid, Inst Invest I 12, Dept Neurosurg, Hosp Univ Octubre 12, Madrid, Spain; [Ramos, Ana; Hilario, Amaya] Univ Complutense Madrid, Hosp Univ Octubre 12, Dept Neuroradiol, Madrid, Spain	Cicuendez, M (corresponding author), Hosp Univ Vall dHebron, Dept Neurosurg, Barcelona, Spain.	marta.cicuendez@gmail.com	Lagares, Alfonso/B-2969-2011; Gomez, Pedro/N-5051-2019; Castano-Leon, Ana M/ABF-6322-2020	Lagares, Alfonso/0000-0003-3996-0554; Gomez, Pedro/0000-0002-4185-5238; Castano-Leon, Ana M/0000-0002-7918-5049	ISCIIIInstituto de Salud Carlos III; FEDER European institutions [PI14/0157]	This research was jointly funded by the ISCIII and FEDER European institutions, with FIS project number PI14/0157. The sponsor had no role in the design or conduct of this research.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Dennis EL, 2015, J NEUROSCI, V35, P10202, DOI 10.1523/JNEUROSCI.1595-15.2015; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gomez PA, 2014, NEUROCIRUGIA, V25, P199, DOI 10.1016/j.neucir.2014.05.001; Hilario A, 2012, AM J NEURORADIOL, V33, P1925, DOI 10.3174/ajnr.A3092; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Lagares A, 2006, NEUROCIRUGIA, V17, P105; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; Leibson CL, 2011, EPIDEMIOLOGY, V22, P836, DOI 10.1097/EDE.0b013e318231d535; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Messori A, 2003, NEURORADIOLOGY, V45, P881, DOI 10.1007/s00234-003-1048-3; Moen KG, 2014, J NEUROTRAUM, V31, P1486, DOI 10.1089/neu.2013.3258; Moen KG, 2014, J NEUROTRAUM, V31, P56, DOI 10.1089/neu.2013.3000; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Treble A, 2013, J NEUROTRAUM, V30, P1609, DOI 10.1089/neu.2013.2934; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	31	14	14	1	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JAN	2017	159	1					25	32		10.1007/s00701-016-3000-4			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EJ2EE	WOS:000393022000009	27796652				2021-06-18	
J	de Koning, ME; Scheenen, ME; van der Horn, HJ; Hageman, G; Roks, G; Yilmaz, T; Spikman, JM; van der Naalt, J				de Koning, M. E.; Scheenen, M. E.; van der Horn, H. J.; Hageman, G.; Roks, G.; Yilmaz, T.; Spikman, J. M.; van der Naalt, J.			Outpatient follow-up after mild traumatic brain injury: Results of the UPFRONT-study	BRAIN INJURY			English	Article						Mild traumatic brain injury; follow-up; hospital admission; outcome; guideline	HEAD-INJURY; SYMPTOMS; MODERATE; TOMOGRAPHY; COMPLAINTS; WORK; BIAS; CARE	Objective: To investigate outpatient follow-up after mild traumatic brain injury (mTBI) by various medical specialists, for both hospitalized and non-hospitalized patients, and to study guideline adherence regarding hospital admission. Methods: Patients (n = 1151) with mTBI recruited from the emergency department received questionnaires 2 weeks (n = 879), 3 months (n = 780) and 6 months (n = 668) after injury comprising outpatient follow-up by various health care providers, and outcome defined by the Glasgow Outcome Scale Extended (GOS-E) after 6 months. Results: Hospitalized patients (60%) were older (46.6 +/- 19.9 vs. 40.6 +/- 18.5 years), more severely injured (GCS <15, 50% vs. 13%) with more Computed Tomography (CT) abnormalities on admission (21% vs. 2%) compared to non-hospitalized patients (p < 0.01). Almost half of the patients visited a neurologist at the outpatient clinic within six months,(60% of the hospitalized and 25% of the non-hospitalized patients (x(2) = 67.10, p < 0.01)), and approximately ten per cent consulted a psychiatrist/psychologist. Outcome was unfavourable (GOS-E <7) in 34% of hospitalized and 21% of non-hospitalized patients (x(2) = 11.89, p <0.01). Conclusion: Two-thirds of all mTBI patients consult one or more specialists within six months after injury, with 30% having an unfavourable outcome. A quarter of non-hospitalized: patients was seen at the outpatient neurology clinic, underling the importance of regular follow-up of mTBI patients irrespective of hospital admittance.	[de Koning, M. E.; van der Horn, H. J.; van der Naalt, J.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9700 RB Groningen, Netherlands; [Scheenen, M. E.; Spikman, J. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Neuropsychol, Groningen, Netherlands; [Hageman, G.] Med Spectrum Twente, Dept Neurol, Enschede, Netherlands; [Roks, G.; Yilmaz, T.] St Elizabeth Hosp, Dept Neurol, Tilburg, Netherlands	van der Naalt, J (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9700 RB Groningen, Netherlands.	j.van.der.naalt@umcg.nl		Spikman, Jacoba/0000-0002-6477-0763; van der Naalt, Joukje/0000-0001-9873-2418; Roks, Gerwin/0000-0002-1393-9848	Dutch Brain Foundation [PS2012-06]	This study was funded by the Dutch Brain Foundation (Grant no. PS2012-06).The authors report no declaration of interest.	Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; de Koning ME, 2015, BRAIN INJURY, V29, P423, DOI 10.3109/02699052.2014.982188; Faul M, 2010, CTR DIS CONTROL PREY, P2; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Laborey M, 2014, J HEAD TRAUMA REHAB, V29, pE28, DOI 10.1097/HTR.0b013e318280f896; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Matuseviciene G, 2015, ORIGINAL REPORT EFFE; Matuseviciene G, 2013, BRAIN INJURY, V27, P318, DOI 10.3109/02699052.2012.750740; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Patel MB, 2015, J NEUROTRAUM, V6; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Scholten AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110905; van der Horn HJ, 2013, ARCH PHYS MED REHAB, V94, P867, DOI 10.1016/j.apmr.2012.11.039; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vikane E, 2014, BRAIN INJURY, V9052, P1; Vos PE, 2012, EUR J NEUROL, V19, P191, DOI 10.1111/j.1468-1331.2011.03581.x; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zonfrillo MR, 2015, ACAD EMERG MED, V22, P872, DOI 10.1111/acem.12696	31	14	14	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	8					1102	1108		10.1080/02699052.2017.1296193			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FC3JI	WOS:000406734500010	28481634	Other Gold, Green Published			2021-06-18	
J	Flatt, JD; Williams, BA; Barnes, D; Goldenson, J; Ahalt, C				Flatt, Jason D.; Williams, Brie A.; Barnes, Deborah; Goldenson, Joe; Ahalt, Cyrus			Post-traumatic stress disorder symptoms and associated health and social vulnerabilities in older jail inmates	AGING & MENTAL HEALTH			English	Article						PTSD; incarceration; geriatric; health	TRAUMATIC BRAIN-INJURY; MEDICAL CONDITIONS; COMBAT EXPOSURE; PRISON; ADULTS; PTSD; PREVALENCE; LIFETIME; RISK; CARE	Objectives: To examine post-traumatic stress disorder (PTSD) symptoms in older jail inmates, and to determine whether adverse social and health-related characteristics were associated with having PTSD symptoms.Method: We performed an exploratory cross-sectional study of 238 older (age 55 years) jail inmates from a county jail. PTSD symptoms were determined using the Primary Care PTSD (PC-PTSD) screen. Reporting three or more PTSD symptoms was defined as a positive screen. Descriptive statistics and multiple regression analyses were used to examine the prevalence of a positive PTSD screen and associations with social and health-related characteristics.Results: The mean age was 59years, 64% were Black, and 82% reported an annual income $15,000. Nearly 40% of older jail inmates had a positive PTSD screen and 10% reported a prior PTSD diagnosis by a physician. Older jail inmates with a positive PTSD screen were significantly more likely than those with a negative PTSD screen to report medication insecurity in the past year, impairment in two or more activities of daily living, traumatic brain injury, pain in the past week, and poor self-rated health.Conclusion: Over one in three of the older jail inmates in this study had a positive PTSD screen, though only one in five of those with a positive screen reported a prior PTSD diagnosis. Screening for PTSD in jails may help identify older inmates who would benefit from additional mental health treatment and reentry planning to improve health in this population.	[Flatt, Jason D.] Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA 94143 USA; [Williams, Brie A.; Ahalt, Cyrus] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA; [Flatt, Jason D.; Williams, Brie A.; Barnes, Deborah] San Francisco VA Med Ctr, San Francisco, CA 94121 USA; [Barnes, Deborah] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA; [Goldenson, Joe] San Francisco Dept Publ Hlth, Jail Hlth Serv, San Francisco, CA USA	Flatt, JD (corresponding author), Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA 94143 USA.; Flatt, JD (corresponding author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA.	Jason.Flatt@ucsf.edu		Flatt, Jason/0000-0003-1244-738X	National Institute of AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG044281]; Jacob & Valeria Langeloth Foundation; Tideswell at UCSF; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG044281] Funding Source: NIH RePORTER	This work was supported by the National Institute of Aging [grant number P30AG044281], the Jacob & Valeria Langeloth Foundation, and Tideswell at UCSF. These funding sources had no role in the preparation, review, or approval of the manuscript. Drs Flatt, Barnes and Williams are employees of the Department of Veterans Affairs. The opinions expressed in this manuscript may not represent those of the VA. The views expressed herein do not necessarily reflect the official policies of the City and County of San Francisco; nor does mention of the San Francisco Department of Public Health imply its endorsement.	Ardino V, 2012, EUR J PSYCHOTRAUMATO, V3, DOI 10.3402/ejpt.v3i0.18968; Asmundson GJG, 2000, BEHAV RES THER, V38, P203, DOI 10.1016/S0005-7967(99)00061-3; Baillargeon J, 2009, AM J PSYCHIAT, V166, P103, DOI 10.1176/appi.ajp.2008.08030416; Beck A., 2010, SEXUAL VICTIMIZATION, P26; Beck A. J., 2006, URB I JAIL REENTR RO; Binswanger IA, 2009, J EPIDEMIOL COMMUN H, V63, P912, DOI 10.1136/jech.2009.090662; Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI 10.1056/NEJMsa064115; Binswanger IA, 2012, J URBAN HEALTH, V89, P98, DOI 10.1007/s11524-011-9614-1; Bottche M, 2012, INT J GERIATR PSYCH, V27, P230, DOI 10.1002/gps.2725; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; BUSH TL, 1989, AM J PUBLIC HEALTH, V79, P1554, DOI 10.2105/AJPH.79.11.1554; Calhoun PS, 2010, PSYCHIAT RES, V178, P330, DOI 10.1016/j.psychres.2009.11.009; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Chodos AH, 2014, AM J PUBLIC HEALTH, V104, P1728, DOI 10.2105/AJPH.2014.301952; Dannefer D, 2003, J GERONTOL B-PSYCHOL, V58, pS327, DOI 10.1093/geronb/58.6.S327; Elbogen EB, 2012, J CONSULT CLIN PSYCH, V80, P1097, DOI 10.1037/a0029967; Goff Ashley, 2007, Crim Behav Ment Health, V17, P152; Hanson RK, 2012, CRIM JUSTICE BEHAV, V39, P1391, DOI 10.1177/0093854812449217; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Haugebrook Sabrina, 2010, J Correct Health Care, V16, P220, DOI 10.1177/1078345810367482; Hills H., 2004, EFFECTIVE PRISON MEN; Jenkinson C, 1997, J PUBLIC HEALTH MED, V19, P179, DOI 10.1093/oxfordjournals.pubmed.a024606; Kaba F, 2015, AM J PUBLIC HEALTH, V105, P1911, DOI 10.2105/AJPH.2015.302699; Kang S, 2016, GERONTOLOGIST, V56, P22, DOI 10.1093/geront/gnv120; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kimerling R, 2006, ADDICT BEHAV, V31, P2074, DOI 10.1016/j.addbeh.2006.02.008; Krause N, 2004, GERONTOLOGIST, V44, P615, DOI 10.1093/geront/44.5.615; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Maschi T, 2014, GERONTOLOGIST, V54, P857, DOI 10.1093/geront/gnt069; Maschi T, 2011, GERONTOLOGIST, V51, P675, DOI 10.1093/geront/gnr074; National Institute on Aging National Institutes of Health U. S. Department of Health and Human Services, 2012, GROWING OLDER IN AME; Nowotny KM, 2016, J AGING HEALTH, V28, P935, DOI 10.1177/0898264315614007; Pietrzak RH, 2012, J AM GERIATR SOC, V60, P296, DOI 10.1111/j.1532-5415.2011.03788.x; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Quanbeck CD, 2005, PSYCHIAT SERV, V56, P847, DOI 10.1176/appi.ps.56.7.847; Regenstein M., 2012, MEDICAID COVERAGE IN; Sachs-Ericsson N, 2016, GERONTOLOGIST, V56, P82, DOI 10.1093/geront/gnv036; Sadeh N, 2015, CRIM JUSTICE BEHAV, V42, P573, DOI 10.1177/0093854814556880; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Sledjeski EM, 2008, J BEHAV MED, V31, P341, DOI 10.1007/s10865-008-9158-3; Smoyer AB, 2009, AM J PUBLIC HEALTH, V99, P1746, DOI 10.2105/AJPH.2008.148726; Snyder H., 2012, ARREST US 1990 2010, P26; Stewart AL, 2012, J AGING HEALTH, V24, P992, DOI 10.1177/0898264312440321; Sudore RL, 2006, J GEN INTERN MED, V21, P867, DOI 10.1111/j.1525-1497.2006.00535.x; van Dam D, 2010, J SUBST ABUSE TREAT, V39, P105, DOI 10.1016/j.jsat.2010.05.005; Wang Emily A, 2012, Am J Public Health, V102, pe22, DOI 10.2105/AJPH.2012.300894; Wang EA, 2010, PUBLIC HEALTH REP, V125, P171, DOI 10.1177/003335491012500205; WEISS DS, 1992, J TRAUMA STRESS, V5, P365, DOI 10.1007/BF00977234; Williams BA, 2014, J PALLIAT MED, V17, P1336, DOI 10.1089/jpm.2014.0160; Williams BA, 2012, AM J PUBLIC HEALTH, V102, P1475, DOI 10.2105/AJPH.2012.300704; Williams BA, 2010, J GEN INTERN MED, V25, P1038, DOI 10.1007/s11606-010-1416-8; Williams WH, 2010, BRAIN INJURY, V24, P1184, DOI 10.3109/02699052.2010.495697	54	14	14	1	11	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1360-7863	1364-6915		AGING MENT HEALTH	Aging Ment. Health		2017	21	10					1106	1112		10.1080/13607863.2016.1201042			7	Geriatrics & Gerontology; Gerontology; Psychiatry	Geriatrics & Gerontology; Psychiatry	FB8KF	WOS:000406387200017	27367335	Green Accepted			2021-06-18	
J	Gardner, AJ; Kohler, RMN; Levi, CR; Iverson, GL				Gardner, Andrew J.; Kohler, Ryan M. N.; Levi, Christopher R.; Iverson, Grant L.			Usefulness of Video Review of Possible Concussions in National Youth Rugby League	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article						concussion; video analysis; injury management; return to play	INCIDENT ANALYSIS; INJURY; SPORT; POSITION; MATCH	A new concussion interchange rule (CIR) was introduced in 2014 for the National Rugby League and National Youth Competition (NYC). The CIR allows a player suspected of having sustained a concussion to be removed from play and assessed without an interchange being tallied against the player's team. Participants included all NYC players who used the CIR during the 2014 season. 2 raters completed video analysis of 131 (of a total of 156 reported) uses of the CIR, describing injury characteristics, situational factors, and concussion signs. The incidence rate was 44.9 (95 % CI: 38.5-52.3) uses of the CIR per 1 000 NYC player match hours, or approximately one CIR use every 1.3 games. Apparent loss of consciousness/unresponsiveness was observed in 13 % of cases, clutching the head in 65 %, unsteadiness of gait in 60 %, and a vacant stare in 23 %. Most incidences occurred from a hit-up (82 %). There appeared to be some instances of video evidence of injury but the athlete was cleared to return to play in the same game. Video review appears to be a useful adjunct for identifying players suffering possible concussion. Further research is required on the usefulness of video review for identifying signs of concussive injury.	[Gardner, Andrew J.] Univ Newcastle, Prior Res Ctr Stroke & Brain Injury, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia; [Levi, Christopher R.] Hunter New England Local Hlth Dist, Sports Concuss Program, New Lambton Hts, Australia; [Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA	Gardner, AJ (corresponding author), Univ Newcastle, Prior Res Ctr Stroke & Brain Injury, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia.	andrew.gardner@neurogard.com.au		Iverson, Grant/0000-0001-7348-9570; Levi, Christopher/0000-0002-9474-796X	Hunter Medical Research Institute; Hunter Medical Research Institute - Greaves Family Early Career Fellowship Fund; Mooney-Reed Charitable Foundation	Andrew J. Gardner and Christopher R. Levi have been funded to conduct research into concussion in rugby league through a New South Wales Sporting Injuries Committee-Sports Research & Injury Prevention Scheme Grant, and a Brain Foundation, Australia-Brain Injury Award. Andrew J. Gardner acknowledges sport concussion research fellowship funding from Jennie Thomas, Life Governor of the Hunter Medical Research Institute, and the Hunter Medical Research Institute supported by the Greaves Family Early Career Fellowship Fund. Grant L. Iverson acknowledges support from the Mooney-Reed Charitable Foundation.	Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Davis G, 2016, J SCI MED SPORT, V19, P898, DOI 10.1016/j.jsams.2016.02.005; Gabbett T, 2009, INT J SPORTS SCI COA, V4, P521, DOI 10.1260/174795409790291402; Gabbett TJ, 2005, J STRENGTH COND RES, V19, P749; Gardner AJ, 2016, INT J SPORTS MED, V37, P267, DOI 10.1055/s-0035-1565203; Gardner AJ, 2015, BRAIN INJ; Gardner A, 2015, BRIT J SPORT MED, V49, P495, DOI 10.1136/bjsports-2013-093102; Gardner AJ, 2015, BRAIN INJURY, V29, P1182, DOI 10.3109/02699052.2015.1034179; Hallgren Kevin A, 2012, Tutor Quant Methods Psychol, V8, P23; Harriss DJ, 2015, INT J SPORTS MED, V36, P1121, DOI 10.1055/s-0035-1565186; Hoskins W, 2006, J SCI MED SPORT, V9, P46, DOI 10.1016/j.jsams.2006.03.013; Hutchison MG, 2013, BRIT J SPORT MED, P1; IBM Corp, IBM SPSS STAT MAC VE; King D, 2010, INT J PERF ANAL SPOR, V10, P241; King DA, 2010, SPORTS MED, V40, P163, DOI 10.2165/11319740-000000000-00000; Koh JO, 2004, BRAIN INJURY, V18, P1287, DOI 10.1080/02699050410001719907; Lincoln AE, 2013, AM J SPORT MED, V41, P756, DOI 10.1177/0363546513476265; Makdissi M, 2016, J SCI MED SPORT, V19, P958, DOI 10.1016/j.jsams.2016.02.014; Makdissi M, 2016, J SCI MED SPORT, V19, P859, DOI 10.1016/j.jsams.2016.02.015; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Miele VJ, 2007, NEUROSURGERY, V60, P307, DOI 10.1227/01.NEU.0000249247.48299.5B; Savage Jason, 2013, J Sports Med (Hindawi Publ Corp), V2013, P304576, DOI 10.1155/2013/304576	23	14	15	0	8	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622	1439-3964		INT J SPORTS MED	Int. J. Sports Med.	JAN	2017	38	1					71	75		10.1055/s-0042-116072			5	Sport Sciences	Sport Sciences	EG9TI	WOS:000391402000008	27737484				2021-06-18	
J	Geytenbeek, M; Fleming, J; Doig, E; Ownsworth, T				Geytenbeek, Megan; Fleming, Jennifer; Doig, Emmah; Ownsworth, Tamara			The occurrence of early impaired self-awareness after traumatic brain injury and its relationship with emotional distress and psychosocial functioning	BRAIN INJURY			English	Article						Metacognition; brain injury; severity; outcome; depression; stress	ANXIETY STRESS SCALES; PSYCHOMETRIC PROPERTIES; REHABILITATION; DEPRESSION; DEFICITS; TRANSITION; ADJUSTMENT; OUTCOMES; HOME; SEVERITY	Objective: To describe the occurrence of impaired self-awareness (ISA) after traumatic brain Injury (TBI) and its association with emotional distress and psychosocial functioning following discharge. Design: Prospective cohort design with data collection at discharge and 1-, 3- and 6-month follow-up. Participants: 81 adults with TBI. Measures: Self-awareness was measured using a discrepancy score generated from the Mayo-Portland Adaptability Index (MPAI-4) Ability subscale, and significant other's ratings of Item 20 on the MPAI-4. Other measures were the Depression Anxiety Stress Scale-21 and Sydney Psychosocial and Reintegration Scale. Results: The discrepancy score method identified more cases of ISA than the single-item rating by significant others. Using discrepancy scores, the occurrence of ISA was 69.1% at discharge, and for those remaining in the study 6 months later, it was 54.3%. Better self-awareness was associated with greater anxiety at discharge, and stress at discharge, 3 and 6 months later, and better psychosocial functioning at all time points. Participants with ISA had significantly poorer relationships at 6 months post-discharge after controlling for injury severity. Conclusion: Whilst self-awareness is associated with greater stress in patients with TBI, It is also associated with better outcomes, Indicating the Importance of targeting ISA In rehabilitation.	[Geytenbeek, Megan; Fleming, Jennifer; Doig, Emmah] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia; [Geytenbeek, Megan; Fleming, Jennifer] Princess Alexandra Hosp, Occupat Therapy Dept, Brisbane, Qld, Australia; [Ownsworth, Tamara] Griffith Univ, Sch Appl Psychol, Mt Gravatt, Qld, Australia; [Ownsworth, Tamara] Griffith Univ, Menzies Hlth Inst Queensland, Mt Gravatt, Qld, Australia	Fleming, J (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia.	j.fleming@uq.edu.au	Doig, Emmah/AAG-6674-2021	Doig, Emmah/0000-0002-7020-053X; Fleming, Jennifer/0000-0002-5603-2410; Ownsworth, Tamara/0000-0003-1835-7094	Acquired Brain Injury Outreach Service; Australian Research Council Linkage ProjectAustralian Research Council [LP0776294]; Department of Communities, Disability Services; NHMRC Postdoctoral Research Fellowship - Centre Research Excellence in Traumatic Brain Injury RecoveryNational Health and Medical Research Council of Australia [APP1023043]	The authors report no conflicts of interest. The project was funded by an Australian Research Council Linkage Project (LP0776294) with the Department of Communities, Disability Services and the Acquired Brain Injury Outreach Service as industry partners. Emmah Doig was in receipt of a NHMRC Postdoctoral Research Fellowship funded by the Centre Research Excellence in Traumatic Brain Injury Recovery (APP1023043).	ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; Bach LJ, 2006, NEUROPSYCHOL REHABIL, V16, P397, DOI 10.1080/09602010500412830; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Carroll E, 2011, NEUROPSYCHOL REHABIL, V21, P289, DOI 10.1080/09602011.2011.555972; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Clare L, 2011, DEMENT GERIATR COGN, V31, P317, DOI 10.1159/000327356; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; De Wolf A, 2010, QUAL LIFE RES, V19, P1185, DOI 10.1007/s11136-010-9685-6; Dirette DK., 2008, BRIT J OCCUPATIONAL, V71, P44, DOI DOI 10.1177/030802260807100202; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; Pagulayan KF, 2007, J INT NEUROPSYCH SOC, V13, P561, DOI 10.1017/S1355617707070713; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fleming JM, 2006, NEUROPSYCHOL REHABIL, V16, P474, DOI 10.1080/09602010500505518; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fleming JM, 2006, BRAIN IMPAIR, V7, DOI [10.1375/brim.7.2.83, DOI 10.1375/BRIM.7.2.83]; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kervick RB, 2005, BRAIN INJURY, V19, P881, DOI 10.1080/02699050400025273; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Malec JF, 2002, ARCH PHYS MED REHAB, V83, P1759, DOI 10.1053/apmr.2002.36072; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; Malec JF., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; Malec JF., 2005, The Mayo-Portland Adaptability Inventory; McBrinn J, 2008, BRAIN INJURY, V22, P765, DOI 10.1080/02699050802372208; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Morton N, 2010, J INT NEUROPSYCH SOC, V16, P1089, DOI 10.1017/S1355617710000925; Nalder E, 2012, J REHABIL MED, V44, P837, DOI 10.2340/16501977-1033; Nalder E, 2012, J HEAD TRAUMA REHAB, V27, P143, DOI 10.1097/HTR.0b013e3182168fb1; Newman AC, 2000, BRAIN INJURY, V14, P333; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Ownsworth T., 2005, NEUROPSYCHOANALYSIS, V7, P83; Ownsworth T, 2007, NEUROPSYCHOL REHABIL, V17, P129, DOI 10.1080/09602010600615506; Ownsworth TL, 2008, NEUROPSYCHOL REHABIL, V18, P692, DOI 10.1080/09602010701595136; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Ponsford J, 2014, J HEAD TRAUMA REHAB, V29, P307, DOI 10.1097/HTR.0000000000000074; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Portney LG, 2009, FDN CLIN RES APPL PR, P451; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Simmond M, 2003, BRIT J OCCUPATIONAL, V66, P447, DOI DOI 10.1177/030802260306601003; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Tabachnick BG, 2007, USING MULTIVARIATE S, P60; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Tate RL, 2011, J REHABIL MED, V43, P609, DOI 10.2340/16501977-0829; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Turner B, 2009, AM J OCCUP THER, V63, P609, DOI 10.5014/ajot.63.5.609; Vanderploeg RD, 2007, J REHABIL RES DEV, V44, P937, DOI 10.1682/JRRD.2006.12.0163; von Holst H, 2004, J REHABIL MED, V36, P8, DOI 10.1080/16501960410023633; Wallace CA, 2000, BRAIN INJURY, V14, P549; Wise K, 2005, BRAIN INJURY, V19, P765, DOI 10.1080/0269905050019977	64	14	14	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	13-14					1791	1798		10.1080/02699052.2017.1346297			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FO2MD	WOS:000416612500010	29058497				2021-06-18	
J	Jalan, D; Saini, N; Zaidi, M; Pallottie, A; Elkabes, S; Heary, RF				Jalan, Devesh; Saini, Neginder; Zaidi, Mohammad; Pallottie, Alexandra; Elkabes, Stella; Heary, Robert F.			Effects of early surgical decompression on functional and histological outcomes after severe experimental thoracic spinal cord injury	JOURNAL OF NEUROSURGERY-SPINE			English	Article						durotomy; duraplasty; DuraSeal; catwalk; contusion; pain; spinal cord injury; thoracic	CEREBRAL-ARTERY INFARCTION; TRAUMATIC BRAIN-INJURY; HYDROGEL DURAL SEALANT; BLADDER FUNCTION; RISK-FACTORS; CRANIECTOMY; REPAIR; MULTICENTER; SURGERY; TRIAL	OBJECTIVE In acute traumatic brain injury, decompressive craniectomy is a common treatment that involves the removal of bone from the cranium to relieve intracranial pressure. The present study investigated whether neurological function following a severe spinal cord injury improves after utilizing either a durotomy to decompress the intradural space and/or a duraplasty to maintain proper flow of cerebrospinal fluid. METHODS Sixty-four adult female rats (n = 64) were randomly assigned to receive either a 3- or 5-level decompressive laminectomy (Groups A and B), laminectomy + durotomy (Groups C and D), or laminectomy + duraplasty with graft (Group E and F) at 24 hours following a severe thoracic contusion injury (200 kilodynes). Duraplasty involved the use of DuraSeal, a hydrogel dural sealant. Uninjured and injured control groups were included (Groups G, H). Hindlimb locomotor function was assessed by open field locomotor testing (BBB) and CatWalk gait analysis at 35 days postinjury. Bladder function was analyzed and bladder wall thickness was assessed histologically. At 35 days postinjury, mechanical and thermal allodynia were assessed by the Von Frey hair filament and hotplate paw withdrawal tests, respectively. Thereafter, the spinal cords were dissected, examined for gross anomalies at the injury site, and harvested for histological analyses to assess lesion volumes and white matter sparing. ANOVA was used for statistical analyses. RESULTS There was no significant improvement in motor function recovery in any treatment groups compared with injured controls. CatWalk gait analysis indicated a significant decrease in interlimb coordination in Groups B, C, and D (p < 0.05) and swing speed in Groups A, B, and D. Increased mechanical pain sensitivity was observed in Groups A, C, and F (p < 0.05). Rats in Group C also developed thermal pain hypersensitivity. Examination of spinal cords demonstrated increased lesion volumes in Groups C and F and increased white matter sparing in Group E (p < 0.05). The return of bladder automaticity was similar in all groups. Examination of the injury site during tissue harvest revealed that, in some instances, expansion of the hydrogel dural sealant caused compression of the spinal cord. CONCLUSIONS Surgical decompression provided no benefit in terms of neurological improvement in the setting of a severe thoracic spinal cord contusion injury in rats at 24 hours postinjury. Decompressive laminectomy and durotomy did not improve motor function recovery, and rats in both of these treatment modalities developed neuropathic pain. Performing a durotomy also led to increased lesion volumes. Placement of DuraSeal was shown to cause compression in some rats in the duraplasty treatment groups. Decompressive duraplasty of 3 levels does not affect functional outcomes after injury but did increase white matter sparing. Decompressive duraplasty of 5 levels led to neuropathic pain development and increased lesion volumes. Further comparison of dural repair techniques is necessary.	[Jalan, Devesh; Saini, Neginder; Zaidi, Mohammad; Elkabes, Stella; Heary, Robert F.] Rutgers State Univ, Dept Neurol Surg, New Jersey Med Sch, 90 Bergen St,Ste 8100, Newark, NJ 07103 USA; [Pallottie, Alexandra] Rutgers State Univ, Grad Sch Biomed Sci, Newark, NJ USA	Heary, RF (corresponding author), Rutgers State Univ, Dept Neurol Surg, New Jersey Med Sch, 90 Bergen St,Ste 8100, Newark, NJ 07103 USA.	heary@njms.rutgers.edu	Elkabes, Stella/AAR-8212-2020; Elkabes, Stella/H-7823-2019	Zaidi, Mohammad/0000-0002-3024-0414	Reynolds Family Spine Laboratory	This study was financed by the Reynolds Family Spine Laboratory. DuraSeal is a registered trademark and DuraSeal Exact spine sealant was donated by Integra LifeSciences Corp. to the laboratory for use in this study. Dr. Heary reports receipt of royalties from DePuy Spine, Zimmer Inc., and Thieme Medical Publishers.	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Abla AA, 2010, J CRANIOVERTEBRAL JU, V1, P29, DOI 10.4103/0974-8237.65479; [Anonymous], 2016, SPIN CORD INJ SCI FA; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Blackburn SL, 2007, J NEUROSURG, V106, P302, DOI 10.3171/ped.2007.106.4.302; Boogaarts JD, 2005, NEUROSURGERY, V57, P146, DOI 10.1227/01.NEU.0000164384.05351.59; Bourassa-Moreau E, 2016, J NEUROTRAUM, V33, P301, DOI 10.1089/neu.2015.3957; Cadotte David W, 2010, F1000 Med Rep, V2, P67, DOI 10.3410/M2-67; Conour LA, 2006, ILAR J, V47, P283, DOI 10.1093/ilar.47.4.283; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cosgrove GR, 2007, J NEUROSURG, V106, P52, DOI 10.3171/jns.2007.106.1.52; DELAMARTER RB, 1995, J BONE JOINT SURG AM, V77A, P1042, DOI 10.2106/00004623-199507000-00010; Detloff MR, 2013, J NEUROTRAUM, V30, P884, DOI 10.1089/neu.2012.2632; Diatchenko L, 2005, HUM MOL GENET, V14, P135, DOI 10.1093/hmg/ddi013; Dvorak MF, 2015, J NEUROTRAUM, V32, P645, DOI 10.1089/neu.2014.3632; Fehlings MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032037; Fouad K, 2009, SPINAL CORD, V47, P727, DOI 10.1038/sc.2009.10; Fowler CJ, 1996, J NEUROL NEUROSUR PS, V60, P6, DOI 10.1136/jnnp.60.1.6; Furlan JC, 2011, J NEUROTRAUM, V28, P1371, DOI 10.1089/neu.2009.1147; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Houle JD, 2003, EXP NEUROL, V182, P247, DOI 10.1016/S0014-4886(03)00029-3; Huang X, 2010, INT J MED SCI, V7, P385; Hulsebosch CE, 2009, BRAIN RES REV, V60, P202, DOI 10.1016/j.brainresrev.2008.12.010; Hutchinson P, 2009, CRIT CARE S1, pP85; Iannotti C, 2006, J NEUROTRAUM, V23, P853, DOI 10.1089/neu.2006.23.853; Jakeman L.B., 2012, ANIMAL MODELS ACUTE, VII, P417, DOI DOI 10.1007/978-1-61779-782-8_37; Kim KD, 2011, SPINE, V36, P1906, DOI 10.1097/BRS.0b013e3181fdb4db; Koopmans GC, 2005, J NEUROTRAUM, V22, P214, DOI 10.1089/neu.2005.22.214; Lee G, 2010, SPINE, V35, pE1522, DOI 10.1097/BRS.0b013e3181edfe2c; Lee Si-Hoon, 2013, Korean J Spine, V10, P44, DOI 10.14245/kjs.2013.10.1.44; Li Yiping, 2014, Front Biol (Beijing), V9, P127; Maikos JT, 2008, J NEUROTRAUM, V25, P38, DOI 10.1089/neu.2007.0348; Mills CD, 2001, J NEUROTRAUM, V18, P743, DOI 10.1089/089771501316919111; Mulder M, 2009, SPINE, V34, pE144, DOI 10.1097/BRS.0b013e31818d5427; Mure PY, 2004, J NEUROSURG, V100, P56, DOI 10.3171/spi.2004.100.1.0056; Nakae A, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/939023; Nesic O, 2005, J NEUROCHEM, V95, P998, DOI 10.1111/j.1471-4159.2005.03462.x; Neuman BJ, 2012, CLIN ORTHOP RELAT R, V470, P1640, DOI 10.1007/s11999-011-2071-z; Neumann M, 2009, J NEUROSCI METH, V176, P34, DOI 10.1016/j.jneumeth.2008.08.026; Osbun JW, 2012, WORLD NEUROSURG, V78, P498, DOI 10.1016/j.wneu.2011.12.011; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; Qvarlander S, 2013, J APPL PHYSIOL, V115, P1474, DOI 10.1152/japplphysiol.00711.2013; Rahimi-Movaghar V, 2005, J SPINAL CORD MED, V28, P415, DOI 10.1080/10790268.2005.11753841; Reddy S, 2014, PLAST RECONSTR SURG, V133, P864, DOI 10.1097/PRS.0000000000000013; Romner B, 2013, NAT REV NEUROL, V9, P185, DOI 10.1038/nrneurol.2013.37; Sahuquillo J, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD003983-PUB2; Santana-Cabrera Luciano, 2012, Int J Crit Illn Inj Sci, V2, P186, DOI 10.4103/2229-5151.100937; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schiariti Marco, 2014, Surg Neurol Int, V5, P171, DOI 10.4103/2152-7806.146154; Siddiqui AM, 2015, PROG BRAIN RES, V218, P15, DOI 10.1016/bs.pbr.2014.12.007; Smith JS, 2010, J BONE JOINT SURG AM, V92A, P1206, DOI 10.2106/JBJS.I.00740; Staykov D, 2011, STROKE, V42, P513, DOI 10.1161/STROKEAHA.110.605642; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Stromqvist F, 2012, EUR SPINE J, V21, P825, DOI 10.1007/s00586-011-2101-2; Tasiou A, 2014, INTERDISCIP NEUROSUR, V1, P107, DOI 10.1016/j.inat.2014.06.005; Than KD, 2008, NEUROSURGERY, V63, P182, DOI 10.1227/01.NEU.0000313116.28200.67; Thavarajah D, 2010, SPINE, V35, pE25, DOI 10.1097/BRS.0b013e3181b9fc45; Timofeev I, 2006, INJURY, V37, P1125, DOI 10.1016/j.injury.2006.07.031; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Watson C, 2008, THE SPINAL CORD; Weiner GM, 2010, NEUROSURGERY, V66, P1111, DOI 10.1227/01.NEU.0000369607.71913.3E; Wing PC, 2008, J SPINAL CORD MED, V31, P360, DOI 10.1080/10790268.2008.11760737; Woods BI, 2011, CLIN ORTHOP RELAT R, V469, P688, DOI 10.1007/s11999-010-1653-5; Wright NM, 2015, SPINE, V40, P505, DOI 10.1097/BRS.0000000000000810; Wu JF, 2013, NEUROTHERAPEUTICS, V10, P520, DOI 10.1007/s13311-013-0198-1; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	66	14	16	1	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	JAN	2017	26	1					62	75		10.3171/2016.6.SPINE16343			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EG0LV	WOS:000390725200011	27636866	Bronze			2021-06-18	
J	King, D; Hume, P; Gissane, C; Clark, T				King, Doug; Hume, Patria; Gissane, Conor; Clark, Trevor			Head impacts in a junior rugby league team measured with a wireless head impact sensor: an exploratory analysis	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						injury; linear; rotational; impact; rugby union; wireless head impact sensor; trauma	KING-DEVICK TEST; COLLEGIATE FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; VISUAL SCREENING TOOL; HIGH-SCHOOL FOOTBALL; EXPOSURE; BIOMECHANICS; STATISTICS; MAGNITUDE	OBJECTIVE The aim of this study was to investigate the frequency, magnitude, and distribution of head impacts sustained by players in a junior rugby league over a season of matches. METHODS The authors performed a prospective cohort analysis of impact magnitude, frequency, and distribution on data collected with instrumented XPatches worn behind the ear of players in an "under-11" junior rugby league team (players under 11 years old). RESULTS A total of 1977 impacts were recorded. Over the course of the study, players sustained an average of 116 impacts (average of 13 impacts per player per match). The measured linear acceleration ranged from 10g to 123g (mean 22g, median 16g, and 95th percentile 57g). The rotational acceleration ranged from 89 rad/sec(2) to 22,928 rad/sec(2) (mean 4041 rad/sec(2), median 2773 rad/sec(2), and 95th percentile 11,384 rad/sec(2)). CONCLUSIONS The level of impact severity based on the magnitude of impacts for linear and rotational accelerations recorded was similar to the impacts reported in studies of American junior and high school football, collegiate football, and youth ice hockey players, but the players in the rugby league cohort were younger, had less body mass, and played at a slower speed than the American players. Junior rugby league players are required to tackle the player to the ground and use a different tackle technique than that used in American football, likely increasing the rotational accelerations recorded at the head.	[King, Doug; Hume, Patria] Auckland Univ Technol, Sports Performance Res Inst New Zealand, Fac Hlth & Environm Sci, Auckland, New Zealand; [Gissane, Conor] St Marys Univ, Sch Sport Hlth & Appl Sci, Twickenham, Middx, England; [Clark, Trevor] Australian Coll Phys Educ, Fac Sport Performance, Sydney Olympic Pk, NSW, Australia	King, D (corresponding author), Hutt Valley Dist Hlth Board, Emergency Dept, Private Bag 31-907, Lower Hutt 5040, New Zealand.	doug.king@clear.net.nz	Gissane, Conor/I-3661-2019; Hume, Patria Anne/P-1084-2017; Hume, Patria/AAN-5514-2021	Gissane, Conor/0000-0003-4677-3853; Hume, Patria/0000-0003-1847-8128; Clark, Dr Trevor/0000-0002-2853-0068			ALTMAN DG, 1994, BRIT MED J, V308, P1552, DOI 10.1136/bmj.308.6943.1552; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daniel RW, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027872; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; DeSouza JFX, 2003, J NEUROPHYSIOL, V89, P1016, DOI 10.1152/jn.00562.2002; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gabbett T, 2008, J SCI MED SPORT, V11, P585, DOI 10.1016/j.jsams.2007.07.004; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Goldsmith W, 2004, AM J FOREN MED PATH, V25, P89, DOI 10.1097/01.paf.0000127407.28071.63; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Harpham JA, 2014, ANN BIOMED ENG, V42, P1, DOI 10.1007/s10439-013-0881-8; Hopkins WG, 2007, CLIN J SPORT MED, V17, P208, DOI 10.1097/JSM.0b013e3180592a68; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; King D, 2015, J NEUROL SCI, V357, P75, DOI 10.1016/j.jns.2015.06.069; King D, 2015, THESIS, P341; King D, 2015, AM J SPORT MED, V43, P614, DOI 10.1177/0363546514560876; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; King DA, 2016, J NEUROSURG-PEDIATR, V18, P65, DOI 10.3171/2015.12.PEDS15605; Krause LM, 2015, J SCI MED SPORT, V18, P358, DOI 10.1016/j.jsams.2014.05.012; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lennon A, 2015, THESIS, P44; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Nevins D, 2015, PROCEDIA ENGINEER, V112, P175, DOI 10.1016/j.proeng.2015.07.195; Ocwieja KE, 2012, ANN BIOMED ENG, V40, P90, DOI 10.1007/s10439-011-0401-7; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rizzo JR, 2016, J NEUROL SCI, V362, P232, DOI 10.1016/j.jns.2016.01.045; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Tjarks BJ, 2013, J NEUROL SCI, V334, P148, DOI 10.1016/j.jns.2013.08.015; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Vopat LM, 2015, IOC MANUAL OF EMERGENCY SPORTS MEDICINE, P205; Wong RH, 2014, CLIN NEUROL NEUROSUR, V118, P1, DOI 10.1016/j.clineuro.2013.11.036; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3; Young TJ, 2014, CLIN J SPORT MED, V24, P416, DOI 10.1097/JSM.0000000000000055; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	51	14	14	1	15	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	JAN	2017	19	1					13	23		10.3171/2016.7.PEDS1684			11	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	EG0LS	WOS:000390724900003	27791705	Bronze			2021-06-18	
J	Lequerica, AH; Botticello, AL; Lengenfelder, J; Chiaravalloti, N; Bushnik, T; Dijkers, MP; Hammond, FM; Kolakowsky-Hayner, SA; Rosenthal, J				Lequerica, Anthony H.; Botticello, Amanda L.; Lengenfelder, Jean; Chiaravalloti, Nancy; Bushnik, Tamara; Dijkers, Marcel P.; Hammond, Flora M.; Kolakowsky-Hayner, Stephanie A.; Rosenthal, Joseph			Factors associated with remission of post-traumatic brain injury fatigue in the years following traumatic brain injury (TBI): a TBI model systems module study	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Fatigue; brain injury	CLINICALLY IMPORTANT DIFFERENCE; DISABILITY RATING-SCALE; SLEEP QUALITY INDEX; 1ST 2 YEARS; HEAD-INJURY; LUPUS-ERYTHEMATOSUS; LIFE SCALE; RECOVERY; PARTICIPATION; SATISFACTION	Post-traumatic brain injury fatigue (PTBIF) is a major problem in the years after traumatic brain injury (TBI), yet little is known about its persistence and resolution. The objective of the study was to identify factors related to PTBIF remission and resolution. TBI Model System registrants at five centres participated in interviews at either one and two years post-injury (Y1-2 Cohort), or two and five years post-injury (Y2-5 Cohort). Characteristics of participants with PTBIF remission were compared to those with PTBIF persistence. Variables studied included the presence of and changes in disability, sleep dysfunction, mood, and community participation. The Functional Independence Measure did not differ significantly between groups or over time. In the Y1-2 Cohort the Fatigue Resolved group scored significantly better on the Disability Rating Scale and Pittsburgh Sleep Quality Index. In the Y2-5 Cohort the Fatigue Resolved group scored significantly higher on a measure of community participation. It was concluded that fewer than half of the sample in each cohort experienced a remission of PTBIF between time points. Persistence of PTBIF 1-2 years post-injury is associated with disability, sleep disturbance, and depression while persistence of fatigue beyond 2 years post-injury appears to be related to participation level, underscoring the potential impact of effective surveillance, assessment, and treatment of this condition in optimising life after TBI. Differences in fatigue progression may point to the presence of different types of PTBIF.	[Lequerica, Anthony H.; Botticello, Amanda L.; Lengenfelder, Jean; Chiaravalloti, Nancy] Kessler Fdn, W Orange, NJ 07052 USA; [Bushnik, Tamara] Rusk Rehabil, New York, NY USA; [Dijkers, Marcel P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Hammond, Flora M.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46202 USA; [Kolakowsky-Hayner, Stephanie A.] Stanford Univ, Concuss & Brain Performance Ctr, Palo Alto, CA 94304 USA; [Rosenthal, Joseph] Ohio State Univ, Dept Phys Med & Rehabil, Wexer Med Ctr, Columbus, OH 43210 USA	Lequerica, AH (corresponding author), Kessler Fdn, W Orange, NJ 07052 USA.	alequerica@kesslerfoundation.org	Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Chiaravalloti, Nancy/0000-0003-2943-7567	National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services [H133A070033, H133A070038, H133A070042, H133A070037, H133A070030]	This research was funded by the National Institute on Disability, Independent Living, and Rehabilitation Research [grants H133A070033, H133A070038, H133A070042, H133A070037, and H133A070030] and carried out by Traumatic Brain Injury Model Systems Centers.	Beaulieu-Bonneau S, 2012, SLEEP MED, V13, P598, DOI 10.1016/j.sleep.2012.02.010; BELZA BL, 1995, J RHEUMATOL, V22, P639; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Buysse DJ, 2008, J CLIN SLEEP MED, V4, P563; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Cantor JB, 2013, NEUROREHABILITATION, V32, P875, DOI 10.3233/NRE-130912; Cantor JB, 2012, J HEAD TRAUMA REHAB, V27, pE1, DOI 10.1097/HTR.0b013e318270f91e; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Goligher EC, 2008, J RHEUMATOL, V35, P635; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P235, DOI 10.1016/S0003-9993(98)90000-4; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Leavitt VM, 2010, PM&R, V2, P332, DOI 10.1016/j.pmrj.2010.03.027; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Pettersson S, 2015, SCAND J RHEUMATOL, V44, P206, DOI 10.3109/03009742.2014.988173; Ponsford JL, 2014, PSYCHIAT CLIN N AM, V37, P77, DOI 10.1016/j.psc.2013.10.001; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Resch JA, 2009, REHABIL PSYCHOL, V54, P51, DOI 10.1037/a0015051; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Stineman MG, 1996, AM J PHYS MED REHAB, V75, P68, DOI 10.1097/00002060-199601000-00018; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P540, DOI 10.1016/j.apmr.2010.12.002; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002	39	14	14	0	3	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2017	27	7					1019	1030		10.1080/09602011.2016.1231120			12	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	FB4WK	WOS:000406142500003	27633955				2021-06-18	
J	Lopez, KC; Leary, JB; Pham, DL; Chou, YY; Dsurney, J; Chan, L				Lopez, Katherine C.; Leary, Jacob B.; Pham, Dzung L.; Chou, Yi-Yu; Dsurney, John; Chan, Leighton			Brain Volume, Connectivity, and Neuropsychological Performance in Mild Traumatic Brain Injury: The Impact of Post-Traumatic Stress Disorder Symptoms	JOURNAL OF NEUROTRAUMA			English	Article						DTI; head injury; learning; memory network; white matter integrity	MEMORY; VETERANS; PTSD; METAANALYSIS; IRAQ; TBI; MRI; US	Post-traumatic stress disorder (PTSD) is commonly associated with mild traumatic brain injury (mTBI). To better understand their relationship, we examined neuroanatomical structures and neuropsychological performance in a sample of individuals with mTBI, with and without PTSD symptoms. Thirty-nine subjects with mTBI were dichotomized into those with (n = 12) and without (n = 27) significant PTSD symptoms based on scores on the PTSD Checklist. Using a region-of-interest approach, fronto-temporal volumes, fiber bundles obtained by diffusion tensor imaging, and neuropsychological scores were compared between the two groups. After controlling for total intracranial volume and age, subjects with mTBI and PTSD symptoms exhibited volumetric differences in the entorhinal cortex, an area associated with memory networks, relative to mTBI-only patients (F = 4.28; p = 0.046). Additionally, subjects with PTSD symptoms showed reduced white matter integrity in the right cingulum bundle (axial diffusivity, F = 6.04; p = 0.020). Accompanying these structural alterations, mTBI and PTSD subjects also showed impaired performance in encoding (F = 5.98; p = 0.019) and retrieval (F = 7.32; p = 0.010) phases of list learning and in tests of processing speed (Wechsler Adult Intelligence Scale Processing Speed Index, F = 12.23; p = 0.001; Trail Making Test A, F = 5.56; p = 0.024). Increased volume and white matter disruptions in these areas, commonly associated with memory functions, may be related to functional disturbances during cognitively demanding tasks. Differences in brain volume and white matter integrity between mTBI subjects and those with mTBI and co-morbid PTSD symptoms point to neuroanatomical differences that may underlie poorer recovery of mTBI subjects who experience PTSD symptoms. These findings support theoretical models of PTSD and its relationship to learning deficits.	[Lopez, Katherine C.; Pham, Dzung L.; Chou, Yi-Yu; Dsurney, John; Chan, Leighton] NIH, Ctr Neurosci & Regenerat Med, Bldg 10, Bethesda, MD 20892 USA; [Leary, Jacob B.; Chan, Leighton] NIH, Ctr Clin, Dept Rehabil Med, Bethesda, MD 20892 USA	Dsurney, J (corresponding author), NIH, Ctr Neurosci & Regenerat Med, Dept Rehabil Med, 10 Ctr Dr,Room 1-1468,MSC1604, Bethesda, MD 20892 USA.	john.dsurney@nih.gov	Pham, Dzung/AAR-8263-2020		Department of Defense (Center for Neuroscience and Regenerative Medicine)United States Department of Defense; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	This work was supported by the Department of Defense (Center for Neuroscience and Regenerative Medicine) and the National Institutes of Health Intramural Research Program.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Anderson MC, 2001, NATURE, V410, P366, DOI 10.1038/35066572; Anderson MC, 2014, TRENDS COGN SCI, V18, P279, DOI 10.1016/j.tics.2014.03.002; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Barlow-Ogden K, 2012, J REHABIL RES DEV, V49, P1101, DOI 10.1682/JRRD.2010.09.0188; Benoit RG, 2012, NEURON, V76, P450, DOI 10.1016/j.neuron.2012.07.025; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; Carass A, 2011, NEUROIMAGE, V56, P1982, DOI 10.1016/j.neuroimage.2011.03.045; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Costanzo ME, 2014, NEUROSCI LETT, V577, P11, DOI 10.1016/j.neulet.2014.05.054; Cristofori I., 2015, HDB CLIN NEUROLOGY, P579; Department of Veterans Affairs Department of Defense, 2009, VA DOD CLIN PRACT GU; Fani N, 2012, NEUROPSYCHOPHARMACOL, V37, P2740, DOI 10.1038/npp.2012.146; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; Gordon SN, 2011, CLIN NEUROPSYCHOL, V25, P337, DOI 10.1080/13854046.2010.550634; Hirni DI, 2013, NEUROPSYCHOLOGIA, V51, P930, DOI 10.1016/j.neuropsychologia.2013.01.013; Hoffman JM, 2012, ARCH PHYS MED REHAB, V93, P287, DOI 10.1016/j.apmr.2011.08.041; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Joormann J, 2009, J ABNORM PSYCHOL, V118, P34, DOI 10.1037/a0013794; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lissek S, 2015, INT J PSYCHOPHYSIOL, V98, P594, DOI 10.1016/j.ijpsycho.2014.11.006; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; Noulhiane M, 2007, BRAIN, V130, P3184, DOI 10.1093/brain/awm258; Paller KA, 2002, TRENDS COGN SCI, V6, P93, DOI 10.1016/S1364-6613(00)01845-3; Paz-Alonso PM, 2013, J NEUROSCI, V33, P5017, DOI 10.1523/JNEUROSCI.3459-12.2013; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; Sasson E, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00032; Scott JC, 2015, PSYCHOL BULL, V141, P105, DOI 10.1037/a0038039; Shandera-Ochsner AL, 2013, CLIN NEUROPSYCHOL, V27, P881, DOI 10.1080/13854046.2013.802017; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; Soble JR, 2013, J CLIN EXP NEUROPSYC, V35, P551, DOI 10.1080/13803395.2013.798398; Swick D, 2012, J INT NEUROPSYCH SOC, V18, P917, DOI 10.1017/S1355617712000458; Takehara-Nishiuchi K, 2014, NEUROSCI RES, V84, P27, DOI 10.1016/j.neures.2014.02.012; Tustison NJ, 2010, IEEE T MED IMAGING, V29, P1310, DOI 10.1109/TMI.2010.2046908; Wall PLH, 2012, J AM PSYCHIAT NURSES, V18, P278, DOI 10.1177/1078390312460578; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	42	14	14	0	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2017	34	1					16	22		10.1089/neu.2015.4323			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EF6DE	WOS:000390420100003	26942337	Green Published			2021-06-18	
J	Majdan, M; Brazinova, A; Rusnak, M; Leitgeb, J				Majdan, Marek; Brazinova, Alexandra; Rusnak, Martin; Leitgeb, Johannes			Outcome Prediction after Traumatic Brain Injury: Comparison of the Performance of Routinely Used Severity Scores and Multivariable Prognostic Models	JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE			English	Article						Abbreviated injury scale; Glasgow coma scale; outcome; prognosis; traumatic brain injury	GLASGOW COMA SCALE; EXTERNAL VALIDATION; MOTOR SCORE; IMPACT; MODERATE; CRASH; CLASSIFICATION; EPIDEMIOLOGY; MORTALITY; SURVIVAL	Objectives: Prognosis of outcome after traumatic brain injury (TBI) is important in the assessment of quality of care and can help improve treatment and outcome. The aim of this study was to compare the prognostic value of relatively simple injury severity scores between each other and against a gold standard model - the IMPACT-extended (IMP-E) multivariable prognostic model. Materials and Methods: For this study, 866 patients with moderate/severe TBI from Austria were analyzed. The prognostic performances of the Glasgow coma scale (GCS), GCS motor (GCSM) score, abbreviated injury scale for the head region, Marshall computed tomographic (CT) classification, and Rotterdam CT score were compared side-by-side and against the IMP-E score. The area under the receiver operating characteristics curve (AUC) and Nagelkerke's R-2 were used to assess the prognostic performance. Outcomes at the Intensive Care Unit, at hospital discharge, and at 6 months (mortality and unfavorable outcome) were used as end-points. Results: Comparing AUCs and R(2)s of the same model across four outcomes, only little variation was apparent. A similar pattern is observed when comparing the models between each other: Variation of AUCs <+/- 0.09 and R(2)s by up to +/- 0.17 points suggest that all scores perform similarly in predicting outcomes at various points (AUCs: 0.65-0.77; R(2)s: 0.09-0.27). All scores performed significantly worse than the IMP-E model (with AUC > 0.83 and R-2 > 0.42 for all outcomes): AUCs were worse by 0.10-0.22 (P < 0.05) and R(2)s were worse by 0.22-0.39 points. Conclusions: All tested simple scores can provide reasonably valid prognosis. However, it is confirmed that well-developed multivariable prognostic models outperform these scores significantly and should be used for prognosis in patients after TBI wherever possible.	[Majdan, Marek; Brazinova, Alexandra; Rusnak, Martin] Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Univ Namestie 1, Trnava 91701, Slovakia; [Majdan, Marek; Brazinova, Alexandra] Med Univ Vienna, Int Neurotrauma Res Org, A-1090 Vienna, Austria; [Leitgeb, Johannes] Med Univ Vienna, Dept Traumatol, A-1090 Vienna, Austria	Majdan, M (corresponding author), Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Univ Namestie 1, Trnava 91701, Slovakia.	mmajdan@truni.sk	Majdan, Marek/K-5017-2012; Brazinova, Alexandra/C-4265-2016	Majdan, Marek/0000-0001-8037-742X; Brazinova, Alexandra/0000-0003-0625-256X			Alvarez M, 1998, CRIT CARE MED, V26, P142, DOI 10.1097/00003246-199801000-00030; [Anonymous], 1971, JAMA, V215, P277; [Anonymous], 1976, ABBR INJ SCAL; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Brazinova A, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0133-z; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; Davis DP, 2006, J TRAUMA, V60, P985, DOI 10.1097/01.ta.0000205860.96209.1c; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Gabbe Belinda J, 2003, Emerg Med (Fremantle), V15, P353, DOI 10.1046/j.1442-2026.2003.00474.x; Han JL, 2014, J NEUROTRAUM, V31, P1146, DOI 10.1089/neu.2013.3003; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Lesko MM, 2013, J NEUROTRAUM, V30, P17, DOI 10.1089/neu.2012.2438; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Majdan M, 2015, J NEUROTRAUM, V32, P101, DOI 10.1089/neu.2014.3438; Majdan M, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/s13049-014-0068-9; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mata-Mbemba D, 2014, ACAD RADIOL, V21, P605, DOI 10.1016/j.acra.2014.01.017; Mauritz W, 2009, EUR J EMERG MED, V16, P153, DOI 10.1097/MEJ.0b013e32832a0864; McNett Molly, 2007, J Neurosci Nurs, V39, P68; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; R Core Team, 2014, R LANG ENV STAT COMP; Raj R, 2014, NEUROSURGERY, V75, P632, DOI 10.1227/NEU.0000000000000533; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; Singh B, 2013, BRAIN INJURY, V27, P293, DOI 10.3109/02699052.2012.743182; Steyerberg EW., 2009, CLIN PREDICTION MODE; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6	42	14	18	0	10	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0976-3147	0976-3155		J NEUROSCI RURAL PRA	J. Neurosci. Rural Pract.	JAN-MAR	2017	8	1					20	29		10.4103/0976-3147.193543			10	Clinical Neurology	Neurosciences & Neurology	ED5GT	WOS:000388880300006	28149077	DOAJ Gold, Green Published			2021-06-18	
J	Pang, AL; Xiong, LL; Xia, QJ; Liu, F; Wang, YC; Liu, F; Zhang, P; Meng, BL; Tan, S; Wang, TH				Pang, Ai-Lan; Xiong, Liu-Lin; Xia, Qing-Jie; Liu, Fen; Wang, You-Cui; Liu, Fei; Zhang, Piao; Meng, Bu-Liang; Tan, Sheng; Wang, Ting-Hua			Neural Stem Cell Transplantation Is Associated with Inhibition of Apoptosis, Bcl-xL Upregulation, and Recovery of Neurological Function in a Rat Model of Traumatic Brain Injury	CELL TRANSPLANTATION			English	Article						neural stem cells; traumatic brain injury; neural behavior; cell apoptosis; Bcl-xL overexpression	SPINAL-CORD-INJURY; CEREBRAL ISCHEMIC-INJURY; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; PARKINSONS-DISEASE; IMPROVE COGNITION; TRANSGENIC MODEL; PROGENITOR CELLS; NERVOUS-SYSTEM; EXPRESSION	Traumatic brain injury (TBI) is a common disease that usually causes severe neurological damage, and current treatment is far from satisfactory. The neuroprotective effects of neural stem cell (NSC) transplantation in the injured nervous system have largely been known, but the underlying mechanisms remain unclear, and their limited sources impede their clinical application. Here, we established a rat model of TBI by dropping a weight onto the cortical motor area of the brain and explored the effect of engrafted NSCs (passage 3, derived from the hippocampus of embryonic 12-to 14-d green fluorescent protein transgenic mice) on TBI rats. Moreover, RT-PCR and Western blotting were employed to investigate the possible mechanism associated with NSC grafts. We found rats with TBI exhibited a severe motor and equilibrium dysfunction, while NSC transplantation could partly improve the motor function and significantly reduce cell apoptosis and increase B-cell lymphoma-extra large (BclxL) expression at 7 d postoperation. However, other genes including Bax, B-cell lymphoma 2, Fas ligand, and caspase3 did not exhibit significant differences in expression. Moreover, to test whether Bcl-xL could be used as a therapeutic target, herpes simplex virus (HSV) 1 carrying Bcl-xL recombinant was constructed and injected into the pericontusional cortices. Bcl-xL overexpression not only resulted in a significant improvement in neurological function but also inhibits cell apoptosis, as compared with the TBI rats, and exhibits the same effects as the administration of NSC. The present study therefore indicated that NSC transplantation could promote the recovery of TBI rats in a manner similar to that of Bcl-xL overexpression. Therefore, Bcl-xL overexpression, to some extent, could be considered as a useful strategy to replace NSC grafting in the treatment of TBI in future clinical practices.	[Pang, Ai-Lan; Tan, Sheng] Southern Med Univ, Dept Neurol, Zhujiang Hosp, Ind Ave 253, Guangzhou 510282, Guangdong, Peoples R China; [Zhang, Piao; Wang, Ting-Hua] Kunming Med Univ, Inst Neurosci, Yuhua St,Spring Rd,1168, Kunming 650500, Peoples R China; [Xiong, Liu-Lin; Xia, Qing-Jie; Liu, Fen; Wang, You-Cui; Liu, Fei; Wang, Ting-Hua] Sichuan Univ, West China Hosp, Translat Neurosci Ctr, Inst Neurol Dis,Dept Anesthesiol, Chengdu, Peoples R China; [Pang, Ai-Lan] Kunming Med Univ, Dept Neurol, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China; [Meng, Bu-Liang] Kunming Med Univ, Dept Human Anat Histol & Embryol, Kunming, Peoples R China	Tan, S (corresponding author), Southern Med Univ, Dept Neurol, Zhujiang Hosp, Ind Ave 253, Guangzhou 510282, Guangdong, Peoples R China.; Wang, TH (corresponding author), Kunming Med Univ, Inst Neurosci, Yuhua St,Spring Rd,1168, Kunming 650500, Peoples R China.	tansheng18@126.com; tinghua_neuron@263.net			National Key Technology Research and Development Program of the Ministry of Science and Technology of ChinaNational Key Technology R&D Program [2014BAI01B10]; Program for IRTSTYN; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81360267]; program Innovative Research Team in Science and Technology in Yunnan province	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by a grant from the National Key Technology Research and Development Program of the Ministry of Science and Technology of China (CN; No. 2014BAI01B10), by the Program for IRTSTYN, together with the program Innovative Research Team in Science and Technology in Yunnan province and the grant from the National Natural Science Foundation of China (Grant No. 81360267).	Ager RR, 2015, HIPPOCAMPUS, V25, P813, DOI 10.1002/hipo.22405; Bergstrom T, 2012, UPSALA J MED SCI, V117, P132, DOI 10.3109/03009734.2012.665096; Blurton-Jones M, 2009, P NATL ACAD SCI USA, V106, P13594, DOI 10.1073/pnas.0901402106; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chang TP, 2010, J TRAUMA, V68, P1401, DOI 10.1097/TA.0b013e3181bb9a87; Chen S, 2009, MOL CELL BIOL, V29, P6149, DOI 10.1128/MCB.01481-08; Chen ZW, 2016, CURR GENE THER; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; Dewall Jeremy, 2010, JEMS, V35, P54, DOI 10.1016/S0197-2510(10)70095-4; Dooley D, 2014, PHARMACOL THERAPEUT, V141, P21, DOI 10.1016/j.pharmthera.2013.08.001; Duan Kuijia, 2016, Nan Fang Yi Ke Da Xue Xue Bao, V36, P32; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Guo YL, 2010, BEHAV BRAIN FUNCT, V6, DOI 10.1186/1744-9081-6-43; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Hong JY, 2014, J BIOL CHEM, V289, DOI 10.1074/jbc.M114.588871; Jaber M, 2013, REV NEUROL-FRANCE, V169, P838, DOI 10.1016/j.neurol.2013.07.026; Krieger DW, 2013, FRONT NEUROL NEUROSC, V32, P76, DOI 10.1159/000346419; Lee DY, 2012, CANCER CELL, V22, P131, DOI 10.1016/j.ccr.2012.05.036; Lee SI, 2009, J NEUROSCI RES, V87, P3186, DOI 10.1002/jnr.22149; Li YQ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060970; Li Z, 2014, GENET MOL RES, V13, P6083, DOI 10.4238/2014.August.7.23; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu GY, 2013, BEHAV BRAIN FUNCT, V9, DOI 10.1186/1744-9081-9-36; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Mansouri S, 2012, J NEUROSCI RES, V90, P759, DOI 10.1002/jnr.22803; Michels Judith, 2013, Int J Cell Biol, V2013, P705294, DOI 10.1155/2013/705294; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Okano H, 2008, PHILOS T R SOC B, V363, P2111, DOI 10.1098/rstb.2008.2264; Okano H, 2010, P JPN ACAD B-PHYS, V86, P438, DOI 10.2183/pjab.86.438; Olanow CW, 1996, J NEURAL TRANSM-SUPP, P75; Parrondo R, 2013, PEERJ, V1, DOI 10.7717/peerj.144; Piccini P, 2005, BRAIN, V128, P2977, DOI 10.1093/brain/awh649; Qi YH, 2014, GENET MOL RES, V13, P1366, DOI 10.4238/2014.February.28.9; Rahmani M, 2013, CANCER RES, V73, P1340, DOI 10.1158/0008-5472.CAN-12-1365; Salewski RP, 2015, STEM CELLS DEV, V24, P36, DOI 10.1089/scd.2014.0096; Seaberg RM, 2002, J NEUROSCI, V22, P1784, DOI 10.1523/JNEUROSCI.22-05-01784.2002; Sharp KG, 2014, EXP NEUROL, V257, P186, DOI 10.1016/j.expneurol.2014.04.008; Shetty AK, 2004, HIPPOCAMPUS, V14, P595, DOI 10.1002/hipo.10206; Steward O, 2014, J NEUROSCI, V34, P14013, DOI 10.1523/JNEUROSCI.3066-14.2014; Tan XF, 2014, NEUROSCI LETT, V571, P23, DOI 10.1016/j.neulet.2014.04.019; Tomishima M., 2008, STEMBOOK; Umschwief G, 2010, J CEREBR BLOOD F MET, V30, P616, DOI 10.1038/jcbfm.2009.234; Wang SH, 2012, CURR NEUROVASC RES, V9, P20, DOI 10.2174/156720212799297137; Wilcox JT, 2014, STEM CELL TRANSL MED, V3, P1148, DOI 10.5966/sctm.2014-0029; Winkler C, 2005, TRENDS NEUROSCI, V28, P86, DOI 10.1016/j.tins.2004.12.006; Xiao JJ, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/618631; Xing RX, 2015, IBRAIN, V1, P36; Yi Bo-Rim, 2013, Lab Anim Res, V29, P131, DOI 10.5625/lar.2013.29.3.131; Zhang W, 2015, NEUROBIOL AGING, V36, P1282, DOI 10.1016/j.neurobiolaging.2014.10.040; Zhang W, 2014, MOL NEUROBIOL, V50, P423, DOI 10.1007/s12035-014-8640-x; Zhao L, 2013, BRAIN RES, V1503, P78, DOI 10.1016/j.brainres.2013.01.051; Zhou FC, 2001, RESTOR NEUROL NEUROS, V18, P95; Zuo FX, 2015, INT J MOL SCI, V16, P26473, DOI 10.3390/ijms161125966	55	14	16	1	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2017	26	7					1262	1275		10.1177/0963689717715168			14	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Cell Biology; Research & Experimental Medicine; Transplantation	EZ4GO	WOS:000404671800013	28933221	DOAJ Gold, Green Published			2021-06-18	
J	Parsons, TD; Barnett, M				Parsons, Thomas D.; Barnett, Michael			Validity of a Newly Developed Measure of Memory: Feasibility Study of the Virtual Environment Grocery Store	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Aging; episodic memory; neuropsychological tests; prospective memory; validation studies; virtual reality	TRAUMATIC BRAIN-INJURY; ECOLOGICAL VALIDITY; EXECUTIVE FUNCTION; EPISODIC MEMORY; OLDER-ADULTS; INDIVIDUAL-DIFFERENCES; REALITY; PERFORMANCE; YOUNG; TASK	Virtual reality-based neuropsychological assessments proffer the potential to address the limited ecological validity of pen-and-paper measures of memory. To investigate the construct validity of a newly developed virtual reality measure of memory, the Virtual Environment Grocery Store (VEGS), traditional neuropsychological measures of memory and executive functioning were administered to 48 older adults and 55 young adults. Performances on the VEGS memory tasks and the traditional neuropsychological assessments of memory were positively correlated, indicating that memory for VEGS content was similar to memory for traditional paper-and-pencil measures. The older adults performed significantly worse than young adults on the VEG Sand the California Verbal Learning Test, but the DKEFS Color-Word Interference failed to differentiate the groups. Furthermore, significant differences were found between groups for the VEGS memory and multitasking measures. The VEGS has the advantage over traditional measures of providing objective measurement of individual components of memory in simulations of everyday activities.	[Parsons, Thomas D.; Barnett, Michael] Univ North Texas, Dept Psychol, Denton, TX 76203 USA	Parsons, TD (corresponding author), Univ North Texas, Dept Psychol, Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA.; Parsons, TD (corresponding author), Univ North Texas, Dept Psychol, Computat Neuropsychol & Simulat CNS Lab, 1155 Union Circle 311280, Denton, TX 76203 USA.; Parsons, TD (corresponding author), Univ North Texas, Dept Psychol, Natl Acad Neuropsychol, 1155 Union Circle 311280, Denton, TX 76203 USA.	Thomas.Parsons@unt.edu		Parsons, Thomas/0000-0003-0331-5019			Adolfsdottir S, 2017, J INT NEUROPSYCH SOC, V23, P90, DOI 10.1017/S1355617716000898; Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; Allain P, 2014, J INT NEUROPSYCH SOC, V20, P468, DOI 10.1017/S1355617714000344; Benoit M, 2015, NEUROPSYCH DIS TREAT, V11, P557, DOI 10.2147/NDT.S73179; Besnard J, 2016, APPL NEUROPSYCH-ADUL, V23, P223, DOI 10.1080/23279095.2015.1048514; Bier N, 2016, J ALZHEIMERS DIS, V52, P1361, DOI 10.3233/JAD-150957; Bohil CJ, 2011, NAT REV NEUROSCI, V12, P752, DOI 10.1038/nrn3122; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Canty AL, 2014, NEUROPSYCHOL REHABIL, V24, P238, DOI 10.1080/09602011.2014.881746; Cargin JW, 2007, J CLIN EXP NEUROPSYC, V29, P706, DOI 10.1080/13825580600954256; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Cohen AL, 2005, APPL COGNITIVE PSYCH, V19, P1177, DOI 10.1002/acp.1154; Cole SN, 2013, Q J EXP PSYCHOL, V66, P1687, DOI 10.1080/17470218.2012.758157; Davis HP, 2003, CORTEX, V39, P1063, DOI 10.1016/S0010-9452(08)70878-5; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis D. C., 2000, CVLT 2 CALIFORNIA VE; Dickerson BC, 2010, NEUROPSYCHOPHARMACOL, V35, P86, DOI 10.1038/npp.2009.126; GRAF P, 1995, J CLIN EXP NEUROPSYC, V17, P390, DOI 10.1080/01688639508405132; Grewe P, 2014, EPILEPSY BEHAV, V31, P57, DOI 10.1016/j.yebeh.2013.11.014; Henry JD, 2004, PSYCHOL AGING, V19, P27, DOI 10.1037/0882-7974.19.1.27; Holdnack H, 2001, WECHSLER TEST ADULT; HUPPERT FA, 1993, J CLIN EXP NEUROPSYC, V15, P805, DOI 10.1080/01688639308402597; Jovanovski D, 2012, APPL NEUROPSYCH-ADUL, V19, P171, DOI 10.1080/09084282.2011.643955; Kliegel M, 2002, PSYCHOL BEITR, V44, P303, DOI DOI 10.1037/0012-1649.44.2.612; Logie RH, 2011, MEM COGNITION, V39, P1561, DOI 10.3758/s13421-011-0120-1; Manchester D, 2004, BRAIN INJURY, V18, P1067, DOI 10.1080/02699050410001672387; Matheis RJ, 2007, CLIN NEUROPSYCHOL, V21, P146, DOI 10.1080/13854040601100668; McDaniel MA, 2000, APPL COGNITIVE PSYCH, V14, pS127, DOI 10.1002/acp.775; McDaniel Mark A, 2015, Front Hum Neurosci, V9, P392, DOI 10.3389/fnhum.2015.00392; Mueller C, 2012, J NEUROSCI METH, V209, P290, DOI 10.1016/j.jneumeth.2012.06.025; Okuda J, 2003, NEUROIMAGE, V19, P1369, DOI 10.1016/S1053-8119(03)00179-4; Parsons T.D., 2008, GERONTECHNOLOGY, V7, P187; Parsons TD, 2013, P 17 IEEE VIRT REAL, P1; Parsons TD, 2008, CYBERPSYCHOL BEHAV, V11, P17, DOI 10.1089/cpb.2007.9934; Parsons TD, 2017, NEUROPSYCHOL REHABIL, V27, P777, DOI 10.1080/09602011.2015.1109524; Parsons TD, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00660; Plancher G, 2012, NEUROPSYCHOLOGIA, V50, P592, DOI 10.1016/j.neuropsychologia.2011.12.013; Plancher G, 2010, NEUROPSYCHOLOGY, V24, P379, DOI 10.1037/a0018680; Rand D, 2009, NEUROPSYCHOL REHABIL, V19, P583, DOI 10.1080/09602010802469074; Raz N, 2005, CEREB CORTEX, V15, P1676, DOI 10.1093/cercor/bhi044; Renison B, 2012, J INT NEUROPSYCH SOC, V18, P440, DOI 10.1017/S1355617711001883; Rose NS, 2010, PSYCHOL AGING, V25, P595, DOI 10.1037/a0019771; Sauzeon H, 2012, EXP PSYCHOL, V59, P99, DOI 10.1027/1618-3169/a000131; Schnitzspahn KM, 2013, DEV PSYCHOL, V49, P1544, DOI 10.1037/a0030579; Shilling VM, 2002, NEUROPSYCHOLOGIA, V40, P605, DOI 10.1016/S0028-3932(01)00157-9; Wilson B, 1989, RIVERMEAD BEHAV MEMO; Woods SP, 2012, J INT NEUROPSYCH SOC, V18, P134, DOI 10.1017/S1355617711001263	47	14	14	0	7	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2017	59	4					1227	1235		10.3233/JAD-170295			9	Neurosciences	Neurosciences & Neurology	FD8BJ	WOS:000407749900007	28759971				2021-06-18	
J	Peltz, CB; Gardner, RC; Kenney, K; Diaz-Arrastia, R; Kramer, JH; Yaffe, K				Peltz, Carrie B.; Gardner, Raquel C.; Kenney, Kimbra; Diaz-Arrastia, Ramon; Kramer, Joel H.; Yaffe, Kristine			Neurobehavioral Characteristics of Older Veterans With Remote Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive impairment; psychiatric disorders; traumatic brain injury; veterans	LONG-TERM OUTCOMES; ALZHEIMERS-DISEASE; HEAD-INJURY; NEUROPSYCHOLOGICAL OUTCOMES; RISK; DEPRESSION; PREVALENCE; HISTORY; STATE	Objective: While traumatic brain injury (TBI) is common across the life span, the detailed neurobehavioral characteristics of older adults with prior TBI remain unclear. Our goal was to compare the clinical profile of older independently living veterans with and without prior TBI. Setting: Two veterans' retirement communities. Participants: Seventy-five participants with TBI and 71 without (mean age = 78 years). Design: Cross-sectional. Main Measures: TBI history was determined by the Ohio State University TBI Questionnaire. We assessed psychiatric and medical history via interviews and chart review and conducted measures assessing functional/lifestyle, psychiatric, and cognitive outcomes. Regression analyses (adjusted for demographics, diabetes, prior depression, substance abuse, and site) were performed to compare between TBI and non-TBI participants. Results: Compared with veterans without TBI, those with TBI had greater functional impairment (adjusted P = .05), endorsed more current depressive (adjusted P = .04) and posttraumatic stress disorder symptoms (adjusted P = .01), and had higher rates of prior depression and substance abuse (both adjusted Ps < .01). While composite memory and language scores did not differ between groups, participants with TBI performed worse on tests of executive functioning/processing speed (adjusted P = .01). Conclusions: Our results suggest that TBI may have adverse long-term neurobehavioral consequences and that TBI-exposed adults may require careful screening and follow-up.	[Peltz, Carrie B.; Gardner, Raquel C.; Yaffe, Kristine] San Francisco VA Med Ctr, 4150 Clement St,116H, San Francisco, CA 94121 USA; [Peltz, Carrie B.; Yaffe, Kristine] NCIRE, San Francisco, CA USA; [Gardner, Raquel C.; Kramer, Joel H.; Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Kenney, Kimbra; Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Rockville, MD USA	Peltz, CB (corresponding author), San Francisco VA Med Ctr, 4150 Clement St,116H, San Francisco, CA 94121 USA.	carrie.peltz2@va.gov		Gardner, Raquel C./0000-0003-4028-440X; Diaz-Arrastia, Ramon/0000-0001-6051-3594	Department of DefenseUnited States Department of Defense [W81XWH-12-1-0581]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23 NS095755]; American Federation for Aging Research; UCSF Pepper Center; Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; Military Clinical Neurosciences Center of Excellence; Department of DefenseUnited States Department of Defense; VAUS Department of Veterans Affairs [W81XWH-12-PHTBI-CENC, W81XHW-14-2-0137]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K24 AG031155]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS095755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K24AG031155, P30AG044281] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001246] Funding Source: NIH RePORTER	This project was supported by the Department of Defense (W81XWH-12-1-0581). R.C.G. receives support from the National Institute of Neurological Disorders and Stroke (K23 NS095755), the American Federation for Aging Research, and the UCSF Pepper Center. K.K. and R.D.-A. receive support from the Center for Neuroscience and Regenerative Medicine and the Military Clinical Neurosciences Center of Excellence. K. Y. receives support from the Department of Defense and VA (W81XWH-12-PHTBI-CENC, W81XHW-14-2-0137) and NIA (K24 AG031155). The authors thank their research participants, the Armed Forces Retirement Home in Washington, District of Columbia, the Veterans Home of California in Yountville, California, and their dedicated study staff including Kim Kelley, Ross Passo, and Leah Harburg.	Benton AL, 1983, MULTILINGUAL APHASIA; Brown AW, 2011, J NEUROTRAUM, V28, P167, DOI 10.1089/neu.2010.1400; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Dahm J, 2015, INJURY, V46, P142, DOI 10.1016/j.injury.2014.07.012; Delis D.C., 2001, DELIS KAPLAN EXECUTI; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; Farias ST, 2011, ALZHEIMERS DEMENT, V7, P593, DOI 10.1016/j.jalz.2011.02.007; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Halldorsson JG, 2013, BRAIN INJURY, V27, P1106, DOI 10.3109/02699052.2013.765599; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kaplan E, 1978, BOSTON NAMING TEST; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; MORRIS JC, 1988, PSYCHOPHARMACOL BULL, V24, P641; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ossenkoppele R, 2015, BRAIN, V138, P2732, DOI 10.1093/brain/awv191; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Rassovsky Y, 2015, J CLIN EXP NEUROPSYC, V37, P354, DOI 10.1080/13803395.2015.1015498; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rooks RN, 2002, J GERONTOL B-PSYCHOL, V57, pS247, DOI 10.1093/geronb/57.4.S247; Ruff RL, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000312; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Swan AR, 2015, J NEUROTRAUM, V32, P1510, DOI 10.1089/neu.2014.3654; Tanielian TL, 2008, INVISIBLE WOUNDS WAR, V720; Taylor C.A., 1998, SEMINARS CLIN NEUROP, V3, P224; Taylor E.M., 1959, PSYCHOL APPRAISAL CH; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Wang S, 2013, ALZHEIMERS ASS INT C; Weathers FW, PTSD CHECKLIST CIVIL; Wechsler D., 1997, WAIS 3 ADM SCORING M; Whiteneck GG, 2016, J HEAD TRAUMA REHAB, V31, pE55, DOI 10.1097/HTR.0000000000000140; YESAVAGE JA, 1988, PSYCHOPHARMACOL BULL, V24, P709; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	44	14	14	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2017	32	1					E8	E15		10.1097/HTR.0000000000000245			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EI2GH	WOS:000392304400015	27323220	Green Accepted			2021-06-18	
J	Rangaprakash, D; Dretsch, MN; Yan, WJ; Katz, JS; Denney, TS; Deshpande, G				Rangaprakash, D.; Dretsch, Michael N.; Yan, Wenjing; Katz, Jeffrey S.; Denney, Thomas S., Jr.; Deshpande, Gopikrishna			Hemodynamic variability in soldiers with trauma: Implications for functional MRI connectivity studies	NEUROIMAGE-CLINICAL			English	Article						Functional magnetic resonance imaging; Hemodynamic response function variability; Functional connectivity; Posttraumatic stress disorder; Mild-traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; RESTING STATE FMRI; BRAIN-INJURY; BOLD; RESPONSES; METAANALYSIS; INHIBITION; SEROTONIN; STRIATUM; NETWORKS	Functional MRI (fMRI) is an indirect measure of neural activity as a result of the convolution of the hemodynamic response function (HRF) and latent (unmeasured) neural activity. Recent studies have shown variability of HRF across brain regions (intra-subject spatial variability) and between subjects (inter-subject variability). Ignoring this HRF variability during data analysis could impair the reliability of such fMRI results. Using whole-brain resting-state fMRI (rs-fMRI), we employed hemodynamic deconvolution to estimate voxel-wise HRF. Studying the impact of mental disorders on HRF variability, we identified HRF aberrations in soldiers (N= 87) with posttraumatic stress disorder (PTSD) and mild-traumatic brain injury (mTBI) compared to combat controls. Certain subcortical and default-mode regions were found to have significant HRF aberrations in the clinical groups. These brain regions have been previously associated with neurochemical alterations in PTSD, which are known to impact the shape of the HRF. We followed-up these findings with seed-based functional connectivity (FC) analysis using regions-of-interest (ROIs) whose HRFs differed between the groups. We found that part of the connectivity group differences reported from traditional FC analysis (no deconvolution) were attributable to HRF variability. These findings raise the question of the degree of reliability of findings from conventional rsfMRI studies (especially in psychiatric populations like PTSD and mTBI), which are corrupted by HRF variability. We also report and discus, for the first time, voxel-level HRF alterations in PTSD and mTBI. To the best of our knowledge, this is the first study to report evidence for the impact of HRF variability on connectivity group differences. Our work has implications for rs-fMRI connectivity studies. We encourage researchers to incorporate hemodynamic deconvolution during pre-processing to minimize the impact of HRF variability.	[Rangaprakash, D.; Yan, Wenjing; Katz, Jeffrey S.; Denney, Thomas S., Jr.; Deshpande, Gopikrishna] Auburn Univ, Dept Elect & Comp Engn, AU MRI Res Ctr, Auburn, AL 36849 USA; [Rangaprakash, D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA; [Dretsch, Michael N.] HQ TRADOC, Human Dimens Div, Ft Eustis, VA USA; [Dretsch, Michael N.] US Army, Aeromed Res Lab, Ft Rucker, AL USA; [Katz, Jeffrey S.; Denney, Thomas S., Jr.; Deshpande, Gopikrishna] Auburn Univ, Dept Psychol, Auburn, AL 36849 USA; [Katz, Jeffrey S.; Denney, Thomas S., Jr.; Deshpande, Gopikrishna] Auburn Univ, Alabama Adv Imaging Consortium, Birmingham, AL USA; [Katz, Jeffrey S.; Denney, Thomas S., Jr.; Deshpande, Gopikrishna] Univ Alabama Birmingham, Birmingham, AL USA	Deshpande, G (corresponding author), Auburn Univ, 560 Devall Dr,Suite 266D, Auburn, AL 36849 USA.	gopi@auburn.edu		Denney, Thomas/0000-0002-6695-4777; Rangaprakash, D/0000-0001-9553-1354	U.S. Army Medical Research and Materiel Command (MRMC)U.S. Army Medical Research & Materiel Command (USAMRMC) [00007218]	The authors acknowledge financial support for this work from the U.S. Army Medical Research and Materiel Command (MRMC) (Grant # 00007218). The views, opinions, and/or findings contained in this article are those of the authors and should not be interpreted as representing the official views or policies, either expressed or implied, of the U.S. Army or the Department of Defense (DoD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors thank the personnel at the TBI clinic (Dr. Marlin Wolf) and behavioral health clinic, Fort Benning, GA, USA and the US Army Aeromedical Research Laboratory, Fort Rucker, AL, USA, and most of all, the soldiers who participated in the study. The authors thank Julie Rodiek and Wayne Duggan for facilitating data acquisition.	Aguirre GK, 1998, NEUROIMAGE, V8, P360, DOI 10.1006/nimg.1998.0369; Amico E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100012; Arichi T, 2012, NEUROIMAGE, V63, P663, DOI 10.1016/j.neuroimage.2012.06.054; Boly M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125337; Brown GG, 2003, J CEREBR BLOOD F MET, V23, P829, DOI 10.1097/01.WCB.0000071887.63724.B2; Busija DW, 2007, BRAIN RES REV, V56, P89, DOI 10.1016/j.brainresrev.2007.05.011; Buzsaki G, 2007, NEURON, V56, P771, DOI 10.1016/j.neuron.2007.11.008; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cisler JM, 2014, J PSYCHIATR RES, V48, P47, DOI 10.1016/j.jpsychires.2013.09.013; Cohen B. H., 2009, ANN M SOC AFF NEUR S; Cohen Z, 1996, PROG NEUROBIOL, V50, P335, DOI 10.1016/S0301-0082(96)00033-0; Deshpande G, 2010, NEUROIMAGE, V52, P884, DOI 10.1016/j.neuroimage.2009.11.060; Di Martino A, 2008, CEREB CORTEX, V18, P2735, DOI 10.1093/cercor/bhn041; Dickstein B.D., 2014, ASSESSMENT; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Friston K, 2007, STATISTICAL PARAMETRIC MAPPING: THE ANALYSIS OF FUNCTIONAL BRAIN IMAGES, P1; Handwerker DA, 2004, NEUROIMAGE, V21, P1639, DOI 10.1016/j.neuroimage.2003.11.029; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Lamichhane B, 2014, BRAIN CONNECT, V4, P619, DOI 10.1089/brain.2014.0243; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Margulies DS, 2007, NEUROIMAGE, V37, P579, DOI 10.1016/j.neuroimage.2007.05.019; Mayer AR, 2014, J NEUROTRAUM, V31, P189, DOI 10.1089/neu.2013.3069; Mifflin K, 2015, MOD TR PHARMACOPSYCH, V30, P94, DOI 10.1159/000435935; Muthukumaraswamy SD, 2012, HUM BRAIN MAPP, V33, P455, DOI 10.1002/hbm.21223; Nikolaus S, 2010, REV NEUROSCIENCE, V21, P119; Poldrack R.A., 2011, HDB FUNCTIONAL MRI D; Power JD, 2015, NEUROIMAGE, V105, P536, DOI 10.1016/j.neuroimage.2014.10.044; Ramage A. E., 2015, SOC COGN AF IN PRESS; Rangaprakash D, 2017, HUM BRAIN MAPP, V38, P2843, DOI 10.1002/hbm.23551; Rangaprakash D., 2015, P ANN M INT SOC MAGN, V23, P4402; Rangaprakash D., 2017, DATA BRIEF IN PRESS; Rosso IM, 2014, DEPRESS ANXIETY, V31, P115, DOI 10.1002/da.22155; Saad ZS, 2012, BRAIN CONNECT, V2, P25, DOI 10.1089/brain.2012.0080; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; Song XW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025031; Southwick S M, 1999, Semin Clin Neuropsychiatry, V4, P242; Thompson SK, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00159; Weathers F.W, 2015, PTSD CHECKLIST DSM 5; Wu GR, 2013, MED IMAGE ANAL, V17, P365, DOI 10.1016/j.media.2013.01.003; Yan CG, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00013	40	14	14	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2017	16						409	417		10.1016/j.nicl.2017.07.016			9	Neuroimaging	Neurosciences & Neurology	FK1IU	WOS:000413235100043	28879082	DOAJ Gold, Green Published			2021-06-18	
J	Schiehser, DM; Delano-Wood, L; Jak, AJ; Hanson, KL; Sorg, SF; Orff, H; Clark, AL				Schiehser, Dawn M.; Delano-Wood, Lisa; Jak, Amy J.; Hanson, Karen L.; Sorg, Scott F.; Orff, Henry; Clark, Alexandra L.			Predictors of cognitive and physical fatigue in post-acute mild-moderate traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Post-traumatic fatigue; traumatic brain injury; psychiatric symptoms; sleep quality; cognition	1ST 2 YEARS; QUALITY-OF-LIFE; MENTAL FATIGUE; IMPACT SCALE; INVENTORY; SLEEP; IDENTIFICATION; VALIDATION; DEPRESSION; SYMPTOMS	Post-traumatic fatigue (PTF) is a common, disabling, and often chronic symptom following traumatic brain injury (TBI). Yet, the impact of chronic cognitive and physical fatigue and their associations with psychiatric, sleep, cognitive, and psychosocial sequelae in mild-moderate TBI remain poorly understood. Sixty Veterans with a history of mild-moderate TBI and 40 Veteran controls (VC) were administered the Modified Fatigue Impact Scale, a validated measure of TBI-related cognitive and physical fatigue as well as measures of neuropsychiatric, psychosocial, sleep, and objective cognitive functioning. Compared to VC, TBI Veterans endorsed significantly greater levels of cognitive and physical fatigue. In TBI, psychiatric symptoms, sleep disturbance, and post-traumatic amnesia (PTA) were associated with both cognitive and physical fatigue, while loss of consciousness (LOC) and poor attention/processing speed were related to elevations in cognitive fatigue only. In regression analyses, anxiety, sleep disturbance, and LOC significantly predicted cognitive fatigue, while only post-traumatic stress symptoms and PTA contributed to physical fatigue. Cognitive and physical fatigue are problematic symptoms following mild-moderate TBI that are differentially associated with specific injury and psychiatric sequelae. Findings provide potential symptom targets for interventions aimed at ameliorating fatigue, and further underscore the importance of assessing and treating fatigue as a multi-dimensional symptom following TBI.	[Schiehser, Dawn M.; Delano-Wood, Lisa; Jak, Amy J.; Hanson, Karen L.; Sorg, Scott F.; Orff, Henry] VA San Diego Healthcare Syst VASDHS, Res & Psychol Serv, 3350 La Jolla Village Dr, San Diego, CA 92161 USA; [Schiehser, Dawn M.; Delano-Wood, Lisa; Jak, Amy J.; Hanson, Karen L.; Orff, Henry] Univ Calif San Diego, Sch Med, Dept Psychiat, 3350 La Jolla Village Dr, San Diego, CA 92161 USA; [Schiehser, Dawn M.; Delano-Wood, Lisa; Jak, Amy J.; Hanson, Karen L.; Orff, Henry] VASDHS, Ctr Excellence Stress & Mental Hlth, 3350 La Jolla Village Dr,151B, San Diego, CA 92161 USA; [Clark, Alexandra L.] Univ Calif San Diego, San Diego State Univ Joint Doctoral Program Clin, San Diego, CA 92103 USA	Schiehser, DM (corresponding author), Univ Calif San Diego, Sch Med, Dept Psychiat, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.; Schiehser, DM (corresponding author), VASDHS, Ctr Excellence Stress & Mental Hlth, 3350 La Jolla Village Dr,151B, San Diego, CA 92161 USA.	dschiehser@ucsd.edu			Department of Veterans Affairs, Veterans Health Administration, Office of Research and DevelopmentUS Department of Veterans Affairs [VA CSRD CDA-2-065-S, CX000842-01A2, 829-CDMH-13858]; Department of DefenseUnited States Department of Defense [W81XWH-10-2-0169]; Veterans AffairsUS Department of Veterans Affairs [IK2RX001512] Funding Source: NIH RePORTER	This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development [VA CSR&D CDA-2-065-S (DMS)], [CX000842-01A2 & 829-CDMH-13858 (LDW)]; and the Department of Defense [LDW: W81XWH-10-2-0169].	Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Babor T., 2001, ALCOHOL USE DISORDER, V2nd ed.; Bay E, 2011, J HEAD TRAUMA REHAB, V26, P355, DOI 10.1097/HTR.0b013e3181f20146; Beaulieu-Bonneau S, 2012, SLEEP MED, V13, P598, DOI 10.1016/j.sleep.2012.02.010; Beck A., 1996, MANUAL BDI 2; Beck A.T., 1990, MANUAL BECK ANXIETY; BECK AT, 1991, J ANXIETY DISORD, V5, P213, DOI 10.1016/0887-6185(91)90002-B; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Belmont A, 2009, NEUROREHAB NEURAL RE, V23, P939, DOI 10.1177/1545968309340327; Brouwer W., 1984, RIDDLES SELECTIVITY; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Bryce S., 2015, SCREENING SUBSTANCE; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Cantor JB, 2012, J HEAD TRAUMA REHAB, V27, pE1, DOI 10.1097/HTR.0b013e318270f91e; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Clark A. L., 2016, BRAIN IMAGING BEHAV; Defense and Veterans Brain Injury Center, 2015, DOD WORLDW NUMB TBI; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; DeLuca J, 2005, ISS CLIN COGN NEUROP, P1; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Feinstein A, 2000, BRAIN COGNITION, V44, P78; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; FISK JD, 1994, CLIN INFECT DIS, V18, pS79, DOI 10.1093/clinids/18.Supplement_1.S79; Johansson B, 2015, NEUROREHABILITATION, V36, P195, DOI 10.3233/NRE-151207; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Keller-Ross ML, 2014, MED SCI SPORT EXER, V46, P1302, DOI 10.1249/MSS.0000000000000244; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Preston J, 2014, CONSUMERS GUIDE PSYC; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; Schiehser DM, 2015, J HEAD TRAUMA REHAB, V30, pE21, DOI 10.1097/HTR.0000000000000065; Schiehser DM, 2015, J HEAD TRAUMA REHAB, V30, P116, DOI 10.1097/HTR.0000000000000019; Schnieders J, 2012, J HEAD TRAUMA REHAB, V27, P404, DOI 10.1097/HTR.0b013e3182306341; Siegert RJ, 2009, J INT NEUROPSYCH SOC, V15, P142, DOI 10.1017/S1355617708090048; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; The Management of Concussion/mTBI Working Group, 2009, VA DOD CLIN PRACT GU; Tombaugh TN, 1996, TEST MEMORY MALINGER; Vanderploeg RD, 2012, J REHABIL RES DEV, V49, P545, DOI 10.1682/JRRD.2011.04.0069; Weathers F. W., 1991, PCLBULLETM DSMBULLET; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	50	14	14	0	1	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2017	27	7					1031	1046		10.1080/09602011.2016.1215999			16	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	FB4WK	WOS:000406142500004	27535726				2021-06-18	
J	Shah, SA; Goldi, Y; Conte, MM; Goldfine, AM; Mohamadpour, M; Fidali, BC; Cicerone, K; Schiff, ND				Shah, Sudhin A.; Goldi, Yelena; Conte, Mary M.; Goldfine, Andrew M.; Mohamadpour, Maliheh; Fidali, Brian C.; Cicerone, Keith; Schiff, Nicholas D.			Executive attention deficits after traumatic brain injury reflect impaired recruitment of resources	NEUROIMAGE-CLINICAL			English	Article						EEG; Traumatic brain injury; Attention network test; Executive attention; Frontal lobe; Medial frontal theta	ANTERIOR CINGULATE CORTEX; BETA-BAND OSCILLATIONS; POSITRON-EMISSION-TOMOGRAPHY; STATISTICAL IMAGE-ANALYSIS; HUMAN THETA-OSCILLATIONS; FRONTAL MIDLINE THETA; SPECTRAL-ANALYSIS; WORKING-MEMORY; AROUSAL REGULATION; REACTION-TIME	Deficits in attention are a common and devastating consequence of traumatic brain injury (TBI), leading to functional impairments, rehabilitation barriers, and long-term disability. While such deficits are well documented, little is known about their underlying pathophysiology hindering development of effective and targeted interventions. Here we evaluate the integrity of brain systems specific to attentional functions using quantitative assessments of electroencephalography recorded during performance of the Attention Network Test (ANT), a behavioral paradigm that separates alerting, orienting, and executive components of attention. We studied 13 patients, at least 6months post-TBI with cognitive impairments, and 24 control subjects. Based on performance on the ANT, TBI subjects showed selective impairment in executive attention. In TBI subjects, principal component analysis combined with spectral analysis of the EEG after target appearance extracted a pattern of increased frontal midline theta power (2.5-7.5 Hz) and suppression of frontal beta power ( 12.5-22.5 Hz). Individual expression of this pattern correlated (r=-0.67, p < 0.001) with executive attention impairment. The grading of this pattern of spatiotemporal dynamics with executive attention deficits reflects impaired recruitment of anterior forebrain resources following TBI; specifically, deafferentation and variable disfacilitation of medial frontal neuronal populations is proposed as the basis of our findings. (C) 2017 The Authors. Published by Elsevier Inc.	[Shah, Sudhin A.; Conte, Mary M.; Fidali, Brian C.; Schiff, Nicholas D.] Weill Cornell Med Coll, Brain & Mind Res Inst, Dept Neurosci, New York, NY 0065 USA; [Goldi, Yelena; Cicerone, Keith] JFK Johnson Rehabil Inst, Cognit Rehabil Dept, Edison, NJ 08820 USA; [Goldi, Yelena; Cicerone, Keith] JFK Johnson Rehabil Inst, Dept Phys Med & Rehabil, Edison, NJ 08820 USA; [Goldfine, Andrew M.] SUNY Stony Brook, Dept Neurol, Stony Brook, NY 11794 USA; [Mohamadpour, Maliheh] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA	Shah, SA (corresponding author), Weill Cornell Med Coll, 1300 York Ave,Room F610, New York, NY 10065 USA.	sut2006@med.cornell.edu	Mohamadpour, Maliheh/I-8041-2019		Jerold B Katz Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD079556] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000457] Funding Source: NIH RePORTER	The Jerold B Katz Foundation supported this work.	Ashman TA, 2006, MT SINAI J MED, V73, P999; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Babadi B, 2014, IEEE T BIO-MED ENG, V61, P1555, DOI 10.1109/TBME.2014.2311996; Baker JL, 2016, J NEUROPHYSIOL, V116, P2383, DOI 10.1152/jn.01129.2015; BARBAS H, 1991, J COMP NEUROL, V313, P65, DOI 10.1002/cne.903130106; Brenner Lisa A, 2011, Dialogues Clin Neurosci, V13, P311; Brinkman L, 2014, J NEUROSCI, V34, P14783, DOI 10.1523/JNEUROSCI.2039-14.2014; Caplan JB, 2003, J NEUROSCI, V23, P4726; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Cazalis F, 2006, BRAIN INJURY, V20, P1019, DOI 10.1080/02699050600664384; Cicerone K. D., 2014, HDB NEUROPSYCHOLOGY, P191, DOI DOI 10.1007/978-1-4939-0784-7_10.; Cimenser A, 2011, P NATL ACAD SCI USA, V108, P8832, DOI 10.1073/pnas.1017041108; Cohen MX, 2008, BRAIN RES, V1238, P127, DOI 10.1016/j.brainres.2008.07.114; Cohen MX, 2013, J NEUROPHYSIOL, V110, P2752, DOI 10.1152/jn.00479.2013; Deiber MP, 2013, NEUROIMAGE, V82, P531, DOI 10.1016/j.neuroimage.2013.06.037; Deiber MP, 1996, J NEUROPHYSIOL, V75, P233; Dockree PM, 2011, INT J PSYCHOPHYSIOL, V82, P53, DOI 10.1016/j.ijpsycho.2011.01.004; Engel AK, 2010, CURR OPIN NEUROBIOL, V20, P156, DOI 10.1016/j.conb.2010.02.015; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Fan J, 2005, NEUROIMAGE, V26, P471, DOI 10.1016/j.neuroimage.2005.02.004; Fan J, 2007, J NEUROSCI, V27, P6197, DOI 10.1523/JNEUROSCI.1833-07.2007; Floden D, 2011, J COGNITIVE NEUROSCI, V23, P867, DOI 10.1162/jocn.2010.21492; Fridman EA, 2014, P NATL ACAD SCI USA, V111, P6473, DOI 10.1073/pnas.1320969111; Gola M, 2012, INT J PSYCHOPHYSIOL, V85, P62, DOI 10.1016/j.ijpsycho.2011.09.001; Goldfine AM, 2011, CLIN NEUROPHYSIOL, V122, P2157, DOI 10.1016/j.clinph.2011.03.022; Goldstein G, 2010, BRAIN INJURY, V24, P625, DOI 10.3109/02699051003670882; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hanif A, 2012, ACTA PSYCHOL, V139, P104, DOI 10.1016/j.actpsy.2011.09.010; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; HJORTH B, 1975, ELECTROEN CLIN NEURO, V39, P526, DOI 10.1016/0013-4694(75)90056-5; Hsieh LT, 2014, NEUROIMAGE, V85, P721, DOI 10.1016/j.neuroimage.2013.08.003; Hu PP, 2013, NEUROSCI LETT, V534, P177, DOI 10.1016/j.neulet.2012.12.038; Jolliffe I, 2002, PRINCIPAL COMPONENT; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kawai N, 2010, J NEUROTRAUM, V27, P2131, DOI 10.1089/neu.2010.1464; Kinomura S, 1996, SCIENCE, V271, P512, DOI 10.1126/science.271.5248.512; Kubat-Silman AK, 2002, BRAIN COGNITION, V50, P178, DOI 10.1016/S0278-2626(02)00502-X; Laureys S, 2012, NEUROIMAGE, V61, P478, DOI 10.1016/j.neuroimage.2011.12.041; Leon-Carrion J, 2012, J REHABIL MED, V44, P505, DOI 10.2340/16501977-0982; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Liu J, 2015, ELIFE, V4, DOI 10.7554/eLife.09215; Luu P, 2004, CLIN NEUROPHYSIOL, V115, P1821, DOI 10.1016/j.clinph.2004.03.031; Mattia M, 2012, Front Neuroeng, V5, P12, DOI 10.3389/fneng.2012.00012; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Mitra P, 2007, OBSERVED BRAIN DYNAM; Mitra PP, 1999, BIOPHYS J, V76, P691, DOI 10.1016/S0006-3495(99)77236-X; Nagai Y, 2004, NEUROIMAGE, V21, P1232, DOI 10.1016/j.neuroimage.2003.10.036; Naito E, 2000, J NEUROPHYSIOL, V83, P1701; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Paus T, 2001, NAT REV NEUROSCI, V2, P417, DOI 10.1038/35077500; Paus T, 1997, J COGNITIVE NEUROSCI, V9, P392, DOI 10.1162/jocn.1997.9.3.392; Percival DB, 1993, SPECTRAL ANAL PHYS A; Petersen SE, 2012, ANNU REV NEUROSCI, V35, P73, DOI 10.1146/annurev-neuro-062111-150525; Raghavachari S, 2001, J NEUROSCI, V21, P3175, DOI 10.1523/JNEUROSCI.21-09-03175.2001; Rodriguez-Bailon M, 2012, SPAN J PSYCHOL, V15, P967, DOI 10.5209/rev_SJOP.2012.v15.n3.39388; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schiff ND, 2013, J NEUROPHYSIOL, V109, P1152, DOI 10.1152/jn.00317.2011; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Slobounov SM, 2000, COGNITIVE BRAIN RES, V9, P287, DOI 10.1016/S0926-6410(00)00009-4; Stierwalt Julie A. G., 2002, Seminars in Speech and Language, V23, P129, DOI 10.1055/s-2002-24989; THOMSON DJ, 1982, P IEEE, V70, P1055, DOI 10.1109/PROC.1982.12433; TREXLER LE, 1988, BRAIN COGNITION, V8, P291, DOI 10.1016/0278-2626(88)90056-5; Tsujimoto T, 2010, J NEUROPHYSIOL, V103, P827, DOI 10.1152/jn.00358.2009; TUCKER DM, 1993, ELECTROEN CLIN NEURO, V87, P154, DOI 10.1016/0013-4694(93)90121-B; Van der Werf YD, 2002, BRAIN RES REV, V39, P107, DOI 10.1016/S0165-0173(02)00181-9; van Donkelaar P, 2005, BRAIN INJURY, V19, P1031, DOI 10.1080/02699050500110363; van Vugt MK, 2007, J NEUROSCI METH, V162, P49, DOI 10.1016/j.jneumeth.2006.12.004; Wang CM, 2005, J NEUROSCI, V25, P604, DOI 10.1523/JNEUROSCI.4151-04.2005; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020	71	14	14	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2017	14						233	241		10.1016/j.nicl.2017.01.010			9	Neuroimaging	Neurosciences & Neurology	FB2OY	WOS:000405984300025	28180082	DOAJ Gold, Green Published			2021-06-18	
J	Sullivan, GM; Armstrong, RC				Sullivan, Genevieve M.; Armstrong, Regina C.			Transplanted Adult Neural Stem Cells Express Sonic Hedgehog In Vivo and Suppress White Matter Neuroinflammation after Experimental Traumatic Brain Injury	STEM CELLS INTERNATIONAL			English	Article							OLIGODENDROCYTE LINEAGE; ASTROCYTES; DIFFERENTIATION	Neural stem cells (NSCs) delivered intraventricularly may be therapeutic for diffuse white matter pathology after traumatic brain injury (TBI). To test this concept, NSCs isolated from adult mouse subventricular zone (SVZ) were transplanted into the lateral ventricle of adult mice at two weeks post-TBI followed by analysis at four weeks post-TBI. We examined sonic hedgehog (Shh) signaling as a candidate mechanism by which transplanted NSCs may regulate neuroregeneration and/or neuroinflammation responses of endogenous cells. Mouse fluorescent reporter lines were generated to enable in vivo genetic labeling of cells actively transcribing Shh or Gli1 after transplantation and/or TBI. Gli1 transcription is an effective readout for canonical Shh signaling. In Shh(CreERT2); R26tdTomato mice, Shh was primarily expressed in neurons and was not upregulated in reactive astrocytes or microglia after TBI. Corroborating results in Gli1(CreERT2); R26tdTomato mice demonstrated that Shh signaling was not upregulated in the corpus callosum, even after TBI or NSC transplantation. Transplanted NSCs expressed Shh in vivo but did not increase Gli1 labeling of host SVZ cells. Importantly, NSC transplantation significantly reduced reactive astrogliosis and microglial/macrophage activation in the corpus callosum after TBI. Therefore, intraventricular NSC transplantation after TBI significantly attenuated neuroinflammation, but did not activate host Shh signaling via Gli1 transcription.	[Sullivan, Genevieve M.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Sullivan, Genevieve M.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA	Armstrong, RC (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.; Armstrong, RC (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	regina.armstrong@usuhs.edu	Sullivan, Genevieve/AAK-7415-2021	Sullivan, Genevieve/0000-0002-3561-223X	Department of Defense in the Center for Neuroscience and Regenerative Medicine (CNRM)	This work was funded by the Department of Defense in the Center for Neuroscience and Regenerative Medicine (CNRM). The authors appreciate the technical assistance of Tuan Le and Laurel Beer. The authors thank Dr. Sohyun Ahn ( National Institute for Child Health, Bethesda, MD) for providing the Gli1<SUP>CreERT2</SUP>; R26YFP and Gli1<SUP>CreERT2</SUP>; R26td-Tomato mice and Dr. Sharon Juliano for providing the C57BL/6-Tg(UBC-GFP) 30Scha/J mice.	Ahn S, 2005, NATURE, V437, P894, DOI 10.1038/nature03994; Ahn S, 2004, CELL, V118, P505, DOI 10.1016/j.cell.2004.07.023; Alvarez JI, 2011, SCIENCE, V334, P1727, DOI 10.1126/science.1206936; Alvarez-Buylla A, 2014, SEMIN CELL DEV BIOL, V33, P105, DOI 10.1016/j.semcdb.2014.05.008; Armstrong RC, 2002, J NEUROSCI, V22, P8574; Brennan D, 2012, VITAM HORM, V88, P55, DOI 10.1016/B978-0-12-394622-5.00003-1; Martinez MC, 2006, BLOOD, V108, P3012, DOI 10.1182/blood-2006-04-019109; Dobson NR, 2012, GLIA, V60, P1378, DOI 10.1002/glia.22356; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Donega M., 2014, J VISUALIZED EXPT, V86; Drago D, 2013, BIOCHIMIE, V95, P2271, DOI 10.1016/j.biochi.2013.06.020; Einstein O, 2009, J NEUROSCI, V29, P15694, DOI 10.1523/JNEUROSCI.3364-09.2009; Farmer WT, 2016, SCIENCE, V351, P849, DOI 10.1126/science.aab3103; Ferent J, 2013, J NEUROSCI, V33, P1759, DOI 10.1523/JNEUROSCI.3334-12.2013; Garcia ADR, 2010, J NEUROSCI, V30, P13597, DOI 10.1523/JNEUROSCI.0830-10.2010; Giusto E, 2014, EXP NEUROL, V260, P19, DOI 10.1016/j.expneurol.2013.03.009; Harfe BD, 2004, CELL, V118, P517, DOI 10.1016/j.cell.2004.07.024; Harwell CC, 2012, NEURON, V73, P1116, DOI 10.1016/j.neuron.2012.02.009; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Ihrie RA, 2011, NEURON, V71, P250, DOI 10.1016/j.neuron.2011.05.018; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Margulies S, 2016, J NEUROTRAUM, V33, P101, DOI 10.1089/neu.2014.3855; Mierzwa AJ, 2015, J NEUROPATH EXP NEUR, V74, P218, DOI 10.1097/NEN.0000000000000165; Mierzwa AJ, 2014, ASN NEURO, V6, DOI 10.1177/1759091414551782; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Palma V, 2005, DEVELOPMENT, V132, P335, DOI 10.1242/dev.01567; Petrova R, 2013, J NEUROSCI, V33, P17490, DOI 10.1523/JNEUROSCI.2042-13.2013; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Rafuse VF, 2005, NEUROSCIENCE, V131, P899, DOI 10.1016/j.neuroscience.2004.11.048; Robbins DJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002906; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Samanta J, 2015, NATURE, V526, P448, DOI 10.1038/nature14957; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Sirko S, 2013, CELL STEM CELL, V12, P426, DOI 10.1016/j.stem.2013.01.019; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Zhang XL, 2013, J IMMUNOL, V191, P4551, DOI 10.4049/jimmunol.1300931; Zhou Q, 2011, NEUROSCI LETT, V500, P202, DOI 10.1016/j.neulet.2011.06.037; Zhou Q, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-50	42	14	14	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1687-966X	1687-9678		STEM CELLS INT	Stem Cells Int.		2017	2017								9342534	10.1155/2017/9342534			16	Cell & Tissue Engineering	Cell Biology	FF8XV	WOS:000409302000001	29081811	DOAJ Gold, Green Published			2021-06-18	
J	Tripodis, Y; Alosco, ML; Zirogiannis, N; Gavett, BE; Chaisson, C; Martin, B; McClean, MD; Mez, J; Kowall, N; Stern, RA				Tripodis, Yorghos; Alosco, Michael L.; Zirogiannis, Nikolaos; Gavett, Brandon E.; Chaisson, Christine; Martin, Brett; McClean, Michael D.; Mez, Jesse; Kowall, Neil; Stern, Robert A.			The Effect of Traumatic Brain Injury History with Loss of Consciousness on Rate of Cognitive Decline Among Older Adults with Normal Cognition and Alzheimer's Disease Dementia	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Alzheimer's disease; APOE; cognitive decline; dementia; loss of consciousness; normal cognition; risk factor; traumatic brain injury	UNIFORM DATA SET; CENTER NACC DATABASE; DIFFUSION-TENSOR; HEAD-INJURY; RISK; ENCEPHALOPATHY; PATHOLOGY; MODERATE; EPIDEMIOLOGY; DISORDERS	Traumatic brain injury (TBI) is thought to be a risk factor for dementia, including dementia due to Alzheimer's disease (AD). However, the influence of TBI history on the neuropsychological course of AD is unknown and, more broadly, the effect of TBI history on age-related cognitive change is poorly understood. We examined the relationship between history of TBI with loss of consciousness (LOC) history and cognitive change in participants with normal cognition and probable AD, stratified by APOE epsilon 4 allele status. The sample included 706 participants (432 with normal cognition; 274 probable AD) from the National Alzheimer's Coordinating Center (NACC) dataset that completed the Uniform Data Set evaluation between 2005 and 2014. Normal and probable AD participants with a history of TBI were matched to an equal number of demographically and clinically similar participants without a TBI history. In this dataset, TBI with LOC was defined as brain trauma with brief or extended unconsciousness. For the normal and probable AD cohorts, there was an average of 3.2 +/- 1.9 and 1.8 +/- 1.1 years of follow-up, respectively. 30.8% of the normal cohort were APOE epsilon 4 carriers, whereas 70.8% of probable AD participants were carriers. Mixed effects regressions showed TBI with LOC history did not affect rates of cognitive change in APOE epsilon 4 carriers and non-carriers. Findings from this study suggest that TBI with LOC may not alter the course of cognitive function in older adults with and without probable AD. Future studies that better characterize TBI (e.g., severity, number of TBIs, history of subconconcussive exposure) are needed to clarify the association between TBI and long-term neurocognitive outcomes.	[Tripodis, Yorghos; Chaisson, Christine; Martin, Brett; McClean, Michael D.; Stern, Robert A.] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Alosco, Michael L.; Mez, Jesse; Kowall, Neil] Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Zirogiannis, Nikolaos] Indiana Univ, Sch Publ & Environm Affairs, Bloomington, IN USA; [Gavett, Brandon E.; Kowall, Neil] Univ Colorado, Dept Psychol, Colorado Springs, CO 80933 USA; VA Boston Healthcare Syst, Neurol Serv, Boston, MA USA	Stern, RA (corresponding author), BU ADC, 72 E Concord St,Suite B7800, Boston, MA 02118 USA.	bobstern@bu.edu	Kowall, Neil/M-5378-2019; , Bob/ABA-8507-2020	Kowall, Neil/0000-0002-6624-0213; Tripodis, Yorghos/0000-0003-2190-7608; Gavett, Brandon/0000-0003-1938-1854	NIA/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG013846]; NIA/NIH Grant [U01 AG016976]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG013846, P30 AG019610, P50 AG008702, P50 AG025688, P50 AG047266, P30 AG010133, P50 AG005146, P50 AG005134, P50 AG016574, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017, P30 AG010161, P50 AG047366, P30 AG010129, P50 AG016573];  [P50 AG016570];  [P50 AG005131];  [P50 AG023501];  [P30 AG035982];  [P30 AG028383];  [P30 AG010124];  [P50 AG005133];  [P50 AG005142];  [P30 AG012300];  [P50 AG005136];  [P50 AG033514];  [P50 AG005681];  [P50 AG047270]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133, P30AG035982, P30AG010129, P50AG005131, P50AG023501, P30AG010124, P30AG013846, P30AG028383, P50AG033514, P50AG025688, P50AG005136, P50AG005146, P50AG047266, P50AG005681, P30AG013854, P50AG047366, P30AG010133, P50AG005138, P50AG008702, P30AG019610, P50AG016570, P50AG005142, U01AG016976, P50AG047270, P50AG016573, P30AG008017, K23AG046377, P30AG010161, P30AG012300, P50AG016574, P30AG008051, P50AG005134] Funding Source: NIH RePORTER	The study is funded by NIA/NIH grant P30 AG013846 (PI Neil Kowall, MD). The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P50 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Steven Ferris, PhD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG016570 (PI Marie-Francoise Chesselet, MD, PhD), P50 AG005131 (PI Douglas Galasko, MD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda VanEldik, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P50 AG005136 (PI Thomas Montine, MD, PhD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), and P50 AG047270 (PI Stephen Strittmatter, MD, PhD).	Ambrose AF, 2013, MATURITAS, V75, P51, DOI 10.1016/j.maturitas.2013.02.009; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Beekly DL, 2004, ALZ DIS ASSOC DIS, V18, P270; Beekly DL, 2007, ALZ DIS ASSOC DIS, V21, P249, DOI 10.1097/WAD.0b013e318142774e; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Doornik J.A., 2009, OBJECT ORIENTED MATR; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Farbota KDM, 2012, J INT NEUROPSYCH SOC, V18, P1006, DOI 10.1017/S1355617712000835; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Hay J, 2016, ANNU REV PATHOL-MECH, V11, P21, DOI 10.1146/annurev-pathol-012615-044116; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Koponen S, 2004, NEUROLOGY, V63, P749, DOI 10.1212/01.WNL.0000134603.57107.2F; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mallinckrodt C H, 2001, J Biopharm Stat, V11, P9, DOI 10.1081/BIP-100104194; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Sayed N, 2013, J NEUROTRAUM, V30, P1117, DOI 10.1089/neu.2012.2638; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Tripodis Y, 2015, INT J CLIN BIOSTAT B, V1; Verghese PB, 2011, LANCET NEUROL, V10, P241, DOI 10.1016/S1474-4422(10)70325-2; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029; Weintraub S, 2009, ALZ DIS ASSOC DIS, V23, P91, DOI 10.1097/WAD.0b013e318191c7dd; Zhou W, 2008, J NEUROTRAUM, V25, P279	56	14	14	1	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2017	59	1					251	263		10.3233/JAD-160585			13	Neurosciences	Neurosciences & Neurology	EZ7CA	WOS:000404876400022	28655133	Green Accepted			2021-06-18	
J	Tuominen, M; Stuart, MJ; Aubry, M; Kannus, P; Parkkari, J				Tuominen, Markku; Stuart, Michael J.; Aubry, Mark; Kannus, Pekka; Parkkari, Jari			Injuries in world junior ice hockey championships between 2006 and 2015	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							DESCRIPTIVE EPIDEMIOLOGY; SURVEILLANCE SYSTEM; SOCCER INJURIES; NECK INJURIES; MENS; HEAD; TOURNAMENTS; PLAYERS; FEDERATION; 7-YEAR	Background Detailed injury data are not available for international ice hockey tournaments played by junior athletes. We report the incidence, type, mechanism and severity of injuries in males under ages 18 and 20 at junior ice hockey World Championships during 2006-2015. Methods All injuries in the International Ice Hockey Federation World Junior under-20 (WJ U20) Championship and under-18 (WJ U18) Championship were collected over a 9-year period using a strict injury definition, a standardised injury reporting system and diagnoses made by a team physician. Results 633 injuries were recorded in 1326 games over a 9-year period, resulting in an injury rate (IR) of 11.0 per 1000 player-games and 39.8/1000 player-game hours. The IRs in all tournaments were 4.3/1000 player-games for the head and face, 3.2 for the upper body, 2.6 for the lower body and 1.0 for the spine and trunk. A laceration was the most common injury type followed by a sprain. Lacerations accounted for 80% (IR 3.6) of facial injuries in WJ U20 tournaments. The shoulder was the most common injury site (IR 2.0) in WJ U18 tournaments. Board contact was the mechanism for 59% of these shoulder injuries. Concussion was the most common head and face injury (46%; IR 1.2) in WJ U18 tournaments. Conclusions and recommendations The risk of injury among male junior ice hockey players was lower than the reported rates in adult men but higher than that in women. Facial lacerations were common in U20 junior players (WJ U20) since most wear only partial facial protection (visor). The IR for shoulder injuries was high in U18 junior players (WJ U18). Suggested strategies for injury prevention include full facial protection for all players and flexible board and glass for all junior tournaments.	[Tuominen, Markku] Medisport Ltd, Keskisenkatu 5, Tampere 33710, Finland; [Stuart, Michael J.] Mayo Clin, Dept Orthoped, Rochester, MN USA; [Aubry, Mark] Ottawa Sport Med Ctr, Ottawa, ON, Canada; [Kannus, Pekka] UKK Inst, Injury & Osteoporosis Res Ctr, Tampere, Finland; [Parkkari, Jari] UKK Inst, Tampere Res Ctr Sports Med, Tampere, Finland	Tuominen, M (corresponding author), Medisport Ltd, Keskisenkatu 5, Tampere 33710, Finland.	markku.tuominen@medisport.fi			International Ice Hockey Federation; Finnish Ministry of Education and Culture	This study was financially supported by the International Ice Hockey Federation and the Finnish Ministry of Education and Culture.	Agel J, 2007, J ATHL TRAINING, V42, P270; Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2010, CAN J SURG, V53, P319; Asplund C, 2009, BRIT J SPORT MED, V43, P993, DOI 10.1136/bjsm.2009.060152; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Clarsen B, 2014, BRIT J SPORT MED, V48, P510, DOI 10.1136/bjsports-2013-093297; Dick R, 2007, J ATHL TRAINING, V42, P194; Engebretsen L, 2014, BRIT J SPORT MED, V48, P1270, DOI 10.1136/bjsports-2014-093992; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Fuller CW, 2011, CLIN J SPORT MED, V21, P356, DOI 10.1097/JSM.0b013e31821f5085; Groger A, 2001, SPORTVERLETZ SPORTSC, V15, P82, DOI 10.1055/s-2001-19047; Junge A, 2004, BRIT J SPORT MED, V38, P168, DOI 10.1136/bjsm.2002.003020; Junge A, 2013, BRIT J SPORT MED, V47, P782, DOI 10.1136/bjsports-2013-092205; LAPRADE RF, 1995, AM J SPORT MED, V23, P773, DOI 10.1177/036354659502300624; LaPrade RF, 2014, BRIT J SPORT MED, V48, P4, DOI 10.1136/bjsports-2013-093020; Leppanen M, 2014, SPORTS MED, V44, P473, DOI 10.1007/s40279-013-0136-8; Meeuwisse Willem H, 2002, Clin J Sport Med, V12, P406; Mukherjee S, 2012, AM J SPORT MED, V40, P686, DOI 10.1177/0363546511426697; Pinto M, 1999, CLIN J SPORT MED, V9, P70, DOI 10.1097/00042752-199904000-00005; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Rishiraj N, 2009, J SPORT MED PHYS FIT, V49, P159; Ruhe A, 2014, BRIT J SPORT MED, V48, P102, DOI 10.1136/bjsports-2012-091609; STUART MJ, 1995, AM J SPORT MED, V23, P458, DOI 10.1177/036354659502300415; Stuart MJ, 2002, AM J SPORT MED, V30, P39, DOI 10.1177/03635465020300012001; Stuart MJ, 2000, AM SOC TEST MATER, V1341, P19, DOI 10.1520/STP15224S; Tuominen M, 2016, BRIT J SPORT MED, V50, P1406, DOI 10.1136/bjsports-2015-094647; Tuominen M, 2015, BRIT J SPORT MED, V49, P30, DOI 10.1136/bjsports-2014-093688; Yard EE, 2008, AM J SPORT MED, V36, P1930, DOI 10.1177/0363546508318047	28	14	15	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2017	51	1					36	+		10.1136/bjsports-2016-095992			9	Sport Sciences	Sport Sciences	EH0EK	WOS:000391435400010	27281776	Bronze, Green Published			2021-06-18	
J	Sharfi, K; Rosenblum, S				Sharfi, Kineret; Rosenblum, Sara			Executive Functions, Time Organization and Quality of Life among Adults with Learning Disabilities	PLOS ONE			English	Article							ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; ACADEMIC-ACHIEVEMENT; CHILDREN; PERFORMANCE; HEALTH; COMPREHENSION; ADOLESCENTS; DEFINITION	Purpose This study compared the executive functions, organization in time and perceived quality of life (QoL) of 55 adults with learning disabilities (LD) with those of 55 matched controls (mean age 30 years). Furthermore, relationships and predictive relationships between these variables among the group with LD were examined. Methods All participants completed the Behavioral Rating Inventory of Executive Functions (BRIEFA), the Time Organization and Participation (TOPS, A-C) and the World Health Organization Quality of Life (WHOQOL) questionnaires. Chi-square tests, independent t-tests and MANOVA were used to examine group differences in each of the subscales scores and ratings of each instrument. Pearson correlations and regression predictive models were used to examine the relationships between the variables in the group with LD. Results Adults with LD had significantly poorer executive functions (BRIEF-A), deficient organization in time abilities (TOPS A-B), accompanied with negative emotional response (TOPS-C), and lower perceived QoL (physical, psychological, social and environmental) in comparison to adults without LD. Regression analysis revealed that Initiation (BRIEF-A) significantly predicted approximately 15% of the participants' organization in time abilities (TOPS A, B scores) beyond group membership. Furthermore, initiation, emotional control (BRIEF-A subscales) and emotional responses following unsuccessful organization of time (TOPS-C) together accounted for 39% of the variance of psychological QoL beyond the contribution of group membership. Conclusions Deficits in initiation and emotional executive functions as well as organization in time abilities and emotional responses to impairments in organizing time affect the QoL of adults with LD and thus should be considered in further research as well as in clinical applications.	[Sharfi, Kineret; Rosenblum, Sara] Univ Haifa, Lab Complex Human Act & Participat, Dept Occupat Therapy, Haifa, Israel	Sharfi, K (corresponding author), Univ Haifa, Lab Complex Human Act & Participat, Dept Occupat Therapy, Haifa, Israel.	kineretsharfi@gmail.com			Israeli Ministry of Science and TechnologyMinistry of Science, Technology and Space (MOST), Israel [3-8634]	This study was funded by the Israeli Ministry of Science and Technology, grant number 3-8634. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to thank all those who participated for their cooperation and interest in the study and to the Israeli Ministry of Science and Technology for their support. The ethics committee for human subject research in the faculty of social welfare and health sciences at Haifa University approved this study in October 2010 (confirmation No. 170/10). An informed consent was signed by each participant and afterwards the subjects' personal identifiers were kept separately from the data.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Bailey CE, 2007, ANN NY ACAD SCI, V1118, P122, DOI 10.1196/annals.1412.011; Barkley R. A., 1994, ADHD REPORT, V2, P1; Barkley RA, 2011, J PSYCHOPATHOL BEHAV, V33, P137, DOI 10.1007/s10862-011-9217-x; Blair C, 2007, CHILD DEV, V78, P647, DOI 10.1111/j.1467-8624.2007.01019.x; Borella E, 2010, J LEARN DISABIL-US, V43, P541, DOI 10.1177/0022219410371676; Braun U, 2015, P NATL ACAD SCI USA, V112, P11678, DOI 10.1073/pnas.1422487112; Brod M, 2006, QUAL LIFE RES, V15, P117, DOI 10.1007/s11136-005-8325-z; Brosnan M, 2002, NEUROPSYCHOLOGIA, V40, P2144, DOI 10.1016/S0028-3932(02)00046-5; Brown TE, 2010, POSTGRAD MED, V122, P42, DOI 10.3810/pgm.2010.09.2200; Bryan T, 2004, LEARN DISABILITY Q, V27, P45, DOI 10.2307/1593631; Bull R, 2001, DEV NEUROPSYCHOL, V19, P273, DOI 10.1207/S15326942DN1903_3; Cavendish W, 2013, J LEARN DISABIL-US, V46, P52, DOI 10.1177/0022219412464352; Christopher ME, 2012, J EXP PSYCHOL GEN, V141, P470, DOI 10.1037/a0027375; Cortiella C., 2014, STATE LEARNING DISAB; Duncan GJ, 2007, DEV PSYCHOL, V43, P1428, DOI 10.1037/0012-1649.43.6.1428; Farnworth L., 2003, J OCCUP SCI, V10, P150; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Felce D, 1997, QUALITY LIFE PEOPLE, P56; Funahashi S, 2001, NEUROSCI RES, V39, P147, DOI 10.1016/S0168-0102(00)00224-8; Gathercole SE, 2004, APPL COGNITIVE PSYCH, V18, P1, DOI 10.1002/acp.934; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Godard J, 2011, PSYCHIAT RES, V190, P244, DOI 10.1016/j.psychres.2011.06.014; Greenhill LL., 2000, LEARNING DISABILITIE; Grinblat N, 2012, THESIS; Hooper SR, 2002, J LEARN DISABIL-US, V35, P57, DOI 10.1177/002221940203500105; Kane MJ, 2007, PSYCHOL SCI, V18, P614, DOI 10.1111/j.1467-9280.2007.01948.x; Karande S, 2009, J TROP PEDIATRICS, V55, P160, DOI 10.1093/tropej/fmn099; Katz N., 2011, COGNITION OCCUPATION, P13; Kavale KA, 2000, J LEARN DISABIL-US, V33, P239, DOI 10.1177/002221940003300303; Kavale KA, 1996, J LEARN DISABIL, V29, P226, DOI 10.1177/002221949602900301; Kavale KA, 2009, LEARN DISABILITY Q, V32, P39, DOI 10.2307/25474661; Koven NS, 2010, PERS INDIV DIFFER, V49, P24, DOI 10.1016/j.paid.2010.02.034; KUYKEN W, 1994, INT J MENT HEALTH, V23, P24, DOI 10.1080/00207411.1994.11449286; LACHMAN ME, 1993, INT J BEHAV DEV, V16, P131, DOI 10.1177/016502549301600203; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; McDougall J, 2011, DEV NEUROREHABIL, V14, P41, DOI 10.3109/17518423.2010.521795; McDougall J, 2010, DEV NEUROREHABIL, V13, P204, DOI 10.3109/17518421003620525; Peleg O, 2009, LEARN DISABILITY Q, V32, P11, DOI 10.2307/25474659; Ponitz CC., 2010, CHILD DEV INTERSECTI, V1, P203, DOI DOI 10.1037/12059-011; Pyne JM, 1997, PSYCHOPHARMACOL BULL, V33, P23; Rosenblum S, 2013, RES DEV DISABIL, V34, P218, DOI 10.1016/j.ridd.2012.07.011; Rosenblum S, 2012, NEUROPSYCHOL REHABIL, V22, P65, DOI 10.1080/09602011.2011.640465; Rosenblum S, 2010, RES DEV DISABIL, V31, P502, DOI 10.1016/j.ridd.2009.10.016; Rotenberg-Shpigelman S., 2008, ISRAELI J OCCUPATION, V17, pH77; Roth R.M., 2005, BEHAV RATING INVENTO; Roth RM, 2013, ARCH CLIN NEUROPSYCH, V28, P425, DOI 10.1093/arclin/act031; Scanlon D, 2013, J LEARN DISABIL-US, V46, P26, DOI 10.1177/0022219412464342; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Sharfi K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106657; Sharma K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125693; Skevington SM, 2004, QUAL LIFE RES, V13, P299, DOI 10.1023/B:QURE.0000018486.91360.00; Stern A, 2013, J ATTEN DISORD, P1; SWANSON HL, 1994, J LEARN DISABIL-US, V27, P34, DOI 10.1177/002221949402700107; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; Theofilou P, 2013, EUR J PSYCHOL, V9, P150, DOI 10.5964/ejop.v9i1.337; Toll SWM, 2011, J LEARN DISABIL-US, V44, P521, DOI 10.1177/0022219410387302; Vasic N, 2008, NEUROPSYCHOLOGIA, V46, P640, DOI 10.1016/j.neuropsychologia.2007.09.002; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wilson AM, 2009, J LEARN DISABIL-US, V42, P24, DOI 10.1177/0022219408326216; World Health Organization, 2001, INT CLASS FUNCT DIS; World Health Organization (WHO), 2004, WHO QUAL LIF QUEST W	62	14	14	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2016	11	12							e0166939	10.1371/journal.pone.0166939			15	Multidisciplinary Sciences	Science & Technology - Other Topics	EI8JY	WOS:000392753900006	27959913	DOAJ Gold, Green Published			2021-06-18	
J	Yumoto, T; Mitsuhashi, T; Yamakawa, Y; Iida, A; Nosaka, N; Tsukahara, K; Naito, H; Nakao, A				Yumoto, Tetsuya; Mitsuhashi, Toshiharu; Yamakawa, Yasuaki; Iida, Atsuyoshi; Nosaka, Nobuyuki; Tsukahara, Kohei; Naito, Hiromichi; Nakao, Atsunori			Impact of Cushing's sign in the prehospital setting on predicting the need for immediate neurosurgical intervention in trauma patients: a nationwide retrospective observational study	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Traumatic brain injury; Hypertension; Bradycardia; Cushing's sign; Prehospital	GLASGOW COMA SCALE; BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; MORTALITY; HYPERTENSION; MANAGEMENT; REFLEX	Background: Cushing's reflex usually results from intracranial hypertension. Although Cushing's sign can implicate severe traumatic brain injury (TBI) in injured patients, no major investigations have been made. The purpose of this study was to assess the predictability of life-threatening brain injury requiring immediate neurosurgical intervention (LT-BI) among trauma patients with Cushing's sign in the prehospital setting. Methods: This was a retrospective study using data from the Japan Trauma Data Bank from the period of 2010 to 2014. Patients 16 years old or older with blunt mechanisms of injury who were transported directly from the scene and Glasgow Coma Scale for eye opening of one in the prehospital setting were included. LT-BI was defined as patients requiring burr hole evacuation or craniotomy within 24 h of hospital arrival and patients who were non-survivors due to isolated severe TBI. Prehospital systolic blood pressure (pSBP) and heart rate (pHR) were assessed using area under the receiver operating characteristic curve (AUROC) and multiple logistic regression analysis to predict LT-BI. Results: Of 6332 eligible patients, 1859 (29%) exhibited LT-BI. AUROC of LT-BI using pSBP and pHR was 0.666 (95% confidence interval (CI); 0.652-0.681, P < 0.001), and 0.578 (95% CI; 0.563-0.594, P < 0.001), respectively. AUROC of pSBP was the highest among the 60 <= pHR <= 99 subgroup, of which AUROC was 0.680 (95% CI; 0.662-0.699, P < 0.001). Multiple logistic regression analysis showed that the higher the pSBP and the lower the pHR, the more likely that the patients had LT-BI. In a group with pSBP >= 180 mmHg and pHR <= 59 beats/min, the odds ratio and 95% CI of LT-BI after adjusting for age, sex, and severity of injuries to other body regions was 4. 77 (2.85-7.97), P < 0.001 was compared with the reference group, which was defined as patients with normal vital signs. Discussion: Our study has found that the combination of hypertension and bradycardia, which are the components of Cushing's sign without eye opening in the prehospital setting was a weak but a significant predictor of LT-BI, or death due to possible isolated severe TBI. Conclusions: Prehospital Cushing's sign with disturbed level of consciousness in trauma patients was a weak but significant predictor of the need for immediate neurosurgical intervention.	[Yumoto, Tetsuya; Yamakawa, Yasuaki; Iida, Atsuyoshi; Nosaka, Nobuyuki; Tsukahara, Kohei; Naito, Hiromichi; Nakao, Atsunori] Okayama Univ Hosp, Adv Emergency & Crit Care Med Ctr, 2-5-1 Kita Ku,Shikata Cho, Okayama, Okayama 7008558, Japan; [Mitsuhashi, Toshiharu] Okayama Univ Hosp, Ctr Innovat Clin Med, 2-5-1 Kita Ku,Shikata Cho, Okayama, Okayama 7008558, Japan	Yumoto, T (corresponding author), Okayama Univ Hosp, Adv Emergency & Crit Care Med Ctr, 2-5-1 Kita Ku,Shikata Cho, Okayama, Okayama 7008558, Japan.	tyumoto@cc.okayama-u.ac.jp		Naito, Hiromichi/0000-0002-7308-1716			Abe T, 2014, CRIT CARE, V18, DOI 10.1186/cc13981; Barmparas G, 2014, J TRAUMA ACUTE CARE, V77, P592, DOI 10.1097/TA.0000000000000382; Barthelemy EJ, 2016, WORLD NEUROSURG, V88, P411, DOI 10.1016/j.wneu.2015.12.044; Brazinova A, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0133-z; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Fodstad H, 2006, NEUROSURGERY, V59, P1132, DOI 10.1227/01.NEU.0000245582.08532.7C; Inokuchi R, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003354; Japan Trauma Care and Research, JAP TRAUM DAT BANK A; Kalmar AF, 2005, BRIT J ANAESTH, V94, P791, DOI 10.1093/bja/aei121; Krishnamoorthy V, 2015, J INTENSIVE CARE, V3, DOI 10.1186/s40560-015-0113-4; Lump D, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-014-0494-0; Majdan M, 2015, J NEUROTRAUM, V32, P101, DOI 10.1089/neu.2014.3438; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Matsushima K, 2015, J TRAUMA ACUTE CARE, V79, P838, DOI 10.1097/TA.0000000000000719; Qiu WS, 2009, CRIT CARE, V13, DOI 10.1186/cc8178; Rangel-Castillo L, 2008, NEUROL CLIN, V26, P521, DOI 10.1016/j.ncl.2008.02.003; Reisner A, 2014, J NEUROTRAUM, V31, P906, DOI 10.1089/neu.2013.3128; Shimoda K, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.08.014; Tohira H, 2012, INJURY, V43, P1924, DOI 10.1016/j.injury.2012.08.024	19	14	14	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	DEC 9	2016	24								147	10.1186/s13049-016-0341-1			7	Emergency Medicine	Emergency Medicine	EG6GA	WOS:000391141400003	27938387	DOAJ Gold, Green Published			2021-06-18	
J	Johnson, KL; Chowdhury, S; Lawrimore, WB; Mao, Y; Mehmani, A; Prabhu, R; Rush, GA; Horstemeyer, MF				Johnson, K. L.; Chowdhury, S.; Lawrimore, W. B.; Mao, Y.; Mehmani, A.; Prabhu, R.; Rush, G. A.; Horstemeyer, M. F.			Constrained topological optimization of a football helmet facemask based on brain response	MATERIALS & DESIGN			English	Article						Traumatic brain injury; Design optimization; Football helmet; Concussion; Finite element analysis; Surrogate modeling	PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; DESIGN OPTIMIZATION; MODEL; IMPACTS; EPIDEMIOLOGY; SIMULATION; COLLEGIATE; INJURY	Surrogate model-based multi-objective design optimization was performed to reduce concussion risk during frontal football helmet impacts. In particular, a topological decomposition of the football helmet facemask was performed to formulate the design problem, and brain injury metrics were exploited as objective functions. A validated finite element model of a helmeted human head was used to recreate facemask impacts. Due to the prohibitive computational expense of the full scale simulations, a surrogate modeling approach was employed. An optimal surrogate model selection framework, called Concurrent Surrogate Model Selection, or COSMOS, was utilized to identify the surrogate models best suited to approximate each objective function. The resulting surrogate models were implemented in the Non-dominated Sorting Genetic Algorithm II (NSGA-II) optimization algorithm. Constraints were implemented to control the solid material fraction in the facemask design space, and binary variables were used to control the placement of the facemask bars. The optimized facemask designs reduced the maximum tensile pressure in the brain by 7.5% and the maximum shear strain by a remarkable 39.5%. This research represents a first-of-its-kind approach to multi-objective design optimization on a football helmet, and demonstrates the possibilities that are achievable in improving human safety by using such a simulation-based design optimization. (C) 2016 Elsevier Ltd. All rights reserved.	[Johnson, K. L.; Lawrimore, W. B.; Horstemeyer, M. F.] Mississippi State Univ, Dept Mech Engn, Mississippi State, MS 39762 USA; [Johnson, K. L.; Lawrimore, W. B.; Horstemeyer, M. F.] Mississippi State Univ, CAVS, Mississippi State, MS 39762 USA; [Chowdhury, S.] SUNY Buffalo, Dept Mech & Aerosp Engn, Buffalo, NY 14260 USA; [Mao, Y.] Predict Design Technol, Starkville, MS 39579 USA; [Mehmani, A.] Columbia Univ, Lenfest Ctr Sustainable Energy, New York, NY 10027 USA; [Prabhu, R.; Rush, G. A.] Mississippi State Univ, Dept Agr & Biol Engn, Mississippi State, MS 39762 USA	Johnson, KL (corresponding author), Mississippi State Univ, Dept Mech Engn, Mississippi State, MS 39762 USA.	kljohnsonmsu@gmail.com	; Prabhu, Raj/M-7188-2017	Horstemeyer, Mark/0000-0003-4230-0063; Prabhu, Raj/0000-0002-6073-4802	Center for Advanced Vehicular Systems, Mississippi State University	The authors would like to thank Dr. G. "Sonny" Rush for his donation of the football helmet and computed tomography for our study. Also, support from the Center for Advanced Vehicular Systems, Mississippi State University is gratefully acknowledged.	Bayraktar HH, 2004, J BIOMECH, V37, P27, DOI 10.1016/S0021-9290(03)00257-4; Belson K., 2014, BRAIN TRAUMA AFFECT, pThe New York Times; Boruah S., 2013, P IRCOBI C; Bouvard JL, 2010, ACTA MECH, V213, P71, DOI 10.1007/s00707-010-0349-y; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Chowdhury S., 2014, CONCURRENT SURROGATE; Craig M.J, 2007, BIOMECHANICS JAW LOA; Deb K, 2002, IEEE T EVOLUT COMPUT, V6, P182, DOI 10.1109/4235.996017; ESKANDARIAN A, 1997, INT J CRASHWORTHINES, V2, P239, DOI DOI 10.1533/CRAS.1997.0048; Fang H, 2005, COMPUT STRUCT, V83, P2121, DOI 10.1016/j.compstruc.2005.02.025; Ganpule S, 2013, BIOMECH MODEL MECHAN, V12, P511, DOI 10.1007/s10237-012-0421-8; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Johnson KL, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026320; King A.I., IRCOBI C 2003, P1; Kurtaran H, 2002, COMPUT MECH, V29, P409, DOI 10.1007/s00466-002-0351-x; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; MCELHANEY JH, 1970, J BIOMECH, V3, P495, DOI 10.1016/0021-9290(70)90059-X; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mehmani A, 2015, STRUCT MULTIDISCIP O, V52, P353, DOI 10.1007/s00158-015-1234-z; Messac A., 2015, OPTIMIZATION PRACTIC; Nahum AM, 1977, INTRACRANIAL PRESSUR; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Prabhu R, 2011, J MECH BEHAV BIOMED, V4, P1067, DOI 10.1016/j.jmbbm.2011.03.015; Prabhu R., 2011, TRAUMATIC BRAIN INJU; Ren WX, 2010, ENG STRUCT, V32, P2455, DOI 10.1016/j.engstruct.2010.04.019; Shuaeib FM, 2007, MATER DESIGN, V28, P182, DOI 10.1016/j.matdes.2005.04.015; Simpson TW, 2001, AIAA J, V39, P2233, DOI 10.2514/2.1234; Stander N., 2004, J AM I AERONAUT ASTR; Tinard V, 2012, MATER DESIGN, V37, P79, DOI 10.1016/j.matdes.2011.12.005; Tse KM, 2015, ACCIDENT ANAL PREV, V79, P13, DOI 10.1016/j.aap.2015.03.012; Viana F.A.C., 2009, INT J NUMER METHODS; Viana FAC, 2014, AIAA J, V52, P670, DOI 10.2514/1.J052375; Viano DC, 2005, SOLID MECH APPL, V124, P121; Yang RJ, 2005, J MECH DESIGN, V127, P1014, DOI 10.1115/1.1906264; Ye KQ, 2000, J STAT PLAN INFER, V90, P145, DOI 10.1016/S0378-3758(00)00105-1; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	44	14	14	0	24	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-1275	1873-4197		MATER DESIGN	Mater. Des.	DEC 5	2016	111						108	118		10.1016/j.matdes.2016.08.064			11	Materials Science, Multidisciplinary	Materials Science	EA8EY	WOS:000386869300013					2021-06-18	
J	Ye, F; Li, XY; Li, F; Li, JX; Chang, W; Yuan, J; Chen, J				Ye, Fang; Li, Xiaoyi; Li, Fen; Li, Jianxin; Chang, Wei; Yuan, Jing; Chen, Jun			Cyclosporin A protects against Lead neurotoxicity through inhibiting mitochondrial permeability transition pore opening in nerve cells	NEUROTOXICOLOGY			English	Article						Pb; Neurotoxicity; CyPD; MPTP; CSA; ROS	INDUCED OXIDATIVE STRESS; TRAUMATIC BRAIN-INJURY; CYCLOPHILIN-D; INDUCED APOPTOSIS; SH-SY5Y CELLS; DEATH; TRANSLOCATION; AUTOPHAGY; EXPOSURE; HIPPOCAMPUS	Mitochondria play a key role in the process of lead (Pb)-induced impairment in nervous system. To further clarify the underlying mechanism of Pb neurotoxicity, this study was designed to investigate the role of mitochondrial permeability transition (MPT) and cyclophilin D (CyPD), a component of MPT pore (MPTP), in Pb-induced mitochondrial apoptosis in nerve cells. In SH-SY5Y and PC12 cells, Cyclosporin A (CSA), a special inhibitor of CyPD, could alleviate cell death, lactate dehydrogenase (LDH) leakage and adenosine 5 triphosphate (ATP) decrease caused by PbAc. In the following experiments, we found PbAc increased the protein level of CyPD and induced MPT pore (MPTP) opening. When cells were pretreated with CSA to inhibit MPTP opening, the Pb-induced impairment of mitochondrial morphology (swelling and rupture) and the loss of mitochondria were attenuated. In addition, CSA obviously ameliorated the Pb-induced damage of mitochondrial function, such as reactive oxygen species (ROS) boost and mitochondrial membrane potential (MMP) collapse, as well as the release of cytochrome C (Cyto C) and apoptosis-inducing factor (AIF) from mitochondria. These beneficial effects could finally result in cell survival under Pb-exposure conditions. Furthermore, scavenging ROS also significantly abrogated MPTP opening and attenuated Pb neurotoxicity. Therefore, we found that MPT played an important role in Pb-induced mitochondrial damage and, ultimately, cell death. Our results provided a potential strategy for inhibiting PbAc neurotoxicity. However, due to the high Pb concentrations used in this study further investigations at Pb concentrations closer to human exposure are needed to verify the results. (C) 2016 Elsevier B.V. All rights reserved.	[Ye, Fang; Li, Fen; Yuan, Jing; Chen, Jun] Huazhong Univ Sci & Technol, Sch Publ Hlth, Dept Occupat & Environm Hlth, Tongji Med Coll, Wuhan, Peoples R China; [Ye, Fang; Yuan, Jing; Chen, Jun] Huazhong Univ Sci & Technol, Sch Publ Hlth, Tongji Med Coll, Minist Educ,Key Lab Environm & Hlth, Wuhan, Peoples R China; [Li, Xiaoyi] Huazhong Univ Sci & Technol, Dept Immunol, Tongji Med Coll, Wuhan, Peoples R China; [Li, Fen] Dis Control & Prevent Ctr Xiqing, Tianjin, Peoples R China; [Li, Jianxin] Xiaonan Matern & Child Hlth Hosp, Dept Internal Med, Xiaogan, Peoples R China; [Chang, Wei] Wuhan Univ Sci & Technol, Dept Publ Hlth, Coll Med, Wuhan, Peoples R China	Chen, J (corresponding author), Huazhong Univ Sci & Technol, Sch Publ Hlth, Dept Occupat & Environm Hlth, Tongji Med Coll, Wuhan, Peoples R China.	chen-jun@hust.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81273019, 81072265]	This work was supported by the National Natural Science Foundation of China (Grant NO. 81273019 and 81072265).	Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Baranowska-Bosiacka I, 2013, TOXICOLOGY, V303, P187, DOI 10.1016/j.tox.2012.10.027; Baranowska-Bosiacka I, 2011, TOXICOLOGY, V280, P24, DOI 10.1016/j.tox.2010.11.004; Bernardi P, 1999, PHYSIOL REV, V79, P1127; Boujrad H, 2007, CELL CYCLE, V6, P2612, DOI 10.4161/cc.6.21.4842; Bustos PL, 2015, PARASITOLOGY, V142, P1024, DOI 10.1017/S0031182015000232; Carreira RS, 2010, AUTOPHAGY, V6, P462, DOI 10.4161/auto.6.4.11553; Cereghetti GM, 2008, P NATL ACAD SCI USA, V105, P15803, DOI 10.1073/pnas.0808249105; Chao SL, 2007, J BIOCHEM MOL TOXIC, V21, P265, DOI 10.1002/jbt.20191; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; Ercal Nuran, 2001, Current Topics in Medicinal Chemistry, V1, P529, DOI 10.2174/1568026013394831; Flora Gagan, 2012, Interdiscip Toxicol, V5, P47, DOI 10.2478/v10102-012-0009-2; Garza A, 2006, MED SCI MONITOR, V12, pRA57; Giorgio V, 2010, BBA-BIOENERGETICS, V1797, P1113, DOI 10.1016/j.bbabio.2009.12.006; Golstein P, 2007, TRENDS BIOCHEM SCI, V32, P37, DOI 10.1016/j.tibs.2006.11.001; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; He LH, 2000, J BIOL CHEM, V275, P12175, DOI 10.1074/jbc.275.16.12175; Izzo V, 2016, TRENDS CELL BIOL, V26, P655, DOI 10.1016/j.tcb.2016.04.006; Katoh H, 2002, CIRCULATION, V105, P2666, DOI 10.1161/01.CIR.0000016831.41648.04; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Lee J, 2010, J INT MED RES, V38, P1561, DOI 10.1177/147323001003800501; Li CC, 2014, NEUROTOXICOL TERATOL, V46, P1, DOI 10.1016/j.ntt.2014.08.007; Lidsky TI, 2003, BRAIN, V126, P5, DOI 10.1093/brain/awg014; Linard D, 2009, ARCH BIOCHEM BIOPHYS, V491, P39, DOI 10.1016/j.abb.2009.09.002; Liu CM, 2012, TOXICOL APPL PHARM, V258, P330, DOI 10.1016/j.taap.2011.11.015; Liu G, 2016, ARCH TOXICOL, V90, P1193, DOI 10.1007/s00204-015-1547-0; Lulic D, 2011, NEUROSURGERY, V68, P1172, DOI 10.1227/NEU.0b013e31820c6cdc; Marchlewicz M, 2004, CHEMOSPHERE, V57, P1553, DOI 10.1016/j.chemosphere.2004.08.102; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Marzetti E, 2008, MECH AGEING DEV, V129, P542, DOI 10.1016/j.mad.2008.05.005; Matas J, 2009, J MOL CELL CARDIOL, V46, P420, DOI 10.1016/j.yjmcc.2008.10.020; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; MENZIES RA, 1971, J BIOL CHEM, V246, P2425; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Osman MM, 2011, NEUROPEPTIDES, V45, P359, DOI 10.1016/j.npep.2011.04.002; Patrick L, 2006, ALTERN MED REV, V11, P114; Patrick L, 2006, ALTERN MED REV, V11, P2; Prins JM, 2010, TOXICOL SCI, V113, P169, DOI 10.1093/toxsci/kfp249; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Sun XY, 1999, TOXICOL APPL PHARM, V156, P40, DOI 10.1006/taap.1999.8622; Toman J, 2011, J BIOENERG BIOMEMBR, V43, P3, DOI 10.1007/s10863-011-9337-8; Tsujimoto Y, 2007, APOPTOSIS, V12, P835, DOI 10.1007/s10495-006-0525-7; Verma SK, 2005, BASIC CLIN PHARMACOL, V96, P475, DOI 10.1111/j.1742-7843.2005.pto_96611.x; Xu J, 2006, TOXICOL LETT, V166, P160, DOI 10.1016/j.toxlet.2006.06.643; Ye F, 2015, FOOD CHEM TOXICOL, V86, P191, DOI 10.1016/j.fct.2015.10.009; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhu HX, 2007, J CLIN INVEST, V117, P1782, DOI 10.1172/JCI27523	47	14	15	0	22	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0161-813X	1872-9711		NEUROTOXICOLOGY	Neurotoxicology	DEC	2016	57						203	213		10.1016/j.neuro.2016.10.004			11	Neurosciences; Pharmacology & Pharmacy; Toxicology	Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology	EE3NT	WOS:000389497000024	27725305				2021-06-18	
J	Zhang, C; Wu, JM; Liao, M; Wang, JL; Xu, CJ				Zhang, Chan; Wu, Jian-Min; Liao, Min; Wang, Jun-ling; Xu, Chao-Jin			The ROCK/GGTase Pathway Are Essential to the Proliferation and Differentiation of Neural Stem Cells Mediated by Simvastatin	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Simvastatin; Neural stem cells; ROCK; GGTase	PROTEIN PRENYLATION; KI-67 ANTIGEN; IN-VITRO; STATINS; CYCLE; CHOLESTEROL; NEUROGENESIS; CONSEQUENCES; SUPPRESSES; MECHANISMS	Simvastatin, a lipophilic and fermentation-derived natural statin, is reported to treat neurological disorders, such as traumatic brain injury, Parkinson's disease (PD), Alzheimer disease (AD), etc. Recently, research also indicated that simvastatin could promote regeneration in the dentate gyrus of adult mice by Wnt/beta-catenin signaling (Robin et al. in Stem Cell Reports 2:9-17, 2014). However, the effect and mechanisms by which simvastatin may affect the neural stem cells (NSCs; from the embryonic day 14.5 (E14.5) SD rat brain) are not fully understood. Here, we investigated the effects of different doses of simvastatin on the survival, proliferation, differentiation, migration, and cell cycle of NSCs as well as underlying intracellular signaling pathways. The results showed that simvastatin not only inhibits the proliferation of NSCs but also enhances the beta III-tubulin(+) neuron differentiation rate. Additionally, we find that simvastatin could also promote NSC migration and induce cell cycle arrest at M2 phrase. All these effects of simvastatin on NSCs were mimicked with an inhibitor of Rho kinase (ROCK) and a specific inhibitor of geranylgeranyl transferase (GGTase). In conclusion, these data indicate that simvastatin could promote neurogenesis of neural stem cells, and these effects were mediated through the ROCK/GGTase pathway.	[Zhang, Chan] Wenzhou Med Univ, Sch Lab Med & Life Sci, Wenzhou 325035, Zhejiang, Peoples R China; [Wu, Jian-Min] Wenzhou Med Univ, Inst Genom Med, Wenzhou 325035, Zhejiang, Peoples R China; [Liao, Min; Xu, Chao-Jin] Wenzhou Med Univ, Dept Histol & Embryol, Inst Neurosci, Wenzhou 325035, Zhejiang, Peoples R China; [Wang, Jun-ling] Fudan Univ, Dept Clin Lab, Affiliated Huadong Hosp, Shanghai 200040, Peoples R China	Xu, CJ (corresponding author), Wenzhou Med Univ, Dept Histol & Embryol, Inst Neurosci, Wenzhou 325035, Zhejiang, Peoples R China.; Wang, JL (corresponding author), Fudan Univ, Dept Clin Lab, Affiliated Huadong Hosp, Shanghai 200040, Peoples R China.	Wangliujunling@163.com; xuzhaojin@gmail.com		Wu, Jianmin/0000-0002-8223-1667	Zhejiang Provincial Natural Science Foundation of ChinaNatural Science Foundation of Zhejiang Province [LY13H090007, LQ13C090004]; National Natural Sciences Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81201589]	The project was supported by the Zhejiang Provincial Natural Science Foundation of China (LY13H090007) and Zhejiang Provincial Natural Science Foundation of China (LQ13C090004) and National Natural Sciences Foundation of China (Grant No. 81201589).	Abe K, 2003, DEV BRAIN RES, V143, P99, DOI 10.1016/S0165-3806(03)00096-8; Bender CM, 1998, CANCER RES, V58, P95; Billuart P, 2001, CELL, V107, P195, DOI 10.1016/S0092-8674(01)00522-0; BRAUN N, 1988, VIRCHOWS ARCH B, V56, P25, DOI 10.1007/BF02889998; CASEY PJ, 1995, BIOCHEM SOC T, V23, P161, DOI 10.1042/bst0230161; CHAN PK, 1987, CANCER RES, V47, P3798; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; GERDES J, 1984, J IMMUNOL, V133, P1710; Huang F, 2010, ACTA BIOCH BIOPH SIN, V42, P325, DOI 10.1093/abbs/gmq025; Kill IR, 1996, J CELL SCI, V109, P1253; Kuipers HF, 2006, GLIA, V53, P115, DOI 10.1002/glia.20269; Lee MH, 2007, STEM CELLS, V25, P1654, DOI 10.1634/stemcells.2006-0753; Lin T, 2012, J ETHNOPHARMACOL, V142, P754, DOI 10.1016/j.jep.2012.05.057; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; MacCallum DE, 2000, J PATHOL, V190, P537; Matzno S, 2005, J PHARM PHARMACOL, V57, P1475, DOI 10.1211/jpp.57.11.0014; McKenney JM, 2003, CLIN CARDIOL, V26, P32, DOI 10.1002/clc.4960261507; Miron VE, 2007, GLIA, V55, P130, DOI 10.1002/glia.20441; Mullen PJ, 2010, BIOCHEM PHARMACOL, V79, P1200, DOI 10.1016/j.bcp.2009.12.007; Neuhaus O, 2004, LANCET NEUROL, V3, P369, DOI 10.1016/S1474-4422(04)00770-7; Robin NC, 2014, STEM CELL REP, V2, P9, DOI 10.1016/j.stemcr.2013.11.002; Roy A, 2011, NEUROSCIENTIST; SatoSuzuki I, 1996, NEUROSCI LETT, V220, P21, DOI 10.1016/S0304-3940(96)13221-3; Sierra S, 2011, J ALZHEIMERS DIS, V23, P307, DOI 10.3233/JAD-2010-101179; Simons M, 2002, ANN NEUROL, V52, P346, DOI 10.1002/ana.10292; Smolders I, 2010, J NEUROSCI RES, V88, P3361, DOI 10.1002/jnr.22490; Storch Alexander, 2002, Journal of Neurology, V249; Sun ZH, 2003, ACT NEUR S, V87, P169; Vuletic S, 2006, DEMENT GERIATR COGN, V22, P392, DOI 10.1159/000095679; Walker AM, 2010, INT J ENV RES PUB HE, V7, P1996, DOI 10.3390/ijerph7051996; Wang XF, 2007, MOL CELL NEUROSCI, V36, P343, DOI 10.1016/j.mcn.2007.07.005; Wolozin B, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-20; Xu CJ, 2011, NEUROPATH APPL NEURO, V37, P135, DOI 10.1111/j.1365-2990.2010.01117.x; Xu CJ, 2016, NEUROCHEM RES, V41, P1211, DOI 10.1007/s11064-016-1829-9; Xu CJ, 2011, MOL CELL BIOCHEM, V358, P173, DOI 10.1007/s11010-011-0932-0; Z-w P, 2013, MOL CELL BIOCHEM, V375, P105; Zhan Y, 2010, NEURAL REGEN RES; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhi WH, 2014, CNS NEUROSCI THER, V20, P218, DOI 10.1111/cns.12190	39	14	16	0	9	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	DEC	2016	60	4					474	485		10.1007/s12031-016-0811-y			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	ED1SS	WOS:000388625800007	27541019				2021-06-18	
J	Del Turco, D; Paul, MH; Schlaudraff, J; Hick, M; Endres, K; Muller, UC; Deller, T				Del Turco, Domenico; Paul, Mandy H.; Schlaudraff, Jessica; Hick, Meike; Endres, Kristina; Mueller, Ulrike C.; Deller, Thomas			Region-Specific Differences in Amyloid Precursor Protein Expression in the Mouse Hippocampus	FRONTIERS IN MOLECULAR NEUROSCIENCE			English	Article						APP; dentategyrus; CA1; immunostaining; western blotting; laser microdissection; in situ hybridization; RT-qPCR	TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE; GENE-EXPRESSION; MESSENGER-RNAS; APPS-ALPHA; FAMILY-MEMBERS; RAT; PLASTICITY; MICE	The physiological role of amyloid precursor protein (APP) has been extensively investigated in the rodent hippocampus. Evidence suggests that APP plays a role in synaptic plasticity, dendritic and spine morphogenesis, neuroprotection and-at the behavioral level-hippocampus-dependent forms of learning and memory. Intriguingly, however, studies focusing on the role of APP in synaptic plasticity have reported diverging results and considerable differences in effect size between the dentate gyrus (DG) and area CA1 of the mouse hippocampus. We speculated that regional differences in APP expression could underlie these discrepancies and studied the expression of APP in both regions using immunostaining, in situ hybridization (ISH), and laser microdissection (LMD) in combination with quantitative reverse transcription polymerase chain reaction (RT-qPCR) and western blotting. In sum, our results show that APP is approximately 1.7-fold higher expressed in pyramidal cells of Ammons horn than in granule cells of the DG. This regional difference in APP expression may explain why loss-of-function approaches using APP-deficient mice revealed a role for APP in Hebbian plasticity in area CA1, whereas this could not be shown in the DG of the same APP mutants.	[Del Turco, Domenico; Paul, Mandy H.; Schlaudraff, Jessica; Hick, Meike; Deller, Thomas] Goethe Univ, Ctr Neurosci, Inst Clin Neuroanat, Frankfurt, Germany; [Hick, Meike; Mueller, Ulrike C.] Heidelberg Univ, IPMB, Heidelberg, Germany; [Endres, Kristina] Univ Med Ctr Mainz, Clin Psychiat & Psychotherapy, Mainz, Germany	Del Turco, D (corresponding author), Goethe Univ, Ctr Neurosci, Inst Clin Neuroanat, Frankfurt, Germany.	delturco@em.uni-frankfurt.de	Endres, Kristina/K-4960-2015		Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG) [FOR 1332]	This research was funded by the Deutsche Forschungsgemeinschaft (DFG FOR 1332 to TD and UCM).	Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Anliker B, 2006, NEURODEGENER DIS, V3, P239, DOI 10.1159/000095262; Aydin D, 2012, EXP BRAIN RES, V217, P423, DOI 10.1007/s00221-011-2861-2; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Burbach GJ, 2003, J NEUROSCI METH, V131, P83, DOI 10.1016/S0165-0270(03)00232-2; CLARRIS HJ, 1995, DEV BRAIN RES, V88, P87, DOI 10.1016/0165-3806(95)00083-P; Cousins SL, 2009, J NEUROCHEM, V111, P1501, DOI 10.1111/j.1471-4159.2009.06424.x; Dawkins E, 2014, J NEUROCHEM, V129, P756, DOI 10.1111/jnc.12675; Dawson GR, 1999, NEUROSCIENCE, V90, P1, DOI 10.1016/S0306-4522(98)00410-2; Del Turco D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084962; Deller T, 1997, PROG NEUROBIOL, V53, P687, DOI 10.1016/S0301-0082(97)00044-0; Deller T, 2000, ANN NY ACAD SCI, V911, P207; Deller T, 2007, PROG BRAIN RES, V163, P501, DOI 10.1016/S0079-6123(07)63027-1; deSilva HAR, 1997, MOL BRAIN RES, V47, P147; Endres K, 2012, EXP BRAIN RES, V217, P343, DOI 10.1007/s00221-011-2885-7; Fahrenholz F, 2007, CURR ALZHEIMER RES, V4, P412, DOI 10.2174/156720507781788837; Fanutza T, 2015, ELIFE, V4, DOI 10.7554/eLife.09743; Fol R, 2016, ACTA NEUROPATHOL, V131, P247, DOI 10.1007/s00401-015-1498-9; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; Guo QX, 2012, J BIOL CHEM, V287, P2437, DOI 10.1074/jbc.M111.315051; HAASS C, 1991, J NEUROSCI, V11, P3783; Heber S, 2000, J NEUROSCI, V20, P7951; Hick M, 2015, ACTA NEUROPATHOL, V129, P21, DOI 10.1007/s00401-014-1368-x; Hoe HS, 2009, J BIOL CHEM, V284, P8495, DOI 10.1074/jbc.M900141200; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; IZUMI R, 1992, GENE, V112, P189, DOI 10.1016/0378-1119(92)90375-Y; Jedlicka P, 2012, EXP BRAIN RES, V217, P441, DOI 10.1007/s00221-011-2911-9; Kaden D, 2012, EUR J CELL BIOL, V91, P234, DOI 10.1016/j.ejcb.2011.01.017; KANG J, 1990, BIOCHEM BIOPH RES CO, V166, P1192, DOI 10.1016/0006-291X(90)90992-V; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kogel D, 2012, EXP BRAIN RES, V217, P471, DOI 10.1007/s00221-011-2932-4; Kuhn PH, 2016, ELIFE, V5, DOI 10.7554/eLife.12748; Lassek M., 2016, FRONT SYNAPTIC NEURO, V7, P21, DOI [10.3389/fnsyn.2015.00021, DOI 10.3389/FNSYN.2015.00021]; Lassek M, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004832; Lassek M, 2014, CURR ALZHEIMER RES, V11, P971; Lassek M, 2013, J NEUROCHEM, V127, P48, DOI 10.1111/jnc.12358; LEBLANC AC, 1991, FEBS LETT, V292, P171, DOI 10.1016/0014-5793(91)80861-V; Li ZW, 1996, P NATL ACAD SCI USA, V93, P6158, DOI 10.1073/pnas.93.12.6158; Lynch G, 1978, Prog Brain Res, V48, P113; MONNING U, 1995, J BIOL CHEM, V270, P7104, DOI 10.1074/jbc.270.13.7104; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Muller UC, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006288; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Prinzen C, 2008, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-66; Ring S, 2007, J NEUROSCI, V27, P7817, DOI 10.1523/JNEUROSCI.1026-07.2007; Saftig P, 2011, EUR J CELL BIOL, V90, P527, DOI 10.1016/j.ejcb.2010.11.005; Schonrock N, 2012, EXP NEUROL, V235, P447, DOI 10.1016/j.expneurol.2011.11.013; Selkoe DJ, 2016, EMBO MOL MED, V8, P595, DOI 10.15252/emmm.201606210; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; Soba P, 2005, EMBO J, V24, P3624, DOI 10.1038/sj.emboj.7600824; Stahl R, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00410; Steward O., 1994, NEUROBIOLOGY CENTRAL, P266; Sun XL, 2012, J NEUROCHEM, V120, P62, DOI 10.1111/j.1471-4159.2011.07515.x; Szczygielski J, 2005, J NEURAL TRANSM, V112, P1547, DOI 10.1007/s00702-005-0326-0; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; Taylor CJ, 2008, NEUROBIOL DIS, V31, P250, DOI 10.1016/j.nbd.2008.04.011; Tuomi JM, 2010, METHODS, V50, P313, DOI 10.1016/j.ymeth.2010.02.003; Turner PR, 2003, PROG NEUROBIOL, V70, P1, DOI 10.1016/S0301-0082(03)00089-3; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vassar R, 2014, J NEUROCHEM, V130, P4, DOI 10.1111/jnc.12715; Vincent B, 2016, BRAIN RES BULL, V126, P154, DOI 10.1016/j.brainresbull.2016.03.020; Vnencak M, 2015, J COMP NEUROL, V523, P1717, DOI 10.1002/cne.23766; Von Koch CS, 1997, NEUROBIOL AGING, V18, P661, DOI 10.1016/S0197-4580(97)00151-6; Wang BP, 2014, J NEUROSCI, V34, P13314, DOI 10.1523/JNEUROSCI.2848-14.2014; Weyer SW, 2011, EMBO J, V30, P2266, DOI 10.1038/emboj.2011.119; Yang P, 2006, PROG NEUROBIOL, V79, P73, DOI 10.1016/j.pneurobio.2006.05.001; Zhang H, 2012, J NEUROCHEM, V120, P9, DOI 10.1111/j.1471-4159.2011.07519.x	72	14	14	0	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5099			FRONT MOL NEUROSCI	Front. Molec. Neurosci.	NOV 29	2016	9								134	10.3389/fnmol.2016.00134			12	Neurosciences	Neurosciences & Neurology	ED1WT	WOS:000388636300002	27965537	DOAJ Gold, Green Published			2021-06-18	
J	Li, XY; Zhu, H; Sun, XC; Zuo, FX; Lei, JF; Wang, ZJ; Bao, XJ; Wang, RZ				Li, Xueyuan; Zhu, Hua; Sun, Xicai; Zuo, Fuxing; Lei, Jianfeng; Wang, Zhanjing; Bao, Xinjie; Wang, Renzhi			Human Neural Stem Cell Transplantation Rescues Cognitive Defects in APP/PS1 Model of Alzheimer's Disease by Enhancing Neuronal Connectivity and Metabolic Activity	FRONTIERS IN AGING NEUROSCIENCE			English	Article						APP/PS1 mice; neuronal connectivity; metabolic activity; cognition; human neural stem cell; Alzheimer's disease	PROTON MR SPECTROSCOPY; TRAUMATIC BRAIN-INJURY; SYNAPTIC PLASTICITY; IMPROVE COGNITION; TRANSGENIC MODEL; AMYLOID-BETA; MOUSE MODELS; MEMORY; IMPAIRMENT; PATHOLOGY	Alzheimer's disease (AD), the most frequent type of dementia, is featured by A beta pathology, neural degeneration and cognitive decline. To date, there is no cure for this disease. Neural stem cell (NSC) transplantation provides new promise for treating AD. Many studies report that intra-hippocampal transplantation of murine NSCs improved cognition in rodents with AD by alleviating neurodegeneration via neuronal complement or replacement. However, few reports examined the potential of human NSC transplantation for AD. In this study, we implanted human brain-derived NSCs (hNSCs) into bilateral hippocampus of an amyloid precursor protein (APP)/presenilin 1 (PS1) transgenic (Tg) mouse model of AD to test the effects of hNSC transplantation on Alzheimer's behavior and neuropathology. Six weeks later, transplanted hNSCs engrafted into the brains of AD mice, migrated dispersedly in broad brain regions, and some of them differentiated into neural cell types of central nervous system (CNS). The hNSC transplantation restored the recognition, learning and memory deficits but not anxiety tasks in AD mice. Although A beta plaques were not significantly reduced, the neuronal, synaptic and nerve fiber density was significantly increased in the frontal cortex and hippocampus of hNSC-treated AD mice, suggesting of improved neuronal connectivity in AD brains after hNSC transplantation. Ultrastructural analysis confirmed that synapses and nerve fibers maintained relatively well-structured shapes in these mice. Furthermore, in vivo magnetic resonance spectroscopy (MRS) showed that hNSC treated mice had notably increased levels of N-acetylaspartate (NAA) and Glu in the frontal cortex and hippocampus, suggesting that neuronal metabolic activity was improved in AD brains after hNSC transplantation. These results suggest that transplanted hNSCs rescued Alzheimer's cognition by enhancing neuronal connectivity and metabolic activity through a compensation mechanism in APP/PS1 mice. This study provides preclinical evidence that hNSC transplantation can be a possible and feasible strategy for treating patients with AD.	[Li, Xueyuan; Zuo, Fuxing; Bao, Xinjie; Wang, Renzhi] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Neurosurg, Beijing, Peoples R China; [Li, Xueyuan; Zuo, Fuxing; Bao, Xinjie; Wang, Renzhi] Peking Union Med Coll, Beijing, Peoples R China; [Zhu, Hua] Chinese Acad Med Sci, Peking Union Med Coll, Comparat Med Ctr, Dept Pathol, Beijing, Peoples R China; [Zhu, Hua] Chinese Acad Med Sci, Inst Lab Anim Sci, Beijing, Peoples R China; [Sun, Xicai; Wang, Zhanjing] Tsinghua Univ, Sch Med, Ctr Stem Cell Biol & Regenerat Med, Ctr Life Sci, Beijing, Peoples R China; [Lei, Jianfeng] Capital Med Univ, Ctr Med Expt & Testing, Beijing, Peoples R China	Bao, XJ; Wang, RZ (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Neurosurg, Beijing, Peoples R China.; Bao, XJ; Wang, RZ (corresponding author), Peking Union Med Coll, Beijing, Peoples R China.	xinjieabao@163.com; wangrz@126.com			National High Technology Research and Development Program of ChinaNational High Technology Research and Development Program of China [2014CB541603, 2013AA020106]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81301061, 81671272]	This work was supported by National High Technology Research and Development Program of China (2014CB541603, 2013AA020106) and National Natural Science Foundation of China (81301061, 81671272).	Ackl N, 2005, NEUROSCI LETT, V384, P23, DOI 10.1016/j.neulet.2005.04.035; Ager RR, 2015, HIPPOCAMPUS, V25, P813, DOI 10.1002/hipo.22405; Alvarez EO, 2004, BEHAV BRAIN RES, V152, P209, DOI 10.1016/j.bbr.2003.10.012; Arturo A., 2004, VITAE ACAD BIOMEDICA, V24, pN226; Blurton-Jones M, 2009, P NATL ACAD SCI USA, V106, P13594, DOI 10.1073/pnas.0901402106; Chen SJ, 2012, RECONFIGURABLE NETWORKS-ON-CHIP, P1, DOI 10.1007/978-1-4419-9341-0; Fereshtehnejad SM, 2014, DRUGS AGING, V2014, P2014, DOI DOI 10.1007/S40266-014-0154-8; Fu TT, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/2412958; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Haus DL, 2016, EXP NEUROL, V281, P1, DOI 10.1016/j.expneurol.2016.04.008; Jessen F, 2006, NEUROLOGY, V67, P528, DOI 10.1212/01.wnl.0000228218.68451.31; Kim JA, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.138; Lee IS, 2015, MOL NEURODEGENER, V10, DOI 10.1186/s13024-015-0035-6; Lee SR, 2015, CELL TRANSPLANT, V24, P191, DOI 10.3727/096368914X678526; Li XY, 2010, NEUROSCIENCE, V169, P357, DOI 10.1016/j.neuroscience.2010.04.075; Li XY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101707; Li XY, 2015, J NEUROSCI RES, V93, P1313, DOI 10.1002/jnr.23555; Li XY, 2016, INT J MOL MED, V37, P271, DOI 10.3892/ijmm.2015.2428; Lo AC, 2013, J ALZHEIMERS DIS, V37, P109, DOI 10.3233/JAD-122296; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Oz G, 2014, RADIOLOGY, V270, P658, DOI 10.1148/radiol.13130531; Pen AE, 2017, ACTA NEUROL SCAND, V135, P57, DOI 10.1111/ane.12545; Prince M., 2015, WORLD ALZHEIMER REPO; Rockenstein E, 2015, STEM CELL RES, V15, P54, DOI 10.1016/j.scr.2015.04.008; Selkoe DJ, 2016, EMBO MOL MED, V8, P595, DOI 10.15252/emmm.201606210; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Shihabuddin LS, 2010, NEUROPHARMACOLOGY, V58, P845, DOI 10.1016/j.neuropharm.2009.12.015; Takamatsu K, 2014, STEM CELL RES, V13, P442, DOI 10.1016/j.scr.2014.10.001; Vadodaria KC, 2014, CELL, V156, DOI 10.1016/j.cell.2014.02.029; Yao ZG, 2013, EVID-BASED COMPL ALT, V2013, DOI DOI 10.1155/2013/518421; Zhang L, 2014, J ALZHEIMERS DIS, V41, P1193, DOI 10.3233/JAD-140066; Zhang N, 2014, CURR ALZHEIMER RES, V11, P367, DOI 10.2174/1567205011666140302200312; Zou CY, 2015, ACTA NEUROPATHOL, V129, P909, DOI 10.1007/s00401-015-1421-4; Zuo FX, 2015, INT J MOL SCI, V16, P26473, DOI 10.3390/ijms161125966	34	14	14	0	28	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1663-4365			FRONT AGING NEUROSCI	Front. Aging Neurosci.	NOV 23	2016	8								282	10.3389/fnagi.2016.00282			14	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	EC8UB	WOS:000388417200002	27932977	DOAJ Gold, Green Published			2021-06-18	
J	Wang, CF; Zhao, CC; Jiang, G; Gu, X; Feng, JF; Jiang, JY				Wang, Chuan-fang; Zhao, Cheng-cheng; Jiang, Gan; Gu, Xiao; Feng, Jun-feng; Jiang, Ji-yao			The Role of Posttraumatic Hypothermia in Preventing Dendrite Degeneration and Spine Loss after Severe Traumatic Brain Injury	SCIENTIFIC REPORTS			English	Article							CONTROLLED CORTICAL IMPACT; NEUROTROPHIC FACTOR BDNF; NMDA RECEPTOR; MODEL; EXPRESSION; MEMORY; SYNAPTOPHYSIN	Posttraumatic hypothermia prevents cell death and promotes functional outcomes after traumatic brain injury (TBI). However, little is known regarding the effect of hypothermia on dendrite degeneration and spine loss after severe TBI. In the present study, we used thy1-GFP transgenic mice to investigate the effect of hypothermia on the dendrites and spines in layer V/VI of the ipsilateral cortex after severe TBI. We found that hypothermia (33 degrees C) dramatically prevented dendrite degeneration and spine loss 1 and 7 days after CCI. The Morris water maze test revealed that hypothermia preserved the learning and memory functions of mice after CCI. Hypothermia significantly increased the expression of the synaptic proteins GluR1 and PSD-95 at 1 and 7 days after CCI in the ipsilateral cortex and hippocampus compared with that of the normothermia TBI group. Hypothermia also increased cortical and hippocampal BDNF levels. These results suggest that posttraumatic hypothermia is an effective method to prevent dendrite degeneration and spine loss and preserve learning and memory function after severe TBI. Increasing cortical and hippocampal BDNF levels might be the mechanism through which hypothermia prevents dendrite degeneration and spine loss and preserves learning and memory function.	[Wang, Chuan-fang; Zhao, Cheng-cheng; Feng, Jun-feng; Jiang, Ji-yao] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, Shanghai 200127, Peoples R China; [Wang, Chuan-fang; Zhao, Cheng-cheng; Feng, Jun-feng; Jiang, Ji-yao] Shanghai Inst Head Trauma, Shanghai 200127, Peoples R China; [Jiang, Gan; Gu, Xiao] Shanghai Jiao Tong Univ, Sch Med, Inst Med Sci, Dept Pharmacol, Shanghai 200127, Peoples R China	Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, Shanghai 200127, Peoples R China.; Jiang, JY (corresponding author), Shanghai Inst Head Trauma, Shanghai 200127, Peoples R China.	jiyaojiang16@163.com	Jiang, Gan/AAO-2173-2020	Jiang, Gan/0000-0003-2011-741X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30901543, 31371406, 81471856]; National Key Basic Research ProgramNational Basic Research Program of China [2012CB518100]; Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [13ZR1424500]; Shanghai Municipal Health Bureau [XYQ2013094]; SMC-Star Award for Young Scholars	This research was supported by grants from the National Natural Science Foundation of China (30901543, 31371406 and 81471856) and the National Key Basic Research Program (2012CB518100). JFF has also received funding from the Science and Technology Commission of Shanghai Municipality (13ZR1424500), Shanghai Municipal Health Bureau (XYQ2013094) and SMC-Star Award for Young Scholars (B).	Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Brodhun M, 2001, ACTA NEUROPATHOL, V101, P424; Caldeira MV, 2007, J BIOL CHEM, V282, P12619, DOI 10.1074/jbc.M700607200; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Choi HA, 2012, NAT REV NEUROL, V8, P214, DOI 10.1038/nrneurol.2012.21; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; D'Cruz BJ, 2002, J CEREBR BLOOD F MET, V22, P843, DOI 10.1097/00004647-200207000-00009; Goodfellow MJ, 2016, ALCOHOL CLIN EXP RES, V40, P309, DOI 10.1111/acer.12958; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Hu XD, 2011, J NEUROSCI, V31, P15597, DOI 10.1523/JNEUROSCI.2445-11.2011; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Jin YC, 2015, J NEUROTRAUM, V32, P1090, DOI 10.1089/neu.2014.3649; Kennedy BC, 2016, AM J PHYSIOL-REG I, V311, pR166, DOI 10.1152/ajpregu.00066.2016; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Kwon SE, 2011, NEURON, V70, P847, DOI 10.1016/j.neuron.2011.04.001; Ma HY, 2012, NEUROCHEM RES, V37, P69, DOI 10.1007/s11064-011-0584-1; Ma M, 2009, EXP NEUROL, V215, P119, DOI 10.1016/j.expneurol.2008.09.024; Meijering E, 2004, CYTOM PART A, V58A, P167, DOI 10.1002/cyto.a.20022; Minichiello L, 2009, NAT REV NEUROSCI, V10, P850, DOI 10.1038/nrn2738; PARDRIDGE WM, 1994, PHARMACEUT RES, V11, P738, DOI 10.1023/A:1018940732550; Park H, 2013, NAT REV NEUROSCI, V14, P7, DOI 10.1038/nrn3379; Popescu C, 2015, J Med Life, V8, P272; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Pyeon HJ, 2012, ANAT CELL BIOL, V45, P97, DOI 10.5115/acb.2012.45.2.97; Rao A, 1997, NEURON, V19, P801, DOI 10.1016/S0896-6273(00)80962-9; Rauskolb S, 2010, J NEUROSCI, V30, P1739, DOI 10.1523/JNEUROSCI.5100-09.2010; Rodriguez A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001997; Sun MK, 2015, TRENDS PHARMACOL SCI, V36, P384, DOI 10.1016/j.tips.2015.04.004; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Wang T, 2016, MOL NEUROBIOL, V53, P3740, DOI 10.1007/s12035-015-9312-1; Wearne SL, 2005, NEUROSCIENCE, V136, P661, DOI 10.1016/j.neuroscience.2005.05.053; Winston CN, 2016, AM J PATHOL, V186, P552, DOI 10.1016/j.ajpath.2015.11.006; Winston CN, 2013, J NEUROTRAUM, V30, P1966, DOI 10.1089/neu.2013.2960; Zhang HS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11773; Zhao S, 2016, MOL NEUROBIOL, V53, P1884, DOI 10.1007/s12035-015-9128-z	40	14	15	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	NOV 11	2016	6								37063	10.1038/srep37063			12	Multidisciplinary Sciences	Science & Technology - Other Topics	EB6FM	WOS:000387477000001	27833158	DOAJ Gold, Green Published			2021-06-18	
J	Frohlich, M; Wafaisade, A; Mansuri, A; Koenen, P; Probst, C; Maegele, M; Bouillon, B; Sakka, SG				Froehlich, Matthias; Wafaisade, Arasch; Mansuri, Anastasios; Koenen, Paola; Probst, Christian; Maegele, Marc; Bouillon, Bertil; Sakka, Samir G.			Which score should be used for posttraumatic multiple organ failure? - Comparison of the MODS, Denver- and SOFA- Scores	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Trauma; Multiple organ failure; Multiple organ dysfunction; Sofa score; Denver Score	AGITATION-SEDATION SCALE; RISK-FACTORS; INJURY; TRAUMA; DYSFUNCTION; EPIDEMIOLOGY; SEPSIS	Background: Multiple organ dysfunction and multiple organ failure (MOF) is still a major complication and challenge in the treatment of severely injured patients. The incidence varies decisively in current studies, which complicates the comparability regarding risk factors, treatment recommendations and patients' outcome. Therefore, we analysed how the currently used scoring systems, the MODS, Denver- and SOFA Score, influence the definition and compared the scores' predictive ability. Methods: Out of datasets of severely injured patients (ISS >= 16, Age >= 16) staying more tha 48 h on the ICU, the scores were calculated, respectively. The scores' predictive ability on day three after trauma for resource requiring measurements and patient specific outcomes were compared using receiver-operating characteristics. Results: One hundred seventy-six patients with a mean ISS 28 +/- 13 could be included. MODS and SOFA score defined the incidence of MOF consistently (46.5 % vs. 52.3 %), while the Denver score defined MOF in 22.2 %. The MODS outperformed Denver-and SOFA score in predicting mortality (area under the curve/AUC: 0.83 vs. 0.67 vs. 0.72), but was inferior predicting the length of stay (AUC 0.71 vs. 0.80 vs. 0.82) and a prolonged time on mechanical ventilation (AUC 0.75 vs. 0.81 vs. 0.84). MODS and SOFA score were comparably sensitive and the Denver score more specific in all analyses. Conclusions: All three scores have a comparable ability to predict the outcome in trauma patients including patients with severe traumatic brain injury (TBI). Either score could be favored depending weather a higher sensitivity or specificity is targeted. The SOFA score showed the most balanced relation of sensitivity and specificity. The incidence of posttraumatic MOF relies decisively on the score applied. Therefore harmonizing the competing scores and definitions is desirable.	[Froehlich, Matthias; Wafaisade, Arasch; Koenen, Paola; Probst, Christian; Maegele, Marc; Bouillon, Bertil] Univ Witten Herdecke, Dept Trauma & Orthoped Surg, Cologne Merheim Med Ctr, Ostmerheimerstr 200, D-51109 Cologne, Germany; [Froehlich, Matthias] Univ Witten Herdecke, Inst Res Operat Med IFOM, Ostmerheimerstr 200, D-51109 Cologne, Germany; [Mansuri, Anastasios; Sakka, Samir G.] Univ Witten Herdecke, Med Ctr Cologne Merheim, Dept Anaesthesiol & Operat Intens Care Med, Cologne, Germany	Frohlich, M (corresponding author), Univ Witten Herdecke, Dept Trauma & Orthoped Surg, Cologne Merheim Med Ctr, Ostmerheimerstr 200, D-51109 Cologne, Germany.; Frohlich, M (corresponding author), Univ Witten Herdecke, Inst Res Operat Med IFOM, Ostmerheimerstr 200, D-51109 Cologne, Germany.	froehlichm@kliniken-koeln.de					Antonelli M, 1999, INTENS CARE MED, V25, P389, DOI 10.1007/s001340050863; Bingold TM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134329; BONE RC, 1991, CRIT CARE MED, V19, P973, DOI 10.1097/00003246-199107000-00024; Ciesla DJ, 2004, ARCH SURG-CHICAGO, V139, P590, DOI 10.1001/archsurg.139.6.590; Dewar D, 2009, INJURY, V40, P912, DOI 10.1016/j.injury.2009.05.024; Dewar DC, 2014, J TRAUMA ACUTE CARE, V77, P624, DOI 10.1097/TA.0000000000000406; Dewar DC, 2013, J TRAUMA ACUTE CARE, V74, P774, DOI 10.1097/TA.0b013e31827a6e69; Evans JA, 2010, WORLD J SURG, V34, P158, DOI 10.1007/s00268-009-0266-1; Frohlich M, 2014, J TRAUMA ACUTE CARE, V76, P921, DOI 10.1097/TA.0000000000000199; Grotz M, 2001, CHIRURG, V72, P723, DOI 10.1007/s001040170130; Lefering R, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0476-2; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Minei JP, 2012, CRIT CARE MED, V40, P1129, DOI 10.1097/CCM.0b013e3182376e9f; Sauaia A, 1996, WORLD J SURG, V20, P392, DOI 10.1007/s002689900062; Sauaia A, 2014, J TRAUMA ACUTE CARE, V76, P582, DOI 10.1097/TA.0000000000000147; Sauaia A, 2009, SHOCK, V31, P438, DOI 10.1097/SHK.0b013e31818ba4c6; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Scholten AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110905; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Vasilevskis EE, 2016, CRIT CARE MED, V44, P138, DOI 10.1097/CCM.0000000000001375; Viglino D, 2016, J THORAC DIS, V8, P311, DOI 10.21037/jtd.2016.02.61; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Vogel JA, 2016, J AM COLL SURGEONS, V222, P73, DOI 10.1016/j.jamcollsurg.2015.10.010; Zygun D, 2006, CRIT CARE, V10, DOI 10.1186/cc5007	25	14	17	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	NOV 3	2016	24								130	10.1186/s13049-016-0321-5			8	Emergency Medicine	Emergency Medicine	EA8BM	WOS:000386860300002	27809885	DOAJ Gold, Green Published			2021-06-18	
J	Fraas, MR; Burchiel, J				Fraas, Michael R.; Burchiel, Jessica			A systematic review of education programmes to prevent concussion in rugby union	EUROPEAN JOURNAL OF SPORT SCIENCE			English	Article						Concussion; rugby union; medical management	KNOWLEDGE TRANSFER; PLAYERS; INJURY; INTERVENTION; BOKSMART; NECK	Background: There is a high incidence of concussion sustained by athletes participating in rugby union, many of which go unreported. A lack of sufficient knowledge about concussion injuries may explain athletes' failure to report. Several rugby union-playing countries have developed injury education and prevention programmes to address this issue. Objective: The aim of the current review was to systematically assess the content and level of evidence on concussion education/prevention programmes in rugby union and to make recommendations for the quality, strength, and consistency of this evidence. Methods: We searched PubMed, PsycInfo, MEDLINE, SPORTDiscuss, Webofscience, and conducted a manual search for articles. Results: Ten articles were included for review. Of these, six focused on the BokSmart injury prevention programme in South Africa, two focused on the RugbySmart injury prevention programme in New Zealand, one was an analysis of prevention programmes, and one was a systematic review of rugby injury prevention strategies. Conclusions: Despite the initiative to develop concussion education and prevention programmes, there is little evidence to support the effectiveness of such programmes. There is evidence to support education of coaches and referees. In addition, there is scant evidence to suggest that education and rule changes may have the benefit of changing athlete behaviours resulting in a reduction in catastrophic injury.	[Fraas, Michael R.; Burchiel, Jessica] Western Washington Univ, Dept Commun Sci & Disorders, 516 High St, Bellingham, WA 98225 USA	Fraas, MR (corresponding author), Western Washington Univ, Dept Commun Sci & Disorders, 516 High St, Bellingham, WA 98225 USA.	michael.fraas@wwu.edu					Baker JF, 2013, IRISH J MED SCI, V182, P121, DOI 10.1007/s11845-012-0846-1; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Boffano P, 2011, J CRANIOFAC SURG, V22, P2053, DOI 10.1097/SCS.0b013e318231988d; Broglio SP, 2010, J SPORT SCI MED, V9, P418; Brown J, 2011, S AFR SPORTS MED, V23, P62; Brown JC, 2015, INJURY PREV, V21, P173, DOI 10.1136/injuryprev-2014-041326; Chalmers DJ, 2004, J SCI MED SPORT, V7, P74, DOI 10.1016/S1440-2440(04)80046-X; Cusimano MD, 2010, NEUROSURGERY, V67, P1404, DOI 10.1227/NEU.0b013e3181f209f1; Ebell M. H., 2004, AM FAM PHYSICIAN, V69, P448; Fraas MR, 2015, IRISH J MED SCI, V184, P425, DOI 10.1007/s11845-014-1137-9; Fraas MR, 2014, PHYS THER SPORT, V15, P136, DOI 10.1016/j.ptsp.2013.08.002; Freitag A, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1587; Gardner AJ, 2014, SPORTS MED, V44, P1717, DOI 10.1007/s40279-014-0233-3; Gianotti S, 2008, BRIT J SPORT MED, V42, P427, DOI 10.1136/bjsm.2008.046987; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Gianotti SM, 2009, J SCI MED SPORT, V12, P371, DOI 10.1016/j.jsams.2008.01.002; IRB, 2010, LAWS GAM RUGB UN 201; Lambert M., 2013, S AFR J SPORTS MED, V25, P38, DOI [10.7196/sajsm.493, DOI 10.7196/SAJSM.493]; Marshall SW, 2001, J ATHL TRAINING, V36, P334; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McIntosh AS, 2010, BRIT J SPORT MED, V44, P188, DOI 10.1136/bjsm.2007.041400; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Posthumus M., 2008, S AFR J SPORTS MED, V20, P64, DOI [10.17159/2078-516X/2008/v20i3a633, DOI 10.17159/2078-516X/2008/V20I3A633]; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Provvidenza C, 2013, BRIT J SPORT MED, V47, P332, DOI 10.1136/bjsports-2012-092099; Quarrie KL, 2007, BRIT MED J, V334, P1150, DOI 10.1136/bmj.39185.605914.AE; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Tommasone BA, 2006, J ATHL TRAINING, V41, P470; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002; Viljoen W, 2012, BRIT J SPORT MED, V46, P692, DOI 10.1136/bjsports-2012-091278	31	14	15	0	46	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1746-1391	1536-7290		EUR J SPORT SCI	Eur. J. Sport Sci.	NOV	2016	16	8					1212	1218		10.1080/17461391.2016.1170207			7	Sport Sciences	Sport Sciences	DV4JG	WOS:000382891300041	27063067				2021-06-18	
J	Karamzadeh, N; Amyot, F; Kenney, K; Anderson, A; Chowdhry, F; Dashtestani, H; Wassermann, EM; Chernomordik, V; Boccara, C; Wegman, E; Diaz-Arrastia, R; Gandjbakhche, AH				Karamzadeh, Nader; Amyot, Franck; Kenney, Kimbra; Anderson, Afrouz; Chowdhry, Fatima; Dashtestani, Hadis; Wassermann, Eric M.; Chernomordik, Victor; Boccara, Claude; Wegman, Edward; Diaz-Arrastia, Ramon; Gandjbakhche, Amir H.			A machine learning approach to identify functional biomarkers in human prefrontal cortex for individuals with traumatic brain injury using functional near-infrared spectroscopy	BRAIN AND BEHAVIOR			English	Article						classification; feature selection; machine learning; near-infrared spectroscopy; traumatic brain injury; time series feature extraction; wrapper method	WORKING-MEMORY; MOTOR IMAGERY; CEREBRAL HEMODYNAMICS; BLOOD-VOLUME; CLASSIFICATION; COMPLEXITY; OSCILLATIONS; FREQUENCY; FMRI; AUTOREGULATION	BackgroundWe have explored the potential prefrontal hemodynamic biomarkers to characterize subjects with Traumatic Brain Injury (TBI) by employing the multivariate machine learning approach and introducing a novel task-related hemodynamic response detection followed by a heuristic search for optimum set of hemodynamic features. To achieve this goal, the hemodynamic response from a group of 31 healthy controls and 30 chronic TBI subjects were recorded as they performed a complexity task. MethodsTo determine the optimum hemodynamic features, we considered 11 features and their combinations in characterizing TBI subjects. We investigated the significance of the features by utilizing a machine learning classification algorithm to score all the possible combinations of features according to their predictive power. Results and ConclusionsThe identified optimum feature elements resulted in classification accuracy, sensitivity, and specificity of 85%, 85%, and 84%, respectively. Classification improvement was achieved for TBI subject classification through feature combination. It signified the major advantage of the multivariate analysis over the commonly used univariate analysis suggesting that the features that are individually irrelevant in characterizing the data may become relevant when used in combination. We also conducted a spatio-temporal classification to identify regions within the prefrontal cortex (PFC) that contribute in distinguishing between TBI and healthy subjects. As expected, Brodmann areas (BA) 10 within the PFC were isolated as the region that healthy subjects (unlike subjects with TBI), showed major hemodynamic activity in response to the High Complexity task. Overall, our results indicate that identified temporal and spatio-temporal features from PFC's hemodynamic activity are promising biomarkers in classifying subjects with TBI.	[Karamzadeh, Nader; Wegman, Edward] George Mason Univ, Dept Computat & Data Sci, Fairfax, VA 22030 USA; [Karamzadeh, Nader; Anderson, Afrouz; Chowdhry, Fatima; Dashtestani, Hadis; Chernomordik, Victor; Gandjbakhche, Amir H.] NICHHD, NIH, Bethesda, MD 20892 USA; [Amyot, Franck; Kenney, Kimbra; Diaz-Arrastia, Ramon] Uniformed Serv, Dept Neurol, Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Wassermann, Eric M.] NIMH, NIH, Bethesda, MD 20892 USA; [Boccara, Claude] Inst Langevin ESPCI ParisTech, Paris, France	Gandjbakhche, AH (corresponding author), NICHHD, NIH, Bethesda, MD 20892 USA.	amir@helix.nih.gov	Wassermann, Eric M./AAC-9064-2020	Wassermann, Eric M./0000-0003-0628-0210; Boccara, Claude/0000-0002-9603-0700; Diaz-Arrastia, Ramon/0000-0001-6051-3594	Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institute of Neurological Disorder and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Department of Defense in Center for Neuroscience and Regenerative MedicineUnited States Department of Defense	We acknowledge the funding of the intramural program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute of Neurological Disorder and Stroke, and Department of Defense in Center for Neuroscience and Regenerative Medicine.	Ahmadlou M, 2010, J NEURAL TRANSM, V117, P1099, DOI 10.1007/s00702-010-0450-3; Amyot F, 2012, NEUROIMAGE, V60, P879, DOI 10.1016/j.neuroimage.2012.01.104; Anderson AA, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00393; Bhambhani Y, 2006, J REHABIL RES DEV, V43, P845, DOI 10.1682/JRRD.2005.09.0151; Bishop CM., 2006, PATTERN RECOGNITION; Bosl W, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-18; Bunce Scott C., 2013, Foundations of Augmented Cognition. 7th International Conference, AC 2013. Held as Part of HCI International 2013. Proceedings, P250, DOI 10.1007/978-3-642-39454-6_26; Cazalis F, 2006, BRAIN INJURY, V20, P1019, DOI 10.1080/02699050600664384; Chernomordikl V, 2016, BRAIN RES, V1639, P194, DOI 10.1016/j.brainres.2016.02.018; Coyle S, 2004, PHYSIOL MEAS, V25, P815, DOI 10.1088/0967-3334/25/4/003; DELPY DT, 1988, PHYS MED BIOL, V33, P1433, DOI 10.1088/0031-9155/33/12/008; Domingos P, 2012, COMMUN ACM, V55, P78, DOI 10.1145/2347736.2347755; Elliott R, 2003, BRIT MED BULL, V65, P49, DOI 10.1093/bmb/65.1.49; Fazli S, 2012, NEUROIMAGE, V59, P519, DOI 10.1016/j.neuroimage.2011.07.084; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Guyon I., 2003, Journal of Machine Learning Research, V3, P1157, DOI 10.1162/153244303322753616; Heeger DJ, 2002, NAT REV NEUROSCI, V3, P142, DOI 10.1038/nrn730; Hibino S, 2013, NEUROL MED-CHIR, V53, P299, DOI 10.2176/nmc.53.299; Holper L, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-34; Izzetoglu M, 2005, IEEE T NEUR SYS REH, V13, P153, DOI 10.1109/TNSRE.2005.847377; Kainerstorfer JM, 2014, ACAD RADIOL, V21, P185, DOI 10.1016/j.acra.2013.10.012; Krueger F, 2009, NEUROREPORT, V20, P1093, DOI 10.1097/WNR.0b013e32832e7ea5; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Liu XY, 2015, J CEREBR BLOOD F MET, V35, P248, DOI 10.1038/jcbfm.2014.192; Lotte F, 2007, J NEURAL ENG, V4, pR1, DOI 10.1088/1741-2560/4/2/R01; Luu S, 2009, J NEURAL ENG, V6, DOI 10.1088/1741-2560/6/1/016003; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Merzagora AC, 2011, J INNOV OPT HEAL SCI, V4, P251, DOI 10.1142/S1793545811001551; Merzagora ACR, 2014, BRAIN IMAGING BEHAV, V8, P446, DOI 10.1007/s11682-013-9258-8; Morchen Fabian, 2003, TIME SERIES FEATURE; Naito M, 2007, IEICE T INF SYST, VE90D, P1028, DOI 10.1093/ietisy/e90-d.7.1028; Hai NT, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00516; Obrig H, 2000, NEUROIMAGE, V12, P623, DOI 10.1006/nimg.2000.0657; Olshen RA, 1984, CLASSIFICATION REGRE; Pare N, 2009, NEUROPSYCHOL REHABIL, V19, P110, DOI 10.1080/09602010802106486; Plichta MM, 2006, NEUROIMAGE, V31, P116, DOI 10.1016/j.neuroimage.2005.12.008; Power SD, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/6/066004; Power SD, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/2/026002; Ramnani N, 2004, NAT REV NEUROSCI, V5, P184, DOI 10.1038/nrn1343; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; Rizk-Jackson A, 2011, NEUROIMAGE, V56, P788, DOI 10.1016/j.neuroimage.2010.04.273; SAFAVIAN SR, 1991, IEEE T SYST MAN CYB, V21, P660, DOI 10.1109/21.97458; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Satyasree K., 2013, INT J EMERG TRENDS T, V2, P109; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Scholkmann F, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.10.105004; Sitaram R, 2007, NEUROIMAGE, V34, P1416, DOI 10.1016/j.neuroimage.2006.11.005; Stahl D, 2012, DEV NEUROPSYCHOL, V37, P274, DOI 10.1080/87565641.2011.650808; Stangl M, 2013, J NEAR INFRARED SPEC, V21, P157, DOI 10.1255/jnirs.1048; Stuss DT., 2000, DIFFERENTIATION STAT, P340; Suykens JAK, 1999, NEURAL PROCESS LETT, V9, P293, DOI 10.1023/A:1018628609742; Tan PN, 2006, INTRO DATA MINING; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y; Villringer A, 1997, TRENDS NEUROSCI, V20, P435, DOI 10.1016/S0166-2236(97)01132-6; Welling M., 2005, FISHER LINEAR DISCRI; Woon WL, 2007, PHYSIOL MEAS, V28, P335, DOI 10.1088/0967-3334/28/4/001	59	14	14	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	2162-3279			BRAIN BEHAV	Brain Behav.	NOV	2016	6	11								10.1002/brb3.541			14	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	EB7RJ	WOS:000387587500004		DOAJ Gold, Green Published			2021-06-18	
J	Merritt, VC; Ukueberuwa, DM; Arnett, PA				Merritt, Victoria C.; Ukueberuwa, Dede M.; Arnett, Peter A.			Relationship between the apolipoprotein E gene and headache following sports-related concussion	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Apolipoprotein E gene; Genetics; Mild traumatic brain injury; Headache; Collegiate athletes	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC HEADACHE; ALZHEIMERS-DISEASE; FOOTBALL PLAYERS; RISK-FACTORS; E EPSILON-4; SEVERITY; EPIDEMIOLOGY; MANAGEMENT; MECHANISM	Introduction: Headache is one of the most commonly reported and longest lasting symptoms that concussed athletes report, yet the etiology of headache symptoms following concussion is not entirely clear. The purpose of this study was to determine whether the e4 allele of the apolipoprotein E (APOE) gene influences the presence and severity of postconcussion headache. Method: Participants were composed of 45 concussed athletes and 43 healthy/nonconcussed athletes who were involved in a clinically based sports concussion management program. All athletes completed the Post-Concussion Symptom Scale (PCSS). The headache symptom from the PCSS was the primary outcome variable. Buccal samples were collected and analyzed to determine APOE genotype. Results: A significantly greater proportion of concussed e4+ athletes than e4- athletes endorsed headache. Furthermore, concussed e4+ athletes endorsed more severe headaches than e4- athletes. When examining the healthy/nonconcussed sample (i.e., athletes at baseline), results showed no differences between e4 allele groups with respect to the presence and severity of headache. Conclusions: These findings show that when compared to concussed e4- athletes, e4+ athletes are more likely to (a) endorse postconcussion headache and (b) report more severe headache symptoms following concussion. Conversely, it appears that the e4 allele does not influence baseline reports of headache. Thus, results suggest that those with the e4 genotype may be at a higher risk for experiencing headache-related difficulties only after a concussion is sustained.	[Merritt, Victoria C.; Ukueberuwa, Dede M.; Arnett, Peter A.] Penn State Univ, Dept Psychol, 372 Moore Bldg, University Pk, PA 16802 USA	Merritt, VC (corresponding author), Penn State Univ, Dept Psychol, 372 Moore Bldg, University Pk, PA 16802 USA.	vca106@psu.edu		Merritt, Victoria/0000-0001-5683-4168	American Psychological Foundation	The research described in this manuscript was supported by a grant to the first author from the American Psychological Foundation.	Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Barth JT, 1989, MILD HEAD INJURY SPO; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Christensen Helen, 2008, BMC Geriatr, V8, P14, DOI 10.1186/1471-2318-8-14; Conidi FX, 2012, HEADACHE, V52, P15, DOI 10.1111/j.1526-4610.2012.02138.x; Crystal SC, 2010, CURR PAIN HEADACHE R, V14, P449, DOI 10.1007/s11916-010-0146-2; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Finnoff JT, 2011, PM&R, V3, pS452, DOI 10.1016/j.pmrj.2011.07.014; Freeman B, 2003, BEHAV GENET, V33, P67, DOI 10.1023/A:1021055617738; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gupta R, 2009, J HEADACHE PAIN, V10, P115, DOI 10.1007/s10194-008-0094-y; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183; Ingelsson M, 2003, CURR PROTOC HUM GENE, V38, P1; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR., 2000, IMPACT IMMEDIATE POS; Mahley RW, 2006, P NATL ACAD SCI USA, V103, P5644, DOI 10.1073/pnas.0600549103; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer CL, 2013, HEADACHE, V53, P1523, DOI 10.1111/head.12173; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Merritt VC, 2016, J INT NEUROPSYCH SOC, V22, P89, DOI 10.1017/S1355617715001022; Merritt VC, 2015, J CLIN EXP NEUROPSYC, V37, P265, DOI 10.1080/13803395.2015.1004303; Packard Russell C, 2005, Curr Pain Headache Rep, V9, P59, DOI 10.1007/s11916-005-0076-6; Pardini D., 2004, BR J SPORTS MED, V38, P661; Pizza Vincenzo, 2012, Open Neurol J, V6, P65, DOI 10.2174/1874205X01206010065; Rainero I, 2002, NEUROSCI LETT, V317, P111, DOI 10.1016/S0304-3940(01)02432-6; Ramadan Nabih M, 2004, Curr Pain Headache Rep, V8, P301, DOI 10.1007/s11916-004-0012-1; Rihn BH, 2009, CLIN EXP MED, V9, P61, DOI 10.1007/s10238-008-0012-2; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Sabin MJ, 2011, CLIN J SPORT MED, V21, P411, DOI 10.1097/JSM.0b013e318223f3a4; Seifert TD, 2013, HEADACHE, V53, P726, DOI 10.1111/head.12087; Seifert TD, 2010, CURR PAIN HEADACHE R, V14, P292, DOI 10.1007/s11916-010-0117-7; Silver JM., 2011, TXB TRAUMATIC BRAIN, V2nd ed.; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8	43	14	14	0	81	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	NOV	2016	38	9					941	949		10.1080/13803395.2016.1177491			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	DT6FA	WOS:000381577900001	27191930				2021-06-18	
J	Ravi, S; Pena, KA; Chu, CT; Kiselyov, K				Ravi, Sreeram; Pena, Karina A.; Chu, Charleen T.; Kiselyov, Kirill			Biphasic regulation of lysosomal exocytosis by oxidative stress	CELL CALCIUM			English	Article						Lysosomes; Exocytosis; Calcium; TRPML1; Oxidative stress	MANGANESE SUPEROXIDE-DISMUTASE; MUCOLIPIDOSIS TYPE-IV; TRANSCRIPTION FACTOR EB; TRAUMATIC BRAIN-INJURY; DOUBLE-EDGED-SWORD; PARKINSONS-DISEASE; REACTIVE OXYGEN; POMPE DISEASE; CELL-DEATH; NEURODEGENERATIVE DISEASES	Oxidative stress drives cell death in a number of diseases including ischemic stroke and neurodegenerative diseases. A better understanding of how cells recover from oxidative stress is likely to lead to better treatments for stroke and other diseases. The recent evidence obtained in several models ties the process of lysosomal exocytosis to the clearance of protein aggregates and toxic metals. The mechanisms that regulate lysosomal exocytosis, under normal or pathological conditions, are only beginning to emerge. Here we provide evidence for the biphasic effect of oxidative stress on lysosomal exocytosis. Lysosomal exocytosis was measured using the extracellular levels of the lysosomal enzyme beta-hexosaminidase (beta-hex). Low levels or oxidative stress stimulated lysosomal exocytosis, but inhibited it at high levels. Deletion of the lysosomal ion channel TRPML1 eliminated the stimulatory effect of low levels of oxidative stress. The inhibitory effects of oxidative stress appear to target the component of lysosomal exocytosis that is driven by extracellular Ca2+. We propose that while moderate oxidative stress promotes cellular repair by stimulating lysosomal exocytosis, at high levels oxidative stress has a dual pathological effect: it directly causes cell damage and impairs damage repair by inhibiting lysosomal exocytosis. Harnessing these adaptive mechanisms may point to pharmacological interventions for diseases involving oxidative proteotoxicity or metal toxicity. (C) 2016 Elsevier Ltd. All rights reserved.	[Ravi, Sreeram; Pena, Karina A.; Kiselyov, Kirill] Dept Biol Sci, Pittsburgh, PA 15260 USA; [Chu, Charleen T.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; [Pena, Karina A.] Univ Pittsburgh, Ctr Biol Imaging, Pittsburgh, PA USA	Kiselyov, K (corresponding author), Dept Biol Sci, Pittsburgh, PA 15260 USA.	kiselyov@pitt.edu	Chu, Charleen T/B-1601-2008	Chu, Charleen T/0000-0002-5052-8271	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD058577, ES01678, NS096755, NS094860, AG026389, NS065789]; Mucolipidosis type IV foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD058577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R21ES016782] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS096755, R01NS065789, R56NS065789, R21NS094860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG026389] Funding Source: NIH RePORTER	These studies were supported by NIH grants HD058577, ES01678, NS096755 and NS094860, and Mucolipidosis type IV foundation grant to KK, and NIH grants AG026389 and NS065789 to CTC.	Arantes RME, 2006, J NEUROSCI, V26, P4630, DOI 10.1523/JNEUROSCI.0009-06.2006; Barnett A, 2011, J ALZHEIMERS DIS, V25, P385, DOI 10.3233/JAD-2011-101989; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Bogeski I, 2012, J PHYSIOL-LONDON, V590, P4193, DOI 10.1113/jphysiol.2012.230565; Bogeski I, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000672; Callio J, 2005, J BIOL CHEM, V280, P18536, DOI 10.1074/jbc.M413224200; Caruano-Yzermans AL, 2006, J BIOL CHEM, V281, P13581, DOI 10.1074/jbc.M601580200; Cheng XP, 2014, NAT MED, V20, P1187, DOI 10.1038/nm.3611; Cherra SJ, 2008, FUTUR NEUROL, V3, P309, DOI 10.2217/14796708.3.3.309; Chu CT, 2013, NAT CELL BIOL, V15, P1197, DOI 10.1038/ncb2837; Coblentz J, 2014, BIOCHEM J, V457, P361, DOI 10.1042/BJ20130647; Colletti GA, 2012, J BIOL CHEM, V287, P8082, DOI 10.1074/jbc.M111.285536; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Dagda RK, 2011, CELL DEATH DIFFER, V18, P1914, DOI 10.1038/cdd.2011.74; Dagda RK, 2009, J BIOL CHEM, V284, P13843, DOI 10.1074/jbc.M808515200; De Filippis B., 2015, BIOL MED, V83, P167; Decressac M, 2013, P NATL ACAD SCI USA, V110, pE1817, DOI 10.1073/pnas.1305623110; Drose S, 2012, ADV EXP MED BIOL, V748, P145, DOI 10.1007/978-1-4614-3573-0_6; Feeney EJ, 2013, AUTOPHAGY, V9, P1117, DOI 10.4161/auto.24920; Fiskum G, 2003, ANN NY ACAD SCI, V991, P111; Gaetke LM, 2003, TOXICOLOGY, V189, P147, DOI 10.1016/S0300-483X(03)00159-8; Gasier HG, 2013, UNDERSEA HYPERBAR M, V40, P125; Giordano S, 2014, REDOX BIOL, V2, P82, DOI 10.1016/j.redox.2013.12.013; Granzotto A, 2015, NEUROBIOL DIS, V81, P25, DOI 10.1016/j.nbd.2015.04.010; Gu F, 2015, CURR OPIN CLIN NUTR, V18, P89, DOI 10.1097/MCO.0000000000000134; Hegde ML, 2011, J ALZHEIMERS DIS, V24, P183, DOI 10.3233/JAD-2011-110281; HRUBAN Z, 1963, AM J PATHOL, V42, P657; Hwang JJ, 2008, J NEUROSCI, V28, P3114, DOI 10.1523/JNEUROSCI.0199-08.2008; Hwang JJ, 2010, BIOMETALS, V23, P997, DOI 10.1007/s10534-010-9346-9; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kalogeris T, 2014, REDOX BIOL, V2, P702, DOI 10.1016/j.redox.2014.05.006; Kim GW, 2002, STROKE, V33, P809, DOI 10.1161/hs0302.103745; Korolchuk VI, 2011, AUTOPHAGY, V7, P927, DOI 10.4161/auto.7.8.15862; Kukic I, 2014, J CELL SCI, V127, P3094, DOI 10.1242/jcs.145318; Kukic I, 2013, BIOCHEM J, V451, P155, DOI 10.1042/BJ20121506; La Spada AR, 2012, AUTOPHAGY, V8, P1845, DOI 10.4161/auto.21862; LaPlante JM, 2006, MOL GENET METAB, V89, P339, DOI 10.1016/j.ymgme.2006.05.016; Lee SJ, 2010, MOL BRAIN, V3, DOI 10.1186/1756-6606-3-30; Lee SJ, 2010, GLIA, V58, P1186, DOI 10.1002/glia.20998; Li XR, 2016, NAT CELL BIOL, V18, P404, DOI 10.1038/ncb3324; MacMillan-Crow LA, 2001, FREE RADICAL RES, V34, P325, DOI 10.1080/10715760100300281; Martina JA, 2014, CELL MOL LIFE SCI, V71, P2483, DOI 10.1007/s00018-014-1565-8; Mazzio EA, 2004, BRAIN RES, V1004, P29, DOI 10.1016/j.brainres.2003.12.034; Medina DL, 2011, DEV CELL, V21, P421, DOI 10.1016/j.devcel.2011.07.016; Miedel MT, 2008, J EXP MED, V205, P1477, DOI 10.1084/jem.20072194; Milton NGN, 2001, NEUROTOXICOLOGY, V22, P767, DOI 10.1016/S0161-813X(01)00064-X; Mortiboys H, 2008, ANN NEUROL, V64, P555, DOI 10.1002/ana.21492; Nowak G, 2006, AM J PHYSIOL-RENAL, V291, pF840, DOI 10.1152/ajprenal.00219.2005; Nunes P, 2014, ANTIOXID REDOX SIGN, V21, P915, DOI 10.1089/ars.2013.5615; Osellame LD, 2014, BRIT J PHARMACOL, V171, P1958, DOI 10.1111/bph.12453; Parellada M, 2012, J PSYCHIATR RES, V46, P394, DOI 10.1016/j.jpsychires.2011.10.004; Pastore N, 2013, AUTOPHAGY, V9, P1094, DOI 10.4161/auto.24469; Pastore N, 2013, EMBO MOL MED, V5, P397, DOI 10.1002/emmm.201202046; Pena K, 2015, CELL CALCIUM, V57, P257, DOI 10.1016/j.ceca.2015.01.005; Pena KA, 2015, BIOCHEM J, V470, P65, DOI 10.1042/BJ20140645; Polishchuk EV, 2014, DEV CELL, V29, P686, DOI 10.1016/j.devcel.2014.04.033; Polito VA, 2014, EMBO MOL MED, V6, P1142, DOI 10.15252/emmm.201303671; Przedborski S, 2005, ANTIOXID REDOX SIGN, V7, P685, DOI 10.1089/ars.2005.7.685; Raben N, 2012, AM J MED GENET C, V160C, P13, DOI 10.1002/ajmg.c.31317; Rabin DM, 2013, AGING-US, V5, P51; Rao SK, 2004, J BIOL CHEM, V279, P20471, DOI 10.1074/jbc.M400798200; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Rossignol DA, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00150; Salazar J, 2008, P NATL ACAD SCI USA, V105, P18578, DOI 10.1073/pnas.0804373105; Samie M, 2013, DEV CELL, V26, P511, DOI 10.1016/j.devcel.2013.08.003; Samie MA, 2014, J LIPID RES, V55, P995, DOI 10.1194/jlr.R046896; Schafer M, 2014, CELL TISSUE RES, V357, P395, DOI 10.1007/s00441-014-1807-y; Schrag M, 2011, PROG NEUROBIOL, V94, P296, DOI 10.1016/j.pneurobio.2011.05.001; Settembre C, 2015, METHOD CELL BIOL, V126, P45, DOI 10.1016/bs.mcb.2014.11.011; Sherer TB, 2005, ANTIOXID REDOX SIGN, V7, P627, DOI 10.1089/ars.2005.7.627; Spampanato C, 2013, EMBO MOL MED, V5, P691, DOI 10.1002/emmm.201202176; Testa CM, 2005, MOL BRAIN RES, V134, P109, DOI 10.1016/j.molbrainres.2004.11.007; Xie YX, 2015, NEURON, V87, P355, DOI 10.1016/j.neuron.2015.06.026; Zhang X, 2012, P NATL ACAD SCI US; Zhang XL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12109	76	14	14	0	13	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0143-4160	1532-1991		CELL CALCIUM	Cell Calcium	NOV	2016	60	5					356	362		10.1016/j.ceca.2016.08.002			7	Cell Biology	Cell Biology	EA8CA	WOS:000386861700007	27593159	Green Accepted			2021-06-18	
J	Strauss, SB; Kim, N; Branch, CA; Kahn, ME; Kim, M; Lipton, RB; Provataris, JM; Scholl, HF; Zimmerman, ME; Lipton, ML				Strauss, S. B.; Kim, N.; Branch, C. A.; Kahn, M. E.; Kim, M.; Lipton, R. B.; Provataris, J. M.; Scholl, H. F.; Zimmerman, M. E.; Lipton, M. L.			Bidirectional Changes in Anisotropy Are Associated with Outcomes in Mild Traumatic Brain Injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							POST-CONCUSSION SYMPTOMS; SICKNESS IMPACT PROFILE; TENSOR IMAGING DETECTS; WHITE-MATTER INJURY; AXONAL INJURY; IMPAIRMENT; ATTENTION; TIME; QUESTIONNAIRE; REGISTRATION	BACKGROUND AND PURPOSE: Mild traumatic brain injury results in a heterogeneous constellation of deficits and symptoms that persist in a subset of patients. This prospective longitudinal study identifies early diffusion tensor imaging biomarkers of mild traumatic brain injury that significantly relate to outcomes at 1 year following injury. MATERIALS AND METHODS: DTI was performed on 39 subjects with mild traumatic brain injury within 16 days of injury and 40 controls; 26 subjects with mild traumatic brain injury returned for follow-up at 1 year. We identified subject-specific regions of abnormally high and low fractional anisotropy and calculated mean fractional anisotropy, axial diffusivity, radial diffusivity, and mean diffusivity across all white matter voxels brain-wide and each of several white matter regions. Assessment of cognitive performance and symptom burden was performed at 1 year. RESULTS: Significant associations of brain-wide DTI measures and outcomes included the following: mean radial diffusivity and mean diffusivity with memory; and mean fractional anisotropy, radial diffusivity, and mean diffusivity with health-related quality of life. Significant differences in outcomes were found between subjects with and without abnormally high fractional anisotropy for the following white matter regions and outcome measures: left frontal lobe and left temporal lobe with attention at 1 year, left and right cerebelli with somatic postconcussion symptoms at 1 year, and right thalamus with emotional postconcussion symptoms at 1 year. CONCLUSIONS: Individualized assessment of DTI abnormalities significantly relates to long-term outcomes in mild traumatic brain injury. Abnormally high fractional anisotropy is significantly associated with better outcomes and might represent an imaging correlate of postinjury compensatory processes.	[Strauss, S. B.; Lipton, M. L.] Montefiore Med Ctr, Dept Radiol, 111 E 210th St, Bronx, NY 10467 USA; [Kim, N.; Lipton, M. L.] Albert Einstein Coll Med, Dept Radiol, Bronx, NY 10461 USA; [Branch, C. A.] Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; [Kim, M.; Lipton, R. B.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA; [Lipton, M. L.] Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Bronx, NY 10461 USA; [Kim, N.; Branch, C. A.; Kahn, M. E.; Scholl, H. F.; Lipton, M. L.] Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, Bronx, NY 10461 USA; [Lipton, R. B.; Zimmerman, M. E.] Albert Einstein Coll Med, Saul R Korey Dept Neurol, Bronx, NY 10461 USA; [Lipton, M. L.] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA; [Provataris, J. M.] Jacobi Med Ctr, Dept Emergency Med, Bronx, NY USA	Lipton, ML (corresponding author), Albert Einstein Coll Med, Jack & Pearl Resnick Campus, Bronx, NY 10461 USA.	michael.lipton@einstein.yu.edu	Lipton, Richard B/B-5060-2011	Lipton, Michael/0000-0001-5421-8441; Lipton, Richard/0000-0003-2652-2897; Kim, Namhee/0000-0003-1618-1363	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS047256, R01NS082432] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG003949, R01AG022374, R01AG034119, R01AG025119, P01AG027734, R01AG012101] Funding Source: NIH RePORTER	Mimi Kim-RELATED: Grant: National Institutes of Health*; UNRELATED: Consultancy: Lupus Foundation of America; Grants/Grants Pending: National Institutes of Health.* Richard B. Lipton-RELATED: Grant: National Institutes of Health R01*; UNRELATED: Consultancy: serves as consultant and advisory board member or has received honoraria from Alder, Allergan, American Headache Society, Autonomic Technologies, Avanir Pharmaceuticals, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Colucid Pharmaceuticals, Dr Reddy's Laboratories, ElectroCore, Eli Lilly, eNeura Therapeutics, Informa, Merck & Co, Novartis, Pfizer, Teva, and Vedanta; Grants/Grants Pending: receives research support from the National Institutes of Health*: PO1AG003949 (Program Director), PO1AG027734 (Project Leader), RO1AG025119 (Investigator), RO1AG022374-06A2 (Investigator), RO1AG034119 (Investigator), RO1AG12101 (Investigator), 23NS05140901A1 (Mentor), and K23NS47256 (Mentor), and the National Headache Foundation*; Payment for Lectures (including service on Speakers Bureaus): lecture honoraria for Continuing Medical Education-accredited lectures from the American Headache Society, the American Academy of Neurology, and the Headache Cooperative of New England; Payment for Development of Educational Presentations: American Headache Society, Comments: Chronic Migraine Education Program; Stock/Stock Options: eNeura Therapeutics. Michael L. Lipton-UNRELATED: Expert Testimony: Various (on behalf of defendants and plaintiffs); Grants/Grants Pending: Resurrecting Lives Foundation,* Comments: grant for research on imaging in blast TBI; Patents (planned, pending or issued): image-processing methodology (patent pending)*; Royalties: Springer (MRI physics book); Other: the Dana Foundation,* Comments: grant for study of imaging in sports TBI. * Money paid to the institution.	Alhilali LM, 2014, RADIOLOGY, V272, P224, DOI 10.1148/radiol.14132670; Ardekani BA, 2005, J NEUROSCI METH, V142, P67, DOI 10.1016/j.jneumeth.2004.07.014; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bocquillon P, 2009, HUM BRAIN MAPP, V30, P2267, DOI 10.1002/hbm.20666; Bonhoeffer T, 2002, NEURON, V35, P1019, DOI 10.1016/S0896-6273(02)00906-6; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Filley CM, 2011, NEUROL CLIN, V29, P81, DOI 10.1016/j.ncl.2010.10.003; Filley CM, 2010, NEUROPSYCHOL REV, V20, P158, DOI 10.1007/s11065-010-9127-9; FOSTER JK, 1994, COGNITIVE NEUROPSYCH, V11, P133, DOI 10.1080/02643299408251971; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Grossman EJ, 2016, J NEUROTRAUM, V33, P163, DOI 10.1089/neu.2015.3965; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Holmes CJ, 1998, J COMPUT ASSIST TOMO, V22, P324, DOI 10.1097/00004728-199803000-00032; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kim N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059382; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Klawiter EC, 2011, NEUROIMAGE, V55, P1454, DOI 10.1016/j.neuroimage.2011.01.007; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2014, HUM BRAIN MAPP, V35, P5457, DOI 10.1002/hbm.22563; Nagahama Y, 2001, CEREB CORTEX, V11, P85, DOI 10.1093/cercor/11.1.85; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Oishi K, 2008, NEUROIMAGE, V43, P447, DOI 10.1016/j.neuroimage.2008.07.009; OLTON DS, 1988, NEUROPSYCHOLOGIA, V26, P307, DOI 10.1016/0028-3932(88)90083-8; Oouchi H, 2007, AM J NEURORADIOL, V28, P1102, DOI 10.3174/ajnr.A0488; Paniak C, 2000, BRAIN INJURY, V14, P219; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Sbordone RJ, 2014, APPL NEUROPSYCH-ADUL, V21, P98, DOI 10.1080/09084282.2012.762630; Scholz J, 2009, NAT NEUROSCI, V12, P1370, DOI 10.1038/nn.2412; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2007, NAT PROTOC, V2, P499, DOI 10.1038/nprot.2007.45; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Williams LM, 2005, INT J NEUROSCI, V115, P1605, DOI 10.1080/00207450590958475; Yuspeh RL, 2000, ARCH CLIN NEUROPSYCH, V15, P319, DOI 10.1016/S0887-6177(99)00020-7	53	14	14	0	7	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	NOV	2016	37	11					1983	1991		10.3174/ajnr.A4851			9	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EC2PI	WOS:000387965400011	27282864	Other Gold, Green Published, Green Accepted			2021-06-18	
J	Tornas, S; Lovstad, M; Solbakk, AK; Schanke, AK; Stubberud, J				Tornas, Sveinung; Lovstad, Marianne; Solbakk, Anne-Kristin; Schanke, Anne-Kristine; Stubberud, Jan			Goal Management Training Combined With External Cuing as a Means to Improve Emotional Regulation, Psychological Functioning, and Quality of Life in Patients With Acquired Brain Injury: A Randomized Controlled Trial	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Clinical trial; Cognition; Emotions; Executive function; Rehabilitation	BEHAVIOR RATING INVENTORY; FUNCTION-ADULT VERSION; EXECUTIVE DYSFUNCTION; COGNITIVE REHABILITATION; SPINA-BIFIDA; ECOLOGICAL VALIDITY; ATTENTION SYSTEM; SELF-REGULATION; AWARENESS; DEFICITS	Objective: To investigate whether goal management training (GMT) expanded to include external cuing and an emotional regulation module is associated with improved emotional regulation, psychological functioning, and quality of life (QOL) after chronic acquired brain injury (ABI). Design: Randomized controlled trial with blinded outcome assessment at baseline, posttraining, and 6-month follow-up. Setting: Outpatient. Participants: Persons with ABI and executive dysfunction (N=70; 64% traumatic brain injury; 52% men; mean age +/- SD, 43 +/- 13y; mean time since injury +/- SD, 8.1 +/- 9.4y). Intervention: Eight sessions of GMT in groups, including a new module addressing emotional regulation, and external cuing. A psychoeducative control condition (Brain Health Workshop) was matched on amount of training, therapist contact, and homework. Main Outcome Measures: Emotional regulation was assessed with the Brain Injury Rehabilitation Trust Regulation of Emotions Questionnaire, the Emotional Control subscale and the Emotion Regulation factor (Behavior Rating Inventory of Executive Function Adult Version), and the Positive and Negative Affect subscales from the Dysexecutive Questionnaire. Secondary outcome measures included psychological distress (Hopkins Symptom Checklist-25) and QOL (Quality of Life After Brain Injury Scale). Results: Findings indicated beneficial effects of GMT on emotional regulation skills in everyday life and in QOL 6 months posttreatment. No intervention effects on measures of psychological distress were registered. Conclusions: GMT is a promising intervention for improving emotional regulation after ABI, even in the chronic phase. More research using objective measures of emotional regulation is needed to investigate the efficacy of this type of training. (C) 2016 by the American Congress of Rehabilitation Medicine	[Tornas, Sveinung; Lovstad, Marianne; Schanke, Anne-Kristine; Stubberud, Jan] Sunnaas Rehabil Hosp, Nesodden, Norway; [Lovstad, Marianne; Solbakk, Anne-Kristin; Schanke, Anne-Kristine] Univ Oslo, Dept Psychol, Oslo, Norway; [Solbakk, Anne-Kristin] Oslo Univ Hosp, Rikshosp, Dept Neurosurg, Div Surg & Clin Neurosci, Oslo, Norway; [Solbakk, Anne-Kristin] Helgeland Hosp, Dept Neuropsychol, Mosjoen, Norway	Tornas, S (corresponding author), Sunnaas Rehabil Hosp, N-1450 Bjornemyrveien, Nesoddtangen, Norway.	Sveinung.tornaas@sunnaas.no			Norwegian Extra Foundation for Health and Rehabilitation through EXTRA funds [2011/2/0204]	Supported by the Norwegian Extra Foundation for Health and Rehabilitation through EXTRA funds (grant no. 2011/2/0204).	Arnemann KL, 2015, NEUROLOGY, V84, P1568, DOI 10.1212/WNL.0000000000001476; Baycrest Centre for Geriatric Care, 2012, GOAL MAN TRAIN TRAIN; Beck AT, 2009, DEPRESSION: CAUSES AND TREATMENT, SECOND EDITION, P1; Becker F, 2014, NEUROREHABILITATION, V34, P87, DOI 10.3233/NRE-131015; Ben-Yishay Y., 2011, HDB HOLISTIC NEUROPS; Benedict R., 1997, BRIEF VISUOSPATIAL M; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; Bertens D, 2015, J INT NEUROPSYCH SOC, V21, P639, DOI 10.1017/S1355617715000764; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cantor J, 2014, ARCH PHYS MED REHAB, V95, P1, DOI 10.1016/j.apmr.2013.08.005; Cattran C, 2011, J CLIN EXP NEUROPSYC, V33, P672, DOI 10.1080/13803395.2010.550603; Chan RCK, 2008, ARCH CLIN NEUROPSYCH, V23, P201, DOI 10.1016/j.acn.2007.08.010; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Chen AJW, 2011, BRAIN, V134, P1541, DOI 10.1093/brain/awr067; Chiesa A, 2011, CLIN PSYCHOL REV, V31, P449, DOI 10.1016/j.cpr.2010.11.003; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KD, 1992, NEUROREHABILITATION, V2, P12, DOI DOI 10.3233/NRE-1992-2304; Cicerone KD, 2012, ARCH PHYS MED REHAB, V93, P188, DOI 10.1016/j.apmr.2011.12.003; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Cisler JM, 2010, J PSYCHOPATHOL BEHAV, V32, P68, DOI 10.1007/s10862-009-9161-1; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cole PM., 1994, MONOGR SOC RES CHILD, V59, P73, DOI [10.1111/j.1540-5834.1994.tb01278.x, DOI 10.1111/J.1540-5834.1994.TB01278.X, DOI 10.2307/1166139]; Conners C. K., 2000, CONNORS CPT 2 CONTIN; D'Zurilla TJ, 2001, HANDBOOK OF COGNITIVE-BEHAVIORAL THERAPIES, SECOND EDITION, P211; Damasio A, 2013, NAT REV NEUROSCI, V14, P143, DOI 10.1038/nrn3403; Dams-O'Connor K, 2013, BRAIN IMPAIR, V14, P51, DOI 10.1017/BrImp.2013.9; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; Donders J, 2016, ARCH CLIN NEUROPSYCH, V31, P29, DOI 10.1093/arclin/acv048; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Duncan J, 2000, SCIENCE, V289, P457, DOI 10.1126/science.289.5478.457; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; FASOTTI L, 2002, COGNITIVE REHABILITA, P107; Finnanger TG, 2015, BEHAV NEUROL, V2015, DOI 10.1155/2015/329241; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fleming JM, 2006, NEUROPSYCHOL REHABIL, V16, P474, DOI 10.1080/09602010500505518; Gioia G.A., 2000, BEHAV RATING INVENTO; Grant M, 2012, NEUROPSYCHOL REHABIL, V22, P852, DOI 10.1080/09602011.2012.693455; Hart T, 2006, J HEAD TRAUMA REHAB, V21, P142, DOI 10.1097/00001199-200603000-00007; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hart T, 2015, CONTEMP CLIN TRIALS, V40, P180, DOI 10.1016/j.cct.2014.12.005; Kabat-Zinn J, 1990, FULL CATASTROPHE LIV; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Knight R., 2002, PRINCIPLES FRONTAL L, P573, DOI DOI 10.1093/ACPROF:OSO/9780195134971.001.0001; Koole S, 2009, COGNITION EMOTION, V23, P4, DOI 10.1080/02699930802619031; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00009; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Logan DE, 2008, PAIN, V136, P366, DOI 10.1016/j.pain.2007.07.015; Maki-Marttunen V, 2015, J NEUROTRAUM, V32, P272, DOI 10.1089/neu.2014.3557; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; McCambridge J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039116; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Miotto EC, 2009, NEUROPSYCHOL REHABIL, V19, P517, DOI 10.1080/09602010802332108; Novakovic-Agopian T, 2011, J HEAD TRAUMA REHAB, V26, P325, DOI 10.1097/HTR.0b013e3181f1ead2; Petersen SE, 2012, ANNU REV NEUROSCI, V35, P73, DOI 10.1146/annurev-neuro-062111-150525; Posner M.I., 1994, IMAGES MIND; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Posner MI, 2007, ANNU REV PSYCHOL, V58, P1, DOI 10.1146/annurev.psych.58.110405.085516; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Ravndal E, 2010, DRUG ALCOHOL DEPEN, V108, P65, DOI 10.1016/j.drugalcdep.2009.11.008; Robertson I. H., 2013, PRINCIPLES FRONTAL L, P742; ROBERTSON IH, 2000, NEW COGNITIVE NEUROS, P563; Roth R.M., 2005, BEHAV RATING INVENTO; Roth RM, 2013, ARCH CLIN NEUROPSYCH, V28, P425, DOI 10.1093/arclin/act031; Ruff HA, 1996, ATTENTION EARLY DEV; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c332; Simblett SK, 2012, NEUROPSYCHOL REHABIL, V22, P874, DOI 10.1080/09602011.2012.703956; Simblett SK, 2011, NEUROPSYCHOL REHABIL, V21, P1, DOI 10.1080/09602011.2011.592099; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Spikman JM, 2013, NEUROPSYCHOL REHABIL, V23, P824, DOI 10.1080/09602011.2013.826138; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; Stubberud J, 2015, REHABIL PSYCHOL, V60, P1, DOI 10.1037/rep0000018; Stubberud J, 2014, NEUROPSYCHOL REHABIL, V24, P26, DOI 10.1080/09602011.2013.847847; Stubberud J, 2013, J INT NEUROPSYCH SOC, V19, P672, DOI 10.1017/S1355617713000209; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Tang YY, 2007, P NATL ACAD SCI USA, V104, P17152, DOI 10.1073/pnas.0707678104; Tornas S, 2016, J INT NEUROPSYCH SOC, V21, P1; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; van der Horn HJ, 2016, J NEUROTRAUM, V33, P1, DOI 10.1089/neu.2015.3905; van Hooren SAH, 2007, PATIENT EDUC COUNS, V65, P205, DOI 10.1016/j.pec.2006.07.010; Vohs K.D., 2004, HDB SELF REGULATION, P283, DOI DOI 10.1037/0003-066X.57,12.1060; von Steinbuechel N, 2005, CURR OPIN NEUROL, V18, P681, DOI 10.1097/01.wco.0000194140.56429.75; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; Wechsler D., 1999, MANUAL WECHSLER ABBR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Ylvisaker M, 2000, BRAIN IMPAIR, V1, P12, DOI DOI 10.1375/BRIM.1.1.12; Zald DH, 2010, NEUROPSYCHOLOGIA, V48, P3377, DOI 10.1016/j.neuropsychologia.2010.08.012; Zeman J, 2006, J DEV BEHAV PEDIATR, V27, P155, DOI 10.1097/00004703-200604000-00014	100	14	14	0	26	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2016	97	11					1841	1852		10.1016/j.apmr.2016.06.014			12	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	EB8IK	WOS:000387634500003	27424292				2021-06-18	
J	Zafardoost, P; Ghasemi, AA; Salehpour, F; Piroti, C; Ziaeii, E				Zafardoost, Peyman; Ghasemi, Amir Abbas; Salehpour, Firooz; Piroti, Chia; Ziaeii, Ehsan			Evaluation of the Effect of Glibenclamide in Patients With Diffuse Axonal Injury Due to Moderate to Severe Head Trauma	TRAUMA MONTHLY			English	Article						Diffuse Axonal Injury; Traumatic Brain Injury; Glibenclamide; Outcome	VASOGENIC EDEMA; BRAIN-INJURY; RAT MODEL; EPIDEMIOLOGY; GLYBURIDE; FLUX	Background: Traumatic brain injury (TBI) is a major health problem worldwide. Secondary injuries after TBI, including diffuse axonal injury (DAI) often occur, and proper treatments are needed in this regard. It has been shown that glibenclamide could reduce secondary brain damage after experimental TBI and improve outcomes. Objectives: We aim to evaluate the role of glibenclamide on the short-term outcome of patients with DAI due to moderate to severe TBI. Patients and Methods: In this controlled randomized clinical trial, 40 patients with moderate to severe TBI were assigned to glibenclamide (n = 20) and control (n = 20) groups. Six hours after admission the intervention group received 1.25 mg glibenclamide every 12 hours. The Glasgow coma scale (GCS) was administered at admission, in the first 24 and 48 hours, at one week post-trauma and at discharge. The Glasgow outcome scale (GOS) was also administered at discharge. All results were evaluated and compared between groups. Results: Patients treated with glibenclamide compared to the control group had a significantly better GCS score one week post-trauma (P = 0.003) and at discharge (P = 0.004), as well as a better GOS score at discharge (P = 0.001). The glibenclamide group also had a shorter length of hospital stay compared to the control group (P = 0.03). In the control group, two patients (10%) died during the first week post-trauma, but there was no mortality in the glibenclamide group (P = 0.48). Conclusions: Treatment with glibenclamide in patients with DAI due to moderate to severe TBI significantly improves short-term outcomes.	[Zafardoost, Peyman; Ghasemi, Amir Abbas; Salehpour, Firooz; Piroti, Chia; Ziaeii, Ehsan] Urmia Univ Med Sci, Dept Neurosurg, Orumiyeh, Iran	Zafardoost, P (corresponding author), Urmia Univ Med Sci, Dept Neurosurg, Orumiyeh, Iran.	peyman_z_2002@yahoo.com	Ziaee, Ehsan/AAP-2112-2021; Ghasemi, Amir abbas/C-9574-2018; Heidari, Mohammad/D-1287-2018	Ghasemi, Amir abbas/0000-0002-7159-4809; Heidari, Mohammad/0000-0002-7159-4809	Urmia University of Medical Sciences, Iran	This research was financially supported by vice chancellor for research, Urmia University of Medical Sciences, Iran.	Ahmed I., 2012, NEUROLOGY, V78; Bartnik BL, 2007, J NEUROTRAUM, V24, P181, DOI 10.1089/neu.2006.0038; Ding J, 2013, CLIN NEUROL NEUROSUR, V115, P2166, DOI 10.1016/j.clineuro.2013.08.010; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Hassan STS, 2013, TRAUMA MON, V18, P56, DOI 10.5812/traumamon.11522; Hattori N, 2004, J NUCL MED, V45, P775; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Kimberly WT, 2014, NEUROCRIT CARE, V20, P193, DOI 10.1007/s12028-013-9917-z; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Rambiritch V, 2014, CLIN PHARMACOL-ADV A, V6, P63, DOI 10.2147/CPAA.S54809; Robles JF, 2009, INT J ENDOCRINOL MET, V7, P72; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sheth KN, 2014, NEUROCRIT CARE, V21, P43, DOI 10.1007/s12028-014-9970-2; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Simard JM, 2012, EXP NEUROL, V233, P829, DOI 10.1016/j.expneurol.2011.11.048; Simard JM, 2012, EXP NEUROL, V233, P566, DOI 10.1016/j.expneurol.2011.11.044; Simard JM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000522; Simard JM, 2010, STROKE, V41, P531, DOI 10.1161/STROKEAHA.109.572644; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; Zhou YL, 2009, BRAIN RES, V1270, P131, DOI 10.1016/j.brainres.2009.03.010; Zweckberger K, 2014, NEUROSCIENCE, V272, P199, DOI 10.1016/j.neuroscience.2014.04.040	23	14	14	0	4	NATL CENTER TRAUMA RESEARCH	TEHRAN	NATL CENTER TRAUMA RESEARCH, TEHRAN, IRAN	2251-7464	2251-7472		TRAUMA MON	Trauma Mon.	NOV	2016	21	5							e25113	10.5812/traumamon.25113			4	Emergency Medicine	Emergency Medicine	ED7QM	WOS:000389064100006	28184360	Green Published			2021-06-18	
J	Cuisinier, A; Maufrais, C; Payen, JF; Nottin, S; Walther, G; Bouzat, P				Cuisinier, Adrien; Maufrais, Claire; Payen, Jean-Francois; Nottin, Stephane; Walther, Guillaume; Bouzat, Pierre			Myocardial function at the early phase of traumatic brain injury: a prospective controlled study	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article							SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; CHAMBER QUANTIFICATION; INTRACRANIAL-PRESSURE; EUROPEAN-ASSOCIATION; AMERICAN-SOCIETY; ECHOCARDIOGRAPHY; DYSFUNCTION; RECOMMENDATIONS; DAMAGE	Background: The concept of brain-heart interaction has been described in several brain injuries. Traumatic brain injury (TBI) may also lead to cardiac dysfunction but evidences are mainly based upon experimental and clinical retrospective studies. Methods: We conducted a prospective case-control study in a level I trauma center. Twenty consecutive adult patients with severe TBI were matched according to age and gender with 20 control patients. The control group included adult patients undergoing a general anesthesia for a peripheral trauma surgery. Conventional and Speckle Tracking Echocardiography (STE) was performed within the first 24 post-traumatic hours in the TBI group and PRE/PER-operative in the control group. The primary endpoint was the left ventricle ejection fraction (LVEF) measured by the Simpson's method. Secondary endpoints included the diastolic function and the STE analysis. Results: We found similar LVEF between the TBI group and the PER-operative control group (61 % [56-76]) vs. 62 % [52-70]). LV morphological parameters and the systolic function were also similar between the two groups. Regarding the diastolic function, the isovolumic relaxation time was significantly higher in the TBI cohort (125 s [84-178] versus 107 s [83-141], p = 0.04), suggesting a subclinical diastolic dysfunction. Using STE parameters, we observed a trend toward higher strains in the TBI group but only the apical circumferential strain and the basal rotation reached statistical significance. STE-derived parameters of the diastolic function tended to be lower in TBI patients. Discussion: No systematic myocardial depression was found in a cohort of severe TBI patients. Conclusions: STE revealed a correct adaptation of the left systolic function, while the diastolic function slightly impaired.	[Cuisinier, Adrien; Payen, Jean-Francois; Bouzat, Pierre] Ctr Hosp Univ Grenoble, Pole Anesthesie Reanimat, Hop Albert Michallon, BP 217,CS 10217, F-38043 Grenoble, France; [Maufrais, Claire] Univ Fribourg, Lab Integrat Cardiovasc & Metab Physiol, Dept Med, Div Physiol, Fribourg, Switzerland; [Nottin, Stephane; Walther, Guillaume] Avignon Univ, LAPEC EA4278, F-84000 Avignon, France; [Payen, Jean-Francois; Bouzat, Pierre] Grenoble Inst Neurosci, INSERM, U1216, F-38043 Grenoble, France; [Payen, Jean-Francois; Bouzat, Pierre] Grenoble Alpes Univ, F-38043 Grenoble, France	Bouzat, P (corresponding author), Ctr Hosp Univ Grenoble, Pole Anesthesie Reanimat, Hop Albert Michallon, BP 217,CS 10217, F-38043 Grenoble, France.; Bouzat, P (corresponding author), Grenoble Inst Neurosci, INSERM, U1216, F-38043 Grenoble, France.	PBouzat@chu-grenoble.fr	Bouzat, Pierre/AAC-4105-2019; Payen, Jean-Francois/L-6667-2014; Bouzat, Pierre/L-6881-2014	Bouzat, Pierre/0000-0003-4667-6738; 	public source (Grenoble University Hospital, France)	the study was funded by public source (Grenoble University Hospital, France).	Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; Bahloul M, 2006, AM J CRIT CARE, V15, P462; Blanc C, 2015, EUR NEUROL, V74, P163, DOI 10.1159/000440717; Cinotti R, 2016, INTENS CARE MED, V42, P173, DOI 10.1007/s00134-015-4106-5; Fang ZY, 2004, CLIN SCI, V106, P53, DOI 10.1042/CS20030153; Huang CC, 2012, AM J EMERG MED, V30, P732, DOI 10.1016/j.ajem.2011.05.003; KOLIN A, 1984, STROKE, V15, P990, DOI 10.1161/01.STR.15.6.990; Kopelnik A, 2005, NEUROCRIT CARE, V3, P132, DOI 10.1385/NCC:3:2:132; Kraigher-Krainer E, 2014, J AM COLL CARDIOL, V63, P447, DOI 10.1016/j.jacc.2013.09.052; Krishnamoorthy Vijay, 2015, Int J Crit Illn Inj Sci, V5, P103, DOI 10.4103/2229-5151.158409; Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005; Lang RM, 2015, EUR HEART J-CARD IMG, V16, P233, DOI 10.1093/ehjci/jev014; Le Ven F, 2011, INT J CARDIOL, V146, P475, DOI 10.1016/j.ijcard.2010.12.028; Mashaly Hazem Antar, 2008, Cleve Clin J Med, V75 Suppl 2, pS26; Mertes PM, 2012, ANN FR ANESTH, V31, P91; Moussouttas M, 2012, NEUROCRIT CARE, V16, P381, DOI 10.1007/s12028-012-9673-5; Najafipour Hamid, 2014, Iranian Biomedical Journal, V18, P225, DOI 10.6091/ibj.13222.2014; OPPENHEIMER SM, 1992, NEUROL CLIN, V10, P167; Patel MB, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-177; Prathep S, 2014, CRIT CARE MED, V42, P142, DOI 10.1097/CCM.0b013e318298a890; Qian R, 2015, AM J CARDIOVASC DIS, V5, P72; Riera M, 2010, J TRAUMA, V68, P13; Salim A, 2008, J TRAUMA, V64, P46, DOI 10.1097/TA.0b013e31815eb15a; Schmidt EA, 2005, ACTA NEUROCHIR SUPPL, V95, P253; Shahul S, 2015, ANESTH ANALG, V121, P1547, DOI 10.1213/ANE.0000000000000943; SHANLIN RJ, 1988, J AM COLL CARDIOL, V12, P727, DOI 10.1016/S0735-1097(88)80065-2; SHIVALKAR B, 1993, CIRCULATION, V87, P230, DOI 10.1161/01.CIR.87.1.230; Tamaki T, 2004, BRIT J NEUROSURG, V18, P158, DOI 10.1080/02688690410001681019; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; Yamamoto Takeshi, 2014, Masui, V63, P954	30	14	15	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	OCT 28	2016	24								129	10.1186/s13049-016-0323-3			7	Emergency Medicine	Emergency Medicine	EA8BL	WOS:000386860200002	27793208	DOAJ Gold, Green Published			2021-06-18	
J	Si, Y; Zhang, Y; Han, L; Chen, LH; Xu, YJ; Sun, F; Ji, MH; Yang, JJ; Bao, HG				Si, Yanna; Zhang, Yuan; Han, Liu; Chen, Lihai; Xu, Yajie; Sun, Fan; Ji, Muhuo; Yang, Jianjun; Bao, Hongguang			Dexmedetomidine Acts via the JAK2/STAT3 Pathway to Attenuate Isoflurane-Induced Neurocognitive Deficits in Senile Mice	PLOS ONE			English	Article							POSTOPERATIVE COGNITIVE DYSFUNCTION; NEUROTROPHIC FACTOR EXPRESSION; NITROUS OXIDE ANESTHESIA; TRAUMATIC BRAIN-INJURY; MEMORY IMPAIRMENT; MITOCHONDRIAL MECHANISMS; AMBULATORY ANESTHESIA; DESFLURANE ANESTHESIA; POSTNATAL MEMORY; MOUSE MODEL	Background Previous studies showed that isoflurane-induced cognitive deficits could be alleviated by dexmedetomidine in young animal subjects. In the current study, we examine whether dexmedetomidine could also alleviate isoflurane-induced cognitive deficits in senile animals. Methods Senile male C57BL/6 mice (20 months) received dexmedetomidine (50 mu g/kg, i.p.) or vehicle 30 minutes prior to isoflurane exposure (1.3% for 4 h). Cognitive function was assessed 19 days later using a 5-day testing regimen with Morris water maze. Some subjects also received pretreatment with alpha 2 adrenoreceptor antagonist atipamezole (250 mu g/kg, i.p.), JAK2 inhibitor AG490 (15 mg/kg i.p.) or STAT3 inhibitor WP1066 (40 mg/kg i.p.) 30 minutes prior to dexmedetomidine. Results Isoflurane exposure increased and reduced the time spent in the quadrant containing the target platform in training sessions. The number of crossings over the original target quadrant was also decreased. Dexmedotomidine attenuated such effects. Effects of dexmedotomidine were reduced by pretreatment with atipamezole, AG490 and WP1066. Increased phosphorylation of JAK2 and STAT3 in the hippocampus induced by isoflurane was augmented by dexmedetomidine. Effects of dexmedetomidine on JAK2/STAT3 phosphorylation were attenuated by atipamezole, AG490 and WP1066. Isoflurane promoted neuronal apoptosis and increased the expression of cleaved caspase-3 and BAD, and reduced Bcl-2 expression. Attenuation of such effects by dexmedotomidine was partially blocked by atipamezole, AG490 and WP1066. Conclusion Dexmedetomidine could protect against isoflurane-induced spatial learning and memory impairment in senile mice by stimulating the JAK2/STAT3 signaling pathway. Such findings encourage the use of dexmedetomidine in geriatric patients receiving isoflurane anesthesia.	[Si, Yanna; Zhang, Yuan; Han, Liu; Chen, Lihai; Xu, Yajie; Sun, Fan; Bao, Hongguang] Nanjing Med Univ, Nanjing Hosp 1, Dept Anesthesiol, Nanjing, Jiangsu, Peoples R China; [Ji, Muhuo; Yang, Jianjun] Southeast Univ, Sch Med, Zhongda Hosp, Dept Anesthesiol, Nanjing, Jiangsu, Peoples R China; [Ji, Muhuo; Yang, Jianjun] Xuzhou Med Coll, Coll Anesthesiol, Jiangsu Prov Key Lab Anesthesiol, Xuzhou, Jiangsu, Peoples R China	Bao, HG (corresponding author), Nanjing Med Univ, Nanjing Hosp 1, Dept Anesthesiol, Nanjing, Jiangsu, Peoples R China.	hongguang_bao@hotmail.com	Yang, Jianjun/AAN-4960-2021		Medical Development Project of Nanjing Science Committee [YKK12085]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81401620]; Jiangsu Provincial Special Program of Medical Science [BL2014012]	This work was supported by grants to YNS from the Medical Development Project of Nanjing Science Committee (YKK12085) and the National Natural Science Foundation of China (81401620), and grant to HGB from Jiangsu Provincial Special Program of Medical Science (BL2014012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by grants to YNS from the Medical Development Project of Nanjing Science Committee (YKK12085) and the National Natural Science Foundation of China (81401620), and grant to HGB from Jiangsu Provincial Special Program of Medical Science (BL2014012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams R, 2013, BRIT J ANAESTH, V111, P703, DOI 10.1093/bja/aet194; Alonzi T, 2001, MOL CELL NEUROSCI, V18, P270, DOI 10.1006/mcne.2001.1018; BEDFORD PD, 1955, LANCET, V2, P259; Bianchi SL, 2008, NEUROBIOL AGING, V29, P1002, DOI 10.1016/j.neurobiolaging.2007.02.009; Callaway JK, 2015, J ALZHEIMERS DIS, V44, P995, DOI 10.3233/JAD-132444; Cao L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051431; Chen JJ, 2013, EXP THER MED, V5, P489, DOI 10.3892/etm.2012.811; Chen WJ, 2015, INT J CLIN EXP MED, V8, P4601; Chiba T, 2009, MOL PSYCHIATR, V14, P206, DOI 10.1038/mp.2008.105; Chiba T, 2009, EXPERT OPIN THER TAR, V13, P1155, DOI 10.1517/14728220903213426; Culley DJ, 2004, ANESTH ANALG, V99, P1393, DOI 10.1213/01.ANE.0000135408.14319.CC; Culley DJ, 2004, ANESTHESIOLOGY, V100, P309, DOI 10.1097/00000542-200402000-00020; Darcet F, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00136; Engelhard K, 2003, ANESTH ANALG, V96, P524, DOI 10.1097/00000539-200302000-00041; Fiskum G, 2003, ANN NY ACAD SCI, V991, P111; Gerlai R, 2002, NEUROPHARMACOLOGY, V43, P235, DOI 10.1016/S0028-3908(02)00078-3; Guo ZH, 2008, J BIOL CHEM, V283, P1754, DOI 10.1074/jbc.M703753200; Hwang L, 2013, INT J MOL MED, V31, P1047, DOI 10.3892/ijmm.2013.1301; Izquierdo I, 1999, BEHAV BRAIN RES, V103, P1, DOI 10.1016/S0166-4328(99)00036-4; Kong FJ, 2012, BIOCHEM PHARMACOL, V84, P558, DOI 10.1016/j.bcp.2012.06.001; Kong FJ, 2011, EUR J PHARMACOL, V670, P168, DOI 10.1016/j.ejphar.2011.08.050; Lee B, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-338; Lee BH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105340; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Li XM, 2014, J MOL NEUROSCI, V52, P286, DOI 10.1007/s12031-013-0141-2; Li YG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111707; Li YJ, 2013, NEUROSCI LETT, V545, P17, DOI 10.1016/j.neulet.2013.04.008; Liang G, 2008, ANESTH ANALG, V106, P492, DOI 10.1213/ane.0b013e3181605b71; Lin DW, 2012, BEHAV BRAIN RES, V228, P319, DOI 10.1016/j.bbr.2011.12.010; Lindqvist M, 2014, ACTA ANAESTH SCAND, V58, P1111, DOI 10.1111/aas.12381; Ma DQ, 2004, EUR J PHARMACOL, V502, P87, DOI 10.1016/j.ejphar.2004.08.044; Mahajan VA, 2007, EUR J ANAESTH, V24, P505, DOI 10.1017/S0265021506001980; Makkar JK, 2016, ANAESTHESIA, V71, P50, DOI 10.1111/anae.13230; Mason SE, 2010, J ALZHEIMERS DIS, V22, pS67, DOI 10.3233/JAD-2010-101086; Monk TG, 2008, ANESTHESIOLOGY, V108, P18, DOI 10.1097/01.anes.0000296071.19434.1e; Negoro S, 2000, CARDIOVASC RES, V47, P797, DOI 10.1016/S0008-6363(00)00138-3; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Ren XY, 2016, J NEUROIMMUNE PHARM, V11, P238, DOI 10.1007/s11481-016-9658-9; Sanders RD, 2010, ACTA ANAESTH SCAND, V54, P710, DOI 10.1111/j.1399-6576.2009.02177.x; Sanders RD, 2009, ANESTHESIOLOGY, V110, P1077, DOI 10.1097/ALN.0b013e31819daedd; Shyu WC, 2008, J CLIN INVEST, V118, P133, DOI 10.1172/JCI32723; Steinmetz J, 2009, ANESTHESIOLOGY, V110, P548, DOI 10.1097/ALN.0b013e318195b569; Tramullas M, 2008, NEUROPHARMACOLOGY, V54, P640, DOI 10.1016/j.neuropharm.2007.11.018; Tyler WJ, 2002, LEARN MEMORY, V9, P224, DOI 10.1101/lm.51202; Uchimoto K, 2014, ANESTHESIOLOGY, V121, P302, DOI 10.1097/ALN.0000000000000269; Wang YJ, 2016, MOL MED REP, V14, P769, DOI 10.3892/mmr.2016.5321; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Yang H, 2008, ANESTHESIOLOGY, V109, P243, DOI 10.1097/ALN.0b013e31817f5c47; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Yon JH, 2005, NEUROSCIENCE, V135, P815, DOI 10.1016/j.neuroscience.2005.03.064; Zhang F, 2014, EXP THER MED, V8, P471, DOI 10.3892/etm.2014.1769; Zhang Q, 2012, CHINESE MED J-PEKING, V125, P2455, DOI 10.3760/cma.j.issn.0366-6999.2012.14.011; Zhang Y, 2003, J NEUROCHEM, V87, P1184, DOI 10.1046/j.1471-4159.2003.02105.x; Zhang YY, 2012, ANN NEUROL, V71, P687, DOI 10.1002/ana.23536; Zhang ZH, 2014, BRAIN RES, V1563, P72, DOI 10.1016/j.brainres.2014.03.036; Zhao H, 2003, J NEUROCHEM, V85, P1026, DOI 10.1046/j.1471-4159.2003.01756.x; Zhou TF, 2013, J SURG RES, V183, P304, DOI 10.1016/j.jss.2012.11.035	58	14	15	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2016	11	10							e0164763	10.1371/journal.pone.0164763			16	Multidisciplinary Sciences	Science & Technology - Other Topics	DZ9OE	WOS:000386205400027	27768775	DOAJ Gold, Green Published			2021-06-18	
J	Perez-Garcia, G; Sosa, MAG; De Gasperi, R; Lashof-Sullivan, M; Maudlin-Jeronimo, E; Stone, JR; Haghighi, F; Ahlers, ST; Elder, GA				Perez-Garcia, Georgina; Sosa, Miguel A. Gama; De Gasperi, Rita; Lashof-Sullivan, Margaret; Maudlin-Jeronimo, Eric; Stone, James R.; Haghighi, Fatemeh; Ahlers, Stephen T.; Elder, Gregory A.			Exposure to a Predator Scent Induces Chronic Behavioral Changes in Rats Previously Exposed to Low-level Blast: Implications for the Relationship of Blast-Related TBI to PTSD	FRONTIERS IN NEUROLOGY			English	Article						animal models; blast; postconcussion syndrome; post-traumatic stress disorder; rat; traumatic brain injury	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; ANIMAL-MODEL; OVERPRESSURE; VETERANS; RISK; CARE	Blast-related mild traumatic brain injury (mTBI) has been unfortunately common in veterans who served in the recent conflicts in Iraq and Afghanistan. The postconcussion syndrome associated with these mTBIs has frequently appeared in combination with post-traumatic stress disorder (PTSD). The presence of PTSD has complicated diagnosis, since clinically, PTSD and the postconcussion syndrome of mTBI have many overlapping symptoms. In particular, establishing how much of the symptom complex can be attributed to the psychological trauma associated with PTSD in contrast to the physical injury of traumatic brain injury has proven difficult. Indeed, some have suggested that much of what is now being called blast-related postconcussion syndrome is better explained by PTSD. The relationship between the postconcussion syndrome of mTBI and PTSD is complex. Association of the two disorders might be viewed as additive effects of independent psychological and physical traumas suffered in a war zone. However, we previously found that rats exposed to repetitive low-level blast exposure in the absence of a psychological stressor developed a variety of anxiety and PTSD-related behavioral traits that were present months following the last blast exposure. Here, we show that a single predator scent challenge delivered 8 months after the last blast exposure induces chronic anxiety related changes in blast-exposed rats that are still present 45 days later. These observations suggest that in addition to independently inducing PTSD-related traits, blast exposure sensitizes the brain to react abnormally to a subsequent psychological stressor. These studies have implications for conceptualizing the relationship between blast-related mTBI and PTSD and suggest that blast-related mTBI in humans may predispose to the later development of PTSD in reaction to subsequent psychological stressors.	[Perez-Garcia, Georgina; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Perez-Garcia, Georgina; Sosa, Miguel A. Gama; De Gasperi, Rita; Haghighi, Fatemeh] James J Peters Dept Vet Affairs Med Ctr, Res & Dev Serv, Bronx, NY USA; [Perez-Garcia, Georgina; Sosa, Miguel A. Gama; De Gasperi, Rita; Haghighi, Fatemeh; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA; [Sosa, Miguel A. Gama; De Gasperi, Rita; Haghighi, Fatemeh; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Lashof-Sullivan, Margaret; Maudlin-Jeronimo, Eric; Ahlers, Stephen T.] Naval Med Res Ctr, Dept Neurotrauma Operat & Undersea Med, Silver Spring, MD USA; [Stone, James R.] Univ Virginia, Dept Radiol & Med Imaging, Charlottesville, VA USA; [Stone, James R.] Univ Virginia, Dept Neurosurg, Charlottesville, VA USA; [Haghighi, Fatemeh] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA; [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY 10468 USA	Elder, GA (corresponding author), Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.; Elder, GA (corresponding author), Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.; Elder, GA (corresponding author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Elder, GA (corresponding author), James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY 10468 USA.	gregory.elder@va.gov			NMRCNational Medical Research Council, Singapore [0000B999.0000.000.A1503]; Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service AwardUS Department of Veterans Affairs [1I01RX000996-01]; Veterans AffairsUS Department of Veterans Affairs [I01RX001705, I01RX000996] Funding Source: NIH RePORTER	This work was supported by NMRC work unit number 0000B999.0000.000.A1503 and by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Award 1I01RX000996-01. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the U.S. Government. ML-S, EM-J, and SA are military service members (or employees of the U.S. Government). This work was prepared as part of their official duties. Title 17 U.S.C. 105 provides that copyright protection under this title is not available for any work of the United States Government. Title 17 U.S.C. 101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person's official duties.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Carr W, 2016, MIL MED, V181, P28, DOI 10.7205/MILMED-D-15-00137; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Cohen H, 2004, ANN NY ACAD SCI, V1032, P167, DOI 10.1196/annals.1314.014; Cohen H, 2014, EUR NEUROPSYCHOPHARM, V24, P1925, DOI 10.1016/j.euroneuro.2014.09.009; De Gasperi Rita, 2012, Front Neurol, V3, P177, DOI 10.3389/fneur.2012.00177; Elder GA, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0591-8; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Fenchel D, 2015, EUR NEUROPSYCHOPHARM, V25, P944, DOI 10.1016/j.euroneuro.2015.02.004; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Goswami S, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00089; Haghighi F, 2015, J NEUROTRAUM, V32, P1200, DOI 10.1089/neu.2014.3640; Harvey AG, 2003, J INT NEUROPSYCH SOC, V9, P663, DOI 10.1017/S1355617703940069; Heldt SA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00002; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Institute of Medicine, 2014, GULF WAR HLTH LONG T; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Joseph S, 1999, J TRAUMA STRESS, V12, P437, DOI 10.1023/A:1024762919372; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Kobeissy F, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00186; Koenigs M, 2008, NAT NEUROSCI, V11, P232, DOI 10.1038/nn2032; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; Mahan AL, 2012, TRENDS NEUROSCI, V35, P24, DOI 10.1016/j.tins.2011.06.007; Ojo JO, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00213; Panzer MB, 2014, EXP NEUROL, V261, P120, DOI 10.1016/j.expneurol.2014.07.002; Saridogan GE, 2015, BEHAV BRAIN RES, V293, P227, DOI 10.1016/j.bbr.2015.07.050; Shumyatsky GP, 2005, CELL, V123, P697, DOI 10.1016/j.cell.2005.08.038; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Zuckerman A, 2017, J NEUROTRAUM, V34, P145, DOI 10.1089/neu.2015.4310	39	14	14	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	OCT 18	2016	7								176	10.3389/fneur.2016.00176			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DZ2BL	WOS:000385647000001	27803688	DOAJ Gold, Green Published			2021-06-18	
J	Du, LN; Empey, PE; Ji, J; Chao, HL; Kochanek, PM; Bayir, H; Clark, RSB				Du, Lina; Empey, Philip E.; Ji, Jing; Chao, Honglu; Kochanek, Patrick M.; Bayir, Hulya; Clark, Robert S. B.			Probenecid and N-Acetylcysteine Prevent Loss of Intracellular Glutathione and Inhibit Neuronal Death after Mechanical Stretch Injury In Vitro	JOURNAL OF NEUROTRAUMA			English	Article						adenosine triphosphate binding cassette transporter C1; gender; multidrug resistance associated protein 1; primary cortical neurons; spinal cord injury; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CORTICAL-NEURONS; MICE; NEUROPROTECTION; APOPTOSIS; INFLAMMASOME; TRANSPORTER; PROTECTS; DAMAGE; RATS	Probenecid and N-acetylcysteine (NAC) can preserve intracellular levels of the vital antioxidant glutathione (GSH) via two distinct biochemical pathways. Probenecid inhibits transporter-mediated GSH efflux and NAC serves as a cysteine donor for GSH synthesis. We hypothesized that probenecid and NAC alone would maintain intracellular GSH concentrations and inhibit neuronal death after traumatic stretch injury, and that the drugs in combination would produce additive effects. Sex-segregated rat primary cortical neurons were treated with probenecid (100M) and NAC (50M), alone and in combination (Pro-NAC), then subjected to mechanical stretch (10s(-1) strain rate, 50% membrane deformation). At 24h, both probenecid and NAC inhibited trauma-induced intracellular GSH depletion, lactate dehydrogenase (LDH) release, and propidium iodide (PI) uptake in both XY- and XX-neurons. Combined Pro-NAC treatment was superior to probenecid or NAC alone in maintenance of intracellular GSH and neuronal death assessed by PI uptake. Interestingly, caspase 3 activity 24h after mechanical trauma was more prominent in XX-neurons, and treatment effects (probenecid, NAC, and Pro-NAC) were observed in XX- but not XY-neurons; however, XY-neurons were ultimately more vulnerable to mechanical stretch-induced injury than their XX counterparts, as was evidenced by more neuronal death detected by LDH release and PI uptake. In addition, after stretch injury in HT22 hippocampal cells, both NAC and probenecid were highly effective at reducing oxidative stress detected by dichlorofluorescein fluorescence. These in vitro data support further testing of this drug combination in models of traumatic neuronal injury in vivo.	[Du, Lina; Ji, Jing; Chao, Honglu; Kochanek, Patrick M.; Bayir, Hulya; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Kochanek, Patrick M.; Bayir, Hulya; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA USA; [Empey, Philip E.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA; [Empey, Philip E.; Clark, Robert S. B.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA; [Ji, Jing] Nanjing Med Univ, Dept Neurosurg, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China; [Kochanek, Patrick M.; Bayir, Hulya; Clark, Robert S. B.] Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Kochanek, Patrick M.; Bayir, Hulya; Clark, Robert S. B.] Childrens Hosp Pittsburgh UPMC, Pittsburgh, PA USA; [Bayir, Hulya] Univ Pittsburgh, Ctr Free Radical & Antioxidant Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA USA	Clark, RSB (corresponding author), Childrens Hosp Pittsburgh, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	clarkrs@ccm.upmc.edu	Empey, Philip/L-9604-2019	Empey, Philip/0000-0001-7474-2339			Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; BOGER WP, 1950, J LAB CLIN MED, V36, P276; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Cole SPC, 2014, J BIOL CHEM, V289, P30880, DOI 10.1074/jbc.R114.609248; Decory HH, 2001, DRUG METAB DISPOS, V29, P1256; Du L, 2009, J BIOL CHEM, V284, P2383, DOI 10.1074/jbc.M804396200; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Eakin K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090617; FRISK AR, 1952, SCAND J CLIN LAB INV, V4, P83, DOI 10.3109/00365515209060641; Guo J, 2015, MOL MED REP, V12, P37, DOI 10.3892/mmr.2015.3390; Hammond CL, 2007, J BIOL CHEM, V282, P14337, DOI 10.1074/jbc.M611019200; Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Ji J, 2012, J NEUROTRAUM, V29, P776, DOI 10.1089/neu.2010.1602; Kanter MZ, 2006, AM J HEALTH-SYST PH, V63, P1821, DOI 10.2146/ajhp060050; Karalija A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041086; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Naziroglu M, 2013, NEUROSCIENCE, V242, P151, DOI 10.1016/j.neuroscience.2013.03.032; Naziroglu M, 2014, CELL MOL NEUROBIOL, V34, P895, DOI 10.1007/s10571-014-0069-2; Nigam SK, 2015, PHYSIOL REV, V95, P83, DOI 10.1152/physrev.00025.2013; Pandya JD, 2014, EXP NEUROL, V257, P106, DOI 10.1016/j.expneurol.2014.04.020; Samuni Y, 2013, BBA-GEN SUBJECTS, V1830, P4117, DOI 10.1016/j.bbagen.2013.04.016; Silverman WR, 2009, J BIOL CHEM, V284, P18143, DOI 10.1074/jbc.M109.004804; Smith DH, 1999, J NEUROSCI, V19, P4263; Sun HY, 2001, PHARM RES-DORDR, V18, P1542, DOI 10.1023/A:1013074229576; Vanden Berghe T, 2014, NAT REV MOL CELL BIO, V15, P134, DOI 10.1038/nrm3737; Wei R, 2015, NEUROSCIENCE, V301, P168, DOI 10.1016/j.neuroscience.2015.05.070; Willyerd FA, 2016, J NEUROTRAUM, V33, P226, DOI 10.1089/neu.2015.3879; Xiong XX, 2014, NEUROCHEM RES, V39, P216, DOI 10.1007/s11064-013-1212-z; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067	31	14	14	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2016	33	20					1913	1917		10.1089/neu.2015.4342			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EA6YO	WOS:000386775300011	26830358	Green Published			2021-06-18	
J	Effgen, GB; Ong, T; Nammalwar, S; Ortuno, AI; Meaney, DF; Bass, CRD; Morrison, B				Effgen, Gwen B.; Ong, Tiffany; Nammalwar, Shruthi; Ortuno, Andrea I.; Meaney, David F.; Bass, Cameron R.Dale; Morrison, Barclay, III			Primary Blast Exposure Increases Hippocampal Vulnerability to Subsequent Exposure: Reducing Long-Term Potentiation	JOURNAL OF NEUROTRAUMA			English	Article						blast; brain; glia neuron; plasticity	TRAUMATIC BRAIN-INJURY; FLUID PERCUSSION INJURY; ADULT-RAT BRAIN; IN-VITRO MODEL; COGNITIVE IMPAIRMENT; AXONAL INJURY; CELL-DEATH; RECURRENT CONCUSSION; SYNAPTIC PLASTICITY; MICROGLIAL CELLS	Up to 80% of injuries sustained by U.S. soldiers in Operation Enduring Freedom and Operation Iraqi Freedom were the result of blast exposure from improvised explosive devices. Some soldiers experience multiple blasts while on duty, and it has been suggested that symptoms of repetitive blast are similar to those that follow multiple non-blast concussions, such as sport-related concussion. Despite the interest in the effects of repetitive blast exposure, it remains unknown whether an initial blast renders the brain more vulnerable to subsequent exposure, resulting in a synergistic injury response. To investigate the effect of multiple primary blasts on the brain, organotypic hippocampal slice cultures were exposed to single or repetitive (two or three total) primary blasts of varying intensities. Long-term potentiation was significantly reduced following two Level 2 (92.7kPa, 1.4msec, 38.5kPa<bold>msec</bold>) blasts delivered 24h apart without altering basal evoked response. This deficit persisted when the interval between injuries was increased to 72h but not when the interval was extended to 144h. The repeated blast exposure with a 24h interval increased microglia staining and activation significantly but did not significantly increase cell death or damage axons, dendrites, or principal cell layers. Lack of overt structural damage and change in basal stimulated neuron response suggest that injury from repetitive primary blast exposure may specifically affect long-term potentiation. Our studies suggest repetitive primary blasts can exacerbate injury dependent on the injury severity and interval between exposures.	[Effgen, Gwen B.; Ong, Tiffany; Nammalwar, Shruthi; Ortuno, Andrea I.; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, 351 Engn Terrace,MC 8904 1210 Amsterdam Ave, New York, NY 10027 USA; [Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Bass, Cameron R.Dale] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA	Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, 351 Engn Terrace,MC 8904 1210 Amsterdam Ave, New York, NY 10027 USA.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Meaney, David/0000-0002-0954-4122	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS088176] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088176] Funding Source: NIH RePORTER		Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Ahmed FA, 2013, ELECTROPHORESIS, V34, P2229, DOI 10.1002/elps.201300077; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Appelboom G, 2012, ACTA NEUROCHIR, V154, P131, DOI 10.1007/s00701-011-1210-3; Arun P, 2012, NEUROREPORT, V23, P342, DOI 10.1097/WNR.0b013e328351b58d; Arun P, 2011, NEUROREPORT, V22, P379, DOI 10.1097/WNR.0b013e328346b138; Aungst S. L., 2014, J CEREB BLOOD FLOW M, P1223; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Centers for Disease Control and Prevention, 2009, BLAST INJ TRAUM BRAI; CLEMEDSON CJ, 1956, AM J PHYSIOL, V184, P119, DOI 10.1152/ajplegacy.1955.184.1.119; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Czapiga M, 1999, J NEUROSCI RES, V56, P644, DOI 10.1002/(SICI)1097-4547(19990615)56:6<644::AID-JNR10>3.3.CO;2-0; De Monte VE, 2005, J CLIN EXP NEUROPSYC, V27, P224, DOI 10.1080/13803390490515766; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Effgen G. B., 2012, 2012 INT IRCOBI C BI; Effgen GB, 2014, J NEUROTRAUM, V31, P1202, DOI 10.1089/neu.2013.3227; Effgen Gwen B, 2012, Front Neurol, V3, P23, DOI 10.3389/fneur.2012.00023; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Evilsizor M. N., 2015, BRAIN NEUROTRAUMA MO, P9; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FISCHER HANNAH, 2015, GUIDE US MILITARY CA; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Girard J, 1996, EUR J PHARMACOL, V300, P43, DOI 10.1016/0014-2999(95)00804-7; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gullotti DM, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027873; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hailer NP, 1996, GLIA, V18, P319, DOI 10.1002/(SICI)1098-1136(199612)18:4<319::AID-GLIA6>3.0.CO;2-S; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Hue C. D., 2015, J NEUROTRAUMA; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Kane MJ, 2011, BRAIN RES, V1425, P123, DOI 10.1016/j.brainres.2011.09.047; Kang WH, 2015, BIOMECH MODEL MECHAN, V14, P561, DOI 10.1007/s10237-014-0622-4; Katz J. M., 2015, NEW YORK TIMES; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Leonardi AD, 2012, J BIOMECH, V45, P2595, DOI 10.1016/j.jbiomech.2012.08.024; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Panizzon KL, 1996, NEUROREPORT, V7, P662, DOI 10.1097/00001756-199601310-00067; Panizzon KL, 1998, NEUROREPORT, V9, P4131, DOI 10.1097/00001756-199812210-00024; Panzer Matthew B, 2012, Front Neurol, V3, P46, DOI 10.3389/fneur.2012.00046; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Rafaels K., 2015, J NEUROTRAUM, p[28, 2319]; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Ryu J, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0153-3; Sajja VSSS, 2014, NEUROSCI LETT, V570, P33, DOI 10.1016/j.neulet.2014.03.072; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Schafer DP, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020545; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Slemmer JE, 2005, NEUROBIOL DIS, V18, P421, DOI 10.1016/j.nbd.2004.09.022; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; Tremblay ME, 2011, J NEUROSCI, V31, P16064, DOI 10.1523/JNEUROSCI.4158-11.2011; U. S. Dept of the Army F-22, 2007, INF RIFL PLAT SQUAD; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Vogel III E. W., 2015, J NEUROTRAUMA; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; Wallis RA, 1995, EUR J PHARMACOL, V294, P475, DOI 10.1016/0014-2999(95)00568-4; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Xing GQ, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00196; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030; Yu GX, 2011, SURGERY, V150, P887, DOI 10.1016/j.surg.2011.04.002; Yu Z, 2009, IEEE ENG MED BIO, P1135; Yuste R, 2001, ANNU REV NEUROSCI, V24, P1071, DOI 10.1146/annurev.neuro.24.1.1071; Zoroya G., 2015, US TODAY	86	14	14	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2016	33	20					1901	1912		10.1089/neu.2015.4327			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EA6YO	WOS:000386775300010	26699926	Green Published			2021-06-18	
J	Tweedie, D; Rachmany, L; Kim, DS; Rubovitch, V; Lehrmann, E; Zhang, YQ; Becker, KG; Perez, E; Pick, CG; Greig, NH				Tweedie, David; Rachmany, Lital; Kim, Dong Seok; Rubovitch, Vardit; Lehrmann, Elin; Zhang, Yongqing; Becker, Kevin G.; Perez, Evelyn; Pick, Chaim G.; Greig, Nigel H.			Mild traumatic brain injury-induced hippocampal gene expressions: The identification of target cellular processes for drug development	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Mild traumatic brain injury (mTBI); Gene expression; Gene ontology; Molecular pathway; Inflammation; Neurological; Neurodegeneration; Dementia	GLUCAGON-LIKE PEPTIDE-1; REVERSES BEHAVIORAL IMPAIRMENTS; RECEPTOR AGONIST; HEAD-INJURY; DONEPEZIL; ALZHEIMERS; EXENDIN-4; DEATH; NEURODEGENERATION; NEURONS	Background: Neurological dysfunction after traumatic brain injury (TBI) poses short-term or long-lasting health issues for family members and health care providers. Presently there are no approved medicines to treat TBI. Epidemiological evidence suggests that TBI may cause neurodegenerative disease later in life. In an effort to illuminate target cellular processes for drug development, we examined the effects of a mild TBI on hippocampal gene expression in mouse. Methods: mTBI was induced in a closed head, weight drop-system in mice (ICR). Animals were anesthetized and subjected to mTBI (30 g). Fourteen days after injury the ipsilateral hippocampus was utilized for cDNA gene array studies. mTBI animals were compared with sham-operated animals. Genes regulated by TBI were identified to define TBI-induced physiological/pathological processes. mTBI regulated genes were divided into functional groupings to provide gene ontologies. Genes were further divided to identify molecular/cellular pathways regulated by mTBI. Results: Numerous genes were regulated after a single mTBI event that mapped to many ontologies and molecular pathways related to inflammation and neurological physiology/pathology, including neurodegenerative disease. Conclusions: These data illustrate diverse transcriptional changes in hippocampal tissues triggered by a single mild injury. The systematic analysis of individual genes that lead to the identification of functional categories, such as gene ontologies and then molecular pathways, illustrate target processes of relevance to TBI pathology. These processes may be further dissected to identify key factors that can be evaluated at the protein level to highlight possible treatments for TBI in human disease and potential biomarkers of neurodegenerative processes. Published by Elsevier B.V.	[Tweedie, David; Kim, Dong Seok; Greig, Nigel H.] NIA, Translat Gerontol Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Rachmany, Lital; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel; [Kim, Dong Seok] Peptron Inc, 37-24 Yuseong Daero,1628 Beon Gil, Daejeon 305811, South Korea; [Lehrmann, Elin; Zhang, Yongqing; Becker, Kevin G.] NIA, Genet Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Perez, Evelyn] NIA, Lab Behav Neurosci, Intramural Res Program, NIH, Baltimore, MD 21224 USA	Tweedie, D (corresponding author), NIA, Translat Gerontol Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA.	tweedieda@grc.nia.nih.gov		Lehrmann, Elin/0000-0002-9869-9475	Intramural Research Program of the National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Sackler School of Medicine, Tel-Aviv University; Ari and Regine Aprijaskis Fund at Tel-Aviv University; Israel Science FoundationIsrael Science Foundation [108/09]; Joseph Sagol fellowships; National Science Council of TaiwanMinistry of Science and Technology, Taiwan; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000333, ZIAAG000311, ZICAG000616] Funding Source: NIH RePORTER	This research was supported in part by (i) the Intramural Research Program of the National Institute on Aging, National Institutes of Health, (ii) the Sackler School of Medicine, Tel-Aviv University, (iii) the Ari and Regine Aprijaskis Fund at Tel-Aviv University, (iv) a grant from the Israel Science Foundation, grant number 108/09, (v) and the Joseph Sagol fellowships and (vi) the National Science Council of Taiwan. This work was performed in partial fulfillment of the requirements for a Ph.D. degree of Lital Rachmany, Sackler Faculty of Medicine, Tel Aviv University, Israel. None of the authors have competing interests in the manuscript.	Azevedo FAC, 2009, J COMP NEUROL, V513, P532, DOI 10.1002/cne.21974; Ballesteros J, 2008, J HEAD TRAUMA REHAB, V23, P171, DOI 10.1097/01.HTR.0000319935.99837.96; Baratz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0237-4; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Becker RE, 2015, LANCET PSYCHIAT, V2, P756, DOI 10.1016/S2215-0366(15)00214-X; Becker RE, 2014, NAT REV DRUG DISCOV, V13, P157, DOI 10.1038/nrd3842-c2; Becker RE, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000446; Bergold PJ, 2015, EXP NEUROL, V2, P3; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; CHOI DW, 1987, J NEUROSCI, V7, P357; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Daneshvar DH, 2015, MOL CELL NEUROSCI, V66, P81, DOI 10.1016/j.mcn.2015.03.007; Ding J, 2015, ARQ NEURO-PSIQUIAT, V73, P342, DOI 10.1590/0004-282X20150006; Eakin K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082016; Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fujiki M, 2008, J CLIN NEUROSCI, V15, P791, DOI 10.1016/j.jocn.2007.07.002; Gomez PA, 2014, J NEUROSURG, V121, P1314, DOI 10.3171/2014.7.JNS131874; Greig NH, 2014, ALZHEIMERS DEMENT, V10, pS62, DOI 10.1016/j.jalz.2013.12.011; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Gry M, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-365; Gupta R, 2015, REV NEUROSCI; Gyorgy AB, 2010, J NEUROSCI METH, V192, P96, DOI 10.1016/j.jneumeth.2010.07.029; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; Holscher C, 2014, BIOCHEM SOC T, V42, P593, DOI 10.1042/BST20140016; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kim SY, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-144; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Korley FK, 2015, J HEAD TRAUMA REHABI; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Lent R, 2012, EUR J NEUROSCI, V35, P1, DOI 10.1111/j.1460-9568.2011.07923.x; Li YZ, 2015, J NEUROCHEM, V135, P1203, DOI 10.1111/jnc.13169; Li YZ, 2010, J ALZHEIMERS DIS, V19, P1205, DOI 10.3233/JAD-2010-1314; Li YZ, 2009, P NATL ACAD SCI USA, V106, P1285, DOI 10.1073/pnas.0806720106; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maier T, 2009, FEBS LETT, V583, P3966, DOI 10.1016/j.febslet.2009.10.036; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Mukherjee S, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00021; Nakamura K, 2012, CELL, V149, P232, DOI 10.1016/j.cell.2012.02.016; Naseem Mehar, 2014, SCI WORLD J; Ozsuer H, 2005, NEUROSURG REV, V28, P143, DOI 10.1007/s10143-004-0374-1; Papa M, 2014, NEUROSCI BIOBEHAV R, V42, P35, DOI 10.1016/j.neubiorev.2014.01.010; Perry T, 2003, J NEUROSCI RES, V72, P603, DOI 10.1002/jnr.10611; Perry T, 2002, J PHARMACOL EXP THER, V302, P881, DOI 10.1124/jpet.102.037481; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Rachmany L, 2013, AGE, V35, P1621, DOI 10.1007/s11357-012-9464-0; Rao VLR, 2001, BRAIN RES, V911, P96; Salcedo I, 2012, BRIT J PHARMACOL, V166, P1586, DOI 10.1111/j.1476-5381.2012.01971.x; Shaw KE, 2013, J NEUROTRAUM, V30, P557, DOI 10.1089/neu.2012.2782; Sheth SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129735; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Stein Donald G, 2015, Handb Clin Neurol, V127, P433, DOI 10.1016/B978-0-444-52892-6.00028-3; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Taverni JP, 1998, BRAIN INJURY, V12, P77; Tuttolomondo A, 2014, DRUG DES DEV THER, V8, P2221, DOI 10.2147/DDDT.S67655; Tweedie D, 2015, ALZHEIMERS DEMENT; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Walls MK, 2015, J NEUROSURG, P1; Wang XH, 2015, BRAIN RES, V1627, P101, DOI 10.1016/j.brainres.2015.09.015; Whelan F J, 2000, Ann Clin Psychiatry, V12, P131; Xiong Y, 2015, EXPERT OPIN INV DRUG, V24, P743, DOI 10.1517/13543784.2015.1021919; Xu WJ, 2015, J INVEST MED, V63, P267, DOI 10.1097/JIM.0000000000000129; Yang LY, 2015, EXP NEUROL, V269, P56, DOI 10.1016/j.expneurol.2015.03.015; Yu TS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118793; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	76	14	14	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	OCT 15	2016	272				SI		4	18		10.1016/j.jneumeth.2016.02.003			15	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	EA6LF	WOS:000386740000002	26868732	Green Accepted			2021-06-18	
J	Vallez Garcia, D; Otte, A; Dierckx, RAJO; Doorduin, J				Vallez Garcia, David; Otte, Andreas; Dierckx, Rudi A. J. O.; Doorduin, Janine			Three Month Follow-Up of Rat Mild Traumatic Brain Injury: A Combined [F-18]FDG and [C-11]PK11195 Positron Emission Study	JOURNAL OF NEUROTRAUMA			English	Article						brain glucose metabolism; mild traumatic brain injury; neuroinflammation; PET; rat model	DIFFUSE AXONAL INJURY; IN-VIVO; MICROGLIAL ACTIVATION; F-18-FDG PET; TERM-MEMORY; HEAD-INJURY; MODEL; NEUROINFLAMMATION; DYSFUNCTION; CONCUSSION	Mild traumatic brain injury (mTBI) is the most common cause of head trauma. The time course of functional pathology is not well defined, however. The purpose of this study was to evaluate the consequences of mTBI in rats over a period of 3 months by determining the presence of neuroinflammation ([C-11]PK11195) and changes in brain metabolism ([F-18]FDG) with positron emission tomography (PET) imaging. Male Sprague-Dawley rats were divided in mTBI (n=8) and sham (n=8) groups. In vivo PET imaging and behavioral tests (open field, object recognition, and Y-maze) were performed at different time points after induction of the trauma. Differences between groups in PET images were explored using volume-of-interest and voxel-based analysis. mTBI did not result in death, skull fracture, or suppression of reflexes. Weight gain was reduced (p=0.003) in the mTBI group compared with the sham-treated group. No statistical differences were found in the behavioral tests at any time point. Volume-of-interest analysis showed neuroinflammation limited to the subacute phase (day 12) involving amygdala, globus pallidus, hypothalamus, pons, septum, striatum, and thalamus (p<0.03, d>1.2). Alterations in glucose metabolism were detected over the 3 month period, with increased uptake in the medulla (p<0.04, d1.2), and decreased uptake in the globus pallidus, striatum, and thalamus (p<0.04, d 1.2). Similar findings were observed in the voxel-based analysis (p<0.05 at corrected cluster level). As a consequence of the mTBI, and in the absence of apparent behavioral alterations, relative brain glucose metabolism was found altered in several brain regions, which mostly correspond with those presenting neuroinflammation in the subacute stage.	[Vallez Garcia, David; Dierckx, Rudi A. J. O.; Doorduin, Janine] Univ Groningen, Univ Med Ctr Groningen, Dept Nucl Med & Mol Imaging, POB 30-001, NL-9700 RB Groningen, Netherlands; [Otte, Andreas] Offenburg Univ, Div Biomed Engn, Dept Elect Engn & Informat Technol, Offenburg, Germany	Vallez Garcia, D (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Nucl Med & Mol Imaging, POB 30-001, NL-9700 RB Groningen, Netherlands.	d.vallez-garcia@umcg.nl	Garcia, David Vallez/N-2348-2015	Garcia, David Vallez/0000-0003-3308-3167; Otte, Andreas/0000-0002-6290-6786; Doorduin, Janine/0000-0003-2925-9959			Banati RB, 2002, GLIA, V40, P206, DOI 10.1002/glia.10144; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Byrnes Kimberly R, 2014, Front Neuroenergetics, V5, P13, DOI 10.3389/fnene.2013.00013; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Chauveau F, 2008, EUR J NUCL MED MOL I, V35, P2304, DOI 10.1007/s00259-008-0908-9; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Doorduin J, 2009, MOL IMAGING BIOL, V11, P386, DOI 10.1007/s11307-009-0211-6; Doorduin J, 2008, CURR PHARM DESIGN, V14, P3297, DOI 10.2174/138161208786549443; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Folkersma H, 2011, J NUCL MED, V52, P1235, DOI 10.2967/jnumed.110.084061; Folkersma H, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-67; Fueger BJ, 2006, J NUCL MED, V47, P999; Gerberding JL, 2003, REP C MILD TRAUM BRA; Gilchrist J., 2011, NONFATAL TRAUMATIC B, P1337; Giza CC, 2001, J ATHL TRAINING, V36, P228; Hardin J. W., 2012, GEN ESTIMATING EQUAT; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Lannsjo M, 2013, EUR J NEUROL, V20, P124, DOI 10.1111/j.1468-1331.2012.03813.x; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Li J, 2012, J NEUROTRAUM, V29, P2635, DOI 10.1089/neu.2012.2411; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marsteller DA, 2006, NUCL MED BIOL, V33, P71, DOI 10.1016/j.nucmedbio.2005.09.003; Maruichi K, 2009, NEUROPATHOLOGY, V29, P132, DOI 10.1111/j.1440-1789.2008.00956.x; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Penny WD, 2006, STAT PARAMETRIC MAPP, P656; Prieto E, 2011, EUR J NUCL MED MOL I, V38, P2228, DOI 10.1007/s00259-011-1905-y; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Roozendaal B, 2010, J NEUROSCI, V30, P5037, DOI 10.1523/JNEUROSCI.5717-09.2010; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Sanchez-Catasus C. A., 2014, PET SPECT NEUROLOGY, P923; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schiffer WK, 2007, J NUCL MED, V48, P277; Schwarz AJ, 2006, NEUROIMAGE, V32, P538, DOI 10.1016/j.neuroimage.2006.04.214; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Siedler DG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00429; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; Turkheimer FE, 2007, J NUCL MED, V48, P158; Vallez Garcia D, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0122363, 10.1371/journal.pone.0143900]; Venneti S, 2007, EXP NEUROL, V207, P118, DOI 10.1016/j.expneurol.2007.06.003; Wang Y, 2014, EUR J NUCL MED MOL I, V41, P1440, DOI 10.1007/s00259-014-2727-5; West TA, 2014, J FAM PRACTICE, V63, P11; Wilkinson Charles W, 2012, Front Neurol, V3, P11, DOI 10.3389/fneur.2012.00011; Wong KP, 2011, J NUCL MED, V52, P800, DOI 10.2967/jnumed.110.085092; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yu I, 2010, J NEUROTRAUM, V27, P1463, DOI 10.1089/neu.2009.1196	64	14	14	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2016	33	20					1855	1865		10.1089/neu.2015.4230			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EA6YO	WOS:000386775300006	26756169				2021-06-18	
J	Dengler, BA; Mendez-Gomez, P; Chavez, A; Avila, L; Michalek, J; Hernandez, B; Grandhi, R; Seifi, A				Dengler, Bradley A.; Mendez-Gomez, Paolo; Chavez, Amanda; Avila, Lacey; Michalek, Joel; Hernandez, Brian; Grandhi, Ramesh; Seifi, Ali			Safety of Chemical DVT Prophylaxis in Severe Traumatic Brain Injury with Invasive Monitoring Devices	NEUROCRITICAL CARE			English	Article						Deep vein thrombosis; Intracranial pressure monitor; Severe traumatic brain injury	MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM PROPHYLAXIS; PHARMACOLOGICAL THROMBOPROPHYLAXIS; INTRACRANIAL HEMORRHAGE; ENOXAPARIN PROPHYLAXIS; HEAD-INJURY; RISK; EFFICACY; COMPLICATIONS	Patients with traumatic brain injuries (TBIs) have an increased risk of developing a deep vein thrombosis (DVT), but the risk of hemorrhage expansion with intracranial monitoring devices remains unknown. We sought to determine the safety of chemical DVT prophylaxis in severe TBI patients with invasive intracranial pressure monitors. We retrospectively reviewed all patients with severe TBI admitted to the neurosurgical intensive care unit of a large tertiary care center over a three-year period. 155 patients were included with an incidence of DVT of 12 %. The median length of time to a stable head CT was 2 days, and the median time to initiation of chemical DVT prophylaxis was 3.6 days. The odds of DVT increased with intraparenchymal hemorrhage [OR 7.21, 95 % CI (1.43-36.47), p = 0.0169], non-White ethnicity [OR 7.86, 95 % CI (1.23-50.35), p = 0.0295], female gender [OR 13.93, 95 % CI (2.47-78.73), p = 0.0029], smoking [OR 4.32, 95 % CI (1.07-17.51), p = 0.0405], no anticoagulation [OR 25.39, 95 % CI (4.26-151.48), p < 0.001], and an IVC filter [OR 15.82, 95 % CI (3.14-79.76), p < 0.001]. Twenty-eight (18 %) of these subjects experienced in-hospital mortality. The risk of in-hospital death was significantly increased among those who did not receive anticoagulation. This study found no association between DVT formation, hemorrhage expansion, or increased risk from invasive monitoring devices between various doses of unfractionated heparin (UH) and low-molecular-weight heparin (LMWH). We conclude that DVT prophylaxis with either LMWH or UH is safe with intracranial pressure monitors in place.	[Dengler, Bradley A.; Grandhi, Ramesh; Seifi, Ali] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurosurg, Mail Code 7843,7703 Floyd Curl Dr MC7843, San Antonio, TX 78229 USA; [Mendez-Gomez, Paolo; Chavez, Amanda; Avila, Lacey] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, San Antonio, TX 78229 USA; [Michalek, Joel; Hernandez, Brian] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA	Seifi, A (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Neurosurg, Mail Code 7843,7703 Floyd Curl Dr MC7843, San Antonio, TX 78229 USA.	seifi@uthscsa.edu	Seifi, Ali/AAR-6163-2020; Dengler, Bradley/AAN-7688-2021				Abdel-Aziz H, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0814-z; Ali SF, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000171; Anderson RCE, 2004, J NEUROSURG, V101, P53, DOI 10.3171/ped.2004.101.2.0053; Arnold JD, 2010, AM SURGEON, V76, P563; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Brain Trauma Foundation American Association of Neurological Surgeons Congress of Neurological Surgeons, 2007, J NEUROTRAUM, V24, P37; Carney N, 2012, J NEUROTRAUM, V29, P2022, DOI 10.1089/neu.2011.2019; Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; Depew AJ, 2008, AM SURGEON, V74, P906; Dimitriou J, 2016, WORLD NEUROSURG, V89, P641, DOI 10.1016/j.wneu.2015.11.037; Dudley RR, 2010, J NEUROTRAUM, V27, P2165, DOI 10.1089/neu.2010.1366; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; Gardner PA, 2009, J NEUROSURG, V110, P1021, DOI 10.3171/2008.9.JNS17661; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Gerlach R, 2003, NEUROSURGERY, V53, P1028, DOI 10.1227/01.NEU.0000088565.15719.22; Hamilton MG, 2011, NEUROSURGERY, V68, P571, DOI 10.1227/NEU.0b013e3182093145; Jamjoom AAB, 2013, J NEUROTRAUM, V30, P503, DOI 10.1089/neu.2012.2584; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Kleindienst A, 2003, ACTA NEUROCHIR, V145, P1085, DOI 10.1007/s00701-003-0142-y; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Koehler DM, 2011, J TRAUMA, V70, P324, DOI 10.1097/TA.0b013e31820b5d22; Kurtoglu M, 2004, WORLD J SURG, V28, P807, DOI 10.1007/s00268-004-7295-6; Levy AS, 2010, J TRAUMA, V68, P886, DOI 10.1097/TA.0b013e3181d27dd5; MCGILL HC, 1988, AM HEART J, V115, P250, DOI 10.1016/0002-8703(88)90645-X; Minshall CT, 2011, J TRAUMA, V71, P396, DOI 10.1097/TA.0b013e31822734c9; Mohseni Shahin, 2012, J Emerg Trauma Shock, V5, P11, DOI 10.4103/0974-2700.93102; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Patel AP, 2013, J NEUROSURG, V118, P505, DOI 10.3171/2012.11.JNS121243; Phelan HA, 2012, J TRAUMA ACUTE CARE, V73, pS122, DOI 10.1097/TA.0b013e3182606327; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Salottolo K, 2011, J TRAUMA, V70, P19, DOI 10.1097/TA.0b013e318207c54d; Scudday T, 2011, J AM COLL SURGEONS, V213, P148, DOI 10.1016/j.jamcollsurg.2011.02.027; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stein PD, 1998, CHEST, V113, P499, DOI 10.1378/chest.113.2.499; Valle EJ, 2014, J TRAUMA ACUTE CARE, V77, P243, DOI 10.1097/TA.0000000000000307; Wahl WL, 2011, J TRAUMA, V71, P399; Zidovetzki R, 1999, STROKE, V30, P651, DOI 10.1161/01.STR.30.3.651	38	14	15	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2016	25	2					215	223		10.1007/s12028-016-0280-8			9	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	DY5YN	WOS:000385181000008	27350548				2021-06-18	
J	Jamall, OA; Feeney, C; Zaw-Linn, J; Malik, A; Niemi, MEK; Tenorio-Jimenez, C; Ham, TE; Jilka, SR; Jenkins, PO; Scott, G; Li, LM; Gorgoraptis, N; Baxter, D; Sharp, DJ; Goldstone, AP				Jamall, Omer A.; Feeney, Claire; Zaw-Linn, Joanna; Malik, Aysha; Niemi, Mari E. K.; Tenorio-Jimenez, Carmen; Ham, Timothy E.; Jilka, Sagar R.; Jenkins, Peter O.; Scott, Gregory; Li, Lucia M.; Gorgoraptis, Nikolaos; Baxter, David; Sharp, David J.; Goldstone, Anthony P.			Prevalence and correlates of vitamin D deficiency in adults after traumatic brain injury	CLINICAL ENDOCRINOLOGY			English	Article							QUALITY-OF-LIFE; HYPOVITAMINOSIS-D; DEPRESSION; METAANALYSIS; DEMENTIA; DYSFUNCTION	Objectives Traumatic brain injury (TBI) is a major cause of long-term disability with variable recovery. Preclinical studies suggest that vitamin D status influences the recovery after TBI. However, there is no published clinical data on links between vitamin D status and TBI outcomes. The aim was to determine the (i) prevalence of vitamin D deficiency/insufficiency, and associations of vitamin D status with (ii) demographic factors and TBI severity, and with (iii) cognitive function, symptoms and quality of life, in adults after TBI. Design Retrospective audit of patients seen between July 2009 and March 2015. Serum vitamin D (25-hydroxy-cholecalciferol) was categorized as deficient (<40 nmol/l), insufficient (4070 nmol/l) or replete (>70 nmol/l). Patients A total of 353 adults seen in tertiary hospital clinic (75.4% lighter skinned, 74.8% male, age median 35.1 year, range 26.6-48.3 year), 0.3-56.5 months after TBI (74.5% moderate-severe). Measurements Serum vitamin D concentrations; Adden-brooke's Cognitive Examination (ACE-R), Beck Depression Inventory-II (BDI-II), SF-36 Quality of Life, Pittsburgh Sleep Quality Index. Results In total, 46.5% of patients after TBI had vitamin D deficiency and 80.2% insufficiency/deficiency. Patients with vitamin D deficiency had lower ACE-R scores than those of vitamin D replete (mean effect size +/- SEM 4.5 +/- 2.1, P = 0.034), and higher BDI-II scores than those of vitamin D insufficient (4.5 +/- 1.6, P = 0.003), correcting for age, gender, time since TBI and TBI severity. There was no association between vitamin D status and markers of TBI severity, sleep or quality of life. Conclusion Vitamin D deficiency is common in patients after TBI and associated with impaired cognitive function and more severe depressive symptoms.	[Jamall, Omer A.; Feeney, Claire; Zaw-Linn, Joanna; Malik, Aysha; Niemi, Mari E. K.; Tenorio-Jimenez, Carmen; Ham, Timothy E.; Jilka, Sagar R.; Jenkins, Peter O.; Scott, Gregory; Li, Lucia M.; Gorgoraptis, Nikolaos; Baxter, David; Sharp, David J.; Goldstone, Anthony P.] Hammersmith Hosp, Imperial Coll London, Div Brain Sci, Computat Cognit & Clin Neuroimaging Lab, London, England; [Feeney, Claire; Tenorio-Jimenez, Carmen; Goldstone, Anthony P.] St Marys Hosp, Imperial Coll Healthcare NHS Trust, Imperial Ctr Endocrinol, London, England; [Goldstone, Anthony P.] Hammersmith Hosp, Imperial Coll London, Div Brain Sci, Ctr Neuropsychopharmacol, London, England	Goldstone, AP (corresponding author), Hammersmith Hosp, Imperial Coll London, Div Brain Sci, Room E313,3rd Floor Burlington Danes Bldg, London W12 0NN, England.	tony.goldstone@imperial.ac.uk	Sharp, David J/A-2119-2013; Tenorio-Jimenez, Carmen/I-1550-2015	Tenorio-Jimenez, Carmen/0000-0002-1773-6036; Niemi, Mari/0000-0003-0696-6175; Gorgoraptis, Nikos/0000-0002-2588-9235; Scott, Gregory/0000-0001-8063-5871; Li, Lucia/0000-0001-7339-4854; Goldstone, Anthony/0000-0001-8179-7071	UK Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [26659]; Imperial College Healthcare Charity [7006/R21U]; Guarantors of Brain; Wellcome-GSK Imperial Translational Training Fellowship; Wellcome TrustWellcome TrustEuropean Commission; National Institute for Health Research (NIHR)National Institute for Health Research (NIHR); National Institute for Health Research (NIHR)National Institute for Health Research (NIHR) [NIHR-RP-011-048]; UK Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Academy of Medical Sciences (AMS)Academy of Medical Sciences (AMS) [AMS-SGCL13-Gorgoraptis] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/K023926/1] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048, CL-2013-21-010] Funding Source: researchfish	We thank Department of Chemical Pathology, Imperial College Healthcare NHS Trust, London, for performing hormone assays. CF is supported by UK Medical Research Council (ref. 26659) and Imperial College Healthcare Charity (ref. 7006/R21U), CT by Imperial College Healthcare Charity (ref. 7006/R21U), POJ by Guarantors of Brain, GS by Wellcome-GSK Imperial Translational Training Fellowship, LL by Wellcome Trust, NG by National Institute for Health Research (NIHR), DJS by National Institute for Health Research (NIHR, ref. NIHR-RP-011-048) and APG by UK Medical Research Council.	Anglin RES, 2013, BRIT J PSYCHIAT, V202, P100, DOI 10.1192/bjp.bp.111.106666; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Balion C, 2012, NEUROLOGY, V79, P1397, DOI 10.1212/WNL.0b013e31826c197f; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cekic M, 2011, NEUROBIOL AGING, V32, P864, DOI 10.1016/j.neurobiolaging.2009.04.017; Ecemis GC, 2013, J ENDOCRINOL INVEST, V36, P622, DOI 10.3275/8898; Etgen T, 2012, DEMENT GERIATR COGN, V33, P297, DOI 10.1159/000339702; Eyles DW, 2005, J CHEM NEUROANAT, V29, P21, DOI 10.1016/j.jchemneu.2004.08.006; Groves NJ, 2014, ANNU REV NUTR, V34, P117, DOI 10.1146/annurev-nutr-071813-105557; Harris SS, 2006, J NUTR, V136, P1126; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Hollis BW, 1996, CALCIFIED TISSUE INT, V58, P4, DOI 10.1007/s002239900002; Hua F, 2012, HORM BEHAV, V61, P642, DOI 10.1016/j.yhbeh.2012.02.017; Hypponen E, 2007, AM J CLIN NUTR, V85, P860; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Ju SY, 2013, J NUTR HEALTH AGING, V17, P447, DOI 10.1007/s12603-012-0418-0; Kimura D, 1996, CURR OPIN NEUROBIOL, V6, P259, DOI 10.1016/S0959-4388(96)80081-X; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kuru P, 2015, RHEUMATOL INT, V35, P315, DOI 10.1007/s00296-014-3099-7; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; McCann JC, 2008, FASEB J, V22, P982, DOI 10.1096/fj.07-9326rev; Meltzer CC, 1998, NEUROPSYCHOPHARMACOL, V18, P407; Mioshi E, 2006, INT J GERIATR PSYCH, V21, P1078, DOI 10.1002/gps.1610; Nice, 2014, NAT I HLTH CAR EXC G; Novack TA, 2000, BRAIN INJURY, V14, P987; Rajakumar K, 2008, OBESITY, V16, P90, DOI 10.1038/oby.2007.23; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Tang BMP, 2007, LANCET, V370, P657, DOI 10.1016/S0140-6736(07)61342-7; Tang HL, 2013, HORM BEHAV, V64, P527, DOI 10.1016/j.yhbeh.2013.06.009; Tanriverdi F, 2015, NEUROPSYCH DIS TREAT, V11, P1835, DOI 10.2147/NDT.S65814; WEISSMAN MM, 1985, TRENDS NEUROSCI, V8, P416, DOI 10.1016/0166-2236(85)90145-6; Wiklund I, 1990, Scand J Prim Health Care Suppl, V1, P15	34	14	14	0	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	OCT	2016	85	4					636	644		10.1111/cen.13045			9	Endocrinology & Metabolism	Endocrinology & Metabolism	DZ4IH	WOS:000385821400019	26921561	Green Published, Other Gold			2021-06-18	
J	Pascarella, A; Trojano, L; Loreto, V; Bilo, L; Moretta, P; Estraneo, A				Pascarella, Angelo; Trojano, Luigi; Loreto, Vincenzo; Bilo, Leonilda; Moretta, Pasquale; Estraneo, Anna			Long-term outcome of patients with disorders of consciousness with and without epileptiform activity and seizures: a prospective single centre cohort study	JOURNAL OF NEUROLOGY			English	Article						Disorders of consciousness; Epileptiform activity; Epileptic seizures; Neurorehabilitation; Outcome	LATE RECOVERY; EEG PATTERNS; EPILEPSY; MECHANISMS; MORTALITY; REHABILITATION; RESPONSIVENESS; MULTICENTER; DEFINITION; PREDICTORS	Brain-injured patients can experience epileptic seizures beyond 1 week from injury (unprovoked remote symptomatic epileptic seizures). In our longitudinal observational study, we analysed occurrence of unprovoked remote epileptic seizures and interictal epileptiform activity in 130 traumatic, vascular or anoxic inpatients with disorders of consciousness (DOC), with a clinical diagnosis of vegetative state (n = 97) or minimally conscious state (n = 33). We also investigated impact of epileptic seizures and epileptiform activity on clinical outcome (30 months post-onset). Epileptic seizures occurred in 35/130 patients (26.9 %), epileptiform activity in 61/130 (46.9 %) patients, without significant differences related to clinical diagnosis or aetiology. Among patients with epileptiform activity, only 26/61 (42.6 %) developed clinically evident seizures. Mortality at 30 months was not significantly influenced by the presence of seizures or epileptiform activity. The proportion of patients who recovered at long-term follow-up was higher in patients without than in patients with epileptic seizures, but was similar in patients with or without epileptiform activity. The presence of epileptic seizures but not of epileptiform activity, significantly affected the level of responsiveness at final outcome. In conclusion, seizures were detected in about one third of the whole sample, and in about a half of patients with epileptiform activity, regardless of clinical diagnosis or aetiology. Although epileptic seizures or epileptiform activity did not significantly affect mortality rate, we demonstrated that epileptic seizures could hamper recovery of consciousness. Epileptic seizures thus qualify as one of the factors largely undetermined at the moment which can influence prognosis in DOC patients.	[Pascarella, Angelo; Loreto, Vincenzo; Moretta, Pasquale; Estraneo, Anna] IRCCS, Salvatore Maugeri Fdn, Inst Sci, Res Lab, Via Bagni Vecchi 1, I-82037 Telese Terme, BN, Italy; [Pascarella, Angelo; Loreto, Vincenzo; Moretta, Pasquale; Estraneo, Anna] IRCCS, Salvatore Maugeri Fdn, Inst Sci, Neurorehabilitat Unit Disorder Consciousness, Via Bagni Vecchi 1, I-82037 Telese Terme, BN, Italy; [Trojano, Luigi] Univ Naples 2, Dept Psychol, Caserta, Italy; [Bilo, Leonilda] Univ Naples Federico II, Dept Neurosci Reprod & Odontostomatol Sci, Naples, Italy	Estraneo, A (corresponding author), IRCCS, Salvatore Maugeri Fdn, Inst Sci, Res Lab, Via Bagni Vecchi 1, I-82037 Telese Terme, BN, Italy.; Estraneo, A (corresponding author), IRCCS, Salvatore Maugeri Fdn, Inst Sci, Neurorehabilitat Unit Disorder Consciousness, Via Bagni Vecchi 1, I-82037 Telese Terme, BN, Italy.	anna.estraneo@fsm.it	Moretta, Pasquale/AAE-5162-2021; Trojano, Luigi/F-2396-2016; Pascarella, Angelo/A-9813-2016	Moretta, Pasquale/0000-0003-2244-254X; Trojano, Luigi/0000-0002-0328-9642; Pascarella, Angelo/0000-0002-0085-9494; Bilo, Leonilda/0000-0002-9817-4193			Amantini A, 2009, NEUROPHYSIOL CLIN, V39, P85, DOI 10.1016/j.neucli.2009.01.006; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Askalan R, 2015, BRAIN RES, V1629, P94, DOI 10.1016/j.brainres.2015.10.020; Bagnato S, 2016, EPILEPSY BEHAV, V56, P83, DOI 10.1016/j.yebeh.2015.12.012; Bagnato S, 2013, EPILEPSY RES, V103, P106, DOI 10.1016/j.eplepsyres.2012.09.008; Beghi E, 2010, EPILEPSIA, V51, P671, DOI 10.1111/j.1528-1167.2009.02285.x; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; Bodien YG, 2016, ARCH PHYS MED REHAB, V97, P490, DOI 10.1016/j.apmr.2015.08.422; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Claassen J, 2013, INTENS CARE MED, V39, P1337, DOI 10.1007/s00134-013-2938-4; Andraus MEC, 2012, ARQ NEURO-PSIQUIAT, V70, P145, DOI 10.1590/S0004-282X2012000200014; Demertzi A, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2010.00245; Estraneo A, 2015, EUR J PHYS REHAB MED, V51, P627; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Estraneo A, 2016, CLIN NEUROPHYSIOL, V127, P2379, DOI 10.1016/j.clinph.2016.03.021; Estraneo A, 2015, CLIN REHABIL, V29, P803, DOI 10.1177/0269215514556002; Estraneo A, 2014, ARCH PHYS MED REHAB, V95, P711, DOI 10.1016/j.apmr.2013.11.004; Estraneo A, 2013, NEUROLOGY, V80, P464, DOI 10.1212/WNL.0b013e31827f0f31; Fitzpatrick W, 2007, CAN J NEUROL SCI, V34, P443, DOI 10.1017/S0317167100007332; Ganesh S, 2013, ARCH PHYS MED REHAB, V94, P1899, DOI 10.1016/j.apmr.2012.12.026; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Guerit JM, 2009, NEUROPHYSIOL CLIN, V39, P71, DOI 10.1016/j.neucli.2009.03.002; Hauser WA, 2008, EPILEPSIA, V49, P8, DOI 10.1111/j.1528-1167.2008.01443.x; Hesdorffer DC, 2009, EPILEPSIA, V50, P1102, DOI 10.1111/j.1528-1167.2008.01945.x; Hirsch LJ, 2013, J CLIN NEUROPHYSIOL, V30, P1, DOI 10.1097/WNP.0b013e3182784729; Hirsch LJ, 2011, EPILEPSIA, V52, P21, DOI 10.1111/j.1528-1167.2011.03228.x; Holtkamp Martin, 2011, Ther Adv Neurol Disord, V4, P169, DOI 10.1177/1756285611403826; Keezer MR, 2016, NEUROLOGY, V86, P704, DOI 10.1212/WNL.0000000000002390; Librizzi L, 2012, ANN NEUROL, V72, P82, DOI 10.1002/ana.23567; Lucke-Wold BP, 2015, SEIZURE-EUR J EPILEP, V33, P13, DOI 10.1016/j.seizure.2015.10.002; Majerus S, 2005, PROG BRAIN RES, V150, P397, DOI 10.1016/S0079-6123(05)50028-1; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; Mula M, 2009, CNS DRUGS, V23, P121, DOI 10.2165/00023210-200923020-00003; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; Neligan A, 2010, EPILEPSIA, V51, P2241, DOI 10.1111/j.1528-1167.2010.02711.x; Noachtar S, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P21; SALINSKY M, 1987, EPILEPSIA, V28, P331, DOI 10.1111/j.1528-1157.1987.tb03652.x; Steppacher I, 2014, ANN CLIN TRANSL NEUR, V1, P401, DOI 10.1002/acn3.63; Striano S, 1992, Acta Neurol (Napoli), V14, P275; Thurman DJ, 2011, EPILEPSIA, V52, P2, DOI 10.1111/j.1528-1167.2011.03121.x; Whyte J, 2013, ARCH PHYS MED REHAB, V94, P1877, DOI 10.1016/j.apmr.2012.12.027; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd	43	14	15	0	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	OCT	2016	263	10					2048	2056		10.1007/s00415-016-8232-y			9	Clinical Neurology	Neurosciences & Neurology	DY5WA	WOS:000385173900017	27416857				2021-06-18	
J	Samson, AJ; Robertson, G; Zagnoni, M; Connolly, CN				Samson, Andrew J.; Robertson, Graham; Zagnoni, Michele; Connolly, Christopher N.			Neuronal networks provide rapid neuroprotection against spreading toxicity	SCIENTIFIC REPORTS			English	Article							OXYGEN-GLUCOSE DEPRIVATION; NMDA RECEPTORS; BRAIN-DAMAGE; CELL-DEATH; CEREBRAL-ISCHEMIA; STROKE; GLUTAMATE; RECOVERY; RATS; EXCITOTOXICITY	Acute secondary neuronal cell death, as seen in neurodegenerative disease, cerebral ischemia (stroke) and traumatic brain injury (TBI), drives spreading neurotoxicity into surrounding, undamaged, brain areas. This spreading toxicity occurs via two mechanisms, synaptic toxicity through hyperactivity, and excitotoxicity following the accumulation of extracellular glutamate. To date, there are no fast-acting therapeutic tools capable of terminating secondary spreading toxicity within a time frame relevant to the emergency treatment of stroke or TBI patients. Here, using hippocampal neurons (DIV 15-20) cultured in microfluidic devices in order to deliver a localized excitotoxic insult, we replicate secondary spreading toxicity and demonstrate that this process is driven by GluN2B receptors. In addition to the modeling of spreading toxicity, this approach has uncovered a previously unknown, fast acting, GluN2A-dependent neuroprotective signaling mechanism. This mechanism utilizes the innate capacity of surrounding neuronal networks to provide protection against both forms of spreading neuronal toxicity, synaptic hyperactivity and direct glutamate excitotoxicity. Importantly, network neuroprotection against spreading toxicity can be effectively stimulated after an excitotoxic insult has been delivered, and may identify a new therapeutic window to limit brain damage.	[Samson, Andrew J.; Connolly, Christopher N.] Univ Dundee, Sch Med, Div Neurosci, Dundee DD1 9SY, Scotland; [Robertson, Graham; Zagnoni, Michele] Univ Strathclyde, Dept Elect & Elect Engn, Ctr Microsyst & Photon, Glasgow G1 1XW, Lanark, Scotland	Connolly, CN (corresponding author), Univ Dundee, Sch Med, Div Neurosci, Dundee DD1 9SY, Scotland.	c.n.connolly@dundee.ac.uk	Robertson, Graham/Q-1414-2016	Robertson, Graham/0000-0002-3841-874X; Connolly, Christopher/0000-0002-0445-8874; Zagnoni, Michele/0000-0003-3198-9491; Samson, Andrew James/0000-0002-4842-5126	MRC doctoral scholarship at the University of DundeeUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Doctoral Training Centre (DTC) in Medical Devices at the University of Strathclyde [EP/F50036X/1]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1314783] Funding Source: researchfish	Funding was provided by an MRC doctoral scholarship at the University of Dundee and the Doctoral Training Centre (DTC) in Medical Devices at the University of Strathclyde (EP/F50036X/1).	Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Aerden LAM, 2004, NEUROSCI LETT, V367, P76, DOI 10.1016/j.neulet.2004.05.083; Ben-Ari Y, 2007, PHYSIOL REV, V87, P1215, DOI 10.1152/physrev.00017.2006; Chang LR, 2016, J ALZHEIMERS DIS, V51, P197, DOI 10.3233/JAD-150942; Cheng MY, 2014, P NATL ACAD SCI USA, V111, P12913, DOI 10.1073/pnas.1404109111; Chhatbar PY, 2016, BRAIN STIMUL, V9, P16, DOI 10.1016/j.brs.2015.09.002; Clarkson AN, 2010, NATURE, V468, P305, DOI 10.1038/nature09511; Cramer SC, 2008, ANN NEUROL, V63, P272, DOI 10.1002/ana.21393; DAVIES CA, 1987, J NEUROL SCI, V78, P151, DOI 10.1016/0022-510X(87)90057-8; Fitzgerald PB, 2011, AUST NZ J PSYCHIAT, V45, P923, DOI 10.3109/00048674.2011.615294; Gouix E, 2009, MOL CELL NEUROSCI, V40, P463, DOI 10.1016/j.mcn.2009.01.002; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911; Hinzman JM, 2015, EXP NEUROL, V267, P243, DOI 10.1016/j.expneurol.2015.03.014; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Jarvis CR, 2001, CEREB CORTEX, V11, P249, DOI 10.1093/cercor/11.3.249; Kramer DR, 2016, J CLIN NEUROSCI, V24, P22, DOI 10.1016/j.jocn.2015.08.004; Lagercrantz H, 2001, ACTA PAEDIATR, V90, P707; Lin CH, 2008, EUR J PHARMACOL, V589, P85, DOI 10.1016/j.ejphar.2008.05.047; Liu AJ, 2015, AM J CHINESE MED, V43, P1541, DOI 10.1142/S0192415X15500883; Liu J., 2014, COCHRANE DB SYST REV, V6; Marshall JWB, 1999, EXP NEUROL, V156, P121, DOI 10.1006/exnr.1998.6994; Marshall JWB, 2000, BRAIN RES BULL, V52, P21, DOI 10.1016/S0361-9230(99)00275-0; Milnerwood AJ, 2010, NEURON, V65, P178, DOI 10.1016/j.neuron.2010.01.008; Monai H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11100; Muir JK, 1996, J CEREBR BLOOD F MET, V16, P1211, DOI 10.1097/00004647-199611000-00015; Munakata Y, 2004, DEVELOPMENTAL SCI, V7, P141, DOI 10.1111/j.1467-7687.2004.00331.x; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Narang Puneet, 2015, Innov Clin Neurosci, V12, P25; Okamoto SI, 2009, NAT MED, V15, P1407, DOI 10.1038/nm.2056; Papadia S, 2008, NAT NEUROSCI, V11, P476, DOI 10.1038/nn2071; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Regenold WT, 2015, BRAIN STIMUL, V8, P855, DOI 10.1016/j.brs.2015.06.011; Robertson G, 2014, INTEGR BIOL-UK, V6, P636, DOI 10.1039/c3ib40221e; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Sattler R, 2000, J NEUROSCI, V20, P22, DOI 10.1523/JNEUROSCI.20-01-00022.2000; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Srejic LR, 2013, J CEREBR BLOOD F MET, V33, P1937, DOI 10.1038/jcbfm.2013.153; Stetler RA, 2014, PROG NEUROBIOL, V114, P58, DOI 10.1016/j.pneurobio.2013.11.005; SYDSERFF SG, 1995, NEURODEGENERATION, V4, P323, DOI 10.1016/1055-8330(95)90022-5; Tu WH, 2010, CELL, V140, P222, DOI 10.1016/j.cell.2009.12.055; Wang RM, 2006, LIFE SCI, V79, P1839, DOI 10.1016/j.lfs.2006.06.041; Wang X, 2014, NEUROSCIENCE, V274, P393, DOI 10.1016/j.neuroscience.2014.05.053; Ward MW, 2005, J NEUROCHEM, V92, P1081, DOI 10.1111/j.1471-4159.2004.02928.x; Wroge CM, 2012, J NEUROSCI, V32, P6732, DOI 10.1523/JNEUROSCI.6371-11.2012; Xu GP, 2002, BRAIN RES, V952, P153, DOI 10.1016/S0006-8993(02)02988-8; Zhang F, 2010, INT J MOL SCI, V11, P2658, DOI 10.3390/ijms11072658; Zhou X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.82	48	14	14	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	SEP 21	2016	6								33746	10.1038/srep33746			11	Multidisciplinary Sciences	Science & Technology - Other Topics	DW3WN	WOS:000383573900001	27650924	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Chen, CH; Chen, NF; Feng, CW; Cheng, SY; Hung, HC; Tsui, KH; Hsu, CH; Sung, PJ; Chen, WF; Wen, ZH				Chen, Chun-Hong; Chen, Nan-Fu; Feng, Chien-Wei; Cheng, Shu-Yu; Hung, Han-Chun; Tsui, Kuan-Hao; Hsu, Chi-Hsin; Sung, Ping-Jyun; Chen, Wu-Fu; Wen, Zhi-Hong			A Coral-Derived Compound Improves Functional Recovery after Spinal Cord Injury through Its Antiapoptotic and Anti-Inflammatory Effects	MARINE DRUGS			English	Article						Sinularia flexibilis; marine natural compound; 11-dehydrosinulariolide; microglia; neuroprotection; spinal cord injury; anti-inflammation	NECROSIS-FACTOR-ALPHA; ACTIVATED PROTEIN-KINASE; FOCAL CEREBRAL-ISCHEMIA; COLONY-STIMULATING FACTOR; MARINE NATURAL-PRODUCTS; ELEMENT-BINDING PROTEIN; SIGNAL-REGULATED KINASE; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; AMP RESPONSE ELEMENT	Background: Our previous in vitro results demonstrated that 11-dehydrosinulariolide significantly reduced 6-hydroxydopamine-induced cytotoxicity and apoptosis in a human neuroblastoma cell line, SH-SY5Y, and suppressed the expression of inducible NO synthase (iNOS) and cyclooxygenase 2 in lipopolysaccharide-stimulated macrophage cells. The neuroprotective and anti-inflammatory effects of 11-dehydrosinulariolide may be suitable for treating spinal cord injury (SCI). Methods: In the present study, Wistar rats were pretreated with 11-dehydrosinulariolide or saline through intrathecal injection after a thoracic spinal cord contusion injury induced using a New York University (NYU) impactor. The apoptotic cells were assessed using the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. The expression and localization of proinflammatory, apoptosis-associated and cell survival-related pathway proteins were examined through immunoblotting and immunohistochemistry. Results: 11-Dehydrosinulariolide attenuated SCI-induced cell apoptosis by upregulating the antiapoptotic protein Bcl-2 and cell survival-related pathway proteins p-Akt and p-ERK, 8 h after SCI. Furthermore, the transcription factor p-CREB, which regulates Bcl-2 expression, was upregulated after 11-dehydrosinulariolide treatment. On day 7 after SCI, 11-dehydrosinulariolide exhibited an anti-inflammatory effect, attenuating SCI-induced upregulation of the inflammatory proteins iNOS and tumor necrosis factor-. 11-Dehydrosinulariolide also induced an increase in the expression of arginase-1 and CD206, markers of M2 microglia, in the injured spinal cord on day 7 after SCI. Thus, the anti-inflammatory effect of 11-dehydrosinulariolide may be related to the promotion of an alternative pathway of microglia activation. Conclusion: The results show that 11-dehydrosinulariolide exerts antiapoptotic effects at 8 h after SCI and anti-inflammatory effects at 7 days after SCI. We consider that this compound may be a promising therapeutic agent for SCI.	[Chen, Chun-Hong; Feng, Chien-Wei; Cheng, Shu-Yu; Hung, Han-Chun; Hsu, Chi-Hsin; Wen, Zhi-Hong] Natl Sun Yat Sen Univ, Doctoral Degree Program Marine Biotechnol, Kaohsiung 80424, Taiwan; [Chen, Chun-Hong; Feng, Chien-Wei; Cheng, Shu-Yu; Hung, Han-Chun] Acad Sinica, Doctoral Degree Program Marine Biotechnol, Taipei 11529, Taiwan; [Chen, Nan-Fu] Kaohsiung Armed Forces Gen Hosp, Div Neurosurg, Dept Surg, Kaohsiung 80284, Taiwan; [Chen, Nan-Fu] Triserv Gen Hosp, Dept Neurol Surg, Natl Def Med Ctr, Taipei 11490, Taiwan; [Tsui, Kuan-Hao] Kaohsiung Vet Gen Hosp, Dept Obstet & Gynecol, Kaohsiung 81362, Taiwan; [Tsui, Kuan-Hao] Natl Yang Ming Univ, Dept Obstet & Gynecol, Taipei 11221, Taiwan; [Tsui, Kuan-Hao] Natl Yang Ming Univ, Inst Clin Med, Taipei 11221, Taiwan; [Tsui, Kuan-Hao] Tajen Univ, Dept Pharm, Yanpu Township 90741, Pingtung County, Taiwan; [Tsui, Kuan-Hao] Tajen Univ, Grad Inst Pharmaceut Technol, Yanpu Township 90741, Pingtung County, Taiwan; [Hsu, Chi-Hsin; Sung, Ping-Jyun; Chen, Wu-Fu; Wen, Zhi-Hong] Natl Sun Yat Sen Univ, Dept Marine Biotechnol & Resources, Kaohsiung 80424, Taiwan; [Sung, Ping-Jyun] Natl Museum Marine Biol & Aquarium, Pingtung 94450, Taiwan; [Sung, Ping-Jyun] Natl Dong Hwa Univ, Grad Inst Marine Biol, Pingtung 94450, Taiwan; [Chen, Wu-Fu] Kaohsiung Chang Gung Mem Hosp, Dept Neurosurg, Kaohsiung 83301, Taiwan; [Chen, Wu-Fu] Chang Gung Univ, Coll Med, Kaohsiung 83301, Taiwan	Wen, ZH (corresponding author), Natl Sun Yat Sen Univ, Doctoral Degree Program Marine Biotechnol, Kaohsiung 80424, Taiwan.; Chen, WF; Wen, ZH (corresponding author), Natl Sun Yat Sen Univ, Dept Marine Biotechnol & Resources, Kaohsiung 80424, Taiwan.; Chen, WF (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Neurosurg, Kaohsiung 83301, Taiwan.; Chen, WF (corresponding author), Chang Gung Univ, Coll Med, Kaohsiung 83301, Taiwan.	chen06688@gmail.com; chen06688@gmail.com; qscjuejuejue@gmail.com; joygetit@gmail.com; hanchun25@gmail.com; khtsui60@gmail.com; hsuch@mail.nsysu.edu.tw; pjsung@nmmba.gov.tw; ma4949@cgmh.org.tw; wzh@mail.nsysu.edu.tw	Wen, Zhi-Hong/AAG-8034-2019; Sung, Ping-Jyun/Z-4162-2019	Wen, Zhi-Hong/0000-0003-4411-044X; Sung, Ping-Jyun/0000-0002-6644-9236	Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [104-2325-B-110-001, 103-2314-B-182A-076, 104-2314-B-182A-038]; Chang Gung Memorial HospitalChang Gung Memorial Hospital [CMRPG8A0151-3]	The study was supported, in part, by grants from the Ministry of Science and Technology, Taiwan (104-2325-B-110-001, 103-2314-B-182A-076, and 104-2314-B-182A-038) and Chang Gung Memorial Hospital (CMRPG8A0151-3).	Abe K, 2000, DEV BRAIN RES, V122, P81, DOI 10.1016/S0165-3806(00)00054-7; Bachstetter AD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-79; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bhat NR, 1998, J NEUROSCI, V18, P1633; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Busch SA, 2009, J NEUROSCI, V29, P9967, DOI 10.1523/JNEUROSCI.1151-09.2009; Chen CH, 2016, EXP NEUROL, V278, P27, DOI 10.1016/j.expneurol.2016.01.023; Chen KB, 2011, SPINE, V36, P1350, DOI 10.1097/BRS.0b013e3181f014ec; Chen NF, 2014, MAR DRUGS, V12, P3792, DOI 10.3390/md12073792; Chen WF, 2008, NEUROSCIENCE, V153, P31, DOI 10.1016/j.neuroscience.2008.01.062; Chen WF, 2015, CNS NEUROSCI THER, V21, P698, DOI 10.1111/cns.12429; Chen WF, 2015, BIOMATERIALS, V53, P1, DOI 10.1016/j.biomaterials.2015.02.069; Chen WF, 2012, N-S ARCH PHARMACOL, V385, P265, DOI 10.1007/s00210-011-0710-2; Chhor V, 2013, BRAIN BEHAV IMMUN, V32, P70, DOI 10.1016/j.bbi.2013.02.005; CORRALIZA IM, 1995, BIOCHEM BIOPH RES CO, V206, P667, DOI 10.1006/bbrc.1995.1094; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Culbert AA, 2006, J BIOL CHEM, V281, P23658, DOI 10.1074/jbc.M513646200; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Endo H, 2006, J CEREBR BLOOD F MET, V26, P1479, DOI 10.1038/sj.jcbfm.9600303; Esposito E, 2011, TRENDS PHARMACOL SCI, V32, P107, DOI 10.1016/j.tips.2010.11.009; Figueroa JD, 2012, J NEUROTRAUM, V29, P551, DOI 10.1089/neu.2011.2141; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Freeland K, 2001, MOL BRAIN RES, V92, P98, DOI 10.1016/S0169-328X(01)00158-9; Galtrey CM, 2007, BRAIN RES REV, V54, P1, DOI 10.1016/j.brainresrev.2006.09.006; Gao HM, 2008, TRENDS IMMUNOL, V29, P357, DOI 10.1016/j.it.2008.05.002; Gao K, 2016, J NEUROCHEM, V138, P139, DOI 10.1111/jnc.13382; Ghosh M, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-015-0463-9; Gibbons HM, 2006, BRAIN RES, V1084, P1, DOI 10.1016/j.brainres.2006.02.032; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Guo Y, 2013, NEUROSCIENCE, V238, P1, DOI 10.1016/j.neuroscience.2013.01.047; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; HERIN M, 1976, B SOC CHIM BELG, V85, P801; Howitt J, 2012, J CELL BIOL, V196, P29, DOI 10.1083/jcb.201105009; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Huang SY, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0280-1; Inukai T, 2009, SPINE, V34, P2848, DOI 10.1097/BRS.0b013e3181b0d078; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kilic E, 2005, FASEB J, V19, P2026, DOI 10.1096/fj.05-3941fje; Kim BJ, 2009, J NEUROL SCI, V279, P70, DOI 10.1016/j.jns.2008.12.025; Kim SS, 2013, J CELL BIOCHEM, V114, P1115, DOI 10.1002/jcb.24452; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Koistinaho M, 2002, GLIA, V40, P175, DOI 10.1002/glia.10151; Kong DX, 2010, DRUG DISCOV TODAY, V15, P884, DOI 10.1016/j.drudis.2010.09.002; Lan WB, 2014, BRAIN RES, V1562, P100, DOI 10.1016/j.brainres.2014.03.020; Leal MC, 2013, TRENDS BIOTECHNOL, V31, P555, DOI 10.1016/j.tibtech.2013.06.004; Lee JY, 2010, ENDOCRINOLOGY, V151, P3815, DOI 10.1210/en.2009-1416; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li YH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19869; Lin YY, 2015, MAR DRUGS, V13, P2559, DOI 10.3390/md13052559; Liu W, 2011, LIFE SCI, V89, P141, DOI 10.1016/j.lfs.2011.05.011; Liu XZ, 1997, J NEUROSCI, V17, P5395; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Mabuchi T, 2001, J NEUROSCI, V21, P9204, DOI 10.1523/JNEUROSCI.21-23-09204.2001; Madinier A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008101; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Martins A, 2014, MAR DRUGS, V12, P1066, DOI 10.3390/md12021066; Montaser R, 2011, FUTURE MED CHEM, V3, P1475, DOI [10.4155/FMC.11.118, 10.4155/fmc.11.118]; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Munder M, 1999, J IMMUNOL, V163, P3771; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Paintlia MK, 2011, J NEUROCHEM, V116, P508, DOI 10.1111/j.1471-4159.2010.07136.x; Pawate S, 2006, ANTIOXID REDOX SIGN, V8, P903, DOI 10.1089/ars.2006.8.903; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Guerrero AR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-40; Ruffell D, 2009, P NATL ACAD SCI USA, V106, P17475, DOI 10.1073/pnas.0908641106; Sato A, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-65; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Sury MD, 2011, NEUROBIOL DIS, V41, P201, DOI 10.1016/j.nbd.2010.09.007; Tian HP, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-139; Tian W, 2013, NEUROCHEM RES, V38, P772, DOI 10.1007/s11064-013-0976-5; Toborek M, 2007, J CELL BIOCHEM, V100, P279, DOI 10.1002/jcb.21013; Walker CL, 2012, PLOS ONE, V7, P315, DOI 10.1371/journal.pone.0030012; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiang H, 2006, MOL CELL BIOL, V26, P8599, DOI 10.1128/MCB.01062-06; Xie GL, 2013, EXP THER MED, V5, P1593, DOI 10.3892/etm.2013.1030; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep20040; Xu L, 2007, ANESTH ANALG, V105, P1838, DOI 10.1213/01.ane.0000287660.29297.7b; Xu Z, 2006, LIFE SCI, V79, P1895, DOI 10.1016/j.lfs.2006.06.023; Yang Y, 2014, NEUROSCI LETT, V568, P44, DOI 10.1016/j.neulet.2014.03.037; Yu FS, 2005, NEUROBIOL DIS, V20, P491, DOI 10.1016/j.nbd.2005.04.004; Yune TY, 2008, J NEUROTRAUM, V25, P1121, DOI 10.1089/neu.2008.0544; Yune TY, 2003, J NEUROTRAUM, V20, P207, DOI 10.1089/08977150360547116; Zhang C, 2014, BRAIN RES, V1555, P1, DOI 10.1016/j.brainres.2014.01.051; Zhang Q, 2016, MOL NEUROBIOL, V53, P662, DOI 10.1007/s12035-014-9035-8; Zhou J, 2015, ASN NEURO, V7, DOI 10.1177/1759091415602463; Zhu HL, 2016, SCI REP-UK, V6, DOI 10.1038/srep26859; Zou JY, 2005, BRAIN RES, V1034, P11, DOI 10.1016/j.brainres.2004.11.014	107	14	14	0	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1660-3397			MAR DRUGS	Mar. Drugs	SEP	2016	14	9							160	10.3390/md14090160			19	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	DZ0LH	WOS:000385529900004	27598175	DOAJ Gold, Green Published			2021-06-18	
J	Church, D; Sparks, T; Clond, M				Church, Dawson; Sparks, Terry; Clond, Morgan			EFT (EMOTIONAL FREEDOM TECHNIQUES) AND RESILIENCY IN VETERANS AT RISK FOR PTSD: A RANDOMIZED CONTROLLED TRIAL	EXPLORE-THE JOURNAL OF SCIENCE AND HEALING			English	Article						veterans; PTSD; resiliency; EFT; emotional freedom techniques	POSTTRAUMATIC-STRESS-DISORDER; ACUPUNCTURE; PSYCHOTHERAPY; STIMULATION; PREVALENCE; CHECKLIST; SYMPTOMS; VIETNAM; TRAUMA; CARE	Prior research indicates elevated but subclinical posttraumatic stress disorder (PTSD) symptoms as a risk factor for a later diagnosis of PTSD. This study examined the progression of symptoms in 21 subclinical veterans. Participants were randomized into a treatment as usual (TAU) wait-list group and an experimental group, which received TAU plus six sessions of clinical emotional freedom techniques (EFT). Symptoms were assessed using the PCL-M (Posttraumatic Checklist Military) on which a score of 35 or higher indicates increased risk for PTSD. The mean pretreatment score of participants was 39 +/- 8.7, with no significant difference between groups. No change was found in the TAU group during the wait period. Afterward, the TAU group received an identical clinical EFT protocol. Posttreatment groups were combined for analysis. Scores declined to a mean of 25 (-64%, P < .0001). Participants maintained their gains, with mean three-month and six-month follow-up PCL-M scores of 27 (P < .0001). Similar reductions were noted in the depth and breadth of psychological conditions such as anxiety. A Cohen's d = 1.99 indicates a large treatment effect. Reductions in traumatic brain injury symptoms (P = .045) and insomnia (P = .004) were also noted. Symptom improvements were similar to those assessed in studies of PTSD-positive veterans. EFT may thus be protective against an increase in symptoms and a later PTSD diagnosis. As a simple and quickly learned self-help method, EFT may be a clinically useful element of a resiliency program for veterans and active-duty warriors.	[Church, Dawson] Natl Inst Integrat Healthcare, 3340 Fulton Rd,442, Fulton, CA 95439 USA; [Sparks, Terry] Oklahoma City VA Hlth Care Syst, Oklahoma City, OK USA; [Clond, Morgan] Ben Gurion Univ Negev, Sch Med, Beer Sheva, Israel	Church, D (corresponding author), Natl Inst Integrat Healthcare, 3340 Fulton Rd,442, Fulton, CA 95439 USA.	dawsonchurch@gmail.com		Clond, Morgan/0000-0002-3036-4193	National Institute for Integrative Healthcare	The study was funded by private individual donations to the nonprofit National Institute for Integrative Healthcare.	Agaibi CE, 2005, TRAUMA VIOLENCE ABUS, V6, P195, DOI 10.1177/1524838005277438; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Andrews B, 2007, AM J PSYCHIAT, V164, P1319, DOI 10.1176/appi.ajp.2007.06091491; Bastien CH, 2001, SLEEP MED, V9, pY307; Berninger A, 2010, AM J IND MED, V53, P1177, DOI 10.1002/ajim.20894; Blake D., 1990, CLIN ADM PTSD SCALE; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Boath E. H., 2013, ENERGY PSYCHOL J, V5, P29, DOI [DOI 10.9769/EPJ.2013.5.2.EB.AC.AS.SU, 10.9769/EPJ.2013.5.2.EB.AC.AS.SU]; Bougea AM, 2013, EXPLORE-NY, V9, P91, DOI 10.1016/j.explore.2012.12.005; Bradley R, 2005, AM J PSYCHIAT, V162, P214, DOI 10.1176/appi.ajp.162.2.214; Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65; Church D, 2010, TRAUMATOLOGY, V16, P55, DOI DOI 10.1177/1534765609347549; Church D, 2015, C ASS COMPR EN PSYCH; Church D., 2012, TRUAMATOLOGY, V18, P73, DOI [10.1177/1534765611426788, DOI 10.1177/1534765611426788]; Church D, 2016, EXPLORE-NY, V10, P162; Church D, 2010, INTEGRATIVE MED, V9, P40; Church D, 2014, TRAUMATOL, DOI [10.1037/h0099831, DOI 10.1037/H0099831]; Church D., 2009, ENERGY PSYCHOL, V1, P9; Church D, 2016, ARCH SCI PS IN PRESS; Church D., 2010, ENERGY PSYCHOL, V2, P9; Church D., 2013, THE EFT MANUAL; Church D, 2009, INT J HEAL CARING, V9, P1; Church D, 2013, PSYCHOLOGY, V4, P645, DOI DOI 10.4236/PSYCH.2013.48092; Church D., 2013, CAPTURE MOMENT SINGL; Church Dawson, 2012, Depress Res Treat, V2012, P257172, DOI 10.1155/2012/257172; Church D, 2014, EXPLORE-NY, V10, P24, DOI 10.1016/j.explore.2013.10.006; Church D, 2013, J NERV MENT DIS, V201, P153, DOI 10.1097/NMD.0b013e31827f6351; Church D, 2012, J NERV MENT DIS, V200, P891, DOI 10.1097/NMD.0b013e31826b9fc1; Connor KM, 2006, J CLIN PSYCHIAT, V67, P46; Craig G, 1995, THE EFT MANUAL; Davison ML, 1997, ASSESSMENT, V4, P259, DOI 10.1177/107319119700400306; Denning Laura, 2014, PREVENTING PSYCHOL D; Dhond RP, 2007, J ALTERN COMPLEM MED, V13, P603, DOI 10.1089/acm.2007.7040; Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944; Feinstein D, 2009, ENERGY PSYCHOL THEOR, V1, P45, DOI [10.9769.EPJ.2009.1.1.DF, DOI 10.9769/EPJ.2009.1.1.DF]; Feinstein D, 2012, REV GEN PSYCHOL, V16, P364, DOI 10.1037/a0028602; Feinstein D, 2010, REV GEN PSYCHOL, V14, P283, DOI 10.1037/a0021252; Feinstein D, 2010, PSYCHOTHERAPY, V47, P385, DOI 10.1037/a0021171; Felmingham K, 2007, PSYCHOL SCI, V18, P127, DOI 10.1111/j.1467-9280.2007.01860.x; Fox L, 2013, ENERGY PSYCHOL THEOR, V5, P15, DOI DOI 10.9769/EPJ.2013.5.2.LF; Gaudiano BA, 2012, RES SOCIAL WORK PRAC, V22, P647, DOI 10.1177/1049731512448468; Geronilla L, 2016, GRAND ROUNDS FORT HO; Goodwin L, 2012, J NERV MENT DIS, V200, P429, DOI 10.1097/NMD.0b013e31825322fe; Gurret J-M, 2012, ENERGY PSYCHOL, V4, P26; Hartung J, 2012, ENERGY PSYCHOL, V4, P33; Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037; Karatzias T, 2011, J NERV MENT DIS, V199, P372, DOI 10.1097/NMD.0b013e31821cd262; Kilpatrick G, 2007, J TRAUMA STRESS, V20, P487, DOI 10.1002/jts.20262; KIM YD, 2013, EVID-BASED COMPL ALT, V2013, DOI DOI 10.1155/2013/615857; Kulka RA, 1988, CONTRACTUAL REPORT F; Lambrou PT, 2003, SUBTLE ENERGIES ENER, V14, P239; Levine SZ, 2009, J TRAUMA STRESS, V22, P282, DOI 10.1002/jts.20409; Monson CM, 2006, J CONSULT CLIN PSYCH, V74, P898, DOI 10.1037/0022-006X.74.5.898; Napadow V, 2007, PAIN, V130, P254, DOI 10.1016/j.pain.2006.12.003; Palmer-Hoffman J, 2011, ENERGY PSYCHOL, V3, P33, DOI DOI 10.9769/EPJ.2011.3.1.JPH; Reynolds AE, 2015, ENERGY PSYCHOL, V7, P14, DOI DOI 10.9769/EPJ.2015.07.01.AR; Rowe JE, 2005, COUNS CLIN PSYCHOL J, V2, P104, DOI DOI 10.1002/JCLP.10189; Schindel-Allon I, 2010, PSYCHOL MED, V40, P1669, DOI 10.1017/S0033291709992248; Schnurr P.P., 2014, PTSD RES Q, V25, P1; Schulz P., 2009, ENERGY PSYCHOL, V1, P15, DOI DOI 10.9769/EPJ.2009.1.1.KS; Smid GE, 2009, J CLIN PSYCHIAT, V70, P1572, DOI 10.4088/JCP.08r04484; Stapleton PB, 2016, C ASS COMPR EN UNPUB; Stapleton Peta, 2013, ISRN Psychiatry, V2013, P573532, DOI 10.1155/2013/573532; Stapleton P, 2011, BEHAV CHANGE, V28, P1, DOI 10.1375/bech.28.1.1; Stein PK, 2011, ENERGY PSYCHOL THEOR, V3, P11, DOI DOI 10.9769/EPJ.2011.3.1.PKS.AJB; Stewart A, 2013, ENERGY PSYCHOL J, V5, P13, DOI DOI 10.9769/EPJ.2013.5.1.AS]; Stewart A, 2016, J PSYCHOL T IN PRESS; Swingle P, 2004, SUBTLE ENERG ENERGY, V15, P75; Vasterling J., 2005, NEUROPSYCHOLOGY PTSD; Veterans Health Administration, 2012, REP VA FAC SPEC OP E; Weathers F., 1991, PTSD CHECKLIST MILIT; WEISS DS, 1992, J TRAUMA STRESS, V5, P365, DOI 10.1007/BF00977234; Wolpe J., 1973, PRACTICE BEHAV THERA; Zoroya G., 2014, US TODAY	75	14	15	2	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1550-8307	1878-7541		EXPLORE-NY	Explore-J Sci. Heal.	SEP-OCT	2016	12	5					355	365		10.1016/j.explore.2016.06.012			11	Integrative & Complementary Medicine	Integrative & Complementary Medicine	DX5CU	WOS:000384398200017	27543343				2021-06-18	
J	Lombardi, NJ; Tucker, B; Freedman, KB; Austin, LS; Eck, B; Pepe, M; Tjoumakaris, FP				Lombardi, Nicholas J.; Tucker, Bradford; Freedman, Kevin B.; Austin, Luke S.; Eck, Brandon; Pepe, Matthew; Tjoumakaris, Fotios P.			Accuracy of Athletic Trainer and Physician Diagnoses in Sports Medicine	ORTHOPEDICS			English	Article								It is standard practice in high school athletic programs for certified athletic trainers to evaluate and treat injured student athletes. In some cases, a trainer refers an athlete to a physician for definitive medical management. This study was conducted to determine the rate of agreement between athletic trainers and physicians regarding assessment of injuries in student athletes. All high school athletes who were injured between 2010 and 2012 at 5 regional high schools were included in a research database. All patients who were referred for physician evaluation and treatment were identified and included in this analysis. A total of 286 incidents met the inclusion criteria. A total of 263 (92%) of the athletic trainer assessments and physician diagnoses were in agreement. In the 23 cases of disagreement, fractures and sprains were the most common injuries. Kappa analysis showed the highest interrater agreement in injuries classified as dislocations and concussions and the lowest interrater agreement in meniscal/labral injuries and fractures. In the absence of a confirmed diagnosis, agreement among health care providers can be used to infer accuracy. According to this principle, as agreement between athletic trainers and physicians improves, there is a greater likelihood of arriving at the correct assessment and treatment plan. Athletic trainers are highly skilled professionals who are well trained in the evaluation of athletic injuries. The current study showed that additional training in identifying fractures may be beneficial to athletic trainers and the athletes they treat.	[Lombardi, Nicholas J.; Tucker, Bradford; Freedman, Kevin B.; Austin, Luke S.; Pepe, Matthew; Tjoumakaris, Fotios P.] Thomas Jefferson Univ, Rothman Inst Orthopaed, 2500 English Creek Rd,Bldg 1300, Egg Harbor Township, NJ 08234 USA; [Eck, Brandon] Mercy Suburban Hosp, East Norriton, PA USA	Tjoumakaris, FP (corresponding author), Thomas Jefferson Univ, Rothman Inst Orthopaed, 2500 English Creek Rd,Bldg 1300, Egg Harbor Township, NJ 08234 USA.	Fotios.Tjoumakaris@rothmaninstitute.com	Tjoumakaris, Fotios/N-7039-2019	Tjoumakaris, Fotios/0000-0002-1013-7735			American Medical Association, 2015, ICD 9 CM 2015 PROF E, V2; American Medical Association, 2015, ICD 9 CM 2015 PROF E, V1; American Medical Association, POL H 470 995 ATHL S; Bernstein J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027620; Comstock RD, NATL HIGH SCH SPORTS; Glover Lori, 2010, Minn Med, V93, P43; SMITH AM, 1990, SPORTS MED, V9, P352, DOI 10.2165/00007256-199009060-00004; SMITH AM, 1994, J ATHL TRAINING, V29, P337; Swenson DM, 2010, CLIN J SPORT MED, V20, P293, DOI 10.1097/JSM.0b013e3181e8fae8	9	14	14	0	4	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	0147-7447	1938-2367		ORTHOPEDICS	Orthopedics	SEP-OCT	2016	39	5					E944	E949		10.3928/01477447-20160623-10			6	Orthopedics	Orthopedics	EJ3JD	WOS:000393107500021	27398784				2021-06-18	
J	Stein, CJ; MacDougall, R; Quatman-Yates, CC; Myer, GD; Sugimoto, D; Dennison, RJ; Meehan, WP				Stein, Cynthia J.; MacDougall, Robert; Quatman-Yates, Catherine C.; Myer, Gregory D.; Sugimoto, Dai; Dennison, Roberta J.; Meehan, William P., III			Young Athletes' Concerns About Sport-Related Concussion: The Patient's Perspective	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; attitude; sports; athlete; pediatric; adolescent; concern; perspective	HIGH-SCHOOL; REPORTED OUTCOMES; RECOVERY; DURATION; SYMPTOMS	Objective:Few studies have examined the experience and concerns of the concussed athlete. The purpose of this study was to identify the most pressing concerns of athletes with concussion.Design:Cross-sectional survey of athletes who presented for evaluation of a new sport-related concussion during an 8-month period.Setting:Tertiary-level sports medicine division of a large academic pediatric medical center.Participants:One hundred twenty one patients (67 male, 54 female) aged 8 to 18 years who had sustained a sport-related concussion participated in the study by responding to What is the worst thing for you about having a concussion? on the study questionnaire. Questionnaires were completed in the clinic waiting room before the visit with a provider.Intervention:Inductive content analysis was used to identify themes in the responses to the study question.Main Outcome Measures:Age, sex, sport played at the time of the current injury, history of previous concussion, known contacts with concussion, and subjective report of worst aspect of concussion.Results:Seventy respondents (57.9%) cited symptoms, and 68 (56.2%) reported loss of activity as the worst part of concussion, including 17 (14.0%) who listed both symptoms and loss of activity.Conclusions:Over half of concussed athletes indicate that the most distressing part of the injury is loss of activities, which may result from symptoms of the injury itself and/or the prescribed treatment.Clinical Relevance:Health care providers should not underestimate the degree to which symptoms and loss of activities affect young athletes' general well-being. In addition to the negative impact of concussion symptoms, there is an obvious cost of physical, cognitive, and social activity restrictions for patients recovering from sport-related concussions that should be explicitly addressed.	[Stein, Cynthia J.; MacDougall, Robert; Sugimoto, Dai; Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, Dept Orthopaed, Boston, MA USA; [Quatman-Yates, Catherine C.] Cincinnati Childrens Hosp Med Ctr, Div Occupat & Phys Therapy, Cincinnati, OH 45229 USA; [Quatman-Yates, Catherine C.; Myer, Gregory D.] Cincinnati Childrens Hosp Med Ctr, Div Sports Med, Cincinnati, OH 45229 USA; [Myer, Gregory D.] Cincinnati Childrens Hosp Med Ctr, Sports Med Biodynam Ctr, Cincinnati, OH 45229 USA; [Myer, Gregory D.] Cincinnati Childrens Hosp Med Ctr, Human Performance Lab, Cincinnati, OH 45229 USA; [Myer, Gregory D.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Myer, Gregory D.] Univ Cincinnati, Coll Med, Dept Orthopaed Surg, Cincinnati, OH USA; [Sugimoto, Dai; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Dennison, Roberta J.] Tufts Univ Family Med Residency, Cambridge Hlth Alliance, Malden, MA USA	Stein, CJ (corresponding author), Boston Childrens Hosp, Div Sports Med, 319 Longwood Ave, Boston, MA 02115 USA.	cynthia.stein@childrens.harvard.edu	Quatman-Yates, Catherine/U-9580-2019; Quatman-Yates, Catherine/AAK-4507-2021; Myer, Gregory/H-6572-2016	Myer, Gregory/0000-0002-9983-8422	National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament	W. P. Meehan receives research funding from the National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament. W. P. Meehan also receives royalties from ABC-Clio Publishing and Wolters-Kluwer Publishing. The other authors report no conflicts of interest.	Ahmed S, 2012, MED CARE, V50, P1060, DOI 10.1097/MLR.0b013e318268aaff; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Bergman K, 2013, J NEUROSCI NURS, V45, P124, DOI 10.1097/JNN.0b013e31828a418b; Bitton A, 2014, AM J MANAG CARE, V20, P281; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Fleurence R, 2013, HEALTH AFFAIR, V32, P393, DOI 10.1377/hlthaff.2012.1176; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Joyce AS, 2015, MED SCI SPORT EXER, V47, P1119, DOI 10.1249/MSS.0000000000000534; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Price RA, 2014, MED CARE RES REV, V71, P522, DOI 10.1177/1077558714541480; Selby JV, 2014, NEW ENGL J MED, V370, P592, DOI 10.1056/NEJMp1313061; Snell DL, 2015, BRAIN INJURY, V29, P291, DOI 10.3109/02699052.2014.976594; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966	24	14	14	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2016	26	5					386	390		10.1097/JSM.0000000000000268			5	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	DW8LH	WOS:000383906800009	26540601				2021-06-18	
J	Vaewpanich, J; Reuter-Rice, K				Vaewpanich, Jarin; Reuter-Rice, Karin			Continuous electroencephalography in pediatric traumatic brain injury: Seizure characteristics and outcomes	EPILEPSY & BEHAVIOR			English	Article						Traumatic brain injury; Continuous electroencephalography; Neurocognitive outcome; Pediatric; Posttraumatic seizure; PICU	SEVERE HEAD-INJURY; NONCONVULSIVE ELECTROGRAPHIC SEIZURES; NONACCIDENTAL TRAUMA; CONTINUOUS EEG; UNITED-STATES; POSTTRAUMATIC SEIZURES; CLINICAL INDICATORS; CONSENSUS STATEMENT; PROGNOSTIC-FACTORS; CHILDREN	Background: Traumatic brain injury (TBI) is a major cause of pediatric morbidity and mortality. Secondary injury that occurs as a result of a direct impact plays a crucial role in patient prognosis. The guidelines for the management of severe TBI target treatment of secondary injury. Posttraumatic seizure, one of the secondary injury sequelae, contributes to further damage to the injured brain. Continuous electroencephalography (cEEG) helps detect both clinical and subclinical seizure, which aids early detection and prompt treatment. Objective: The aim of this study was to examine the relationship between cEEG findings in pediatric traumatic brain injury and neurocognitive/functional outcomes. Methods: This study focuses on a subgroup of a larger prospective parent study that examined children admitted to a level-1 trauma hospital. The subgroup included sixteen children admitted to the pediatric intensive care unit (PICU) who received cEEG monitoring. Characteristics included demographics, cEEG reports, and antiseizure medication. We also examined outcome scores at the time of discharge and 4-6 weeks postdischarge using the Glasgow Outcome Scale Extended Pediatrics and center-based speech pathology neurocognitive/functional evaluation scores. Results: Sixteen patients were included in this study. Patients with severe TBI made up the majority of those that received cEEG monitoring. Nonaccidental trauma was the most frequent TBI etiology (75%), and subdural hema-toma was the most common lesion diagnosed by CT scan (75%). Fifteen patients received antiseizure medication, and levetiracetam was the medication of choice. Four patients (25%) developed seizures during PICU admission, and 3 patients had subclinical seizures that were detected by cEEG. One of these patients also had both a clinical and subclinical seizure. Nonaccidental trauma was an etiology of TBI in all patients with seizures. Characteristics of a nonreactive pattern, severe/burst suppression, and lack of sleep architecture, on cEEG, were associated with poor neurocognitive/functional outcome. Conclusion: Continuous electroencephalography demonstrated a pattern that associated seizures and poor outcomes in patients with moderate to severe traumatic brain injury, particularly in a subgroup of patients with nonaccidental trauma. Best practice should include institution-based TBI cEEG protocols, which may detect seizure activity early and promote outcomes. Future studies should include examination of individual cEEG characteristics to help improve outcomes in pediatric TBI. (C) 2016 Elsevier Inc. All rights reserved.	[Vaewpanich, Jarin] Mahidol Univ, Ramathibodi Hosp, Dept Pediat, 270 Rama 6 Rd, Bangkok 10400, Thailand; [Reuter-Rice, Karin] Duke Univ, Duke Inst Brain Sci, 307 Trent Dr,DUMC 3322, Durham, NC 27710 USA; [Reuter-Rice, Karin] Duke Inst Brain Sci, Sch Nursing, 307 Trent Dr,DUMC 3322, Durham, NC 27710 USA; [Reuter-Rice, Karin] Duke Inst Brain Sci, Dept Pediat, Sch Med, 307 Trent Dr,DUMC 3322, Durham, NC 27710 USA; [Vaewpanich, Jarin] Duke Univ, Childrens Hosp, Durham, NC USA	Reuter-Rice, K (corresponding author), Duke Inst Brain Sci, Sch Nursing, 307 Trent Dr,DUMC 3322, Durham, NC 27710 USA.	jarivaew@yahoo.com; karin.reuter-rice@duke.edu		Reuter-Rice, Karin/0000-0003-1501-8994	NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [P30 NR014139] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [P30NR014139] Funding Source: NIH RePORTER		Abend NS, 2013, LANCET NEUROL, V12, P1170, DOI 10.1016/S1474-4422(13)70246-1; Abend NS, 2011, NEUROCRIT CARE, V15, P70, DOI 10.1007/s12028-010-9380-z; [Anonymous], 1993, EPILEPSIA, V34, P592; Arndt DH, 2016, J CHILD NEUROL, V31, P46, DOI 10.1177/0883073814562249; Arndt DH, 2013, EPILEPSIA, V54, P1780, DOI 10.1111/epi.12369; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Beers SR, 2012, J NEUROTRAUM, V29, P1126, DOI 10.1089/neu.2011.2272; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Chung MG, 2016, PEDIATR CRIT CARE ME, V17, P150, DOI 10.1097/PCC.0000000000000588; Claassen J, 2014, NEUROCRIT CARE, V21, P129, DOI 10.1007/s12028-014-0022-8; Claassen J, 2013, INTENS CARE MED, V39, P1337, DOI 10.1007/s00134-013-2938-4; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Deans KJ, 2013, J TRAUMA ACUTE CARE, V75, P157, DOI 10.1097/TA.0b013e3182984acb; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Estroff JM, 2015, J EMERG MED, V48, P274, DOI 10.1016/j.jemermed.2014.07.030; EVANS BM, 1995, J NEUROL NEUROSUR PS, V59, P17, DOI 10.1136/jnnp.59.1.17; Gallentine WB, 2013, J CLIN NEUROPHYSIOL, V30, P126, DOI 10.1097/WNP.0b013e3182872adf; Greiner MV, 2012, CHILD NERV SYST, V28, P889, DOI 10.1007/s00381-012-1714-z; Hasbani DM, 2013, PEDIATR CRIT CARE ME, V14, P709, DOI 10.1097/PCC.0b013e3182917b83; Herman ST, 2015, J CLIN NEUROPHYSIOL, V32, P87, DOI 10.1097/WNP.0000000000000166; Hofmeijer J, 2014, CLIN NEUROPHYSIOL, V125, P947, DOI 10.1016/j.clinph.2013.10.017; Inaba K, 2013, J TRAUMA ACUTE CARE, V74, P766, DOI 10.1097/TA.0b013e3182826e84; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Lan YH, 2015, NEUROPEDIATRICS, V46, P211, DOI 10.1055/s-0035-1548673; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; O'Neill BR, 2015, J NEUROSURG-PEDIATR, V16, P167, DOI 10.3171/2014.12.PEDS14263; Patel N, 2013, J TRAUMA ACUTE CARE, V74, P771; RamachandranNair R, 2005, PEDIATR NEUROL, V33, P345, DOI 10.1016/j.pediatrneurol.2005.05.007; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Roach JP, 2014, PEDIATR SURG INT, V30, P1103, DOI 10.1007/s00383-014-3598-3; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schreiber JM, 2012, NEUROCRIT CARE, V17, P31, DOI 10.1007/s12028-012-9715-z; Stanley RM, 2012, PEDIATRICS, V129, pE24, DOI 10.1542/peds.2011-2074; Theilen HJ, 2000, CRIT CARE MED, V28, P3522, DOI 10.1097/00003246-200010000-00029; Vavilala MS, 2014, CRIT CARE MED, V42, P2258, DOI 10.1097/CCM.0000000000000507; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Zafar SN, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-30	44	14	14	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	SEP	2016	62						225	230		10.1016/j.yebeh.2016.07.012			6	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	DX5AP	WOS:000384392500040	27500827	Green Accepted			2021-06-18	
J	Verfaellie, M; Lee, LO; Lafleche, G; Spiro, A				Verfaellie, Mieke; Lee, Lewina O.; Lafleche, Ginette; Spiro, Avron			Self-Reported Sleep Disturbance Mediates the Relationship Between PTSD and Cognitive Outcome in Blast-Exposed OEF/OIF Veterans	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						blast injuries; cognition; mediation; posttraumatic stress disorder; sleep; traumatic brain injury	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; NEUROPSYCHOLOGICAL OUTCOMES; COMBAT VETERANS; PHYSICAL HEALTH; DEPRIVATION; INSOMNIA; PERFORMANCE; SYMPTOMS; MILITARY	Objectives: To examine the contribution of sleep disturbance to cognitive performance following blast exposure. Design: Correlational research evaluating self-reported sleep disturbance as a mediator of the association between the primary blast-related comorbidities of mild traumatic brain injury (mTBI) and posttraumatic stress disorder and cognitive outcome. Participants: One hundred sixty Operation Enduring Freedom/Operation Iraqi Freedom Veterans with a history of blast exposure assigned to 1 of 3 groups (no TBI, mTBI without loss of consciousness, and mTBI with loss of consciousness). Main Outcome Measures: Neuropsychological measures and self-report of sleep disturbance. Results: Increased posttraumatic stress disorder symptomatology was associated with worse performance inmultiple cognitive domains. This association was mediated in part by self-reported sleep disturbance. Traumatic brain injury with loss of consciousness was associated with lower manual dexterity, but this association was not mediated by sleep disturbance. Conclusions: Our results highlight the importance of sleep disturbance as a factor contributing to cognitive outcome in individuals with posttraumatic stress disorder symptoms. They point to the importance of considering sleep problems in the diagnosis and treatment of cognitive deficits in veterans with blast exposure.	[Verfaellie, Mieke; Lafleche, Ginette] VA Boston Healthcare Syst, Memory Disorders Res Ctr, 151-A,150 South Huntington Ave, Boston, MA 02130 USA; [Verfaellie, Mieke; Lee, Lewina O.; Lafleche, Ginette; Spiro, Avron] Boston Univ, Sch Med, Boston, MA 02118 USA; [Lee, Lewina O.; Spiro, Avron] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA; [Lee, Lewina O.; Spiro, Avron] Boston Univ, Sch Publ Hlth, Boston, MA USA	Verfaellie, M (corresponding author), VA Boston Healthcare Syst, Memory Disorders Res Ctr, 151-A,150 South Huntington Ave, Boston, MA 02130 USA.	verf@bu.edu		Verfaellie, Mieke/0000-0001-5535-4584; /0000-0002-1652-8198; Spiro III, Avron/0000-0003-4080-8621	Merit Review grants - Clinical Science Research and Development Service and Rehabilitation Research and Development Service of the Department of Veterans AffairsUS Department of Veterans Affairs; Clinical Science Research and Development Service of the Department of Veterans Affairs; Veterans AffairsUS Department of Veterans Affairs [I01RX000216] Funding Source: NIH RePORTER	The research was supported by Merit Review grants awarded by the Clinical Science Research and Development Service and Rehabilitation Research and Development Service of the Department of Veterans Affairs to Dr Verfaellie. Drs Verfaellie and Spiro are supported by the Clinical Science Research and Development Service of the Department of Veterans Affairs. The contents do not represent the views of the U.S. Department of Veterans Affairs or the US Government.	Banks S, 2007, J CLIN SLEEP MED, V3, P519; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Benedict R., 1997, BRIEF VISUOSPATIAL M; Bentler PM, 2007, PERS INDIV DIFFER, V42, P825, DOI 10.1016/j.paid.2006.09.024; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bloomfield ILM, 2010, J INT NEUROPSYCH SOC, V16, P17, DOI 10.1017/S1355617709990798; Brownlow JA, 2014, J TRAUMA STRESS, V27, P217, DOI 10.1002/jts.21906; Burri A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057826; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Campbell TA, 2009, PSYCHIAT ANN, V39, P796, DOI 10.3928/00485713-20090728-01; Capaldi VF, 2011, MIL MED, V176, P879, DOI 10.7205/MILMED-D-10-00440; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Clum GA, 2001, J NERV MENT DIS, V189, P618, DOI 10.1097/00005053-200109000-00008; Collen J, 2012, CHEST, V142, P622, DOI 10.1378/chest.11-1603; Couyoumdjian A, 2010, J SLEEP RES, V19, P64, DOI 10.1111/j.1365-2869.2009.00774.x; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Diekelmann S, 2010, NAT REV NEUROSCI, V11, P114, DOI 10.1038/nrn2762; Draganich C, 2014, J EXP PSYCHOL LEARN, V40, P857, DOI 10.1037/a0035546; Drummond SPA, 2006, J SLEEP RES, V15, P261, DOI 10.1111/j.1365-2869.2006.00535.x; Engdahl BE, 2000, BIOL PSYCHIAT, V47, P520, DOI 10.1016/S0006-3223(99)00201-2; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; Fortier-Brochu E, 2012, SLEEP MED REV, V16, P83, DOI 10.1016/j.smrv.2011.03.008; Fulda S, 2001, SLEEP MED REV, V5, P423, DOI 10.1053/smrv.2001.0157; Germain A, 2013, AM J PSYCHIAT, V170, P372, DOI 10.1176/appi.ajp.2012.12040432; Gilbert KS, 2015, CLIN PSYCHOL REV, V40, P195, DOI 10.1016/j.cpr.2015.05.008; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Halstead WC, 1947, BRAIN INTELLIGENCE; Harvey AG, 2003, CLIN PSYCHOL REV, V23, P377, DOI 10.1016/S0272-7358(03)00032-1; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hubel KA, 2013, J CLIN EXP NEUROPSYC, V35, P745, DOI 10.1080/13803395.2013.824070; Hurwitz TD, 1998, BIOL PSYCHIAT, V44, P1066, DOI 10.1016/S0006-3223(98)00089-4; Inman D. J., 1990, J TRAUMA STRESS, V3, P429, DOI [10.1002/jts.2490030311, DOI 10.1007/BF00974782]; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kendall-Tackett K, 2009, PSYCHOL TRAUMA-US, V1, P35, DOI 10.1037/a0015128; Killgore WDS, 2010, PROG BRAIN RES, V185, P105, DOI 10.1016/B978-0-444-53702-7.00007-5; Kinoshita LM, 2012, SLEEP BREATH, V16, P1201, DOI 10.1007/s11325-011-0632-8; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Kobayashi I, 2007, PSYCHOPHYSIOLOGY, V44, P660, DOI 10.1111/j.1469-8986.2007.537.x; Lamarche LJ, 2007, J CLIN PSYCHIAT, V68, P1257, DOI 10.4088/JCP.v68n0813; Landry GJ, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00325; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lim J, 2010, PSYCHOL BULL, V136, P375, DOI 10.1037/a0018883; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; Muthen L.K., 1998, MPLUS USERS GUIDE, V8th; Nelson NW, 2012, J INT NEUROPSYCH SOC, V18, P845, DOI 10.1017/S1355617712000616; Neylan TC, 1998, AM J PSYCHIAT, V155, P929, DOI 10.1176/ajp.155.7.929; Nilsson JP, 2005, J SLEEP RES, V14, P1, DOI 10.1111/j.1365-2869.2005.00442.x; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P1390, DOI 10.1176/appi.ajp.161.8.1390; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Oudiette D, 2013, TRENDS COGN SCI, V17, P142, DOI 10.1016/j.tics.2013.01.006; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; ROSS RJ, 1989, AM J PSYCHIAT, V146, P697; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; SAMKOFF JS, 1991, ACAD MED, V66, P687, DOI 10.1097/00001888-199111000-00013; Schneider C, 2004, J SLEEP RES, V13, P373, DOI 10.1111/j.1365-2869.2004.00427.x; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Spira AP, 2014, CURR OPIN PSYCHIATR, V27, P478, DOI 10.1097/YCO.0000000000000106; Spoormaker VI, 2008, SLEEP MED REV, V12, P169, DOI 10.1016/j.smrv.2007.08.008; Tiffin J., 1968, PURDUE PEGBOARD EXAM; Tombaugh TN, 2000, ARCH CLIN NEUROPSYCH, V15, P817; TUCKER LR, 1973, PSYCHOMETRIKA, V38, P1, DOI 10.1007/bf02291170; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Verfaellie M, 2012, PTSD MILD TRAUMATIC, P82; Verfaellie M, 2014, NEUROPSYCHOLOGY, V28, P337, DOI 10.1037/neu0000027; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Waldron-Perrine B, 2012, MIL MED, V177, P1293, DOI 10.7205/MILMED-D-12-00169; Walker MP, 2009, ANN NY ACAD SCI, V1156, P168, DOI 10.1111/j.1749-6632.2009.04416.x; Waters F, 2011, J INT NEUROPSYCH SOC, V17, P571, DOI 10.1017/S1355617711000610; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wechsler D., 1997, WAIS 3 ADM SCORING M; Yaffe K, 2014, LANCET NEUROL, V13, P1017, DOI 10.1016/S1474-4422(14)70172-3; Yaffe K, 2010, ARCH GEN PSYCHIAT, V67, P608, DOI 10.1001/archgenpsychiatry.2010.61; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	93	14	14	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2016	31	5					309	319		10.1097/HTR.0000000000000197			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DX2ZY	WOS:000384243600009	26580692	Green Accepted			2021-06-18	
J	Wiseman-Hakes, C; Duclos, C; Blais, H; Dumont, M; Bernard, F; Desautels, A; Menon, DK; Gilbert, D; Carrier, J; Gosselin, N				Wiseman-Hakes, Catherine; Duclos, Catherine; Blais, Helene; Dumont, Marie; Bernard, Francis; Desautels, Alex; Menon, David K.; Gilbert, Danielle; Carrier, Julie; Gosselin, Nadia			Sleep in the Acute Phase of Severe Traumatic Brain Injury: A Snapshot of Polysomnography	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; sleep; polysomnography; orthopedic injury; acute care	INTENSIVE-CARE-UNIT; WAKE DISTURBANCES; CLINICAL-IMPLICATIONS; PRACTICAL SCALE; HEAD-INJURY; WAKEFULNESS; STATEMENT; NEURONS; IMPACT; MICE	Background and Objectives. The onset of pervasive sleep-wake disturbances associated with traumatic brain injury (TBI) is poorly understood. This study aimed to (a) determine the feasibility of using polysomnography in patients in the acute, hospitalized stage of severe TBI and (b) explore sleep quality and sleep architecture during this stage of recovery, compared to patients with other traumatic injuries. Methods. A cross-sectional case-control design was used. We examined the sleep of 7 patients with severe TBI (17-47 years; 20.3 +/- 15.0 days postinjury) and 6 patients with orthopedic and/or spinal cord injuries (OSCI; 19-58 years; 16.9 +/- 4.9 days postinjury). One night of ambulatory polysomnography was performed at bedside. Results. Compared to OSCI patients, TBI patients showed a significantly longer duration of nocturnal sleep and earlier nighttime sleep onset. Sleep efficiency was low and comparable in both groups. All sleep stages were observed in both groups with normal proportions according to age. Conclusion. Patients in the acute stage of severe TBI exhibit increased sleep duration and earlier sleep onset, suggesting that the injured brain enhances sleep need and/or decreases the ability to maintain wakefulness. As poor sleep efficiency could compromise brain recovery, further studies should investigate whether strategies known to optimize sleep in healthy individuals are efficacious in acute TBI. While there are several inherent challenges, polysomnography is a useful means of examining sleep in the early stage of recovery in patients with severe TBI.	[Wiseman-Hakes, Catherine; Duclos, Catherine; Blais, Helene; Dumont, Marie; Bernard, Francis; Desautels, Alex; Gilbert, Danielle; Carrier, Julie; Gosselin, Nadia] Hop Sacre Coeur, Montreal, PQ, Canada; [Wiseman-Hakes, Catherine; Duclos, Catherine; Dumont, Marie; Bernard, Francis; Desautels, Alex; Gilbert, Danielle; Carrier, Julie; Gosselin, Nadia] Univ Montreal, Montreal, PQ, Canada; [Menon, David K.] Univ Cambridge, Cambridge, England	Gosselin, N (corresponding author), Hop Sacre Coeur, Ctr Adv Res Sleep Med, 5400 Boul Gouin Ouest,Local E-0330, Montreal, PQ H4J 1C5, Canada.	nadia.gosselin@umontreal.ca	Wiseman-Hakes, Catherine/AAC-8303-2021	Wiseman-Hakes, Catherine/0000-0001-8441-884X; Carrier, Julie/0000-0001-5311-2370	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Fonds pour la recherche du Quebec-Sante; Reseau provincial de recherche en adaptation-readaptation; Consortium pour la recherche en traumatologie du Quebec; Fondation Neurotrauma Marie-Robert; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Canadian Institutes of Health Research (grant to NG and scholarship to CD), by the Fonds pour la recherche du Quebec-Sante (grant to NG), by the Reseau provincial de recherche en adaptation-readaptation (fellowship to CWH), by the Consortium pour la recherche en traumatologie du Quebec (grant to NG), and by the Fondation Neurotrauma Marie-Robert (scholarship to CD).	Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Beecroft JM, 2008, INTENS CARE MED, V34, P2076, DOI 10.1007/s00134-008-1180-y; Bijwadia JS, 2009, CURR OPIN CRIT CARE, V15, P25, DOI 10.1097/MCC.0b013e3283220dc7; Bourne RS, 2007, CRIT CARE, V11, DOI 10.1186/cc5966; Cantor JB, 2012, J HEAD TRAUMA REHAB, V27, pE1, DOI 10.1097/HTR.0b013e318270f91e; Chiu HY, 2014, INT J NURS STUD, V51, P892, DOI 10.1016/j.ijnurstu.2013.10.020; Dimsdale JE, 2007, J CLIN SLEEP MED, V3, P33; Drouot X, 2008, SLEEP MED REV, V12, P391, DOI 10.1016/j.smrv.2007.11.004; Duclos C, 2014, PATHOL BIOL, V62, P252, DOI 10.1016/j.patbio.2014.05.014; Duclos C, 2014, NEUROREHAB NEURAL RE, V28, P472, DOI 10.1177/1545968313517756; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hagen C, 1973, RANCHO LEVELS COGNIT; Hardin KA, 2009, CHEST, V136, P284, DOI 10.1378/chest.08-1546; Iber C, 2007, AASM MANUAL SCORING; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lim MM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007092; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Meerlo P, 2009, SLEEP MED REV, V13, P187, DOI 10.1016/j.smrv.2008.07.004; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mollayeva T, 2013, ENCY SLEEP, V2, P330; Ouellet MC, 2015, LANCET NEUROL, V14, P746, DOI 10.1016/S1474-4422(15)00068-X; ROSENBERG J, 1995, EUR J ANAESTH, V12, P28; Rowe RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082507; Sabir M, 2015, BRAIN BEHAV IMMUN, V47, P118, DOI 10.1016/j.bbi.2014.12.023; Skopin MD, 2015, J NEUROTRAUM, V32, P289, DOI 10.1089/neu.2014.3664; Suchecki Deborah, 2012, Front Neurol, V3, P41, DOI 10.3389/fneur.2012.00041; TEASDALE G, 1974, LANCET, V2, P81; Tononi G, 2014, NEURON, V81, P12, DOI 10.1016/j.neuron.2013.12.025; Valko PO, 2015, ANN NEUROL, V77, P177, DOI 10.1002/ana.24298; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Willie JT, 2012, J NEUROTRAUM, V29, P1908, DOI 10.1089/neu.2012.2404; Wiseman-Hakes C, 2009, CRIT REV PHYS REHABI, V21, P317, DOI DOI 10.1615/CRITREVPHYSREHABILMED.V21.I3-4.70	34	14	14	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	SEP	2016	30	8					713	721		10.1177/1545968315619697			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DU9WJ	WOS:000382568500002	26704256	Bronze			2021-06-18	
J	Mao, SS; Li, XH; Wang, J; Ding, X; Zhang, CY; Li, L				Mao, Susu; Li, Xiuhua; Wang, Jin; Ding, Xin; Zhang, Chenyu; Li, Liang			miR-17-92 facilitates neuronal differentiation of transplanted neural stem/precursor cells under neuroinflammatory conditions	JOURNAL OF NEUROINFLAMMATION			English	Article						miR-17-92; Neural stem/precursor cells; Transplantation; Neuroinflammation; JAK-STAT pathway; Differentiation	TRAUMATIC BRAIN-INJURY; STEM-CELLS; PRECURSOR CELLS; STEM/PROGENITOR CELLS; IN-VITRO; ASTROCYTE; LEUKEMIA; INFLAMMATION; ACTIVATION; CLUSTER	Background: Neural stem/precursor cells (NSCs) are of particular interest because of their potential application in cell therapy for brain damage. However, most brain injury cases are followed with neuroinflammatory stress, which affects the lineage selection of grafted NSCs by promoting astrocytogenesis, thus hampering the potential for neural replacement. The present study investigated the role of miR-17-92 in protecting against detrimental effects of neuroinflammation on NSC differentiation in cell therapy. Methods: NSCs were treated with conditioned medium from lesioned astrocytes with/without neutralizing antibodies of leukemia inhibitory factor (LIF) or/and ciliary neurotrophic factor (CNTF), respectively. Afterward, the levels of p-STAT3 and p-JAK2 were determined by western blotting while expression of glial fibrillary acidic protein (GFAP) and beta-tubulin III was assessed by immunostaining. The activation of JAK-STAT pathway and cell differentiation were also evaluated after we overexpressed miR-17-92 in NSCs under different neuroinflammatory conditions. After the transplantation of miR-17-92-overexpressing NSCs into injured mouse cortex, PH3, nestin, GFAP, and NeuN were analyzed by immunostaining. In addition, motor coordination of mice was evaluated by rotarod test. Results: Conditioned medium from lesioned astrocytes activated JAK-STAT pathway and facilitated astrocytic differentiation in NSCs while neutralizing antibodies of LIF and CNTF remarkably attenuated such effects. miR-17-92 cluster repressed the expression of multiple proteins including GP130, CNTFR, JAK2, and STAT3 in JAK-STAT pathway. Overexpression of miR-17-92 in NSCs systematically blocked the activation of JAK-STAT pathway mediated by LIF and CNTF, which facilitated neuronal differentiation in vitro. Furthermore, miR-17-92 increased neuronal generation of grafted NSCs and reduced astrogliosis, which resulted in the improvement of motor coordination of brain-injured mice. Conclusions: Our results suggest that miR-17-92 promotes neuronal differentiation of grafted NSCs under neuroinflammatory condition via inhibition of multiple proteins in JAK-STAT pathway.	[Mao, Susu; Li, Xiuhua; Wang, Jin; Ding, Xin; Zhang, Chenyu; Li, Liang] Nanjing Univ, Jiangsu Engn Res Ctr MicroRNA Biol & Biotechnol, State Key Lab Pharmaceut Biotechnol,Sch Life Sci, NJU Adv Inst Life Sci,Collaborat Innovat Ctr Chem, 163 Xianlin Rd, Nanjing 210023, Jiangsu, Peoples R China; [Mao, Susu] Nantong Univ, Jiangsu Key Lab Neuroregenerat, Coinnovat Ctr Neuroregenerat, Nantong 226001, Peoples R China	Li, L (corresponding author), Nanjing Univ, Jiangsu Engn Res Ctr MicroRNA Biol & Biotechnol, State Key Lab Pharmaceut Biotechnol,Sch Life Sci, NJU Adv Inst Life Sci,Collaborat Innovat Ctr Chem, 163 Xianlin Rd, Nanjing 210023, Jiangsu, Peoples R China.	lijing@sibs.ac.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31471019]	This work was supported by grants from the National Natural Science Foundation of China (31471019).	Bauer S, 2007, NAT REV NEUROSCI, V8, P221, DOI 10.1038/nrn2054; Bertrand N, 2002, NAT REV NEUROSCI, V3, P517, DOI 10.1038/nrn874; Brites D, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00476; Butzkueven H, 2006, GLIA, V53, P696, DOI 10.1002/glia.20321; Carraro G, 2009, DEV BIOL, V333, P238, DOI 10.1016/j.ydbio.2009.06.020; Chau MJ, 2014, STEM CELLS, V32, P3075, DOI 10.1002/stem.1802; Coorey NJ, 2015, INVEST OPHTH VIS SCI, V56, P2151, DOI 10.1167/iovs.14-15695; Covacu R, 2017, NEUROSCIENTIST, V23, P27, DOI 10.1177/1073858415616559; DeVito WJ, 1999, J CELL BIOCHEM, V74, P278; Faijerson J, 2006, J NEUROSCI RES, V84, P1415, DOI 10.1002/jnr.21044; Fan XL, 2010, NEUROCHEM INT, V56, P291, DOI 10.1016/j.neuint.2009.11.001; Fan Z, 2016, MOL NEUROBIOL, V53, P7057, DOI 10.1007/s12035-015-9620-5; Foshay KM, 2009, DEV BIOL, V326, P431, DOI 10.1016/j.ydbio.2008.11.016; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; He F, 2005, NAT NEUROSCI, V8, P616, DOI 10.1038/nn1440; Hirabayashi Y, 2005, NEUROSCI RES, V51, P331, DOI 10.1016/j.neures.2005.01.004; Hulsmans M, 2013, CARDIOVASC RES, V100, P7, DOI 10.1093/cvr/cvt161; Ideguchi M, 2008, J NEUROSCI RES, V86, P1936, DOI 10.1002/jnr.21652; Jhaveri K, 2016, CLIN BREAST CANCER, V16, P113, DOI 10.1016/j.clbc.2015.11.006; Kang SS, 2013, NEUROBIOL DIS, V49, P68, DOI 10.1016/j.nbd.2012.08.020; Kim DY, 2015, CELL DEATH DIFFER, V22, P2034, DOI 10.1038/cdd.2015.123; Kokaia Z, 2012, NAT NEUROSCI, V15, P1078, DOI 10.1038/nn.3163; Laterza C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3597; Laywell ED, 2005, J COMP NEUROL, V493, P321, DOI 10.1002/cne.20722; Le MTN, 2009, MOL CELL BIOL, V29, P5290, DOI 10.1128/MCB.01694-08; Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005; Li HD, 2007, GLIA, V55, P24, DOI 10.1002/glia.20434; Li J, 2015, SCI REP-UK, V5, DOI 10.1038/srep17212; Li YM, 2012, BLOOD, V119, P4486, DOI 10.1182/blood-2011-09-378687; Liu Q, 2016, NAT NEUROSCI, V19, P243, DOI 10.1038/nn.4211; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lukovic D, 2015, STEM CELLS, V33, P1036, DOI 10.1002/stem.1959; Ma SS, 2016, ONCOTARGET, V7, P13502, DOI 10.18632/oncotarget.6284; Makri G, 2010, STEM CELLS, V28, P127, DOI 10.1002/stem.258; Mao SS, 2015, PROTEIN CELL, V6, P529, DOI 10.1007/s13238-015-0168-y; Mao SS, 2014, FEBS J, V281, P1144, DOI 10.1111/febs.12680; MAYER M, 1994, DEVELOPMENT, V120, P143; Molyneaux BJ, 2007, NAT REV NEUROSCI, V8, P427, DOI 10.1038/nrn2151; Mosher KI, 2012, NAT NEUROSCI, V15, P1485, DOI 10.1038/nn.3233; Naka-Kaneda H, 2014, P NATL ACAD SCI USA, V111, P1604, DOI 10.1073/pnas.1315567111; Nicola NA, 2015, CYTOKINE GROWTH F R, V26, P533, DOI 10.1016/j.cytogfr.2015.07.001; Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071; Philippe L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00070; Seo H, 2016, BMB REP, V49, P128, DOI 10.5483/BMBRep.2016.49.2.202; Sun Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083067; Wang FW, 2011, STEM CELL RES, V7, P41, DOI 10.1016/j.scr.2011.03.004; Wu W, 2013, BRIT J CANCER, V108, P653, DOI 10.1038/bjc.2012.587; Zhang JF, 2016, J MOL NEUROSCI, V58, P507, DOI 10.1007/s12031-016-0712-0; Zhang MM, 2011, J IMMUNOL, V186, P4716, DOI 10.4049/jimmunol.1002989; Zhang X, 2013, NEUROBIOL AGING, V34, P663, DOI 10.1016/j.neurobiolaging.2012.06.012; Zhang YL, 2016, AM J CHINESE MED, V44, P103, DOI 10.1142/S0192415X16500075; Zhou YJ, 2016, J CELL MOL MED, V20, P939, DOI 10.1111/jcmm.12782	52	14	16	0	17	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	AUG 27	2016	13								208	10.1186/s12974-016-0685-5			14	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	DV4ER	WOS:000382878600001	27567678	DOAJ Gold, Green Published			2021-06-18	
J	Sun, H; Lingsma, HF; Steyerberg, EW; Maas, AIR				Sun, Hong; Lingsma, Hester F.; Steyerberg, Ewout W.; Maas, Andrew I. R.			External Validation of the International Mission for Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury: Prognostic Models for Traumatic Brain Injury on the Study of the Neuroprotective Activity of Progesterone in Severe Traumatic Brain Injuries Trial	JOURNAL OF NEUROTRAUMA			English	Article						case-mix; external validation; outcome; prognostic model; traumatic brain injury	IMPACT; PREDICTION; MODERATE; CRASH	Prediction models for patients with traumatic brain injury (TBI) are important for multiple reasons, including case-mix adjustment, trial design, and benchmarking for quality-of-care evaluation. Models should be generalizable and therefore require regular external validation. We aimed to validate the International Mission for Prognosis and Analysis of Clinical Trials in TBI (IMPACT) prognostic models for moderate and severe TBI in a recent randomized controlled trial. We studied 1124 patients enrolled in the multi-center randomized placebo-controlled Study of the Neuroprotective Activity of Progesterone in Severe Traumatic Brain Injuries (SyNAPSe) trial that evaluated the efficacy of progesterone in TBI. Treatment and placebo groups were combined for analysis. We evaluated the predictive performance of the three prognostic models (core, extended, and lab) from the IMPACT study with regard to discrimination (area under the receiver operating characteristic curve [AUC]) and calibration (comparison of observed to predicted risks). Substantial differences were found in case-mix and outcome distribution between IMPACT and SyNAPSe. In line with the more homogeneous case-mix of a clinical trial, the discriminative performance was reasonable. For the core model, an AUC of 0.677 and 0.684 was obtained for 6-month mortality and unfavorable outcome, respectively. Performance was slightly better for the extended model (0.693 and 0.705) and for the lab model (0.689 and 0.711, respectively). For calibration, we found overestimation ofmortality, especially at higher risk predictions, and underestimation of unfavorable outcome, especially at lower risk predictions. This pattern of miscalibration was consistent across all three models. In a contemporary trial setting, the IMPACT models have reasonable discrimination if enrollment restrictions apply. Observed changes in outcome distribution necessitate updating of previously developed prognostic models.	[Sun, Hong; Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium; [Sun, Hong; Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium; [Lingsma, Hester F.; Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands	Maas, AIR (corresponding author), Univ Antwerp Hosp, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium.	andrew.maas@uza.be					DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Han JL, 2014, J NEUROTRAUM, V31, P1146, DOI 10.1089/neu.2013.3003; Harrell Frank E., 2001, REGRESSION MODELING; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Lu J, 2010, J NEUROTRAUM, V27, P843, DOI 10.1089/neu.2010.1293; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Moons KGM, 2015, ANN INTERN MED, V162, pW1, DOI 10.7326/M14-0698; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Slieker FJA, 2008, NEUROSURGERY, V62, P1321, DOI 10.1227/01.neu.0000333304.79931.4d; Sorani MD, 2009, J TRAUMA, V67, P75, DOI 10.1097/TA.0b013e31818234e8; Steyerberg EW., 2009, CLIN PREDICTION MODE; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Van Buuren S., 2012, FLEXIBLE IMPUTATION; Vergouwe Y, 2010, AM J EPIDEMIOL, V172, P971, DOI 10.1093/aje/kwq223; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wong GKC, 2013, J CLIN NEUROSCI, V20, P1693, DOI 10.1016/j.jocn.2012.12.032	22	14	15	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2016	33	16					1535	1543		10.1089/neu.2015.4164			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DU6ED	WOS:000382305900007	26652051				2021-06-18	
J	Xu, Z; Lv, XA; Dai, Q; Ge, YQ; Xu, J				Xu, Zhen; Lv, Xiao-Ai; Dai, Qun; Ge, Yu-Qing; Xu, Jie			Acute upregulation of neuronal mitochondrial type-1 cannabinoid receptor and it's role in metabolic defects and neuronal apoptosis after TBI	MOLECULAR BRAIN			English	Article						Apoptosis; Mitochondrial type-1 cannabinoid receptor; Metabolic defects; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; CELL-DEATH; AKT; CB1; PROTEIN; PHOSPHORYLATION; DYSFUNCTION; ACTIVATION; ISCHEMIA; ENDOCANNABINOIDS	Metabolic defects and neuronal apoptosis initiated by traumatic brain injury (TBI) contribute to subsequent neurodegeneration. They are all regulated by mechanisms centered around mitochondrion. Type-1 cannabinoid receptor (CB1) is a G-protein coupled receptor (GPCR) enriched on neuronal plasma membrane. Recent evidences point to the substantial presence of CB1 receptors on neuronal mitochondrial outer membranes (mtCB1) and the activation of mtCB1 influences aerobic respiration via inhibiting mitochondrial cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA)/complex I pathway. The expression and role of neuronal mtCB1 under TBI are unknown. Using TBI models of cultured neurons, wild type and CB1 knockout mice, we found mtCB1 quickly upregulated after TBI. Activation of mtCB1 promoted metabolic defects accompanied with ATP shortage but protected neurons from apoptosis. Selective activation of plasma membrane CB1 showed no effects on neuronal metabolism and apoptosis. Activation of mtCB1 receptors inhibited mitochondrial cAMP/PKA/complex I and resulted in exacerbated metabolic defects accompanied with a higher ratio of ATP reduction to oxygen consumption decrease as well as neuronal apoptosis. Further research found the remarkable accumulation of protein kinase B (AKT) on neuronal mitochondria following TBI and the activation of mtCB1 upregulated mitochondrial AKT/complex V activity. Upregulation of mitochondrial AKT/complex V activity showed anti-apoptosis effects and alleviated ATP shortage in metabolic defects. Taken together, we have identified mtCB1 quickly upregulate after TBI and a dual role the mtCB1 might play in metabolic defects and neuronal apoptosis initiated by TBI: the inhibition of mitochondrial cAMP/PKA/complex I aggravates metabolic defects, energy insufficiency as well as neuronal apoptosis, but the coactivation of mitochondrial AKT/complex V mitigates energy insufficiency and neuronal apoptosis.	[Xu, Zhen] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Neurosurg, 54 Youdian Lane, Hangzhou 310006, Zhejiang, Peoples R China; [Lv, Xiao-Ai] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Surg, 54 Youdian Lane, Hangzhou 310006, Zhejiang, Peoples R China; [Dai, Qun; Ge, Yu-Qing] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Cent Lab, 54 Youdian Lane, Hangzhou 310006, Zhejiang, Peoples R China; [Xu, Jie] Huzhou Cent Hosp, Dept Neurosurg, 198 Hongqi Lane, Huzhou 313003, Peoples R China	Xu, Z (corresponding author), Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Neurosurg, 54 Youdian Lane, Hangzhou 310006, Zhejiang, Peoples R China.	xuzhenhangzhou@yeah.net			Zhejiang provincial natural science foundationNatural Science Foundation of Zhejiang Province [LY16H090014]; Zhejiang provincial medical health and science and technology project foundation [2016KYB213]	This work was supported by Zhejiang provincial natural science foundation (LY16H090014) and Zhejiang provincial medical health and science and technology project foundation (2016KYB213).	Benard G, 2012, NAT NEUROSCI, V15, P558, DOI 10.1038/nn.3053; Bijur GN, 2003, J NEUROCHEM, V87, P1427, DOI 10.1046/j.1471-4159.2003.02113.x; Caballero-Caballero A, 2013, J NEUROCHEM, V124, P749, DOI 10.1111/jnc.12133; Cabral GA, 2005, J LEUKOCYTE BIOL, V78, P1192, DOI 10.1189/jlb.0405216; Cammarota M, 1999, J NEUROCHEM, V72, P2272, DOI 10.1046/j.1471-4159.1999.0722272.x; Carre E, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00146; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Console-Bram L, 2012, PROG NEURO-PSYCHOPH, V38, P4, DOI 10.1016/j.pnpbp.2012.02.009; De Sarno P, 2002, NEUROPHARMACOLOGY, V43, P1158, DOI 10.1016/S0028-3908(02)00215-0; del Pulgar T, 2000, BIOCHEM J, V347, P369, DOI 10.1042/bj3470369; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Golech SA, 2004, MOL BRAIN RES, V132, P87, DOI 10.1016/j.molbrainres.2004.08.025; Heimann AS, 2007, P NATL ACAD SCI USA, V104, P20588, DOI 10.1073/pnas.0706980105; Hoshi M, 1996, P NATL ACAD SCI USA, V93, P2719, DOI 10.1073/pnas.93.7.2719; Keightley ML, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00139; Madathil SK, 2010, J NEUROTRAUM, V27, P95, DOI 10.1089/neu.2009.1002; Maresz K, 2005, J NEUROCHEM, V95, P437, DOI 10.1111/j.1471-4159.2005.03380.x; Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839; Nagayama T, 1999, J NEUROSCI, V19, P2987; Nguyen VH, 2012, PHARMACOLOGY, V89, P64, DOI 10.1159/000335368; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Pacher P, 2008, BRIT J PHARMACOL, V153, P252, DOI 10.1038/sj.bjp.0707582; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P1, DOI 10.1007/s10863-007-9070-5; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Rozenfeld R, 2008, FASEB J, V22, P2311, DOI 10.1096/fj.07-102731; Sheng WS, 2005, GLIA, V49, P211, DOI 10.1002/glia.20108; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Su CC, 2012, AM J PHYSIOL-HEART C, V302, pH716, DOI 10.1152/ajpheart.00455.2011; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; Wender R, 2000, J NEUROSCI, V20, P6804, DOI 10.1523/JNEUROSCI.20-18-06804.2000; Wright MJ, 2013, BRAIN IMAGING BEHAV, V7, P307, DOI 10.1007/s11682-013-9231-6; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yang JY, 2013, J MOL CELL CARDIOL, V59, P167, DOI 10.1016/j.yjmcc.2013.02.016	39	14	15	0	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1756-6606			MOL BRAIN	Mol. Brain	AUG 2	2016	9								75	10.1186/s13041-016-0257-8			14	Neurosciences	Neurosciences & Neurology	DS7RJ	WOS:000380980300002	27485212	DOAJ Gold, Green Published			2021-06-18	
J	Masgutov, RF; Masgutova, GA; Zhuravleva, MN; Salafutdinov, II; Mukhametshina, RT; Mukhamedshina, YO; Lima, LM; Reis, HJ; Kiyasov, AP; Palotas, A; Rizvanov, AA				Masgutov, Ruslan F.; Masgutova, Galina A.; Zhuravleva, Margarita N.; Salafutdinov, Ilnur I.; Mukhametshina, Regina T.; Mukhamedshina, Yana O.; Lima, Luciana M.; Reis, Helton J.; Kiyasov, Andrey P.; Palotas, Andras; Rizvanov, Albert A.			Human adipose-derived stem cells stimulate neuroregeneration	CLINICAL AND EXPERIMENTAL MEDICINE			English	Article						Autonerve graft; Human adipose-derived stem cell (hADSC); Xenotransplantation; Peripheral nerve injury; Regenerative medicine; Repair	DORSAL-ROOT GANGLIA; PERIPHERAL-NERVE REGENERATION; SENSORY NEURONS; MICROGLIA; REPAIR; MACROPHAGES; APOPTOSIS; SYSTEM; GROWTH; MOUSE	Traumatic brain injuries and degenerative neurological disorders such as Alzheimer's dementia, Parkinson's disease, amyotrophic lateral sclerosis and many others are characterized by loss of brain cells and supporting structures. Restoring microanatomy and function using stem cells is a promising therapeutic approach. Among the many various sources, adipose-derived stem cells (ADSCs) are one of the most easily harvested alternatives, they multiply rapidly, and they demonstrate low immunogenicity with an ability to differentiate into several cell types. The objective of this study was to evaluate the effect of xenotransplanted human ADSCs on post-traumatic regeneration of rat sciatic nerve. Peripheral reconstruction following complete sciatic transection and autonerve grafting was complemented by intra-operative injection of hADSCs into the proximal and distal stumps. The injury caused gliosis and apoptosis of sensory neurons in the lumbar 5 (L5) ganglia in the control rodents; however, animals treated with hADSCs demonstrated a smaller amount of cellular loss. Formation of amputation neuroma, which hinders axonal repair, was less prominent in the experimental group, and immunohistochemical analysis of myelin basic protein showed good myelination 65 days after surgery. At this point, control groups still exhibited high levels of microglia/macrophage-specific marker Iba-1 and proliferating cell nuclear antigen, the mark of an ongoing inflammation and incomplete axonal growth 2 months after the injury. This report demonstrates that hADSCs promote neuronal survival in the spinal ganglion, fuel axonal repair and stimulate the regeneration of peripheral nerves.	[Masgutov, Ruslan F.; Masgutova, Galina A.; Zhuravleva, Margarita N.; Salafutdinov, Ilnur I.; Mukhametshina, Regina T.; Mukhamedshina, Yana O.; Kiyasov, Andrey P.; Palotas, Andras; Rizvanov, Albert A.] Kazan Volga Reg Fed Univ, Inst Fundamental Med & Biol, Kazan, Russia; [Masgutov, Ruslan F.; Salafutdinov, Ilnur I.] Republ Clin Hosp, Kazan, Russia; [Lima, Luciana M.] Univ Fed Vicosa, Vicosa, MG, Brazil; [Reis, Helton J.] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil; [Palotas, Andras] Asklepios Med Private Med Practice & Res Ctr, Kossuth Lajos Sgt 23, H-6722 Szeged, Hungary	Palotas, A; Rizvanov, AA (corresponding author), Kazan Volga Reg Fed Univ, Inst Fundamental Med & Biol, Kazan, Russia.; Palotas, A (corresponding author), Asklepios Med Private Med Practice & Res Ctr, Kossuth Lajos Sgt 23, H-6722 Szeged, Hungary.	palotas@asklepios-med.eu; albert.rizvanov@kpfu.ru	Rizvanov, Albert/H-4486-2013; Lima, Luciana Moreira/X-7039-2018; Reis, Helton/AAD-4337-2020	Rizvanov, Albert/0000-0002-9427-5739; Lima, Luciana Moreira/0000-0001-5349-1577; Reis, Helton/0000-0002-4055-701X; Kiassov, Andrey/0000-0003-4460-4140	Russian Foundation for Basic ResearchRussian Foundation for Basic Research (RFBR) [13-04-12035]; Russian FederationRussian Federation [4020.2015.7]; Ministry of Education of Russia [RFMEFI59414X0003]; Interdisciplinary center for analytical microscopy; Pharmaceutical Research and Education Center, Kazan (Volga Region) Federal University, Kazan, Russia	The study was supported by Grant 13-04-12035 from Russian Foundation for Basic Research. This work was performed in accordance with Program of Competitive Growth of Kazan Federal University and subsidy allocated to Kazan Federal University for the state assignment in the sphere of scientific activities. Yana O. Mukhamedshina was supported by Presidential grant for government support of young scientists (PhD) from the Russian Federation (4020.2015.7). Some of the experiments were conducted using equipment at the Interdisciplinary center for collective use of Kazan Federal University supported by Ministry of Education of Russia (ID RFMEFI59414X0003), Interdisciplinary center for analytical microscopy, and Pharmaceutical Research and Education Center, Kazan (Volga Region) Federal University, Kazan, Russia. The authors are also indebted to Drs. Gallyamov and Bogov for their assistance in animal handling.	Abram SE, 2006, ANESTHESIOLOGY, V105, P146, DOI 10.1097/00000542-200607000-00024; Arkhipova S S, 2010, Neurosci Behav Physiol, V40, P609, DOI 10.1007/s11055-010-9303-7; Berg A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079395; Chen LK, 2014, J NANOSCI NANOTECHNO, V14, P969, DOI 10.1166/jnn.2014.9126; Cheng C, 2003, DIABETES, V52, P2363, DOI 10.2337/diabetes.52.9.2363; Cheutin T, 2004, MOL CELL BIOL, V24, P3157, DOI 10.1128/MCB.24.8.3157-3167.2004; Dezawa Mari, 2005, Current Neuropharmacology, V3, P257, DOI 10.2174/157015905774322507; Dubovy Petr, 2004, Anatomical Science International, V79, P198, DOI 10.1111/j.1447-073x.2004.00090.x; Faroni A, 2013, INT REV NEUROBIOL, V108, P121, DOI 10.1016/B978-0-12-410499-0.00005-8; Ginhoux F, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00045; Goldberg JL, 2000, NATURE, V403, P369, DOI 10.1038/35000309; Gordon T, 2011, J NEUROSCI, V31, P5325, DOI 10.1523/JNEUROSCI.6156-10.2011; Kalinina NI, 2011, ACTA NATURAE, V3, P30, DOI 10.32607/20758251-2011-3-4-30-37; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kingham PJ, 2007, EXP NEUROL, V207, P267, DOI 10.1016/j.expneurol.2007.06.029; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; Marconi S, 2012, TISSUE ENG PT A, V18, P1264, DOI [10.1089/ten.tea.2011.0491, 10.1089/ten.TEA.2011.0491]; Masgutov R, 2011, CELL TRANSPLANT TISS, V6, P67; McKay Hart A., 2002, EXP BRAIN RES, V142, P308; Momeni HR, 2013, CELL J, V15, P212; Otoshi K, 2010, SPINE, V35, P264, DOI 10.1097/BRS.0b013e3181b8b04f; Perry VH, 2013, SEMIN IMMUNOPATHOL, V35, P601, DOI 10.1007/s00281-013-0382-8; Radtke C, 2011, CELL TRANSPLANT, V20, P145, DOI 10.3727/096368910X522081; Raginov I S, 2003, Morfologiia, V124, P47; Reid AJ, 2011, NEUROSCIENCE, V199, P515, DOI 10.1016/j.neuroscience.2011.09.064; Ribeiro-Resende VT, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-34; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Shachpazyan NR, 2012, CELL TRANSPLANT TISS, V7, P23; Solovyeva V.V., 2013, WORLD APPL SCI J, V26, pP., DOI DOI 10.5829/idosi.wasj.2013.26.07.13539; Tamaki T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091257; Tandrup T, 2000, J COMP NEUROL, V422, P172, DOI 10.1002/(SICI)1096-9861(20000626)422:2<172::AID-CNE2>3.0.CO;2-H; Vigneswara V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057861; Weerasuriya A, 2011, METHODS MOL BIOL, V686, P149, DOI 10.1007/978-1-60761-938-3_6; Wood MD, 2011, ANN ANAT, V193, P321, DOI 10.1016/j.aanat.2011.04.008	34	14	14	1	32	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1591-8890	1591-9528		CLIN EXP MED	Clin. Exper. Med.	AUG	2016	16	3					451	461		10.1007/s10238-015-0364-3			11	Medicine, Research & Experimental	Research & Experimental Medicine	DS3FM	WOS:000380668500025	26047869	Green Published			2021-06-18	
J	Rigon, A; Voss, MW; Turkstra, LS; Mutlu, B; Duff, MC				Rigon, Arianna; Voss, Michelle W.; Turkstra, Lyn S.; Mutlu, Bilge; Duff, Melissa C.			Frontal and Temporal Structural Connectivity Is Associated with Social Communication Impairment Following Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						White matter; Communication; Diffusion tensor imaging; Fractional anisotropy; Frontal lobe; Temporal lobe	WHITE-MATTER INTEGRITY; COGNITIVE NEUROSCIENCE; DISCOURSE ABILITIES; BEHAVIORAL-CHANGES; DECISION-MAKING; HEAD-INJURY; DIFFUSION; DAMAGE; DEFICITS; ADULTS	Objectives: Although it has been well documented that traumatic brain injury (TBI) can result in communication impairment, little work to date has examined the relationship between social communication skills and structural brain integrity in patients with TBI. The aim of the current study was to investigate the association between self- and other-perceived communication problems and white matter integrity in patients with mild to severe TBI. Methods: Forty-four individuals (TBI=24) and people with whom they frequently communicate, as well as demographically matched normal healthy comparisons (NC) and their frequent communication partners, were administered, respectively, the La-Trobe Communication Questionnaire Self form (LCQ-SELF) and Other form (LCQ-OTHER). In addition, diffusion tensor imaging data were collected, and fractional anisotropy (FA) measures were extracted for each lobe in both hemispheres. Results: Within the TBI group, but not within the NC group, participants who were perceived by their close others as having more communication problems had lower FA in the left frontal and temporal lobes (p<.01), but not in other brain regions. Conclusions: Frontotemporal white matter microstructural integrity is associated with social communication abilities in adults with TBI. This finding contributes to our understanding of the mechanisms leading to communication impairment following TBI and can inform the development of new neuromodulation therapies as well as diagnostic tools.	[Rigon, Arianna; Voss, Michelle W.; Duff, Melissa C.] Univ Iowa, Interdisciplinary Neurosci Program, Iowa City, IA USA; [Voss, Michelle W.] Univ Iowa, Dept Psychol & Brain Sci, Iowa City, IA USA; [Turkstra, Lyn S.] Univ Wisconsin, Dept Commun Sci & Disorders, Madison, WI 53706 USA; [Turkstra, Lyn S.] Univ Wisconsin, Interdisciplinary Program Neurosci, Madison, WI 53706 USA; [Mutlu, Bilge] Univ Wisconsin, Dept Comp Sci, Madison, WI 53706 USA; [Duff, Melissa C.] Univ Iowa, Dept Commun Sci & Disorders, Iowa City, IA USA; [Duff, Melissa C.] Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA	Rigon, A (corresponding author), 420-1 Seashore Hall,328 Iowa Ave, Iowa City, IA 52242 USA.	arianna-rigon@uiowa.edu			NICHD/NCMRR grant [R01 HD071089]; University of Iowa Magnetic Resonance Research Facilities; University of Iowa Graduate and Professional Student Government; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD071089] Funding Source: NIH RePORTER	This work was supported by NICHD/NCMRR grant R01 HD071089, the University of Iowa Magnetic Resonance Research Facilities and a research grant from the University of Iowa Graduate and Professional Student Government. The authors thank Joel Bruss, Ruth Hansen, and Kristina Warndahl for their help. The authors have no conflicts of interest to disclose.	ADAMS JH, 1984, LANCET, V2, P1420; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Adolphs R, 2003, NAT REV NEUROSCI, V4, P165, DOI 10.1038/nrn1056; Ahles TA, 2003, PSYCHO-ONCOL, V12, P612, DOI 10.1002/pon.742; Andersson J.L.R., 2007, TR07JA1 FMRIB; Andersson J.L.R., 2007, NONLINEAR REGISTRATI; ARON A, 1992, J PERS SOC PSYCHOL, V63, P596, DOI 10.1037/0022-3514.63.4.596; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Beauchamp MS, 2015, TRENDS COGN SCI, V19, P489, DOI 10.1016/j.tics.2015.07.002; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bernicot J, 2001, INT J LANG COMM DIS, V36, P245; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Bosco FM, 2015, INT J LANG COMM DIS, V50, P63, DOI 10.1111/1460-6984.12114; Champagne-Lavau M, 2007, BRAIN, V130, DOI 10.1093/brain/awl311; Ciaramelli E, 2012, J INT NEUROPSYCH SOC, V18, P962, DOI 10.1017/S1355617712000690; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Coelho CA, 1996, J SPEECH HEAR RES, V39, pS5, DOI 10.1044/jshr.3905.s5; Costa PJ, 2014, J BIOPHARM STAT, V24, P1115, DOI 10.1080/10543406.2014.926366; Crewe-Brown SJ, 2011, S AFR J COMMUN DISOR, V58, P48; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Cummings Louise, 2007, Seminars in Speech and Language, V28, P96, DOI 10.1055/s-2007-970568; Dardier V, 2011, J COMMUN DISORD, V44, P359, DOI 10.1016/j.jcomdis.2011.02.001; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; Despins EH, 2016, ARCH PHYS MED REHAB, V97, pS26, DOI 10.1016/j.apmr.2014.06.023; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Douglas JM, 2010, J SPEECH LANG HEAR R, V53, P365, DOI 10.1044/1092-4388(2009/08-0205); Duff MC, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00069; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; EdwardsLee T, 1997, BRAIN, V120, P1027, DOI 10.1093/brain/120.6.1027; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Garcia-Molina A, 2013, MED CLIN-BARCELONA, V140, P527, DOI 10.1016/j.medcli.2012.09.047; GORDON NG, 1972, J CLIN PSYCHOL, V28, P167, DOI 10.1002/1097-4679(197204)28:2<167::AID-JCLP2270280212>3.0.CO;2-X; Gordon RG, 2015, BRAIN INJURY, V29, P1300, DOI 10.3109/02699052.2015.1042408; Gordon RG, 2014, NEUROPSYCHOLOGY, V28, P624, DOI 10.1037/neu0000073; Hayes JP, 2016, J INT NEUROPSYCH SOC, V22, P120, DOI 10.1017/S1355617715000740; Head D, 2004, CEREB CORTEX, V14, P410, DOI 10.1093/cercor/bhh003; Holdnack JA, 2011, ASSESSMENT, V18, P178, DOI 10.1177/1073191110393106; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Johnstone B, 1996, ARCH CLIN NEUROPSYCH, V11, P513, DOI 10.1016/0887-6177(96)82330-4; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Koenigs M, 2007, NATURE, V446, P908, DOI 10.1038/nature05631; Koenigs M, 2007, J NEUROSCI, V27, P951, DOI 10.1523/JNEUROSCI.4606-06.2007; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; LEVIN HS, 1992, CURR OPIN NEUROL NEU, V5, P673; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/pms.1991.73.3f.1139; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rosenberg H, 2014, J INT NEUROPSYCH SOC, V20, P994, DOI 10.1017/S1355617714000940; Rousseaux M, 2010, EUR J NEUROL, V17, P922, DOI 10.1111/j.1468-1331.2009.02945.x; Ryan NP, 2015, BRAIN LANG, V142, P86, DOI 10.1016/j.bandl.2015.01.007; Saxe R, 2006, CURR OPIN NEUROBIOL, V16, P235, DOI 10.1016/j.conb.2006.03.001; Sen PN, 2005, BIOPHYS J, V89, P2927, DOI 10.1529/biophysj.105.063016; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; SHEWAN CM, 1980, J SPEECH HEAR DISORD, V45, P308, DOI 10.1044/jshd.4503.308; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Stolk A, 2015, CURR BIOL, V25, P1469, DOI 10.1016/j.cub.2015.03.057; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Struchen MA, 2008, BRAIN INJURY, V22, P940, DOI 10.1080/02699050802425410; Tompkins Connie A., 1998, Seminars in Speech and Language, V19, P303, DOI 10.1055/s-2008-1064052; Vigneau M, 2006, NEUROIMAGE, V30, P1414, DOI 10.1016/j.neuroimage.2005.11.002; Voss MW, 2013, HUM BRAIN MAPP, V34, P2972, DOI 10.1002/hbm.22119; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Werring DJ, 1999, NEUROLOGY, V52, P1626, DOI 10.1212/WNL.52.8.1626; Whelan BM, 2007, J HEAD TRAUMA REHAB, V22, P192, DOI 10.1097/01.HTR.0000271120.04405.db; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME, V4th; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020	85	14	14	1	22	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	AUG	2016	22	7					705	716		10.1017/S1355617716000539			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	DU8SQ	WOS:000382485100002	27405965	Green Accepted			2021-06-18	
J	Birchley, G; Jones, K; Huxtable, R; Dixon, J; Kitzinger, J; Clare, L				Birchley, Giles; Jones, Kerry; Huxtable, Richard; Dixon, Jeremy; Kitzinger, Jenny; Clare, Linda			Dying well with reduced agency: a scoping review and thematic synthesis of the decision-making process in dementia, traumatic brain injury and frailty	BMC MEDICAL ETHICS			English	Article						End-of-life; Good Death; Mental capacity; Decision-making; Scoping review; Thematic synthesis; Frailty; Dementia; Traumatic brain injury	END-OF-LIFE; NURSING-HOME RESIDENTS; LONG-TERM-CARE; COGNITIVE IMPAIRMENT; QUALITATIVE RESEARCH; ADVANCE DIRECTIVES; OLDER-ADULTS; GOOD DEATH; PEOPLE; FAMILY	Background: In most Anglophone nations, policy and law increasingly foster an autonomy-based model, raising issues for large numbers of people who fail to fit the paradigm, and indicating problems in translating practical and theoretical understandings of 'good death' to policy. Three exemplar populations are frail older people, people with dementia and people with severe traumatic brain injury. We hypothesise that these groups face some over-lapping challenges in securing good end-of-life care linked to their limited agency. To better understand these challenges, we conducted a scoping review and thematic synthesis. Methods: To capture a range of literature, we followed established scoping review methods. We then used thematic synthesis to describe the broad themes emerging from this literature. Results: Initial searches generated 22,375 references, and screening yielded 49, highly heterogeneous, studies that met inclusion criteria, encompassing 12 countries and a variety of settings. The thematic synthesis identified three themes: the first concerned the processes of end-of-life decision-making, highlighting the ambiguity of the dominant shared decision-making process, wherein decisions are determined by families or doctors, sometimes explicitly marginalising the antecedent decisions of patients. Despite this marginalisation, however, the patient does play a role both as a social presence and as an active agent, by whose actions the decisions of those with authority are influenced. The second theme examined the tension between predominant notions of a good death as 'natural' and the drive to medicalise death through the lens of the experiences and actions of those faced with the actuality of death. The final theme considered the concept of antecedent end-of-life decision-making (in all its forms), its influence on policy and decision-making, and some caveats that arise from the studies. Conclusions: Together these three themes indicate a number of directions for future research, which are likely to be applicable to other conditions that result in reduced agency. Above all, this review emphasises the need for new concepts and fresh approaches to end of life decision-making that address the needs of the growing population of frail older people, people with dementia and those with severe traumatic brain injury.	[Birchley, Giles; Huxtable, Richard] Univ Bristol, Ctr Eth Med, Bristol, Avon, England; [Jones, Kerry] Open Univ, Fac Hlth & Social Care, Milton Keynes, Bucks, England; [Dixon, Jeremy] Univ Bath, Dept Social & Policy Sci, Bath, Avon, England; [Kitzinger, Jenny] Cardiff Univ, Coma & Disorders Consciousness Res Ctr, Cardiff, S Glam, Wales; [Clare, Linda] Univ Exeter, REACH Ctr Res Ageing & Cognit Hlth, Exeter, Devon, England	Birchley, G (corresponding author), Univ Bristol, Ctr Eth Med, Bristol, Avon, England.	giles.birchley@bristol.ac.uk	Jones, K/AAD-6630-2019	Jones, Kerry/0000-0003-2756-8029; Birchley, Giles/0000-0002-2973-2163; Clare, Linda/0000-0003-3989-5318; Dixon, Jeremy/0000-0003-0656-5646	GW4 Building Communities Programme (Accelerator Fund) [GW4- 81-PA]	This work was funded through a GW4 Building Communities Programme (Accelerator Fund) Grant no: GW4- 81-PA.	Abarshi EA, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X578052; Allen RS, 2003, GERONTOLOGIST, V43, P309, DOI 10.1093/geront/43.3.309; Anquinet L, 2013, J AM GERIATR SOC, V61, P1768, DOI 10.1111/jgs.12447; Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [DOI 10.1080/1364557032000119616, 10.1080/1364557032000119616]; Ayalon L, 2012, INT PSYCHOGERIATR, V24, P1798, DOI 10.1017/S1041610212000877; Bagshaw SM, 2013, CURR OPIN CRIT CARE, V19, P496, DOI 10.1097/MCC.0b013e328364d570; Baker A, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X625175; Barclay S, 2014, BRIT J GEN PRACT, V64, pE576, DOI 10.3399/bjgp14X681397; Barnett-Page E, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-59; Basic D, 2015, J AGING HEALTH, V27, P670, DOI 10.1177/0898264314558202; Birchley G, 2014, HEALTH CARE ANAL, V22, P203, DOI 10.1007/s10728-013-0267-y; Black BS, 2009, J AGING HEALTH, V21, P627, DOI 10.1177/0898264309333316; Bosek Marcia Sue DeWolf, 2003, JONAS Healthc Law Ethics Regul, V5, P34, DOI 10.1097/00128488-200306000-00006; Bottrell MM, 2001, GERIATR NURS, V22, P313, DOI 10.1067/mgn.2001.120994; Brazil K, 2012, SCAND J CARING SCI, V26, P513, DOI 10.1111/j.1471-6712.2011.00956.x; Cavalieri Thomas A., 2002, Journal of the American Osteopathic Association, V102, P541; Chan HYL, 2011, J CLIN NURS, V20, P1454, DOI 10.1111/j.1365-2702.2010.03670.x; Chan HYL, 2010, J CLIN NURS, V19, P3073, DOI 10.1111/j.1365-2702.2010.03353.x; Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3; Cigolle CT, 2009, J AM GERIATR SOC, V57, P830, DOI 10.1111/j.1532-5415.2009.02225.x; De Jong JD, 2009, J PALLIAT CARE, V25, P61, DOI 10.1177/082585970902500107; Demertzi A, 2011, J NEUROL, V258, P1058, DOI 10.1007/s00415-010-5882-z; Demertzi A, 2014, BRAIN INJURY, V28, P1209, DOI 10.3109/02699052.2014.920526; Dening KH, 2013, PALLIATIVE MED, V27, P409, DOI 10.1177/0269216312464094; Dening KH, 2012, BMJ SUPPORT PALLIAT, V2, P103, DOI 10.1136/bmjspcare-2011-000178; Department of Health, 2008, END OF LIFE CARE STR; Di Giulio P, 2008, J PALLIAT MED, V11, P1023, DOI 10.1089/jpm.2008.0020; Doron, 2014, LAW ETHICS DEMENTIA, P15; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Evans WG, 2006, J PALLIAT MED, V9, P100, DOI 10.1089/jpm.2006.9.100; Ferrucci L, 2003, CRIT REV ONCOL HEMAT, V46, P127, DOI 10.1016/S1040-8428(02)00177-4; Forbes S, 2000, J NURS SCHOLARSHIP, V32, P251, DOI 10.1111/j.1547-5069.2000.00251.x; Fried TR, 1997, J AM GERIATR SOC, V45, P265, DOI 10.1111/j.1532-5415.1997.tb00938.x; Gawande A., 2014, WELLCOME SERIES; Good MJD, 2004, SOC SCI MED, V58, P939, DOI 10.1016/j.socscimed.2003.10.043; Hallam E, 1999, BEYOND THE BODY DEAT; Haller IV, 2007, J PALLIAT MED, V10, P400, DOI 10.1089/jpm.2006.0129; Herring J., 2014, THE LAW AND ETHICS O, P301; Hick G, 2010, PHYSIOLOGICAL RESILI, P89; Hofstede G., 1984, COMPARING VALUES BEH; Jox RJ, 2015, ARCH PHYS MED REHAB, V96, P323, DOI 10.1016/j.apmr.2014.09.030; Khangura S, 2012, SYST REV, V1, DOI 10.1186/2046-4053-1-10; Kitzinger C, 2015, J MED ETHICS, V41, DOI 10.1136/medethics-2013-101799; Kitzinger J, 2013, SOCIOL HEALTH ILL, V35, P1095, DOI 10.1111/1467-9566.12020; Lamberg JL, 2005, J AM GERIATR SOC, V53, P1396, DOI 10.1111/j.1532-5415.2005.53426.x; Lavrijsen J, 2005, BRAIN INJURY, V19, P67, DOI 10.1080/02699050410001720013; Livingston G, 2013, INT PSYCHOGERIATR, V25, P1849, DOI 10.1017/S1041610213001221; Livingston G, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4184; McDermott C, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X653589; Monteleoni C, 2004, BMJ-BRIT MED J, V329, P491, DOI 10.1136/bmj.329.7464.491; Mor Vincent, 2005, J Palliat Med, V8, P58, DOI 10.1089/jpm.2005.8.58; Munthe C, 2012, HEALTH CARE ANAL, V20, P231, DOI 10.1007/s10728-011-0183-y; Nakanishi M, 2009, ARCH GERONTOL GERIAT, V48, P296, DOI 10.1016/j.archger.2008.02.009; NatCen Social Research, 2013, BRITISH SOCIAL ATTIT; Office for National Statistics, 2015, NATIONAL POPULATION; Parsons C, 2014, INT J GERIATR PSYCH, V29, P281, DOI 10.1002/gps.4006; PIJNENBORG L, 1995, ARCH INTERN MED, V155, P286, DOI 10.1001/archinte.155.3.286; Pollack KM, 2010, HEALTH POLICY, V96, P57, DOI 10.1016/j.healthpol.2010.01.004; Potkins D, 2000, INT J GERIATR PSYCH, V15, P1005, DOI 10.1002/1099-1166(200011)15:11<1005::AID-GPS223>3.0.CO;2-0; Prince M., 2014, DEMENTIA UK UPDATE; Reinhardt JP, 2014, J SOC WORK END-LIFE, V10, P112, DOI 10.1080/15524256.2014.906371; Rich BA, 2004, WIEN KLIN WOCHENSCHR, V116, P420, DOI 10.1007/BF03040929; Robinson L, 2013, PALLIATIVE MED, V27, P401, DOI 10.1177/0269216312465651; Rockwood K, 2006, J AM GERIATR SOC, V54, P975, DOI 10.1111/j.1532-5415.2006.00738.x; Rodrigue C, 2013, NEUROETHICS-NETH, V6, P25, DOI 10.1007/s12152-011-9142-4; Rurup ML, 2006, PATIENT EDUC COUNS, V61, P372, DOI 10.1016/j.pec.2005.04.016; Sampson EL, 2011, PALLIATIVE MED, V25, P197, DOI 10.1177/0269216310391691; Sampson EL, 2009, BRIT J PSYCHIAT, V195, P61, DOI 10.1192/bjp.bp.108.055335; Schlosser M., 2015, THE STANFORD ENCYCLO; Sloane PD, 2008, GERONTOLOGIST, V48, P741, DOI 10.1093/geront/48.6.741; Solloway Michele, 2005, J Palliat Med, V8, P789, DOI 10.1089/jpm.2005.8.789; Soskis CW, 1997, SOC WORK HEALTH CARE, V25, P107, DOI 10.1300/J010v25n01_11; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Thomas J, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-45; Triplett P, 2008, J AGING HEALTH, V20, P583, DOI 10.1177/0898264308317822; Turgeon AF, 2013, CRIT CARE MED, V41, P1086, DOI 10.1097/CCM.0b013e318275d046; van der Steen JT, 2005, ALZ DIS ASSOC DIS, V19, P148, DOI 10.1097/01.wad.0000175525.99104.b7; Vandervoort A, 2014, J PAIN SYMPTOM MANAG, V47, P245, DOI 10.1016/j.jpainsymman.2013.03.009	78	14	14	0	26	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1472-6939			BMC MED ETHICS	BMC Med. Ethics	JUL 27	2016	17								46	10.1186/s12910-016-0129-x			15	Ethics; Medical Ethics; Social Sciences, Biomedical	Social Sciences - Other Topics; Medical Ethics; Biomedical Social Sciences	DS7UC	WOS:000380987400001	27461340	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Narayanan, V; Veeramuthu, V; Ahmad-Annuar, A; Ramli, N; Waran, V; Chinna, K; Bondi, MW; Delano-Wood, L; Ganesan, D				Narayanan, Vairavan; Veeramuthu, Vigneswaran; Ahmad-Annuar, Azlina; Ramli, Norlisah; Waran, Vicknes; Chinna, Karuthan; Bondi, Mark William; Delano-Wood, Lisa; Ganesan, Dharmendra			Missense Mutation of Brain Derived Neurotrophic Factor (BDNF) Alters Neurocognitive Performance in Patients with Mild Traumatic Brain Injury: A Longitudinal Study	PLOS ONE			English	Article							FACTOR VAL66MET POLYMORPHISM; APOLIPOPROTEIN-E POLYMORPHISM; FACTOR GENE; VAL(66)MET POLYMORPHISM; HIPPOCAMPAL ACTIVITY; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; MEMORY FORMATION; RAT HIPPOCAMPUS; ASSOCIATION	The predictability of neurocognitive outcomes in patients with traumatic brain injury is not straightforward. The extent and nature of recovery in patients with mild traumatic brain injury (mTBI) are usually heterogeneous and not substantially explained by the commonly known demographic and injury-related prognostic factors despite having sustained similar injuries or injury severity. Hence, this study evaluated the effects and association of the Brain Derived Neurotrophic Factor (BDNF) missense mutations in relation to neurocognitive performance among patients with mTBI. 48 patients with mTBI were prospectively recruited and MRI scans of the brain were performed within an average 10.1 (SD 4.2) hours post trauma with assessment of their neuropsychological performance post full Glasgow Coma Scale (GCS) recovery. Neurocognitive assessments were repeated again at 6 months follow-up. The paired t-test, Cohen's d effect size and repeated measure ANOVA were performed to delineate statistically significant differences between the groups [wildtype G allele (Val homozygotes) vs. minor A allele (Met carriers)] and their neuropsychological performance across the time point (T-1 = baseline/admission vs. T-2 = 6th month follow-up). Minor A allele carriers in this study generally performed more poorly on neuropsychological testing in comparison wildtype G allele group at both time points. Significant mean differences were observed among the wildtype group in the domains of memory (M = -11.44, SD = 10.0, p = .01, d = 1.22), executive function (M = -11.56, SD = 11.7, p = .02, d = 1.05) and overall performance (M = -6.89 SD = 5.3, p = .00, d = 1.39), while the minor A allele carriers showed significant mean differences in the domains of attention (M = -11.0, SD = 13.1, p = .00, d = .86) and overall cognitive performance ( M = -5.25, SD = 8.1, p = .01, d = .66). The minor A allele carriers in comparison to the wildtype G allele group, showed considerably lower scores at admission and remained impaired in most domains across the timepoints, although delayed signs of recovery were noted to be significant in the domains attention and overall cognition. In conclusion, the current study has demonstrated the role of the BDNF rs6265 Val66Met polymorphism in influencing specific neurocognitive outcomes in patients with mTBI. Findings were more detrimentally profound among Met allele carriers.	[Narayanan, Vairavan; Veeramuthu, Vigneswaran; Waran, Vicknes; Ganesan, Dharmendra] Univ Malaya, Fac Med, Dept Surg, Div Neurosurg, Kuala Lumpur, Wilayah Perseku, Malaysia; [Ahmad-Annuar, Azlina] Univ Malaya, Fac Med, Dept Mol Med, Kuala Lumpur 50603, Wilayah Perseku, Malaysia; [Ramli, Norlisah] Univ Malaya, Res Imaging Ctr, Kuala Lumpur, Wilayah Perseku, Malaysia; [Chinna, Karuthan] Univ Malaya, Julius Ctr, Dept Social & Prevent Med, Kuala Lumpur, Wilayah Perseku, Malaysia; [Bondi, Mark William; Delano-Wood, Lisa] VA San Diego Healthcare Syst, San Diego, CA USA; [Bondi, Mark William; Delano-Wood, Lisa] Univ Calif San Diego, Dept Psychiat, San Diego, CA USA	Narayanan, V; Veeramuthu, V (corresponding author), Univ Malaya, Fac Med, Dept Surg, Div Neurosurg, Kuala Lumpur, Wilayah Perseku, Malaysia.	nvairavan@um.edu.my; vicveera@gmail.com	AHMAD ANNUAR, AZLINA/B-8305-2010; RAMLI, NORLISAH MOHD/I-6372-2016; Ramli, Norlisah M/G-5209-2010; GANESAN, DHARMENDRA/B-8437-2010; NARAYANAN, VAIRAVAN/B-9191-2010; Mathaneswaran, Vickneswaran/E-5180-2010; Veeramuthu, Vigneswaran/F-2220-2015	RAMLI, NORLISAH MOHD/0000-0001-7497-8093; Ramli, Norlisah M/0000-0001-7497-8093; NARAYANAN, VAIRAVAN/0000-0002-1118-5042; Veeramuthu, Vigneswaran/0000-0003-2052-0858	University Malaya Research Grant (UMRG) [RG447-12HTM]; High Impact Research Grant of University of Malaya [HIR-UM.C/625/1/HIRMOHE/12]	This study was partially funded by University Malaya Research Grant (UMRG; RG447-12HTM) (to VN)-Link: http://umresearch.um.edu.my/; High Impact Research Grant of University of Malaya (HIR-UM.C/625/1/HIRMOHE/12) (VW)-Link: http://hir.um.edu.my/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Anderson GD, 2009, EPILEPSY BEHAV, V16, P501, DOI 10.1016/j.yebeh.2009.08.025; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Ashman TA, 2006, MT SINAI J MED, V73, P999; Bales James W, 2010, Open Drug Discov J, V2, P119; Barbey AK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088733; Bekinschtein P, 2008, NEUROSCIENTIST, V14, P147, DOI 10.1177/1073858407305850; Bennett ER, 2016, TRANSLATIONAL RES TR; Beste C, 2010, J NEUROSCI, V30, P10727, DOI 10.1523/JNEUROSCI.2493-10.2010; Binder DK, 2004, GROWTH FACTORS, V22, P123, DOI 10.1080/08977190410001723308; Blyth BJ, 2010, EMERG MED CLIN N AM, V28, P571, DOI 10.1016/j.emc.2010.03.003; Cabelli RJ, 1997, NEURON, V19, P63, DOI 10.1016/S0896-6273(00)80348-7; Chao HM, 2008, AM J MED GENET B, V147B, P505, DOI 10.1002/ajmg.b.30619; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Cohen-Cory S, 2010, DEV NEUROBIOL, V70, P271, DOI 10.1002/dneu.20774; Comings DE, 1996, PHARMACOGENETICS, V6, P223, DOI 10.1097/00008571-199606000-00004; Coronado VG, 2011, SURVEILLANCE TRAUMAT; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Cunningham F, 2015, NUCLEIC ACIDS RES, V43, pD662, DOI 10.1093/nar/gku1010; DEKOSKY ST, 1998, SEMIN CLIN NEUROPSYC, V3, P176; Dennis NA, 2011, HIPPOCAMPUS, V21, P980, DOI 10.1002/hipo.20809; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Dutcher SA, 2001, NEUROL RES, V23, P203, DOI 10.1179/016164101101198343; Ebstein RP, 2000, EUR J PHARMACOL, V410, P205, DOI 10.1016/S0014-2999(00)00852-9; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Failla M.D., 2015, NEUROREHABIL NEURAL; Failla MD, 2016, NEUROREHAB NEURAL RE, V30, P83, DOI 10.1177/1545968315586465; Gajewski PD, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2011.06.010; Gennarelli T. A., 2005, TXB TRAUMATIC BRAIN, P27; Getzmann S, 2013, NEUROIMAGE, V64, P290, DOI 10.1016/j.neuroimage.2012.08.079; Gogos JA, 1998, P NATL ACAD SCI USA, V95, P9991, DOI 10.1073/pnas.95.17.9991; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Harris SE, 2006, MOL PSYCHIATR, V11, P505, DOI 10.1038/sj.mp.4001799; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hashimoto R, 2008, NEUROSCI RES, V61, P360, DOI 10.1016/j.neures.2008.04.003; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; Hong CJ, 2011, BRAIN RES BULL, V86, P287, DOI 10.1016/j.brainresbull.2011.08.019; Horch HW, 1999, NEURON, V23, P353; Huang CC, 2014, PSYCHONEUROENDOCRINO, V39, P94, DOI 10.1016/j.psyneuen.2013.09.027; Huang R, 2007, J MED GENET, V44, DOI 10.1136/jmg.2006.044883; Jonsson EG, 2006, PROG NEURO-PSYCHOPH, V30, P924, DOI 10.1016/j.pnpbp.2006.02.008; Kang JI, 2010, NEUROPHARMACOLOGY, V58, P1109, DOI 10.1016/j.neuropharm.2010.02.001; Karpova NN, 2014, NEUROPHARMACOLOGY, V76, P709, DOI 10.1016/j.neuropharm.2013.04.002; Kauppi K, 2013, NEUROPSYCHOLOGIA, V51, P2462, DOI 10.1016/j.neuropsychologia.2012.11.028; Korley FK, 2016, J NEUROTRAUM, V33, P215, DOI 10.1089/neu.2015.3949; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; Kulbatski I, 2005, CURR DRUG TARGETS, V6, P111, DOI 10.2174/1389450053345037; Kurowski BG, 2015, J HEAD TRAUMA REHAB, DOI [10.1097/HTR.0000000000000162, DOI 10.1097/HTR.00000000000001621545968315586465]; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Laurer HL, 2001, CURR PHARM DESIGN, V7, P1505, DOI 10.2174/1381612013397285; Lin WJ, 2013, FRONT ENDOCRINOL, P4; Marshall S, 2012, CAN FAM PHYSICIAN, V58, P257; Martinez-Lucas P, 2005, INTENS CARE MED, V31, P1168, DOI 10.1007/s00134-005-2715-0; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; McAllister AK, 1996, NEURON, V17, P1057, DOI 10.1016/S0896-6273(00)80239-1; McAllister TW, 2012, J NEUROTRAUM, V29, P1111, DOI 10.1089/neu.2011.1930; McAllister TW, 2010, PM&R, V2, pS241, DOI 10.1016/j.pmrj.2010.10.005; McAllister TW, 2014, HDB CLIN NEUROL, V128, P723; Michael DB, 2005, J CLIN NEUROSCI, V12, P284, DOI 10.1016/j.jocn.2004.11.003; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Miyajima F, 2008, GENES BRAIN BEHAV, V7, P411, DOI 10.1111/j.1601-183X.2007.00363.x; Mohajeri MH, 2012, BRAIN RES BULL, V88, P429, DOI 10.1016/j.brainresbull.2011.12.003; Morley KI, 2001, BEHAV GENET, V31, P511, DOI 10.1023/A:1013337209957; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Ninan I, 2014, NEUROPHARMACOLOGY, V76, P684, DOI 10.1016/j.neuropharm.2013.04.011; Okada T, 2006, MOL PSYCHIATR, V11, P695, DOI 10.1038/sj.mp.4001822; Organization W H, 2013, WHO GLOB STAT REP RO; Parasuraman R, 2002, NEUROPSYCHOLOGY, V16, P254, DOI 10.1037//0894-4105.16.2.254; Perkovic MN, 2014, PSYCHOPHARMACOLOGY, V231, P3757, DOI 10.1007/s00213-014-3515-4; Petryshen TL, 2010, MOL PSYCHIATR, V15, P810, DOI 10.1038/mp.2009.24; Pezawas L, 2004, J NEUROSCI, V24, P10099, DOI 10.1523/JNEUROSCI.2680-04.2004; Pivac N, 2009, CROAT MED J, V50, P43, DOI 10.3325/cmj.2009.50.43; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Pruthi N, 2010, NEUROL INDIA, V58, P264, DOI 10.4103/0028-3886.63810; Quan N, 2002, HISTOL HISTOPATHOL, V17, P273, DOI 10.14670/HH-17.273; Rostami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027389; Rybakowski JK, 2003, BIPOLAR DISORD, V5, P468, DOI 10.1046/j.1399-5618.2003.00071.x; Rybakowski JK, 2006, MOL PSYCHIATR, V11, P122, DOI 10.1038/sj.mp.4001765; Savitz J, 2006, GENES BRAIN BEHAV, V5, P311, DOI 10.1111/j.1601-183X.2005.00163.x; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Shimizu E, 2004, AM J MED GENET B, V126B, P122, DOI 10.1002/ajmg.b.20118; Stam AH, 2009, J NEUROL NEUROSUR PS, V80, P1125, DOI 10.1136/jnnp.2009.177279; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Tost H, 2013, NEUROPSYCHOPHARMACOL, V38, P525, DOI 10.1038/npp.2012.214; UniProt Consortium, UNIPROTKB P23560 BDN; Uzan M, 2005, ACTA NEUROCHIR, V147, P715, DOI 10.1007/s00701-005-0529-z; van Wingen G, 2010, NEUROIMAGE, V50, P1212, DOI 10.1016/j.neuroimage.2010.01.058; Veeramuthu V, 2015, J NEUROTRAUM, V32, P1497, DOI 10.1089/neu.2014.3750; Voineskos AN, 2011, ARCH GEN PSYCHIAT, V68, P198, DOI 10.1001/archgenpsychiatry.2010.194; Wang HY, 2013, NEURAL REGEN RES, V8, P843, DOI 10.3969/j.issn.1673-5374.2013.09.009; Wang JC, 2004, HUM MOL GENET, V13, P1903, DOI 10.1093/hmg/ddh194; Weese-Mayer DE, 2002, AM J MED GENET, V107, P306, DOI 10.1002/ajmg.10133; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; World Health Organization, 2009, GLOB STAT REP ROAD S; World Health Organization, 2006, NEUR DIS PUBL HLTH C; Yue JK, 2015, NEUROSURGERY, V62, P225	102	14	14	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2016	11	7							e0158838	10.1371/journal.pone.0158838			15	Multidisciplinary Sciences	Science & Technology - Other Topics	DR8TL	WOS:000380170100024	27438599	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Citron, BA; Ameenuddin, S; Uchida, K; Suo, WZ; SantaCruz, K; Festoff, BW				Citron, Bruce A.; Ameenuddin, Syed; Uchida, K.; Suo, William Z.; SantaCruz, Karen; Festoff, Barry W.			Membrane lipid peroxidation in neurodegeneration: Role of thrombin and proteinase-activated receptor-1	BRAIN RESEARCH			English	Article						Membrane lipid peroxidation; Reactive oxygen; Apoptosis; Neurodegenerative diseases; Spinal cord injury	PROTHROMBIN-MESSENGER-RNA; SPINAL-CORD-INJURY; OXIDATIVE STRESS; SERINE PROTEASES; CELL-DEATH; 4-HYDROXYNONENAL PROTEIN; ALZHEIMERS-DISEASE; MOUSE MODEL; PROINFLAMMATORY CYTOKINES; SIGNAL-TRANSDUCTION	Thrombin and membrane lipid peroxidation (MLP) have been implicated in various central nervous system (CNS) disorders from CNS trauma to stroke, Alzheimer's (AD) and Parkinson's (PD) diseases. Because thrombin also induces MLP in platelets and its involvement in neurodegenerative diseases we hypothesized that its deleterious effects might, in part, involve formation of MLP in neuronal cells. We previously showed that thrombin induced caspase-3 mediated apoptosis in motor neurons, via a proteinase-activated receptor (PAR1). We have now investigated thrombin's influence on the oxidative state of neurons leading to induction of MLP-protein adducts. Translational relevance of thrombin-induced MLP is supported by increased levels of 4-hydroxynonenal-protein adducts (HNEPA) in AD and PD brains. We now report for the first time that thrombin dose-dependently induces formation of HNEPA in NSC34 mouse motor neuron cells using anti-HNE and anti-acrolein monoclonal antibodies. The most prominent immunoreactive band, in SDS-PAGE, was at similar to 54 kDa. Membrane fractions displayed higher amounts of the protein-adduct than cytosolic fractions. Thrombin induced MLP was mediated, at least in part, through PAR1 since a PAR1 active peptide, PAR1AP, also elevated HNEPA levels. Of interest, glutamate and Fe2SO4 also increased the similar to 54 kDa HNEPA band in these cells but to a lesser extent. Taken together our results implicate the involvement of thrombin and MLP in neuronal cell loss observed in various CNS degenerative and traumatic pathologies. (c) 2016 Published by Elsevier B.V.	[Citron, Bruce A.; Ameenuddin, Syed; Suo, William Z.; SantaCruz, Karen; Festoff, Barry W.] Dept Vet Affairs Med Ctr, Neurobiol Res Lab, Kansas City, MO 64128 USA; [Citron, Bruce A.; Suo, William Z.; Festoff, Barry W.] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66170 USA; [Festoff, Barry W.] Univ Kansas, Med Ctr, Dept Pharmacol, Kansas City, KS 66170 USA; [Festoff, Barry W.] Univ Kansas, Med Ctr, Dept Toxicol, Kansas City, KS 66170 USA; [Festoff, Barry W.] Univ Kansas, Med Ctr, Dept Therapeut, Kansas City, KS 66170 USA; [SantaCruz, Karen] Univ Kansas, Med Ctr, Dept Pathol, Kansas City, KS 66170 USA; [SantaCruz, Karen] Univ Kansas, Med Ctr, Dept Lab Med, Kansas City, KS 66170 USA; [Festoff, Barry W.] Univ Kansas, Med Ctr, Dept Mol, Kansas City, KS 66170 USA; [Festoff, Barry W.] Univ Kansas, Med Ctr, Dept Integrat Physiol, Kansas City, KS 66170 USA; [Uchida, K.] Nagoya Univ, Lab Food & Biodynam, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan; [Citron, Bruce A.] Bay Pines VA Healthcare Syst, Res & Dev 151, Bldg 22,Rm 123,POB 4125, Bay Pines, FL 33744 USA; [Citron, Bruce A.] Univ S Florida, Morsani Coll Med, Dept Mol Med, Res & Dev 151, Bldg 22,Rm 123,POB 4125, Bay Pines, FL 33744 USA; [Ameenuddin, Syed] Mayo Clin & Mayo Fdn, Cellular Neurobiol Lab, 1501 Guggenheim Bldg,200 First St SW, Rochester, MN 55905 USA; [SantaCruz, Karen] Univ New Mexico, Dept Pathol, MSC8 4640, Albuquerque, NM 87131 USA	Festoff, BW (corresponding author), PHLOGISTIX Neurodiagnost, 4220 Shawnee Mission Pkwy Suite 350B, Fairway, KS 66205 USA.	bwfestoff@mac.com		Uchida, Koji/0000-0003-3894-5299	Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development)US Department of Veterans Affairs; Lied Fund of the University of Kansas Medical Center Research Institute, Inc.; Alzheimer's AssociationAlzheimer's Association; ALS Association; Veterans AffairsUS Department of Veterans Affairs [I01RX001520] Funding Source: NIH RePORTER	We thank Drs. N. Cashman, J.W. Fenton, II, Thomas Anderson and Michael D'Andrea for providing NSC34 cell lines, human alpha-thrombin, PAR1AP and PAR1C antibody, respectively. The authors are grateful to Michael Lucido and Sonia Malburg for expert technical assistance. This work was supported, in part, by the Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development), the Lied Fund of the University of Kansas Medical Center Research Institute, Inc., the Alzheimer's Association, and the ALS Association.	Abarikwu SO, 2012, BASIC CLIN PHARMACOL, V110, P441, DOI 10.1111/j.1742-7843.2011.00834.x; Ando Y, 1998, J NEUROL SCI, V156, P172, DOI 10.1016/S0022-510X(98)00042-2; Arai T, 2006, J NEUROPATH EXP NEUR, V65, P19, DOI 10.1097/01.jnen.0000196133.74087.cb; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Bednar MM, 2000, EXPERT OPIN INV DRUG, V9, P355, DOI 10.1517/13543784.9.2.355; BEECHER KL, 1994, J NEUROSCI RES, V37, P108, DOI 10.1002/jnr.490370115; Ben Shimon M, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00151; Blanc EM, 1997, J NEUROCHEM, V69, P570; Blanc EM, 1998, J NEUROCHEM, V70, P958; Blanc EM, 1998, GLIA, V22, P149, DOI 10.1002/(SICI)1098-1136(199802)22:2<149::AID-GLIA6>3.0.CO;2-2; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRAAK H, 1994, NEUROBIOL AGING, V15, P355, DOI 10.1016/0197-4580(94)90032-9; Bruce-Keller AJ, 1998, J NEUROPATH EXP NEUR, V57, P257, DOI 10.1097/00005072-199803000-00007; BUCZYNSKI A, 1993, ATHEROSCLEROSIS, V100, P223, DOI 10.1016/0021-9150(93)90208-C; Butterfield DA, 2006, NEUROSCI LETT, V397, P170, DOI 10.1016/j.neulet.2005.12.017; Camerer E, 2006, BLOOD, V107, P3912, DOI 10.1182/blood-2005-08-3130; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; Chapman J, 2013, SEMIN THROMB HEMOST, V39, P876, DOI 10.1055/s-0033-1357482; CHOI BH, 1995, NEUROBIOL AGING, V16, P675, DOI 10.1016/0197-4580(95)00065-M; Citron BA, 1997, NEUROSCI LETT, V230, P25, DOI 10.1016/S0304-3940(97)00468-0; Citron BA, 2000, J NEUROTRAUM, V17, P1191, DOI 10.1089/neu.2000.17.1191; Clark IA, 2015, BRIT J PHARMACOL, V172, P3714, DOI 10.1111/bph.13181; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; Donovan FM, 1997, J NEUROSCI, V17, P5316; Dugina TN, 2002, BIOCHEMISTRY-MOSCOW+, V67, P65, DOI 10.1023/A:1013952114485; Farooqui AA, 1998, CELL MOL NEUROBIOL, V18, P599, DOI 10.1023/A:1020261600498; Festoff BM, 2000, MOL MED, V6, P410, DOI 10.1007/BF03401784; Festoff BW, 2001, INT REV CYTOL, V211, P153, DOI 10.1016/S0074-7696(01)11018-1; Festoff BW, 1996, SEMIN THROMB HEMOST, V22, P267, DOI 10.1055/s-2007-999018; Figueroa BE, 1998, STROKE, V29, P1202, DOI 10.1161/01.STR.29.6.1202; Freixes M, 2006, NEUROBIOL AGING, V27, P1807, DOI 10.1016/j.neurobiolaging.2005.10.006; Gabazza EC, 2004, INT J HEMATOL, V79, P117, DOI 10.1532/IJH97.03165; Gard AL, 2001, MICROSC RES TECHNIQ, V52, P709, DOI 10.1002/jemt.1055; Gingrich MB, 2000, TRENDS NEUROSCI, V23, P399, DOI 10.1016/S0166-2236(00)01617-9; GOROG P, 1995, ATHEROSCLEROSIS, V115, P121, DOI 10.1016/0021-9150(94)05506-E; Grammas P, 2006, J ALZHEIMERS DIS, V9, P51; Hanisch UK, 2004, J BIOL CHEM, V279, P51880, DOI 10.1074/jbc.M408318200; HO GJ, 1994, BIOMED PHARMACOTHER, V48, P296, DOI 10.1016/0753-3322(94)90175-9; HURST JS, 1987, CHEM-BIOL INTERACT, V61, P109, DOI 10.1016/0009-2797(87)90033-0; Hyman BT, 1997, J NEUROPATH EXP NEUR, V56, P1095, DOI 10.1097/00005072-199710000-00002; Ilic M, 2011, BIOORG MED CHEM LETT, V21, P4705, DOI 10.1016/j.bmcl.2011.06.089; Ji KA, 2004, GLIA, V48, P102, DOI 10.1002/glia.20059; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kabuta C., 2015, BIOCH BIOPHYSICAL RE; Kabuta C, 2015, BIOCHEM BIOPH RES CO, V463, P82, DOI 10.1016/j.bbrc.2015.05.027; Karabiyikoglu M, 2004, J CEREBR BLOOD F MET, V24, P159, DOI 10.1097/01.WCB.0000100062.36077.84; Kario K, 1999, STROKE, V30, P1033, DOI 10.1161/01.STR.30.5.1033; Kataoka H, 2003, BLOOD, V102, P3224, DOI 10.1182/blood-2003-04-1130; Kataoka S, 2000, J NEUROL SCI, V181, P82, DOI 10.1016/S0022-510X(00)00435-4; Krantic S, 2005, TRENDS NEUROSCI, V28, P670, DOI 10.1016/j.tins.2005.09.011; Krenzlin H, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010084; LeBlanc Andrea C., 2005, Current Alzheimer Research, V2, P389, DOI 10.2174/156720505774330573; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Liu Quan, 2003, Molecular Aspects of Medicine, V24, P305, DOI 10.1016/S0098-2997(03)00025-6; Ludeman MJ, 2005, J BIOL CHEM, V280, P13122, DOI 10.1074/jbc.M410381200; Luo J, 2005, NEUROCHEM RES, V30, P291, DOI 10.1007/s11064-005-2602-7; Luo W, 2007, BRAIN RES REV, V56, P331, DOI 10.1016/j.brainresrev.2007.08.002; MALLE E, 1995, ARTERIOSCL THROM VAS, V15, P377, DOI 10.1161/01.ATV.15.3.377; Mark RJ, 1997, J NEUROSCI, V17, P1046; Mark RJ, 1997, J NEUROCHEM, V68, P255; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; Mattson MP, 1998, INT J DEV NEUROSCI, V16, P737, DOI 10.1016/S0736-5748(98)00082-3; Mattson MP, 1997, NEUROREPORT, V8, P2275, DOI 10.1097/00001756-199707070-00036; Mattson MP, 1998, TRENDS NEUROSCI, V21, P53, DOI 10.1016/S0166-2236(97)01188-0; Montine KS, 1998, J NEUROPATH EXP NEUR, V57, P415, DOI 10.1097/00005072-199805000-00005; Murphy TC, 2003, J NEUROCHEM, V84, P1313, DOI 10.1046/j.1471-4159.2003.01628.x; Narayanan S, 1999, ANN CLIN LAB SCI, V29, P275; NICLOU S, 1994, CELL MOL BIOL, V40, P421; Niclou SP, 1998, EUR J NEUROSCI, V10, P1590, DOI 10.1046/j.1460-9568.1998.00183.x; Nicole O, 2005, J NEUROSCI, V25, P4319, DOI 10.1523/JNEUROSCI.5200-04.2005; NOSAL R, 1993, J LIPID MEDIATOR, V8, P121; Okonkwo DO, 2003, CLIN SPORT MED, V22, P467, DOI 10.1016/S0278-5919(02)00107-2; Pappolla MA, 1998, AM J PATHOL, V152, P871; Pedersen WA, 1998, ANN NEUROL, V44, P819, DOI 10.1002/ana.410440518; Pedersen WA, 1999, EXP NEUROL, V155, P1, DOI 10.1006/exnr.1998.6890; Perluigi M, 2009, PROTEOM CLIN APPL, V3, P682, DOI 10.1002/prca.200800161; Przedborski S, 2005, PARKINSONISM RELAT D, V11, pS3, DOI 10.1016/j.parkreldis.2004.10.012; Riek-Burchardt M, 2002, NEUROSCI LETT, V329, P181, DOI 10.1016/S0304-3940(02)00645-6; Rofina JE, 2004, AMYLOID, V11, P90, DOI 10.1080/13506120412331285779; Rohatgi T, 2004, NEUROSCIENTIST, V10, P501, DOI 10.1177/1073858404269955; Ryu J, 2000, J BIOL CHEM, V275, P29955, DOI 10.1074/jbc.M001220200; Sayre LM, 1997, J NEUROCHEM, V68, P2092; Siddiqui MA, 2012, HUM EXP TOXICOL, V31, P336, DOI 10.1177/0960327111432500; Smirnova IV, 1998, J NEUROBIOL, V36, P64, DOI 10.1002/(SICI)1097-4695(199807)36:1<64::AID-NEU6>3.0.CO;2-8; Smirnova IV, 1998, J MOL NEUROSCI, V10, P31, DOI 10.1007/BF02737083; Smirnova IV, 2001, J NEUROBIOL, V48, P87, DOI 10.1002/neu.1044.abs; Smith MA, 1998, J NEUROCHEM, V70, P2212, DOI 10.1046/j.1471-4159.1998.70052212.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITHSWINTOSKY VL, 1995, J NEUROCHEM, V65, P1415; Springer JE, 1997, J NEUROCHEM, V68, P2469; Steinhoff M, 2005, ENDOCR REV, V26, P1, DOI 10.1210/er.2003-0025; Suo Z., 2004, Current Drug Targets - Inflammation and Allergy, V3, P105, DOI 10.2174/1568010043483953; Suo ZM, 2003, J BIOL CHEM, V278, P37681, DOI 10.1074/jbc.M301406200; Suo ZM, 2003, J BIOL CHEM, V278, P31177, DOI 10.1074/jbc.M302137200; Suo ZM, 2002, J NEUROCHEM, V80, P655, DOI 10.1046/j.0022-3042.2001.00745.x; Thirumangalakudi L, 2009, NEUROSCI LETT, V452, P172, DOI 10.1016/j.neulet.2009.01.045; Turgeon VL, 1997, BRAIN RES REV, V25, P85, DOI 10.1016/S0165-0173(97)00015-5; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742; Uchida K, 2015, FREE RADICAL RES, V49, P896, DOI 10.3109/10715762.2015.1036052; Uchida K, 1998, J BIOL CHEM, V273, P16058, DOI 10.1074/jbc.273.26.16058; Uchida K, 1998, P NATL ACAD SCI USA, V95, P4882, DOI 10.1073/pnas.95.9.4882; Volkel W, 2006, NEUROCHEM INT, V48, P679, DOI 10.1016/j.neuint.2005.12.003; Wang H, 2003, BIOL CHEM, V384, P193, DOI 10.1515/BC.2003.021; Weinstein JR, 2005, J NEUROCHEM, V95, P1177, DOI 10.1111/j.1471-4159.2005.03499.x; WEINSTEIN JR, 1995, J NEUROSCI, V15, P2906; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; Xu W, 2005, SPINAL CORD, V43, P204, DOI 10.1038/sj.sc.3101674; Yang MS, 2004, BIOCHEM BIOPH RES CO, V317, P811, DOI 10.1016/j.bbrc.2004.03.118; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696; Zarkovic Kamelija, 2003, Molecular Aspects of Medicine, V24, P293, DOI 10.1016/S0098-2997(03)00024-4	110	14	15	1	21	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 15	2016	1643						10	17		10.1016/j.brainres.2016.04.071			8	Neurosciences	Neurosciences & Neurology	DP4EE	WOS:000378448200002	27138068				2021-06-18	
J	Brennan, FH; Kurniawan, ND; Vukovic, J; Bartlett, PF; Kasermann, F; Arumugam, TV; Basta, M; Ruitenberg, MJ				Brennan, Faith H.; Kurniawan, Nyoman D.; Vukovic, Jana; Bartlett, Perry F.; Kasermann, Fabian; Arumugam, Thiruma V.; Basta, Milan; Ruitenberg, Marc J.			IVIg attenuates complement and improves spinal cord injury outcomes in mice	ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY			English	Article							DOSE INTRAVENOUS IMMUNOGLOBULIN; WHITE-MATTER PATHOLOGY; FC-GAMMA-RIIB; ACUTE-INFLAMMATION; BRAIN-INJURY; CELL-DEATH; RECOVERY; THERAPY; MODEL; SYSTEM	Objective: Traumatic spinal cord injury ( SCI) elicits immediate neural cell death, axonal damage, and disruption of the blood-spinal cord barrier, allowing circulating immune cells and blood proteins into the spinal parenchyma. The inflammatory response to SCI involves robust complement system activation, which contributes to secondary injury and impairs neurological recovery. This study aimed to determine whether intravenous immunoglobulin ( IVIg), an FDA-approved treatment for inflammatory conditions, can scavenge complement activation products and improve recovery from contusive SCI. Methods: We used functional testing, noninvasive imaging, and detailed postmortem analysis to assess whether IVIg therapy is effective in a mouse model of severe contusive SCI. Results: IVIg therapy at doses of 0.5-2 g/kg improved the functional and histopathological outcomes from SCI, conferring protection against lesion enlargement, demyelination, central canal dilation, and axonal degeneration. The benefits of IVIg were detectable through noninvasive diffusion tensor imaging ( DTI), with IVIg treatment counteracting the progressive SCI-induced increase in radial diffusivity ( RD) in white matter. Diffusion indices significantly correlated with the functional performance of individual mice and accurately predicted the degree of myelin preservation. Further experiments revealed that IVIg therapy reduced the presence of complement activation products and phagocytically active macrophages at the lesion site, providing insight as to its mechanisms of action. Interpretation: Our findings highlight the potential of using IVIg as an immunomodulatory treatment for SCI, and the value of DTI to assess tissue damage and screen for the efficacy of candidate intervention strategies in preclinical models of SCI, both quantitatively and noninvasively.	[Brennan, Faith H.; Vukovic, Jana; Ruitenberg, Marc J.] Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; [Kurniawan, Nyoman D.] Univ Queensland, Ctr Adv Imaging, Brisbane, Qld 4072, Australia; [Vukovic, Jana; Bartlett, Perry F.; Ruitenberg, Marc J.] Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia; [Kasermann, Fabian] CSL Behring, Res, CH-3000 Bern, Switzerland; [Arumugam, Thiruma V.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117597, Singapore; [Basta, Milan] BioVisions Inc, 9012 Wandering Trail Dr, Potomac, MD 20854 USA; [Ruitenberg, Marc J.] Univ Queensland, Brisbane Diamantina Hlth Partners, Trauma Crit Care & Recovery, Brisbane, Qld, Australia	Ruitenberg, MJ (corresponding author), Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia.; Basta, M (corresponding author), BioVisions Inc, 9012 Wandering Trail Dr, Potomac, MD 20854 USA.	basta.milan@gmail.com; m.ruitenberg@uq.edu.au	Vukovic, Jana/B-4845-2013; Kurniawan, Nyoman/D-9764-2011; Arumugam, Thiruma/AAG-6958-2019	Vukovic, Jana/0000-0002-3739-1688; Kurniawan, Nyoman/0000-0001-6340-182X; Ruitenberg, Marc/0000-0002-6917-0708; Arumugam, Thiruma/0000-0002-3377-0939; Kasermann, Fabian/0000-0002-4255-9350; Brennan, Faith/0000-0002-9201-2476			Ankeny DP, 2009, J CLIN INVEST, V119, P2990, DOI 10.1172/JCI39780; Arumugam TV, 2007, P NATL ACAD SCI USA, V104, P14104, DOI 10.1073/pnas.0700506104; Bar-Or D, 2006, CRIT CARE MED, V34, P1707, DOI 10.1097/01.CCM.0000217923.53680.4C; BASTA M, 1989, BLOOD, V74, P326; Basta M, 2003, NAT MED, V9, P431, DOI 10.1038/nm836; BASTA M, 1994, J CLIN INVEST, V94, P1729, DOI 10.1172/JCI117520; BASTA M, 1989, J CLIN INVEST, V84, P1974, DOI 10.1172/JCI114387; Basta M, 2008, MOL IMMUNOL, V45, P4073, DOI 10.1016/j.molimm.2008.07.012; Bayry J, 2011, NAT REV RHEUMATOL, V7, P349, DOI 10.1038/nrrheum.2011.61; Belayev L, 1999, BRAIN RES, V845, P107, DOI 10.1016/S0006-8993(99)01952-6; Brennan FH, 2016, SEMIN IMMUNOL, V28, P292, DOI 10.1016/j.smim.2016.03.015; Brennan FH, 2015, NEURAL REGEN RES, V10, P1596, DOI 10.4103/1673-5374.165268; Brennan FH, 2015, J NEUROSCI, V35, P6517, DOI 10.1523/JNEUROSCI.5218-14.2015; Brennan FH, 2013, NEUROIMAGE, V82, P574, DOI 10.1016/j.neuroimage.2013.06.019; Brennan FH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-137; Cain LD, 2007, J NEUROSCI RES, V85, P1558, DOI 10.1002/jnr.21265; Carpenter RS, 2015, EXP NEUROL, V271, P432, DOI 10.1016/j.expneurol.2015.07.011; Chen B, 2014, PEDIATR RES, V75, P612, DOI 10.1038/pr.2014.12; Courtine G, 2007, NAT MED, V13, P561, DOI 10.1038/nm1595; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; DUCKER TB, 1994, SPINE, V19, P2281, DOI 10.1097/00007632-199410150-00006; Nguyen DH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-224; Dvorak MF, 2014, J NEUROTRAUM, V31, P1540, DOI 10.1089/neu.2013.3278; Ephrem A, 2005, CLIN EXP MED, V5, P135, DOI 10.1007/s10238-005-0079-y; Gensel JC, 2011, EXPERT OPIN THER TAR, V15, P505, DOI 10.1517/14728222.2011.553605; Hui ES, 2010, NEUROIMAGE, V49, P2366, DOI 10.1016/j.neuroimage.2009.10.022; Jeong S, 2014, J NEUROIMMUNOL, V276, P112, DOI 10.1016/j.jneuroim.2014.08.626; Karsten CM, 2012, NAT MED, V18, P1401, DOI 10.1038/nm.2862; Katz U, 2007, AUTOIMMUN REV, V6, P257, DOI 10.1016/j.autrev.2006.08.011; Kelley BJ, 2014, J NEUROTRAUM, V31, P1362, DOI 10.1089/neu.2013.3238; Kim JH, 2007, MAGN RESON MED, V58, P253, DOI 10.1002/mrm.21316; Kim JH, 2010, J NEUROTRAUM, V27, P587, DOI 10.1089/neu.2009.1063; Konrad S, 2006, BRIT J HAEMATOL, V134, P345, DOI 10.1111/j.1365-2141.2006.06185.x; Loy DN, 2007, J NEUROTRAUM, V24, P979, DOI 10.1089/neu.2006.0253; Miller SM, 2008, J NEUROSURG ANESTH, V20, P140, DOI 10.1097/01.ana.0000314442.40952.0d; Mulcahey MJ, 2012, SPINE, V37, pE797, DOI 10.1097/BRS.0b013e3182470a08; Nakahara J, 2003, DEV CELL, V4, P841, DOI 10.1016/S1534-5807(03)00155-2; Neher MD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-95; Neher MD, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-90; Okun E, 2010, NEUROMOL MED, V12, P164, DOI 10.1007/s12017-009-8099-5; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Radojicic M, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-30; Schwab I, 2013, NAT REV IMMUNOL, V13, P176, DOI 10.1038/nri3401; Shushakova N, 2002, J CLIN INVEST, V110, P1823, DOI 10.1172/JCI200216577; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Spycher M, 2009, VOX SANG, V97, P348, DOI 10.1111/j.1423-0410.2009.01217.x; Stahel Philip F, 2006, Expert Rev Clin Immunol, V2, P445, DOI 10.1586/1744666X.2.3.445; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Widiapradja Alexander, 2014, Exp Transl Stroke Med, V6, P7, DOI 10.1186/2040-7378-6-7; Widiapradja A, 2012, J NEUROCHEM, V122, P321, DOI 10.1111/j.1471-4159.2012.07754.x	51	14	14	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2328-9503			ANN CLIN TRANSL NEUR	Ann. Clin. Transl. Neurol.	JUL	2016	3	7					495	511		10.1002/acn3.318			17	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DX1JJ	WOS:000384122800002	27386499	DOAJ Gold, Green Published			2021-06-18	
J	Choi, BY; Kim, IY; Kim, JH; Lee, BE; Lee, SH; Kho, AR; Jung, HJ; Sohn, M; Song, HK; Suh, SW				Choi, Bo Young; Kim, In Yeol; Kim, Jin Hee; Lee, Bo Eun; Lee, Song Hee; Kho, A. Ra; Jung, Hee Jae; Sohn, Min; Song, Hong Ki; Suh, Sang Won			Decreased cysteine uptake by EAAC1 gene deletion exacerbates neuronal oxidative stress and neuronal death after traumatic brain injury	AMINO ACIDS			English	Article						EAAC1; Cysteine; Zinc; TBI; Reactive oxygen species; Microglia	TRANSIENT CEREBRAL-ISCHEMIA; ALTERS ZINC HOMEOSTASIS; GLUTAMATE TRANSPORTER; MICROGLIAL ACTIVATION; GLUTATHIONE; MICE; SUSCEPTIBILITY; SUPEROXIDE; INCREASES; RELEASE	Excitatory amino acid carrier type 1 (EAAC1), a high-affinity glutamate transporter, can expend energy to move glutamate into neurons. However, under normal physiological conditions, EAAC1 does not have a great effect on glutamate clearance but rather participates in the neuronal uptake of cysteine. This process is critical to maintaining neuronal antioxidant function by providing cysteine for glutathione synthesis. Previous study showed that mice lacking EAAC1 show increased neuronal oxidative stress following transient cerebral ischemia. In the present study, we sought to characterize the role of EAAC1 in neuronal resistance after traumatic brain injury (TBI). Young adult C57BL/6 wild-type or EAAC1 (-/-) mice were subjected to a controlled cortical impact model for TBI. Neuronal death after TBI showed more than double the number of degenerating neurons in the hippocampus in EAAC1 (-/-) mice compared with wild-type mice. Superoxide production, zinc translocation and microglia activation similarly showed a marked increase in the EAAC1 (-/-) mice. Pretreatment with N-acetyl cysteine (NAC) reduced TBI-induced neuronal death, superoxide production and zinc translocation. These findings indicate that cysteine uptake by EAAC1 is important for neuronal antioxidant function and survival following TBI. This study also suggests that administration of NAC has therapeutic potential in preventing TBI-induced neuronal death.	[Choi, Bo Young; Kim, In Yeol; Kim, Jin Hee; Lee, Bo Eun; Lee, Song Hee; Kho, A. Ra; Jung, Hee Jae; Suh, Sang Won] Hallym Univ, Coll Med, Dept Physiol, 1 Okcheon Dong,39 Hallymdaehak Gil, Chunchon 200702, South Korea; [Song, Hong Ki] Hallym Univ, Coll Med, Dept Neurol, Chunchon, South Korea; [Sohn, Min] Inha Univ, Dept Nursing, Incheon, South Korea	Suh, SW (corresponding author), Hallym Univ, Coll Med, Dept Physiol, 1 Okcheon Dong,39 Hallymdaehak Gil, Chunchon 200702, South Korea.	swsuh@hallym.ac.kr		Choi, Bo Young/0000-0002-9579-3503; SOHN, MIN/0000-0003-4021-2051	National Research Foundation of Korea (NRF) - Korea government (MEST)Ministry of Education, Science and Technology, Republic of KoreaNational Research Foundation of KoreaKorean Government [2012R1A2A2A01046132]; Hallym University [HRF-S-52]	This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (2012R1A2A2A01046132) and by Hallym University Specialization Fund (HRF-S-52).	Aoyama K, 2006, NAT NEUROSCI, V9, P119, DOI 10.1038/nn1609; Aoyama K, 2008, J PHARMACOL SCI, V108, P227, DOI 10.1254/jphs.08R01CR; Bains JS, 1997, BRAIN RES REV, V25, P335, DOI 10.1016/S0165-0173(97)00045-3; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P49; Chen YM, 2003, J NEUROCHEM, V84, P1332, DOI 10.1046/j.1471-4159.2003.01630.x; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Choi BY, 2014, INT J MOL SCI, V15, P19444, DOI 10.3390/ijms151119444; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; DEVRIES N, 1993, J CELL BIOCHEM, P270; Dringen R, 2000, PROG NEUROBIOL, V62, P649, DOI 10.1016/S0301-0082(99)00060-X; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; Himi T, 2003, J NEURAL TRANSM, V110, P1337, DOI 10.1007/s00702-003-0049-z; Jang BG, 2012, J TRACE ELEM MED BIO, V26, P85, DOI 10.1016/j.jtemb.2012.04.010; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Lane MC, 2014, NEUROCHEM INT, V73, P152, DOI 10.1016/j.neuint.2013.11.013; Lee SA, 2009, ANESTH ANALG, V109, P1506, DOI 10.1213/ANE.0b013e3181b6709a; Li LL, 2011, J CEREBR BLOOD F MET, V31, P1283, DOI 10.1038/jcbfm.2010.222; Mazor D, 1996, EUR J HAEMATOL, V57, P241; Murakami K, 1998, J NEUROSCI, V18, P205; Peghini P, 1997, EMBO J, V16, P3822, DOI 10.1093/emboj/16.13.3822; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rao VLR, 2001, J NEUROSCI, V21, P1876, DOI 10.1523/JNEUROSCI.21-06-01876.2001; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; Silva AJ, 1997, NEURON, V19, P755, DOI 10.1016/S0896-6273(00)80958-7; Singh P, 2003, NEUROL INDIA, V51, P215; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J; Suh SW, 2008, J CEREBR BLOOD F MET, V28, P1697, DOI 10.1038/jcbfm.2008.61; Suh SW, 2007, J CLIN INVEST, V117, P910, DOI 10.1172/JCI30077; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Watabe M, 2008, J NEUROSCI, V28, P9404, DOI 10.1523/JNEUROSCI.3351-08.2008; Watase K, 1998, EUR J NEUROSCI, V10, P976, DOI 10.1046/j.1460-9568.1998.00108.x; Won SJ, 2010, J NEUROSCI, V30, P15409, DOI 10.1523/JNEUROSCI.2084-10.2010; Zerangue N, 1996, J PHYSIOL-LONDON, V493, P419, DOI 10.1113/jphysiol.1996.sp021393	45	14	15	0	7	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0939-4451	1438-2199		AMINO ACIDS	Amino Acids	JUL	2016	48	7					1619	1629		10.1007/s00726-016-2221-4			11	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	DN9OU	WOS:000377409900008	27040821				2021-06-18	
J	Chronister, J; Johnson, ET; Chan, F; Tu, WM; Chung, YC; Lee, GK				Chronister, Julie; Johnson, Ebonee T.; Chan, Fong; Tu, Wei-Mo; Chung, Yi-Chieh; Lee, Gloria K.			Positive Person-Environment Factors as Mediators of the Relationship Between Perceived Burden and Quality of Life of Caregivers for Individuals With Traumatic Brain Injuries	REHABILITATION COUNSELING BULLETIN			English	Article						traumatic brain injury; caregiver; social support; quality of life; family adaptation; rehabilitation counseling; stress and coping	SOCIAL SUPPORT; FAMILY CAREGIVERS; STRESS; NEEDS; MODEL; SATISFACTION; PREDICTORS; DEPRESSION; APPRAISAL; MODERATOR	The purpose of this study was to determine whether personal (caregiving mastery and problem-solving coping) and environmental (social support and professional and community support) caregiver resources mediate the relationship between caregiver perceived burden and quality of life (QOL). The sample consisted of 108 caregivers recruited from support groups who were predominantly White women. The majority of care-recipients had a severe head injury. Measures administered were the Interpersonal Support Evaluation List, the COPE, Family Needs Questionnaire, Modified Caregiving Appraisal Scale, and the World Health Organization Quality of Life-Brief Version. Results showed that social, professional, and community supports mediate the link between perceived burden and QOL. Caregivers of persons with traumatic brain injury frequently face elevated levels of burden, stress, and depression. Positive personal and environmental support, particularly social support, professional/community supports, and mastery, could lessen the negative impact of caregiving burden on QOL of the caregiver.	[Chronister, Julie] San Francisco State Univ, San Francisco, CA 94132 USA; [Johnson, Ebonee T.] Southern Univ, Baton Rouge, LA USA; [Chan, Fong; Tu, Wei-Mo] Univ Wisconsin, Madison, WI 53706 USA; [Chan, Fong] Natl Changhua Univ Educ, Changhua, Taiwan; [Chung, Yi-Chieh] Natl Pingtung Univ, Pingtung, Taiwan; [Lee, Gloria K.] Michigan State Univ, E Lansing, MI 48824 USA	Chronister, J (corresponding author), San Francisco State Univ, Dept Counseling Coordinator, Rehabil Counselor Training Program, 1600 Holloway Ave,Burk Hall 525, San Francisco, CA 94131 USA.	jchronis@sfsu.edu		Johnson, Ebonee/0000-0001-9464-2693; Tu, Wei-Mo/0000-0003-2964-542X			ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; Aneshensel C.S., 1995, PROFILES CAREGIVING; Arango-Lasprilla JC, 2010, BRAIN INJURY, V24, P1017, DOI 10.3109/02699052.2010.490516; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Beach SR, 2000, PSYCHOL AGING, V15, P259, DOI 10.1037//0882-7974.15.2.259; Bergman MM, 2002, J HEAD TRAUMA REHAB, V17, P431, DOI 10.1097/00001199-200210000-00005; Bishop M, 2006, AUST J REHABIL COUNS, V12, P73, DOI 10.1375/jrc.12.2.73; Brissette I, 2002, J PERS SOC PSYCHOL, V82, P102, DOI 10.1037//0022-3514.82.1.102; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Chan F, 2009, REHABIL COUNS BULL, V52, P114, DOI 10.1177/0034355208323947; Chronister J, 2006, REHABIL PSYCHOL, V51, P190, DOI 10.1037/0090-5550.51.3.190; Chronister J, 2010, NEUROREHABILITATION, V27, P49, DOI 10.3233/NRE-2010-0580; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; Cohen CA, 2002, INT J GERIATR PSYCH, V17, P184, DOI 10.1002/gps.561; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COHEN S, 1983, J APPL SOC PSYCHOL, V13, P99, DOI 10.1111/j.1559-1816.1983.tb02325.x; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310; Cohen S, 2003, PSYCHOSOM MED, V65, P652, DOI 10.1097/01.PSY.0000077508.57784.DA; COHEN S, 2001, EMOTION SOCIAL RELAT, P221; COHEN S, 1983, SOCIAL SUPPORT THEOR, P73; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Degeneffe CE, 2015, FAMILIES REHABILITAT, P153; Degeneffe CE, 2011, REHABIL PSYCHOL, V56, P243, DOI 10.1037/a0024465; DEW DW, 1989, J REHABIL, V55, P41; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; ERGH TC, 2002, THE JOURNAL OF HEAD, V17, P155, DOI DOI 10.1097/00001199-200204000-00006; Evans JP, 2011, T I BRIT GEOGR, V36, P223, DOI 10.1111/j.1475-5661.2010.00420.x; Feldman PJ, 2004, PSYCHOL HEALTH, V19, P353, DOI 10.1080/0887044042000193497; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Gordon W. A., 2003, REH SERV ADM WORK GR; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Harris J, 2001, ENV MANAG HLTH, V12, P529; Hayward B., 2002, STAT OF THE SCI C CO; Hilgeman MM, 2007, PSYCHOL AGING, V22, P361, DOI 10.1037/0882-7974.22.2.361; KREUTZER JS, 1994, THE JOURNAL OF HEAD, V9, P104; LAWTON MP, 1989, J GERONTOL, V44, pP61, DOI 10.1093/geronj/44.3.P61; MacKinnon DP, 2002, PSYCHOL METHODS, V7, P83, DOI 10.1037/1082-989X.7.1.83; Maki D. R., 2012, PROFESSIONAL PRACTIC, P83; Man DWK, 1998, BRAIN INJURY, V12, P245, DOI 10.1080/026990598122728; McLeod S. A., 2010, STRESS MANAGEMENT PR; Moules S, 1999, BRAIN INJURY, V13, P983; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Parveen S, 2011, J HEALTH PSYCHOL, V16, P862, DOI 10.1177/1359105310392416; Patterson J., 2011, REHABILITATION COUNS, P27; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Rapp SR, 2000, AGING MENT HEALTH, V4, P142, DOI 10.1080/13607860050008664; Reinhard SC, 2008, PATIENT SAFETY QUALI, P341; Rivera P, 2007, NEUROREHABILITATION, V22, P3; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Rodakowski J, 2012, ARCH PHYS MED REHAB, V93, P2229, DOI 10.1016/j.apmr.2012.07.004; Sandhaug M, 2012, DISABIL REHABIL, V34, P904, DOI 10.3109/09638288.2011.626484; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; Shrout PE, 2002, PSYCHOL METHODS, V7, P422, DOI 10.1037//1082-989X.7.4.422; STRUCHEN MA, 2002, THE JOURNAL OF HEAD, V17, P132; THOITS PA, 1987, J HEALTH SOC BEHAV, V28, P7, DOI 10.2307/2137137; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; World Health Organization, 2001, INT CLASS FUNCT DIS; Wortman CB, 1985, SOCIAL SUPPORT HLTH, P281; Zuger R. R., 2002, VOCATIONAL REHABILIT	70	14	14	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0034-3552	1538-4853		REHABIL COUNS BULL	Rehabil. Couns. Bull.	JUL	2016	59	4					235	246		10.1177/0034355215601072			12	Rehabilitation	Rehabilitation	EC5GS	WOS:000388162000005					2021-06-18	
J	Gad, SC; Sullivan, DW; Spasojevic, I; Mujer, CV; Spainhour, CB; Crapo, JD				Gad, Shayne Cox; Sullivan, Dexter W., Jr.; Spasojevic, Ivan; Mujer, Cesar V.; Spainhour, Charles B.; Crapo, James D.			Nonclinical Safety and Toxicokinetics of MnTnBuOE-2-PyP5+ (BMX-001)	INTERNATIONAL JOURNAL OF TOXICOLOGY			English	Article						BMX-001; MnTnBuOE-2-PyP5+; oncology; metalloporphyrin; anti-inflammatory; antioxidant; glioblastoma	NORMAL TISSUE-INJURY; OXIDATIVE STRESS; MANGANESE PORPHYRIN; RADIATION; TOXICITY; MITIGATION; AMIFOSTINE; FUTURE	BMX-001, a manganese porphyrin that has anti-inflammatory, antioxidant, and antitumor properties, is being developed as a potential therapeutic for high-grade glioma (HGG) and head and neck (H&N) cancer. An IND has been opened for BMX-001 in the treatment of HGG (NCT02655601) and another is in preparation for H&N. The safety of BMX-001 has been evaluated in a battery of nonclinical Good Laboratory Practice (GLP)-compliant studies. Systemic toxicity has been evaluated using the intended cGMP product administered subcutaneously for periods of up to 5 weeks in both the mouse and the monkey and included toxicokinetic evaluations to characterize systemic exposure and tissue distribution and clearance of BMX-001. In additional GLP studies, BMX-001 was not irritating to the skin or eye and caused no changes in cardiac rate or rhythm or blood pressure. Mixed results for genotoxicity were seen with the weight of evidence indicating that BMX-001 poses no genotoxic risk in humans. In systemic mouse and monkey studies, loading/maintenance dose no observed adverse effect levels were 12/2 mg/kg/dose and 6/2 mg/kg/dose, respectively, with maintenance doses administered every 3 days after the initial loading dose. Systemic data were used to determine a Food and Drug Administration-approved safe starting dose for the initial clinical study in patients with HGG. BMX-001 was detected in analyzed tissues, including the brain, persisting well past the short plasma clearance period. The highest levels of BMX-001 were seen in the liver and kidneys, with amounts in these tissues returning to close to undetectable levels after a 2-week cessation of dosing.	[Gad, Shayne Cox; Sullivan, Dexter W., Jr.] Gad Consulting Serv, 4008 Barrett Dr, Raleigh, NC 27609 USA; [Spasojevic, Ivan] Duke Univ, Med Ctr, Durham, NC USA; [Mujer, Cesar V.; Spainhour, Charles B.] Calvert Labs, Scott Township, PA USA; [Crapo, James D.] BioMimetix JV LLC, Englewood, CO USA	Gad, SC (corresponding author), Gad Consulting Serv, 4008 Barrett Dr, Raleigh, NC 27609 USA.	scgad@ix.netcom.com					[Anonymous], 2009, GUID NONCL SAF STUD; Ashcraft KA, 2015, INT J RAD ONCOL BIOL, V93, P892; Batinic-Haberle I, 2014, ANTIOXID REDOX SIGN, V20, P2372, DOI 10.1089/ars.2012.5147; Batinic-Haberle I, 2011, FREE RADICAL BIO MED, V51, P1035, DOI 10.1016/j.freeradbiomed.2011.04.046; Draize JH, 1944, J PHARMACOL EXP THER, V82, P377; Gad SC, 2013, INT J TOXICOL, V32, P274, DOI 10.1177/1091581813490203; Gridley DS, 2007, ANTICANCER RES, V27, P3101; International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Harmonised Tripartite Guideline, 2011, GUID GEN TEST DAT IN; Khan I, 2009, REDOX REP, V14, P236, DOI 10.1179/135100009X12525712409698; Kumar S, 2005, TOXICOL LETT, V157, P175, DOI 10.1016/j.toxlet.2005.03.004; Lee MYK, 2010, J VASC RES, V47, P287, DOI 10.1159/000265563; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; Moulder JE, 2007, SEMIN RADIAT ONCOL, V17, P141, DOI 10.1016/j.semradonc.2006.11.010; Navarro J, 1997, FREE RADICAL BIO MED, V22, P1203, DOI 10.1016/S0891-5849(96)00554-0; OECD, 2014, VIVO MAMMALIAN ALKAL, P1; Rabbani ZN, 2009, FREE RADICAL BIO MED, V47, P992, DOI 10.1016/j.freeradbiomed.2009.07.001; Rajic Z, 2012, FREE RADICAL BIO MED, V52, P1828, DOI 10.1016/j.freeradbiomed.2012.02.006; Stone HB, 2004, RADIAT RES, V162, P711, DOI 10.1667/RR3276; TAKAHASHI I, 1986, INT J RADIAT ONCOL, V12, P935, DOI 10.1016/0360-3016(86)90388-3; Tannehill SP, 1996, SEMIN ONCOL, V23, P69; Thunell S, 2000, SCAND J CLIN LAB INV, V60, P509, DOI 10.1080/003655100448310; Tovmasyan A, 2013, MED PRIN PRACT, V22, P103, DOI 10.1159/000341715; Weitzel DH, 2015, MOL CANCER THER, V14, P70, DOI 10.1158/1535-7163.MCT-14-0343; Zhao WL, 2009, CURR MED CHEM, V16, P130, DOI 10.2174/092986709787002790	24	14	14	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1091-5818	1092-874X		INT J TOXICOL	Int. J. Toxicol.	JUL-AUG	2016	35	4					438	453		10.1177/1091581816642766			16	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	DR8AU	WOS:000380121600007	27098749	Bronze			2021-06-18	
J	Preiksaitis, A; Krakauskaite, S; Petkus, V; Rocka, S; Chomskis, R; Dagi, TF; Ragauskas, A				Preiksaitis, Aidanas; Krakauskaite, Solventa; Petkus, Vytautas; Rocka, Saulius; Chomskis, Romanas; Dagi, Teodoro Forcht; Ragauskas, Arminas			Association of Severe Traumatic Brain Injury Patient Outcomes With Duration of Cerebrovascular Autoregulation Impairment Events	NEUROSURGERY			English	Article						Cerebrovascular autoregulation monitoring; Duration of cerebrovascular autoregulation impairment; Traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; HEAD-INJURY; WAVE-FORM; REACTIVITY; CONSENSUS	BACKGROUND: Cerebrovascular autoregulation (CA) is an important hemodynamic mechanism that protects the brain against inappropriate fluctuations in cerebral blood flow in the face of changing cerebral perfusion pressure. Temporal CA failure is associated with worse outcomes in various acute neurological diseases. An integrative approach is presently used according to the existing paradigm for the association of series of temporal CA impairments with the outcomes of patients with traumatic brain injury (TBI). OBJECTIVE: To explore the influence of the duration of CA impairment events on severe TBI patient outcomes. Patient age was also included in the analysis of the prospectively collected clinical data. METHODS: CA monitoring included 33 prospective severe TBI patients. The pressure reactivity index [PRx(t)] was continuously monitored to collect information on the dynamics of CA status and to analyze associations between the duration of the longest CA impairment event and patient outcomes. RESULTS: The Glasgow outcome scale and the duration of the longest CA impairment were negatively correlated. The duration of autoregulation impairment significantly correlated with worse outcomes. Multidimensional representation of Glasgow outcome scale plots showed that better outcomes were obtained for younger patients (age, 47 years) and those whose longest CA impairment event was shorter than 40 minutes if PRx (t) was above 0.7 in the CA impairment event. CONCLUSION: Unfavorable outcomes for TBI patients are more significantly associated with the duration of the single longest CA impairment episode at a high PRx(t) value, rather than with averaged PRx(t) values or the average time of all CA impairment episodes.	[Preiksaitis, Aidanas; Rocka, Saulius] Vilnius Univ, Fac Med, Clin Neurol & Neurosurg, Vilnius, Lithuania; [Preiksaitis, Aidanas] Lithuanian Univ Hlth Sci, Med Acad, Dept Neurol, Kaunas, Lithuania; [Krakauskaite, Solventa; Petkus, Vytautas; Chomskis, Romanas; Ragauskas, Arminas] Kaunas Univ Technol, Hlth Telemat Sci Inst, Kaunas, Lithuania; [Dagi, Teodoro Forcht] Harvard Univ, Harvard Med Sch, Cambridge, MA 02138 USA	Ragauskas, A (corresponding author), K Barsausko St 59,Room A560, LT-51423 Kaunas, Lithuania.	telematics@ktu.lt			Research Council of LithuaniaResearch Council of Lithuania (LMTLT) [MIP-118/2012]; Swiss-Lithuanian ProjectResearch Council of Lithuania (LMTLT) [CH-3-SMM-01/06]	Funding was received from the Research Council of Lithuania Grant No. MIP-118/2012 and Swiss-Lithuanian Project No. CH-3-SMM-01/06. The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.	Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Aries MJH, 2010, STROKE, V41, P2697, DOI 10.1161/STROKEAHA.110.594168; Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; CZOSNYKA M, 1994, ACTA NEUROCHIR, P468; Czosnyka M, 2007, NEUROL RES, V29, P672, DOI 10.1179/016164107X240053; Hakim AM, 1998, NEUROLOGY, V51, pS44, DOI 10.1212/WNL.51.3_Suppl_3.S44; Kasprowicz M, 2010, PHYSIOL MEAS, V31, P1217, DOI 10.1088/0967-3334/31/9/011; Kirkness C J, 2001, Biol Res Nurs, V2, P175, DOI 10.1177/109980040100200303; Lavinio A, 2008, ACTA NEUROCHIR SUPPL, V102, P3, DOI 10.1007/978-3-211-85578-2_1; Le Roux P, 2014, INTENS CARE MED, V40, P1189, DOI 10.1007/s00134-014-3369-6; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Palomares SM, 2011, J NEUROL NEUROPHYSIO, V2011, DOI DOI 10.4172/2155-9562.S1-004; Petkus V, 2014, ELEKTRON ELEKTROTECH, V20, P24, DOI 10.5755/j01.eee.20.8.5464; Petkus V, 2014, COMP MED SY, P427, DOI 10.1109/CBMS.2014.44; Ragauskas A, 2003, MED ENG PHYS, V25, P667, DOI 10.1016/S1350-4533(03)00082-1; Ragauskas A, 2015, CARNET2015 ABSTRACT, V1, P78; Rasulo FA, 2012, J NEUROSURG ANESTH, V24, P3, DOI 10.1097/ANA.0b013e318224030a; Reinhard M, 2012, ACTA NEUROL SCAND, V125, P156, DOI 10.1111/j.1600-0404.2011.01515.x; Rickards CA, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00120; Schmidt B, 2014, IJCNMH S1, V1, pS18; Schondorf R, 2001, J APPL PHYSIOL, V91, P2493; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Sviri G. E., 2010, OPEN NEUROSERG J, V3, P6; Thomas KN, 2009, J APPL PHYSIOL, V107, P506, DOI 10.1152/japplphysiol.91650.2008	29	14	14	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2016	79	1					75	82		10.1227/NEU.0000000000001192			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DU6OK	WOS:000382334300019	26695090				2021-06-18	
J	Yousuf, MA; Tan, CF; Torres-Altoro, MI; Lu, FM; Plautz, E; Zhang, SR; Takahashi, M; Hernandez, A; Kernie, SG; Plattner, F; Bibb, JA				Yousuf, Mohammad A.; Tan, Chunfeng; Torres-Altoro, Melissa I.; Lu, Fang-Min; Plautz, Erik; Zhang, Shanrong; Takahashi, Masaya; Hernandez, Adan; Kernie, Steven G.; Plattner, Florian; Bibb, James A.			Involvement of aberrant cyclin-dependent kinase 5/p25 activity in experimental traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						cyclin-dependent kinase 5; microtubule-associated protein tau; neuroinflammation; p25; retinoblastoma protein; traumatic brain injury	CONTROLLED CORTICAL IMPACT; CDK5 ACTIVATOR P35; SYNAPTIC PLASTICITY; MOUSE MODEL; HEAD-INJURY; CELL-DEATH; PHOSPHORYLATION; NEURODEGENERATION; CALPAIN; P25	Traumatic brain injury (TBI) is associated with adverse effects on brain functions, including sensation, language, emotions and/or cognition. Therapies for improving outcomes following TBI are limited. A better understanding of the pathophysiological mechanisms of TBI may suggest novel treatment strategies to facilitate recovery and improve treatment outcome. Aberrant activation of cyclin-dependent kinase 5 (Cdk5) has been implicated in neuronal injury and neurodegeneration. Cdk5 is a neuronal protein kinase activated via interaction with its cofactor p35 that regulates numerous neuronal functions, including synaptic remodeling and cognition. However, conversion of p35 to p25 via Ca2+-dependent activation of calpain results in an aberrantly active Cdk5/p25 complex that is associated with neuronal damage and cell death. Here, we show that mice subjected to controlled cortical impact (CCI), a well-established experimental TBI model, exhibit increased p25 levels and consistently elevated Cdk5-dependent phosphorylation of microtubule-associated protein tau and retinoblastoma (Rb) protein in hippocampal lysates. Moreover, CCI-induced neuroinflammation as indicated by increased astrocytic activation and number of reactive microglia. Brain-wide conditional Cdk5 knockout mice (Cdk5 cKO) subjected to CCI exhibited significantly reduced edema, ventricular dilation, and injury area. Finally, neurophysiological recordings revealed that CCI attenuated excitatory post-synaptic potential field responses in the hippocampal CA3-CA1 pathway 24h after injury. This neurophysiological deficit was attenuated in Cdk5 cKO mice. Thus, TBI induces increased levels of p25 generation and aberrant Cdk5 activity, which contributes to pathophysiological processes underlying TBI progression. Hence, selectively preventing aberrant Cdk5 activity may be an effective acute strategy to improve recovery from TBI.	[Yousuf, Mohammad A.; Tan, Chunfeng; Torres-Altoro, Melissa I.; Lu, Fang-Min; Hernandez, Adan; Plattner, Florian; Bibb, James A.] Univ Texas Southwestern Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Plautz, Erik; Bibb, James A.] Univ Texas Southwestern Med Ctr, Dept Neurol & Neurotherapeut, Dallas, TX USA; [Zhang, Shanrong; Takahashi, Masaya] Univ Texas Southwestern Med Ctr, Adv Imaging Res Ctr, Dallas, TX USA; [Kernie, Steven G.] Columbia Univ, Dept Pediat & Pathol & Cell Biol, New York, NY USA; [Bibb, James A.] Univ Texas Southwestern Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA	Bibb, JA (corresponding author), Univ Texas Southwestern Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	james.bibb@utsouthwestern.edu	Kernie, Steven/AAT-9912-2020	Kernie, Steven/0000-0003-1371-0549; Hernandez-Cortes, Adan/0000-0002-7098-870X; Plautz, Erik/0000-0001-8949-3064; Plattner, Florian/0000-0002-3150-1866	Texas Institute for Brain Injury and Repair; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH79710, MH083711]; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [DA018343, DA033485]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS073855, NS083077]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH083711, R01MH079710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS073855, R21NS083077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA016672, P30DA018343, R01DA033485] Funding Source: NIH RePORTER	We thank G. Mettlach for technical assistance, Dr P. Davis for phospho-tau antibodies, and the Beatrice Mennen Haggerty Center for Research on Brain Injury and Repair in Strokes for facilitating this research. This work was supported by a Discovery Award from the Texas Institute for Brain Injury and Repair, and National Institute of Mental Health grants (MH79710, MH083711), National Institute on Drug Abuse grants (DA018343, DA033485) and National Institute of Neurological Disorders and Stroke grants (NS073855) to J.A.B. and (NS083077) to S.G.K. The authors have no conflict of interest to declare and no competing financial interests exist.	Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; Angelo M, 2006, J NEUROCHEM, V99, P353, DOI 10.1111/j.1471-4159.2006.04040.x; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Cheung ZH, 2007, PLOS BIOL, V5, P865, DOI 10.1371/journal.pbio.0050063; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; Elliott MB, 2008, J NEUROSCI METH, V168, P320, DOI 10.1016/j.jneumeth.2007.10.019; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fischer Andrew H, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot4986; Futatsugi A, 2012, CELL CYCLE, V11, P1603, DOI 10.4161/cc.20009; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hamdane M, 2005, J CELL SCI, V118, P1291, DOI 10.1242/jcs.01724; Hashiguchi M, 2002, J BIOL CHEM, V277, P44525, DOI 10.1074/jbc.M207426200; Hawasli AH, 2007, NAT NEUROSCI, V10, P880, DOI 10.1038/nn1914; Herskovits AZ, 2006, NEUROBIOL DIS, V23, P398, DOI 10.1016/j.nbd.2006.04.004; Hisanaga S, 2012, CELL CYCLE, V11, P2049, DOI 10.4161/cc.20536; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Lee KY, 1999, NEUROSCI RES, V34, P21, DOI 10.1016/S0168-0102(99)00026-7; Lee KY, 1997, J BIOL CHEM, V272, P5622, DOI 10.1074/jbc.272.9.5622; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meyer DA, 2014, J NEUROSCI, V34, P8259, DOI 10.1523/JNEUROSCI.4368-13.2014; Meyer DA, 2008, P NATL ACAD SCI USA, V105, P18561, DOI 10.1073/pnas.0806078105; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Nguyen MD, 2001, NEURON, V30, P135, DOI 10.1016/S0896-6273(01)00268-9; Nikolic M, 1998, NATURE, V395, P194; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Plattner F, 2014, NEURON, V81, P1070, DOI 10.1016/j.neuron.2014.01.022; Pozo K, 2013, CANCER CELL, V24, P499, DOI 10.1016/j.ccr.2013.08.027; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SHAPIRA Y, 1989, Neurological Research, V11, P169; SINCLAIR RA, 1981, J CLIN PATHOL, V34, P859, DOI 10.1136/jcp.34.8.859; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith PD, 2003, P NATL ACAD SCI USA, V100, P13650, DOI 10.1073/pnas.2232515100; Stiefel MF, 2005, J NEUROSURG, V103, P707, DOI 10.3171/jns.2005.103.4.0707; Sundaram JR, 2013, J NEUROSCI, V33, P334, DOI 10.1523/JNEUROSCI.3593-12.2013; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; von Baumgarten L, 2008, J CEREBR BLOOD F MET, V28, P1353, DOI 10.1038/jcbfm.2008.30; Wang J, 2003, NAT NEUROSCI, V6, P1039, DOI 10.1038/nn1119; Zheng YL, 2005, EMBO J, V24, P209, DOI 10.1038/sj.emboj.7600441; Zheng YL, 2002, EUR J BIOCHEM, V269, P4427, DOI 10.1046/j.1432-1033.2002.03133.x	63	14	15	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUL	2016	138	2					317	327		10.1111/jnc.13620			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	DS0CT	WOS:000380263700010	26998748	Green Accepted			2021-06-18	
